PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	EDWARDS, RA; HERRERASOSA, H; OTTO, J; BRYAN, J				EDWARDS, RA; HERRERASOSA, H; OTTO, J; BRYAN, J			CLONING AND EXPRESSION OF A MURINE FASCIN HOMOLOG FROM MOUSE-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BUNDLING PROTEIN; URCHIN EGG EXTRACTS; GELATION; CELLS	The fascins are a widely distributed family of proteins that organize filamentous actin into bundles. We have cloned, sequenced, and expressed the murine homolog, Fascin is most abundant in brain and is found in other tissues including uterus and spleen. The deduced open reading frame encodes a protein of 493 amino acids with a molecular mass of 54,412 Ha. Previous solubility problems with bacterially expressed fascins were overcome by producing the mouse protein as a fusion with Escherichia coli thioredoxin, A method for cleaving the fusion protein and for purifying active recombinant fascin is described. The N-terminal sequence and molecular mass estimated on SDS gels indicate that recombinant fascin is full-length, Two-dimensional gel electrophoresis suggests that recombinant fascin is post-translationally modified in a manner similar to that observed in mouse brain, Recombinant fascin and the fusion protein are recognized by monoclonal anti-fascin antibodies and will bundle rabbit skeletal muscle F-actin in vitro at a stoichiometry of 4.1:1 actin to fascin. Electron cryomicroscopy images show that the reconstituted bundles are highly ordered, However, their fine structure differs from that of echinoid fascin-actin bundles, This structural difference can be attributed to fascin.	PURDUE UNIV, DEPT BIOL SCI, W LAFAYETTE, IN 47909 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	EDWARDS, RA (corresponding author), BAYLOR COLL MED, DEPT CELL BIOL, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA.							ALLIS CD, 1979, P NATL ACAD SCI USA, V76, P4857, DOI 10.1073/pnas.76.10.4857; BRYAN J, 1982, METHOD CELL BIOL, V25, P175, DOI 10.1016/S0091-679X(08)61425-9; BRYAN J, 1993, P NATL ACAD SCI USA, V90, P9115, DOI 10.1073/pnas.90.19.9115; BRYAN J, 1978, J MOL BIOL, V125, P207, DOI 10.1016/0022-2836(78)90345-5; CANT K, 1994, J CELL BIOL, V125, P369, DOI 10.1083/jcb.125.2.369; DEROSIER D, 1977, J MOL BIOL, V113, P679, DOI 10.1016/0022-2836(77)90230-3; DEROSIER DJ, 1981, J MOL BIOL, V146, P77, DOI 10.1016/0022-2836(81)90367-3; DUH FM, 1994, DNA CELL BIOL, V13, P821, DOI 10.1089/dna.1994.13.821; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HOLTHUIS JCM, 1994, BBA-GENE STRUCT EXPR, V1219, P184, DOI 10.1016/0167-4781(94)90267-4; HUANG KP, 1986, J BIOL CHEM, V261, P2134; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KANE RE, 1975, J CELL BIOL, V66, P305, DOI 10.1083/jcb.66.2.305; KANE RE, 1976, J CELL BIOL, V71, P704, DOI 10.1083/jcb.71.3.704; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; MOSIALOS G, 1994, J VIROL, V68, P7320, DOI 10.1128/JVI.68.11.7320-7328.1994; OTTO JJ, 1981, CELL MOTIL CYTOSKEL, V1, P179, DOI 10.1002/cm.970010203; OTTO JJ, 1980, CELL MOTIL CYTOSKEL, V1, P31, DOI 10.1002/cm.970010104; OVERTON J, 1967, J MORPHOL, V122, P367, DOI 10.1002/jmor.1051220406; PATERSON J, 1991, GENETICS, V129, P1073; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIROYA Y, 1993, DEV GROWTH DIFFER, V35, P323; SPUDICH JA, 1971, J BIOL CHEM, V246, P4860; VIOLAND BN, 1994, PROTEIN SCI, V3, P1089, DOI 10.1002/pro.5560030712; YAMASHIROMATSUMURA S, 1986, J CELL BIOL, V103, P631, DOI 10.1083/jcb.103.2.631; YAMASHIROMATSUMURA S, 1985, J BIOL CHEM, V260, P5087	30	61	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10764	10770		10.1074/jbc.270.18.10764	http://dx.doi.org/10.1074/jbc.270.18.10764			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738015	hybrid			2022-12-25	WOS:A1995QW60100059
J	QI, Z; HUANG, QQ; LEE, KY; LEW, J; WANG, JH				QI, Z; HUANG, QQ; LEE, KY; LEW, J; WANG, JH			RECONSTITUTION OF NEURONAL CDC2-LIKE KINASE FROM BACTERIA-EXPRESSED CDK5 AND AN ACTIVE FRAGMENT OF THE BRAIN-SPECIFIC ACTIVATOR - KINASE ACTIVATION IN THE ABSENCE OF CDK5 PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-2; DIRECTED PROTEIN-KINASE; HUMAN CELL-CYCLE; TYROSINE PHOSPHORYLATION; CATALYTIC SUBUNIT; P34CDC2 KINASE; BOVINE BRAIN; YEAST; CDC2; GENE	Three truncated forms of p35 including the one corresponding to the 25-kDa subunit of the kinase have been expressed in Escherichia coli and shown to activate a bacteria-expressed Cdk5 with equal efficacy. The shortest truncated form of p35, p21, spanning amino acid residues 88 to 291, has been used to reconstitute active Cdk5 kinase and to characterize the activation reaction. The purified kinase displays similar specific enzyme activity and similar phosphorylation site specificity as the neuronal Cdc2-like kinase purified from bovine brain, Bovine brain extract contains Cdk5 uncomplexed with p35 or p25 which has also been found to be activated by p21 or p25. The results substantiate the previous suggestion that p35 is a specific Cdk5 activator, Several observations suggest that, unlike other well characterized Cdc2-like kinases whose activities depend on the phosphorylation of the catalytic subunits at a specific site by a distinct kinase, the reconstituted Cdk5/p21 does not depend on the phosphorylation of Cdk5 for activity. The reconstitution of the highly active Cdk5 kinase was achieved without requiring any other kinase in the reconstitution reaction. The possibility of autophosphorylation of Cdk5 on the putative activation site has been ruled out as no phosphorylation occurred on Cdk5 during the enzyme reaction. The rate and extent of the kinase reconstitution were not significantly affected by Mg2+ ATP.	UNIV CALGARY,FAC MED,DEPT MED BIOCHEM,MED RES COUNCIL GRP SIGNAL TRANSDUCT,CALGARY,AB T2N 4N1,CANADA	University of Calgary								BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DRAETTA G, 1988, ONCOGENE, V2, P553; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Fantes P, 1989, CURR OPIN CELL BIOL, V1, P250, DOI 10.1016/0955-0674(89)90096-3; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKUDA T, 1992, ONCOGENE, V7, P2249; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1990, New Biologist, V2, P389; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TSAI LH, 1993, ONCOGENE, V8, P1593; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; XIONG Y, 1993, CELL, V71, P505	59	91	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10847	10854		10.1074/jbc.270.18.10847	http://dx.doi.org/10.1074/jbc.270.18.10847			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738023	hybrid			2022-12-25	WOS:A1995QW60100071
J	ROHLFS, EM; DANIEL, KW; PREMONT, RT; KOZAK, LP; COLLINS, S				ROHLFS, EM; DANIEL, KW; PREMONT, RT; KOZAK, LP; COLLINS, S			REGULATION OF THE UNCOUPLING PROTEIN GENE (UCP) BY BETA(1), BETA(2), AND BETA(3)-ADRENERGIC RECEPTOR SUBTYPES IN IMMORTALIZED BROWN ADIPOSE CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; BETA-3-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; CYCLIC-AMP; NOREPINEPHRINE INFUSION; MOLECULAR-CLONING; ADENYLYL CYCLASES; PRIMARY CULTURE; EXON STRUCTURE; FAT-CELLS	Immortalized brown adipocyte cell lines derived from a mouse hibernoma express all three beta-adrenergic receptor subtypes, including beta(3)-adrenergic receptor (AR). In response to norepinephrine, cAMP production by plasma membranes from four clonal cell lines was stimulated to levels comparable with brown adipocytes isolated from interscapular brown adipose tissue (72.8-89.6 versus 97.8 pmol cAMP/min/mg of protein, respectively), Ah cell lines responded to the highly selective beta(3)-adrenergic receptor agonist CL316,243 by stimulating adenylyl cyclase activity (3-10-fold over basal), beta(1)-, beta(2)-, and beta(3)-adrenergic receptor mRNA was detected by Northern blotting and/or reverse transcriptase-polymerase chain reaction, Competition binding assays with the antagonists CGP20712A and I-125-cyanopindolol showed the proportions of beta(1)AR and beta(2)AR in immortalized cells to be similar to brown adipocytes from tissue (cells: 35% beta(1)AR, 65% beta(2)AR; brown adipocytes from tissue: beta(1)AR 41%, 59% beta(2)AR), Expression of brown fat-specific mitochondrial uncoupling protein (Ucp) was stimulated by beta-adrenergic agonists in two of the four cell lines, The ability of individual beta AR subtypes to regulate Ucp expression was examined with combinations of selective beta-adrenergic agonists and antagonists, Expression of Ucp could be induced by any of the beta-adrenergic receptor subtypes, However, the greatest response was obtained by stimulating all three beta-adrenergic receptor subtypes simultaneously (100 mu M: isoproterenol), Incubation of membranes from cultured cells or brown adipocytes from tissue with CL316,243 at an optimal concentration (5 mu M) did not prevent norepinephrine from further stimulating adenylyl cyclase activity, suggesting that the combined activation of beta(1)AR/beta(2)AR, plus beta(3)AR, together produced an additive cAMP response, Multiple forms of adenylyl cyclase were identified in brown and white adipocyte cell lines and tissues, Northern blot analysis detected adenylyl cyclase types 5, 6, and 10, Screening of reverse transcriptase-PCR products by DNA sequencing confirmed the identities of these forms and lower levels of additional isoforms, raising the possibility that beta-adrenergic receptor subtypes in adipocytes couple to distinct adenylyl cyclases, Because these cell lines display functional and phenotypic similarities to interscapular brown adipocytes, they will be a useful model to study the regulation of beta-adrenergic receptor expression and function, and the control of Ucp expression and activity.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; JACKSON LAB,BAR HARBOR,ME 04609; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PSYCHIAT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BEHAV SCI,DURHAM,NC 27710; DUKE UNIV,MED CTR,SARAH W STEDMAN CTR NUTR STUDIES,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Jackson Laboratory; Duke University; Duke University; Duke University; Duke University				Premont, Richard/0000-0002-8053-5026	NICHD NIH HHS [HD08431] Funding Source: Medline; NIDDK NIH HHS [T32-DK07568, DK46793] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007568, R29DK046793] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; BLOOM JD, 1992, J MED CHEM, V35, P3081, DOI 10.1021/jm00094a025; BOUILLAUD F, 1984, J BIOL CHEM, V259, P1583; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONNIKOV G, 1992, J BIOL CHEM, V267, P2006; CARPENE C, 1993, J PHARMACOL EXP THER, V265, P237; CASTEILLA L, 1991, EUR J BIOCHEM, V189, P195; CHAMPIGNY O, 1992, MOL CELL ENDOCRINOL, V86, P73, DOI 10.1016/0303-7207(92)90177-8; CHAMPIGNY O, 1991, P NATL ACAD SCI USA, V88, P10774, DOI 10.1073/pnas.88.23.10774; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS S, 1990, J BIOL CHEM, V265, P19330; COLLINS S, 1988, J BIOL CHEM, V263, P9067; COLLINS S, 1994, MOL ENDOCRINOL, V8, P518, DOI 10.1210/me.8.4.518; DOOLEY DJ, 1986, EUR J PHARMACOL, V130, P137, DOI 10.1016/0014-2999(86)90193-7; FEVE B, 1990, J BIOL CHEM, V265, P16343; FEVE B, 1992, J BIOL CHEM, V267, P15909; FOREST C, 1987, EXP CELL RES, V168, P233, DOI 10.1016/0014-4827(87)90431-9; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GELOEN A, 1988, AM J PHYSIOL, V254, pC175, DOI 10.1152/ajpcell.1988.254.1.C175; GETTYS TW, 1991, J BIOL CHEM, V266, P15949; GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HERRON D, 1990, FEBS LETT, V268, P196; HIMMSHAGEN J, 1983, NUTR REV, V41, P261, DOI 10.1111/j.1753-4887.1983.tb07196.x; HOLLENGA C, 1991, EUR J PHARMACOL, V200, P325, DOI 10.1016/0014-2999(91)90590-M; HOLLENGA C, 1991, BRIT J PHARMACOL, V102, P577, DOI 10.1111/j.1476-5381.1991.tb12215.x; IRELAND RC, 1986, J BIOL CHEM, V261, P1779; KLAUS S, 1994, J CELL SCI, V107, P313; KLAUS S, 1991, J CELL BIOL, V115, P1783, DOI 10.1083/jcb.115.6.1783; KOPECKY J, 1990, J BIOL CHEM, V265, P22204; KOZAK LP, 1988, J BIOL CHEM, V263, P12274; KOZAK UC, 1994, ENDOCRINOLOGY, V134, P906, DOI 10.1210/en.134.2.906; KOZAK UC, 1992, MOL ENDOCRINOL, V6, P763, DOI 10.1210/me.6.5.763; KUUSELA P, 1986, LIFE SCI, V38, P589, DOI 10.1016/0024-3205(86)90052-4; LAFONTAN M, 1993, J LIPID RES, V34, P1057; LAI E, 1982, J BIOL CHEM, V257, P6691; LANGIN D, 1991, EUR J PHARMACOL, V199, P281; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; NANTEL F, 1993, MOL PHARMACOL, V43, P548; Pieroni J P, 1993, Curr Opin Neurobiol, V3, P345, DOI 10.1016/0959-4388(93)90127-K; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; PREMONT RT, 1994, METHOD ENZYMOL, V238, P116; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; RICQUIER D, 1986, J BIOL CHEM, V261, P13905; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; SMITH U, 1984, J BIOL CHEM, V259, P8758; SMYTH MJ, 1993, J CELL SCI, V106, P1; TATE KM, 1991, EUR J BIOCHEM, V196, P357, DOI 10.1111/j.1432-1033.1991.tb15824.x; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; VANSPRONSEN A, 1993, EUR J BIOCHEM, V213, P1117, DOI 10.1111/j.1432-1033.1993.tb17861.x; WHITE JE, 1958, P SOC EXP BIOL MED, V99, P375; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; ZHAO J, 1994, AM J PHYSIOL, V67, pC969	58	77	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10723	10732		10.1074/jbc.270.18.10723	http://dx.doi.org/10.1074/jbc.270.18.10723			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738011	hybrid			2022-12-25	WOS:A1995QW60100055
J	DONOHUE, PJ; ALBERTS, GF; GUO, Y; WINKLES, JA				DONOHUE, PJ; ALBERTS, GF; GUO, Y; WINKLES, JA			IDENTIFICATION BY TARGETED DIFFERENTIAL DISPLAY OF AN IMMEDIATE-EARLY GENE ENCODING A PUTATIVE SERINE/THREONINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; THREONINE PROTEIN-KINASE; CULTURED MOUSE CELLS; MOLECULAR-CLONING; CONSERVED FEATURES; MULTIGENE FAMILY; G0/G1 TRANSITION; HEPARIN-BINDING; RESPONSE GENES; FIBROBLAST	Fibroblast growth factor (FGF)-1 mitogenic signal transduction is mediated in part by gene products that are specifically expressed in response to cell surface receptor binding and activation, We have used a targeted differential display method to identify PGF-1-inducible genes in murine NIH 3T3 fibroblasts, Here we report that one of these genes is predicted to encode a novel serine/threanine-specific protein kinase. This putative kinase has been named Fnk, for PGF-inducible kinase. The deduced Fnk amino acid sequence has 49, 36, 33, 32, and 22% overall identity to mouse serum-inducible kinase (Snk), mouse polo-like kinase (Plk), Drosophila polo, Saccharomyces Cdc5, and mouse Snk/Plk-akin kinase (Sak), respectively, These proteins are all members of the polo subfamily of structurally related serine/threonine binases, The Plk, polo, Cdc5, and Sak kinases are required for cell division. FGF-1 induction of Fnk mRNA expression is first detected at 30 min after mitogen addition, reflects transcriptional activation, and does not require de novo protein synthesis. FGF-2, platelet-derived growth factor-BE, calf serum, or phorbol myristate acetate treatment of quiescent cells also induces fnk gene expression. Fnk mRNA is expressed in vivo in a tissue-specific manner, with relatively high levels detected in newborn and adult mouse skin, These results indicate that Fnk may be a transiently expressed protein kinase involved in the early signaling events required for growth factor-stimulated cell cycle progression.	AMER RED CROSS, DEPT BIOL MOLEC, HOLLAND LAB, ROCKVILLE, MD 20855 USA	American Red Cross					NHLBI NIH HHS [HL-39727] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039727, R01HL039727] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1995, REGULATION PROLIFERA; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHOWDHURY K, 1987, CELL, V48, P771, DOI 10.1016/0092-8674(87)90074-2; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DONOHUE PJ, 1994, J BIOL CHEM, V269, P8604; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; FODE C, 1994, P NATL ACAD SCI USA, V91, P6388, DOI 10.1073/pnas.91.14.6388; GALLAGHER JT, 1994, J CLIN CHEM CLIN BIO, V32, P239; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; GOMPERTS M, 1990, ONCOGENE, V5, P1081; GRUNERT S, 1994, EMBO J, V13, P3618, DOI 10.1002/j.1460-2075.1994.tb06669.x; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HATAI M, 1994, FEBS LETT, V350, P113, DOI 10.1016/0014-5793(94)00745-4; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; HSU DKW, 1993, BIOCHEM BIOPH RES CO, V197, P1483, DOI 10.1006/bbrc.1993.2644; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; MATRISIAN LM, 1985, NUCLEIC ACIDS RES, V13, P711, DOI 10.1093/nar/13.3.711; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NELKI D, 1990, NUCLEIC ACIDS RES, V18, P3655, DOI 10.1093/nar/18.12.3655; NIKAIDO T, 1991, EXP CELL RES, V192, P102, DOI 10.1016/0014-4827(91)90163-O; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; STONE B, 1994, NUCLEIC ACIDS RES, V22, P2612, DOI 10.1093/nar/22.13.2612; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; TAUTZ D, 1983, ANAL BIOCHEM, V132, P14, DOI 10.1016/0003-2697(83)90419-0; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; VINCENT S, 1993, ONCOGENE, V8, P1603; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS GT, 1992, MOL CELLULAR APPROAC, P115; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZUMSTEIN P, 1987, J BIOL CHEM, V262, P11252	52	183	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10351	10357		10.1074/jbc.270.17.10351	http://dx.doi.org/10.1074/jbc.270.17.10351			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730342	hybrid			2022-12-25	WOS:A1995QV41700091
J	GOODNIGHT, J; MISCHAK, H; KOLCH, W; MUSHINSKI, JF				GOODNIGHT, J; MISCHAK, H; KOLCH, W; MUSHINSKI, JF			IMMUNOCYTOCHEMICAL LOCALIZATION OF 8 PROTEIN-KINASE-C ISOZYMES OVEREXPRESSED IN NIH 3T3 FIBROBLASTS - ISOFORM-SPECIFIC ASSOCIATION WITH MICROFILAMENTS, GOLGI, ENDOPLASMIC-RETICULUM, AND NUCLEAR AND CELL-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; CYTOSKELETAL REARRANGEMENT; TRANSMEMBRANE PROTEINS; SUBSTRATE-SPECIFICITY; EMBRYO FIBROBLASTS; PLASMA-MEMBRANE; ACTIN FILAMENT; BETA-II; FAMILY; EXPRESSION	We have used immunocytochemical analyses to characterize the subcellular distribution of protein kinase C (PKC)-alpha; -beta I, -beta II, -gamma, -delta, -epsilon, -xi, and -eta in NIH 3T3 fibroblasts that overexpress these different PKC isozymes. Immunofluorescence studies and Western blotting with antibodies specific for individual isoforms revealed that before activation the majority of the PKCs are not membrane-bound and are diffusely distributed throughout the cytoplasm. In addition, a fraction of PKC-delta and -eta appears membrane-bound and concentrated in the Golgi apparatus, Activation of each isozyme's kinase activity (with the exception of PKC-xi) by treatment of these cells with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate results in isozyme specific alterations of cell morphology, as well as in a rapid, selective redistribution of the different PKC isozymes to distinct subcellular structures, Within minutes after 12-O-tetradecanoylphorbol-13-acetate treatment, PKC-alpha and -epsilon concentrate at cell margins. In addition, PKC-alpha accumulates in the endoplasmic reticulum, PKC-beta II associates with actin-rich microfilaments of the cytoskeleton, PKC-gamma accumulates in Golgi organelles, and PKC-epsilon associates with nuclear membranes. Our results demonstrate that each activated PKC isozyme specifically associates with a particular cellular structure, presumably containing the substrate for that isozyme. These findings support the hypothesis that PKC substrate specificity in vivo is mediated, at least in part, by the restricted subcellular locale for each PKC isozyme and its target protein.	NCI, GENET LAB, MOLEC GENET SECT, BETHESDA, MD 20892 USA; GSF MUNICH, FORSCHUNGSZENTRUM HAMATOL, INST CLIN MOLEC BIOL & TUMOR GENET, D-81377 MUNICH, GERMANY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022; Mischak, Harald/E-8685-2011	Kolch, Walter/0000-0001-5777-5016; Mischak, Harald/0000-0003-0323-0306				AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BLUMBERG PM, 1976, NATURE, V264, P446, DOI 10.1038/264446a0; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CACACE AM, 1993, ONCOGENE, V8, P2095; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIDA K, 1994, MOL CELL BIOL, V14, P3782, DOI 10.1128/MCB.14.6.3782; COUSSENS L, 1987, DNA-J MOLEC CELL BIO, V6, P389, DOI 10.1089/dna.1987.6.389; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; DRIEDGER PE, 1977, CANCER RES, V37, P3257; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P6438; GREGORIO CC, 1994, J CELL BIOL, V125, P345, DOI 10.1083/jcb.125.2.345; GREIF H, 1992, MOL CELL BIOL, V12, P1304, DOI 10.1128/MCB.12.3.1304; GUSOVSKY F, 1991, MOL PHARMACOL, V39, P124; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; ISHIZUKA T, 1992, BIOCHEM BIOPH RES CO, V183, P814, DOI 10.1016/0006-291X(92)90556-Z; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KONIG B, 1985, J CELL BIOCHEM, V29, P37, DOI 10.1002/jcb.240290105; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LITCHFIELD DW, 1986, BIOCHEM BIOPH RES CO, V134, P1276, DOI 10.1016/0006-291X(86)90388-8; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MCCAFFREY PG, 1987, BIOCHEM BIOPH RES CO, V146, P140, DOI 10.1016/0006-291X(87)90702-9; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MIKI M, 1987, EUR J BIOCHEM, V165, P125, DOI 10.1111/j.1432-1033.1987.tb11202.x; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1991, J IMMUNOL, V147, P3981; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; NAIRN AC, 1992, CIBA F SYMP, V164, P145; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; OSADA S, 1990, J BIOL CHEM, V265, P22434; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHLIWA M, 1984, J CELL BIOL, V99, P1045, DOI 10.1083/jcb.99.3.1045; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; TANG DG, 1993, EXP CELL RES, V207, P361, DOI 10.1006/excr.1993.1203; TIMAR J, 1993, CELL MOTIL CYTOSKEL, V26, P49, DOI 10.1002/cm.970260106; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WERTH DK, 1984, J BIOL CHEM, V259, P5264; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121	62	291	291	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9991	10001		10.1074/jbc.270.17.9991	http://dx.doi.org/10.1074/jbc.270.17.9991			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730383	hybrid			2022-12-25	WOS:A1995QV41700045
J	TROTTI, D; VOLTERRA, A; LEHRE, KP; ROSSI, D; GJESDAL, O; RACAGNI, G; DANBOLT, NC				TROTTI, D; VOLTERRA, A; LEHRE, KP; ROSSI, D; GJESDAL, O; RACAGNI, G; DANBOLT, NC			ARACHIDONIC-ACID INHIBITS A PURIFIED AND RECONSTITUTED GLUTAMATE TRANSPORTER DIRECTLY FROM THE WATER PHASE AND NOT VIA THE PHOSPHOLIPID MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC ACID; RAT-BRAIN; PRIMARY CULTURES; FATTY-ACIDS; STRIATAL NEURONS; GLIAL-CELLS; ASTROCYTES; RECEPTORS; SYNAPTOSOMES; SENSITIVITY	Glutamate is believed to be the major excitatory transmitter in the mammalian central nervous system. Keeping the extracellular concentration of glutamate low, the glutamate transporters are required for normal brain function. Arachidonic acid (AA) inhibits glutamate uptake in relatively intact preparations (cells, tissue slices, and synaptosomes (Rhoads, D. E., Ockner, R. K., Peterson, N. A., and Raghupathy, E. (1983) Biochemistry 22, 1965-1970 and Volterra, A., Trotti, D., Cassutti, P., Tromba, C., Salvaggio, A., Melcangi, R. C., and Racagni, G. (1992b) J. Neurochem. 59, 600-606). The present study demonstrates that the effect of AA occurs also in a reconstituted system, consisting of a purified glutamate transporter protein incorporated into artificial cell membranes (liposomes). The characteristics of the AA effect in this system and in intact cells are similar with regard to specificity, sensitivity, time course, changes in V-max, and affinity. AA-ethyl ester is inactive, suggesting that the free carboxylic group is required for inhibitory activity. When incubated with proteoliposomes, AA (300 mu M, 15 min) mostly partitions to the lipid phase (lipid/water about 95:5). However, uptake inhibition is abolished by rapid dilution (6.5-fold) of the incubation medium (water phase), a procedure that does not modify the amount of AA associated with lipids. On the contrary, inhibition remains sustained if the same dilution volume contains as little as 5 mu M AA, a concentration inactive before saturation of liposome lipids with 300 mu M AA The same degree of inhibition (60%) is obtained by 5 mu M following preincubation with the inactive AA-ethyl ester (300 mu M) instead of AA. The Lipids apparently inactivate AA by extracting it from the mater phase. The results suggest that AA acts on the transporter from the water phase rather than via the membrane. This could be true for other proteins as well since gamma-aminobutyric acid uptake is similarly affected by AA.	UNIV OSLO, INST BASIC MED SCI, DEPT ANAT, N-0317 OSLO, NORWAY; UNIV MILAN, INST PHARMACOL SCI, CTR NEUROPHARMACOL, I-20133 MILAN, ITALY	University of Oslo; University of Milan			Danbolt, Niels Christian/A-1907-2014; Gjesdal, Ola/C-1941-2015; Rossi, Daniela Maria/AAA-3401-2021; Racagni, Giorgio A./B-5826-2011	Danbolt, Niels Christian/0000-0003-4227-4520; Rossi, Daniela Maria/0000-0002-3346-1327; Trotti, Davide/0000-0001-6338-6404; Gjesdal, Ola/0000-0003-1913-6445; Volterra, Andrea/0000-0003-1069-1602	Telethon [586] Funding Source: Medline	Telethon(Fondazione Telethon)		ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; CASPERS ML, 1993, BRAIN RES, V602, P215, DOI 10.1016/0006-8993(93)90685-G; CHAN PH, 1983, J NEUROCHEM, V40, P309, DOI 10.1111/j.1471-4159.1983.tb11284.x; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1994, PROG NEUROBIOL, V44, P377, DOI 10.1016/0301-0082(94)90033-7; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; DUMUIS A, 1993, MOL PHARMACOL, V43, P976; DUMUIS A, 1990, NATURE, V347, P182, DOI 10.1038/347182a0; DURING MJ, 1993, LANCET, V341, P1607; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; HARDY SJ, 1994, J NEUROCHEM, V62, P1546; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; LAZAREWICZ JW, 1990, J NEUROCHEM, V55, P1875, DOI 10.1111/j.1471-4159.1990.tb05771.x; LEHRE KP, 1995, J NEUROSCI, V15, P1835; LEVY LM, 1993, FEBS LETT, V317, P79, DOI 10.1016/0014-5793(93)81495-L; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH MA, 1994, NEUROSCI RES COMMUN, V14, P53; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; OKUN IM, 1992, GEN PHYSIOL BIOPHYS, V11, P589; OLNEY JW, 1990, ANNU REV PHARMACOL, V30, P47; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; RHOADS DE, 1983, BIOCHEMISTRY-US, V22, P1965, DOI 10.1021/bi00277a035; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; SANFELIU C, 1990, BRAIN RES, V526, P241, DOI 10.1016/0006-8993(90)91228-9; SIESJO BK, 1989, ANN NY ACAD SCI, V559, P323; STELLA N, 1994, J NEUROSCI, V14, P568; VOLTERRA A, 1992, J NEUROCHEM, V59, P600, DOI 10.1111/j.1471-4159.1992.tb09411.x; VOLTERRA A, 1992, ADV EXP MED BIOL, V318, P147; VOLTERRA A, 1994, MOL PHARMACOL, V46, P986; YU ACH, 1986, J NEUROCHEM, V47, P1181; ZAFRA F, 1990, BIOCHEM J, V271, P237, DOI 10.1042/bj2710237	38	101	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9890	9895		10.1074/jbc.270.17.9890	http://dx.doi.org/10.1074/jbc.270.17.9890			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730372				2022-12-25	WOS:A1995QV41700031
J	BANEULOS, S; ARRONDO, JLR; GONI, FM; PIFAT, G				BANEULOS, S; ARRONDO, JLR; GONI, FM; PIFAT, G			SURFACE-CORE RELATIONSHIPS IN HUMAN LOW-DENSITY-LIPOPROTEIN AS STUDIED BY INFRARED-SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN APOLIPOPROTEIN-B; SECONDARY STRUCTURE; PROTEINS; OXIDATION; SEQUENCE; RECEPTOR; DOMAINS; B-100	The secondary structure of human apolipoprotein B at 37 degrees C is estimated to be 24% alpha-helix, 23% beta-sheet, 6% beta-turns, 24% unordered structure, and 24% ''beta-strands,'' characterized by a band around 1618 cm(-1), and consistent with extended string-like chains in contact with the lipid moiety not forming beta-sheets. When cooled to a temperature below the cholesteryl ester transition at 30 degrees C, the ordering of the low density lipoprotein core results in reversible changes in the protein conformation, decreasing the apparent amount of alpha-helix, beta-strand, and unordered structure below 30 degrees C and increasing beta-sheet and beta-turns. Lowering the ionic strength affects the core-associated transitions, shifting their temperature from 30 to 20 degrees C, and modifying protein conformation below the transition, An additional thermal event is ob served at 75 degrees C, leading to irreversible protein denaturation, In the broad temperature range between the 30 and 75 degrees C transitions, apolipoprotein B is stable toward both temperature and ionic strength changes, After thermal denaturation, the protein retains a certain degree of ordered structure.	UNIV BASQUE COUNTRY, DEPT BIOQUIM, E-48080 BILBAO, SPAIN; RUDJER BOSKOVIC INST, ZAGREB 41001, CROATIA	University of Basque Country; Rudjer Boskovic Institute			Goni, Felix M/M-5425-2015; Banuelos, Sonia/N-9128-2019	Goni, Felix M/0000-0001-6270-9216; Banuelos, Sonia/0000-0002-1399-381X				ARRONDO JLR, 1994, BIOCHEMISTRY-US, V33, P11650, DOI 10.1021/bi00204a029; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; ARRONDO JLR, 1987, J BIOL CHEM, V262, P9037; ARRONDO JLR, 1988, BIOCHIM BIOPHYS ACTA, V952, P261, DOI 10.1016/0167-4838(88)90125-2; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHATTERTON JE, 1991, J BIOL CHEM, V266, P5955; DEARBORN DG, 1969, P NATL ACAD SCI USA, V62, P179, DOI 10.1073/pnas.62.1.179; DECKELBAUM RJ, 1977, J BIOL CHEM, V252, P744; DECKELBAUM RJ, 1975, SCIENCE, V190, P392, DOI 10.1126/science.170681; EFIMOV AV, 1993, PROG BIOPHYS MOL BIO, V60, P201, DOI 10.1016/0079-6107(93)90015-C; GOORMAGHTIGH E, 1993, BIOCHEMISTRY-US, V32, P6104, DOI 10.1021/bi00074a023; GOORMAGHTIGH E, 1989, BIOCHIM BIOPHYS ACTA, V1006, P147, DOI 10.1016/0005-2760(89)90338-X; HALTIA T, 1994, BIOCHEMISTRY-US, V33, P9731, DOI 10.1021/bi00198a044; HERAK JN, 1988, CHEM PHYS LIPIDS, V59, P135; HERZYK E, 1987, BIOCHIM BIOPHYS ACTA, V922, P145, DOI 10.1016/0005-2760(87)90148-2; JACKSON M, 1991, BIOCHEMISTRY-US, V30, P9681, DOI 10.1021/bi00104a016; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; MUGA A, 1993, ARCH BIOCHEM BIOPHYS, V300, P451, DOI 10.1006/abbi.1993.1061; NAUMANN D, 1993, BIOCHEMISTRY-US, V32, P3162, DOI 10.1021/bi00063a031; PIERCE JA, 1990, ANAL CHEM, V62, P477, DOI 10.1021/ac00204a011; PIFAT G, 1981, INT J BIOL MACROMOL, V3, P282, DOI 10.1016/0141-8130(81)90043-X; RUDEL LL, 1986, J LIPID RES, V27, P465; SCANU A, 1969, P NATL ACAD SCI USA, V62, P171, DOI 10.1073/pnas.62.1.171; SCHNITZER E, 1994, CHEM PHYS LIPIDS, V70, P63, DOI 10.1016/0009-3084(94)90048-5; SESHADRI S, 1994, BIOCHEMISTRY-US, V33, P1351, DOI 10.1021/bi00172a010; STEELE JCH, 1979, J BIOL CHEM, V254, P1633; Susi H., 1969, STRUCTURE STABILITY, P575; TALL AR, 1978, J CLIN INVEST, V62, P1354, DOI 10.1172/JCI109256; WALSH MT, 1986, J LIPID RES, V27, P316; WALSH MT, 1990, J LIPID RES, V31, P1051; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YANG PW, 1987, BIOCHEMISTRY-US, V26, P2706, DOI 10.1021/bi00384a009	33	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9192	9196						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721835				2022-12-25	WOS:A1995QU08900023
J	FREEMANTLE, SJ; TAYLOR, SM; KRYSTAL, G; MORAN, RG				FREEMANTLE, SJ; TAYLOR, SM; KRYSTAL, G; MORAN, RG			UPSTREAM ORGANIZATION OF AND MULTIPLE TRANSCRIPTS FROM THE HUMAN FOLYLPOLY-GAMMA-GLUTAMATE SYNTHETASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; FOLATE-DEPENDENT ENZYMES; TRANSFER-RNA-SYNTHETASES; CHINESE-HAMSTER CELLS; ONE-CARBON METABOLISM; MAMMALIAN-CELLS; RAT-LIVER; METHOTREXATE POLYGLUTAMATES; MESSENGER-RNAS; OVARY CELLS	Folylpoly-gamma-glutamate synthetase (FPGS) is essential for the survival of proliferating mammalian cells and central to the action of all ''classical'' folate antimetabolites. We report the isolation of cDNAs corresponding to the 5' ends of FPGS mRNA from both human and hamster cells which include a start codon upstream of and in-frame with the AUG in the previously reported FPGS open reading frame. The predicted hamster and human amino-terminal extension peptides have features consistent with a mitochondrial targeting sequence. Ribo-nuclease protection and 5'-rapid amplification of cDNA ends assays indicated multiple transcriptional start sites consistent with the sequence of the promoter region of this gene, which was highly GC-rich and did not contain TATA or CCAAT elements. These start sites would generate two classes of transcripts, one including the upstream AUG and one in which only the downstream AUG would be available for translation initiation. Transfection of the full length human cDNA into cells lacking FPGS restored their ability to grow in the absence of glycine, a product of mitochondrial folate metabolism, as well as of thymidine and purines. Therefore, we propose that the mitochondrial and cytosolic forms of FPGS are derived from the same gene, arising from the use of the two different translation initiation codons, and that the translation products differ by the presence of a 42-residue amino-terminal mitochondrial leader peptide.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MASSEY CANC CTR,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University					NCI NIH HHS [CA 27605] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027605] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BARREDO J, 1992, MOL PHARMACOL, V42, P687; BARREDO JC, 1994, BLOOD, V84, P564; BELTZER JP, 1988, J BIOL CHEM, V263, P368; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; CHANG ZF, 1993, CANCER RES, V53, P3253; CHATTON B, 1988, J BIOL CHEM, V263, P52; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; JONES C, 1980, CYTOGENET CELL GENET, V28, P181, DOI 10.1159/000131529; KIKUCHI G, 1973, MOL CELL BIOCHEM, V1, P169, DOI 10.1007/BF01659328; KIM YK, 1991, J BIOL CHEM, V267, P2723; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIN BF, 1993, J BIOL CHEM, V268, P21674; LIN BF, 1994, J BIOL CHEM, V269, P9705; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCGUIRE JJ, 1981, MOL CELL BIOCHEM, V38, P19, DOI 10.1007/BF00235686; MORAN RG, 1984, ANAL BIOCHEM, V140, P326, DOI 10.1016/0003-2697(84)90174-X; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; ODA T, 1990, J BIOL CHEM, V265, P7513; OSBORNE CB, 1993, J BIOL CHEM, V268, P21657; RUMBERGER BG, 1990, CANCER RES, V50, P4639; Sambrook J, 1989, MOL CLONING LABORATO; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; SIROTNAK FM, 1988, BIOCHEM PHARMACOL, V37, P4239, DOI 10.1016/0006-2952(88)90122-0; SUZUKI T, 1992, EUR J BIOCHEM, V207, P767, DOI 10.1111/j.1432-1033.1992.tb17107.x; TAYLOR RT, 1977, ARCH BIOCHEM BIOPHYS, V181, P331, DOI 10.1016/0003-9861(77)90512-4; TAYLOR RT, 1982, ARCH BIOCHEM BIOPHYS, V217, P609, DOI 10.1016/0003-9861(82)90543-4; TAYLOR S M, 1986, P937; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WHITEHEAD VM, 1992, BLOOD, V80, P1316; WHITEHEAD VM, 1990, BLOOD, V76, P44; WITTWER AJ, 1981, J BIOL CHEM, V256, P4109; WU M, 1987, J BIOL CHEM, V262, P12275	41	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9579	9584		10.1074/jbc.270.16.9579	http://dx.doi.org/10.1074/jbc.270.16.9579			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721888	hybrid			2022-12-25	WOS:A1995QU08900077
J	HIGAZI, AAR; BARGHOUTI, II; ABUMUCH, R				HIGAZI, AAR; BARGHOUTI, II; ABUMUCH, R			IDENTIFICATION OF AN INHIBITOR OF TISSUE-TYPE PLASMINOGEN ACTIVATOR-MEDIATED FIBRINOLYSIS IN HUMAN NEUTROPHILS - A ROLE FOR DEFENSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOTTING SYSTEM; SKIN REACTIONS; HYPERSENSITIVITY; UROKINASE; KINETICS; BINDING; LIPOPROTEIN(A); STREPTOKINASE; DEPOSITION; LEUKOCYTES	An inhibitor of tissue-type plasminogen activator (tPA)-mediated and plasminogen-dependent fibrinolysis was isolated from human neutrophils. On a G-50 gel filtration column, the antifibrinolytic activity present in neutrophil homogenates comigrated with proteins of <13 kDa, The inhibitory fraction had only a slight effect on urokinase with plasminogen- or plasmin-mediated fibrinolysis and no effect on urokinase- or plasmin-mediated cleavage of H-D-valyl-L-leucyl-L-lysine-p-nitroanilide (S-2251). The neutrophil-derived fraction inhibited tPA with plasminogen activity on S-2251 but not on H-D-isoleucyl-L-prolyl-L-arginine-p-nitroanilide (S-2288). The inhibition of tPA-mediated and plasminogen-dependent fibrinolysis or S-2251 cleavage showed a competitive pattern and could be relieved by increasing the concentration of plasminogen. The same fraction also inhibited binding of plasminogen to fibrin. Consecutive purification steps revealed that the molecular mass of the inhibitor was 1-5 kDa, Polylysine-Sepharose affinity chromatography indicated that the inhibitor is a protein of 4 kDa, migrating as one band on SDS-polyacrylamide gel electrophoresis. Amino acid sequence analysis of this band showed the presence of two sequences, differing by one amino acid, which are identical to defensin I and II. Comparison of the sequences of plasminogen and defensin showed homology of defensin to the plasminogen kringles known to contain the lysine binding sites. The close structural similarity between defensin and plasminogen kringles and the ability of defensin to compete with plasminogen on binding to fibrin explain the ability of defensin to inhibit tPA-mediated, plasminogen-dependent fibrinolysis, These results suggest that the antifibrinolytic activity of defensin may have a biological function in preventing the spread of infection.	HADASSAH UNIV HOSP,DEPT CLIN BIOCHEM,IL-91120 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem								BATEMAN A, 1991, J BIOL CHEM, V266, P7524; CAMIOLO SM, 1971, P SOC EXP BIOL MED, V138, P277; CASTELLINO FJ, 1981, CHEM REV, V81, P431, DOI 10.1021/cr00045a001; CHURCH WR, 1991, HYBRIDOMA, V10, P659, DOI 10.1089/hyb.1991.10.659; COLVIN RB, 1979, J CLIN INVEST, V63, P1302, DOI 10.1172/JCI109425; COLVIN RB, 1975, J IMMUNOL, V114, P377; COLVIN RB, 1973, J EXP MED, V138, P686, DOI 10.1084/jem.138.3.686; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; EDWARDS RL, 1978, SCIENCE, V200, P541, DOI 10.1126/science.644314; EDWARDS RL, 1992, SEMIN HEMATOL, V29, P202; GABAY JE, 1993, CURR OPIN IMMUNOL, V5, P97, DOI 10.1016/0952-7915(93)90087-9; GONZALEZGRONOW M, 1989, BIOCHEMISTRY-US, V28, P2374, DOI 10.1021/bi00432a005; HIGAZI AA, 1992, BIOCHEM J, V282, P863, DOI 10.1042/bj2820863; HIGAZI AA, 1994, BIOCHEM J, V300, P251, DOI 10.1042/bj3000251; HOWARD GC, 1993, LAB INVEST, V69, P373; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; KAGAN BL, 1994, TOXICOLOGY, V87, P131, DOI 10.1016/0300-483X(94)90158-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLINAS M, 1983, EUR J BIOCHEM, V135, P379, DOI 10.1111/j.1432-1033.1983.tb07665.x; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MATZNER Y, 1984, J LAB CLIN MED, V103, P227; MAYER M, 1990, CLIN BIOCHEM, V23, P197, DOI 10.1016/0009-9120(90)90601-P; Menkin V, 1938, PHYSIOL REV, V18, P366, DOI 10.1152/physrev.1938.18.3.366; MOVAT HZ, 1960, BRIT J EXP PATHOL, V41, P97; PANYUTICH AV, 1993, J LAB CLIN MED, V122, P202; PERDUE JF, 1981, J BIOL CHEM, V256, P2767; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; SAKSELA O, 1985, BIOCHIM BIOPHYS ACTA, V823, P35, DOI 10.1016/0304-419X(85)90014-9; SCHULMAN G, 1991, KIDNEY INT, V40, P1069, DOI 10.1038/ki.1991.316; SENIOR RM, 1986, J CLIN INVEST, V77, P1014, DOI 10.1172/JCI112353; SHAVIT R, 1983, SCIENCE, V220, P728; SINGH A, 1988, BIOCHEM BIOPH RES CO, V155, P524, DOI 10.1016/S0006-291X(88)81118-5; TAKADA A, 1987, THROMB RES, V45, P371, DOI 10.1016/0049-3848(87)90226-X; TAKADA A, 1983, THROMB RES, V30, P309, DOI 10.1016/0049-3848(83)90085-3; VERHEIJEN JH, 1982, THROMB RES, V27, P377, DOI 10.1016/0049-3848(82)90055-X; VERSTRAETE M, 1985, DRUGS, V29, P236, DOI 10.2165/00003495-198529030-00003; VERSTRAETE M, 1986, BLOOD, V67, P1529; VICTOR J., 1994, HEMOSTASIS THROMBOSI, P1023; WALLEN P, 1978, PROGR CHEM FIBRINOLY, V3, P167	40	47	48	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9472	9477		10.1074/jbc.270.16.9472	http://dx.doi.org/10.1074/jbc.270.16.9472			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721874	hybrid			2022-12-25	WOS:A1995QU08900063
J	KLEIN, HG; DUVERGER, N; ALBERS, JJ; MARCOVINA, S; BREWER, HB; SANTAMARINAFOJO, S				KLEIN, HG; DUVERGER, N; ALBERS, JJ; MARCOVINA, S; BREWER, HB; SANTAMARINAFOJO, S			IN-VITRO EXPRESSION OF STRUCTURAL DEFECTS IN THE LECITHIN-CHOLESTEROL ACYLTRANSFERASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISH EYE DISEASE; SITE-DIRECTED MUTAGENESIS; DIFFERENT ALLELIC MUTATIONS; HIGH-DENSITY-LIPOPROTEIN; AMINO-ACID EXCHANGE; LCAT DEFICIENCY; SECONDARY STRUCTURE; FAMILIAL LECITHIN; MOLECULAR DEFECT; ESTERIFICATION RATE	Classic LCAT deficiency (CLD) and fish eye disease (FED) are two clinically distinct syndromes, associated with defects in the lecithin-cholesterol acyltransferase (LCAT) gene resulting in total (CLD) or partial (FED) enzyme deficiency. In order to investigate the underlying molecular mechanisms that lead to different phenotypic expression in CLD and FED, LCAT mutants associated with either CLD (LCAT(147), LCAT(156), and LCAT(228)) or FED (LCAT(10), LCAT(123), LCAT(158), LCAT(293), LCAT(300), and LCAT(347)) were expressed in vitro in human embryonic kidney 293 cells and characterized with respect to LCAT expression and enzyme activity, Evaluation of mutant LCAT gene transcription by Northern blot analysis demonstrated LCAT mRNA of normal size and concentration. Although all constructs gave rise to similar intracellular LCAT mass, the amount of enzyme present in the media for LCAT(147), LCAT(156),and LCAT(300) was reduced to less than 10% of normal, suggesting that these mutations disrupted LCAT secretion. Western blot analysis of cell culture media containing wild type or mutant LCAT demonstrated the presence of a single normal-sized band of 67 kDa. The ability of the different enzymes to esterify free cholesterol in high density lipoprotein-like proteoliposomes (alpha-LCAT-specific activity) was reduced to less than 5% of normal for CLD mutants LCAT(147) and LCAT(228) and FED mutants LCAT(10) LCAT(123), LCAT(293), and LCAT(347), whereas that of LCAT(156), LCAT(158), and LCAT(300) ranged from 45 to 110% LCAT of control. Although most FED mutant LCAT enzymes retained the ability to esterify free cholesterol present in alpha- and beta-lipoproteins of heat-inactivated plasma, esterification was undetectable in all CLD mutants (LCAT(147), LCAT(156), and LCAT(228)). In contrast, all mutant enzymes retained the ability to hydrolyze the water soluble, short-chained fatty acid substrate p-nitrophenol-butyrate, In summary, our studies establish the functional significance of nine LCAT gene defects associated with either FED or CLD. Characterization of the expressed LCAT mutants identified multiple, overlapping functional abnormalities that include defects in secretion and/or disruption of enzymic activity. All nine LCAT mutants retained the ability to hydrolyze the water-soluble PNPB substrate, indicating intact hydrolytic function, Based on these studies we propose that mutations in LCAT residues 147, 156, 228 (CLD) and 10, 123, 158, 293, 300, and 347 (FED) do not disrupt the functional domain mediating LCAT phospholipase activity, but alter structural domains involved in lipid binding or transesterification.	NHLBI,MOLEC DIS BRANCH,BETHESDA,MD 20892; WASHINGTON UNIV,SCH MED,NW LIPID RES CTR,DEPT MED,SEATTLE,WA 98103	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NHLBI NIH HHS [HL 3-00H6] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1981, J LIPID RES, V22, P1206; ALBERS JJ, 1981, J CLIN INVEST, V67, P141, DOI 10.1172/JCI110006; Assmann G, 1991, CURR OPIN LIPIDOL, V2, P110; BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BONELLI FS, 1989, J BIOL CHEM, V264, P14723; BUJO H, 1991, BIOCHEM BIOPH RES CO, V181, P933, DOI 10.1016/0006-291X(91)92026-G; CARLSON LA, 1982, EUR J CLIN INVEST, V12, P41, DOI 10.1111/j.1365-2362.1982.tb00938.x; CHEN CH, 1982, J LIPID RES, V23, P680; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLET X, 1991, BIOCHEMISTRY-US, V30, P3228, DOI 10.1021/bi00227a010; DOBIASOVA M, 1986, PHYSIOL BOHEMOSLOV, V35, P319; FRANCONE OL, 1991, BIOCHEMISTRY-US, V30, P10074, DOI 10.1021/bi00106a002; FRANCONE OL, 1991, P NATL ACAD SCI USA, V88, P1716, DOI 10.1073/pnas.88.5.1716; FRANCONE OL, 1993, BIOCHIM BIOPHYS ACTA, V1166, P301, DOI 10.1016/0005-2760(93)90110-U; FUNKE H, 1991, P NATL ACAD SCI USA, V88, P4855, DOI 10.1073/pnas.88.11.4855; FUNKE H, 1993, J CLIN INVEST, V91, P677, DOI 10.1172/JCI116248; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GASCUEL O, 1988, COMPUT APPL BIOSCI, V4, P357; GOTODA T, 1991, LANCET, V338, P778, DOI 10.1016/0140-6736(91)90665-C; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMQUIST L, 1987, ACTA MED SCAND, V222, P23; JAUHIAINEN M, 1988, J BIOL CHEM, V263, P6525; JAUHIAINEN M, 1986, J BIOL CHEM, V261, P7032; JAUHIAINEN M, 1989, J BIOL CHEM, V264, P1963; JONAS A, 1987, PLASMA LIPOPROTEINS, P299; KARMIN O, 1993, J LIPID RES, V34, P81; KLEIN HG, 1992, J CLIN INVEST, V89, P499, DOI 10.1172/JCI115612; KLEIN HG, 1993, J LIPID RES, V34, P49; KLEIN HG, 1993, J CLIN INVEST, V92, P479, DOI 10.1172/JCI116591; MAEDA E, 1991, BIOCHEM BIOPH RES CO, V178, P460, DOI 10.1016/0006-291X(91)90129-U; MCLEAN J, 1986, NUCLEIC ACIDS RES, V14, P9397, DOI 10.1093/nar/14.23.9397; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NOVOTNY J, 1984, NUCLEIC ACIDS RES, V12, P243, DOI 10.1093/nar/12.1Part1.243; RADLOFF R, 1967, P NATL ACAD SCI USA, V57, P1514, DOI 10.1073/pnas.57.5.1514; ROGNE S, 1987, BIOCHEM BIOPH RES CO, V148, P161, DOI 10.1016/0006-291X(87)91090-4; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SEGREST JP, 1992, J LIPID RES, V33, P141; SKRETTING G, 1992, BIOCHEM BIOPH RES CO, V182, P583, DOI 10.1016/0006-291X(92)91772-I; SKRETTING G, 1992, FEBS LETT, V309, P307, DOI 10.1016/0014-5793(92)80795-I; STOKKE KT, 1971, SCAND J CLIN LAB INV, V27, P21, DOI 10.3109/00365517109080184; TARAMELLI R, 1990, HUM GENET, V85, P195; YANG CY, 1987, J BIOL CHEM, V262, P3086	44	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9443	9447		10.1074/jbc.270.16.9443	http://dx.doi.org/10.1074/jbc.270.16.9443			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721870	hybrid			2022-12-25	WOS:A1995QU08900059
J	NISHIKAWA, N; OISHI, M; KIYAMA, R				NISHIKAWA, N; OISHI, M; KIYAMA, R			CONSTRUCTION OF A HUMAN GENOMIC LIBRARY OF CLONES CONTAINING POLY(DG-DA)CENTER-DOT-POLY(DT-DC) TRACTS BY MG2+-DEPENDENT TRIPLEX AFFINITY CAPTURE - DNA POLYMORPHISM ASSOCIATED WITH THE TRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER CHROMATID EXCHANGE; SITE-SPECIFIC CLEAVAGE; GENETIC-LINKAGE MAP; HANDED Z-DNA; HELIX FORMATION; H-DNA; SEQUENCES; PURIFICATION; ELEMENT; INVITRO	Microsatellite DNA is a useful tool for detecting DNA polymorphisms among species or individuals, especially those among closely related individuals, We constructed a library of clones that contained poly(dG-dA). poly(dT-dC) tracts from human genomic DNA by Mg2+-dependent tripler DNA formation, Examination of tripler DNA formation in the presence of various metal ions Mg2+, Mn2+, or Zn2+ revealed that the procedure worked best in the presence of Mg2+, Affinity enrichment was performed with AluI-digested chromosomal DNA mixed with biotinylated (dG-dA)(17) in the presence of Mg2+, A library constructed after three cycles of affinity enrich ment showed that over 80% of the clones contained at least one poly(dG-dA) poly(dT-dC) tract, Most of them contained a perfect (dG-dA)(n) repeat 30-84 base pairs in length, while some contained variants such as (dC-dT)(10)-(dC)-(dC-dT)(9). Using the clones from the library as a probe, we detected DNA polymorphisms associated with the repeat length of the tracts in the Japanese population, We also detected a microsatellite instability among the tracts in a cancer tissue sample.	UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; BERNUES J, 1990, NUCLEIC ACIDS RES, V18, P4067, DOI 10.1093/nar/18.14.4067; BLAHO JA, 1986, P NATL ACAD SCI USA, V37, P107; BLAHO JA, 1989, PROG NUCLEIC ACID RE, V37, P107; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DUALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FOX KR, 1992, NUCLEIC ACIDS RES, V20, P1235, DOI 10.1093/nar/20.6.1235; GUT SH, 1987, NUCLEIC ACIDS RES, V15, P9691, DOI 10.1093/nar/15.23.9691; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HEARNE CM, 1992, TRENDS GENET, V8, P288, DOI 10.1016/0168-9525(92)90256-4; ITO T, 1992, P NATL ACAD SCI USA, V89, P495, DOI 10.1073/pnas.89.2.495; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KIYAMA R, 1991, P NATL ACAD SCI USA, V88, P10450, DOI 10.1073/pnas.88.23.10450; KIYAMA R, 1994, J MOL BIOL, V237, P193, DOI 10.1006/jmbi.1994.1221; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LAPIDOT A, 1989, NUCLEIC ACIDS RES, V17, P883, DOI 10.1093/nar/17.3.883; LEBLANCSTRACESKI JM, 1994, GENOMICS, V19, P341, DOI 10.1006/geno.1994.1067; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LYAMICHEV VI, 1991, NUCLEIC ACIDS RES, V19, P1633, DOI 10.1093/nar/19.7.1633; MALKOV VA, 1993, NUCLEIC ACIDS RES, V21, P585, DOI 10.1093/nar/21.3.585; MALKOV VA, 1992, NUCLEIC ACIDS RES, V20, P4889, DOI 10.1093/nar/20.18.4889; MANOR H, 1988, J MOL EVOL, V27, P96, DOI 10.1007/BF02138367; MARTINEZBALBAS A, 1993, NUCLEIC ACIDS RES, V21, P2557, DOI 10.1093/nar/21.11.2557; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NOGUCHI CT, 1991, BLOOD, V78, P2548; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; STROBEL SA, 1991, SCIENCE, V254, P1639, DOI 10.1126/science.1836279; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; USDIN K, 1989, J BIOL CHEM, V264, P15681; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEINREB A, 1990, J BIOL CHEM, V265, P1352; WEINREB A, 1988, P NATL ACAD SCI USA, V85, P529, DOI 10.1073/pnas.85.2.529; WEISSENBACH J, 1993, CURR OPIN GENET DEV, V3, P414, DOI 10.1016/0959-437X(93)90114-5; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; WROGEMANN K, 1993, EXS, V67, P141; YOKOTA H, 1994, ANAL BIOCHEM, V219, P131, DOI 10.1006/abio.1994.1241	45	11	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9258	9264		10.1074/jbc.270.16.9258	http://dx.doi.org/10.1074/jbc.270.16.9258			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721845	hybrid			2022-12-25	WOS:A1995QU08900033
J	WONGKAJORNSILP, A; ROSENBERRY, TL				WONGKAJORNSILP, A; ROSENBERRY, TL			UPTAKE OF EXOGENOUS SN-1-ACYL-2-LYSO-PHOSPHATIDYLINOSITOL INTO HELA S3 CELLS - REACYLATION ON THE CELL-SURFACE AND METABOLISM TO GLUCOSAMINYL(ACYL)PHOSPHATIDYLINOSITOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; GLYCOINOSITOL PHOSPHOLIPID ANCHOR; BACILLUS-THURINGIENSIS; MAMMALIAN-CELLS; PHOSPHATIDYLINOSITOL; BIOSYNTHESIS; MEMBRANES; KINETICS; MUTANTS	A HeLa S3 subline is unusual in accumulating relatively large amounts of glucosaminyl(acyl)phosphatidylinositol (GlcN(acyl)PI), a derivative of phosphatidylinositol (PI) in which both GlcN and a fatty acid are linked to inositol hydroxyl groups (D, Sevlever, D, Humphrey, and T, L, Rosenberry, submitted for publication), This lipid is a proposed intermediate on the biosynthetic pathway for glycosyl-PI (GPI) anchors of membrane proteins, In this study we demonstrate for the first time that exogenous inositol phospholipids can enter this biosynthetic pathway and be metabolized to GlcN(acyl)PI. When HeLa S3 cells were incubated for 24 h with exogenous PI or sn-1-acyl-2-lyso-phosphatidylinositol (lyse-PI) labeled with H-3 in the inositol group, 25-30% of the label was recovered in cell-associated lipids and most of the remaining 70-75% in hydrophilic metabolites in the medium, The predominant labeled lipid was PI, with smaller amounts of lyso-PI, phosphatidylinositol 4-phosphate (PIP), and GlcN(acyl)PI. Both exogenous lipid precursors gave the same distribution of labeled lipids, and a similar distribution was observed for endogenous inositol phospholipids metabolically labeled with [H-3]inositol. Addition of excess inositol had no effect on the conversion of [H-3]lyso-PI to [H-3]GlcN(acyl)PI, indicating that the conversion did not result from breakdown to [H-3]inositol followed by resynthesis, The cellular orientation of incorporated PI and lyse-PI was determined by incubating cells at 4 degrees C with PI-specific phospholipase C (PI-PLC), This enzyme cleaves only PI and lyse-PI on the outer leaflet of the cell membrane, After 24-h incubation with either precursor, only about 15% of cell-associated [H-3]PI or [H-3]lyso-PI was on the outer leaflet, However, more than 60% of the [H-3]PI was on the outer leaflet after 1-h incubation with either precursor, suggesting that substantial sn-2 acylation of exogenous [H-3]lyso-PI occurred in the outer leaflet, This suggestion was confirmed by examining labeled lipids in cells after uptake of [H-3]lyso-PI at 4 degrees C, No transmembrane translocation of lyso-PI, PI phosphorylation, or PI glycosylation occurred at this temperature, but some sn-2 acylation was apparent and more than 90% of the [H-3]PI formed was on the outer leaflet, These data indicate that sn-2 acylation can occur in the outer leaflet of the cell membrane, perhaps by transacylation from other cell surface phospholipids.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHARMACOL, CLEVELAND, OH 44106 USA; MAHIDOL UNIV, SIRIRAJ HOSP, FAC MED, DEPT PHARMACOL, BANGKOK 10700, THAILAND	Case Western Reserve University; Mahidol University			Wongkajornsilp, Adisak/AAH-7668-2019	Wongkajornsilp, Adisak/0000-0002-3965-0997	NIDDK NIH HHS [DK38181] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1989, METHOD ENZYMOL, V172, P49; ARMSTRONG C, 1992, J BIOL CHEM, V267, P25347; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BESTERMAN JM, 1992, BIOCHEMISTRY-US, V31, P2046, DOI 10.1021/bi00122a022; BUTIKOFER P, 1990, J BIOL CHEM, V265, P16035; CATT KJ, 1989, ANNU REV MED, V40, P487; DARNELL JC, 1991, BIOCHIM BIOPHYS ACTA, V1084, P279, DOI 10.1016/0005-2760(91)90070-X; DEEG MA, 1992, J BIOL CHEM, V267, P18573; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERRELL JE, 1985, BIOCHEMISTRY-US, V24, P2857, DOI 10.1021/bi00333a007; GANONG BR, 1991, AM J MED SCI, V302, P304, DOI 10.1097/00000441-199111000-00009; GARDAM MA, 1989, BIOCHEMISTRY-US, V28, P884, DOI 10.1021/bi00428a072; HENDRICKSON HS, 1992, BIOCHEMISTRY-US, V31, P12169, DOI 10.1021/bi00163a028; HENNER DJ, 1988, NUCLEIC ACIDS RES, V16, P10383, DOI 10.1093/nar/16.21.10383; HIDAKA M, 1993, BIOCHEM BIOPH RES CO, V191, P571, DOI 10.1006/bbrc.1993.1256; HIGGINS JA, 1989, BIOCHEM J, V259, P913, DOI 10.1042/bj2590913; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOHENGASSER CJM, 1986, J BIOL CHEM, V261, P6255; LOW MG, 1977, BIOCHEM J, V162, P235, DOI 10.1042/bj1620235; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROSS TS, 1986, J BIOL CHEM, V261, P1119; SILVIUS JR, 1993, BIOCHEMISTRY-US, V32, P3153, DOI 10.1021/bi00063a030; SINGH N, 1994, MOL CELL BIOL, V14, P21, DOI 10.1128/MCB.14.1.21; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; TAKAHASHI M, 1993, J EXP MED, V177, P517, DOI 10.1084/jem.177.2.517; TING AE, 1990, J BIOL CHEM, V265, P5337; UEDA E, 1993, J BIOL CHEM, V268, P9998; VOLWERK JJ, 1992, J CELL PHYSIOL, V151, P613, DOI 10.1002/jcp.1041510322; WALTER EI, 1990, J IMMUNOL, V144, P1030; YAMASHINA M, 1990, NEW ENGL J MED, V323, P1184, DOI 10.1056/NEJM199010253231707	30	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9147	9153		10.1074/jbc.270.16.9147	http://dx.doi.org/10.1074/jbc.270.16.9147			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721829	hybrid			2022-12-25	WOS:A1995QU08900017
J	FORD, HL; ZAIN, SB				FORD, HL; ZAIN, SB			INTERACTION OF METASTASIS-ASSOCIATED MTS1 PROTEIN WITH NONMUSCLE MYOSIN	ONCOGENE			English	Article						MTS1; METASTASIS; PROTEIN-PROTEIN INTERACTIONS; MOTILITY; MYOSIN	CALCIUM-BINDING PROTEINS; MESSENGER-RNA; HEAVY-CHAIN; MOLECULAR-CLONING; CELLULAR MYOSIN; GENE-PRODUCT; EXPRESSION; CELLS; SEQUENCE; FAMILY	The mts1 gene codes for a 101 amino acid protein which belongs to the subfamily of S100 Ca2+-binding proteins and is overexpressed in metastatic cancers as compared to their nonmetastatic counterparts, While the Mts1 protein is putatively involved in cytoskeletal-membrane interactions, its exact physiological role is not known, In order to gain insight into the biological function of Mts1, its expression was monitored throughout mouse embryogenesis as well as in normal adult mouse tissues. In situ hybridizations of mouse embryos showed expression of mts1 mRNA to be highest in trophoblast cells of a day 8 old embryo, In normal adult mouse tissues, immunocytochemistry revealed Mts1 expression in a T-cell specific pattern in both the thymus and spleen, These results indicate that the expression of mts1 is prevalent in motile cell types, and to further elucidate the role of Mts1, gel overlay and GST-fusion protein experiments were performed to identify proteins that interact with the Mts1 protein, Nonmuscle myosin II was found to interact with Mts1, suggesting a role for Mts1 in the process of motility and lending credence to the hypothesis that Mtsl may enhance metastatic potential by increasing the motility of cancerous cells.	UNIV ROCHESTER,SCH MED,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NATIONAL CANCER INSTITUTE [R01CA062376, P30CA011198] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA11198, R01CA62376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGERER LM, 1987, APPL NEUROBIOLOGY, P42; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; DAVIES BR, 1993, ONCOGENE, V8, P999; DELEON M, 1991, J NEUROSCI RES, V29, P155; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ENGELKAMP D, 1992, BIOCHEMISTRY-US, V31, P10258, DOI 10.1021/bi00157a012; ENGELKAMP D, 1993, P NATL ACAD SCI USA, V90, P6547, DOI 10.1073/pnas.90.14.6547; FELDER CC, 1991, J PHARMACOL EXP THER, V257, P967; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; GENBACEV O, 1992, PLACENTA, V13, P439, DOI 10.1016/0143-4004(92)90051-T; GENBACEV O, 1993, PLACENTA, V14, P463, DOI 10.1016/S0143-4004(05)80466-7; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; GRIGORIAN M, 1994, ELECTROPHORESIS, V15, P463, DOI 10.1002/elps.1150150163; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAKIUCHI S, 1981, FEBS LETT, V126, P203, DOI 10.1016/0014-5793(81)80242-6; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KOHN EC, 1992, CANCER RES, V52, P3208; KOHN EC, 1994, CANCER RES, V54, P935; KORCZAK B, 1991, CELL GROWTH DIFFER, V2, P335; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIOTTA LA, 1983, LAB INVEST, V49, P636; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MIZUTANI T, 1993, CANCER, V72, P2083, DOI 10.1002/1097-0142(19931001)72:7<2083::AID-CNCR2820720705>3.0.CO;2-1; NGUYEN HT, 1982, P NATL ACAD SCI-BIOL, V79, P5230, DOI 10.1073/pnas.79.17.5230; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; OVADI J, 1992, CURR TOP CELL REGUL, V33, P105; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; SAHASRABUDHE DM, 1993, J IMMUNOL, V151, P6302; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIRRMACHER V, 1985, ADV CANCER RES, V43, P1, DOI 10.1016/S0065-230X(08)60942-2; SENIN VM, 1983, EKSP ONKOL, V5, P35; SENIN VM, 1984, VESTNIK USSR ACAD ME, V5, P85; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STRICKLAND S, 1992, CELL, V71, P355, DOI 10.1016/0092-8674(92)90503-5; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TAKENAGA K, 1994, BIOCHEM BIOPH RES CO, V202, P94, DOI 10.1006/bbrc.1994.1898; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; TANIGUCHI S, 1990, BIOCHEM BIOPH RES CO, V168, P520, DOI 10.1016/0006-291X(90)92352-Z; TOOTHAKER LE, 1991, BLOOD, V78, P1826; TULCHINSKY E, 1993, ONCOGENE, V8, P79; VALVERDE I, 1979, SCIENCE, V206, P225, DOI 10.1126/science.225798; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WALLACE RW, 1987, BIOCHEMISTRY-US, V26, P2766, DOI 10.1021/bi00384a017; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; WETERMAN MAJ, 1992, CANCER RES, V52, P1291	59	78	80	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1597	1605						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731714				2022-12-25	WOS:A1995QU68100016
J	DUPORT, C; BAYSSE, C; MICHELBRIAND, Y				DUPORT, C; BAYSSE, C; MICHELBRIAND, Y			MOLECULAR CHARACTERIZATION OF PYOCIN S3, A NOVEL S-TYPE PYOCIN FROM PSEUDOMONAS-AERUGINOSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; CYSTIC-FIBROSIS; DNASE; DETERMINANT; SEQUENCE; CLONING; GENES; AP41	The genetic determinant for the soluble pyocin S3 was isolated from a genomic library constructed in the plasmid pGV1122, of Pseudomonas aeruginosa strain P12 isolated from a cystic fibrosis patient. The nucleotide sequence of a 3270-base pair DNA fragment was determined, and the two structural genes, pyoS3A and pyoS3I, and the 3'- and 5'-flanking regions were localized. Transcription (Northern blot) analysis showed that the two genes were co-transcribed. The genes pyoS3A and pyoS3I code for polypeptides of 767 and 154 amino acids, respectively, with calculated molecular weights of 81,385 and 17,047. Pyocin S3 was produced in Escherichia coli from a plasmid and purified as a complex of two components (S3A and S3I) corresponding to the pyoS3A and pyoS3I gene products, respectively. The S3A component, like pyocin S3, had a killing effect involving DNase activity and was inhibited by the S3I protein. Comparisons of the predicted amino acid sequence of the two components of pyocin S3 to those of pyocins S1, S2, and AP41 indicate that pyocin S3 is a new type of S-type pyocin.			DUPORT, C (corresponding author), FAC MED BESANCON, BACTERIOL LAB, F-25030 BESANCON, FRANCE.			Baysse, Christine/0000-0003-1318-2192				BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; CARLOMAGNO MS, 1985, J BACTERIOL, V163, P362, DOI 10.1128/JB.163.1.362-368.1985; DERETIC V, 1989, BIO-TECHNOL, V7, P1250; FEGAN M, 1991, J CLIN MICROBIOL, V29, P2151, DOI 10.1128/JCM.29.10.2151-2157.1991; FYFE JAM, 1984, J CLIN MICROBIOL, V20, P47, DOI 10.1128/JCM.20.1.47-50.1984; Godard C, 1993, Eur J Med, V2, P117; Govan J. R. W., 1978, METHOD MICROBIOL, V10, P61, DOI 10.1016/S0580-9517(08)70660-3; GOVAN JRW, 1974, J GEN MICROBIOL, V80, P1; GOVAN JRW, 1986, SCAND J INFECT DIS, P31; HAMON Y, 1956, ANN I PASTEUR PARIS, V91, P82; HAMON Y, 1961, ANN I PASTEUR, V88, P193; HIGERD TB, 1967, J BACTERIOL, V93, P1976, DOI 10.1128/JB.93.6.1976-1986.1967; HOLLOWAY BW, 1960, J PATHOL BACTERIOL, V80, P448, DOI 10.1002/path.1700800237; ITO S, 1970, J GEN APPL MICROBIOL, V16, P205, DOI 10.2323/jgam.16.3_205; JACOB F, 1954, ANN I PASTEUR PARIS, V86, P149; KAGEYAMA M, 1964, J BIOCHEM-TOKYO, V55, P49, DOI 10.1093/oxfordjournals.jbchem.a127839; KIEFFER BL, 1991, GENE, P115; KURODA K, 1979, J BIOCHEM, V85, P7, DOI 10.1093/oxfordjournals.jbchem.a132332; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LEEMANS J, 1982, GENE, V19, P361, DOI 10.1016/0378-1119(82)90027-0; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MATSUI H, 1993, J BACTERIOL, V175, P1257, DOI 10.1128/JB.175.5.1257-1263.1993; OHKAWA I, 1980, J BIOCHEM-TOKYO, V87, P323, DOI 10.1093/oxfordjournals.jbchem.a132740; PATERSON AC, 1965, J GEN MICROBIOL, V39, P295, DOI 10.1099/00221287-39-3-295; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; Sambrook J, 1989, MOL CLONING LABORATO; SANO Y, 1984, J BACTERIOL, V158, P562, DOI 10.1128/JB.158.2.562-570.1984; SANO Y, 1981, J BACTERIOL, V146, P733, DOI 10.1128/JB.146.2.733-739.1981; SANO Y, 1993, J BACTERIOL, V175, P2907, DOI 10.1128/JB.175.10.2907-2916.1993; SANO Y, 1993, MOL GEN GENET, V237, P161, DOI 10.1007/BF00282797; SANO Y, 1993, J BACTERIOL, V175, P6179, DOI 10.1128/JB.175.19.6179-6185.1993; SANO Y, 1993, J BACTERIOL, V175, P912, DOI 10.1128/JB.175.3.912-915.1993; SANO Y, 1990, PSEUDOMONAS : BIOTRANSFORMATIONS, PATHOGENESIS, AND EVOLVING BIOTECHNOLOGY, P352; SAVIOZ A, 1993, MOL GEN GENET, V238, P74, DOI 10.1007/BF00279533; SCHATT E, 1989, J BACTERIOL, V171, P6218, DOI 10.1128/jb.171.11.6218-6226.1989; SEO YH, 1990, BIOCHEM BIOPH RES CO, V172, P455, DOI 10.1016/0006-291X(90)90694-I; SMITH AW, 1992, J BACTERIOL, V174, P4847, DOI 10.1128/JB.174.14.4847-4849.1992; TREDGETT MW, 1990, J MED MICROBIOL, V32, P169, DOI 10.1099/00222615-32-3-169; VLIEGENTHART JS, 1991, ANTIMICROB AGENTS CH, V35, P892, DOI 10.1128/AAC.35.5.892; WEST SEH, 1988, NUCLEIC ACIDS RES, V16, P9323, DOI 10.1093/nar/16.19.9323; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANISCHPERRON C, 1985, GENE, V33, P13	42	53	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8920	8927		10.1074/jbc.270.15.8920	http://dx.doi.org/10.1074/jbc.270.15.8920			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721800	hybrid			2022-12-25	WOS:A1995QT44800079
J	KIM, JH; LEE, KN; YI, GS; YU, MH				KIM, JH; LEE, KN; YI, GS; YU, MH			A THERMOSTABLE MUTATION LOCATED AT THE HYDROPHOBIC CORE OF ALPHA(1)-ANTITRYPSIN SUPPRESSES THE FOLDING DEFECT OF THE Z-TYPE VARIANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOBILE REACTIVE CENTER; ALPHA-1-PROTEINASE INHIBITOR; CONFORMATIONAL-CHANGES; BETA-SHEET; SITE LOOP; SERPINS; ALPHA-1-ANTITRYPSIN; INTACT; TRANSITION; STABILITY	A thermostable mutation, F51L, at the hydrophobic core of human alpha(1)-antitrypsin (alpha(1)AT) increased the conformational stability of the molecule by decreasing the unfolding rate significantly without altering the refolding rate, The mutation specifically influenced the transition between the native state and a compact intermediate, which retained similar to 70% of the far-UV CD signal, but which had most of the fluorescence signal already de quenched. The mutant alpha(1)AT protein was more resistant than the wild-type protein to the insertion of the tetradecapeptide mimicking the sequence of the reactive center loop, indicating that the mutation increases the closing of the central beta-sheet, the A-sheet, in the native state. The F51L mutation enhanced the folding efficiency of the Z-type (E342K) genetic variation, which causes aggregation of the molecule in the liver. It has been shown previously that the aggregation of the Z protein occurs via loop sheet polymerization, in which the reactive center loop of one molecule is inserted into the opening of the A-sheet of another molecule. Our results strongly suggest that the hydrophobic core of alpha(1)AT regulates the opening-closing of the A-sheet and that certain genetic variations that cause opening of the A-sheet can be corrected by inserting an additional stable mutation into the hydrophobic core.	KOREA ADV INST SCI & TECHNOL,GENET ENGN RES INST,PROT ENGN GRP,TAEJON 305333,SOUTH KOREA	Korea Advanced Institute of Science & Technology (KAIST)			Yi, Gwan-Su/A-7896-2011	Yi, Gwan-Su/0000-0003-0012-6546				BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; Bode W, 1991, CURR OPIN STRUC BIOL, V1, P45, DOI 10.1016/0959-440X(91)90010-Q; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; CROWTHER D C, 1992, Current Opinion in Biotechnology, V3, P399, DOI 10.1016/0958-1669(92)90169-J; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ENGH RA, 1990, PROTEIN ENG, V3, P469, DOI 10.1093/protein/3.6.469; FLETTERICK RJ, 1994, NAT STRUCT BIOL, V1, P201, DOI 10.1038/nsb0494-201; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; HERVE M, 1990, EUR J BIOCHEM, V191, P653, DOI 10.1111/j.1432-1033.1990.tb19171.x; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KWON KS, 1994, J BIOL CHEM, V269, P9627; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15338; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; PERKINS SJ, 1992, J MOL BIOL, V228, P1235, DOI 10.1016/0022-2836(92)90329-I; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1991, EUR J BIOCHEM, V202, P1147, DOI 10.1111/j.1432-1033.1991.tb16483.x; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251	29	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8597	8601		10.1074/jbc.270.15.8597	http://dx.doi.org/10.1074/jbc.270.15.8597			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721761	hybrid			2022-12-25	WOS:A1995QT44800037
J	KOEPP, AE; HEZARI, M; ZAJICEK, J; VOGEL, BS; LAFEVER, RE; LEWIS, NG; CROTEAU, R				KOEPP, AE; HEZARI, M; ZAJICEK, J; VOGEL, BS; LAFEVER, RE; LEWIS, NG; CROTEAU, R			CYCLIZATION OF GERANYLGERANYL DIPHOSPHATE TO TAXA-4(5),11(12)-DIENE IS THE COMMITTED STEP OF TAXOL BIOSYNTHESIS IN PACIFIC YEW	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE QUANTUM NMR; TAXUS-BREVIFOLIA; BARK; CHEMISTRY; AGENTS; H-1	The biosynthesis of taxol (paclitaxel) and related tax aids in Pacific yew (Taxus brevifolia) is thought to involve the cyclization of geranylgeranyl diphosphate to a taxadiene followed by extensive oxygenation of this diterpene olefin intermediate, A cell-free preparation from sapling yew stems catalyzed the conversion of [1-H-3]geranylgeranyl diphosphate to a cyclic diterpene oIefin that, when incubated with stem sections, was converted in good radiochemical yield to several highly functionalized taxanes, including 10-deacetyl baccatin III and taxol itself. Addition of the labeled olefin to a yew bark extract, followed by radiochemically guided fractionation, provided sufficient product to establish the structure as taxa-4(5),11(12)-diene by two-dimensional NMR spectroscopic methods, Therefore, the first dedicated step in taxol biosynthesis is the conversion of the universal diterpenoid precursor geranylgeranyl diphosphate to taxa-4(5),11(12)-diene, rather than to the 4(20),11(12)-diene isomer previously suggested an the basis of the abundance of taxoids with double bonds in these positions. The very common occurrence of taxane derivatives bearing the 4(20)-ene-5-oxy functional grouping, and the lack of oxygenated derivatives bearing a 4(5)-double bond, suggest that hydroxylation at C-5 of taxadiene with allylic rearrangement of the double bond is an early step in the conversion of this olefin intermediate to taxol.	WASHINGTON STATE UNIV, INST BIOL CHEM, PULLMAN, WA 99164 USA; WASHINGTON STATE UNIV, UNIV NMR SPECT CTR, PULLMAN, WA 99164 USA	Washington State University; Washington State University				Lewis, Norman/0000-0001-5742-032X	NATIONAL CANCER INSTITUTE [R37CA055254, R01CA055254] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55254] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1981, J MAGN RESON, V42, P501, DOI 10.1016/0022-2364(81)90272-9; BEGLEY MJ, 1990, TETRAHEDRON, V46, P4907, DOI 10.1016/S0040-4020(01)85602-7; BORMAN S, 1994, CHEM ENG NEWS, V72, P32, DOI 10.1021/cen-v072n008.p032; CRAGG GM, 1993, J NAT PROD, V56, P1657, DOI 10.1021/np50100a001; CRAGG GM, 1991, CANCER CELL-MON REV, V3, P233; DEMARCANO DP, 1969, J CHEM SOC CHEM COMM, P1282, DOI 10.1039/c29690001282; ELLIS D, 1993, 1993 P INT YEW RES C; FETTNETO AG, 1992, BIO-TECHNOL, V10, P1572, DOI 10.1038/nbt1292-1572; FLEMING PE, 1994, J AM CHEM SOC, V116, P4137, DOI 10.1021/ja00088a083; FLEMING PE, 1993, J AM CHEM SOC, V115, P805, DOI 10.1021/ja00055a072; FLOSS HG, 1995, TAXOL SCI APPLICATIO; GEORG GI, 1994, EXPERT OPIN THER PAT, V4, P109; GIBSON DM, 1993, PLANT CELL REP, V12, P479, DOI 10.1007/BF00236091; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GUENARD D, 1993, ACCOUNTS CHEM RES, V26, P160, DOI 10.1021/ar00028a005; GUERITTEVOEGELEIN F, 1987, J NAT PROD, V50, P9, DOI 10.1021/np50049a002; HARRISON JW, 1966, J CHEM SOC C, P1933, DOI 10.1039/j39660001933; HOLMES FA, 1995, ACS SYM SER, V583, P31; KELSEY RG, 1992, J NAT PROD, V55, P912, DOI 10.1021/np50085a010; KINGSTON DGI, 1991, PHARMACOL THERAPEUT, V52, P1, DOI 10.1016/0163-7258(91)90085-Z; KINGSTON DGI, 1993, PROG CHEM ORG NAT PR, V61, P1; KINGSTON DGI, 1995, TAXANE ANTICANCER AG, P203; LAFEVER RE, 1994, ARCH BIOCHEM BIOPHYS, V313, P139, DOI 10.1006/abbi.1994.1370; LEWINSOHN E, 1991, PLANT PHYSIOL, V96, P38, DOI 10.1104/pp.96.1.38; NETO AGF, 1992, PLANTA MED, V58, P464, DOI 10.1055/s-2006-961515; NICOLAOU KC, 1994, ANGEW CHEM INT EDIT, V33, P15, DOI 10.1002/anie.199400151; SATTERWHITE DM, 1988, J CHROMATOGR, V452, P61, DOI 10.1016/S0021-9673(01)81437-0; STIERLE A, 1993, SCIENCE, V260, P214, DOI 10.1126/science.8097061; STROBEL GA, 1992, PLANT SCI, V84, P65, DOI 10.1016/0168-9452(92)90209-5; STROBEL GA, 1993, PLANT SCI, V92, P1, DOI 10.1016/0168-9452(93)90060-D; VANCE NC, 1994, PHYTOCHEMISTRY, V36, P1241, DOI 10.1016/S0031-9422(00)89644-2; VIDENSEK N, 1990, J NAT PROD, V53, P1609, DOI 10.1021/np50072a039; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; West C. A., 1981, BIOSYNTHESIS ISOPREN, V1, P375; WHEELER NC, 1992, J NAT PROD, V55, P432, DOI 10.1021/np50082a005; WHEELER NC, 1993, J FOREST, V91, P15; WITHERUP KM, 1990, J NAT PROD, V53, P1249, DOI 10.1021/np50071a017; ZAMIR LO, 1992, TETRAHEDRON LETT, V33, P5235, DOI 10.1016/S0040-4039(00)79141-6; [No title captured]; [No title captured]	42	167	188	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8686	8690		10.1074/jbc.270.15.8686	http://dx.doi.org/10.1074/jbc.270.15.8686			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721772	hybrid			2022-12-25	WOS:A1995QT44800050
J	MENG, QH; BERGERON, J; SPARKS, DL; MARCEL, YL				MENG, QH; BERGERON, J; SPARKS, DL; MARCEL, YL			ROLE OF APOLIPOPROTEIN-A-I IN CHOLESTEROL TRANSFER BETWEEN LIPOPROTEINS - EVIDENCE FOR INVOLVEMENT OF SPECIFIC APOA-I DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; CELL-DERIVED CHOLESTEROL; UNESTERIFIED CHOLESTEROL; PLASMA-LIPOPROTEINS; PHOSPHATIDYLCHOLINE; ACYLTRANSFERASE; MECHANISM; LECITHIN; EXCHANGE; COMPLEXES	A series of monoclonal antibodies against epitopes spanning different domains of apoA-I have been tested for their effects on unesterified cholesterol transfer be tween low density lipoprotein (LDL) and well-defined homogenous lipoproteins reconstituted with phosphatidylcholine, cholesterol, and apoA-I (LpA-I). Antibodies 2G11 (reacting between residues 25 and 110), A05 (residues 25-82), A03 (residues 135-140), A44 and r5G9 (residues 149-186), and 4A12 (residues 173-205) significantly inhibit cholesterol transfer from LDL to Lp2A-I while they enhance transfer in the opposite direction, thus causing an increased net transfer to LDL. Most of these monoclonal antibodies (mAbs) also enhance phospholipid transfer to LDL but in a lesser and variable proportion relative to cholesterol. Their epitopes are mainly contained within domains that are predicted to be amphipathic alpha-helices. In contrast, mAbs 4H1 (residues 2-8), 3G10 (residues 96-121), and 5F6 (residues 116-141) have little or no effect on either cholesterol or phospholipid transfer, and the epitopes for these three mAbs have been shown in earlier studies to be structurally and functionally related, Their immunoreactivity responds similarly to variation in lipoprotein cholesterol content, and the antibodies binding to these sites compete with one another and have similar effects on the cholesterol esterification reaction. Thus, the current results are compatible with the hypothesis that they form an integrated domain with a common function in cholesterol metabolism, possibly as part of a hinge domain. Most mAbs were found to increase significantly the a-helicity of apoA-I in the Lp2A-I immunecomplexes, suggesting that they may increase the stability of the lipid-bound apoA-I, However, not unexpectedly, there is no correlation between the effects of mAbs on alpha-helicity and their effects on cholesterol or phospholipid transfer since each mAb has a discrete effect on these transfers. These studies demonstrate the specificity of LpA-I particles in cholesterol transport and document the existence of apoA-I domains with different functions in cholesterol transport.	UNIV OTTAWA,INST HEART,LIPOPROT & ATHEROSCLEROSIS GRP,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,DEPT PATHOL & LAB MED,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,DEPT BIOCHEM,OTTAWA,ON K1Y 4E9,CANADA	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa								AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; BAKA CL, 1994, J BIOL CHEM, V269, P10288; BIELICKI JK, 1992, J LIPID RES, V33, P1699; BITTMAN R, 1984, BIOCHIM BIOPHYS ACTA, V772, P117, DOI 10.1016/0005-2736(84)90034-8; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEN GC, 1986, METHOD ENZYMOL, V128, P519; FIELDING PE, 1994, BIOCHEMISTRY-US, V33, P6981, DOI 10.1021/bi00188a030; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; HANDA T, 1992, BIOCHEMISTRY-US, V31, P1415, DOI 10.1021/bi00120a018; HUANG YD, 1993, ARTERIOSCLER THROMB, V13, P445, DOI 10.1161/01.ATV.13.3.445; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1985, BIOCHEMISTRY-US, V24, P3508, DOI 10.1021/bi00335a018; LEBLOND L, 1991, J BIOL CHEM, V266, P6058; LETIZIA JY, 1991, BIOCHEMISTRY-US, V30, P866, DOI 10.1021/bi00217a041; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCHOOMUN J, 1994, BBA-LIPID LIPID MET, V1212, P319, DOI 10.1016/0005-2760(94)90206-2; LUNDKATZ S, 1984, BIOCHEMISTRY-US, V23, P1130, DOI 10.1021/bi00301a015; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; LUNDKATZ S, 1982, BIOCHEMISTRY-US, V21, P2964, DOI 10.1021/bi00541a025; MARCEL YL, 1987, J LIPID RES, V28, P768; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MASSEY JB, 1985, BIOCHEMISTRY-US, V24, P7110, DOI 10.1021/bi00346a014; MATZ CE, 1982, J BIOL CHEM, V257, P4541; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; MENG QH, 1993, J BIOL CHEM, V268, P16966; MENG QH, 1994, IN PRESS J BIOL CHEM; MIIDA T, 1990, BIOCHEMISTRY-US, V29, P10469, DOI 10.1021/bi00498a007; MILNE R, 1987, MOL IMMUNOL, V24, P127, DOI 10.1016/0161-5890(87)90084-8; NICHOLS AV, 1983, BIOCHIM BIOPHYS ACTA, V750, P353, DOI 10.1016/0005-2760(83)90040-1; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; PETIT E, 1987, BIOCHIM BIOPHYS ACTA, V919, P287, DOI 10.1016/0005-2760(87)90268-2; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; STECK TL, 1988, J BIOL CHEM, V263, P13023; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; TALL AR, 1978, BIOCHIM BIOPHYS ACTA, V513, P185, DOI 10.1016/0005-2736(78)90172-4; WILLIAMS PT, 1991, J LIPID RES, V31, P1131	40	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8588	8596		10.1074/jbc.270.15.8588	http://dx.doi.org/10.1074/jbc.270.15.8588			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721760	hybrid			2022-12-25	WOS:A1995QT44800036
J	RIESE, DJ; DIMAIO, D				RIESE, DJ; DIMAIO, D			AN INTACT PDGF SIGNALING PATHWAY IS REQUIRED FOR EFFICIENT GROWTH TRANSFORMATION OF MOUSE C127 CELLS BY THE BOVINE PAPILLOMAVIRUS E5 PROTEIN	ONCOGENE			English	Article						VIRAL ONCOGENE; PDGF RECEPTOR; GROWTH FACTOR RECEPTORS	EARLY REGION TRANSFORMATION; OPEN READING FRAME; FACTOR RECEPTOR; TUMORIGENIC TRANSFORMATION; MORPHOLOGIC TRANSFORMATION; DNA-SYNTHESIS; AMINO-ACIDS; GENE; TYPE-1; VIRUS	The bovine papillomavirus type 1 (BPV) E5 protein is a 44 amino acid, membrane-associated protein that induces growth transformation of cultured rodent and;bovine fibroblasts. In transformed fibroblasts, the BPV E5 protein activates the endogenous platelet-derived growth factor (PDGF) beta receptor, and the introduction of the PDGF beta receptor gene into heterologous cell types normally lacking PDGF beta receptor expression permits transformation by the E5 protein. However, neither the endogenous PDGF beta receptor nor its signaling pathway has been shown to be required for efficient growth transformation of fibroblasts by the BPV E5 gene. Here we have tested whether the endogenous PDGF beta receptor serves as a target for the BPV E5 protein in mouse C127 fibroblasts. We isolated variant C127 cell Lines that displayed reduced DNA synthesis in response to PDGF but a normal response to other mitogens, suggesting that they harbor specific defects in the PDGF signaling pathway. The variant lines also exhibited a specific reduction in the level of DNA synthesis induced by the acute expression of the BPV E5 gene, and a variant cell line containing a reduced level of PDGF beta receptor also displayed reduced stable growth transformation by the BPV E5 and v-sis oncogenes. These results provide genetic support for the model that the PDGF beta receptor signaling pathway is required for efficient growth transformation of C127 cells by the BPV E5 gene.	YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Yale University			Riese, David/AAF-3581-2020	Riese, David/0000-0002-8823-5802	NCI NIH HHS [CA37157, CA16038] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037157, R37CA037157, P01CA016038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGMAN P, 1988, ONCOGENE, V2, P453; BERNARD HU, 1985, EXP CELL RES, V158, P237, DOI 10.1016/0014-4827(85)90446-X; BURKHARDT A, 1987, EMBO J, V6, P2381, DOI 10.1002/j.1460-2075.1987.tb02515.x; COHEN BD, 1993, MOL CELL BIOL, V13, P6462, DOI 10.1128/MCB.13.10.6462; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; CUADRADO A, 1990, CELL GROWTH DIFFER, V1, P9; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DIMAIO D, 1991, ADV CANCER RES, V56, P133; DOTTO GP, 1985, NATURE, V318, P472; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; HORWITZ BH, 1989, J VIROL, V63, P4515, DOI 10.1128/JVI.63.11.4515-4519.1989; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KULKE R, 1991, J VIROL, V65, P4943, DOI 10.1128/JVI.65.9.4943-4949.1991; KULKE R, 1992, J VIROL, V66, P505, DOI 10.1128/JVI.66.1.505-511.1992; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; LEPTAK C, 1992, J VIROL, V66, P1833; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MEYER AN, 1994, P NATL ACAD SCI USA, V91, P4634, DOI 10.1073/pnas.91.11.4634; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; PETTI L, 1991, ORIGINS OF HUMAN CANCER, P707; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; RABSON MS, 1986, J VIROL, V60, P626, DOI 10.1128/JVI.60.2.626-634.1986; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SEFTON BM, 1978, J VIROL, V28, P957, DOI 10.1128/JVI.28.3.957-971.1978; SETTLEMAN J, 1989, MOL CELL BIOL, V9, P5563, DOI 10.1128/MCB.9.12.5563; SETTLEMAN J, 1988, P NATL ACAD SCI USA, V85, P9007, DOI 10.1073/pnas.85.23.9007; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STETTEN G, 1977, EXP CELL RES, V108, P447, DOI 10.1016/S0014-4827(77)80055-4; WATERS CM, 1992, J CELL PHYSIOL, V152, P253, DOI 10.1002/jcp.1041520206; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Zar J. H., 2009, BIOSTATISTICAL ANAL	48	39	40	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1431	1439						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731695				2022-12-25	WOS:A1995QR65100022
J	JI, Y; JONAS, A				JI, Y; JONAS, A			PROPERTIES OF AN N-TERMINAL PROTEOLYTIC FRAGMENT OF APOLIPOPROTEIN AI IN SOLUTION AND IN RECONSTITUTED HIGH-DENSITY-LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; RECEPTOR-BINDING DOMAIN; FUNCTIONAL-PROPERTIES; STRUCTURAL DOMAINS; MICELLAR COMPLEXES; PLASMA; ACTIVATION; PHOSPHATIDYLCHOLINES; PARTICLES; MEMBRANES	Limited proteolysis was used to study the domain structure and to produce a large N-terminal fragment of human apolipoprotein AI (apoAI), Digestion of reconstituted high density lipoprotein (rHDL) prepared with apoAI and dipalmitoyl phosphatidylcholine or palmitoyloleoyl phosphatidylcholine by chymotrypsin, trypsin, elastase, and subtilisin generated a major fragment of 22 kDa. Under milder conditions proteolysis of lipid-free apoAI produced a fragment of similar size, The fragments shared the same N terminus as intact apoAI, and the chymotryptic fragment had a molecular weight of 22,384 as determined by electrospray ionization mass spectrometry, Thus the fragment consists of the N-terminal 192 amino acid residues of apoAI, and the region around Tyr(192) seems to be especially accessible to proteases. In aqueous solution the fragment, apoAI-(1-192), had an alpha-helix content similar to that of apoAI (similar to 52%) but existed only as monomers and dimers, ApoAI-(1-192) lysed dimyristoyl phosphatidylcholine liposomes slowly compared with apoAI but did form rHDL complexes with palmitoyloleoyl phosphatidylcholine or dipalmitoyl phosphatidylcholine when prepared by the sodium cholate dialysis method, ApoAI-(1-192) rHDL exhibited sizes and size distributions distinct from apoAI: rHDL but displayed similar stability against denaturation, The isolated apoAI-(1-192) rHDLs retained a high ability to activate lecithin-cholesterol acyltransferase, comparable with the most effective apoAI rHDL, The results suggest that the C-terminal domain of apoAI is crucial for self-association and initial lipid binding but is not involved in specific lecithin-cholesterol acyltransferase activation.	UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					NHLBI NIH HHS [HL-16059] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016059] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN CM, 1993, BIOCHEM J, V290, P449, DOI 10.1042/bj2900449; BANKA CL, 1991, J BIOL CHEM, V266, P23886; BOGUSKI MS, 1986, J LIPID RES, V27, P1011; BOLIN DJ, 1994, J BIOL CHEM, V269, P7429; BYRNE RE, 1983, BIOCHEMISTRY-US, V22, P2894, DOI 10.1021/bi00281a018; CAMEJO G, 1969, BIOCHIM BIOPHYS ACTA, V175, P290, DOI 10.1016/0005-2795(69)90007-5; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Cleland W W, 1979, Methods Enzymol, V63, P103; CREIGHTON TE, 1983, PROTEINS STRUCTURES, P316; DALTON MB, 1993, J BIOL CHEM, V268, P19274; GRAHAM DL, 1987, J BIOL CHEM, V262, P7439; JONAS A, 1986, BIOCHIM BIOPHYS ACTA, V876, P474, DOI 10.1016/0005-2760(86)90034-2; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1991, J LIPID RES, V32, P97; JONAS A, 1993, J BIOL CHEM, V268, P1596; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1986, METHOD ENZYMOL, V128, P553; Jonas A., 1992, STRUCTURE FUNCTION A, P217; LINS L, 1993, BIOCHIM BIOPHYS ACTA, V1151, P137, DOI 10.1016/0005-2736(93)90096-I; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MATZ CE, 1982, J BIOL CHEM, V257, P4541; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MINNICH A, 1992, J BIOL CHEM, V267, P16553; MORRISON J, 1991, J BIOL CHEM, V266, P18780; MORRISON JR, 1992, J BIOL CHEM, V267, P13205; POWNALL HJ, 1978, BIOCHEMISTRY-US, V17, P1183, DOI 10.1021/bi00600a008; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SHORE VG, 1978, BIOCHIM BIOPHYS ACTA, V529, P319, DOI 10.1016/0005-2760(78)90075-9; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; STOKKE KT, 1971, SCAND J CLIN LAB INV, V27, P21, DOI 10.3109/00365517109080184; SWANEY JB, 1983, J LIPID RES, V24, P245; WALD JH, 1990, J BIOL CHEM, V265, P20037; WALD JH, 1990, J BIOL CHEM, V265, P20044; WETTERAU JR, 1988, J BIOL CHEM, V263, P6240; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	39	120	126	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11290	11297		10.1074/jbc.270.19.11290	http://dx.doi.org/10.1074/jbc.270.19.11290			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744765	hybrid			2022-12-25	WOS:A1995QX86500042
J	KIM, TK; ZHAO, YM; GE, H; BERNSTEIN, R; ROEDER, RG				KIM, TK; ZHAO, YM; GE, H; BERNSTEIN, R; ROEDER, RG			TATA-BINDING PROTEIN RESIDUES IMPLICATED IN A FUNCTIONAL INTERPLAY BETWEEN NEGATIVE COFACTOR NC2 (DR1) AND GENERAL FACTORS TFIIA AND TFIIB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; PREINITIATION COMPLEX; ACTIVATION DOMAIN; BASIC REPEAT; DNA-BINDING; INITIATION; INVITRO; TBP; MECHANISM	The TATA-binding protein (TBP) plays a key role in transcription initiation. Several negative cofactors (NC1, NC2, and Dr1) are known to interact with TBP in a manner that prevents productive interactions of transcription factors TFIIA and TFIIB with promoter-bound TBP. To gain insights into the regulatory interplay on the surface of TBP, we have employed mutant forms of TBP to identify amino acid residues important for interactions with the negative regulatory cofactor NC2 and the general factor TFIIB, The results show the involvement of distinct domains of TBP in these interactions. Residues (Lys-133, Lys-145, and Lys-151) in the basic repeat region are important for interactions with NC2, as well as with TFIIA (Buratowski, S., and Zhou, H. (1992) Science 255, 1130-1132; Lee, D. K,, DeJong, J., Hashimoto, S., Horikoshi, M., and Roeder, R. G. (1992) Mel. Cell. Biol. 12, 5189-5196), whereas a residue (Leu-189) in the second stirrup-like loop spanning S2' and S3' is required for interaction with TFIIB. In addition, we demonstrate that NC2 is identical to the previously cloned negative cofactor Drl. The implications of these results for TBP structure and function are discussed.			KIM, TK (corresponding author), ROCKEFELLER UNIV, BIOCHEM & MOLEC BIOL LAB, NEW YORK, NY 10021 USA.							ASO T, 1994, EMBO J, V13, P435, DOI 10.1002/j.1460-2075.1994.tb06278.x; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; GE H, 1994, J BIOL CHEM, V269, P17136; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; INOSTROZA JA, 1992, CELL, V70, P477; KIM K, 1994, J BIOL CHEM, V269, P4891; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM TK, 1994, NUCLEIC ACIDS RES, V22, P251, DOI 10.1093/nar/22.2.251; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KIM TK, 1993, J BIOL CHEM, V268, P20866; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	39	68	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10976	10981		10.1074/jbc.270.18.10976	http://dx.doi.org/10.1074/jbc.270.18.10976			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738039	hybrid			2022-12-25	WOS:A1995QW60100088
J	PELEG, S; SASTRY, M; COLLINS, ED; BISHOP, JE; NORMAN, AW				PELEG, S; SASTRY, M; COLLINS, ED; BISHOP, JE; NORMAN, AW			DISTINCT CONFORMATIONAL-CHANGES INDUCED BY 20-EPI ANALOGS OF 1-ALPHA,25-DIHYDROXYVITAMIN-D3 ARE ASSOCIATED WITH ENHANCED ACTIVATION OF THE VITAMIN-D-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; GENE; DIFFERENTIATION; BINDING; HORMONE; CELLS; METABOLISM; SEQUENCES; REQUIRES; GROWTH	The relative affinities of the 1 alpha,25-dihydroxyvitamin D-3 (1,25-D-3) analogues 20-epi-1 alpha,25-dihydroxyvitamin D-3 (IE) and 20-epi-22-oxa-24a,26a,27a-tri-homo-1 alpha,25-dihydroxyvitamin D-3 (ID) to the nuclear vitamin D receptor (VDR) are similar to that of 1,25 D-3, but their antiproliferative action is 1000-fold greater. We tested whether the greater antiproliferative effect of these analogues is due to a differential activation of the VDR. In ROS 17/2.8 cells, the effective doses required to produce 50% maximal stimulation (ED(50)) of transfected reporter genes driven by either the osteocalcin or the osteopontin vitamin D-response elements (VDRE) were 5 x 10(-9) M, 10(-10) M, and 10(-11) M for 1,25 D-3, ID, and IE, respectively. Similar results were obtained when recombinant human VDR was cotransfected into CV-1 cells with an osteocalcin VDRE-reporter plasmid. We found that in vitro the sensitivity of 1,25-D-3-induced and analogue-induced receptors to proteases was different. The ED(50) for binding to VDRE, as determined by electrophoretic mobility shift assays, was significantly higher for 1,25-D-3-induced than for analogue-induced VDR. The concentration of retinoid X receptor (RXR) was significantly lower in 1,25-D-3-induced than analogue-induced VDR complexes with VDRE. We therefore conclude that IE and ID augment transcriptional activity of VDR more than 1,25-D-3 does, by producing conformational changes that enhance dimerization of MDR with RXR. We suggest that these conformational changes are due to differences in the contact sites of the 20-epi analogues and 1,25-D-3 with the VDR.	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED SPECIALTIES,HOUSTON,TX 77030	University of California System; University of California Riverside; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK009012, R01DK009012] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672] Funding Source: Medline; NIDDK NIH HHS [DK-09012] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN GF, 1992, J BIOL CHEM, V267, P19513; AMENTO E P, 1987, Steroids, V49, P55, DOI 10.1016/0039-128X(87)90079-1; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BINDERUP L, 1991, BIOCHEM PHARMACOL, V42, P1565; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; DILWORTH FJ, 1994, BIOCHEM PHARMACOL, V47, P987; FARACHCARSON MC, 1991, ENDOCRINOLOGY, V129, P1878; HAUSSLER MR, 1986, ANNU REV NUTR, V6, P527, DOI 10.1146/annurev.nu.06.070186.002523; KOEFFLER HP, 1984, CANCER RES, V44, P5624; KUIL CW, 1994, MOL CELL ENDOCRINOL, V102, pR1, DOI 10.1016/0303-7207(94)90112-0; LIEBERHERR M, 1989, J BIOL CHEM, V264, P20403; NEMERE I, 1984, ENDOCRINOLOGY, V115, P1467; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; NORMAN AW, 1993, J BIOL CHEM, V268, P13811; OZONO K, 1990, J BIOL CHEM, V265, P21881; PELEG S, 1993, MOL ENDOCRINOL, V7, P999, DOI 10.1210/me.7.8.999; Peleg S, 1989, Henry Ford Hosp Med J, V37, P194; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; SCHWARTZ Z, 1992, ENDOCRINOLOGY, V130, P2495, DOI 10.1210/en.130.5.2495; SCULE R, 1990, CELL, V61, P497; SIMBOLICAMPBELL M, 1992, CELL SIGNAL, V4, P99, DOI 10.1016/0898-6568(92)90011-V; SIMBOLICAMPBELL M, 1993, J BIOL CHEM, V269, P3257; SONE T, 1991, J BIOL CHEM, V266, P23296; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; Wecksler W R, 1980, Methods Enzymol, V67, P488; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHOU JY, 1989, BLOOD, V74, P82; ZHOU JY, 1991, BLOOD, V78, P75	30	185	188	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10551	10558		10.1074/jbc.270.18.10551	http://dx.doi.org/10.1074/jbc.270.18.10551			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737990	hybrid			2022-12-25	WOS:A1995QW60100031
J	SAITOH, H; DASSO, M				SAITOH, H; DASSO, M			THE RCC1 PROTEIN INTERACTS WITH RAN, RANBP1, HSC70, AND A 340-KDA PROTEIN IN XENOPUS EXTRACTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; CHROMOSOME CONDENSATION; KARYOPHILIC PROTEINS; CELL-CYCLE; REGULATOR; CLEAVAGE; NUCLEUS; MITOSIS	RCC1 is an abundant, highly conserved, chromatin-associated protein whose function is necessary for the preservation of a properly ordered cell cycle, RCC1 is also necessary for numerous nuclear processes, including nuclear transport and RNA metabolism; and it functions enzymatically as a guanine nucleotide exchange factor for a small, ras related GTPase called Ran. Studies in several organisms suggest that RCC1 may be part of a large complex containing multiple proteins. There is also evidence that RCC1 associates with chromatin through other proteins and that the binding of the complex to chromatin varies within the cell cycle. In order to characterize this putative complex, we have identified a number of other proteins as candidate compo nents of the complex by their association with a GST-RCC1 fusion protein. Three of these proteins have previously been identified (Ran, RanBP1, and hsc70). The fourth protein is novel and has a molecular mass of 340 kDa. In this report, we discuss a preliminary characterization of the interactions between these proteins.	NICHHD,MOLEC EMBRYOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Dasso, Mary/0000-0002-5410-1371				ANDERSON CW, 1973, J VIROL, V106, P1445; BEDDOW AL, 1995, IN PRESS P NATL ACAD; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF RF, 1991, NATURE, V355, P80; BISCHOFF RF, 1995, EMBO J, V14, P705; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; GOLFARB DS, 1994, CURR BIOL, V4, P57; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Harlow E., 1988, ANTIBODIES LAB MANUA, V2nd, P479; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; LEE A, 1993, J CELL SCI, V106, P287; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MOORE MS, 1994, TRENDS BIOCHEM SCI, V19, P211, DOI 10.1016/0968-0004(94)90024-8; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; SEINO H, 1992, J CELL SCI, V102, P393; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8	26	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10658	10663		10.1074/jbc.270.18.10658	http://dx.doi.org/10.1074/jbc.270.18.10658			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738003	hybrid			2022-12-25	WOS:A1995QW60100046
J	BERGE, A; BJORCK, L				BERGE, A; BJORCK, L			STREPTOCOCCAL CYSTEINE PROTEINASE RELEASES BIOLOGICALLY-ACTIVE FRAGMENTS OF STREPTOCOCCAL SURFACE-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; CLOSELY LINKED GENES; BINDING PROTEIN; NUCLEOTIDE-SEQUENCE; IMMUNOGLOBULIN-G; CELL-SURFACE; RECEPTOR; PYOGENES; IDENTIFICATION; INFECTIONS	Streptococcus pyogenes are important pathogenic bacteria which produce an extracellular cysteine protein ase contributing to their virulence and pathogenicity. S. pyogenes also express surface molecules, M proteins, that are major virulence determinants due to their antiphagocytic property. In the present work live S. pyogenes bacteria of the M1 serotype were incubated with purified cysteine proteinase. Several peptides were solubilized, and analysis of their protein-binding properties and amino acid sequences revealed two internal fibrinogen-binding fragments of M1 protein (17 and 21 kDa, respectively), and a 36-kDa IgG-binding NH2-terminal fragment of protein H, an IgGFc-binding surface molecule, M protein also plays a role in streptococcal adherence, and removal of this and other surface proteins could promote bacterial dissemination, whereas the generation of soluble complexes between immunoglobulins and immunoglobulin-binding streptococcal surface proteins could be an etiological factor in the development of glomerulonephritis and rheumatic fever, Thus, in these serious complications to S. pyogenes infections immune complexes are found in affected organs. The cysteine proteinase also solubilized a 116-kDa internal fragment of C5a peptidase, another streptococcal surface protein, Activation of the complement system generates C5a, a peptide stimulating leukocyte chemotaxis, C5a-mediated granulocyte migration was blocked by the 116-kDa fragment. This mechanism, by which phagocytes could be prevented from reaching the site of infection, may also contribute to the pathogenicity and virulence of S. pyogenes.	LUND UNIV, DEPT CELL & MOLEC BIOL, MOLEC PATHOGENESIS SECT, S-22100 LUND, SWEDEN	Lund University								AKERSTROM B, 1992, J IMMUNOL, V148, P3238; AKESSON P, 1990, MOL IMMUNOL, V27, P523, DOI 10.1016/0161-5890(90)90071-7; AKESSON P, 1994, BIOCHEM J, V300, P877, DOI 10.1042/bj3000877; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BENNASR A, 1995, BIOCHEM J, V305, P173, DOI 10.1042/bj3050173; BERGE A, 1993, J BIOL CHEM, V268, P25417; BESSEN DE, 1992, INFECT IMMUN, V60, P124, DOI 10.1128/IAI.60.1.124-135.1992; BJORCK L, 1989, NATURE, V337, P385, DOI 10.1038/337385a0; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CHEN CC, 1990, J BIOL CHEM, V265, P3161; CLEARY PP, 1992, INFECT IMMUN, V60, P5219, DOI 10.1128/IAI.60.12.5219-5223.1992; DAHLBOGE H, 1989, GENE, V79, P325; ELLEN RP, 1972, INFECT IMMUN, V5, P826, DOI 10.1128/IAI.5.5.826-830.1972; ELLIOTT SD, 1945, J EXP MED, V81, P573, DOI 10.1084/jem.81.6.573; ENGLARD S, 1990, METHOD ENZYMOL, V182, P285; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; GERLACH D, 1983, ZBL BAKT-INT J MED M, V255, P221, DOI 10.1016/S0174-3031(83)80161-9; GOMI H, 1990, J IMMUNOL, V144, P4046; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; GRUBB A, 1982, INT ARCH ALLER A IMM, V67, P369, DOI 10.1159/000233049; HAANES EJ, 1992, J BACTERIOL, V174, P4967, DOI 10.1128/JB.174.15.4967-4976.1992; HAUSER AR, 1990, J BACTERIOL, V172, P4536, DOI 10.1128/jb.172.8.4536-4542.1990; HEATH DG, 1987, INFECT IMMUN, V55, P1233, DOI 10.1128/IAI.55.5.1233-1238.1987; HOLM SE, 1992, J INFECT DIS, V166, P31, DOI 10.1093/infdis/166.1.31; JOHNSON DR, 1992, J INFECT DIS, V166, P374, DOI 10.1093/infdis/166.2.374; KANTOR FS, 1965, J EXP MED, V121, P849, DOI 10.1084/jem.121.5.849; KAPUR V, 1993, P NATL ACAD SCI USA, V90, P7676, DOI 10.1073/pnas.90.16.7676; KAPUR V, 1993, MICROB PATHOGENESIS, V15, P327, DOI 10.1006/mpat.1993.1083; KASTERN W, 1992, J BIOL CHEM, V267, P12820; KRONVALL G, 1973, J IMMUNOL, V111, P1401; LAPENTA D, 1994, MOL MICROBIOL, V12, P873, DOI 10.1111/j.1365-2958.1994.tb01075.x; LINDAHL G, 1989, MOL MICROBIOL, V3, P239, DOI 10.1111/j.1365-2958.1989.tb01813.x; LINDAHL G, 1989, MOL GEN GENET, V216, P372, DOI 10.1007/BF00334378; LINDAHL G, 1990, EPIDEMIOL INFECT, V105, P87, DOI 10.1017/S0950268800047683; Liu T. Y., 1971, ENZYMES, VIII, P609; LO SS, 1984, ANAL BIOCHEM, V136, P89, DOI 10.1016/0003-2697(84)90309-9; MARTIN DR, 1993, J INFECT DIS, V167, P1112, DOI 10.1093/infdis/167.5.1112; NELSON RD, 1975, J IMMUNOL, V115, P1650; NELSON RD, 1981, INVESTIGATION PHAGOC, P19; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NILSON BHK, 1992, J BIOL CHEM, V267, P2234; PHILLIPS GN, 1981, P NATL ACAD SCI-BIOL, V78, P4689, DOI 10.1073/pnas.78.8.4689; Rentzsch G, 1970, Z Laryngol Rhinol Otol, V49, P391; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STENBERG L, 1992, MOL MICROBIOL, V6, P1185, DOI 10.1111/j.1365-2958.1992.tb01557.x; TAI JY, 1976, J BIOL CHEM, V251, P1955; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYLEWSKA SK, 1988, CURR MICROBIOL, V16, P209, DOI 10.1007/BF01568531; WEXLER DE, 1985, P NATL ACAD SCI USA, V82, P8144, DOI 10.1073/pnas.82.23.8144; WEXLER DE, 1983, INFECT IMMUN, V39, P239, DOI 10.1128/IAI.39.1.239-246.1983; WEXLER DE, 1985, INFECT IMMUN, V50, P757, DOI 10.1128/IAI.50.3.757-764.1985; YARNALL M, 1986, J IMMUNOL, V136, P2670	53	180	185	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9862	9867		10.1074/jbc.270.17.9862	http://dx.doi.org/10.1074/jbc.270.17.9862			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730368	hybrid			2022-12-25	WOS:A1995QV41700027
J	GAO, ZH; ZHI, G; HERRING, BP; MOOMAW, C; DEOGNY, L; SLAUGHTER, CA; STULL, JT				GAO, ZH; ZHI, G; HERRING, BP; MOOMAW, C; DEOGNY, L; SLAUGHTER, CA; STULL, JT			PHOTOAFFINITY-LABELING OF A PEPTIDE SUBSTRATE TO MYOSIN LIGHT-CHAIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RABBIT SKELETAL-MUSCLE; STEADY-STATE KINETICS; MGATP-BINDING SITE; INTRASTERIC REGULATION; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; SMOOTH-MUSCLE; CALMODULIN; ACTIVATION	The substrate binding properties of skeletal muscle myosin light chain kinase were investigated with a synthetic peptide containing the photoreactive amino acid p-benzoylphenylalanine (Bpa) incorporated amino-terminal of the phosphoacceptor serine (BpaKKRAAR-ATSNVFA), When photolyzed at 350 nm, the peptide was cross-linked stoichiometrically to myosin light chain kinase in a Ca2+/calmodulin-dependent manner, Peptide incorporation into kinase inhibited light chain phosphorylation, and the loss of kinase activity was proportional to the extent of peptide incorporated, After peptide I was incorporated into myosin light chain kinase, it was partially phosphorylated in the absence of Ca2+/calmodulin, The extent of phosphorylation increased in the presence of Ca2+/calmodulin. The cross-linked photoadduct was digested, labeled peptides were purified by high performance liquid chromatography, and sites of covalent modification were determined by amino acid sequencing and analysis, The covalent modification in the catalytic core occurred on Ile-373 (66%) and in a peptide containing residues Asn-422 to Met-437 (14%), respectively, Lys-572 in the autoinhibitory region accounted for 20% of the incorporated label, The coincident covalent modification of the autoinhibitory domain suggests that it is located near the catalytic site, Based upon a model of the catalytic core, the substrate peptide is predicted to bind in the cleft between the two lobes of the kinase, The orientation of the substrate peptide on myosin light chain kinase is similar to the orientation of the substrate recognition fragment, but not the high affinity binding fragment, of inhibitor peptide of cAMP-dependent protein kinase in the catalytic subunit of the cAMP-dependent protein kinase.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06296] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGCHI IC, 1992, MOL ENDOCRINOL, V6, P621, DOI 10.1210/me.6.4.621; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; GALLAGHER PJ, 1993, J BIOL CHEM, V268, P26578; GAO ZH, 1992, BIOCHEMISTRY-US, V31, P6126, DOI 10.1021/bi00141a024; GEUSS U, 1985, EUR J BIOCHEM, V153, P327, DOI 10.1111/j.1432-1033.1985.tb09305.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERRING BP, 1992, J BIOL CHEM, V267, P25945; HERRING BP, 1990, J BIOL CHEM, V265, P1724; HERRING BP, 1990, J BIOL CHEM, V265, P16588; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KAUER JC, 1986, J BIOL CHEM, V261, P695; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KENNELLY PJ, 1991, FEBS LETT, V286, P217, DOI 10.1016/0014-5793(91)80977-B; KENNELLY PJ, 1992, BIOCHEMISTRY-US, V31, P5394, DOI 10.1021/bi00138a022; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MICHNOFF CH, 1986, J BIOL CHEM, V261, P8320; MILLER WT, 1988, P NATL ACAD SCI USA, V85, P5429, DOI 10.1073/pnas.85.15.5429; MITCHELL RD, 1995, IN PRESS BIOCHEMISTR; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; STEWART JM, 1984, SOLID PHASE PEPTIDE, P63; STULL JT, 1991, HYPERTENSION, V17, P723, DOI 10.1161/01.HYP.17.6.723; STULL JT, 1986, ENZYMES, P113; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P414, DOI 10.1073/pnas.87.1.414; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; WALSH D A, 1992, Current Opinion in Cell Biology, V4, P241, DOI 10.1016/0955-0674(92)90039-F; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; ZHI G, 1994, J BIOL CHEM, V269, P24723; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	40	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10125	10135		10.1074/jbc.270.17.10125	http://dx.doi.org/10.1074/jbc.270.17.10125			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730316	hybrid			2022-12-25	WOS:A1995QV41700063
J	MANDRIOTA, SJ; SEGHEZZI, G; VASSALLI, JD; FERRARA, N; WASI, S; MAZZIERI, R; MIGNATTI, P; PEPPER, MS				MANDRIOTA, SJ; SEGHEZZI, G; VASSALLI, JD; FERRARA, N; WASI, S; MAZZIERI, R; MIGNATTI, P; PEPPER, MS			VASCULAR ENDOTHELIAL GROWTH-FACTOR INCREASES UROKINASE RECEPTOR EXPRESSION IN VASCULAR ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR-BINDING SITE; PLASMINOGEN-ACTIVATOR; INHIBITOR PAI-1; U937 MONOCYTES; HUMAN-TUMOR; ANGIOGENESIS; CLONING; CHAIN; DEGRADATION; ANTIBODIES	Vascular endothelial growth factor (VEGF) is a potent angiogenic factor and endothelial cell-specific mitogen that stimulates urokinase-type plasminogen activator (uPA) activity in vascular endothelial cells. Here, we report that VEGP increases the high affinity binding of uPA to the same cells and that this binding is prevented by a peptide corresponding to the uPA receptor (uPAR) binding growth factor-like domain of uPA. Ligand crosslinking, ligand blotting, and uPA-Sepharose affinity chromatography revealed an increase in a cell surface uPA binding protein that corresponds to the uPAR on the basis of its affinity for uPA, M(r) of 50,000-55,000, and phosphatidylinositol-specific phospholipase C sensitivity. By Scatchard analysis, VEGF increased the number of uPAR molecules by 2.83.5 fold and concomitantly decreased their affinity for uPA By northern blotting uPAR mRNA was increased in a dose- and time dependent manner in response to VEGF. Taken together, these findings demonstrate that VEGF-induced angiogenesis is accompanied by increased uPAR expression and uPA activity on the endothelial cell surface. These observations are consistent with the notion that the uPA-uPAR interaction facilitates cellular invasion.	UNIV GENEVA, MED CTR, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND; UNIV PAVIA, DIPARTIMENTO GENET & MICROBIOL, I-27100 PAVIA, ITALY; GENENTECH INC, DEPT CARDIOVASC RES, San Francisco, CA 94080 USA; HEART & STROKE FDN CANADA, OTTAWA, ON K1N 9M2, CANADA	University of Geneva; University of Pavia; Roche Holding; Genentech			Mazzieri, Roberta/C-9773-2015; Pepper, Michael S./M-6143-2014	Mazzieri, Roberta/0000-0002-5172-0927; Pepper, Michael S./0000-0001-6406-2380; Mignatti, Paolo/0000-0002-8157-457X				APPELLA E, 1987, J BIOL CHEM, V262, P4437; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BUSSO N, 1986, J BIOL CHEM, V261, P9309; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark ER, 1932, AM J ANAT, V51, P49, DOI 10.1002/aja.1000510104; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DUMLER I, 1994, FEBS LETT, V343, P103, DOI 10.1016/0014-5793(94)80298-X; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FERRARA N, 1991, METHOD ENZYMOL, V198, P391; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FIBBI G, 1990, EXP CELL RES, V187, P33, DOI 10.1016/0014-4827(90)90112-N; FISHER R, 1985, J BIOL CHEM, V260, P1223; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FURIE MB, 1984, J CELL BIOL, V98, P1033, DOI 10.1083/jcb.98.3.1033; GROSS JL, 1982, J CELL BIOL, V95, P974, DOI 10.1083/jcb.95.3.974; HADDOCK RC, 1991, J BIOL CHEM, V266, P21466; HOLLAS W, 1991, CANCER RES, V51, P3690; HOYERHANSEN G, 1992, J BIOL CHEM, V267, P18224; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; KRATZSCHMAR J, 1993, GENE, V125, P177, DOI 10.1016/0378-1119(93)90325-W; KRISTENSEN P, 1984, FEBS LETT, V168, P33, DOI 10.1016/0014-5793(84)80201-X; LARSSON LI, 1984, J CELL BIOL, V98, P894, DOI 10.1083/jcb.98.3.894; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; NUSRAT AR, 1991, J CLIN INVEST, V87, P1091, DOI 10.1172/JCI115070; OSSOWSKI L, 1991, CANCER RES, V51, P274; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y; PEPPER MS, 1994, EXP CELL RES, V210, P298, DOI 10.1006/excr.1994.1042; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PYKE C, 1991, AM J PATHOL, V138, P1059; QUAX PHA, 1991, CELL REGUL, V2, P793, DOI 10.1091/mbc.2.10.793; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SAKSELA O, 1987, J CELL BIOL, V105, P957, DOI 10.1083/jcb.105.2.957; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; TSAFRIRI A, 1989, ENDOCRINOLOGY, V124, P415, DOI 10.1210/endo-124-1-415; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; VASSALLI JD, 1994, FIBRINOLYSIS, V8, P172, DOI 10.1016/0268-9499(94)90715-3; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; WEI Y, 1994, J BIOL CHEM, V269, P32380	65	235	243	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9709	9716		10.1074/jbc.270.17.9709	http://dx.doi.org/10.1074/jbc.270.17.9709			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730348	Green Published, hybrid			2022-12-25	WOS:A1995QV41700006
J	ROSIERS, CD; DIDONATO, L; COMTE, B; LAPLANTE, A; MARCOUX, C; DAVID, F; FERNANDEZ, CA; BRUNENGRABER, H				ROSIERS, CD; DIDONATO, L; COMTE, B; LAPLANTE, A; MARCOUX, C; DAVID, F; FERNANDEZ, CA; BRUNENGRABER, H			ISOTOPOMER ANALYSIS OF CITRIC-ACID CYCLE AND GLUCONEOGENESIS IN RAT-LIVER - REVERSIBILITY OF ISOCITRATE DEHYDROGENASE AND INVOLVEMENT OF ATP-CITRATE LYASE IN GLUCONEOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KREBS CYCLE; HEPATOCYTE HETEROGENEITY; HEPATIC GLUCONEOGENESIS; QUANTITATIVE-ANALYSIS; GLYCOGEN REPLETION; PERFUSED LIVERS; C-14 TRACER; METABOLISM; GLUCOSE; PYRUVATE	We conducted an extensive mass isotopomer analysis of citric acid cycle and gluconeogenic metabolites isolated from livers of overnight fasted rats perfused with 4 mM glucose, 0.2 mM octanoate, 1 mM [U-C-13(3)]lactate, and 0.2 mM [U-C-13(3)]pyruvate, in the anterograde or retrograde mode, In both perfusion modes, two distinct isotopomer patterns were observed: (i) those of phosphoenolpyruvate, glucose, malate, and aspartate and (ii) those of citrate, alpha-ketoglutarate, glutamate, and glutamine. Key citric acid cycle parameters and, hence, rates of gluconeogenesis, calculated (Lee. W.-N. P. (1989) J. Biol. Chem. 264, 13002-13004 and Lee, W.-N. P. (1993) J. Biol. Chem. 268, 25522-25526) from our mass isotopomer data did not only vary, but lead to conclusions inconsistent with Lee's citric acid cycle model, Compared to lactate and pyruvate uptake, which sets an upper limit to glucose production, rates of gluconeogenesis calculated (i) with the phosphoenolpyruvate and citrate data were similar, but those calculated (ii) with the glutamate data amounted to only 60%, which is unlikely, All these conclusions are independent of the perfusion modes, We provide evidence that the following processes contribute to the observed labeling discrepancy: (i) the reversibility of the isocitrate dehydrogenase reaction and (ii) an active citrate cleavage pathway for the transfer of the oxaloacetate carbon skeleton from mitochondria to the cytosol. Also, a good fit of our labeling data was obtained with a model of citric acid cycle and gluconeogenesis which we developed to incorporate the above reactions (Fernandez, C. A., and Des Rosiers, C. (1995) J. Biol. Chem. 270, 10037-10042), The following conclusions can be drawn from the calculated reaction rates: (i) about half of the lactate conversion to glucose occurs via the citrate cleavage pathway, (ii) the flux through the reversal of the isocitrate dehydrogenase reaction is almost as fast as that through the citrate synthase reaction, and (iii) the Bur through citrate synthase and alpha-ketoglutarate dehydrogenase is 1.6 and 3.2-fold that through pyruvate carboxylase, respectively.	UNIV MONTREAL, DEPT NUTR, MONTREAL, PQ H3C 3J7, CANADA; UNIV MONTREAL, DEPT BIOCHEM, MONTREAL, PQ H3C 3J7, CANADA; CASE WESTERN RESERVE UNIV, DEPT NUTR, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT BIOMED ENGN, CLEVELAND, OH 44106 USA	Universite de Montreal; Universite de Montreal; Case Western Reserve University; Case Western Reserve University			Rosiers, Christine Des/O-6285-2014		NIDDK NIH HHS [DK35543] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035543] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARANYAI JM, 1989, BIOCHEM J, V258, P121, DOI 10.1042/bj2580121; BARTELS H, 1987, FEBS LETT, V221, P277, DOI 10.1016/0014-5793(87)80940-7; Bergmeyer H.U., 1974, METHOD ENZYMAT AN, V4, P1696; Bergmeyer H.U., 1974, METHOD ENZYMAT AN, VVol. 3., P1196; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN, P1836; Bernt E., 1974, METHODS ENZYMATIC AN, P1704, DOI DOI 10.1016/B978-0-12-091304-6.50017-3; BEYLOT M, 1993, ANAL BIOCHEM, V212, P526, DOI 10.1006/abio.1993.1363; BRUNENGRABER H, 1973, J BIOL CHEM, V248, P2656; COHEN SM, 1983, J BIOL CHEM, V258, P4294; DADAMO AF, 1965, J BIOL CHEM, V240, P613; DESROSIERS C, 1994, J BIOL CHEM, V269, P27179; DESROSIERS C, 1994, P INT FEDERATION AUT, P354; DIDONATO L, 1993, J BIOL CHEM, V268, P4170; DIDONATO L, 1993, FASEB J, V7, pA866; DIDONATO L, 1992, FASEB J, V6, pA1520; DUSZYNSKI J, 1978, J BIOL CHEM, V253, P6149; ESENMO E, 1992, AM J PHYSIOL, V263, pE36, DOI 10.1152/ajpendo.1992.263.1.E36; FERNANDEZ C, 1994, P INT FEDERATION AUT, P367; FERNANDEZ CA, 1995, J BIOL CHEM, V270, P10037, DOI 10.1074/jbc.270.17.10037; GUTMANN I, 1974, METHOD ENZYMAT AN, V4, P1464; HAUSSINGER D, 1983, EUR J BIOCHEM, V133, P269, DOI 10.1111/j.1432-1033.1983.tb07458.x; HEATH DF, 1985, BIOCHEM J, V227, P851, DOI 10.1042/bj2270851; HEATH DF, 1972, BIOCHEM J, V127, P453, DOI 10.1042/bj1270453; HETENYI G, 1979, CAN J PHYSIOL PHARM, V57, P767, DOI 10.1139/y79-119; HETENYI G, 1982, FED PROC, V41, P104; HETENYI G, 1982, QUANTITATION PHYSL M, P201; JUNGERMANN K, 1992, ENZYME, V46, P33, DOI 10.1159/000468777; KALDERON B, 1986, FEBS LETT, V204, P29, DOI 10.1016/0014-5793(86)81381-3; KATZ J, 1993, J BIOL CHEM, V268, P25509; Katz J, 1976, Curr Top Cell Regul, V10, P237; KATZ J, 1985, AM J PHYSIOL, V248, pR391, DOI 10.1152/ajpregu.1985.248.4.R391; KATZ J, 1989, J BIOL CHEM, V264, P12994; KELLEHER JK, 1985, AM J PHYSIOL, V248, pE252, DOI 10.1152/ajpendo.1985.248.2.E252; KELLEHER JK, 1986, AM J PHYSIOL, V250, pE296, DOI 10.1152/ajpendo.1986.250.3.E296; KORNACKER MS, 1965, BIOCHEM J, V94, P209, DOI 10.1042/bj0940209; KREBS HA, 1966, BIOCHEM J, V101, P242, DOI 10.1042/bj1010242; LANDAU BR, 1993, AM J PHYSIOL, V265, pE636, DOI 10.1152/ajpendo.1993.265.4.E636; LEE WNP, 1991, BIOCHEM MED METAB B, V45, P298, DOI 10.1016/0885-4505(91)90034-I; LEE WNP, 1993, J BIOL CHEM, V268, P25522; Lund P., 1974, METHODS ENZYMATIC AN, V4, P1719; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; MULLHOFER G, 1977, EUR J BIOCHEM, V75, P331, DOI 10.1111/j.1432-1033.1977.tb11533.x; MULLHOFER G, 1977, EUR J BIOCHEM, V75, P319, DOI 10.1111/j.1432-1033.1977.tb11532.x; MULLHOFER G, 1972, H-S Z PHYSIOL CHEM, V353, P1461, DOI 10.1515/bchm2.1972.353.2.1461; ROGNSTAD R, 1977, J BIOL CHEM, V252, P1831; ROGNSTAD R, 1988, Medical Science Research, V16, P293; ROGNSTAD R, 1993, BIOCHEM ARCH, V9, P15; ROSIERS CD, 1988, ANAL BIOCHEM, V173, P96, DOI 10.1016/0003-2697(88)90165-0; ROSIERS CD, 1991, J BIOL CHEM, V266, P1574; SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X; SCHUMANN WC, 1991, J BIOL CHEM, V266, P6985; SHULMAN GI, 1987, J CLIN INVEST, V80, P387, DOI 10.1172/JCI113084; SOKELL S, 1976, USE ISOLATED LINEAR, P29; SRERE PA, 1993, BIOL CHEM H-S, V374, P833; SRERE PA, 1967, BIOCHEM BIOPH RES CO, V26, P556, DOI 10.1016/0006-291X(67)90101-5; STERNICZUK A, 1991, EUR J BIOCHEM, V196, P151, DOI 10.1111/j.1432-1033.1991.tb15798.x; STRISOWER EH, 1952, J BIOL CHEM, V198, P115; Takeda Y., 1969, METHOD ENZYMOL, V13, P153, DOI [DOI 10.1016/0076-6879(69)13032-3, 10.1016/0076-6879(69)13032-3]; TISSOT S, 1990, DIABETOLOGIA, V33, P449, DOI 10.1007/BF00405104; TSERNG KY, 1983, AM J PHYSIOL, V245, pE476, DOI 10.1152/ajpendo.1983.245.5.E476; WILLIAMSON JR, 1969, J BIOL CHEM, V244, P4617	61	100	100	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10027	10036		10.1074/jbc.270.17.10027	http://dx.doi.org/10.1074/jbc.270.17.10027			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730304	hybrid			2022-12-25	WOS:A1995QV41700049
J	MATSUMOTO, K; OKUWAKI, M; KAWASE, H; HANDA, H; HANAOKA, F; NAGATA, K				MATSUMOTO, K; OKUWAKI, M; KAWASE, H; HANDA, H; HANAOKA, F; NAGATA, K			STIMULATION OF DNA-TRANSCRIPTION BY THE REPLICATION FACTOR FROM THE ADENOVIRUS GENOME IN A CHROMATIN-LIKE STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-ORIENTED TRANSCRIPTION; MAJOR LATE PROMOTER; RNA POLYMERASE-II; CORE PROTEIN; VIRAL-DNA; INVITRO; INITIATION; BINDING; ACTIVATION; INFECTION	Adenovirus (Ad) genome DNA is complexed with viral core proteins in the virus particle and in host cells during the early stages of infection. This DNA protein complex, called Ad core, is thought to be the template for transcription and DNA replication in infected cells. The Ad core functioned as template for DNA replication in the cell-free system consisting of viral replication proteins, uninfected HeLa nuclear extracts, and a novel factor, template activating factor-I (TAF-I) that we have isolated from uninfected HeLa cytoplasmic fractions. The Ad core did not function as an efficient template in the cell-free transcription system with nuclear extracts of uninfected HeLa cells. The addition of TAF-I resulted in the stimulation of transcription from E1A and ML promoters on the Ad core, TAF-I was required, at least, for the formation of preinitiation complexes. These observations suggest that, in addition to factors essential for transcription on naked DNA template, the factor such as TAF-I needed for replication of the Ad core is also required for transcription from the Ad genome in a chromatin-like structure.	TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,DEPT BIOMOLEC ENGN,YOKOHAMA,KANAGAWA 227,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN; INST PHYS & CHEM RES,CELLULAR PHYSIOL LAB,SAITAMA 35101,JAPAN	Tokyo Institute of Technology; RIKEN			Matsumoto, Ken/F-9083-2013; Okuwaki, Mitsuru/R-3038-2019	Matsumoto, Ken/0000-0002-7864-3394; Okuwaki, Mitsuru/0000-0003-2118-442X				ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; BROWN DT, 1975, J VIROL, V16, P366, DOI 10.1128/JVI.16.2.366-387.1975; BURATOWSKI S, 1993, SCIENCE, V260, P37, DOI 10.1126/science.8465198; CHATTERJEE PK, 1986, EMBO J, V5, P1633, DOI 10.1002/j.1460-2075.1986.tb04406.x; CONTRERAS R, 1982, NATURE, V300, P500, DOI 10.1038/300500a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GODING CR, 1983, EMBO J, V2, P339, DOI 10.1002/j.1460-2075.1983.tb01428.x; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; JANSENDURR P, 1989, J VIROL, V63, P5124, DOI 10.1128/JVI.63.12.5124-5132.1989; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KAPLAN LM, 1979, P NATL ACAD SCI USA, V76, P5534, DOI 10.1073/pnas.76.11.5534; KOIKEDA S, 1990, BIOCHIM BIOPHYS ACTA, V1048, P85, DOI 10.1016/0167-4781(90)90026-X; KORN R, 1986, VIROLOGY, V150, P342, DOI 10.1016/0042-6822(86)90299-0; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEITH IR, 1989, J GEN VIROL, V70, P3235, DOI 10.1099/0022-1317-70-12-3235; MATSUMOTO K, 1989, BIOCHEM BIOPH RES CO, V164, P1212, DOI 10.1016/0006-291X(89)91798-1; MATSUMOTO K, 1993, J BIOL CHEM, V268, P10582; MATSUMOTO K, 1991, FEBS LETT, V280, P53, DOI 10.1016/0014-5793(91)80202-E; MAVROMARANAZOS P, 1987, VIROLOGY, V161, P593, DOI 10.1016/0042-6822(87)90156-5; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NAKANISHI Y, 1986, BIOCHEM BIOPH RES CO, V136, P86, DOI 10.1016/0006-291X(86)90880-6; RUSSELL WC, 1971, J GEN VIROL, V11, P35, DOI 10.1099/0022-1317-11-1-35; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID A, 1992, CELL, V71, P853, DOI 10.1016/0092-8674(92)90560-Y; TAMANOI F, 1982, P NATL ACAD SCI-BIOL, V79, P2221, DOI 10.1073/pnas.79.7.2221; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; THOMAS GP, 1980, CELL, V22, P523; TOTH M, 1992, NUCLEIC ACIDS RES, V20, P5143, DOI 10.1093/nar/20.19.5143; WEIL PA, 1979, CELL, V18, P469; WOLFFE AP, 1991, J CELL SCI, V99, P201; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x	32	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9645	9650		10.1074/jbc.270.16.9645	http://dx.doi.org/10.1074/jbc.270.16.9645			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721897	hybrid			2022-12-25	WOS:A1995QU08900086
J	PADMAKUMAR, R; BANERJEE, R				PADMAKUMAR, R; BANERJEE, R			EVIDENCE FROM ELECTRON-PARAMAGNETIC-RESONANCE SPECTROSCOPY OF THE PARTICIPATION OF RADICAL INTERMEDIATES IN THE REACTION CATALYZED BY METHYLMALONYL-COENZYME-A MUTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT METHIONINE SYNTHASE; COA MUTASE; ESCHERICHIA-COLI; CLOSTRIDIUM-THERMOACETICUM; ADENOSYLCOBALAMIN; REARRANGEMENT; ENZYME; MODEL; COB(II)ALAMIN; MECHANISM	Recombinant methylmalonyl-coenzyme A (CoA) mutase from Propionibacterium shermanii has been purified 20-fold to near homogeneity in a highly active form, Neither the apoenzyme (the form in which the enzyme is isolated) nor the holoenzyme (reconstituted with the cofactor, adenosylcobalamin) has an electron paramagnetic resonance (EPR) spectrum associated with it, However, the addition of either the substrate, methyl malonyl CoA, or the product, succinyl-CoA results in the appearance of a transient EPR signal, The signal has hyperfine features that indicate coupling of the unpaired electron to the cobalt nucleus, In the presence of [CD3]methylmalonyl-CoA, an EPR signal is also seen and is similar to that obtained in the presence of protiated substrate, Power saturation studies reveal the presence of two components, a slow relaxing species (with an apparent g value of 2.11) and a fast relaxing species (with an apparent g value of 2.14) that can be partially resolved at low temperature and high power, The EPR-active intermediate is observed under catalytic conditions and is approximately midway in its resonance position between a free radical and cob(II)alamin, It is postulated to represent an exchange coupled cob(II)alamin free radical pair, The signal bears close resemblance to those observed with partially dehydrated polycrystalline adenosylcobalamin following laser photolysis (Ghanekar, V, D., Lin, R. J., Coffman, R, E., and Blakley, R, L, (1981) Biochem. Biophys, Res, Commun, 101, 215-221) and with the adenosylcobalamin-dependent ribonucleotide reductase under freeze-quench conditions (Orme-Johnson, W, H., Beinert, H., and Blakley, R, L, (1974) J. Biol, Chem, 249, 2338-2343), When cob(II)alamin is generated under noncatalytic conditions (i.e. in the presence of propionyl-CoA or by electrochemical reduction of enzyme-bound hydroxocob(III)alamin), a different EPR signal is observed with g perpendicular to = 2.26 and g parallel to = 2.00, typical of base on cob(II)alamin.	UNIV NEBRASKA,DEPT BIOCHEM,LINCOLN,NE 68583	University of Nebraska System; University of Nebraska Lincoln					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045776, R01DK045776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAGAM A, 1986, ELECTRON PARAMAGNETI, P491; ALLEN SHG, 1964, J BACTERIOL, V87, P171, DOI 10.1128/JB.87.1.171-187.1964; AN G, 1980, GENE, V12, P33, DOI 10.1016/0378-1119(80)90013-X; BABIOR B, 1969, BIOCHEM BIOPH RES CO, V34, P441, DOI 10.1016/0006-291X(69)90401-X; BABIOR BM, 1974, J BIOL CHEM, V249, P4537; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; BEUTTNER GR, 1977, BIOCHIM BIOPHYS ACTA, V480, P495; CHANEKAR VD, 1981, BIOCHEM BIOPH RES CO, V101, P215; CHOI GY, 1990, P NATL ACAD SCI USA, V87, P3174, DOI 10.1073/pnas.87.8.3174; COCKLE SA, 1972, J AM CHEM SOC, V94, P275, DOI 10.1021/ja00756a050; COFFMAN RE, 1976, BIOCHIM BIOPHYS ACTA, V444, P307, DOI 10.1016/0304-4165(76)90247-6; DOWD P, 1992, J AM CHEM SOC, V114, P7949, DOI 10.1021/ja00046a073; FINKE RG, 1990, MOLECULAR MECHANISMS IN BIOORGANIC PROCESSES, P244; FINLAY TH, 1973, J BIOL CHEM, V248, P1285; FRASCA V, 1988, BIOCHEMISTRY-US, V27, P8458, DOI 10.1021/bi00422a025; HALPERN J, 1985, SCIENCE, V227, P869, DOI 10.1126/science.2857503; HARDER SR, 1989, ANAL BIOCHEM, V181, P283, DOI 10.1016/0003-2697(89)90244-3; HARDER SR, 1989, BIOCHEMISTRY-US, V28, P9080, DOI 10.1021/bi00449a019; HARKINS TT, 1994, SCIENCE, V263, P958, DOI 10.1126/science.8310292; HAY BP, 1987, J AM CHEM SOC, V109, P8012, DOI 10.1021/ja00260a011; HULL WE, 1988, EUR J BIOCHEM, V173, P191, DOI 10.1111/j.1432-1033.1988.tb13984.x; KEEP NH, 1993, BIOCHEM J, V295, P387, DOI 10.1042/bj2950387; KELLERMEYER RW, 1964, J BIOL CHEM, V239, P2562; LEUTBECHER U, 1992, FEBS LETT, V307, P144, DOI 10.1016/0014-5793(92)80754-5; MATSUI SM, 1983, NEW ENGL J MED, V308, P857, DOI 10.1056/NEJM198304143081501; MCKIE N, 1990, BIOCHEM J, V269, P293, DOI 10.1042/bj2690293; MICHEL C, 1992, EUR J BIOCHEM, V205, P767, DOI 10.1111/j.1432-1033.1992.tb16841.x; ORMEJOHNSON WH, 1974, J BIOL CHEM, V249, P2338; PADMAKUMAR R, 1993, ANAL BIOCHEM, V214, P318, DOI 10.1006/abio.1993.1494; PILBROW JR, 1982, B12, P431; RAGSDALE SW, 1987, J BIOL CHEM, V262, P14289; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; SCHEPLER KL, 1975, BIOCHIM BIOPHYS ACTA, V397, P510, DOI 10.1016/0005-2744(75)90141-2; STUBBE J, 1988, BIOCHEMISTRY-US, V27, P3893, DOI 10.1021/bi00411a001; TAOKA S, 1994, J BIOL CHEM, V269, P31630; WOLLOWITZ S, 1984, J AM CHEM SOC, V106, P8319, DOI 10.1021/ja00338a066; ZHAO Y, 1994, EUR J BIOCHEM, V225, P891, DOI 10.1111/j.1432-1033.1994.0891b.x; ZHAO Y, 1992, ANGEW CHEM INT EDIT, V31, P215, DOI 10.1002/anie.199202151	38	69	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9295	9300		10.1074/jbc.270.16.9295	http://dx.doi.org/10.1074/jbc.270.16.9295			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721850	hybrid			2022-12-25	WOS:A1995QU08900038
J	SOUID, AK; PENEFSKY, HS				SOUID, AK; PENEFSKY, HS			ENERGETICS OF ATP DISSOCIATION FROM THE MITOCHONDRIAL ATPASE DURING OXIDATIVE-PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SITE COOPERATIVITY; BEEF-HEART; ADENOSINE-TRIPHOSPHATASE; SUBMITOCHONDRIAL PARTICLES; PARACOCCUS-DENITRIFICANS; RESPIRATORY-CHAIN; MECHANISM; HYDROLYSIS; KINETICS; F0F1-ATPASE	The dissociation constant (K-dATP) for ATP bound in the high affinity catalytic site of membrane-bound beef heart mitochondrial ATPase (F-1) was calculated from the ratio of the rate constants for the reverse dissociation step (k(-1)) and the forward binding step (k(+1)). k(-1) for ATP bound to submitochondrial particles or to submitochondrial particles washed with KCl so as to activate ATPase activity was accelerated by about five orders of magnitude during respiratory chain-linked oxidations of NADH, In the presence of NADH and 0.1 mM ADP, k(-1) increased more than six orders of magnitude, These energy-dependent dissociations of ATP were sensitive to the uncoupler carbonyl cyanide p-trifluoromethyloxyphenylhydrazone. Only small changes in k(+1) were observed in the presence of NADH or NADH and ADP. K-dATP at 23 degrees C in the absence of NADH and ADP was 10(-12) M, in the presence of NADH, 3 mu M, and in the presence of NADH and 0.1 mM ADP, 60 mu M. Thus, the dissociation of ATP during the transition from non-energized to energized states was, under these conditions, accompanied by observed free energy changes of 8 and 9.7 kcal/mol, respectively.	SUNY HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT PEDIAT, SYRACUSE, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021737] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21737] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1990, J BIOL CHEM, V265, P4402; BELTRAN C, 1986, EUR J BIOCHEM, V160, P163, DOI 10.1111/j.1432-1033.1986.tb09953.x; BEYER RE, 1967, METHOD ENZYMOL, V10, P186; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CROSS RL, 1982, J BIOL CHEM, V257, P2101; FELDMAN RI, 1985, J BIOL CHEM, V260, P3088; FERGUSON SJ, 1976, BIOCHEM J, V159, P347, DOI 10.1042/bj1590347; FERGUSON SJ, 1977, BIOCHEM J, V168, P299, DOI 10.1042/bj1680299; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HARRIS DA, 1977, BIOCHIM BIOPHYS ACTA, V459, P560, DOI 10.1016/0005-2728(77)90054-8; HATEFI Y, 1993, EUR J BIOCHEM, V218, P759, DOI 10.1111/j.1432-1033.1993.tb18431.x; HELDT HW, 1972, EUR J BIOCHEM, V30, P434, DOI 10.1111/j.1432-1033.1972.tb02115.x; LINDBERG O, 1956, METHODS BIOCHEMICAL, V3, P1; MAGNUSSON RP, 1976, J BIOL CHEM, V251, P7417; MATSUNOYAGI A, 1985, J BIOL CHEM, V260, P4424; MATSUNOYAGI A, 1986, J BIOL CHEM, V261, P14031; MATSUNOYAGI A, 1988, BIOCHEMISTRY-US, V27, P335, DOI 10.1021/bi00401a050; MATSUNOYAGI A, 1993, J BIOL CHEM, V268, P1539; MATSUNOYAGI A, 1985, P NATL ACAD SCI USA, V82, P7550, DOI 10.1073/pnas.82.22.7550; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; PENEFSKY H, 1991, ADV ENZYMOL REL AREA, V64, P173; PENEFSKY HS, 1985, J BIOL CHEM, V260, P3728; PENEFSKY HS, 1985, P NATL ACAD SCI USA, V82, P1589, DOI 10.1073/pnas.82.6.1589; PENEFSKY HS, 1985, J BIOL CHEM, V260, P3735; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PEREZ JA, 1990, BIOCHEMISTRY-US, V29, P10503, DOI 10.1021/bi00498a013; PEREZ JA, 1990, BIOCHEMISTRY-US, V29, P10518, DOI 10.1021/bi00498a014; PULLMAN ME, 1960, J BIOL CHEM, V235, P3322; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; ROSING J, 1972, BIOCHIM BIOPHYS ACTA, V267, P275, DOI 10.1016/0005-2728(72)90116-8; Senior A E, 1979, Methods Enzymol, V55, P391; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; WEBER J, 1994, J BIOL CHEM, V269, P20462	37	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9074	9082		10.1074/jbc.270.16.9074	http://dx.doi.org/10.1074/jbc.270.16.9074			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721821	hybrid			2022-12-25	WOS:A1995QU08900009
J	LARMINAT, F; BEECHAM, EJ; LINK, CJ; MAY, A; BOHR, VA				LARMINAT, F; BEECHAM, EJ; LINK, CJ; MAY, A; BOHR, VA			DNA-REPAIR IN THE ENDOGENOUS AND EPISOMAL AMPLIFIED C-MYC ONCOGENE LOCI IN HUMAN TUMOR-CELLS	ONCOGENE			English	Article						DNA REPAIR; C-MYC ONCOGENE; DOUBLE-MINUTE CHROMOSOME	COMPLEMENTATION GROUP-C; HOMOGENEOUSLY STAINING REGIONS; DIHYDROFOLATE-REDUCTASE GENE; HUMAN-COLON CARCINOMA; MATRIX ASSOCIATED DNA; ULTRAVIOLET-LIGHT; DOUBLE MINUTES; TRANSCRIPTION; AMPLIFICATION; FIBROBLASTS	We have studied the repair of u.v.-induced cyclobutane pyrimidine diners (CPDs) in amplified c-myr: oncogene loci in human colon cancer cells to better understand the relationship between chromatin structure, transcription and DNA repair. To assess the variation in DNA repair in the same gene whether located in a chromosomal site or in a extra-chromosomal site, we have quantitated the efficiency of excision repair after u.v. exposure in the endogenous and episomal c-myc genes isolated from COLO320HSR and DM cells. In the HSR cells, c-myc is localized in a homogeneously staining region (HSR), and in the DM cells, the gene is localized in double minute chromosomes (DM). Our results indicate that the repair is less efficient in c-myc amplicons organized as double minute chromosomes than in the endogenous c-myc amplicons, The episomal gene is not repaired with the same efficiency as when it is intrachromosomal. This may reflect differences in chromatin structure. An advantage of this biological system is that the cells possess two different alleles of the c-myc gene, one that is active and another which is inactive. We have studied the relationship between DNA repair and transcriptional activity in the c-myc locus by measuring the efficiency of excision repair after u.v. exposure in the normal and rearranged alleles of the c-myc gene. Surprisingly, the c-myc gene is repaired with similar efficiency in the highly transcribed allele as in the poorly expressed allele. However, u.v. damage is selectively removed from the transcribed strand of the active c-myc allele, but DNA repair is not strand specific in the non-expressed c-myc allele.	NIA, MOLEC GENET LAB, BALTIMORE, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)			Bohr, Vilhelm/AAP-5931-2020					ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BEECHAM EJ, 1991, MOL CELL BIOL, V11, P3095, DOI 10.1128/MCB.11.6.3095; BIANCHI NO, 1991, DNA CELL BIOL, V10, P125, DOI 10.1089/dna.1991.10.125; Biedler JL, 1983, ADV CELL NEUROBIOL, V4, P268; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1986, J BIOL CHEM, V261, P6666; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; BOHR VA, 1988, DNA REPAIR LABORATOR, P347; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; CLEAVER JE, 1983, J MOL BIOL, V170, P305, DOI 10.1016/S0022-2836(83)80150-8; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; COWELL JK, 1982, ANNU REV GENET, V16, P21, DOI 10.1146/annurev.ge.16.120182.000321; DESALUM SB, 1984, CANCER GENET CYTOGEN, V11, P53, DOI 10.1016/0165-4608(84)90098-0; HAHN PJ, 1993, BIOESSAYS, V15, P477, DOI 10.1002/bies.950150707; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; MADHANI HD, 1986, CELL, V45, P417, DOI 10.1016/0092-8674(86)90327-2; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITCHELL DL, 1994, PHOTOCHEM PHOTOBIOL, V60, P221, DOI 10.1111/j.1751-1097.1994.tb05094.x; MULLENDERS LHF, 1988, NUCLEIC ACIDS RES, V16, P10607, DOI 10.1093/nar/16.22.10607; MULLENDERS LHF, 1984, MUTAT RES, V141, P75, DOI 10.1016/0165-7992(84)90014-9; QUINN LA, 1979, CANCER RES, V39, P4914; RONAI ZA, 1988, ONCOGENE, V2, P201; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHIMKE RT, 1982, GENE AMPLIFICATION, P317; SCHWAB M, 1986, MOL CELL BIOL, V6, P2752, DOI 10.1128/MCB.6.7.2752; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; SHTIVELMAN E, 1990, MOL CELL BIOL, V10, P1835, DOI 10.1128/MCB.10.4.1835; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; VANDEVANTER DR, 1993, GENE CHROMOSOME CANC, V6, P190, DOI 10.1002/gcc.2870060310; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; YANG JK, 1984, J MOL BIOL, V176, P169, DOI 10.1016/0022-2836(84)90419-4	36	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1639	1645						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731719				2022-12-25	WOS:A1995QU68100021
J	BROWN, NF; WEIS, BC; HUSTI, JE; FOSTER, DW; MCGARRY, JD				BROWN, NF; WEIS, BC; HUSTI, JE; FOSTER, DW; MCGARRY, JD			MITOCHONDRIAL CARNITINE PALMITOYLTRANSFERASE-I ISOFORM SWITCHING IN THE DEVELOPING RAT-HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; MALONYL-COA; ENZYME-SYSTEM; METABOLISM; CLONING; KETOGENESIS; EXPRESSION	The expression pattern of mitochondrial carnitine palmitoyltransferase (CPT) enzymes was examined in the developing rat heart. Whereas the specific activity of CPT II increased similar to 3 fold during the first month of life, the profile for CPT I, which is composed of both liver (L) and muscle (M) isoforms, was more complex. Exposure of mitochondria to [H-3]etomoxir (a covalent ligand for CPT I), followed by fluorographic analysis of the membrane proteins, established that while in the adult heart L-CPT I represents a very minor constituent, its contribution is much greater in the newborn animal. Use of the related inhibitor, 2-[6-(2,4-dinitrophenoxy)hexyl]oxirane-2-carboxylic acid (specific for L-CPT I), allowed the activities of the two CPT I variants to be quantified separately. The results showed that in the neonatal heart, L-CPT I contributes similar to 25% to total CPT I activity (in V-max terms), the value falling during growth of the pups (with concomitant increasing expression of the Id isoform) to its adult level of 2-3%. Because the myocardial carnitine content is very low at birth and rises dramatically over the next several weeks, it can be estimated that L-CPT I (K-m for carnitine of only 30 mu M compared with a value of 500 CCM for M-CPT I) is responsible for some 60% of total cardiac fatty acid oxidation in the newborn rat; the value falls to similar to 4% in adult animals. Should these findings have a parallel in humans, they could have important implications for understanding the pathophysiological consequences of inherited L CPT I deficiency syndromes.	UNIV TEXAS, SW MED CTR, SW MED SCH, DEPT INTERNAL MED, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, SW MED SCH, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, SW MED SCH, GIFFORD LABS DIABET RES, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018573, P01DK042582, R01DK018573] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18573, DK42582] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AWAN MM, 1993, BIOCHEM J, V295, P61, DOI 10.1042/bj2950061; BERGMAN AJIW, 1994, PEDIATR RES, V36, P582, DOI 10.1203/00006450-199411000-00007; BRITTON CH, 1995, P NATL ACAD SCI USA, V92, P1984, DOI 10.1073/pnas.92.6.1984; CHEN SY, 1994, DIABETES, V43, P878, DOI 10.2337/diabetes.43.7.878; DECLERCQ PE, 1987, J BIOL CHEM, V262, P812; DEMAUGRE F, 1988, PEDIATR RES, V24, P308, DOI 10.1203/00006450-198809000-00006; DUAN C, 1992, J APPL PHYSIOL, V72, P901, DOI 10.1152/jappl.1992.72.3.901; ESSER V, 1993, J BIOL CHEM, V268, P5817; FINOCCHIARO G, 1991, P NATL ACAD SCI USA, V88, P661, DOI 10.1073/pnas.88.2.661; FOLEY JE, 1992, DIABETES CARE, V15, P773, DOI 10.2337/diacare.15.6.773; GLICK MR, 1974, ANAL BIOCHEM, V61, P32, DOI 10.1016/0003-2697(74)90329-7; JONES CT, 1985, PHYSIOL REV, V65, P357, DOI 10.1152/physrev.1985.65.2.357; LOPASCHUK GD, 1994, J BIOL CHEM, V269, P25871; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1992, CURRENT CONCEPTS IN CARNITINE RESEARCH, P137; MCGARRY JD, 1985, METHOD ENZYMAT AN, P474; MILLS SE, 1984, BIOCHEM J, V219, P601, DOI 10.1042/bj2190601; MURTHY MSR, 1994, J BIOL CHEM, V269, P18283; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; ROBLESVALDES C, 1976, J BIOL CHEM, V251, P6007; SADDIK M, 1993, J BIOL CHEM, V268, P25836; SAUDUBRAY JM, 1992, PROG CLIN BIOL RES, V375, P271; THUMELIN S, 1994, BIOCHEM J, V300, P583, DOI 10.1042/bj3000583; WARSHAW JB, 1972, DEV BIOL, V28, P537, DOI 10.1016/0012-1606(72)90001-2; WEIS BC, 1994, J BIOL CHEM, V269, P26443; WEIS BC, 1994, J BIOL CHEM, V269, P18712; WITTELS B, 1965, J CLIN INVEST, V44, P1639, DOI 10.1172/JCI105270; WOELTJE KF, 1987, J BIOL CHEM, V262, P9822; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOELTJE KF, 1990, J BIOL CHEM, V265, P10714	34	136	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8952	8957		10.1074/jbc.270.15.8952	http://dx.doi.org/10.1074/jbc.270.15.8952			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721804	hybrid			2022-12-25	WOS:A1995QT44800083
J	CASEY, JR; DING, Y; KOPITO, RR				CASEY, JR; DING, Y; KOPITO, RR			THE ROLE OF CYSTEINE RESIDUES IN THE ERYTHROCYTE PLASMA-MEMBRANE ANION-EXCHANGE PROTEIN, AE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; SITE-DIRECTED MUTAGENESIS; ANKYRIN-BINDING SITE; BAND-3 PROTEIN; TRANSPORT PROTEIN; BACTERIORHODOPSIN MUTANTS; TRANSMEMBRANE PROTEINS; RECEPTOR; CDNA; ASSOCIATION	AE1 (Band 3), a congruent to 110-kDa integral plasma membrane protein, facilitates the electroneutral movement of Cl- and HCO3- across the erythrocyte membrane and serves as the primary attachment site for the erythrocyte spectrin-actin cytoskeleton. In this investigation, we have characterized the role of native cysteines in the function of AE1, We have constructed a mutant version of human AE1 (AE1C(-)) in which all five cysteines of AE1 were replaced with serines. Wild-type and AE1C(-) cDNAs were expressed by transient transfection of human embryonic kidney cells. Two of the mutated cysteines in AE1C(-) are in a region involved in ankyrin binding, and ankyrin binding has previously been shown to be sensitive to the oxidation state of these cysteines. However, the K-D values for ankyrin binding by AE1 and AE1C(-) were indistinguishable, suggesting that AE1 cysteines are not essential components of the ankyrin-binding site. Using size exclusion chromatography, both AE1 and AE1C(-) were found to associate as a mixture of dimers and high molecular mass complexes. The rate of anion exchange by AE1C(-), as measured in a reconstituted microsome sulfate transport assay, was indistinguishable from that by AE1 and was inhibited by 4,4'-diisothiocyanodihydrostilbene- 2,2'-disulfonate. We conclude that the cysteines of AE1 are not required for the anion exchange or cytoskeletal binding roles of the protein.	STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA	Stanford University				Casey, Joseph/0000-0002-9890-5056				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BEPPU M, 1990, J BIOL CHEM, V265, P3226; CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P207, DOI 10.1007/BF01870088; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; CASEY JR, 1991, J BIOL CHEM, V266, P15726; CASEY JR, 1989, METHOD ENZYMOL, V173, P494; COX JV, 1988, MOL CELL BIOL, V8, P1327, DOI 10.1128/MCB.8.3.1327; Creighton TE, 1983, PROTEINS STRUCTURES; DAVIS L, 1989, J BIOL CHEM, V264, P9665; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DING Y, 1994, J BIOL CHEM, V269, P32201; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; FLITSCH SL, 1989, BIOCHEMISTRY-US, V28, P7800, DOI 10.1021/bi00445a041; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUBNER S, 1992, BIOCHEM J, V285, P17; IWAARDEN PR, 1991, BIOCHEMISTRY-US, V30, P9595; JENNINGS ML, 1989, ANNU REV BIOPHYS BIO, V18, P397, DOI 10.1146/annurev.bb.18.060189.002145; JUNG K, 1993, BIOCHEMISTRY-US, V32, P12273, DOI 10.1021/bi00097a001; KANG DC, 1994, BBA-BIOMEMBRANES, V1194, P341, DOI 10.1016/0005-2736(94)90317-4; KAY MMB, 1984, P NATL ACAD SCI-BIOL, V81, P5753, DOI 10.1073/pnas.81.18.5753; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KOPITO RR, 1985, J CELL BIOCHEM, V29, P1, DOI 10.1002/jcb.240290102; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1991, J BIOL CHEM, V266, P11443; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; NAKASHIMA H, 1980, J BIOCHEM-TOKYO, V88, P933, DOI 10.1093/oxfordjournals.jbchem.a133081; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OKUBO K, 1991, J BIOL CHEM, V266, P16420; REITHMEIER RAF, 1979, J BIOL CHEM, V254, P6151; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; REITHMEIER RAF, 1992, J BIOL CHEM, V2, P181; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; THEVENIN BJM, 1989, J BIOL CHEM, V264, P15886; THOMAS HA, 1989, AM J PHYSIOL, V26, pC537; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJI A, 1988, BIOCHEMISTRY-US, V27, P7447, DOI 10.1021/bi00419a041; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893	59	56	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8521	8527		10.1074/jbc.270.15.8521	http://dx.doi.org/10.1074/jbc.270.15.8521			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721750	hybrid			2022-12-25	WOS:A1995QT44800026
J	MORELLA, KK; LAI, CF; KUMAKI, S; KUMAKI, N; WANG, YP; BLUMAN, EM; WITTHUHN, BA; IHLE, JN; GIRI, J; GEARING, DP; COSMAN, D; ZIEGLER, SF; TWEARDY, DJ; CAMPOS, SP; BAUMANN, H				MORELLA, KK; LAI, CF; KUMAKI, S; KUMAKI, N; WANG, YP; BLUMAN, EM; WITTHUHN, BA; IHLE, JN; GIRI, J; GEARING, DP; COSMAN, D; ZIEGLER, SF; TWEARDY, DJ; CAMPOS, SP; BAUMANN, H			THE ACTION OF INTERLEUKIN-2 RECEPTOR SUBUNITS DEFINES A NEW-TYPE OF SIGNALING MECHANISM FOR HEMATOPOIETIN RECEPTORS IN HEPATIC CELLS AND FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; RAT ALPHA-1-ACID GLYCOPROTEIN; GROWTH-HORMONE-RECEPTOR; PLASMA-PROTEIN GENES; CILIARY NEUROTROPHIC FACTOR; LEUKEMIA INHIBITORY FACTOR; NATURAL-KILLER-CELLS; ERYTHROPOIETIN RECEPTOR; GAMMA-CHAIN; CYTOKINE RECEPTORS	The gene regulatory functions of the human IL-2 receptor (IL-2R) were reconstituted in transiently transfected hepatoma cells. The combination of IL-2R beta and -gamma mediated a strong stimulation via the cytokine response element of the alpha(1)-acid glycoprotein gene and the hematopoietin receptor response element, but none via the IL-6 response element of the sis-inducible element. IL-2R alpha enhanced 10-fold the sensitivity of the IL-2R beta .gamma complex to respond to IL-2 or IL-15, but did not modify the specificity or the magnitude of maximal gene regulation. A homodimerizing chimeric receptor G-CSFR-IL-2R beta could mimic the IL-2R action. The IL-2R-mediated gene regulation was similar to that seen with receptors for IL-4 and IL-7, but differed from that for IL-6 type cytokines, thrombopoietin, erythropoietin, and growth hormone. The activation of STAT proteins by the IL-2R was assessed in transfected L-cells and COS-1 cells. Although IL-2R subunits were highly expressed in these cells, no STAT protein activation was detectable. Transient overexpression of JAK3 was unable to change the signaling specificity of the hematopoietin receptors in rat hepatoma, L-, and COS cells, but established a prominent activation of the IL-6 response elements by the IL-2R and IL-4R in HepG2 cells. The data support the model that the IL-2R and related hematopoietin receptors produce at least two separate signals which control gene expression.	ROSWELL PK CANC INST, DEPT MOLEC & CELLULAR BIOL, BUFFALO, NY 14263 USA; IMMUNEX RES & DEV CORP, SEATTLE, WA 98101 USA; CHILDRENS HOSP BUFFALO, DIV ENDOCRINOL, BUFFALO, NY 14222 USA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38101 USA; SYSTEMIX INC, PALO ALTO, CA 94304 USA; DARWIN MOLEC CORP, BOTHELL, WA 98021 USA; PITTSBURGH CANC INST, PITTSBURGH, PA 15213 USA	Roswell Park Cancer Institute; St Jude Children's Research Hospital; Novartis; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute			Bluman, Eric M./K-5849-2019; Tweardy, David/L-3929-2019; witthuhn, bruce/GSE-3193-2022	Bluman, Eric M./0000-0002-3848-1677; 	NCI NIH HHS [CA26122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BANCROFT GJ, 1993, CURR OPIN IMMUNOL, V5, P503, DOI 10.1016/0952-7915(93)90030-V; BAUMANN H, 1993, J IMMUNOL, V151, P1456; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; BAUMANN H, 1993, J IMMUNOL, V151, P4248; BAUMANN H, 1992, CIBA F SYMP, V167, P100; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CAMPOS SP, 1994, CYTOKINE, V6, P485, DOI 10.1016/1043-4666(94)90075-2; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLOSI P, 1993, J BIOL CHEM, V268, P12617; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IMMENSCHUH S, 1994, J BIOL CHEM, V269, P12654; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARINKOVIC S, 1990, MOL CELL BIOL, V10, P1573, DOI 10.1128/MCB.10.4.1573; MATOS ME, 1993, J EXP MED, V178, P1079, DOI 10.1084/jem.178.3.1079; MINAMI Y, 1994, J IMMUNOL, V152, P5680; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NOGUCHI M, 1993, J BIOL CHEM, V268, P13601; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; PRUITT SC, 1988, GENE, V66, P121, DOI 10.1016/0378-1119(88)90230-2; QUELLE DE, 1991, P NATL ACAD SCI USA, V88, P4801, DOI 10.1073/pnas.88.11.4801; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAO MS, 1992, NEUROREPORT, V3, P865, DOI 10.1097/00001756-199210000-00011; RAO MS, 1992, DEV BIOL, V150, P281, DOI 10.1016/0012-1606(92)90242-9; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STEINMAN RA, 1994, BLOOD, V83, P119; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TORRIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674; TRIPP CS, 1993, P NATL ACAD SCI USA, V90, P3725, DOI 10.1073/pnas.90.8.3725; ULTSCH M, 1993, J MOL BIOL, V231, P1133, DOI 10.1006/jmbi.1993.1359; VIGON I, 1993, ONCOGENE, V8, P2607; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	88	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8298	8310		10.1074/jbc.270.14.8298	http://dx.doi.org/10.1074/jbc.270.14.8298			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713938	hybrid			2022-12-25	WOS:A1995QR52600077
J	MURIAUX, D; GIRARD, PM; BONNETMATHONIERE, B; PAOLETTI, J				MURIAUX, D; GIRARD, PM; BONNETMATHONIERE, B; PAOLETTI, J			DIMERIZATION OF HIV-1(LAI) RNA AT LOW IONIC-STRENGTH - AN AUTOCOMPLEMENTARY SEQUENCE IN THE 5' LEADER REGION IS EVIDENCED BY AN ANTISENSE OLIGONUCLEOTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN RETICULOENDOTHELIOSIS VIRUS; MOLONEY MURINE LEUKEMIA; REVERSE TRANSCRIPTION; NUCLEOCAPSID PROTEIN; DIMER FORMATION; RETROVIRAL RNA; CIS ELEMENTS; GENOMIC RNA; INVITRO; RECOMBINATION	Genomic human immunodeficiency virus type 1 (HIV-1) RNA consists of two identical RNA molecules joined noncovalently near their 5' ends in a region called the dimer linkage structure (DLS). Previous work has shown that the putative DLS is localized in a 113-nucleotide domain encompassing the 5' end of the gag gene. This region contains conserved purine tracks that are thought to mediate dimerization through purine quartets. However, recently, an HIV-1(Mal) RNA dimerization model was proposed as the HIV-1(Mal) RNA dimerization initiation site, involving another region upstream from the splice donor site and possibly confined within a stem-loop. In the present study, we have investigated the dimerization of HIV-1(Lai) RNA, using in vitro dimerization assays under conditions of low ionic strength, predictive RNA secondary structures determined by computer folding, and antisense DNA oligonucleotides in order to discriminate between these two models. Our results suggest that purine quartets are not involved in the dimer structure of HIV-1(Lai) RNA and have led to the identification of a region upstream from the splice donor site. This region, comprising an autocomplementary sequence in a possible stem-loop structure, is responsible for the formation of dimeric HIV-1(Lai) RNA.	INST GUSTAVE ROUSSY,PHARMACOL & PHYSICOCHIM MACROMOLEC LAB,CNRS,URA 147,UNITE BIOCHIM ENZYMOL,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy								AWANG G, 1993, BIOCHEMISTRY-US, V32, P11453, DOI 10.1021/bi00093a024; BENDER W, 1978, J VIROL, V25, P888, DOI 10.1128/JVI.25.3.888-896.1978; BERKHOUT B, 1993, FASEB J, V7, P181, DOI 10.1096/fasebj.7.1.8422965; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; COFFIN JM, 1984, RNA TUMOR VIRUSES, V1, P261; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DARLIX JL, 1992, J VIROL, V66, P7245, DOI 10.1128/JVI.66.12.7245-7252.1992; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; FU W, 1994, J VIROL, V68, P5013, DOI 10.1128/JVI.68.8.5013-5018.1994; HARRISON GP, 1992, J VIROL, V66, P4144, DOI 10.1128/JVI.66.7.4144-4153.1992; HASELTINE WA, 1977, P NATL ACAD SCI USA, V74, P989, DOI 10.1073/pnas.74.3.989; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; KATOH I, 1993, J VIROL, V67, P1830, DOI 10.1128/JVI.67.4.1830-1839.1993; KIM HJ, 1994, VIROLOGY, V198, P336, DOI 10.1006/viro.1994.1037; KUNG HJ, 1976, CELL, V7, P609, DOI 10.1016/0092-8674(76)90211-7; LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035; Maniatis T., 1982, MOL CLONING; MARQUET R, 1994, NUCLEIC ACIDS RES, V22, P145, DOI 10.1093/nar/22.2.145; MARQUET R, 1991, NUCLEIC ACIDS RES, V18, P2349; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MURTI KG, 1981, J VIROL, V37, P411, DOI 10.1128/JVI.37.1.411-419.1981; MYERS G, 1992, HUMAN RETROVIRUSES A; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PERSSON C, 1990, EMBO J, V9, P3767, DOI 10.1002/j.1460-2075.1990.tb07590.x; PRATS AC, 1990, J VIROL, V64, P774, DOI 10.1128/JVI.64.2.774-783.1990; ROY C, 1990, NUCLEIC ACIDS RES, V18, P7287, DOI 10.1093/nar/18.24.7287; SAKAGUCHI K, 1993, P NATL ACAD SCI USA, V90, P5219, DOI 10.1073/pnas.90.11.5219; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; STUHLMANN H, 1992, J VIROL, V66, P2378, DOI 10.1128/JVI.66.4.2378-2388.1992; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; TEMIN HM, 1991, TRENDS GENET, V7, P71, DOI 10.1016/0168-9525(91)90048-U; TURNER DH, 1987, COLD SPRING HARB SYM, V52, P123, DOI 10.1101/SQB.1987.052.01.017; WEISS S, 1992, GENE, V121, P203, DOI 10.1016/0378-1119(92)90123-7; WEISS S, 1993, NUCLEIC ACIDS RES, V21, P4879, DOI 10.1093/nar/21.21.4879; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7	35	129	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8209	8216		10.1074/jbc.270.14.8209	http://dx.doi.org/10.1074/jbc.270.14.8209			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713927	hybrid			2022-12-25	WOS:A1995QR52600066
J	SEKLER, I; LO, RS; MASTROCOLA, T; KOPITO, RR				SEKLER, I; LO, RS; MASTROCOLA, T; KOPITO, RR			SULFATE TRANSPORT MEDIATED BY THE MAMMALIAN ANION-EXCHANGERS IN RECONSTITUTED PROTEOLIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; BICARBONATE TRANSPORT; ERYTHROCYTE-MEMBRANE; INTRACELLULAR PH; CYTOSOLIC PH; CHLORIDE; BINDING; PROTON; PROTEIN; LINE	The kinetic properties of sulfate transport mediated by the anion exchangers AE1 and AE2 have been examined, Microsomes isolated from HEK cells transiently overexpressing either protein were reconstituted in unilamellar, 200-600-nm diameter proteoliposomes. Transport mediated by the exchangers was monitored by loading the reconstituted proteoliposomes with the slowly transportable anion SO42- using [S-35]SO42- as a tracer and performing [S-35]SO42-/SO42- exchange. The following data suggest that AE1 and AE2 have been functionally reconstituted: (i) the rate of SO42- transport in AE1 and AE2 containing proteoliposomes was 10-20 times higher than in proteoliposomes derived from control microsomes; (ii) the transport of SO42- was strongly dependent on the presence of a trans anion; and (iii) the anion exchanger inhibitors, 4,4'-diisothiocyanostilbene-2,2'-disulfonate (DIDS) and 4,4'-dinitrostilbene-2,2'-disulfonate (DNDS) totally abolished SO42- transport, Furthermore, DIDS inhibits SO42- transport only when occluded inside the vesicles, indicating a uniform, asymmetrical, inside out orientation of the reconstituted exchangers, The K-i values of the stilbene disulfonate compound DNDS were 2.5 and 4 mu M for AE1 and AE2, respectively, suggesting that the two exchangers pos sess similar high affinity sites for stilbene compounds. Both AE1 and AE2 showed the same steep pH dependence of sulfate transport, which was maximal at pH 5.5 and reduced to less than 10% (of the value at pH 5.5) at pH 8.5, suggesting that an acidic residue shared by AE1 and AE2 participates in the pH regulation of sulfate transport.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NIGMS NIH HHS [GM38543] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER SL, 1988, J BIOL CHEM, V263, P17092; ARONSON PS, 1989, ANNU REV PHYSIOL, V51, P419; BARZILAY M, 1979, MEMBRANE BIOCHEM, V2, P227, DOI 10.3109/09687687909063866; CABANTCHIK ZI, 1992, AM J PHYSIOL, V31, pC803; DARNELL J, 1990, MOL CELL BIOL, P489; FROHLICH O, 1982, J MEMBRANE BIOL, V65, P111, DOI 10.1007/BF01870474; GASKO OD, 1976, ANAL BIOCHEM, V72, P57, DOI 10.1016/0003-2697(76)90506-6; GREEN J, 1990, J GEN PHYSIOL, V95, P121, DOI 10.1085/jgp.95.1.121; GUNN RB, 1973, ERYTHROCYTES THROMBO, P77; HE XJ, 1993, AM J PHYSIOL, V264, pC1075, DOI 10.1152/ajpcell.1993.264.4.C1075; HOPFER U, 1987, ANNU REV PHYSIOL, V49, P51, DOI 10.1146/annurev.ph.49.030187.000411; HUMPHREYS BD, 1994, AM J PHYSIOL, V36, pC1295; JENNINGS ML, 1976, J MEMBRANE BIOL, V28, P187, DOI 10.1007/BF01869697; JENNINGS ML, 1989, ANNU REV BIOPHYS BIO, V18, P397, DOI 10.1146/annurev.bb.18.060189.002145; KAPLAN JH, 1976, FEBS LETT, V62, P182, DOI 10.1016/0014-5793(76)80048-8; KARNISKI LP, 1987, AM J PHYSIOL, V253, pF513, DOI 10.1152/ajprenal.1987.253.3.F513; KNAUF PA, 1986, MEMBRANE TRANSPORT D, P191; KOHNE W, 1981, BIOCHIM BIOPHYS ACTA, V229, P547; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KRUPKA RM, 1989, J MEMBRANE BIOL, V109, P159, DOI 10.1007/BF01870855; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; LEE BS, 1991, J BIOL CHEM, V266, P11448; LUKACOVIC MF, 1981, BIOCHEMISTRY-US, V20, P3145, DOI 10.1021/bi00514a025; MILANICK MA, 1982, J GEN PHYSIOL, V79, P87, DOI 10.1085/jgp.79.1.87; MILANICK MA, 1984, AM J PHYSIOL, V247, pC247, DOI 10.1152/ajpcell.1984.247.3.C247; MUALLEM S, 1985, J BIOL CHEM, V260, P6641; PASSOW H, 1986, REV PHYSL BIOCH PHAR, V103, P62; REINERTSEN KV, 1988, J BIOL CHEM, V263, P11117; RUETZ S, 1993, J CELL BIOL, V121, P37, DOI 10.1083/jcb.121.1.37; SAITO Y, 1983, J PHYSIOL-LONDON, V336, P635, DOI 10.1113/jphysiol.1983.sp014602; SCHNELL KF, 1977, J MEMBRANE BIOL, V30, P319; SEE H, 1990, BIOCHEM J, V271, P147, DOI 10.1042/bj2710147; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VAUGHANJONES RD, 1979, J PHYSIOL-LONDON, V295, P111, DOI 10.1113/jphysiol.1979.sp012957; WOOD PG, 1992, J MEMBRANE BIOL, V127, P139	35	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11251	11256		10.1074/jbc.270.19.11251	http://dx.doi.org/10.1074/jbc.270.19.11251			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744759	hybrid			2022-12-25	WOS:A1995QX86500036
J	KIM, HY; THOMAS, D; HANLEY, MR				KIM, HY; THOMAS, D; HANLEY, MR			CHROMATOGRAPHIC RESOLUTION OF AN INTRACELLULAR CALCIUM INFLUX FACTOR FROM THAPSIGARGIN-ACTIVATED JURKAT CELLS - EVIDENCE FOR MULTIPLE ACTIVITIES INFLUENCING CALCIUM ELEVATION IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MESSENGER; CA2+	Acid extracts of thapsigargin-stimulated Jurkat cells revealed both intracellular and extracellular activities stimulating Ca2+-dependent Cl- currents on Xenopus laevis oocytes. Chromatographic fractionation of these extracts on gel filtration separated two active fractions of M(r) approximately 600 and 400. Moreover, the M(r) 600 fraction exhibited both intracellular and extracellular activities. However, the intracellular activity was absent from extracts of unstimulated Jurkat cells, suggesting its production was stimulated by thapsigargin. The further purification of this fraction by high performance thin layer chromatography resolved a single fraction which was active only on microinjection and which required calcium entry for activation of current responses. These results suggest that a single authentic calcium influx factor can be resolved by purification from confounding activities detected in crude acid extracts.	UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	University of California System; University of California Davis								BERRIDGE MJ, 1993, NATURE, V361, P314; FERGUSON JE, 1992, ARCH BIOCHEM BIOPHYS, V297, P388, DOI 10.1016/0003-9861(92)90689-T; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; THOMAS D, 1995, J BIOL CHEM, V270, P6429, DOI 10.1074/jbc.270.12.6429	7	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9706	9708		10.1074/jbc.270.17.9706	http://dx.doi.org/10.1074/jbc.270.17.9706			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730347	hybrid			2022-12-25	WOS:A1995QV41700005
J	MATSUO, M; YOKOGAWA, T; NISHIKAWA, K; WATANABE, K; OKADA, N				MATSUO, M; YOKOGAWA, T; NISHIKAWA, K; WATANABE, K; OKADA, N			HIGHLY SPECIFIC AND EFFICIENT CLEAVAGE OF SQUID TRNA(LYS) CATALYZED BY MAGNESIUM-IONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE TRANSFER-RNA; YEAST TRANSFER-RNAPHE; DIVALENT METAL-IONS; SELF-CLEAVAGE; BINDING-SITES; ACCEPTOR STEM; MITOCHONDRIA; REFINEMENT; MECHANISM; RIBOZYME	Two lysine isoacceptor tRNAs corresponding to the codons AAA and AAG, respectively, were isolated from squid (Loligo bleekeri), and their nucleotide sequences were determined. During this analysis, we discovered that the tRNA with the anticodon CUU was efficiently cleaved at a specific site in the presence of magnesium ions, whereas the tRNA with the anticodon UUU was not. Cleavage occurred almost exclusively at the phosphodiester linkage between G(15) and D-16 (p16). The most remarkable feature of this cleavage reaction is that the end product was not a 2',3'-cyclic phosphate but was mainly a 3'-phosphate. Thus, this reaction was distinct from the well characterized cleavage of yeast tRNA(Phe) by lead and from reactions catalyzed by various other metalloribozymes. The presence of a cytidine residue at position 60 was required for efficient cleavage but was not crucial for the reaction, and the entire tRNA molecule had to be intact for this specific and efficient cleavage reaction. The present study provides evidence that there exists a new catalytic mechanism for cleavage of tRNA that exploits biologically ubiquitous ions rather than toxic, nonessential ions such as lead.	TOKYO INST TECHNOL, FAC BIOSCI & BIOTECHNOL, MIDORI KU, YOKOHAMA, KANAGAWA 226, JAPAN; UNIV TOKYO, FAC ENGN, DEPT CHEM & BIOTECHNOL, BUNKYO KU, TOKYO 113, JAPAN	Tokyo Institute of Technology; University of Tokyo								ALTMAN S, 1989, ADV ENZYMOL RAMB, V62, P1; BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; BROWN RS, 1983, NATURE, V303, P543, DOI 10.1038/303543a0; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CIESIOLKA J, 1989, EUR J BIOCHEM, V186, P71, DOI 10.1111/j.1432-1033.1989.tb15179.x; CIESIOLKA J, 1986, BIOPHOSPHATES THEIR, P409; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; DENG HY, 1992, BIOCHEMISTRY-US, V31, P10518, DOI 10.1021/bi00158a015; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; FUJIMOTO M, 1974, AGR BIOL CHEM TOKYO, V38, P1555, DOI 10.1080/00021369.1974.10861384; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; HINGERTY B, 1978, J MOL BIOL, V124, P523, DOI 10.1016/0022-2836(78)90185-7; HOLBROOK SR, 1977, NUCLEIC ACIDS RES, V4, P2811, DOI 10.1093/nar/4.8.2811; JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; KRZYZOSIAK WJ, 1988, BIOCHEMISTRY-US, V27, P5771, DOI 10.1021/bi00415a056; KUCHINO Y, 1987, METHOD ENZYMOL, V155, P379; LIMMER S, 1993, P NATL ACAD SCI USA, V90, P6199, DOI 10.1073/pnas.90.13.6199; MARCINIEC T, 1989, FEBS LETT, V243, P293, DOI 10.1016/0014-5793(89)80148-6; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; NISHIMURA S, 1969, BIOCHEMISTRY-US, V8, P832, DOI 10.1021/bi00831a011; PAN T, 1992, NATURE, V358, P560, DOI 10.1038/358560a0; PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; QUIGLEY GJ, 1978, P NATL ACAD SCI USA, V75, P64, DOI 10.1073/pnas.75.1.64; RORDORF BF, 1976, BIOPOLYMERS, V15, P1491, DOI 10.1002/bip.1976.360150805; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAMPSON JR, 1987, COLD SPRING HARB SYM, V52, P267, DOI 10.1101/SQB.1987.052.01.032; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; STOUT CD, 1978, ACTA CRYSTALLOGR B, V34, P1529, DOI 10.1107/S0567740878006056; SUH YA, 1993, NUCLEIC ACIDS RES, V21, P3277, DOI 10.1093/nar/21.14.3277; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; WATSON JD, 1987, MOL BIOL GENE, P1097; WERNER C, 1976, BIOCHIM BIOPHYS ACTA, V432, P161, DOI 10.1016/0005-2787(76)90158-1; WINTERMEYER W, 1973, BIOCHIM BIOPHYS ACTA, V299, P82, DOI 10.1016/0005-2787(73)90399-7; YOKOGAWA T, 1989, NUCLEIC ACIDS RES, V17, P2623, DOI 10.1093/nar/17.7.2623	40	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10097	10104		10.1074/jbc.270.17.10097	http://dx.doi.org/10.1074/jbc.270.17.10097			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730314	hybrid			2022-12-25	WOS:A1995QV41700059
J	PONGUBALA, JMR; ATCHISON, ML				PONGUBALA, JMR; ATCHISON, ML			ACTIVATING TRANSCRIPTION FACTOR-1 AND CYCLIC-AMP RESPONSE ELEMENT MODULATOR CAN MODULATE THE ACTIVITY OF THE IMMUNOGLOBULIN-KAPPA 3' ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-REGULATED ENHANCER; LIGHT-CHAIN EXPRESSION; DNA-BINDING; CDNA CLONES; GENE; PROTEIN; SITE; CREM; INDUCIBILITY; PROMOTER	Previously we determined that the immunoglobulin kappa 3' enhancer (kappa E3') contains at least two functional DNA sequences (PU.1/NF-EM5 and E2A) within its 132-base pair active core. We have determined that the activities of these two sequences are insufficient to account for the entire activity of the 132-base pair core. Using site-directed linker scan mutagenesis across the core fragment we identified several additional functional sequences. We used one of these functional sequences to screen a lambda gt11 cDNA expression library resulting in the isolation of cDNA clones encoding the transcription factors ATF-1 (activating transcription factor) and CREM. (cyclic AMP response element modulator). Because ATF-1 and CREM are known to bind to cAMP response elements (CRE), this functional sequence was named the kappa E3'-CRE. We show that dibutyryl cAMP can increase kappa E3' enhancer activity, and in transient expression assays ATF-1 caused a 4-5-fold increase in the activity of the core enhancer while CREM-alpha expression resulted in repression of enhancer activity. RNA analyses showed increased levels of ATF-1 mRNA during B cell development and some changes in CREIM transcript processing. By joining various fragments of the kappa E3' enhancer to the kappa E3'-CRE, we observed that the kappa E3'-CRE can synergistically increase transcription in association with the PU.1/NF-EM5 binding sites, suggesting a functional interaction between the proteins that bind to these DNA sequences. Consistent with this possibility, we found that ATF-1 and CREM can physically interact with PU.1. The isolation of activator and repressor proteins that bind to the kappa E3'-CRE may relate to previous conflicting results concerning the role of the cAMP signal transduction pathway in kappa gene transcription.	UNIV PENN,SCH VET MED,DEPT ANIM BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania					NIGMS NIH HHS [R01 GM42415] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042415] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; ATCHISON ML, 1990, EMBO J, V9, P3109, DOI 10.1002/j.1460-2075.1990.tb07508.x; ATCHISON ML, 1988, EMBO J, V7, P4213, DOI 10.1002/j.1460-2075.1988.tb03318.x; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; BRISKIN M, 1988, SCIENCE, V242, P1036, DOI 10.1126/science.3143155; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GIRI JG, 1984, J IMMUNOL, V132, P223; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGMAN J, 1990, GENE DEV, V4, P978, DOI 10.1101/gad.4.6.978; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; JUDDE JG, 1992, MOL CELL BIOL, V12, P5206, DOI 10.1128/MCB.12.11.5206; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MCGILLIS JP, 1993, CELL IMMUNOL, V150, P405, DOI 10.1006/cimm.1993.1208; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PONGUBALA JMR, 1992, MOL CELL BIOL, V11, P1041; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WEEKS RS, 1988, J IMMUNOL, V140, P1312; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	42	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10304	10313		10.1074/jbc.270.17.10304	http://dx.doi.org/10.1074/jbc.270.17.10304			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730336	hybrid			2022-12-25	WOS:A1995QV41700085
J	SZABO, P; MOITRA, J; RENCENDORJ, A; RAKHELY, G; RAUCH, T; KISS, I				SZABO, P; MOITRA, J; RENCENDORJ, A; RAKHELY, G; RAUCH, T; KISS, I			IDENTIFICATION OF A NUCLEAR FACTOR-I FAMILY PROTEIN-BINDING SITE IN THE SILENCER REGION OF THE CARTILAGE MATRIX PROTEIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; TRANSCRIPTION FACTORS; DNA-REPLICATION; DEVELOPING LIMB; PROMOTER; SEQUENCE; CELLS; ENHANCER; CLONING; GROWTH	Cartilage matrix protein (CMP) is synthesized by chondrocytes in a developmentally regulated manner, Here we have dissected promoter upstream elements involved in its transcriptional regulation We show that although the 79-base pair CMP minimal promoter is promiscuous, 1137 base pairs of 5'-flanking region are capable of directing tissue and developmental stage specific transcription when fused to a reporter gene, This results from two positive control regions which, in proliferating chondrocytes, relieve the repression mediated by two non-tissue-specific negative control regions. Characterization of the promoter proximal silencer by DNase I footprinting and gel shifts revealed the presence of two elements, SI and SII, which bound mesenchymal cell proteins, Methylation interference analysis indicated a gapped palindromic binding site similar to nuclear factor I (NF-I) family proteins within SI, but only a half-site within SII. Gel shift assays with specific NF-I and mutated SI competitors, binding of recombinant NF-I, as well as supershift analysis with NF-I-specific antiserum verified the binding of NF-I family proteins to the SI element, Double-stranded SI and SII oligonucleotides inserted in single copy in either orientation were found to repress both homologous and heterologous promoters upon transfection into mesenchymal cells, Transcriptional repression also occurred when a consensus NF-I site itself was fused to the CMP minimal promoter, We conclude that NF-I-related protein(s) can mediate transcriptional repression in cells of mesenchymal origin.	HUNGARIAN ACAD SCI, BIOL RES CTR, INST BIOCHEM, H-6701 SZEGED, HUNGARY	Hungarian Academy of Sciences; Hungarian Biological Research Center			Rakhely, Gabor/K-3696-2014	Rakhely, Gabor/0000-0003-2557-3641; Szabo, Piroska/0000-0001-9314-7009				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; ADOLPHE M, 1992, BIOL REGULATION CHON, P1; ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; ASZODI A, 1994, MATRIX BIOL, V14, P181, DOI 10.1016/0945-053X(94)90007-8; AUSUBEL FM, 1988, CURRENT PROTOCOLS MO, P201; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; CORTHESY B, 1990, MOL CELL BIOL, V10, P3926, DOI 10.1128/MCB.10.8.3926; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DUSSERRE Y, 1992, MOL CELL BIOL, V12, P5228, DOI 10.1128/MCB.12.11.5228; FRANZEN A, 1987, DIFFERENTIATION, V36, P199, DOI 10.1111/j.1432-0436.1987.tb00194.x; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GUERIN SL, 1993, EUR J BIOCHEM, V213, P399, DOI 10.1111/j.1432-1033.1993.tb17774.x; HALL B, 1991, CARTILAGE MOL ASPECT, V1, P153; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAUSER N, 1994, J BIOL CHEM, V269, P25747; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; HUNTER E, 1979, METHOD ENZYMOL, V58, P381; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JETT M, 1977, J BIOL CHEM, V252, P2134; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KISS I, 1989, J BIOL CHEM, V264, P8126; KISS I, 1990, MOL CELL BIOL, V10, P2432, DOI 10.1128/MCB.10.5.2432; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; KUJAWA MJ, 1989, EXP CELL RES, V183, P45, DOI 10.1016/0014-4827(89)90417-5; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEVITT D, 1975, DEV BIOL, V43, P75, DOI 10.1016/0012-1606(75)90132-3; MAINI PK, 1991, INT REV CYTOL, V129, P91; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUNDLOS S, 1994, DEV DYNAM, V199, P241, DOI 10.1002/aja.1001990308; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PAULSSON M, 1979, BIOCHEM J, V183, P539, DOI 10.1042/bj1830539; PERKINS SJ, 1994, J MOL BIOL, V238, P104, DOI 10.1006/jmbi.1994.1271; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROY RJ, 1992, NUCLEIC ACIDS RES, V20, P401, DOI 10.1093/nar/20.3.401; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SEALEY L, 1987, MOL CELL BIOL, V7, P787, DOI 10.1128/MCB.7.2.787; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STIRPE NS, 1989, DEVELOPMENT, V107, P23; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; [No title captured]	57	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10212	10221		10.1074/jbc.270.17.10212	http://dx.doi.org/10.1074/jbc.270.17.10212			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730325				2022-12-25	WOS:A1995QV41700073
J	DESOUZA, S; LOCHNER, J; MACHIDA, CM; MATRISIAN, LM; CIMENT, G				DESOUZA, S; LOCHNER, J; MACHIDA, CM; MATRISIAN, LM; CIMENT, G			A NOVEL NERVE GROWTH FACTOR-RESPONSIVE ELEMENT IN THE STROMELYSIN-1 (TRANSIN) GENE THAT IS NECESSARY AND SUFFICIENT FOR GENE-EXPRESSION IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE PRODUCT; ONCOGENE-INDUCED TRANSIN; PHOSPHOLIPASE-C-GAMMA; DNA-BINDING PROTEINS; MESSENGER-RNA; TYROSINE PHOSPHORYLATION; NEURONAL DIFFERENTIATION; PHEOCHROMOCYTOMA CELLS; PROTEASE TRANSIN; RAT FIBROBLASTS	Stromelysin-1 (ST-1) is an extracellular matrix metalloproteinase whose expression is transcriptionally regulated by nerve growth factor (NGF) in the PC12 rat pheochromocytoma cell line. In this paper, we define sequences in the proximal ST-1 promoter that contain a novel NGF-responsive element(s). We show that this cis-acting promoter element can bind nuclear proteins from both untreated and NGF-treated PC12 cells in a specific and saturable manner and is sufficient to confer NGF-inducibility to a heterologous promoter. At least a portion of this NGF-responsive element lies within a 12-base pair region between positions -241 and -229 of the ST-1 promoter and bears no sequence homology to other known transcriptional elements. In contrast to what has been reported for fibroblasts, an AP1 site centered around position -68 does not seem to be involved in the growth factor regulation of ST-1 in PC12 cells. These results suggest that the NGF regulation of ST-1 gene expression involves different promoter elements, and possibly different transcription factors, from that described for ST-1 induction by other growth factors.	LEWIS & CLARK COLL,DEPT CHEM,PORTLAND,OR 97219; VANDERBILT UNIV,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232	Vanderbilt University	DESOUZA, S (corresponding author), OREGON HLTH SCI UNIV,SCH MED,DEPT CELL BIOL & ANAT L215,PORTLAND,OR 97201, USA.				NINDS NIH HHS [NS27886] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027886] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN JM, 1987, MOL BRAIN RES, V3, P39, DOI 10.1016/0169-328X(87)90042-8; ALOE L, 1979, P NATL ACAD SCI USA, V76, P1246, DOI 10.1073/pnas.76.3.1246; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHIN JR, 1985, J BIOL CHEM, V260, P2367; COCHET C, 1991, J BIOL CHEM, V266, P637; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DAY ML, 1990, J BIOL CHEM, V265, P15253; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HAGENBUCHLE O, 1992, NUCLEIC ACIDS RES, V20, P3555, DOI 10.1093/nar/20.14.3555; HAWLEY RJ, 1992, J NEUROSCI, V12, P2573; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KERR LD, 1988, J BIOL CHEM, V263, P16999; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LENORMAND P, 1992, MOL CELL BIOL, V12, P2793, DOI 10.1128/MCB.12.6.2793; LEONARD DGB, 1988, J CELL BIOL, V106, P181, DOI 10.1083/jcb.106.1.181; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LINDENBAUM MH, 1988, J BIOL CHEM, V263, P5662; LOEB DM, 1992, NEURON, V9, P1053, DOI 10.1016/0896-6273(92)90065-L; MACHIDA CM, 1988, MOL CELL BIOL, V8, P2479, DOI 10.1128/MCB.8.6.2479; MACHIDA CM, 1991, J CELL BIOL, V114, P1037, DOI 10.1083/jcb.114.5.1037; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MANDEL G, 1988, P NATL ACAD SCI USA, V85, P924, DOI 10.1073/pnas.85.3.924; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MINTHWORBY CA, 1995, J BIOL CHEM, V269, P15460; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NG NFL, 1993, J BIOL CHEM, V268, P25329; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NORDSTROM LA, 1995, IN PRESS MOL CELL NE; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SALTON SRJ, 1991, J NEUROCHEM, V57, P991, DOI 10.1111/j.1471-4159.1991.tb08248.x; Sambrook J, 1989, MOL CLONING LABORATO; SANZ L, 1994, J BIOL CHEM, V269, P10044; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; THOMPSON MA, 1992, MOL CELL BIOL, V12, P2501, DOI 10.1128/MCB.12.6.2501; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU BY, 1989, J BIOL CHEM, V264, P9000	72	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9106	9114		10.1074/jbc.270.16.9106	http://dx.doi.org/10.1074/jbc.270.16.9106			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721824	hybrid			2022-12-25	WOS:A1995QU08900012
J	JEFFERSON, AB; MAJERUS, PW				JEFFERSON, AB; MAJERUS, PW			PROPERTIES OF TYPE-II INOSITOL POLYPHOSPHATE 5-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PLASMA-MEMBRANE; HUMAN-ERYTHROCYTES; CARBOXYL METHYLATION; PHOSPHOLIPASE-C; HUMAN-PLATELETS; BOVINE BRAIN; RAT-BRAIN; POLYPHOSPHOINOSITIDES	We have isolated additional cDNA clones encoding type II inositol polyphosphate 5-phosphatase (5-phosphatase II) resulting in a combined cDNA of 3076 nucleotides encoding a protein of 942 amino acids. The 5-phosphatase II hydrolyzed both Ins(1,4,5)P-3 to Ins(1,4)P-2 and the phospholipid PtdIns(4,B)P-2 to PtdIns(4)P both in vitro and in vivo. There are two motifs highly conserved between types I and II 5-phosphatase and several other proteins presumed to be inositol phosphatases suggesting a possible role in catalysis. The type II Fi-phosphatase also contains homology to several GTPase activating proteins although no such activity for 5-phosphatase II was found. The predicted protein ends with the sequence CNPL, suggesting that it is iso prenylated as a mechanism for membrane attachment. We found evidence for isoprenylation by demonstrating incorporation of [H-3]mevalonate into native but not C939S mutant B-phosphatase II expressed in Sig insect cells. Furthermore, we showed that membrane localization and the activity of 5-phosphatase II toward its lipid substrate PtdIns(4,5)P-2 is reduced by eliminating 5-phosphatase II isoprenylation in the mutant C939S relative to the native enzyme.			JEFFERSON, AB (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016634, P50HL014147, R37HL016634, T32HL007088] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16634, HL 14147, HL 07088] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BALDWIN GS, 1993, TRENDS BIOCHEM SCI, V18, P378, DOI 10.1016/0968-0004(93)90093-3; BECK KA, 1991, J BIOL CHEM, V266, P4442; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CALDWELL KK, 1991, J BIOL CHEM, V266, P18378; CHAUHAN A, 1991, ARCH BIOCHEM BIOPHYS, V287, P283, DOI 10.1016/0003-9861(91)90480-7; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CONNOLLY TM, 1987, J BIOL CHEM, V262, P2146; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; COOPER PH, 1975, BIOCHEM J, V150, P537, DOI 10.1042/bj1500537; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DESMEDT F, 1994, FEBS LETT, V347, P639; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; ERNEUX C, 1989, EUR J BIOCHEM, V181, P317, DOI 10.1111/j.1432-1033.1989.tb14726.x; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GOLDSCHMIDTCLER.PJ, 1990, SCIENCE, V247, P1575; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, J BIOL CHEM, V266, P20840; HODGKIN M, 1994, BIOCHEM J, V297, P637, DOI 10.1042/bj2970637; HUANG FL, 1991, J BIOL CHEM, V266, P8727; INGLESE J, 1992, J BIOL CHEM, V267, P1422; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; KING CE, 1989, BIOCHEM J, V259, P893, DOI 10.1042/bj2590893; KING CE, 1987, BIOCHEM J, V244, P209, DOI 10.1042/bj2440209; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LAXMINARAYAN KM, 1993, J BIOL CHEM, V268, P4968; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LEE CZ, 1994, VIROLOGY, V199, P169, DOI 10.1006/viro.1994.1109; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; MEMON AR, 1989, BIOCHEM BIOPH RES CO, V162, P1295, DOI 10.1016/0006-291X(89)90814-0; MISSIAEN L, 1989, BIOCHEM J, V261, P1055, DOI 10.1042/bj2611055; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; MULLER E, 1986, BIOCHEM J, V235, P775; MUMBY S M, 1990, Methods (Orlando), V1, P216, DOI 10.1016/S1046-2023(05)80320-2; NIJJAR MS, 1977, BIOCHIM BIOPHYS ACTA, V480, P390, DOI 10.1016/0005-2744(77)90032-8; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; PALMER FBS, 1990, BIOCHEM CELL BIOL, V68, P800; PALMER FBS, 1994, J BIOL CHEM, V269, P3403; ROACH PD, 1981, BIOCHIM BIOPHYS ACTA, V661, P323, DOI 10.1016/0005-2744(81)90021-8; ROSS TS, 1991, J BIOL CHEM, V266, P20283; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10; TAKIMOTO K, 1989, J BIOCHEM-TOKYO, V106, P684, DOI 10.1093/oxfordjournals.jbchem.a122917; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085; VERJANS B, 1992, EUR J BIOCHEM, V204, P1083, DOI 10.1111/j.1432-1033.1992.tb16732.x; VERJANS B, 1990, CELL SIGNAL, V2, P595, DOI 10.1016/0898-6568(90)90082-L	59	113	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9370	9377		10.1074/jbc.270.16.9370	http://dx.doi.org/10.1074/jbc.270.16.9370			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721860	hybrid			2022-12-25	WOS:A1995QU08900049
J	PHILIPS, N; BASHEY, RI; JIMENEZ, SA				PHILIPS, N; BASHEY, RI; JIMENEZ, SA			INCREASED ALPHA-1(I) PROCOLLAGEN GENE-EXPRESSION IN TIGHT-SKIN (TSK) MICE MYOCARDIAL FIBROBLASTS IS DUE TO A REDUCED INTERACTION OF A NEGATIVE REGULATORY SEQUENCE WITH AP-1 TRANSCRIPTION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ALPHA-1(I) COLLAGEN GENE; BIOCHEMICAL-CHARACTERIZATION; CARDIAC FIBROBLASTS; CONNECTIVE-TISSUE; MESSENGER-RNAS; 1ST INTRON; FOS JUN; MOUSE; PROMOTER; BINDING	The TSK mouse, a model of fibrosis, displays exaggerated connective tissue accumulation in skin and visceral organs including the heart, To study the mechanisms of myocardial fibrosis in TSK mice, we established several strains of TSK mice myocardial fibroblasts in culture and examined the regulation of collagen gene expression in these cells, These strains displayed increased collagen gene expression in comparison with myocardial fibroblasts established from normal mice. On an average, the TSK myocardial fibroblast cultures showed a 4-fold increase in collagen synthesis and 4.4- and 3.6-fold increases, respectively, in alpha 1(I) and alpha 1(III) collagen mRNA steady state levels, The increased alpha 1(I) and alpha 1(III) collagen mRNA levels were mainly due to increased transcription rates (3.4- and 3.8-fold higher, respectively) of the respective genes, Furthermore, we showed that the up-regulation of alpha 1(I) procollagen gene transcription in TSK mice myocardial fibroblasts was due to the lack of the strong inhibitory influence of a regulatory sequence contained in the promoter region encompassing nucleotides -675 to -804, Nuclear extracts from TSK mice myocardial fibroblasts showed lower DNA binding activity to oligonucleotides spanning the mapped regulatory sequence as well as to a consensus AP-1 sequence, but not to a consensus SP-l sequence, and supershift experiments with an AP-1 antibody confirmed the interaction of these oligonucleotides with AP-1 protein. These observations indicate that a strong negative regulatory sequence contained within -0.675 to -0.804 kilobase of the alpha 1(I) procollagen promoter binds AP-1 transcription factor and mediates inhibition of gene transcription in normal murine myocardial fibroblasts, The TSK mice myocardial fibroblasts lack this inhibitory control, due to lower available amounts and/or decreased binding activity to this inhibitory sequence, and hence display increased alpha 1(I) procollagen gene expression.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV RHEUMATOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University				Jimenez, Sergio/0000-0001-5213-1203	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM032564] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 32564] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASHEY RI, 1983, CONNECT TISSUE RES, V12, P17, DOI 10.3109/03008208309005608; BASHEY RI, 1993, CARDIOVASC RES, V27, P1061, DOI 10.1093/cvr/27.6.1061; BASHEY RI, 1992, J MOL CELL CARDIOL, V24, P691, DOI 10.1016/0022-2828(92)93383-U; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPMAN D, 1990, CARDIOVASC RES, V24, P578, DOI 10.1093/cvr/24.7.578; DAVIS LG, 1986, BASIC METHODS MOL BI, P147; DIEGELMANN RF, 1972, DEV BIOL, V28, P443, DOI 10.1016/0012-1606(72)90028-0; EGHBALI M, 1991, CIRC RES, V69, P483, DOI 10.1161/01.RES.69.2.483; EGHBALI M, 1988, J MOL CELL CARDIOL, V20, P267, DOI 10.1016/S0022-2828(88)80059-2; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRENCH BT, 1985, GENE, V39, P311, DOI 10.1016/0378-1119(85)90329-4; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN MC, 1976, AM J PATHOL, V82, P493; HARBERS K, 1984, P NATL ACAD SCI-BIOL, V81, P1504, DOI 10.1073/pnas.81.5.1504; JIMENEZ SA, 1986, J BIOL CHEM, V261, P657; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; JIMENEZ SA, 1984, ARTHRITIS RHEUM-US, V27, P180, DOI 10.1002/art.1780270209; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KATAI H, 1992, MOL CELL BIOCHEM, V118, P119; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIAN JB, 1991, J CELL BIOCHEM, V45, P9, DOI 10.1002/jcb.240450106; LIAU G, 1985, J BIOL CHEM, V260, P3773; MARTY FL, 1985, NCUELCI ACIDS RES, V13, P1431; OSBORN TG, 1987, J MOL CELL CARDIOL, V19, P581, DOI 10.1016/S0022-2828(87)80363-2; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SARIBAN E, 1988, J CLIN INVEST, V81, P1506, DOI 10.1172/JCI113482; SIMKEVICH CP, 1992, BIOCHEM J, V286, P179, DOI 10.1042/bj2860179; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; YAO JL, 1992, CIRC RES, V71, P831, DOI 10.1161/01.RES.71.4.831; YOON K, 1988, GENE, V66, P11, DOI 10.1016/0378-1119(88)90220-X; [No title captured]	36	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9313	9321		10.1074/jbc.270.16.9313	http://dx.doi.org/10.1074/jbc.270.16.9313			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721853	hybrid			2022-12-25	WOS:A1995QU08900041
J	SOKOLOV, BP; ALAKOKKO, L; DHULIPALA, R; ARITA, M; KHILLAN, JS; PROCKOP, DJ				SOKOLOV, BP; ALAKOKKO, L; DHULIPALA, R; ARITA, M; KHILLAN, JS; PROCKOP, DJ			TISSUE-SPECIFIC EXPRESSION OF THE GENE FOR TYPE-I PROCOLLAGEN (COL1A1) IN TRANSGENIC MICE - ONLY 476 BASE-PAIRS OF THE PROMOTER ARE REQUIRED IF COLLAGEN GENES ARE USED AS REPORTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-BETA; PUTATIVE REGULATORY SEQUENCES; PARTIALLY DELETED GENE; MESSENGER-RNA LEVELS; 1ST INTRON; OSTEOGENESIS IMPERFECTA; TRANSCRIPTIONAL CONTROL; LUNG FIBROBLASTS; DNA-SEQUENCES; PHENOTYPE	Inconsistent data have been reported on the size of the promoter that is necessary for high levels of tissue-specific expression of the COL1A1 gene for type I procollagen. Some of the inconsistencies may be traced to the use of reporter gene constructs. Therefore, we prepared transgenic mice with modifications of the intact gene engineered so that the level of expression of the transgene could be assayed both as mRNA and protein that were similar to the products from the endogenous COL1A1 gene. The results with a mini-COL1A1 gene lacking 41 internal exons and introns indicated that the first intron and 90% of the 3'-untranslated region were not essential for tissue-specific expression. In a hybrid COL1A1/COL2A1 construct, a 1,9-kilobase 5'-fragment from the COL1A1 gene that contained only 476 of the promoter was linked to a promoterless 29.5 kilobase fragment of the human COL2A1 gene for type II procollagen. The hybrid COL1A1/COL2A1 construct was expressed as both mRNA and protein in tissues that normally synthesize type I procollagen but not type II procollagen. Apparently, 476 base pairs of the promoter are sufficient to drive tissue-specific expression of the COL1A1 gene and totally inappropriate expression of the COL2A1 gene.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, JEFFERSON INST MOLEC MED, DEPT BIOCHEM & MOLEC BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740, P01AR038188] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-38188, AR-39740] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALAKOKKO L, 1991, J BIOL CHEM, V266, P14175; BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BEDALOV A, 1994, J BIOL CHEM, V269, P4903; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BOAST S, 1990, J BIOL CHEM, V265, P13351; BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; BORNSTEIN P, 1989, PROG NUCLEIC ACID RE, V37, P67; CHOE I, 1987, J BIOL CHEM, V262, P5408; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONSTANTINOU CD, 1989, J CLIN INVEST, V83, P574, DOI 10.1172/JCI113920; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; DECROMBRUGGHE B, 1991, ANN RHEUM DIS, V50, P872, DOI 10.1136/ard.50.Suppl_4.872; FINE A, 1987, J BIOL CHEM, V262, P3897; FINE A, 1989, J BIOL CHEM, V264, P16988; GANGULY A, 1994, P NATL ACAD SCI USA, V91, P7365, DOI 10.1073/pnas.91.15.7365; HELMINEN HJ, 1993, J CLIN INVEST, V92, P582, DOI 10.1172/JCI116625; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; KHILLAN JS, 1991, J BIOL CHEM, V266, P23373; KHILLAN JS, 1994, P NATL ACAD SCI USA, V91, P6298, DOI 10.1073/pnas.91.14.6298; KING SL, 1994, J BIOL CHEM, V269, P13156; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; LISKA DJ, 1990, CELL REGUL, V1, P487, DOI 10.1091/mbc.1.6.487; MAATTA A, 1993, BIOCHEM J, V294, P365, DOI 10.1042/bj2940365; MATHEWS MB, 1980, BIOL COLLAGEN, P193; MOREIRA J L, 1992, Methods in Molecular and Cellular Biology, V3, P23; OLSEN AS, 1991, J BIOL CHEM, V266, P1117; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PEREIRA R, 1994, J CLIN INVEST, V93, P1765, DOI 10.1172/JCI117161; PEREIRA R, 1993, J CLIN INVEST, V91, P709, DOI 10.1172/JCI116252; PIERCE RA, 1987, J BIOL CHEM, V262, P1652; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; PROCKOP DJ, 1994, IN PRESS ANN REV BIO; RAGHOW R, 1989, MOL CELL BIOCHEM, V86, P5; RIPPE RA, 1989, MOL CELL BIOL, V9, P2224, DOI 10.1128/MCB.9.5.2224; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; Rossert J., 1994, Matrix Biology, V14, P370, DOI 10.1016/0945-053X(94)90073-6; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROSSOUW CMS, 1987, J BIOL CHEM, V262, P15151; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066; SOKOLOV BP, 1993, BIOCHEMISTRY-US, V32, P9242, DOI 10.1021/bi00086a033; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; THOREY IS, 1993, MOL CELL BIOL, V13, P6742, DOI 10.1128/MCB.13.11.6742; TROMP G, 1988, BIOCHEM J, V253, P919, DOI 10.1042/bj2530919; VANDENBERG P, 1991, P NATL ACAD SCI USA, V88, P7640, DOI 10.1073/pnas.88.17.7640; WALSH MJ, 1987, J BIOL CHEM, V262, P10814	47	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9622	9629		10.1074/jbc.270.16.9622	http://dx.doi.org/10.1074/jbc.270.16.9622			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721894	hybrid			2022-12-25	WOS:A1995QU08900083
J	STREUSAND, VJ; BJORK, I; GETTINS, PGW; PETITOU, M; OLSON, ST				STREUSAND, VJ; BJORK, I; GETTINS, PGW; PETITOU, M; OLSON, ST			MECHANISM OF ACCELERATION OF ANTITHROMBIN-PROTEINASE REACTIONS BY LOW-AFFINITY HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED PROTEASE INACTIVATION; MOLECULAR WEIGHT HEPARIN; ANTI-THROMBIN-III; FACTOR-XA; CONFORMATIONAL CHANGE; CIRCULAR-DICHROISM; TRANSIENT KINETICS; BINDING-SITE; SPECTROSCOPY; INHIBITION	The role of the sequence-specific pentasaccharide region of high affinity heparin (HAH) in heparin acceleration of antithrombin-proteinase reactions was elucidated by determining the accelerating mechanism of low affinity heparin (LAH) lacking this sequence, LAH was shown to be free of HAH (<0.001%) from the lack of exchange of added fluorescein-labeled HAH into LAH after separating the polysaccharides by antithrombin-agarose chromatography, Fluorescence titrations showed that LAH bound to antithrombin with a 1000-fold weaker affinity (K-D 19 +/- 6 mu M) and 5-6-fold smaller fluorescence enhancement (8 +/- 3%) than HAH. LAH accelerated the antithrombin-thrombin reaction with a bell shaped dependence on heparin concentration resembling that of HAH, but with the bell-shaped curve shifted to similar to 100-fold higher polysaccharide concentrations and with a similar to 100-fold reduced maximal accelerating effect, Rapid kinetic studies indicated these differences arose from a reverse order of assembly of an intermediate heparin-thrombin-antithrombin ternary complex and diminished ability of LAH to bridge antithrombin and thrombin in this complex, as compared to HAH, By contrast, LAH and HAH both accelerated the antithrombin factor Xa reaction with a simple saturable dependence on heparin or inhibitor concentrations which paralleled the formation of an antithrombin-heparin binary complex, The maximal accelerations of the two heparins in this case correlated with the inhibitor fluorescence enhancements induced by the polysaccharides, consistent with the accelerations arising from conformational activation of antithrombin. H-1 NMR difference spectroscopy of antithrombin complexes with LAH and HAH and competitive binding studies were consistent with LAH accelerating activity being mediated by binding to the same site on the inhibitor as HAH, These results demonstrate that LAH accelerates antithrombin-proteinase reactions by bridging and conformational activation mechanisms similar to those of HAH, with the reduced magnitude of LAH accelerations resulting both from a decreased antithrombin affinity and the inability to induce a full activating conformational change in the inhibitor.	UNIV ILLINOIS,CTR MOLEC BIOL ORAL DIS,CHICAGO,IL 60612; UNIV ILLINOIS,DEPT BIOCHEM,CHICAGO,IL 60612; HENRY FORD HOSP,DIV BIOCHEM RES,DETROIT,MI 48202; SWEDISH UNIV AGR SCI,DEPT VET MED CHEM,UPPSALA,SWEDEN; SANOFI RECH,GENTILLY,FRANCE	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Henry Ford Health System; Henry Ford Hospital; Swedish University of Agricultural Sciences; Sanofi-Aventis; Sanofi France					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049234, R37HL049234, R37HL039888, R01HL039888, R29HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-39888, HL-49234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BRAY B, 1989, BIOCHEM J, V262, P225, DOI 10.1042/bj2620225; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DANIELSSON A, 1978, EUR J BIOCHEM, V90, P7, DOI 10.1111/j.1432-1033.1978.tb12568.x; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; FAN BQ, 1994, FEBS LETT, V354, P84, DOI 10.1016/0014-5793(94)01083-8; GAN ZR, 1994, J BIOL CHEM, V269, P1301; GETTINS P, 1987, BIOCHEMISTRY-US, V26, P1391, DOI 10.1021/bi00379a027; GETTINS P, 1992, J BIOL CHEM, V267, P21946; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; GRAY E, 1994, THROMB HAEMOSTASIS, V71, P203; Griffin J H, 1976, Methods Enzymol, V45, P56; GRIFFITH MJ, 1982, J BIOL CHEM, V257, P7360; JACQUES LB, 1977, METHOD BIOCHEM ANAL, V24, P203; JORDAN R, 1979, J BIOL CHEM, V254, P2902; JORDAN RE, 1980, J BIOL CHEM, V255, P81; LANE DA, 1984, BIOCHEM J, V218, P725, DOI 10.1042/bj2180725; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LAURENT TC, 1978, BIOCHEM J, V175, P691, DOI 10.1042/bj1750691; NAGASAWA K, 1978, BIOCHIM BIOPHYS ACTA, V544, P430, DOI 10.1016/0304-4165(78)90110-1; NESHEIM ME, 1983, J BIOL CHEM, V253, P14708; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; NORDENMAN B, 1980, THROMB RES, V17, P595, DOI 10.1016/0049-3848(80)90100-0; NORDENMAN B, 1978, EUR J BIOCHEM, V90, P1, DOI 10.1111/j.1432-1033.1978.tb12567.x; NORDENMAN B, 1978, BIOCHEMISTRY-US, V17, P3339, DOI 10.1021/bi00609a026; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; Olson Steven T., 1994, Perspectives in Drug Discovery and Design, V1, P479, DOI 10.1007/BF02171861; OWEN BA, 1990, BIOCHEMISTRY-US, V29, P9412, DOI 10.1021/bi00492a015; PETITOU M, 1987, CARBOHYD RES, V167, P67, DOI 10.1016/0008-6215(87)80268-9; STONE AL, 1982, P NATL ACAD SCI-BIOL, V79, P7190, DOI 10.1073/pnas.79.23.7190; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; TOLLEFSEN DM, 1989, HEPARIN CHEM BIOL PR, P257; UCHIYAMA H, 1981, J BIOCHEM-TOKYO, V89, P185, DOI 10.1093/oxfordjournals.jbchem.a133180	44	75	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9043	9051		10.1074/jbc.270.16.9043	http://dx.doi.org/10.1074/jbc.270.16.9043			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721817	hybrid			2022-12-25	WOS:A1995QU08900005
J	TREMEAU, O; LEMAIRE, C; DREVET, P; PINKASFELD, S; DUCANCEL, F; BOULAIN, JC; MENEZ, A				TREMEAU, O; LEMAIRE, C; DREVET, P; PINKASFELD, S; DUCANCEL, F; BOULAIN, JC; MENEZ, A			GENETIC-ENGINEERING OF SNAKE TOXINS - THE FUNCTIONAL SITE OF ERABUTOXIN-A, AS DELINEATED BY SITE-DIRECTED MUTAGENESIS, INCLUDES VARIANT RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIAL PROTEIN REFINEMENT; NAJA-NIGRICOLLIS VENOM; ACETYLCHOLINE-RECEPTOR; ALPHA-BUNGAROTOXIN; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; 0.140-NM RESOLUTION; CURAREMIMETIC TOXIN; SEQUENCE-ANALYSIS; ELECTRON-DENSITY	Using site-directed mutagenesis, we previously identified some residues that probably belong to the site by which Erabutoxin a (Ea), a sea snake toxin, recognizes the nicotinic acetylcholine receptor (AcChoR) (Pillet, L., Tremeau, O., Ducancel, F. Drevet, P., Zinn-Justin, S., Pinkasfeld, S., Boulain, J.-C., and Menez, A. (1993) J. Biol. Chem. 268, 909-916). We have now studied the effect of mutating 26 new positions on the affinity of Ea for AcChoR. The mutations are F4A, N5V, H6A, Q7L, S9G, Q10A, P11N, Q12A, T13V, T14A, K15A, T16A, Delta S18, E21A, Y25F, Q28A, S30A, T35A, I36R, P44V, T45A, V46A, K47A, P48Q, I50Q, and S53A. Binding affinity decreases upon mutation at Gln-7, Gln-10 and to a lesser extent at His-6, Ser-9 and Tyr-25 whereas it increases upon mutation at Ile-36. Other mutations have no effect on Ea affinity. In addition, new mutations of the previously explored Ser-8, Asp-81, Arg-33, and Glu-38 better explain the functional role of these residues in Ea. The previous and present mutational analysis suggest that the ''functional'' site of Ea covers a homogeneous surface of at least 680 A(2), encompassing the three toxin loops, and includes both conserved and variant residues. The variable residues might contribute to the selectivity of Ea for some AcChoRs, including those from fish, the prey of sea snakes.	CEA, DSV, DEPT INGN ETUD PROT, F-91191 GIF SUR YVETTE, FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay								AGARD DA, 1982, ACTA CRYSTALLOGR A, V38, P186, DOI 10.1107/S0567739482000436; ARNOUX B, 1994, FEBS LETT, V342, P12, DOI 10.1016/0014-5793(94)80574-1; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BOURNE PE, 1985, EUR J BIOCHEM, V153, P521, DOI 10.1111/j.1432-1033.1985.tb09333.x; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BOYOT P, 1990, FEBS LETT, V266, P87, DOI 10.1016/0014-5793(90)81513-N; BURDEN SJ, 1975, P NATL ACAD SCI USA, V72, P3245, DOI 10.1073/pnas.72.8.3245; Chang C.C., 1979, SNAKE VENOMS, P309; CHANGEUX JP, 1990, TRENDS PHARMACOL SCI, V11, P485, DOI 10.1016/0165-6147(90)90049-E; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CORFIELD PWR, 1989, J BIOL CHEM, V264, P9239; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DUCANCEL F, 1989, PROTEIN ENG, V3, P139, DOI 10.1093/protein/3.2.139; Dufton M.J., 1991, P259; Endo T., 1991, P165; FAURE G, 1983, BIOCHEMISTRY-US, V22, P2068, DOI 10.1021/bi00278a006; FULACHIER MH, 1994, FEBS LETT, V338, P331, DOI 10.1016/0014-5793(94)80294-7; HARVEY AL, 1984, BRIT J PHARMACOL, V82, P709, DOI 10.1111/j.1476-5381.1984.tb10810.x; Heatwole H., 1987, SEA SNAKES; HERVE M, 1992, EUR J BIOCHEM, V208, P125, DOI 10.1111/j.1432-1033.1992.tb17165.x; HORI H, 1976, BIOCHEM J, V153, P217, DOI 10.1042/bj1530217; INAGAKI F, 1978, EUR J BIOCHEM, V89, P433, DOI 10.1111/j.1432-1033.1978.tb12546.x; ISHIKAWA Y, 1977, TOXICON, V15, P477, DOI 10.1016/0041-0101(77)90098-8; ISHIKAWA Y, 1985, BRAIN RES, V346, P82, DOI 10.1016/0006-8993(85)91097-2; JANIN J, 1990, J BIOL CHEM, V265, P16027; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; KAMMORGAN LNW, 1993, P NATL ACAD SCI USA, V90, P3958, DOI 10.1073/pnas.90.9.3958; LAPLANTE SR, 1990, INT J PEPT PROT RES, V36, P227; Lee C.Y., 1976, P193; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; LOW BW, 1986, EUR J BIOCHEM, V161, P579, DOI 10.1111/j.1432-1033.1986.tb10481.x; LOW BW, 1976, P NATL ACAD SCI USA, V73, P2991, DOI 10.1073/pnas.73.9.2991; LOW BW, 1979, HDB EXPT PHARMACOLOG, V52, P213; LOWENADLER B, 1987, GENE, V58, P87, DOI 10.1016/0378-1119(87)90032-1; MENEZ A, 1982, TOXICON, V20, P95, DOI 10.1016/0041-0101(82)90172-6; MENEZ A, 1971, FEBS LETT, V17, P333, DOI 10.1016/0014-5793(71)80180-1; MENEZ A, 1984, J PHYSIOLOGY PARIS, V79, P196; MORI N, 1991, J PHARM PHARMACOL, V43, P785, DOI 10.1111/j.2042-7158.1991.tb03482.x; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; NUSS JM, 1993, PROTEINS, V15, P121, DOI 10.1002/prot.340150204; PILLET L, 1993, J BIOL CHEM, V268, P909; PRASAD L, 1993, J BIOL CHEM, V268, P10705; ROSENTHAL JA, 1994, J BIOL CHEM, V269, P11178; RUAN KH, 1990, P NATL ACAD SCI USA, V87, P6156, DOI 10.1073/pnas.87.16.6156; RYDEN L, 1973, INT J PEPT PROT RES, V5, P261; SAITOH T, 1980, FEBS LETT, V116, P30, DOI 10.1016/0014-5793(80)80522-9; SALUDJIAN P, 1992, ACTA CRYSTALLOGR B, V48, P520, DOI 10.1107/S010876819200096X; SATO S, 1970, J BIOCHEM, V68, P867, DOI 10.1093/oxfordjournals.jbchem.a129425; SATO S, 1971, BIOCHEM J, V122, P453, DOI 10.1042/bj1220453; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAMIYA T, 1985, BIOCHIMIE, V67, P185, DOI 10.1016/S0300-9084(85)80046-8; TSERNOGLOU D, 1977, P NATL ACAD SCI USA, V74, P971, DOI 10.1073/pnas.74.3.971; TSERNOGLOU D, 1976, FEBS LETT, V68, P1, DOI 10.1016/0014-5793(76)80390-0; WALKINSHAW MD, 1980, P NATL ACAD SCI-BIOL, V77, P2400, DOI 10.1073/pnas.77.5.2400; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011; ZINNJUSTIN S, 1994, PROTEIN ENG, V7, P917, DOI 10.1093/protein/7.7.917	59	133	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9362	9369		10.1074/jbc.270.16.9362	http://dx.doi.org/10.1074/jbc.270.16.9362			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721859	hybrid			2022-12-25	WOS:A1995QU08900048
J	PHAM, CD; ARLINGHAUS, RB; ZHENG, CF; GUAN, KL; SINGH, B				PHAM, CD; ARLINGHAUS, RB; ZHENG, CF; GUAN, KL; SINGH, B			CHARACTERIZATION OF MEK1 PHOSPHORYLATION BY THE V-MOS PROTEIN	ONCOGENE			English	Note						MOS ONCOGENE; MAP KINASE KINASE; PROTEIN KINASE ACTIVATION; PHOSPHORYLATION SITES	MAP KINASE-KINASE; MAMMALIAN SOMATIC-CELLS; XENOPUS-OOCYTES; IN-VITRO; METAPHASE ARREST; ONCOGENE PRODUCT; 3T3 CELLS; ACTIVATION; MATURATION; INDUCTION	Activation of MAP kinase/Erk Kinase (MEK) via direct phosphorylation by Mos may be crucial for cellular transformation by the activated c-mos or v-mos gene, Recent studies on a number of different protein kinases showed that phosphorylation within a subdomain of the catalytic domain may represent a common mode of activation, In this regard, activation of MEK1 by Raf involves phosphorylation of serine residues 218 and 222, Here we show that recombinant kinase-inactive MEK1 is phosphorylated by v-Mos with equal efficiency at both Ser 218 and Ser 222 in vitro, Tryptic phosphopeptide analysis of glutathione-S-transferase (GST)-MEK1 K97R and its alanine-for-serine mutants indicated that Ser 222 is the preferred phosphorylation site. Wild-type GST-MEK1 was phosphorylated at the same sites but contained a significantly lower amount of doubly phosphorylated species then its K97R kinase-inactive mutant, The ratio of GST-MEK1 species phosphorylated at two serines to those phosphorylated at one serine was similar in auto-phosphorylated and v-Mos-phosphorylated GST-MEK1, Consistent with the in vitro data, phosphopeptide mapping of MEK1 immunoprecipitated from mos transformed cells showed an increased amount of singly phosphorylated phosphopeptide compared to nontransformed cells, MEK1 was found to be more highly activated in NM3T3 cells transformed by an activated c-mos or v-mos gene than in cells growing normally in medium containing serum, Our data indicate that Mos activates MEK1 in vitro as well as in vivo by phosphorylating Ser 222.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOLEC PATHOL, HOUSTON, TX 77030 USA; UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, INST GERONTOL, ANN ARBOR, MI 48109 USA	University of Texas System; UTMD Anderson Cancer Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NCI NIH HHS [CA 45125] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045125] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROTT BK, 1993, CELL GROWTH DIFFER, V4, P921; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; GOTOH Y, 1994, ONCOGENE, V9, P1891; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIU JX, 1990, ONCOGENE, V5, P171; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PAULES RS, 1992, ONCOGENE, V7, P2489; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1992, MOL CARCINOGEN, V6, P182, DOI 10.1002/mc.2940060303; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	35	28	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1683	1688						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731726				2022-12-25	WOS:A1995QU68100028
J	FONSECA, MI; BUTTON, DC; BROWN, RD				FONSECA, MI; BUTTON, DC; BROWN, RD			AGONIST REGULATION OF ALPHA(1B)-ADRENERGIC RECEPTOR SUBCELLULAR-DISTRIBUTION AND FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SMOOTH-MUSCLE CELLS; DDT1 MF-2 CELLS; ALPHA-1-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; INTRACELLULAR CA-2+; DESENSITIZATION; SUBTYPES; CDNA; EXPRESSION	We have monitored agonist-induced alpha(1B)-adrenergic receptor (alpha(1B)AR) redistribution by immunocytochemical procedures in concert with functional measurements of agonist-elicited [H-3]inositol phosphate (InsP) production in human embryonal kidney 293 cells stably expressing alpha(1B)AR cDNA (HEK293/alpha(1B)). Anti-peptide antibodies directed against the carboxyl-terminal decapeptide of the alpha(1B)AR were prepared and shown to react specifically with alpha(1B)AR on immunoblots and in situ in HEK293/alpha(1B) transfectants. Treatment of HEK293/alpha(1B) cells with norepinephrine (10 mu M) results in a rapid (5-15 min) and striking internalization of cell surface receptor as visualized by confocal immunofluorescence microscopy. Receptor redistribution is sustained in the presence of agonist, rapidly reversed upon agonist removal, and prevented by the alpha(1) antagonist prazosin. Receptor internalizes to endosomes, as shown by colocalization with transferrin receptor, an endosomal marker. Activation of protein kinase C (PKC) with phorbol 12-myristate 13-acetate (50 nM) causes receptor endocytosis similar to agonist; agonist-induced internalization is blocked by the PKC inhibitor staurosporine (0.5 mu M). In parallel experiments, agonist-induced [H-3]InsP production is abolished by phorbol 12-myristate 13-acetate but potentiated by staurosporine. Inhibition of receptor internalization with hypertonic sucrose attenuates agonist-induced [H-3]InsP formation; this effect is reversed by concomitant inhibition of PKC with staurosporine. These results suggest that PKC-dependent phosphorylation occurring as a consequence of alpha(1)AR stimulation induces receptor desensitization and internalization. Internalized receptor is reactivated and continuously recycled to the cell surface during agonist exposure.	UNIV ILLINOIS,DEPT PHARMACOL MC 868,CHICAGO,IL 60612; NIMH,CELL BIOL LAB,BETHESDA,MD 20892	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)					NIGMS NIH HHS [GM 41470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBLER SK, 1984, MOL PHARMACOL, V26, P405; BAHOUTH SW, 1991, TRENDS PHARMACOL SCI, V12, P338, DOI 10.1016/0165-6147(91)90593-H; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BAZAN E, 1993, EUR J PHARM-MOLEC PH, V245, P173, DOI 10.1016/0922-4106(93)90125-S; BOLTON TB, 1979, PHYSIOL REV, V59, P606, DOI 10.1152/physrev.1979.59.3.606; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RD, 1986, MOL PHARMACOL, V29, P531; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; COWLEN MS, 1987, J PHARMACOL EXP THER, V243, P527; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DROOGMANS G, 1977, J GEN PHYSIOL, V70, P129, DOI 10.1085/jgp.70.2.129; FONSECA MI, 1991, BRIAN RES, V563, P63; FRATELLI M, 1987, FEBS LETT, V212, P149, DOI 10.1016/0014-5793(87)81575-2; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAN C, 1987, MOL PHARMACOL, V32, P505; HAN C, 1987, NATURE, V329, P333, DOI 10.1038/329333a0; HANFT G, 1989, BRIT J PHARMACOL, V97, P691, DOI 10.1111/j.1476-5381.1989.tb12005.x; HARDEN TK, 1980, SCIENCE, V210, P44; HARLOW E, 1988, ANTIBODIES LABORATOR; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HUGHES RJ, 1986, MOL PHARMACOL, V29, P521; HUTSON NJ, 1976, J BIOL CHEM, V251, P5200; KAN WH, 1979, BIOCHEM BIOPH RES CO, V91, P303, DOI 10.1016/0006-291X(79)90618-1; KURZ JB, 1991, MOL PHARMACOL, V41, P375; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LOMASNEY JW, 1991, J BIOL CHEM, V266, P6365; LURIE KG, 1985, J PHARMACOL EXP THER, V234, P147; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; MINNEMAN KP, 1988, MOL PHARMACOL, V33, P509; MINNEMAN KP, 1987, ALPHA1 ADRENERGIC RE, P269; MORROW AL, 1986, MOL PHARMACOL, V29, P321; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; REECE JF, 1990, CALCIUM CHANNEL MODULATORS IN HEART AND SMOOTH MUSCLE, P125; RUFFOLO RR, 1991, PHARMACOL REV, V43, P275; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; SHAO YP, 1993, MOL PHARMACOL, V44, P247; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; SMALL GM, 1988, ANAL BIOCHEM, V169, P405, DOI 10.1016/0003-2697(88)90304-1; STAEHELIN M, 1982, EMBO J, V1, P187, DOI 10.1002/j.1460-2075.1982.tb01145.x; TERMAN BI, 1988, BIOCHEM J, V253, P363, DOI 10.1042/bj2530363; TOEWS ML, 1987, MOL PHARMACOL, V31, P58; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WICKBERG JES, 1983, LIFE SCI, V33, P1409; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3; YU SS, 1993, J BIOL CHEM, V268, P337; Zhu S.-J., 1993, Society for Neuroscience Abstracts, V19, P500	50	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8902	8909		10.1074/jbc.270.15.8902	http://dx.doi.org/10.1074/jbc.270.15.8902			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721798	hybrid			2022-12-25	WOS:A1995QT44800077
J	IWAMOTO, T; WAKABAYASHI, S; SHIGEKAWA, M				IWAMOTO, T; WAKABAYASHI, S; SHIGEKAWA, M			GROWTH FACTOR-INDUCED PHOSPHORYLATION AND ACTIVATION OF AORTIC SMOOTH-MUSCLE NA+/CA2+ EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SARCOLEMMAL NA+-CA2+ EXCHANGER; SODIUM-CALCIUM EXCHANGE; MEMBRANE CA-2+ PUMP; DEPENDENT PHOSPHORYLATION; FUNCTIONAL EXPRESSION; PRIMARY CULTURE; SQUID AXONS; CELLS; CLONING	Although the Na+/Ca2+ exchanger is one of the major Ca2+ extrusion systems in excitable tissues, little is known about its regulation via protein phosphorylation. We now present evidence that the Na+/Ca2+ exchanger is phosphorylated in quiescent and growth factor-stimulated cultured aortic smooth muscle cells. The Na+/Ca2+ exchanger was isolated from P-32-labeled cells by immunoprecipitation with a specific polyclonal antibody. Phosphorylation of the exchanger was increased by up to 1.7-fold in response to platelet-derived growth factor-EE (PDGF-BB), alpha-thrombin, or phorbol 12-myristate 13-acetate (PMA). However, angiotensin II did not enhance the phosphorylation significantly. The extent of phosphorylation appeared to correlate with the growth factor-induced increase in cell 1,2-diacylglycerol. At least four phosphopeptides (P1 to P4) were detected by tryptic phosphopeptide map analysis of the phosphorylated exchanger, suggesting that phosphorylation occurred at multiple sites. PDGF-BB and PMA increased phosphorylation of the same phosphopeptides (in particular P1). Phosphorylated amino acids were exclusively serine residues in both quiescent and stimulated cells. We found that growth factors enhanced Na+/Ca2+ exchange activity and that there was a good correlation between the growth factor-induced stimulations tions of phosphorylation and exchange activity. PDGF-BB-induced induced activation of the exchanger was abolished by prior long treatment of cells with PMA. These results suggest that the Na+/Ca2+ exchanger is activated by protein kinase C-dependent phosphorylation in response to growth factors in vascular smooth muscle cells.	NATL CARDIOVASC CTR, RES INST, DEPT MOLEC PHYSIOL, SUITA, OSAKA 565, JAPAN	National Cerebral & Cardiovascular Center - Japan								BLOCK LH, 1989, P NATL ACAD SCI USA, V86, P2388, DOI 10.1073/pnas.86.7.2388; CARONI P, 1983, EUR J BIOCHEM, V132, P451, DOI 10.1111/j.1432-1033.1983.tb07383.x; CHAMLEY JH, 1977, CELL TISSUE RES, V177, P503; CHOYI MA, 1991, AM J PHYSIOL, V261, pC685; CIRILLO M, 1993, CIRC RES, V72, P847, DOI 10.1161/01.RES.72.4.847; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DILIBERTO PA, 1990, J CELL BIOCHEM, V44, P39, DOI 10.1002/jcb.240440104; DIPOLO R, 1987, BIOCHIM BIOPHYS ACTA, V897, P347, DOI 10.1016/0005-2736(87)90432-9; DIPOLO R, 1984, J GEN PHYSIOL, V84, P895, DOI 10.1085/jgp.84.6.895; DIPOLO R, 1994, AM J PHYSIOL, V266, pC1382, DOI 10.1152/ajpcell.1994.266.5.C1382; DULLEY JR, 1975, ANAL BIOCHEM, V64, P136, DOI 10.1016/0003-2697(75)90415-7; FUKUDA T, 1990, J BIOCHEM-TOKYO, V108, P629, DOI 10.1093/oxfordjournals.jbchem.a123254; FURMAN I, 1993, FEBS LETT, V319, P105, DOI 10.1016/0014-5793(93)80046-W; FURUKAWA KI, 1989, J BIOL CHEM, V264, P4844; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; FURUKAWA KI, 1991, J BIOL CHEM, V266, P12337; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1992, J PHYSIOL-LONDON, V454, P59, DOI 10.1113/jphysiol.1992.sp019254; HUANG CL, 1987, J BIOL CHEM, V262, P14134; IWAMOTO T, 1994, CAN J PHARM PHYSL S1, V72, P527; IWATA Y, 1993, FEBS LETT, V329, P227, DOI 10.1016/0014-5793(93)80227-L; IWATA Y, 1994, FEBS LETT, V355, P65, DOI 10.1016/0014-5793(94)01174-5; KHOYI MA, 1993, AM J PHYSIOL, V265, pC1325; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; LI ZP, 1991, J BIOL CHEM, V266, P1014; LI ZP, 1994, J BIOL CHEM, V269, P17434; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MOOLENAAR WH, 1986, ANNU REV PHYSIOL, V48, P363; NAKASAKI Y, 1993, J BIOCHEM-TOKYO, V114, P528, DOI 10.1093/oxfordjournals.jbchem.a124211; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; OGURUSU T, 1990, J BIOCHEM-TOKYO, V108, P222, DOI 10.1093/oxfordjournals.jbchem.a123184; PANET R, 1991, J CELL BIOL, V114, P337, DOI 10.1083/jcb.114.2.337; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Philipson K D, 1993, Int Rev Cytol, V137C, P199; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; REILLY RF, 1992, AM J PHYSIOL, V262, pF1105, DOI 10.1152/ajprenal.1992.262.6.F1105; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; SMITH JB, 1990, AM J PHYSIOL, V259, pC302, DOI 10.1152/ajpcell.1990.259.2.C302; SMITH JB, 1989, AM J PHYSIOL, V256, pC147, DOI 10.1152/ajpcell.1989.256.1.C147; VIGNE P, 1988, J BIOL CHEM, V263, P8078; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583	45	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8996	9001		10.1074/jbc.270.15.8996	http://dx.doi.org/10.1074/jbc.270.15.8996			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721810	hybrid			2022-12-25	WOS:A1995QT44800090
J	ZHANG, QY; ROMBEL, I; REDDY, GN; GANG, JB; SHEN, CKJ				ZHANG, QY; ROMBEL, I; REDDY, GN; GANG, JB; SHEN, CKJ			FUNCTIONAL ROLES OF IN-VIVO FOOTPRINTED DNA MOTIFS WITHIN AN ALPHA-GLOBIN ENHANCER - ERYTHROID LINEAGE AND DEVELOPMENTAL STAGE SPECIFICITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE ERYTHROLEUKEMIA-CELLS; REGULATORY ELEMENT UPSTREAM; LOCUS-CONTROL REGION; TRANSCRIPTION FACTOR; TRANSGENIC MICE; GENE-EXPRESSION; MOLECULAR-GENETICS; INDUCIBLE ENHANCER; HUMAN-HEMOGLOBIN; FAR UPSTREAM	Transcriptional regulation of the human alpha-like globin genes, embryonic zeta 2 and adult alpha, during erythroid development is mediated by a distal enhancer, HS 40. Previous protein-DNA binding studies have shown that HS-40 consists of multiple nuclear factor binding motifs that are occupied in vivo in an erythroid lineage- and developmental stage-specific manner. We have systematically analyzed the functional roles of these factor binding motifs of HS-40 by site-directed mutagenesis and transient expression assay in erythroid cell cultures. Three of these HS-40 enhancer motifs, 5'NF-E2/ AP1, GT II, and GATA-1(c), positively regulate the zeta 2-globin promoter activity in embryonic/fetal erythroid K562 cells and the adult alpha-globin promoter activity in adult erythroid MEL cells. On the other hand, the 3'NF-E2/AP1 motif is able to exert both positive and negative regulatory effects on the zeta 2-globin promoter activity in K562 cells, and this dual function appears to be modulated through differential binding of the ubiquitous AP1 factors and the erythroid-enriched NF-E2 factor. Mutation in the GATA-1(d) motif, which exhibits an adult erythroid-specific genomic footprint, decreases the HS-40 enhancer function in dimethyl sulfoxide-induced MEL cells but not in K562 cells. These studies have defined the regulatory roles of the different HS-40 moths. The remarkable correlation between genomic footprinting data and the mutagenesis results also suggests that the erythroid lineage- and developmental stage-specific regulation of human alpha-like globin promoters is indeed modulated by stable binding of specific nuclear factors in vivo.	UNIV CALIF DAVIS,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029800] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-29800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ALBITAR M, 1989, BLOOD, V74, P629; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11371; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V12, P2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; CHUI DHK, 1989, BLOOD, V74, P1409; COLLINS FS, 1984, PROG NUCLEIC ACID RE, V31, P315, DOI 10.1016/S0079-6603(08)60382-7; DEISSEROTH A, 1979, P NATL ACAD SCI USA, V76, P2185, DOI 10.1073/pnas.76.5.2185; ELLIS J, 1993, EMBO J, V12, P129; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOURDON G, 1994, NUCLEIC ACIDS RES, V22, P4139, DOI 10.1093/nar/22.20.4139; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HIGGS DR, 1989, BLOOD, V73, P1081; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MILLER JL, 1993, BLOOD, V82, P1900; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; MOI P, 1990, P NATL ACAD SCI USA, V87, P9000, DOI 10.1073/pnas.87.22.9000; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PONDEL MD, 1992, NUCLEIC ACIDS RES, V20, P237, DOI 10.1093/nar/20.2.237; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; REDDY PMS, 1993, MOL CELL BIOL, V13, P1093, DOI 10.1128/MCB.13.2.1093; REN SC, 1993, BLOOD, V81, P1058; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Sambrook J, 1989, MOL CLONING LABORATO; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHARPE JA, 1992, EMBO J, V11, P4565, DOI 10.1002/j.1460-2075.1992.tb05558.x; SHARPE JA, 1993, P NATL ACAD SCI USA, V90, P11262, DOI 10.1073/pnas.90.23.11262; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; STAMATOYANNOPOU.G, 1991, SCIENCE, V252, P383; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; VYAS P, 1992, BLOOD, V80, P1832; ZHANG QY, 1993, MOL CELL BIOL, V13, P2298, DOI 10.1128/MCB.13.4.2298	59	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8501	8505		10.1074/jbc.270.15.8501	http://dx.doi.org/10.1074/jbc.270.15.8501			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721747	hybrid			2022-12-25	WOS:A1995QT44800023
J	BERNARDO, K; HURWITZ, R; ZENK, T; DESNICK, RJ; FERLINZ, K; SCHUCHMAN, EH; SANDHOFF, K				BERNARDO, K; HURWITZ, R; ZENK, T; DESNICK, RJ; FERLINZ, K; SCHUCHMAN, EH; SANDHOFF, K			PURIFICATION, CHARACTERIZATION, AND BIOSYNTHESIS OF HUMAN ACID CERAMIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LONG-CHAIN BASES; AMINO-ACIDS; INHIBITION; SPHINGOMYELINASE; DIFFERENTIATION; CHROMATOGRAPHY; SPHINGOSINE; SPHINGANINE; DERIVATIVES	Acid ceramidase (N-acylsphingosine deacylase, EC 3.5.1.23) is the lysosomal enzyme catalyzing the hydrolysis of ceramide to sphingosine and free fatty acid, Its inherited deficiency causes ceramide accumulation in Farber's disease. The enzyme was purified to apparent homogeneity from human urine by sequential chromatography on octyl-Sepharose, concanavalin A-Sepharose, blue-Sepharose, and DEAE-cellulose. The final preparation, which was enriched similar to 4450-fold over the starting material, resulted in a polypeptide of similar to 50 kDa and could be reduced into two subunits of similar to 13 (alpha) and similar to 40 (beta) kDa. Treatment of the purified enzyme with endoglycosidase H or peptide-N-glycanase F reduced the molecular mass of the beta subunit to similar to 30-35 and similar to 27 kDa, respectively. In contrast, the molecular mass of the alpha subunit was unchanged, The purified enzyme had an apparent K-m of 149 mu M and a V-max of 136 nmol/mg/h using N-lauroylsphingosine as substrate. Polyclonal antibodies were raised against the purified urinary enzyme and used to investigate the biosynthesis of acid ceramidase. Immunoprecipitation studies on metabolically labeled skin fibroblasts indicated that both subunits arose from a single precursor of similar to 55 kDa. A minor portion of newly synthesized acid ceramidase was secreted into the me dium as a monomeric 47-kDa protein, indicating that generation of the mature heterodimeric enzyme occurred in endosomal and/or lysosomal compartments.	UNIV BONN,INST ORGAN CHEM & BIOCHEM,D-53121 BONN,GERMANY; CUNY MT SINAI SCH MED,DEPT HUMAN GENET,NEW YORK,NY 10029	University of Bonn; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								ARORA RC, 1972, J LIPID RES, V13, P86; CHEN WW, 1981, ARCH BIOCHEM BIOPHYS, V208, P444, DOI 10.1016/0003-9861(81)90531-2; CHEN WW, 1979, FED PROC, V38, P405; Freund J, 1942, P SOC EXP BIOL MED, V49, P548; FREUND J, 1952, ADV TUBERC RES, V7, P130; GATT S, 1963, J BIOL CHEM, V238, P3131; GATT S, 1966, J BIOL CHEM, V241, P3724; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HERBERT WJ, 1986, HDB EXPT IMMUNOLOGY; JARRETT HW, 1986, ANAL BIOCHEM, V153, P189, DOI 10.1016/0003-2697(86)90079-5; KAN CC, 1993, TRENDS GLYCOSCI GLYC, V5, P99; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MORELL P, 1972, J LIPID RES, V13, P203; MOSER HW, 1983, METABOLIC BASIS INHE, P820; NIELSON A, 1969, BIOCHIM BIOPHYS ACTA, V176, P339; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PENTCHEV PG, 1973, J BIOL CHEM, V248, P5256; POOLE TB, 1987, UFAW HDB CARE MANAGE, P56; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; ROTH M, 1971, ANAL CHEM, V43, P880, DOI 10.1021/ac60302a020; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; SCHAGGER H, 1987, ANAL BIOCHEM, V106, P368; SCHNABEL D, 1992, J BIOL CHEM, V267, P3312; SHAPIRO D, 1961, J AM CHEM SOC, V83, P3327, DOI 10.1021/ja01476a033; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG E, 1991, J BIOL CHEM, V266, P14486; WEITZ G, 1986, ENZYMES LIPID METABO, V2, P261; WILSON E, 1986, J BIOL CHEM, V261, P2616; YAMANAKA T, 1982, J NEUROCHEM, V38, P1753, DOI 10.1111/j.1471-4159.1982.tb06659.x; YAVIN E, 1969, BIOCHEMISTRY-US, V8, P1692, DOI 10.1021/bi00832a052; ZIMMERMANN P, 1988, LIEBIGS ANN CHEM, P663	38	161	174	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11098	11102		10.1074/jbc.270.19.11098	http://dx.doi.org/10.1074/jbc.270.19.11098			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744740	hybrid			2022-12-25	WOS:A1995QX86500015
J	JANSSEN, JJM; BOVEEGEURTS, PHM; MERKX, M; DEGRIP, WJ				JANSSEN, JJM; BOVEEGEURTS, PHM; MERKX, M; DEGRIP, WJ			HISTIDINE TAGGING BOTH ALLOWS CONVENIENT SINGLE-STEP PURIFICATION OF BOVINE RHODOPSIN AND EXERTS IONIC STRENGTH-DEPENDENT EFFECTS ON ITS PHOTOCHEMISTRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							META-II; DIFFERENCE SPECTROSCOPY; RECOMBINANT PROTEINS; INSECT CELLS; EXPRESSION; BACULOVIRUS; GENE; PROTONATION; MEMBRANE; INVITRO	For rapid single-step purification of recombinant rhodopsin, a baculovirus expression vector was constructed containing the bovine opsin coding sequence extended at the 3'-end by a short sequence encoding six histidine residues, Recombinant baculovirus-infected Spodoptera frugiperda cells produce bovine opsin carrying a C terminal histidine tag (v-opshis(6x)). The presence of this tag was confirmed by immunoblot analysis. Incubation with 11-cis-retinal produced a photosensitive pigment (v-Rhohis(6x)) at a level of 15-20 pmol/10(6) cells. The histidine tag was exploited to purify v-rthohis(6x) via immobilized metal affinity chromatography. Optimized immobilized metal affinity chromatography yielded a binding capacity of greater than or equal to 35 nmol of v-Rhohis(6x) per ml of resin and purification factors up to 500. Best samples were at least 85% pure, with an average age purity of 70% (A(280) nm/A(500) nm = 2.5 +/- 0.4, n = 7). Remaining contamination was largely removed upon reconstitution into lipids, yielding rhodopsin proteoliposomes with a purity over 95%. Spectral analysis of v-Rhohis(6x) showed a small but significant red shift (501 +/- 1 nm) compared to wild type rhodopsin (498 +/- 1 nm). The pK(a) of the Meta I <-> Meta II equilibrium in v-Rhohis(6x) is down-shifted from 7.3 to 6.4 resulting in a significant shift at pH 6.5 toward the Meta I photointermediate. Both effects are reversed upon increasing the ionic strength. FT-IR analysis of the Rho --> Meta II transition shows that the corresponding structural changes are identical in wild type and v-Rhohis(6x).			JANSSEN, JJM (corresponding author), UNIV NIJMEGEN,CTR EYE RES,DEPT BIOCHEM,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.		Merkx, Maarten/E-7009-2011; Merkx, Matthias AW/H-8074-2014; DeGrip, Willem/L-4335-2015	Merkx, Matthias AW/0000-0002-0687-9760; DeGrip, Willem/0000-0001-7637-4920				BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; BROEKHUYSE RM, 1968, BIOCHIM BIOPHYS ACTA, V152, P307, DOI 10.1016/0005-2760(68)90038-6; CHEN XS, 1993, EUR J BIOCHEM, V214, P845, DOI 10.1111/j.1432-1033.1993.tb17988.x; COTTON RGH, 1993, MUTAT RES, V285, P125, DOI 10.1016/0027-5107(93)90060-S; de Grip W. J., 1985, PROG RETIN RES, V4, P137; DeCaluwe G. L. J., 1993, METHODS NEUROSCI, V15, P307; DEGRIP WJ, 1988, PHOTOCHEM PHOTOBIOL, V48, P497, DOI 10.1111/j.1751-1097.1988.tb02852.x; DEGRIP WJ, 1983, BIOCHIM BIOPHYS ACTA, V734, P168, DOI 10.1016/0005-2736(83)90115-3; DEGRIP WJ, 1985, BIOCHIM BIOPHYS ACTA, V809, P97, DOI 10.1016/0005-2728(85)90172-0; DEGRIP WJ, 1979, CHEM PHYS LIPIDS, V23, P321, DOI 10.1016/0009-3084(79)90010-0; FAHMY K, 1993, P NATL ACAD SCI USA, V90, P10206, DOI 10.1073/pnas.90.21.10206; GENTZ R, 1988, EMBO J, V7, P225, DOI 10.1002/j.1460-2075.1988.tb02803.x; HENDRIKS T, 1976, BIOCHIM BIOPHYS ACTA, V433, P271, DOI 10.1016/0005-2736(76)90093-6; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; JANSEN JJM, 1991, BIOCHIM BIOPHYS ACTA, V1089, P68, DOI 10.1016/0167-4781(91)90086-2; JANSSEN JJM, 1988, MOL BIOL REP, V13, P65, DOI 10.1007/BF00539052; JANSSEN JJM, 1990, FEBS LETT, V260, P113, DOI 10.1016/0014-5793(90)80080-3; KHORANA HG, 1988, P NATL ACAD SCI USA, V85, P7917, DOI 10.1073/pnas.85.21.7917; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Molday RS, 1989, PROG RET RES, V8, P173; NATHANS J, 1989, VISION RES, V29, P907, DOI 10.1016/0042-6989(89)90105-3; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; OPRIAN DD, 1991, BIOCHEMISTRY-US, V30, P11367, DOI 10.1021/bi00112a002; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; RATH P, 1993, BIOCHEMISTRY-US, V32, P10277, DOI 10.1021/bi00090a001; REDDY RG, 1994, ARCH BIOCHEM BIOPHYS, V312, P219, DOI 10.1006/abbi.1994.1302; ROTHSCHILD KJ, 1987, BIOPHYS J, V51, P345, DOI 10.1016/S0006-3495(87)83341-6; ROTHSCHILD KJ, 1980, BIOCHIM BIOPHYS ACTA, V596, P338, DOI 10.1016/0005-2736(80)90121-2; SMITH MC, 1988, J BIOL CHEM, V263, P7211; SUMMERS MD, 1987, TEX AGR EXP STN B, P1555; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; WANG MY, 1994, BIOTECHNOL BIOENG, V43, P349, DOI 10.1002/bit.260430502; ZOZULYA SA, 1990, PROTEIN ENG, V3, P453, DOI 10.1093/protein/3.5.453; ZUIDEMA D, 1990, J GEN VIROL, V71, P2201, DOI 10.1099/0022-1317-71-10-2201	36	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11222	11229		10.1074/jbc.270.19.11222	http://dx.doi.org/10.1074/jbc.270.19.11222			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744755	Green Published, Green Submitted, hybrid			2022-12-25	WOS:A1995QX86500032
J	KOVACSOVICS, TJ; BACHELOT, C; TOKER, A; VLAHOS, CJ; DUCKWORTH, B; CANTLEY, LC; HARTWIG, JH				KOVACSOVICS, TJ; BACHELOT, C; TOKER, A; VLAHOS, CJ; DUCKWORTH, B; CANTLEY, LC; HARTWIG, JH			PHOSPHOINOSITIDE 3-KINASE INHIBITION SPARES ACTIN ASSEMBLY IN ACTIVATING PLATELETS BUT REVERSES PLATELET-AGGREGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PROTEIN-KINASE-C; THROMBIN-STIMULATED PLATELETS; HUMAN BLOOD-PLATELETS; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; 3-PHOSPHORYLATED PHOSPHOINOSITIDES; MONOCLONAL-ANTIBODIES	Platelet stimulation by thrombin leads to the activation of phosphoinositide 3-kinase (PI 3-K) and to the production of the D3 phosphoinositides, phosphatidylinositol 3,4-bisphosphate (PdtIns-3,4-P-2) and 3,4,5-trisphosphate (PdtIns-3,4,5-P-3). Because changes in the levels of these phosphoinositides correlate with the kinetics of actin assembly, they have been proposed to mediate actin assembly, causing cell shape changes, Wortmannin and LY294002, two unrelated inhibitors of PI 3-K, were used to investigate the role of PI 3-K in platelet actin assembly and aggregation. Both PI 3-K inhibitors abrogated the production of PdtIns-3,4-P-2 and PdtIns-3,4,5-P-3 in thrombin receptor-activating peptide (TRAP)-stimulated cells. However, neither wortmannin nor LY294002 altered the kinetics of actin assembly or the exposure of nucleation sites in TRAP-stimulated cells. In contrast, PI 3-K inhibitors showed a specific inhibitory pattern of cell aggregation, characterized by a primary phase of aggregation followed by progressive disaggregation. Flow cytometry analysis with the PAC1 monoclonal antibody or with FITC-labeled fibrinogen indicated that wortmannin inhibited the maintenance of the platelet integrin GPIIb-IIIa in its active state. Wortmannin also inhibited, in a dose-dependent manner, platelet aggregation induced by the binding of the monoclonal antibodies P256 and LIBS-6 to GPIIb-IIIa. LIBS Fab-induced aggregation also led to the production of PdtIns 3,4 P-2. Platelet secretion, as evidenced by the release of preloaded C-14-5-hydroxytryptamine secretion or P-selectin up-regulation, was not affected by PI 3-K inhibition. These results demonstrate that the generation of D3 phosphoinositides is not required for actin assembly in TRAP-activated platelets, However, PI 3-K stimulation is necessary for prolonged GPIIb-IIIa activation and irreversible platelet aggregation, PI 3-K stimulation downstream of GPIIb-IIIa engagement may provide positive feedback required to sustain active GPIIb-IIIa.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV EXPTL MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT ANAT & CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; ELI LILLY & CO,LILLY RES LABS,CARDIOVASC RES,INDIANAPOLIS,IN 46285; BETH ISRAEL HOSP,DEPT MED,DIV SIGNAL TRANSDUCT,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Eli Lilly; Harvard University; Beth Israel Deaconess Medical Center			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Bachelot-Loza, Christilla/0000-0002-6264-902X	NHLBI NIH HHS [HL47874] Funding Source: Medline; NIGMS NIH HHS [GM41890, R01 GM041890] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041890, R01GM041890] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRANOFF BW, 1983, J BIOL CHEM, V258, P2076; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACHELOT C, 1990, EUR J BIOCHEM, V190, P177, DOI 10.1111/j.1432-1033.1990.tb15562.x; BACHELOT C, 1991, BIOCHEM J, V284, P923; BACHELOT C, 1991, CELL SIGNAL, V3, P539; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BENGTSSON T, 1989, J BIOL CHEM, V263, P17385; BILLAH MM, 1982, J BIOL CHEM, V257, P2705; CALVETE JJ, 1994, THROMB HAEMOSTASIS, V72, P1; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CASELLA JF, 1981, NATURE, V293, P302, DOI 10.1038/293302a0; CHANG JD, 1993, J BIOL CHEM, V268, P14208; CRABOS M, 1992, BIOCHEM J, V288, P891, DOI 10.1042/bj2880891; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; EBERLE M, 1990, J BIOL CHEM, V265, P16725; FARADAY N, 1994, J LAB CLIN MED, V123, P728; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GRABER SE, 1982, J BIOL CHEM, V257, P4606; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HANNUN YA, 1987, J BIOL CHEM, V262, P13620; HARTWIG JH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P64, DOI 10.1016/0167-4889(89)90185-7; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P17078; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HUANG RS, 1991, J BIOL CHEM, V266, P18435; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KING WG, 1991, BIOCHEM J, V278, P475, DOI 10.1042/bj2780475; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MICHELSON AD, 1991, BLOOD, V77, P770; MORII N, 1992, J BIOL CHEM, V267, P20921; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NAKASHIMA S, 1991, BIOCHEM J, V275, P355, DOI 10.1042/bj2750355; NOLAN RD, 1990, J BIOL CHEM, V265, P2441; OKADA T, 1994, J BIOL CHEM, V269, P3563; POWIS G, 1994, CANCER RES, V54, P2419; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; RIDLEY AJ, 1992, CELL, V70, P410; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1987, BLOOD, V70, P307; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SULTAN C, 1991, J BIOL CHEM, V266, P23554; SULTAN C, 1990, BIOCHEM J, V269, P831, DOI 10.1042/bj2690831; THOMAS KM, 1990, J BIOL CHEM, V265, P20061; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOKER A, 1994, J BIOL CHEM, V269, P32358; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; VANWILLIGEN G, 1991, BIOCHEM J, V273, P115, DOI 10.1042/bj2730115; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VLAHOS CJ, 1995, IN PRESS DRUGS FUTUR; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WATSON SP, 1988, BIOCHEM J, V246, P345; WENNSTROM S, 1994, ONCOGENE, V9, P651; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YANO H, 1993, J BIOL CHEM, V268, P25846; YATOMI Y, 1992, BIOCHEM J, V285, P745, DOI 10.1042/bj2850745; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHANG J, 1993, J BIOL CHEM, V268, P22251	79	190	191	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11358	11366		10.1074/jbc.270.19.11358	http://dx.doi.org/10.1074/jbc.270.19.11358			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744773	hybrid			2022-12-25	WOS:A1995QX86500050
J	MOLINO, M; BLANCHARD, N; BELMONTE, E; TARVER, AP; ABRAMS, C; HOXIE, JA; CERLETTI, C; BRASS, LF				MOLINO, M; BLANCHARD, N; BELMONTE, E; TARVER, AP; ABRAMS, C; HOXIE, JA; CERLETTI, C; BRASS, LF			PROTEOLYSIS OF THE HUMAN PLATELET AND ENDOTHELIAL-CELL THROMBIN RECEPTOR BY NEUTROPHIL-DERIVED CATHEPSIN-G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHONUCLEAR LEUKOCYTES; ACTIVATION; PEPTIDES; ANTIPROTEINASES; MECHANISM; RESPONSES; ELASTASE; CLONING; RELEASE; BINDING	Cathepsin G is a neutrophil-derived protease that has been shown to inhibit the effects of thrombin on some cells expressing thrombin receptors while acting as an agonist on others, The present studies examine whether cleavage of the thrombin receptor by cathepsin G can account for these diverse effects, When added to cells that normally respond to thrombin, cathepsin G prevented a subsequent cytosolic Ca2+ increase caused by thrombin, but had no effect on responses to the thrombin receptor agonist peptide, SFLLRN. These effects were observed in cells in which cathepsin G had little or no agonist effect (human umbilical vein endothelial cells and HEL cells), as well as in cells in which cathepsin G acted as an agonist (platelets and CHRF-288 cells), Binding studies using monoclonal antibodies with defined epitopes within the first 60 residues of the thrombin receptor N-terminus showed that incubation of platelets and endothelial cells with cathepsin G abolished the binding of all of the antibodies, while thrombin abolished only the binding of antibodies whose epitopes were N-terminal to the known thrombin cleavage site between Arg(41) and Ser(42). Analysis of peptide proteolytic fragments identified three potential cleavage sites for cathepsin G: Arg(41)-Ser(42), Phe(43)-Leu(44), and phe(55)-Trp(56). Cleavage at phe(55)-Trp(56) would account for both the observed loss of all of the antibody binding sites and the inhibition of receptor activation by thrombin. Two approaches were used to determine whether a solitary cleavage at Arg(41)-Ser(42) could result in receptor activation, In the first, HEL cells were exposed to cathepsin G or thrombin in the presence of an antibody whose epitope includes Phe(55), The antibody inhibited responses to thrombin, but augmented the response to cathepsin G. In the second, COS-1 cells were transfected with variant thrombin receptors in which Phe(65) and Trp(56) were mutated to alanine, Transfected wild-type receptors responded to thrombin, but not cathepsin G, while the variant receptors responded to both proteases, These results 1) suggest that the ability of cathepsin G to inhibit responses to thrombin, but not SFLLRN, is due to cleavage of the receptor at Phe(55) Trp(56), deleting the tethered ligand domain, and 2) show that cathepsin G can activate thrombin receptors, but only if the cleavage site at phe(55)-Trp(56) is mutated or otherwise protected, This defines one mechanism by which neutrophil activation can prevent cellular responses to thrombin, while suggesting that the agonist effects of cathepsin G are less likely to be due to activation of the one known form of the human thrombin receptor unless post-translational modifications or local structural constraints prevent access of the enzyme to the phe(55)-Trp(58) site.	UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; IST RIC FARMACOL MARIO NEGRI,CONSORZIO MARIO NEGRI SUD,I-66030 SANTA MARIA IMBAR,ITALY	University of Pennsylvania; University of Pennsylvania; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS			Cerletti, Chiara/K-6447-2016	Cerletti, Chiara/0000-0002-4759-3179	NCI NIH HHS [CA-16520] Funding Source: Medline; NHLBI NIH HHS [HL40387] Funding Source: Medline; NIDDK NIH HHS [DK-19525] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016520] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL040387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BRASS LF, 1991, J BIOL CHEM, V266, P958; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BRASS LF, 1994, J BIOL CHEM, V269, P2943; BRASS LF, 1992, J BIOL CHEM, V267, P13795; BRASS LF, 1994, ANN NY ACAD SCI, V714, P1, DOI 10.1111/j.1749-6632.1994.tb12025.x; DEAN NM, 1989, ANAL BIOCHEM, V183, P199, DOI 10.1016/0003-2697(89)90468-5; ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318; EVANGELISTA V, 1993, BLOOD, V81, P2947; EVANGELISTA V, 1991, BLOOD, V77, P2379; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; JAFFE EA, 1994, J CLIN INVEST, V52, P2745; LAROSA CA, 1994, BLOOD, V84, P158; LAROSA CA, 1994, J VASC SURG, V19, P306, DOI 10.1016/S0741-5214(94)70106-7; LEROY EC, 1984, J CLIN INVEST, V74, P1003, DOI 10.1172/JCI111467; MAISON CM, 1991, J IMMUNOL, V147, P921; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; MEHTA J, 1989, CIRCULATION, V79, P546; MOLINO M, 1993, BLOOD, V82, P2442; MOLINO M, 1992, BIOCHEM J, V288, P741, DOI 10.1042/bj2880741; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; PIDARD D, 1994, BIOCHEM J, V303, P489, DOI 10.1042/bj3030489; PINTUCCI G, 1993, J LAB CLIN MED, V122, P69; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; ROMSON JL, 1983, CIRCULATION, V67, P1016, DOI 10.1161/01.CIR.67.5.1016; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SELAK MA, 1990, BIOCHEM J, V266, P55, DOI 10.1042/bj2660055; SELAK MA, 1994, BIOCHEM J, V297, P269, DOI 10.1042/bj2970269; SELAK MA, 1988, BIOCHEM J, V251, P293, DOI 10.1042/bj2510293; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; TOTANI L, 1994, ARTERIOSCLER THROMB, V14, P125, DOI 10.1161/01.ATV.14.1.125; TURKINGTON PT, 1992, THROMB RES, V67, P147, DOI 10.1016/0049-3848(92)90134-V; TURKINGTON PT, 1991, THROMB RES, V63, P399, DOI 10.1016/0049-3848(91)90226-M; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WEKSLER BB, 1989, BLOOD, V74, P1627; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868	41	139	143	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11168	11175		10.1074/jbc.270.19.11168	http://dx.doi.org/10.1074/jbc.270.19.11168			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744748	hybrid			2022-12-25	WOS:A1995QX86500024
J	BUCALA, R; MITCHELL, R; ARNOLD, K; INNERARITY, T; VLASSARA, H; CERAMI, A				BUCALA, R; MITCHELL, R; ARNOLD, K; INNERARITY, T; VLASSARA, H; CERAMI, A			IDENTIFICATION OF THE MAJOR SITE OF APOLIPOPROTEIN-B MODIFICATION BY ADVANCED GLYCOSYLATION END-PRODUCTS BLOCKING UPTAKE BY THE LOW-DENSITY-LIPOPROTEIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYVINYLIDENE DIFLUORIDE; LYSINE RESIDUES; BINDING; INVIVO; APOPROTEINS; COMPONENT; MEMBRANES; SEQUENCE; B-100; RICH	Advanced glycosylation end products (AGEs) arise from glucose-derived Amadori products and have been implicated in the pathogenesis of diabetic vascular disease, We recently reported the presence of an AGE-modified form of low density lipoprotein (LDL) that circulates in high amounts in patients with diabetes or renal insufficiency and that exhibits impaired plasma clearance kinetics, We utilized AGE-specific antibodies to identify the major sites of AGE modification within protease-digested preparations of apolipoprotein B that impair the binding of the AGE-modified form of LDL by human fibroblast LDL receptors, The predominant site of AGE immunoreactivity was found to lie within a single, 67-amino acid region located 1791 residues NH2-terminal of the putative LDL receptor binding domain, These data point to the high reactivity and specificity of this site for AGE formation and provide further evidence for important structural interactions between the LDL receptor binding domain and remote regions of the apolipoprotein B polypeptide.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes	BUCALA, R (corresponding author), PICOWER INST MED RES,350 COMMUNITY DR,MANHASSET,NY 11030, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019655] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19655-15] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWN WV, 1994, MED CLIN N AM, V78, P143, DOI 10.1016/S0025-7125(16)30180-8; BUCALA R, 1994, DRUG DEVELOP RES, V32, P77, DOI 10.1002/ddr.430320204; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; BUCALA R, 1994, P NATL ACAD SCI USA, V91, P9441, DOI 10.1073/pnas.91.20.9441; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN GC, 1989, BIOCHEMISTRY-US, V28, P2477, DOI 10.1021/bi00432a019; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; IBERG N, 1986, J BIOL CHEM, V261, P3542; Innerarity T L, 1986, Methods Enzymol, V129, P542; INNERARITY TL, 1987, P NATL ACAD SCI USA, V84, P6919, DOI 10.1073/pnas.84.19.6919; JENSEN T, 1988, DIABETOLOGIA, V31, P142, DOI 10.1007/BF00276846; KIKUGAWA K, 1992, ANAL BIOCHEM, V202, P249, DOI 10.1016/0003-2697(92)90102-D; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; LUNDKATZ S, 1988, J BIOL CHEM, V263, P13831; LUNDKATZ S, 1989, ARTERIOSCLEROSIS, V9, P715; MAHLEY RW, 1979, J CLIN INVEST, V64, P743, DOI 10.1172/JCI109518; MAHLEY RW, 1977, J BIOL CHEM, V252, P7279; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MAKITA Z, 1991, NEW ENGL J MED, V325, P836, DOI 10.1056/NEJM199109193251202; MAKITA Z, 1992, SCIENCE, V258, P651, DOI 10.1126/science.1411574; MAKITA Z, 1994, LANCET, V343, P1519, DOI 10.1016/S0140-6736(94)92935-1; MARCEL YL, 1987, ARTERIOSCLEROSIS, V7, P166, DOI 10.1161/01.ATV.7.2.166; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILNE R, 1989, J BIOL CHEM, V264, P19754; MIYATA T, 1993, J CLIN INVEST, V92, P1243, DOI 10.1172/JCI116696; Njoroge F G, 1989, Prog Clin Biol Res, V304, P85; RUDERMAN NB, 1984, PROG CARDIOVASC DIS, V26, P373, DOI 10.1016/0033-0620(84)90011-2; SHAPIRO R, 1980, J BIOL CHEM, V255, P3120; STONE KL, 1991, HPLC PEPTIDES PROTEI; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; WITZTUM JL, 1982, DIABETES, V31, P283, DOI 10.2337/diabetes.31.4.283; 1992, ANN DATA REPORT	33	112	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10828	10832		10.1074/jbc.270.18.10828	http://dx.doi.org/10.1074/jbc.270.18.10828			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738020	hybrid			2022-12-25	WOS:A1995QW60100068
J	CORCORAN, ML; KIBBEY, MC; KLEINMAN, HK; WAHL, LM				CORCORAN, ML; KIBBEY, MC; KLEINMAN, HK; WAHL, LM			LAMININ SIKVAV PEPTIDE INDUCTION OF MONOCYTE-MACROPHAGE PROSTAGLANDIN E(2) AND MATRIX METALLOPROTEINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IV COLLAGENASE; BASEMENT-MEMBRANE; TUMOR-GROWTH; A-CHAIN; INHIBITION; ACTIVATION; RECEPTOR; INVIVO; CELLS	The laminin-derived synthetic peptide containing the SIKVAV (Ser-Ile-Lys-Val-Ala-Val) amino acid sequence has been previously shown to regulate tumor invasion, metastasis, and angiogenesis. Here, we demonstate that this peptide also modulates human monocyte responses. Moreover, the monocytic responses elicited by this peptide are influenced by the culture conditions. When elutriated monocytes were cultured on SIKVAV substrate or in suspension with this peptide, the synthesis of prostaglandin E(2), interstitial collagenase, and gelatinase B was induced and was further enhanced in the presence of concanavalin A (ConA). However, when monocytes were adhered before adding soluble SIKVAV, the peptide alone failed to induce the production of prostaglandin E(2) or matrix metalloproteinases. If adherent monocytes were exposed to SIKVAV in the presence of ConA, this peptide enhanced the ConA induced production of these mediators. In contrast to SIKVAV, the intact laminin molecule failed to influence these monocyte responses. This is the first demonstration that a laminin derived peptide is capable of inducing or enhancing monocyte inflammatory responses that may influence a number of biological activities such as wound healing or excessive connective tissue destruction associated with chronic inflammation.	NIDR,IMMUNOL LAB,CELLULAR IMMUNOL SECT,BETHESDA,MD 20892; NIDR,DEV BIOL LAB,CELL BIOL SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BEEZHOLD DH, 1992, J LEUKOCYTE BIOL, V51, P59, DOI 10.1002/jlb.51.1.59; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CHANG ZL, 1993, J LEUKOCYTE BIOL, V53, P79, DOI 10.1002/jlb.53.1.79; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GRANT DS, 1992, J CELL PHYSIOL, V153, P614, DOI 10.1002/jcp.1041530324; GUDEWICZ PW, 1994, J LEUKOCYTE BIOL, V55, P423, DOI 10.1002/jlb.55.4.423; KANEMOTO T, 1991, INVAS METAST, V11, P84; KIBBEY MC, 1992, J NATL CANCER I, V84, P1633, DOI 10.1093/jnci/84.21.1633; KIBBEY MC, 1994, J CELL PHYSIOL, V160, P185, DOI 10.1002/jcp.1041600121; KLEINMAN HK, 1993, VITAM HORM, V47, P161, DOI 10.1016/S0083-6729(08)60446-X; KOHN FR, 1991, EXP HEMATOL, V19, P653; LASKIN DL, 1994, AM J RESP CELL MOL, V10, P58, DOI 10.1165/ajrcmb.10.1.8292381; MERTZ PM, 1994, J BIOL CHEM, V269, P21322; SHAPIRO SD, 1993, J BIOL CHEM, V268, P8170; STACK S, 1991, BIOCHEMISTRY-US, V30, P2073, DOI 10.1021/bi00222a011; SWEENEY TM, 1991, CANCER METAST REV, V10, P245, DOI 10.1007/BF00050795; TASHIRO K, 1991, J CELL PHYSIOL, V146, P451, DOI 10.1002/jcp.1041460316; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WAHL LM, 1990, J IMMUNOL, V144, P3518; WAHL LM, 1987, CELL IMMUNOL, V105, P411, DOI 10.1016/0008-8749(87)90088-8; WAHL LM, 1981, MANUAL MACROPHAGE ME, P423; WATANABE H, 1993, J CELL SCI, V104, P991	24	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10365	10368		10.1074/jbc.270.18.10365	http://dx.doi.org/10.1074/jbc.270.18.10365			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737965	hybrid			2022-12-25	WOS:A1995QW60100002
J	ERNST, OP; HOFMANN, KP; SAKMAR, TP				ERNST, OP; HOFMANN, KP; SAKMAR, TP			CHARACTERIZATION OF RHODOPSIN MUTANTS THAT BIND TRANSDUCIN BUT FAIL TO INDUCE GTP NUCLEOTIDE UPTAKE - CLASSIFICATION OF MUTANT PIGMENTS BY FLUORESCENCE, NUCLEOTIDE RELEASE, AND FLASH-INDUCED LIGHT-SCATTERING ASSAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PHOTORECEPTOR-MEMBRANES; SCHIFF-BASE COUNTERION; G-PROTEIN; METARHODOPSIN-II; OUTER SEGMENTS; AMINO-ACID; ACTIVATION; EQUILIBRIUM; RECEPTOR; COMPLEX	The photoreceptor rhodopsin is a seven-transmembrane helix receptor that activates the G protein transducin in response to light. Several site-directed rhodopsin mutants have been reported to be defective in transducin activation. Two of these mutants bound transducin in response to light, but failed to release the bound transducin in the presence of GTP (Franke, R. R., Konig, B., Sakmar, T. P., Khorana, H. G., and Hofmann, K. P. (1990) Science 250, 123-125). The present study was carried out to determine the nucleotide-binding state of transducin as it interacts with rhodopsin mutants. Five mutant bovine opsin genes were prepared by site-specific mutagenesis. Three mutant genes had deletions from one cytoplasmic loop each: AB Delta 70-71; CD Delta 143-150; and EF Delta 237-249. Two additional loop CD mutant genes were prepared: E134R/R135E had a reversal of a conserved charge pair, and CD r140-152 had a 13-amino acid sequence replaced by a sequence derived from the amino terminal tail. Three types of assays were carried out: 1) a fluorescence assay of photoactivated rhodopsin (R*) dependent guanosine 5'-O-(3-thiotriphosphate) uptake by transducin, 2) an assay of R*-dependent release of labeled GDP from the alpha-subunit of transducin holoenzyme (G(t alpha)). GDP, and 3) a light-scattering assay of R* G(t) complex formation and dissociation. We show that the mutant pigments, which are able to bind transducin in a light-dependent manner but lack the ability to activate transducin, most likely form R*. G(t alpha beta gamma). GDP complexes that are impaired in GDP release.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; UNIV FREIBURG,INST BIOPHYS & STRAHLENBIOL,D-79104 FREIBURG,GERMANY	Howard Hughes Medical Institute; Rockefeller University; University of Freiburg			Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953				ARNIS S, 1994, J BIOL CHEM, V269, P23879; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BENNETT N, 1985, J BIOL CHEM, V260, P4156; BORNANCIN F, 1989, EUR J BIOCHEM, V184, P687, DOI 10.1111/j.1432-1033.1989.tb15068.x; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; EMEIS D, 1982, FEBS LETT, V143, P29, DOI 10.1016/0014-5793(82)80266-4; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P9165, DOI 10.1021/bi00086a023; FAHMY K, 1994, BIOCHEMISTRY-US, V33, P13700, DOI 10.1021/bi00250a021; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HOFMANN KP, 1976, BIOPHYS STRUCT MECH, V2, P61, DOI 10.1007/BF00535653; HOFMANN KP, 1983, BIOCHIM BIOPHYS ACTA, V725, P60, DOI 10.1016/0005-2728(83)90224-4; HOFMANN KP, 1992, SIGNAL TRANSDUCTION, P71; KAHLERT M, 1990, J BIOL CHEM, V265, P18928; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; KUHN H, 1981, P NATL ACAD SCI-BIOL, V78, P6873, DOI 10.1073/pnas.78.11.6873; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; MIN KC, 1993, J BIOL CHEM, V268, P9400; MORO O, 1993, J BIOL CHEM, V268, P22273; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PANICO J, 1990, J BIOL CHEM, V265, P18922; PULVERMULLER A, 1993, BIOCHEMISTRY-US, V32, P14082, DOI 10.1021/bi00214a002; SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SCHLEICHER A, 1987, J MEMBRANE BIOL, V95, P271, DOI 10.1007/BF01869489; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STRYER L, 1991, J BIOL CHEM, V266, P10711; WEISS ER, 1987, J BIOL CHEM, V262, P4319; ZVYAGA TA, 1994, BIOCHEMISTRY-US, V33, P9753, DOI 10.1021/bi00198a046; ZVYAGA TA, 1993, J BIOL CHEM, V268, P4661; ZVYAGA TA, 1993, J BIOL CHEM, V269, P13056	42	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10580	10586		10.1074/jbc.270.18.10580	http://dx.doi.org/10.1074/jbc.270.18.10580			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737995	hybrid			2022-12-25	WOS:A1995QW60100036
J	KUDLICKI, W; ODOM, OW; KRAMER, G; HARDESTY, B; MERRILL, GA; HOROWITZ, PM				KUDLICKI, W; ODOM, OW; KRAMER, G; HARDESTY, B; MERRILL, GA; HOROWITZ, PM			THE IMPORTANCE OF THE N-TERMINAL SEGMENT FOR DNAJ-MEDIATED FOLDING OF RHODANESE WHILE BOUND TO RIBOSOMES AS PEPTIDYL-TRANSFER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LIVER RHODANESE; TRANSCRIPTION TRANSLATION; BINDING	Two lines of evidence indicate the importance of the N-terminal portion of rhodanese for correct folding of the nascent ribosome-bound polypeptide. A mutant gene lacking the codons for amino acids 1-23 of the wild-type protein is expressed very efficiently by coupled transcription/translation on Escherichia coli ribosomes; however, the mutant protein that is released from the ribosomes is enzymatically inactive. The mutant protein does not undergo the reaction that is promoted by the bacterial chaperone, DnaJ, which appears to be essential for folding of ribosome-bound rhodanese into the native conformation, The effect of DnaJ is monitored by fluorescence from coumarin cotranslationally incorporated at the N terminus of nascent rhodanese. Secondly, a synthetic peptide corresponding to the N-terminal 17 amino acids of the wild-type protein interferes with the synthesis of wild-type rhodanese but has much less effect on the synthesis of the N-terminal deletion mutant. The N-terminal peptide inhibits the effect of DnaJ on the nascent wild-type rhodanese and blocks the chaperone-mediated release and activation of ribosome-bound full-length rhodanese polypeptides that accumulate during in, vitro synthesis. The results lead to the hypothesis that the N-terminal segment of rhodanese is required for its chaperone-dependent folding on the ribosome.	UNIV TEXAS, DEPT CHEM & BIOCHEM, AUSTIN, TX 78712 USA; BROOKE ARMY MED CTR, DEPT CLIN INVEST, FT SAM HOUSTON, TX 78234 USA; UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Austin; San Antonio Military Medical Center; United States Department of Defense; United States Army; University of Texas System; University of Texas Health San Antonio					NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Cundliffe E., 1980, RIBOSOMES STRUCTURE, P555; EISENSTEIN M, 1994, SUPRAMOLECULAR STRUC, P231; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GU ZP, 1994, P NATL ACAD SCI USA, V91, P5612, DOI 10.1073/pnas.91.12.5612; GU ZP, 1994, J BACTERIOL, V176, P6238, DOI 10.1128/jb.176.20.6238-6244.1994; HARDESTY B, 1993, TRANSLATIONAL APPARA, P847; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HOL WGJ, 1983, FUND APPL TOXICOL, V3, P370, DOI 10.1016/S0272-0590(83)80007-4; HOROWITZ PM, 1993, ACS SYM SER, V516, P167; JARABAK R, 1974, BIOCHEMISTRY-US, V13, P3233, DOI 10.1021/bi00713a006; KUDLICKI W, 1994, J BIOL CHEM, V269, P16549; KUDLICKI W, 1994, J MOL BIOL, V244, P319, DOI 10.1006/jmbi.1994.1732; KUDLICKI W, 1992, ANAL BIOCHEM, V206, P389, DOI 10.1016/0003-2697(92)90383-I; KUDLICKI W, 1994, ANAL BIOCHEM, V217, P12, DOI 10.1006/abio.1994.1077; MENDOZA JA, 1994, J PROTEIN CHEM, V13, P15, DOI 10.1007/BF01891988; MERRILL GA, 1992, J PROTEIN CHEM, V11, P193, DOI 10.1007/BF01025225; MOFFAT JG, 1994, J BACTERIOL, V176, P7115, DOI 10.1128/JB.176.22.7115-7117.1994; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; ODOM OW, 1984, BIOCHEMISTRY-US, V23, P5069, DOI 10.1021/bi00316a037; PICKING WD, 1992, BIOCHEMISTRY-US, V31, P2368, DOI 10.1021/bi00123a023; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; Stewart JM, 1984, SOLID PHASE PEPTIDE; TSALKOVA T, 1993, BIOCHEMISTRY-US, V32, P3377, DOI 10.1021/bi00064a022; WESTLEY J, 1973, ADV ENZYMOL RAMB, V39, P327; [No title captured]	27	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10650	10657		10.1074/jbc.270.18.10650	http://dx.doi.org/10.1074/jbc.270.18.10650			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738002	hybrid			2022-12-25	WOS:A1995QW60100045
J	PANGALOS, MN; EFTHIMIOPOULOS, S; SHIOI, J; ROBAKIS, NK				PANGALOS, MN; EFTHIMIOPOULOS, S; SHIOI, J; ROBAKIS, NK			THE CHONDROITIN SULFATE ATTACHMENT SITE OF APPICAN IS FORMED BY SPLICING OUT EXON-15 OF THE AMYLOID PRECURSOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALZHEIMERS-DISEASE; PROTEOGLYCAN FORM; MESSENGER-RNA; PROTEIN GENE; MUTATION; BRAIN; CDNA; GLYCOSAMINOGLYCANS; LOCALIZATION; PEPTIDES	Appicans are secreted and cell-associated chondroitin sulfate proteoglycans containing Alzheimer amyloid precursor (APP) as their core protein, Appicans are found in brain tissue, and in cell cultures their expression depends on both cell type and growth conditions. Here we report that the core protein of appicans derives from an APP mRNA lacking exon 15. Splicing out of this exon creates a new consensus sequence for the attachment of a chondroitin sulfate chain in the resulting APP product. Transfection of C6 glioma or 293 kidney fibroblast cells with APP cDNAs containing exon 15 produced no appican, while transfection with an APP cDNA lacking this exon induced high levels of appican production. Polymerase chain reactions indicated that appican-producing cells contained an APP mRNA species without exon 15, whereas cells without this mRNA produced no appican. Site directed mutagenesis combined with immunoreactivity experiments showed that the chondroitin sulfate chain is attached to a serine residue 16 amino acids upstream of the amino terminus of the A beta sequence of APP. The attachment of a glycosaminoglycan chain close to the A beta sequence of APP may affect the proteolytic processing of APP and production of A beta. The proteoglycan nature of APP suggests that addition of the chondroitin sulfate glycosaminoglycan is important for the implementation of the biological function of these proteins.	CUNY MT SINAI SCH MED, DEPT PSYCHIAT, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, FISHBERG RES CTR NEUROBIOL, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Robakis, Nikolaos/AAA-1838-2021; Efthimiopoulos, Spiros/H-3956-2013	Efthimiopoulos, Spiros/0000-0001-9244-4570	NIA NIH HHS [AG05138, AG08200] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [RF1AG008200, R01AG008200, P50AG005138] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BRITTIS PA, 1992, SCIENCE, V255, P733, DOI 10.1126/science.1738848; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; BUEE L, 1993, BRAIN RES, V601, P154, DOI 10.1016/0006-8993(93)91706-X; DEWITT DA, 1993, EXP NEUROL, V121, P149, DOI 10.1006/exnr.1993.1081; EFTHIMIOPOULOS S, 1994, J NEUROSCI RES, V38, P81, DOI 10.1002/jnr.490380111; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONIG G, 1992, J BIOL CHEM, V267, P10804; LEVINE JM, 1994, J NEUROSCI, V14, P4716; MARGOLIS RK, 1993, EXPERIENTIA, V49, P429, DOI 10.1007/BF01923587; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; OKAMOTO M, 1994, NEUROSCI LETT, V172, P51, DOI 10.1016/0304-3940(94)90660-2; PANGALOS MN, 1995, IN PRESS J NEUROCHEM; REFOLO LM, 1989, BIOCHEM BIOPH RES CO, V164, P664, DOI 10.1016/0006-291X(89)91511-8; Robakis Nikolaos K., 1994, P317; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SHIOI J, 1993, NEUROSCI LETT, V154, P121, DOI 10.1016/0304-3940(93)90186-O; SHIOI J, 1992, J BIOL CHEM, V267, P13819; SHIOI J, 1995, IN PRESS J BIOL CHEM, V270; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; SU JH, 1992, NEUROSCIENCE, V51, P801, DOI 10.1016/0306-4522(92)90521-3; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367	30	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10388	10391		10.1074/jbc.270.18.10388	http://dx.doi.org/10.1074/jbc.270.18.10388			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737970	hybrid			2022-12-25	WOS:A1995QW60100008
J	PRIES, F; KINGMA, J; KROOSHOF, GH; JERONIMUSSTRATINGH, CM; BRUINS, AP; JANSSEN, DB				PRIES, F; KINGMA, J; KROOSHOF, GH; JERONIMUSSTRATINGH, CM; BRUINS, AP; JANSSEN, DB			HISTIDINE-289 IS ESSENTIAL FOR HYDROLYSIS OF THE ALKYL-ENZYME INTERMEDIATE OF HALOALKANE DEHALOGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSOMAL EPOXIDE HYDROLASE; CATALYTIC MECHANISM; ESCHERICHIA-COLI; MUTAGENESIS; EXPRESSION; SITE; RESIDUE	Haloalkane dehalogenase (DhIA) from Xanthobacter autotrophicus GJ10 catalyzes the hydrolytic cleavage of carbon-halogen bonds in a broad range of halogenated aliphatic compounds, Previous work has shown that Asp(124), which is located close to the internal substrate-binding cavity, carries out a nucleophilic attack on the C-alpha of the alkylhalide, displacing the halogen, The resulting alkyl-enzyme intermediate is subsequently hydrolyzed, In order to study the role of His(289) in the hydrolysis of the intermediate, a His(289) --> Gln mutant was constructed by site-directed mutagenesis. The purified mutant enzyme was not catalytically active with haloalkanes, but a halide burst stoichiometric to the amount of enzyme was observed with 1,2-dibromoethane. Using ion spray mass spectrometry, accumulation of the covalent alkyl-enzyme and binding of the alkyl moiety of the substrate to an Asp(124)-containing tryptic peptide were shown, Fluorescence-quenching experiments indicated that halide ions are strongly bound by the alkyl-enzyme but not by the substrate-free enzyme, The results show that His(289) is the base catalyst for the dealkylation of the covalent intermediate, but that it is not essential for the initial nucleophilic attack of Asp(124) on the C-1 atom of the haloalkane. Furthermore, the halide ion that is released in the first step probably leaves the active site only after hydrolysis of the alkyl-enzyme.	UNIV GRONINGEN,DEPT BIOCHEM,9747 AG GRONINGEN,NETHERLANDS; UNIV GRONINGEN,DEPT PHARM,9747 AG GRONINGEN,NETHERLANDS	University of Groningen; University of Groningen								ARAND M, 1994, FEBS LETT, V338, P251, DOI 10.1016/0014-5793(94)80278-5; BELL PA, 1993, J BIOL CHEM, V268, P14011; BRUINS AP, 1987, ANAL CHEM, V59, P2642, DOI 10.1021/ac00149a003; BRUINS AP, 1988, 36TH P ASMS C MASS S, P1242; CHANG JY, 1983, METHOD ENZYMOL, V91, P455; CHEAH E, 1993, PROTEINS, V16, P64, DOI 10.1002/prot.340160108; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; DIPERSIO LP, 1991, J BIOL CHEM, V266, P4033; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; GIBNEY G, 1990, P NATL ACAD SCI USA, V87, P7546, DOI 10.1073/pnas.87.19.7546; JANSSEN DB, 1989, J BACTERIOL, V171, P6791, DOI 10.1128/jb.171.12.6791-6799.1989; LACOURCIERE GM, 1993, J AM CHEM SOC, V115, P10466, DOI 10.1021/ja00075a115; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PRIES F, 1994, BIOCHEMISTRY-US, V33, P1242, DOI 10.1021/bi00171a026; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHANSTRA JP, 1993, PROTEIN EXPRES PURIF, V4, P479, DOI 10.1006/prep.1993.1063; SCHRAG JD, 1993, J MOL BIOL, V230, P575, DOI 10.1006/jmbi.1993.1171; VERSCHUEREN KHG, 1993, BIOCHEMISTRY-US, V32, P9031, DOI 10.1021/bi00086a008; VERSCHUEREN KHG, 1993, J MOL BIOL, V232, P856, DOI 10.1006/jmbi.1993.1436; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0	22	78	86	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10405	10411		10.1074/jbc.270.18.10405	http://dx.doi.org/10.1074/jbc.270.18.10405			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737973	Green Submitted, hybrid			2022-12-25	WOS:A1995QW60100011
J	REYNOLDS, WF				REYNOLDS, WF			DEVELOPMENTAL STAGE-SPECIFIC REGULATION OF XENOPUS TRANSFER-RNA GENES BY AN UPSTREAM PROMOTER ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-III; TRANSCRIPTION FACTOR-IIIB; STABLE COMPLEX-FORMATION; YEAST TRANSFER-RNA; DIFFERENTIAL EXPRESSION; 5'-FLANKING SEQUENCES; 5-S RNA; OOCYTE; BINDING; REGION	Typically the internal promoter elements of tRNA genes are necessary and sufficient to support transcription. Here a sequence element preceding a Xenopus tRNA gene is shown to be required for transcription in late stage, but not early stage oocyte extracts. The constitutive tyro gene is expressed in both early and late oocyte extracts, whereas the early oocyte specific tyr-Cooc gene is only expressed in early extracts. An upstream promoter element (URR), between positions -42 and -14 of the tyro gene, mediates this differential expression. The URR is required for tyro transcription in late oocyte extracts. Placing the URR upstream of the tyrCooc gene allows this gene to be transcribed in late extracts. The URR is irrelevant to transcription in early extracts; transcription of tyro or tyrCooc requires only the internal promoter sequences. This indicates the polymerase III transcriptional machinery changes during oogenesis, resulting in a stringent upstream sequence requirement. Mutations within the URR are shown to alter the preferred site of initiation by RNA polymerase III. Shifting the position of the URR upstream by one half helical turn also repositioned the site of initiation, suggesting the URR directs the placement of the initiation factor complex or polymerase itself.			REYNOLDS, WF (corresponding author), SAN DIEGO REG CANC CTR,SAN DIEGO,CA 92121, USA.				NCRR NIH HHS [RR09118-09] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009118] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDREWS MT, 1991, DEV BIOL, V146, P250, DOI 10.1016/0012-1606(91)90466-G; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BOGENHAGEN DF, 1982, CELL, V28, P413, DOI 10.1016/0092-8674(82)90359-2; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GOTTESFELD JM, 1994, SCIENCE, V263, P81, DOI 10.1126/science.8272869; GOUILLOUD E, 1986, J BIOL CHEM, V261, P486; HUIBREGTSE JM, 1989, MOL CELL BIOL, V9, P3244, DOI 10.1128/MCB.9.8.3244; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEVEILLARD T, 1991, J BIOL CHEM, V266, P5162; LOFQUIST A, 1986, J BIOL CHEM, V261, P4600; MORRY MJ, 1986, MOL CELL BIOL, V6, P105, DOI 10.1128/MCB.6.1.105; MULLER F, 1987, NUCLEIC ACIDS RES, V15, P7191, DOI 10.1093/nar/15.17.7191; OEI SL, 1990, J BIOL CHEM, V265, P7485; PALIDA FA, 1993, NUCLEIC ACIDS RES, V21, P5875, DOI 10.1093/nar/21.25.5875; PALMER JM, 1990, TRENDS BIOCHEM SCI, V15, P300, DOI 10.1016/0968-0004(90)90018-7; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; RAYMOND GJ, 1983, NUCLEIC ACIDS RES, V11, P5969, DOI 10.1093/nar/11.17.5969; REYNOLDS WF, 1989, NUCLEIC ACIDS RES, V17, P9381; REYNOLDS WF, 1988, MOL CELL BIOL, V8, P5056, DOI 10.1128/MCB.8.11.5056; REYNOLDS WF, 1988, NUCLEIC ACIDS RES, V16, P3391, DOI 10.1093/nar/16.8.3391; REYNOLDS WF, 1992, MOL CELL BIOL, V12, P946, DOI 10.1128/MCB.12.3.946; REYNOLDS WF, 1993, NUCLEIC ACIDS RES, V21, P4372, DOI 10.1093/nar/21.18.4372; ROONEY RJ, 1988, NUCLEIC ACIDS RES, V16, P2509, DOI 10.1093/nar/16.6.2509; SCHAACK J, 1984, J BIOL CHEM, V259, P1461; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SEIDEL CW, 1992, J MOL BIOL, V227, P1009, DOI 10.1016/0022-2836(92)90517-N; SETZER DR, 1985, J BIOL CHEM, V260, P2483; SHAW KJ, 1984, MOL CELL BIOL, V4, P657, DOI 10.1128/MCB.4.4.657; STUTZ F, 1989, GENE DEV, V3, P1190, DOI 10.1101/gad.3.8.1190; SULLIVAN HS, 1994, MOL CELL BIOL, V14, P1806, DOI 10.1128/MCB.14.3.1806; TAPPING RI, 1994, J BIOL CHEM, V269, P21812; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; YOUNG LS, 1986, P NATL ACAD SCI USA, V83, P374, DOI 10.1073/pnas.83.2.374	37	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10703	10710		10.1074/jbc.270.18.10703	http://dx.doi.org/10.1074/jbc.270.18.10703			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738008	hybrid			2022-12-25	WOS:A1995QW60100052
J	BUIJS, A; SHERR, S; VANBAAL, S; VANBEZOUW, S; VANDERPLAS, D; VANKESSEL, AG; RIEGMAN, P; DEPREZ, RL; ZWARTHOFF, E; HAGEMEIJER, A; GROSVELD, G				BUIJS, A; SHERR, S; VANBAAL, S; VANBEZOUW, S; VANDERPLAS, D; VANKESSEL, AG; RIEGMAN, P; DEPREZ, RL; ZWARTHOFF, E; HAGEMEIJER, A; GROSVELD, G			TRANSLOCATION (12-22) (P13-Q11) IN MYELOPROLIFERATIVE DISORDERS RESULTS IN FUSION OF THE ETS-LIKE TEL GENE ON 12P13 TO THE MN1 GENE ON 22Q11	ONCOGENE			English	Article						TRANSLOCATION; TEL; MN1; MYELOID LEUKEMIA; CHROMOSOME 12P	ACUTE NONLYMPHOCYTIC LEUKEMIA; MYELOID-LEUKEMIA; CHROMOSOMAL REARRANGEMENT; SUBSTRATE RECOGNITION; PROTEIN; IDENTIFICATION; ACTIVATION; BREAKPOINT; KINASES; DOMAIN	In myeloid and lymphoid leukemias recurrent chromosomal aberrations can be detected in chromosome region 12p13, We characterized the genes involved in t(12;22) (p13;q11) in two patients with myeloid leukemia and one with myelodysplastic syndrome (MDS). MN1, a gene on chromosome 22q11 was shown to be fused to TEL, a member of the family of ETS transcription factors on chromosome 12p13. The translocation results in transcription of the reciprocal fusion mRNAs, MN1-TEL and TEL-MN1, of which MN1-TEL is likely to encode an aberrant transcription factor containing the ETS DNA-binding domain of TEL. In addition to fusion of TEL to the PDGF beta receptor in t(5;12) in chronic myelomonocytic leukemia (CMML), our data suggest that the involvement of this protein in myeloid leukemogenesis could be dual; its isolated protein-protein dimerization and DNA-binding domains may be crucial for the oncogenic activation of functionally different fusion proteins.	ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38101 USA; ERASMUS UNIV ROTTERDAM, DEPT PATHOL, 3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT CELL BIOL & GENET, 3000 DR ROTTERDAM, NETHERLANDS; UNIV NIJMEGEN HOSP, DEPT HUMAN GENET, 6500 HB NIJMEGEN, NETHERLANDS	St Jude Children's Research Hospital; Erasmus University Rotterdam; Erasmus University Rotterdam; Radboud University Nijmegen			van Kessel, Ad Geurts/A-2810-2010; Riegman, Peter/GLS-0041-2022		NCI NIH HHS [P30 CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADRIAANSEN HJ, 1992, THESIS ERASMUS U ROT, P123; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BUIJS A, 1995, ONCOGENE, V10, P1511; CALLEN DF, 1991, CANCER GENET CYTOGEN, V51, P255, DOI 10.1016/0165-4608(91)90138-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DELATTRE O, 1992, NATURE, V359, P1962; DEPREZ RHL, 1991, AM J HUM GENET, V48, P783; ENGEL E, 1977, NEW ENGL J MED, V296, P1295; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HAGEMEIJER A, 1981, CANCER GENET CYTOGEN, V3, P109, DOI 10.1016/0165-4608(81)90065-0; HAGEMEIJER A, 1979, CYTOGENET CELL GENET, V23, P208, DOI 10.1159/000131327; HAGEMEIJER A, 1993, GENE CHROMOSOME CANC, V8, P237, DOI 10.1002/gcc.2870080406; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHANSSON B, 1990, CANCER GENET CYTOGEN, V48, P119, DOI 10.1016/0165-4608(90)90224-X; KASHIMURA M, 1993, CANCER GENET CYTOGEN, V65, P81, DOI 10.1016/0165-4608(93)90066-U; KRANCE RA, 1992, LEUKEMIA, V6, P251; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Mertens F., 1991, CATALOG CHROMOSOME A; MORRIS SW, 1992, GENE CHROMOSOME CANC, V5, P385, DOI 10.1002/gcc.2870050414; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; RAIMONDI SC, 1986, BLOOD, V68, P69; Sambrook J, 1989, MOL CLONING LABORATO; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; VANDERBLIJPHILIPSEN M, 1977, HUM GENET, V39, P229, DOI 10.1007/BF00287017; VANDERPLAS DC, 1995, LEUKEMIA, V8, P2041; VANKESSEL AG, 1994, CANCER GENET CYTOGEN, V72, P105, DOI 10.1016/0165-4608(94)90124-4; VANKESSEL AHMG, 1981, CYTOGENET CELL GENET, V30, P83; VERMA RS, 1979, CYTOGENET CELL GENET, V23, P274, DOI 10.1159/000131338; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x	43	242	249	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1511	1519						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731705				2022-12-25	WOS:A1995QU68100006
J	KLINGELHUTZ, AJ; HEDRICK, L; CHO, KR; MCDOUGALL, JK				KLINGELHUTZ, AJ; HEDRICK, L; CHO, KR; MCDOUGALL, JK			THE DCC GENE SUPPRESSES THE MALIGNANT PHENOTYPE OF TRANSFORMED HUMAN EPITHELIAL-CELLS	ONCOGENE			English	Article						DCC; TUMOR SUPPRESSOR GENE; HUMAN PAPILLOMAVIRUS; CELL TRANSFORMATION	HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN KERATINOCYTES; ADHESION MOLECULES; FREQUENT LOSS; EXPRESSION; PROGRESSION; CARCINOMA; CANCER; HPV-18; P53	Loss of heterozygosity and loss of expression of the deleted in colon cancer (DCC) gene is frequently observed in a number of different cancer types. To determine if the DCC gene plays a direct role in tumor suppression, wild-type full-length or truncated DCC cDNA constructs were transfected into nitrosomethylurea (NMU) transformed tumorigenic HPV-immortalized human epithelial cells that had allelic loss and reduced expression of DCC. Full-length DCC suppressed tumorigenicity whereas truncated DCC did not. Tumorigenic reversion of initially suppressed transfectants was associated,vith loss of DCC expression and loss or rearrangement of transfected DCC sequences. These results provide the first direct evidence that DCC is a tumor suppressor gene.	JOHNS HOPKINS UNIV, DEPT PATHOL, BALTIMORE, MD 21205 USA	Johns Hopkins University	KLINGELHUTZ, AJ (corresponding author), FRED HUTCHINSON CANC RES CTR, CANC BIOL PROGRAM, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Klingelhutz, Aloysius/L-9081-2018	Klingelhutz, Aloysius/0000-0003-4258-5046; Cho, Kathleen/0000-0003-0500-9998	NATIONAL CANCER INSTITUTE [T32CA009657, P01CA042792] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42792, CA-09657] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1993, LAB INVEST, V68, P4; ASSELINEAU D, 1985, EXP CELL RES, V159, P536, DOI 10.1016/S0014-4827(85)80027-6; ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BLANTON RA, 1991, AM J PATHOL, V138, P673; BROOKS JD, 1993, J UROLOGY, V150, P1278, DOI 10.1016/S0022-5347(17)35760-9; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHO KR, 1992, J CELL BIOCHEM, P137; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DOHERTY P, 1991, CELL, V67, P21, DOI 10.1016/0092-8674(91)90569-K; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GAO X, 1993, CANCER RES, V53, P2723; GARRETT LR, 1993, CARCINOGENESIS, V14, P329, DOI 10.1093/carcin/14.2.329; GIMA T, 1994, INT J CANCER, V57, P480, DOI 10.1002/ijc.2910570407; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; HEDRICK L, 1992, COLD SPRING HARB SYM, V57, P345, DOI 10.1101/SQB.1992.057.01.039; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HOHNE MW, 1992, CANCER RES, V52, P2616; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG Y, 1992, CANCER RES, V52, P6525; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KAUR P, 1989, VIROLOGY, V173, P302, DOI 10.1016/0042-6822(89)90247-X; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; KIM MS, 1993, ANTICANCER RES, V13, P1405; KLINGELHUTZ AJ, 1993, ONCOGENE, V8, P95; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; MIYAKE K, 1993, BLOOD, V82, P927; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NARAYANAN R, 1992, ONCOGENE, V7, P553; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; PORFIRI E, 1993, BLOOD, V81, P2696; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; Sambrook J, 1989, MOL CLONING LABORATO; SCHECK AC, 1993, CANCER RES, V53, P5605; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHUCK PH, 1989, GEO IMMIGR LJ, V3, P1; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287; UCHINO S, 1992, CANCER RES, V52, P3099; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	44	93	99	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1581	1586						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731713				2022-12-25	WOS:A1995QU68100014
J	AHMED, A; PETER, GJ; TAYLOR, PM; HARPER, AA; RENNIE, MJ				AHMED, A; PETER, GJ; TAYLOR, PM; HARPER, AA; RENNIE, MJ			SODIUM-INDEPENDENT CURRENTS OF OPPOSITE POLARITY EVOKED BY NEUTRAL AND CATIONIC AMINO-ACIDS IN NEUTRAL AND BASIC-AMINO-ACID TRANSPORTER CRNA-INJECTED OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; RAT-KIDNEY; EXPRESSION CLONING; CYSTINE; SYSTEM; CDNA	To elucidate the electrical events associated with the movement of amino acids by the neutral and basic amino acid transporter (NBAT)-encoded protein (Yan, N., Mosckovitz, R., Gerber, L. D., Mathew, S., Murty, V. V. V. S., Tate, S. S., and Udenfriend, S. (1994) Proc. Natl. Acad. Sci. USA 91, 7548-7552), we have investigated the membrane potential and current changes associated with the increased transport of amino acids across the cell membrane of NBAT cRNA injected Xenopus laevis oocytes. Superfusion of 0.05 mM L-phenylalanine, in current-clamped NBAT-injected oocytes, caused a hyperpolarization (8.5 +/- 0.9 mV), but superfusion of L-arginine caused a depolarization (18.3 +/- 1.3 mV). In voltage-clamped (-60 mV) oocytes, superfusion of L-phenylalanine evoked a sodium- and chloride-independent, saturable (K-m = 0.34 +/- 0.02 mM, I-max = 31.3 +/- 0.5 nA), outward current. This outward current was reduced in the presence of high external [K] and was barium-sensitive. Outward currents were also evoked by L-leucine, L-glutamine, L-alanine, D-phenylalanine, and L-beta-phenylalanine. Superfusion of L-arginine evoked a saturable (K-m = 0.09 +/- 0.02 mM, I-max = -29.2 +/- 1.8 nA) inward current; L-lysine and D-arginine also evoked inward currents. L-Glutamate and beta-alanine failed to evoke any currents. Effluxes of L-[H-3]phenylalanine and L-[H-3]arginine were trans-stimulated in the presence of either amino acid. Flux-current comparisons indicated amino acid:charge movement stoichiometry of 1:1 for both neutral and cationic amino acids. These findings indicate that the amino acid transport activity(ies) expressed in NBAT cRNA-injected oocytes is electrogenic by a mechanism including the outward movement of a net positive charge (potassium ion or cationic amino acid) in exchange for uptake of a neutral amino acid.			AHMED, A (corresponding author), UNIV DUNDEE,DEPT ANAT & PHYSIOL,DUNDEE DD1 4HN,SCOTLAND.		Taylor, Peter M/A-4667-2010; Harper, Alexander/A-4688-2010	Ahmed, Aamir/0000-0001-7405-5336				BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BUSCH AE, 1994, J BIOL CHEM, V269, P25581; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; MAGAGNIN S, 1992, J BIOL CHEM, V267, P15384; MOSCKOVITZ R, 1993, P NATL ACAD SCI USA, V90, P4022, DOI 10.1073/pnas.90.9.4022; PICKEL VM, 1993, P NATL ACAD SCI USA, V90, P7779, DOI 10.1073/pnas.90.16.7779; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; TAYLOR MA, 1987, DEV BIOL, V124, P287, DOI 10.1016/0012-1606(87)90480-5; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; VANWINKLE LJ, 1993, BIOCHIM BIOPHYS ACTA, V1154, P157, DOI 10.1016/0304-4157(93)90009-D; VEYHL M, 1993, J BIOL CHEM, V268, P25041; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; YAN N, 1994, P NATL ACAD SCI USA, V91, P7548, DOI 10.1073/pnas.91.16.7548	15	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8482	8486		10.1074/jbc.270.15.8482	http://dx.doi.org/10.1074/jbc.270.15.8482			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721744	hybrid			2022-12-25	WOS:A1995QT44800020
J	VANDENHAZEL, HB; KIELLANDBRANDT, MC; WINTHER, JR				VANDENHAZEL, HB; KIELLANDBRANDT, MC; WINTHER, JR			RANDOM SUBSTITUTION OF LARGE PARTS OF THE PROPEPTIDE OF YEAST PROTEINASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH-REPAIR; SACCHAROMYCES-CEREVISIAE; VACUOLAR HYDROLASES; CARBOXYPEPTIDASE-Y; ESCHERICHIA-COLI; HOST STRAINS; PEP4 GENE; SYSTEM; AUTOACTIVATION; MATURATION	The yeast aspartic protease, proteinase A, has a 54 amino-acid propeptide, which is removed during activation of the zymogen in the vacuole. Apart from being involved inhibition/activation, the propeptide has been shown to be essential for formation of a stable active enzyme (van den Hazel, H. B., Kielland-Brandt, M. C., and Winther, J. R. (1993) J. Biol. Chem. 268, 18002-18007). We have investigated the sequence requirements for function of the propeptide. The N-terminal half and the C-terminal half of the propeptide were replaced by random sequences at the genetic level, and collections of the mutants were subjected to a colony screen for ones exhibiting activity. A high frequency (around 1%) of active constructs was found, which indicates a very high tolerance for mutations in the propeptide. Thirty-nine functional mutant forms containing random sequence at either the N- or C-terminal half of the propeptide were characterized. Comparison of the propeptides of the active constructs suggests that a particular lysine residue is important for efficient biosynthesis of proteinase A.	CARLSBERG LAB, DEPT YEAST GENET, DK-2500 COPENHAGEN, DENMARK				Kielland-Brandt, Morten C./D-2563-2015; Winther, Jakob R./K-4451-2014	Winther, Jakob R./0000-0001-6995-9154; Kielland-Brandt, Morten/0000-0002-1272-3877				AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; FOLTMANN B, 1988, BIOL CHEM H-S, V369, P311; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HIRSCH HH, 1992, EUR J BIOCHEM, V207, P867, DOI 10.1111/j.1432-1033.1992.tb17118.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KOBAYASHI T, 1992, J MOL BIOL, V226, P931, DOI 10.1016/0022-2836(92)91042-N; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; LEWIS MK, 1990, NUCLEIC ACIDS RES, V18, P3439, DOI 10.1093/nar/18.12.3439; OLESEN K, 1993, PROTEIN ENG, V6, P409, DOI 10.1093/protein/6.4.409; RAMOS C, 1994, J BIOL CHEM, V269, P7006; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIELECKI AR, 1991, J MOL BIOL, V219, P671, DOI 10.1016/0022-2836(91)90664-R; SIKORSKI RS, 1989, GENETICS, V122, P19; SORENSEN SO, 1994, EUR J BIOCHEM, V220, P19, DOI 10.1111/j.1432-1033.1994.tb18594.x; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; VANDENHAZEL HB, 1992, EUR J BIOCHEM, V207, P277; VANDENHAZEL HB, 1993, J BIOL CHEM, V268, P18002; WINTHER JR, 1994, J BIOL CHEM, V269, P22007; WINTHER JR, 1989, THESIS U COPENHAGEN; WINTHER JR, 1991, EUR J BIOCHEM, V197, P61; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; WOOLFORD CA, 1993, J BIOL CHEM, V268, P8990; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x	37	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8602	8609		10.1074/jbc.270.15.8602	http://dx.doi.org/10.1074/jbc.270.15.8602			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721762	hybrid			2022-12-25	WOS:A1995QT44800038
J	WATANABE, T; WAGA, I; HONDA, Z; KUROKAWA, K; SHIMIZU, T				WATANABE, T; WAGA, I; HONDA, Z; KUROKAWA, K; SHIMIZU, T			PROSTAGLANDIN-F2-ALPHA STIMULATES FORMATION OF P21(RAS)-GTP COMPLEX AND MITOGEN-ACTIVATED PROTEIN-KINASE IN NIH-3T3 CELLS VIA G(Q)-PROTEIN-COUPLED PATHWAYS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; MAP KINASE; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; GENE-EXPRESSION; BETA-GAMMA; 3T3 CELLS; PHOSPHORYLATION; FIBROBLASTS; RECEPTOR	Prostaglandin (PG) F-2 alpha activated mitogen-activated protein (MAP) kinase and MAP kinase kinase in NIH-3T3 cells by a mechanism that was completely inhibited by protein kinase inhibitors, staurosporine (20 nM) or H-7 (20 mu M), but was insensitive to pretreatment with islet-activating protein (100 ng/ml; 24 h) or 12-O-tetradecanoylphorbol 13-acetate (2.5 mu M; 24 h). PGF(2 alpha) stimulation also led to a significant increase in Ras . GTP complex. Transfection of a cDNA encoding a constitutively active mutant of G(q) alpha-subunit (Q209L) mimicked PGF(2 alpha)-induced MAP kinase activation, increase in Ras GTP complex, and DNA synthesis in these cells, suggesting that activation of G(q) mediates the PGF(2 alpha)-activation of Ras-MAP kinase pathway and mitogenesis in NIH-3T3 cells. These data provide a new insight into regulatory mechanisms of Pas-MAP kinase pathway through heterotrimeric G-protein-mediated pathways.	UNIV TOKYO, FAC MED, DEPT BIOCHEM, TOKYO 113, JAPAN	University of Tokyo	WATANABE, T (corresponding author), UNIV TOKYO, FAC MED, DEPT INTERNAL MED, DIV 1, TOKYO 113, JAPAN.							ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CARAUBON S, 1993, BIOCHEM J, V293, P381; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JIMENEZDEASUA L, 1975, P NATL ACAD SCI USA, V72, P2724; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KANAMORI M, 1981, J PHARMACOL EXP THER, V217, P494; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; NAKAMURA T, 1983, J BIOCHEM-TOKYO, V94, P1029, DOI 10.1093/oxfordjournals.jbchem.a134444; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKAO A, 1993, J CELL PHYSIOL, V155, P257, DOI 10.1002/jcp.1041550206; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; Sambrook J, 1989, MOL CLONING LABORATO; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SETH A, 1991, J BIOL CHEM, V266, P23521; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOBE K, 1991, J BIOL CHEM, V266, P24793; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WATANABE T, 1991, BIOCHIM BIOPHYS ACTA, V1074, P398, DOI 10.1016/0304-4165(91)90091-T; WATANABE T, 1994, J BIOL CHEM, V269, P17619; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU DQ, 1992, J BIOL CHEM, V267, P1811; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	50	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8984	8990		10.1074/jbc.270.15.8984	http://dx.doi.org/10.1074/jbc.270.15.8984			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721808	hybrid			2022-12-25	WOS:A1995QT44800088
J	COLAMONICI, OR; PLATANIAS, LC; DOMANSKI, P; HANDA, R; GILMOUR, KC; DIAZ, MO; REICH, N; PITHAROWE, P				COLAMONICI, OR; PLATANIAS, LC; DOMANSKI, P; HANDA, R; GILMOUR, KC; DIAZ, MO; REICH, N; PITHAROWE, P			TRANSMEMBRANE SIGNALING BY THE ALPHA-SUBUNIT OF THE TYPE-I INTERFERON RECEPTOR IS ESSENTIAL FOR ACTIVATION OF THE JAK KINASES AND THE TRANSCRIPTIONAL FACTOR ISGF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; HUMAN CHROMOSOME-21; IFN-ALPHA; PROTEIN; BETA; GENE; DOMAINS; BINDING; CELLS	The Type I interferon (IFN) receptor has a multisubunit structure. The component of the receptor that has been most thoroughly studied is the alpha subunit. Expression of the alpha subunit in mouse L-929 cells confers antiviral response to human IFN alpha 8, but not to human IFN alpha 2 or IFN beta. This antiviral effect is observed without a significant increase in IFN binding. It has not been determined why mouse cells expressing the human alpha subunit show different response to the antiviral activity of distinct human Type I IFNs. In this report, we demonstrate that the response to human Type I IFNs in mouse cells expressing the alpha subunit is dependent on cross-binding to the mouse receptor. This is supported by the finding that human IFN alpha 8, but not human IFN alpha 2, cross-binds to the mouse receptor even in the absence of expression of the human alpha subunit. We also demonstrate that only mouse cells expressing the human alpha subunit are able to tyrosine-phosphorylate p135(tyk2) and JAK-1 and to form the ISGF3 complex in response to human IFN alpha 8. These results demonstrate that the alpha subunit is essential for IFN alpha signaling through the JAK kinases and ISGF3.	LOYOLA UNIV,DIV HEMATOL ONCOL,CHICAGO,IL; EDWARD HINES JR VET ADM MED CTR,MAYWOOD,IL 60153; SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231	Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Johns Hopkins University; Johns Hopkins Medicine	COLAMONICI, OR (corresponding author), UNIV TENNESSEE,DEPT PATHOL,899 MADISON AVE,MEMPHIS,TN 38163, USA.				NATIONAL CANCER INSTITUTE [R01CA055079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI019737, R01AI019737] Funding Source: NIH RePORTER; NCI NIH HHS [CA55079, R29CA507703] Funding Source: Medline; NIAID NIH HHS [AI19737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMOVICH C, 1994, CYTOKINE, V6, P414, DOI 10.1016/1043-4666(94)90066-3; BAZAN JF, 1990, CELL, V61, P753, DOI 10.1016/0092-8674(90)90182-E; BENOIT P, 1993, J IMMUNOL, V150, P707; CLEARY CM, 1994, J BIOL CHEM, V269, P18747; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1994, J BIOL CHEM, V269, P9598; COLAMONICI OR, 1990, P NATL ACAD SCI USA, V87, P7230, DOI 10.1073/pnas.87.18.7230; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; EPSTEIN CJ, 1982, BIOCHEM BIOPH RES CO, V107, P1060, DOI 10.1016/0006-291X(82)90629-5; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GILMOUR KC, 1994, P NATL ACAD SCI USA, V91, P6850, DOI 10.1073/pnas.91.15.6850; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P231, DOI 10.1007/BF01233359; LEVY DE, 1989, GENE DEV, V3, P1203; LIM JK, 1994, FEBS LETT, V350, P281, DOI 10.1016/0014-5793(94)00787-X; LUTFALLA G, 1992, J BIOL CHEM, V267, P2802; MEISTER A, 1986, J GEN VIROL, V67, P1633, DOI 10.1099/0022-1317-67-8-1633; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; PLATANIAS LC, 1993, J IMMUNOL, V150, P3226; RAZIUDDIN A, 1984, P NATL ACAD SCI-BIOL, V81, P5504, DOI 10.1073/pnas.81.17.5504; REVEL M, 1976, NATURE, V260, P139, DOI 10.1038/260139a0; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SOH JM, 1994, J BIOL CHEM, V269, P18102; TAN YH, 1976, NATURE, V260, P141, DOI 10.1038/260141a0; TAN YH, 1974, SCIENCE, V186, P61, DOI 10.1126/science.186.4158.61; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z	38	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8188	8193		10.1074/jbc.270.14.8188	http://dx.doi.org/10.1074/jbc.270.14.8188			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713924	hybrid			2022-12-25	WOS:A1995QR52600063
J	MATTIONI, T; JACKSON, PK; VANHUIJSDUIJNEN, OBH; PICARD, D				MATTIONI, T; JACKSON, PK; VANHUIJSDUIJNEN, OBH; PICARD, D			CELL-CYCLE ARREST BY TYROSINE KINASE ABL INVOLVES ALTERED EARLY MITOGENIC RESPONSE	ONCOGENE			English	Article						ABL TRYOSINE KINASE; CELL CYCLE; ESTROGEN RECEPTOR; MITOGENIC RESPONSE; GROWTH INHIBITION	C-ABL; V-ABL; SIGNAL-TRANSDUCTION; FUSION PROTEINS; FOS PROTEINS; GENE-PRODUCT; TRANSFORMATION; LEUKEMIA; BINDING; LOCALIZATION	Activated forms of the nuclear and cytoplasmic tyrosine kinase c-Abl are completely cytoplasmic and oncogenic, The overexpression of c-AbI, and in certain fibroblast cell lines even of v-Abl, leads to a cell cycle arrest revealing an alternative Abl function, To facilitate the analysis of this growth inhibitory function we have taken advantage of regulable Abl-estrogen receptor (ABL:ER) fusion proteins, Oncogenic in the presence of estrogen, they are reversibly switched to inhibit cell proliferation upon removal of hormone, Using this system, we demonstrate that inhibition is effected by Abl derivatives which we have previously shown to be hypo-phosphorylated and to have low kinase activity. Since an almost exclusively cytoplasmic ABL:ER protein is fully growth inhibitory, relevant interactions may occur in the cytoplasm. We identify the cell cycle arrest as an early G1 or G0-like block. Interestingly, growth inhibition correlates with an altered expression pattern of early serum response genes; c-Jun mRNA and c-Fos protein levels are elevated in Abl-blocked cells. In view of the two functional modes of overexpressed Abl proteins, one can speculate that normal c-Abl may be involved in relaying growth regulatory signals from the membrane to the nucleus.	UNIV GENEVA, DEPT BIOL CELLULAIRE, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva				Jackson, Peter/0000-0002-1742-2539				AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BENNETT RL, 1992, DEVELOPMENT, V116, P953; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DHUT S, 1991, ONCOGENE, V6, P1459; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MATTIONI T, 1994, METHOD CELL BIOL, V43, P335; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Picard Didier, 1993, Trends in Cell Biology, V3, P278, DOI 10.1016/0962-8924(93)90057-8; Picard Didier, 1994, Current Opinion in Biotechnology, V5, P511, DOI 10.1016/0958-1669(94)90066-3; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WATANABE SM, 1983, J VIROL, V45, P1028, DOI 10.1128/JVI.45.3.1028-1036.1983; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WICK M, 1994, J CELL SCI, V107, P227; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	40	36	36	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1325	1333						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731683				2022-12-25	WOS:A1995QR65100009
J	DEROUICHE, R; BENEDETTI, H; LAZZARONI, JC; LAZDUNSKI, C; LLOUBES, R				DEROUICHE, R; BENEDETTI, H; LAZZARONI, JC; LAZDUNSKI, C; LLOUBES, R			PROTEIN COMPLEX WITHIN ESCHERICHIA-COLI INNER MEMBRANE - TOLA N-TERMINAL DOMAIN INTERACTS WITH TOLQ AND TOLR PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATION SYSTEM; NUCLEOTIDE-SEQUENCES; ENERGY TRANSDUCTION; OUTER-MEMBRANE; TONB; IMPORT; TOPOLOGY; GENES; EXBD; LOCALIZATION	The TolA, TolB, TolQ, and TolR proteins are involved in maintaining the integrity of the Escherichia coli outer membrane and in the import of group A colicins and filamentous phage DNA. TolA, TolQ, and TolR are localized in the inner membrane while TolB is periplasmic, although a small amount of membrane-associated TolB is always found. In vivo cross-linking experiments with formaldehyde were performed in order to determine the proteins interacting with TolA In wild-type strains, two specific complexes of 65 and 71 kDa, com prising TolA, were identified. These complexes were absent in a tolQ strain, while only the 65-kDa complex was absent in a tolR strain. When the tol strains were transformed with plasmids encoding TolR or TolQ, the specific complexes were restored. Moreover, immunoprecipitation experiments with the antiserum directed against TolA indicated that TolQ and TolR were co-immunoprecipitated with TolA after cross-linking. These data demonstrate that TolA interacts directly with TolR and TolQ. Two truncated TolA proteins devoid of either the C-terminal or the central domains of the protein were subjected to in vivo cross-linking. Since these two TolA derivatives still formed specific complexes with TolR and TolQ, we concluded that the TolA N-terminal domain interacted with these proteins.	CNRS, INGN & DYNAM SYST MEMBRANAIRES LAB, F-13402 MARSEILLE 20, FRANCE; UNIV LYON 1, CNRS, UMR 106, MICROBIOL & GENET MOLEC LAB, F-69622 VILLEURBANNE, FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1				LLOUBES, Roland/0000-0002-9520-1053				Bachmann B.J., 1987, E COLI S TYPHIMURIUM, V2, P1192; BENEDETTI H, 1991, EMBO J, V10, P1989, DOI 10.1002/j.1460-2075.1991.tb07728.x; BOURDINEAUD JP, 1989, J BACTERIOL, V171, P2458, DOI 10.1128/jb.171.5.2458-2465.1989; BOUVERET E, 1995, J BIOL CHEM, V270, P11071, DOI 10.1074/jbc.270.19.11071; BRAUN V, 1993, MOL MICROBIOL, V8, P261, DOI 10.1111/j.1365-2958.1993.tb01570.x; DAVIES JK, 1975, J BACTERIOL, V123, P96, DOI 10.1128/JB.123.1.96-101.1975; EICKHELMERICH K, 1989, J BACTERIOL, V171, P5117, DOI 10.1128/jb.171.9.5117-5126.1989; ESPESSET D, 1994, MOL MICROBIOL, V13, P1121, DOI 10.1111/j.1365-2958.1994.tb00503.x; FISCHER E, 1989, J BACTERIOL, V171, P5129; FOGNINILEFEBVRE N, 1987, MOL GEN GENET, V209, P391, DOI 10.1007/BF00329670; GELI V, 1993, FEMS MICROBIOL LETT, V109, P335; GUIHARD G, 1994, J BIOL CHEM, V269, P5874; ISNARD M, 1994, J BACTERIOL, V176, P6392, DOI 10.1128/jb.176.20.6392-6396.1994; JASKULA JC, 1994, J BACTERIOL, V176, P2326, DOI 10.1128/JB.176.8.2326-2338.1994; KAMPFENKEL K, 1993, J BACTERIOL, V175, P4485, DOI 10.1128/JB.175.14.4485-4491.1993; KAMPFENKEL K, 1992, J BACTERIOL, V174, P5485, DOI 10.1128/JB.174.16.5485-5487.1992; KAMPFENKEL K, 1993, J BIOL CHEM, V268, P6050; KARLSSON M, 1993, MOL MICROBIOL, V8, P379, DOI 10.1111/j.1365-2958.1993.tb01581.x; LARSEN RA, 1994, MOL MICROBIOL, V13, P627, DOI 10.1111/j.1365-2958.1994.tb00457.x; LARSEN RA, 1993, MOL MICROBIOL, V10, P943, DOI 10.1111/j.1365-2958.1993.tb00966.x; LAZZARONI JC, 1995, J MOL BIOL, V246, P1, DOI 10.1006/jmbi.1994.0058; LEVENGOOD SK, 1991, P NATL ACAD SCI USA, V88, P5939, DOI 10.1073/pnas.88.14.5939; LEVENGOOD SK, 1989, J BACTERIOL, V171, P6600, DOI 10.1128/jb.171.12.6600-6609.1989; LEVENGOODFREYERMUTH SK, 1993, J BACTERIOL, V175, P222, DOI 10.1128/JB.175.1.222-228.1993; MULLER MM, 1993, J BACTERIOL, V175, P6059, DOI 10.1128/JB.175.18.6059-6061.1993; POSTLE K, 1993, J BIOENERG BIOMEMBR, V25, P591; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; ROOF SK, 1991, J BACTERIOL, V173, P5554, DOI 10.1128/jb.173.17.5554-5557.1991; SKARE JT, 1991, MOL MICROBIOL, V5, P2883, DOI 10.1111/j.1365-2958.1991.tb01848.x; SKARE JT, 1993, J BIOL CHEM, V268, P16302; SUN TP, 1986, J BACTERIOL, V165, P107, DOI 10.1128/jb.165.1.107-115.1986; SUN TP, 1987, J BACTERIOL, V169, P2667, DOI 10.1128/jb.169.6.2667-2674.1987; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIANNEY A, 1994, J BACTERIOL, V176, P822, DOI 10.1128/jb.176.3.822-829.1994; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x	36	108	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11078	11084		10.1074/jbc.270.19.11078	http://dx.doi.org/10.1074/jbc.270.19.11078			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744737	hybrid			2022-12-25	WOS:A1995QX86500012
J	HORIUCHI, H; GINER, A; HOFLACK, B; ZERIAL, M				HORIUCHI, H; GINER, A; HOFLACK, B; ZERIAL, M			A GDP/GTP EXCHANGE-STIMULATORY ACTIVITY FOR THE RAB5-RABGDI COMPLEX ON CLATHRIN-COATED VESICLES FROM BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; GDP DISSOCIATION INHIBITOR; RAB GERANYLGERANYL TRANSFERASE; SMG P25A; COMPONENT-A; YEAST; SECRETION; MEMBRANE; SEC4; PURIFICATION	Small GTPases of the Rab family are key regulators of intracellular transport, They are associated with the cytoplasmic surface of distinct exocytic and endocytic organelles and with transport vesicles connecting these compartments, Rab proteins are also present in the cytosol in the GDP-bound conformation complexed to Rab GDP dissociation inhibitor (RabGDI), Upon membrane association, RabGDI is released, and the Rab protein is converted into the GTP-bound form, In this paper we have investigated whether Rab5, which regulates the clathrin-coated vesicle-mediated pathway of endocytosis, can directly associate with the membrane of clathrin-coated vesicles (CCV) purified from bovine brain in vitro. We found that RabGDI can specifically deliver Rab5 but not Rab7, which is localized to late endosomes, to CCV, Furthermore, CCV contain a heat- and trypsin-sensitive activity that stimulates the dissociation of GDP from Rab5, but not from Rab7, and the subsequent binding of GTP, The activity was found to be associated with the CCV membrane but not with the coat components. CCV weakly stimulated GDP release from either post-translationally modified or unmodified Rab5 alone, However, maximal GDP dissociation stimulation required the presence of RabGDI, suggesting that the factor(s) responsible for the membrane association and GDP/GTP exchange of Rab5 recognize the protein complexed to RabGDI, These data demonstrate that CCV are competent for acquiring Rab5 and for converting the molecule into the GTP-bound active form.	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			HOFLACK, Bernard/AAZ-6668-2020					ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; BURSTEIN ES, 1993, J BIOL CHEM, V268, P22247; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; HORIUCHI H, 1995, IN PRESS METHODS ENZ; LI GP, 1993, J BIOL CHEM, V268, P24475; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NISHIMURA N, 1994, J BIOL CHEM, V269, P14191; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; REGAZZI R, 1992, J BIOL CHEM, V267, P17512; SAHAGIAN G, 1985, J BIOL CHEM, V260, P9338; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SASAKI T, 1991, MOL CELL BIOL, V11, P2909, DOI 10.1128/MCB.11.5.2909; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STAHL B, 1994, J BIOL CHEM, V269, P24770; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; STENMARK H, 1994, EMBO J, V13, P128; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; ULLRICH O, 1995, IN PRESS METHODS ENZ; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	49	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11257	11262		10.1074/jbc.270.19.11257	http://dx.doi.org/10.1074/jbc.270.19.11257			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744760	hybrid			2022-12-25	WOS:A1995QX86500037
J	MORIYAMA, Y; YAMAMOTO, A; YAMADA, H; TASHIRO, Y; TOMOCHIKA, KI; TAKAHASHI, M; MAEDA, M; FUTAI, M				MORIYAMA, Y; YAMAMOTO, A; YAMADA, H; TASHIRO, Y; TOMOCHIKA, KI; TAKAHASHI, M; MAEDA, M; FUTAI, M			MICROVESICLES ISOLATED FROM BOVINE POSTERIOR PITUITARY ACCUMULATE NOREPINEPHRINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMAFFIN GRANULE MEMBRANES; SYNAPTIC-LIKE MICROVESICLES; PANCREATIC BETA-CELLS; VACUOLAR H+-ATPASE; SENSITIVE ATPASE; HORMONE-RELEASE; PROTON PUMP; VESICLES; TRANSPORT; NEUROHYPOPHYSIS	Histochemical study indicated that the posterior pituitary possesses numerous microvesicles (MVs) containing synaptophysin, a marker protein specific for brain synaptic vesicles (Navone, F., Di Gioia, G., Jahn, R., Browning, M., Greengard, P., and De Carnilli, P. (1989) J. Cell Biol. 109, 3425-2433). By monitoring cross-reactivity with anti synaptophysin antibody, the MVs were highly purified from bovine posterior pituitaries by a combination of differential and sucrose density gradient centrifugations. The purified MVs had an average diameter of about 60 nm and were associated with synaptophysin as revealed by immunoelectron microscopy. The vesicles contained ATPase activity partially sensitive to bafilomycin A(1) and to vanadate. The membrane fraction immunoisolated with anti-synaptophysin antibody also exhibited similar ATPase activity. The two ATPases could be purified separately; the vanadate-sensitive enzyme was identified as a 115-kDa polypeptide immunochemically similar to chromaffin granule P-ATPase (forming phosphoenzyme intermediate), and the bafilomycin A(1) sensitive ATPase showed essentially the same properties as those of vacuolar type H+-ATPases. Upon addition of ATP, the MVs formed an electrochemical gradient of protons and took up norepinephrine in a reserpine-sensitive manner, indicating the presence of secondary monoamine transporter coupled with vacuolar type H+-ATPase. No uptake of L-glutamate, gamma-aminobutyrate, glycine, or acetylcholine was observed, The identification of MVs as organelles responsible for storage of monoamines is important for understanding the physiological function of the posterior pituitary.	OSAKA UNIV,INST SCI & IND RES,DEPT BIOCHEM & ORGAN CHEM,IBARAKI,OSAKA 567,JAPAN; KANSAI MED UNIV,DEPT PHYSIOL,MORIGUCHI,OSAKA 570,JAPAN; OKAYAMA UNIV,FAC PHARMACEUT SCI,OKAYAMA 700,JAPAN; MITSUBISHI LIFE SCI INST,MACHIDA,TOKYO 194,JAPAN	Osaka University; Kansai Medical University; Okayama University			Yamada, Hiroshi/AGZ-4497-2022; YAMADA, Hiroshi/B-2251-2011	Yamada, Hiroshi/0000-0002-9328-3446; YAMADA, Hiroshi/0000-0002-9328-3446				ANNAERT WG, 1993, J NEUROCHEM, V60, P1746, DOI 10.1111/j.1471-4159.1993.tb13399.x; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BROADWELL RD, 1984, J COMP NEUROL, V228, P155, DOI 10.1002/cne.902280203; CRUBER KA, 1976, P NATL ACAD SCI USA, V73, P1314; Douglas WW, 1970, MEM SOC ENDOCR, V19, P353; FORGAC M, 1992, PHYSIOL REV, V69, P765; GERSCHENFELD HM, 1960, ENDOCRINOLOGY, V66, P741, DOI 10.1210/endo-66-5-741; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1990, J BIOL CHEM, V265, P9165; MORIYAMA Y, 1990, J BIOCHEM, V108, P689, DOI 10.1093/oxfordjournals.jbchem.a123264; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MORIYAMA Y, 1991, ARCH BIOCHEM BIOPHYS, V286, P252, DOI 10.1016/0003-9861(91)90037-J; MORIYAMA Y, 1988, J BIOL CHEM, V263, P8521; MORRIS JF, 1980, NEUROSCIENCE, V5, P639, DOI 10.1016/0306-4522(80)90061-5; NAVONE F, 1989, J CELL BIOL, V109, P3425, DOI 10.1083/jcb.109.6.3425; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; NORDMANN JJ, 1976, NATURE, V261, P723, DOI 10.1038/261723a0; OBATA K, 1986, BRAIN RES, V375, P37, DOI 10.1016/0006-8993(86)90956-X; ONEAL SG, 1979, BIOCHEM BIOPH RES CO, V89, P845, DOI 10.1016/0006-291X(79)91855-2; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; REGIERVIGOUROUX A, 1993, NEUROCHEM RES, V18, P59; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; RUSSELL JT, 1987, CURR TOP MEMBR TRANS, V31, P277; RUSSELL JT, 1984, J BIOL CHEM, V259, P9496; SCHERMAN D, 1982, BIOCHEMISTRY-US, V21, P687, DOI 10.1021/bi00533a016; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; THOMASREETZ A, 1993, P NATL ACAD SCI USA, V90, P5317, DOI 10.1073/pnas.90.11.5317; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; TWEEDLE CD, 1983, PROG BRAIN RES, V60, P259; WALCHSOLIMENA C, 1993, J NEUROSCI, V13, P3895	33	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11424	11429		10.1074/jbc.270.19.11424	http://dx.doi.org/10.1074/jbc.270.19.11424			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744779	hybrid			2022-12-25	WOS:A1995QX86500058
J	PHILIPS, MR; FEOKTISTOV, A; PILLINGER, MH; ABRAMSON, SB				PHILIPS, MR; FEOKTISTOV, A; PILLINGER, MH; ABRAMSON, SB			TRANSLOCATION OF P21(RAC2) FROM CYTOSOL TO PLASMA-MEMBRANE IS NEITHER NECESSARY NOR SUFFICIENT FOR NEUTROPHIL NADPH OXIDASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; GTP-BINDING PROTEIN; DEPENDENT SUPEROXIDE PRODUCTION; ADENINE-DINUCLEOTIDE PHOSPHATE; CHRONIC GRANULOMATOUS-DISEASE; GDP DISSOCIATION INHIBITOR; REGULATORY PROTEIN; SUBCELLULAR-LOCALIZATION; GUANINE-NUCLEOTIDES	Activation of the membrane-associated NADPH oxidase of neutrophils requires several cytosolic factors including p47(phox), p67(phox) and p21(rac2), We compared NADPH oxidase activity with the membrane translocation of p47(phox), p67(phox), and p21(rac2), In a cell-free system, GTP gamma S stimulated translocation of p47(phox) and p67(phox) to the plasma membrane only in the presence of arachidonate, and this translocation correlated with NADPH oxidase activity of the reisolated plasma membranes (R = 0.94 and 0.97, respectively), In contrast, GTP gamma S-stimulated p21(rac2) translocation with or without arachidonate, and the extent of translocation did not correlate with oxidase activity (R = 0.17), Neutrophil cytoplasts were used to relate membrane translocation of p47(phox), p67(phox) and p21(rac2) to membrane oxidase activity in response to the inflammatory agonists, Whereas N-formyl-methionyl-leucyl-phenylalanine stimulated equimolar, transient membrane translocation of p47(phox) and p67(phox) which kinetically paralleled NADPH oxidase activity, relatively little p21(rac2) translocated (moles of p47(phox)/p21(rac2) = 16.6), Moreover, although phorbol 12-myristate 13-acetate stimulated both the stable translocation of p47(phox) and p67(phox) and sustained NADPH oxidase activity, it did not stimulate p21(rac2) translocation, From these data we conclude that membrane translocation of p21(rac2) does not regulate NADPH oxidase activity stoichiometrically.			PHILIPS, MR (corresponding author), NYU,SCH MED,DEPT MED,550 1ST AVE,NEW YORK,NY 10016, USA.			Abramson, Steven/0000-0002-0668-6344; Pillinger, Michael/0000-0003-3168-1542; Mark, Philips/0000-0002-1179-8156	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036224, R29AI036224] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR011949, R37AR011949] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19721] Funding Source: Medline; NIAID NIH HHS [AI-36224] Funding Source: Medline; NIAMS NIH HHS [AR11949] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; ABO A, 1992, NATURE, V353, P668; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DEWALD B, 1979, J CLIN INVEST, V63, P21, DOI 10.1172/JCI109273; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; HEYWORTH PG, 1986, BIOCHEM J, V239, P723, DOI 10.1042/bj2390723; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P1217, DOI 10.1091/mbc.4.11.1217; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; ISOMURA M, 1991, ONCOGENE, V6, P119; IYER SS, 1994, J BIOL CHEM, V269, P22405; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KORCHAK HM, 1983, P NATL ACAD SCI-BIOL, V80, P4968, DOI 10.1073/pnas.80.16.4968; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; LANG P, 1993, BIOCHEM BIOPH RES CO, V196, P1522, DOI 10.1006/bbrc.1993.2424; LECABEC V, 1994, BIOCHEM BIOPH RES CO, V198, P1216, DOI 10.1006/bbrc.1994.1172; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; PARK JW, 1992, J BIOL CHEM, V267, P19901; PARK JW, 1992, J BIOL CHEM, V267, P17327; PEVERI P, 1992, P NATL ACAD SCI USA, V89, P2494, DOI 10.1073/pnas.89.6.2494; PHILIPS MR, 1991, J BIOL CHEM, V266, P1289; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PHILIPS MR, 1994, CLIN RES, V42, pA150; PHILIPS MR, 1993, CLIN RES, V41, pA322; PILLINGER MH, 1994, J BIOL CHEM, V269, P1486; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; REIBMAN J, 1988, J BIOL CHEM, V263, P6322; ROOS D, 1983, J CELL BIOL, V97, P368, DOI 10.1083/jcb.97.2.368; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; SEGAL AW, 1978, LANCET, V2, P446; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017; UEDA T, 1990, J BIOL CHEM, V265, P9373; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; VOLKER C, 1990, Methods (Orlando), V1, P283, DOI 10.1016/S1046-2023(05)80329-9; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138	58	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11514	11521		10.1074/jbc.270.19.11514	http://dx.doi.org/10.1074/jbc.270.19.11514			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744791	hybrid			2022-12-25	WOS:A1995QX86500070
J	BANEYX, F; BERTSCH, U; KALBACH, CE; VANDERVIES, SM; SOLL, J; GATENBY, AA				BANEYX, F; BERTSCH, U; KALBACH, CE; VANDERVIES, SM; SOLL, J; GATENBY, AA			SPINACH CHLOROPLAST CPN21 CO-CHAPERONIN POSSESSES 2 FUNCTIONAL DOMAINS FUSED TOGETHER IN A TOROIDAL STRUCTURE AND EXHIBITS NUCLEOTIDE-DEPENDENT BINDING TO PLASTID CHAPERONIN-60	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; GROES-LIKE CHAPERONIN; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; LARGE SUBUNITS; PEA-CHLOROPLASTS; GENE DUPLICATION; IDENTIFICATION; ATP	Chloroplasts contain a 21-kDa co-chaperonin polypeptide (cpn21) formed by two GroES-like domains fused together in tandem. Expression of a double-domain spinach cpn21 in Escherichia coli groES mutant strains supports growth of bacteriophages lambda and T5, and will also suppress a temperature-sensitive growth phenotype of a groES619 strain. Each domain of cpn21 expressed separately can function independently to support bacteriophage lambda growth, and the N-terminal domain will additionally suppress the temperature-sensitive growth phenotype. These results indicate that chloroplast cpn21 has two functional domains, either of which can interact with GroEL in vivo to facilitate bacteriophage morphogenesis. Purified spinach cpn21 has a ring-like toroidal structure and forms a stable complex with E. coli GroEL in the presence of ADP and is functionally interchangeable with bacterial GroES in the chaperonin-facilitated refolding of denatured ribulose-1,5-bisphosphate carboxylase. Cpn21 also inhibits the ATPase activity of GroEL. Cpn21 binds with similar efficiency to both the alpha and beta subunits of spinach cpn60 in the presence of adenine nucleotides, with ATP being more effective than ADP. The tandemly fused domains of cpn21 evolved early and are present in a wide range of photosynthetic eukaryotes examined, indicating a high degree of conservation of this structure in chloroplasts.	DUPONT CO INC,CENT RES & DEV,DIV MOLEC BIOL,EXPTL STN,WILMINGTON,DE 19880; INST BOT,D-24098 KIEL,GERMANY; UNIV GENEVA,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND	DuPont; University of Geneva								ARGOS P, 1990, J MOL BIOL, V211, P943, DOI 10.1016/0022-2836(90)90085-Z; BANEYX F, 1992, J BIOL CHEM, V267, P11637; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BERTSCH U, 1992, P NATL ACAD SCI USA, V89, P8696, DOI 10.1073/pnas.89.18.8696; BLOOM MV, 1983, P NATL ACAD SCI-BIOL, V80, P1013, DOI 10.1073/pnas.80.4.1013; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BURT WJE, 1994, FEBS LETT, V339, P139, DOI 10.1016/0014-5793(94)80401-X; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ELLIS RJ, 1988, PHOTOSYNTH RES, V16, P101, DOI 10.1007/BF00039488; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GATENBY AA, 1994, ANNU REV PLANT PHYS, V45, P469; GATENBY AA, 1981, NATURE, V291, P117, DOI 10.1038/291117a0; GATENBY AA, 1988, EMBO J, V7, P1307, DOI 10.1002/j.1460-2075.1988.tb02945.x; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LIANG H, 1993, P NATL ACAD SCI USA, V90, P7010, DOI 10.1073/pnas.90.15.7010; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; LUBBEN TH, 1990, P NATL ACAD SCI USA, V87, P7683, DOI 10.1073/pnas.87.19.7683; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MARTEL R, 1990, GENE, V94, P181, DOI 10.1016/0378-1119(90)90385-5; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MAYR EM, 1994, J MOL BIOL, V235, P84, DOI 10.1016/S0022-2836(05)80017-8; MCLACHLAN AD, 1987, COLD SPRING HARB SYM, V52, P411, DOI 10.1101/SQB.1987.052.01.048; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MUSGROVE JE, 1987, EUR J BIOCHEM, V163, P529, DOI 10.1111/j.1432-1033.1987.tb10900.x; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROSPERT S, 1993, P NATL ACAD SCI USA, V90, P10967, DOI 10.1073/pnas.90.23.10967; ROY H, 1982, J CELL BIOL, V94, P20, DOI 10.1083/jcb.94.1.20; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; TANG J, 1978, NATURE, V271, P618, DOI 10.1038/271618a0; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; ZEILSTRARYALLS J, 1993, J BACTERIOL, V175, P1134, DOI 10.1128/JB.175.4.1134-1143.1993; ZWEIG M, 1973, J MOL BIOL, V80, P505, DOI 10.1016/0022-2836(73)90418-X	44	52	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10695	10702		10.1074/jbc.270.18.10695	http://dx.doi.org/10.1074/jbc.270.18.10695			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738007	hybrid			2022-12-25	WOS:A1995QW60100051
J	CRUZ, MA; YUAN, HB; LEE, JR; WISE, RJ; HANDIN, RI				CRUZ, MA; YUAN, HB; LEE, JR; WISE, RJ; HANDIN, RI			INTERACTION OF THE VON-WILLEBRAND-FACTOR (VWF) WITH COLLAGEN - LOCALIZATION OF THE PRIMARY COLLAGEN-BINDING SITE BY ANALYSIS OF RECOMBINANT VWF A DOMAIN POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN VONWILLEBRAND-FACTOR; PLATELET GLYCOPROTEIN-IB; FACTOR-VIII; FIBRINOGEN BINDING; FIBRILLAR COLLAGEN; IIB/IIIA COMPLEX; ESCHERICHIA-COLI; CROSS-LINKING; IX COMPLEX; AGGREGATION	The von Willebrand factor (vWF) mediates platelet adhesion to the vascular subendothelium by binding to collagen, other matrix constituents, and the platelet receptor glycoproteins Ib/IX and IIb/IIIa, Although substantial progress has been made in defining vWF structure-function relationships, there are conflicting data regarding the location of its collagen-binding site(s), Possible collagen-binding sites have been localized in the A1 and A3 domains of vWF, To study the proposed binding sites, we have expressed cDNA sequences encoding the A1 and A3 domains of vWF in Escherichia coli and purified the resulting proteins from bacterial inclusion bodies. In addition, a chimeric molecule containing residues 465-598 of the vWF A1 domain polypeptide (vWF-A1) fused in frame to residues 1018-1114 of the vWF A3 domain polypeptide (vWF-A3) was also expressed, Each of the three recombinant proteins purified as a monomer and contained a single disulfide bond, As previously reported (Cruz, M. A., Handin, R. I., and Wise, R. J, (1993) J. Biol. Chem, 268, 21238-21245), recombinant vWF-A1 inhibited ristocetin-induced platelet agglutination, but did not compete with vWF multimers for collagen binding, In contrast, vWF-A3 inhibited the binding of multimeric vWF to immobilized collagen, but did not inhibit ristocetin-induced platelet agglutination, Metabolically labeled vWF-A3 bound to immobilized collagen in a saturable and reversible manner with a K-d of 1.8 x 10(-6) M. The vWF-A1/A3 chimera was bifunctional, It inhibited vWF binding to platelet glycoprotein Ib/IX with an IC50 of 0.6 x 10(-6) M and inhibited vWF binding to collagen with an IC50 of 0.5-1.0 x 10(-6) M. These results, taken together, provide firm evidence that the major collagen-binding site in vWF resides in the A3 domain.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School								ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; AZUMA H, 1991, J BIOL CHEM, V266, P12342; BERNDT MC, 1992, BIOCHEMISTRY-US, V31, P11144, DOI 10.1021/bi00160a027; BOCKENSTEDT P, 1986, J CLIN INVEST, V78, P551, DOI 10.1172/JCI112608; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; CHRISTOPHE O, 1991, BLOOD, V78, P2310; CRUZ MA, 1992, J BIOL CHEM, V267, P1303; CRUZ MA, 1993, J BIOL CHEM, V268, P21238; DEMARCO L, 1985, P NATL ACAD SCI USA, V82, P7424; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; DENIS C, 1993, ARTERIOSCLER THROMB, V13, P398, DOI 10.1161/01.ATV.13.3.398; DONG ZY, 1994, BLOOD, V84, pA388; FUJIMURA Y, 1991, BLOOD, V77, P113; FUJIMURA Y, 1987, J BIOL CHEM, V262, P1734; GIRMA JP, 1987, BLOOD, V70, P605; GRALNICK HR, 1992, P NATL ACAD SCI USA, V89, P7880, DOI 10.1073/pnas.89.17.7880; GRALNICK HR, 1985, J CLIN INVEST, V75, P19; Jorieux S, 1990, Blood Coagul Fibrinolysis, V1, P375, DOI 10.1097/00001721-199010000-00004; KALAFATIS M, 1987, BLOOD, V5, P1577; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOHRI H, 1988, J BIOL CHEM, V263, P17901; MORTON LF, 1983, THROMB RES, V32, P545, DOI 10.1016/0049-3848(83)90056-7; NYMAN D, 1980, THROMB RES, V17, P209, DOI 10.1016/0049-3848(80)90307-2; PARETI FI, 1987, J BIOL CHEM, V262, P13835; PARETI FI, 1986, J BIOL CHEM, V261, P15310; PIETU G, 1989, BIOCHEM BIOPH RES CO, V164, P1339; RAND JH, 1991, J CLIN INVEST, V88, P253, DOI 10.1172/JCI115285; ROTH GJ, 1986, BIOCHEMISTRY-US, V25, P8357, DOI 10.1021/bi00374a004; SANTORO SA, 1982, COLLAGEN REL RES, V2, P31; SANTORO SA, 1981, THROMB RES, V21, P689, DOI 10.1016/0049-3848(81)90272-3; SHELTONINLOES BB, 1986, BIOCHEMISTRY-US, V25, P3164, DOI 10.1021/bi00359a014; SIXMA JJ, 1984, J CLIN INVEST, V74, P736, DOI 10.1172/JCI111489; SIXMA JJ, 1991, EUR J BIOCHEM, V688, P1; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; TAKAGI J, 1989, J BIOL CHEM, V264, P6017; TURITTO VT, 1984, J CLIN INVEST, V74, P1730, DOI 10.1172/JCI111591; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; WEISS HJ, 1978, J LAB CLIN MED, V92, P750; WISE RJ, 1991, J BIOL CHEM, V266, P21948; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9	43	123	130	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10822	10827		10.1074/jbc.270.18.10822	http://dx.doi.org/10.1074/jbc.270.18.10822			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738019	hybrid			2022-12-25	WOS:A1995QW60100067
J	LIU, HI; SONO, M; KADKHODAYAN, S; HAGER, LP; HEDMAN, B; HODGSON, KO; DAWSON, JH				LIU, HI; SONO, M; KADKHODAYAN, S; HAGER, LP; HEDMAN, B; HODGSON, KO; DAWSON, JH			X-RAY-ABSORPTION NEAR-EDGE STUDIES OF CYTOCHROME P-450-CAM, CHLOROPEROXIDASE, AND MYOGLOBIN - DIRECT EVIDENCE FOR THE ELECTRON RELEASING CHARACTER OF A CYSTEINE THIOLATE PROXIMAL LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; CO BOND ANGLE; ACTIVE-SITE; STRUCTURAL CHARACTERIZATION; PARAMAGNETIC RESONANCE; EXAFS SPECTROSCOPY; XANES SPECTROSCOPY; CRYSTAL-STRUCTURE; COMPOUND-II; LIGATION	The low spin ferric and low and high spin ferrous forms of myoglobin, bacterial cytochrome P-450-CAM, and chloroperoxidase have been examined by Fe-K x-ray absorption edge spectroscopy. The positions of the absorption edge and the shapes of preedge and edge regions of imidazole adducts of ferric P-450-CAM and chloroperoxidase are essentially the same when compared with thiolate-ligated ferric myoglobin. As these three protein derivatives all have six-coordinate, low spin, ferric hemes with axial imidazole and thiolate ligands, the superposition of x-ray absorption edge spectral properties demonstrates that the protein environment does not effect the spectra, provided one compares heme iron centers with identical coordination numbers, spin and oxidation states, and ligand sets. In contrast, a 0.96 eV difference is observed in the energy of the absorption edge for imidazole- and thiolate-ligated ferric myoglobin with the latter shifted to lower energy as observed for ferrous myoglobin states. Similarly, in the low spin ferric-imidazole and ferrous-CO states, the energies of the absorption edge for chloroperoxidase and P-450-CAM are shifted in the direction of the ferrous state (to lower energy) when compared with those for analogous myoglobin derivatives. In the deoxyferrous high spin state, comparison of the edge spectra of chloroperoxidase with analogous data for cytochrome P-450-CAM suggests that the electron density at the iron is similar for these two protein states. The shifts observed in the energies of the x-ray absorption edge for the thiolate ligated states of these proteins relative to derivatives lacking a thiolate ligand provide a direct measure of the electron releasing character of a thiolate axial ligand. These results therefore support the suggested role of the cysteinate proximal ligand of P-450 as a strong internal electron donor to promote O-O bond cleavage in the putative ferric-peroxide intermediate to generate the proposed ferryl oxo ''active oxygen'' state of the reaction cycle.	STANFORD UNIV,STANFORD SYNCHROTRON RADIAT LAB,STANFORD,CA 94305; UNIV S CAROLINA,DEPT CHEM & BIOCHEM,COLUMBIA,SC 29208; UNIV S CAROLINA,SCH MED,COLUMBIA,SC 29208; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of Illinois System; University of Illinois Urbana-Champaign	LIU, HI (corresponding author), STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305, USA.		Dawson, John/HDM-6702-2022	Dawson, John H/0000-0002-4902-4295	NCRR NIH HHS [RR-01209] Funding Source: Medline; NIGMS NIH HHS [GM-07768] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Anderson LA, 1990, STRUCT BOND, V74, P1; BIANCONI A, 1985, NATURE, V318, P685, DOI 10.1038/318685a0; BUCHLER JW, 1978, ANGEW CHEM INT EDIT, V17, P407, DOI 10.1002/anie.197804071; CARTIER C, 1982, BIOCHIM BIOPHYS ACTA, V1119, P169; CHANCE B, 1983, BIOCHEMISTRY-US, V22, P3820, DOI 10.1021/bi00285a017; CHANG CS, 1993, BIOCHEMISTRY-US, V32, P923, DOI 10.1021/bi00054a025; CONGIUCASTELLAN.A, 1987, BIOCHEM BIOPH RES CO, V147, P31; Cramer S. P., 1979, PROG INORG CHEM, V25, P1, DOI [DOI 10.1002/9780470166260.CH1, 10.1002/9780470166260.ch1]; CRAMER SP, 1978, J AM CHEM SOC, V100, P7282, DOI 10.1021/ja00491a027; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DAWSON JH, 1986, J AM CHEM SOC, V108, P8114, DOI 10.1021/ja00285a052; DAWSON JH, 1992, J INORG BIOCHEM, V45, P179, DOI 10.1016/0162-0134(92)80043-U; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; DAWSON JH, 1976, J AM CHEM SOC, V98, P3707, DOI 10.1021/ja00428a054; ECCLES TK, 1977, THESIS STANFORD U; EISENBERGER P, 1976, P NATL ACAD SCI USA, V73, P491, DOI 10.1073/pnas.73.2.491; EISENBERGER P, 1978, NATURE, V294, P30; HAHN JE, 1982, J BIOL CHEM, V257, P934; HEWSON DW, 1978, PORPHYRINS, V7, P295; HOLLENBERG PF, 1980, J BIOL CHEM, V255, P4801; KADHKODAYAN S, 1992, MECHANISTIC STUDIES; MORRIS DR, 1966, J BIOL CHEM, V241, P1763; MORRIS DR, 1966, J BIOL CHEM, V241, P7495; O'Keeffe D H, 1978, Methods Enzymol, V52, P151; Penner-Hahn J. E., 1989, IRON PORPHYRINS 3, P235; PENNERHAHN JE, 1986, J AM CHEM SOC, V108, P7819, DOI 10.1021/ja00284a054; PERUTZ MF, 1982, NATURE, V295, P535, DOI 10.1038/295535a0; PICKARD MA, 1982, CAN J MICROBIOL, V27, P1298; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1985, J BIOL CHEM, V260, P6122; POWERS L, 1984, BIOCHEMISTRY-US, V23, P5519, DOI 10.1021/bi00318a021; RAAG R, 1992, FRONTIERS BIOTRANSFO, V7, P1; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; SHIRO Y, 1991, BIOCHIM BIOPHYS ACTA, V1115, P101, DOI 10.1016/0304-4165(91)90018-C; SHIRO Y, 1990, J AM CHEM SOC, V112, P2921, DOI 10.1021/ja00164a012; SONO M, 1982, J BIOL CHEM, V257, P8308; UNGER BP, 1986, BACTERIA, V10, P558; WANG S, 1989, PHYSICA B, V158, P119, DOI 10.1016/0921-4526(89)90222-6; WATANABE Y, 1992, ENZYMES, V20, P405; ZHANG K, 1991, PROTEINS, V10, P279, DOI 10.1002/prot.340100402	41	38	38	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10544	10550		10.1074/jbc.270.18.10544	http://dx.doi.org/10.1074/jbc.270.18.10544			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737989	hybrid			2022-12-25	WOS:A1995QW60100030
J	QUAN, LT; CAPUTO, A; BLEACKLEY, RC; PICKUP, DJ; SALVESEN, GS				QUAN, LT; CAPUTO, A; BLEACKLEY, RC; PICKUP, DJ; SALVESEN, GS			GRANZYME-B IS INHIBITED BY THE COWPOX VIRUS SERPIN CYTOKINE RESPONSE MODIFIER-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DEATH GENE CED-3; SERINE PROTEASES; PROTEIN; ENZYME; PURIFICATION; APOPTOSIS; CYTOLYSIS; SUBSTRATE; ENCODES	The ability of cytolytic cells to cause apoptosis in target cells is in part due to the action of the serine proteinase granzyme B, We demonstrate that granzyme B is inhibited, with an association rate constant of 2.9 x 10(5) M(-1) S-1, by the cowpox viral serpin cytokine response modifier A (CrmA). Previously we have shown CrmA to be an inhibitor of the cysteine proteinase interleukin-1 beta-converting enzyme (ICE), Thus the mechanism of CrmA involves the unusual ability to efficiently inhibit proteinases from two distinct catalytic classes, in this case serine and cysteine proteinases. Granzyme B and ICE are both used to combat viral infection, and we propose that cowpox virus uses CrmA to evade the contribution of these two proteinases, Thus, through CrmA, the virus may influence two of the pathways normally used to kill virus-infected cells: acting on endogenous proteinases such as ICE and on exogenous proteinases delivered by cytotoxic lymphocytes to infected cells.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA	Duke University; Duke University; University of Alberta					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI032982, R01AI032982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038860] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32982] Funding Source: Medline; NIGMS NIH HHS [GM38860] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BLACK RA, 1989, J BIOL CHEM, V264, P5323; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KOMIYAMA T, 1994, TECHNIQUES IN PROTEIN CHEMISTRY V, P305; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; PALUMBO GJ, 1989, VIROLOGY, V172, P262, DOI 10.1016/0042-6822(89)90128-1; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; POE M, 1991, J BIOL CHEM, V266, P98; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SMYTH MJ, 1994, CLIN EXP PHARMACOL P, V21, P67, DOI 10.1111/j.1440-1681.1994.tb02438.x; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P2641, DOI 10.1021/bi00408a001; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	26	230	233	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10377	10379		10.1074/jbc.270.18.10377	http://dx.doi.org/10.1074/jbc.270.18.10377			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737968	hybrid			2022-12-25	WOS:A1995QW60100005
J	CASTAING, B; ZELWER, C; LAVAL, J; BOITEUX, S				CASTAING, B; ZELWER, C; LAVAL, J; BOITEUX, S			HU PROTEIN OF ESCHERICHIA-COLI BINDS SPECIFICALLY TO DNA THAT CONTAINS SINGLE-STRAND BREAKS OR GAPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-LIKE PROTEIN; POLY(ADP-RIBOSE) POLYMERASE; FPG PROTEINS; REPAIR; EXCISION; REPLICATION; GLYCOSYLASE; SITE; IHF; OVERPRODUCTION	In this study, we have identified a protein in Escherichia coli that specifically binds to double-stranded DNA containing a single-stranded gap of one nucleotide. The gap-DNA binding (GDB) protein was purified to apparent homogeneity, The analysis of the amino-terminal sequencing of the GDB protein shows two closely related sequences we identify as the alpha and beta subunits of the HU protein, Furthermore, the GDB protein is not detected in the crude extract of an E. coli double mutant strain hupA hupB that has no functional HU protein. These results led us to identify the GDB protein as the HU protein. HU binds strongly to double stranded 30-mer oligonucleotides containing a nick or a single-stranded gap of one or two nucleotides, Apparent dissociation constants were measured for these various DNA duplexes using a gel retardation assay, The K-D(app) values were 8 nM for the 30-mer duplex that contains a nick and 4 and 2 nM for those that contain a 1- or a 2-nucleotide gap, respectively, The affinity of HU for these ligands is at least 100-fold higher than for the same 30-mer DNA duplex without nick or gap. Other single-stranded breaks or gaps, which are intermediate products in the repair of abasic sites after incision by the Fpg, Nth, or Nfo proteins, are also preferentially bound by the HU protein, Due to specific: binding to DNA strand breaks, HU may play a role in replication, recombination, and repair.	INST GUSTAVE ROUSSY,CNRS,URA 147,REPARAT LES RADIO & CHIMIOIND GRP,F-94805 VILLEJUIF,FRANCE; CTR BIOPHYS MOLEC,CNRS,UPR 4301,EQUIPE CRISTALLOG BIOL,F-45071 ORLEANS 2,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC)				Castaing, Bertrand/0000-0001-5077-8978				BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1993, J PHOTOCH PHOTOBIO B, V19, P87, DOI 10.1016/1011-1344(93)87101-R; BOITEUX S, 1989, MOL GEN GENET, V215, P300, DOI 10.1007/BF00339732; BONNEFOY E, 1994, J MOL BIOL, V242, P116, DOI 10.1006/jmbi.1994.1563; BONNEFOY E, 1992, EMBO J, V11, P4489, DOI 10.1002/j.1460-2075.1992.tb05550.x; BONNEFOY E, 1991, EMBO J, V10, P687, DOI 10.1002/j.1460-2075.1991.tb07998.x; BONNEFOY E, 1989, P NATL ACAD SCI USA, V86, P7691, DOI 10.1073/pnas.86.20.7691; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BROYLES SS, 1986, J MOL BIOL, V187, P47, DOI 10.1016/0022-2836(86)90405-5; CASTAING B, 1993, NUCLEIC ACIDS RES, V21, P2899, DOI 10.1093/nar/21.12.2899; CASTAING B, 1992, NUCLEIC ACIDS RES, V20, P389, DOI 10.1093/nar/20.3.389; CHARNEAU P, 1991, J VIROL, V65, P2415, DOI 10.1128/JVI.65.5.2415-2421.1991; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DING RC, 1992, J BIOL CHEM, V267, P12804; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FLASHNER Y, 1988, CELL, V54, P713, DOI 10.1016/S0092-8674(88)80016-3; GRAVES RJ, 1992, J BIOL CHEM, V267, P14429; HARTKE A, 1991, MUTAT RES, V255, P39, DOI 10.1016/0921-8777(91)90016-I; HAYS JB, 1970, J MOL BIOL, V48, P297, DOI 10.1016/0022-2836(70)90162-2; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; HWANG DS, 1992, J BIOL CHEM, V267, P23083; JOHNSON RC, 1986, CELL, V46, P531, DOI 10.1016/0092-8674(86)90878-0; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LECAER JP, 1988, ANAL BIOCHEM, V169, P246, DOI 10.1016/0003-2697(88)90281-3; LECAM E, 1994, J MOL BIOL, V235, P1062, DOI 10.1006/jmbi.1994.1057; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MILLS JB, 1994, BIOCHEMISTRY-US, V33, P1797, DOI 10.1021/bi00173a024; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x; PREOBRAJENSKAYA O, 1994, IN PRESS MOL MICROBI; ROUVIEREYANIV J, 1975, P NATL ACAD SCI USA, V72, P3428, DOI 10.1073/pnas.72.9.3428; ROUVIEREYANIV J, 1979, CELL, V17, P265, DOI 10.1016/0092-8674(79)90152-1; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; THRAVES PJ, 1985, CANCER RES, V45, P386; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; WADA M, 1989, GENE, V76, P345, DOI 10.1016/0378-1119(89)90174-1	46	127	129	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10291	10296		10.1074/jbc.270.17.10291	http://dx.doi.org/10.1074/jbc.270.17.10291			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730334	hybrid			2022-12-25	WOS:A1995QV41700083
J	FERNANDEZ, CA; ROSIERS, CD				FERNANDEZ, CA; ROSIERS, CD			MODELING OF LIVER CITRIC-ACID CYCLE AND GLUCONEOGENESIS BASED ON C-13 MASS ISOTOPOMER DISTRIBUTION ANALYSIS OF INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KREBS CYCLE; RAT-LIVER; QUANTITATIVE-ANALYSIS; METABOLISM; INVIVO; CARBON; <U-C-13>GLUCOSE; GLUCOSE; LACTATE; ATOMS	We have developed and implemented a model that can predict the positional isotopomer distribution of various hepatic metabolites labeled with [U-C-13(3)]lactate and/or [U-C-13(3)]pyruvate for given relative flux rates through the citric acid cycle and gluconeogenesis reactions, Our model includes (i) isotopic exchange between alpha-ketoglutarate and glutamate, (ii) a reversible isocitrate dehydrogenase reaction, (iii) an active ATP-citrate lyase, and (iv) aspartate and malate shuttles with separate cytosolic and mitochondrial pools for oxaloacetate, malate, and fumarate. A parameter estimation routine fit the mass isotopomer distribution of selected metabolites measured by gas chromatography-mass spectrometry to the model predicted distributions, We fit measured mass isotopomer distributions of phosphoenolpyruvate, citrate, alpha-ketoglutarate, glutamate, and pyruvate isolated fi om fasted rat livers perfused with [U-C-13(3)]lactate + [U-C-13(3)]pyruvate. This fitting yielded rates which we express relative to that of pyruvate carboxylase: citric acid cycle represented by the irreversible alpha-ketoglutarate dehydrogenase = 0.32; citrate synthase = 0.64; reversal of isocitrate dehydrogenase = 0.52; citrate lyase = 0.33, aspartate shuttle = 0.24, and malate shuttle = 0.44, Rates calculated for the cytosolic and mitochondrial fumarate and malate dehydrogenase reactions are subject to uncertainties as indicated by identifiability analyses. Previous forms of our model that did not include pyruvate kinase, exchange of cu ketoglutarate with glutamate, reversibility of isocitrate dehydrogenase, and/or ATP-citrate lyase activity were not as successful at predicting our measured values, This model offers a general tool for studying the regulation of the citric acid cycle and gluconeogenesis and can be readily modified for any C-13-labeled lactate or pyruvate substrate.	CASE WESTERN RESERVE UNIV, DEPT BIOMED ENGN, CLEVELAND, OH 44106 USA; UNIV MONTREAL, DEPT NUTR, MONTREAL, PQ H3C 3J7, CANADA	Case Western Reserve University; Universite de Montreal			Rosiers, Christine Des/O-6285-2014					BARANYAI JM, 1989, BIOCHEM J, V258, P121, DOI 10.1042/bj2580121; COHEN SM, 1983, J BIOL CHEM, V258, P4294; DESROSIERS C, 1994, J BIOL CHEM, V269, P27179; DIDONATO L, 1993, J BIOL CHEM, V268, P4170; Dongarra J. J., 1979, LINPACK USERS GUIDE; DUSZYNSKI J, 1978, J BIOL CHEM, V253, P6149; FERNANDEZ C, 1994, P INT FEDERATION AUT, P365; GOEBEL R, 1982, FED PROC, V41, P96; HEATH DF, 1985, BIOCHEM J, V227, P851, DOI 10.1042/bj2270851; HETENYI G, 1982, FED PROC, V41, P104; JUNGERMANN K, 1992, ENZYME, V46, P33, DOI 10.1159/000468777; KATZ J, 1993, J BIOL CHEM, V268, P25509; KATZ J, 1985, AM J PHYSIOL, V248, pR391, DOI 10.1152/ajpregu.1985.248.4.R391; KATZ J, 1989, J BIOL CHEM, V264, P12994; KELLEHER JK, 1985, AM J PHYSIOL, V248, pE252, DOI 10.1152/ajpendo.1985.248.2.E252; KELLEHER JK, 1986, AM J PHYSIOL, V250, pE296, DOI 10.1152/ajpendo.1986.250.3.E296; LANDAU BR, 1993, AM J PHYSIOL, V265, pE636, DOI 10.1152/ajpendo.1993.265.4.E636; LASDON LS, 1989, GRG 2 USERS GUIDE; Lee W. N. P., 1989, J BIOL CHEM, V264, P13002; LEE WNP, 1991, BIOCHEM MED METAB B, V45, P298, DOI 10.1016/0885-4505(91)90034-I; LEE WNP, 1993, J BIOL CHEM, V268, P25522; LEE WNP, 1991, STABLE ISOTOPES PEDI, P179; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; MULLHOFER G, 1977, EUR J BIOCHEM, V75, P319, DOI 10.1111/j.1432-1033.1977.tb11532.x; ROGNSTAD R, 1993, BIOCHEM ARCH, V9, P15; ROSIERS CD, 1995, J BIOL CHEM, V270, P10027, DOI 10.1074/jbc.270.17.10027; ROSIERS CD, 1991, J BIOL CHEM, V266, P1574; Rothery P, 1993, MODELS BIOL MATH STA; SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X; SHULMAN GI, 1987, J CLIN INVEST, V80, P387, DOI 10.1172/JCI113084; SRERE PA, 1993, BIOL CHEM H-S, V374, P833; Stoer J., 2013, INTRO NUMERICAL ANAL, VVolume 12, DOI [10.1007/978-0-387-21738-3, DOI 10.1007/978-0-387-21738-3]; STRISOWER EH, 1952, J BIOL CHEM, V198, P115; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; VOGT JA, 1994, AM J PHYSIOL, V266, pE1012, DOI 10.1152/ajpendo.1994.266.6.E1012; ZUPKE C, 1994, P INT FEDERATION AUT, P394	36	44	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10037	10042		10.1074/jbc.270.17.10037	http://dx.doi.org/10.1074/jbc.270.17.10037			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730305	hybrid			2022-12-25	WOS:A1995QV41700050
J	FUJIHARA, S; ABE, H; YONEYAMA, T				FUJIHARA, S; ABE, H; YONEYAMA, T			A NEW POLYAMINE 4-AMINOBUTYLCADAVERINE - OCCURRENCE AND ITS BIOSYNTHESIS IN ROOT-NODULES OF ADZUKI BEAN PLANT VIGNA-ANGULARIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATOGRAPHY-MASS-SPECTROMETRY; EXTREME THERMOPHILE; DIAMINE OXIDASE; HOMOSPERMIDINE SYNTHASE; CHEMOTAXONOMIC MARKER; GAS-CHROMATOGRAPHY; PURIFICATION; BRADYRHIZOBIUM; RHIZOBIUM; SEEDLINGS	Root nodules of adzuki bean plant (Vigna angularis) contained a novel polyamine. The chemical structure of the new polyamine was determined to be NH2(CH2)(5)-NH(CH2)(4)NH2 (4-aminobutylcadaverine) based on gas chromatography-mass spectrometry. The occurrence of 4-aminobutylcadaverine was specific to the root nodules, since the unusual triamine was not detected in other organs of the adzuki bean plant. Bacteroids, isolated from root nodules, contained both sym-homospermidine and 4-aminobutylcadaverine, whereas the plant cytosol fraction contained large quantities of putrescine and cadaverine. A cell-free extract of bacteroids showed the ability to form this triamine from putrescine and cadaverine under the presence of NAD(+) and K+. 1,3-Diaminopropane and NADH were inhibitory for the synthesis of both sym-homospermidine and 4 aminobutylcadaverine. [1,4-N-15]Putrescine was incorporated not only into sym-homospermidine but also into 4-aminobutylcadaverine by the cell-free extract of bacteroids when incubated with excess cadaverine. Analysis of the frag ment ion peaks in the N-15-enriched 4-aminobutylcadaverine indicated the transfer of a aminobutyl moiety to the amino terminus of cadaverine. These results suggest that, in adzuki bean, 4-aminobutylcadaverine is formed through the action of homospermidine synthase in nodule bacteroids under a cadaverine-rich environment.	NATL AGR RES CTR,PLANT NUTR & DIAG LAB,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN	National Agriculture & Food Research Organization - Japan; University of Tsukuba								ALHONENHONGISTO L, 1980, BIOCHEM BIOPH RES CO, V93, P1005, DOI 10.1016/0006-291X(80)90589-6; ANGELINI R, 1985, PHYTOCHEMISTRY, V24, P2511, DOI 10.1016/S0031-9422(00)80657-3; Bergersen FJ, 1974, BIOL NITROGEN FIXATI, P473; BOTTCHER F, 1993, PHYTOCHEMISTRY, V32, P679, DOI 10.1016/S0031-9422(00)95154-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSE J, 1988, SYST APPL MICROBIOL, V11, P1; DELHAIZE E, 1987, PHYTOCHEMISTRY, V26, P641, DOI 10.1016/S0031-9422(00)84757-3; DEROSA M, 1976, BIOCHEM BIOPH RES CO, V69, P253, DOI 10.1016/S0006-291X(76)80300-2; FLORES HE, 1982, PLANT PHYSIOL, V69, P701, DOI 10.1104/pp.69.3.701; FLORIS G, 1983, PHYTOCHEMISTRY, V22, P1871, DOI 10.1016/0031-9422(83)80004-1; FUJIHARA S, 1982, BIOCHEM BIOPH RES CO, V107, P403, DOI 10.1016/0006-291X(82)91718-1; FUJIHARA S, 1994, PLANT CELL PHYSIOL, V35, P1127, DOI 10.1093/oxfordjournals.pcp.a078705; FUJIHARA S, 1986, J CHROMATOGR, V383, P271, DOI 10.1016/S0378-4347(00)83473-8; FUJIHARA S, 1989, BIOCHEM BIOPH RES CO, V165, P659, DOI 10.1016/S0006-291X(89)80016-6; FUJIHARA S, 1993, APPL ENVIRON MICROB, V59, P1104, DOI 10.1128/AEM.59.4.1104-1109.1993; HAMANA K, 1992, CRIT REV MICROBIOL, V18, P261, DOI 10.3109/10408419209113518; HAMANA K, 1990, FEMS MICROBIOL LETT, V71, P71, DOI 10.1111/j.1574-6968.1990.tb03800.x; HOLTTA E, 1983, BIOCHEM J, V210, P945; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; MATSUDA H, 1981, PLANT CELL PHYSIOL, V22, P737; NIITSU M, 1993, J CHROMATOGR, V641, P115, DOI 10.1016/0021-9673(93)83465-5; OKADA M, 1979, J BIOCHEM, V85, P1235; OSHIMA T, 1982, J BIOL CHEM, V257, P9913; OSHIMA T, 1975, BIOCHEM BIOPH RES CO, V63, P1093, DOI 10.1016/0006-291X(75)90681-6; OSHIMA T, 1979, J BIOL CHEM, V254, P8720; PAULUS TJ, 1982, J BACTERIOL, V152, P291; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Phillips G. C., 1991, BIOCH PHYSL POLYAMIN, P121; SABO DL, 1974, BIOCHEMISTRY-US, V13, P662, DOI 10.1021/bi00701a005; SANCHEZ F, 1991, ANNU REV PLANT PHYS, V42, P507, DOI 10.1146/annurev.pp.42.060191.002451; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; SMITH TA, 1985, BIOCHEM SOC T, V13, P319, DOI 10.1042/bst0130319; SMITH TA, 1985, ANNU REV PLANT PHYS, V36, P117, DOI 10.1146/annurev.pp.36.060185.001001; SRIVENUGOPAL KS, 1980, BIOCHEM J, V190, P461, DOI 10.1042/bj1900461; Suresh M. R., 1976, Phytochemistry, V15, P483, DOI 10.1016/S0031-9422(00)88952-9; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; TABOR CW, 1964, J BIOL CHEM, V239, P2194; Tait GH, 1979, BIOCHEM SOC T, V7, P199, DOI 10.1042/bst0070199; TAIT GH, 1985, BIOCHEM SOC T, V13, P316, DOI 10.1042/bst0130316; TAJIMA S, 1982, PLANT PHYSIOL, V70, P388, DOI 10.1104/pp.70.2.388; YAMAMOTO S, 1993, J BIOCHEM-TOKYO, V114, P45, DOI 10.1093/oxfordjournals.jbchem.a124137	41	27	27	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9932	9938		10.1074/jbc.270.17.9932	http://dx.doi.org/10.1074/jbc.270.17.9932			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730376	hybrid			2022-12-25	WOS:A1995QV41700037
J	GAO, F; LIPSCOMB, B; WU, IM; RICHTER, ML				GAO, F; LIPSCOMB, B; WU, IM; RICHTER, ML			IN-VITRO ASSEMBLY OF THE CORE CATALYTIC COMPLEX OF THE CHLOROPLAST ATP SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING FACTOR-I; NUCLEOTIDE-BINDING-SITES; ISOLATED BETA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; ESCHERICHIA-COLI; ALPHA-3-BETA-3 COMPLEX; RHODOSPIRILLUM-RUBRUM; ISOLATED ALPHA; RECONSTITUTION; F1-ATPASE	The regulatory gamma subunit and an alpha beta complex were isolated from the catalytic F-1 portion of the chloroplast ATP synthase, The isolated gamma subunit was devoid of catalytic activity, whereas the alpha beta complex exhibited a very low ATPase activity (similar to 200 nmol/min/mg of protein), The alpha beta complex migrated as a hexameric alpha(3) beta(3) complex during ultracentrifugation and gel filtration but reversibly dissociated into alpha and beta monomers after freezing and thawing in the presence of ethylenediamine tetraacetic acid and in the absence of nucleotides, Conditions are described in which the gamma and alpha beta preparations were combined to rapidly and efficiently reconstitute a fully functional catalytic core enzyme complex, The reconstituted enzyme exhibited normal tight binding and sensitivity to the inhibitory epsilon subunit and to the allosteric inhibitor tentoxin, However, neither the alpha beta complex nor the isolated gamma subunit alone could bind the epsilon subunit or tentoxin with high affinity, Similarly, high affinity binding sites for ATP and ADP, which are characteristic of the core alpha(3) beta(3) gamma enzyme, were absent from the alpha beta complex, The results indicate that when the gamma subunit binds to the alpha beta complex, it induces a three-dimensional conformation in the enzyme, which is necessary for tight binding of the inhibitors and for high-affinity, asymmetric nucleotide binding.	UNIV KANSAS,DEPT BIOCHEM,LAWRENCE,KS 66045	University of Kansas								ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADMON A, 1987, BIOCHEMISTRY-US, V26, P3193, DOI 10.1021/bi00385a038; ALOISE P, 1990, J BIOL CHEM, V266, P10368; ANDRALOJC PJ, 1992, FEBS LETT, V310, P187, DOI 10.1016/0014-5793(92)81326-H; AVITAL S, 1991, J BIOL CHEM, V266, P7067; AVNI A, 1992, SCIENCE, V257, P1245, DOI 10.1126/science.1387730; BOEKEMA EJ, 1992, BIOCHIM BIOPHYS ACTA, V1098, P131, DOI 10.1016/S0005-2728(05)80328-7; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN GG, 1994, P NATL ACAD SCI USA, V91, P11497, DOI 10.1073/pnas.91.24.11497; CHEN ZG, 1992, FEBS LETT, V298, P69, DOI 10.1016/0014-5793(92)80024-B; COLVERT KK, 1992, BIOCHEMISTRY-US, V31, P3130; DUNN SD, 1980, J BIOL CHEM, V255, P113; FUTAI M, 1977, BIOCHEM BIOPH RES CO, V79, P1231, DOI 10.1016/0006-291X(77)91138-X; GIRAULT G, 1988, J BIOL CHEM, V263, P14690; GROMETELHANAN Z, 1984, BIOCHEMISTRY-US, V23, P1022, DOI 10.1021/bi00300a034; HARADA M, 1991, BIOCHIM BIOPHYS ACTA, V1056, P279, DOI 10.1016/S0005-2728(05)80059-3; HISABORI T, 1986, J BIOCHEM-TOKYO, V100, P663, DOI 10.1093/oxfordjournals.jbchem.a121758; HSU SY, 1984, BIOCHEMISTRY-US, V23, P988, DOI 10.1021/bi00300a029; HU NM, 1993, J BIOL CHEM, V268, P8536; ISSARTEL JP, 1984, BIOCHEMISTRY-US, V23, P6591, DOI 10.1021/bi00321a048; KAGAWA Y, 1989, FEBS LETT, V249, P67, DOI 10.1016/0014-5793(89)80017-1; KANANSHVILI D, 1983, J BIOL CHEM, V258, P3714; LARSON EM, 1989, BIOCHIM BIOPHYS ACTA, V973, P67, DOI 10.1016/S0005-2728(89)80404-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCARTY RE, 1985, ENZYMES BIOL MEMBR, P383; MILLS DA, 1991, J BIOL CHEM, V266, P7440; MILLS DA, 1990, CURRENT PROGR PHOTOS, V3, P6; MIWA K, 1989, P NATL ACAD SCI USA, V86, P6484, DOI 10.1073/pnas.86.17.6484; NALIN CM, 1988, CURR TOP BIOENERG, V15, P273; OHTA S, 1980, J BIOCHEM-TOKYO, V87, P1609, DOI 10.1093/oxfordjournals.jbchem.a132904; PATRIE WJ, 1984, J BIOL CHEM, V259, P1121; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENEFSKY HS, 1990, ADV ENZYMOL, V64, P173; RICHTER ML, 1984, J BIOL CHEM, V259, P7371; RICHTER ML, 1986, J BIOL CHEM, V261, P2109; RICHTER ML, 1985, BIOCHEMISTRY-US, V24, P5755, DOI 10.1021/bi00342a011; SHAPIRO AB, 1990, J BIOL CHEM, V265, P4340; SHAPIRO AB, 1991, J BIOL CHEM, V266, P4194; SHAPIRO AB, 1991, J BIOL CHEM, V266, P17276; SHAPIRO AB, 1988, J BIOL CHEM, V263, P14160; SHOSHAN V, 1980, J BIOL CHEM, V255, P384; STEELE JA, 1976, P NATL ACAD SCI USA, V73, P2245, DOI 10.1073/pnas.73.7.2245; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; XUE ZX, 1987, BIOCHEMISTRY-US, V26, P3749, DOI 10.1021/bi00387a001; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480; YOSHIDA M, 1982, J BIOL CHEM, V265, P2483	48	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9763	9769		10.1074/jbc.270.17.9763	http://dx.doi.org/10.1074/jbc.270.17.9763			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730354	hybrid			2022-12-25	WOS:A1995QV41700013
J	GENOT, EM; PARKER, PJ; CANTRELL, DA				GENOT, EM; PARKER, PJ; CANTRELL, DA			ANALYSIS OF THE ROLE OF PROTEIN-KINASE-C-ALPHA, PROTEIN-KINASE-EPSILON, AND PROTEIN-KINASE-ZETA IN T-CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; SIGNAL-TRANSDUCTION; RECEPTOR; DOMAIN; GENE; DIACYLGLYCEROL; TRANSCRIPTION; P21(RAS); BINDING	T cells express multiple isotypes of protein kinase C (PKC) and although it is well accepted that PKCs have an important role in T cell activation, little is known about the function of individual PRC isotypes. To address this issue, mutationally active PKC-alpha, -epsilon, or -zeta have been transfected into T cells and the consequences for T cell activation determined, p21(ras) plays an essential role in T cell activation, Accordingly, the effects of the constitutively active PKCs were compared to the effects of mutationally activated p21(ras), The data indicate that PKC-epsilon and, to a lesser extent PKC-alpha but not -zeta can regulate the transcription factors AP-1 and nuclear factor of activated T cells (NF-AT-1), The ability of PKC-epsilon to induce transactivation of NF-AT-1 and AP-I was similar to the stimulatory effect of a constitutively activated p21(ras), PKC-epsilon, but not PKC-alpha nor activated p21(ras), was able to induce NF-KB activity, Phorbol esters induce expression of CD69 whereas none of the activated PKC isotypes tested were able to have this effect. Activated Src and p21(ras) were able to induce CD69 expression. These results indicate selective functions for different PKC isotypes in T cells. Moreover, the data comparing the effects of activated has and PKC mutants suggest that PKC-alpha, p21(ras), and PKC-epsilon are not positioned linearly on a single signal transduction pathway.	IMPERIAL CANC RES FUND,LYMPHOCYTE ACTIVAT LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,PROT PHOSPHORYLAT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK; Cancer Research UK			Genot, Elisabeth/G-8031-2014; Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933				AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BAIER G, 1993, J BIOL CHEM, V268, P4997; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BERRY N, 1990, EUR J BIOCHEM, V189, P205, DOI 10.1111/j.1432-1033.1990.tb15478.x; DAMBROSIO D, 1994, EUR J IMMUNOL, V24, P616, DOI 10.1002/eji.1830240319; DAUM G, 1994, TRENDS BIOCHEM SCI, V227, P474; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V227, P470; DECOCK JBJ, 1994, FEBS LETT, V356, P275, DOI 10.1016/0014-5793(94)01283-0; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GOODE NT, 1994, FEBS LETT, V340, P145, DOI 10.1016/0014-5793(94)80190-8; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HARA T, 1986, J EXP MED, V164, P1988, DOI 10.1084/jem.164.6.1988; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NUNES J, 1993, INT IMMUNOL, V5, P311, DOI 10.1093/intimm/5.3.311; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; ORR JW, 1992, J BIOL CHEM, V267, P15263; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; PULVERER BJ, 1993, ONCOGENE, V8, P407; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; SCHAAP D, 1989, FEBS LETT, V243, P352; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TSUTSUMI A, 1993, J IMMUNOL, V150, P1754; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS DH, 1992, BIOCHIM BIOPHYS ACTA, V1180, P9, DOI 10.1016/0925-4439(92)90020-N; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; WOTTON D, 1993, J BIOL CHEM, V268, P17975	35	177	179	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9833	9839		10.1074/jbc.270.17.9833	http://dx.doi.org/10.1074/jbc.270.17.9833			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730364	hybrid			2022-12-25	WOS:A1995QV41700023
J	HUA, SB; LI, XQ; COFFINO, P; WANG, CC				HUA, SB; LI, XQ; COFFINO, P; WANG, CC			RAT ANTIZYME INHIBITS THE ACTIVITY BUT DOES NOT PROMOTE THE DEGRADATION OF MOUSE ORNITHINE DECARBOXYLASE IN TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULOCYTE LYSATE; INTRACELLULAR DEGRADATION; NEUROSPORA-CRASSA; POLYAMINE; PROTEIN; EXPRESSION; PUTRESCINE; DIFLUOROMETHYLORNITHINE; TARGET; ENZYME	Ornithine decarboxylase (ODC) of African kypanosomes is an important target for anti-trypanosomal chemotherapy because of its remarkable stability in vivo, The in vivo activity and stability of mammalian ODC are regulated by polyamines, Polyamines induce antizyme, which inactivates ODC by tight association and promotes degradation of ODC by the mammalian 26 S proteasome, Here we found, in contrast to mammalian cells, that polyamines caused no reduction of ODC activity in Trypanosoma brucei, Mouse ODC expressed in T. brucei was also unaffected by exogenous polyamines, suggesting that a mammalian antizyme equivalent may be absent in T. brucei, The rat antizyme expressed in T. brucei was found capable of inhibiting mouse ODC activity by the formation of rat antizyme-mouse ODC complex, However, complex formation did not lead to degradation of mouse ODC in T. brucei, Further in vitro experiments suggested the presence of an inhibitory factor(s) in trypanosome, which interferes with the degradation of mouse ODC, We also demonstrated the presence of proteasomes in T. brucei, But the mobility of the trypanosomal proteasome on native gel is different from that of the mammalian proteasome, Thus, the absence of antizyme, the presence of inhibitory factor(s), and the differences between trypanosomal and mammalian proteasome may account for the stability of mouse ODC in T. brucei cells,	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco				Coffino, Philip/0000-0003-0344-5083	NIAID NIH HHS [AI21786] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI021786, R01AI021786, R56AI021786] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AFFRANCHINO JL, 1993, GENE, V132, P75, DOI 10.1016/0378-1119(93)90516-6; BABY TG, 1991, BIOCHIM BIOPHYS ACTA, V1092, P161, DOI 10.1016/0167-4889(91)90150-V; BACCHI CJ, 1980, SCIENCE, V210, P332, DOI 10.1126/science.6775372; BACCHI CJ, 1983, MOL BIOCHEM PARASIT, V7, P209, DOI 10.1016/0166-6851(83)90022-1; BARNETT GR, 1988, J BIOL CHEM, V263, P10005; BASS KE, 1992, J BIOL CHEM, V267, P11034; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; DAVIS RH, 1985, P NATL ACAD SCI USA, V82, P4105, DOI 10.1073/pnas.82.12.4105; FONG WF, 1976, BIOCHIM BIOPHYS ACTA, V428, P456, DOI 10.1016/0304-4165(76)90054-4; FONZI WA, 1989, J BIOL CHEM, V264, P18110; FRIEDMAN H, 1994, P NATL ACAD SCI USA, V91, P2031, DOI 10.1073/pnas.91.6.2031; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1990, J BIOL CHEM, V265, P11823; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GUPTA M, 1985, J BIOL CHEM, V260, P2941; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HELLER JS, 1976, P NATL ACAD SCI USA, V73, P1858, DOI 10.1073/pnas.73.6.1858; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HUA SB, 1994, J CELL BIOCHEM, V54, P20, DOI 10.1002/jcb.240540104; JANNE J, 1989, ORNITHINE DECARBOXYL, P59; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; MAMROUDKIDRON E, 1994, FEBS LETT, V337, P239, DOI 10.1016/0014-5793(94)80199-1; MATSUFUJI S, 1990, J BIOCHEM-TOKYO, V108, P365, DOI 10.1093/oxfordjournals.jbchem.a123207; MITCHELL JLA, 1983, BIOCHEM J, V214, P345, DOI 10.1042/bj2140345; MIYAZAKI Y, 1992, GENE, V113, P191, DOI 10.1016/0378-1119(92)90395-6; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1985, BIOCHEM J, V226, P893, DOI 10.1042/bj2260893; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; MURAKAMI Y, 1993, BIOCHEM J, V295, P305, DOI 10.1042/bj2950305; NATHAN HC, 1981, BIOCHEM PHARMACOL, V30, P3010, DOI 10.1016/0006-2952(81)90270-7; OKA T, 1989, ORNITHINE DECARBOXYL, P7; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; PHILLIPS MA, 1988, J BIOL CHEM, V263, P17933; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SJOERDSMA A, 1984, CLIN PHARMACOL THER, V35, P287, DOI 10.1038/clpt.1984.33; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TEKWANI BL, 1992, MOL CELL BIOCHEM, V117, P53, DOI 10.1007/BF00230410; TOKUNAGA F, 1994, J BIOL CHEM, V269, P17382; TORRI AF, 1993, MOL BIOCHEM PARASIT, V57, P305, DOI 10.1016/0166-6851(93)90206-D	49	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10264	10271		10.1074/jbc.270.17.10264	http://dx.doi.org/10.1074/jbc.270.17.10264			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730330	hybrid			2022-12-25	WOS:A1995QV41700079
J	YIN, WS; SMILEY, E; GERMILLER, J; MECHAM, RP; FLORER, JB; WENSTRUP, RJ; BONADIO, J				YIN, WS; SMILEY, E; GERMILLER, J; MECHAM, RP; FLORER, JB; WENSTRUP, RJ; BONADIO, J			ISOLATION OF A NOVEL LATENT TRANSFORMING GROWTH-FACTOR-BETA BINDING-PROTEIN GENE (LTBP-3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT COMPLEX; SMOOTH-MUSCLE CELLS; EGF-LIKE DOMAIN; HUMAN FACTOR-IX; TGF-BETA; EXTRACELLULAR-MATRIX; PROCESSING ENDOPROTEASES; OSTEOBLAST PHENOTYPE; EXPRESSION PATTERN; ENDOTHELIAL-CELLS	This paper reports the molecular cloning of a novel gene in the mouse that shows structural similarities to the microfibril protein fibrillin and to the latent trans forming growth factor-beta (TGF-beta) binding protein (LTBP), a component of the latent TGF-beta complex. The gene was initially isolated during a low stringency polymerase chain reaction screen of a NIH 3T3 cell cDNA library using primers that amplify a human fibrillin-1 epidermal growth factor-like repeat, Three lines of evidence suggest that the mouse gene is a third member of the LTBP gene family, which we designate LTBP-3. First, the deduced polypeptide, which consists of 15 epidermal growth factor-like repeats, 3 TGF binding protein repeats, and 2 proline- and glycine-rich sequences, shows 38.4% identity with LTBP-1 but only 27% identity with fibrillin-1. Second, the gene appears to be co-expressed in developing mouse tissues with TGF-beta. Third, immunoprecipitation studies using mouse preosteoblast MC3T3-E1 cells and a specific anti-peptide polyclonal antiserum reveal that the mouse polypeptide forms a complex with the TGF-beta 1 precursor. Finally, we note that the LTBP-3 gene was recently localized to a distinct genetic locus (Li, X., Yin, W., Perez-Jurado, L., Bonadio, J., and Francke, U. (1995) Mamm. Genome 6, 42-45). Identification of a third binding protein provides further insight into a mechanism by which latent TGF-beta complexes can be targeted to connective tissue matrices and cells.	UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; CHILDRENS HOSP RES FDN,DEPT PEDIAT,DIV HUMAN GENET,CINCINNATI,OH 45229	University of Michigan System; University of Michigan; Washington University (WUSTL); Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation					NHLBI NIH HHS [HL-41926] Funding Source: Medline; NIAMS NIH HHS [AR-40586] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040586] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMARNANI S, 1993, J BONE MINER RES, V8, P157; ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENEZRA M, 1993, BLOOD, V81, P3324; BONADIO J, 1985, J BIOL CHEM, V260, P1734; BONEWALD LF, 1991, MOL ENDOCRINOL, V5, P741, DOI 10.1210/mend-5-6-741; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEN YP, 1993, J BIOL CHEM, V268, P27381; COLOSETTI P, 1993, FEBS LETT, V320, P140, DOI 10.1016/0014-5793(93)80079-A; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DALLAS SL, 1994, J BIOL CHEM, V269, P6815; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FALCONE DJ, 1993, J BIOL CHEM, V268, P11951; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; GERSTENFELD LC, 1987, DEV BIOL, V122, P49, DOI 10.1016/0012-1606(87)90331-9; GRONKE RS, 1989, P NATL ACAD SCI USA, V86, P3609, DOI 10.1073/pnas.86.10.3609; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LEHNERT SA, 1988, DEVELOPMENT, V104, P263; LI X, 1995, MAMM GENOME, V6, P42, DOI 10.1007/BF00350892; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MILLAN FA, 1991, DEVELOPMENT, V111, P131; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; MIYAZONO K, 1992, J BIOL CHEM, V267, P5668; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1993, GASTROENTEROL JPN, V28, P81; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MOREN A, 1994, J BIOL CHEM, V269, P32469; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; OLOFSSON A, 1992, J BIOL CHEM, V267, P19482; PELTON RW, 1989, DEVELOPMENT, V106, P759; PELTON RW, 1990, DEVELOPMENT, V110, P609; PELTON RW, 1990, DEV BIOL, V141, P456, DOI 10.1016/0012-1606(90)90401-4; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PIRCHER R, 1986, BIOCHEM BIOPH RES CO, V136, P30, DOI 10.1016/0006-291X(86)90872-7; PIRCHER R, 1984, CANCER RES, V44, P5538; QUARLES LD, 1992, J BONE MINER RES, V7, P683; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; Sambrook J, 1989, MOL CLONING LABORATO; SATO Y, 1993, J CELL BIOL, V123, P1249, DOI 10.1083/jcb.123.5.1249; SELANDERSUNNERH.M, 1992, J BIOL CHEM, V0267; SEYEDIN SM, 1986, J BIOL CHEM, V261, P5693; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STENFLO J, 1987, P NATL ACAD SCI USA, V84, P368, DOI 10.1073/pnas.84.2.368; STENMAN G, 1994, CYTOGENET CELL GENET, V66, P117, DOI 10.1159/000133680; STREULI CH, 1993, J CELL BIOL, V120, P253, DOI 10.1083/jcb.120.1.253; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TAKETAZU F, 1994, LAB INVEST, V70, P620; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; TWARDZIK DR, 1990, ANN NY ACAD SCI, V593, P276, DOI 10.1111/j.1749-6632.1990.tb16119.x; VANVLASSELAER P, 1994, J CELL BIOL, V124, P569, DOI 10.1083/jcb.124.4.569; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; YIN WS, 1995, J BIOL CHEM, V270, P1798, DOI 10.1074/jbc.270.4.1798; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	62	124	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10147	10160		10.1074/jbc.270.17.10147	http://dx.doi.org/10.1074/jbc.270.17.10147			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730318	hybrid			2022-12-25	WOS:A1995QV41700065
J	GURNETT, CA; KAHL, SD; ANDERSON, RD; CAMPBELL, KP				GURNETT, CA; KAHL, SD; ANDERSON, RD; CAMPBELL, KP			ABSENCE OF THE SKELETAL-MUSCLE SARCOLEMMA CHLORIDE CHANNEL CLC-1 IN MYOTONIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							1,4-DIHYDROPYRIDINE RECEPTOR; RYANODINE RECEPTOR; RELEASE CHANNEL; CONDUCTANCE; PROTEINS; VOLTAGE; IDENTIFICATION; EXPRESSION; POTASSIUM; MEMBRANES	The voltage dependent chloride channel CIC-1 stabilizes resting membrane potential in skeletal muscle. Mutations in the CIC-1 gene are responsible for both human autosomal recessive generalized myotonia and autosomal dominant myotonia congenita. To understand the tissue distribution and subcellular localization of CIC-1 and to evaluate its role in an animal model of myotonia, antibodies were raised against the carboxyl terminus of this protein. Expression of the 130-kDa CIC-1 protein is unique to skeletal muscle, consistent with its mRNA tissue distribution. Immunolocalization shows prominent CIC-1 antigen in the sarcolemma of both type I and II muscle fibers. Sarcolemma localization is confirmed by Western analysis of skeletal muscle subcellular fractions. The ADR myotonic mouse (phenotype ADR, genotype adr/adr), in which defective CIC-1 mRNA has been identified, is shown here to be absent in CIC-1 protein expression, whereas other skeletal muscle sarcolemma protein expression appears normal, Immunohistochemistry of skeletal muscle from ADR and other mouse models of human muscle disease demonstrate that the absence of CIC-1 chloride channel is a defect specific to ADR mice.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa				Gurnett, Christina/0000-0001-9129-315X; Kahl, Steven/0000-0001-7085-9556; Campbell, Kevin/0000-0003-2066-5889				ADRIAN RH, 1976, J PHYSIOL-LONDON, V258, P125, DOI 10.1113/jphysiol.1976.sp011410; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; BRYANT SH, 1971, J PHYSIOL-LONDON, V219, P367, DOI 10.1113/jphysiol.1971.sp009667; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DULHUNTY AF, 1979, J MEMBRANE BIOL, V45, P293, DOI 10.1007/BF01869290; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; GRONEMEIER M, 1994, J BIOL CHEM, V269, P5963; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HEINY JA, 1990, PFLUG ARCH EUR J PHY, V416, P288, DOI 10.1007/BF00392065; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; LORENZ C, 1994, HUM MOL GENET, V3, P941, DOI 10.1093/hmg/3.6.941; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MILLER C, 1984, P NATL ACAD SCI-BIOL, V81, P2772, DOI 10.1073/pnas.81.9.2772; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PALADE PT, 1977, J GEN PHYSIOL, V69, P325, DOI 10.1085/jgp.69.3.325; PUSCH M, 1994, PHYSIOL REV, V74, P813, DOI 10.1152/physrev.1994.74.4.813; RUDEL R, 1985, PHYSIOL REV, V65, P310, DOI 10.1152/physrev.1985.65.2.310; SHARP AH, 1987, J BIOL CHEM, V262, P12309; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA S, 1993, J BIOL CHEM, V268, P3821; WEBERSCHURHOLZ S, 1993, J BIOL CHEM, V268, P547; WISCHMEYER E, 1993, NEUROMUSCULAR DISORD, V3, P267, DOI 10.1016/0960-8966(93)90019-G	32	57	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9035	9038		10.1074/jbc.270.16.9035	http://dx.doi.org/10.1074/jbc.270.16.9035			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721815				2022-12-25	WOS:A1995QU08900003
J	MACH, V; TAKIYA, S; OHNO, K; HANDA, H; IMAI, T; SUZUKI, Y				MACH, V; TAKIYA, S; OHNO, K; HANDA, H; IMAI, T; SUZUKI, Y			SILK GLAND FACTOR-I INVOLVED IN THE REGULATION OF BOMBYX SERICIN-1 GENE CONTAINS FORK HEAD MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING-DOMAIN; NUCLEAR FACTOR-III; TRANSCRIPTIONAL ACTIVATION; DROSOPHILA; PROTEIN; FAMILY; SITES; PROMOTER	Silk gland factor-1 (SGF-1) regulates transcription of the Bombyx sericin-l gene via interaction with the SA site. In this study, two related SGF-1 polypeptides of apparent molecular masses of 40 and 41 kDa were purified. Specific interaction of these proteins with the SA site was demonstrated by electrophoretic mobility shift and dimethyl sulfate methylation interference assays. The SGF-1 40-kDa protein was partially sequenced and characterized as a new member of the fork head/HNF-3 family. Several full-length cDNAs encoding the SGF-1 40-kDa and possibly also the 41-kDa proteins were cloned and sequenced. SGF-1 mRNA is expressed consistently with the presumed role of the SGF-1 protein product in regulating the sericin-l gene. The SGF-1 protein contains putative transactivation domains, We conclude that the 40- and 41-kDa SGF-1 proteins affect transcription of the sericin-1 gene via binding to the SA site.	NATL INST BASIC BIOL,OKAZAKI,AICHI 444,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Tokyo Institute of Technology			Takiya, Shigeharu/A-6439-2012	Ohno, Kaoru/0000-0001-7648-3940; Imai, Takeshi/0000-0002-9503-7353				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; FUKUTA M, 1993, J BIOL CHEM, V268, P19471; HACKER U, 1992, P NATL ACAD SCI USA, V89, P8754, DOI 10.1073/pnas.89.18.8754; HUI CC, 1990, J MOL BIOL, V213, P651, DOI 10.1016/S0022-2836(05)80253-0; INOMATA Y, 1992, ANAL BIOCHEM, V206, P109, DOI 10.1016/S0003-2697(05)80018-1; KAESTNER KH, 1993, P NATL ACAD SCI USA, V90, P7628, DOI 10.1073/pnas.90.16.7628; KIGUCHI K, 1981, J INSECT PHYSIOL, V27, P805, DOI 10.1016/0022-1910(81)90072-X; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LEMAIGRE FP, 1993, J BIOL CHEM, V268, P19896; MATSUNO K, 1990, NUCLEIC ACIDS RES, V18, P1853, DOI 10.1093/nar/18.7.1853; MATSUNO K, 1989, J BIOL CHEM, V264, P18707; OBARA T, 1988, DEV BIOL, V127, P384, DOI 10.1016/0012-1606(88)90325-9; ORTIZ ML, 1992, FEBS LETT, V296, P300, DOI 10.1016/0014-5793(92)80309-5; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PAULWEBER B, 1993, MOL CELL BIOL, V13, P1534, DOI 10.1128/MCB.13.3.1534; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sambrook J, 1989, MOL CLONING LABORATO; SUZUKI Y, 1994, INT J DEV BIOL, V38, P231; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5	24	78	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9340	9346		10.1074/jbc.270.16.9340	http://dx.doi.org/10.1074/jbc.270.16.9340			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721856				2022-12-25	WOS:A1995QU08900045
J	MIKHAILENKO, I; KOUNNAS, MZ; STRICKLAND, DK				MIKHAILENKO, I; KOUNNAS, MZ; STRICKLAND, DK			LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR MEDIATES THE CELLULAR INTERNALIZATION AND DEGRADATION OF THROMBOSPONDIN - A PROCESS FACILITATED BY CELL-SURFACE PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING COMPETITIVE INHIBITOR; LDL-RECEPTOR; PLASMINOGEN-ACTIVATOR; PLATELET THROMBOSPONDIN; EXTRACELLULAR-MATRIX; HIGH-AFFINITY; ENDOTHELIAL-CELLS; APOLIPOPROTEIN-E; MESSENGER-RNA; GROWTH-FACTOR	Thrombospondin (TSP) is a cell and matrix glycoprotein that interacts with a variety of molecules. Newly synthesized thrombospondin is either incorporated into the extracellular matrix, or binds to the cell surface where it is rapidly internalized and degraded (McKeown-Longo, P. J., Hanning, R., and Mosher, D. F. (1984) J. Cell Biol. 98, 22-28). In the current investigation we identify the low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor (LRP) as a receptor responsible for mediating the internalization of TSP leading to its degradation. LRP is a large cell surface receptor consisting of a 515-kDa heavy chain and an 85-kDa light chain proteolytically derived from a 600-kDa precursor. A specific and high affinity interaction between purified LRP and TSP was demonstrated by homologous ligand competition experiments, where a K-D of 3-20 nM was measured using different preparations of TSP. The binding of TSP to purified LRP was completely inhibited by the 39-kDa receptor associated protein, a known antagonist of ligand binding by LRP. Cultured fibroblasts rapidly internalize and degrade I-125-labeled TSP via a receptor-mediated process. This process is inhibited by receptor-associated protein and by antibodies against LRP, indicating that LRP is mediating the cellular internalization of TSP. Our studies also confirm that the efficient catabolism of TSP requires the participation of cell surface proteoglycans, since digestion of cells with heparitinase markedly reduces the extent of LRP-mediated TSP degradation. The ability of LRP to directly bind and mediate the cellular internalization and degradation of TSP indicates that this receptor may play an important role in the catabolism of TSP in vivo.	AMER RED CROSS,HOLLAND LAB,DEPT BIOCHEM,ROCKVILLE,MD 20855	American Red Cross					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50787] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BAENZIGER NL, 1972, J BIOL CHEM, V247, P2723; BARBER DL, 1991, J BIOL CHEM, V266, P18761; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CONESE M, 1994, J BIOL CHEM, V269, P17886; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; DIXIT VM, 1984, J BIOL CHEM, V259, P100; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOGG PJ, 1993, J BIOL CHEM, V268, P7139; HOGG PJ, 1992, BIOCHEMISTRY-US, V31, P265, DOI 10.1021/bi00116a036; HOGG PJ, 1993, J BIOL CHEM, V268, P21811; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JAFFE EA, 1983, P NATL ACAD SCI-BIOL, V80, P998, DOI 10.1073/pnas.80.4.998; KORENBERG JR, 1994, GENOMICS, V22, P88, DOI 10.1006/geno.1994.1348; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; LAHAV J, 1982, CELL, V31, P253, DOI 10.1016/0092-8674(82)90425-1; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1985, J CELL BIOL, V103, P1635; LAWLER J, 1986, J BIOL CHEM, V258, P12098; MAJACK RA, 1988, J CELL BIOL, V106, P415, DOI 10.1083/jcb.106.2.415; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MARGOSSIAN SS, 1994, J BIOL CHEM, V256, P7495; MCKEOWNLONGO PJ, 1984, J CELL BIOL, V98, P22, DOI 10.1083/jcb.98.1.22; MEDH JD, 1994, J BIOL CHEM, V270, P536; MOESTRUP SK, 1990, J BIOL CHEM, V265, P12623; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; MUMBY SM, 1984, J CELL BIOL, V98, P646, DOI 10.1083/jcb.98.2.646; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; OSHEA KS, 1988, J CELL BIOL, V107, P2737, DOI 10.1083/jcb.107.6.2737; RAUGI GJ, 1982, J CELL BIOL, V95, P351, DOI 10.1083/jcb.95.1.351; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; STRICKLAND DK, 1994, FIBRINOLYSIS, V8, P204, DOI 10.1016/0268-9499(94)90718-8; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	61	126	128	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9543	9549		10.1074/jbc.270.16.9543	http://dx.doi.org/10.1074/jbc.270.16.9543			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721883	hybrid			2022-12-25	WOS:A1995QU08900072
J	PRENDERGAST, JA; PTAK, C; ARNASON, TG; ELLISON, MJ				PRENDERGAST, JA; PTAK, C; ARNASON, TG; ELLISON, MJ			INCREASED UBIQUITIN EXPRESSION SUPPRESSES THE CELL-CYCLE DEFECT ASSOCIATED WITH THE YEAST UBIQUITIN-CONJUGATING ENZYME, CDC34 (UBC3) - EVIDENCE FOR A NONCOVALENT INTERACTION BETWEEN CDC34 AND UBIQUITIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; DEPENDENT PROTEOLYSIS; MULTIUBIQUITIN CHAIN; SACCHAROMYCES-CEREVISIAE; RNA-POLYMERASE; GENE-PRODUCTS; PROTEIN; DEGRADATION; RAD6; E2	The yeast ubiquitin (Uh) conjugating enzyme CDC34 plays a crucial role in the progression of the cell cycle from the G(1) to S phase, In an effort to identify proteins that interact with CDC34 we undertook a genetic screen to isolate genes whose increased expression suppressed the cell cycle defect associated with the cdc34-2 temperature-sensitive allele, From this screen, the poly-Ub gene UBI4 was identified as a moderately strong suppressor, The fact that the overexpression of a gene encoding a single Ub protein could also suppress the cdc34-2 allele indicated that suppression was related to the increased abundance of Ub, Ub overexpression was found to suppress two other structurally unrelated cdc34 mutations, in addition to the cdc34-2 allele, In all three cases, suppression depended on the expression of Ub with an intact carboxyl terminus, Only the cdc34-2 allele, however, could be suppressed by Ub with an amino acid substitution at lysine 48 which is known to be involved in multi-Ub chain assembly, Genetic results showing allele specific suppression of cdc34 mutations by various Ub derivatives suggested a specific noncovalent interaction between Ub and CDC34, Consistent with this prediction, we have shown by chemical crosslinking the existence of a specific noncovalent Ub binding site on CDC34, Together, these genetic and biochemical experiments indicate that Ub suppression of these cdc34 mutations results from the combined contributions of Ub-CDC34 thiol ester formation and a noncovalent interaction between Ub and CDC34 and therefore suggest that the correct positioning of Uh on a surface of the ubiquitin conjugating enzyme is a requirement of enzyme function.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA	University of Alberta								ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; BAMEZAI S, 1989, BIOCHEM BIOPH RES CO, V162, P89, DOI 10.1016/0006-291X(89)91966-9; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BUSHMAN JL, 1993, MOL CELL BIOL, V13, P4618, DOI 10.1128/MCB.13.8.4618; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; COOK WJ, 1992, J BIOL CHEM, V267, P16467; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; ECKER DJ, 1987, J BIOL CHEM, V262, P3524; ELLISON KS, 1991, J BIOL CHEM, V266, P24116; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FINLEY D, 1992, MOL CELLULAR BIOL YE, V2, P539; GIROD PA, 1993, J BIOL CHEM, V268, P955; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; HOLLINGSWORTH NM, 1993, GENETICS, V133, P785; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KOLMAN CJ, 1992, EMBO J, V11, P3081, DOI 10.1002/j.1460-2075.1992.tb05380.x; LAVOIE C, 1994, J BIOL CHEM, V269, P14625; MOLZ L, 1993, EMBO J, V12, P1723, DOI 10.1002/j.1460-2075.1993.tb05817.x; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PTAK C, 1994, J BIOL CHEM, V269, P26539; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SHERMAN F, 1981, METHODS YEAST GENETI, P163; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; WILKINSON KD, 1981, J BIOL CHEM, V256, P9235	47	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9347	9352		10.1074/jbc.270.16.9347	http://dx.doi.org/10.1074/jbc.270.16.9347			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721857	hybrid			2022-12-25	WOS:A1995QU08900046
J	PYTOWSKI, B; JUDGE, TW; MCGRAW, TE				PYTOWSKI, B; JUDGE, TW; MCGRAW, TE			AN INTERNALIZATION MOTIF IS CREATED IN THE CYTOPLASMIC DOMAIN OF THE TRANSFERRIN RECEPTOR BY SUBSTITUTION OF A TYROSINE AT THE FIRST POSITION OF A PREDICTED TIGHT TURN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID; SIGNAL; ENDOCYTOSIS; SEQUENCE; CONFORMATION; MUTAGENESIS; PROTEINS; PATHWAY; CDNA; LDL	Receptors are internalized from the plasma membrane at similar to 10 times the rate of bulk membrane. The pre dominant model for the motif that promotes rapid internalization proposes a requirement for a tyrosine located in the first position of a tight turn. In this report we show that an internalization motif can be created de novo by substituting a tyrosine for the first or last residues of a tetrapeptide GDNS (residues 31-34) that is predicted to form a tight turn within the cytoplasmic domain of the human transferrin receptor. These substitutions restore wild-type levels of internalization to transferrin receptors that are poorly internalized due to missense mutations in the native internalization motif. The introduction of a tyrosine at the first or last position of the GDNS tetrapeptide in a transferrin receptor containing an unmodified wild-type internalization motif significantly increases the internalization rate above that of the wild-type receptor. Our results indicate that a functional novel internalization motif can be created by placing specific aromatic amino acids within the overall structure of an existing beta-turn in a cytoplasmic domain of a receptor.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Columbia University								BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOU PY, 1979, BIOPHYS J, V26, P367, DOI 10.1016/S0006-3495(79)85259-5; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; JADOT M, 1992, J BIOL CHEM, V267, P11069; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MCGRAW TE, 1988, J CELL BIOL, V106, P1061, DOI 10.1083/jcb.106.4.1061; ROTH MG, 1993, ADV CELL MOL BIOL M, V1, P19; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WILEY HS, 1982, J BIOL CHEM, V257, P4222	24	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9067	9073		10.1074/jbc.270.16.9067	http://dx.doi.org/10.1074/jbc.270.16.9067			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721820	hybrid			2022-12-25	WOS:A1995QU08900008
J	SANDS, BE; OGATA, H; LYNCHDEVANEY, K; DEBEAUMONT, M; EZZELL, RM; PODOLSKY, DK				SANDS, BE; OGATA, H; LYNCHDEVANEY, K; DEBEAUMONT, M; EZZELL, RM; PODOLSKY, DK			MOLECULAR-CLONING OF THE RAT INTESTINAL TREFOIL FACTOR GENE - CHARACTERIZATION OF AN INTESTINAL GOBLET CELL-ASSOCIATED PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SPASMOLYTIC POLYPEPTIDE PSP; SUCRASE-ISOMALTASE GENE; PROTEIN-KINASE-C; REPORTER GENE; TRANSCRIPTIONAL ELEMENTS; RESPONSIVE ELEMENT; SEQUENCE-ANALYSIS; MESSENGER-RNA; P-DOMAIN	Intestinal trefoil factor (ITF) is a small peptide bearing the unique motif of intrachain disulfide bonds characteristic of the trefoil family, Previous work had localized expression of ITF primarily within goblet cells in the small and large bowel, making it a candidate gene for the study of the molecular basis of intestinal and goblet cell-specific gene expression, In order to study the regulation of ITF expression, we have cloned the rat ITF gene and sequenced 1.7 kilobases of the 5'-flanking region, RNase protection analysis demonstrated a single transcriptional start site, Various lengths of the 5'-flanking region were linked to the reporter gene luciferase and transfected into the colon cancer cell lines LS174T and Caco-2, representing, respectively, cells with and without goblet cell-like phenotype, Expression in the goblet cell-like LS174T colon cancer cell line was nearly 10-fold greater than expression in Caco-2 cells which exhibit columnar enterocyte-like phenotype, The pattern of goblet cell-associated selective transcription required only 153 base pairs of the rat ITF 5'-flanking sequence, Transfection of a construct of human growth hormone under the control of the rat ITF promoter in the N2 subclone of HT-29 cells demonstrated expression of the reporter gene only in those cells exhibiting a goblet cell phenotype as assessed by expression of immuno-reactive mucin, These initial studies of the 5' flanking region of the ITF gene demonstrate the presence of cis-regulatory elements capable of directing goblet cell specific expression.	MASSACHUSETTS GEN HOSP,CTR STUDY INFLAMMATORY BOWEL DIS,GASTROINTESTINAL UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,SURG RES LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Sands, Bruce/R-7887-2019; Ogata, H/B-3964-2014	Sands, Bruce/0000-0001-5762-5042; 	NIDDK NIH HHS [DK46906, DK43351] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, R01DK046906] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABYATSKY MW, 1994, GASTROENTEROLOGY, V106, pA43; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BOLL W, 1991, AM J HUM GENET, V48, P889; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; CHINERY R, 1992, BIOCHEM J, V285, P5, DOI 10.1042/bj2850005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNASS A, 1994, J CLIN INVEST, V94, P376, DOI 10.1172/JCI117332; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P66; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; HOFFMANN W, 1993, TRENDS BIOCHEM SCI, V18, P239, DOI 10.1016/0968-0004(93)90170-R; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; JEFFREY GP, 1994, GASTROENTEROLOGY, V106, P336, DOI 10.1016/0016-5085(94)90590-8; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P1401, DOI 10.1093/nar/15.4.1401; JORGENSEN KH, 1982, REGUL PEPTIDES, V3, P207, DOI 10.1016/0167-0115(82)90126-4; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEFEBVRE O, 1993, J CELL BIOL, V122, P191, DOI 10.1083/jcb.122.1.191; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; MILLAN JL, 1987, NUCLEIC ACIDS RES, V15, P10599, DOI 10.1093/nar/15.24.10599; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; OGATA S, 1993, CANCER RES, V52, P5971; OHMORI H, 1994, J BIOL CHEM, V269, P17833; OLSEN J, 1989, FEBS LETT, V251, P275, DOI 10.1016/0014-5793(89)81470-X; PHILLIPS TE, 1988, GASTROENTEROLOGY, V94, P1390, DOI 10.1016/0016-5085(88)90678-6; PODOLSKY DK, 1986, J CLIN INVEST, V77, P1251, DOI 10.1172/JCI112428; PODOLSKY DK, 1993, J BIOL CHEM, V268, P6694; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; RIO MC, 1991, GASTROENTEROLOGY, V100, P375, DOI 10.1016/0016-5085(91)90205-Y; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; ROBINE S, 1993, J BIOL CHEM, V268, P11426; Sambrook J, 1989, MOL CLONING LABORATO; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; TAUPIN DR, 1994, GASTROENTEROLOGY, V106, pA195; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; TOMASETTO C, 1990, EMBO J, V9, P407, DOI 10.1002/j.1460-2075.1990.tb08125.x; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VELCICH A, 1993, J BIOL CHEM, V268, P13956; WRIGHT NA, 1990, J PATHOL, V162, P279, DOI 10.1002/path.1711620402; WU GD, 1992, J BIOL CHEM, V267, P7863	51	43	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9353	9361		10.1074/jbc.270.16.9353	http://dx.doi.org/10.1074/jbc.270.16.9353			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721858	hybrid			2022-12-25	WOS:A1995QU08900047
J	SCHWEIZER, A; ROHRER, J; KORNFELD, S				SCHWEIZER, A; ROHRER, J; KORNFELD, S			DETERMINATION OF THE STRUCTURAL REQUIREMENTS FOR PALMITOYLATION OF P63	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STOMATITIS-VIRUS GLYCOPROTEIN; SITE-SPECIFIC MUTAGENESIS; DIPEPTIDYL PEPTIDASE-IV; GROWTH CONE PROTEIN; ACYL-COENZYME-A; FATTY-ACID; TRANSFERRIN RECEPTOR; MEMBRANE ATTACHMENT; TRANSPORT VESICLES; CYSTEINE RESIDUES	Palmitoylation of p63, a type II membrane protein localized in the endoplasmic reticulum, is induced in a reversible manner by the drug brefeldin A. To study the requirements for palmitoylation, mutant forms of p63 were expressed in COS cells and analyzed by metabolic labeling with [H-3]palmitate, immunoprecipitation, and SDS-polyacrylamide gel electrophoresis. By investigating deletion and point mutations, Cys(100) in the 106-amino acid cytoplasmic tail of p63 has been identified as the site of acylation. Site directed mutagenesis of residues 99-105 together with cytoplasmic tail truncation mutants showed that the amino acids surrounding Cys(100) are not critical for palmitoylation of this residue. Analysis of a chimeric construct between p63 and the plasma membrane protein dipeptidylpeptidase IV further revealed that p63 palmitoylation is not dependent on its transmembrane domain. In contrast, the six-amino acid distance between the end of the predicted transmembrane domain and the palmitoylation site was found to be essential for proper acylation of p63.			SCHWEIZER, A (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA.			Rohrer, Jack/0000-0002-2058-490X	NCI NIH HHS [CA08759] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONATTI S, 1989, J BIOL CHEM, V264, P12590; CRISE B, 1992, J BIOL CHEM, V267, P13593; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GALBIATI F, 1994, BIOCHEM J, V303, P697, DOI 10.1042/bj3030697; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GUTIERREZ L, 1991, BIOCHIM BIOPHYS ACTA, V1078, P147, DOI 10.1016/0167-4838(91)99003-B; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONG WJ, 1990, J CELL BIOL, V111, P323, DOI 10.1083/jcb.111.2.323; HONG WJ, 1987, P NATL ACAD SCI USA, V84, P7962, DOI 10.1073/pnas.84.22.7962; JAMES G, 1989, J BIOL CHEM, V264, P20998; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; JING SQ, 1990, J BIOL CHEM, V265, P11555; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KINET JP, 1985, BIOCHEMISTRY-US, V24, P7342, DOI 10.1021/bi00346a048; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOCH N, 1986, J BIOL CHEM, V261, P3434; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YC, 1993, BIOCHEMISTRY-US, V32, P10714, DOI 10.1021/bi00091a023; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; MUNDY DI, 1992, J CELL BIOL, V116, P135, DOI 10.1083/jcb.116.1.135; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OGATA S, 1989, J BIOL CHEM, V264, P3596; OMARY MB, 1981, J BIOL CHEM, V256, P4715; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PAPAC DI, 1992, J BIOL CHEM, V267, P16889; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROSE JK, 1984, P NATL ACAD SCI-BIOL, V81, P2050, DOI 10.1073/pnas.81.7.2050; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESINGER MJ, 1980, J BIOL CHEM, V255, P21; SCHLESINGER MJ, 1994, LIPID MODIFICATION P; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P1687, DOI 10.1073/pnas.76.4.1687; SCHMIDT MFG, 1979, CELL, V17, P813, DOI 10.1016/0092-8674(79)90321-0; SCHMIDT MFG, 1982, VIROLOGY, V116, P327, DOI 10.1016/0042-6822(82)90424-X; SCHWEIZER A, 1994, J CELL BIOL, V126, P25, DOI 10.1083/jcb.126.1.25; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1993, J CELL SCI, V104, P685; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; STAUFENBIEL M, 1987, MOL CELL BIOL, V7, P2981, DOI 10.1128/MCB.7.8.2981; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VEIT M, 1991, J VIROL, V65, P2491, DOI 10.1128/JVI.65.5.2491-2500.1991; VEIT M, 1993, FEBS LETT, V336, P243, DOI 10.1016/0014-5793(93)80812-9; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0	55	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9638	9644		10.1074/jbc.270.16.9638	http://dx.doi.org/10.1074/jbc.270.16.9638			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721896				2022-12-25	WOS:A1995QU08900085
J	SUZUKI, H; WATANABE, M; FUJINO, T; YAMAMOTO, T				SUZUKI, H; WATANABE, M; FUJINO, T; YAMAMOTO, T			MULTIPLE PROMOTERS IN RAT ACYL-COA SYNTHETASE GENE MEDIATE DIFFERENTIAL EXPRESSION OF MULTIPLE TRANSCRIPTS WITH 5'-END HETEROGENEITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; CANDIDA-LIPOLYTICA; SACCHAROMYCES-CEREVISIAE; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; MAMMALIAN-CELLS; MESSENGER-RNA; CLONING; DNA; LIVER	Nucleotide sequence analysis of six independently isolated cDNAs for rat acyl-CoA synthetase (ACS) revealed three forms of ACS mRNA, designated form-A, -B, and -C mRNAs, which differ in their 5'-untranslated regions. Form-A mRNA was preferentially detected in normal and peroxisome-induced livers, whereas form-B mRNA was found in peroxisome-induced livers but not in normal livers and hearts, and form-C mRNA was preferentially found in normal hearts and peroxisome-induced livers. Analysis of two overlapping genomic clones for the rat ACS gene revealed that the three 5'-untranslated regions of the mRNAs are individually encoded by three different exons located within a 20-kilobase genomic fragment. The transcription start sites of the three forms of ACS mRNA were determined and nucleotide sequences of 5'-upstream regions of the three 5'-end exons were determined. The 5'-upstream regions were fused to the chloramphenicol acetyltransferase gene and transcription units of the three forms of ACS mRNAs were determined. These data indicate that the three forms of ACS mRNA with 5'-end heterogeneity are generated by alternative transcription from three promoters in the rat ACS gene.	TOHOKU UNIV,CTR GENE RES,AOBA KU,SENDAI,MIYAGI 981,JAPAN	Tohoku University								ABE T, 1992, J BIOCHEM-TOKYO, V111, P123, DOI 10.1093/oxfordjournals.jbchem.a123707; BLACK PN, 1992, J BIOL CHEM, V267, P25513; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONNERTON IF, 1990, MOL MICROBIOL, V4, P451, DOI 10.1111/j.1365-2958.1990.tb00611.x; DEVIRGILIO C, 1992, YEAST, V8, P1043, DOI 10.1002/yea.320081207; DEWET JR, 1985, P NATL ACAD SCI USA, V82, P7870; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENE JJ, 1988, CURRENT PROTOCOLS MO; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIJIKATA M, 1990, J BIOL CHEM, V265, P4600; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; ISHII N, 1987, J BIOL CHEM, V262, P8144; KAMIRYO T, 1979, P NATL ACAD SCI USA, V76, P4390, DOI 10.1073/pnas.76.9.4390; KAMIRYO T, 1977, P NATL ACAD SCI USA, V74, P4947, DOI 10.1073/pnas.74.11.4947; LEE F, 1984, NUCLEIC ACIDS RES, V12, P4191, DOI 10.1093/nar/12.10.4191; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZOYA E, 1988, EUR J BIOCHEM, V176, P661, DOI 10.1111/j.1432-1033.1988.tb14328.x; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MACONOCHIE MK, 1992, MOL GEN GENET, V234, P211, DOI 10.1007/BF00283841; MARTINEZBLANCO H, 1993, GENE, V130, P265, DOI 10.1016/0378-1119(93)90429-7; MASUDA T, 1989, GENE, V77, P265; MISHINA M, 1978, EUR J BIOCHEM, V89, P321, DOI 10.1111/j.1432-1033.1978.tb12533.x; MISHINA M, 1978, EUR J BIOCHEM, V82, P347, DOI 10.1111/j.1432-1033.1978.tb12029.x; MIYAZAWA S, 1985, J BIOCHEM, V98, P723, DOI 10.1093/oxfordjournals.jbchem.a135330; OSUMI T, 1987, J BIOL CHEM, V262, P8138; PHILLIPS M, 1986, J BIOL CHEM, V261, P821; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOONJANS K, 1993, EUR J BIOCHEM, V216, P615, DOI 10.1111/j.1432-1033.1993.tb18181.x; SHIMOMURA I, 1992, BIOCHIM BIOPHYS ACTA, V1124, P112, DOI 10.1016/0005-2760(92)90086-B; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TANAKA T, 1979, EUR J BIOCHEM, V98, P165, DOI 10.1111/j.1432-1033.1979.tb13173.x; TOMODA H, 1991, J BIOL CHEM, V266, P4214; WEINER FR, 1991, J BIOL CHEM, V266, P23525; WOOD KV, 1989, SCIENCE, V244, P700, DOI 10.1126/science.2655091	41	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9676	9682		10.1074/jbc.270.16.9676	http://dx.doi.org/10.1074/jbc.270.16.9676			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721900	hybrid			2022-12-25	WOS:A1995QU08900091
J	AFINK, GB; NISTER, M; STASSEN, BHGJ; JOOSTEN, PHLJ; RADEMAKERS, PJH; BONGCAMRUDLOFF, E; VANZOELEN, EJJ; MOSSELMAN, S				AFINK, GB; NISTER, M; STASSEN, BHGJ; JOOSTEN, PHLJ; RADEMAKERS, PJH; BONGCAMRUDLOFF, E; VANZOELEN, EJJ; MOSSELMAN, S			MOLECULAR-CLONING AND FUNCTIONAL-CHARACTERIZATION OF THE HUMAN PLATELET-DERIVED GROWTH-FACTOR-ALPHA RECEPTOR GENE PROMOTER	ONCOGENE			English	Note						PDGF; RECEPTOR; CAMP; GENE; RETINOIC ACID; TRANSCRIPTION	DEVELOPMENTAL EXPRESSION; PDGF RECEPTOR; TRANSCRIPTION FACTOR; RETINOIC ACID; CELLS; TISSUE; BETA; EMBRYOGENESIS; ESTABLISHES; SEQUENCE	Expression of the platelet-derived growth factor alpha receptor (PDGF alpha R) is strictly regulated during mammalian development and tumorigenesis. The molecular mechanisms involved in the specific regulation of PDGF alpha R expression are unknown, but transcriptional regulation of the PDGF alpha R gene is most likely to be involved, This study describes the molecular cloning of the non-coding exon 1 and approximately 2 kb of 5' flanking region of the human PDGF alpha R gene, This 5' flanking region is a functional promoter of the PDGF alpha R gene as concluded from its capacity to drive luciferase reporter gene expression in an orientation dependent way, Analysis of 5' promoter deletion mutants revealed that the region from -441 to +118, relative to the transcription initiation site, is sufficient to establish high level promoter activity, In addition, the morphogen retinoic acid, alone or in combination with dibutyryl cAMP, gives a 22-fold induction of PDGF alpha R gene promoter activity in human teratocarcinoma cells, This effect is mediated through specific transcription factor binding within the -52/+118 region of the PDGF alpha R gene.	UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital	AFINK, GB (corresponding author), CATHOLIC UNIV NIJMEGEN,DEPT CELL BIOL,TOERNOOIVELD 1,6525 ED NIJMEGEN,NETHERLANDS.		Afink, Gijs/AAB-2832-2021; Afink, Gijs/A-2025-2009	Afink, Gijs/0000-0002-2155-725X				BOWENPOPE DF, 1991, TRENDS GENET, V7, P413, DOI 10.1016/0168-9525(91)90222-C; CHAUDHRY A, 1992, CANCER RES, V52, P1006; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; DO MS, 1992, ONCOGENE, V7, P1567; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FITZERATTAS C, 1993, INT J CANCER, V53, P315, DOI 10.1002/ijc.2910530224; GRONWALD RGK, 1989, J BIOL CHEM, V264, P8120; HAMPE A, 1989, ONCOGENE RES, V4, P9; HENRIKSEN R, 1993, CANCER RES, V53, P4550; HERMANSON M, 1992, CANCER RES, V52, P3213; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KUMABE T, 1992, ONCOGENE, V7, P627; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; MERCOLA M, 1988, SCIENCE, V241, P1223, DOI 10.1126/science.3413486; MOSSELMAN S, 1989, FEBS LETT, V247, P154, DOI 10.1016/0014-5793(89)81260-8; MOSSELMAN S, 1994, CANCER RES, V54, P220; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NISTER M, 1991, J BIOL CHEM, V266, P16755; ORRURTREGER A, 1992, DEVELOPMENT, V115, P289; OUELLETTE MM, 1992, ONCOGENE, V7, P1075; PRINGLE NP, 1992, DEVELOPMENT, V115, P535; RAINES EW, 1991, PEPTIDE GROWTH FACTO, V1, P173; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; ROBERTS WM, 1992, BLOOD, V79, P586; ROSS R, 1990, PHILOS T ROY SOC B, V327, P155, DOI 10.1098/rstb.1990.0051; Sambrook J, 1989, MOL CLONING LABORATO; SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P123; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TSUKAMOTO T, 1991, J BIOL CHEM, V266, P10143; VANDIJK MA, 1991, MOL CELL ENDOCRINOL, V81, P81, DOI 10.1016/0303-7207(91)90207-9; WANG CY, 1994, P NATL ACAD SCI USA, V91, P7061, DOI 10.1073/pnas.91.15.7061; WANG CY, 1990, MOL CELL BIOL, V10, P6781, DOI 10.1128/MCB.10.12.6781; WATSON AJ, 1992, MOL REPROD DEV, V31, P87, DOI 10.1002/mrd.1080310202; WESTERMARK B, 1993, ACTA ONCOL, V32, P101, DOI 10.3109/02841869309083897; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YEH HJ, 1993, P NATL ACAD SCI USA, V90, P1952, DOI 10.1073/pnas.90.5.1952; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	43	37	39	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1667	1672						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731723				2022-12-25	WOS:A1995QU68100025
J	PELICCI, G; GIORDANO, S; ZHEN, Z; SALCINI, AE; LANFRANCONE, L; BARDELLI, A; PANAYOTOU, G; WATERFIELD, MD; PONZETTO, C; PELICCI, PG; COMOGLIO, PM				PELICCI, G; GIORDANO, S; ZHEN, Z; SALCINI, AE; LANFRANCONE, L; BARDELLI, A; PANAYOTOU, G; WATERFIELD, MD; PONZETTO, C; PELICCI, PG; COMOGLIO, PM			THE MOTOGENIC AND MITOGENIC RESPONSES TO HGF ARE AMPLIFIED BY THE SHC ADAPTER PROTEIN	ONCOGENE			English	Article						MET ONCOGENE; HEPATOCYTE GROWTH FACTOR; SCATTER FACTOR; SHC; CELL MOTILITY	HEPATOCYTE GROWTH-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; SCATTER FACTOR-RECEPTOR; C-MET PROTOONCOGENE; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; RAS PROTEINS; GRB2	The receptor of Hepatocyte Growth Factor-Scatter Factor (HGF) is a tyrosine kinase which regulates cell motility and growth. After ligand-induced tyrosine phosphorylation, the HGF receptor associates with the Shc adaptor, via the SH2 domain. Site-directed mutagenesis of the HGF receptor indicates that phosphotyrosines y(1349)VHV and (YVNV)-V-1356 can work as docking sites for Shc. The K-d of this interaction, measured in real time using synthetic phosphopeptides and recombinant She on a BIAcore biosensor, is 150 nm for both sites. After stimulation of the HGF receptor, Shc is phosphorylated on (YVNV)-V-317, generating an high affinity binding site for Gr62 (K-d = 15 nM). This duplicates the high affinity binding site for Grb2 present on the HGF receptor ((YVNV)-V-1356). Thus HGF stimulation can trigger the Ras pathway by recruiting Gr62 both directly through the receptor, and indirectly, through Site. Overexpression of wild-type She, but not of the Y-317 --> F mutant, enhances cell migration and growth in response to HGF. These data show that Shc is a relevant substrate of the HGF receptor, and works as an 'amplifier' of the motogenic as well as of the mitogenic response.	UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,TURIN,ITALY; UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	University of Turin; University of Perugia; Ludwig Institute for Cancer Research			Pelicci, Giuliana/AAA-8921-2022; Pelicci, Pier Giuseppe/AAL-6572-2020; Salcini, Anna Elisabetta/G-4472-2017; Giordano, Silvia/J-9858-2018; Lanfrancone, Luisa/AAC-8671-2019; BARDELLI, Alberto/J-9721-2018	Pelicci, Giuliana/0000-0003-0986-8255; Giordano, Silvia/0000-0003-1854-1086; Lanfrancone, Luisa/0000-0002-4523-3815; BARDELLI, Alberto/0000-0003-1647-5070; Comoglio, Paolo/0000-0002-7056-5328; Salcini, Anna Elisabetta/0000-0001-5828-2512				ALBINI A, 1987, CANCER RES, V47, P3239; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CREPALDI T, 1994, J BIOL CHEM, V269, P1750; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWRICK PG, 1991, CYTOKINE, V3, P299, DOI 10.1016/1043-4666(91)90498-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GHERARDI E, 1991, CANCER CELLS, V31, P227; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU C, 1992, ONCOGENE, V7, P181; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MORUZZI EV, 1993, J BIOL CHEM, V268, P18176; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; OBERMEIER A, 1993, J BIOL CHEM, V267, P22963; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SEGATTO O, 1993, ONCOGENE, V8, P2105; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SONGYANG Z, 1993, CELL, V71, P1; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097	55	186	197	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1631	1638						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731718				2022-12-25	WOS:A1995QU68100020
J	ARYSTARKHOVA, E; GIBBONS, DL; SWEADNER, KJ				ARYSTARKHOVA, E; GIBBONS, DL; SWEADNER, KJ			TOPOLOGY OF THE NA,K-ATPASE - EVIDENCE FOR EXTERNALIZATION OF A LABILE TRANSMEMBRANE STRUCTURE DURING HEATING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; ALPHA-SUBUNIT; CYTOPLASMIC SURFACE; CATALYTIC SUBUNIT; EXTRACELLULAR DOMAIN; CATION OCCLUSION; PROTEIN-KINASE; OUTER MEDULLA; NA+/K+-ATPASE; NA/K-ATPASE	The topological organization of the Na,K-ATPase alpha subunit is controversial. Detection of extracellular proteolytic cleavage sites would help define the topology, and so attempts were made to find conditions and proteases that would permit digestion of Na,K-ATPase in sealed right-side-out vesicles from renal medulla, The beta subunit is predominantly extracellular and could mask the surface of the alpha subunit, Most of the tested proteases cleaved beta, and some digested it extensively, However, without further disruption of structure, there was still no digestion of the alpha subunit. Reduction (at 50 degrees C) of disulfide bonds that might stabilize the beta subunit fragments, or heating alone at 55 degrees C, permitted tryptic digestion of alpha at a site close to the C terminus, while simultaneously increasing digestion of beta. A 90-kDa N-terminal fragment of alpha was recovered, but the C-terminal fragment was further digested. Heating and reduction resulted in the extracellular exposure of a protein kinase A phosphorylation site, Ser-938, and the C terminus, both of which have been proposed to be located on the intracellular surface. At the same time, access to a distant protein kinase C phosphorylation site was not increased. The data suggest that the harsh treatment simultaneously resulted in alteration of the beta subunit and the extrusion of a segment of alpha that normally spans the membrane, without causing complete denaturation or opening the sealed vesicles. Preincubation with Rb+ was protective, consistent with prior evidence that it stabilizes the protein segments in the C-terminal third of alpha. We conclude that this portion of the alpha subunit contains a transmembrane structure with unique lability to heating.	MASSACHUSETTS GEN HOSP, MEMBRANE BIOL LAB, BOSTON, MA 02129 USA	Harvard University; Massachusetts General Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036271] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36271] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BALL WJ, 1987, BIOCHIM BIOPHYS ACTA, V916, P100, DOI 10.1016/0167-4838(87)90216-0; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYER R, 1990, BIOCHEMISTRY-US, V29, P2251, DOI 10.1021/bi00461a007; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; BEGUIN P, 1994, J BIOL CHEM, V269, P24437; BESANCON M, 1992, ACTA PHYSIOL SCAND, V146, P77; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHIBALIN AV, 1992, J BIOL CHEM, V267, P22378; CHIBALIN AV, 1993, J BIOENERG BIOMEMBR, V25, P61, DOI 10.1007/BF00768069; CHIN GJ, 1985, BIOCHEMISTRY-US, V24, P5943, DOI 10.1021/bi00342a038; DZHANDZHUGAZYAN KN, 1985, BIOCHIM BIOPHYS ACTA, V817, P165, DOI 10.1016/0005-2736(85)90079-3; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EMERICK MC, 1993, J BIOL CHEM, V268, P23455; FARLEY RA, 1986, BIOCHIM BIOPHYS ACTA, V873, P136, DOI 10.1016/0167-4838(86)90199-8; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; FESCHENKO MS, 1994, J BIOL CHEM, V269, P30436; FISCHER TH, 1983, BIOCHEM J, V211, P771, DOI 10.1042/bj2110771; FISONE G, 1994, J BIOL CHEM, V269, P9368; FORBUSH B, 1982, J BIOL CHEM, V257, P2678; GEERING K, 1993, AM J PHYSIOL, V265, pC1169, DOI 10.1152/ajpcell.1993.265.4.C1169; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GOLDSHLEGER R, 1994, SODIUM PUMP, P309; GOLDSHLEGER R, 1994, BIOPHYS J, V66, pA235; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; HOMAREDA H, 1993, BIOCHEM CELL BIOL, V71, P410, DOI 10.1139/o93-060; HOMAREDA H, 1989, MOL CELL BIOL, V9, P5742, DOI 10.1128/MCB.9.12.5742; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V25, P2889; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KAWAMURA M, 1985, BIOCHIM BIOPHYS ACTA, V821, P115, DOI 10.1016/0005-2736(85)90161-0; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; KYTE J, 1987, BIOCHEMISTRY-US, V26, P8350, DOI 10.1021/bi00399a049; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LINGREL JB, 1994, KIDNEY INT, V45, pS32; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MERCIER F, 1993, BIOCHIM BIOPHYS ACTA, V1149, P151, DOI 10.1016/0005-2736(93)90036-Y; MILLER RP, 1988, BIOCHIM BIOPHYS ACTA, V954, P50, DOI 10.1016/0167-4838(88)90054-4; MILLER RP, 1990, BIOCHEMISTRY-US, V29, P1524, DOI 10.1021/bi00458a025; MODYANOV N, 1991, SOC GEN PHY, V46, P99; MODYANOV N, 1992, ACTA PHYSIOL SCAND, V146, P49; MODYANOV NN, 1992, ANN NY ACAD SCI, V671, P134; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P269, DOI 10.1016/0014-5793(87)80676-2; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P230, DOI 10.1016/0014-5793(88)80904-9; ROBINSON JD, 1980, BIOCHIM BIOPHYS ACTA, V598, P543, DOI 10.1016/0005-2736(80)90034-6; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCOTT DR, 1992, BIOCHIM BIOPHYS ACTA, V1112, P246, DOI 10.1016/0005-2736(92)90398-6; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; SHIN JM, 1994, J BIOL CHEM, V269, P8642; SHYJAN AW, 1989, BIOCHEMISTRY-US, V28, P4531, DOI 10.1021/bi00437a002; SUN Y, 1992, AM J PHYSIOL, V262, pC1491, DOI 10.1152/ajpcell.1992.262.6.C1491; SWEADNER KJ, 1985, J BIOL CHEM, V260, P9016; SWEADNER KJ, 1992, ANN NY ACAD SCI, V671, P217, DOI 10.1111/j.1749-6632.1992.tb43798.x; SWEADNER KJ, 1990, BIOCHIM BIOPHYS ACTA, V1029, P13, DOI 10.1016/0005-2736(90)90431-M; THIBAULT D, 1993, BIOCHEMISTRY-US, V32, P2813, DOI 10.1021/bi00062a012; YOON KL, 1994, J BIOL CHEM, V269, P28249	67	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8785	8796		10.1074/jbc.270.15.8785	http://dx.doi.org/10.1074/jbc.270.15.8785			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721785	hybrid			2022-12-25	WOS:A1995QT44800063
J	DIALLINAS, G; GORFINKIEL, L; ARST, HN; CECCHETTO, G; SCAZZOCCHIO, C				DIALLINAS, G; GORFINKIEL, L; ARST, HN; CECCHETTO, G; SCAZZOCCHIO, C			GENETIC AND MOLECULAR CHARACTERIZATION OF A GENE ENCODING A WIDE SPECIFICITY PURINE PERMEASE OF ASPERGILLUS-NIDULANS REVEALS A NOVEL FAMILY OF TRANSPORTERS CONSERVED IN PROKARYOTES AND EUKARYOTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATOR CONSTITUTIVE MUTATION; NITROGEN METABOLITE REPRESSION; ACID-XANTHINE PERMEASE; PUTATIVE ZINC FINGER; SACCHAROMYCES-CEREVISIAE; REGULATORY GENE; NEUROSPORA-CRASSA; ESCHERICHIA-COLI; SEQUENCE; PROTEIN	In Aspergillus nidulans, loss of-function mutations in the uapA and azgA genes, encoding the major uric acid-xanthine and hypoxanthine-adenine-guanine permeases, respectively, result in impaired utilization of these purines as sole nitrogen sources. The residual growth of the mutant strains is due to the activity of a broad specificity purine permease. We have identified uapC, the gene coding for this third permease through the isolation of both gain-of-function and loss-of-function mutations. Uptake studies with wild-type and mutant strains confirmed the genetic analysis and showed that the UapC protein contributes 30% and 8-10% to uric acid and hypoxanthine transport rates, respectively. The uapC gene was cloned, its expression studied, its sequence and transcript map established, and the sequence of its putative product analyzed. uapC message accumulation is: (i) weakly induced by 2-thiouric acid; (ii) repressed by ammonium; (iii) dependent on functional uaY and areA regulatory gene products (mediating uric acid induction and nitrogen metabolite repression, respectively); (iv) increased by uapC gain-of-function mutations which specifically, but partially, suppress a leucine to valine mutation in the zinc finger of the protein coded by the areA gene. The putative uapC gene product is a highly hydrophobic protein of 580 amino acids (M(r) = 61,251) including 12-14 putative transmembrane segments. The UapC protein is highly similar (58% identity) to the UapA permease and significantly similar (23-34% identity) to a number of bacterial transporters. Comparisons of the sequences and hydropathy profiles of members of this novel family of transporters yield insights into their structure, functionally important residues, and possible evolutionary relationships.	ROYAL POSTGRAD MED SCH,DEPT INFECT DIS & BACTERIOL,LONDON W12 0NN,ENGLAND; UNIV REPUBL MONTEVIDEO,FAC CIENCIAS,SECC BIOQUIM,MONTEVIDEO,URUGUAY	Imperial College London; Universidad de la Republica, Uruguay	DIALLINAS, G (corresponding author), UNIV PARIS 11,INST GENET & MICROBIOL,CNRS,UA 1354,BATIMENT 409,F-91405 ORSAY,FRANCE.		Diallinas, George/AAE-8457-2019	Diallinas, George/0000-0002-3426-726X				ALDERSON T, 1967, MUTAT RES, V4, P567, DOI 10.1016/0027-5107(67)90043-7; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARST HN, 1975, NATURE, V254, P31, DOI 10.1038/254031a0; ARST HN, 1973, MOL GEN GENET, V126, P111, DOI 10.1007/BF00330988; BRYNESTAD S, 1994, MICROBIOL-UK, V140, P97, DOI 10.1099/13500872-140-1-97; BURLAND V, 1993, GENOMICS, V16, P551, DOI 10.1006/geno.1993.1230; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; CRAIG JE, 1994, MOL MICROBIOL, V11, P1159, DOI 10.1111/j.1365-2958.1994.tb00392.x; DARLINGTON AJ, 1967, J BACTERIOL, V93, P937, DOI 10.1128/JB.93.3.937-940.1967; DIALLINAS G, 1989, GENETICS, V122, P341; DIALLINAS G, 1989, THESIS U PARIS 11 FR; EISENBERG D, 1982, ANN REV BIOCH, V53, P595; FIDEL S, 1988, GENE, V70, P283, DOI 10.1016/0378-1119(88)90200-4; FU YH, 1990, P NATL ACAD SCI USA, V87, P5331, DOI 10.1073/pnas.87.14.5331; FU YH, 1990, MOL CELL BIOL, V10, P1056, DOI 10.1128/MCB.10.3.1056; GHIM SY, 1994, J BACTERIOL, V176, P3698, DOI 10.1128/JB.176.12.3698-3707.1994; GORFINKIEL L, 1993, J BIOL CHEM, V268, P23376; GORTON DJ, 1983, THESIS U ESSEX UK; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; GRENSON M, 1992, MOL ASPECTS TRANSPOR, V21, P219; GRIFFITH DA, 1993, J BIOL CHEM, V268, P20085; GRIFFITH J K, 1992, Current Opinion in Cell Biology, V4, P684, DOI 10.1016/0955-0674(92)90090-Y; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; HYNES MJ, 1970, MOL GEN GENET, V108, P97, DOI 10.1007/BF02430516; IRNIGER S, 1994, P NATL ACAD SCI USA, V91, P257, DOI 10.1073/pnas.91.1.257; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; LLOYD AT, 1991, MOL GEN GENET, V230, P288, DOI 10.1007/BF00290679; LOCKINGTON RA, 1985, GENE, V33, P137, DOI 10.1016/0378-1119(85)90088-5; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MCCULLY KS, 1965, GENET RES, V6, P352, DOI 10.1017/S0016672300004249; OESTREICHER N, 1993, J BIOL CHEM, V268, P23382; PAJOR AM, 1993, J BIOL CHEM, V267, P3557; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PONTECORVO G, 1953, ADV GENET, V5, P141, DOI 10.1016/S0065-2660(08)60408-3; PROUDFOOT NJ, 1979, NATURE, V279, P376, DOI 10.1038/279376a0; QUINN CL, 1991, J BIOL CHEM, V266, P9113; RAI R, 1988, J BACTERIOL, V170, P266, DOI 10.1128/jb.170.1.266-271.1988; REIZER J, 1993, PROTEIN SCI, V2, P20, DOI 10.1002/pro.5560020103; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; SAIER MH, 1994, BIOESSAYS, V16, P23, DOI 10.1002/bies.950160104; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCAZZOCC.C, 1968, BIOCHIM BIOPHYS ACTA, V166, P557, DOI 10.1016/0005-2787(68)90243-8; SCAZZOCCHIO C, 1982, GENETICS, V100, P185; SCAZZOCCHIO C, 1973, MOL GEN GENET, V125, P147, DOI 10.1007/BF00268868; SCAZZOCCHIO C, 1978, NATURE, V274, P177, DOI 10.1038/274177a0; SCAZZOCCHIO C, 1994, IN PRESS ASPERGILLUS, P221; Scazzocchio C., 1977, GENETICS PHYSL ASPER, P255; SEALYLEWIS HM, 1978, MOL GEN GENET, V164, P303, DOI 10.1007/BF00333161; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; SOPHIANOPOULOU V, 1989, MOL MICROBIOL, V3, P705, DOI 10.1111/j.1365-2958.1989.tb00219.x; STRUCK DK, 1978, J BIOL CHEM, V253, P5786; SUAREZ T, 1991, MOL GEN GENET, V230, P359, DOI 10.1007/BF00280292; SUAREZ T, 1991, MOL GEN GENET, V230, P369, DOI 10.1007/BF00280293; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; TURNER RJ, 1994, J BACTERIOL, V176, P3708, DOI 10.1128/JB.176.12.3708-3722.1994; YOO HS, 1992, YEAST, V8, P997, DOI 10.1002/yea.320081202	62	85	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8610	8622						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721763				2022-12-25	WOS:A1995QT44800039
J	GUZDER, SN; BAILLY, V; SUNG, P; PRAKASH, L; PRAKASH, S				GUZDER, SN; BAILLY, V; SUNG, P; PRAKASH, L; PRAKASH, S			YEAST DNA-REPAIR PROTEIN RAD23 PROMOTES COMPLEX-FORMATION BETWEEN TRANSCRIPTION FACTOR TFIIH AND DNA-DAMAGE RECOGNITION FACTOR RAD14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; GENE; ENCODES; ENDONUCLEASE; HELICASE; EXCISION; ATPASE; CTD	Saccharomyces cerevisiae, the multisubunit RNA polymerase II general transcription factor TFIIH is indispensable for transcription initiation and some of its subunits are known to be required for nucleotide excision repair (NER) of DNA damaged by ultraviolet light. RAD3, a subunit of TFIIH, binds UV-damaged DNA in an ATP-dependent manner. It has, however, remained unclear how TFIIH is assembled with the other damage recognition component RAD14. Here, we demonstrate a higher order complex consisting of TFIIH, RAD14, and another NER protein RAD23, and complex formation between TFIIH and RAD14 is facilitated by the RAD23 protein.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Louise/C-7891-2012	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NATIONAL CANCER INSTITUTE [R01CA041261, R37CA041261] Funding Source: NIH RePORTER; NCI NIH HHS [CA41261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; MILLER RD, 1982, MOL GEN GENET, V188, P235, DOI 10.1007/BF00332681; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; SAYER MH, 1992, J BIOL CHEM, V267, P23376; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SUNG P, 1994, J BIOL CHEM, V269, P8303; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555	23	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8385	8388		10.1074/jbc.270.15.8385	http://dx.doi.org/10.1074/jbc.270.15.8385			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721729	hybrid			2022-12-25	WOS:A1995QT44800004
J	HARRINGTON, L; HULL, C; CRITTENDEN, J; GREIDER, C				HARRINGTON, L; HULL, C; CRITTENDEN, J; GREIDER, C			GEL SHIFT AND UV CROSS-LINKING ANALYSIS OF TETRAHYMENA TELOMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL TRANSFERASE-ACTIVITY; REVERSE-TRANSCRIPTASE; PRIMER SPECIFICITY; RNA-POLYMERASE; RIBONUCLEOPROTEIN; IDENTIFICATION; ELONGATION; MECHANISM; CLEAVAGE; SEQUENCE	Telomerase is an unusual ribonucleoprotein that synthesizes new telomeres onto chromosome ends. The enzyme has been most extensively characterized in ciliates, where the RNA component has been cloned from several species, and its elongation properties have been characterized in detail. To understand the substrate specificity and protein composition of telomerase, we have used gel shift and UV cross-linking to characterize the enzyme from the ciliate Tetrahymena thermophila. In a mobility shift assay, a complex was identified that contained telomerase RNA,co-purified with telomerase activity, and was sensitive to nuclease treatment. The mobility shift complexes specifically formed using several different single-stranded, telomeric sequences but not non-telomeric primers. These results suggest that the specificity of telomerase for G-rich primer sequences occurs at least in part at the level of primer binding. UV cross-linking analysis identified a 100-kDa cross-linked protein that may be a telomerase component.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; SUNY STONY BROOK,GENET PROGRAM,STONY BROOK,NY 11794	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Crittenden, Jill/0000-0002-1981-1917				AUTEXIER C, 1994, GENE DEV, V8, P563, DOI 10.1101/gad.8.5.563; AVILION AA, 1992, DEV GENET, V13, P80, DOI 10.1002/dvg.1020130113; BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BLACKBURN EH, 1989, GENOME, V31, P553, DOI 10.1139/g89-104; CHAMBERLIN MJ, 1993, IN PRESS HARVEY LECT, V88; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; FLORES O, 1992, J BIOL CHEM, V267, P2786; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; HARRINGTON LA, 1993, CHARACTERIZATION PUR; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; JOUNG I, 1992, J VIROL, V66, P5788, DOI 10.1128/JVI.66.10.5788-5796.1992; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; MANTELL LL, 1994, EMBO J, V13, P3211, DOI 10.1002/j.1460-2075.1994.tb06620.x; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MORIN GB, 1909, NATURE, V353, P454; NG L, 1993, J BIOL CHEM, V268, P13571; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; Sambrook J, 1989, MOL CLONING LABORATO; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953	37	35	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8893	8901		10.1074/jbc.270.15.8893	http://dx.doi.org/10.1074/jbc.270.15.8893			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721797	hybrid			2022-12-25	WOS:A1995QT44800076
J	LIU, JN; GUREWICH, V				LIU, JN; GUREWICH, V			INACTIVATION OF THE INTRINSIC ACTIVITY OF PROUROKINASE BY DIISOPROPYL FLUOROPHOSPHATE IS REVERSIBLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SINGLE-CHAIN UROKINASE; PLASMINOGEN ACTIVATION; GLU-PLASMINOGEN; PROUROKINASE; PROENZYME; FIBRIN; FORM	Single chain urokinase-type plasminogen activator or pro-urokinase (pro-UK) has been reported to have a significant intrinsic amidolytic and plasminogen activator activity, estimated to be about 0.2-0.6% that of two-chain urokinase (UK). However, it has also been suggested that this reported activity is related entirely to trace UK contaminants generated during the analytic procedures. In an attempt to resolve this controversy, it was decided to measure the incorporation of diisopropyl fluorophosphate (DFP) by pro-UK and UK. Surprisingly, it was found that although >98% of the apparent intrinsic activity of pro-UK was inhibited by 5 mM DFP, >97% of this activity was recoverable after exhaustive dialysis of the preparation. This finding could not be explained by UK generation, which was excluded. Instead, the findings indicated that DFP inhibition of pro-UK, in contrast to UK and other serine proteases, was largely reversible. The reaction rate of the reversible inhibition was significantly slower than that of irreversible inhibition by DFP. When the hydrolysis of DFP (2 mM) during incubation (37 degrees C) with or without pro-UK (20 mu M) was compared, a >5-fold acceleration of DFP hydrolysis in the presence of pro-UK was found, whereas little loss of DFP occurred in the presence of UK (20 mu M), consistent with 1:1 stoichiometry. This suggested that pro-UK acted as a slow DFPase in the reaction, a finding consistent with a reversible DFP-enzyme reaction. It was concluded that pro-UK has a distinct and measurable intrinsic catalytic activity, which is qualitatively unique and thereby distinguishable from that of UK as well as other serine proteases.	HARVARD UNIV,DEACONESS HOSP,SCH MED,INST PREVENT CARDIOVASC DIS,VASC RES LAB,BOSTON,MA 02215	Harvard University; Harvard Medical School								COLLEN D, 1986, J BIOL CHEM, V261, P1259; ELLIS V, 1987, J BIOL CHEM, V262, P14998; HUSAIN SS, 1983, ARCH BIOCHEM BIOPHYS, V220, P31, DOI 10.1016/0003-9861(83)90383-1; HUSAIN SS, 1991, BIOCHEMISTRY-US, V30, P5797, DOI 10.1021/bi00237a024; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIU JN, 1992, BIOCHEMISTRY-US, V31, P6311, DOI 10.1021/bi00142a021; LIU JN, 1992, J BIOL CHEM, V267, P15289; LIU JN, 1991, J CLIN INVEST, V88, P2012, DOI 10.1172/JCI115528; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; PANNELL R, 1986, BLOOD, V67, P1215; PANNELL R, 1987, BLOOD, V69, P22; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; STRYER L, 1988, BIOCHEMISTRY-US, P223; URANO T, 1988, ARCH BIOCHEM BIOPHYS, V264, P222, DOI 10.1016/0003-9861(88)90588-7; WUN TC, 1982, J BIOL CHEM, V257, P7262	15	14	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8408	8410		10.1074/jbc.270.15.8408	http://dx.doi.org/10.1074/jbc.270.15.8408			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721734	hybrid			2022-12-25	WOS:A1995QT44800010
J	NOVOKHATNY, V; MEDVED, L; LIJNEN, HR; INGHAM, K				NOVOKHATNY, V; MEDVED, L; LIJNEN, HR; INGHAM, K			TISSUE-TYPE PLASMINOGEN-ACTIVATOR (TPA) INTERACTS WITH UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (UPA) VIA TPAS LYSINE BINDING-SITE - AN EXPLANATION OF THE POOR FIBRIN AFFINITY OF RECOMBINANT TPA/UPA CHIMERIC MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYOCARDIAL-INFARCTION; AMINO-ACIDS 1; T-PA; SCU-PA; SYNERGISTIC COMBINATIONS; THROMBOLYTIC PROPERTIES; PROTHROMBIN FRAGMENT-2; DOMAIN-STRUCTURE; FUSION PROTEIN; SPECIFICITY	Differential scanning calorimetry was used to study the domain structure and intramolecular interactions of tPA/uPA chimeras. A high temperature transition centered near 90 degrees C was observed upon melting of the tPA/uPA chimera (amino acids 1-274 of tPA and 138-411 of uPA) and its variant lacking the finger and epidermal growth factor-like modules (residues 1-3 and 87-274 of tPA and 138-411 of uPA). Since neither of the two parent plasminogen activators display such a stable structure, one may suggest that a new stabilizing intramolecular interaction occurs in the chimeras, We found that occupation of the lysine binding site of tPA by a lysine or arginine side chain from the urokinase moiety is responsible for the high temperature transition as well as for the failure of the chimeras to exhibit the expected fibrin binding properties, All uPA species, single- and two-chain high molecular weight uPA (pro-Uk and HMW-Uk) and two-chain low molecular weight uPA (LMW-Uk), interact intermolecularly with tPA and its kringle-containing derivatives. This intermolecular interaction was strongly inhibited by epsilon-aminocaproic acid indicating that the lysine binding site of tPA is involved. The binding of uPA with the fluorescein-labeled A-chain of tPA, registered by changes in fluorescence anisotropy, was estimated to have a K-d range of 1-7 mu M. The interaction of tPA with uPA determined by solid-phase assays appeared to be tighter, with a K-d range of 50-300 nM. Two synthetic peptides, with and without carboxyl-terminal lysine, corresponding to urokinase residues 144-158 and 144-157, were similar to 100-fold more potent than epsilon-aminocaproic acid with respect to inhibition of the tPA-uPA interaction, indicating that the tPA binding site on urokinase is located within this sequence, close to the activation site Lys(158)-Ile(159). The discovered intermolecular interaction may be related to the reported synergistic effect of simultaneous administration of these two plasminogen activators.	AMER RED CROSS, JEROME H HOLLAND LAB, ROCKVILLE, MD 20855 USA; CATHOLIC UNIV LEUVEN, CTR MOLEC & VASC BIOL, B-3000 LOUVAIN, BELGIUM	American Red Cross; KU Leuven			Lijnen, Roger/AAA-4085-2020	Medved, Leonid/0000-0002-3665-9849				APPELLA E, 1987, J BIOL CHEM, V262, P4437; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BOCK PE, 1992, J BIOL CHEM, V267, P14974; CASTELLINO FJ, 1981, J BIOL CHEM, V256, P4778; COLLEN D, 1986, PROG HEMOST THROMB, V8, P1; COLLEN D, 1986, AM HEART J, V112, P1083, DOI 10.1016/0002-8703(86)90323-6; COLLEN D, 1986, THROMB HAEMOSTASIS, V56, P35; COLLEN D, 1987, THROMB HAEMOSTASIS, V58, P943; COLLEN D, 1987, AM J CARDIOL, V60, P431, DOI 10.1016/0002-9149(87)90280-3; DEMUNK GAW, 1989, BIOCHEMISTRY-US, V28, P7318, DOI 10.1021/bi00444a026; DESERRANO VS, 1992, BIOCHEMISTRY-US, V31, P3326, DOI 10.1021/bi00128a004; DEVRIES C, 1988, BIOCHEMISTRY-US, V27, P2565, DOI 10.1021/bi00407a044; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; GHEYSEN D, 1987, J BIOL CHEM, V262, P11779; GUREWICH V, 1986, THROMB RES, V44, P217, DOI 10.1016/0049-3848(86)90137-4; HOLMBERG L, 1976, BIOCHIM BIOPHYS ACTA, V445, P215, DOI 10.1016/0005-2744(76)90174-1; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; ICHINOSE A, 1986, J CLIN INVEST, V78, P163, DOI 10.1172/JCI112546; INGHAM KC, 1981, BIOCHIM BIOPHYS ACTA, V670, P181, DOI 10.1016/0005-2795(81)90007-6; LARSEN GR, 1988, J BIOL CHEM, V263, P1023; LEE SG, 1988, J BIOL CHEM, V263, P2917; LI X, 1994, J MOL BIOL, V235, P1548, DOI 10.1006/jmbi.1994.1106; LIJNEN HR, 1988, J BIOL CHEM, V263, P19083; LIJNEN HR, 1994, EUR J BIOCHEM, V224, P567, DOI 10.1111/j.1432-1033.1994.00567.x; LIJNEN HR, 1991, THROMB HAEMOSTASIS, V66, P88; LIJNEN HR, 1987, SEMIN THROMB HEMOST, V13, P152, DOI 10.1055/s-2007-1003486; LO KM, 1991, BIOCHIM BIOPHYS ACTA, V1088, P217; MUNK GAW, 1990, FIBRINOLYSIS, V4, P1; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; NELLES L, 1990, THROMB HAEMOSTASIS, V64, P53; NELLES L, 1987, J BIOL CHEM, V262, P10855; NOVOKHATNY V, 1992, J BIOL CHEM, V267, P3878; NOVOKHATNY VV, 1984, J MOL BIOL, V179, P215, DOI 10.1016/0022-2836(84)90466-2; NOVOKHATNY VV, 1989, THROMB RES, V53, P243, DOI 10.1016/0049-3848(89)90099-6; NOVOKHATNY VV, 1991, J BIOL CHEM, V266, P12994; PIERARD L, 1987, J BIOL CHEM, V262, P11771; Privalov P L, 1986, Methods Enzymol, V131, P4; RADEK JT, 1988, ARCH BIOCHEM BIOPHYS, V267, P776, DOI 10.1016/0003-9861(88)90087-2; ROBBINS KC, 1987, SEMIN THROMB HEMOST, V13, P131, DOI 10.1055/s-2007-1003483; SONG A, 1992, SCI CHINA SER B, V35, P966; SPRIGGS DJ, 1989, BLOOD, V73, P1207; STEPHENS RW, 1992, BIOCHEMISTRY-US, V31, P7572, DOI 10.1021/bi00148a019; STUMP DC, 1986, J BIOL CHEM, V261, P7120; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670	45	14	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8680	8685		10.1074/jbc.270.15.8680	http://dx.doi.org/10.1074/jbc.270.15.8680			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721771	hybrid			2022-12-25	WOS:A1995QT44800049
J	RAMIREZ, MT; POST, GR; SULAKHE, PV; BROWN, JH				RAMIREZ, MT; POST, GR; SULAKHE, PV; BROWN, JH			M(1) MUSCARINIC RECEPTORS HETEROLOGOUSLY EXPRESSED IN CARDIAC MYOCYTES MEDIATE RAS-DEPENDENT CHANGES IN GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT CHAIN-2; PROTEIN-KINASE-C; ATRIAL-NATRIURETIC-FACTOR; ALPHA-ADRENERGIC STIMULATION; MYOCARDIAL-CELLS; ACETYLCHOLINE-RECEPTORS; ADENYLYL CYCLASE; HEART MYOCYTES; HYPERTROPHY; SUBTYPES	Stimulation of alpha(1)-adrenergic receptors in neonatal ventricular cardiomyocytes induces hypertrophic changes including activation of the atrial natriuretic factor (ANF) gene. This receptor couples to G(q) to activate phospholipase C (PLC) and protein kinase C, which have been implicated as mediators of the hypertrophic response. To directly determine whether receptor coupling to G(q)/PLC is sufficient to induce ANF expression, we expressed wild-type and chimeric muscarinic cholinergic receptors (mAChRs) with altered G-protein coupling properties in cardiac myocytes and examined their ability to activate an ANF promoter/luciferase reporter gene. The cholinergic agonist carbachol failed to induce transcriptional activation of the ANF reporter gene through endogenous G(i)-linked M(2)mAChRs or in cells transfected with M(2)mAChRs. In contrast, in cells transfected with M(1)mAChRs, which effectively couple to G(q)/PLC, carbachol increased ANF reporter gene expression 10-fold and also increased ANF protein, as deter mined by immunofluorescence. Carbachol-mediated ANF gene expression was inhibited by the mAChR antagonist pirenzepine with a K-i value characteristic of an M(1)mAChR. Studies using chimeric M(1)- and M(2)mAChRs demonstrated that the N-terminal 21 amino acids of the third intracellular loop of the M(1)mAChR were required for receptor coupling to ANF gene expression. This region, previously shown to specify receptor coupling to G(q)/PLC, also conferred partial activity to a chimeric M(2) receptor. We further demonstrated that M(1)mAChR coupling to ANF gene expression was Ras-dependent since co-expression of dominant-interfering Ala-15 Ras inhibited M(1)mAChR-induced ANF expression by 60%. In contrast, ANF expression induced by the chimeric M(2) receptor was not blocked by dominant interfering Ras. We suggest that receptor coupling to G(q)/PLC is sufficient to induce ANF expression and that a Ras-dependent pathway contributes additional signals required for maximal M(1)mAChR-mediated ANF gene expression.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, BIOMED SCI GRAD PROGRAM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028143, P01HL046345, T32HL007444, R37HL028143] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07444, HL46345, HL28143] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BONNER TI, 1992, TRENDS PHARMACOL SCI, V13, P48, DOI 10.1016/0165-6147(92)90021-W; BRAUN AP, 1990, EUR J PHARM-MOLEC PH, V189, P201, DOI 10.1016/0922-4106(90)90024-R; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; DORJE F, 1991, J PHARMACOL EXP THER, V256, P727; DORJE F, 1991, MOL PHARMACOL, V40, P459; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; HAMMER R, 1980, NATURE, V283, P90, DOI 10.1038/283090a0; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1081, DOI 10.1016/0022-2828(88)90588-3; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JONES LG, 1988, CIRC RES, V62, P299, DOI 10.1161/01.RES.62.2.299; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEE HR, 1988, J BIOL CHEM, V263, P7352; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; RAMIREZ MT, 1994, FASEB J, V8, pA385; RAMIREZ MT, 1995, MOLMECHANISMS MUSCAR; SEI CA, 1991, J BIOL CHEM, V266, P15910; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; SHUBEITA HE, 1992, P NATL ACAD SCI USA, V89, P1305, DOI 10.1073/pnas.89.4.1305; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, BIOCHEM BIOPH RES CO, V202, P1586, DOI 10.1006/bbrc.1994.2113; WASPE LE, 1990, J CLIN INVEST, V85, P1206, DOI 10.1172/JCI114554; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WESS J, 1990, MOL PHARMACOL, V38, P517; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WONG SKF, 1994, J BIOL CHEM, V269, P18968; WONG SKF, 1990, J BIOL CHEM, V265, P6219; WU DQ, 1992, J BIOL CHEM, V267, P25798; YANG CM, 1993, AM J PHYSIOL, V265, pC666, DOI 10.1152/ajpcell.1993.265.3.C666	44	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8446	8451		10.1074/jbc.270.15.8446	http://dx.doi.org/10.1074/jbc.270.15.8446			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721739	hybrid			2022-12-25	WOS:A1995QT44800015
J	WOLFF, EC; LEE, YB; CHUNG, SI; FOLK, JE; PARK, MH				WOLFF, EC; LEE, YB; CHUNG, SI; FOLK, JE; PARK, MH			DEOXYHYPUSINE SYNTHASE FROM RAT TESTIS - PURIFICATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR EIF-4D; POSTTRANSLATIONAL FORMATION; SACCHAROMYCES-CEREVISIAE; HYPUSINE FORMATION; PROTEIN; SPERMIDINE; POLYAMINES; CELLS; IDENTIFICATION; PROLIFERATION	Deoxyhypusine synthase is the first enzyme involved in the post translational formation of hypusine, a unique amino acid that occurs at one position in a single cellular protein, eukaryotic translation initiation factor 5A (eIF-5A). This NAD-dependent enzyme catalyzes the formation of deoxyhypusine by transfer of the butylamine portion of spermidine to the epsilon-amino group of a specific lysine residue in the eIF-5A precursor. Its purification from rat testis was accomplished by ammonium sulfate fractionation and successive ion-exchange chromatographic steps, followed by chromatofocusing on a hydrophilic resin (Mono P). A pI of 4.7 was determined by isoelectric focusing, Amino acid sequences of five tryptic peptides of the pure enzyme did not correspond to any sequences in the protein data banks. The enzyme migrates as a single band ton SDS-polyacrylamide gel electrophoresis with an apparent monomer molecular mass of similar to 42,000 Da. Matrix-assisted laser desorption mass spectrometry gave a monomer mass of 40,800 Da. There is evidence, however, that the active enzyme exists as a tetramer of this subunit. Rabbit polyclonal antibodies to the 42-kDa protein precipitated deoxyhypusine synthase activity. The enzyme shows a strict specificity for NAD. Purified deoxyhypusine synthase catalyzes the overall synthesis of deoxyhypusine and, in the absence of the eIF-5A precursor, catalyzes the cleavage of spermidine.			WOLFF, EC (corresponding author), NIDR,CELLULAR DEV & ONCOL LAB,ENZYME CHEM SECT,BLDG 30,RM 211,30 CONVENT DR,MSC 4330,BETHESDA,MD 20892, USA.							ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; BENINATI S, 1988, BIOCHIM BIOPHYS ACTA, V952, P325, DOI 10.1016/0167-4838(88)90134-3; BERGSTROM J, 1982, PROTIDES BIOL FLUIDS, P641; Bollag DM, 1991, PROTEIN METHODS, P95; BYERS TL, 1992, BIOCHEM J, V287, P717, DOI 10.1042/bj2870717; CHEN KY, 1983, BIOCHIM BIOPHYS ACTA, V756, P395, DOI 10.1016/0304-4165(83)90350-1; CHEN KY, 1988, FEBS LETT, V229, P325, DOI 10.1016/0014-5793(88)81149-9; COOPER HL, 1982, CELL, V29, P791, DOI 10.1016/0092-8674(82)90441-X; DOU QP, 1990, BIOCHIM BIOPHYS ACTA, V1036, P128, DOI 10.1016/0304-4165(90)90024-Q; GERNER EW, 1986, BIOCHEM J, V239, P379, DOI 10.1042/bj2390379; HANAUSKEABEL HM, 1994, BBA-MOL CELL RES, V1221, P115, DOI 10.1016/0167-4889(94)90003-5; JAKUS J, 1993, J BIOL CHEM, V268, P13151; JOE YA, 1994, J BIOL CHEM, V269, P25916; JOE YS, UNPUB; KANG HA, 1994, J BIOL CHEM, V269, P3934; KANG K, UNPUB; KIM HT, 1990, J BIOL CHEM, V265, P3636; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; PARK MH, 1983, METHOD ENZYMOL, V94, P458; PARK MH, 1994, J BIOL CHEM, V269, P27827; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1989, J BIOL CHEM, V264, P18531; PARK MH, 1993, BIOFACTORS, V4, P95; PARK MH, 1988, J BIOL CHEM, V263, P15264; PARK MH, 1991, J BIOL CHEM, V266, P7988; SACKETT DL, 1989, ANAL BIOCHEM, V180, P319, DOI 10.1016/0003-2697(89)90439-9; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SCHWELBERGER HG, 1993, J BIOL CHEM, V268, P14018; SMITH PK, 1985, ANAL BIOCHEM, V150, P75; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P18527; TAO Y, 1994, FASEB J, V8, pA1359; TORRELIO BM, 1984, EXP CELL RES, V154, P454, DOI 10.1016/0014-4827(84)90169-1; WEBER K, 1971, J BIOL CHEM, V246, P4504; WOHL T, 1993, MOL GEN GENET, V241, P305; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; YANG YC, 1990, BIOCHIM BIOPHYS ACTA, V1033, P133; 1982, CHROMATOFOCUSING POL	37	55	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8660	8666		10.1074/jbc.270.15.8660	http://dx.doi.org/10.1074/jbc.270.15.8660			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721768	hybrid			2022-12-25	WOS:A1995QT44800046
J	BAZAR, L; MEIGHEN, D; HARRIS, V; DUNCAN, R; LEVENS, D; AVIGAN, M				BAZAR, L; MEIGHEN, D; HARRIS, V; DUNCAN, R; LEVENS, D; AVIGAN, M			TARGETED MELTING AND BINDING OF A DNA REGULATORY ELEMENT BY A TRANSACTIVATOR OF C-MYC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPERCOILED PM2 DNA; SINGLE-STRANDED-DNA; MUNG BEAN NUCLEASE; IONIC ENVIRONMENT; TRANSCRIPTION; PROTEIN; CELLS; GENE; SEQUENCES; PROMOTER	A far upstream element (FUSE) of c-myc stimulates promoter activity when bound by a newly identified trans-acting protein, which is expressed in cycling cells. Since FUSE binding protein (FBP) binds only the noncoding strand (NCS) of its regulatory element in a sequence-specific manner, and not double-stranded (ds) DNA, formation of the protein . DNA complex in vivo first requires unwinding of the DNA helix. In this report, we show evidence that FBP forces strand separation of short stretches of linear dsDNA. Because FUSE is contained within a region of helical instability that is partially unwound in negatively supercoiled DNA, it is a target for more extensive duplex strand separation by FBP, which first exposes and then selectively binds its NCS cognate sequence. In contrast, other single-stranded DNA binding proteins (SSBs) do not demonstrate this FUSE targeting activity. The novel linkage of regional dsDNA melting with cis-element binding by a transcriptional activator has broad implications in the regulation of eukaryotic gene expression.	GEORGETOWN UNIV, SCH MED, DEPT PATHOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, SCH MED, DEPT MED, WASHINGTON, DC 20007 USA; NCI, PATHOL LAB, BETHESDA, MD 20892 USA	Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Duncan, Robert/I-8168-2015; Levens, David/C-9216-2009	Duncan, Robert/0000-0001-8409-2501; Levens, David/0000-0002-7616-922X	NATIONAL CANCER INSTITUTE [R29CA054818] Funding Source: NIH RePORTER; NCI NIH HHS [CA54818] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; BOEHMER PE, 1993, J VIROL, V67, P711, DOI 10.1128/JVI.67.2.711-715.1993; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; DAYN A, 1992, NUCLEIC ACIDS RES, V20, P5991, DOI 10.1093/nar/20.22.5991; DROGE P, 1991, NUCLEIC ACIDS RES, V19, P2941, DOI 10.1093/nar/19.11.2941; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HORWITZ MSZ, 1988, SCIENCE, V241, P703, DOI 10.1126/science.2456617; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; KOWALSKI D, 1984, NUCLEIC ACIDS RES, V12, P7071, DOI 10.1093/nar/12.18.7071; KOWALSKI D, 1982, J BIOL CHEM, V257, P7820; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Lohman TM., 1990, BIOL NONSPECIFIC DNA, P131; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Maxam A M, 1980, Methods Enzymol, V65, P499; McKnight S.L., 1992, TRANSCRIPTIONAL REGU; NEGISHI Y, 1994, ONCOGENE, V9, P1133; PANAYOTATOS N, 1987, J BIOL CHEM, V262, P11364; RIOU JF, 1993, FEBS LETT, V334, P369, DOI 10.1016/0014-5793(93)80714-6; SHEFLIN LG, 1984, NUCLEIC ACIDS RES, V12, P7087, DOI 10.1093/nar/12.18.7087; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SUNITHA I, 1994, BBA-MOL CELL RES, V1221, P348, DOI 10.1016/0167-4889(94)90260-7; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; UMEK RM, 1987, NUCLEIC ACIDS RES, V15, P4467; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; WITTIG B, 1992, EMBO J, V11, P4653, DOI 10.1002/j.1460-2075.1992.tb05567.x; YANG L, 1989, P NATL ACAD SCI USA, V86, P6121, DOI 10.1073/pnas.86.16.6121	33	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8241	8248		10.1074/jbc.270.14.8241	http://dx.doi.org/10.1074/jbc.270.14.8241			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713931	hybrid			2022-12-25	WOS:A1995QR52600070
J	KOBAYASHI, H; GOTOH, J; HIRASHIMA, Y; FUJIE, M; SUGINO, D; TERAO, T				KOBAYASHI, H; GOTOH, J; HIRASHIMA, Y; FUJIE, M; SUGINO, D; TERAO, T			INHIBITORY EFFECT OF A CONJUGATE BETWEEN HUMAN UROKINASE AND URINARY TRYPSIN-INHIBITOR ON TUMOR-CELL INVASION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL FRAGMENT; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANES; RECEPTOR; METASTASIS; PURIFICATION; DEGRADATION; BINDING; PROTEIN	Proteolytic enzymes such as urokinase-type plasminogen activator (uPA), plasmin, and collagenase mediate proteolysis by a variety of tumor cells. uPA secreted by tumor cells can be bound to a cell surface receptor via a growth factor-like domain within the amino-terminal fragment (ATF) of the uPA molecule with high affinity. Urinary trypsin inhibitor (UTI) efficiently inhibits the soluble and the tumor cell-surface receptor-bound plasmin and subsequently reduces tumor cell invasion and the formation of metastasis. The anti-invasive effect is dependent on the anti-plasmin activity of the UTI molecule, domain II in particular. We synthesized a conjugate between ATF of human uPA and a native UTI molecule or domain II of UTI (HI-8). The effect of the conjugates (ATF . UTI or ATF . HI-8) on tumor cell invasion in vitro was investigated. ATF . UTI and ATF . HI-8 bound to U937 cells in a rapid, saturable, dose-dependent, and reversible manner. A large part of receptor-bound ATF . UTI and ATF . HI-8 remains on the cell surface for at least 5 h at 37 degrees C. Inhibition of tumor cell surface receptor-bound plasmin by ATF . UTI and ATF . HI-8 was markedly enhanced when compared with tumor cells treated either with ATF, UTI, or HI-8. Results of a cell invasion assay showed that ATF . UTI and ATF . HI-8 is very effective at targeting HI-8 specifically to uPA receptor-expressing tumor cells, whereas tumor cells devoid of uPA receptor may be less affected by the conjugates. Our results indicate that cell surface uPA and plasmin activity is essential to the invasive process and that the conjugates exhibit plasmin inhibition to the close environment of the cell surface and subsequently inhibit the tumor cell invasion through Matrigel in an in vitro invasion assay.	HAMAMATSU UNIV SCH MED, CTR EQUIPMENT, HAMAMATSU, SHIZUOKA 43131, JAPAN; NISSIN FOOD PROD CO LTD, NISSIN CENT RES INST, KUSATSU, SHIGA 525, JAPAN	Hamamatsu University School of Medicine	KOBAYASHI, H (corresponding author), HAMAMATSU UNIV SCH MED, DEPT OBSTET & GYNECOL, HANDACHO 3600, HAMAMATSU, SHIZUOKA 43131, JAPAN.							CAJOT JF, 1989, J CELL BIOL, V109, P915, DOI 10.1083/jcb.109.2.915; CAVALLARO U, 1993, J BIOL CHEM, V268, P23186; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; HEARING VJ, 1988, CANCER RES, V48, P1270; HELMAN CM, 1985, J BIOL CHEM, V260, P11581; KOBAYASHI H, 1994, J BIOL CHEM, V269, P20642; KOBAYASHI H, 1994, CLIN EXP METASTAS, V12, P117, DOI 10.1007/BF01753978; KOBAYASHI H, 1994, THROMB HAEMOSTASIS, V71, P474; KOBAYASHI H, 1994, INT J CANCER, V57, P378, DOI 10.1002/ijc.2910570315; KOBAYASHI H, 1994, INT J CANCER, V57, P727, DOI 10.1002/ijc.2910570520; KOBAYASHI H, 1993, BRIT J CANCER, V67, P537, DOI 10.1038/bjc.1993.99; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; LIOTTA LA, 1983, LAB INVEST, V49, P636; MAEDA M, 1987, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V39, P256; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; OLSON D, 1992, J BIOL CHEM, V267, P9129; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; OSTROWSKI LE, 1986, CANCER RES, V46, P4121; PLOUG M, 1991, J BIOL CHEM, V266, P1926; REICH R, 1988, CANCER RES, V48, P3307; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; TSUBOI R, 1990, INT J CANCER, V46, P56, DOI 10.1002/ijc.2910460112; WACHTER E, 1981, H-S Z PHYSIOL CHEM, V362, P1351, DOI 10.1515/bchm2.1981.362.2.1351; WUN TC, 1989, J BIOL CHEM, V264, P7862	28	71	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8361	8366		10.1074/jbc.270.14.8361	http://dx.doi.org/10.1074/jbc.270.14.8361			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713945	hybrid			2022-12-25	WOS:A1995QR52600084
J	MARIKOVSKY, M; LAVI, S; PINKASKRAMARSKI, R; KARUNAGARAN, D; LIU, N; WEN, DZ; YARDEN, Y				MARIKOVSKY, M; LAVI, S; PINKASKRAMARSKI, R; KARUNAGARAN, D; LIU, N; WEN, DZ; YARDEN, Y			ERBB-3 MEDIATES DIFFERENTIAL MITOGENIC EFFECTS OF NDF HEREGULIN ISOFORMS ON MOUSE KERATINOCYTES	ONCOGENE			English	Article						EGF FAMILY; TYROSINE KINASE; GROWTH FACTOR; SIGNAL TRANSDUCTION; ONCOGENE	FACTOR RECEPTOR FAMILY; GROWTH-FACTOR; HUMAN-BREAST; SIGNAL TRANSDUCTION; TYROSINE KINASE; MAMMARY-TUMORS; NERVOUS-SYSTEM; LIGAND; CELLS; EXPRESSION	The family of Neu differentiation factors (NDFs, or heregulins) includes a dozen secreted glycoproteins, whose receptor binding domain displays two variants, alpha and beta, and they bind to two receptor tyrosine kinases, ErbB3 and ErbB-4. Certain isoforms were reported to induce growth-arrest and differentiation of mammary tumor cells, while other breast cancer cell lines responded mitogenically, The present study addressed the biologic effects of various NDF isoforms on normal EGF-dependent epithelial cells, Balb/MK keratinocytes, that can undergo either proliferation or differentiation, We found that beta isoforms of NDF induced a mitogenic effect, that was significantly smaller than the maximal response to EGF, By contrast with NDF-beta, NDF-alpha isoforms exerted almost no mitogenic effect, but they were sufficient to maintain keratinocytes in culture, Consistent with their higher mitogenic potency, NDF-beta isoforms bound to Balb/MK cells with higher affinity (K-d=2.2 nM) than alpha isoforms, however both groups shared their receptor, that we identified as ErbB-3. No transcript of ErbB-4 was detectable in the keratinocytes, but these cells express multiple NDF mRNAs and also ErbB-2, We conclude that different isoforms of NDF induce distinct growth regulatory effects on cultured keratinocytes, through direct interaction with ErbB-3.	AMGEN INC, AMGEN CTR, THOUSAND OAKS, CA 91320 USA; WEIZMANN INST SCI, DEPT CELL BIOL, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL	Amgen; Weizmann Institute of Science; Weizmann Institute of Science			YARDEN, YOSEF/K-1467-2012; Karunagaran, Devarajan/A-8148-2010	Karunagaran, Devarajan/0000-0001-9331-8947	NCI NIH HHS [CA51712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACUS SS, 1993, CANCER RES, V53, P5251; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1991, J CELL PHYSIOL, V146, P277, DOI 10.1002/jcp.1041460213; FALCO JP, 1988, ONCOGENE, V2, P573; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JAHODA CAB, 1984, NATURE, V311, P560, DOI 10.1038/311560a0; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ORRURTREGER A, 1992, P NATL ACAD SCI USA, P1746; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SAFRAN A, 1990, ONCOGENE, V5, P635; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLOWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STANCOVSKI I, 1993, REGULATORY MECHANISM, P161; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UNDERWOOD LE, 1986, CLIN ENDOCRINOL META, V1, P59; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	49	76	77	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1403	1411						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731691				2022-12-25	WOS:A1995QR65100018
J	EPSTEIN, JA; LAM, P; JEPEAL, L; MAAS, RL; SHAPIRO, DN				EPSTEIN, JA; LAM, P; JEPEAL, L; MAAS, RL; SHAPIRO, DN			PAX3 INHIBITS MYOGENIC DIFFERENTIATION OF CULTURED MYOBLAST CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR ALVEOLAR RHABDOMYOSARCOMA; PAIRED BOX GENE; WAARDENBURG SYNDROME; DOMAIN GENE; DNA; MUTATION; PROTEIN; HOMEODOMAIN; FIBROBLASTS; RECOGNITION	Pax3 is an evolutionarily conserved transcription factor expressed in the lateral dermomyotome, a region that gives rise to limb muscle progenitors. Mutations in Pax-3 account for the mouse mutant Splotch which develops without limb musculature. We demonstrate that Pax3 can inhibit myogenic differentiation of C2C12 myoblasts normally induced by exposure to low serum. Specific missense mutations that affect the DNA binding characteristics of the two distinct DNA binding domains of Pax3 abolish this effect. Furthermore, we show that Pax3 can inhibit myogenic differentiation of 10T1/2 fibroblasts transfected with MyoD, but not of 10T1/2 cells transfected with myogenin. This anti-myogenic property is shared by a PAX3-forkhead fusion protein resulting from a t(2;13) chromosomal translocation found in pediatric alveolar rhabdomyosarcomas. These results suggest that Pax3 may suppress the terminal differentiation of migrating limb myoblasts and that the PAX3-forkhead fusion may contribute to the phenotype of alveolar rhabdomyosarcoma by preventing terminal differentiation.	BRIGHAM & WOMENS HOSP, DEPT GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38101 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; St Jude Children's Research Hospital	EPSTEIN, JA (corresponding author), BRIGHAM & WOMENS HOSP, HOWARD HUGHES MED INST, DIV CARDIOL, THORN 910, 20 SHATTUCK ST, BOSTON, MA 02115 USA.			Epstein, Jonathan/0000-0001-8637-4465	NCI NIH HHS [CA-23099, CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, P01CA023099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BOBER E, 1994, DEVELOPMENT, V120, P603; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; FRANZ T, 1993, ANAT EMBRYOL, V187, P371; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOTH CF, 1993, AM J HUM GENET, V52, P455; KOZMIK Z, 1993, MOL CELL BIOL, V13, P6024, DOI 10.1128/MCB.13.10.6024; KRIEG PA, 1987, METHOD ENZYMOL, V155, P313; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; SHAFER BW, 1994, NUCLEIC ACIDS RES, V22, P4574; SHAPIRO DN, 1993, CANCER RES, V53, P5108; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREISMAN J, 1989, CELL, V59, P553; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9	39	177	181	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11719	11722		10.1074/jbc.270.20.11719	http://dx.doi.org/10.1074/jbc.270.20.11719			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744814	hybrid			2022-12-25	WOS:A1995QY73600005
J	MACLEOD, AR; ROULEAU, J; SZYF, M				MACLEOD, AR; ROULEAU, J; SZYF, M			REGULATION OF DNA METHYLATION BY THE RAS SIGNALING PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; DENOVO METHYLATION; MOUSE CELLS; HA-RAS; METHYLTRANSFERASE; PROTEIN; TRANSCRIPTION; PROMOTER; SEQUENCE; TRANSFORMATION	We demonstrate that DNA methylation in an adrenocortical tumor cell line, Y1, is controlled by the Ras signaling pathway. Forced expression of a cDNA encoding human GAP(120) (hGAP), a down-modulator of Ras activity or partial derivative 9-Jun a transdominant negative mutant of Jun, in Y1 cells reverts the transformed morphology of the cells and results in a reduction in the level of DNA methylation, DNA methyltransferase (MeTase) mRNA, and enzymatic activity, Introduction of an oncogenic Ha-ras into the GAP transfectants results in reversion to a transformed morphology and an increase in the levels of DNA methylation and DNA MeTase activity. Transient transfection CAT assays demonstrate that the expression of DNA MeTase promoter in Y1 cells is regulated by Ras and AP-1. These results establish a molecular link between a major signaling pathway involved in tumorigenesis and DNA methylation.	MCGILL UNIV, DEPT PHARMACOL & THERAPEUT, MONTREAL, PQ H3G 1Y6, CANADA	McGill University								ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KESHET E, 1983, NUCLEIC ACIDS RES, V11, P3571, DOI 10.1093/nar/11.11.3571; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MICHALOWSKY LA, 1989, MOL CELL BIOL, V9, P885, DOI 10.1128/MCB.9.3.885; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RAZIN A, 1985, BIOCH BIOL DNA METHY, P239; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SZYF M, 1992, J BIOL CHEM, V267, P12831; SZYF M, 1985, J BIOL CHEM, V260, P8653; SZYF M, 1989, P NATL ACAD SCI USA, V86, P6853, DOI 10.1073/pnas.86.18.6853; SZYF M, 1991, J BIOL CHEM, V266, P10027; SZYF M, 1991, BIOCHEM CELL BIOL, V69, P764, DOI 10.1139/o91-117; SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4; SZYF M, 1984, P NATL ACAD SCI-BIOL, V81, P3278, DOI 10.1073/pnas.81.11.3278; SZYF M, 1990, MOL ENDOCRINOL, V4, P1144, DOI 10.1210/mend-4-8-1144; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UHLER MD, 1987, J BIOL CHEM, V262, P15202; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; YASUMURA Y, 1966, CANCER RES, V26, P529	43	170	176	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11327	11337		10.1074/jbc.270.19.11327	http://dx.doi.org/10.1074/jbc.270.19.11327			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744770	hybrid			2022-12-25	WOS:A1995QX86500047
J	MARKS, MS; GERMAIN, RN; BONIFACINO, JS				MARKS, MS; GERMAIN, RN; BONIFACINO, JS			TRANSIENT AGGREGATION OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II CHAINS DURING ASSEMBLY IN NORMAL SPLEEN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA-DR MOLECULES; INVARIANT CHAIN; ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; BINDING-PROTEIN; PEPTIDE BINDING; MICE LACKING; ASSOCIATION; EXPRESSION; ANTIGENS	Many cell surface proteins exist as complexes of multiple subunits. It is well established that most such complexes are assembled within the endoplasmic reticulum (ER). However, the mechanistic details of the assembly process are largely unknown. We show here that alpha and beta subunits of major histocompatibility complex class II antigens in spleen cells of normal mice pass through a transiently aggregated phase in the ER prior to assembly with the invariant chain (Ii). Aggregates form immediately after synthesis and disappear concomitantly with assembly of mature alpha beta Ii complexes. In spleen cells lacking Ii, aggregates fail to be efficiently dissociated over time, implicating subunit assembly as a requirement for disaggregation. Two ER chaperones, BiP and calnexin, bind to newly synthesized class II MHC chains but do not contribute appreciably to the large size of the aggregates. Our observations suggest that some subunits of multisubunit complexes pass through a transient, dynamic high molecular weight aggregate phase during the physiological process of assembly. The results further suggest a novel role for Ii in promoting stable dissociation of preformed aggregates containing alpha and beta subunits rather than in preventing their formation.	NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892; NIAID,IMMUNOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Marks, Michael S/Q-7223-2019; Germain, Ronald N./Z-1945-2019; Germain, Ronald/ABE-7090-2020	Marks, Michael S/0000-0001-7435-7262; Bonifacino, Juan S./0000-0002-5673-6370				ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BONNEROT C, 1994, EMBO J, V13, P934, DOI 10.1002/j.1460-2075.1994.tb06338.x; CLAESSONWELSH L, 1985, J IMMUNOL, V135, P3551; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; ELLIOTT EA, 1994, J EXP MED, V179, P681, DOI 10.1084/jem.179.2.681; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KOCH N, 1987, EMBO J, V6, P1677, DOI 10.1002/j.1460-2075.1987.tb02417.x; KOCH N, 1982, NATURE, V299, P644, DOI 10.1038/299644a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAMB CA, 1992, J IMMUNOL, V148, P3478; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LE AQ, 1994, J BIOL CHEM, V269, P7514; LOKEN MR, 1982, J IMMUNOL METHODS, V50, P85; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MEHRINGER JH, 1991, J IMMUNOL, V146, P920; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NGUYEN QV, 1989, J BIOL CHEM, V264, P1631; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; ROTHENHAUSLER B, 1990, P NATL ACAD SCI USA, V87, P352, DOI 10.1073/pnas.87.1.352; SANT AJ, 1991, J EXP MED, V174, P799, DOI 10.1084/jem.174.4.799; SCHAIFF WT, 1991, J IMMUNOL, V147, P603; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; SCHREIBER KL, 1994, INT IMMUNOL, V6, P101, DOI 10.1093/intimm/6.1.101; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WADA I, 1994, J BIOL CHEM, V269, P7464; YILLA M, 1992, J CELL BIOL, V118, P245, DOI 10.1083/jcb.118.2.245	51	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10475	10481		10.1074/jbc.270.18.10475	http://dx.doi.org/10.1074/jbc.270.18.10475			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737982	hybrid			2022-12-25	WOS:A1995QW60100020
J	OLIVEIRA, PL; KAWOOYA, JK; RIBEIRO, JMC; MEYER, T; POORMAN, R; ALVES, EW; WALKER, FA; MACHADO, EA; NUSSENZVEIG, RH; PADOVAN, GJ; MASUDA, H				OLIVEIRA, PL; KAWOOYA, JK; RIBEIRO, JMC; MEYER, T; POORMAN, R; ALVES, EW; WALKER, FA; MACHADO, EA; NUSSENZVEIG, RH; PADOVAN, GJ; MASUDA, H			A HEME-BINDING PROTEIN FROM HEMOLYMPH AND OOCYTES OF THE BLOODSUCKING INSECT, RHODNIUS-PROLIXUS - ISOLATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBIN GENE-CLUSTER; NUCLEOTIDE-SEQUENCE; HEMOPEXIN; RABBIT; DEGRADATION	A heme-binding protein has been isolated and characterized from both the hemolymph and oocytes of the blood sucking insect, Rhodnius prolixus, The protein from both sources is identical in most aspects studied. The Rhodnius heme binding protein (RHBP) is com posed of a single 15-kDa polypeptide chain coiled in a highly alpha-helical structure which binds non-covalently one heme/polypeptide chain, This RHBP is not produced by limited degradation of hemoglobin from the vertebrate host, since specific polyclonal antibodies against it do not cross-react with rabbit hemoglobin, and since it differs from hemoglobin in having a distinct amino-acid composition and NH2-terminal sequence, The spectrum of the dithionite-reduced protein has peaks at 426, 530, and 559 nm and resembles that of a b-type cytochrome. RHBP from hemolymph is not saturated with heme and promptly binds heme added to the solution, The oocyte protein, on the other hand, is fully saturated and is not capable of binding additional heme.	UNIV SAO PAULO,FAC MED RIBEIRAO PRETO,DEPT CLIN MED,BR-14049900 RIBEIRAO PRET,BRAZIL; UNIV SAO PAULO,FAC MED RIBEIRAO PRETO,CTR INTERDEPT QUIM PROT,BR-14049900 RIBEIRAO PRET,BRAZIL; CEPHALON INC,W CHESTER,PA 19380; UNIV ARIZONA,DEPT ENTOMOL,TUCSON,AZ 85721; UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721; UNIV ARIZONA,DEPT CHEM,TUCSON,AZ 85721	Universidade de Sao Paulo; Universidade de Sao Paulo; Teva Pharmaceutical Industries; Cephalon Inc.; University of Arizona; University of Arizona; University of Arizona	OLIVEIRA, PL (corresponding author), UNIV FED RIO DE JANEIRO,INST CIENCIAS BIOMED,DEPT BIOQUIM MED,POB 68041,BR-21941590 RIO JANEIRO,BRAZIL.		Walker, Frances A/O-4395-2016; Machado, Ednildo A/G-9725-2013; L. Oliveira, Pedro/A-9438-2010	L. Oliveira, Pedro/0000-0003-0307-354X; Machado, Ednildo/0000-0002-4428-3829; Ribeiro, Jose/0000-0002-9107-0818	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018694, R37AI018694] Funding Source: NIH RePORTER; NIAID NIH HHS [NIAID 18694] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AFT RL, 1984, J BIOL CHEM, V259, P301; ALONZO N, 1968, ANAL BIOCHEM, V23, P272, DOI 10.1016/0003-2697(68)90359-X; [Anonymous], 1991, BIOL BLOOD SUCKING I; Ascoli F, 1981, Methods Enzymol, V76, P72; CHANG CT, 1978, ANAL BIOCHEM, V19, P13; CHENG JF, 1986, J BIOL CHEM, V261, P839; DANSAPETRETSKI M, 1994, J BIOL CHEM, V279, P10893; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRIEND WG, 1965, CAN J ZOOL, V43, P892; GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861; Hagihara B, 1975, ENZYMES, P549; HRKAL Z, 1971, BIOCHEMISTRY-US, V10, P1746, DOI 10.1021/bi00786a002; KUNKEL JG, 1985, COMPREHENSIVE INSECT, V1, P83; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCAS B, 1980, ANAL BIOCHEM, V109, P192, DOI 10.1016/0003-2697(80)90028-7; MARGOT JB, 1989, J MOL BIOL, V205, P15, DOI 10.1016/0022-2836(89)90362-8; MORGAN WT, 1972, J BIOL CHEM, V247, P7181; MORGAN WT, 1976, ANN CLIN RES, V8, P223; MORGAN WT, 1984, J BIOL CHEM, V19, P12001; Nomenclature Committee of the International Union of Biochemistry (NC-IUB), 1989, J BIOL CHEM, V267, P665; OLIVEIRA PL, 1989, INSECT BIOCHEM, V19, P489; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; TAKETANI S, 1987, J BIOL CHEM, V262, P4639; TAPPEL AL, 1955, J BIOL CHEM, V217, P721; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VINCENT SH, 1988, ARCH BIOCHEM BIOPHYS, V265, P539, DOI 10.1016/0003-9861(88)90159-2; WALKER FA, 1988, J AM CHEM SOC, V110, P6234, DOI 10.1021/ja00226a045; Wigglesworth VB, 1943, PROC R SOC SER B-BIO, V131, P313, DOI 10.1098/rspb.1943.0010	28	77	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10897	10901		10.1074/jbc.270.18.10897	http://dx.doi.org/10.1074/jbc.270.18.10897			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738030				2022-12-25	WOS:A1995QW60100078
J	IZQUIERDO, JM; RICART, J; OSTRONOFF, LK; EGEA, G; CUEZVA, JM				IZQUIERDO, JM; RICART, J; OSTRONOFF, LK; EGEA, G; CUEZVA, JM			CHANGING PATTERNS OF TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL CONTROL OF BETA-F-1-ATPASE GENE-EXPRESSION DURING MITOCHONDRIAL BIOGENESIS IN LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE BETA-SUBUNIT; MUSCLE ADP/ATP TRANSLOCATOR; TISSUE-SPECIFIC ISOFORMS; CYTOCHROME-C-OXIDASE; RNA-BINDING PROTEIN; ATP SYNTHASE; RAT-LIVER; MESSENGER-RNA; ALPHA-SUBUNIT; GAMMA-SUBUNIT	To elucidate the mechanisms that regulate the expression of nuclear genes during biogenesis of mammalian mitochondria, the expression pattern of the beta-subunit of the ATP synthase gene has been characterized in rat liver between day 20 in utero and 12 weeks postnatal. The parallelism existing between transcriptional activity of the gene and the amount of beta-F-1-ATPase protein in liver indicates that proliferation of mitochondria is controlled at the transcriptional level. On the other hand, an increased stability (4-5-fold) of beta-F-1-ATPase mRNA during early neonataI life as well as a rapid postnatal activation of translation rates affecting mitochondrial proteins appear to control mitochondrial differentiation. Immunoelectron microscopy of the F-1-ATPase complex during liver development revealed that the rapid postnatal increase in the in vivo rate of F-1-ATPase synthesis was mostly used for functional differentiation of pre-existing organelles (VaIcarce, C., Navarrete, it. M., Encabo, P., Loeehes, E., Satrustegui, J., and Cuezva, J. M. (1988) J. Biol Chem. 263, 7767-7775). The findings support that beta-F-1-ATPase mRNA decay is developmentally regulated in liver, indicating that gene expression is also controlled at this level during physiological transitions that affect biogenesis of mitochondria.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOLEC SEVERO OCHOA, DEPT BIOL MOLEC, E-28049 MADRID, SPAIN; UNIV BARCELONA, FAC MED, DEPT BIOL CELULAR & ANAT PATOL, E-08036 BARCELONA, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); University of Barcelona			Egea, Gustavo/I-2394-2014; Cuezva, Jose M/F-8381-2011; Cuezva, Jose M/AAR-5392-2020	Egea, Gustavo/0000-0001-5242-150X; Cuezva Marcos, Jose Manuel/0000-0003-1118-248X				ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; ATTARDI G, 1990, BIOCHEM SOC T, V18, P509, DOI 10.1042/bst0180509; BABISS LE, 1986, P NATL ACAD SCI USA, V83, P6504, DOI 10.1073/pnas.83.17.6504; BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BARATGUERIDE M, 1987, MITOCHONDRIA PRACTIC, P245; BEINERT H, 1993, FASEB J, V7, P1442, DOI 10.1096/fasebj.7.15.8262329; Belasco J. G., 1993, CONTROL MESSENGER RN, P475; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BREEN GAM, 1988, BIOCHEM BIOPH RES CO, V152, P264, DOI 10.1016/S0006-291X(88)80709-5; BREEN GAM, 1988, BIOCHEMISTRY-US, V27, P3955, DOI 10.1021/bi00411a010; CANTATORE P, 1986, CELL DIFFER DEV, V19, P125, DOI 10.1016/0045-6039(86)90069-2; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; CHRZANOWSKALIGHTOWLERS ZMA, 1994, J BIOL CHEM, V269, P27322; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U; CUEZVA JM, 1990, REPROD BIOL, P113; CUEZVA JM, 1993, PHYSL BASIS PERINATA, P47; ENDO H, 1994, J BIOL CHEM, V269, P12488; GADALETA MN, 1990, EUR J BIOCHEM, V187, P501, DOI 10.1111/j.1432-1033.1990.tb15331.x; GARBOCZI DN, 1988, BIOCHEMISTRY-US, V27, P553, DOI 10.1021/bi00402a008; GAY NJ, 1985, EMBO J, V4, P3519, DOI 10.1002/j.1460-2075.1985.tb04111.x; GOPALAKRISHNAN L, 1994, J BIOL CHEM, V269, P105; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; GRIFFITHS G, 1986, J HISTOCHEM CYTOCHEM, V34, P1389, DOI 10.1177/34.11.3534077; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARAGUCHI Y, 1994, J BIOL CHEM, V269, P9330; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOMMES FA, 1975, NORMAL PATHOLOGICAL, P1; IZQUIERDO JM, 1990, J BIOL CHEM, V265, P9090; IZQUIERDO JM, 1993, FEBS LETT, V323, P109, DOI 10.1016/0014-5793(93)81459-D; IZQUIERDO JM, 1993, BIOCHEM BIOPH RES CO, V196, P55, DOI 10.1006/bbrc.1993.2215; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KIKUCHI K, 1992, J BIOL CHEM, V267, P21505; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LI K, 1990, J BIOL CHEM, V265, P20585; LUIS AM, 1989, BIOCHEM BIOPH RES CO, V159, P216, DOI 10.1016/0006-291X(89)92425-X; LUIS AM, 1993, J BIOL CHEM, V268, P1868; LYONNET S, 1988, J CLIN INVEST, V81, P1682, DOI 10.1172/JCI113506; Marzluff W. F., 1984, TRANSCRIPTION TRANSL, P89; MATSUDA C, 1993, J BIOL CHEM, V268, P24950; MATSUDA C, 1993, FEBS LETT, V325, P281, DOI 10.1016/0014-5793(93)81089-I; MAYOR F, 1985, BIOL NEONATE, V48, P185, DOI 10.1159/000242171; NAGLEY P, 1991, TRENDS GENET, V7, P1, DOI 10.1016/0168-9525(91)90002-8; NECKELMANN N, 1989, GENOMICS, V5, P829, DOI 10.1016/0888-7543(89)90125-0; OHTA S, 1988, J BIOL CHEM, V263, P11257; PATEL MS, 1982, BIOCH DEV FETUS NEON, P553; PIERCE DJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P265, DOI 10.1016/0167-4781(92)90160-2; POLLAK JK, 1980, TRENDS BIOCHEM SCI, V5, P23, DOI 10.1016/S0968-0004(80)80073-9; POLOSA PL, 1991, J BIOL CHEM, V266, P10011; PREISS T, 1993, J BIOL CHEM, V268, P10659; PREISS T, 1993, J BIOL CHEM, V268, P24523; ROHR HP, 1971, LAB INVEST, V24, P128; RUIZ J P G, 1978, Proceedings of the National Academy of Sciences of the United States of America, V75, P4189, DOI 10.1073/pnas.75.9.4189; SANTAREN JF, 1993, J BIOCHEM, V113, P129, DOI 10.1093/oxfordjournals.jbchem.a124014; SCARPULLA RC, 1986, J BIOL CHEM, V261, P4660; Schimke R T, 1975, Methods Enzymol, V40, P241; STEPIEN G, 1992, J BIOL CHEM, V267, P14592; SUZUKI H, 1991, J BIOL CHEM, V266, P2333; TOMURA H, 1990, J BIOL CHEM, V265, P6525; TORRONI A, 1990, J BIOL CHEM, V265, P20589; VALCARCE C, 1991, FEBS LETT, V294, P225, DOI 10.1016/0014-5793(91)81435-B; VALCARCE C, 1990, J BIOCHEM, V108, P642; VALCARCE C, 1988, J BIOL CHEM, V263, P7767; VALCARCE C, 1994, BIOCHEM J, V303, P855, DOI 10.1042/bj3030855; VANDERZEE CA, 1994, J BIOL CHEM, V269, P6972; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; WALKER JE, 1989, BIOCHEMISTRY-US, V28, P4702, DOI 10.1021/bi00437a029; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOOWARREN H, 1981, J BIOL CHEM, V256, P224	76	83	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10342	10350		10.1074/jbc.270.17.10342	http://dx.doi.org/10.1074/jbc.270.17.10342			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730341	hybrid			2022-12-25	WOS:A1995QV41700090
J	KARUNAGARAN, D; TZAHAR, E; LIU, NL; WEN, DZ; YARDEN, Y				KARUNAGARAN, D; TZAHAR, E; LIU, NL; WEN, DZ; YARDEN, Y			NEU DIFFERENTIATION FACTOR INHIBITS EGF BINDING - A MODEL FOR TRANSREGULATION WITHIN THE ERBB FAMILY OF RECEPTOR TYROSINE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; AMINO-ACID SUBSTITUTION; HIGH-AFFINITY RECEPTORS; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; PHORBOL ESTERS; PHOSPHORYLATION; PROTEIN; CELLS; FIBROBLASTS	Neu differentiation factor (NDF, or heregulin) and epidermal growth factor (EGF) are structurally related proteins that bind to distinct members of the ErbB family of receptor tyrosine kinases. Here we show that NDF inhibits EGF binding in a cell type-specific manner. The inhibitory effect is distinct from previously characterized mechanisms that involve protein kinase C and receptor internalization because it occurred at 4 degrees C and displayed reversibility. The extent of inhibition correlated with both receptor saturation and affinity of different NDF isoforms, and it was abolished upon overexpression of either EGF receptor or ErbB-2. Binding kinetics and equilibrium analyses indicated that NDF reduced the affinity, rather than the number, of EGF receptors, through an acceleration of the rate of ligand dissociation and deceleration of the association rate, On the basis of co-immunoprecipitation of EGF and NDF receptors, we attribute the inhibitory effect to the formation of receptor heterodimers. According to this model, EGF binding to NDF-occupied heterodimers is partially blocked. This model of negative trans-regulation within the ErbB family is relevant to other subgroups of receptor tyrosine kinases and may have physiological implications.	AMGEN INC, AMGEN CTR, THOUSAND OAKS, CA 91320 USA	Amgen	KARUNAGARAN, D (corresponding author), WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL.		Karunagaran, Devarajan/A-8148-2010; YARDEN, YOSEF/K-1467-2012	Karunagaran, Devarajan/0000-0001-9331-8947; 	NCI NIH HHS [CA51712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRD TA, 1990, J BIOL CHEM, V265, P235; BOEYNAEMS JM, 1980, OUTLINES RECEPTOR TH; BOWENPOPE DF, 1983, J CELL BIOL, V96, P679, DOI 10.1083/jcb.96.3.679; BRANDTRAUF PW, 1989, J PROTEIN CHEM, V8, P749, DOI 10.1007/BF01024899; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; COCHET C, 1988, J BIOL CHEM, V263, P3290; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; DAVIS RJ, 1987, J BIOL CHEM, V262, P6832; DAVIS RJ, 1985, CANCER CELL, V3, P101; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; DOUGALL WC, 1993, J CELL BIOCHEM, V53, P61, DOI 10.1002/jcb.240530108; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GULLICK WJ, 1990, INT J CANCER, P55; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LEE LS, 1978, SCIENCE, V202, P313, DOI 10.1126/science.308698; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; STANCOVSKI I, 1994, REGULATORY MECHANISM; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WOFSY C, 1992, BIOPHYS J, V63, P98, DOI 10.1016/S0006-3495(92)81572-2; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1981, BIOCHIM BIOPHYS ACTA, V674, P188, DOI 10.1016/0304-4165(81)90377-9; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	48	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9982	9990		10.1074/jbc.270.17.9982	http://dx.doi.org/10.1074/jbc.270.17.9982			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730382	hybrid			2022-12-25	WOS:A1995QV41700044
J	COLOGNATOPYKE, H; OREAR, JJ; YAMADA, Y; CARBONETTO, S; CHENG, YS; YURCHENCO, PD				COLOGNATOPYKE, H; OREAR, JJ; YAMADA, Y; CARBONETTO, S; CHENG, YS; YURCHENCO, PD			MAPPING OF NETWORK-FORMING, HEPARIN-BINDING, AND ALPHA-1-BETA-1 INTEGRIN-RECOGNITION SITES WITHIN THE ALPHA-CHAIN SHORT ARM OF LAMININ-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEIN; MEDIATE CELL ATTACHMENT; NEURITE OUTGROWTH; GLOBULAR DOMAIN; CALCIUM-BINDING; LONG-ARM; MULTIDOMAIN PROTEIN; COLLAGEN RECEPTOR; NIDOGEN COMPLEX; B1 CHAIN	Cell-interactive and architecture-forming functions are associated with the short arms of basement membrane laminin-1. To map and characterize these functions, we expressed recombinant mouse laminin-1 alpha-chain extending from the N terminus through one third of domain IIIb. This dumbbell-shaped glycoprotein (r alpha 1(VI-IVb)'), secreted by mammalian cells, was found to possess three activities. 1) Laminin polymerization was quantitatively inhibited by recombinant protein, supporting an alpha-chain role for a three-short arm interaction model of laminin self-assembly. 2) r alpha 1(VI IVb)' bound to heparin, and the activity was localized to a subfragment corresponding to domain VI by I-125-heparin blotting. 3) PC12 rat pheochromocytoma cells adhered to, and rapidly extended branching neurites on, r alpha 1(VI-IVb)', with adhesion inhibited by alpha 1 and beta 1 integrin chain-specific antibodies. The ability of anti-laminin antibody to block PC12 cell adhesion to laminin was selectively prevented by absorption with r alpha 1(VI-IVb)' or alpha-chain domain VI fragment. This active integrin-recognition site could furthermore be distinguished from a second cryptic alpha 1 beta 1-binding site exposed by heat treatment of fragment P1', a short arm fragment lacking globules. Thus, a polymer-forming, a heparin-binding, and the active alpha 1 beta 1 integrin-recognition site are all clustered at the end of the alpha-chain short arm, the latter two resident solely in domain VI.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MICROBIOL & MOLEC GENET,PISCATAWAY,NJ 08854; NIDR,BETHESDA,MD 20892; MCGILL UNIV,CTR RES NEUROSCI,MONTREAL,PQ H3A 2B2,CANADA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); McGill University				Yurchenco, Peter/0000-0003-0387-2317	NIDDK NIH HHS [R01-DK36425] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036425] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRUCH M, 1989, EUR J BIOCHEM, V185, P271, DOI 10.1111/j.1432-1033.1989.tb15112.x; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CALOF AL, 1991, J CELL BIOL, V115, P779, DOI 10.1083/jcb.115.3.779; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLYMAN RI, 1994, J CELL SCI, V107, P1007; COLOGNATOPYKE H, 1994, MOL BIOL CELL, V5, pA304; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; DUBAND JL, 1992, DEVELOPMENT, V116, P585; DUBAND JL, 1988, DEVELOPMENT, V101, P461; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; EDGAR D, 1984, EMBO J, V3, P1463, DOI 10.1002/j.1460-2075.1984.tb01997.x; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GLUKHOVA M, 1993, DEV BIOL, V157, P437, DOI 10.1006/dbio.1993.1147; GOODMAN SL, 1991, J CELL BIOL, V113, P931, DOI 10.1083/jcb.113.4.931; GOODMAN SL, 1987, J CELL BIOL, V105, P589, DOI 10.1083/jcb.105.1.589; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; KOUZIKOLIAKOS K, 1989, J BIOL CHEM, V264, P17971; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLIER T, 1994, DEV BIOL, V162, P451, DOI 10.1006/dbio.1994.1101; LALLIER T, 1992, J CELL BIOL, V119, P1335, DOI 10.1083/jcb.119.5.1335; MANN K, 1988, EUR J BIOCHEM, V178, P71, DOI 10.1111/j.1432-1033.1988.tb14430.x; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; NISCHT R, 1991, EUR J BIOCHEM, V200, P529, DOI 10.1111/j.1432-1033.1991.tb16214.x; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PERRIS R, 1989, DEV BIOL, V136, P222, DOI 10.1016/0012-1606(89)90144-9; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; RAO CN, 1990, BIOCHEMISTRY-US, V29, P6768, DOI 10.1021/bi00481a004; REH TA, 1987, NATURE, V330, P68, DOI 10.1038/330068a0; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; SANANTONIO JD, 1994, J CELL BIOL, V125, P1179, DOI 10.1083/jcb.125.5.1179; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; SKUBITZ APN, 1991, J CELL BIOL, V115, P1137, DOI 10.1083/jcb.115.4.1137; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; TAWIL N, 1993, J CELL BIOL, V120, P261, DOI 10.1083/jcb.120.1.261; TAWIL NJ, 1990, BIOCHEMISTRY-US, V29, P6540, DOI 10.1021/bi00479a028; TOMASELLI KJ, 1993, J NEUROSCI, V13, P4880; TOMASELLI KJ, 1990, NEURON, V5, P651, DOI 10.1016/0896-6273(90)90219-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER DC, 1987, DEV BIOL, V121, P510, DOI 10.1016/0012-1606(87)90187-4; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; Yurchenco P.D., 1993, MOL CELLULAR ASPECTS, P19; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636	54	107	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9398	9406		10.1074/jbc.270.16.9398	http://dx.doi.org/10.1074/jbc.270.16.9398			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721864	hybrid			2022-12-25	WOS:A1995QU08900053
J	MUNN, KE; WALKER, RA; VARLEY, JM				MUNN, KE; WALKER, RA; VARLEY, JM			FREQUENT ALTERATIONS OF CHROMOSOME-1 IN DUCTAL CARCINOMA IN-SITU OF THE BREAST	ONCOGENE			English	Note						DCIA; BREAST; CHROMOSOME 1; MICRODISSECTION	INTRADUCTAL CARCINOMA; FOLLOW-UP; CANCER; GENE; HETEROZYGOSITY; DISTINCT; DELETION; REGIONS; BIOPSY; INSITU	Ductal carcinoma in situ (DCIS) of the breast is commonly described as a premalignant lesion, Using PCR to amplify DNA from areas of tumour cells which have been microdissected from fixed material, we have studied the involvement of chromosome 1 in 19 cases of DCIS, A series of microsatellite repeat polymorphisms has been used to define regions of allelic imbalance and this has confirmed the involvement in DCIS of six of the regions previously implicated in studies of invasive breast tumours. This suggests that these regions may harbour tumour suppressor genes, the inactivation of which is important for the early stages of breast tumour development. Analysis of separate ducts from within the same tumour has revealed-that the same genetic alterations are not necessarily present throughout the lesion. In addition we have found that in three cases where frank invasive carcinoma is also present, similar alterations can be detected in the in situ and invasive component.	CHRISTIE HOSP & HOLT RADIUM INST,PATERSON INST CANC RES,DEPT CANC GENET,CRC,MANCHESTER M20 9BX,LANCS,ENGLAND; UNIV LEICESTER,DEPT PATHOL,LEICESTER LE2 7LX,LEICS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Leicester								BETSILL WL, 1978, JAMA-J AM MED ASSOC, V239, P1863, DOI 10.1001/jama.239.18.1863; BIECHE I, 1993, CANCER RES, V53, P1990; BIECHE I, 1990, HUM GENET, V85, P101; BORG A, 1992, GENE CHROMOSOME CANC, V5, P311, DOI 10.1002/gcc.2870050406; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; COXMATISE T, 1994, NAT GENET, V6, P384; CROPP CS, 1993, CANCER RES, V53, P5617; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FRYKBERG ER, 1994, ADV SURG, V26, P29; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V52, P205; HOGGARD N, 1995, GENE CHROMOSOME CANC, V12, P24, DOI 10.1002/gcc.2870120105; KLEIN KG, 1994, CANCER GENET CYTOGEN, V73, P109, DOI 10.1016/0165-4608(94)90194-5; KUGOH HM, 1990, ONCOGENE, V5, P1637; MERLO GR, 1989, CANCER RES, V49, P6966; MITCHELL ELD, 1990, GENE CHROMOSOME CANC, V2, P278, DOI 10.1002/gcc.2870020405; NIELSEN KV, 1989, ACTA ONCOL, V28, P919, DOI 10.3109/02841868909092332; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; Sambrook J., 1989, MOL CLONING; SCHWARTZ GF, 1992, CANCER, V70, P2468, DOI 10.1002/1097-0142(19921115)70:10<2468::AID-CNCR2820701013>3.0.CO;2-K; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; VERBEEK AL, 1984, LANCET, P1222; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	26	76	76	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1653	1657						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731721				2022-12-25	WOS:A1995QU68100023
J	COOL, DR; FENGER, M; SNELL, CR; LOH, YP				COOL, DR; FENGER, M; SNELL, CR; LOH, YP			IDENTIFICATION OF THE SORTING SIGNAL MOTIF WITHIN PROOPIOMELANOCORTIN FOR THE REGULATED SECRETORY PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; B SECRETOGRANIN-I; DISULFIDE BOND; PROTEIN; CELLS; PROOPIOMELANOCORTIN; PITUITARY; GRANULES; PEPTIDES; AGGREGATION	The NH2-terminal region of pro-opiomelanocortin (POMC) is highly conserved across species, having two disulfide bridges that cause the formation of an amphipathic hairpin loop structure between the 2nd and 3rd cysteine residues (Cys(8) to Cys(20)). The role that the NH2-terminal region of pro-opiomelanocortin plays in acting as a molecular sorting signal for the regulated secretory pathway was investigated by using site-directed mutagenesis either to disrupt one or more of the disulfide bridges or to delete the amphipathic loop entirely. When POMC was expressed in Neuro-2a cells, ACTH immunoreactive material was localized in punctate secretory granules in the cell body and along the neurites, with heavy labeling at the tips. ACTH was secreted from these POMC-transfected cells in a regulated manner. Disruption of both disulfide bridges or the second disulfide bridge or removal of the amphipathic hairpin loop resulted in constitutive secretion of the mutant POMC from the cells and a lack of punctate secretory granule immunostaining within the cells. We have modeled the NH2-terminal POMC Cys(8) to Cys(20) domain and have identified it as an amphipathic loop containing four highly conserved hydrophobic and acidic amino acid residues (Asp(10)-Leu(11)-Glu(14)-Leu(18)). Thus the sorting signal for POMC to the regulated secretory pathway appears to be encoded by a specific conformational motif comprised of a 13-amino acid amphipathic loop structure stabilized by a disulfide bridge, located at the NH2 terminus of the molecule.	SANDOZ INST MED RES, LONDON WC1E 6BN, ENGLAND	Novartis; Sandoz	COOL, DR (corresponding author), NICHHD, DEV NEUROBIOL LAB, CELLULAR NEUROBIOL SECT, BLDG 49, RM 5A38, BETHESDA, MD 20892 USA.							ARVAN P, 1991, J BIOL CHEM, V266, P14171; BAKER BI, 1974, CELL TISSUE RES, V151, P481; BENNETT HPJ, 1986, INT J PEPT PROT RES, V27, P306; BROWNSTEIN MJ, 1980, SCIENCE, V207, P373, DOI 10.1126/science.6153132; BURGESS TL, 1987, J CELL BIOL, V105, P659, DOI 10.1083/jcb.105.2.659; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CHEVRIER D, 1991, MOL CELL ENDOCRINOL, V79, P109, DOI 10.1016/0303-7207(91)90101-W; CHEVRIER D, 1993, MOL CELL ENDOCRINOL, V94, P213, DOI 10.1016/0303-7207(93)90170-O; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; COOL DR, 1994, BIOCHIMIE, V76, P265, DOI 10.1016/0300-9084(94)90156-2; DAY NC, 1993, NEUROPEPTIDES, V24, P253, DOI 10.1016/0143-4179(93)90013-Z; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; ELKABES S, 1989, DEV BRAIN RES, V46, P85, DOI 10.1016/0165-3806(89)90145-4; ESTIVARIZ FE, 1992, J BIOL CHEM, V267, P7456; KAWAUCHI H, 1983, ARCH BIOCHEM BIOPHYS, V227, P343, DOI 10.1016/0003-9861(83)90462-9; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KITAHARA N, 1988, COMP BIOCHEM PHYS B, V91, P365, DOI 10.1016/0305-0491(88)90155-1; KLEBE RJ, 1969, J CELL BIOL, V43, pA69; LOH YP, 1985, J BIOL CHEM, V260, P7194; LOH YP, 1988, MOL MECHANISMS SECRE, P525; Maniatis T., 1982, MOL CLONING; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MILGRAM SL, 1994, J CELL SCI, V107, P737; NOEL G, 1989, J NEUROCHEM, V52, P1050, DOI 10.1111/j.1471-4159.1989.tb01846.x; OLMSTED JB, 1970, P NATL ACAD SCI USA, V65, P129, DOI 10.1073/pnas.65.1.129; ORCI L, 1987, CELL, V51, P1089; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; ROY P, 1991, MOL CELL ENDOCRINOL, V82, P237, DOI 10.1016/0303-7207(91)90037-S; SALBERT G, 1992, MOL ENDOCRINOL, V6, P1605, DOI 10.1210/me.6.10.1605; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SCOTT AP, 1974, J ENDOCRINOL, V63, pP24; SEVARINO KA, 1991, J BIOL CHEM, V266, P18507; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; YILLA M, 1992, J CELL BIOL, V118, P245, DOI 10.1083/jcb.118.2.245	38	137	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8723	8729		10.1074/jbc.270.15.8723	http://dx.doi.org/10.1074/jbc.270.15.8723			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721777	hybrid			2022-12-25	WOS:A1995QT44800055
J	MELCHER, T; MAAS, S; HIGUCHI, M; KELLER, W; SEEBURG, PH				MELCHER, T; MAAS, S; HIGUCHI, M; KELLER, W; SEEBURG, PH			EDITING OF ALPHA-AMINO-3-HYDROXY-5-METHYLISOXAZOLE-4-PROPIONIC ACID RECEPTOR GLUR-B PRE-MESSENGER-RNA IN-VITRO REVEALS SITE-SELECTIVE ADENOSINE TO INOSINE CONVERSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B; RNA; CHANNELS	In neurons of the mammalian brain primary transcripts of genes encoding subunits of glutamate receptor channels can undergo RNA editing, leading to altered properties of the transmitter-activated channel. Editing of these transcripts is a nuclear process that targets specific adenosines and requires a double-stranded RNA structure configured from complementary exonic and intronic sequences. We show here that the two independent editing sites in alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR-B pre-mRNA are edited with positional accuracy by nuclear extract from HeLa cells. Nucleotide analysis by thin layer chromatography of the edited RNA sequences revealed selective adenosine to inosine conversion, mast likely reflecting the participation of double-stranded RNA adenosine deaminase. Our results predict the presence of inosine-containing codons in other mammalian mRNAs.	UNIV HEIDELBERG,CTR MOLEC BIOL,MOLEC NEUROENDOCRINOL LAB,D-69120 HEIDELBERG,GERMANY; UNIV BASEL,BIOCTR,CH-4056 BASEL,SWITZERLAND	Ruprecht Karls University Heidelberg; University of Basel								BASILIO C, 1962, P NATL ACAD SCI USA, V48, P613, DOI 10.1073/pnas.48.4.613; BASS BL, 1993, RNA WORLD, P383; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; CHAN L, 1992, J BIOL CHEM, V267, P25621; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HODGES P, 1992, TRENDS BIOCHEM SCI, V17, P77, DOI 10.1016/0968-0004(92)90506-5; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Kim U, 1993, Semin Cell Biol, V4, P285, DOI 10.1006/scel.1993.1034; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; KOHLER M, 1994, J BIOL CHEM, V269, P17367; KUCHINO Y, 1987, METHOD ENZYMOL, V155, P379; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OCONNELL MA, 1994, P NATL ACAD SCI USA, V91, P10596, DOI 10.1073/pnas.91.22.10596; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; RUSHIZKY GW, 1963, J BIOL CHEM, V238, P371; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; SHUB DA, 1994, RNA PROCESSING PRACT, V2, P211; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; Wahle E., 1994, RNA PROCESSING PRACT, VII, P1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	25	88	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8566	8570		10.1074/jbc.270.15.8566	http://dx.doi.org/10.1074/jbc.270.15.8566			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721757	hybrid			2022-12-25	WOS:A1995QT44800033
J	SCHONHERR, E; HAUSSER, H; BEAVAN, L; KRESSE, H				SCHONHERR, E; HAUSSER, H; BEAVAN, L; KRESSE, H			DECORIN-TYPE-I COLLAGEN INTERACTION - PRESENCE OF SEPARATE CORE PROTEIN-BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCAN; SKIN PROTEODERMATAN SULFATE; FIBRILLAR COLLAGEN; TENDON COLLAGEN; LOCALIZATION; FIBROBLASTS; TISSUES; FIBRONECTIN; ENDOCYTOSIS; EXPRESSION	Interactions between the core protein of the small dermatan sulfate proteoglycan decorin and type I collagen have been considered to influence the kinetics of collagen fibrillogenesis and the diameter of and the distance between the fibrils. A variety of recombinant core protein fragments were expressed in Escherichia coli, extracted from inclusion bodies, and renatured in the presence of bovine serum albumin, which was essential for obtaining functional activity. A recombinant protein lacking the first 14 amino acids of the mature core protein (P15-329) interacted with reconstituted type I collagen fibrils and inhibited collagen fibrillogenesis almost as efficiently as intact decorin purified from fibroblast secretions under non-denaturing conditions, Peptides comprising amino acids 15-183 (P15-183) and 185-329 (P185-329) were able to compete for the binding of wild-type decorin, with P15-183 being more active than P185-329, Several other peptides were much less effective, Binding studies using radioactively labeled peptides P15-183 and P185-329 gave direct evidence for the independent binding of both peptides, Peptides 15-183 and 15-125 had the capability of inhibiting collagen fibrillogenesis, whereas peptide 185-329 was inactive, These data suggest (i) that there are at least two separate binding domains for the interaction between decorin core protein and type I collagen and (ii) that binding is not necessarily correlated with an alteration of collagen fibrillogenesis.			SCHONHERR, E (corresponding author), UNIV MUNSTER, INST PHYSIOL CHEM & PATHOBIOCHEM, WALDEYERSTR 15, D-48149 MUNSTER, GERMANY.							BEAVAN LA, 1993, J BIOL CHEM, V268, P9856; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHOPRA RK, 1985, BIOCHEM J, V232, P277, DOI 10.1042/bj2320277; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; DAY AA, 1986, NUCLEIC ACIDS RES, V14, P9861, DOI 10.1093/nar/14.24.9861; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; GLOSSL J, 1983, BIOCHEM J, V215, P295; HAUSSER H, 1989, BIOCHEM J, V263, P137, DOI 10.1042/bj2630137; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; POGANY G, 1992, BIOCHEM BIOPH RES CO, V189, P165, DOI 10.1016/0006-291X(92)91539-3; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; ROSENBERG L, 1993, DERMATAN SULPHATE PR, P225; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; SCOTT PG, 1990, CONNECT TISSUE RES, V24, P225, DOI 10.3109/03008209009152151; Spiro R. C., 1994, Molecular Biology of the Cell, V5, p303A; ULDBJERG N, 1988, BIOCHEM J, V251, P643, DOI 10.1042/bj2510643; VANKUPPEVELT THMSM, 1987, HISTOCHEM J, V19, P520, DOI 10.1007/BF01675423; VOGEL KG, 1987, BIOCHEM BIOPH RES CO, V148, P658, DOI 10.1016/0006-291X(87)90927-2; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VOSS B, 1986, J HISTOCHEM CYTOCHEM, V34, P1013, DOI 10.1177/34.8.2426331; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WITSCHPREHM P, 1992, ARTHRITIS RHEUM-US, V35, P1042, DOI 10.1002/art.1780350909; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	37	180	181	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8877	8883		10.1074/jbc.270.15.8877	http://dx.doi.org/10.1074/jbc.270.15.8877			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721795	hybrid			2022-12-25	WOS:A1995QT44800074
J	LO, YYC; CRUZ, TF				LO, YYC; CRUZ, TF			INVOLVEMENT OF REACTIVE OXYGEN SPECIES IN CYTOKINE AND GROWTH-FACTOR INDUCTION OF C-FOS EXPRESSION IN CHONDROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR-NECROSIS-FACTOR; ARACHIDONIC-ACID METABOLITES; COLONY-STIMULATING FACTOR; FACTOR-ALPHA; MAP KINASE; PHOSPHOLIPASE ACTIVATION; TRANSCRIPTION FACTOR; HYDROGEN-PEROXIDE; CELLS-INVITRO; PHORBOL ESTER	The cytokine tumor necrosis factor alpha (TNF alpha) and the growth factor basic fibroblast growth factor (bFGF) are known to induce early response genes such as c-fos and c-jun in various cell types. Activation of AP-1, a heterodimeric complex of Fos and Jun proteins, is required for matrix metalloproteinase production and cell proliferation. However, the signaling pathways by which these two factors influence the expression and activities of AP-1 remain currently poorly characterized. Several studies have shown that cytokines induce reactive oxygen species (ROS) production, but growth factor induction of ROS has not been reported. In the present study we demonstrate that both TNF alpha and bFGF induce ROS production, and that this is a common signaling event involved in the stimulation of c-fos gene expression in chondrocytes. To our knowledge, this is the first report directly demonstrating ROS production upon stimulation with a growth factor. TNF alpha and bFGF induction of ROS production is mediated through flavonoid-containing enzymes such as NADPH oxidase. Moreover, the ROS nitric oxide is not responsible for the induction of c-fos expression by TNF alpha and bFGF. In addition, the inhibitory effects of antioxidants on c-fos expression may account for their protective roles against proliferative and inflammatory diseases such as cancer, cardiovascular diseases, and arthritis.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, CONNECT TISSURE RES GRP, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT CELLULAR & MOLEC PATHOL, TORONTO, ON M5S 1A8, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto								AGNEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BLAKE DR, 1987, BRIT MED BULL, V43, P371, DOI 10.1093/oxfordjournals.bmb.a072188; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BRETT J, 1989, J EXP MED, V169, P1977, DOI 10.1084/jem.169.6.1977; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAMUSSI G, 1991, EUR J BIOCHEM, V202, P3, DOI 10.1111/j.1432-1033.1991.tb16337.x; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK MA, 1988, BIOCHEM J, V250, P125, DOI 10.1042/bj2500125; CONQUER JA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P1, DOI 10.1016/0167-4889(92)90021-3; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; CRUZ TF, 1990, BIOCHEM J, V269, P717, DOI 10.1042/bj2690717; DAMOULIS PD, 1994, BIOCHEM BIOPH RES CO, V201, P924, DOI 10.1006/bbrc.1994.1790; DEUCHER GP, 1992, FREE RADICALS AGING, P428; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRANSEN L, 1986, CELL IMMUNOL, V100, P260, DOI 10.1016/0008-8749(86)90025-0; FREESWICK PD, 1994, J SURG RES, V57, P205, DOI 10.1006/jsre.1994.1132; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HENDERSON LM, 1993, EUR J BIOCHEM, V211, P157, DOI 10.1111/j.1432-1033.1993.tb19882.x; IMAMURA K, 1988, J BIOL CHEM, V263, P10247; ISACCHI A, 1992, ANGIOGENESIS KEY PRI, P101; KNAUER MF, 1990, J CELL PHYSIOL, V142, P469, DOI 10.1002/jcp.1041420305; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LOBB RR, 1986, ANAL BIOCHEM, V154, P1, DOI 10.1016/0003-2697(86)90487-2; LUNDJOHANSEN F, 1992, CYTOMETRY, V13, P693, DOI 10.1002/cyto.990130705; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; PALOMBELLA VJ, 1989, J BIOL CHEM, V264, P18128; PATTE C, 1992, CELL MOL BIOL, V38, P429; PUCHACZ E, 1993, BRAIN RES, V610, P39, DOI 10.1016/0006-8993(93)91214-D; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RICHTER J, 1989, J IMMUNOL, V142, P3199; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; ROSE RC, 1993, FASEB J, V7, P1135, DOI 10.1096/fasebj.7.12.8375611; RUBINEK T, 1993, BIOCHIM BIOPHYS ACTA, V1176, P51, DOI 10.1016/0167-4889(93)90176-P; SA G, 1994, J BIOL CHEM, V269, P3219; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHERMAN ML, 1990, J CLIN INVEST, V85, P442, DOI 10.1172/JCI114457; SPORN MB, 1990, HDB EXPT PHARM PEPTI, V95, P3; STEFANOVICRACIC M, 1993, ARTHRITIS RHEUM, V36, P1036, DOI 10.1002/art.1780360803; STEVENSON MA, 1994, CANCER RES, V54, P12; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TIKU ML, 1990, J IMMUNOL, V145, P690; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; ZAFARULLAH M, 1992, FEBS LETT, V306, P169, DOI 10.1016/0014-5793(92)80992-P	57	452	462	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11727	11730		10.1074/jbc.270.20.11727	http://dx.doi.org/10.1074/jbc.270.20.11727			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744816	hybrid			2022-12-25	WOS:A1995QY73600007
J	FINCH, PW; LENGEL, C; CHEDID, M				FINCH, PW; LENGEL, C; CHEDID, M			CLONING AND CHARACTERIZATION OF THE PROMOTER REGION OF THE HUMAN KERATINOCYTE GROWTH-FACTOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY REGIONS; FACTOR RECEPTORS; OVALBUMIN GENE; EXPRESSION; SEQUENCE; IDENTIFICATION; TRANSCRIPTION; PROTEIN; FAMILY; INTERLEUKIN-6	Keratinocyte growth factor (KGF), a member of the fibroblast growth factor family of related proteins, is expressed by stromal fibroblasts and acts on epithelial cells in a paracrine fashion. To understand the mechanisms responsible for regulating normal KGF expression and how these might be altered in disease, the 5'-flanking region of this gene was cloned. The presence of two KGF transcription initiation sites was suggested by ribonuclease protection assay and confirmed by primer extension analysis. Examination of the genomic DNA sequence revealed the presence of the putative promoter sequences TATTTA and CCAAT, located 31 and 50 base pairs upstream, respectively, from the first of the two mRNA start points, and putative initiator sequences surrounding each transcription start site, Transient transfection into murine NIH/3T3 fibroblasts demonstrated that the region required for basal level KGF promoter activity was located between bases -225 and +190. Inclusion of sequences between -1503 and -775 markedly reduced promoter activation, indicating the presence of negative regulatory element(s) in this region. A similar pattern of promoter activation was detected in human fibroblasts and in murine C2C12 myoblasts. In contrast, no chloramphenicol acetyltransferase activity was observed in macrophages and epithelial and lymphoid cells transfected with the same constructs. Northern blot analysis revealed a strong correlation between KGF RNA expression and promoter activation in all cells tested. Activation of the KGF promoter could be induced by the proinflammatory cytokines interleukin 1 and interleukin 6 and by the adenylate cyclase activator forskolin. Taken together, these results indicate the existence of cis-acting element(s) responsible for selective activation of the KGF promoter only in cells that express KGF mRNA and may provide a mechanistic basis for KGF gene expression during inflammation.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; BROWN UNIV,RHODE ISL HOSP,DEPT CLIN NEUROSCI,PROVIDENCE,RI 02903	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Brown University; Lifespan Health Rhode Island; Rhode Island Hospital								ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHEDID M, 1994, J BIOL CHEM, V269, P10753; DAS HK, 1988, J BIOL CHEM, V263, P11452; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DRESCENZI M, 1994, J CELL BIOL, V125, P1137; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; HEBST RS, 1989, P NATL ACAD SCI USA, V83, P7653; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIRANO T, 1992, CLIN IMMUNOL IMMUNOP, V62, pS60, DOI 10.1016/0090-1229(92)90042-M; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KELLEY MJ, 1992, P NATL ACAD SCI USA, V89, P9287, DOI 10.1073/pnas.89.19.9287; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; LE JM, 1989, LAB INVEST, V61, P588; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MASON JJ, 1994, MECH DEVELOP, V45, P15; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MELTON DW, 1986, CELL, V44, P319, DOI 10.1016/0092-8674(86)90766-X; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TAYLOR KA, 1994, J VIROL, V68, P6421, DOI 10.1128/JVI.68.10.6421-6431.1994; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; WEISSMAN JD, 1991, MOL CELL BIOL, V11, P4228, DOI 10.1128/MCB.11.8.4228; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	50	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11230	11237		10.1074/jbc.270.19.11230	http://dx.doi.org/10.1074/jbc.270.19.11230			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744756	hybrid			2022-12-25	WOS:A1995QX86500033
J	HANIEL, A; WELGELUSSEN, U; KUHN, K; POSCHL, E				HANIEL, A; WELGELUSSEN, U; KUHN, K; POSCHL, E			IDENTIFICATION AND CHARACTERIZATION OF A NOVEL TRANSCRIPTIONAL SILENCER IN THE HUMAN COLLAGEN TYPE-IV GENE COL4A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; F9 TERATOCARCINOMA CELLS; COMMON PROMOTER REGION; GROWTH-FACTOR-BETA; RNA POLYMERASE-II; HEAD-TO-HEAD; DIVERGENT TRANSCRIPTION; EUKARYOTIC TRANSCRIPTION; BIDIRECTIONAL PROMOTER; BINDING PROTEIN	Collagen type IV [alpha 1(IV)(2) alpha 2(IV)] is the basic structural component of all basement membranes. The two subunit genes COL4A1 and COL4A2 are found closely linked in the human and murine genomes and are transcribed divergently from a common promoter, Previously, activating elements had been detected within both genes which are indispensable for efficient transcription. An additional negative regulatory element has now been identified within the third intron of the COL4A2 gene which is able to inhibit transcription of both COL4 genes from their shared promoter, as well as the nonrelated herpes simplex virus thymidine kinase promoter. The element exerts its inhibitory effect largely independently from its relative orientation and distance from the initiation site of transcription. Therefore, the element represents a silencer, which is named the ''COL4 silencer.'' The minimal functional silencer could be narrowed down by deletion mapping to a sequence element located within intron 3 of the COL4A2 gene. This motif is specifically recognized by a nuclear protein, named ''SILBF,'' and the binding site of which was determined by footprinting assays. Mutation studies and deletion analysis proved that the presence of this sequence element and its interaction with SILBF is not only essential but also sufficient for the silencing function. We assume that the COL4 silencer plays an important role in the control of overall expression and the balance of divergent transcription of both COL4 genes.	UNIV ERLANGEN NURNBERG,INST EXPTL MED,D-91054 ERLANGEN,GERMANY; MAX PLANCK INST BIOCHEM,BINDEGEWEBSFORSCH ABT,D-82152 MARTINSRIED,GERMANY	University of Erlangen Nuremberg; Max Planck Society								BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURBELO PD, 1990, J BIOL CHEM, V265, P4839; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; CHIANG PK, 1992, J BIOL CHEM, V267, P4988; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FISCHER G, 1993, BIOCHEM J, V292, P687, DOI 10.1042/bj2920687; GARABEDIAN MJ, 1985, P NATL ACAD SCI USA, V82, P1396, DOI 10.1073/pnas.82.5.1396; GENERSCH E, 1994, EMBO J, V14, P791; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; GUO XD, 1991, NATURE, V349, P707, DOI 10.1038/349707a0; HEIKKILA P, 1993, J BIOL CHEM, V268, P24677; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; JACKSON ME, 1991, J CELL SCI, V100, P1; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KALLURI R, 1991, J BIOL CHEM, V266, P24018; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KARSENTY G, 1991, J BIOL CHEM, V266, P24842; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; KAYTES P, 1988, J BIOL CHEM, V263, P19274; KHOURY G, 1983, CELL, V33, P313, DOI 10.1016/0092-8674(83)90410-5; KOHNO K, 1985, J BIOL CHEM, V260, P4441; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARIYAMA M, 1992, GENOMICS, V13, P809, DOI 10.1016/0888-7543(92)90157-N; NATARAJAN V, 1984, P NATL ACAD SCI-BIOL, V81, P6290, DOI 10.1073/pnas.81.20.6290; OSLEY MA, 1986, CELL, V45, P537, DOI 10.1016/0092-8674(86)90285-0; POLLNER R, 1990, ANN NY ACAD SCI, V580, P44, DOI 10.1111/j.1749-6632.1990.tb17916.x; POSCHL E, 1994, EMBO J, V13, P3741, DOI 10.1002/j.1460-2075.1994.tb06683.x; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; RAVAZZOLO R, 1991, J BIOL CHEM, V266, P7382; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; ROGERS MB, 1990, J CELL BIOL, V110, P1767, DOI 10.1083/jcb.110.5.1767; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SCHMIDT C, 1993, BIOCHIM BIOPHYS ACTA, V1174, P1, DOI 10.1016/0167-4781(93)90085-R; SOININEN R, 1988, J BIOL CHEM, V263, P17217; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; WILLIAMS TJ, 1986, MOL CELL BIOL, V6, P4558, DOI 10.1128/MCB.6.12.4558; YAMADA Y, 1990, ANN NY ACAD SCI, V580, P81, DOI 10.1111/j.1749-6632.1990.tb17920.x; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449	54	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11209	11215		10.1074/jbc.270.19.11209	http://dx.doi.org/10.1074/jbc.270.19.11209			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744753	hybrid			2022-12-25	WOS:A1995QX86500030
J	GARRED, O; VANDEURS, B; SANDVIG, K				GARRED, O; VANDEURS, B; SANDVIG, K			FURIN-INDUCED CLEAVAGE AND ACTIVATION OF SHIGA TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREFELDIN-A; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; RETROGRADE TRANSPORT; PROTECTIVE ANTIGEN; SECRETORY PROTEINS; GOLGI-COMPLEX; CELL-SURFACE; ENDOPROTEASE; ENDOCYTOSIS	Shiga toxin has a single A subunit non-covalently associated with a pentamer of B subunits. The toxin has a trypsin-sensitive region near the COOH-terminal end of the A-chain, and upon cleavage, two disulfide bonded fragments, A(1) and A(2), are generated. These fragments are also formed upon incubation with cells. The disulfide loop contains the sequence (Arg-X-X-Arg), which is a consensus motif for cleavage by the membrane-anchored protease furin. We found that a soluble form of furin cleaves intact A-chain producing A(1) and A(2) fragments, and furin also seems to be responsible for rapid cellular cleavage of Shiga toxin. LoVo cells, which normally do not produce functional furin, cleave intact A-chain very efficiently when transfected with furin (LoVo/fur), whereas a control cell (LoVo/neo) cleaves the toxin very slowly. To investigate the role of this cleavage for intoxication of cells, we studied the ability of unnicked and furin-nicked toxin to inhibit protein synthesis in LoVo/fur and LoVo/neo cells. LoVo/fur cells were intoxicated equally well with unnicked and nicked toxin, whereas in LoVo/neo cells nicked toxin was about 20 times more active than unnicked toxin. The results suggest that cleavage of Shiga toxin is important for intoxication of cells, and they indicate that furin can cleave and thereby activate Shiga toxin in cells.	NORWEGIAN RADIUM HOSP, INST CANC RES, N-0310 OSLO, NORWAY; UNIV COPENHAGEN, PANUM INST, DEPT ANAT, STRUCT CELL BIOL UNIT, DK-2200 COPENHAGEN, DENMARK	University of Oslo; University of Copenhagen								BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BURGESS BJ, 1993, MOL MICROBIOL, V10, P171, DOI 10.1111/j.1365-2958.1993.tb00913.x; CHIRON MF, 1994, J BIOL CHEM, V269, P18167; COHEN A, 1987, J BIOL CHEM, V262, P17088; DAMKE H, 1991, J BIOL CHEM, V266, P24829; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; ENDO Y, 1988, EUR J BIOCHEM, V171, P45, DOI 10.1111/j.1432-1033.1988.tb13756.x; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FUJIWARA T, 1989, CELL STRUCT FUNCT, V14, P605, DOI 10.1247/csf.14.605; HALBAN PA, 1994, BIOCHEM J, V299, P1; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; KIRSCHKE H, 1977, EUR J BIOCHEM, V74, P293, DOI 10.1111/j.1432-1033.1977.tb11393.x; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; KONGMUANG U, 1988, FEMS MICROBIOL LETT, V56, P105, DOI 10.1016/0378-1097(88)90135-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; OBRIEN AD, 1992, PATHOGENESIS SHIGELL, P65; OLSNES S, 1981, J BIOL CHEM, V256, P8732; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; SAMUEL JE, 1994, J BIOL CHEM, V269, P4853; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SANDVIG K, 1991, J CELL BIOL, V113, P553, DOI 10.1083/jcb.113.3.553; SANDVIG K, 1992, NATURE, V358, P510, DOI 10.1038/358510a0; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SANDVIG K, 1994, J CELL BIOL, V126, P53, DOI 10.1083/jcb.126.1.53; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SAXENA SK, 1989, J BIOL CHEM, V264, P596; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; VANDEURS B, 1989, INT REV CYTOL, V117, P131; YAMASHINA S, 1990, CELL STRUCT FUNCT, V15, P31, DOI 10.1247/csf.15.31	44	167	177	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10817	10821						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738018				2022-12-25	WOS:A1995QW60100066
J	SOLDAINI, E; PLA, M; BEERMANN, F; ESPEL, E; CORTHESY, P; BARANGE, S; WAANDERS, GA; MACDONALD, HR; NABHOLZ, M				SOLDAINI, E; PLA, M; BEERMANN, F; ESPEL, E; CORTHESY, P; BARANGE, S; WAANDERS, GA; MACDONALD, HR; NABHOLZ, M			MOUSE INTERLEUKIN-2 RECEPTOR-ALPHA GENE-EXPRESSION - DELIMITATION OF CIS-ACTING REGULATORY ELEMENTS IN TRANSGENIC MICE AND BY MAPPING OF DNASE-I HYPERSENSITIVE SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMATURE LYT-2-/L3T4 THYMOCYTES; GROWTH-FACTOR RECEPTORS; MONOCLONAL-ANTIBODIES; CHAIN GENE; LYMPHOCYTE-T; STEM-CELLS; IL-2; ACTIVATION; CHROMATIN; MURINE	The alpha chain of the interleukin-2 receptor (IL-2R alpha) is a key regulator of lymphocyte proliferation, To analyze the mechanisms controlling its expression in normal cells, we used the 5'-flanking region (base pairs -2539/+93) of the mouse gene to drive chloramphenicol acetyltransferase expression in four transgenic mouse lines, Constitutive transgene activity was restricted to lymphoid organs, In mature T lymphocytes, transgene and endogenous IL-2R alpha gene expression was stimulated by concanavalin A and up regulated by IL-2 with very similar kinetics, In thymic T cell precursors, IL-1 and IL-2 cooperatively induced transgene and IL-2R alpha gene expression, These results show that regulation of the endogenous IL-2R alpha gene occurs mainly at the transcrip tional level, They demonstrate that cis-acting elements in the 5'-flanking region present in the transgene confer correct tissue specificity and inducible expression in mature T cells and their precursors in response to antigen, IL-1, and IL-2, In a complementary approach, we screened the 5' end of the endogenous IL-2R alpha gene for DNase-I hypersensitive sites, We found three lymphocyte specific DNase-I hypersensitive sites. Two, at -0.05 and -5.3 kilobase pairs, are present in resting T cells, A third site appears at -1.35 kilobase pairs in activated T cells, It co-localizes with IL-2-responsive elements identified by transient transfection experiments.	SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND; LUDWIG INST CANC RES,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research; Ludwig Institute for Cancer Research			Espel, Enric/ABD-3481-2020; Pla, Maria/K-5170-2017	Espel, Enric/0000-0003-1666-3821; Pla, Maria/0000-0003-4382-5494				ARDAVIN C, 1992, EUR J IMMUNOL, V22, P859, DOI 10.1002/eji.1830220334; BALLARD D W, 1989, New Biologist, V1, P83; BEERMANN F, 1993, MECH DEVELOP, V42, P59, DOI 10.1016/0925-4773(93)90098-I; BISMUTH G, 1985, EUR J IMMUNOL, V15, P723, DOI 10.1002/eji.1830150716; BRAUN MY, 1993, EUR J IMMUNOL, V23, P1462, DOI 10.1002/eji.1830230710; BROMBACHER F, 1994, INT IMMUNOL, V6, P189, DOI 10.1093/intimm/6.2.189; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CAO XQ, 1993, P NATL ACAD SCI USA, V90, P8464, DOI 10.1073/pnas.90.18.8464; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CHEN JZ, 1994, INT IMMUNOL, V6, P1265, DOI 10.1093/intimm/6.8.1265; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DEPPER JM, 1985, P NATL ACAD SCI USA, V82, P4230, DOI 10.1073/pnas.82.12.4230; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; ERARD F, 1984, J EXP MED, V160, P584, DOI 10.1084/jem.160.2.584; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FREIMUTH WW, 1989, J IMMUNOL, V143, P3064; FURTH PA, 1991, NUCLEIC ACIDS RES, V19, P6205, DOI 10.1093/nar/19.22.6205; GEPPERT TD, 1987, J IMMUNOL, V138, P1660; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; HOGAN B, 1986, MANIPULATING MOUSE E; HOWE RC, 1988, J IMMUNOL, V140, P1047; HYDE JE, 1979, NUCLEIC ACIDS RES, V7, P31, DOI 10.1093/nar/7.1.31; IKUTA K, 1992, ANNU REV IMMUNOL, V10, P759; KIMURA A, 1981, EUR J IMMUNOL, V11, P475, DOI 10.1002/eji.1830110607; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LEONARD WJ, 1985, SCIENCE, V230, P633, DOI 10.1126/science.2996141; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LIN BB, 1990, MOL CELL BIOL, V10, P850, DOI 10.1128/MCB.10.2.850; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LOUGHNAN MS, 1987, P NATL ACAD SCI USA, V84, P5399, DOI 10.1073/pnas.84.15.5399; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; LOWENTHAL JW, 1985, J IMMUNOL, V135, P3988; LOWENTHAL JW, 1986, J IMMUNOL, V137, P2579; MALEK TR, 1985, J EXP MED, V161, P1575, DOI 10.1084/jem.161.6.1575; MILLER AE, 1992, IMMUNOGENETICS, V35, P24, DOI 10.1007/BF00216623; MILLER MR, 1978, BIOCHEMISTRY-US, V17, P1073, DOI 10.1021/bi00599a021; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MOREAU JL, 1987, EUR J IMMUNOL, V17, P929, DOI 10.1002/eji.1830170706; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; PHILIP R, 1993, J BIOL CHEM, V268, P16087; PIMENTELMUINOS FX, 1994, J IMMUNOL, V152, P5714; PLAETINCK G, 1990, J IMMUNOL, V145, P3340; POMERANTZ JL, 1989, J IMMUNOL, V143, P4275; RAULET DH, 1985, NATURE, V314, P101, DOI 10.1038/314101a0; ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455; ROCHA B, 1993, J IMMUNOL, V140, P1076; ROEDERER M, 1991, Methods (Orlando), V2, P248, DOI 10.1016/S1046-2023(05)80067-2; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; ROMAN D, 1990, New Biologist, V2, P642; ROTHENBERG EV, 1994, EUR J IMMUNOL, V24, P24, DOI 10.1002/eji.1830240105; SOLDAINI E, 1992, EUR J IMMUNOL, V22, P1707, DOI 10.1002/eji.1830220707; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; STEWART AF, 1991, NUCLEIC ACIDS RES, V19, P3157, DOI 10.1093/nar/19.11.3157; TAKACS L, 1985, CLIN EXP IMMUNOL, V59, P37; TANAKA T, 1991, J IMMUNOL, V147, P2222; TOLEDANO MB, 1990, P NATL ACAD SCI USA, V87, P1830, DOI 10.1073/pnas.87.5.1830; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; WAGA S, 1993, J BIOL CHEM, V268, P6429; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WILSON A, 1994, EUR J IMMUNOL, V24, P1729, DOI 10.1002/eji.1830240802; ZHANG L, 1990, NUCLEIC ACIDS RES, V18, P1797, DOI 10.1093/nar/18.7.1797; ZURAWSKI SM, 1986, J IMMUNOL, V137, P3354	69	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10733	10742		10.1074/jbc.270.18.10733	http://dx.doi.org/10.1074/jbc.270.18.10733			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738012				2022-12-25	WOS:A1995QW60100056
J	AQVIST, J; MOWBRAY, SL				AQVIST, J; MOWBRAY, SL			SUGAR RECOGNITION BY A GLUCOSE/GALACTOSE RECEPTOR - EVALUATION OF BINDING ENERGETICS FROM MOLECULAR-DYNAMICS SIMULATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; HYDROGEN-BONDS; PROTEIN; GALACTOSE; SIMULATIONS; CHEMOTAXIS; TRANSPORT; ENERGY	A new theoretical method for free energy calculations is used to compute the absolute binding constants for beta-D-glucose and methyl-beta-D-galactoside to the periplasmic glucose/galactose receptor from Salmonella typhimurium. The computer simulation results agree well with available experimental data and make it possible to assess the sources of both the high affinity as well as the specificity for glucose. It was found that the major contribution to the binding energy comes from electrostatic interactions and particularly hydrogen bonds of the charge-dipole type. We also predict the structure of the complex with methyl-galactoside as this has not yet been experimentally determined.			AQVIST, J (corresponding author), SWEDISH UNIV AGR SCI,UPPSALA BIOMED CTR,DEPT MOLEC BIOL,BOX 590,S-75124 UPPSALA,SWEDEN.		Mowbray, Sherry L/D-2141-2013					ANRAKU Y, 1968, J BIOL CHEM, V243, P3116; AQVIST J, 1990, J PHYS CHEM-US, V94, P8021, DOI 10.1021/j100384a009; AQVIST J, 1994, PROTEIN ENG, V7, P385, DOI 10.1093/protein/7.3.385; AQVIST J, 1994, J PHYS CHEM-US, V98, P8253, DOI 10.1021/j100084a049; AQVIST J, 1993, J AM CHEM SOC, V115, P631; BOOS W, 1969, EUR J BIOCHEM, V10, P66; FLOCCO MM, 1994, J BIOL CHEM, V269, P8931; HAZELBAUER GL, 1971, NATURE-NEW BIOL, V230, P101, DOI 10.1038/newbio230101a0; LEE FS, 1992, J CHEM PHYS, V97, P3100, DOI 10.1063/1.462997; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MILLER DM, 1980, J BIOL CHEM, V255, P2465; MIYAMOTO S, 1993, P NATL ACAD SCI USA, V90, P8402, DOI 10.1073/pnas.90.18.8402; Mowbray S L, 1990, Receptor, V1, P41; PFLUGRATH JW, 1985, NATURE, V314, P257, DOI 10.1038/314257a0; RICHARME G, 1983, BIOCHIM BIOPHYS ACTA, V742, P16, DOI 10.1016/0167-4838(83)90353-9; ROTMAN B, 1972, Journal of Bacteriology, V111, P791; STRAATSMA TP, 1992, ANNU REV PHYS CHEM, V43, P407; van Gunsteren W. F., 1987, GRONINGEN MOL SIMULA; VERMERSCH PS, 1992, J MOL BIOL, V226, P923, DOI 10.1016/0022-2836(92)91041-M; WARSHEL A, 1991, ANNU REV BIOPHYS BIO, V20, P267, DOI 10.1146/annurev.biophys.20.1.267; Warshel A, 1989, COMPUTER SIMULATIONS, P120; ZOU JY, 1993, J MOL BIOL, V233, P739, DOI 10.1006/jmbi.1993.1549; ZUKIN RS, 1977, BIOCHEMISTRY-US, V16, P381, DOI 10.1021/bi00622a007	23	69	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9978	9981						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730381				2022-12-25	WOS:A1995QV41700043
J	ENGLANDER, EW; HOWARD, BH				ENGLANDER, EW; HOWARD, BH			NUCLEOSOME POSITIONING BY HUMAN ALU ELEMENTS IN CHROMATIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-III; REPEATED DNA-SEQUENCES; TUMOR VIRUS PROMOTER; MAMMALIAN GENOMES; TRANSGENIC MICE; XENOPUS-LAEVIS; GLOBIN GENES; TRANSCRIPTION; FAMILY; ORGANIZATION	Alu sequences are interspersed throughout the genomes of primate cells, occurring singly and in clusters around RNA polymerase II-transcribed genes, Because these repeat elements are capable of positioning nucleosomes in in vitro reconstitutes (Englander, E. W., Wolffe, A. P., and Howard, B. H. (1993) J. Biol. Chem. 268, 19565-19573), we investigated whether they also influence in vivo chromatin structure. When assayed collectively using consensus sequence probes and native chromatin as template, Alu family members were found to confer rotational positioning on nucleosomes or nucleosome-like particles. In particular, a 10-base pair pattern of DNase I nicking that spanned the RNA polymerase III box A promoter motif extended upstream to cover diverse 5'-flanking sequences, suggesting that Alu repeats may in fluence patterns of nucleosome formation over neighboring regions. Computational analysis of a set of naturally occurring Alu sequences indicated that nucleosome positioning information is intrinsic to these elements, Inasmuch as local chromatin organization influences gene expression, the capacity of Alu sequences to affect chromatin structure as demonstrated here may help to clarify some features of these elements.	NICHHD, MOLEC GROWTH REGULAT LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; ARVEILER B, 1992, MAMM GENOME, V3, P661, DOI 10.1007/BF00444360; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P865, DOI 10.1093/nar/20.4.865; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; BUTTINELLI M, 1993, P NATL ACAD SCI USA, V90, P9315, DOI 10.1073/pnas.90.20.9315; CALLADINE CR, 1986, J MOL BIOL, V192, P907, DOI 10.1016/0022-2836(86)90036-7; CHEN EY, 1991, GENOMICS, V10, P792, DOI 10.1016/0888-7543(91)90465-Q; CHIPEV CC, 1992, MOL CELL BIOL, V12, P45, DOI 10.1128/MCB.12.1.45; COSTANZO G, 1990, J MOL BIOL, V216, P363, DOI 10.1016/S0022-2836(05)80327-4; DANIELS GR, 1985, NATURE, V317, P819, DOI 10.1038/317819a0; DEININGER PL, 1992, TRENDS GENET, V8, P307, DOI 10.1016/0168-9525(92)90262-3; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DUNCAN C, 1979, P NATL ACAD SCI USA, V76, P5095, DOI 10.1073/pnas.76.10.5095; DUNCAN CH, 1981, GENE, V13, P185, DOI 10.1016/0378-1119(81)90007-X; EDWARDS A, 1990, GENOMICS, V6, P593, DOI 10.1016/0888-7543(90)90493-E; ELDER JT, 1981, NUCLEIC ACIDS RES, V9, P1171, DOI 10.1093/nar/9.5.1171; ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565; FITZGERALD PC, 1985, J BIOL CHEM, V260, P5318; FUHRMAN SA, 1981, NUCLEIC ACIDS RES, V9, P6439, DOI 10.1093/nar/9.23.6439; GIBBS PEM, 1987, BIOCHEMISTRY-US, V26, P1332, DOI 10.1021/bi00379a020; GOTTESFELD JM, 1987, MOL CELL BIOL, V7, P1612, DOI 10.1128/MCB.7.5.1612; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; HELLMANNBLUMBERG U, 1993, MOL CELL BIOL, V13, P4523, DOI 10.1128/MCB.13.8.4523; HOUCK CM, 1979, J MOL BIOL, V132, P289, DOI 10.1016/0022-2836(79)90261-4; HOWARD B H, 1990, New Biologist, V2, P759; HWU HR, 1986, P NATL ACAD SCI USA, V83, P3875, DOI 10.1073/pnas.83.11.3875; IRIS FJM, 1993, NAT GENET, V3, P137, DOI 10.1038/ng0293-137; JELINEK WR, 1982, ANNU REV BIOCHEM, V51, P813, DOI 10.1146/annurev.bi.51.070182.004121; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; LIU WM, 1994, NUCLEIC ACIDS RES, V22, P1087, DOI 10.1093/nar/22.6.1087; MARTINGALLARDO A, 1992, NAT GENET, V1, P34, DOI 10.1038/ng0492-34; MATERA AG, 1990, MOL CELL BIOL, V10, P5424, DOI 10.1128/MCB.10.10.5424; MCCOMBIE WR, 1992, NAT GENET, V1, P348, DOI 10.1038/ng0892-348; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MOYZIS RK, 1989, GENOMICS, V4, P273, DOI 10.1016/0888-7543(89)90331-5; NEZNANOV NS, 1993, MOL CELL BIOL, V13, P1815, DOI 10.1128/MCB.13.3.1815; Okada N, 1991, CURR OPIN GENET DEV, V1, P498, DOI 10.1016/S0959-437X(05)80198-4; PAN J, 1981, NUCLEIC ACIDS RES, V9, P1151; PANNING B, 1993, MOL CELL BIOL, V13, P3231, DOI 10.1128/MCB.13.6.3231; PANNING B, 1994, VIROLOGY, V202, P408, DOI 10.1006/viro.1994.1357; PEREZSTABLE C, 1984, P NATL ACAD SCI-BIOL, V81, P5291, DOI 10.1073/pnas.81.17.5291; PINA B, 1990, J MOL BIOL, V216, P975, DOI 10.1016/S0022-2836(99)80015-1; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PRUNELL A, 1982, EMBO J, V1, P173, DOI 10.1002/j.1460-2075.1982.tb01143.x; ROGERS JH, 1985, INT REV CYTOL, V93, P187, DOI 10.1016/S0074-7696(08)61375-3; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; Schmid C, 1992, CURR OPIN GENET DEV, V2, P874, DOI 10.1016/S0959-437X(05)80110-8; SCHMID CW, 1991, NUCLEIC ACIDS RES, V19, P5613, DOI 10.1093/nar/19.20.5613; SHEN C-K J, 1982, Journal of Molecular and Applied Genetics, V1, P343; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SINGER MF, 1982, INT REV CYTOL, V76, P67, DOI 10.1016/S0074-7696(08)61789-1; SINGER MF, 1982, CELL, V28, P433, DOI 10.1016/0092-8674(82)90194-5; TANAKA S, 1992, EMBO J, V11, P1187, DOI 10.1002/j.1460-2075.1992.tb05159.x; THOREY IS, 1993, MOL CELL BIOL, V13, P6742, DOI 10.1128/MCB.13.11.6742; ULLU E, 1985, NATURE, V318, P371, DOI 10.1038/318371a0; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; WILLARD C, 1987, J MOL EVOL, V26, P180, DOI 10.1007/BF02099850; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	63	87	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10091	10096		10.1074/jbc.270.17.10091	http://dx.doi.org/10.1074/jbc.270.17.10091			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730313	hybrid			2022-12-25	WOS:A1995QV41700058
J	RODRIGUEZ, PL; CARRASCO, L				RODRIGUEZ, PL; CARRASCO, L			POLIOVIRUS PROTEIN 2C CONTAINS 2 REGIONS INVOLVED IN RNA-BINDING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOVEMENT PROTEIN; ESCHERICHIA-COLI; BREFELDIN-A; REPLICATION; RECOGNITION; MUTANTS; DOMAIN; MOTIFS; CDNA; BOX	Poliovirus protein 2C is involved in poliovirus RNA replication, although the exact function of 2C is still unknown. Recently, it was shown that 2C can be purified to high levels when expressed as a fusion protein with maltose binding protein (MBP), Evidence was pre presented that 2C has ATPase and GTPase activities; preliminary results also indicated that 2C interacts with RNA (Rodriguez, P. L., and Carrasco, L. (1993) J. Biol. Chem. 268, 8105-8110), In the present study, 20 variants of 2C have been generated, and their NTPase and RNA binding activities were analyzed. Moreover, an easy procedure to obtain genuine 2C after factor Xa cleavage of an MBP(2)-2C fusion protein is described. This work has determined that 2C has two regions involved in RNA binding: a NH2-terminal region located between amino acids 21 and 45 and a COOH-terminal region involving an Arg-rich region located between amino acids 312 and 319. Deletion of either the NH2- or COOH-terminal RNA-binding region abolishes RNA binding. Deletion of an internal region of protein 2C that includes the nucleotide-binding motif does not affect RNA binding, whereas this deletion destroys ATPase and GTPase activities. Therefore, the NTPase activity and the RNA binding capacity of protein 2C are located in different regions of the molecule.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOLEC, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Rodriguez, Pedro L./K-4605-2014; Carrasco, Luis/E-2435-2012; Carrasco, Luis/H-3001-2017	Rodriguez, Pedro L./0000-0002-5886-9425; Carrasco, Luis/0000-0003-3833-8835				Atabekov J G, 1990, Adv Virus Res, V38, P201, DOI 10.1016/S0065-3527(08)60863-5; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BERNSTEIN HD, 1986, J VIROL, V60, P1040, DOI 10.1128/JVI.60.3.1040-1049.1986; BIAMONTI G, 1994, FEBS LETT, V340, P1, DOI 10.1016/0014-5793(94)80162-2; BIENZ K, 1992, J VIROL, V66, P2740, DOI 10.1128/JVI.66.5.2740-2747.1992; BIENZ K, 1990, J VIROL, V64, P1156, DOI 10.1128/JVI.64.3.1156-1163.1990; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CITOVSKY V, 1992, PLANT CELL, V4, P397, DOI 10.1105/tpc.4.4.397; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DOMIER LL, 1987, VIROLOGY, V158, P20, DOI 10.1016/0042-6822(87)90233-9; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUINEA R, 1990, EMBO J, V9, P2011, DOI 10.1002/j.1460-2075.1990.tb08329.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HELLEN CUT, 1992, VIROLOGY, V187, P391, DOI 10.1016/0042-6822(92)90440-Z; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HULL R, 1989, ANNU REV PHYTOPATHOL, V27, P213; IRURZUN A, 1992, VIROLOGY, V191, P166, DOI 10.1016/0042-6822(92)90178-R; JOHNSON KL, 1991, J VIROL, V65, P4341, DOI 10.1128/JVI.65.8.4341-4349.1991; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; LEE CZ, 1993, J VIROL, V67, P2221, DOI 10.1128/JVI.67.4.2221-2227.1993; LI JP, 1988, J VIROL, V62, P4016, DOI 10.1128/JVI.62.11.4016-4021.1988; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MAYNELL LA, 1992, J VIROL, V66, P1985, DOI 10.1128/JVI.66.4.1985-1994.1992; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; MIRZAYAN C, 1994, VIROLOGY, V199, P176, DOI 10.1006/viro.1994.1110; MOLLA A, 1993, J VIROL, V67, P5932, DOI 10.1128/JVI.67.10.5932-5938.1993; MOLLA A, 1992, NATURE, V356, P255, DOI 10.1038/356255a0; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; OSMAN TAM, 1993, J GEN VIROL, V74, P2453, DOI 10.1099/0022-1317-74-11-2453; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; PAUL AV, 1994, VIROLOGY, V199, P188, DOI 10.1006/viro.1994.1111; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PINCUS SE, 1986, J VIROL, V60, P793, DOI 10.1128/JVI.60.2.793-796.1986; RODRIGUEZ PL, 1994, BIOTECHNIQUES, V17, P702; RODRIGUEZ PL, 1995, BIOTECHNIQUES, V18, P238; RODRIGUEZ PL, 1993, J BIOL CHEM, V268, P8105; ROMISCH K, 1990, J CELL BIOL, V111, P1793, DOI 10.1083/jcb.111.5.1793; Sambrook J, 1989, MOL CLONING LABORATO; SARNOW P, 1990, CURR TOP MICROBIOL, V161, P155; SEMLER BL, 1988, RNA GENETICS, V1, P23; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; TETERINA NL, 1992, J GEN VIROL, V73, P1977, DOI 10.1099/0022-1317-73-8-1977; TOLSKAYA EA, 1994, J MOL BIOL, V236, P1310, DOI 10.1016/0022-2836(94)90060-4; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033	49	95	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10105	10112		10.1074/jbc.270.17.10105	http://dx.doi.org/10.1074/jbc.270.17.10105			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730315	hybrid			2022-12-25	WOS:A1995QV41700060
J	WU, J; DUNHAM, WR; WEISS, B				WU, J; DUNHAM, WR; WEISS, B			OVERPRODUCTION AND PHYSICAL CHARACTERIZATION OF SOXR, A [2FE-2S] PROTEIN THAT GOVERNS AN OXIDATIVE RESPONSE REGULON IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARAMAGNETIC-RESONANCE SPECTROSCOPY; DISTRIBUTED SYSTEMS; STRESS REGULON; GENES; EXPRESSION; IRON; DEHYDROGENASE; CLUSTER; RES	SoxR protein governs the soxRS (superoxide response) regulon of Escherichia coli by becoming a transcriptional activator when the cells are exposed to compounds that mediate univalent redox reactions, many of which produce superoxide as a by-product, SoxR was overproduced and purified to near homogeneity from a strain bearing an expression vector, It could bind specifically to the soxS operator even in the absence of RNA polymerase, The aerobically purified protein, which is readily autooxidized, could activate the transcription of soxS DNA even without exposure to known inducing agents, SoxR is a globular homodimer, It contains one [2Fe-2S] cluster per polypeptide chain, as demonstrated by optical and EPR spectroscopy combined with stoichiometric analysis of iron content, unpaired electron-spin density, and reduction by dithionite. The protein is active in its oxidized ([2Fe-2S](2+)) state. The presence of a prosthetic group capable of univalent redox reactions may help to explain the activation of the regulon in vivo by compounds that can mediate such reactions.	UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DIV BIOPHYS RES, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00042] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2019, DOI 10.1093/nar/20.suppl.2019; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL C, 1981, J BIOL CHEM, V256, P2673; BURLEIGH BD, 1969, ANAL BIOCHEM, V27, P536, DOI 10.1016/0003-2697(69)90067-0; CAMMACK R, 1985, BIOCHEM SOC T, V13, P572, DOI 10.1042/bst0130572; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; CHAN E, 1987, P NATL ACAD SCI USA, V84, P3189, DOI 10.1073/pnas.84.10.3189; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V28, P4861, DOI 10.1021/bi00437a051; HAGEN WR, 1985, J MAGN RESON, V61, P233, DOI 10.1016/0022-2364(85)90078-2; HAGEN WR, 1985, J MAGN RESON, V61, P220, DOI 10.1016/0022-2364(85)90077-0; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HOLMQUIST B, 1988, METHOD ENZYMOL, V158, P6, DOI 10.1016/0076-6879(88)58042-4; HUNT J, 1993, J BIOL CHEM, V268, P18685; LIOCHEV SI, 1994, P NATL ACAD SCI USA, V91, P1328, DOI 10.1073/pnas.91.4.1328; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; MAYHEW SG, 1969, J BIOL CHEM, V244, P2830; MILMAN G, 1987, METHOD ENZYMOL, V153, P482; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; ORMEJOHNSON WH, 1982, IRON SULFUR PROTEINS, P67; Rogers S G, 1980, Methods Enzymol, V65, P201; Sambrook J., 1989, MOLECULAR CLONING LA; Smith M. H., 1968, CRC HDB BIOCH, pC3; Steczko J, 1991, Protein Expr Purif, V2, P221, DOI 10.1016/1046-5928(91)90075-T; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSANEVA IR, 1990, J BACTERIOL, V172, P4197, DOI 10.1128/jb.172.8.4197-4205.1990; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WEISS B, 1994, INT CONGR SER, V1058, P241; WERTH MT, 1992, FEBS LETT, V299, P1, DOI 10.1016/0014-5793(92)80086-V; WU J, 1992, J BACTERIOL, V174, P3915, DOI 10.1128/jb.174.12.3915-3920.1992; WU J, 1991, J BACTERIOL, V173, P2864, DOI 10.1128/JB.173.9.2864-2871.1991; YOON PS, 1980, BIOCHEMISTRY-US, V19, P2172, DOI 10.1021/bi00551a027	36	90	97	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10323	10327		10.1074/jbc.270.17.10323	http://dx.doi.org/10.1074/jbc.270.17.10323			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730338	hybrid			2022-12-25	WOS:A1995QV41700087
J	GILBERT, DM; NEILSON, A; MIYAZAWA, H; DEPAMPHILIS, ML; BURHANS, WC				GILBERT, DM; NEILSON, A; MIYAZAWA, H; DEPAMPHILIS, ML; BURHANS, WC			MIMOSINE ARRESTS DNA-SYNTHESIS AT REPLICATION FORKS BY INHIBITING DEOXYRIBONUCLEOTIDE METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE DOMAIN; CHINESE-HAMSTER CELLS; AMINO-ACID MIMOSINE; SIMIAN VIRUS-40; XENOPUS EGGS; PLASMID DNA; RIBONUCLEOTIDE REDUCTASE; GENE AMPLIFICATION; PURIFIED DNA; CHO CELLS	Mimosine has been reported to specifically prevent initiation of DNA replication in the chromosomes of mammalian nuclei. To test this hypothesis, the effects of mimosine were examined in several DNA replication systems and compared with the effects of aphidicolin, a specific inhibitor of replicative DNA polymerases. Our results demonstrated that mimosine inhibits DNA synthesis in mitochondrial, nuclear, and simian virus 40 (SV40) genomes to a similar extent. Furthermore, mimosine and aphidicolin were indistinguishable in their ability to arrest SV40 replication forks and mammalian nuclear chromosomal replication forks. In contrast to aphidicolin, mimosine did not inhibit DNA replication in lysates of mammalian cells supplied with exogenous deoxyribonucleotide triphosphate precursors for DNA synthesis. Mimosine also had no effect on initiation or elongation of DNA replication in Xenopus eggs or egg extracts containing high levels of deoxyribonucleotide triphosphates. In parallel with its inhibitory effect on DNA synthesis in mammalian cells, mimosine altered deoxyribonucleotide triphosphate pools in a manner similar to that reported for another DNA replication inhibitor that affects deoxyribonucleotide metabolism, hydroxyurea. Taken together, these results show that mimosine inhibits DNA synthesis at the level of elongation of nascent chains by altering deoxyribonucleotide metabolism.	ROSWELL PK CANC INST, DEPT MOLEC & CELLULAR BIOL, BUFFALO, NY 14263 USA; ROCHE INST MOLEC BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA	Roswell Park Cancer Institute; Roche Holding					NCI NIH HHS [CA16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANACHKOVA B, 1989, MOL CELL BIOL, V9, P532, DOI 10.1128/MCB.9.2.532; ANDREASSEN PR, 1992, P NATL ACAD SCI USA, V89, P2272, DOI 10.1073/pnas.89.6.2272; BESTWICK RK, 1982, J BIOL CHEM, V257, P9305; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; BLOW JJ, 1990, J CELL SCI, V95, P383; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; BURHANS WC, 1986, P NATL ACAD SCI USA, V83, P7790, DOI 10.1073/pnas.83.20.7790; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7; DAI YM, 1994, VIROLOGY, V205, P210, DOI 10.1006/viro.1994.1636; DECKER RS, 1986, MOL CELL BIOL, V6, P3815, DOI 10.1128/MCB.6.11.3815; DEPAMPHILIS ML, 1993, J BIOL CHEM, V268, P1; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1, P99; DIJKWEL PA, 1992, MOL CELL BIOL, V12, P3715, DOI 10.1128/MCB.12.9.3715; DINTERGOTTLIEB G, 1983, J BIOL CHEM, V258, P3809; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; FELDMAN ST, 1994, CANCER RES, V54, P494; GILBERT DM, 1993, COLD SPRING HARB SYM, V58, P475, DOI 10.1101/SQB.1993.058.01.054; GILBERT DM, 1992, NUCLEIC ACIDS RES, V20, P4525, DOI 10.1093/nar/20.17.4525; GILBERT DM, 1987, CELL, V50, P59, DOI 10.1016/0092-8674(87)90662-3; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; HANAUSKEABEL HM, 1994, BBA-MOL CELL RES, V1221, P115, DOI 10.1016/0167-4889(94)90003-5; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; HEINTZ NH, 1982, P NATL ACAD SCI-BIOL, V79, P4083, DOI 10.1073/pnas.79.13.4083; HEINTZ NH, 1988, MOL CELL BIOL, V8, P1923, DOI 10.1128/MCB.8.5.1923; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUI EKW, 1993, FEBS LETT, V318, P193, DOI 10.1016/0014-5793(93)80020-U; HYRIEN O, 1992, NUCLEIC ACIDS RES, V20, P1463, DOI 10.1093/nar/20.7.1463; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; Kornberg A., 1992, DNA REPLICATION; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEVENSON V, 1993, NUCLEIC ACIDS RES, V21, P3997, DOI 10.1093/nar/21.17.3997; MAHBUBANI HM, 1992, NUCLEIC ACIDS RES, V20, P1457, DOI 10.1093/nar/20.7.1457; MARRACINO RL, 1990, MOL BIOL CELL, V3, P389; MOSCA PJ, 1992, MOL CELL BIOL, V12, P4375, DOI 10.1128/MCB.12.10.4375; MUDZINSKI SP, 1993, TOXICOL APPL PHARM, V119, P166, DOI 10.1006/taap.1993.1057; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; NEWPORT J, 1989, J CELL SCI, P149; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; REICHARD P, 1978, FED PROC, V37, P9; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ JA, 1992, J CELL SCI, V103, P907; SKOOG L, 1971, EUR J BIOCHEM, V19, P81, DOI 10.1111/j.1432-1033.1971.tb01290.x; SNAPKA RM, 1991, NUCLEIC ACIDS RES, V19, P5065, DOI 10.1093/nar/19.18.5065; TAPPER DP, 1978, J MOL BIOL, V120, P401, DOI 10.1016/0022-2836(78)90427-8; TELFER JF, 1993, FEBS LETT, V329, P238, DOI 10.1016/0014-5793(93)80229-N; THOMPSON JF, 1969, ANNU REV BIOCHEM, V38, P137, DOI 10.1146/annurev.bi.38.070169.001033; TIMSON J, 1975, MUTAT RES, V32, P115, DOI 10.1016/0165-1110(75)90002-0; TOBEY RA, 1970, J CELL BIOL, V46, P151, DOI 10.1083/jcb.46.1.151; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANGH LJ, 1989, J CELL SCI, V93, P1; WATSON PA, 1991, CYTOMETRY, V12, P242, DOI 10.1002/cyto.990120306; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WOODLAND HR, 1972, BIOCHEM J, V127, P597, DOI 10.1042/bj1270597; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOSHIDA M, 1992, CANCER RES, V52, P6676	60	109	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9597	9606		10.1074/jbc.270.16.9597	http://dx.doi.org/10.1074/jbc.270.16.9597			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721891	hybrid			2022-12-25	WOS:A1995QU08900080
J	HAAS, AL; BABOSHINA, O; WILLIAMS, B; SCHWARTZ, LM				HAAS, AL; BABOSHINA, O; WILLIAMS, B; SCHWARTZ, LM			COORDINATED INDUCTION OF THE UBIQUITIN CONJUGATION PATHWAY ACCOMPANIES THE DEVELOPMENTALLY PROGRAMMED DEATH OF INSECT SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; DEPENDENT PROTEOLYSIS; DEGRADATION SIGNAL; ALZHEIMERS-DISEASE; PROTEIN; APOPTOSIS; ATP; LOCALIZATION; SYSTEM; GENE	The developmentally programmed cell death of abdominal intersegmental muscles in the tobacco hawkmoth Manduca sexta is coincident with a 10-fold induction of the polyubiquitin gene as a hormonally regulated event (Schwartz, L. M., Myer, A., Kosz, L., Engelstein, M., and Maier, C. (1990) Neuron 5, 411-419), Solid phase immunochemical assays measuring intersegmental muscle pools of free and conjugated ubiquitin reveal that the induction of polyubiquitin mRNA is accompanied by a proportional increase in total ubiquitin polypeptide, Ubiquitin conjugate pools increase 10-fold at eclosion, during which loss of muscle protein mass is maximum, A smaller but measurable increase in ubiquitin conjugates is observed earlier in pupal development coincident with a modest enhanced degradation of myofibrillar proteins, Accumulation of ubiquitin conjugates is accompanied by induction in the pathway for polypeptide ligation, including the activating enzyme (E1), several carrier protein (E2) isoforms, and ubiquitin:protein isopeptide ligase (E3), Both accumulation of ubiquitin polypeptide and the enzymes of the conjugation pathway are subject to regulation by declining titers of the insect molting hormone 20-hydroxyecdysone, which signals onset of programmed cell death in the intersegmental muscles, Thus, programmed cell death within the intersegmental muscles is accomplished in part by stimulation of the ubiquitin-mediated degradative pathway through a coordinated induction of ubiquitin and the enzymes responsible for its conjugation to yield proteolytic intermediates, This suggests enzymes required for ubiquitin conjugation may represent additional genes recruited for developmentally programmed death.	UNIV MASSACHUSETTS,DEPT BIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst	HAAS, AL (corresponding author), MED COLL WISCONSIN,DEPT BIOCHEM,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226, USA.		Williams, Bart/A-3539-2013	Williams, Bart/0000-0002-5261-5301	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040458, R01GM034009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K04AG000492] Funding Source: NIH RePORTER; NIA NIH HHS [AG00492] Funding Source: Medline; NIGMS NIH HHS [GM34009, GM40458] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; D'MELLO SR, 1993, NEUROREPORT, V4, P355, DOI 10.1097/00001756-199304000-00003; DELIC J, 1993, MOL CELL BIOL, V13, P4875, DOI 10.1128/MCB.13.8.4875; DUNTEN RL, 1991, J BIOL CHEM, V266, P3260; FAHRBACH SE, 1994, J COMP NEUROL, V343, P464, DOI 10.1002/cne.903430309; FINLAYSON LH, 1956, Q J MICROSC SCI, V97, P215; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GREGORI L, 1987, J BIOL CHEM, V262, P2562; HAAS AL, 1985, J BIOL CHEM, V260, P4694; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1987, J BIOL CHEM, V262, P345; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HAAS AL, 1988, CURRENT COMMUNICATIO, P178; HAAS AL, 1988, UBIQUITIN, P173; HAYASHI T, 1992, J NEUROSCI RES, V31, P561, DOI 10.1002/jnr.490310321; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; KATO H, 1993, BRAIN RES, V619, P339, DOI 10.1016/0006-8993(93)91631-2; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; LAUZON RJ, 1993, CELL TISSUE RES, V272, P115, DOI 10.1007/BF00323577; LOCKSHIN RA, 1969, J INSECT PHYSIOL, V15, P1505, DOI 10.1016/0022-1910(69)90172-3; LOCKSHIN RICHARD A., 1965, J INSECT PHYSIOL, V11, P123, DOI 10.1016/0022-1910(65)90099-5; LOWE J, 1988, J PATHOL, V155, P9, DOI 10.1002/path.1711550105; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN DP, 1992, J NEUROBIOL, V23, P1205, DOI 10.1002/neu.480230911; MAYER RJ, 1991, BIOCHIM BIOPHYS ACTA, V1089, P141, DOI 10.1016/0167-4781(91)90002-4; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1989, ARCH BIOCHEM BIOPHYS, V272, P114, DOI 10.1016/0003-9861(89)90201-4; PICKART CM, 1991, DEV GROWTH DIFFER, V33, P587; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RILEY DA, 1988, J HISTOCHEM CYTOCHEM, V36, P621, DOI 10.1177/36.6.2835410; Schueler P A, 1988, J Chem Neuroanat, V1, P165; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SCHWARTZ LM, 1993, DEV BIOL, V158, P448, DOI 10.1006/dbio.1993.1202; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SCHWARTZ LM, 1983, DEV BIOL, V99, P103, DOI 10.1016/0012-1606(83)90257-9; SCHWARTZ LM, 1990, NEURON, V5, P411, DOI 10.1016/0896-6273(90)90080-Y; SCHWARTZ LM, 1982, J NEUROBIOL, V23, P1312; SUN DH, 1995, J NEUROBIOL, V26, P119, DOI 10.1002/neu.480260110; TABATON M, 1991, P NATL ACAD SCI USA, V88, P2098, DOI 10.1073/pnas.88.6.2098; WIGHTMAN G, 1992, NEUROSCI LETT, V139, P269, DOI 10.1016/0304-3940(92)90569-S; WING SS, 1993, AM J PHYSIOL, V264, pE668, DOI 10.1152/ajpendo.1993.264.4.E668; WOLFF T, 1991, DEVELOPMENT, V113, P825; YEE WM, 1993, EXP BRAIN RES, V94, P193	56	119	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9407	9412		10.1074/jbc.270.16.9407	http://dx.doi.org/10.1074/jbc.270.16.9407			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721865	hybrid			2022-12-25	WOS:A1995QU08900054
J	MICHELOTTI, EF; TOMONAGA, T; KRUTZSCH, H; LEVENS, D				MICHELOTTI, EF; TOMONAGA, T; KRUTZSCH, H; LEVENS, D			CELLULAR NUCLEIC-ACID BINDING-PROTEIN REGULATES THE CT ELEMENT OF THE HUMAN C-MYC PROTOONCOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEIN; CHROMATIN STRUCTURE; GROWTH-FACTOR; K-PROTEIN; GENE; EXPRESSION; TRANSCRIPTION; RIBONUCLEOPROTEIN; REGION; CELLS	The CT element of the c-myc gene is required for promoter P1 usage and can drive expression of a heterologous promoter, Both double strand (Sp1) and single strand (hnRNP K) CT-binding proteins have been implicated as mediators of CT action, Although significant levels of CT activity persisted following Sp1 immunodepletion, EGTA totally abolished transactivation, thus implicating another metal requiring factor in CT element activity, As hnRNP K binds to one strand of the CT element, but has no metal requirement, the opposite (purine-rich strand) was examined as a target for a met al-dependent protein, A zinc-requiring purine strand binding activity was identified as cellular nucleic acid binding protein (CNBP), a protein previously implicated in the regulation of sterol responsive genes. Two forms of CNBP differed in their relative binding to the CT- or sterol-response elements, CNBP was shown to be a bona fide regulator of the CT element by cotransfection of a CNBP expression vector that stimulated expression of a CT-driven but not an AP1-dependent reporter. These data suggest that hnRNP K and CNBP bind to opposite strands and co-regulate the CT element.	NCI,DEPT PATHOL,PATHOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Levens, David/C-9216-2009	Levens, David/0000-0002-7616-922X				COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COONEY M, 1989, SCIENCE, V241, P456; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KRUTZSCH HC, 1993, ANAL BIOCHEM, V209, P109, DOI 10.1006/abio.1993.1089; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	29	212	212	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9494	9499		10.1074/jbc.270.16.9494	http://dx.doi.org/10.1074/jbc.270.16.9494			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721877	hybrid			2022-12-25	WOS:A1995QU08900066
J	OLIVARES, L; ARAGON, C; GIMENEZ, C; ZAFRA, F				OLIVARES, L; ARAGON, C; GIMENEZ, C; ZAFRA, F			THE ROLE OF N-GLYCOSYLATION IN THE TARGETING AND ACTIVITY OF THE GLYT1 GLYCINE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE DOPAMINE TRANSPORTER; NA+ GLUCOSE COTRANSPORTER; CENTRAL-NERVOUS-SYSTEM; BRUSH-BORDER MEMBRANE; HIGH AFFINITY UPTAKE; RAT-BRAIN; SPINAL-CORD; FUNCTIONAL-CHARACTERIZATION; LINKED OLIGOSACCHARIDES; SEROTONIN TRANSPORTER	To elucidate the role of N-glycosylation in the function of the high affinity glycine transporter GLYT1, we have investigated the effect of the glycosylation inhibitor tunicamycin as well as the effect of the disruption of the putative glycosylation sites by site-directed mutagenesis, SDS-polyacrylamide gel electrophoresis of proteins from GLYT1-transfected COS cells reveals a major band of 80-100 kDa and a minor one of 57 kDa, Treatment with tunicamycin produces a 40% inhibition in transport activity and a decrease in the intensity of the 80-100-kDa band, whereas the 57-kDa band decreases in size to yield a 47-kDa protein corresponding to the unglycosylated form of the transporter, Simultaneous mutation of Asn-169, Asn-172, Asn-182, and Asn-188 to Gln also produces the 47-kDa form of the protein, indicating that there are no additional sites for N-glycosylation, Progressive mutation of the potential glycosylation sites produces a progressive decrease in transport activity and in size of the protein, indicating that the four putative glycosylation sites are actually glycosylated. N-Glycosylation of the GLYT1 is not indispensable for the transport activity itself, as demonstrated by enzymatic deglycosylation of the transporter, Analysis of surface proteins by biotinylation and by immunofluorescence demonstrates that a significant portion of the unglycosylated GLYT1 mutant remains in the intracellular compartment, This suggests that the carbohydrate moiety of glycine transporter GLYT1 is necessary for the proper trafficking of the protein to the plasma membrane.	UNIV AUTONOMA MADRID,FAC CIENCIAS,CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Aragon, Carmen/K-9783-2014; Gimenez, Cecilio/K-8027-2014; Zafra, Francisco/A-6121-2008	Aragon, Carmen/0000-0001-8287-9386; Gimenez, Cecilio/0000-0001-6726-8405; Zafra, Francisco/0000-0003-3801-3109				ASANO T, 1991, J BIOL CHEM, V266, P24632; ASANO T, 1993, FEBS LETT, V324, P258, DOI 10.1016/0014-5793(93)80129-I; BALCAR VJ, 1973, J NEUROCHEM, V20, P529, DOI 10.1111/j.1471-4159.1973.tb12152.x; BENNETT JP, 1973, J NEUROCHEM, V21, P1533, DOI 10.1111/j.1471-4159.1973.tb06037.x; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BOROWSKY B, 1993, NEURON, V10, P851, DOI 10.1016/0896-6273(93)90201-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASADO M, 1993, J BIOL CHEM, V268, P27313; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; FEDELE E, 1992, BRAIN RES, V572, P154, DOI 10.1016/0006-8993(92)90464-K; FEUGEAS JP, 1990, BIOCHIM BIOPHYS ACTA, V1030, P60, DOI 10.1016/0005-2736(90)90238-J; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAYES G, 1994, J BIOL CHEM, V269, P24143; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; HENN FA, 1971, P NATL ACAD SCI USA, V68, P2686, DOI 10.1073/pnas.68.11.2686; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HIRAYAMA BA, 1992, BIOCHIM BIOPHYS ACTA, V1103, P37, DOI 10.1016/0005-2736(92)90054-P; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; JOHNSTON GA, 1971, J NEUROCHEM, V18, P1951, DOI 10.1111/j.1471-4159.1971.tb09601.x; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KEINAN S, 1992, BIOCHEMISTRY-US, V31, P1974; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KIM KM, 1994, MOL PHARMACOL, V45, P608; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; LEW R, 1992, BRAIN RES, V584, P266, DOI 10.1016/0006-8993(92)90905-O; LIU QR, 1993, J BIOL CHEM, V268, P22802; LIU QR, 1993, J BIOL CHEM, V268, P2106; LIU QR, 1992, P NATL ACAD SCI USA, V89, P6639, DOI 10.1073/pnas.89.14.6639; LOGAN WJ, 1972, BRAIN RES, V42, P413, DOI 10.1016/0006-8993(72)90540-9; LOPEZCORCUERA B, 1992, J BIOL CHEM, V267, P17491; LOPEZCORCUERA B, 1991, J BIOL CHEM, V266, P24809; LOPEZCORCUERA B, 1989, EUR J BIOCHEM, V181, P519, DOI 10.1111/j.1432-1033.1989.tb14754.x; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; NUNEZ E, 1994, J BIOL CHEM, V269, P16920; OLIVARES L, 1994, J BIOL CHEM, V269, P28400; OTT RJ, 1992, J BIOL CHEM, V267, P133; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PATEL A, 1993, J NEUROCHEM, V61, P496; PETERSON GL, 1977, ANAL BIOCHEM, V83, P246; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; RADIAN R, 1986, J BIOL CHEM, V261, P5437; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; Schousboe A, 1981, Int Rev Neurobiol, V22, P1, DOI 10.1016/S0074-7742(08)60289-5; SERSHEN H, 1979, J NEUROCHEM, V32, P719, DOI 10.1111/j.1471-4159.1979.tb04554.x; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TATE CG, 1994, J BIOL CHEM, V269, P26303; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P8230; YUSUFI ANK, 1988, J BIOL CHEM, V263, P13683; ZAFRA F, 1986, BRAIN RES, V397, P108, DOI 10.1016/0006-8993(86)91374-0; ZAFRA F, 1995, IN PRESS J NEUROSCI	61	90	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9437	9442		10.1074/jbc.270.16.9437	http://dx.doi.org/10.1074/jbc.270.16.9437			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721869	hybrid			2022-12-25	WOS:A1995QU08900058
J	REDDY, LG; JONES, LR; CALA, SE; OBRIAN, JJ; TATULIAN, SA; STOKES, DL				REDDY, LG; JONES, LR; CALA, SE; OBRIAN, JJ; TATULIAN, SA; STOKES, DL			FUNCTIONAL RECONSTITUTION OF RECOMBINANT PHOSPHOLAMBAN WITH RABBIT SKELETAL CA2+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; 3'-5'-MONOPHOSPHATE-DEPENDENT PROTEIN KINASE; PUMP ATPASE; MONOCLONAL-ANTIBODY; CALCIUM-TRANSPORT; CA-2+ PUMP; PHOSPHORYLATION; CA2+; SLOW; PURIFICATION	Phospholamban (PLB) is a small, transmembrane protein that resides in the cardiac sarcoplasmic reticulum (SR) and regulates the activity of Ca2+-ATPase in response to P-adrenergic stimulation. We have used the baculovirus expression system in Sf21 cells to express milligram quantities of wild-type PLB. After purification by antibody affinity chromatography, the function of this recombinant PLB was tested by reconstitution with Ca2+-ATPase purified from skeletal SR. The results obtained with recombinant PLB were indistinguishable from those obtained with purified, canine cardiac PLB. In particular, PLB reduced the apparent calcium affinity of Ca2+-ATPase but had no effect on V-max. At pCa 6.8, PLB inhibited both calcium uptake and ATPase activity of Ca2+-ATPase by 50%. This inhibition was fully reversed by addition of a monoclonal antibody to PLB, which mimics the physiological effects of PLB phosphorylation. Maximal PLB regulatory effects occurred at a molar stoichiometry of similar to 3:1, PLB/Ca2+-ATPase. We also investigated peptides corresponding to the two main domains of PLB. The membrane-spanning domain, PLB(26-52), appeared to uncouple ATPase hydrolysis from calcium transport, even though the permeability of the reconstituted vesicles was not altered. The cytoplasmic peptide, PLB(1-31), had little effect, even at a 300:1 molar excess over Ca2+-ATPase.	INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,DEPT MED,INDIANAPOLIS,IN 46202; UNIV VIRGINIA,HLTH SCI CTR,DEPT MOLEC PHYSIOL & BIOL PHYS,CHARLOTTESVILLE,VA 22908; DUPONT MERCK PHARMACEUT CO,WILMINGTON,DE 19806	Indiana University System; Indiana University-Purdue University Indianapolis; University of Virginia; DuPont					NHLBI NIH HHS [HL49428, HL06308, HL48807] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049428, P01HL048807, R37HL049428] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; CALA SE, 1993, BIOPHYS J, V64, pA375; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; COLYER J, 1993, CARDIOVASC RES, V27, P1766, DOI 10.1093/cvr/27.10.1766; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUJII J, 1989, J BIOL CHEM, V264, P12950; FUJII J, 1987, J CLIN INVEST, V79, P301, DOI 10.1172/JCI112799; FUJII J, 1990, FEBS LETT, V273, P232, DOI 10.1016/0014-5793(90)81092-3; HARLOW E, 1988, ANTIBODIES LABORATOR; HUGHES G, 1994, BIOCHEM J, V303, P511, DOI 10.1042/bj3030511; JAKAB G, 1988, BIOCHEMISTRY-US, V27, P3799, DOI 10.1021/bi00410a042; JONES LR, 1993, J BIOL CHEM, V268, P11486; JONES LR, 1985, J BIOL CHEM, V260, P7721; JORGENSEN AO, 1986, J BIOL CHEM, V261, P3775; KIM HW, 1990, J BIOL CHEM, V265, P1702; KIMURA Y, 1991, J MOL CELL CARDIOL, V23, P1223, DOI 10.1016/0022-2828(91)90080-6; KIRCHBERGER MA, 1976, J BIOL CHEM, V251, P725; KOVACS RJ, 1988, J BIOL CHEM, V263, P18364; KRANIAS EG, 1985, J BIOL CHEM, V260, P1006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEVIN D, 1990, J VIROL, V64, P37; LEVY D, 1990, BIOCHIM BIOPHYS ACTA, V1025, P179, DOI 10.1016/0005-2736(90)90096-7; LEVY D, 1990, BIOCHEMISTRY-US, V29, P9480, DOI 10.1021/bi00492a022; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; MANNS A, 1991, BIOTECHNIQUES, V10, P154; MARTONOSI A, 1964, J BIOL CHEM, V239, P648; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; RAEYMAEKERS L, 1990, CELL CALCIUM, V11, P261, DOI 10.1016/0143-4160(90)90002-C; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; STOKES DL, 1990, BIOPHYS J, V57, P1, DOI 10.1016/S0006-3495(90)82501-7; SZYMANSKA G, 1990, MEMBRANE BIOCHEM, V9, P1; TADA M, 1989, BIOESSAYS, V10, P157, DOI 10.1002/bies.950100505; TADA M, 1974, J BIOL CHEM, V249, P6174; TATULIAN SA, 1995, IN PRESS BIOCHEMISTR; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; VORHERR T, 1993, PROTEIN SCI, V2, P339; VORHERR T, 1992, BIOCHEMISTRY-US, V31, P371, DOI 10.1021/bi00117a009; VOSS J, 1994, BIOPHYS J, V67, P1900; WEGENER AD, 1984, J BIOL CHEM, V259, P1834	48	100	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9390	9397		10.1074/jbc.270.16.9390	http://dx.doi.org/10.1074/jbc.270.16.9390			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721863	hybrid			2022-12-25	WOS:A1995QU08900052
J	WATSON, A; LATCHMAN, D				WATSON, A; LATCHMAN, D			THE CYCLIC-AMP RESPONSE ELEMENT IN THE CALCITONIN CALCITONIN-GENE-RELATED PEPTIDE GENE PROMOTER IS NECESSARY BUT NOT SUFFICIENT FOR ITS ACTIVATION BY NERVE GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT SENSORY NEURONS; FACTOR REGULATES EXPRESSION; CAT-REPORTER GENE; PC12 CELLS; C-FOS; TRANSCRIPTION; PROTEIN; BINDING; CREB; PHOSPHORYLATION	The gene encoding calcitonin gene related peptide (CGRP) is inducible by nerve growth factor (NGF) in primary dorsal root ganglion neurons. By transfecting these primary neurons, we have defined a region of the CGRP promoter from -140 to -72 relative to the transcriptional start site which is essential for its inducibility by NGF as well as by cyclic AMP and which can confer these responses on a heterologous promoter. A cyclic AMP response element (CRE) within this region is essential for both these responses which are abolished by site directed mutagenesis of this element. In contrast to the intact fragment the isolated CRE can confer responsiveness to cyclic AMP but not NGF on a heterologous promoter. The reasons for the different role of the CRE in the response of the CGRP promoter to cyclic AMP and NGF are discussed.	UCL, SCH MED, DEPT MOLEC PATHOL, LONDON W1P 6DB, ENGLAND	University of London; University College London; UCL Medical School								ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DONG YH, 1993, NUCLEIC ACIDS RES, V21, P771, DOI 10.1093/nar/21.3.771; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; GABELLINI N, 1992, J CELL BIOL, V118, P131, DOI 10.1083/jcb.118.1.131; GALLI E, 1994, J BIOL CHEM, V269, P17359; GILCHRIST CA, 1992, BIOCHEM BIOPH RES CO, V187, P1395, DOI 10.1016/0006-291X(92)90457-V; GILCHRIST CA, 1991, DNA CELL BIOL, V10, P743, DOI 10.1089/dna.1991.10.743; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; KENDALL G, 1994, MOL BRAIN RES, V25, P73, DOI 10.1016/0169-328X(94)90280-1; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; Levi-Montalcini R, 1976, Prog Brain Res, V45, P235, DOI 10.1016/S0079-6123(08)60993-0; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LINDSAY RM, 1990, EUR J NEUROSCI, V2, P389, DOI 10.1111/j.1460-9568.1990.tb00431.x; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; Lo D C, 1992, Curr Opin Neurobiol, V2, P336, DOI 10.1016/0959-4388(92)90125-5; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MILLBRANDT J, 1987, SCIENCE, V238, P797; MILLBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789; MILLBRANDT J, 1988, NEURON, V1, P183; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; SYMES AJ, 1992, FEBS LETT, V306, P229, DOI 10.1016/0014-5793(92)81006-8; WATSON A, 1995, INP RESS EUR J NERUO; WINTER J, 1988, NEURON, V1, P973, DOI 10.1016/0896-6273(88)90154-7; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	38	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9655	9660		10.1074/jbc.270.16.9655	http://dx.doi.org/10.1074/jbc.270.16.9655			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721899	hybrid			2022-12-25	WOS:A1995QU08900088
J	HAUPT, Y; ROWAN, S; OREN, M				HAUPT, Y; ROWAN, S; OREN, M			P53-MEDIATED APOPTOSIS IN HELA-CELLS CAN BE OVERCOME BY EXCESS PRB	ONCOGENE			English	Article						P53; APOPTOSIS; PRB; TUNEL; TUMOR SUPPRESSION	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; TUMOR-SUPPRESSOR GENE; DNA-DAMAGING AGENTS; CYCLE CONTROL; GROWTH SUPPRESSION; PROTEIN; DEATH; IDENTIFICATION	Studies on DNA tumor viruses have suggested a link between p53 and pRB in the control of cell growth and apoptosis. We examined the role of pRB in the control of p53-mediated apoptosis in HeLa cells, in which the activities of p53 and members of the pRB family are very low, Transient overexpression of wild type (wt) p53 in HeLa cells induced apoptotic cell death. Importantly, coexpression of functional pRB resulted in significant protection of HeLa cells from p53-mediated apoptosis, without interfering with the transcriptional activity of wt p53. These results suggest that pRB, and possibly other pRB-related proteins, play a major role in the decision of whether cells respond to activated p53 by undergoing growth arrest or apoptosis. Our findings demonstrate a direct link between these two tumor suppressors in the control of cell growth and cell death.			HAUPT, Y (corresponding author), WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL.		Rowan, Sheldon/AAA-3271-2019	Rowan, Sheldon/0000-0002-1123-6743	NCI NIH HHS [R01 CA 4009] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BERNS A, 1994, CURR BIOL, V4, P137, DOI 10.1016/S0960-9822(94)00031-X; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FANNING E, 1992, MALIGNANT TRANSFORMA, P1; Farthing Alan J., 1994, Trends in Microbiology, V2, P170, DOI 10.1016/0966-842X(94)90667-X; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1991, NATURE, V349, P802; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORCZYCA W, 1993, CANCER RES, V53, P1945; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHAELMICHALOV.D, 1991, J VIROL, V65, P4160; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OREN M, 1994, CANCER BIOL, V5, P1; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STRATTON MR, 1990, ONCOGENE, V5, P1297; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VOGELSTEIN B, 1994, NATURE, V370, P174, DOI 10.1038/370174a0; VOUDSEN KH, 1993, ONCOGENE, V8, P1697; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; YONISHROUACH E, 1993, PROGRAMMED CELL DEAT, P187; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	79	157	158	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1563	1571						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731711				2022-12-25	WOS:A1995QU68100012
J	SHAOUL, E; REICHSLOTKY, R; BERMAN, B; RON, D				SHAOUL, E; REICHSLOTKY, R; BERMAN, B; RON, D			FIBROBLAST GROWTH-FACTOR RECEPTORS DISPLAY BOTH COMMON AND DISTINCT SIGNALING PATHWAYS	ONCOGENE			English	Article						FGF RECEPTORS SIGNALING; PROLIFERATION; LIGAND DEPENDENT TRANSFORMATION; TYROSINE PHOSPHORYLATION; KGF; AFGF	HIGH-AFFINITY RECEPTOR; FGF RECEPTOR; EXPRESSION PATTERN; TYROSINE KINASE; FACTOR FAMILY; CDNA CLONING; GENE FAMILY; BINDING; HEPARIN; MOUSE	We compared the mitogenic and signaling pathways of three Fibroblast Growth Factor Receptors (FGFRs), FGFR1, KGFR and FGFR4 in the same cell line. Each receptor was expressed in L6E9 rat myoblasts that do not normally express detectable levels of FGFRs and clones that express comparable levels of each receptor were selected. Our results show that FGFs induce an effective survival and growth of FGFR1 and KGFR expressing cells. In addition, these cells exhibit a morphology that is reminiscent of that of malignantly transformed cells and display anchorage independent growth in a ligand dependent manner. Unlike KGFR and FGFR1, FGFR4 mediates a less effective growth, and cells overexpressing this receptor do not undergo any morphological changes nor do they display an anchorage independent growth in response to FGFs, All three receptors exhibit both quantitative and qualitative differences in their ability to induce tyrosine phosphorylation of cellular substrates, Both FGFR1 and KGFR induce strong phosphorylation of phospholipase C-gamma and a 90 kDa protein, while FGFR4 induces a relatively weak phosphorylation of phospholipase C-gamma and completely fails to induce phosphorylation of the 90 kDa. The three receptors also induce phosphorylation of the mitogen activated protein kinases (MAPK) but the effect of FGFR1 is far stronger than that of the other two receptors, Since FGFR4 is expressed in myoblasts in vivo, we examined whether this receptor can function in the differentiation pathway of myoblasts. Contrary to its weak mitogenic activity, FGFR4 effectively mediates the inhibition of myogenic differentiation in L6E9 cells and also suppresses the expression of the myogenic regulatory protein myogenin, Taken together, our results suggest that the signaling mechanism of FGFR4 differs from that of FGFR1 and KGFR, and that the primary role of FGFR4 in myoblasts may be the maintenance of their non differentiated state.	TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL	Technion Israel Institute of Technology								ARNAUD PC, 1991, ONCOGENE, V6, P979; AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; EISEMANN A, 1991, ONCOGENE, V6, P1195; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GINARD BN, 1978, CELL, V15, P855; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOSPODAROWICZ D, 1975, J BIOL CHEM, V250, P2515; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOUHARA H, 1994, ONCOGENE, V9, P455; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1992, P NATL ACAD SCI USA, V89, P3315, DOI 10.1073/pnas.89.8.3315; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARICS I, 1989, ONCOGENE, V4, P335; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PAWSON T, 1993, DEV GENET, V14, P333, DOI 10.1002/dvg.1020140502; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; REICHSLOTKY R, 1994, J BIOL CHEM, V269, P32279; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RON D, 1993, J BIOL CHEM, V268, P2984; RON D, 1993, J BIOL CHEM, V268, P5388; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEED J, 1988, DEV BIOL, V128, P40, DOI 10.1016/0012-1606(88)90264-3; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STARK KL, 1991, DEVELOPMENT, V113, P641; STOCKDALE FE, 1992, DEV BIOL, V154, P284, DOI 10.1016/0012-1606(92)90068-R; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TEMPLETON TJ, 1992, DEV BIOL, V154, P169, DOI 10.1016/0012-1606(92)90057-N; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	64	118	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1553	1561						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731710				2022-12-25	WOS:A1995QU68100011
J	CHOUDHARY, SK; WYKES, SM; KRAMER, JA; MOHAMED, AN; KOPPITCH, F; NELSON, JE; KRAWETZ, SA				CHOUDHARY, SK; WYKES, SM; KRAMER, JA; MOHAMED, AN; KOPPITCH, F; NELSON, JE; KRAWETZ, SA			A HAPLOID EXPRESSED GENE-CLUSTER EXISTS AS A SINGLE CHROMATIN DOMAIN IN HUMAN SPERM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN GENE; BASIC NUCLEAR-PROTEIN; I-SENSITIVE DOMAIN; TRANSGENIC MICE; SEQUENCE; LOCUS; TRANSCRIPTION; PROTAMINE-1; EVOLUTION; REGION	Mammalian spermiogenesis is marked by the initial disruption of the nuclear-histone-DNA complex by the transition proteins for ultimate replacement with protamines. The genes for three of these low molecular weight basic nuclear proteins exist as a single linear array of PRM1, PRM2, and TNP2 on human chromosome 16p13.2. To begin to address the mechanism governing their transcriptional potentiation, a region of similar to 40 kilobases of the human genome encompassing these genes was introduced into the germ line of mice. Fluorescence in situ hybridization and Southern analysis showed that this segment of the human genome integrated into independent chromosomal sites while maintaining its fidelity. Transcript analysis demonstrated that the expression of the endogenous mouse protamine Prm1 and Prm2 genes as well as the mouse transition protein Tnp2 gene were expressed along with their human transgene counterparts. The pattern of expression of these transgenic human genes within this multigenic cluster faithfully represented that observed in vivo. In addition, all members of this transgenic gene cluster were expressed in proportions similar to those in human testis. Copy number-dependent and position-independent expression of the transgenic construct demonstrated that the corresponding biological locus was contained within this segment of the human genome. Furthermore, DNase I sensitivity established that in sperm the human PRM1-->PRM2-->TNP2 genic domain was contained as an similar to 28.5-kilobase contiguous segment bounded by an array of nuclear matrix associated topoisomerase II consensus sites. This is the first description of a multigenic male gamete-specific domain as a fundamental gene regulatory unit. A model of haploid-specific gene determination is presented.	WAYNE STATE UNIV, SCH MED, DEPT OBSTET & GYNECOL, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, CTR MOLEC MED & GENET, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, CTR HUMAN GROWTH & DEV, DETROIT, MI 48201 USA; HARPER GRACE HOSP, DEPT PATHOL, DETROIT, MI 48201 USA	Wayne State University; Wayne State University; Wayne State University			krawetz, stephen/GQQ-3308-2022		NICHD NIH HHS [1RO1HD285040A1, N01-HD-0-2911] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028504, N01HD002911] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARONE JG, 1994, J ANDROL, V15, P139; BEHRINGER RR, 1988, P NATL ACAD SCI USA, V85, P2648, DOI 10.1073/pnas.85.8.2648; BEISEL J, 1991, ACT CYTOGENETICS LAB, P183; BOULIKAS T, 1993, J CELL BIOCHEM, V53, P1, DOI 10.1002/jcb.240530102; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; BRITTEN RJ, 1969, SCIENCE, V165, P349, DOI 10.1126/science.165.3891.349; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIXON GH, 1986, CHROMOSOMAL PROTEINS, P287; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P113; GATEWOOD JM, 1987, SCIENCE, V236, P962, DOI 10.1126/science.3576213; GOUDINE M, 1983, P NATL ACAD SCI USA, V80, P7551; GRIMES SR, 1975, BIOCHEM BIOPH RES CO, V67, P182, DOI 10.1016/0006-291X(75)90300-9; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HOGANB, 1986, MANIPULATING MOUSE E, P174; JANTZEN K, 1986, NUCLEIC ACIDS RES, V14, P6085, DOI 10.1093/nar/14.15.6085; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P10618, DOI 10.1073/pnas.89.22.10618; KRAWETZ SA, 1988, J MOL EVOL, V27, P291, DOI 10.1007/BF02101190; LAWSON GM, 1982, J BIOL CHEM, V257, P1501; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEVYWILSON B, 1989, J BIOL CHEM, V264, P21196; LIN CC, 1975, CAN J GENET CYTOL, V17, P81, DOI 10.1139/g75-009; MCCARREY JR, 1992, DEV BIOL, V154, P160, DOI 10.1016/0012-1606(92)90056-M; Meistrich M., 1989, HISTONES OTHER BASIC, P165; NELSON JE, 1993, J BIOL CHEM, V268, P2932; NELSON JE, 1994, J BIOL CHEM, V269, P31067; NELSON JE, 1995, DNA SEQUENCE, V5, P163, DOI 10.3109/10425179509029356; OLIVA R, 1990, J MOL EVOL, V30, P333, DOI 10.1007/BF02101888; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; PESCHON JJ, 1989, ANN NY ACAD SCI, V564, P186, DOI 10.1111/j.1749-6632.1989.tb25897.x; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; QUERALT R, 1993, GENE, V133, P197, DOI 10.1016/0378-1119(93)90638-J; RASSOULZADEGAN M, 1993, CELL, V75, P997, DOI 10.1016/0092-8674(93)90543-Y; SCHULTER G, 1989, BIOCHEM BIOPH RES CO, V197, P110; SELLOS D, 1990, EUR J BIOCHEM, V190, P21, DOI 10.1111/j.1432-1033.1990.tb15540.x; SIPPEL AE, 1993, COLD SPRING HARB SYM, V58, P37, DOI 10.1101/SQB.1993.058.01.007; SMITH RD, 1984, BIOCHEMISTRY-US, V23, P2970, DOI 10.1021/bi00308a019; STEWART TA, 1988, MOL CELL BIOL, V8, P1748, DOI 10.1128/MCB.8.4.1748; SVINARICH DM, 1992, J BIOL CHEM, V267, P14382; TOMILIN NV, 1990, FEBS LETT, V263, P69, DOI 10.1016/0014-5793(90)80707-P; UNNI E, 1992, J BIOL CHEM, V267, P25359; VOGELSTEIN B, 1980, CELL, V22, P79, DOI 10.1016/0092-8674(80)90156-7; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WU J, 1990, MOL CELL BIOL, V10, P1209, DOI 10.1128/MCB.10.3.1209; ZAMBROWICZ BP, 1994, BIOL REPROD, V50, P65, DOI 10.1095/biolreprod50.1.65; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071	51	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8755	8762		10.1074/jbc.270.15.8755	http://dx.doi.org/10.1074/jbc.270.15.8755			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721781	hybrid			2022-12-25	WOS:A1995QT44800059
J	MEZGUELDI, M; MENDRE, C; CALAS, B; KASSAB, R; FATTOUM, A				MEZGUELDI, M; MENDRE, C; CALAS, B; KASSAB, R; FATTOUM, A			CHARACTERIZATION OF THE REGULATORY DOMAIN OF GIZZARD CALPONIN - INTERACTIONS OF THE 145-163-REGION WITH F-ACTIN, CALCIUM-BINDING PROTEINS, AND TROPOMYOSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALPONIN; CALMODULIN-BINDING; FUNCTIONAL DOMAINS; TROPONIN-T; KINASE-C; CALDESMON; INHIBITION; PURIFICATION; PHOSPHATASE; SEQUENCE	Earlier, we proposed that the interaction of gizzard calponin with F-actin, promoting the inhibition of the actomyosin ATPase activity, involves the NH2-terminal portion of the calponin segment Ala(145)-Tyr(182) (Mezgueldi, M., Fattoum, A., Derancourt, J., and Kassab, R. (1992) J. Biol. Chem. 267, 15943-15951), In this work, we have directly probed this region for actin binding sites using five peptide analogs covering different stretches of the sequence Thr(133)-Ile(163). Co-sedimentation with F-actin, actomyosin ATPase measurements, and zero-length cross-linking reactions demonstrated that the 19-residue sequence Ala(145)-Ile(163) is essential for actin interaction and ATPase inhibition, Furthermore, each peptide was tested for binding to the Ca2+-dependent proteins, caltropin and calmodulin, in both an actomyosin ATPase assay and an affinity chromatographic assay, The results revealed the Ii-residue segment Gln(153)-Ile(163), representing the COOH-terminal moiety of the F-actin binding sequence, as a crucial region for the high affinity binding of these regulatory proteins with concomitant removal of the ATPase inhibition, The 153-163 stretch contained also interactive sites for tropomyosin as assessed by affinity chromatography and spectrofluorometry. Collectively, the data support our initial results and highlight the ability of the multifunctional 145-163 region to serve as a potent regulatory domain of the smooth muscle calponin.	UNIV MONTPELLIER 1,CNRS,CTR RECH BIOCHIM MACROMOLEC,INSERM,U249,F-34033 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier								ABE M, 1990, J BIOCHEM-TOKYO, V108, P835, DOI 10.1093/oxfordjournals.jbchem.a123289; APPLEGATE D, 1994, J BIOL CHEM, V269, P10683; CHILDS TJ, 1992, BIOCHIM BIOPHYS ACTA, V1121, P41, DOI 10.1016/0167-4838(92)90334-A; DEARRUDA MV, 1992, J BIOL CHEM, V267, P13079; FUJII T, 1994, J BIOCHEM-TOKYO, V116, P121, DOI 10.1093/oxfordjournals.jbchem.a124484; FUJII T, 1991, CHEM PHARM BULL, V39, P2622; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GONG BJ, 1993, J BIOCHEM-TOKYO, V114, P453, DOI 10.1093/oxfordjournals.jbchem.a124197; HAEBERLE JR, 1994, J BIOL CHEM, V269, P12424; HORIUCHI KY, 1991, BIOCHEM BIOPH RES CO, V176, P1487, DOI 10.1016/0006-291X(91)90455-G; ICHIKAWA K, 1993, BIOCHEM BIOPH RES CO, V193, P827, DOI 10.1006/bbrc.1993.1700; ITOH T, 1994, EUR J PHYSL, V427, P301; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SS, 1984, BIOCHEMISTRY-US, V23, P1591, DOI 10.1021/bi00303a001; Li Bing, 1994, Molecular Biology of the Cell, V5, p399A; MAKUCH R, 1991, BIOCHEM J, V280, P33, DOI 10.1042/bj2800033; MANI RS, 1990, BIOCHEMISTRY-US, V29, P1398, DOI 10.1021/bi00458a009; MARSTON SB, 1994, J BIOL CHEM, V269, P8134; MEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; MEZGUELDI M, 1994, J BIOL CHEM, V269, P12824; NAGUMO H, 1994, BIOCHEM BIOPH RES CO, V203, P1502, DOI 10.1006/bbrc.1994.2355; NAKA M, 1990, BIOCHEM BIOPH RES CO, V171, P933, DOI 10.1016/0006-291X(90)90773-G; NAKAMURA F, 1993, J BIOL CHEM, V268, P6194; NORTH AJ, 1994, J CELL SCI, V107, P437; REDWOOD CS, 1993, J BIOL CHEM, V268, P10969; Roberts G. D., 1994, Molecular Biology of the Cell, V5, p400A; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; TAKAHASHI K, 1990, J MUSCLE RES CELL M, V11, P435; TAKAHASHI K, 1986, BIOCHEM BIOPH RES CO, V141, P20, DOI 10.1016/S0006-291X(86)80328-X; TAKAHASHI K, 1988, HYPERTENSION, V11, P620, DOI 10.1161/01.HYP.11.6.620; TAKAHASHI K, 1991, J BIOL CHEM, V226, P13284; VALEMBOIS C, 1992, TETRAHEDRON LETT, V33, P4005, DOI 10.1016/0040-4039(92)88085-J; VANCOMPERNOLLE K, 1990, FEBS LETT, V274, P146, DOI 10.1016/0014-5793(90)81350-W; WILLS FL, 1993, BIOCHEMISTRY-US, V32, P2321, DOI 10.1021/bi00060a025; WILLS FL, 1994, BIOCHEMISTRY-US, V33, P5562, DOI 10.1021/bi00184a027; WILLS FL, 1994, BIOPHYS J, V66, pA198; WINDER SJ, 1993, BIOCHEM J, V296, P827, DOI 10.1042/bj2960827; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; WINDER SJ, 1992, BIOCHEM J, V286, P197, DOI 10.1042/bj2860197; WINDER SJ, 1993, BIOCHEMISTRY-US, V32, P13327, DOI 10.1021/bi00211a046; WINDER SJ, 1992, BIOCHEM J, V288, P733, DOI 10.1042/bj2880733	41	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8867	8876		10.1074/jbc.270.15.8867	http://dx.doi.org/10.1074/jbc.270.15.8867			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721794	hybrid			2022-12-25	WOS:A1995QT44800073
J	YANG, XD; FYODOROV, D; DENERIS, ES				YANG, XD; FYODOROV, D; DENERIS, ES			TRANSCRIPTIONAL ANALYSIS OF ACETYLCHOLINE-RECEPTOR ALPHA-3 GENE PROMOTER MOTIFS THAT BIND SP1 AND AP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; SODIUM-CHANNEL GENE; FUNCTIONAL DIVERSITY; REGULATORY ELEMENTS; SILENCER ELEMENT; SCG10 GENE; RAT; EXPRESSION; SUBUNIT; FAMILY	In this study, we performed an analysis of the neuronal nicotinic acetylcholine receptor alpha 3 subunit gene promoter region, -238/+47, to identify cis and trans elements that are important for basal activity in PC12 cells. Sequence analyses of the alpha 3 promoter and foot-print assays revealed an Sp1 binding site between -79 and -57 (termed the alpha 3 GA motif) and an AP2 binding site between -30 and -7. Using mobility shift analysis, we found that PC12 cell extracts contain proteins that specifically bind to the alpha 3 GA motif and are immunologically related to Sp1. Mutation of the alpha 3 GA motif, which prevented binding of Sp1, resulted in a 75% decrease in promoter activity. Mutation of the AP2 site resulted in only a minor loss of promoter activity, which is consistent with the lack of AP2 binding activity in PC12 extracts. In Drosophila Schneider line 2 (S2) cell cotransfection assays, Sp1 activated the alpha 3 promoter in a GA motif dependent manner. Furthermore, multimerization of the GA motif upstream of the beta-globin TATA box conferred Sp1 responsiveness. Our results indicate that Sp1 can activate transcription through direct interaction with the alpha 3 GA motif and that this motif plays a major role in alpha 3 promoter basal activity in PC12 cells.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT NEUROSCI,CLEVELAND,OH 44106	Case Western Reserve University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029123] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS29123] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAI G, 1993, BIOCHIM BIOPHYS ACTA, V1152, P197, DOI 10.1016/0005-2736(93)90249-Y; BESSIS A, 1993, NUCLEIC ACIDS RES, V21, P2185, DOI 10.1093/nar/21.9.2185; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; BOULTER J, 1990, J BIOL CHEM, V265, P4472; CORRIVEAU RA, 1993, J NEUROSCI, V13, P2662, DOI 10.1523/JNEUROSCI.13-06-02662.1993; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, V2, P743; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; DENERIS ES, 1991, TRENDS PHARMACOL SCI, V12, P34, DOI 10.1016/0165-6147(91)90486-C; DINELEYMILLER K, 1992, MOL BRAIN RES, V16, P339, DOI 10.1016/0169-328X(92)90244-6; DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HENSON JW, 1994, J BIOL CHEM, V269, P1046; HU MJ, 1994, J NEUROCHEM, V62, P392; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JOHNSON MR, 1992, J BIOL CHEM, V267, P12202; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KIRKNESS EF, 1993, J BIOL CHEM, V268, P4420; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; MA L, 1992, NUCLEIC ACIDS RES, V20, P217, DOI 10.1093/nar/20.2.217; MANDELZYS A, 1994, J NEUROSCI, V14, P2357; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MOTEJLEK K, 1994, J BIOL CHEM, V269, P15265; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PECORINO LT, 1991, MOL CELL BIOL, V11, P3139, DOI 10.1128/MCB.11.6.3139; RAIMONDI E, 1992, GENOMICS, V12, P849, DOI 10.1016/0888-7543(92)90324-L; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; ROGERS SW, 1992, J NEUROSCI, V12, P4611; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; VERNALLIS AB, 1993, NEURON, V10, P451, DOI 10.1016/0896-6273(93)90333-M; WADA E, 1990, BRAIN RES, V526, P45, DOI 10.1016/0006-8993(90)90248-A; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X; YANG XD, 1994, J BIOL CHEM, V269, P10252; ZHU H, 1993, MOL CELL BIOL, V13, P4432, DOI 10.1128/MCB.13.7.4432	46	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8514	8520		10.1074/jbc.270.15.8514	http://dx.doi.org/10.1074/jbc.270.15.8514			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721749	hybrid			2022-12-25	WOS:A1995QT44800025
J	BRAND, T; SCHNEIDER, MD				BRAND, T; SCHNEIDER, MD			INACTIVE TYPE-II AND TYPE-I RECEPTORS FOR TGF-BETA ARE DOMINANT INHIBITORS OF TGF-BETA-DEPENDENT TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; SERINE THREONINE KINASE; SIGNAL TRANSDUCTION; ACTIVIN RECEPTOR; XENOPUS EMBRYOS; TRANSFORMING GROWTH-FACTOR-BETA-1; CARDIAC MYOCYTES; TRANSGENIC MICE; EXPRESSION; GENE	Although transforming growth factor-beta (TGF beta) is implicated in differentiation and disease, proof of in vivo function requires specific inhibitors of the TGF beta cascade. TGF beta binds a family of type I and type II receptors (T beta RI, T beta RII), containing a cytoplasmic serine/threonine kinase domain. We previously reported that kinase-deficient T beta RII (Delta kT beta RII) blocks TGF-beta-dependent transcription in cardiac myocytes. It is controversial whether both receptors are needed in all cells for gene regulation by TGF beta or whether they mediate distinct subsets of TGF-beta-dependent events. To resolve this uncertainty, TGF-beta-dependent transcription was investigated in cardiac myocytes versus mink lung epithelial cells. 1) Delta kT beta RII inhibits induction of a TGF beta-responsive reporter gene, in both cell backgrounds. 2) Charged-to-alanine mutations of key residues of the T beta RII kinase, including consensus ATP binding and amino acid recognition motifs, are competent for binding but not transcriptional activation. Each inactive receptor inhibits TGF beta-dependent transcription in both cell types. 3) Kinase-deficient T beta RI (Delta kT beta RI) likewise impairs TGF beta-dependent transcription, less completely than Delta kT beta RII; kinase-deficient activin type I receptor has no effect. 4) TGF-beta-binding proteins in cardiac cells and Mv1Lu cells are comparable by affinity labeling and immunoprecipitation; however, Mv1Lu cells express up to 3-fold higher levels of T beta RII and T beta RI. Thus, the model inferred from TGF beta-resistant cell lines (that T beta RII and T beta RI are necessary in tandem for the TGF beta-signaling complex to regulate transcription) is valid for cardiac myocytes, the cell type most prominently affected in TGF beta-deficient animals.	BAYLOR COLL MED, DEPT MED, MOLEC CARDIOL UNIT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT PHYSIOL & MOLEC BIOPHYS, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine			Brand, Thomas/AAR-7545-2020	Brand, Thomas/0000-0001-7090-5356	NHLBI NIH HHS [P01 HL49953, R01 HL47567, T32 HL07706] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953, R01HL047567, T32HL007706] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BARNETT JV, 1994, DEV DYNAM, V199, P12, DOI 10.1002/aja.1001990103; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BASSING CH, 1994, J BIOL CHEM, V269, P14861; BRAND T, 1993, J BIOL CHEM, V268, P11500; BRANDES ME, 1991, J BIOL CHEM, V266, P19697; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; COKER KJ, 1994, P NATL ACAD SCI USA, V91, P6967, DOI 10.1073/pnas.91.15.6967; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FAFEUR V, 1993, MOL BIOL CELL, V4, P135, DOI 10.1091/mbc.4.2.135; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GEISER AG, 1993, P NATL ACAD SCI USA, V90, P9944, DOI 10.1073/pnas.90.21.9944; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAWLER S, 1994, DEVELOPMENT, V120, P165; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; LIN HY, 1994, CELL MOL BIOL, V40, P337; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATZUAKI K, 1993, J BIOL CHEM, V268, P12719; MILLER DM, 1992, MOL ENDOCRINOL, V6, P694, DOI 10.1210/me.6.5.694; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NISHIMATSU S, 1992, FEBS LETT, V312, P169, DOI 10.1016/0014-5793(92)80928-A; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; PIERCE DF, 1993, GENE DEV, V7, P2308, DOI 10.1101/gad.7.12a.2308; POTTS JD, 1991, P NATL ACAD SCI USA, V88, P1516, DOI 10.1073/pnas.88.4.1516; ROBERTS AB, 1992, J CLIN INVEST, V90, P2056, DOI 10.1172/JCI116087; ROLBAND GC, 1993, BIOCHEMISTRY-US, V32, P13545, DOI 10.1021/bi00212a021; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SLAGER HG, 1993, DEV GENET, V14, P212, DOI 10.1002/dvg.1020140308; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TENDIJKE P, 1993, ONCOGENE, V8, P2879; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1470; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XU JM, 1994, P NATL ACAD SCI USA, V91, P7957, DOI 10.1073/pnas.91.17.7957	69	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8274	8284		10.1074/jbc.270.14.8274	http://dx.doi.org/10.1074/jbc.270.14.8274			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713935	hybrid			2022-12-25	WOS:A1995QR52600074
J	HU, P; YIN, C; ZHANG, KM; WRIGHT, LD; NIXON, TE; WECHSLER, AS; SPRATT, JA; BRIGGS, FN				HU, P; YIN, C; ZHANG, KM; WRIGHT, LD; NIXON, TE; WECHSLER, AS; SPRATT, JA; BRIGGS, FN			TRANSCRIPTIONAL REGULATION OF PHOSPHOLAMBAN GENE AND TRANSLATIONAL REGULATION OF SERCA2 GENE PRODUCES COORDINATE EXPRESSION OF THESE 2 SARCOPLASMIC-RETICULUM PROTEINS DURING SKELETAL-MUSCLE PHENOTYPE SWITCHING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLOW; CA-2+-ATPASE; SEQUENCE; ATPASE; TWITCH; KINASE; FIBERS	Chronic 1 Hz stimulation of the canine latissimus dorsi muscle produced a time-dependent switch from the fast-twitch to the slow-twitch phenotype, This included changes in the proteins of the sarcoplasmic reticulum, After 3 days of muscle stimulation, there was down-regulation of fast-twitch Ca-ATPase (SERCA1a) mRNA and induction of slow-twitch Ca-ATPase (SERCA2a) mRNA; most changes in both mRNAs were nearly complete after 14 days of stimulation, Although the induction of phospholamban mRNA began after 3 days of muscle stimulation, its up-regulation was not completed until the muscle had been stimulated for 42 days, The time course of expression of SERCA2a protein was very different from that of SERCA2a mRNA, suggesting that SERCA2 gene expression is regulated at the translational as well as the transcriptional level, The time course of expression of phospholamban protein closely followed that of phospholamban mRNA, suggesting that this gene is under transcriptional control, Thus coordinated expression of SERCA2a and phospholamban proteins is achieved via translational control of the SERCA2 gene and transcriptional control of the phospholamban gene.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYSIOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045957, R55HL045957] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45957] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1992, AM J PHYSIOL, V262, pC614, DOI 10.1152/ajpcell.1992.262.3.C614; BRIGGS FN, 1990, FEBS LETT, V259, P269, DOI 10.1016/0014-5793(90)80025-E; BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; JORGENSEN AO, 1988, CELL MOTIL CYTOSKEL, V9, P164, DOI 10.1002/cm.970090208; JORGENSEN AO, 1986, J BIOL CHEM, V261, P3775; KANDARIAN SC, 1994, AM J PHYSIOL, V266, pC1190, DOI 10.1152/ajpcell.1994.266.5.C1190; KIRCHBERGER MA, 1976, J BIOL CHEM, V251, P725; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1989, EUR J BIOCHEM, V185, P51, DOI 10.1111/j.1432-1033.1989.tb15080.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; OHLENDIECK K, 1991, EUR J BIOCHEM, V202, P739, DOI 10.1111/j.1432-1033.1991.tb16428.x; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PETTE D, 1984, MED SCI SPORT EXER, V16, P517; SALMONS S, 1976, NATURE, V263, P30, DOI 10.1038/263030a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHULTE LM, 1993, AM J PHYSIOL, V264, pC1308, DOI 10.1152/ajpcell.1993.264.5.C1308; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344	21	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11619	11622		10.1074/jbc.270.19.11619	http://dx.doi.org/10.1074/jbc.270.19.11619			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744801	hybrid			2022-12-25	WOS:A1995QX86500083
J	LEUSEN, JHW; FLUITER, K; HILARIUS, PM; ROOS, D; VERHOEVEN, AJ; BOLSCHER, BGJM				LEUSEN, JHW; FLUITER, K; HILARIUS, PM; ROOS, D; VERHOEVEN, AJ; BOLSCHER, BGJM			INTERACTIONS BETWEEN THE CYTOSOLIC COMPONENTS P47(PHOX) AND P67(PHOX) OF THE HUMAN NEUTROPHIL NADPH OXIDASE THAT ARE NOT REQUIRED FOR ACTIVATION IN THE CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; GTP-BINDING PROTEIN; PLASMA-MEMBRANE; CYTOCHROME-B558; OXIDOREDUCTASE; RECONSTITUTION; PURIFICATION; EXPRESSION; P47-PHOX	Activation of the human NADPH oxidase requires the interaction of at least four cytosolic proteins and one membrane bound heterodimeric protein. Src homology 3 (SH3) domains and their proline rich counterstructures have been shown to play an important role in protein-protein interactions. Because it was found that the cytosolic oxidase components p67(phox), p47(phox), and p40(phox) reside in a complex in resting neutrophils, we studied the role of SH3 domains in their interaction by use of an overlay technique. Wild-type and mutated labeled p67(phox) and p47(phox) were used to detect immobilized cytosolic proteins on a protein blot. A specific association of native p67(phox) to blotted p47(phox) and blotted p40(phox) was found. These interactions were not disturbed by deleting the only proline-rich region (amino acids 227-231) in p67(phox). We also found a specific association of native p47(phox) with blotted p67(phox). Deletions in a putative SH3-binding region of p47(phox) completely abrogated the interaction with p67(phox). Other results suggest that the C terminus of p47(phox) exposes this SH3-binding domain for interaction with p67(phox). Similar results were obtained when the binding of cytosolic p67(phox) to wild-type or mutated p47(phox) were studied in solution. Interestingly, mutants of p47(phox) unable to bind to p67(phox) were fully capable of supporting superoxide production under cell-free activation conditions, We conclude that an interaction between the C-terminal proline-rich region of p47(phox) and the second SH3 domain of p67(phox) is not required for oxidase activity in the cell-free assay.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,1066 CX AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,1066 CX AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,EMMA CHILDRENS HOSP,ACAD MED CTR,DEPT PEDIAT,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam			Fluiter, Kees/H-2828-2015; Leusen, Jeanette/I-9010-2014; , Jeanette/AAG-3736-2019	Fluiter, Kees/0000-0003-0898-7260; Leusen, Jeanette/0000-0003-4982-6914				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AMBRUSO DR, 1990, J BIOL CHEM, V265, P924; AMBRUSO DR, 1990, J BIOL CHEM, V265, P19370; BOLSCHER BGJM, 1989, J CLIN INVEST, V83, P757, DOI 10.1172/JCI113954; BOLSCHER BGJM, 1990, J BIOL CHEM, V265, P15782; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; FINAN P, 1994, J BIOL CHEM, V269, P13752; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LEUSEN JHW, 1994, J CLIN INVEST, V95, P2120; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; PARK JW, 1994, BIOCHEMISTRY-US, V33, P2907, DOI 10.1021/bi00176a021; PARK JW, 1992, J BIOL CHEM, V267, P17327; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Roos D, 1986, Methods Enzymol, V132, P225; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH RM, 1991, BLOOD, V77, P673; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; TSUNAWAKI S, 1994, BIOCHEM BIOPH RES CO, V199, P1378, DOI 10.1006/bbrc.1994.1383; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557	31	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11216	11221		10.1074/jbc.270.19.11216	http://dx.doi.org/10.1074/jbc.270.19.11216			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744754	hybrid			2022-12-25	WOS:A1995QX86500031
J	SCHLEMMER, SR; YANG, CH; SIROTNAK, FM				SCHLEMMER, SR; YANG, CH; SIROTNAK, FM			FUNCTIONAL MODULATION OF MULTIDRUG RESISTANCE-RELATED P-GLYCOPROTEIN BY CA2+-CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMA-MEMBRANE VESICLES; HAMSTER OVARY CELLS; GENE-PRODUCT; TRANSPORT; LEUKEMIA; CHANNEL; EFFLUX; DNA	Studies with inside-out plasma membrane vesicles from multidrug-resistant (MDR 3) murine erythroleukemia (MEL/VCR-6) cells have provided evidence for down-modulation of P-glycoprotein (P-gp) function by Ca-2+-calmodulin (CLM). These studies showed that CLM in the presence or absence of Ca2+ had no effect on binding of [H-3]vinblastine (VBL) by P-gp in inside out plasma membrane vesicles. However, profound inhibition of ATP-dependent [H-3]VBL efflux by these vesicles was demonstrated by the addition of subnanomolar concentrations of CLM (IC50 = 0.15 +/- 0.02 nM). The addition of 1 mM Ca2+ reduced the inhibition of [H-3]VBL efflux by CLM, shifting the concentration required for inhibition to the nM range (IC50 = 2.55 +/- 0.35 nM). The inhibition of [H-3]VBL efflux by 0.6 nM CLM was reduced with as little as 0.01 mM Ca2+, and no inhibition occurred with concentrations greater than 0.2 mM Ca2+. Binding of CLM, itself, to P-gp was demonstrated in two ways, The P-gp content of detergent-solubilized plasma membrane from MEL/VCR-6 cells could be appreciably depleted by treating this material with CLM-Sepharose beads as shown by SDS-polyacrylamide gel electrophoresis (PAGE) and Western blotting with anti-P-gp antibody (C219) before and after CLM-Sepharose treatment. Also, depletion of P-gp from solution by CLM was less in the presence of 1 mM Ca2+. Blotting of P-gp after SDS-PAGE of plasma membrane from MEL/VCR-6 cells was also obtained using I-125-CLM as a probe. These results strongly suggest that the MDR 3 homolog of P-gp is a CLM-binding protein and that direct interaction of Ca2+-CLM with P-gp, while not affecting its binding of [H-3]VBL, down-modulates the translocation of this agent in the presence of ATP.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC PHARMACOL & EXPTL THERAPEUT,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University					NCI NIH HHS [CA 18856, CA 08748, CA 56517] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA056517, P30CA008748, P01CA018856] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ALTENBERG GA, 1993, P NATL ACAD SCI USA, V90, P9735, DOI 10.1073/pnas.90.20.9735; BECK WT, 1987, BIOCHEM PHARMACOL, V26, P2879; BIEDLER JL, 1970, CANCER RES, V30, P1174; CHEUNG WY, 1979, SCIENCE, V207, P19; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; FORD JM, 1990, PHARMACOL REV, V42, P155; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HISSIN PJ, 1978, BIOCHIM BIOPHYS ACTA, V508, P401, DOI 10.1016/0005-2736(78)90342-5; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JAYANTHI LD, 1994, J BIOL CHEM, V269, P14424; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KLEE CB, 1988, ANN REV BIOCH, V49, P489; KUNTEBOMMANAHAL.NT, 1985, CANCER RES, V45, P5382; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; REUTZ S, 1993, P NATL ACAD SCI USA, V90, P11588; REUTZ S, 1994, J BIOL CHEM, V269, P12277; RIORDAN JR, 1985, PHARMACOL THERAPEUT, V28, P51, DOI 10.1016/0163-7258(85)90082-8; ROEPE PD, 1992, BIOCHEMISTRY-US, V31, P12555, DOI 10.1021/bi00165a003; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; SCHLEMMER SR, 1992, J BIOL CHEM, V267, P14746; SCHLEMMER SR, 1994, J BIOL CHEM, V269, P31059; SIMON S, 1994, P NATL ACAD SCI USA, V91, P1128, DOI 10.1073/pnas.91.3.1128; TOWBIN H, 1979, P NATL ACAD SCI USA, V70, P4350; TSURUO T, 1984, CANCER RES, V44, P5095; TUPPER JT, 1977, J CELL BIOL, V75, P12, DOI 10.1083/jcb.75.1.12; VANDERBLIEK AM, 1986, MOL CELL BIOL, V6, P1671, DOI 10.1128/MCB.6.5.1671	32	17	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11040	11042		10.1074/jbc.270.19.11040	http://dx.doi.org/10.1074/jbc.270.19.11040			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744732	hybrid			2022-12-25	WOS:A1995QX86500005
J	DUGAN, JM; DEWIT, C; MCCONLOGUE, L; MALTESE, WA				DUGAN, JM; DEWIT, C; MCCONLOGUE, L; MALTESE, WA			THE RAS-RELATED GTP-BINDING PROTEIN, RAB1B, REGULATES EARLY STEPS IN EXOCYTIC TRANSPORT AND PROCESSING OF BETA-AMYLOID PRECURSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; ALZHEIMERS-DISEASE; INTRACELLULAR-TRANSPORT; ENDOCYTIC PATHWAY; CRYSTAL-STRUCTURE; GOLGI-COMPLEX; BREFELDIN-A; PEPTIDE; CLEAVAGE	The role of the Ras-related GTP-binding protein, Rab1B, in intracellular trafficking of beta-amyloid precursor protein (beta APP) was studied in cultured 293 cells, beta APP is processed via one of two alternative routes. In the major secretory pathway, beta APP is cleaved by alpha-secretase within the region comprising the beta-amyloid peptide (A beta), resulting in release of a soluble NH2-terminal exodomain (APP(alpha)) and a 3-kDa peptide (p3) derived from the carboxyl-terminal tail. In the alternative amyloidogenic pathway, beta APP is cleaved by beta-secretase, with the release of a truncated exodomain (APP(beta)) and an intact A beta peptide. When beta APP(751) was coexpressed with Rab1B(wt) or dominant negative Rab1B mutants (Rab1B(N121I) or Rab1B(S22N)) there was a marked decrease in conversion of the immature Endo-H sensitive form of beta APP(751) (108 kDa) to the mature O-glycosylated form of beta APP(751) (130 kDa) in cells expressing the mutant forms of Rab1B. The block in Golgi-dependent processing of beta APP was accompanied by inhibition of secretion of APP(S) (APP(alpha)). A similar decrease in secretion of APP(S) (APP, + APP(beta)) was observed in cells that were coexpressing Rab1B(N121I) with the ''Swedish'' variant of beta APP(751) (i.e. beta APPSW(751)), which undergoes increased amyloidogenic processing. Coincident with the decline in APP(8) secretion, the cells coexpressing beta APPSW(751) with Rab1B(N121I) showed a 90% decrease in AP secretion. The data indicate that Rab1B plays a key role in endoplasmic reticulum --> Golgi transport of beta APP, and that beta APP must pass through a late Golgi compartment before entering either the alpha-secretase or the amyloidogenic beta-secretase pathway. The results also suggest that mutant versions of other Rab proteins that function in different parts of the exocytic and endocytic pathways may be useful in defining the specific routes of beta APP transport involved in the biogenesis of A beta.	WEIS CTR RES, GEISINGER CLIN, DANVILLE, PA 17822 USA; ATHENA NEUROSCI, S SAN FRANCISCO, CA 94080 USA						NATIONAL CANCER INSTITUTE [R01CA034569] Funding Source: NIH RePORTER; NCI NIH HHS [CA34569] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BERANGER F, 1994, J BIOL CHEM, V269, P13637; BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BRUNGER AT, 1990, P NATL ACAD SCI USA, V87, P4849, DOI 10.1073/pnas.87.12.4849; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHEN YT, 1993, P NATL ACAD SCI USA, V90, P6508, DOI 10.1073/pnas.90.14.6508; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GANDY S, 1994, INT REV NEUROBIOL, V36, P29, DOI 10.1016/S0074-7742(08)60302-5; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Higuchi R., 1989, PCR TECHNOLOGY, P61; HO DY, 1993, P NATL ACAD SCI USA, V90, P3655, DOI 10.1073/pnas.90.8.3655; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; KNOPS J, 1995, J BIOL CHEM, V270, P2419, DOI 10.1074/jbc.270.6.2419; KNOPS J, 1991, J BIOL CHEM, V266, P7285; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI GP, 1993, J BIOL CHEM, V268, P24475; LO ACY, 1994, J BIOL CHEM, V269, P30966; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MANLEY TF, 1990, NUCLEIC ACIDS RES, V18, P937; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; OVERMEYER JH, 1992, J BIOL CHEM, V267, P22686; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PRICE DL, 1993, P NATL ACAD SCI USA, V90, P6381, DOI 10.1073/pnas.90.14.6381; ROBERTS SB, 1994, J BIOL CHEM, V269, P3111; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMAN R, 1993, J BIOL CHEM, V268, P16602; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; ULMER JB, 1991, J BIOL CHEM, V266, P9173; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WILSON AL, 1993, J BIOL CHEM, V268, P14561; WILSON BS, 1994, J CELL BIOL, V125, P557, DOI 10.1083/jcb.125.3.557; ZHONG ZY, 1994, J BIOL CHEM, V269, P627	73	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10982	10989		10.1074/jbc.270.18.10982	http://dx.doi.org/10.1074/jbc.270.18.10982			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738040	hybrid			2022-12-25	WOS:A1995QW60100089
J	DEISSLER, H; LOTTSPEICH, F; RAJEWSKY, MF				DEISSLER, H; LOTTSPEICH, F; RAJEWSKY, MF			AFFINITY PURIFICATION AND CDNA CLONING OF RAT NEURAL DIFFERENTIATION AND TUMOR-CELL SURFACE-ANTIGEN GP130(RB13-6) REVEALS RELATIONSHIP TO HUMAN AND MURINE PC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MEMBRANE GLYCOPROTEIN PC-1; FIBROBLAST GROWTH-FACTOR; 5'-NUCLEOTIDE PHOSPHODIESTERASE; NUCLEOTIDE PYROPHOSPHATASE; MONOCLONAL-ANTIBODY; PROTEIN-KINASE; IDENTIFICATION; EXPRESSION; PHOSPHORYLATION	Monoclonal antibody RB13-6 recognizes a subset of rat brain glial precursor cells that are highly susceptible to malignant conversion by the carcinogen N-ethyl-N-nitrosourea. The corresponding cell surface antigen was identified as a membrane glycoprotein (gp130(RB13-6)) and purified by immunoaffinity chromatography from the tumorigenic neuroectodermal rat cell line BT4Ca, Sequencing of 5 endoproteinase generated peptides of the purified antigen permitted the specific amplification of a cDNA fragment by reverse transcription-polymerase chain reaction and subsequent isolation of the complete coding sequence from a fetal rat brain cDNA library, The derived amino acid sequence indicates that the RB13-6 antigen is related to the human and murine plasma cell membrane protein PC-1, a nucleotide pyrophosphatase/alkaline phosphodiesterase and ectoprotein kinase. Similarly, purified gp130(RB13-6) possesses 5'-nucleotidase activity that can be inhibited with EDTA. Different from PC-1, gp130(RB13-6) isolated from BT4Ca cells is not a disulfide-linked dimer and contains an RGD-tripeptide sequence which, together with other structural features, suggests a possible function in cell adhesion and its subversion in malignant phenotypes.	UNIV ESSEN GESAMTHSCH,SCH MED,INST CELL BIOL CANC RES,D-45122 ESSEN,GERMANY; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	University of Duisburg Essen; Max Planck Society								Arch J R, 1978, Essays Biochem, V14, P82; AURIVILLIUS M, 1990, FEBS LETT, V264, P267, DOI 10.1016/0014-5793(90)80264-J; BAUGHMAN G, 1992, J IMMUNOL, V149, P1488; BELLI SI, 1993, EUR J BIOCHEM, V217, P421, DOI 10.1111/j.1432-1033.1993.tb18261.x; BUCKLEY MF, 1990, J BIOL CHEM, V265, P17506; CLEEVES V, 1991, BIOCH CHARAKTERISIER; CULP JS, 1985, J BIOL CHEM, V260, P8320; DRUCKREY H, 1966, NATURE, V210, P1378, DOI 10.1038/2101378a0; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; DUX R, 1991, J IMMUNOL METHODS, V144, P175, DOI 10.1016/0022-1759(91)90084-S; DUX R, 1991, CYTOMETRY, V12, P422, DOI 10.1002/cyto.990120507; DZHANDZHUGAZYAN K, 1993, FEBS LETT, V336, P279, DOI 10.1016/0014-5793(93)80820-K; EBERLE GM, 1989, THESIS U ESSEN ESSEN; ECKERSKORN C, 1989, CHROMATOGRAPHIA, V28, P92, DOI 10.1007/BF02290390; FRANK W, 1972, EXP CELL RES, V70, P390, DOI 10.1016/0014-4827(72)90151-6; GODING JW, 1982, J IMMUNOL, V129, P2636; GRUNDMANN U, 1990, DNA CELL BIOL, V9, P243, DOI 10.1089/dna.1990.9.243; HARAHAP AR, 1988, J IMMUNOL, V141, P2317; JENNE D, 1991, BIOCH BIOPHSY RES CO, V176, P10000; KINDLERROHRBORN A, 1985, DIFFERENTIATION, V30, P53, DOI 10.1111/j.1432-0436.1985.tb00513.x; KINDLERROHRBORN A, 1994, DIFFERENTIATION, V57, P215, DOI 10.1007/s002580050057; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAERUM OD, 1977, Z KREBSFORSCH KLIN O, V89, P273, DOI 10.1007/BF00283783; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURATA J, 1994, J BIOL CHEM, V269, P30479; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; ODA Y, 1991, J BIOL CHEM, V266, P16791; ODA Y, 1993, J BIOL CHEM, V268, P27318; PATTHY L, 1988, J MOL BIOL, V202, P689, DOI 10.1016/0022-2836(88)90550-5; RAJEWSKY MF, 1985, THEORIES MODELS CELL, P155; RAJEWSKY MF, 1977, ORIGINS HUMAN CANCER, P709; REBBE NF, 1991, P NATL ACAD SCI USA, V88, P5192, DOI 10.1073/pnas.88.12.5192; REBBE NF, 1993, MOL IMMUNOL, V30, P87, DOI 10.1016/0161-5890(93)90429-F; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; Sambrook J, 1989, MOL CLONING LABORATO; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; TAKAHASHI T, 1970, J EXP MED, V131, P1325, DOI 10.1084/jem.131.6.1325; URIARTE M, 1993, BIOCHEM J, V293, P93, DOI 10.1042/bj2930093; VANDRIEL IR, 1987, J BIOL CHEM, V262, P4882	42	68	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9849	9855		10.1074/jbc.270.17.9849	http://dx.doi.org/10.1074/jbc.270.17.9849			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730366	hybrid			2022-12-25	WOS:A1995QV41700025
J	KNIGHT, JB; YAMAUCHI, K; PESSIN, JE				KNIGHT, JB; YAMAUCHI, K; PESSIN, JE			DIVERGENT INSULIN AND PLATELET-DERIVED GROWTH-FACTOR REGULATION OF FOCAL ADHESION KINASE (PP125(FAK)) TYROSINE PHOSPHORYLATION, AND REARRANGEMENT OF ACTIN STRESS FIBERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; PAXILLIN; IDENTIFICATION; CYTOSKELETON; STIMULATION; ACTIVATION; PP125FAK; BOMBESIN	Insulin treatment of Chinese hamster ovary cells expressing high levels of the human insulin receptor resulted in the tyrosine dephosphorylation of the 125-kDa focal adhesion kinase (pp125(FAK)). The decrease in pp125(FAK) tyrosine phosphorylation paralleled a decrease in the cellular content of actin stress fibers, and these changes were independent of the extracellular matrix on which the cells were grown. The reduction in both pp125(FAK) tyrosine phosphorylation and actin stress fibers occurred in an insulin concentration-dependent manner, with significant effects at approximately 0.3 nM and a maximal effect at 3 nM. However, in the continuous presence of insulin, the decreases in the tyrosine phosphorylation state of pp125(FAK) and actin stress fiber content were transient, Maximal reduction of pp125(FAK) tyrosine phosphorylation was observed following 15 min of insulin treatment, with a return to unstimulated control levels by 60 min. Similarly, actin stress fiber content was maximally reduced by 15 min of insulin treatment and fully recovered by 60 min. In contrast to insulin, platelet-derived growth factor stimulation increased actin stress fiber content and enhanced pp125(FAK) tyrosine phosphorylation, These data demonstrate a novel signaling role for insulin in inducing the tyrosine dephosphorylation of pp125(FAK) and a concomitant reorganization of actin stress fibers, which underlies at least one aspect of signaling divergence between the insulin and platelet-derived growth factor receptor tyrosine kinases.	UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa					NIDDK NIH HHS [DK25295, DK33823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033823, R01DK033823, P30DK025295] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; FRATTALI AL, 1991, J BIOL CHEM, V266, P9829; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; LI SL, 1993, EXP CELL RES, V205, P353, DOI 10.1006/excr.1993.1097; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Otey C A, 1990, Semin Cell Biol, V1, P391; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SABA H, 1994, P NATL ACAD SCI USA, V91, P3984; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; TURNER CE, 1993, J CELL SCI, V105, P637; WENG ZG, 1993, J BIOL CHEM, V268, P14956; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	33	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10199	10203		10.1074/jbc.270.17.10199	http://dx.doi.org/10.1074/jbc.270.17.10199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730324	hybrid			2022-12-25	WOS:A1995QV41700071
J	SHINOMURA, T; ZAKO, M; ITO, K; UJITA, M; KIMATA, K				SHINOMURA, T; ZAKO, M; ITO, K; UJITA, M; KIMATA, K			THE GENE STRUCTURE AND ORGANIZATION OF MOUSE PG-M, A LARGE CHONDROITIN SULFATE PROTEOGLYCAN - GENOMIC BACKGROUND FOR THE GENERATION OF MULTIPLE PG-M TRANSCRIPTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERSICAN; CHONDROGENESIS; AMPLIFICATION; SEQUENCE; CLONING; CDNAS; BUD	We previously showed not only the presence of multiple RNA transcripts of different sizes encoding the core protein of mouse PG-M, but also their tissue-dependent expression, Major causes for the multiple forms were found to be due to alternative usage of the two different chondroitin sulfate attachment domains (alpha and beta). In this study, genomic DNA analysis has revealed that these domains are encoded by two large exons, exon VII (2880 base pairs) and exon VIII (5229 base pairs), The splice sites of these two exons were consistent with the occurrence of alternative splicing without frameshift. Furthermore, the mouse PG-M gene was shown to have four distinct polyadenylation signals and three candidates for the transcription initiation site as well. These genomic structural variations may contribute to the multiplicity of PG-M transcripts. Northern hybridization analysis showed that at least three different transcripts were generated by different usage of the distinct polyadenylation signals.	AICHI MED UNIV,INST MOLEC SCI MED,NAGAKUTE,AICHI 48011,JAPAN	Aichi Medical University								DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GREENE JM, 1994, CURRENT PROTOCOLS MO; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; KIMATA K, 1986, J BIOL CHEM, V261, P3517; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; SHINOMURA T, 1990, DEV GROWTH DIFFER, V32, P243; UJITA M, 1994, J BIOL CHEM, V269, P27603; VIHINEN T, 1993, J BIOL CHEM, V268, P17261; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	16	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10328	10333		10.1074/jbc.270.17.10328	http://dx.doi.org/10.1074/jbc.270.17.10328			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730339	hybrid			2022-12-25	WOS:A1995QV41700088
J	WANG, F; KAN, M; YAN, GC; XU, JM; MCKEEHAN, WL				WANG, F; KAN, M; YAN, GC; XU, JM; MCKEEHAN, WL			ALTERNATELY SPLICED NH2-TERMINAL IMMUNOGLOBULIN-LIKE LOOP-I IN THE ECTODOMAIN OF THE FIBROBLAST GROWTH-FACTOR (FGF) RECEPTOR-1 LOWERS AFFINITY FOR BOTH HEPARIN AND FGF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; EXPRESSION; KINASE; RAT	Alternate splicing of a single exon encoding an NH2-terminal immunoglobulin (Ig) disulfide loop in the ectodomain of the fibroblast growth factor receptor (FGFR) types 1 and 2 results in alpha and beta isoforms that exhibit 3- and 2-Ig loops, respectively, Previously we demonstrated that alternately spliced Loop I has no independent ligand binding activity but is sufficiently interactive with the ligand- and heparin-binding site formed by Loops II and III to lower affinity for the same fibroblast growth factor (FGF) ligand. Here we show that a lower affinity of FGFR1 alpha for heparin parallels the lower affinity for FGF-1. A mutant of FGFR1 alpha in which the sequence between Loops I and II was deleted exhibits high affinity for both FGF-1 and heparin and other properties of the FGPR1 beta isoform, which include resistance to degradation by trypsin and display of specific antibody epitopes, This suggests that the interloop sequence facilitates the interaction of Loop I with Loops II and III, Lack of expression of both exons coding for Loop I and the sequence between Loops I and II in the FGFR2 gene characterizes rat prostate tumor cells, which exhibit a loss of the low affinity class of FGF receptors, Although the exon coding for the sequence between Loops I and II is alternately spliced in the FGFR2 beta isoform, coordinate expression with the exon coding for Loop I results in the functional differences between the FGFR alpha and FGPR beta variants.	TEXAS A&M UNIV,ALBERT B ALKEK INST BIOSCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,HOUSTON,TX 77030	Texas A&M University System					NCI NIH HHS [CA59971] Funding Source: Medline; NIDDK NIH HHS [DK35310, DK38639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035310, P01DK038639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOU JZ, 1992, J BIOL CHEM, V267, P17804; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KOBRIN MS, 1993, CANCER RES, V53, P4741; MANSSON PE, 1989, CANCER RES, V49, P2485; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; XU JM, 1992, J BIOL CHEM, V267, P17792; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; YAN GC, 1993, BIOCHEM BIOPH RES CO, V194, P512, DOI 10.1006/bbrc.1993.1849	13	117	130	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10231	10235		10.1074/jbc.270.17.10231	http://dx.doi.org/10.1074/jbc.270.17.10231			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730327	hybrid			2022-12-25	WOS:A1995QV41700075
J	WU, DQ; JIANG, HP; SIMON, MI				WU, DQ; JIANG, HP; SIMON, MI			DIFFERENT ALPHA-1-ADRENERGIC RECEPTOR SEQUENCES REQUIRED FOR ACTIVATING DIFFERENT G-ALPHA SUBUNITS OF GQ CLASS OF G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; SIGNAL-TRANSDUCTION PATHWAYS; PHOSPHOLIPASE-C; ADRENERGIC-RECEPTORS; GAMMA; CELLS; SELECTIVITY; SPECIFICITY; SUBTYPES; FAMILY	In order to understand the specific interactions between receptors and guanine nucleotide-binding regulatory protein (G proteins), we attempted to delineate the alpha 1B-adrenergic receptor sequences involved in activation of the alpha subunits of the Gq class of G proteins. A number of specific mutations were introduced into the third inner loop of the receptor, and the mutants were tested for their abilities to activate different G alpha subunits of the Gq class. Our results indicate that the receptor sequences required for activating G alpha q/11, G alpha 14, or G alpha 16 are different. The sequence extending from residues Lys(240) to His(252) is required for activation of G alpha q/11, but not for activation of G alpha 14 or G alpha 16. Two segments in the third loop of the receptor are required for activation of G alpha 14: one is located at the N terminus of the loop ending at residue Asn(226), and the other is located at the C terminus of the loop starting from residue Ser(278). The fatter contains a BBXXB motif, which is apparently critical for G alpha 14 coupling, but not for G alpha 16 or G alpha q/11 conpling. Furthermore, the three amino acids stretch (Tyr(217) to Val(219)) included in the N-terminal segment is not only required for G alpha 14 coupling, but also for G alpha q/11 coupling. It may be involved to some extent in G alpha 16 coupling as well.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology	WU, DQ (corresponding author), UNIV ROCHESTER,DEPT PHARMACOL,601 ELMWOOD AVE,ROCHESTER,NY 14642, USA.							AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V90, P163; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOSUGI S, 1992, J BIOL CHEM, V267, P24153; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; RONDA ES, 1994, J BIOL CHEM, V269, P326; RUBENSTEIN RC, 1991, BIOCHEMISTRY-US, V30, P10769, DOI 10.1021/bi00108a023; SCHWINN DA, 1991, MOL PHARMACOL, V40, P619; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; UEDA N, 1994, J BIOL CHEM, V269, P4388; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WONG SKF, 1994, J BIOL CHEM, V269, P18968; WONG SKF, 1990, J BIOL CHEM, V265, P6219; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	32	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9828	9832		10.1074/jbc.270.17.9828	http://dx.doi.org/10.1074/jbc.270.17.9828			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730363	hybrid			2022-12-25	WOS:A1995QV41700022
J	XU, LZ; HARRISON, RW; WEBER, IT; PILKIS, SJ				XU, LZ; HARRISON, RW; WEBER, IT; PILKIS, SJ			HUMAN BETA-CELL GLUCOKINASE - DUAL ROLE OF SER-151 IN CATALYSIS AND HEXOSE AFFINITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN HEXOKINASE; AMINO-ACID SEQUENCE; C-TERMINAL HALVES; YEAST HEXOKINASE; LIVER GLUCOKINASE; CLONED CDNA; EXPRESSION; MUTAGENESIS; INSULIN; ENZYME	Glucokinase is distinguished from yeast hexokinase and low K-m mammalian hexokinases by its low affinity for glucose and its cooperative behavior, even though glucose binding residues and catalytic residues are highly conserved in all of these forms of hexokinase, The roles of Ser-151 and Asn-166 as determinants of hexose affinity and cooperative behavior of human glucokinase have been evaluated by site-directed mutagenesis, expression and purification of the wild-type and mutant enzymes, and steady-state kinetic analysis. Mutation of Asn-166 to arginine increased apparent affinity for both glucose and ATP by a factor of 3, Mutation of Ser-151 to cysteine, aIanine, or glycine lowered the K-m for glucose by factors of 2, 26-, and 40-fold, respectively, decreased V-max abolished cooperativity for glucose, and also decreased K-m for mannose and fructose. The Ser-151 mutants had hexose R, values similar to those of yeast hexokinase, hexokinase I, and the recombinantly expressed COOH-terminal half of hexokinase I. However, the K-i values for the competitive inhibitors, N-acetylglucosamine and glucose-6-P, were unchanged, suggesting that Ser-151 is not important for inhibitor binding, Mutation of Ser-151 also increased the K-m for ATP about 5-fold and abolished the enzyme's low ATPase activity, which indicates it is essential for ATP hydrolysis. The substrate-induced change in intrinsic fluorescence of S151A occurred at a much lower glucose concentration than that for wild-type enzyme. The results implicate a dual role for Ser-151 as a determinant of hexose affinity and catalysis, exclusive of the glucose-induced conformational change, and suggest that the low hexose affinity of glucokinase is dependent on interaction of Ser-151 with other regions of the protein.	UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107; SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794	University of Minnesota System; University of Minnesota Twin Cities; Jefferson University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Harrison, Robert/0000-0003-2449-1214	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046562] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK46562] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; ANDREONE TL, 1989, J BIOL CHEM, V264, P363; ARORA KK, 1990, J BIOL CHEM, V265, P6481; ARORA KK, 1993, J BIOL CHEM, V268, P18259; ARORA KK, 1993, J BIOL CHEM, V266, P5359; BAIJAL M, 1992, ARCH BIOCHEM BIOPHYS, V298, P271, DOI 10.1016/0003-9861(92)90123-E; CARDENAS ML, 1984, EUR J BIOCHEM, V145, P163, DOI 10.1111/j.1432-1033.1984.tb08536.x; CHARLES RS, 1994, DIABETES, V43, P784, DOI 10.2337/diab.43.6.784; DELAFUEN.G, 1970, EUR J BIOCHEM, V16, P226; FROHLICH KU, 1985, GENE, V36, P105, DOI 10.1016/0378-1119(85)90074-5; GIDHJAIN M, 1993, P NATL ACAD SCI USA, V90, P1932, DOI 10.1073/pnas.90.5.1932; GRANNER DK, 1990, J BIOL CHEM, V265, P10171; HARRISON RW, 1985, THESIS YALE U NEW HA; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KOPETZKI E, 1985, GENE, V39, P95, DOI 10.1016/0378-1119(85)90113-1; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROMIZU K, 1979, FED PROC, V35, P302; LANGE AJ, 1991, BIOCHEM J, V277, P159, DOI 10.1042/bj2770159; LIN SX, 1990, J BIOL CHEM, V265, P9670; LIU F, 1991, BIOCHEM BIOPH RES CO, V177, P305, DOI 10.1016/0006-291X(91)91983-J; MAGNANI M, 1992, BIOCHEM J, V285, P193, DOI 10.1042/bj2850193; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MENEZES LC, 1976, EUR J BIOCHEM, V65, P41, DOI 10.1111/j.1432-1033.1976.tb10387.x; NISHI S, 1988, BIOCHEM BIOPH RES CO, V157, P937, DOI 10.1016/S0006-291X(88)80964-1; PILKIS SJ, 1994, J BIOL CHEM, V269, P21925; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; ROSE IA, 1967, J BIOL CHEM, V242, P1635; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; URETA T, 1982, COMP BIOCHEM PHYS B, V71, P549, DOI 10.1016/0305-0491(82)90461-8; VIOLA RE, 1982, BIOCHEMISTRY-US, V21, P1295, DOI 10.1021/bi00535a029; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7; XU LZ, 1994, J BIOL CHEM, V269, P27458; XU LZ, 1995, IN PRESS BIOCHEMISTR	35	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9939	9946		10.1074/jbc.270.17.9939	http://dx.doi.org/10.1074/jbc.270.17.9939			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730377	hybrid			2022-12-25	WOS:A1995QV41700038
J	ATTIEH, JM; HANSON, AD; SAINI, HS				ATTIEH, JM; HANSON, AD; SAINI, HS			PURIFICATION AND CHARACTERIZATION OF A NOVEL METHYLTRANSFERASE RESPONSIBLE FOR BIOSYNTHESIS OF HALOMETHANES AND METHANETHIOL IN BRASSICA-OLERACEA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL S-METHYLTRANSFERASE; PHELLINUS-POMACEUS; METHYLATED SULFUR; BIOGENIC SULFUR; SULFIDE; CHLOROMETHANE; SEAWATER; CHLORIDE; VOLATILE; DONOR	A novel S-adenosyl-L-methionine:halide/bisulfide methyltransferase (EC 2.1.1.-) was purified approximately 1000-fold to apparent homogeneity from leaves of Brassica oleracea, The enzyme catalyzed the S adenosyl-L-methionine-dependent methylation of the halides iodide, bromide, and chloride to monohalomethanes and of bisulfide to methanethiol. The dual function of the enzyme was demonstrated through co-purification of the halide- and bisulfide-methylating activities in the same ratio and by studies of competition between the alternative substrates iodide and bisulfide, The purification procedure included gel filtration, anion exchange chromatography, and affinity chromatography on adenosine-agarose. Elution of the protein from a chromate-focusing column indicated a pI value of 4.8. The pH optimum of halide methylation (5.5-7.0) was different from that of bisulfide methylation (7.0-8.0). The molecular mass values for the native and denatured protein were 29.5 and 28 kDa, respectively, suggesting that the active enzyme is a monomer, The enzyme had the highest specificity constant for iodide and the next highest for bisulfide, Substrate interaction kinetics and product inhibition patterns were consistent with an Ordered Bi Bi mechanism.	UNIV MONTREAL, INST RECH BIOL VEGETALE, MONTREAL, PQ H1X 2B2, CANADA	Universite de Montreal								ANEJA VP, 1989, ACS SYM SER, V393, P2; Bell E. A., 1980, Encyclopedia of Plant Physiology. New Series. Volume 8. Secondary plant products [Bell, A.E.; Charlwood, B.V. (Editors)]., P403; BORCHARDT RT, 1978, BIOCHIM BIOPHYS ACTA, V522, P340, DOI 10.1016/0005-2744(78)90068-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brasseur G. P., 1991, TRACE GAS EMISSION P, P1; Crampton MR., 1974, CHEM THIOL GROUP, P379; DECAROLIS E, 1989, BIOCHEM CELL BIOL, V67, P763, DOI 10.1139/o89-115; DESILVA JJR, 1991, BIOL CHEM ELEMENTS, P453; DIXON M, 1979, ENZYMES, P332; Dixon M., 1979, ENZYMES, P47; DROTAR A, 1987, APPL ENVIRON MICROB, V53, P2111, DOI 10.1128/AEM.53.9.2111-2118.1987; DROTAR A, 1985, PLANT CELL PHYSIOL, V26, P847; DROTAR A, 1987, APPL ENVIRON MICROB, V53, P1626, DOI 10.1128/AEM.53.7.1626-1631.1987; DUMAS B, 1988, PLANTA, V176, P36, DOI 10.1007/BF00392477; Fiske CH, 1925, J BIOL CHEM, V66, P375; GSCHWEND PM, 1985, SCIENCE, V227, P1033, DOI 10.1126/science.227.4690.1033; HARPER DB, 1990, APPL ENVIRON MICROB, V56, P3450, DOI 10.1128/AEM.56.11.3450-3457.1990; HARPER DB, 1993, MET IONS BIOL SYST, V29, P345; HARPER DB, 1986, J GEN MICROBIOL, V132, P1231; HARPER DB, 1989, APPL ENVIRON MICROB, V55, P1981, DOI 10.1128/AEM.55.8.1981-1989.1989; HEANEY RK, 1983, Z PFLANZENZUCHT, V91, P219; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOVELOCK JE, 1972, NATURE, V237, P452, DOI 10.1038/237452a0; LOVELOCK JE, 1975, NATURE, V256, P193, DOI 10.1038/256193a0; MANLEY SL, 1987, LIMNOL OCEANOGR, V32, P709, DOI 10.4319/lo.1987.32.3.0709; MCCARTY S, 1993, FEMS MICROBIOL LETT, V112, P93, DOI 10.1111/j.1574-6968.1993.tb06429.x; MORRISON JF, 1971, J BIOL CHEM, V246, P3977; Neidleman S L, 1983, Biochem Soc Symp, V48, P39; NRIAGU JO, 1987, SCIENCE, V237, P1189, DOI 10.1126/science.237.4819.1189; OHIGASHI K., 1951, MED JOUR OSAKA UNIV, V2, P111; PRATHER MJ, 1990, NATURE, V344, P729, DOI 10.1038/344729a0; Rennenberg H., 1991, TRACE GAS EMISSIONS, P217, DOI [10.1016/B978-0-12-639010-0.50015-7, DOI 10.1016/B978-0-12-639010-0.50015-7]; SAINI HS, 1995, IN PRESS PLANT CELL; TAKASUGI M, 1988, B CHEM SOC JPN, V61, P285, DOI 10.1246/bcsj.61.285; WEISIGER RA, 1979, ARCH BIOCHEM BIOPHYS, V196, P631, DOI 10.1016/0003-9861(79)90317-5; WEISIGER RA, 1980, BIOCHEM PHARMACOL, V29, P2885, DOI 10.1016/0006-2952(80)90029-5; WEISIGER RA, 1980, ENZYMATIC BASIS DETO, V2, P131; WHITE RH, 1982, ARCH MICROBIOL, V132, P100, DOI 10.1007/BF00690827; WUOSMAA AM, 1990, SCIENCE, V249, P160, DOI 10.1126/science.2371563; ZAFIRIOU OC, 1975, J MAR RES, V33, P75	40	102	104	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9250	9257		10.1074/jbc.270.16.9250	http://dx.doi.org/10.1074/jbc.270.16.9250			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721844	hybrid			2022-12-25	WOS:A1995QU08900032
J	ZHENG, Y; OLSON, MF; HALL, A; CERIONE, RA; TOKSOZ, D				ZHENG, Y; OLSON, MF; HALL, A; CERIONE, RA; TOKSOZ, D			DIRECT INVOLVEMENT OF THE SMALL GTP-BINDING PROTEIN-RHO IN LBC ONCOGENE FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GUANINE-NUCLEOTIDE EXCHANGE; YEAST SACCHAROMYCES-CEREVISIAE; TYROSINE KINASE; CELL POLARITY; GENE-PRODUCT; RAS; GROWTH; CDC42; VAV	The lbc oncogene is tumorigenic in nude mice, transforms NIH 3T3 fibroblasts, and encodes a Dbl homology domain found in several transforming gene products including the dbl oncogene product. While both lbc- and dbl-transformed NM 3T3 foci exhibited a comparable gross appearance, Ibc-transformed cell morphology was clearly distinct from that of dbl-transformed cells. Given these differences, we investigated the biochemical activity and target specificity of the Lbc oncoprotein both in vivo and in vitro. Here we show that Lbc associates specifically with the GTP-binding protein Rho in vivo, but not with the Ras, Rac, or Cdc42Hs GTP binding proteins, and that recombinant, affinity-purified Lbc specifically catalyzes the guanine-nucleotide exchange activity of Rho in vitro. Consistent with an in vivo role for Lbc in Rho regulation, we further demonstrate that micro-injected onco-lbc potently induces actin stress fiber formation in quiescent Swiss 3T3 fibroblasts indistinguishable from that induced by Rho. Finally, Ibc-induced NIH 3T3 focus formation is inhibited by co transfection with a rho dominant-negative mutant. These results strongly indicate that the lbc oncogene encodes a specific guanine nucleotide exchange factor for Rho and causes cellular transformation through activation of the Rho signaling pathway.	UCL, MRC,MOLEC CELL BIOL LABS,CRC, ONCOGENE & SIGNAL TRANSDUCT GRP, LONDON WC1E, ENGLAND; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT HEMATOL ONCOL, BOSTON, MA 02115 USA	University of London; University College London; Harvard University; Boston Children's Hospital; Harvard Medical School	ZHENG, Y (corresponding author), CORNELL UNIV, DEPT PHARMACOL, SCHURMAN HALL, ITHACA, NY 14853 USA.		Zheng, Yi/J-7235-2015; Olson, Michael F/A-3240-2011; Olson, Michael/ABA-4240-2021	Zheng, Yi/0000-0001-7089-6074; Olson, Michael/0000-0003-3428-3507	NCI NIH HHS [R29CA62029] Funding Source: Medline; NIGMS NIH HHS [GM47458] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA062029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HART MJ, 1994, J BIOL CHEM, V269, P16992; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1062; SELF AJ, 1993, ONCOGENE, V8, P655; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STACEY DW, 1991, ONCOGENE, V6, P2297; TOKSOZ D, 1994, ONCOGENE, V9, P621; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZHENG Y, 1993, J BIOL CHEM, V268, P24629	31	148	154	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9031	9034		10.1074/jbc.270.16.9031	http://dx.doi.org/10.1074/jbc.270.16.9031			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721814	hybrid			2022-12-25	WOS:A1995QU08900002
J	KONOLA, JT; NASTRI, HG; LOGAN, KM; KNIGHT, KL				KONOLA, JT; NASTRI, HG; LOGAN, KM; KNIGHT, KL			MUTATIONS AT PRO(67) IN THE RECA PROTEIN P-LOOP MOTIF DIFFERENTIALLY MODIFY COPROTEASE FUNCTION AND SEPARATE COPROTEASE FROM RECOMBINATION ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOSIDE TRIPHOSPHATES; CONFORMATIONAL-CHANGES; ATP-BINDING; DNA; LEXA; MUTAGENESIS; CLEAVAGE; REPAIR; PHAGE	The functional significance of residues in the RecA protein P-loop motif was assessed by analyzing 100 unique mutants with single amino acid substitutions in this region. Comparison of the effects on the LexA coprotease and recombination activities shows that Pro(67) is unique among these residues because only at this position did we find substitutions that caused differential effects on these functions. One mutant, Pro(67) --> Trp, displays high constitutive coprotease activity and a moderate inhibitory effect on recombination functions. Glu and Asp substitutions result in low level constitutive coprotease activity but dramatically reduce recombination activity. The purified Pro(67) --> Trp protein shows a completely relaxed specificity for NTP cofactors in LexA cleavage assays and can use shorter length oligonucleotides as cofactors for cleavage of lambda cI repressor than can wild type RecA. Interestingly, both the mutant protein and wild type RecA can use very short oligonucleotides, e.g. (dA)(6) and (dT)(6), as cofactors for LexA cleavage. We have also found two mutations at position 67, which are completely defective for LexA coprotease activity in vivo but still maintain recombinational DNA repair (Pro(67) --> Lys) and homologous recombination (Pro(67) --> Lys and Pro(67) --> Arg) activities. These findings show that the recombination activities of RecA are mutationally separable from the coprotease function and that Pro(67) is located in a functionally important position in the RecA structure.			KONOLA, JT (corresponding author), UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01655, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044772] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-44772] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; COX MM, 1991, MOL MICROBIOL, V5, P1295, DOI 10.1111/j.1365-2958.1991.tb00775.x; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DUTREIX M, 1989, J BACTERIOL, V171, P2415, DOI 10.1128/jb.171.5.2415-2423.1989; EGELMAN EH, 1993, CURR OPIN STRUC BIOL, V3, P189, DOI 10.1016/S0959-440X(05)80151-4; EGELMAN EH, 1988, J MOL BIOL, V200, P329, DOI 10.1016/0022-2836(88)90245-8; HIGASHITANI N, 1992, J BACTERIOL, V174, P1612, DOI 10.1128/jb.174.5.1612-1618.1992; KOBAYASHI N, 1987, BIOCHEMISTRY-US, V26, P6801, DOI 10.1021/bi00395a033; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P468; LEVINSON A, 1984, Journal of Molecular and Applied Genetics, V2, P507; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1980, P NATL ACAD SCI-BIOL, V77, P3225, DOI 10.1073/pnas.77.6.3225; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LITTLE JW, 1993, J BACTERIOL, V175, P4943, DOI 10.1128/JB.175.16.4943-4950.1993; LOGAN KM, 1993, J MOL BIOL, V232, P1048, DOI 10.1006/jmbi.1993.1459; MCENTEE K, 1981, P NATL ACAD SCI-BIOL, V78, P6061, DOI 10.1073/pnas.78.10.6061; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NASTRI HG, 1994, J BIOL CHEM, V269, P26311; Ogawa H, 1986, Adv Biophys, V21, P135, DOI 10.1016/0065-227X(86)90019-5; PETERSON KR, 1988, J BACTERIOL, V170, P1; ROBERTS JW, 1978, COL SPRING HARBOR S, V43, P909; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SKIBA MC, 1994, J BIOL CHEM, V269, P3823; STOLE E, 1994, J BIOL CHEM, V269, P7919; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG WB, 1988, J BACTERIOL, V170, P4823, DOI 10.1128/jb.170.10.4823-4827.1988; WANG WB, 1988, J BACTERIOL, V170, P4816, DOI 10.1128/jb.170.10.4816-4822.1988; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; YU X, 1992, J MOL BIOL, V225, P193, DOI 10.1016/0022-2836(92)91036-O; YU X, 1993, J MOL BIOL, V231, P29, DOI 10.1006/jmbi.1993.1254; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2	38	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8411	8419		10.1074/jbc.270.15.8411	http://dx.doi.org/10.1074/jbc.270.15.8411			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721735	hybrid			2022-12-25	WOS:A1995QT44800011
J	GU, WG; REINES, D				GU, WG; REINES, D			IDENTIFICATION OF A DECAY IN TRANSCRIPTION POTENTIAL THAT RESULTS IN ELONGATION-FACTOR DEPENDENCE OF RNA-POLYMERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-S-II; INITIATION FACTOR-ALPHA; ESCHERICHIA-COLI; TERNARY COMPLEXES; MESSENGER-RNA; EUKARYOTIC TRANSCRIPTION; FACTOR-SII; STRUCTURAL-ANALYSIS; CHAIN ELONGATION; KINETOPLAST DNA	The rate of RNA elongation by RNA polymerase II (pol II) is affected by DNA sequences called intrinsic arrest sites. Efficient transcription through these sites requires elongation factor SII. In addition to the sequence-specific features of the DNA, we show that the acquisition of SII-dependence is a function of its ''dwell-time'' at an arrest site. This temperature-dependent decay in elongation potential appears irreversible, implying that factor-dependent and factor-independent elongation complexes are not mutually interconvertible at this position. TFIIF and NH4Cl are known to increase the elongation rate of pol II. Both agents preempt arrest, consistent with the idea that elongation dwell time influences the process. TFIIF and SII act upon different steps in a complementary way to prevent or resolve arrest, respectively. They are probably instrumental in facilitating the efficient transcription of large eukaryotic genes in vivo.	EMORY UNIV,SCH MED,GRAD PROGRAM BIOCHEM & MOLEC BIOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University; Emory University			excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046331] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; CHEN HC, 1992, GENE, V116, P253, DOI 10.1016/0378-1119(92)90522-Q; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; FLORES O, 1989, J BIOL CHEM, V264, P8913; GRIFFITH J, 1986, CELL, V46, P717, DOI 10.1016/0092-8674(86)90347-8; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LANG WH, 1994, CELL, V79, P527, DOI 10.1016/0092-8674(94)90261-5; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; MARINI JC, 1984, J BIOL CHEM, V259, P8974; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MOTE J, 1994, J MOL BIOL, V236, P725, DOI 10.1006/jmbi.1994.1185; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; REINES D, 1991, J BIOL CHEM, V266, P10510; REINES D, 1994, TRANSCRIPTION MECHAN, P263; ROBERTS J, 1992, TRANSCRIPTIONAL REGU, P389; SLUDER AE, 1988, J BIOL CHEM, V263, P9917; TAN SY, 1994, BIOTECHNIQUES, V16, P824; THUMMEL CS, 1992, SCIENCE, V255, P39, DOI 10.1126/science.1553530; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WIEST DK, 1992, J BIOL CHEM, V267, P7733; WIEST DK, 1990, MOL CELL BIOL, V10, P5782, DOI 10.1128/MCB.10.11.5782; XU QH, 1994, J BIOL CHEM, V269, P3100; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	63	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11238	11244		10.1074/jbc.270.19.11238	http://dx.doi.org/10.1074/jbc.270.19.11238			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744757	Green Accepted, hybrid			2022-12-25	WOS:A1995QX86500034
J	RAZI, N; LINDAHL, U				RAZI, N; LINDAHL, U			BIOSYNTHESIS OF HEPARIN HEPARAN-SULFATE - THE D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE REACTIONS - TARGET AND INHIBITOR SACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITHROMBIN-BINDING SEQUENCE; HIGH-AFFINITY; SUBSTRATE-SPECIFICITY; NITROUS-ACID; DEPOLYMERIZATION; FRAGMENTS; RESIDUES; REGION; CELLS	O-Sulfation at C-3 of N-sulfated GlcN units concludes polymer modification and the formation of antithrombin binding regions in the biosynthesis of heparin/heparan sulfate, The resulting GlcNSO(3)(3-OSO3) units are largely restricted to heparin chains with high affinity for antithrombin (H-A heparin). Low affinity (L(A)) heparin fails to serve as a substrate in the 3-O-sulfotransferase reaction yet contains potential 3-O-sulfate acceptor sites (Kusche, M., Torri, G., Casu, B., and Lindahl, U. (1990) J. Biol, Chem, 265, 7292-7300), as verified in the present study using a novel sequencing procedure, O-Desulfated, re-N-sulfated L(A) heparin, as well as an octasaccharide fraction isolated after heparinase I digestion of L(A) heparin, both yielded labeled H-A components following incubation with solubilized mouse mastocytoma microsomal enzymes and [S-35]adenosine 3'-phosphate 5'phosphosulfate (PAPS), suggesting that the 3-O-sulfotransferase may be inhibited by sulfated saccharide sequences outside the 3-O-sulfate acceptor region, Indeed, the addition of L(A) heparin precluded enzymatic 3-O-sulfation of a synthetic pentasaccharide substrate, The K-m for the pentasaccharide was determined to similar to be 6 mu M. Incubations of mixed pentasaccharide substrate and saccharide inhibitors revealed K-i values for intact L(A) heparin and for a heparin octasaccharide fraction of similar to 1.3 and similar to 0.7 mu M, respectively, Inhibition experiments with selectively desulfated heparin indicated that both IdoA 2-O-sulfate and GlcN 6-O-sulfate groups contributed to the inhibition of the 3-O-sulfotransferase. By contrast, chondroitin sulfate or dermatan sulfate showed no significant inhibitory activity, It is proposed that the regulation of GlcN 3-O-sulfation during biosynthesis of heparin/heparan sulfate depends on the topological organization of the membrane-bound enzyme machinery in the intact cell.			RAZI, N (corresponding author), UNIV UPPSALA,CTR BIOMED,DEPT MED & PHYSIOL CHEM,BOX 575,S-75123 UPPSALA,SWEDEN.							ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CONRAD HE, 1992, ADV EXP MED BIOL, V313, P31; FURTH J, 1957, P SOC EXP BIOL MED, V95, P824; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HOOK M, 1976, FEBS LETT, V66, P90, DOI 10.1016/0014-5793(76)80592-3; JACOBSSON I, 1984, J BIOL CHEM, V259, P1056; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; KUSCHE M, 1991, J BIOL CHEM, V266, P7400; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LANE DA, 1986, J BIOL CHEM, V261, P3980; LAURENT TC, 1978, BIOCHEM J, V175, P691, DOI 10.1042/bj1750691; LEVY L, 1962, P SOC EXP BIOL MED, V190, P901; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LOGANATHAN D, 1990, BIOCHEMISTRY-US, V29, P4362, DOI 10.1021/bi00470a015; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; PEJLER G, 1988, J BIOL CHEM, V263, P5197; PEJLER G, 1987, J BIOL CHEM, V262, P5036; PETITOU M, 1988, CARBOHYD RES, V179, P163, DOI 10.1016/0008-6215(88)84116-8; PETITOU M, 1987, CARBOHYD RES, V167, P67, DOI 10.1016/0008-6215(87)80268-9; RENOSTO F, 1977, ARCH BIOCHEM BIOPHYS, V180, P416, DOI 10.1016/0003-9861(77)90056-X; RIESENFELD J, 1981, J BIOL CHEM, V256, P2389; ROBBINS PW, 1962, METHOD ENZYMOL, V5, P964, DOI 10.1016/S0076-6879(62)05343-4; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; VANBOECKEL CAA, 1993, ANGEW CHEM INT EDIT, V32, P1671, DOI 10.1002/anie.199316713	43	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11267	11275		10.1074/jbc.270.19.11267	http://dx.doi.org/10.1074/jbc.270.19.11267			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744762	hybrid			2022-12-25	WOS:A1995QX86500039
J	WU, J; SPIEGEL, S; STURGILL, TW				WU, J; SPIEGEL, S; STURGILL, TW			SPHINGOSINE 1-PHOSPHATE RAPIDLY ACTIVATES THE MITOGEN-ACTIVATED PROTEIN-KINASE PATHWAY BY A G-PROTEIN-DEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; NECROSIS-FACTOR-ALPHA; MAP KINASE; CELL-PROLIFERATION; 3T3 CELLS; CERAMIDE; IDENTIFICATION; SPHINGOSINE-1-PHOSPHATE; SPHINGOMYELINASE; DIFFERENTIATION	Addition of sphingosine 1-phosphate induces proliferation of quiescent Swiss 3T3 fibroblasts by unknown mechanisms. To identify the pathways involved, the ability of sphingosine 1-phosphate to activate mitogen-activated protein (MAP) kinase was studied. Sphingosine 1-phosphate rapidly activated the Raf/MAP kinase kinase (MKK)/MAP kinase pathway, and the concentration dependence for MAP kinase activation correlated with that for induction of DNA synthesis. Both MKK1 and MKK2 were activated by sphingosine 1-phosphate, assessed by specific immune complex kinase assays. Prior treatment of the Swiss 3T3 cells with pertussis toxin inhibited 70-80% of the sphingosine 1-phosphate-stimulated MAP kinase activity, Thus, one of the direct or indirect targets of exogenous sphingosine 1-phosphate appears to be a G(i)/G(o) protein.	UNIV VIRGINIA,HLTH SCI CTR,HOWARD HUGHES MED INST,DEPT MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,MARKEY CTR CELL SIGNALING,CHARLOTTESVILLE,VA 22908; GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007	Howard Hughes Medical Institute; University of Virginia; University of Virginia; University of Virginia; Georgetown University			Wu, Jie/R-2404-2019	Wu, Jie/0000-0002-2864-1606	NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041077] Funding Source: NIH RePORTER; NCI NIH HHS [CA61774] Funding Source: Medline; NIDDK NIH HHS [NIDK41077] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DESAI NN, 1993, J CELL BIOL, V121, P385; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DURIEUX ME, 1993, TRENDS PHARMACOL SCI, V14, P249, DOI 10.1016/0165-6147(93)90021-B; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; JALINK K, 1994, IN PRESS BIOCH J; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; KIM MY, 1991, J BIOL CHEM, V266, P484; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RAINES MA, 1993, J BIOL CHEM, V268, P14572; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SPIEGEL S, 1993, ADV LIPID RES, V25, P105; SU Y, 1994, J BIOL CHEM, V269, P16512; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZHANG H, 1990, J BIOL CHEM, V265, P21309	46	181	183	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11484	11488		10.1074/jbc.270.19.11484	http://dx.doi.org/10.1074/jbc.270.19.11484			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744787	hybrid			2022-12-25	WOS:A1995QX86500066
J	FEVE, B; PIETRIROUXEL, F; ELHADRI, K; DRUMARE, MF; STROSBERG, AD				FEVE, B; PIETRIROUXEL, F; ELHADRI, K; DRUMARE, MF; STROSBERG, AD			LONG-TERM PHORBOL ESTER TREATMENT DOWN-REGULATES THE BETA(3)-ADRENERGIC RECEPTOR IN 3T3-F442A ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BETA-ADRENERGIC-RECEPTOR; HUMAN BETA-3-ADRENERGIC RECEPTOR; 3T3-L1 FIBROBLASTS; ADENYLATE-CYCLASE; RAT ADIPOCYTES; MOLECULAR CHARACTERIZATION; INSULIN; PHOSPHORYLATION; DESENSITIZATION	The role of protein kinase C (PKC) in the regulation of the beta(3)-adrenergic receptor (beta(3)-AR) gene was examined in murine 3T3-F442A adipocytes, which express this receptor subtype at a high level, We also investigated the involvement of this kinase in the modulation of beta(3)-AR gene expression by insulin, Long term exposure of 3T3-F442A adipocytes to phorbol 12-myristate 13-acetate (PMA) decreased beta(3)-AR mRNA content in a time- and concentration dependent manner, with maximal changes observed at 6 h (6.5-fold decrease) and at 100 nM PMA. This inhibition was selective for beta(3)-AR transcripts, since beta(1)- and beta(2)-AR mRNA content remained unchanged, Also, (-)-[I-125] cyanopindolol saturation and competition binding experiments on adipocyte membranes indicated that PMA induced an similar to 2-fold decrease in beta(3)-AR expression, while that of the two other subtypes was not affected, This correlated with a lower efficacy of beta(3)-AR agonists to stimulate adenylyl cyclase, Conversely, long term exposure to PMA did not alter adenylyl cyclase activity in response to guanosine 5'-O-(3-thiotriphosphate) or forskolin, The inactive phorbol ester 4 alpha-phorbol 12,13-didecanoate did not repress beta(3)-AR mRNA levels. Inhibition of beta(3)-AR mRNA by PMA was suppressed by the PKC-selective inhibitor bisindolylmaleimide, and was not observed in PKC-depleted cells, indicating that PKC was involved in this response, mRNA turnover experiments showed that the half-life of beta(3)-AR transcripts was not affected by long term PMA exposure. When 3T3-F442A adipocytes were pretreated with PMA for 24 h to downregulate PKC, or with bisindolylmaleimide, the insulin-induced inhibition of beta(3)-AR mRNA levels was reduced by 44-67%, These findings demonstrate that sustained PKC activation exerts a specific control of beta(3)-AR gene expression and is involved, at least in part, in the modulation by insulin of this adrenergic receptor subtype.	CNRS,UPR 0415,F-75014 PARIS,FRANCE; UNIV PARIS 07,INST COCHIN GENET MOLEC,F-75014 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	FEVE, B (corresponding author), HOP HENRI MONDOR,INSERM,U82,F-94010 CRETEIL,FRANCE.			EL HADRI, KHADIJA/0000-0002-1275-9861; Feve, Bruno/0000-0001-6577-9009; Pietri-Rouxel, France/0000-0002-6258-7594				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ARCH JRS, 1993, MED RES REV, V13, P663, DOI 10.1002/med.2610130604; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; BLIN N, 1993, MOL PHARMACOL, V44, P1094; BOUVIER M, 1991, FEBS LETT, V279, P243, DOI 10.1016/0014-5793(91)80159-Z; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BROWN JA, 1994, DNA SEQUENCE, V4, P319, DOI 10.3109/10425179409020858; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHAMBAUTGUERIN AM, 1987, EUR J BIOCHEM, V170, P381, DOI 10.1111/j.1432-1033.1987.tb13711.x; CHERQUI G, 1986, ENDOCRINOLOGY, V118, P1759, DOI 10.1210/endo-118-5-1759; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS S, 1991, ANNU REV PHYSIOL, V53, P497, DOI 10.1146/annurev.physiol.53.1.497; EDWARDS DR, 1994, TRENDS PHARMACOL SCI, V15, P239, DOI 10.1016/0165-6147(94)90318-2; EGAN JJ, 1990, P NATL ACAD SCI USA, V87, P1052, DOI 10.1073/pnas.87.3.1052; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; FEVE B, 1991, J BIOL CHEM, V266, P20329; FEVE B, 1990, J BIOL CHEM, V265, P16343; FEVE B, 1992, J BIOL CHEM, V267, P15909; FEVE B, 1994, P NATL ACAD SCI USA, V91, P5677, DOI 10.1073/pnas.91.12.5677; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GRANNEMAN JG, 1994, ENDOCRINOLOGY, V135, P1025, DOI 10.1210/en.135.3.1025; GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; HEIDENREICH KA, 1993, J BIOL CHEM, V268, P1463; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; JOHNSON JA, 1990, MOL PHARMACOL, V38, P289; KELLEHER DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4316, DOI 10.1073/pnas.81.14.4316; KRIEF S, 1994, J BIOL CHEM, V269, P6664; LAI E, 1982, J BIOL CHEM, V257, P6691; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MESSINA JL, 1994, ENDOCRINOLOGY, V135, P2327, DOI 10.1210/en.135.6.2327; MESSINA JL, 1992, J BIOL CHEM, V267, P9223; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; NAKADA MT, 1990, J PHARMACOL EXP THER, V253, P221; NAKADA MT, 1987, MOL PHARMACOL, V31, P377; NAKADA MT, 1989, BIOCHEM J, V260, P53, DOI 10.1042/bj2600053; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NANTEL F, 1994, J BIOL CHEM, V269, P13148; NANTEL F, 1993, MOL PHARMACOL, V43, P548; OBRIEN RM, 1991, P NATL ACAD SCI USA, V88, P6580, DOI 10.1073/pnas.88.15.6580; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SIBLEY DR, 1984, BIOCHEM BIOPH RES CO, V121, P973, DOI 10.1016/0006-291X(84)90772-1; SMAL J, 1989, P NATL ACAD SCI USA, V86, P4705, DOI 10.1073/pnas.86.12.4705; SRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; STANDAERT ML, 1993, ENDOCRINOLOGY, V132, P689, DOI 10.1210/en.132.2.689; STEIN B, 1993, EMBO J, V10, P3879; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; STUMPO DJ, 1994, J BIOL CHEM, V269, P21184; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANSPRONSEN A, 1993, EUR J BIOCHEM, V213, P1117, DOI 10.1111/j.1432-1033.1993.tb17861.x; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WELSH GI, 1993, FEBS LETT, V316, P241, DOI 10.1016/0014-5793(93)81300-O; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; YUAN NY, 1994, J BIOL CHEM, V269, P23032; ZHAO L, 1994, ENDOCRINOLOGY, V135, P2504, DOI 10.1210/en.135.6.2504	60	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10952	10959		10.1074/jbc.270.18.10952	http://dx.doi.org/10.1074/jbc.270.18.10952			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738037	hybrid			2022-12-25	WOS:A1995QW60100085
J	REDDY, JC; MORRIS, JC; WANG, J; ENGLISH, MA; HABER, DA; SHI, Y; LICHT, JD				REDDY, JC; MORRIS, JC; WANG, J; ENGLISH, MA; HABER, DA; SHI, Y; LICHT, JD			WT1-MEDIATED TRANSCRIPTIONAL ACTIVATION IS INHIBITED BY DOMINANT-NEGATIVE MUTANT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR GENE-PRODUCT; ZINC FINGER PROTEIN; DNA-BINDING SITE; WILMS-TUMOR; KIDNEY DEVELOPMENT; PROMOTER ACTIVITY; POINT MUTATIONS; WT1 GENE; LOCUS; EXPRESSION	The WT1 tumor suppressor gene encodes four isoforms of a zinc finger transcription factor with both activation and repression functions which are dependent upon promoter architecture, Using a simple HSV-tk promoter containing 5'-Egr-1/WT1-binding sites, we found that WT1 isoforms (A) and (B) strongly activated transcription, WT1(A) and (B) bound equally well to the Egr-1/WT1 binding site, but WT1(B), which contains a 17 amino acid insertion compared to WT1(A), was a consistently stronger activator of transcription than WT1(A), Transcriptional activation by wild-type WT1 was inhibited by coexpression of WT(PM) or WT(AR), genetically defined dominant negative alleles of WT1, In vitro, as well as in the yeast two-hybrid system, WT1 protein associated with itself and with dominant negative mutant proteins, The major domain required for self-association and inhibition of transcriptional activation mapped to the first 182 amino acids of WT1, Dominant negative WT1 alleles may play a role in tumorigenesis by associating with wild-type WT1 proteins and decreasing their transcriptional activity.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DEPT MED,DIV MOLEC MED,NEW YORK,NY 10029; CUNY MT SINAI SCH MED,DERALD H RUTTENBERG CANC CTR,DIV NEOPLAST DIS,NEW YORK,NY 10029; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital			Licht, Jonathan/L-4239-2019	Licht, Jonathan/0000-0002-3942-1369	NATIONAL CANCER INSTITUTE [R01CA058596, R37CA058596, R01CA058997, R01CA059998] Funding Source: NIH RePORTER; NCI NIH HHS [CA59998, CA58997, CA58596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BARDEESY N, 1994, GENOMICS, V21, P663, DOI 10.1006/geno.1994.1333; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; DELUCA NA, 1987, NUCLEIC ACIDS RES, V15, P4491, DOI 10.1093/nar/15.11.4491; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEVINE M, 1989, CELL, V59, P105; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MORRIS JF, 1991, ONCOGENE, V6, P2339; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	43	148	154	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10878	10884		10.1074/jbc.270.18.10878	http://dx.doi.org/10.1074/jbc.270.18.10878			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738027	hybrid			2022-12-25	WOS:A1995QW60100075
J	SCHWARZ, A; RAPAPORT, E; HIRSCHBERG, K; FUTERMAN, AH				SCHWARZ, A; RAPAPORT, E; HIRSCHBERG, K; FUTERMAN, AH			A REGULATORY ROLE FOR SPHINGOLIPIDS IN NEURONAL GROWTH - INHIBITION OF SPHINGOLIPID SYNTHESIS AND DEGRADATION HAVE OPPOSITE EFFECTS ON AXONAL BRANCHING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; CULTURED HIPPOCAMPAL-NEURONS; CERAMIDE ANALOG; CELL-SURFACE; GLYCOSPHINGOLIPID SYNTHESIS; ANTISENSE OLIGONUCLEOTIDES; GLUCOSYLCERAMIDE SYNTHESIS; INOSITOL TRISPHOSPHATE; NEURITE OUTGROWTH; SECRETORY PATHWAY	Sphingolipids, particularly gangliosides, are enriched in neuronal membranes where they have been implicated as mediators of various regulatory events, We recently provided evidence that sphingolipid synthesis is necessary to maintain neuronal growth by demonstrating that in hippocampal neurons, inhibition of ceramide synthesis by Fumonisin B-1 (FB1) disrupted axonal outgrowth (Harel, R, and Futerman, A, H, (1993) J, Biol, Chem, 268, 14476-14481), We now analyze further the relationship between neuronal growth and sphingolipid metabolism by examining the effect of an inhibitor of glucosylceramide synthesis, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) and by examining the effects of both FB1 and PDMP at various stages of neuronal development, No effects of FB1 or PDMP were observed during the first 2 days in culture, but by day 3 axonal morphology was significantly altered, irrespective of the time of addition of the inhibitors to the cultures, Cells incubated with FB1 or PDMP had a shorter axon plexus and less axonal branches, FB1 appeared to cause a retraction of axonal branches between days 2 and 3, although long term incubation had no apparent effect on neuronal morphology or on the segregation of axonal or dendritic proteins, In contrast, incubation of neurons with conduritol B-epoxide, an inhibitor of glucosylceramide degradation, caused an increase in the number of axonal branches and a corresponding increase in the length of the axon plexus, A direct correlation was observed between the number of axonal branch points per cell and the extent of inhibition of either sphingolipid synthesis or degradation, These results suggest that sphingolipids play an important role in the formation or stabilization of axonal branches.	UNIV BATH,DEPT BIOCHEM,BATH BA2 7AY,AVON,ENGLAND	University of Bath	SCHWARZ, A (corresponding author), WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL.			Futerman, Anthony/0000-0003-0013-0115				BERSHADSKY AD, 1994, P NATL ACAD SCI USA, V91, P5686, DOI 10.1073/pnas.91.12.5686; BLACKBURN CC, 1986, J BIOL CHEM, V261, P2873; BRAY D, 1978, P NATL ACAD SCI USA, V75, P5226, DOI 10.1073/pnas.75.10.5226; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CACERES A, 1986, J NEUROSCI, V6, P714; DOHERTY P, 1992, J CELL BIOL, V117, P1093, DOI 10.1083/jcb.117.5.1093; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; FELDINGHABERMANN B, 1990, BIOCHEMISTRY-US, V29, P6314, DOI 10.1021/bi00478a028; FENTIE IH, 1993, J NEUROCYTOL, V22, P498, DOI 10.1007/BF01181569; FERREIRA A, 1992, J CELL BIOL, V117, P595, DOI 10.1083/jcb.117.3.595; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1994, TRENDS GLYCOSCI GLYC, V6, P143; Futerman Anthony H., 1994, V40, P93; GOSLIN K, 1988, NATURE, V336, P672, DOI 10.1038/336672a0; Goslin K., 1991, CULTURING NERVE CELL, P251; HAKAMORI S, 1990, J BIOL CHEM, V265, P18713; HANADA K, 1992, J BIOL CHEM, V267, P23527; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAREL R, 1993, J BIOL CHEM, V268, P14476; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; INOKUCHI J, 1990, CANCER RES, V50, P6731; INOKUCHI JI, 1989, J CELL PHYSIOL, V141, P573, DOI 10.1002/jcp.1041410316; JAREB M I, 1991, Society for Neuroscience Abstracts, V17, P739; JOSHI HC, 1993, J CELL BIOL, V121, P1191, DOI 10.1083/jcb.121.6.1191; KAN CC, 1992, J BIOL CHEM, V267, P9663; KIRSCH J, 1990, J NEUROCHEM, V55, P1031, DOI 10.1111/j.1471-4159.1990.tb04593.x; LEDEEN RW, 1989, NEUROBIOLOGY GLYCOCO, P43; Legler G, 1977, Methods Enzymol, V46, P368; LEIN PJ, 1991, DEV BRAIN RES, V60, P187, DOI 10.1016/0165-3806(91)90047-M; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1990, P NATL ACAD SCI USA, V87, P7419, DOI 10.1073/pnas.87.19.7419; MAHDIYOUN S, 1992, ARCH BIOCHEM BIOPHYS, V292, P506, DOI 10.1016/0003-9861(92)90023-P; MEIVARLEVY I, 1994, BIOCHEM J, V303, P377, DOI 10.1042/bj3030377; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MORRIS R, 1985, DEV NEUROSCI-BASEL, V7, P133, DOI 10.1159/000112283; OKADA Y, 1988, FEBS LETT, V235, P25, DOI 10.1016/0014-5793(88)81227-4; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Radin N S, 1981, Methods Enzymol, V72, P673; RADIN NS, 1993, ADV LIPID RES, V26, P183; ROSENWALD AG, 1992, BIOCHEMISTRY-US, V31, P3581, DOI 10.1021/bi00129a005; ROSENWALD AG, 1993, J BIOL CHEM, V268, P4577; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; SHUKLA GS, 1991, BIOCHIM BIOPHYS ACTA, V1083, P101, DOI 10.1016/0005-2760(91)90130-A; SIEGEL DA, 1994, J NEUROCHEM, V62, P1852; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SOFER A, 1995, IN PRESS J BIOL CHEM, V270; SPIEGEL S, 1986, J CELL BIOL, V102, P1898, DOI 10.1083/jcb.102.5.1898; UEMURA K, 1990, J BIOCHEM-TOKYO, V108, P525; UEMURA K, 1991, J BIOCHEM-TOKYO, V110, P96, DOI 10.1093/oxfordjournals.jbchem.a123549; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; WALSH FS, 1992, GPI MEMBRANE ANCHORS, P294; WANG E, 1991, J BIOL CHEM, V266, P14486; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; WU GS, 1990, J NEUROCHEM, V55, P484, DOI 10.1111/j.1471-4159.1990.tb04161.x; Yu R.K., 1989, NEUROBIOLOGY GLYCOCO, P1; YU WQ, 1994, J NEUROSCI, V14, P5872; ZELLER CB, 1992, AM J PHYSIOL, V262, pC1341, DOI 10.1152/ajpcell.1992.262.6.C1341	62	145	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10990	10998		10.1074/jbc.270.18.10990	http://dx.doi.org/10.1074/jbc.270.18.10990			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738041	hybrid			2022-12-25	WOS:A1995QW60100090
J	GOOD, DW				GOOD, DW			HYPEROSMOLALITY INHIBITS BICARBONATE ABSORPTION IN RAT MEDULLARY THICK ASCENDING LIMB VIA A PROTEIN-TYROSINE KINASE-DEPENDENT PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-VOLUME REGULATION; NA+/H+ EXCHANGER; PHOSPHATASE-ACTIVITY; SIGNAL TRANSDUCTION; HERBIMYCIN-A; PHOSPHORYLATION; ACTIVATION; LYMPHOCYTES; MECHANISMS; SHRINKAGE	In the rat medullary thick ascending limb (MTAL), hyperosmolality inhibits transepithelial HCO, absorption (JHCO(3)(-)) by inhibiting apical membrane Na+/H+ exchange, To examine signaling mechanisms involved in this regulatory response, MTALs were isolated and perfused in vitro with 25 mM HCO3- solutions (290 mosmol/kg H2O). Osmolality was increased in lumen and bath solutions by addition of 300 mM mannitol or 75 mM NaCl. Addition of mannitol reduced JHCO(3)(-) by 60% and addition of NaCl reduced JHCO(3)(-) by 50%. With the protein tyrosine kinase (PTK) inhibitor genistein (7 mu M) or herbimycin A (1 mu M) in the bath, addition of mannitol reduced JHCO(3)(-) only by 11% and addition of NaCl reduced JHCO(3)(-) only by 15%. Staurosporine (10(-7) M) or forskolin (10(-6) M) in the bath had no effect on inhibition of JHCO(3)(-) by hypertonic NaCl. Genistein had no effect on inhibition of JHCO(3)(-) by vasopressin (a cyclic AMP-dependent process) or stimulation of JHCO(3)(-) by prostaglandin E(2) (a protein kinase C-dependent process). Under isosmotic conditions, addition of genistein or herbimycin A to the bath increased JHCO(3)(-) by 30% through stimulation of apical membrane Na+/H+ exchange, Addition of the tyrosine phosphatase inhibitor molybdate (50 mu M) to the bath reproduced the inhibition of JHCO(3)(-) observed with hyperosmolality. These data indicate that 1) the effect of hyperosmolality to inhibit MTAL HCO3- absorption through inhibition of apical membrane Na+/H+ exchange is mediated via a PTK-dependent pathway that functions independent of regulation by cyclic AMP and protein kinase C, and 2) a constitutive PTR activity inhibits apical membrane Na+/H+ exchange and HCO3- absorption under isosmotic conditions, Our results suggest that tyrosine phosphorylation is a critical step in inhibition of the apical Na+/H+ exchanger isoform NHE-3 by hyperosmolality.	UNIV TEXAS, MED BRANCH, DEPT PHYSIOL & BIOPHYS, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	GOOD, DW (corresponding author), UNIV TEXAS, MED BRANCH, DEPT INTERNAL MED, 301 UNIV BLVD, 4 200 JOHN SEALY HOSP E-62, GALVESTON, TX 77555 USA.				NIDDK NIH HHS [DK38217] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038217] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; BORENSZTEIN P, 1994, J AM SOC NEPHROL, V5, P248; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHAMBERLIN ME, 1989, AM J PHYSIOL, V257, pC159, DOI 10.1152/ajpcell.1989.257.2.C159; DAVIS BA, 1992, AM J PHYSIOL, V262, pC533, DOI 10.1152/ajpcell.1992.262.2.C533; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; Good David W., 1992, Journal of the American Society of Nephrology, V3, P777; GOOD DW, 1984, AM J PHYSIOL, V247, pF35, DOI 10.1152/ajprenal.1984.247.1.F35; GOOD DW, 1992, J CLIN INVEST, V89, P184, DOI 10.1172/JCI115560; GOOD DW, 1993, SEMIN NEPHROL, V13, P225; GOOD DW, 1990, J CLIN INVEST, V85, P1006, DOI 10.1172/JCI114530; GOOD DW, 1994, J AM SOC NEPHROL, V5, P679; GREEN J, 1988, J BIOL CHEM, V263, P5012; GRINSTEIN S, 1985, J GEN PHYSIOL, V85, P765, DOI 10.1085/jgp.85.5.765; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1986, J BIOL CHEM, V261, P8009; GRINSTEIN S, 1985, J CELL BIOL, V101, P269, DOI 10.1083/jcb.101.1.269; Grinstein Sergio, 1992, News in Physiological Sciences, V7, P232; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEBERT SC, 1986, AM J PHYSIOL, V250, pC920, DOI 10.1152/ajpcell.1986.250.6.C920; HEBERT SC, 1986, AM J PHYSIOL, V250, pC907, DOI 10.1152/ajpcell.1986.250.6.C907; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; JENNINGS ML, 1990, J GEN PHYSIOL, V95, P1021, DOI 10.1085/jgp.95.6.1021; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KIRK KL, 1984, J MEMBRANE BIOL, V79, P53, DOI 10.1007/BF01868526; KNOX KA, 1994, CELL IMMUNOL, V155, P62, DOI 10.1006/cimm.1994.1102; LANE PJL, 1991, J IMMUNOL, V146, P715; MAHER PA, 1993, P NATL ACAD SCI USA, V90, P11177, DOI 10.1073/pnas.90.23.11177; PARKER JC, 1990, J GEN PHYSIOL, V96, P1141, DOI 10.1085/jgp.96.6.1141; SOLEIMANI M, 1994, J BIOL CHEM, V269, P15613; SUN AM, 1994, J AM SOC NEPHROL, V5, P263; TILLY BC, 1993, J BIOL CHEM, V268, P19919; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TSE M, 1993, J AM SOC NEPHROL, V4, P969; TSUNODA Y, 1993, AM J PHYSIOL, V264, pG351, DOI 10.1152/ajpgi.1993.264.2.G351; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WATTS B A III, 1991, Journal of the American Society of Nephrology, V2, P715; WATTS BA, 1994, J BIOL CHEM, V269, P20250; YAO XR, 1993, CELL IMMUNOL, V149, P364, DOI 10.1006/cimm.1993.1162	46	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9883	9889		10.1074/jbc.270.17.9883	http://dx.doi.org/10.1074/jbc.270.17.9883			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730371	hybrid			2022-12-25	WOS:A1995QV41700030
J	HALDEMAN, MT; FINLEY, D; PICKART, CM				HALDEMAN, MT; FINLEY, D; PICKART, CM			DYNAMICS OF UBIQUITIN CONJUGATION DURING ERYTHROID-DIFFERENTIATION IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; DEPENDENT PROTEOLYTIC PATHWAY; PROTEIN LIGASE SYSTEM; REPAIR GENE RAD6; N-END RULE; CARRIER PROTEINS; RETICULOCYTE MATURATION; AFFINITY PURIFICATION; MULTIUBIQUITIN CHAIN; E6 ONCOPROTEIN	To gain insight into the role of ubiquitin-mediated proteolysis in erythroid differentiation, levels of ubiquitin conjugating enzymes (E2s) and ubiquitin conjugates were analyzed during in vitro differentiation of murine erythroleukemic (MEL) cells, After 4 days of culture in the presence of the inducer dimethyl sulfoxide, MEL cells expressed high levels of the erythroid-specific proteins, globin, and band 3. During the same interval, cellular contents (mol/cell) of E2-14K, E2-25K, and E2-35K decreased up to similar to 5-fold; as suggested by results obtained with E2-25K, this reflected a lower level of mRNA in differentiating cells. Concentrations of these E2s changed more modestly during in vitro differentiation, since cellular volume also decreased. Comparison of levels of the three E2s in undifferentiated MEL cells and reticulocytes suggests that their concentrations remain fairly constant during in vivo differentiation of proerythroblasts into reticulocytes. Thus, these components of the ubiquitin-mediated proteolytic pathway are likely to function constitutively during this interval. Two dimensional Western blots showed a broad spectrum of ubiquitin conjugates, including free multiubiquitin chains, in undifferentiated MEL cells. As seen for several E2s, the concentration of ubiquitin conjugates (including free chains) decreased modestly during in vitro differentiation. E2-20K and E2-230K, which are abundant in reticulocytes, were low or absent in undifferentiated and differentiated MEL cells, In erythroid cells these two E2s are reticulocyte-specific; apparently MEL cells do not differentiate far enough to allow induction of their expression.	SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT BIOCHEM, BUFFALO, NY 14214 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043769] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43769] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BERLETH ES, 1990, BIOCHEM BIOPH RES CO, V171, P705, DOI 10.1016/0006-291X(90)91203-5; BOCHES FS, 1982, SCIENCE, V215, P978, DOI 10.1126/science.7156977; BOND U, 1988, J BIOL CHEM, V263, P2384; BULL BS, 1990, HEMATOLOGY, P297; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DICOLA D, 1991, FEBS LETT, V280, P137, DOI 10.1016/0014-5793(91)80222-O; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GREGORI L, 1990, J BIOL CHEM, V265, P8354; GUO GG, 1994, J BIOL CHEM, V269, P12399; GUPTAROY B, 1992, J BIOL CHEM, V267, P15326; HAAS AL, 1985, J BIOL CHEM, V260, P4694; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1991, ADV EXP MED BIOL, V307, P191; HAAS AL, 1987, J BIOL CHEM, V262, P345; HADARI T, 1992, J BIOL CHEM, V267, P719; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HERSHKO A, 1982, J BIOL CHEM, V257, P13694; HERSHKO A, 1982, P NATL ACAD SCI USA, V77, P1783; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; KLEMPERER NS, 1989, BIOCHEMISTRY-US, V28, P6035, DOI 10.1021/bi00440a047; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENK SE, 1992, J CELL BIOL, V118, P301, DOI 10.1083/jcb.118.2.301; MA CP, 1994, J BIOL CHEM, V269, P3539; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MAGNANI M, 1986, J BIOL CHEM, V261, P8327; MAGNANI M, 1991, J BIOL CHEM, V266, P21018; MAGNANI M, 1994, BBA-PROTEIN STRUCT M, V1206, P180, DOI 10.1016/0167-4838(94)90206-2; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARAG HA, 1987, EMBO J, V6, P55, DOI 10.1002/j.1460-2075.1987.tb04718.x; PARKER D, 1985, J BIOL CHEM, V260, P604; PATEL VP, 1987, J CELL BIOL, V105, P3105, DOI 10.1083/jcb.105.6.3105; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1992, J BIOL CHEM, V267, P14418; PICKART CM, 1989, ARCH BIOCHEM BIOPHYS, V272, P114, DOI 10.1016/0003-9861(89)90201-4; PICKART CM, 1991, DEV GROWTH DIFFER, V33, P587; PICKART CM, 1988, J BIOL CHEM, V263, P12028; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; RAPOPORT SM, 1986, RETICULOCYTE; RAVIV O, 1987, BIOCHEM BIOPH RES CO, V145, P658, DOI 10.1016/0006-291X(87)91015-1; RAWNSLEY HM, 1981, CLIN BIOCH HEMATOLOG; REISS Y, 1990, J BIOL CHEM, V265, P3685; SAWYER ST, 1987, METHOD ENZYMOL, V147, P340; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; SHIMBARA N, 1992, J BIOL CHEM, V267, P18100; SHIMBARA N, 1993, FEBS LETT, V322, P235, DOI 10.1016/0014-5793(93)81577-M; SPEISER S, 1982, J BIOL CHEM, V257, P4122; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; STECK TL, 1971, BIOCHEMISTRY-US, V10, P2617, DOI 10.1021/bi00789a031; TSUKAHARA T, 1990, EXP CELL RES, V188, P111, DOI 10.1016/0014-4827(90)90284-H; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; VOLLOCH V, 1982, J CELL BIOL, V93, P390, DOI 10.1083/jcb.93.2.390; WFES I, 1995, IN PRESS P NATL ACAD; WING SS, 1992, J BIOL CHEM, V267, P6495	79	25	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9507	9516		10.1074/jbc.270.16.9507	http://dx.doi.org/10.1074/jbc.270.16.9507			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721879	Green Submitted, hybrid			2022-12-25	WOS:A1995QU08900068
J	SEELIG, GF; PROSISE, WW; HAWKINS, JC; SENIOR, MM				SEELIG, GF; PROSISE, WW; HAWKINS, JC; SENIOR, MM			DEVELOPMENT OF A RECEPTOR PEPTIDE ANTAGONIST TO HUMAN GAMMA-INTERFERON AND CHARACTERIZATION OF ITS LIGAND-BOUND CONFORMATION USING TRANSFERRED NUCLEAR OVERHAUSER EFFECT SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; EXTRACELLULAR DOMAIN; IFN-GAMMA; PROTEIN; ANTIBODY; COMPLEX; BINDING; ANTIGEN; IDENTIFICATION; RECOGNITION	Polyclonal anti-idiotypic antibody raised to a synthetic discontinuous peptide derived from the human gamma-interferon (huIFN-gamma) sequence recognizes soluble human gamma-interferon receptor (Seelig, G. F., Prosise, W. W., and Taremi, S, S, (1994) J. Biol, Chem, 269, 358-363), We sought to use this reagent to identify a ligand-binding domain within IFN-gamma-receptor. To do this, the neutralizing anti-idiotypic antibody was used to probe overlapping linear peptide octamers of the extracellular do main of the huIFN-gamma receptor, A 22-amino acid residue receptor segment 120-141 identified by the antibody was synthesized, CD and NMR analysis indicates that peptide 120-141 has no apparent secondary structure in water or in water containing 50% trifluoroethanol, The synthetic receptor peptide inhibited huIFN-gamma induced expression of HLA/DR antigen on Cole 205 cells with an approximate IC50 of 35 mu M. Immobilized peptide specifically bound recombinant huIFN-gamma but did not bind human granulocyte-macrophage colony-stimulating factor on a microtiter plate in a direct binding enzyme-linked immunosorbent assay. The binding results are supported by two-dimensional transferred nuclear Overhauser effect (TRNOE) NMR data obtained on the peptide in the presence of recombinant huIFN-gamma. Characterization of the conformation of the bound peptide by TRNOE suggests that this peptide assumes a distinct conformation. Intramolecular interactions within the bound peptide were detected at two non-contiguous regions and at a third region comprising a p-turn formed by the sequence DIRK. We believe that this represents the structure of the receptor within the ligand-binding domain.	SCHERING PLOUGH CORP,RES INST,DEPT PHYS ANALYT CHEM RES & DEV,KENILWORTH,NJ 07033	Merck & Company; Schering Plough Corporation	SEELIG, GF (corresponding author), SCHERING PLOUGH CORP,RES INST,DEPT STRUCT CHEM,KENILWORTH,NJ 07033, USA.							AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSHWELLER JH, 1991, BIOCHEMISTRY-US, V30, P8144, DOI 10.1021/bi00247a008; CAMPBELL AP, 1991, J MAGN RESON, V93, P77, DOI 10.1016/0022-2364(91)90033-P; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIGHE AS, 1993, J BIOL CHEM, V268, P10645; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FOUNTOULAKIS M, 1991, J BIOL CHEM, V266, P14970; FOUNTOULAKIS M, 1992, EUR J BIOCHEM, V208, P781, DOI 10.1111/j.1432-1033.1992.tb17248.x; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GAROTTA G, 1990, J BIOL CHEM, V265, P6908; GEORGIADES JA, 1984, INTERFERONS THEIR AP, V71, P305; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GIBBS VC, 1992, MOL CELL BIOL, V11, P5860; GIBSON UEM, 1989, J IMMUNOL METHODS, V125, P105, DOI 10.1016/0022-1759(89)90083-5; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; GRAY PW, 1983, P S BIOL BASIS NEW D, P35; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNN CA, 1992, J BIOL CHEM, V267, P17920; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NAGABHUSAN TL, 1989, Patent No. 4751078; NAGABHUSHAN TL, 1985, INTERFERON ALPHA 2 P, P1; NEUHAUS D, 1989, NUCLEAR OVERHAUSER E, P175; NOGGLE JH, 1971, NUCLEAR OVERHAUSER E, P4; OTTING G, 1993, CURR OPIN STRUC BIOL, V3, P760, DOI 10.1016/0959-440X(93)90061-O; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; RIZO J, 1992, ANNU REV BIOCHEM, V61, P387, DOI 10.1146/annurev.bi.61.070192.002131; SCHERF T, 1992, BIOCHEMISTRY-US, V31, P6884, DOI 10.1021/bi00145a004; SEELIG GF, 1992, J CELL BIOCHEM, V16, P101; SEELIG GF, 1994, J BIOL CHEM, V269, P858; SEELIG GF, 1989, J INTERFERON RES, V4, P184; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STRADLEY SJ, 1993, BIOCHEMISTRY-US, V32, P12586, DOI 10.1021/bi00210a006; STUBER D, 1993, BIOCHEMISTRY-US, V32, P2432; SUKES B, 1991, J MAGN RESON, V93, P77; SZENTE BE, 1994, BIOCHEM BIOPH RES CO, V208, P1645; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; TROTTA P, 1987, Patent No. 883064214; TROTTA PP, 1986, INTERFERONS CELL GRO, P497; VANVOLKENBURG MA, 1993, J IMMUNOL, V151, P6206; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P162	59	7	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9241	9249		10.1074/jbc.270.16.9241	http://dx.doi.org/10.1074/jbc.270.16.9241			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721843	hybrid			2022-12-25	WOS:A1995QU08900031
J	IIDAKLEIN, A; GUO, J; XIE, LY; JUPPNER, H; POTTS, JT; KRONENBERG, HM; BRINGHURST, FR; ABOUSAMRA, AB; SEGRE, GV				IIDAKLEIN, A; GUO, J; XIE, LY; JUPPNER, H; POTTS, JT; KRONENBERG, HM; BRINGHURST, FR; ABOUSAMRA, AB; SEGRE, GV			TRUNCATION OF THE CARBOXYL-TERMINAL REGION OF THE RAT PARATHYROID-HORMONE (PTH)/PTH-RELATED PEPTIDE RECEPTOR ENHANCES PTH STIMULATION OF ADENYLYL-CYCLASE BUT NOT PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; VASOACTIVE-INTESTINAL-PEPTIDE; OSTEOBLAST-LIKE CELLS; EXPRESSION CLONING; INOSITOL TRISPHOSPHATE; MOLECULAR-CLONING; SARCOMA CELLS; CALCIUM; CAMP; POLYPEPTIDE	The functional role of the rat parathyroid hormone(PTH)/PTH-related peptide (PTHrP) receptor's carboxyl-terminal region was characterized by comparing the binding and signaling properties of receptors that have 78 and 111 amino acid deletions (R513 and R480, respectively), with those of the 591-amino acid wild-type (WT) receptor. R480 and R513 have 4- and 1.5-fold lower apparent K-d values for rat PTH-(1-34) (rPTH), compared with the WT receptor (WT, 1.81 +/- 0.19 nM; R513, 1.24 +/- 0.12 nM; R480, 0.48 +/- 0.05 nM, mean +/- S.E.). PTH (100 nM) stimulated cAMP accumulation and polyphosphoinositide hydrolysis both correlated positively with receptor expression. However, whereas PTH-stimulated polyphosphoinositide hydrolysis was indistinguishable among WT and either truncated mutant at comparable levels of expressed receptors, maximal PTH-stimulated cAMP accumulation was 4-6- and 2-3-fold higher in cells expressing R480 and R513, respectively. Furthermore, pretreatment of COS-7 cells with 100 ng/ml of pertussis toxin (PTX) enhanced PTH-stimulated cAMP accumulation in cells expressing the WT receptor, but failed to do so in cells expressing either R480 or R513. Thus, sequences in the PTH/PTHrP receptor's carboxyl-terminal tail lower the affinity of the WT receptor for agonist; directly interact with, or indirectly facilitate the interaction of the receptor with a PTX-sensitive G protein that inhibits adenylyl cyclase; and decrease the efficacy with which the receptor interacts with G(s).	MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Abou-Samra, Abdul/ABE-8723-2020	Abou-Samra, Abdul/0000-0001-8735-1142	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794, F32DK008751] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47034, DK11794, 1-F32-DK08751] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V124, P1107, DOI 10.1210/endo-124-3-1107; ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V125, P2594; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRINGHURST FR, 1992, ENDOCRINOLOGY, V132, P2090; Bylund D.B., 1990, METHODS NEUROTRANSMI, P1; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CIVETELLI R, 1988, AM J PHYSIOL, V253, pE660; EDELMAN A, 1986, AM J PHYSIOL, V251, pC483, DOI 10.1152/ajpcell.1986.251.4.C483; FEYEN JHM, 1984, PROSTAGLANDINS, V28, P269; GUO J, 1993, J BONE MINER RES, V8, pS176; IIDAKLEIN A, 1989, J BONE MINER RES, V4, P767; IIDAKLEIN A, 1991, ENDOCRINOLOGY, V129, P1016, DOI 10.1210/endo-129-2-1016; IIDAKLEIN A, 1989, J BONE MINER RES  S1, V4, P879; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Juppner H, 1994, Curr Opin Nephrol Hypertens, V3, P371; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; KRONENBERG HM, 1993, HDB EXPT PHARM, V107, P507; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; MAYO KE, 1992, MOL ENDOCRINOL, V6, P1734, DOI 10.1210/me.6.10.1734; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PINES M, 1986, BONE MINER, V1, P15; REAGAN JD, 1994, J BIOL CHEM, V269, P9; REID IR, 1987, AM J PHYSIOL, V225, pE9; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SEGRE JV, 1992, J ENDOCRINOL INVEST, V15, P11; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; WANK SA, 1993, P NATIONAL ACADEMY S, V90, P6345; YAMAGUCHI TD, 1987, J BIOL CHEM, V262, P7711	42	84	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8458	8465		10.1074/jbc.270.15.8458	http://dx.doi.org/10.1074/jbc.270.15.8458			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721741	hybrid			2022-12-25	WOS:A1995QT44800017
J	LANDINI, P; VOLKERT, MR				LANDINI, P; VOLKERT, MR			TRANSCRIPTIONAL ACTIVATION OF THE ESCHERICHIA-COLI ADAPTIVE RESPONSE GENE AIDB IS MEDIATED BY BINDING OF METHYLATED ADA PROTEIN - EVIDENCE FOR A NEW CONSENSUS SEQUENCE FOR ADA-BINDING SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYLATING-AGENTS; ALKA GENE; EXPRESSION; DNA; INDUCTION; IDENTIFICATION; REGULATOR; ELEMENTS; PROMOTER; REPAIR	The Escherichia coli aidB gene is part of the adaptive response to DNA methylation damage. Genes belonging to the adaptive response are positively regulated by the ada gene; the Ada protein acts as a transcriptional activator when methylated in one of its cysteine residues at position 69. Through DNaseI protection assays, we show that methylated Ada ((me)Ada) is able to bind a DNA sequence between 40 and 60 base pairs upstream of the aidB transcriptional startpoint. Binding of (me)Ada is necessary to activate transcription of the adaptive response genes; accordingly, in vitro transcription of aidB is dependent on the presence of (me)Ada. Unmethylated Ada protein shows no protection against DNaseI digestion in the aidB promoter region nor does it promote aidB in vitro transcription. The aidB Ada-binding site shows only weak homology to the proposed consensus sequences for Ada-binding sites in E. coli (AAANNAA and AAAGCGCA) but shares a higher degree of similarity with the Ada-binding regions from other bacterial species, such as Salmonella typhimurium and Bacillus subtilis. Based on the comparison of five different Ada-dependent promoter regions, we suggest that a possible recognition sequence for (me)Ada might be AATnnnnnnG-CAA. Higher concentrations of Ada are required for the binding of aidB than for the ada promoter, suggesting lower affinity of the protein for the aidB Ada-binding site. Common features in the Ada-binding regions of ada and aidB are a high A/T content, the presence of an inverted repeat structure, and their position relative to the transcriptional start site. We propose that these elements, in addition to the proposed recognition sequence, are important for binding of the Ada protein.	UNIV MASSACHUSETTS,SCH MED,DEPT MOLEC GENET & MICROBIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester			Landini, Paolo/B-7859-2017	Landini, Paolo/0000-0003-0999-426X; Volkert, Michael/0000-0002-0045-0912	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037052] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37052] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIMARU H, 1990, J MOL BIOL, V216, P261, DOI 10.1016/S0022-2836(05)80318-3; BERTRANDBURGGRAF E, 1990, EMBO J, V9, P2265, DOI 10.1002/j.1460-2075.1990.tb07397.x; HAKURA A, 1991, J BACTERIOL, V173, P3663, DOI 10.1128/JB.173.12.3663-3672.1991; JEGGO P, 1979, J BACTERIOL, V139, P783, DOI 10.1128/JB.139.3.783-791.1979; KATAOKA H, 1983, J BACTERIOL, V153, P1301, DOI 10.1128/JB.153.3.1301-1307.1983; LANDINI P, 1994, J BACTERIOL, V176, P6583, DOI 10.1128/JB.176.21.6583-6589.1994; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; MOROHOSHI F, 1993, J BACTERIOL, V175, P6010, DOI 10.1128/JB.175.18.6010-6017.1993; MOROHOSHI F, 1990, NUCLEIC ACIDS RES, V18, P5473, DOI 10.1093/nar/18.18.5473; NAKABEPPU Y, 1984, J BIOL CHEM, V259, P3730; NAKABEPPU Y, 1986, P NATL ACAD SCI USA, V83, P6297, DOI 10.1073/pnas.83.17.6297; NAKAMURA T, 1988, J MOL BIOL, V202, P483, DOI 10.1016/0022-2836(88)90280-X; PEREZMARTIN J, 1994, MICROBIOL REV, V58, P268; RAIBAUD O, 1984, ANNU REV GENET, V18, P173, DOI 10.1146/annurev.ge.18.120184.001133; SAGET BM, 1994, P NATL ACAD SCI USA, V91, P9730, DOI 10.1073/pnas.91.21.9730; SAKUMI K, 1989, J MOL BIOL, V205, P373, DOI 10.1016/0022-2836(89)90348-3; SAKUMI K, 1993, J BACTERIOL, V175, P2455, DOI 10.1128/JB.175.8.2455-2457.1993; SAMSON L, 1977, NATURE, V267, P281, DOI 10.1038/267281a0; SKLAR R, 1981, NATURE, V289, P417, DOI 10.1038/289417a0; SMIRNOVA GV, 1994, MUTAT RES, V314, P51, DOI 10.1016/0921-8777(94)90060-4; TEO I, 1986, CELL, V45, P315, DOI 10.1016/0092-8674(86)90396-X; VOLKERT MR, 1989, J BACTERIOL, V171, P1196, DOI 10.1128/jb.171.2.1196-1198.1989; VOLKERT MR, 1986, GENETICS, V112, P11; VOLKERT MR, 1989, MUTAT RES, V217, P109, DOI 10.1016/0921-8777(89)90062-1	24	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8285	8289		10.1074/jbc.270.14.8285	http://dx.doi.org/10.1074/jbc.270.14.8285			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713936	hybrid			2022-12-25	WOS:A1995QR52600075
J	SLACK, BE; BREU, J; PETRYNIAK, MA; SRIVASTAVA, K; WURTMAN, RJ				SLACK, BE; BREU, J; PETRYNIAK, MA; SRIVASTAVA, K; WURTMAN, RJ			TYROSINE PHOSPHORYLATION-DEPENDENT STIMULATION OF AMYLOID PRECURSOR PROTEIN SECRETION BY THE M3 MUSCARINIC ACETYLCHOLINE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; SWISS 3T3 CELLS; KINASE-C; BETA-PROTEIN; ALZHEIMERS-DISEASE; PHOSPHOLIPASE-C; PHORBOL ESTER; ADENYLYL CYCLASE; RAT ADIPOCYTES; CLEAVAGE SITE	Stimulation of m1 and m3 muscarinic acetylcholine receptors, which are coupled to phosphoinositide hydrolysis and protein kinase C activation, has been shown to increase the release of soluble amyloid precursor protein derivatives (APPs). The effect is mimicked by phorbol esters, which directly activate protein kinase C. Using human embryonic kidney cells expressing individual muscarinic receptor subtypes, we found that stimulation of APPs release by the muscarinic agonist carbachol was only partially reduced by a specific inhibitor of protein kinase C (the bisindolylmaleimide GF 109203X), while the response to phorbol 12-myristate 13-acetate (PMA) was abolished. The increase in APPs release elicited by carbachol and PMA was accompanied by elevated tyrosine phosphorylation of several proteins and reduced by tyrosine kinase inhibitors; GF 109203X significantly reduced the stimulation of tyrosine phosphorylation by carbachol and PMA. Inhibition of protein tyrosine phosphatases by vanadyl hydroperoxide markedly increased cellular tyrosine phosphorylation and enhanced APPs release as effectively as PMA and carbachol. Direct phosphorylation of amyloid precursor protein on tyrosine residues following treatment with carbachol, PMA, or vanadyl hydroperoxide was not observed. The results implicate both tyrosine phosphorylation and protein kinase C dependent mechanisms in the regulation of APPs release by G protein-coupled receptors, and suggest that carbachol and PMA increase APPs release from human embryonic kidney cells expressing m3 muscarinic receptors via partially divergent pathways that converge at a tyrosine phosphorylation-dependent step.			SLACK, BE (corresponding author), MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139, USA.		Slack, Barbara/AAU-9917-2021	Slack, Barbara/0000-0002-7619-410X				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; ATKINSON TP, 1993, J IMMUNOL, V151, P1448; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BISHOP R, 1983, BIOCHEM BIOPH RES CO, V115, P536, DOI 10.1016/S0006-291X(83)80178-8; BLANK JL, 1991, J BIOL CHEM, V266, P18206; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; EMMERLING MR, 1993, BIOCHEM BIOPH RES CO, V197, P292, DOI 10.1006/bbrc.1993.2474; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GREENBERG SM, 1994, P NATL ACAD SCI USA, V91, P7104, DOI 10.1073/pnas.91.15.7104; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HU BR, 1993, J NEUROCHEM, V61, P1789, DOI 10.1111/j.1471-4159.1993.tb09817.x; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUNG AY, 1993, J BIOL CHEM, V268, P22959; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LEE KM, 1993, J BIOL CHEM, V268, P9945; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LUTZ MP, 1993, J BIOL CHEM, V268, P11119; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROCH JM, 1992, J BIOL CHEM, V267, P2214; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHAPIRO IP, 1991, J NEUROCHEM, V56, P1154, DOI 10.1111/j.1471-4159.1991.tb11405.x; SHISHEVA A, 1993, J BIOL CHEM, V268, P6463; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLACK BE, 1993, J BIOL CHEM, V268, P21097; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; STRATTON KR, 1989, P NATL ACAD SCI USA, V86, P2498, DOI 10.1073/pnas.86.7.2498; SUZUKI T, 1992, NEUROSCIENCE, V48, P755, DOI 10.1016/0306-4522(92)90264-3; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VENER AV, 1993, FEBS LETT, V328, P6, DOI 10.1016/0014-5793(93)80953-R; WANG R, 1991, J BIOL CHEM, V266, P16960; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	75	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8337	8344		10.1074/jbc.270.14.8337	http://dx.doi.org/10.1074/jbc.270.14.8337			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713942	hybrid			2022-12-25	WOS:A1995QR52600081
J	ODA, S; NISHIDA, J; NAKABEPPU, Y; SEKIGUCHI, M				ODA, S; NISHIDA, J; NAKABEPPU, Y; SEKIGUCHI, M			STABILIZATION OF CYCLIN-E AND CDK2 MESSENGER-RNAS AT G1/S TRANSITION IN RAT-1A CELLS EMERGING FROM THE G0 STATE	ONCOGENE			English	Article						IMMEDIATE-EARLY GENES; DELAYED-EARLY GENES; DELTA-FOSB; FOSB CELL CYCLE; CELL PROLIFERATION	IMMEDIATE-EARLY GENES; CULTURED MOUSE CELLS; 3T3 CELLS; MESSENGER-RNA; C-FOS; SHORT FORM; EXPRESSION; PROTEIN; JUN; FIBROBLASTS	mRNAs for cyclin E and Cdk2 have a role in the commitment to DNA replication in the cell cycle, and are induced in Rat-1A cells by serum stimulation. Cyclin E and cdk2 genes are transcribed in quiescent cells, but their transcripts rapidly turn over and levels are kept low. The rate of transcription of the cdk2 gene is slightly increased after serum stimulation, while that of cyclin E is fairly constant. At the G1/S transition of serum-stimulated cells, transient stabilization of the two types of mRNAs occurs, an event which may lead to induction of each mRNA. Artificial expression of an immediate-early protein Delta FosB results in proliferation of quiescent Rat-1A cells, and this is accompanied by an efficient induction of cyclin E and cdk2 mRNAs. In Delta FosB-expressing cells, two types of mRNAs are stabilized to the same extent seen in serum-stimulated cells. The expression of cyclin E and cdk2 genes is upregulated by stabilization of their transcripts, at least in part. We propose that Delta FosB may have a role in regulation of progression of the cell cycle in serum-stimulated Rat-1A cells by triggering stabilization of mRNAs for cyclin E and Cdk2.	KYUSHU UNIV 69, MED INST BIOREGULAT, DEPT BIOCHEM, FUKUOKA 812, JAPAN	Kyushu University			Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; DULBECCO R, 1973, NATURE, V246, P197, DOI 10.1038/246197a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FINANCSEK I, 1982, GENE, V18, P115; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOVARY K, 1991, NEW BIOL, V3, P870; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LU XP, 1992, J BIOL CHEM, V267, P2841; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; METZ R, 1994, EMBO J, V13, P3832, DOI 10.1002/j.1460-2075.1994.tb06694.x; MILLER AD, 1984, CELL, V36, P51; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NAKABEPPU Y, 1985, J BIOL CHEM, V260, P7281; NATHANS D, 1991, ORIGINS OF HUMAN CANCER, P353; NIKAIDO T, 1991, EXP CELL RES, V192, P102, DOI 10.1016/0014-4827(91)90163-O; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NOGUCHI E, 1993, BIOCHEM BIOPH RES CO, V197, P1524, DOI 10.1006/bbrc.1993.2650; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sambrook J, 1989, MOL CLONING LABORATO; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TAMURA K, 1993, ONCOGENE, V8, P2113; TODARO GJ, 1965, J CELL COMPAR PHYSL, V66, P325, DOI 10.1002/jcp.1030660310; TREMBLEY JH, 1994, CELL GROWTH DIFFER, V5, P99; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WIMMEL A, 1994, ONCOGENE, V9, P995; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	56	25	25	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1343	1351						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731685				2022-12-25	WOS:A1995QR65100011
J	FUTTER, CE; CONNOLLY, CN; CUTLER, DF; HOPKINS, CR				FUTTER, CE; CONNOLLY, CN; CUTLER, DF; HOPKINS, CR			NEWLY SYNTHESIZED TRANSFERRIN RECEPTORS CAN BE DETECTED IN THE ENDOSOME BEFORE THEY APPEAR ON THE CELL-SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC-LIKE MICROVESICLES; CYTOPLASMIC DOMAIN; GOLGI-COMPLEX; MDCK CELLS; INTERNALIZATION; EFFICIENT; SIGNAL; ENDOCYTOSIS; MOTIF; SITE	It is well established that a proportion of newly synthesized lysosomal enzymes and class II major histocompatibility complex antigens are delivered directly to the endocytic pathway from the Golgi complex. Here we show that a significant proportion of newly synthesized transferrin receptors can be detected in endosomes before reaching the cell surface. These newly synthesized transferrin receptors are delivered to the endosome more efficiently than either constitutively secreted soluble proteins or glycophosphatidylinositol-anchored plasma membrane proteins suggesting that their transfer to the endosome is signal-dependent. Identification of a signal-dependent transfer step for proteins like the transferrin receptor operating on the exocytic pathway has important implications for membrane biogenesis, especially in the establishment of cell surface polarity.	UCL, MRC, MOLEC CELL BIOL LAB, LONDON WC1E 6BQ, ENGLAND; UCL, DEPT BIOL, LONDON WC1E 6BQ, ENGLAND	University of London; University College London; University of London; University College London				Cutler, Daniel/0000-0002-4288-7530; Connolly, Christopher/0000-0002-0445-8874; Futter, Clare/0000-0001-5559-9389				BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHANG ACY, 1988, FOCUS, V10, P66; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CONNOLLY CN, 1994, J CELL BIOL, V127, P641, DOI 10.1083/jcb.127.3.641; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUTTER CE, 1989, J CELL SCI, V94, P685; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HALL J, 1990, J BIOL CHEM, V265, P19996; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; STOORVOGEL W, 1988, J CELL BIOL, V106, P1821, DOI 10.1083/jcb.106.6.1821; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021	26	151	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10999	11003		10.1074/jbc.270.18.10999	http://dx.doi.org/10.1074/jbc.270.18.10999			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738042	hybrid			2022-12-25	WOS:A1995QW60100091
J	RUMSEY, SC; GALEANO, NF; LIPSCHITZ, B; DECKELBAUM, RJ				RUMSEY, SC; GALEANO, NF; LIPSCHITZ, B; DECKELBAUM, RJ			OLEATE AND OTHER LONG-CHAIN FATTY-ACIDS STIMULATE LOW-DENSITY-LIPOPROTEIN RECEPTOR ACTIVITY BY ENHANCING ACYL-COENZYME A-CHOLESTEROL ACYLTRANSFERASE ACTIVITY AND ALTERING INTRACELLULAR REGULATORY CHOLESTEROL POOLS IN CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEP G2 CELLS; MOUSE PERITONEAL-MACROPHAGES; RAT-LIVER MICROSOMES; HMG-COA REDUCTASE; DIETARY-FAT; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; ESTER ACCUMULATION; MONONUCLEAR-CELLS; HUMAN-FIBROBLASTS; J774 MACROPHAGES	Modification of dietary fatty acid composition results in changes in plasma cholesterol levels in man. We examined the effect of in vitro fatty acid supplementation on low density lipoprotein (LDL) receptor activity in cultured cells and questioned whether changes were related to fatty acid-induced alterations in acyl-CoA: cholesterol acyltransferase (ACAT) activity, Preincubation of cultured cells (i.e, human skin fibroblasts, J774 macrophages, and HepG2 cells) with oleic acid (oleic acid:bovine serum albumin molar ratio 2:1) at 37 degrees C for longer than 2 h resulted in a 1.2- to 1.5-fold increase in LDL cell binding at 4 degrees C and LDL cell degradation at 37 degrees C, Scatchard analysis showed that oleic acid increased LDL receptor number but not LDL affinity (K-d). Fatty acid supplementation of J774 macrophages increased both LDL receptor activity and cholesteryl ester accumulation, The ACAT inhibitor, 58-035, eliminated both effects, and increased ACAT activity preceded stimulation of LDL receptor activity by 1-2 h, Supplementation of macrophages with triolein emulsion particles also increased LDL cell binding and degradation, and addition of cholesterol to the emulsions abolished this effect. Among fatty acids tested, oleate (18:1), arachidonate (20:4), and eicosapentanoate (20:5) demonstrated the greatest effects, We hypothesize that certain fatty acids delivered to cells either in free form, or as triglyceride, first increase cellular ACAT activity, which then causes a decrease in an intracellular free cholesterol pool, signaling a need for increased LDL receptor activity. This mechanism may play a role in the effect of certain dietary fatty acids on LDL metabolism in vivo.	COLUMBIA UNIV,DEPT PEDIAT,NEW YORK,NY 10032; COLUMBIA UNIV,INST HUMAN NUTR,NEW YORK,NY 10032	Columbia University; Columbia University					NHLBI NIH HHS [HL 21006, HL 40404] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006, R01HL040404] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BERRY EM, 1991, AM J CLIN NUTR, V53, P899, DOI 10.1093/ajcn/53.4.899; BIHAIN BE, 1989, J BIOL CHEM, V264, P17316; BIHAIN BE, 1992, BIOCHEMISTRY-US, V13, P4628; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHATTERJEE S, 1993, J BIOL CHEM, V268, P3401; DAUMERIE CM, 1992, P NATL ACAD SCI USA, V89, P10797, DOI 10.1073/pnas.89.22.10797; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FIELD FJ, 1987, J LIPID RES, V28, P50; FREEMAN DA, 1992, J LIPID RES, V33, P1139; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; GAVIGAN SJP, 1981, BIOCHIM BIOPHYS ACTA, V665, P632, DOI 10.1016/0005-2760(81)90283-6; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOODMAN DS, 1964, J BIOL CHEM, V239, P1335; GRUNDY SM, 1990, J LIPID RES, V31, P1149; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HASHIMOTO S, 1978, BIOCHEM BIOPH RES CO, V82, P1111, DOI 10.1016/0006-291X(78)90302-9; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAYES KC, 1992, FASEB J, V6, P2600, DOI 10.1096/fasebj.6.8.1592210; HEGSTED DM, 1993, AM J CLIN NUTR, V57, P875, DOI 10.1093/ajcn/57.6.875; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; JOHNSON MR, 1983, ARTERIOSCLEROSIS, V8, P242; KEYS A, 1957, LANCET, V1, P66; KUO P, 1990, ARTERIOSCLEROSIS, V10, P111, DOI 10.1161/01.ATV.10.1.111; KUO P, 1990, BIOCHEMISTRY-US, V29, P6626, DOI 10.1021/bi00480a011; KUO PC, 1989, ARTERIOSCLEROSIS, V9, P919, DOI 10.1161/01.ATV.9.6.919; LOSCALZO J, 1987, ARTERIOSCLEROSIS, V7, P450, DOI 10.1161/01.ATV.7.5.450; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHUR SN, 1983, BIOCHIM BIOPHYS ACTA, V751, P401, DOI 10.1016/0005-2760(83)90299-0; MATTSON FH, 1985, J LIPID RES, V26, P194; MCCLOSKEY HM, 1988, BIOCHIM BIOPHYS ACTA, V963, P456, DOI 10.1016/0005-2760(88)90314-1; MENSINK RP, 1989, NEW ENGL J MED, V321, P436, DOI 10.1056/NEJM198908173210705; MITROPOULOS KA, 1980, BIOCHIM BIOPHYS ACTA, V619, P247, DOI 10.1016/0005-2760(80)90073-9; ONTKO JA, 1972, J BIOL CHEM, V247, P1788; ROTH M, 1991, P NATL ACAD SCI USA, V88, P1888, DOI 10.1073/pnas.88.5.1888; RUDLING M, 1992, J LIPID RES, V33, P493; RUSTAN AC, 1988, J BIOL CHEM, V263, P8126; SCHWIEGELSHOHN B, 1995, J BIOL CHEM, V270, P1761, DOI 10.1074/jbc.270.4.1761; SHARKEY MF, 1990, J LIPID RES, V31, P2167; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SPADY DK, 1993, ANNU REV NUTR, V13, P355, DOI [10.1146/annurev.nutr.13.1.355, 10.1146/annurev.nu.13.070193.002035]; SPADY DK, 1990, J LIPID RES, V31, P1809; SPECTOR AA, 1979, J LIPID RES, V20, P536; SPECTOR AA, 1980, J LIPID RES, V21, P169; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TABAS I, 1988, J BIOL CHEM, V263, P1266; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; TABAS I, 1985, P NATL ACAD SCI USA, V82, P416, DOI 10.1073/pnas.82.2.416; TAM SP, 1991, J BIOL CHEM, V266, P16764; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WONG S, 1987, ATHEROSCLEROSIS, V64, P139, DOI 10.1016/0021-9150(87)90239-5; WOOLLETT LA, 1992, J LIPID RES, V33, P77; WOOLLETT LA, 1992, J CLIN INVEST, V89, P1133, DOI 10.1172/JCI115694; XU XX, 1991, J BIOL CHEM, V266, P24849	56	73	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10008	10016		10.1074/jbc.270.17.10008	http://dx.doi.org/10.1074/jbc.270.17.10008			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730302	hybrid			2022-12-25	WOS:A1995QV41700047
J	TAKAGI, Y; NINOMIYA, H; SAKAMOTO, A; MIWA, S; MASAKI, T				TAKAGI, Y; NINOMIYA, H; SAKAMOTO, A; MIWA, S; MASAKI, T			STRUCTURAL BASIS OF G-PROTEIN SPECIFICITY OF HUMAN ENDOTHELIN RECEPTORS - A STUDY WITH ENDOTHELIN(A/B) CHIMERAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEINS; SIGNAL-TRANSDUCTION; LIGAND-BINDING; SUBTYPES; DOMAINS; CLONING; CELLS; CDNA; EXPRESSION; DELINEATION	The endothelin (ET) family of peptides acts via two subtypes of guanine nucleotide-binding regulatory protein (G protein) coupled receptors termed ET(A) and ET(B). ET-1 stimulated cAMP formation in Chinese hamster ovary (CHO) cells stably expressing human wild-type ET(A) (CHO/hET(A) cells) while it inhibited cAMP formation in CHO cells expressing human wild-type ET(B) (CHO/hET(B) cells), and pharmacological evidence indicated that the opposite effects were due to the selective coupling of each receptor subtype with G alpha s/G alpha i. To find out a receptor domain(s) that determined the selective coupling, a series of chimeric receptors between hET(A) and hET(B) was expressed on CHO cells, and the effect of ET-1 on cAMP formation in each cell line was tested. hET(A) with the replacement of second and/or third intracellular loop (ICLII and/or -III) to the corresponding region(s) of hET(B) failed to transmit the stimulatory effect of ET-1. hET(B) with the replacement of ICLIII to the corresponding region of hET(A) failed to transmit the inhibitory effect of ET-1. A chimeric receptor with ICLII of hET(B) and with ICLIII of hET(A) failed to transmit both effects. In cells expressing chimeric receptors with ICLII of hET(A) and with ICLIII of hET(B), ET-1 inhibited cAMP formation while it stimulated cAMP formation when cells were pretreated with pertussis toxin. These results indicated the roles of ICLII and -III of hETR as a major determinant of the selective coupling of hET(A) and hET(B) with G alpha s/G alpha i, respectively. We also demonstrated that each receptor subtype expressed on the same cell could work independently, i.e. for hET(A) to activate G alpha s and for hET(B) to activate G alpha i, resulting in dose dependent dual effects of ET-1 on cAMP formation.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN	Kyoto University			Miwa, Soichi/D-8468-2012	Takagi, Yasutaka/0000-0002-5787-0379				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; BONNER TI, 1992, TRENDS PHARMACOL SCI, V13, P48, DOI 10.1016/0165-6147(92)90021-W; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; EGUCHI S, 1993, ENDOCRINOLOGY, V132, P524, DOI 10.1210/en.132.2.524; HASHIDO K, 1993, CELL MOL BIOL RES, V39, P3; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA K, 1994, P NATL ACAD SCI USA, V91, P4892, DOI 10.1073/pnas.91.11.4892; JAMES AF, 1994, NATURE, V370, P297, DOI 10.1038/370297a0; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LIN WW, 1993, MOL PHARMACOL, V44, P158; MIHARA S, 1993, J PHARMACOL EXP THER, V268, P1122; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; ODA K, 1992, FEBS LETT, V299, P187, DOI 10.1016/0014-5793(92)80244-B; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; ONO K, 1994, NATURE, V370, P301, DOI 10.1038/370301a0; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STRADER CD, 1987, J BIOL CHEM, V262, P16439; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; WESS J, 1990, MOL PHARMACOL, V38, P517; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	32	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10072	10078		10.1074/jbc.270.17.10072	http://dx.doi.org/10.1074/jbc.270.17.10072			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730310				2022-12-25	WOS:A1995QV41700055
J	COHLBERG, JA; HAJARIAN, H; TRAN, T; ALIPOURJEDDI, P; NOVEEN, A				COHLBERG, JA; HAJARIAN, H; TRAN, T; ALIPOURJEDDI, P; NOVEEN, A			NEUROFILAMENT PROTEIN HETEROTETRAMERS AS ASSEMBLY INTERMEDIATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE TROPOMYOSIN; FILAMENT PROTEINS; MOLECULAR ARCHITECTURE; BOVINE NEUROFILAMENTS; SIZED FILAMENTS; INVITRO; PHOSPHORYLATION; DYNAMICS; SUBUNITS; VIMENTIN	Evidence is presented for the existence of a soluble heterotetramer containing the low and middle molecular weight neurofilament (NF) proteins, NF-L and NF-M, and one containing the low and high molecular weight proteins, NF-L and NF-H, and for their role in filament assembly. When a mixture of either pair of proteins was renatured in 2 M urea, 20 mM Tris, pH 7.2, a new band representing a complex was observed in native gel electrophoresis. No new band was observed with a mixture of NF-M and NF-H. Two-dimensional gel electrophoresis showed that treatment of the complexes with SDS caused them to dissociate into their constituent polypeptide chains. Native neurofilaments dissociated in 2 M urea into a mixture of LM and LH complexes. Titration of NF-L with NF-M indicated that complex formation was complete at an approximately equimolar ratio of the two proteins. The LM complex had a sedimentation coefficient, s(20,w), of 4.4 S, consistent with a tetrameric structure. Dialysis of a solution of the LM complex against 50 mM. 4-morpholineethanesuIfonic acid, 0.17 M NaCl, pH 6.25, led to the formation of 10-nm filaments in good yield. These results suggest that NF protein heterooligomers are intermediates in NF assembly and disassembly.			COHLBERG, JA (corresponding author), CALIF STATE UNIV LONG BEACH,DEPT CHEM & BIOCHEM,1250 BELLFLOWER BLVD,LONG BEACH,CA 90840, USA.							ANGELIDES KJ, 1989, J CELL BIOL, V108, P1495, DOI 10.1083/jcb.108.4.1495; BALIN BJ, 1991, BRAIN RES, V556, P196, DOI 10.1016/0006-8993(91)90307-H; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HR, 1985, P NATL ACAD SCI USA, V82, P2354; CARDEN MJ, 1983, BIOCHEM J, V215, P227, DOI 10.1042/bj2150227; CARDEN MJ, 1986, BIOCHEM J, V234, P587, DOI 10.1042/bj2340587; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; COHLBERG JA, 1987, J BIOL CHEM, V262, P17009; COHLBERG JA, 1992, MOL BIOL CELL, V3, pA365; EAGLES PAM, 1990, CELLULAR MOL BIOL IN, P37; FLIEGNER KH, 1991, INT REV CYTOL, V131, P109, DOI 10.1016/S0074-7696(08)62018-5; FRANKE WW, 1983, P NATL ACAD SCI-BIOL, V80, P7113, DOI 10.1073/pnas.80.23.7113; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GEISLER N, 1981, FEBS LETT, V125, P253, DOI 10.1016/0014-5793(81)80732-6; GEISLER N, 1981, J MOL BIOL, V151, P565, DOI 10.1016/0022-2836(81)90011-5; GEISLER N, 1980, EUR J BIOCHEM, V111, P425, DOI 10.1111/j.1432-1033.1980.tb04957.x; GOTOW T, 1992, EUR J CELL BIOL, V58, P331; GUAN RJ, 1991, J BIOL CHEM, V266, P8262; GUILLERMO R, 1990, THESIS CALIFORNIA ST; HAJARIAN H, 1987, Journal of Cell Biology, V105, p209A; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HIROKAWA N, 1991, NEURONAL CYTOSKELETO, P5; HISANAGA S, 1990, J MOL BIOL, V211, P871, DOI 10.1016/0022-2836(90)90080-6; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HISANAGA S, 1990, J MOL BIOL, V211, P857, DOI 10.1016/0022-2836(90)90079-2; HISANAGA S, 1994, MOL BIOL CELL, V5, P161, DOI 10.1091/mbc.5.2.161; ITZHAKI RF, 1964, ANAL BIOCHEM, V9, P401, DOI 10.1016/0003-2697(64)90200-3; JANCSO A, 1991, J BIOL CHEM, V266, P5891; KAUFMANN E, 1985, J MOL BIOL, V185, P733, DOI 10.1016/0022-2836(85)90058-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LEHRER SS, 1990, J BIOL CHEM, V265, P1134; LIEM RKH, 1982, BIOCHEMISTRY-US, V21, P3221, DOI 10.1021/bi00256a029; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; LIFSICS MR, 1984, BIOCHEMISTRY-US, V23, P2866, DOI 10.1021/bi00308a004; MULLIGAN L, 1991, J STRUCT BIOL, V106, P145, DOI 10.1016/1047-8477(91)90084-A; NELSON WJ, 1982, J CELL SCI, V57, P25; NIXON RA, 1992, CELL MOTIL CYTOSKEL, V22, P81, DOI 10.1002/cm.970220202; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; NIXON RA, 1993, BRAIN PATHOL, V3, P29, DOI 10.1111/j.1750-3639.1993.tb00723.x; OKABE S, 1993, J CELL BIOL, V121, P375, DOI 10.1083/jcb.121.2.375; PARRY DAD, 1990, CELLULAR MOL BIOL IN, P175; QUINLAN RA, 1984, J MOL BIOL, V178, P365, DOI 10.1016/0022-2836(84)90149-9; QUINLAN RA, 1986, J MOL BIOL, V192, P337, DOI 10.1016/0022-2836(86)90369-4; SACHER MG, 1994, J BIOL CHEM, V269, P18480; SCHERAGA HA, 1953, J AM CHEM SOC, V75, P179, DOI 10.1021/ja01097a047; SHAW G, 1991, NEURONAL CYTOSKELETO, P185; SHECKET G, 1980, J NEUROCHEM, V35, P1335, DOI 10.1111/j.1471-4159.1980.tb09007.x; SHULMAN S, 1953, ARCH BIOCHEM BIOPHYS, V44, P230, DOI 10.1016/0003-9861(53)90028-9; STEINERT PM, 1993, J BIOL CHEM, V268, P24916; STEINERT PM, 1988, ANN REV BIOCH, V59, P593; STEINERT PM, 1982, COLD SPRING HARB SYM, V46, P465; TANFORD C, 1967, J AM CHEM SOC, V89, P729, DOI 10.1021/ja00980a001; TRONCOSO JC, 1989, CYTOSKELETAL EXTRACE, P33; ZACKROFF RV, 1982, P NATL ACAD SCI-BIOL, V79, P754, DOI 10.1073/pnas.79.3.754	55	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9334	9339		10.1074/jbc.270.16.9334	http://dx.doi.org/10.1074/jbc.270.16.9334			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721855	hybrid			2022-12-25	WOS:A1995QU08900044
J	OOI, J; YAJNIK, V; IMMANUEL, D; GORDON, M; MOSKOW, JJ; BUCHBERG, AM; MARGOLIS, B				OOI, J; YAJNIK, V; IMMANUEL, D; GORDON, M; MOSKOW, JJ; BUCHBERG, AM; MARGOLIS, B			THE CLONING OF GRB10 REVEALS A NEW FAMILY OF SH2 DOMAIN PROTEINS	ONCOGENE			English	Article						SH2 DOMAIN; EGF; GRB1O; GRB7; MIG1O; GROWTH FACTOR RECEPTOR	GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; EGF RECEPTOR; CAENORHABDITIS-ELEGANS; EXPRESSION CLONING; SIGNALING PROTEINS; ADAPTER PROTEIN; BINDING-SITE; HUMAN-BREAST; RAS	SH2 domains function to bind proteins containing phosphotyrosine and are components of proteins that are important signal transducers for tyrosine kinases. We have cloned SH2 domain proteins by screening bacterial expression libraries with the tyrosine phosphorylated carboxyterminus of the epidermal growth factor (EGF) receptor. Here we report the identification of a new SH2 domain protein, Grb10, Grb10 is highly related to Grb7, an SH2 domain protein that we have previously identified, In addition to an SH2 domain, Grb7 and Grb10 have a central domain with similarity to a putative C, elegans gene likely to be involved in neuronal migration. At least three forms of Grb10 exist in fibroblasts apparently due to alternate translational start sites, Grb10 undergoes serine but not tyrosine phosphorylation after EGF treatment resulting in a shift mobility in a large fraction of Grb10 molecules, However Grb10 appears to bind poorly to EGF-Receptor and the true binding partner for the Grb10 SH2 domain is unclear, Grb10 maps to mouse chromosome 11 very close to the EGF-Receptor which is remarkably similar to Grb7 that maps near the EGF-Receptor related HER2 receptor, The finding of multiple family members with evolutionarily conserved domains indicates that these SH2 domain proteins are likely to have an important, although as of yet, unidentified function.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON CANC INST,DEPT IMMUNOL & MICROBIOL,PHILADELPHIA,PA 19107	New York University; New York University; Jefferson University				Buchberg, Arthur/0000-0002-0543-5631	NCI NIH HHS [CA58586] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058586] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BUCHBERG AM, 1993, MAMM GENOME, V4, pS164, DOI 10.1007/BF00360837; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWEERS M, 1994, HUM MOL GENET, V3, P161, DOI 10.1093/hmg/3.1.161; DIETRICH W, 1992, GENETICS, V131, P423; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Green E.L., 1981, MOUSE BIOMEDICAL RES, P91; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARINI JC, 1993, GENOMICS, V15, P200, DOI 10.1006/geno.1993.1034; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RON D, 1992, BIOTECHNIQUES, V13, P866; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Wadsworth William G., 1992, Current Opinion in Neurobiology, V2, P36, DOI 10.1016/0959-4388(92)90159-I; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	58	136	143	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1621	1630						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731717				2022-12-25	WOS:A1995QU68100019
J	ANCIAN, P; LAMBEAU, G; MATTEI, MG; LAZDUNSKI, M				ANCIAN, P; LAMBEAU, G; MATTEI, MG; LAZDUNSKI, M			THE HUMAN 180-KDA RECEPTOR FOR SECRETORY PHOSPHOLIPASES A(2) - MOLECULAR-CLONING, IDENTIFICATION OF A SECRETED SOLUBLE FORM, EXPRESSION, AND LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; PANCREATIC-TYPE PHOSPHOLIPASE-A2; AFFINITY BINDING-PROTEIN; MANNOSE RECEPTOR; TOXIC PHOSPHOLIPASES-A2; SKELETAL-MUSCLE; MESSENGER-RNA; SNAKE-VENOM; CELLS; SITE	Secretory phospholipases A(2) (sPLA(2)) are structurally related enzymes found in mammals as well as in insect and snake venoms. They have been associated with several physiological, pathological, and toxic processes. Some of these effects are apparently linked to the existence of specific receptors for both venom and mammalian sPLA(2)s. We report here the molecular cloning and expression of one of these sPLA(2) receptors from human kidney. Two transcripts were detected. One encodes for a transmembrane form of the sPLA(2) receptor and the other one is an alternatively processed transcript, caused by polyadenylation occurring at a site within an intron in the C terminus part of the transcriptional unit. This transcript encodes for a shortened secreted soluble sPLA(2) receptor lacking the coding region for the transmembrane segment, Quantitative polymerase chain reaction experiments indicate a 1.6:1 ratio between the levels of transcripts encoding for the membrane bound and soluble forms of the receptor, respectively. Soluble and membrane bound human sPLA(2) receptors both bind sPLA(2) with high affinities. However, the binding properties of the human receptors are different from those obtained with the rabbit membrane-bound sPLA(2) receptor. The 180 kDa human sPLA(2) receptor gene has been mapped in the q23-q24 bands of chromosome 2.	CNRS,UPR 411,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE; FAC MED MARSEILLE,INSERM,U406,UNITE GENET MED & DEV,F-13385 MARSEILLE 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite			Lambeau, Gerard/GRJ-5624-2022	Lambeau, Gerard/0000-0002-9239-518X				ARITA H, 1991, J BIOL CHEM, V266, P19139; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P118, DOI 10.1016/0005-2744(68)90249-0; DENNIS AD, 1994, J BIOL CHEM, V269, P12057; DENNIS EA, 1983, ENZYMES, P307; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; FILMOREHEBERT M, 1979, J MOL BIOL, V135, P897; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANASAKI K, 1992, BIOCHIM BIOPHYS ACTA, V1127, P233, DOI 10.1016/0005-2760(92)90226-L; Hawgood B., 1991, HDB NATURAL TOXINS R, V5, P3; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P493; HOURCADE D, 1988, J EXP MED, V168, P1255, DOI 10.1084/jem.168.4.1255; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KRUSKAL BA, 1992, J EXP MED, V176, P1673, DOI 10.1084/jem.176.6.1673; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LAI CJ, 1978, CELL, V14, P971, DOI 10.1016/0092-8674(78)90351-3; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; LAMBEAU G, 1991, FEBS LETT, V293, P29, DOI 10.1016/0014-5793(91)81145-X; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LAMBEAU G, 1991, NEUROCHEM RES, V16, P651, DOI 10.1007/BF00965551; LAMBEAU G, 1989, J BIOL CHEM, V64, P11503; LENNARTZ MR, 1987, BIOCHEM J, V245, P705, DOI 10.1042/bj2450705; LOBEL P, 1988, J BIOL CHEM, V263, P2563; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MUKHERJEE AB, 1992, DNA CELL BIOL, V11, P233, DOI 10.1089/dna.1992.11.233; MULHERKAR R, 1993, FEBS LETT, V317, P263, DOI 10.1016/0014-5793(93)81289-C; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; NAKAJIMA M, 1992, FEBS LETT, V309, P261, DOI 10.1016/0014-5793(92)80785-F; NEVINS JR, 1978, CELL, V15, P1477, DOI 10.1016/0092-8674(78)90071-5; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; SOMMERS CD, 1992, EUR J PHARMACOL, V216, P87, DOI 10.1016/0014-2999(92)90213-N; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TOJO H, 1988, J BIOL CHEM, V263, P5724; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; VADAS P, 1986, LAB INVEST, V55, P391; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WIESNER RJ, 1992, BIOCHEM BIOPH RES CO, V183, P553, DOI 10.1016/0006-291X(92)90517-O; YING Z, 1993, EUR J BIOCHEM, V215, P91, DOI 10.1111/j.1432-1033.1993.tb18010.x	53	175	183	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8963	8970		10.1074/jbc.270.15.8963	http://dx.doi.org/10.1074/jbc.270.15.8963			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721806	hybrid			2022-12-25	WOS:A1995QT44800085
J	HUR, MW; EDENBERG, HJ				HUR, MW; EDENBERG, HJ			CELL-SPECIFIC FUNCTION OF CIS-ACTING ELEMENTS IN THE REGULATION OF HUMAN ALCOHOL-DEHYDROGENASE-5 GENE-EXPRESSION AND EFFECT OF THE 5'-NONTRANSLATED REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT FORMALDEHYDE DEHYDROGENASE; POLYMERASE-II TRANSCRIPTION; BOX-BINDING-PROTEINS; ENZYMATIC-PROPERTIES; TISSUE DISTRIBUTION; MAMMALIAN-CELLS; CPG ISLANDS; CHI-ADH; CLONING; LIVER	The human alcohol dehydrogenase 5 gene (ADH5) differs from all other human alcohol dehydrogenase genes in its ubiquitous expression, although there are tissue-specific differences in the level of expression, To under stand the expression of ADH5, we characterized the structure and function of its 5' region by DNase I footprinting and transient transfection assays. The region from base pair (bp) -34 to +61, flanking the major transcription start site, had strong promoter activity in three different cell lines: HeLa, H4IIE-C3, and CV-1, and could explain the ubiquitous expression, Two Sp1 sites within that region are footprinted by nuclear extracts from all tissues and cells tested. There are sites further upstream that show cell- and tissue-specific differences in both their patterns of occupancy and their effects on promoter activity. The region between bp -34 and -64 strongly increases promoter activity in H4IIE-C3 cells, weakly activates in CV-1 cells, but has no effect in HeLa cells. The region between bp -127 and -163 is a positive element in both HeLa cells and CV-1 cells, but is a negative regulatory element in H4IIE-C3 cells. These differences in part explain the levels of expression of ADH5 in various tissues. Two regions (bp -64 to -127 and bp -163 to -365) contain negative regulatory elements that reduce promoter activity in all three cells. The 5'-nontranslated region of ADH5 contains two upstream ATGs. Insertion of 12 bp within the putative coding region of these upstream ATGs led to a 1.6-2.3-fold increase in activity. This suggests that the 5'-nontranslated region has regulatory significance.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MOLEC & MED GENET,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis				Edenberg, Howard/0000-0003-0344-9690	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006460, R01AA006460] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA06460] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ADINOLFI A, 1984, ANN HUM GENET, V48, P1, DOI 10.1111/j.1469-1809.1984.tb00828.x; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BROWN CJ, 1992, GENE, V121, P313, DOI 10.1016/0378-1119(92)90136-D; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DULEY JA, 1985, ALCOHOL CLIN EXP RES, V9, P263, DOI 10.1111/j.1530-0277.1985.tb05747.x; EDENBERG HJ, 1992, PHARMACOGENETICS, V2, P185, DOI 10.1097/00008571-199210000-00001; EDENBERG HJ, 1991, GENETIC BASIS ALCOHO, P165; EDENBERG HJ, 1991, ADV EXP MED BIOL, V284, P233; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GIRI PR, 1989, BRAIN RES, V481, P131; GIRI PR, 1989, BIOCHEM BIOPH RES CO, V164, P453, DOI 10.1016/0006-291X(89)91741-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1983, VIROLOGY, V52, P456; GUTHEIL WG, 1992, BIOCHEMISTRY-US, V31, P475, DOI 10.1021/bi00117a025; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HOLMES RS, 1986, ALCOHOL ALCOHOLISM, V21, P41; HOLMES RS, 1986, ALCOHOL CLIN EXP RES, V10, P623, DOI 10.1111/j.1530-0277.1986.tb05157.x; Hur M W, 1992, DNA Seq, V3, P167, DOI 10.3109/10425179209034012; HUR MW, 1992, GENE, V121, P305, DOI 10.1016/0378-1119(92)90135-C; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JULIA P, 1987, EUR J BIOCHEM, V162, P179, DOI 10.1111/j.1432-1033.1987.tb10559.x; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAISER R, 1988, BIOCHEMISTRY-US, V27, P1132, DOI 10.1021/bi00404a009; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOIVUSALO M, 1989, FEBS LETT, V257, P105, DOI 10.1016/0014-5793(89)81797-1; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LOCKER J, 1993, GENE TRANSCRIPTION P, P321; Maniatis T., 1982, MOL CLONING; PARES X, 1981, BIOCHEM BIOPH RES CO, V98, P122, DOI 10.1016/0006-291X(81)91878-7; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SEELEY TL, 1984, COMP BIOCHEM PHYS B, V78, P131, DOI 10.1016/0305-0491(84)90156-1; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHARMA CP, 1989, BIOCHEM BIOPH RES CO, V164, P631, DOI 10.1016/0006-291X(89)91507-6; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; WAGNER FW, 1984, BIOCHEMISTRY-US, V23, P2193, DOI 10.1021/bi00305a014; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	43	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					9002	9009		10.1074/jbc.270.15.9002	http://dx.doi.org/10.1074/jbc.270.15.9002			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721811	hybrid			2022-12-25	WOS:A1995QT44800091
J	PAN, ZQ; DURST, F; WERCKREICHHART, D; GARDNER, HW; CAMARA, B; CORNISH, K; BACKHAUS, RA				PAN, ZQ; DURST, F; WERCKREICHHART, D; GARDNER, HW; CAMARA, B; CORNISH, K; BACKHAUS, RA			THE MAJOR PROTEIN OF GUAYULE RUBBER PARTICLES IS A CYTOCHROME-P450 - CHARACTERIZATION BASED ON CDNA CLONING AND SPECTROSCOPIC ANALYSIS OF THE SOLUBILIZED ENZYME AND ITS REACTION-PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLENE OXIDE SYNTHASE; POLYACRYLAMIDE-GEL ELECTROPHORESIS; PARTHENIUM-ARGENTATUM GRAY; HYDROPEROXIDE ISOMERASE; PLANT-TISSUES; ACID; METABOLISM; MECHANISM; PURIFICATION; EXPRESSION	Guayule plants accumulate large quantities of rubber within parenchyma cells of their stembark tissues. This rubber is packed within discrete organelles called rubber particles composed primarily of a lipophilic, cis-polyisoprene core, small amounts of lipids, and several proteins, the most abundant of which is the M(r) 53,000 rubber particle protein (RPP). We have cloned and sequenced a full-length cDNA for RPP and show that it has 65% amino acid identity and 85% similarity to a cytochrome P450 known as allene oxide synthase (AOS), recently identified from flaxseed. RPP contains the same unusual heme-binding region and possesses a similar defective I-helix region as AOS, suggesting an equivalent biochemical function. Spectral analysis of solubilized RPP verifies it as a P450, and enzymatic assays reveal that it also metabolizes 13(S)hydroperoxy-(SZ,11E)-octadecadienoic acid into the expected ketol fatty acids at rates comparable with flaxseed AOS, RPP is unusual in that it lacks the amino-terminal membrane anchor and the established organelle targeting sequences found on other conventional P450s. Together, these factors place RPP in the CYP74 family of P450s and establish it as the first P450 localized in rubber particles and the first eukaryotic P450 to be identified outside endoplasmic reticulum, mitochondria, or plastids.	ARIZONA STATE UNIV,DEPT BOT,TEMPE,AZ 85287; UNIV STRASBOURG 1,INST BOT,DEPT ENZYMOL CELLULAIRE & MOLEC,INST BIOL MOLEC PLANTES,CNRS,F-67083 STRASBOURG,FRANCE; USDA ARS,PEORIA,IL 61064; CNRS,INST BIOL MOLEC PLANTES,F-67084 STRASBOURG,FRANCE; USDA ARS,WESTERN REG RES CTR,ALBANY,CA 94710	Arizona State University; Arizona State University-Tempe; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; United States Department of Agriculture (USDA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; United States Department of Agriculture (USDA)			WERCK-REICHHART, Danièle/U-3713-2019; Cornish, Katrina/A-9773-2013	WERCK-REICHHART, Danièle/0000-0003-2869-4262; Cornish, Katrina/0000-0002-3327-2454				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON JM, 1989, 2ND MESSENGERS PLANT, P181; Archer B.L., 1973, PHYTOCHEMISTRY, VII, P310; ASHBY MN, 1990, MOL BIOL ATHEROSCLER, P27; BACKHAUS RA, 1991, PHYTOCHEMISTRY, V30, P2493, DOI 10.1016/0031-9422(91)85088-H; BACKHAUS RA, 1985, ISRAEL J BOT, V34, P283; BACKHAUS RA, 1983, BOT GAZ, V144, P391, DOI 10.1086/337388; BENEDICT CR, 1990, PLANT PHYSIOL, V92, P816, DOI 10.1104/pp.92.3.816; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CORNISH K, 1994, PHYTOCHEMISTRY, V35, P1425, DOI 10.1016/S0031-9422(00)86868-5; CORNISH K, 1990, PHYTOCHEMISTRY, V29, P3809, DOI 10.1016/0031-9422(90)85337-F; Cornish K., 1993, Journal of Natural Rubber Research, V8, P275; DURST F, 1992, BIOCHEM SOC T, V20, P353, DOI 10.1042/bst0200353; DURST F, 1993, HDB EXPT PHARM, V105, P293; FARMER EE, 1992, PLANT PHYSIOL, V98, P995, DOI 10.1104/pp.98.3.995; GARDNER HW, 1987, PHYTOCHEMISTRY, V26, P621, DOI 10.1016/S0031-9422(00)84753-6; GARDNER HW, 1970, J LIPID RES, V11, P311; GOMEZ JB, 1975, P INT RUBBER C KUALA, V2, P143; HAMBERG M, 1987, BIOCHIM BIOPHYS ACTA, V920, P76, DOI 10.1016/0005-2760(87)90313-4; HASMA H, 1986, Journal of Natural Rubber Research, V1, P30; Hasma H., 1991, Journal of Natural Rubber Research, V6, P105; HO CC, 1975, P INT RUBB C KUAL LU, V2, P441; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KALB VF, 1988, P NATL ACAD SCI USA, V85, P7221, DOI 10.1073/pnas.85.19.7221; KRETZ KA, 1989, NUCLEIC ACIDS RES, V17, P5864, DOI 10.1093/nar/17.14.5864; LAU SMC, 1993, BIOCHEMISTRY-US, V32, P1945, DOI 10.1021/bi00059a010; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OMURA T, 1964, J BIOL CHEM, V239, P2379; OMURA T, 1964, J BIOL CHEM, V239, P2370; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Siler D. J., 1994, Industrial Crops and Products, V2, P307, DOI 10.1016/0926-6690(94)90122-8; SILER DJ, 1993, PHYTOCHEMISTRY, V32, P1097, DOI 10.1016/S0031-9422(00)95072-6; SILER DJ, 1994, PHYTOCHEMISTRY, V36, P623, DOI 10.1016/S0031-9422(00)89786-1; SILER DJ, 1992, P INT LAT C SENS LAT, V34, P46; SONG WC, 1993, J BIOL CHEM, V268, P6293; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; SZCZESNASKORUPA E, 1993, ARCH BIOCHEM BIOPHYS, V304, P170, DOI 10.1006/abbi.1993.1335; TEUTSCH HG, 1993, P NATL ACAD SCI USA, V90, P4102, DOI 10.1073/pnas.90.9.4102; VICK BA, 1987, PLANT PHYSIOL, V85, P1073, DOI 10.1104/pp.85.4.1073; Vick Brady A., 1993, P167; VIOQUE E, 1962, ARCH BIOCHEM BIOPHYS, V99, P522, DOI 10.1016/0003-9861(62)90301-6; ZIMMERMAN DC, 1978, LIPIDS, V13, P313, DOI 10.1007/BF02533720; ZIMMERMAN DC, 1970, PLANT PHYSIOL, V46, P445, DOI 10.1104/pp.46.3.445; ZIMMERMAN DC, 1966, BIOCHEM BIOPH RES CO, V23, P398, DOI 10.1016/0006-291X(66)90740-6; [No title captured]	52	121	137	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8487	8494		10.1074/jbc.270.15.8487	http://dx.doi.org/10.1074/jbc.270.15.8487			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721745	hybrid			2022-12-25	WOS:A1995QT44800021
J	HANNAN, RD; LUYKEN, J; ROTHBLUM, LI				HANNAN, RD; LUYKEN, J; ROTHBLUM, LI			REGULATION OF RDNA TRANSCRIPTION FACTORS DURING CARDIOMYOCYTE HYPERTROPHY INDUCED BY ADRENERGIC AGENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA SYNTHESIS; PROTEIN-KINASE-C; RAT MYOCARDIAL-CELLS; CARDIAC-HYPERTROPHY; ALPHA-1-ADRENERGIC RECEPTOR; HEART-CELLS; FACTOR UBF; STIMULATION; GROWTH; DNA	Ribosomal DNA transcription is important to the regulation of cardiomyocyte ribosome content and, as a consequence, the rate of protein synthesis and accumulation during cardiac hypertrophy. We studied the regulation of ribosomal RNA synthesis and the levels of RNA polymerase I and the ribosomal DNA transcription factor, UBF, during norepinephrine-induced hypertrophy of contraction-arrested neonatal cardiomyocytes in culture. Nuclear run-on assays and Western blots demonstrated that, concomitant with hypertrophy, norepinephrine (1 mu M) increased the rate of ribosomal DNA transcription, without causing an increase in the amount of RNA polymerase I. However, the elevated rate of rRNA synthesis was accompanied by an increased cellular content of UBF protein as determined by Western analysis. Northern blots demonstrated norepinephrine-induced increases in UBF mRNA in neonatal cardiomyocytes indicating that the response was regulated, at least in part, at the pretranslational stage. Both alpha- and beta-adrenergic agents increased the level of UBF mRNA. The beta-adrenergic response was mimicked by forskolin (1 mu M) and the cyclic AMP analog dibutyryl cAMP (10 mu M). However, activation of protein kinase C by phorbol 12-myristate 13-acetate (0.1 mu M) did not increase expression of UBF. These results implicate UBF as a possible regulatory factor of the accelerated rDNA transcription observed during norepinephrine-mediated cardiomyocyte hypertrophy.	GEISINGER MED CLIN,SIGFRIED & JANET WEIS CTR RES,DANVILLE,PA 17822	Geisinger Medical Center				Hannan, Ross/0000-0002-2166-4493	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046991] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47638] Funding Source: Medline; NIGMS NIH HHS [GM46991] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLO SN, 1991, J BIOL CHEM, V266, P22003; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HANNAN RD, 1993, J MOL CELL CARDIOL, V25, P1137, DOI 10.1006/jmcc.1993.1127; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KUHN A, 1994, EMBO J, V13, P416, DOI 10.1002/j.1460-2075.1994.tb06276.x; LALLI E, 1994, J BIOL CHEM, V269, P17359; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; MCDERMOTT PJ, 1991, J BIOL CHEM, V266, P4409; MCDERMOTT PJ, 1989, J BIOL CHEM, V264, P18220; MCDERMOTT PJ, 1989, CIRC RES, V64, P540; MEIDELL RS, 1986, AM J PHYSIOL, V251, P1076; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; Morgan HECB, 1992, HEART CARDIOVASCULAR, P1505; MOSS T, 1995, IN PRESS P NUCLEIC A; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OMAHONY DJ, 1992, NUCLEIC ACIDS RES, V20, P1301; OMAHONY DJ, 1991, P NATL ACAD SCI USA, V88, P3180, DOI 10.1073/pnas.88.8.3180; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; Sambrook J, 1989, MOL CLONING LABORATO; SIEHL D, 1985, AM J PHYSIOL, V248, pC309, DOI 10.1152/ajpcell.1985.248.3.C309; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SIMPSON PC, 1991, MOL CELL BIOCHEM, V104, P35; SIMPSON PC, 1990, MOL BIOL CARDIOVASCU; Smith S. David, 1993, Gene Expression, V3, P229; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WOODCOCK EA, 1987, CIRC RES, V61, P625, DOI 10.1161/01.RES.61.5.625; XIE WQ, 1991, BIOTECHNIQUES, V11, P324; ZIERHUT W, 1989, CIRC RES, V65, P1417, DOI 10.1161/01.RES.65.5.1417	39	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8290	8297		10.1074/jbc.270.14.8290	http://dx.doi.org/10.1074/jbc.270.14.8290			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713937	hybrid			2022-12-25	WOS:A1995QR52600076
J	YANG, B; JUNG, D; MOTTO, D; MEYER, J; KORETZKY, G; CAMPBELL, KP				YANG, B; JUNG, D; MOTTO, D; MEYER, J; KORETZKY, G; CAMPBELL, KP			SH3 DOMAIN-MEDIATED INTERACTION OF DYSTROGLYCAN AND GRB2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DYSTROPHIN-GLYCOPROTEIN COMPLEX; RECEPTOR TYROSINE KINASES; SKELETAL-MUSCLE; EXTRACELLULAR-MATRIX; MUSCULAR-DYSTROPHY; PROTEIN; DEFICIENCY; SARCOLEMMA; INTEGRINS; ACTIN	Dystroglycan is a novel laminin receptor that links the extracellular matrix and sarcolemma in skeletal muscle. The dystroglycan complex containing alpha- and beta-dystroglycan also serves as an agrin receptor in muscle, where it may regulate agrin-induced acetylcholine receptor clustering at the neuromuscular junction. beta-Dystroglycan has now been expressed in vitro and shown to directly interact with Grb2, an adapter protein involved in signal transduction and cytoskeletal organization. Protein binding assays with two Grb2 mutants, Grb2/P49L and Grb2/G203R, which correspond to the loss of-function mutants in the Caenorhabditis elegans sem-5, demonstrated that the dystroglycan-Grb2 association is through beta-dystroglycan C-terminal proline-rich domains and Grb2 Src homology 3 domains. Affinity chromatography has also shown endogenous skeletal muscle Grb2 interacts with beta-dystroglycan. Immunoprecipitation experiments have demonstrated that Grb2 associates with alpha/beta-dystroglycan in vivo in both skeletal muscle and brain. The specific dystroglycan-Grb2 interaction may play an important role in extracellular matrix-mediated signal transduction and/or cytoskeleton organization in skeletal muscle that may be essential for muscle cell viability.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa			Koretzky, Gary/AAU-5381-2021	Campbell, Kevin/0000-0003-2066-5889				BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IBRAGHIMOVBESKR.O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHINOVBESKR, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KIM WH, 1994, CANCER RES, V54, P5005; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; OHLENDIECK K, 1991, FEBS LETT, V283, P230, DOI 10.1016/0014-5793(91)80595-T; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHLAEPFER DD, 1994, NATURE, V372, P786; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	33	233	240	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11711	11714		10.1074/jbc.270.20.11711	http://dx.doi.org/10.1074/jbc.270.20.11711			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744812	hybrid			2022-12-25	WOS:A1995QY73600003
J	SASAOKA, T; LANGLOIS, WJ; ROSE, DW; OLEFSKY, JM				SASAOKA, T; LANGLOIS, WJ; ROSE, DW; OLEFSKY, JM			MECHANISMS OF ENHANCED TRANSMEMBRANE SIGNALING BY AN INSULIN-RECEPTOR LACKING A CYTOPLASMIC BETA-SUBUNIT DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; GROWTH FACTOR-I; PROTEIN; AUTOPHOSPHORYLATION; PHOSPHORYLATION; SUBSTRATE-1; FIBROBLASTS; ANTIBODIES; ADIPOCYTES; EXPRESSION	We have recently characterized a mutant insulin receptor (HIR Delta 978) in which the insulin receptor beta-subunit was truncated at amino acid residue 978, Compared with parental Rat1 cells, the cells expressing the truncated receptor exhibited enhanced sensitivity to insulin's biologic actions, All of these effects are now extended to transcriptional events, since we now show enhanced sensitivity to insulin stimulation of c-fos mRNA expression, These effects were insulin-specific, since insulin-like growth factor-1 stimulation of glucose incorporation into glycogen, cy-aminoisobutyric acid uptake, and thymidine incorporation into DNA were normal, In addition, the truncated receptor exhibited enhanced sensitivity only in vivo, but not in vitro, since the kinase activity of wheat germ agglutinin-purified recep tor preparations was comparable between HIR Delta 978 and parental Rat1 insulin receptors, Parental rat endogenous insulin like growth factor-1 receptors and transfected human insulin receptors form hybrid receptors as well as homologous tetrameric receptors, The normal heterotetrameric receptors possess kinase activity in vivo leading to tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) and its association with the p85 regulatory subunit of phosphatidyl inositol 3-kinase, Interestingly, preincubation with human-specific anti-insulin receptor antibody abolished the increased insulin sensitivity in glucose incorporation into glycogen in HIR Delta 978 cells, Furthermore, microinjection of anti-IRS-1 antibody into HIR Delta 978 cells inhibited insulin stimulation of DNA synthesis, In summary: 1) truncated receptors on the cell surface confer enhanced insulin sensitivity in vivo; 2) the normal heterotetrameric receptors are functionally active and couple to IRS-1 efficiently; and 3) IRS-1 is an important molecule transmitting insulin's biological signals in HIR Delta 978 cells.	UNIV CALIF SAN DIEGO,DEPT MED 0673,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; VET ADM MED CTR,MED RES SERV,SAN DIEGO,CA 92161	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIDDK NIH HHS [DK33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; CHOU CK, 1987, J BIOL CHEM, V262, P1842; HEIDENREICH KA, 1984, J BIOL CHEM, V259, P6511; MAEGAWA H, 1988, J BIOL CHEM, V263, P1629; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SASAOKA T, 1988, DIABETES, V37, P1515, DOI 10.2337/diabetes.37.11.1515; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SASAOKA T, P NATL ACAD SCI USA, V90, P4379; SIDDLE K, 1987, BIOCHEM SOC T, V15, P47, DOI 10.1042/bst0150047; STUMPO DJ, 1991, J BIOL CHEM, V266, P455; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAKATA Y, 1992, J BIOL CHEM, V267, P9065; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YAMAMOTOHONDA R, 1993, J BIOL CHEM, V268, P16859; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958	22	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10885	10892		10.1074/jbc.270.18.10885	http://dx.doi.org/10.1074/jbc.270.18.10885			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738028	hybrid			2022-12-25	WOS:A1995QW60100076
J	TAGUCHI, F; YAMAMOTO, Y; SATOH, K				TAGUCHI, F; YAMAMOTO, Y; SATOH, K			RECOGNITION OF THE STRUCTURE AROUND THE SITE OF CLEAVAGE BY THE CARBOXYL-TERMINAL PROCESSING PROTEASE FOR D1 PRECURSOR PROTEIN OF THE PHOTOSYSTEM-II REACTION-CENTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCENEDESMUS-OBLIQUUS; PARTIAL-PURIFICATION; SPINACH; SIGNAL; POLYPEPTIDE; ENZYME; PHOTOACTIVATION; TRANSLATION; SUBUNITS; COMPLEX	In order to analyze the structural requirement(s) for proteolytic cleavage, synthetic oligopeptides corresponding to the carboxyl-terminal (COOH-terminal) sequence of the precursor to the D1 protein (pD1) of the photosystem II reaction center, with or without substituted side chain(s) around the cleavage site, were subjected to enzymatic analysis with partially purified processing protease from spinach. The efficiency of action as a competitive inhibitor of the enzymatic cleavage of the COOH-terminal extension, as well as the capacity to serve as a substrate, was used as an indication of effective binding to the protease. Neither a COOH-terminal fragment consisting of the 9 amino acids that are cleaved from pD1 by the protease nor a COOH-terminal fragment of the mature protein consisting of 15 amino acids inhibited the enzymatic processing of pD1. By contrast, a COOH-terminal fragment of pD1 consisting of 24 amino acids, which included the sequences of both the COOH-terminal extension and the COOH-terminal 15 amino acids of the mature protein, was effective both as a competitive inhibitor and as a substrate. This result suggests that the structure formed by linkage between these two parts of the protein moiety is important in the substrate-enzyme interaction. Among substitutions around the cleavage site, the replacement of Leu-343 by Ala (L343A) specifically destroyed the ability of the oligopeptide to serve as either a substrate or an inhibitor, suggesting that the presence of the hydrophobic Leu residue is crucial for the formation of the recognition site. A series of six substitutions at Ala-345 had marked effects on the value of V-max, without affecting the binding affinity, as represented by K-m; the order of substitutions at residue 345 in terms of their effects on V-max was Ala, Ser, Phe, Cys > Gly > Val much greater than Pro. With a Pro residue at position 345, the oligopeptide was practically inactive as a substrate.	OKAYAMA UNIV, FAC SCI, DEPT BIOL, OKAYAMA 700, JAPAN; NATL INST BASIC BIOL, DIV BIOL REGULAT & PHOTOBIOL, OKAZAKI, AICHI 444, JAPAN	Okayama University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)								ANBUDURAI PR, 1994, P NATL ACAD SCI USA, V91, P8082, DOI 10.1073/pnas.91.17.8082; BORCHERT TV, 1991, J BACTERIOL, V173, P276, DOI 10.1128/jb.173.1.276-282.1991; BOWYER JR, 1992, J BIOL CHEM, V267, P5424; DEBUS RJ, 1988, P NATL ACAD SCI USA, V85, P427, DOI 10.1073/pnas.85.2.427; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DINER BA, 1988, J BIOL CHEM, V263, P8972; ELLIS RJ, 1981, ANNU REV PLANT PHYS, V32, P111, DOI 10.1146/annurev.pp.32.060181.000551; FIKES JD, 1990, J BIOL CHEM, V265, P3417; FUJITA S, 1989, FEBS LETT, V255, P1, DOI 10.1016/0014-5793(89)81049-X; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GERWIN BI, 1966, J BIOL CHEM, V241, P3331; INAGAKI N, 1989, FEBS LETT, V246, P218, DOI 10.1016/0014-5793(89)80286-8; INAGAKI N, 1990, CURRENT RES PHOTOSYN, V3, P763; KELLER M, 1984, FEBS LETT, V175, P173, DOI 10.1016/0014-5793(84)80593-1; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERS A, 1992, J BIOL CHEM, V267, P17494; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; MINAMI E, 1985, PLANT CELL PHYSIOL, V26, P839; MOHAMED A, 1993, MOL GEN GENET, V238, P161, DOI 10.1007/BF00279543; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; REISFELD A, 1982, EUR J BIOCHEM, V124, P125, DOI 10.1111/j.1432-1033.1982.tb05914.x; SASAKI T, 1984, J BIOL CHEM, V259, P2489; SATOH K, 1988, PHYSIOL PLANTARUM, V72, P209, DOI 10.1111/j.1399-3054.1988.tb06645.x; SATOH K, 1992, NATO ADV SCI I A-LIF, V226, P375; SATOH K, 1993, PHOTOSYNTHETIC REACT, V1, P289; SATOH K, 1992, RES PHOTOSYNTHESIS, V2, P3; SHESTAKOV SV, 1994, J BIOL CHEM, V269, P19354; SVENSSON B, 1991, Z NATURFORSCH C, V46, P765; TAGUCHI F, 1993, FEBS LETT, V326, P227, DOI 10.1016/0014-5793(93)81796-3; TAKAHASHI M, 1988, FEBS LETT, V240, P6, DOI 10.1016/0014-5793(88)80330-2; TAKAHASHI Y, 1990, PLANT CELL PHYSIOL, V31, P273; TAYLOR MA, 1988, FEBS LETT, V237, P229, DOI 10.1016/0014-5793(88)80207-2; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WATANABE A, 1982, P NATL ACAD SCI-BIOL, V79, P6304, DOI 10.1073/pnas.79.20.6304; ZURAWSKI G, 1982, P NATL ACAD SCI-BIOL, V79, P6260, DOI 10.1073/pnas.79.20.6260	37	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10711	10716		10.1074/jbc.270.18.10711	http://dx.doi.org/10.1074/jbc.270.18.10711			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738009	hybrid			2022-12-25	WOS:A1995QW60100053
J	TSAI, AL; KULMACZ, RJ; PALMER, G				TSAI, AL; KULMACZ, RJ; PALMER, G			SPECTROSCOPIC EVIDENCE FOR REACTION OF PROSTAGLANDIN-H SYNTHASE-1 TYROSYL RADICAL WITH ARACHIDONIC-ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; HIGHER OXIDATION-STATES; CYCLOOXYGENASE CATALYSIS; ENDOPEROXIDE SYNTHASE; PEROXIDASE REACTION; PHOTOSYSTEM-II; PENTADIENYL; ENZYME; POTENTIALS	The coupling between the peroxidase and cyclooxygenase activities of prostaglandin H synthase (PGHS) has been proposed to be mediated by a critical tyrosyl radical through a branched chain mechanism (Dietz, R,, Nastainczyk, W,, and Ruf, H. H, (1988) fur. J, Biochem, 171, 321-328), In this study, we have examined the ability of PGHS isoform-1 (PGHS-1) tyrosyl radicals to react with arachidonate, Anaerobic addition of arachidonate following formation of the peroxide-induced wide doublet or wide singlet tyrosyl radical led to disappearance of the tyrosyl radicals and emergence of a new EPR signal, which is distinct from known PGHS-1 tyrosyl radicals, The new radical was clearly derived from arachidonate because its EPR line shape changed when 5,6,8,9,11,12,14,15-octadeuterated arachidonate was used, Subsequent addition of oxygen to samples containing the fatty acyl radical resulted in regeneration of tyrosyl radical EPR, In contrast, the peroxide-generated tyrosyl radical in indomethacin-treated PGHS-1 (a narrow singlet) failed to react with arachidonate, consistent with the cyclooxygenase inhibition by indomethacin, These results indicate that the peroxide-generated wide doublet and wide singlet tyrosyl radicals serve as immediate oxidants of arachidonate bound at the cyclooxygenase active site to form a carbon-centered fatty acyl radical, which reacts with oxygen to form a hydroperoxide, These observations represent the first direct evidence of chemical coupling between the peroxidase reaction and arachidonate oxygenation in PGHS-1 and support the proposed role for a tyrosyl radical in cyclooxygenase catalysis.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University	TSAI, AL (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV HEMATOL,6431 FANNIN ST,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021337, R01GM021337] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44911, GM21337] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRY BA, 1990, J BIOL CHEM, V265, P20139; BASCETTA E, 1982, J CHEM SOC CHEM COMM, P110, DOI 10.1039/c39820000110; DAVIES AG, 1981, J CHEM SOC PERK T 2, P633, DOI 10.1039/p29810000633; DEFELIPPIS MR, 1989, BIOCHEMISTRY-US, V28, P4847, DOI 10.1021/bi00437a049; DEGRAY JA, 1992, J BIOL CHEM, V267, P23583; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; DUTTON PL, 1971, BIOCHIM BIOPHYS ACTA, V226, P63, DOI 10.1016/0005-2728(71)90178-2; HINCHLIFFE A, 1974, J MOL STRUCT, V23, P273, DOI 10.1016/0022-2860(74)85041-6; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KOPPENOL WH, 1990, FEBS LETT, V264, P165, DOI 10.1016/0014-5793(90)80239-F; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; NELSON MJ, 1990, BIOCHEMISTRY-US, V29, P6897, DOI 10.1021/bi00481a020; NELSON MJ, 1994, BIOCHEMISTRY-US, V33, P4966, DOI 10.1021/bi00182a027; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SCHREIBER J, 1986, ARCH BIOCHEM BIOPHYS, V249, P126, DOI 10.1016/0003-9861(86)90567-9; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; SUSTMANN R, 1979, CHEM BER-RECL, V112, P1440, DOI 10.1002/cber.19791120437; TSAI AL, 1994, J BIOL CHEM, V269, P5085; TSAI AL, 1992, J BIOL CHEM, V267, P17753; TSAI AL, 1983, BIOCHIM BIOPHYS ACTA, V722, P349, DOI 10.1016/0005-2728(83)90083-X; WERTZ JE, 1986, ELECTRON SPIN RESON, P462	28	113	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10503	10508		10.1074/jbc.270.18.10503	http://dx.doi.org/10.1074/jbc.270.18.10503			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737984	hybrid			2022-12-25	WOS:A1995QW60100024
J	ALONSO, G; KOEGL, M; MAZURENKO, N; COURTNEIDGE, SA				ALONSO, G; KOEGL, M; MAZURENKO, N; COURTNEIDGE, SA			SEQUENCE REQUIREMENTS FOR BINDING OF SRC FAMILY TYROSINE KINASES TO ACTIVATED GROWTH-FACTOR RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-I; PDGF BETA-RECEPTOR; SIGNAL-TRANSDUCTION; SH2 DOMAIN; C-SRC; PROTEIN; PHOSPHORYLATION; IDENTIFICATION; ASSOCIATION; MOLECULES	Activation of growth factor receptor protein tyrosine kinases frequently results in the binding of numerous proteins to their tyrosine-phosphorylated cytoplasmic domains, These interactions involve the SH2 domains of the binding proteins and phosphorylated tyrosines on the receptor molecules, with the specificity of interaction dictated by the amino acid composition surrounding the phosphorylated tyrosine, In the case of the platelet derived growth factor (PDGF) receptor, the major binding site for Src family tyrosine kinases is in the juxtamembrane domain and includes tyrosine 579 (Mori, S,, Ronnstrand, L., Yokote, K., Engstrom, Angstrom, Courtneidge, S, A, Claesson Welsh, L,, and Heldin, C-H. (1993) EMBO J. 12, 2257-2264), To analyze in more detail which amino acids surrounding the phosphorylated tyrosine at position 579 were important for high affinity interaction with Src family kinases, we synthesized a series of phosphopeptides corresponding to this binding site in which single amino acids were individually changed and tested their ability to compete with the PDGF receptor for binding of Fyn, We found that not only the three residues carboxyl-terminal to the phosphorylated tyrosine were important but that also residues at positions -1 and +4 relative to the tyrosine were required, Phosphorylation of both tyrosines 579 and 581 significantly increased competition efficiency, The activated colony stimulating factor-1 (CSF-1) receptor, which is known to associate with Src family kinases, has a sequence in its juxtamembrane region similar to that surrounding Tyr 579 of the PDGF receptor, and a phosphopeptide modeled on this sequence competed the association of Fyn with the receptor in vitro, Furthermore, mutational analysis demonstrated that these sequences were required for the efficient association of Src family kinases with the activated CSF-1 receptor in vivo, Phosphopeptides corresponding to the Src family binding sites of both PDGF and CSF-1 receptors activated Src kinase activity in vitro, These observations support a model in which the enzymatic activity of Src family tyrosine kinases is controlled by intra- and intermolecular interactions of tyrosine phosphorylated peptides with the SH2 domain of the kinases.	EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, D-69012 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)				Ronnstrand, Lars/0000-0003-1275-5809				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOEGL M, 1994, BIOCHEM J, V302, P737, DOI 10.1042/bj3020737; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAROSE L, 1993, ONCOGENE, V8, P2493; LIU XQ, 1993, ONCOGENE, V8, P1119; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	171	174	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9840	9848		10.1074/jbc.270.17.9840	http://dx.doi.org/10.1074/jbc.270.17.9840			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730365	hybrid			2022-12-25	WOS:A1995QV41700024
J	LAMBERG, A; PIHLAJANIEMI, T; KIVIRIKKO, KI				LAMBERG, A; PIHLAJANIEMI, T; KIVIRIKKO, KI			SITE-DIRECTED MUTAGENESIS OF THE ALPHA-SUBUNIT OF HUMAN PROLYL 4-HYDROXYLASE - IDENTIFICATION OF 3 HISTIDINE-RESIDUES CRITICAL FOR CATALYTIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; ISOPENICILLIN-N-SYNTHASE; BETA-SUBUNIT; MOLECULAR-CLONING; ENDOPLASMIC-RETICULUM; LYSYL HYDROXYLASE; ENZYME; SEQUENCE; 2-OXOGLUTARATE; INHIBITORS	Prolyl 4-hydroxylase (EC 1.14.11.2) catalyzes the formation of hydroxyproline in collagens, The vertebrate enzyme is an alpha(2) beta(2) tetramer in which the alpha subunits contribute to most parts of the two catalytic sites, To study the roles of histidine and cysteine residues in this catalytic activity we converted all 5 histidines that are conserved between species, 4 nonconserved histidines, and 3 conserved cysteines of the human a subunit individually to serine and expressed the mutant a subunits together with the mild-type beta subunit in insect cells by means of baculovirus vectors, Mutation of any of the 3 conserved histidines, residues 412, 485, and 501, inactivated the enzyme completely or essentially completely, with no effect on tetramer assembly or binding of the tetramer to poly(L-proline), These histidines are likely to provide the three ligands needed for the binding of Fe2+ to a catalytic site, Mutation of either of the other 2 conserved histidines reduced the amount of enzyme tetramer by 20-25% and the activity of the tetramer by 30-60%, Mutation of the nonconserved histidine 324 to tally prevented tetramer assembly, whereas mutation of the 3 other nonconserved histidines had no effects, Two of the 3 cysteine to serine mutations, those involving residues 486 and 511, totally prevented tetramer assembly under the present conditions, whereas the third, involving residue 150, had only a minor effect in reducing tetramer assembly and activity, The data do not support previous suggestions that cysteine residues are involved in Fe2+ binding sites, Additional mutagenesis experiments demonstrated that the two glycosylated asparagines have no role in tetramer assembly or catalytic activity.	UNIV OULU, DEPT MED BIOCHEM, SF-90220 OULU, FINLAND; UNIV OULU, COLLAGEN RES UNIT, SF-90220 OULU, FINLAND	University of Oulu; University of Oulu				Pihlajaniemi, Taina/0000-0002-1664-9045				BASSUK JA, 1989, P NATL ACAD SCI USA, V86, P7382, DOI 10.1073/pnas.86.19.7382; BRITSCH L, 1993, EUR J BIOCHEM, V217, P745, DOI 10.1111/j.1432-1033.1993.tb18301.x; DEJONG L, 1984, BIOCHIM BIOPHYS ACTA, V787, P105; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; HANAUSKEABEL HM, 1982, J THEOR BIOL, V94, P421, DOI 10.1016/0022-5193(82)90320-4; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HELAAKOSKI T, 1994, J BIOL CHEM, V269, P27847; HELAAKOSKI T, 1995, IN PRESS P NATL ACAD; JIA S, 1994, P NATL ACAD SCI USA, V91, P7227, DOI 10.1073/pnas.91.15.7227; JIANG F, 1991, BIOCHEMISTRY-US, V30, P11437, DOI 10.1021/bi00112a010; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; JOHN DCA, 1994, BIOCHEMISTRY-US, V33, P14018, DOI 10.1021/bi00251a009; KAO WWY, 1988, CONNECT TISSUE RES, V18, P157, DOI 10.3109/03008208809016805; KEDERSHA NL, 1985, BIOCHEMISTRY-US, V24, P5952, DOI 10.1021/bi00342a040; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; KIVIRIKKO KI, 1987, METHOD ENZYMOL, V144, P96; KIVIRIKKO KI, 1990, ANN NY ACAD SCI, V580, P132, DOI 10.1111/j.1749-6632.1990.tb17925.x; KOIVU J, 1987, J BIOL CHEM, V262, P6447; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MAJAMAA K, 1986, J BIOL CHEM, V261, P7819; MAJAMAA K, 1984, EUR J BIOCHEM, V138, P239, DOI 10.1111/j.1432-1033.1984.tb07907.x; MING LJ, 1991, BIOCHEMISTRY-US, V30, P11653, DOI 10.1021/bi00114a007; MYLLYLA R, 1992, BIOCHEM J, V286, P923, DOI 10.1042/bj2860923; MYLLYLA R, 1977, EUR J BIOCHEM, V80, P349, DOI 10.1111/j.1432-1033.1977.tb11889.x; MYLLYLA R, 1984, J BIOL CHEM, V259, P5403; NOIVA R, 1992, J BIOL CHEM, V267, P3553; PARKKONEN T, 1988, BIOCHEM J, V256, P1005, DOI 10.1042/bj2561005; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; RANDALL CR, 1993, BIOCHEMISTRY-US, V32, P6664, DOI 10.1021/bi00077a020; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TUDERMAN L, 1975, EUR J BIOCHEM, V52, P9, DOI 10.1111/j.1432-1033.1975.tb03967.x; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; VUORI K, 1992, EMBO J, V11, P4213, DOI 10.1002/j.1460-2075.1992.tb05515.x	37	61	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9926	9931		10.1074/jbc.270.17.9926	http://dx.doi.org/10.1074/jbc.270.17.9926			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730375	hybrid			2022-12-25	WOS:A1995QV41700036
J	SATO, T; XIAO, DM; LI, H; HUANG, FL; HUANG, KP				SATO, T; XIAO, DM; LI, H; HUANG, FL; HUANG, KP			STRUCTURE AND REGULATION OF THE GENE ENCODING THE NEURON-SPECIFIC PROTEIN-KINASE-C SUBSTRATE NEUROGRANIN (RC3 PROTEIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPSIN-I GENE; CALMODULIN-BINDING DOMAIN; TYROSINE-HYDROXYLASE GENE; TRANSCRIPTION FACTOR AP-2; INTESTINAL-PEPTIDE GENE; BRAIN-SPECIFIC GENE; CYCLIC-AMP; PHOSPHORYLATION SITE; 5'-FLANKING REGION; ENHANCER ACTIVITY	A 13-kilobase pair genomic DNA encoding a 78-amino acid brain-specific calmodulin-binding protein kinase C (PKC) substrate, neurogranin (Ng/RC3; also known as RC3 or p17), has been sequenced, The Ng/RC3 gene is composed of four exons and three introns, with the protein-coding region located in the first and second exons. This gene was found to have multiple transcriptional start sites clustered within 20 base pairs (bp); it lacks the TATA, GC, and CCAAT boxes in the proximal up stream region of the start sites. The promoter activity was characterized by transfection of 293 cells with nested deletion mutants of the 5'-flanking region fused to the luciferase reporter gene. A minimal construct containing bp +11 to +256 was nearly as active as that covering bp -1508 to +256, whereas a shorter one covering bp +40 to +256 had a greatly reduced activity. Between bp +11 and +40 lies a 12-nucleotide sequence (CCCCGCCCGACCC) containing overlapping binding sites for AP2 (CCGCCCACCC) and SP1 (CCCGCC); this region may be important for conferring the basal transcriptional activity of the Ng/BC3 gene. The expression of a Ng/RC3-luciferase fusion construct (-1508/+256) in transfected 293 cells was stimulated by phorbol 12-myristate 13-acetate (PMA), but not by cAMP, arachidonic acid, vitamin D, retinoic acid, or thyroxines T-3 and T-4. PMA caused a 2-4-fold stimulation of all the reporter gene constructs ranging from +11/+256 to -1508/+256. The stimulatory effects of PMA could be magnified by cotransfection with both Ca2+-dependent and -independent phorbol ester-binding PKC-alpha, -beta(I), -beta(II), -gamma, -delta, and -epsilon cDNAs, but not by non-phorbol ester-binding PHC-xi cDNA. The Ng/RC3 and PKC-gamma genes have a similar expression pattern in the brain during development. These two genes share at least four conserved sequence segments 1.5 kiIobase pair upstream from their transcriptional start sites and a gross similarity in that they possess several AT-rich segments within bp -550 to -950, A near homogeneous 20-kDa DNA-binding protein purified from rat brain was able to bind to these AT-rich regions of both Ng/RC3 and PKC-gamma genes with footprints containing ATTA, ATAA, and AATA sequences.	NICHHD, ENDOCRINOL & REPROD RES BRANCH, METAB REGULAT SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN SY, 1986, J NEUROSCI, V6, P3618; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHEN KH, 1990, J BIOL CHEM, V265, P19961; CHEN KH, 1993, FEBS LETT, V325, P210, DOI 10.1016/0014-5793(93)81075-B; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FINK JS, 1991, J BIOL CHEM, V266, P3882; FINK JS, 1988, P NATL ACAD SCI USA, V85, P6662, DOI 10.1073/pnas.85.18.6662; GRABCZYK E, 1990, EUR J NEUROSCI, V2, P822, DOI 10.1111/j.1460-9568.1990.tb00393.x; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; HOWLAND DS, 1991, MOL BRAIN RES, V11, P345, DOI 10.1016/0169-328X(91)90044-X; HUANG FL, 1993, METHODS NEUROSCI, V18, P127; HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463; INGRAHAM HA, 1986, MOL CELL BIOL, V6, P2923, DOI 10.1128/MCB.6.8.2923; INIGUEZ MA, 1993, ENDOCRINOLOGY, V133, P467, DOI 10.1210/en.133.2.467; IZUMI R, 1992, GENE, V112, P189, DOI 10.1016/0378-1119(92)90375-Y; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KLANN E, 1992, J NEUROCHEM, V58, P1576, DOI 10.1111/j.1471-4159.1992.tb11382.x; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LANDIS SC, 1990, TRENDS NEUROSCI, V13, P344, DOI 10.1016/0166-2236(90)90147-3; LEDOUARIN NM, 1990, ANN NY ACAD SCI, V599, P131; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; MAHONEY CW, 1994, PROTEIN KINASE C, P16; Maxam A M, 1980, Methods Enzymol, V65, P499; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; MONCOLLIN V, 1994, TRANSCRIPTION MECHAN, P45; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; NEDIVI E, 1992, J NEUROSCI, V12, P691; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLIVA D, 1991, GENOMICS, V10, P157, DOI 10.1016/0888-7543(91)90496-2; PETTERSSON M, 1987, GENE DEV, V1, P962, DOI 10.1101/gad.1.9.962; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; SAKIMURA K, 1987, GENE, V60, P103, DOI 10.1016/0378-1119(87)90218-6; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SANGAMESWARAN L, 1993, MOL BRAIN RES, V19, P62, DOI 10.1016/0169-328X(93)90149-J; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SHASKUS J, 1992, J BIOL CHEM, V267, P18821; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; THIEL G, 1991, P NATL ACAD SCI USA, V88, P3431, DOI 10.1073/pnas.88.8.3431; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VANDERHOORN FA, 1987, J MOL BIOL, V193, P255, DOI 10.1016/0022-2836(87)90217-8; VANHOOFF COM, 1988, J NEUROSCI, V8, P1789; VIBERT M, 1989, EUR J BIOCHEM, V181, P33, DOI 10.1111/j.1432-1033.1989.tb14690.x; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868	62	38	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10314	10322		10.1074/jbc.270.17.10314	http://dx.doi.org/10.1074/jbc.270.17.10314			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730337	hybrid			2022-12-25	WOS:A1995QV41700086
J	WANG, LH; SUDHOF, TC; ANDERSON, RGW				WANG, LH; SUDHOF, TC; ANDERSON, RGW			THE APPENDAGE DOMAIN OF ALPHA-ADAPTIN IS A HIGH-AFFINITY BINDING-SITE FOR DYNAMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED PITS; DROSOPHILA-MELANOGASTER; INVITRO BINDING; AP-2 SUBUNIT; PROTEIN; SHIBIRE; VESICLES; ENDOCYTOSIS; MUTATIONS; RECEPTOR	Dynamin is a GTPase that appears to be required for endocytosis. Even though this molecule is known to be in surface-coated pits, the identity of the resident coat proteins that account for this localization is not known, Here we show that dynamin is one of three synaptic terminal proteins that bind with specificity to the ap pendage domain of alpha-adaptin. Binding is sensitive to both salt and pH levels but is not affected by nucleotides. Using recombinant dynamin expressed in SF9 cells, we estimate that the binding affinity is similar to 200 nM. Binding does not require GTP, and the GTPase activity of dynamin is not stimulated by this interaction. These results suggest that the COOH terminus of alpha-adaptin may be a domain within AP2 that mediates the initial interactions between dynamin and surface-coated pits, This may be an essential step in the regulation of coated pit budding.	UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CROWTHER RA, 1981, J CELL BIOL, V91, P790, DOI 10.1083/jcb.91.3.790; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAVID C, 1994, MOL BIOL CELL, V5, P194; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; LIU JP, 1994, J BIOL CHEM, V269, P21043; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PATHAK RK, 1989, J HISTOCHEM CYTOCHEM, V37, P69, DOI 10.1177/37.1.2491753; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; POODRY CA, 1973, DEV BIOL, V32, P373, DOI 10.1016/0012-1606(73)90248-0; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; ZHOU SB, 1993, J BIOL CHEM, V268, P12655	32	171	172	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10079	10083		10.1074/jbc.270.17.10079	http://dx.doi.org/10.1074/jbc.270.17.10079			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730311	hybrid			2022-12-25	WOS:A1995QV41700056
J	GOODWIN, GW; ARTEAGA, JR; TAEGTMEYER, H				GOODWIN, GW; ARTEAGA, JR; TAEGTMEYER, H			GLYCOGEN TURNOVER IN THE ISOLATED WORKING RAT-HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER; DEGRADATION; HEPATOCYTES; METABOLISM; LACTATE	The isolated working rat heart was adapted for simultaneous determination of glycogen synthesis and degradation using a dual isotope technique. After prelabeling of glycogen with [U-C-14]glucose, glycogenolysis was determined continuously from the washout of (CO2)-C-14 plus [C-14]lactate. Glycogen synthesis was determined during the same period from incorporation of [5-H-3]glucose, In the absence of added hormones, hearts were predominantly glycogenolytic (1.5 mu mol/min/g, dry weight), and there was simultaneous synthesis (11% of the rate of glycogenolysis). The percentage of glucose taken up by the heart that could traverse the glycogen pool as a consequence of glycogen turnover was minor (5%). Insulin (10 milliunits/ml) predictably stimulated glycogen synthesis (3.6 fold) and nearly abolished glycogenolysis. Addition of glucagon (1 mu g/ml) increased contractile performance and initially stimulated glycogenolysis (3.8 fold) until glycogen was largely depleted, Net tritium incorporation was unaffected by glucagon, Both hormones stimulated glycolytic flux from exogenous glucose ((H2O)-H-3 from [5-H-3]glucose) as well as total glycolytic flux ((H2O)-H-3 plus glycogenolysis). The initial stimulation in total glycolytic flux with glucagon was largely from glycogen, explaining the lag in stimulation from exogenous glucose. The relationship between the specific radioactivity and amount of glycogen remaining after different degrees of glycogenolysis suggests that the preference of glycogenolysis for newly synthesized glycogen is only partial,	UNIV TEXAS, SCH MED, DEPT INTERNAL MED, DIV CARDIOL, HOUSTON, TX 77030 USA	University of Texas System					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043133] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-43133] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT EJ, 1994, METABOLISM, V43, P285, DOI 10.1016/0026-0495(94)90094-9; Bergmeyer H.U., 1974, METHOD ENZYMAT AN, VVol. 3., P1196; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; BRAINARD JR, 1989, BIOCHEMISTRY-US, V28, P9766, DOI 10.1021/bi00451a033; CHALLISS RAJ, 1987, EUR J BIOCHEM, V163, P205, DOI 10.1111/j.1432-1033.1987.tb10756.x; DAVID M, 1990, J CLIN INVEST, V86, P612, DOI 10.1172/JCI114752; DEPRE C, 1993, ACTA CARDIOL, V48, P147; DEVOS P, 1979, EUR J BIOCHEM, V99, P161, DOI 10.1111/j.1432-1033.1979.tb13242.x; GERTZ EW, 1981, CIRCULATION, V63, P1273, DOI 10.1161/01.CIR.63.6.1273; GOODWIN GW, 1994, AM J PHYSIOL, V267, pH462, DOI 10.1152/ajpheart.1994.267.2.H462; HUE L, 1974, BIOCHEM BIOPH RES CO, V58, P532, DOI 10.1016/S0006-291X(74)80453-5; KATZ J, 1967, BIOCHEMISTRY-US, V6, P1, DOI 10.1021/bi00853a001; KATZ J, 1979, BIOCHEM J, V180, P389, DOI 10.1042/bj1800389; LAUGHLIN MR, 1988, J BIOL CHEM, V263, P2285; MAGNUSSON I, 1994, AM J PHYSIOL, V266, pE796, DOI 10.1152/ajpendo.1994.266.5.E796; POSTLE AD, 1980, BIOCHEM J, V192, P65, DOI 10.1042/bj1920065; SHULMAN GI, 1988, J BIOL CHEM, V263, P5027; TAEGTMEYER H, 1980, BIOCHEM J, V186, P701, DOI 10.1042/bj1860701; WAJNGOT A, 1991, METABOLISM, V40, P877, DOI 10.1016/0026-0495(91)90019-S; WALAAS O, 1950, J BIOL CHEM, V187, P769	20	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9234	9240		10.1074/jbc.270.16.9234	http://dx.doi.org/10.1074/jbc.270.16.9234			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721842	hybrid			2022-12-25	WOS:A1995QU08900030
J	HENDY, GN; BENNETT, HPJ; GIBBS, BF; LAZURE, C; DAY, R; SEIDAH, NG				HENDY, GN; BENNETT, HPJ; GIBBS, BF; LAZURE, C; DAY, R; SEIDAH, NG			PROPARATHYROID HORMONE IS PREFERENTIALLY CLEAVED TO PARATHYROID-HORMONE BY THE PROHORMONE CONVERTASE FURIN - A MASS-SPECTROMETRIC STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KEX2-LIKE PROCESSING ENDOPROTEASE; HUMAN PREPROPARATHYROID HORMONE; CONSTITUTIVE SECRETORY PATHWAY; PHASE LIQUID-CHROMATOGRAPHY; SUBTILISIN-LIKE PROTEASE; RAT PITUITARY; PROPROTEIN CONVERTASE; NUCLEOTIDE-SEQUENCE; SERINE PROTEASES; MESSENGER-RNA	Parathyroid hormone (PTH), an 84-amino acid pep tide, is the major regulator of blood calcium homeostasis. Its mRNA, in addition to encoding the mature peptide, also encodes a ''pre'' sequence of 25 amino acids and a basic ''pro'' hexapeptide, To assess which of the subtilisin like prohormone convertases can process proPTH to PTH we coinfected cells with a vaccinia virus construct expressing human preproPTH and vaccinia virus constructs expressing furin, PC1 or PC2. BSC-40 cells, having a constitutive secretory pathway, and GH4C1 cells, having a regulated secretory pathway, were used. PTH biosynthetic products in cell extracts and media were purified by high performance liquid chromatography, identified by radioimmunoassay, and unambiguously defined as either proPTH or PTH by ion spray mass spectrometry, In both cell types, furin was the most effective in processing proPTH to PTH. In all cases only PTH was released into the medium. In addition, partially purified furin and PC1 were tested for their ability to appropriately cleave a tridecapeptide spanning the prohormone cleavage site found in proPTH. Here too furin was much more effective at cleaving at the correct site. Northern blot analysis and in situ hybridization showed that furin and preproPTH mRNA are co expressed in the parathyroid, whereas PC1, PC2, and PC5 are not and PACE4 is expressed only at very low levels. Taken together these studies strongly suggest that furin is the enzyme responsible for the physiological processing of proPTH to PTH.	MCGILL UNIV,DEPT MED,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ,CANADA; BIOTECHNOL RES INST,MONTREAL,PQ H4P 2R2,CANADA; UNIV MONTREAL,CLIN RES INST MONTREAL,NEUROPEPTIDES STRUCT & METAB LAB,MONTREAL,PQ H2W 1R7,CANADA; UNIV MONTREAL,CLIN RES INST MONTREAL,JA DESEVE LAB BIOCHEM NEUROENDOCRINOL,MONTREAL,PQ H2W 1R7,CANADA	McGill University; McGill University; National Research Council Canada; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	HENDY, GN (corresponding author), ROYAL VICTORIA HOSP,CALCIUM RES LAB,RM H4 67,687 PINE AVE W,MONTREAL,PQ H3A 1A1,CANADA.		Seidah, Nabil/I-3596-2013	Seidah, Nabil/0000-0001-6503-9342				BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENJANNET S, 1992, J BIOL CHEM, V267, P11417; BENNETT HPJ, 1981, BIOCHEMISTRY-US, V20, P4530, DOI 10.1021/bi00519a004; BENNETT HPJ, 1981, BIOCHEM J, V197, P391, DOI 10.1042/bj1970391; CASTILLO MJ, 1979, ANAL BIOCHEM, V99, P53, DOI 10.1016/0003-2697(79)90043-5; COHN DV, 1972, P NATL ACAD SCI USA, V69, P1521, DOI 10.1073/pnas.69.6.1521; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DRESS BM, 1994, ENDOCRINOLOGY, V134, P2057; HABENER JF, 1979, J CELL BIOL, V80, P715, DOI 10.1083/jcb.80.3.715; HABENER JF, 1976, J CLIN ENDOCR METAB, V42, P520, DOI 10.1210/jcem-42-3-520; HABENER JF, 1975, ENDOCRINOLOGY, V97, P431, DOI 10.1210/endo-97-2-431; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HEINRICH G, 1984, J BIOL CHEM, V259, P3320; HELLERMAN JG, 1984, P NATL ACAD SCI-BIOL, V81, P5340, DOI 10.1073/pnas.81.17.5340; HENDY GN, 1981, P NATL ACAD SCI-BIOL, V78, P7365, DOI 10.1073/pnas.78.12.7365; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; HUTTON JC, 1987, BIOCHEM J, V244, P457, DOI 10.1042/bj2440457; JAMES S, 1994, ANAL BIOCHEM, V217, P84, DOI 10.1006/abio.1994.1086; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JEAN F, 1991, ANAL BIOCHEM, V194, P399, DOI 10.1016/0003-2697(91)90248-R; KEMPER B, 1974, P NATL ACAD SCI USA, V71, P3731, DOI 10.1073/pnas.71.9.3731; KEMPER B, 1972, P NATL ACAD SCI USA, V69, P643, DOI 10.1073/pnas.69.3.643; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; LINDBERG I, 1991, MOL ENDOCRINOL, V5, P1361, DOI 10.1210/mend-5-10-1361; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MACGREGOR RR, 1986, J BIOL CHEM, V261, P1929; MALIDE D, 1995, J HISTOCHEM CYTOCHEM, V48, P11; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; PAQUET L, 1994, J BIOL CHEM, V269, P19279; RABBANI SA, 1988, J BIOL CHEM, V263, P1307; RABBANI SA, 1990, BIOCHEMISTRY-US, V29, P10080, DOI 10.1021/bi00495a010; Sambrook J, 1989, MOL CLONING LABORATO; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STEINER DF, 1992, J BIOL CHEM, V267, P23435; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; WATANABE T, 1993, FEBS LETT, V320, P215, DOI 10.1016/0014-5793(93)80589-M; WIREN KM, 1988, J BIOL CHEM, V263, P19771	49	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9517	9525		10.1074/jbc.270.16.9517	http://dx.doi.org/10.1074/jbc.270.16.9517			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721880	hybrid			2022-12-25	WOS:A1995QU08900069
J	TURNER, H; REIF, K; RIVERA, J; CANTRELL, DA				TURNER, H; REIF, K; RIVERA, J; CANTRELL, DA			REGULATION OF THE ADAPTER MOLECULE GRB2 BY THE FC-EPSILON-R1 IN THE MAST-CELL LINE RBL2H3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; BASOPHILIC LEUKEMIA-CELLS; ANTIGEN RECEPTOR; HIGH-AFFINITY; PHOSPHOLIPASE C-GAMMA-1; SIGNAL TRANSDUCTION; SH3 DOMAINS; ZETA-CHAIN; T-CELLS; RAS	Antigenic cross-linking of the high affinity IgE receptor (Fc epsilon R1) on mast cells results in protein tyrosine kinase activation. The object of the present study was to explore the regulation of the SH2 and SH3 domain containing adapter molecule Grb2 by Fc epsilon R1-stimulated PTK signal transduction pathways. Affinity purification of in vivo Grb2 complexes together with in vitro experiments with Grb2 glutathione S-transferase fusion proteins were used to analyze Grb2 complexes in the mast cell line RBL2H3. The data show that in RBL2H3 cells several different proteins are complexed to the SH3 domains of Grb2. These include the p21ras guanine nucleotide exchange factor Sos, two basally tyrosine-phosphorylated 110- and 120-kDa molecules, and a 75-kDa protein that is a substrate for Fc epsilon R1-activated PTKs. By analogy with Sos, p75, p110 and p120 are candidates for Grb2 effector proteins which suggests that Grb2 may be a pleiotropic adapter. Two Grb2 SH2-binding proteins were also characterized in RBL2H3 cells; the adapter She and a 33-kDa molecule. She is constitutively tyro sine phosphorylated in unstimulated cells and Fc epsilon R1 ligation induces no changes in its phosphorylation or binding to Grb2. In contrast, p33 is a substrate for Fc epsilon R1-activated PTKs and binds to Grb2 SH2 domains in Fc epsilon R1 activated but not quiescent cells. The beta subunit of the Fc epsilon R1 is a 33-kDa tyrosine phosphoprotein, but the p33 Grb2-binding protein described in the present report is not the Fc epsilon R1 beta chain and its identity is unknown. The present report thus demonstrates that there are multiple Grb2 containing protein complexes in mast cells of which a subset are Fc epsilon R1-regulated. Two other of the Grb2-binding proteins described herein are tyrosine phosphorylated in response to Fc epsilon R1 ligation: the 75-kDa protein which binds to Grb2 SH3 domains and the 33-kDa protein that associates with the Grb2 SH2 domain. We propose that protein complex formation by Grb2 is an important consequence of Fc epsilon R1 cross-linking and that this may be a signal transduction pathway which acts synergistically with calcium/PKC signals to bring about optimal mast cell end function.	IMPERIAL CANC RES FUND,LYMPHOCYTE ACTIVAT LAB,LONDON WC2A 3PX,ENGLAND; NIASD,BETHESDA,MD 20892	Cancer Research UK			Reif, Karin/AAD-4692-2020	Reif, Karin/0000-0001-5490-8389				BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUCCIONE R, 1994, BIOCHEM J, V298, P149, DOI 10.1042/bj2980149; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BURKHARDT AL, 1994, MOL CELL BIOL, V14, P1095, DOI 10.1128/MCB.14.2.1095; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EISEMAN E, 1992, NATURE, V355, P78; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; FUKAMACHI H, 1994, J IMMUNOL, V152, P642; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PARK DJ, 1991, J BIOL CHEM, V266, P24237; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REIF K, 1994, J BIOL CHEM, V269, P14081; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCOLNIK EY, 1993, EMBO J, V12, P1929; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMIT L, 1994, J BIOL CHEM, V269, P20209; SU J, 1994, J BIOL CHEM, V269, P18731; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	48	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9500	9506		10.1074/jbc.270.16.9500	http://dx.doi.org/10.1074/jbc.270.16.9500			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721878	hybrid			2022-12-25	WOS:A1995QU08900067
J	WANG, P; WU, P; SIEGEL, MI; EGAN, RW; BILLAH, MM				WANG, P; WU, P; SIEGEL, MI; EGAN, RW; BILLAH, MM			INTERLEUKIN (IL)-10 INHIBITS NUCLEAR FACTOR KAPPA-B (NF-KAPPA-B) ACTIVATION IN HUMAN MONOCYTES - IL-10 AND IL-4 SUPPRESS CYTOKINE SYNTHESIS BY DIFFERENT MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-C; ALPHA PROMOTER REGION; TRANSCRIPTION FACTOR; GENE; BINDING; MACROPHAGE; EXPRESSION; LIPOPOLYSACCHARIDE; SUBUNIT	Our previous studies in human monocytes have demonstrated that interleukin (IL)-10 inhibits lipopolysaccharide (LPS)-stimulated production of inflammatory cytokines, lL-1 beta, IL-6, IL-8, and tumor necrosis factor (TNF)-alpha by blocking gene transcription. Using electrophoretic mobility shift assays (EMSA), we now show that, in monocytes stimulated with LPS or TNF alpha, IL-10 inhibits nuclear localization of nuclear factor kappa B (NF kappa B), a transcription factor involved in the expression of inflammatory cytokine genes. Several other transcription factors including NF-IL-6, AP-1, AP-2, GR, CREB, Oct-1, and Sp-1 are not affected by IL-10, This selective inhibition by IL-10 of NF kappa B activation occurs rapidly and in a dose-dependent manner and correlates well with IL-10's cytokine synthesis inhibitory activity in terms of both kinetics and dose responsiveness. Furthermore, compounds such as tosylphenylalanyl chloromethyl ketone and pyrrolidinedithiocarbamate that are known to selectively inhibit NF kappa B activation block cytokine gene transcription in LPS-stimulated monocytes. Taken together, these results suggest that inhibition of NF kappa B activation may be an important mechanism for IL-10 supression of cytokine gene transcription in human monocytes. IL-4, another cytokine that inhibits cytokine mRNA accumulation in monocytes, shows little inhibitory effect on LPS-induced NF kappa B activation. Further examination reveals that, unlike IL-10, IL-4 enhances mRNA degradation and does not suppress cytokine gene transcription. These data indicate that IL-10 and IL-4 inhibit cytokine production by different mechanisms.			WANG, P (corresponding author), SCHERING PLOUGH CORP,RES INST,KENILWORTH,NJ 07033, USA.							BOGDAN C, 1992, J BIOL CHEM, V267, P23301; BOMSZTYK K, 1991, CELL REGUL, V2, P329, DOI 10.1091/mbc.2.4.329; DOKTER WHA, 1993, BLOOD, V81, P337; DROOGMANS L, 1991, DNA SEQUENCE, V3, P115; DROUET C, 1991, J IMMUNOL, V147, P1694; ECK SL, 1993, MOL CELL BIOL, V13, P6530, DOI 10.1128/MCB.13.10.6530; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FIORENTINO DF, 1991, J IMMUNOL, V146, P344; GAUTAM S, 1992, J IMMUNOL, V148, P1725; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIEBERMANN TA, 1990, MOL CELL BIOL, V10, P2327; MALEFYT RD, 1991, J EXP MED, V174, P1209; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; NATSUKA S, 1992, BLOOD, V79, P460; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SERKKOLA E, 1993, EUR J BIOCHEM, V213, P243, DOI 10.1111/j.1432-1033.1993.tb17754.x; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SHIRAKAWA F, 1993, MOL CELL BIOL, V13, P1332, DOI 10.1128/MCB.13.3.1332; SPERGEL JM, 1992, J VIROL, V66, P1021, DOI 10.1128/JVI.66.2.1021-1030.1992; TAKASHIBA S, 1993, GENE, V131, P307, DOI 10.1016/0378-1119(93)90314-S; WAHL LM, 1984, CELL IMMUNOL, V85, P373, DOI 10.1016/0008-8749(84)90251-X; WANG P, 1994, J IMMUNOL, V153, P811; WANG P, 1994, BLOOD, V83, P2678, DOI 10.1182/blood.V83.9.2678.bloodjournal8392678; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831; ZHENG S, 1993, J BIOL CHEM, V268, P17233; ZHOU YL, 1994, J LEUKOCYTE BIOL, V56, P507, DOI 10.1002/jlb.56.4.507; ZIEGLERHEITBROC.HW, 1993, J IMMUNOL, V151, P6986	40	603	632	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9558	9563		10.1074/jbc.270.16.9558	http://dx.doi.org/10.1074/jbc.270.16.9558			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721885	hybrid			2022-12-25	WOS:A1995QU08900074
J	ZHIDKOVA, NI; JUSTICE, SK; MAYNE, R				ZHIDKOVA, NI; JUSTICE, SK; MAYNE, R			ALTERNATIVE MESSENGER-RNA PROCESSING OCCURS IN THE VARIABLE REGION OF THE PRO-ALPHA-1(XI) AND PRO-ALPHA-2(XI) COLLAGEN CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL PROPEPTIDE; ARGININE-RICH PROTEIN; XI COLLAGEN; V COLLAGEN; NH2-TERMINAL DOMAIN; MESSENGER-RNAS; DIFFERENTIAL EXPRESSION; MOLECULAR-CLONING; HUMAN CARTILAGE; II PROCOLLAGEN	An analysis was performed of differential splicing of primary transcripts in the noncollagenous variable region located in the amino terminus of the pro-alpha 1(XI) and pro-alpha 2(XI) collagen chains. The results for the pro-alpha 2(XI) chain showed that human cartilage or fibroblasts in culture contain transcripts in which a single highly acidic exon encoding for 21 amino acids is present or absent. For the chicken pro-alpha 1(XI) chain a more complex pattern of alternative splicing was detected with six possible variants. Of special interest was the alternative use of two exons (called IIA and IIB) in which DA encodes for 39 amino acids and is highly acidic (estimated pI = 3.2), whereas IIB encodes for 49 amino acids and is highly basic (estimated pI = 10.6). A similar alternative use of exon IIA or exon IIB was also observed for human chondrocytes. Northern blotting with probes specific for IIA or IIB showed that both exons are present in transcripts from cartilage but exon IIB is preferentially utilized in transcripts from tendon. Present results suggest that both the pro-alpha 1(XI) and pro-alpha 2(XI) chains of type XI collagen undergo limited processing in vivo and that the noncollagenous variable region is initially retained on the surface of the fibrils. Differential splicing in the variable region may potentially influence the interaction of collagen fibrils with other molecules of the extracellular matrix and more specifically with sulfated glycosaminoglycan chains or with hyaluronan. Such interactions may play a key role in establishing both the organization of the collagen fibrils within the extracellular matrix and in limiting the diameter of collagen fibrils.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NATIONAL EYE INSTITUTE [R01EY009908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR030481, R01AR030481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008228] Funding Source: NIH RePORTER; NEI NIH HHS [EY09908] Funding Source: Medline; NIAMS NIH HHS [AR30481] Funding Source: Medline; NIDCR NIH HHS [DE08228] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; Adolphe, 1992, BIOL REGULATION CHON, P33; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; BIRK DE, 1990, J CELL SCI, V95, P649; BORK P, 1992, FEBS LETT, V307, P49, DOI 10.1016/0014-5793(92)80900-2; BOYD CD, 1993, MATRIX, V13, P457, DOI 10.1016/S0934-8832(11)80112-5; BREWTON RG, 1992, EUR J BIOCHEM, V205, P443, DOI 10.1111/j.1432-1033.1992.tb16798.x; BROWN KE, 1991, J BIOL CHEM, V266, P23268; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DHARMAVARAM RM, 1993, MATRIX, V13, P125, DOI 10.1016/S0934-8832(11)80071-5; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; Eyre D, 1987, STRUCTURE FUNCTION C, P261; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; FESSLER LI, 1985, J BIOL CHEM, V260, P3286; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; Keene D. R., 1993, Molecular Biology of the Cell, V4, p289A; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; KNOTH K, 1988, NUCLEIC ACIDS RES, V16, P10932, DOI 10.1093/nar/16.22.10932; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; METSARANTA M, 1991, J BIOL CHEM, V266, P16862; MORADIAMELI M, 1994, MATRIX BIOL, V14, P233, DOI 10.1016/0945-053X(94)90187-2; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; NAH HD, 1992, J BIOL CHEM, V267, P22581; NAH HD, 1991, J BIOL CHEM, V266, P23446; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; NG LJ, 1993, DEV BIOL, V159, P403, DOI 10.1006/dbio.1993.1251; NIYIBIZI C, 1993, BIOCHIM BIOPHYS ACTA, V1203, P304, DOI 10.1016/0167-4838(93)90099-D; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; Parry DA, 1984, ULTRASTRUCTURE CONNE, P34; PETIT B, 1993, HISTOCHEMISTRY, V100, P231, DOI 10.1007/BF00269096; ROBBINS JR, 1994, EUR J CELL BIOL, V64, P264; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SANDBERG MM, 1993, BIOCHEM J, V294, P595, DOI 10.1042/bj2940595; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SEEGMILL.R, 1972, J ULTRA MOL STRUCT R, V38, P288, DOI 10.1016/S0022-5320(72)90006-8; SEEGMILLER R, 1971, J CELL BIOL, V48, P580, DOI 10.1083/jcb.48.3.580; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; THOM JR, 1991, J BIOL CHEM, V266, P7262; TSUMAKI N, 1995, J BIOL CHEM, V270, P2372, DOI 10.1074/jbc.270.5.2372; Vandenberg P., 1994, Matrix Biology, V14, P415, DOI 10.1016/0945-053X(94)90161-9; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; WALCHLI C, 1993, EUR J BIOCHEM, V212, P483, DOI 10.1111/j.1432-1033.1993.tb17685.x; WOODBURY D, 1989, J BIOL CHEM, V264, P2735; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; Yoshioka H., 1994, Matrix Biology, V14, P365, DOI 10.1016/0945-053X(94)90062-0; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M	54	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9486	9493		10.1074/jbc.270.16.9486	http://dx.doi.org/10.1074/jbc.270.16.9486			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721876	hybrid			2022-12-25	WOS:A1995QU08900065
J	AKAZAWA, C; ISHIBASHI, M; SHIMIZU, C; NAKANISHI, S; KAGEYAMA, R				AKAZAWA, C; ISHIBASHI, M; SHIMIZU, C; NAKANISHI, S; KAGEYAMA, R			A MAMMALIAN HELIX-LOOP-HELIX FACTOR STRUCTURALLY RELATED TO THE PRODUCT OF DROSOPHILA PRONEURAL GENE ATONAL IS A POSITIVE TRANSCRIPTIONAL REGULATOR EXPRESSED IN THE DEVELOPING NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACHAETE-SCUTE HOMOLOG-1; DNA-BINDING; MOLECULAR CHARACTERIZATION; NEURAL-TUBE; NEGATIVE REGULATOR; CELL PATTERN; N-MYC; ENHANCER; PROTEINS; HAIRY	We report the molecular characterization of a mouse basic helix-loop-helix factor, designated MATH-1, structurally related to the product of the Drosophila proneural gene atonal. MATH-1 mRNA is first detected in the cranial ganglions and the dorsal part of the central nervous system on embryonic day 9.5 (E9.5). From E10.5 onward, prominent expression of MATH-1 continues in the dorsal part of the central nervous system but becomes restricted to the external granular layer of the cerebellum by E18 and is undetectable in the adult nervous system. MATH-1 activates E box dependent transcription in collaboration with E47, but the activity is completely antagonized by the negative regulator of neurogenesis HES-1. These results suggest that MATH-1 may be a target of HES-1 and play a role in the differentiation of subsets of neural cells by activating E box-dependent transcription.	KYOTO UNIV,FAC MED,INST IMMUNOL,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT ANAT,KYOTO 606,JAPAN	Kyoto University; Kyoto University								AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; CAMPOSORTEGA JA, 1909, ANN REV NEUROSCI, V14, P399; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ELLIS HM, 1990, CELL, V62, P27; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FEDER JN, 1993, MOL CELL BIOL, V13, P105, DOI 10.1128/MCB.13.1.105; GARRELL J, 1990, CELL, V62, P39; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAMILTON WJ, 1962, HUMAN EMBRYOLOGY PRE, P315; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; ISHIBASHI M, 1994, EMBO J, V13, P1799, DOI 10.1002/j.1460-2075.1994.tb06448.x; Jacobson M., 1991, DEV NEUROBIOLOGY; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; OW DW, 1986, SCIENCE, V234, P856, DOI 10.1126/science.234.4778.856; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAGAMI T, 1994, BIOCHEM BIOPH RES CO, V203, P594, DOI 10.1006/bbrc.1994.2224; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; TAKEBAYASHI K, 1995, J BIOL CHEM, V270, P1342, DOI 10.1074/jbc.270.3.1342; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	50	309	331	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8730	8738		10.1074/jbc.270.15.8730	http://dx.doi.org/10.1074/jbc.270.15.8730			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721778	hybrid			2022-12-25	WOS:A1995QT44800056
J	MARTIN, L; CRIMAUDO, C; GERACE, L				MARTIN, L; CRIMAUDO, C; GERACE, L			CDNA CLONING AND CHARACTERIZATION OF LAMINA-ASSOCIATED POLYPEPTIDE 1C (LAP1C), AN INTEGRAL PROTEIN OF THE INNER NUCLEAR-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-RECEPTOR; ENVELOPE; BINDING; CHROMOSOMES; CELLS	Lamina-associated polypeptides 1A-1C (LAPs1A-1C) are related integral membrane proteins of the inner nuclear membrane that bind to both A- and B-type lamins and have a putative role in the membrane attachment and assembly of the nuclear lamina. In this study, we have cloned a cDNA encoding LAP1C. The DNA sequence predicts a 506-amino acid protein of largely hydrophilic character with a single membrane-spanning region between residues 311-333. Mapping of the epitope recognized by the anti-LAP1 monoclonal antibody RL13 indicates that the hydrophilic domain containing residues 1-310 is exposed to the nucleoplasm and thus that LAP1C is a type II integral membrane protein. A second class of LAP1 cDNAs was isolated that contains two protein coding nucleotide insertions in the LAP1C sequence. These probably encode parts of LAPs1A and/or -1B, suggesting that LAP1 isotypes arise from alternative splicing. Immunoblot analysis of mouse P19 teratocarcinoma cells and the P19MES-differentiated derivative of the latter suggest that LAP1 isotypes are differentially expressed during development, similar to members of the nuclear lamin family. Since the different LAP1 isotypes appear to bind lamins with different affinities, these changes in expression could be important for developmentally regulated alterations in nuclear structure.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute								BAILER SM, 1990, J CELL BIOL, V110, P1489; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; GEORGATOS SD, 1994, CURR OPIN CELL BIOL, V6, P347, DOI 10.1016/0955-0674(94)90025-6; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; Gerace Larry, 1994, Trends in Cell Biology, V4, P127, DOI 10.1016/0962-8924(94)90067-1; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; HENNEKES H, 1994, J CELL SCI, V107, P1019; HOGER TH, 1991, EXP CELL RES, V197, P280, DOI 10.1016/0014-4827(91)90434-V; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIZARDI PM, 1983, METHOD ENZYMOL, V96, P24; LUDERUS MEE, 1994, MOL CELL BIOL, V14, P6297, DOI 10.1128/MCB.14.9.6297; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; McKeon F, 1991, CURR OPIN CELL BIOL, V3, P82, DOI 10.1016/0955-0674(91)90169-Y; MUMMERY CL, 1986, EXP CELL RES, V165, P229, DOI 10.1016/0014-4827(86)90547-1; NIGG E A, 1992, Current Opinion in Cell Biology, V4, P105, DOI 10.1016/0955-0674(92)90066-L; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PADAN R, 1990, J BIOL CHEM, V265, P7808; Sambrook J, 1989, MOL CLONING LABORATO; SENIOR A, 1988, J CELL BIOL, V107, P2029, DOI 10.1083/jcb.107.6.2029; SHOEMAN RL, 1990, J BIOL CHEM, V265, P9055; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STEWART C, 1987, CELL, V51, P383, DOI 10.1016/0092-8674(87)90634-9; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; YE Q, 1994, J BIOL CHEM, V269, P11306; YUAN J, 1991, J BIOL CHEM, V266, P9211	32	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8822	8828		10.1074/jbc.270.15.8822	http://dx.doi.org/10.1074/jbc.270.15.8822			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721789	hybrid			2022-12-25	WOS:A1995QT44800067
J	ROBERTS, SC; WILSON, ME; DONELSON, JE				ROBERTS, SC; WILSON, ME; DONELSON, JE			DEVELOPMENTALLY-REGULATED EXPRESSION OF A NOVEL 59-KDA PRODUCT OF THE MAJOR SURFACE PROTEASE (MSP OR GP63) GENE FAMILY OF LEISHMANIA-CHAGASI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; DONOVANI-CHAGASI; CUTANEOUS LEISHMANIASIS; EFFECTIVE IMMUNIZATION; GLYCOPROTEIN GP63; PROTEINASE GP63; MEMBRANE ANCHOR; PROMASTIGOTES; MACROPHAGES; ATTACHMENT	All species of Leishmania express a major surface protease (Msp or gp63) that facilitates the interactions of the parasite with its environment at several steps in its life cycle. The msp gene family in Leishmania chagasi contains three classes of genes whose mRNAs are differentially expressed during parasite growth, Logarithmic phase (low infectivity) promastigotes express only 63-kDa versions of Msp, whereas stationary phase (high infectivity) promastigotes express both 63- and 59-kDa Msps. The different migrations of the 59- and 63-kDa proteins on acrylamide gels are not due to differences in N-linked glycosylation or the membrane anchor. Plasmid transfections of Leishmania demonstrate that mspS2 of the stationary gene class encodes a 59 kDa protein. Expression of the 59-kDa protein in stationary phase promastigotes ceases after about 12 weeks of in vitro cultivation when the parasites become attenuated. Attenuated parasites can be stimulated to re express the 59-kDa Msp by passage through mice followed by several in vitro passages of recovered promastigotes. Amastigotes express yet another subset of Msp proteins. Thus, the 59-kDa product of mspS2 is expressed only in stationary phase promastigotes and only after recent exposure to environmental changes encountered in the mammalian host cell.	UNIV IOWA, VET ADM MED CTR, DEPT BIOCHEM, IOWA CITY, IA 52242 USA; UNIV IOWA, VET ADM MED CTR, DEPT MICROBIOL & INTERNAL MED, IOWA CITY, IA 52242 USA; HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Howard Hughes Medical Institute			Donelson, John E/F-5795-2010	Wilson, Mary/0000-0001-8680-7275	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030126, R01AI032135, R21AI032135] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30126, AI32135] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beverley S M, 1993, Methods Mol Biol, V21, P333; BORDIER C, 1986, P NATL ACAD SCI USA, V83, P5988, DOI 10.1073/pnas.83.16.5988; BORDIER C, 1987, PARASITOL TODAY, V3, P151, DOI 10.1016/0169-4758(87)90199-2; BOUVIER J, 1989, MOL BIOCHEM PARASIT, V37, P235, DOI 10.1016/0166-6851(89)90155-2; BUTTON LL, 1991, MOL BIOCHEM PARASIT, V44, P213, DOI 10.1016/0166-6851(91)90007-S; BUTTON LL, 1989, MOL BIOCHEM PARASIT, V32, P271, DOI 10.1016/0166-6851(89)90076-5; CHANG CS, 1986, MOL BIOCHEM PARASIT, V18, P197, DOI 10.1016/0166-6851(86)90038-1; CHANG KP, 1990, ANNU REV MICROBIOL, V44, P499, DOI 10.1146/annurev.mi.44.100190.002435; CHAUDHURI G, 1989, J BIOL CHEM, V264, P7483; CONNELL ND, 1993, P NATL ACAD SCI USA, V90, P11473, DOI 10.1073/pnas.90.24.11473; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DASILVA R, 1987, INFECT IMMUN, V55, P2802, DOI 10.1128/IAI.55.11.2802-2806.1987; ETGES R, 1986, EMBO J, V5, P597, DOI 10.1002/j.1460-2075.1986.tb04252.x; FROMMEL TO, 1990, MOL BIOCHEM PARASIT, V38, P25, DOI 10.1016/0166-6851(90)90201-V; FUNK VA, 1994, MOL BIOCHEM PARASIT, V63, P23, DOI 10.1016/0166-6851(94)90005-1; HARLOW E, 1988, ANTIBODIES LABORATOR; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; LIU X, 1992, P NATL ACAD SCI USA, V89, P4991, DOI 10.1073/pnas.89.11.4991; MEDINAACOSTA E, 1989, MOL BIOCHEM PARASIT, V37, P263, DOI 10.1016/0166-6851(89)90158-8; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V57, P31, DOI 10.1016/0166-6851(93)90241-O; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; ROBERTS SC, 1993, MOL BIOCHEM PARASIT, V62, P157, DOI 10.1016/0166-6851(93)90106-8; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUSSELL DG, 1988, J IMMUNOL, V140, P1274; RUSSELL DG, 1989, IMMUNOL TODAY, V10, P328, DOI 10.1016/0167-5699(89)90188-6; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; SACKS DL, 1985, J IMMUNOL, V135, P564; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; SCHNEIDER P, 1992, EXP PARASITOL, V75, P196, DOI 10.1016/0014-4894(92)90179-E; SOTERIADOU KP, 1992, J BIOL CHEM, V267, P13980; STEINKRAUS HB, 1993, MOL BIOCHEM PARASIT, V62, P173, DOI 10.1016/0166-6851(93)90107-9; TURCO SJ, 1988, PARASITOL TODAY, V4, P255, DOI 10.1016/0169-4758(88)90144-5; WEBB JR, 1991, MOL BIOCHEM PARASIT, V48, P173, DOI 10.1016/0166-6851(91)90113-K; WILSON ME, 1990, J IMMUNOL, V144, P4825; WILSON ME, 1986, J IMMUNOL, V136, P4681; WILSON ME, 1988, J IMMUNOL, V141, P265; WILSON ME, 1989, J IMMUNOL, V143, P678; WILSON ME, 1988, INFECT IMMUN, V56, P363, DOI 10.1128/IAI.56.2.363-369.1988; ZARLEY JH, 1991, J CLIN INVEST, V88, P1511, DOI 10.1172/JCI115461	40	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8884	8892		10.1074/jbc.270.15.8884	http://dx.doi.org/10.1074/jbc.270.15.8884			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721796	hybrid			2022-12-25	WOS:A1995QT44800075
J	KROOG, GS; SAINZ, E; WORLAND, PJ; AKESON, MA; BENYA, RV; JENSEN, RT; BATTEY, JF				KROOG, GS; SAINZ, E; WORLAND, PJ; AKESON, MA; BENYA, RV; JENSEN, RT; BATTEY, JF			THE GASTRIN-RELEASING PEPTIDE RECEPTOR IS RAPIDLY PHOSPHORYLATED BY A KINASE OTHER THAN PROTEIN-KINASE-C AFTER EXPOSURE TO AGONIST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SWISS 3T3 CELLS; MUSCARINIC CHOLINERGIC RECEPTORS; LIGHT-DEPENDENT PHOSPHORYLATION; PHOTORECEPTOR MEMBRANES; INDUCED DESENSITIZATION; ADENYLATE-CYCLASE; BOMBESIN RECEPTOR; HOMOLOGOUS DESENSITIZATION; BETA-2-ADRENERGIC RECEPTOR	Several guanine nucleotide-binding protein-coupled receptors are known to be rapidly phosphorylated after agonist exposure. In this study we show that the gastrin-releasing peptide receptor (GRP-R) is rapidly phosphorylated in response to agonist exposure. When [P-32]orthophosphate-labeled cells were exposed to bombesin, the receptor was maximally phosphorylated on serine and threonine residues within 1 min. Although addition of 12-O-tetradecanoylphorbol 13-acetate also resulted in phosphorylation of the GRP-R, elimination of protein kinase C activity using the inhibitor 7-hydroxystaurosporine did not prevent bombesin-induced GRP-R phosphorylation. We conclude that a kinase other than protein kinase C is principally responsible for the rapid, agonist-induced phosphorylation of the GRP-R.	NIDDK,DIGEST DIS BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	KROOG, GS (corresponding author), NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,BIOL CHEM LAB,BLDG 37,RM 5D02,BETHESDA,MD 20892, USA.							BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P11983, DOI 10.1073/pnas.89.24.11983; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P471, DOI 10.1073/pnas.89.2.471; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; BROWN KD, 1988, BIOCHEM J, V252, P227, DOI 10.1042/bj2520227; BROWN KD, 1987, BIOCHEM J, V245, P631, DOI 10.1042/bj2450631; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; DAVIS LG, 1994, BASIC METHODS MOL BI, P624; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FELDMAN RI, 1990, J BIOL CHEM, V265, P17364; FRANK RN, 1973, J BIOL CHEM, V248, P596; FRANKEL A, 1993, EXP CELL RES, V209, P398, DOI 10.1006/excr.1993.1327; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARDEN TK, 1983, PHARMACOL REV, V35, P5; HARGRAVE P A, 1980, Neurochemistry International, V1, P231, DOI 10.1016/0197-0186(80)90063-7; HARLOW E, 1988, ANTIBODIES LAB MANUA, P474; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; KRIS RM, 1987, J BIOL CHEM, V262, P11215; KUHN H, 1973, BIOCHEMISTRY-US, V12, P2495; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MOODY TW, 1978, P NATL ACAD SCI USA, V75, P5372, DOI 10.1073/pnas.75.11.5372; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; RAYMOND JR, 1991, J BIOL CHEM, V266, P14747; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; SIBLEY DR, 1985, J BIOL CHEM, V260, P3883; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; STADEL JM, 1983, P NATL ACAD SCI-BIOL, V80, P3173, DOI 10.1073/pnas.80.11.3173; SWOPE SL, 1990, MOL PHARMACOL, V37, P758; TAKUWA N, 1987, J BIOL CHEM, V262, P182; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; WALSH JH, 1993, J CELL PHYSIOL, V156, P333, DOI 10.1002/jcp.1041560216; WANG LH, 1993, BIOCHIM BIOPHYS ACTA, V1175, P232, DOI 10.1016/0167-4889(93)90028-N; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	53	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8217	8224		10.1074/jbc.270.14.8217	http://dx.doi.org/10.1074/jbc.270.14.8217			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713928	hybrid			2022-12-25	WOS:A1995QR52600067
J	LI, WQ; YU, JC; SHIN, DY; PIERCE, JH				LI, WQ; YU, JC; SHIN, DY; PIERCE, JH			CHARACTERIZATION OF A PROTEIN-KINASE C-DELTA (PKC-DELTA) ATP BINDING MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWN-REGULATION; SACCHAROMYCES-CEREVISIAE; SIGNAL TRANSDUCTION; DIFFERENTIATION; ALPHA; ACTIVATION; COMPLEX; CELLS; NPKC; CDNA	To investigate the function of protein kinase C (PKC)-delta, we mutated its ATP binding site by converting the invariant lysine in the catalytic domain (amino acid 376) to an arginine, Expression vectors containing wild type and mutant PKC-delta cDNAs were generated either with or without an influenza virus hemagglutinin epitope tag. After expression in 32D cells by transfection, the PRC-delta ATP binding mutant (PKC-delta K376R) was not able to phosphorylate itself or the PKC-delta pseudosubstrate region derived substrate, indicating that PKC-delta R376R was an inactive enzyme, PKC activity was inhibited by 67% in 32D cells coexpressing both PKC-delta wild type (PKC-delta WT) and PKC-delta R376R when compared to 32D cells expressing only PKC-delta WT, Mixture of PKC-delta WT and PKC-delta K376R kinase sources in vitro also reduced the enzymatic activity of PKC-delta WT. These results suggest that PKC-delta K376R competes with PRC-delta WT and inhibits PKC-delta WT phosphorylation of its in vitro substrate. While PKC-delta WT overexpressed in 32D cells demonstrated 12-O-tetradecanoylphorbol-13-acetate (TPA)-dependent translocation from the cytosolic to the membrane fraction, PKC-delta K376R was exclusively localized in the membrane fraction even prior to TPA stimulation. Unlike PKC-delta WT which was phosphorylated on tyrosine residue(s) only after TPA treatment, PKC-delta K376R was constitutively phosphorylated on tyrosine residue(s). Although exposure of PKC-delta WT transfectants to TPA induced 32D monocytic differentiation, the 32D/PKC-delta K376R transfectants were resistant to TPA-induced differentiation. Thus, expression of active PRC-delta is required to mediate 32D monocytic differentiation in response to TPA stimulation.	NCI, MOLEC & CELLULAR BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BELL RM, 1991, J BIOL CHEM, V266, P4661; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FREISEWINKEL I, 1991, FEBS LETT, V280, P262, DOI 10.1016/0014-5793(91)80307-O; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OHNO S, 1990, J BIOL CHEM, V265, P6296; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; ORR JW, 1994, J BIOL CHEM, V269, P27715; PEARS C, 1991, FEBS LETT, V284, P120, DOI 10.1016/0014-5793(91)80776-Y; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VALTIERI M, 1987, J IMMUNOL, V138, P3829; ZHANG J, 1994, J BIOL CHEM, V269, P19578	22	88	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8311	8318		10.1074/jbc.270.14.8311	http://dx.doi.org/10.1074/jbc.270.14.8311			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713939	hybrid			2022-12-25	WOS:A1995QR52600078
J	BUSHEL, P; KIM, JH; CHANG, W; CATINO, JJ; RULEY, HE; KUMAR, CC				BUSHEL, P; KIM, JH; CHANG, W; CATINO, JJ; RULEY, HE; KUMAR, CC			2 SERUM RESPONSE ELEMENTS MEDIATE TRANSCRIPTIONAL REPRESSION OF HUMAN SMOOTH-MUSCLE ALPHA-ACTIN PROMOTER IN RAS-TRANSFORMED CELLS	ONCOGENE			English	Article						ALPHA-ACTIN PROMOTER; SRES; RAS-ONCOGENE; REPRESSION	C-FOS; FIBROBLAST CELLS; GENE-EXPRESSION; ACTIVATION; CDNA; ONCOGENES; PROTEIN; YY1; TUMORIGENICITY; SUPPRESSION	The mechanism by which activated uas expression leads to repression genes specific actin filament proteins not understood, However, these changes associated with loss of organized actin filaments, are necessary to maintain the transformed phenotype. The human smooth muscle (sm) alpha-actin promoter is repressed in ras-transformed fibroblast cells and derepressed in revertant cell lines. In this study, we demonstrate that two serum response elements (SREs) present in the alpha-actin promoter are required for transcriptional repression in ras-transformed cells and the two SREs act synergistically to repress heterologous promoters in a ras-transformation dependent manner, Serum response factor (SRF), which can bind to the sm alpha-actin SREs, restores alpha-actin promoter activity in ras-transformed cells. c-Fos, c-Jun and YY1 also repress alpha-actin promoter through SREs, suggesting that these transcription factors may play a role in repressing alpha-actin promoter in uas-transformed cells.	SCHERING PLOUGH CORP, RES INST, DEPT TUMOR BIOL, KENILWORTH, NJ 07033 USA; MIT, CTR CANC RES, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Merck & Company; Schering Plough Corporation; Massachusetts Institute of Technology (MIT)			Kim, Jae-Hong/B-2530-2009; Chang, Wen/AAA-5076-2021	Kim, Jae-Hong/0000-0002-8019-0208; Chang, Wen/0000-0003-3369-083X	NCI NIH HHS [R01CA40602] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040602] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASSIN RH, 1987, ADV VIRAL ONCOL, V6, P103; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLANK RS, 1992, J BIOL CHEM, V267, P984; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; CARROLL SL, 1986, J BIOL CHEM, V261, P8955; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GAFFNEY DF, 1985, NUCLEIC ACIDS RES, V13, P7847, DOI 10.1093/nar/13.21.7847; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; KIM JH, 1993, BIOCHEM BIOPH RES CO, V190, P1115, DOI 10.1006/bbrc.1993.1165; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KUMAR CC, 1992, CANCER RES, V52, P6877; KUMAR CC, 1992, CELL GROWTH DIFFER, V3, P1; KUMAR CC, 1991, EXP BIOL M, P47; LEAVITT J, 1985, NATURE, V316, P840, DOI 10.1038/316840a0; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MIN BH, 1990, J BIOL CHEM, V265, P16667; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; POLLACK R, 1984, ADV VIRAL ONCOL, V4, P3; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; REDDY S, 1990, J BIOL CHEM, V265, P1683; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Treisman R, 1990, Semin Cancer Biol, V1, P47; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x	39	31	35	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1361	1370						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731687				2022-12-25	WOS:A1995QR65100013
J	ALTSCHULER, DL; PETERSON, SN; OSTROWSKI, MC; LAPETINA, EG				ALTSCHULER, DL; PETERSON, SN; OSTROWSKI, MC; LAPETINA, EG			CYCLIC-AMP-DEPENDENT ACTIVATION OF RAP1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTP-BINDING PROTEINS; GDP/GTP EXCHANGE PROTEIN; BOVINE BRAIN CYTOSOL; SMG P21; SIGNAL TRANSDUCTION; MUTATIONAL ANALYSIS; MOLECULAR-CLONING; EFFECTOR DOMAIN; HUMAN-PLATELETS; KREV-1 PROTEIN	Rap1 proteins belong to the Ras superfamily of small molecular weight GTP-binding proteins. Although Rap1 and Pas share approximately 50% overall amino acid sequence identity, the effector domains of the two proteins are identical, suggesting either similar or antagonistic signaling roles. Several pathways leading to Ras activation have been defined, including those initiated by agonist binding to tyrosine kinase or G(i)-coupled receptors, Nothing is known about such events for Rap1 proteins. The cAMP-mediated inhibition of Ras-dependent MAP kinase activation is well documented and resembles that caused by expression of GTPase-deficient Rap1. We have developed a system whereby signals leading to Rap1b activation, i.e. an increase in Rap1b-bound GTP/GDP ratio, can be measured. We report here that treatment of cells with agents that elevate intracellular cAMP levels result in Rap1b activation, These results demonstrate for the first time agonist-dependent activation of Rap1 proteins.	BURROUGHS WELLCOME CO,DIV CELL BIOL,RES TRIANGLE PK,NC 27709; DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710	Burroughs Wellcome Fund; Duke University			Ostrowski, Michael/H-3108-2011	Ostrowski, Michael/0000-0003-2948-6297	NCI NIH HHS [CA53271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ALTSCHULER D, 1993, J BIOL CHEM, V268, P7527; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAMPA MJ, 1991, BIOCHEM BIOPH RES CO, V174, P1, DOI 10.1016/0006-291X(91)90475-M; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HATA Y, 1991, J BIOL CHEM, V266, P6571; HATA Y, 1990, J BIOL CHEM, V265, P7104; JELINEK MA, 1992, ONCOGENE, V7, P1687; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LEROSEY I, 1991, BIOCHEM BIOPH RES CO, V175, P430, DOI 10.1016/0006-291X(91)91582-W; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; POLAKIS P, 1992, J BIOL CHEM, V267, P10780; POLAKIS PG, 1990, P NATL ACAD SCI USA, V88, P239; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; SAKODA T, 1992, ONCOGENE, V7, P1705; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YATANI A, 1991, J BIOL CHEM, V266, P22222; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	45	118	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10373	10376		10.1074/jbc.270.18.10373	http://dx.doi.org/10.1074/jbc.270.18.10373			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737967	hybrid			2022-12-25	WOS:A1995QW60100004
J	MHAOUTY, S; COHEN-TANNOUDJI, J; BOUETALARD, R; LIMONBOULEZ, I; MALTIER, JP; LEGRAND, C				MHAOUTY, S; COHEN-TANNOUDJI, J; BOUETALARD, R; LIMONBOULEZ, I; MALTIER, JP; LEGRAND, C			CHARACTERISTICS OF THE ALPHA(2)/BETA(2)-ADRENERGIC RECEPTOR-COUPLED ADENYLYL-CYCLASE SYSTEM IN RAT MYOMETRIUM DURING PREGNANCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-ADRENERGIC RECEPTOR; HAMSTER OVARY CELLS; BETA-GAMMA-SUBUNITS; ADRENERGIC-RECEPTOR; ALPHA-2B-ADRENERGIC RECEPTOR; PHARMACOLOGICAL CHARACTERIZATION; MOLECULAR-CLONING; G-PROTEINS; EXPRESSION; SUBTYPES	alpha(2A)- and alpha(2B)-adrenoreceptors (AR), identified by Northern blotting in rat myometrium, showed a differential expression during the course of pregnancy, Indeed, the alpha(2A)-AR transcript was present at mid-pregnancy, whereas high levels of alpha(2B)-AR mRNA could be detected at term, The role of these subtypes in modulating beta(2)-AR-stimulated adenylyl cyclase activity was investigated on myometrial membranes from mid-pregnancy and term, At nanomolar concentrations of clonidine (full alpha(2)-AR agonist) or oxymetazoline (partial alpha(2A)-AR agonist), adenylyl cyclase activity was inhibited by up to 50 +/- 7% at mid-pregnancy or 75 +/- 7% at term, whereas at micromolar concentrations, alpha(2)-AR agonists potentiate adenylyl cyclase activity by 140-170% at midpregnancy, Both inhibitory and stimulatory components of this biphasic response were blocked by yohimbine, a selective alpha(2)-AR antagonist, Preincubation of myometrial membranes with G(i2) and/or G(i3) antisera eliminated alpha(2)-AR mediated attenuation or potentiation of isoproterenol stimulated adenylyl cyclase, thus indicating that both the inhibitory and stimulatory components are mediated via G(i2) and G(i3). In addition, type II and IV adenylyl cyclases were identified by Northern blotting in the pregnant rat myometrium, Altogether these data strongly suggest that the alpha(2A)-AR at mid-pregnancy potentiates adenylyl cyclase types II and IV through beta gamma released from G(i2) and G(i3) proteins, whereas the alpha(2B)-AR expression at term may be related to persistent inhibition.	UNIV PARIS 06, REPROD PHYSIOL LAB, CNRS, URA 1449, F-75230 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite			Limon, Isabelle/AAJ-6169-2020; Limon, Isabelle/P-2750-2017	Limon, Isabelle/0000-0002-8773-6971; Limon, Isabelle/0000-0002-8773-6971; Mhaouty-Kodja, Sakina/0000-0001-9743-5243				BYLUND DB, 1992, MOL PHARMACOL, V42, P1; BYLUND DB, 1988, J PHARMACOL EXP THER, V245, P600; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COHEN-TANNOUDJI J, 1991, J MOL ENDOCRINOL, V6, P137, DOI 10.1677/jme.0.0060137; COHENTANNOUDJI J, 1995, IN PRESS BIOL REPROD, V182; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; DUZIC E, 1992, J BIOL CHEM, V267, P24045; EASON MG, 1992, J BIOL CHEM, V267, P15795; ELWARDYMEREZAK J, 1994, J MOL ENDOCRINOL, V13, P23, DOI 10.1677/jme.0.0130023; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FLORDELLIS CS, 1990, HYPERTENSION, V15, P881, DOI 10.1161/01.HYP.15.6.881; FLORDELLIS CS, 1991, P NATL ACAD SCI USA, V88, P1019, DOI 10.1073/pnas.88.3.1019; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; HANDY DE, 1993, HYPERTENSION, V21, P861, DOI 10.1161/01.HYP.21.6.861; HARRISON JK, 1991, MOL PHARMACOL, V40, P407; JONES SB, 1991, MOL PHARMACOL, V39, P239; JONES SB, 1988, J BIOL CHEM, V263, P14236; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LEGRAND C, 1993, J PHARMACOL EXP THER, V266, P439; LEGRAND C, 1991, J PHARMACOL EXP THER, V256, P767; LEHBARCH H, 1977, BIOCHEMISTRY-US, V16, P473; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; LORENZ W, 1990, MOL PHARMACOL, V38, P599; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MALTIER JP, 1989, BIOL REPROD, V40, P531, DOI 10.1095/biolreprod40.3.531; Maniatis T., 1989, MOL CLONING LABORATO, P21; MARSHALL JM, 1981, AM J PHYSIOL, V240, pC165, DOI 10.1152/ajpcell.1981.240.5.C165; MORIMOTO BH, 1994, J BIOL CHEM, V269, P4065; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PAPKA RE, 1985, CELL TISSUE RES, V242, P475; PEPPERL DJ, 1993, MOL PHARMACOL, V44, P802; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; RUFFOLO RR, 1988, ALPHA 2 ADRENERGIC R, P187; TANFIN Z, 1991, FEBS LETT, V278, P4, DOI 10.1016/0014-5793(91)80070-J; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; VIVAT V, 1992, J BIOL CHEM, V267, P7975; VOIGT MM, 1991, FEBS LETT, V278, P45, DOI 10.1016/0014-5793(91)80080-M; WEINSHANK RL, 1990, MOL PHARMACOL, V38, P681; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	44	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					11012	11016		10.1074/jbc.270.18.11012	http://dx.doi.org/10.1074/jbc.270.18.11012			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738044	hybrid			2022-12-25	WOS:A1995QW60100093
J	PARDON, E; HAEZEBROUCK, P; DEBAETSELIER, A; HOOKE, SD; FANCOURT, KT; DESMET, J; DOBSON, CM; VANDAEL, H; JONIAU, M				PARDON, E; HAEZEBROUCK, P; DEBAETSELIER, A; HOOKE, SD; FANCOURT, KT; DESMET, J; DOBSON, CM; VANDAEL, H; JONIAU, M			A CA2+-BINDING CHIMERA OF HUMAN LYSOZYME AND BOVINE ALPHA-LACTALBUMIN THAT CAN FORM A MOLTEN GLOBULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-ION BINDING; NMR-SPECTROSCOPY; CHICKEN LYSOZYME; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL UNITS; STRUCTURAL UNITS; EXONS; EXCHANGE; STATE; SITE	In contrast to lysozymes, which undergo two-state thermal denaturation, the Ca2+-free form of the homologous alpha-lactalbumins forms an intermediate ''molten globule'' state, To understand this difference, we have produced a chimera of human lysozyme and bovine alpha-lactalbumin, In the synthetic gene of the former the sequence coding for amino acid residues 76-102 was replaced by that for bovine alpha-lactalbumin 72-97, which represents the Ca2+-binding loop and the central helix C, The chimeric protein, LYLA1, expressed in Saccharomyces cerevisiae was homogeneous on electrophoresis and mass spectrometry, Its Ca2+ binding constant was 2.50 (+/-0.04) x 10(8) M(-1), and its muramidase activity 10% of that of human lysozyme, One dimensional NMR spectroscopy indicated the presence of a compact, well structured protein, From two-dimensional NMR spectra, main chain resonances for 118 of a total of 129 residues could be readily assigned, Nuclear Overhauser effect analysis and hydrogen-deuterium exchange measurements indicated the presence and persistence of all expected secondary structure elements, Thermal denaturation, measured by circular dichroism, showed a single transition temperature for the Ca2+ form at 90 degrees C, whereas unfolding of the apo form occurred at 73 degrees C in the near-UV and 81 degrees C in the far-UV range. These observations illustrate that by transplanting the central part of bovine alpha-lactalbumin, we have introduced into human lysozyme two important properties of alpha-lactalbumins, i.e. stabilization through Ca2+ binding and molten globule behavior.	KATHOLIEKE UNIV LEUVEN,INTERDISCIPLINARY RES CTR,B-8500 KORTRIJK,BELGIUM; UNIV OXFORD,OXFORD CTR MOLEC SCI,NEW CHEM LAB,OXFORD OX1 3QT,ENGLAND; INNOGENET,B-9052 GHENT,BELGIUM	KU Leuven; University of Oxford; Innogenetics NV								ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; ALEXANDRESCU AT, 1993, BIOCHEMISTRY-US, V32, P1707, DOI 10.1021/bi00058a003; ARTYMIUK PJ, 1981, J MOL BIOL, V152, P737, DOI 10.1016/0022-2836(81)90125-X; BARR PJ, 1987, J EXP MED, V165, P1160, DOI 10.1084/jem.165.4.1160; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLAKE CCF, 1979, NATURE, V277, P598, DOI 10.1038/277598a0; BREW K, 1967, J BIOL CHEM, V242, P3747; CANFIELD RE, 1971, NATURE-NEW BIOL, V232, P16, DOI 10.1038/newbio232016a0; CHIPMAN DM, 1967, J BIOL CHEM, V242, P4388; DEBAETSELIER A, 1989, Patent No. 89870140; DELHAISE P, 1984, J MOL GRAPHICS, V2, P103, DOI 10.1016/0263-7855(84)80002-8; DESMET J, 1987, BIOCHIM BIOPHYS ACTA, V912, P211, DOI 10.1016/0167-4838(87)90091-4; DESMET J, 1991, EUR BIOPHYS J BIOPHY, V20, P263, DOI 10.1007/BF00450561; DOBSON CM, 1991, CIBA F SYMP, V161, P167; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ERHART E, 1983, J BACTERIOL, V156, P625, DOI 10.1128/JB.156.2.625-635.1983; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GO M, 1983, P NATL ACAD SCI-BIOL, V80, P1964, DOI 10.1073/pnas.80.7.1964; HAEZEBROUCK P, 1995, J MOL BIOL, V246, P382, DOI 10.1006/jmbi.1994.0093; HAEZEBROUCK P, 1993, PROTEIN ENG, V6, P643, DOI 10.1093/protein/6.6.643; HAEZEBROUCK P, 1992, BIOCHIM BIOPHYS ACTA, V1122, P305, DOI 10.1016/0167-4838(92)90409-7; HAYNIE DT, 1983, PROTEIN-STRUCT FUNCT, V16, P115; HOOKE SD, 1994, BIOCHEMISTRY-US, V33, P5867, DOI 10.1021/bi00185a026; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; IKEGUCHI M, 1986, J BIOCHEM-TOKYO, V99, P1191, DOI 10.1093/oxfordjournals.jbchem.a135582; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JUNG A, 1980, P NATL ACAD SCI-BIOL, V77, P5759, DOI 10.1073/pnas.77.10.5759; KIKUCHI M, 1982, P NATL ACAD SCI USA, V85, P9411; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRONMAN MJ, 1989, CRIT REV BIOCHEM MOL, V24, P565, DOI 10.3109/10409238909080054; KUCHINKE W, 1989, BIOCHEM BIOPH RES CO, V159, P927, DOI 10.1016/0006-291X(89)92197-9; KUMAGAI I, 1992, P NATL ACAD SCI USA, V89, P5887, DOI 10.1073/pnas.89.13.5887; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V81, P4642; KUROKI R, 1989, P NATL ACAD SCI USA, V86, P6903, DOI 10.1073/pnas.86.18.6903; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MALCOLM BA, 1989, P NATL ACAD SCI USA, V86, P133, DOI 10.1073/pnas.86.1.133; MURAKAMI K, 1982, BIOCHEMISTRY-US, V21, P5488, DOI 10.1021/bi00265a017; NITTA K, 1988, BIOL CHEM H-S, V369, P671, DOI 10.1515/bchm3.1988.369.2.671; NITTA K, 1989, EUR J BIOCHEM, V182, P111, DOI 10.1111/j.1432-1033.1989.tb14806.x; PENG ZY, 1994, BIOCHEMISTRY-US, V33, P2136, DOI 10.1021/bi00174a021; REDFIELD C, 1990, BIOCHEMISTRY-US, V29, P7201, DOI 10.1021/bi00483a007; SEGAWA T, 1983, J BIOCHEM-TOKYO, V93, P1321, DOI 10.1093/oxfordjournals.jbchem.a134266; SHEWALE JG, 1984, J BIOL CHEM, V259, P4947; SMITH SG, 1987, BIOCHEM J, V342, P353; STOLTZFUS A, 1994, SCIENCE, V265, P202, DOI 10.1126/science.8023140; STUART DI, 1986, NATURE, V324, P84, DOI 10.1038/324084a0; TRAUT TW, 1988, P NATL ACAD SCI USA, V85, P2944, DOI 10.1073/pnas.85.9.2944; VANDAEL H, 1993, BIOCHEMISTRY-US, V32, P11886, DOI 10.1021/bi00095a018; VIAENE A, 1991, EUR J BIOCHEM, V202, P471, DOI 10.1111/j.1432-1033.1991.tb16396.x; VILOTTE JL, 1987, BIOCHIMIE, V69, P609, DOI 10.1016/0300-9084(87)90180-5; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K., 1986, NMR PROTEINS NUCL AC	56	36	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10514	10524		10.1074/jbc.270.18.10514	http://dx.doi.org/10.1074/jbc.270.18.10514			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737986	hybrid			2022-12-25	WOS:A1995QW60100026
J	PENNICA, D; SHAW, KJ; SWANSON, TA; MOORE, MW; SHELTON, DL; ZIONCHECK, KA; ROSENTHAL, A; TAGA, T; PAONI, NF; WOOD, WI				PENNICA, D; SHAW, KJ; SWANSON, TA; MOORE, MW; SHELTON, DL; ZIONCHECK, KA; ROSENTHAL, A; TAGA, T; PAONI, NF; WOOD, WI			CARDIOTROPHIN-1 - BIOLOGICAL-ACTIVITIES AND BINDING TO THE LEUKEMIA INHIBITORY FACTOR-RECEPTOR GP130 SIGNALING COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; ADAPTIVE PHYSIOLOGICAL-RESPONSE; CARDIAC GENE-EXPRESSION; EMBRYONIC STEM-CELLS; CYTOKINE RECEPTORS; STIMULATING FACTOR; MOLECULAR-CLONING; FACTOR MAINTAINS; CNTF RECEPTOR; GROWTH-FACTOR	Cardiotrophin-1 (CT-1) is a newly isolated cytokine that was identified based on its ability to induce cardiac myocyte hypertrophy, It is a member of the family of cytokines that includes interleukins-6 and -11, leukemia inhibitory factor (LIF), ciliary neurotrophic factor, and oncostatin M, These cytokines induce a pleiotropic set of growth and differentiation activities via receptors that use a common signaling subunit, gp130. In this work we determine the activity of CT-1 in six in vitro biological assays and examine the composition of its cell surface receptor, We find that CT-1 is inactive in stimulating the growth of the hybridoma cell line, B9 and inhibits the growth of the mouse myeloid leukemia cell line, M1. CT-1 induces a phenotypic switch in rat sympathetic neurons and promotes the survival of rat dopaminergic and chick ciliary neurons. CT-1 also inhibits the differentiation of mouse embryonic stem cells. CT-1 and LIF cross-compete for binding to M1 cells, K-d [CT-1] similar to 0.7 nM, and this binding is inhibited by an anti-gp130 monoclonal antibody, Both ligands can be specifically crosslinked to a protein on M1 cells with the mobility of the LIF receptor (similar to 200 kDa), In addition, CT-1 binds directly to a purified, soluble form of the LIF receptor in solution K-d, similar to 211 nM). These data show that CT-1 has a wide range of hematopoietic, neuronal, and developmental activities and that it can act via the LIF receptor and the gp130 signaling subunit.	GENENTECH INC, DEPT BIOL MOLEC, San Francisco, CA 94080 USA; GENENTECH INC, DEPT CELL GENET, San Francisco, CA 94080 USA; GENENTECH INC, DEPT NEUROBIOL, San Francisco, CA 94080 USA; GENENTECH INC, DEPT IMMUNOL, San Francisco, CA 94080 USA; GENENTECH INC, DEPT CARDIOVASC BIOL, San Francisco, CA 94080 USA; OSAKA UNIV, INST MOLEC & CELLULAR BIOL, OSAKA 565, JAPAN	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Osaka University								AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BAUMANN G, 1994, J CLIN ENDOCR METAB, V78, P1113, DOI 10.1210/jc.78.5.1113; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BRAUNWALD E, 1994, HEART DISEASE, P393; Bruce A. Gregory, 1992, Progress in Growth Factor Research, V4, P157, DOI 10.1016/0955-2235(92)90029-H; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIEN KR, 1993, SCIENCE, V260, P916, DOI 10.1126/science.8493528; CONOVER JC, 1993, DEVELOPMENT, V119, P559; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; Davis S, 1993, CURR OPIN CELL BIOL, V5, P281, DOI 10.1016/0955-0674(93)90117-9; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; FONNUM F, 1969, BIOCHEM J, V115, P465, DOI 10.1042/bj1150465; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GLADEK A, 1983, ARCH IMMUNOL THER EX, V31, P541; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Hawrot E, 1979, Methods Enzymol, V58, P574; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; Ip Nancy Y., 1992, Progress in Growth Factor Research, V4, P139, DOI 10.1016/0955-2235(92)90028-G; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KITAMURA T, 1994, TRENDS ENDOCRIN MET, V5, P8, DOI 10.1016/1043-2760(94)90115-5; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; LAYTON MJ, 1994, J BIOL CHEM, V269, P17048; LEUNG DW, 1992, NEURON, V8, P1045, DOI 10.1016/0896-6273(92)90126-X; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LIU JW, 1992, J BIOL CHEM, V267, P16763; LOWE DG, 1989, DNA-J MOLEC CELL BIO, V8, P351, DOI 10.1089/dna.1.1989.8.351; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MANTHORPE M, 1989, NERVE GROWTH FACTORS, V12, P31; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; METCALF D, 1989, P NATL ACAD SCI USA, V86, P5948, DOI 10.1073/pnas.86.15.5948; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOSLEY B, 1994, CYTOKINE, V6, P554; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NORDAN RP, 1986, SCIENCE, V233, P566, DOI 10.1126/science.3726549; PATTERSON PH, 1994, P NATL ACAD SCI USA, V91, P7833, DOI 10.1073/pnas.91.17.7833; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; POULSEN KT, 1994, NEURON, V13, P1245, DOI 10.1016/0896-6273(94)90062-0; RAO MS, 1993, J NEUROBIOL, V24, P215, DOI 10.1002/neu.480240208; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; RICHARDSON PM, 1994, PHARMACOL THERAPEUT, V63, P187, DOI 10.1016/0163-7258(94)90045-0; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; ROCKMAN HA, 1993, CIRCULATION, V87, P14; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; ROSE TM, 1994, CYTOKINE, V6, P48, DOI 10.1016/1043-4666(94)90007-8; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAITO M, 1992, J IMMUNOL, V148, P4066; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SPORENO E, 1994, J BIOL CHEM, V269, P10991; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAKAHASHI R, 1994, NAT GENET, V7, P79, DOI 10.1038/ng0594-79; TOMIDA M, 1994, J BIOCHEM-TOKYO, V115, P557, DOI 10.1093/oxfordjournals.jbchem.a124375; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WARD LD, 1994, J BIOL CHEM, V269, P23286; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; YIN TG, 1994, EXP HEMATOL, V22, P467; YOSHIDA K, 1994, MECH DEVELOP, V45, P163, DOI 10.1016/0925-4773(94)90030-2; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	84	411	428	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10915	10922		10.1074/jbc.270.18.10915	http://dx.doi.org/10.1074/jbc.270.18.10915			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738033	hybrid			2022-12-25	WOS:A1995QW60100081
J	BROSS, P; JESPERSEN, C; JENSEN, TG; ANDRESEN, BS; KRISTENSEN, MJ; WINTER, V; NANDY, A; KRAUTLE, F; GHISLA, S; BOLUND, L; KIM, JJP; GREGERSEN, N				BROSS, P; JESPERSEN, C; JENSEN, TG; ANDRESEN, BS; KRISTENSEN, MJ; WINTER, V; NANDY, A; KRAUTLE, F; GHISLA, S; BOLUND, L; KIM, JJP; GREGERSEN, N			EFFECTS OF 2 MUTATIONS DETECTED IN MEDIUM-CHAIN ACYL-COA DEHYDROGENASE (MCAD)-DEFICIENT PATIENTS ON FOLDING, OLIGOMER ASSEMBLY, AND STABILITY OF MCAD ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DEHYDROGENASE; TRANSMEMBRANE CONDUCTANCE REGULATOR; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; ESCHERICHIA-COLI; ISOVALERYL-COENZYME; LIVER MITOCHONDRIA; MESSENGER-RNA; PROTEIN; DEFICIENCY	We have used expression of human medium chain acyl-CoA dehydrogenase (MCAD) in Escherichia coli as a model system for dissecting the molecular effects of two mutations detected in patients with MCAD deficiency, We demonstrate that the R28C mutation predominantly affects polypeptide folding. The amounts of active R28C mutant enzyme produced could be modulated between undetectable to 100% of the wild-type control by manipulating the level of available chaperonins and the growth temperature, For the prevalent K304E mutation, however, the amounts of active mutant enzyme could be modulated only in a range from undetectable to approximately 50% of the wild-type, and the as sembled mutant enzyme displayed a decreased thermal stability. Two artificially constructed mutants (R304Q and K304E/D346K) yielded clearly higher amounts of active MCAD enzyme than the K304E mutant but were also responsive to chaperonin co-overexpression and growth at low temperature. The thermal stability profile of the H304E/D346K double mutant was shifted to even lower temperatures than that of the K304E mutant, whereas that of the K804Q mutant was closely similar to the wild-type, Taken together, the results show that the K304E mutation affects (i) polypeptide folding due to elimination of the positively charged lysine and (ii) oligomer assembly and stability due to replacement of lysine 304 with the negatively charged glutamic acid.	AARHUS UNIV,INST HUMAN GENET,DK-8000 AARHUS C,DENMARK; MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226; UNIV KONSTANZ,FAC BIOL,W-7750 CONSTANCE,GERMANY	Aarhus University; Medical College of Wisconsin; University of Konstanz	BROSS, P (corresponding author), AARHUS UNIV HOSP,SKEJBY SYGEHUS,FAC HLTH SCI,CTR MED MOLEC BIOL,BRENDSTRUPGARDSVEJ,DK-8200 AARHUS N,DENMARK.		Bross, Peter/B-7219-2013; Andresen, Brage/D-2515-2012	Bross, Peter/0000-0001-9526-8525; Andresen, Brage/0000-0001-7488-3035				ANDRESEN BS, 1994, AM J HUM GENET, V54, P975; ANDRESEN BS, 1993, AM J HUM GENET, V53, P730; Beinert H., 1963, ENZYMES, P447; BROSS P, 1994, BIOCHEM MED METAB B, V52, P36, DOI 10.1006/bmmb.1994.1031; BROSS P, 1993, BIOCHIM BIOPHYS ACTA, V1182, P264, DOI 10.1016/0925-4439(93)90068-C; BROSS P, 1990, J BIOL CHEM, V265, P7116; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DURAN M, 1985, J PEDIATR-US, V107, P397, DOI 10.1016/S0022-3476(85)80514-X; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GORDON CL, 1994, J BIOL CHEM, V269, P27941; GORDON CL, 1994, GENETICS, V136, P427; GREGERSEN N, 1993, HUM HERED, V43, P342, DOI 10.1159/000154157; GREGERSEN N, 1991, HUM GENET, V86, P545; HALE DE, 1992, J PEDIATR-US, V121, P1, DOI 10.1016/S0022-3476(05)82532-6; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; IAFOLLA AK, 1994, J PEDIATR-US, V124, P409, DOI 10.1016/S0022-3476(94)70363-9; INDO Y, 1991, GENOMICS, V111, P609; IZAI K, 1992, J BIOL CHEM, V267, P1027; JENSEN TG, 1995, IN PRESS HUM MUTAT; KELLY DP, 1987, P NATL ACAD SCI USA, V84, P4068, DOI 10.1073/pnas.84.12.4068; KELLY DP, 1990, P NATL ACAD SCI USA, V97, P9326; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; KOLVRAA S, 1982, CLIN CHIM ACTA, V126, P53, DOI 10.1016/0009-8981(82)90361-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; MATSUBARA Y, 1990, J CLIN INVEST, V85, P1058, DOI 10.1172/JCI114536; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; MATSUBARA Y, 1990, BIOCHEM BIOPH RES CO, V171, P498, DOI 10.1016/0006-291X(90)91421-N; MATSUBARA Y, 1987, J BIOL CHEM, V262, P10104; MATTHEWS BW, 1993, CURR OPIN STRUC BIOL, V3, P589, DOI 10.1016/0959-440X(93)90088-3; MITRAKI A, 1993, J BIOL CHEM, V268, P20071; NAITO E, 1990, J CLIN INVEST, V85, P1575, DOI 10.1172/JCI114607; NAITO E, 1989, J CLIN INVEST, V83, P1605, DOI 10.1172/JCI114058; SAIJO T, 1994, J BIOL CHEM, V269, P4401; Tanaka K., 1992, Human Mutation, V1, P271, DOI 10.1002/humu.1380010402; VANDYCK L, 1994, J BIOL CHEM, V269, P238; WILCKEN B, 1994, ARCH DIS CHILD, V70, P410, DOI 10.1136/adc.70.5.410; YOKOTA I, 1992, J BIOL CHEM, V267, P26004; YOKOTA I, 1990, J CLIN INVEST, V86, P100	42	75	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10284	10290		10.1074/jbc.270.17.10284	http://dx.doi.org/10.1074/jbc.270.17.10284			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730333	Green Published			2022-12-25	WOS:A1995QV41700082
J	CHU, W; BURNS, DK; SWERLICK, RA; PRESKY, DH				CHU, W; BURNS, DK; SWERLICK, RA; PRESKY, DH			IDENTIFICATION AND CHARACTERIZATION OF A NOVEL CYTOKINE-INDUCIBLE NUCLEAR-PROTEIN FROM HUMAN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; DNA-BINDING ACTIVITY; PLASMINOGEN-ACTIVATOR INHIBITOR; FACTOR-ALPHA; GROWTH-FACTOR; TRANSCRIPTION FACTORS; LEUKOCYTE ADHESION; GENE-EXPRESSION; MESSENGER-RNA	Vascular endothelial cells undergo profound changes upon cellular activation including expression of a spectrum of cell activation-associated genes. These changes play important roles in many physiological and pathological events, By differential screening of a cDNA library prepared from interleukin-1 alpha and tumor necrosis factor-alpha-stimulated human dermal microvascular endothelial cells, we have identified a novel cytokine-inducible gene, designated as C-193, The compiled cDNA sequence of C-193 is 1901 base pairs long and shows no significant homology with any known gene sequence, Genomic DNA analysis revealed that C-193 is encoded by a single gene, which is conserved in different mammalian species. The C-193 gene was localized to human chromosome 10 by Southern blot analysis of somatic cell hybrids, Multiple AT-rich mRNA decay elements were identified in the 3'-untranslated region, C-193 mRNA expression was rapidly and transiently induced by treatment with interleukin-1 alpha or tumor necrosis factor-alpha, reached a peak of expression about 16 h post tumor necrosis factor-alpha stimulation, and the induction of C-193 was protein synthesis independent, Lipopolysaccharide and cycloheximide were also potent inducers of C-193 mRNA Therefore, C-193 represents a new addition to the primary response gene family, In vitro translation of C-193 yielded a 36-kDa protein product, consistent with the predicted open reading frame of 818 amino acids and a calculated molecular mass of 36 kDa for C-193 protein, The predicted protein sequence contains a basic amino acid cluster similar to a nuclear localization signal, four tandem repeats of ankyrin-like se quence, and multiple consensus protein phosphorylation sites, C-193 was engineered with a FLAG tag at its carboxyl terminus and transiently expressed in COS cells, Consistent with the presence of a putative nuclear localization signal, the C-193-FLAG protein was localized to the nucleus of transfected COS cells by indirect immunofluorescence microscopy, C-193-FLAG prepared in vitro was capable of binding DNA cellulose, These results indicate that C-193 protein may play an important role in endothelial cell activation.	HOFFMANN LA ROCHE INC,ROCHE RES CTR,DEPT INFLAMMAT AUTOIMMUNE DIS,NUTLEY,NJ 07110; EMORY UNIV,SCH MED,DEPT DERMATOL,ATLANTA,GA 30322	Roche Holding; Emory University			Swerlick, Robert/AAY-1998-2020	Swerlick, Robert/0000-0002-9802-4144				AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1990, SCIENCE, V242, P540; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BLANK V, 1991, EMBO J, V13, P4159; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CHU W, 1994, J IMMUNOL, V153, P4179; CHU W, 1994, EUR J BIOCHEM, V225, P695, DOI 10.1111/j.1432-1033.1994.00695.x; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN E, 1993, EMBO J, V12, P2733; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GHERSA P, 1992, J BIOL CHEM, V267, P19226; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MCMAHON SB, 1992, FASEB J, V6, P2707, DOI 10.1096/fasebj.6.9.1612295; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; POLYANOVSKY OL, 1990, BIOESSAYS, V12, P205, DOI 10.1002/bies.950120503; PONGRATZ I, 1991, J BIOL CHEM, V266, P16813; RINGOLD GM, 1984, P NATL ACAD SCI-BIOL, V81, P3964, DOI 10.1073/pnas.81.13.3964; ROBINSON EA, 1989, P NATL ACAD SCI USA, V86, P1850, DOI 10.1073/pnas.86.6.1850; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LABORATO; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; SWERLICK RA, 1993, J INVEST DERMATOL, V100, pS111, DOI 10.1111/1523-1747.ep12356595; SWERLICK RA, 1992, J IMMUNOL, V148, P78; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WOLF FW, 1992, J BIOL CHEM, V267, P1317	57	94	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10236	10245		10.1074/jbc.270.17.10236	http://dx.doi.org/10.1074/jbc.270.17.10236			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730328	hybrid			2022-12-25	WOS:A1995QV41700076
J	ROTHENBERG, ME; EILERTSON, CD; KLEIN, K; ZHOU, Y; LINDBERG, I; MCDONALD, JK; MACKIN, RB; NOE, BD				ROTHENBERG, ME; EILERTSON, CD; KLEIN, K; ZHOU, Y; LINDBERG, I; MCDONALD, JK; MACKIN, RB; NOE, BD			PROCESSING OF MOUSE PROGLUCAGON BY RECOMBINANT PROHORMONE CONVERTASE-1 AND IMMUNOPURIFIED PROHORMONE CONVERTASE-2 IN-VITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; PROPROTEIN CONVERTASE; ENDOPROTEASE FAMILY; ESCHERICHIA-COLI; MESSENGER-RNAS; YEAST KEX2; PC2; FURIN; RAT; IDENTIFICATION	The mouse tumor cell line alpha TC1-6 was used as a model system to examine the post-translational processing of proglucagon. Determination of the mouse preproglucagon cDNA sequence and comparison with the published sequences of rat and human preproglucagons revealed nucleic acid homologies of 89.1 and 84%, respectively, and amino acid homologies of 94 and 89.4%, respectively. Immunohistochemical analyses with antibodies directed against PC2 and glucagon colocalized both the enzyme and substrate within the same secretory granules. PC1 was also immunolocalized in secretory gran granules. Cells were metabolically labeled with [H-3]tryptophan, and extracts were analyzed by reverse-phase high pressure liquid chromatography. Radioactive peptides with retention times identical to those of synthetic peptide standards were recovered and subjected to peptide mapping to verify their identities. To determine the potential role of PC1 and PC2 in proglucagon processing, H-3-labeled proglucagon was incubated in vitro with recombinant PC1 and/or immunopurified PC2. Both enzymes cleaved proglucagon to yield the major proglucagon fragment, glicentin, and oxyntomodulin, whereas only PC1 released glucagon-like peptide-I from the major proglucagon fragment. Neither PCI nor PC2 processed glucagon from proglucagon in vitro. These results suggest a potential role for PC1 and/or PC2 in cleaving several of the normal products, excluding glucagon, from the mouse proglucagon precursor.	EMORY UNIV, DEPT ANAT & CELL BIOL, ATLANTA, GA 30322 USA; LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, NEW ORLEANS, LA 70112 USA; CREIGHTON UNIV, DEPT BIOMED SCI, OMAHA, NE 68178 USA	Emory University; Louisiana State University System; Creighton University			Lindberg, Iris/Q-3825-2019		NIDA NIH HHS [R01 DA005084, R56 DA005084] Funding Source: Medline; NIDDK NIH HHS [DK 44986] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005084, R56DA005084] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANDREWS PC, 1987, EXPERIENTIA, V43, P784, DOI 10.1007/BF01945356; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BLACHE P, 1994, FEBS LETT, V344, P65, DOI 10.1016/0014-5793(94)00371-8; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRUBAKER PL, 1991, ADV EXP MED BIOL, V291, P143; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HAN VKM, 1986, J NEUROSCI RES, V16, P97, DOI 10.1002/jnr.490160110; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOLST JJ, 1994, J BIOL CHEM, V269, P18827; HORIMOTO T, 1994, J VIROL, V68, P6074, DOI 10.1128/JVI.68.9.6074-6078.1994; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KORNER J, 1991, P NATL ACAD SCI USA, V88, P6834, DOI 10.1073/pnas.88.15.6834; LIN KH, 1991, BIOTECHNIQUES, V11, P748; LINDBERG I, 1992, BIOCHEM BIOPH RES CO, V183, P1, DOI 10.1016/0006-291X(92)91599-L; LUI EY, 1990, ENDOCRINOLOGY, V126, P110, DOI 10.1210/endo-126-1-110; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MACKIN RB, 1987, J BIOL CHEM, V262, P6453; MARCINKIEWICZ M, 1994, ENDOCRINOLOGY, V135, P1651, DOI 10.1210/en.135.4.1651; MARCINKIEWICZ M, 1993, P NATL ACAD SCI USA, V90, P4922, DOI 10.1073/pnas.90.11.4922; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MILGRAM SL, 1989, PEPTIDES, V10, P1013, DOI 10.1016/0196-9781(89)90184-8; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; NAGAMUNE H, 1995, ENDOCRINOLOGY, V136, P357, DOI 10.1210/en.136.1.357; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; NEERMANARBEZ M, 1994, BIOCHEM J, V300, P57, DOI 10.1042/bj3000057; NOE BD, 1986, PEPTIDES, V7, P331, DOI 10.1016/0196-9781(86)90232-9; ORCI L, 1994, J CELL BIOL, V126, P1149, DOI 10.1083/jcb.126.5.1149; ORSKOV C, 1992, DIABETOLOGIA, V35, P701; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; RINDLER M J, 1992, Current Opinion in Cell Biology, V4, P616, DOI 10.1016/0955-0674(92)90080-V; ROUILLE Y, 1994, P NATL ACAD SCI USA, V91, P3242, DOI 10.1073/pnas.91.8.3242; Sambrook J, 1989, MOL CLONING LABORATO; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TSUJI A, 1994, BIOCHEM BIOPH RES CO, V200, P943, DOI 10.1006/bbrc.1994.1541; TSUJI A, 1994, BIOCHEM BIOPH RES CO, V202, P1452, DOI 10.1006/bbrc.1994.2094; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378; YI Z, 1993, J BIOL CHEM, V268, P5615	59	57	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10136	10146		10.1074/jbc.270.17.10136	http://dx.doi.org/10.1074/jbc.270.17.10136			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730317	hybrid			2022-12-25	WOS:A1995QV41700064
J	CONDRESCU, M; GARDNER, JP; CHERNAYA, G; ACETO, JF; KROUPIS, C; REEVES, JP				CONDRESCU, M; GARDNER, JP; CHERNAYA, G; ACETO, JF; KROUPIS, C; REEVES, JP			ATP-DEPENDENT REGULATION OF SODIUM-CALCIUM EXCHANGE IN CHINESE-HAMSTER OVARY CELLS TRANSFECTED WITH THE BOVINE CARDIAC SODIUM-CALCIUM EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUID GIANT-AXONS; NA+-CA2+ EXCHANGE; SARCOLEMMAL VESICLES; DYNAMIC PROPERTIES; STEADY-STATE; HEART-CELLS; EXPRESSION; PH; STIMULATION; MODULATION	Chinese hamster ovary cells expressing the bovine cardiac Na/Ca exchanger were treated with ouabain to increase [Na+](i) and stimulate Ca2+ influx by Na/Ca exchange, Depletion of cellular ATP inhibited Ca-45 uptake by 40% or more and reduced the half-maximal Na+ concentration for inhibition of Ca-45 uptake from 90 to 55 mM. ATP depletion also reduced the rate of rise in [Ca2+](i) when [Na+](o) was reduced and inhibited the decline in [Ca2+](i) when high [Na+](o) was restored, The effects of ATP depletion were either absent or reduced in cells expressing a mutant exchanger missing most of the cytosolic hydrophilic domain, We were unable to detect a phosphorylated form of the exchanger in immunoprecipitates from P-32-labeled cells. ATP depletion caused a breakdown in the actin cytoskeleton of the cells, Treatment of the cells with cytochalasin D mimicked the effects of ATP depletion on the [Na+] inhibition profile for Ca-45 uptake, Thus, ATP depletion inhibits both the Ca2+ influx and Ca2+ efflux modes of Na/Ca exchange, and may alter the competitive interactions of extracellular Na+ and Ca2+ with the transporter. The latter effect appears to be related to changes in the actin cytoskeleton.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PHYSIOL,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,HYPERTENS RES CTR,NEWARK,NJ 07103; HOFFMANN LA ROCHE INC,ROCHE RES CTR,ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Roche Holding			Kroupis, Christos/K-2725-2013	Kroupis, Christos/0000-0002-5876-2599	NHLBI NIH HHS [HL49932] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049932] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACETO JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P553, DOI 10.1016/0003-9861(92)90449-7; BAKER PF, 1969, J PHYSIOL-LONDON, V200, P431, DOI 10.1113/jphysiol.1969.sp008702; BERSHADSKY AD, 1980, EXP CELL RES, V127, P421, DOI 10.1016/0014-4827(80)90446-2; BLAUSTEIN MP, 1977, BIOPHYS J, V20, P79, DOI 10.1016/S0006-3495(77)85538-0; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; CONDRESCU M, 1994, BIOPHYS J, V66, pA332; CONDRESCU M, 1993, BIOPHYS J, V46, pA399; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; DIPOLO R, 1987, J GEN PHYSIOL, V90, P505, DOI 10.1085/jgp.90.4.505; DIPOLO R, 1991, ANN NY ACAD SCI, V639, P100, DOI 10.1111/j.1749-6632.1991.tb17294.x; DIPOLO R, 1974, J GEN PHYSIOL, V64, P503, DOI 10.1085/jgp.64.4.503; DIPOLO R, 1994, AM J PHYSIOL, V266, pC1382, DOI 10.1152/ajpcell.1994.266.5.C1382; DIPOLO R, 1993, J PHYSIOL-LONDON, V462, P71, DOI 10.1113/jphysiol.1993.sp019544; HAWORTH RA, 1987, CIRC RES, V60, P586, DOI 10.1161/01.RES.60.4.586; HAWORTH RA, 1992, CIRC RES, V71, P210, DOI 10.1161/01.RES.71.1.210; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; HILGEMANN DW, 1992, J PHYSIOL-LONDON, V454, P59, DOI 10.1113/jphysiol.1992.sp019254; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI ZP, 1993, J BIOL CHEM, V268, P11489; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MATSUOKA S, 1992, IN PRESS J GEN PHYSL; MILLS JW, 1994, FASEB J, V8, P1161, DOI 10.1096/fasebj.8.14.7958622; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PHILIPSON KD, 1982, CIRC RES, V50, P287, DOI 10.1161/01.RES.50.2.287; PIJUAN V, 1993, AM J PHYSIOL, V264, pC1066, DOI 10.1152/ajpcell.1993.264.4.C1066; REEVES JP, 1994, BIOPHYS J, V66, pA148; REEVES JP, 1983, J BIOL CHEM, V258, P3178; SANGER JW, 1983, EUR J CELL BIOL, V31, P197; SMITH JB, 1990, AM J PHYSIOL, V252, pC302; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012	34	92	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9137	9146		10.1074/jbc.270.16.9137	http://dx.doi.org/10.1074/jbc.270.16.9137			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721828	hybrid			2022-12-25	WOS:A1995QU08900016
J	PATTERSON, SD; GROSSMAN, JS; DANDREA, P; LATTER, GI				PATTERSON, SD; GROSSMAN, JS; DANDREA, P; LATTER, GI			REDUCED NUMATRIN B23 NUCLEOPHOSMIN LABELING IN APOPTOTIC JURKAT T-LYMPHOBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MATRIX PROTEIN; PROGRAMMED CELL-DEATH; DIMENSIONAL GEL-ELECTROPHORESIS; INDUCED DNA FRAGMENTATION; AMINO-ACID-SEQUENCE; HELA-CELLS; NUCLEOLAR PROTEIN-B23; VENTRAL PROSTATE; LYMPHOCYTES-T; ACTINOMYCIN-D	Jurkat T-lymphoblasts were induced to undergo apoptosis by treatment with either EGTA (5 mM/24 h) or a high concentration of lovastatin (100 mu M/48 h) to identify proteins that exhibited coordinate regulation between the two treatments and thus provide candidate proteins in the common apoptotic induction pathway. A pure population of apoptotic cells, as determined by morphology, ''DNA laddering,'' and flow cytometry, was obtained by Percoll density gradient centrifugation, Cells of increased buoyant density were clearly apoptotic by all criteria. Following this gradient centrifugation, the cells were labeled with [S-35]methionine/cysteine, and lysates were separated by two-dimensional polyacrylamide gel electrophoresis. Surprisingly, the two-dimensional polyacrylamide gel electrophoresis patterns generated from the apoptotic cells did not differ dramatically from that of control cells, Thus, apoptotic Jurkat cells are able to synthesize new proteins and do not exhibit extensive proteolysis. Subsequent quantitative analysis revealed that only five proteins exhibited decreases in turnover that were common to the two treatments, No increases in protein turnover were able to be confirmed across the replicate experiments, One of the proteins that showed decreased labeling by both apoptotic inductions was an abundant nuclear protein with a pI of 5.1 and M(r) 40,000, This protein was identified as numatrin/B23/nucleophosmin (NPM) based on internal amino acid sequence, and this identity was confirmed by immunoblotting and mass spectrometry, NPM is implicated in a range of diverse cellular functions, but its role in apoptosis is unclear.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory			Patterson, Scott/A-7404-2009		NCI NIH HHS [P30-CA45508] Funding Source: Medline; NCRR NIH HHS [P41-RR02188] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002188] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADACHI Y, 1993, J BIOL CHEM, V268, P13930; AEBERSOLD R, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P71; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BANSAL N, 1989, LEUKEMIA RES, V13, P875, DOI 10.1016/0145-2126(89)90040-4; BAXTER GD, 1992, J IMMUNOL, V148, P1949; BAZAR LS, 1992, EXP HEMATOL, V20, P80; BECKMANN R, 1992, EUR J BIOCHEM, V210, P45, DOI 10.1111/j.1432-1033.1992.tb17388.x; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BOR AMS, 1992, INT J CANCER, V52, P658, DOI 10.1002/ijc.2910520427; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BRAND SR, 1994, J IMMUNOL, V152, P4120; BRUNO S, 1992, LEUKEMIA, V6, P1113; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHAN PK, 1985, EXP CELL RES, V161, P101, DOI 10.1016/0014-4827(85)90494-X; CHAN PK, 1986, J BIOL CHEM, V261, P1868; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHANG JH, 1990, J BIOL CHEM, V265, P18227; COHEN JJ, 1993, HOSP PRACT, V28, P35, DOI 10.1080/21548331.1993.11442887; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COTTER TG, 1990, ANTICANCER RES, V10, P1153; DELBINO G, 1991, EXP CELL RES, V193, P27, DOI 10.1016/0014-4827(91)90534-2; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; FALCIERI E, 1993, BIOCHEM BIOPH RES CO, V193, P19, DOI 10.1006/bbrc.1993.1584; FALCIERI E, 1994, HISTOCHEMISTRY, V102, P221; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FEUERSTEIN N, 1990, BIOCHIM BIOPHYS ACTA, V1087, P127, DOI 10.1016/0167-4781(90)90196-9; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; FEUERSTEIN N, 1991, J BIOL CHEM, V266, P16200; FINCH RA, 1992, ONCOLOGY, V49, P223; FINCH RA, 1993, J BIOL CHEM, V268, P5823; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GARRELS JI, 1989, J BIOL CHEM, V264, P5283; GARRELS JI, 1989, J BIOL CHEM, V264, P5269; GAZITT Y, 1994, CANCER RES, V54, P950; GOLDSTONE SD, 1993, BIOCHEM BIOPH RES CO, V196, P619, DOI 10.1006/bbrc.1993.2294; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; GORCZYCA W, 1993, INT J ONCOL, V3, P627; HAMBLIN AS, 1987, LYMPHOCYTES PRACTICA, P209; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HESS D, 1993, PROTEIN SCI, V2, P1342, DOI 10.1002/pro.5560020817; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JONES CE, 1981, BIOCHIM BIOPHYS ACTA, V667, P209, DOI 10.1016/0005-2795(81)90081-7; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LEE C, 1987, J UROLOGY, V138, P903, DOI 10.1016/S0022-5347(17)43413-6; LEGER JG, 1987, BIOCHEM BIOPH RES CO, V147, P196, DOI 10.1016/S0006-291X(87)80106-7; LEITINGER N, 1993, J CELL BIOCHEM, V52, P153, DOI 10.1002/jcb.240520207; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MONARDO PJ, 1994, COMPUT APPL BIOSCI, V10, P137; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MUMBY S M, 1990, Methods (Orlando), V1, P216, DOI 10.1016/S1046-2023(05)80320-2; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; PATTERSON SD, 1994, ANAL BIOCHEM, V221, P1, DOI 10.1006/abio.1994.1371; PATTERSON SD, 1993, BIOTECHNIQUES, V15, P1076; PATTERSON SD, 1994, CELL BIOL LABORATORY, V3, P249; PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359; PFAFF M, 1988, BIOCHIM BIOPHYS ACTA, V969, P100, DOI 10.1016/0167-4889(88)90093-6; ROBAYE B, 1994, ELECTROPHORESIS, V15, P503, DOI 10.1002/elps.1150150168; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SENSIBAR JA, 1990, J UROLOGY, V143, P161, DOI 10.1016/S0022-5347(17)39902-0; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; STEWART BW, 1994, JNCI-J NATL CANCER I, V86, P1286, DOI 10.1093/jnci/86.17.1286; TELFORD WG, 1991, CELL PROLIFERAT, V24, P447, DOI 10.1111/j.1365-2184.1991.tb01173.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VILLA P, 1994, J NEUROCHEM, V62, P1468; VORIS BP, 1981, J BIOL CHEM, V256, P1319; WADEWITZ AG, 1988, FEBS LETT, V241, P19, DOI 10.1016/0014-5793(88)81022-6; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1982, AM J PATHOL, V109, P78; WYLLIE AH, 1994, PHILOS T R SOC B, V345, P237, DOI 10.1098/rstb.1994.0099; YAMADA T, 1980, INT J RADIAT BIOL, V37, P695, DOI 10.1080/713857566; YUNG BYM, 1990, INT J CANCER, V46, P272, DOI 10.1002/ijc.2910460222	82	47	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9429	9436		10.1074/jbc.270.16.9429	http://dx.doi.org/10.1074/jbc.270.16.9429			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721868	hybrid			2022-12-25	WOS:A1995QU08900057
J	DANIEL, R; CAI, YL; WONG, PMC; CHUNG, SW				DANIEL, R; CAI, YL; WONG, PMC; CHUNG, SW			DEREGULATION OF C-ABL MEDIATED CELL-GROWTH AFTER RETROVIRAL TRANSFER AND EXPRESSION OF ANTISENSE SEQUENCES	ONCOGENE			English	Article						C-ABL; ANTISENSE; CELL CYCLE	HEMATOPOIETIC STEM-CELLS; TYROSINE KINASE; BINDING; GENE; PROTEIN; CYCLE; ACTIVATION; ONCOGENE	To determine the role of c-abl during cell growth, we constructed a retrovirus vector alpha A, capable of expressing an antisense RNA directed against the abl mRNA, Based on v-abl-mediated 3T3 transformation assay, we showed that the number of transformed foci was reduced 50-94% when alpha A-infected 3T3 cells were superinfected with A-MuLV, Up to a 100% of inhibition could be observed when the time of infection was lengthened. Introduction of the antisense sequence into NM3T3 cells resulted in reduction of growth rate. These cells entered into S phase from G1 phase of the cell cycle earlier in time than untransduced cells, Thus c-abl serves as a checkpoint during G1/S transition in the cell cycle, and its reduction resulted in deregulation of cell growth.	TEMPLE UNIV,FELS INST CANC RES & MOLEC BIOL,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,DEPT LAB MED & PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140; SUNY DOWNSTATE MED CTR,MORSE INST MOLEC GENET,DEPT IMMUNOL & MICROBIOL,BROOKLYN,NY	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center				Daniel, Rene/0000-0002-3876-6242	NCI NIH HHS [5P30CA12227] Funding Source: Medline; NHLBI NIH HHS [HL46547] Funding Source: Medline; NIDDK NIH HHS [DK41298] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041298] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASKARAN R, 1993, P NATL ACAD SCI USA, V98, P11167; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; CHUNG SW, 1988, BLOOD, V71, P973; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; CHUNG SW, 1994, ONCOGENE, V9, P3527; CHUNG SW, 1995, IN PRESS ONCOGENE; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; HAN XD, 1991, P NATL ACAD SCI USA, V88, P10129, DOI 10.1073/pnas.88.22.10129; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Sambrook J., 1989, MOL CLONING; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; TYBULEWICZ VLJ, 1991, CELL, V65, P1097; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WONG BY, 1994, J VIROL, V68, P5523, DOI 10.1128/JVI.68.9.5523-5531.1994; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798	26	20	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1607	1614						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731715				2022-12-25	WOS:A1995QU68100017
J	PAPIN, C; EYCHENE, A; BRUNET, A; PAGES, G; POUYSSEGUR, J; CALOTHY, G; BARNIER, JV				PAPIN, C; EYCHENE, A; BRUNET, A; PAGES, G; POUYSSEGUR, J; CALOTHY, G; BARNIER, JV			B-RAF PROTEIN ISOFORMS INTERACT WITH AND PHOSPHORYLATE MEK-1 ON SERINE RESIDUE-218 AND RESIDUE-222	ONCOGENE			English	Note						B-RAF; C-RMIL; MEK-1; MAP KINASE CASCADE; SERINE THREONINE KINASES	KINASE; PROTOONCOGENE; COMPLEX; CELLS	The B-raf/c-Rmil proto-oncogene belongs to the raf/mil family of serine/threonine protein kinases, Tt encodes multiple protein isoforms resulting from alternative splicing of two exons located upstream of the kinase domain, Recent studies suggested that B-Raf could be the intermediate molecule between Ras and Mek-1 (MAP Kinase Kinase) in signalling pathways specific of neural cells. However, there has been no evidence for a direct interaction between B-Raf and Mek-1, We report here that different B-Raf isoforms can be co-immunoprecipitated with anti-Mek-1 antisera in COS-1 cells and that the kinase activity of B-Raf is not required for its interaction with Mek-1. We also show that all B-Raf isoforms tested phosphorylate Mek-1 in a time-dependent manner, whereas kinase defective mutants fail to do so. Finally, we demonstrate that the constitutively activated S218D, S222D and S218D/S222D mutants of Mek-1 interact similarly with B-Raf. However, only the S218D and S222D mutants, and not the S218D/S222D double mutant, can be phosphorylated by B-Raf isoforms. Therefore, serine residues 218 and 222, previously shown to regulate Mek-1 activity, appear to be the major phosphorylation sites by B-Raf in vitro.	CTR UNIV ORSAY,INST CURIE,LAB 110,CNRS,UNITE MIXTE RECH 146,F-91405 ORSAY,FRANCE; UNIV NICE,CTR BIOCHIM,CNRS,F-06108 NICE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Eychene, Alain/M-8838-2017; Pages, Gilles/N-7135-2017	EYCHENE, Alain/0000-0002-6818-7225				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BRUNET A, 1994, ONCOGENE, V9, P3379; CALOGERAKI I, 1993, BIOCHEM BIOPH RES CO, V193, P1324, DOI 10.1006/bbrc.1993.1770; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; EYCHENE A, 1995, ONCOGENE, V10, P1159; EYCHENE A, 1992, ONCOGENE, V7, P1315; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARX M, 1988, EMBO J, V7, P3369, DOI 10.1002/j.1460-2075.1988.tb03209.x; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	21	41	41	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1647	1651						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731720				2022-12-25	WOS:A1995QU68100022
J	IMAMOTO, N; TACHIBANA, T; MATSUBAE, M; YONEDA, Y				IMAMOTO, N; TACHIBANA, T; MATSUBAE, M; YONEDA, Y			A KARYOPHILIC PROTEIN FORMS A STABLE COMPLEX WITH CYTOPLASMIC COMPONENTS PRIOR TO NUCLEAR-PORE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 STEPS; IMPORT; TRANSPORT; TRANSLOCATION; INVITRO; INHIBITION; ANTIBODIES; ENVELOPE; SIGNALS; CELLS	Targeting of karyophilic proteins to nuclear pores is known to require several cytoplasmic factors, including the nuclear location signal-binding protein. Using a digitonin-permeabilized cell-free transport assay, we have obtained a cytoplasmic fraction containing factors that specifically bind to karyophilic protein and support the nuclear binding step of the transport. Components in this fraction form a stable complex with the karyophile through interaction with nuclear location signal. Since this complex shows nuclear pore binding activity prior to nuclear entry in the absence of other cytosolic factors, we call it nuclear pore-targeting complex. It consists of karyophilic protein and four proteins of 54, 56, 66, and 90 kDa. In our reconstitution experiments, a complex with 54 and 90 kDa proteins is capable of targeting karyophiles to the nuclear pores.	OSAKA UNIV, SCH MED, DEPT ANAT & CELL BIOL, SUITA, OSAKA 565, JAPAN	Osaka University			Imamoto, Naoko/A-7458-2015	Imamoto, Naoko/0000-0002-2886-3022				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; TACHIBANA T, 1994, J BIOL CHEM, V269, P24542; YONEDA Y, 1987, EXP CELL RES, V170, P439, DOI 10.1016/0014-4827(87)90319-3; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	18	143	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8559	8565		10.1074/jbc.270.15.8559	http://dx.doi.org/10.1074/jbc.270.15.8559			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721756	hybrid			2022-12-25	WOS:A1995QT44800032
J	MENON, RK; STEPHAN, DA; SINGH, M; MORRIS, SM; ZOU, LL				MENON, RK; STEPHAN, DA; SINGH, M; MORRIS, SM; ZOU, LL			CLONING OF THE PROMOTER-REGULATORY REGION OF THE MURINE GROWTH-HORMONE RECEPTOR GENE - IDENTIFICATION OF A DEVELOPMENTALLY-REGULATED ENHANCER ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; RAT HEPATOCYTES; ONTOGENY; LIVER; EXPRESSION; MEMBRANES; VECTORS; INSULIN; FETAL; DNA	The growth hormone (GH) receptor is essential for the actions of GH on postnatal growth and metabolism. To identify DNA sequences involved in the regulation of transcription of the murine GH receptor gene, a 17-kilobase genomic clone containing the 5'-flanking region, exon 1, and part of intron 1 of the murine GH receptor gene was isolated. Utilizing primer extension and ribonuclease protection assays, two major transcription start sites were identified in RNA from liver of male, female, and pregnant mice. Transient transfection stud ies using a reporter gene demonstrated promoter activity in a variety of eukaryotic cells. Deletional analysis and DNA protein binding assays led to the identification of a 30-base pair enhancer element located about 3.4 kilobases upstream of the transcription start sites. Computer analysis of the nucleotide sequence of the enhancer element did not reveal any potential DNA binding motifs for known transcription factors, and this DNA element failed to exhibit binding activity for some common transcription factors. Analysis of both functional activity and DNA-protein binding activity of this enhancer element in adult and fetal hepatocytes suggests that this DNA element may play a role in the developmental expression of the GH receptor gene.	UNIV PITTSBURGH, CHILDRENS HOSP PITTSBURGH, SCH MED, DEPT MOLEC GENET & BIOCHEM, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	MENON, RK (corresponding author), UNIV PITTSBURGH, CHILDRENS HOSP PITTSBURGH,SCH MED,DEPT PEDIAT, DIV ENDOCRINOL, 3705 5TH AVE, PITTSBURGH, PA 15213 USA.		Morris, Sidney M/I-3440-2015		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD000986, P30HD028836] Funding Source: NIH RePORTER; NICHD NIH HHS [HD28836, K08-HD00986] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS TE, 1990, MOL CELL ENDOCRINOL, V73, P135, DOI 10.1016/0303-7207(90)90126-S; BADINGA L, 1987, MOL CELL ENDOCRINOL, V52, P85, DOI 10.1016/0303-7207(87)90100-6; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BREIER BH, 1988, J ENDOCRINOL, V119, P43, DOI 10.1677/joe.0.1190043; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DESANTE DC, 1984, BIOCHEM J, V223, P39, DOI 10.1042/bj2230039; FREEMARK M, 1986, AM J PHYSIOL, V251, pE328, DOI 10.1152/ajpendo.1986.251.3.E328; GINOT F, 1989, EUR J BIOCHEM, V180, P289, DOI 10.1111/j.1432-1033.1989.tb14646.x; GLUCKMAN PD, 1986, OXFORD REV REPROD B, V8, P1; GLUCKMAN PD, 1981, ENDOCR REV, V2, P363, DOI 10.1210/edrv-2-4-363; GLUCKMAN PD, 1983, ENDOCRINOLOGY, V112, P1607, DOI 10.1210/endo-112-5-1607; GLUCKMAN PD, 1990, ENDOCR REV, V366, P73; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OMAHONEY JV, 1994, MOL CELL ENDOCRINOL, V101, P129, DOI 10.1016/0303-7207(94)90227-5; PONDER KP, 1991, HUM GENE THER, V2, P41, DOI 10.1089/hum.1991.2.1-41; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; STEPHAN DA, 1993, J DEV PHYSL OXF; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160; WALKER JL, 1992, PEDIATR RES, V31, P335, DOI 10.1203/00006450-199204000-00006; WATERS MJ, 1990, ACTA PAEDIATR SCAND, P60	31	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8851	8859		10.1074/jbc.270.15.8851	http://dx.doi.org/10.1074/jbc.270.15.8851			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721793	hybrid			2022-12-25	WOS:A1995QT44800071
J	TOESCU, EC; PETERSEN, OH				TOESCU, EC; PETERSEN, OH			REGION-SPECIFIC ACTIVITY OF THE PLASMA-MEMBRANE CA2+ PUMP AND DELAYED ACTIVATION OF CA2+ ENTRY CHARACTERIZE THE POLARIZED, AGONIST-EVOKED CA2+ SIGNALS IN EXOCRINE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; CYTOSOLIC CA-2+ GRADIENTS; INTRACELLULAR CA2+; INOSITOL 1,4,5-TRISPHOSPHATE; OSCILLATIONS; RECEPTOR; CHANNELS; STORES; RELEASE; INFLUX	The initial release of Ca2+ from the intracellular Ca2+ stores is followed by a second phase during which the agonist-dependent Ca2+ response becomes sensitive to the extracellular Ca2+, indicating the involvement of the plasma membrane (PM) Ca2+ transport systems. The time course of activation of these transport systems, which consist of both Ca2+ extrusion and Ca2+ entry pathways, is not well established. To investigate the participation of these processes during the agonist-evoked Ca2+ response, isolated pancreatic acinar cells were exposed to maximal concentrations of an inositol 1,4,5-trisphosphate-mobilizing agonist (acetylcholine, 10 mu M) in different experimental conditions. Following the increase of [Ca2+](i), there was an almost immediate activation of the PM Ca2+ extrusion system, and maximal activity was reached within less than 2 s. The rate of Ca2+ extrusion was dependent on the level of [Ca2+](i), with a steep activation at values just above the resting [Ca2+](i) and reached a plateau value at 700 nM Ca2+. In contrast, the PM Ca2+ entry pathway was activated with a much slower time course. There was also a delay of 3-4 s between the maximal effective depletion of the intracellular Ca2+ stores and the activation of this entry pathway. By use of digital imaging data, the PM Ca2+ transport systems were also analyzed independently in two regions of the cells, the lumenal and the basal poles. With respect to the activation of the Ca2+ entry path ways, no significant difference existed between these two regions. In contrast, the PM Ca2+ pump displayed a different pattern of activity in these regions. In the basal pole, the pump activity was more sensitive to changes of [Ca2+](i) and had a higher maximal activity. Also, in the lumenal pole, the pump became saturated at values of [Ca2+](i) around 700 nM, whereas at the basal pole [Ca2+](i) had a biphasic effect on the pump activity, and higher [Ca2+](i) inhibited the pump. It is argued that these differences in sensitivity to the levels of [Ca2+](i) and the different relationship between [Ca2+](i) and the rate of extrusion at the two functional poles of the pancreatic acinar cells indicate that the plasma membrane Ca(2+)ATPase might play an important role in the polarization of the Ca2+ response.	UNIV LIVERPOOL, PHYSIOL LAB, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND	University of Liverpool			Petersen, Ole H/E-8708-2010	Petersen, Ole/0000-0002-6998-0380				ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; BERRIDGE MJ, 1994, BIOCHEM J, V302, P545, DOI 10.1042/bj3020545; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; CARAFOLI E, 1994, J NEUROBIOL, V25, P312, DOI 10.1002/neu.480250311; ELLIOTT AC, 1992, PFLUG ARCH EUR J PHY, V422, P245, DOI 10.1007/BF00376209; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; FADOOL DA, 1992, NEURON, V9, P907, DOI 10.1016/0896-6273(92)90243-7; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FELDER CC, 1992, P NATL ACAD SCI USA, V89, P509, DOI 10.1073/pnas.89.2.509; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; KASAI H, 1993, NEUROSCI RES, V16, P1, DOI 10.1016/0168-0102(93)90002-8; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KASS GEN, 1994, BIOCHEM J, V302, P5, DOI 10.1042/bj3020005; KESSLER F, 1990, J BIOL CHEM, V265, P16012; KHAN AA, 1992, SCIENCE, V249, P1166; KOCH BD, 1994, BIOCHEM J, V302, P187, DOI 10.1042/bj3020187; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LAWRIE AM, 1993, CELL CALCIUM, V14, P698, DOI 10.1016/0143-4160(93)90096-O; LEE KM, 1993, J BIOL CHEM, V268, P9945; LINO M, 1993, EMBO J, V12, P5287, DOI 10.1002/j.1460-2075.1993.tb06224.x; LLOPIS J, 1992, BIOCHEM J, V284, P243, DOI 10.1042/bj2840243; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; PETERSEN CCH, 1993, J BIOL CHEM, V268, P22262; PETERSEN CCH, 1991, EMBO J, V10, P527, DOI 10.1002/j.1460-2075.1991.tb07979.x; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; THELER JM, 1992, J BIOL CHEM, V267, P18110; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TOESCU EC, 1994, BIOCHEM J, V304, P313, DOI 10.1042/bj3040313; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; TOESCU EC, 1993, J BIOL CHEM, V268, P18654; TOESCU EC, 1994, PFLUG ARCH EUR J PHY, V427, P325, DOI 10.1007/BF00374541; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VANDEPUT FHMM, 1994, J BIOL CHEM, V269, P12438; XU X, 1994, J BIOL CHEM, V269, P12645	47	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8528	8535		10.1074/jbc.270.15.8528	http://dx.doi.org/10.1074/jbc.270.15.8528			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721751	hybrid			2022-12-25	WOS:A1995QT44800027
J	YAMADA, S; MURAKAMI, T; TSUDA, H; YOSHIDA, K; SUGAHARA, K				YAMADA, S; MURAKAMI, T; TSUDA, H; YOSHIDA, K; SUGAHARA, K			ISOLATION OF THE PORCINE HEPARIN TETRASACCHARIDES WITH GLUCURONATE 2-O-SULFATE - HEPARINASE CLEAVES GLUCURONATE 2-O-SULFATE-CONTAINING DISACCHARIDES IN HIGHLY SULFATED BLOCKS IN HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; IDURONATE 2-SULFATE RESIDUES; HUMAN-ENDOTHELIAL CELLS; PROTEIN-LINKAGE REGION; III-BINDING SITE; FLAVOBACTERIUM-HEPARINUM; SUBSTRATE-SPECIFICITY; INTESTINAL HEPARIN; HIGH-AFFINITY; 2 SERIES	Eleven tetrasaccharides were isolated from the repeating disaccharide region of porcine intestinal heparin after strong digestion with Flavobacterium heparinase. Their structures were determined by composition analysis, enzymatic analysis, and H-1 NMR spectroscopy. Nine of them have the common tetrasaccharide backbone, Delta HexA alpha 1-4GlcN alpha 1-4IdoA alpha 1-4GlcN, where Delta HexA and IdoA represent 4,5-unsaturated hexuronic acid and L-iduronic acid, respectively, and their structural variations are based upon the positions of sulfate groups, The nine compounds include one hexasulfated, three pentasulfated and five tetrasulfated compounds, and four of them have not been isolated previously as discrete structures. The other two of the 11 tetrasaccharides have the following hitherto unreported structures with novel glucuronate 2-O-sulfate at the internal position: Delta HexA(2-sulfate)alpha 1-4GlcN(N, 6-disulfate)alpha 1-4GlcA(2-sulfate)beta 1-4GlcN(N-sulfate) and Delta HexA(2-sulphate)alpha 1-4GlcN(N,6-disulfate) alpha 1-4GlcA(2-sulfate)beta 1-4GlcN(N,6-disulfate). Thus, 2-O-sulfated glucuronate in the highly sulfated tetrasaccharide structures typical of heparin has been demonstrated. The former and the latter tetrasaccharides account for 0.31 and 0.32% (w/w) of the starting heparin, respectively. Their yield, however, is an underestimation, since these tetrasaccharide structures in longer sequences will be degraded by heparinase. Although the latter tetrasaccharide described above was unexpectedly cleaved by heparinase into two disaccharide units, the former was not degraded by the enzyme most likely due to the lack of the 6-O-sulfate group on the GlcN residue at the reducing terminus. The results indicate its capability of catalyzing both anti and syn elimination, a property shared by heparitinases I and II and chondroitinase ABC. Both tetrasaccharides were degraded into disaccharides by heparitinase II. Therefore, it is necessary to reevaluate the disaccharide composition of heparin/heparan sulfate or oligosaccharide structures, which were previously determined after heparinase or heparitinase II digestion. It is no longer possible to conclude that the 2-O-sulfated unsaturated uronic acid residues obtained from heparin/heparan sulfate by lyase digestions are always derived from iduronate 2-O-sulfate residues in the original polymer. It is quite possible that the novel glucuronate 2-O-sulfate structure in the highly sulfated region of heparin is involved in some of the biological activities of heparin.	KOBE PHARMACEUT UNIV,DEPT BIOCHEM,HIGASHINADA KU,KOBE 658,JAPAN; SEIKAGAKU CORP,TOKYO RES INST,HIGASHIYAMATO,TOKYO 207,JAPAN	Kobe Pharmaceutical University; Seikagaku Corporation								BAME KJ, 1991, J BIOL CHEM, V266, P10287; BARZU T, 1989, J CELL PHYSIOL, V140, P538, DOI 10.1002/jcp.1041400320; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CIFONELLI JA, 1962, BIOCHEM BIOPH RES CO, V7, P41, DOI 10.1016/0006-291X(62)90141-9; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; DESAI UR, 1993, BIOCHEMISTRY-US, V32, P8140, DOI 10.1021/bi00083a012; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FOLKMAN J, 1989, HEPARIN, P317; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HISCOCK DRR, 1994, J BIOL CHEM, V269, P4539; HORNE A, 1992, CARBOHYD RES, V225, P43, DOI 10.1016/0008-6215(92)80038-3; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; KOVENSKY J, 1993, CARBOHYD RES, V245, P361, DOI 10.1016/0008-6215(93)80085-S; KUSCHE M, 1991, J BIOL CHEM, V266, P7400; KUSCHE M, 1990, J BIOL CHEM, V265, P15403; LINDAHL U, 1965, J BIOL CHEM, V240, P2821; Lindahl U., 1989, HEPARIN, P159; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LINKER A, 1984, CARBOHYD RES, V127, P75, DOI 10.1016/0008-6215(84)85107-1; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P11208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1989, HEPARIN, P275; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; MERCHANT ZM, 1985, BIOCHEM J, V229, P369, DOI 10.1042/bj2290369; NADER HB, 1990, J BIOL CHEM, V265, P16807; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; RICE KG, 1989, CARBOHYD RES, V190, P219, DOI 10.1016/0008-6215(89)84127-8; Roden L., 1989, HEPARIN CHEM BIOL PR, P1; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1992, BIOCHEM J, V283, P99, DOI 10.1042/bj2830099; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; SUGAHARA K, 1987, ARCH BIOCHEM BIOPHYS, V258, P391, DOI 10.1016/0003-9861(87)90360-2; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1991, BIOCHEM J, V277, P297, DOI 10.1042/bj2770297; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; TYRRELL DJ, 1993, J BIOL CHEM, V268, P4684; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WALKER A, 1994, J BIOL CHEM, V269, P931; YAMADA S, 1992, J BIOCHEM-TOKYO, V112, P440, DOI 10.1093/oxfordjournals.jbchem.a123919; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; YAMADA SH, 1993, J BIOL CHEM, V268, P4780; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YAMAUCHI F, 1968, BIOCHEM BIOPH RES CO, V33, P721, DOI 10.1016/0006-291X(68)90218-0; YOSHIDA K, 1989, 10TH P INT S GLYC JE, P330	59	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8696	8705						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721774				2022-12-25	WOS:A1995QT44800052
J	CROSS, AR; HEYWORTH, PG; RAE, J; CURNUTTE, JT				CROSS, AR; HEYWORTH, PG; RAE, J; CURNUTTE, JT			A VARIANT X-LINKED CHRONIC GRANULOMATOUS-DISEASE PATIENT (X91(+)) WITH PARTIALLY FUNCTIONAL CYTOCHROME-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; PHAGOCYTE NADPH OXIDASE; HUMAN-NEUTROPHILS; POLYMORPHONUCLEAR LEUKOCYTES; MICROBICIDAL OXIDASE; ACTIVATION; SUPEROXIDE; COMPONENT; SUBUNITS; PROTEIN	Genetic analysis of a patient with the variant cytochrome b(-245)-positive form of chronic granulomatous disease revealed a missense mutation resulting in a Arg(54) --> Ser substitution in the gp91(phox) subunit of cytochrome b(-245). As a consequence, although no O-2(-) is made, NADPH oxidase-associated FAD accepts electrons from NADPH in the cell-free activation system and becomes reduced. The reduced flavin exhibits normal levels of iodonitrotetrazolium violet diaphorase activity, and the patient's neutrophils exhibit high levels of intracellular oxidant production and show a low level of NBT staining in the NBT slide test. Thus, this mutation appears to render the heme center of NADPH oxidase present but nonfunctional, while leaving the flavin center fully functional.			CROSS, AR (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, CAL-1, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NCRR NIH HHS [RR00833] Funding Source: Medline; NIAID NIH HHS [AI24838] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1988, J BIOL CHEM, V263, P1713; BADWEY JA, 1982, BIOCHEM BIOPH RES CO, V106, P170, DOI 10.1016/0006-291X(82)92073-3; BAEHNER RL, 1976, BLOOD, V48, P309; BASS DA, 1983, J IMMUNOL, V130, P1910; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BRIGGS RT, 1975, J CELL BIOL, V67, P566, DOI 10.1083/jcb.67.3.566; CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; CROSS AR, 1982, BIOCHEM J, V208, P759, DOI 10.1042/bj2080759; CROSS AR, 1994, J BIOL CHEM, V269, P21448; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1989, J CLIN INVEST, V83, P1236, DOI 10.1172/JCI114006; CURNUTTE JT, 1993, CLIN IMMUNOL IMMUNOP, V67, pS2; DINAUER MC, 1989, J CLIN INVEST, V84, P2012, DOI 10.1172/JCI114393; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HOPKINS PJ, 1992, AM J HUM GENET, V51; HURST JK, 1991, J BIOL CHEM, V266, P1627; JOHNSTON RB, 1975, J CLIN INVEST, V55, P1357, DOI 10.1172/JCI108055; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NAKANISHI A, 1992, J BIOL CHEM, V267, P19072; OCHS HD, 1973, J PEDIATR-US, V83, P77, DOI 10.1016/S0022-3476(73)80316-6; OKAMURA N, 1988, BLOOD, V72, P811; PARKOS CA, 1989, BLOOD, V73, P1416; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; ROOS D, 1994, IMMUNOL REV, V138, P121, DOI 10.1111/j.1600-065X.1994.tb00850.x; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SPARKMAN TB, 1985, BIOCHIM BIOPHYS ACTA, V846, P8, DOI 10.1016/0167-4889(85)90103-X; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8	34	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8194	8200		10.1074/jbc.270.14.8194	http://dx.doi.org/10.1074/jbc.270.14.8194			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713925	hybrid			2022-12-25	WOS:A1995QR52600064
J	MYERS, RL; RAY, SK; ELDRIDGE, R; CHOTANI, MA; CHIU, IM				MYERS, RL; RAY, SK; ELDRIDGE, R; CHOTANI, MA; CHIU, IM			FUNCTIONAL-CHARACTERIZATION OF THE BRAIN-SPECIFIC FGF-1 PROMOTER, FGF-1.B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; EMBRYONAL CARCINOMA-CELLS; FACTOR MESSENGER-RNA; FACTOR-I; TRANSCRIPTION INITIATION; REGULATORY ELEMENTS; FACTOR FAMILY; INT-2 GENE; EXPRESSION; CLONING	Expression of alternatively spliced human FGF-1 (or aFGF) transcripts is regulated in a tissue-specific manner via multiple promoters. To identify the cis-regulatory elements in the brain-specific FGF-1.B promoter, we constructed a series of promoter deletions fused to the luciferase reporter gene and transfected into an FGF-1.B positive glioblastoma cell line, U1240MG, and a 1.B negative cell line, U1242MG. Results of transient transfections indicate three elements that are involved in the positive regulation of FGF-1.B expression. The core promoter is located in a 40-base pair region (between -92 and -49), and two regulatory regions (RR-1 and RR-2) are located within the 540-base pair region 5' to the major transcription start site (defined as +1). Electrophoretic mobility shift assays and footprinting analysis have identified sequence-specific binding sites in RR-1 and RR-2. Mutants of RR-2 abolished binding to nuclear proteins and showed diminished luciferase reporter activity. The effects seen are specific for the U1240MG cell line, supporting a role for RR-2 in the tissue-specific regulation of FGF-1.B. Southwestern analysis using an oligonucleotide probe derived from RR-2 (nucleotides -489 to -467) further identified a 37-kDa protein that is present in nuclear extracts from U1240MG and brain but not from U1242MG.	OHIO STATE UNIV, DAVIS MED RES CTR, DEPT INTERNAL MED, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, CTR COMPREHENS CANC, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University			Chotani, Maqsood/E-2891-2011; Chiu, Ing-Ming/B-1534-2008		NCI NIH HHS [R01 CA45611, K04 CA01369, T32 CA09338] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045611, T32CA009338, K04CA001369] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BUNNAG P, 1991, IN VITRO CELL DEV B, V27, P89; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHIU IM, 1990, FID RES FDN, V3, P57; CHIU IM, 1990, ONCOGENE, V5, P755; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOSPODAROWICZ D, 1987, METHOD ENZYMOL, V147, P106; GRINBERG D, 1991, CELL GROWTH DIFFER, V2, P137; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; LOGAN A, 1988, MOL CELL ENDOCRINOL, V58, P275, DOI 10.1016/0303-7207(88)90164-5; MAURO VP, 1985, NUCLEIC ACIDS RES, V13, P239, DOI 10.1093/nar/13.1.239; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MYERS RL, 1993, ONCOGENE, V8, P341; PAYSON RA, 1993, NUCLEIC ACIDS RES, V21, P489, DOI 10.1093/nar/21.3.489; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMITH JD, 1988, J BIOL CHEM, V263, P8300; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Weich HA, 1990, GROWTH FACTORS, V2, P313, DOI 10.3109/08977199009078019; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WINKLES JA, 1987, P NATL ACAD SCI USA, V84, P7124, DOI 10.1073/pnas.84.20.7124; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	37	39	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8257	8266		10.1074/jbc.270.14.8257	http://dx.doi.org/10.1074/jbc.270.14.8257			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713933	hybrid			2022-12-25	WOS:A1995QR52600072
J	BLACKMAN, CF; BLANCHARD, JP; BENANE, SG; HOUSE, DE				BLACKMAN, CF; BLANCHARD, JP; BENANE, SG; HOUSE, DE			THE ION PARAMETRIC RESONANCE MODEL PREDICTS MAGNETIC-FIELD PARAMETERS THAT AFFECT NERVE-CELLS	FASEB JOURNAL			English	Article						PC-12 CELLS; NERVE GROWTH FACTOR; NGF, MAGNETIC FIELDS; IPR MODEL	GROWTH-FACTOR; PHEOCHROMOCYTOMA CELLS; QUANTITATIVE BIOASSAY; NEURITE OUTGROWTH; PC12 CELLS; PROTEIN-2; KINASE; LINE	An ion parametric resonance (IPR) model recently developed by Blanchard and Blackman predicts distinct magnetic field interactions with biological systems based on a selective relation among four factors: the flux density of the static magnetic field, the frequency and flux density (B-ac) of the parallel ac magnetic field, and the charge to-mass ratio of ions of biological relevance, To test this model, PC-12 cells stimulated by nerve growth factor to produce neurites were exposed for 23 h in a 5% CO2 incubator using a multiple coil exposure system to produce 45 Hz ac and de (366 mG parallel to ac; less than 2 mG perpendicular to ac) magnetic fields, Our earlier work showed a cycle of inhibition/no inhibition of neurite outgrowth consistent with the IPR model predictions for B-ac exposures between 0 and 468 mG rms, The work described here tests neurite outgrowth over a broader range of B-ac (233-1416 mG rms), The experimental results remain consistent with earlier results, and with IPR model predictions of a second cycle of inhibition, return to control values, followed by a third cycle of inhibition of neurite outgrowth, These responses support the fundamental relationships predicted by the IPR model, The results have broad significance for biology.	BECHTEL CORP,RES & DEV,SAN FRANCISCO,CA 94119		BLACKMAN, CF (corresponding author), US EPA,HLTH EFFECTS RES LAB,MD-68,RES TRIANGLE PK,NC 27711, USA.		Blackman, Carl/O-1951-2016	Blackman, Carl/0000-0003-3267-5224				BLACKMAN CF, 1994, BIOELECTROMAGNETICS, V15, P239, DOI 10.1002/bem.2250150307; BLACKMAN CF, 1993, FASEB J, V7, P801, DOI 10.1096/fasebj.7.9.8330687; BLACKMAN CF, 1993, BIOELECTROMAGNETICS, V14, P273, DOI 10.1002/bem.2250140310; BLANCHARD JP, 1994, BIOELECTROMAGNETICS, V15, P217, DOI 10.1002/bem.2250150306; BLANCHARD JP, 1994, IN PRESS BIOELECTROM; BLANCHARD JP, 1994, NATURE ELECTROMAGNET, P43; CARPENTER DO, 1994, BIOL EFFECTS ELECTRI, V2; CARPENTER DO, 1994, BIOL EFFECTS ELECTRI, V1; FREY AH, 1994, NATURE ELECTROMAGNET; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1977, BRAIN RES, V133, P350, DOI 10.1016/0006-8993(77)90770-3; KOBAYASHI AK, 1995, NATURE, V374, P123, DOI 10.1038/374123a0; LANDRETH GE, 1990, J NEUROCHEM, V55, P514, DOI 10.1111/j.1471-4159.1990.tb04165.x; RUKENSTEIN A, 1983, BRAIN RES, V263, P177, DOI 10.1016/0006-8993(83)91218-0; SANO M, 1992, J NEUROCHEM, V59, P1263, DOI 10.1111/j.1471-4159.1992.tb08436.x; SMITH RF, 1988, BIOELECTROMAGNETICS, V9, P387, DOI 10.1002/bem.2250090409; TRILLO A, 1994, 16TH ANN M BIOEL SOC	17	53	55	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1995	9	7					547	551		10.1096/fasebj.9.7.7737464	http://dx.doi.org/10.1096/fasebj.9.7.7737464			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX148	7737464				2022-12-25	WOS:A1995QX14800013
J	BRAUN, KP; CODY, RB; JONES, DR; PETERSON, CM				BRAUN, KP; CODY, RB; JONES, DR; PETERSON, CM			A STRUCTURAL ASSIGNMENT FOR A STABLE ACETALDEHYDE-LYSINE ADDUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENT BINDING; SERUM-ALBUMIN; HEMOGLOBIN; PROTEINS; BACTERIORHODOPSIN; TEETOTALERS; ALDEHYDES; INVIVO; PLASMA	Acetaldehyde is the first oxidation product of ethanol in vivo. Lysine residues in proteins such as hemoglobin have been implicated as target structures for acetaldehyde adducts resulting from ethanol consumption. Although the presence of both stable and unstable acetaldehyde-hemoglobin adducts has been established, the structural characterization of the adducts has received relatively little attention, As a model for such adduct formation, we studied the peptide pentalysine in vitro. Pentalysine has several potential sites for adduct formation, The amino-terminal amine group as well as the E-amine groups of each lysine side chain can serve as potential sites for modification by acetaldehyde, Mass spectrometry, nuclear magnetic resonance, and Raman spectroscopy were employed to demonstrate that acetaldehyde forms a stable linkage to lysine amine groups via a Schiff base.	CALIF POLYTECH STATE UNIV SAN LUIS OBISPO,SAN LUIS OBISPO,CA 93407; JEOL USA,PEABODY,MA 01960	California State University System; California Polytechnic State University San Luis Obispo; Jeol Ltd; JEOL USA	BRAUN, KP (corresponding author), SANSUM MED RES FDN,2219 BATH ST,SANTA BARBARA,CA 93105, USA.		Peterson, Karen/E-8084-2015	Peterson, Karen/0000-0001-6737-8698	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007614] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA07614] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AUSTIN JE, 1992, P NATL ACAD SCI USA, V89, P8439, DOI 10.1073/pnas.89.18.8439; BARRY RE, 1987, LIVER, V7, P364; BEHRENS UJ, 1988, BIOCHEM BIOPH RES CO, V154, P584, DOI 10.1016/0006-291X(88)90180-5; DING A, 1993, P NATL ACAD SCI USA, V90, P3797, DOI 10.1073/pnas.90.9.3797; DONOHUE TM, 1983, ARCH BIOCHEM BIOPHYS, V220, P239, DOI 10.1016/0003-9861(83)90406-X; FRAENKELCONRAT H, 1988, P NATL ACAD SCI USA, V85, P3759; GROSS MD, 1994, ALCOHOL ALCOHOLISM, V29, P31; HALVORSON MR, 1993, ALCOHOL, V10, P409, DOI 10.1016/0741-8329(93)90029-N; HAZELETT SE, 1993, ALCOHOL CLIN EXP RES, V17, P1107, DOI 10.1111/j.1530-0277.1993.tb05672.x; HOBERMAN HD, 1981, ALCOHOL CLIN EXP RES, V6, P260; HOFFMANN T, 1993, ALCOHOL CLIN EXP RES, V17, P69, DOI 10.1111/j.1530-0277.1993.tb00728.x; JAFFE EK, 1990, BIOCHEMISTRY-US, V29, P8345, DOI 10.1021/bi00488a021; JENNETT RB, 1987, ARCH BIOCHEM BIOPHYS, V256, P10, DOI 10.1016/0003-9861(87)90420-6; KOENIG RJ, 1976, NEW ENGL J MED, V295, P417, DOI 10.1056/NEJM197608192950804; LIVNAH N, 1993, BIOCHEMISTRY-US, V32, P7223, DOI 10.1021/bi00079a019; LORD RC, 1970, J MOL BIOL, V50, P509, DOI 10.1016/0022-2836(70)90208-1; MAUCH TJ, 1987, ALCOHOL ALCOHOLISM, V2, P103; MCKINNON G, 1987, NEUROSCI LETT, V79, P163, DOI 10.1016/0304-3940(87)90690-2; MONNIER VM, 1989, MAILLARD REACTION AG, P1; NGUYEN LB, 1985, ALDEHYDE ADDUCTS ALC; PETERSON CM, 1987, ALCOHOL, V4, P477, DOI 10.1016/0741-8329(87)90089-9; PETERSON CM, 1974, ANN INTERN MED, V81, P152, DOI 10.7326/0003-4819-81-2-152; PETERSON CM, 1993, ALCOHOL, V10, P327, DOI 10.1016/0741-8329(93)90015-G; SANDORFY C, 1970, CHEM CARBON NITROGEN; SANGEORGE RC, 1986, J BIOL CHEM, V261, P6811; SAVOLAINEN MJ, 1987, LIFE SCI, V40, P841, DOI 10.1016/0024-3205(87)90032-4; SILLANAUKEE P, 1992, J LAB CLIN MED, V120, P42; STAHOVEC WL, 1984, J CHROMATOGR, V298, P399; STEVENS VJ, 1981, J CLIN INVEST, V67, P361, DOI 10.1172/JCI110043; THOMPSON LK, 1992, BIOCHEMISTRY-US, V31, P7931, DOI 10.1021/bi00149a026; TUMA DJ, 1987, ALCOHOL CLIN EXP RES, V11, P579, DOI 10.1111/j.1530-0277.1987.tb00178.x; TUMA DJ, 1985, ALDEHYDE ADDUCTS ALC, P3	32	43	45	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11263	11266		10.1074/jbc.270.19.11263	http://dx.doi.org/10.1074/jbc.270.19.11263			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744761	hybrid			2022-12-25	WOS:A1995QX86500038
J	KNOLL, LJ; JOHNSON, DR; GORDON, JI				KNOLL, LJ; JOHNSON, DR; GORDON, JI			COMPLEMENTATION OF SACCHAROMYCES-CEREVISIAE STRAINS CONTAINING FATTY-ACID ACTIVATION GENE (FAA) DELETIONS WITH A MAMMALIAN ACYL-COA SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; ESCHERICHIA-COLI; RECOMBINANT THIOESTERASE; OLE1 GENE; EXPRESSION; INHIBITION; TRIACSINS; PROLIFERATION; DESATURASE; TRANSPORT	Four unlinked fatty acid activation (FAA) genes encoding acyl-CoA synthetases have been identified in Saccharomyces cerevisiae and characterized by noting the phenotypes of isogenic strains containing all possible combinations of faa null alleles, None of these genes is required for vegetative growth when acyl-CoA production by the fatty acid synthetase (Fas) complex is active. When Fas is inhibited by cerulenin, exponentially growing cells are not viable on media containing a fermentable carbon source unless supplemented with fatty acids such as myristate, palmitate, or oleate, The functionally interchangeable FAA1 and FAA4 genes are responsible for activation of these imported fatty acids. Analysis of lysates prepared from isogenic FAA1FAA4 and faa1 Delta faa4 Delta strains indicated that Faa1p and Faa4p together account for 99% of total cellular myristoyl-CoA and palmitoyl-CoA synthetase activities. Genetic complementation studies revealed that rat liver acyl-CoA synthetase (RLACS) rescues the viability of faa1 Delta faa4 Delta cells in media containing a fermentable carbon source, myristate or palmitate, plus cerulenin. Rescue is greater at 37 degrees C compared with 24 degrees C, paralleling the temperature-dependent changes in RLACS activity in vitro as well as the enzyme's ability to direct incorporation of tritiated myristate and palmitate into cellular phospholipids in vivo. Complementation by RLACS is blocked by treatment of cells with triacsin C (1-hydroxy-3-(E,E,E,2',4',7'-undecatrienylidine) triazene), Even though Faa1p, Faa4p, and RLACS are all able to activate imported myristate and palmitate in S. cerevisiae, the sensitivity of Faa4p and RLACS, but not Faa1p, to inhibition by triacsin C suggests that the rat liver enzyme is functionally more analogous to Faa4p than to Faa1p, Finally, an assessment of myristate and palmitate import into FAA1FAA4 and faa1 Delta faa4 Delta strains, with or without episomes that direct overexpression of Faa1p, Faa4p or RLACS, indicated that fatty acid uptake is not coupled to activation in S. cerevisiae.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, U01AI030188] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30188, AI27179] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE T, 1992, J BIOCHEM-TOKYO, V111, P123, DOI 10.1093/oxfordjournals.jbchem.a123707; BARTANA J, 1973, BIOCHEM J, V135, P411, DOI 10.1042/bj1350411; BARTANA J, 1973, BIOCHEM J, V131, P199, DOI 10.1042/bj1310199; BERG P, 1956, J BIOL CHEM, V222, P991; BERG P, 1958, SCIENCE, V129, P895; BLACK PN, 1991, J BACTERIOL, V173, P435, DOI 10.1128/jb.173.2.435-442.1991; BLACK PN, 1992, J BIOL CHEM, V267, P25513; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; CAUSERET C, 1993, BIOL CELL, V77, P89, DOI 10.1016/S0248-4900(05)80178-9; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; FUNABASHI H, 1989, J BIOCHEM-TOKYO, V105, P751, DOI 10.1093/oxfordjournals.jbchem.a122739; HORI T, 1987, J BIOCHEM-TOKYO, V101, P949, DOI 10.1093/oxfordjournals.jbchem.a121964; JOHNSON DR, 1994, J BIOL CHEM, V269, P18037; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; KNOLL LJ, 1994, J BIOL CHEM, V269, P16348; KNOLL LJ, 1993, J BIOL CHEM, V268, P4281; KOHLWEIN SD, 1983, BIOCHIM BIOPHYS ACTA, V792, P310; LAI K, 1994, J BIOL CHEM, V269, P2245; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; MISHINA M, 1980, EUR J BIOCHEM, V111, P79; NOMURA S, 1972, J BIOCHEM-TOKYO, V71, P783, DOI 10.1093/oxfordjournals.jbchem.a129827; NUNN WD, 1986, J BIOL CHEM, V261, P167; OMURA S, 1986, J ANTIBIOT, V39, P1211, DOI 10.7164/antibiotics.39.1211; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; PAZIRANDEH M, 1991, J BIOL CHEM, V266, P20946; PAZIRANDEH M, 1989, J BIOL CHEM, V264, P18195; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SCHOONJANS K, 1993, EUR J BIOCHEM, V216, P615, DOI 10.1111/j.1432-1033.1993.tb18181.x; STUKEY JE, 1989, J BIOL CHEM, V264, P16537; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TANAKA H, 1982, J ANTIBIOT, V35, P157, DOI 10.7164/antibiotics.35.157; TOMODA H, 1991, J BIOL CHEM, V266, P4214; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; TRIGATTI BL, 1992, BIOCHEM CELL BIOL, V70, P76, DOI 10.1139/o92-011; VANCE D, 1972, BIOCHEM BIOPH RES CO, V48, P649, DOI 10.1016/0006-291X(72)90397-X; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993	42	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10861	10867		10.1074/jbc.270.18.10861	http://dx.doi.org/10.1074/jbc.270.18.10861			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738025				2022-12-25	WOS:A1995QW60100073
J	SCHIAVO, G; SHONE, CC; BENNETT, MK; SCHELLER, RH; MONTECUCCO, C				SCHIAVO, G; SHONE, CC; BENNETT, MK; SCHELLER, RH; MONTECUCCO, C			BOTULINUM NEUROTOXIN TYPE-C CLEAVES A SINGLE LYS-ALA BOND WITHIN THE CARBOXYL-TERMINAL REGION OF SYNTAXINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETANUS TOXIN; NEUROTRANSMITTER RELEASE; SYNAPTIC VESICLES; PROTEIN; ZINC; IDENTIFICATION; RECEPTORS; SEQUENCE; SNAP-25; FUSION	Botulinum neurotoxin serotype C (BoNT/C) is a 150-kDa protein produced by Clostridium botulinum, which causes animal botulism. In contrast to the other botulinum neurotoxins that contain one atom of zinc, highly purified preparations of BoNT/C bind two atoms of zinc per toxin molecule. BoNT/C is a zinc endopeptidase that cleaves syntaxin 1A at the Lys(253)-Ala(254) and syntaxin 1B at the Lys(252)-Ala(253) peptide bonds, only when they are inserted into a lipid bilayer. The other Lys-Ala bond present within the carboxyl-terminal region is not hydrolyzed. Syntaxin isoforms 2 and 3 are also cleaved by BoNT/C, while syntaxin 4 is resistant. These data suggest that BoNT/C recognizes a specific spatial organization of syntaxin, adopted upon membrane insertion, which brings a selected Lys-Ala peptide bond of its carboxyl-terminal region to the active site of this novel metalloproteinase.	UNIV PADUA,DIPARTIMENTO SCI BIOMED,I-35121 PADUA,ITALY; PUBL HLTH LAB SERV,CTR APPL MICROBIOL & RES,PROT TOXINS SECT,SALISBURY SP4 0JG,WILTS,ENGLAND; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; STANFORD UNIV,HOWARD HUGHES MED INST,DEPT CELLULAR & MOLEC PHYSIOL,STANFORD,CA 94305	University of Padua; University of California System; University of California Berkeley; Howard Hughes Medical Institute; Stanford University	SCHIAVO, G (corresponding author), UNIV PADUA,CTR CONSIGLIO NAZL RIC BIOMEMBRANE,VIA TRIESTE 75,I-35121 PADUA,ITALY.			Schiavo, Giampietro/0000-0002-4319-8745	Telethon [473] Funding Source: Medline	Telethon(Fondazione Telethon)		BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAUSER D, 1990, NUCLEIC ACIDS RES, V18, P4924, DOI 10.1093/nar/18.16.4924; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; INOUE A, 1992, J BIOL CHEM, V267, P10613; JANKOVIC J, 1994, THERAPY BOTULINUM TO; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; MONTECUCCO C, 1993, TRENDS BIOCHEM SCI, V18, P324, DOI 10.1016/0968-0004(93)90065-U; OGUMA K, 1990, LANCET, V336, P1449, DOI 10.1016/0140-6736(90)93157-K; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PATARNELLO T, 1993, NATURE, V364, P581, DOI 10.1038/364581b0; Powers J.C., 1986, PROTEINASE INHIBITOR, P219; ROSSETTO O, 1994, NATURE, V372, P415, DOI 10.1038/372415a0; ROSSETTO O, 1992, BIOCHEM J, V285, P9, DOI 10.1042/bj2850009; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, EMBO J, V11, P3577, DOI 10.1002/j.1460-2075.1992.tb05441.x; SCHIAVO G, 1992, J BIOL CHEM, V267, P23479; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; Schiavo G, 1993, Trends Microbiol, V1, P170, DOI 10.1016/0966-842X(93)90086-7; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SCHIAVO G, 1991, EUR J BIOCHEM, V199, P705, DOI 10.1111/j.1432-1033.1991.tb16174.x; SCHIAVO G, 1994, J BIOL CHEM, V269, P20213; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; Smith L. D. S., 1988, BOTULISM ORGANISM IT; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WRIGHT JF, 1992, J BIOL CHEM, V267, P9053; YAMASAKI S, 1994, P NATL ACAD SCI USA, V91, P4688, DOI 10.1073/pnas.91.11.4688; YAMASAKI S, 1994, J BIOL CHEM, V269, P12764; YAMASAKI S, 1994, BIOCHEM BIOPH RES CO, V200, P829, DOI 10.1006/bbrc.1994.1526	42	231	238	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10566	10570		10.1074/jbc.270.18.10566	http://dx.doi.org/10.1074/jbc.270.18.10566			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737992				2022-12-25	WOS:A1995QW60100033
J	VOSSEBELD, PJM; KESSLER, J; VONDEMBORNE, AEGK; ROOS, D; VERHOEVEN, AJ				VOSSEBELD, PJM; KESSLER, J; VONDEMBORNE, AEGK; ROOS, D; VERHOEVEN, AJ			HETEROTYPIC FC-GAMMA-R CLUSTERS EVOKE A SYNERGISTIC CA2+ RESPONSE IN HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED RESPIRATORY BURST; IMMUNE-COMPLEXES; CROSS-LINKING; TUMOR-CELLS; RECEPTOR; RII; PHAGOCYTOSIS; GRANULOCYTES; MECHANISMS; DISTINCT	Both Fc gamma receptors on human neutrophils (Fc gamma RIIa and Fc gamma RIIIb) are capable of initiating signal transduction after multivalent cross-linking. However, immune complexes most likely activate neutrophils by a combined homotypic and heterotypic cross-linking of Fc gamma Rs. We have investigated the effect of homotypic and heterotypic Fc gamma R cluster formation on changes in the intracellular free Ca2+ concentration. Combined heterotypic and homotypic cluster formation resulted in a Ca2+ response that was strongly enhanced as compared to the sum of both individual Fc gamma R responses. This synergistic response was caused by the formation of heterotypic clusters of Fc gamma Rs and not by the simultaneous formation of homotypic clusters. This conclusion was supported by experiments with a bispecific antibody binding to both Fc gamma RIIa and Fc gamma RIIb. The heterotypic Fc gamma R cross-linking results in efficient activation of Ca2+ influx, probably caused by a more pronounced depletion of intracellular Ca2+ stores. Stimulation with immune complexes also induced Ca2+ influx in normal neutrophils, but not in Fc gamma RIIIb-deficient neutrophils. The synergism between both Fc gamma Rs was also apparent in other responses of neutrophils, such as the activation of the respiratory burst. This study shows that the two different Fc gamma Rs on neutrophils complement each other in mediating an important cellular response.	UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,1066 CX AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT HEMATOL,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	VOSSEBELD, PJM (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,PUBLICAT SECRETARIAT,PLESMANLAAN 125,1066 CX AMSTERDAM,NETHERLANDS.		Kessler, Jan/C-5559-2009					ANDERSON CL, 1990, J EXP MED, V171, P1333, DOI 10.1084/jem.171.4.1333; BIJSTERBOSCH MK, 1986, BIOCHEM BIOPH RES CO, V137, P500, DOI 10.1016/0006-291X(86)91238-6; BOROS P, 1991, J EXP MED, V173, P1473, DOI 10.1084/jem.173.6.1473; BRUNKHORST BA, 1992, J BIOL CHEM, V267, P20659; CROCKETTTORABI E, 1990, J IMMUNOL, V145, P3026; DEMAUREX N, 1994, BIOCHEM J, V297, P595, DOI 10.1042/bj2970595; EDBERG JC, 1992, IMMUNOL RES, V11, P239, DOI 10.1007/BF02919130; EDBERG JC, 1994, J IMMUNOL, V152, P2826; EMMENDORFFER A, 1990, J IMMUNOL METHODS, V131, P269, DOI 10.1016/0022-1759(90)90198-5; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GRAZIANO RF, 1987, J IMMUNOL, V139, P3536; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLAM TJ, 1988, BIOCHEM J, V255, P179, DOI 10.1042/bj2550179; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2365; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2359; HUIZINGA TWJ, 1990, J IMMUNOL, V144, P1432; HUIZINGA TWJ, 1988, NATURE, V333, P667, DOI 10.1038/333667a0; HUIZINGA TWJ, 1990, BLOOD, V76, P1927; HUNDT M, 1992, EUR J IMMUNOL, V22, P811, DOI 10.1002/eji.1830220327; INDIK Z, 1991, J CLIN INVEST, V88, P1766, DOI 10.1172/JCI115496; KIMBERLY RP, 1990, J EXP MED, V171, P1239, DOI 10.1084/jem.171.4.1239; KOENDERMAN L, 1989, J IMMUNOL, V142, P623; LANIER LL, 1988, J IMMUNOL, V141, P3478; NAZIRUDDIN B, 1992, J IMMUNOL, V149, P3702; ORY PA, 1991, BLOOD, V77, P2682; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROSALES C, 1991, J IMMUNOL, V146, P3937; ROSENFELD SI, 1985, J CLIN INVEST, V76, P2317, DOI 10.1172/JCI112242; ROTHE G, 1991, J IMMUNOL METHODS, V138, P133, DOI 10.1016/0022-1759(91)90074-P; SALMON JE, 1987, J EXP MED, V166, P1798, DOI 10.1084/jem.166.6.1798; SALMON JE, 1991, J IMMUNOL, V146, P997; SHEN L, 1989, MOL IMMUNOL, V26, P959, DOI 10.1016/0161-5890(89)90114-4; STENDAHL O, 1994, SCIENCE, V265, P1439, DOI 10.1126/science.8073285; TOSI MF, 1988, J IMMUNOL, V141, P2097; WALKER BAM, 1991, J IMMUNOL, V146, P735; WILLIS HE, 1988, J IMMUNOL, V140, P234; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407	37	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10671	10679		10.1074/jbc.270.18.10671	http://dx.doi.org/10.1074/jbc.270.18.10671			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738004	hybrid			2022-12-25	WOS:A1995QW60100048
J	NWAKA, S; KOPP, M; HOLZER, H				NWAKA, S; KOPP, M; HOLZER, H			EXPRESSION AND FUNCTION OF THE TREHALASE GENES NTH1 AND YBR0106 IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK; CATABOLITE INACTIVATION; INDUCED ACCUMULATION; NEUTRAL TREHALASE; ACID TREHALASE; YEAST; STRESS; PURIFICATION; DISRUPTION; PROTEINS	The biological function of the trehalose-degrading yeast enzyme neutral trehalase consists of the control of the concentration of trehalose, which is assumed to play a role in thermotolerance, in germination of spores, and in other life functions of yeast, Resequencing of the neutral trehalase gene NTH1 on chromosome IV resulted in the observation of two possible start codons (Kopp, M., Nwaka, S., and Holzer, H. (1994) Gene (Amst.) 150, 403-404). We show here that only the most upstream start codon which initiates translation of the longest possible ORF is used for expression of NTH1 in vivo. A gene with 77% identity with NTH1, YBR0106, which was discovered during sequencing of chromosome II (Wolfe, K. H., and Lohan, A. J. E. (1994) Yeast 10, S41-S46), is shown here to be expressed into mRNA. Experiments with a mutant disrupted in the YBR0106 ORF showed, in contrast to a NTH1 deletion mutant, no changes in trehalase activity and in trehalose concentration, However, similar to the NTH1 gene a requirement of the intact YBR0106 gene for thermotolerance is demonstrated in experiments with the respective mutants. This indicates that the products of the likely duplicated YBR0106 gene and the NTH1 gene serve a heat shock protein function, In case of the YBR0106 gene, this is the only phenotypic feature found at present.	UNIV FREIBURG,INST BIOCHEM,D-79104 FREIBURG,GERMANY	University of Freiburg								APP H, 1989, J BIOL CHEM, V264, P17583; ATTFIELD PV, 1987, FEBS LETT, V225, P259, DOI 10.1016/0014-5793(87)81170-5; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fischer E, 1895, BERICHTE DTSCH CHEM, V28, P1429, DOI [10.1002/CBER.18950280243, DOI 10.1002/CBER.18950280243]; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HIRSCH HH, 1992, EUR J BIOCHEM, V207, P867, DOI 10.1111/j.1432-1033.1992.tb17118.x; HOLZER H, 1989, RBC-CELL BIOL REV, V21, P305; HOLZER H, 1976, TRENDS BIOCHEM SCI, V1, P178, DOI 10.1016/S0968-0004(76)80018-7; HOTTIGER T, 1987, J BACTERIOL, V169, P5518, DOI 10.1128/jb.169.12.5518-5522.1987; HOTTIGER T, 1992, EUR J BIOCHEM, V210, P125, DOI 10.1111/j.1432-1033.1992.tb17399.x; IGLOI GL, 1993, BIOTECHNIQUES, V15, P486; IT H, 1984, AGR BIOL CHEM TOKYO, V48, P175; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KIENLE I, 1993, YEAST, V9, P607, DOI 10.1002/yea.320090607; KOBAYASHI N, 1993, MOL CELL BIOL, V13, P248, DOI 10.1128/MCB.13.1.248; KOPP M, 1993, J BIOL CHEM, V268, P4766; KOPP M, 1994, GENE, V150, P403, DOI 10.1016/0378-1119(94)90462-6; LONDESBOROUGH J, 1984, BIOCHEM J, V219, P511, DOI 10.1042/bj2190511; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGASANIK B, 1961, COLD SPRING HARB SYM, V26, P249, DOI 10.1101/SQB.1961.026.01.031; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MITTENBUHLER K, 1988, J BIOL CHEM, V263, P8537; MONOD J, 1947, GROWTH, V11, P223; NORTHEMANN W, 1988, BIOCHEMISTRY-US, V27, P9194, DOI 10.1021/bi00426a018; NORTHEMANN W, 1989, J BIOL CHEM, V264, P16072; NWAKA S, 1995, FEBS LETT, V360, P286, DOI 10.1016/0014-5793(95)00105-I; NWAKA S, 1994, FEBS LETT, V344, P225, DOI 10.1016/0014-5793(94)00385-8; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J, 1989, MOL CLONING LABORATO; Sherman F., 1986, METHODS YEAST GENETI; THEVELEIN JM, 1988, EXP MYCOL, V12, P1, DOI 10.1016/0147-5975(88)90011-4; THEVELEIN JM, 1984, MICROBIOL REV, V48, P42, DOI 10.1128/MMBR.48.1.42-59.1984; TOHE A, 1993, YEAST, V9, P481, DOI 10.1002/yea.320090504; WINKLER K, 1991, FEBS LETT, V291, P261; WOLFE KH, 1994, YEAST, V10, pS41, DOI 10.1002/yea.320100006; WOLSKAMITASZKO B, 1981, ANAL BIOCHEM, V116, P241, DOI 10.1016/0003-2697(81)90351-1	41	90	93	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10193	10198		10.1074/jbc.270.17.10193	http://dx.doi.org/10.1074/jbc.270.17.10193			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730323	hybrid			2022-12-25	WOS:A1995QV41700070
J	PRATICO, D; LAWSON, JA; FITZGERALD, GA				PRATICO, D; LAWSON, JA; FITZGERALD, GA			CYLOOXYGENASE-DEPENDENT FORMATION OF THE ISOPROSTANE, 8-EPI PROSTAGLANDIN FA(2-ALPHA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITES; PLATELET; THROMBOXANE; RECEPTOR; SYNTHASE; SERIES; 8-EPI-PROSTAGLANDIN-F2-ALPHA; NONCYCLOOXYGENASE; DISCRIMINATION; PHOSPHOLIPIDS	Isoprostanes are a family of prostaglandin (PG) isomers formed in an enzyme-independent manner. They circulate in plasma and are excreted in urine. One of them, 8-epi PGF(2 alpha) is a vasoconstrictor and mitogen, effects which are prevented by thromboxane antagonists. Given that 8-epi PGF(2 alpha) may be formed by cyclooxygenase (COX) (Corey, E. J., Shih, C., Shig, N-Y., and Shimoji, K. (1984) Tetrahedron Letts. 44, 5013-5016; Hecker, M., Ullrich, V., Fischer, C., and Meese, C. O. (1987) fur J. Biochem. 169, 113-123) and that this might confound its use as an index of free radical generation, we sought to characterize the mechanism of its formation by human platelets. Activation of platelets by threshold concentrations of collagen, thrombin, and arachidonic acid resulted in formation of 8-epi PGF(2 alpha) coincident with that of the COX product, thromboxane, and the 12 lipoxygenase product, 12-hydroxyeicosatetraenoic acid, as detected by selected ion monitoring assays using gas chromatography-mass spectrometry. The effect appeared selective for 8 epi PGF(2 alpha) among the F-2 isoprostanes. Pretreatment of platelets with aspirin or indomethacin abolished 8-epi PGF(2 alpha) formation. COX-independent activation of platelets by high doses of collagen or thrombin, by the phorbol ester, phorbol 12-myristate IS-acetate, or the prostaglandin endoperoxide analog U 46619 was not associated with 8-epi PGF(2 alpha) formation. Confirmation of the nature of the material formed by platelet COX as 8-epi PGF(2 alpha) included its cochromatography over three highly resolving high performance liquid chromatography systems, identification by electron impact mass spectrometry, and its formation by partially purified COX. Inhibition of platelet thromboxane formation was associated with augmented 8-epi PGF(2 alpha) formation. A major component of 8 epi PGF(2 alpha) formed in serum by healthy volunteers was shown to be sensitive to inhibition by aspirin err vivo. In addition to its generation by free radical catalyzed mechanisms, 8 epi PGF(2 alpha) may be formed as a PG by human platelets. Given that activation of platelet COX characterizes many of the human syndromes which are putatively associated with free radical generation, assessment of the contribution of this pathway is relevant to the use of 8 epi PGF(2 alpha) as an index of lipid peroxidation in vivo.	UNIV PENN,CTR EXPTL THERAPEUT,PHILADELPHIA,PA 19104	University of Pennsylvania			FitzGerald, Garret A/A-4222-2010					BANERJEE M, 1992, AM J PHYSIOL, V263, pH660, DOI 10.1152/ajpheart.1992.263.3.H660; COREY EJ, 1984, TETRAHEDRON LETT, V44, P5013; DABBAGH AJ, 1994, BIOCHEM J, V330, P799; FITZGERALD DJ, 1988, CIRCULATION, V77, P142, DOI 10.1161/01.CIR.77.1.142; FITZGERALD GA, 1983, J CLIN INVEST, V71, P676, DOI 10.1172/JCI110814; FITZGERALD GA, 1985, CIRCULATION, V72, P1194, DOI 10.1161/01.CIR.72.6.1194; FUNK CD, 1993, MOL PHARMACOL, V44, P934; FUNKAGA M, 1993, AM J PHYSIOL, V264, P1619; FURCI L, 1991, J PHARMACOL EXP THER, V258, P74; GOPAUL NK, 1994, BIOCHEM BIOPH RES CO, V200, P338, DOI 10.1006/bbrc.1994.1453; GOPAUL NK, 1994, FEBS LETT, V348, P297, DOI 10.1016/0014-5793(94)00628-8; GORMAN RR, 1983, PROSTAGLANDINS, V26, P325, DOI 10.1016/0090-6980(83)90099-0; HECKER M, 1987, EUR J BIOCHEM, V169, P113, DOI 10.1111/j.1432-1033.1987.tb13587.x; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; KAYAMA N, 1981, PROSTAGLANDINS, V21, P543, DOI 10.1016/0090-6980(81)90003-4; KAYGANICHHARRIS.KA, 1993, J LIPID RES, V34, P1229; KINGSLEY Y, 1994, J PHARMACOL EXP THER, V270, P1192; KINSELLA BT, 1994, ANN NY ACAD SCI, V714, P270, DOI 10.1111/j.1749-6632.1994.tb12054.x; LAWSON JA, 1994, ANN NY ACAD SCI, V744, P139; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; MIDDLEDITCH BS, 1973, ANAL BIOCHEM, V55, P509, DOI 10.1016/0003-2697(73)90140-1; MORROW JD, 1994, BBA-LIPID LIPID MET, V1210, P244, DOI 10.1016/0005-2760(94)90128-7; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; MORROW JD, 1992, PROSTAGLANDINS, V44, P155, DOI 10.1016/0090-6980(92)90077-7; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; MORROW JD, 1992, J CLIN INVEST, V90, P250; NOWAK J, 1987, CIRCULATION, V76, P6, DOI 10.1161/01.CIR.76.1.6; NUSING RM, 1993, J BIOL CHEM, V268, P25253; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; RIM EB, 1993, NEW ENGL J MED, V328, P1450; ROBERTS LJ, 1979, BIOCHIM BIOPHYS ACTA, V575, P185, DOI 10.1016/0005-2760(79)90020-1; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; TAKAHARA K, 1990, J BIOL CHEM, V265, P6836; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156	37	241	244	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9800	9808		10.1074/jbc.270.17.9800	http://dx.doi.org/10.1074/jbc.270.17.9800			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730359	hybrid			2022-12-25	WOS:A1995QV41700018
J	RODD, D; HERSH, LB				RODD, D; HERSH, LB			ENDOPEPTIDASE-24.16B-A NEW VARIANT OF ENDOPEPTIDASE-24.16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; RAT-BRAIN; METALLOENDOPEPTIDASE ENKEPHALINASE; NEUTRAL ENDOPEPTIDASE; DEGRADING PEPTIDASE; LEUKEMIA ANTIGEN; NEUROTENSIN; PURIFICATION; IDENTIFICATION; SPECIFICITY	A peptidase, isolated from rat testes, is inhibited by 1 mM o-phenanthroline, 1 mu M N-(1-(R,S)-carboxyl-3-phenyl-propyl)-Ala-Ala-Phe-p-aminobenzoate, and 6 mM Pro-ILe, properties similar to those ascribed to endopeptidase 24.16. The enzyme hydrolyzes dynorphin A-8, neurotensin 1-13, angiotensin I, and substance P. Kinetic analysis of a series of angiotensin I analogs showed that substitutions at P-1, P-1', or P-2' had little effect on K-m or k(cat). Variation of peptide size with a series of dynorphin A peptides showed chain length to be significant. The peptidase cleaved dynorphin A-8 at both Leu(5)-Arg(6) and Arg(6)-Arg(7), and neurotensin 1-13 at Pro(10)-Tyr(11) and Arg(8)-Arg(9). In contrast, rat endopeptidase 24.16 cleaves dynorphin A-8 at Gly(4)-Leu(5) and Leu(5)-Arg(6), and neurotensin 1-13 only at Pro(10)-Tyr(11). These findings, as well as the observation that endopeptidase 24.16 exhibits a considerably higher affinity for Pro-Ile, K-i = 90 mu M, indicates the peptidase isolated in this study is related to, but distinct from, rat endopeptidase 24.16. We propose that this new endopeptidase be referred to as endopeptidase 24.16B, while the originally described enzyme be referred to as endopeptidase 24.16A	UNIV KENTUCKY, ALBERT B CHANDLER MED CTR,DEPT BIOCHEM, LEXINGTON, KY 40536 USA	University of Kentucky					NIDA NIH HHS [DA 02243] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA002243] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BARELLI H, 1993, EUR J BIOCHEM, V211, P79, DOI 10.1111/j.1432-1033.1993.tb19872.x; BARKER JL, 1978, SCIENCE, V199, P1451, DOI 10.1126/science.204016; BENSON JR, 1975, P NATL ACAD SCI USA, V72, P619, DOI 10.1073/pnas.72.2.619; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY ML, 1991, J BIOL CHEM, V266, P23041; CHABRY J, 1990, J NEUROSCI, V10, P3916, DOI 10.1523/JNEUROSCI.10-12-03916.1990; CHECLER F, 1986, J BIOL CHEM, V261, P1274; CHECLER F, 1983, J NEUROCHEM, V41, P375, DOI 10.1111/j.1471-4159.1983.tb04753.x; CHECLER F, 1993, BIOCHEM SOC T, V21, P692, DOI 10.1042/bst0210692; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; DAHMS P, 1992, EUR J BIOCHEM, V208, P145, DOI 10.1111/j.1432-1033.1992.tb17168.x; DAUCH P, 1991, EUR J BIOCHEM, V202, P269, DOI 10.1111/j.1432-1033.1991.tb16372.x; DAUCH P, 1991, BIOCHEM J, V280, P421, DOI 10.1042/bj2800421; DIXON DM, 1990, BRIT J PHARMACOL, V101, P674, DOI 10.1111/j.1476-5381.1990.tb14139.x; FERRARIO CM, 1991, HYPERTENSION, V18, pS126, DOI 10.1161/01.HYP.18.5_Suppl.III126; GAFFORD JT, 1983, BIOCHEMISTRY-US, V22, P3265, DOI 10.1021/bi00282a035; KERR MA, 1974, BIOCHEM J, V137, P489, DOI 10.1042/bj1370489; KOBAYASHI R, 1991, GASTROENTEROLOGY, V100, P25, DOI 10.1016/0016-5085(91)90578-9; LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247; LOTVALL JO, 1990, BRIT J PHARMACOL, V100, P69; LYRENAS S, 1988, OBSTET GYNECOL, V72, P54; MALFROY B, 1978, NATURE, V276, P523, DOI 10.1038/276523a0; MILLICAN PE, 1991, BIOCHEM J, V276, P583, DOI 10.1042/bj2760583; ONDETTI MA, 1977, SCIENCE, V196, P441, DOI 10.1126/science.191908; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; OSEI SY, 1993, EUR J PHARMACOL, V234, P35, DOI 10.1016/0014-2999(93)90703-K; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; WAKSMAN G, 1986, P NATL ACAD SCI USA, V83, P1523, DOI 10.1073/pnas.83.5.1523; WELCHES WR, 1991, J HYPERTENS, V9, P631, DOI 10.1097/00004872-199107000-00008	29	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10056	10061		10.1074/jbc.270.17.10056	http://dx.doi.org/10.1074/jbc.270.17.10056			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730308	hybrid			2022-12-25	WOS:A1995QV41700053
J	GROVES, JD; TANNER, MJA				GROVES, JD; TANNER, MJA			COEXPRESSED COMPLEMENTARY FRAGMENTS OF THE HUMAN RED-CELL ANION-EXCHANGER (BAND-3, AE1) GENERATE STILBENE DISULFONATE-SENSITIVE ANION TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; ERYTHROCYTE-MEMBRANE; ESCHERICHIA-COLI; XENOPUS-OOCYTES; OLIGOMERIZATION; RECONSTITUTION; OVALOCYTOSIS; COEXPRESSION; RECEPTORS; CLEAVAGE	We have constructed cDNA clones encoding various portions of the human red cell anion transporter (band 3), a well characterized integral membrane protein with up to 14 transmembrane segments, The biosynthesis, stability, cell surface expression, and functionality of these band 3 fragments were investigated by expression from the cRNAs into microsomal membranes using the reticulocyte cell-free translation system and in Xenopus oocytes, Co expression of the pairs of recombinants encoding the first 8 and last 6 transmembrane spans (8+6) or the first 12 and last 2 spans (12+2) of band 3 generated stilbene disulfonate-sensitive anion transport in oocytes. When the pairs of fragments 8+6 or 12+2 were co-expressed with glycophorin A (GPA), translocation to the plasma membrane of the fragment corresponding to the first 12 or the first 8 transmembrane spans was greater than in the absence of GPA Only the fragment encoding the first 12 transmembrane spans showed GPA-dependent translocation when expressed in the absence of its complementary fragment, A truncated form of band 3 encoding all 14 transmembrane spans but lacking the carboxyl-terminal 30 amino acids of the cytoplasmic tail did not induce anion transport activity in oocytes and was not translocated to the plasma membrane but appeared to be degraded in oocytes. Our results suggest that there is no single signal for the insertion of the different transmembrane spans of band 3 into membranes and that the integrity of the loops between transmembrane spans 8-9 or 12-13 is not essential for anion transport function. Our data also suggest that a region of transmembrane spans 9-12 of band 3 is involved in the process by which GPA facilitates the translocation of band 3 to the surface.	UNIV BRISTOL, SCH MED SCI, DEPT BIOCHEM, BRISTOL BS8 1TD, AVON, ENGLAND	University of Bristol								BIBI E, 1992, P NATL ACAD SCI USA, V89, P1524, DOI 10.1073/pnas.89.5.1524; BORMANN BJ, 1992, ANNU REV BIOPH BIOM, V21, P223, DOI 10.1146/annurev.bb.21.060192.001255; BRUCE LJ, 1994, J BIOL CHEM, V269, P16155; BRUCE LJ, 1994, BLOOD, V84, P916; COPE DL, 1994, BIOCHEM J, V300, P291, DOI 10.1042/bj3000291; GROVES JD, 1994, J MEMBRANE BIOL, V140, P81; GROVES JD, 1994, MOL MEMBR BIOL, V11, P31, DOI 10.3109/09687689409161027; GROVES JD, 1992, J BIOL CHEM, V267, P22163; GROVES JD, 1993, FEBS LETT, V330, P186, DOI 10.1016/0014-5793(93)80270-5; JAY D, 1986, ANNU REV BIOCHEM, V55, P511, DOI 10.1146/annurev.bi.55.070186.002455; JENNINGS ML, 1989, ANNU REV BIOPHYS BIO, V18, P397, DOI 10.1146/annurev.bb.18.060189.002145; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P6144, DOI 10.1021/bi00141a027; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOSTER W, 1990, MOL GEN GENET, V223, P379; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lemmon MA., 1992, CURR OPIN STRUC BIOL, V2, P511; LEPKE S, 1992, BIOCHIM BIOPHYS ACTA, V1106, P13, DOI 10.1016/0005-2736(92)90215-8; LIU SC, 1990, NEW ENGL J MED, V323, P1530, DOI 10.1056/NEJM199011293232205; LOO TW, 1994, J BIOL CHEM, V269, P7750; MAGGIO R, 1993, FEBS LETT, V319, P195, DOI 10.1016/0014-5793(93)80066-4; OIKAWA K, 1985, BIOCHEMISTRY-US, V24, P2843, DOI 10.1021/bi00333a005; OKUBO K, 1994, J BIOL CHEM, V269, P1918; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; POPOT JL, 1990, ANNU REV BIOPHYS BIO, V19, P369; POPOT JL, 1993, CURR OPIN STRUC BIOL, V3, P532, DOI 10.1016/0959-440X(93)90079-Z; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOFIELD AE, 1992, J MOL BIOL, V223, P949, DOI 10.1016/0022-2836(92)90254-H; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TANNER MJA, 1989, METHOD ENZYMOL, V173, P423; TANNER MJA, 1993, SEMIN HEMATOL, V30, P34; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x; WANG DN, 1994, EMBO J, V13, P3230, DOI 10.1002/j.1460-2075.1994.tb06624.x; WOOD PG, 1992, PROGR CELL RES, V2, P325; WRUBEL W, 1990, J BACTERIOL, V172, P5374, DOI 10.1128/jb.172.9.5374-5381.1990	39	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9097	9105		10.1074/jbc.270.16.9097	http://dx.doi.org/10.1074/jbc.270.16.9097			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721823	hybrid			2022-12-25	WOS:A1995QU08900011
J	MIZUGUCHI, G; KANEIISHII, C; TAKAHASHI, T; YASUKAWA, T; NAGASE, T; HORIKOSHI, M; YAMAMOTO, T; ISHII, S				MIZUGUCHI, G; KANEIISHII, C; TAKAHASHI, T; YASUKAWA, T; NAGASE, T; HORIKOSHI, M; YAMAMOTO, T; ISHII, S			C-MYB REPRESSION OF C-ERBB-2 TRANSCRIPTION BY DIRECT BINDING TO THE C-ERBB-2 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTO-ONCOGENE PRODUCT; GROWTH-FACTOR RECEPTOR; HUMAN-BREAST-CANCER; NEU ONCOGENE; B-MYB; LEUCINE-ZIPPER; V-MYB; EXPRESSION; GENE; CELLS	The c-myb proto oncogene product (c-Myb) is a transcriptional activator that can bind to the specific DNA sequences. Although c-Myb also represses an artificial promoter containing the Myb binding sites, natural target genes transcriptionally repressed by c-Myb have not been identified. We have found that the human c-erbB-a promoter activity is repressed by c-Myb or B-Myb in a chloramphenicol acetyltransferase co-transfection assay. Domain analyses of c-Myb suggested that Myb re presses the c-erbB-a promoter activity by competing with positive regulators of the c-erbB-2 promoter. In in vitro transcription assays, Myb proteins containing only the DNA binding domain could repress c-erbB-2 promoter activity. Two Myb binding sites in the c-erbB-2 promoter were critical for transcriptional repression by c-Myb. One of the two Myb binding sites overlaps the TATA box, and DNase I footprint analyses indicated that c-Myb can compete with TFIID. These results suggest that Myb-induced trans-repression of the c-erbB-2 promoter partly involves competition between Myb and TFIID.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; UNIV TSUKUBA,INST BASIC MED SCI,TSUKUBA,IBARAKI 305,JAPAN; UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; University of Tsukuba; University of Tokyo	MIZUGUCHI, G (corresponding author), RIKEN,INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,GENET MOLEC LAB,TSUKUBA,IBARAKI 305,JAPAN.		Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BROWN KE, 1992, J BIOL CHEM, V267, P4625; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GUERIN M, 1990, ONCOGENE, V5, P131; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; HIGUCHI R, 1990, PCR TECHNOLOGY PRINC, P61; HU YL, 1991, ONCOGENE, V6, P1549; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; KU DH, 1993, J BIOL CHEM, V268, P2255; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUSHGER B, 1990, GENE DEV, V4, P2235; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MIZUGUCHI G, 1994, FEBS LETT, V348, P80, DOI 10.1016/0014-5793(94)00578-8; MORI S, 1989, LAB INVEST, V61, P93; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NESS SA, 1989, CELL, V59, P115; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NOMURA T, 1993, J BIOL CHEM, V268, P21914; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; RAMSAY RG, 1992, CELL GROWTH DIFFER, V3, P723; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; TASHIRO S, 1995, IN PRESS ONCOGENE; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1987, CANCER RES, V47, P5266; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTA J, 1986, LANCET, V1, P765; ZOBEL A, 1991, ONCOGENE, V6, P1397	45	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9384	9389		10.1074/jbc.270.16.9384	http://dx.doi.org/10.1074/jbc.270.16.9384			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721862	hybrid			2022-12-25	WOS:A1995QU08900051
J	PINZ, KG; SHIBUTANI, S; BOGENHAGEN, DF				PINZ, KG; SHIBUTANI, S; BOGENHAGEN, DF			ACTION OF MITOCHONDRIAL-DNA POLYMERASE-GAMMA AT SITES OF BASE LOSS OR OXIDATIVE DAMAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; 3'->5' EXONUCLEASE; CATALYTIC SUBUNIT; XENOPUS-LAEVIS; CELLS; NUCLEAR; REPAIR; IDENTIFICATION; PURIFICATION; FIDELITY	Mitochondrial DNA is subject to oxidative damage generating 7,8-dihydro-8-oxo-2'-deoxyguanosine (8-oxo-dG) residues and to spontaneous or induced base loss generating abasic sites, Synthetic oligonucleotides containing these lesions were prepared and used as templates to determine their effects on the action of Xenopus Laevis DNA polymerase gamma, An analogue of an abasic site in DNA, tetrahydrofuran, was found to inhibit elongation by DNA polymerase gamma, When the DNA polymerase was able to complete translesional synthesis, a dA residue was incorporated opposite the abasic site, In contrast, elongation by DNA polymerase gamma was not inhibited by an 8-oxo-dG residue in the template strand. The polymerase inserted dA opposite 8-oxo-dG in approximately 27% of the extended products, The effects of these lesions on the 3' --> 5' exonuclease proofreading activity of DNA polymerase gamma were also investigated, The 3' --> 5' exonuclease activity excised any of the four normal bases positioned opposite either a tetrahydrofuran residue or 8-oxo-dG, suggesting that proofreading may not play a major role in avoiding misincorporation at abasic sites or 8-oxo-dG residues in the template, Thus, both of these lesions have the prospect of causing high rates of mutation during mtDNA replication.	SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Shibutani, Shinya/0000-0003-4190-9512	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES004068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029681] Funding Source: NIH RePORTER; NIEHS NIH HHS [P01-ES04068] Funding Source: Medline; NIGMS NIH HHS [R01-GM29681] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKER JM, 1980, SCIENCE, V209, P297, DOI 10.1126/science.6770466; BODEPUDI V, 1991, NUCLEOS NUCLEOT NUCL, V10, P755, DOI 10.1080/07328319108046660; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; FOURY F, 1989, J BIOL CHEM, V264, P20552; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; GRAY H, 1992, J BIOL CHEM, V267, P5835; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HAYAKAWA M, 1991, BIOCHEM BIOPH RES CO, V176, P87, DOI 10.1016/0006-291X(91)90893-C; HEGLER J, 1993, CARCINOGENESIS, V14, P2309, DOI 10.1093/carcin/14.11.2309; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; NIRANJAN BG, 1982, SCIENCE, V215, P73, DOI 10.1126/science.6797067; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; OLSON MW, 1992, J BIOL CHEM, V267, P23136; RICHTER C, 1992, MUTAT RES, V275, P249, DOI 10.1016/0921-8734(92)90029-O; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIBUTANI S, 1993, CHEM RES TOXICOL, V6, P625, DOI 10.1021/tx00035a006; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TOMKINSON AE, 1988, J BIOL CHEM, V263, P12532; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WILLIAMS AJ, 1993, J BIOL CHEM, V268, P24855	35	109	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9202	9206		10.1074/jbc.270.16.9202	http://dx.doi.org/10.1074/jbc.270.16.9202			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721837	hybrid			2022-12-25	WOS:A1995QU08900025
J	SALIMATH, PV; SPIRO, RC; FREEZE, HH				SALIMATH, PV; SPIRO, RC; FREEZE, HH			IDENTIFICATION OF A NOVEL GLYCOSAMINOGLYCAN CORE-LIKE MOLECULE .2. ALPHA-GALNAC-CAPPED XYLOSIDES CAN BE MADE BY MANY CELL-TYPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; BETA-D-XYLOSIDES; CHONDROITIN SULFATE BIOSYNTHESIS; EMBRYONIC-CHICKEN CARTILAGE; BREFELDIN-A; LINKED OLIGOSACCHARIDES; HEPARAN-SULFATE; SHARK CARTILAGE; HUMAN-MELANOMA; PROTEOGLYCANS	The accompanying article (Manzi, A., Salimath, P, V,, Spiro, R, C,, Keifer, P, A., and Freeze, H, H, (1995) J, Biol, Chem, 270, 9154-9163) reported the complete structure of a novel molecule made by human melanoma cells incubated with 1 mM 4-methylumbelliferyl-beta Xyl (Xyl beta MU), The product resembles a common pentasaccharide core region found in chondroitin/dermatan sulfate glycosaminoglycans, except that a terminal alpha-GalNAc residue is found in a location normally occupied by beta-GalNAc in these chains or alpha-GlcNAc in heparan sulfate chains, In this paper we show that several other human cancer cell lines and Chinese hamster ovary cells also make alpha-GalNAc-capped xylosides, The [6-H-3]galactose-labeled Xyl beta MU product binds to immobilized alpha-GalNAc-specific lectin from Helix pomatia and the binding is competed by GalNAc, but not by Glc, Binding to the lectin is destroyed by digestion with alpha-N-acetylgalactosaminidase, but not beta-hexosaminidase. The nature of the aglycone influences the amount and relative proportion of this material made, with p-nitrophenyl-beta-xyloside being a better promoter of alpha-GalNAc-terminated product than Xyl beta MU. This novel oligosaccharide ac counts for 45-65% of xyloside-based products made by both human melanoma and Chinese hamster ovary cells when they are incubated with 30 mu M Xyl beta MU, but at 1 mM both the total amount and the proportion decreases to only 5-10%, In both cell lines this product is replaced by a corresponding amount of Sia alpha 2,3Gal beta 4Xyl beta MU. Preferential synthesis of the alpha-GalNAc-capped material at very low xyloside concentration argues that it is a normal biosynthetic product and not an experimental artifact, This pentasaccharide may be a previously unrecognized intermediate in glycosaminoglycan chain biosynthesis, Since this alpha-GalNAc residue occurs at a position that determines whether chondroitin or heparan chains are added to the acceptor, it may influence the timing, type, and extent of further chain elongation.	LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA; TELIOS PHARMACEUT INC, SAN DIEGO, CA 92121 USA	Sanford Burnham Prebys Medical Discovery Institute				Freeze, Hudson/0000-0001-6316-0501	NATIONAL CANCER INSTITUTE [R01CA049243] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA49094, R01 CA49243] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen H. J., 1992, GLYCOCONJUGATES COMP; CARRINO DA, 1994, MATRIX BIOL, V14, P121, DOI 10.1016/0945-053X(94)90002-7; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; DO SI, 1992, J BIOCHEM BIOPH METH, V24, P153, DOI 10.1016/0165-022X(94)90068-X; ESKO JD, 1993, CURRENT PROTOCOLS MO; ETCHISON JR, 1995, J BIOL CHEM, V270, P756, DOI 10.1074/jbc.270.2.756; FARACH MC, 1988, BIOL REPROD, V39, P443, DOI 10.1095/biolreprod39.2.443; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; FRITZ TA, 1994, J BIOL CHEM, V269, P300; GALLIGANI L, 1975, J BIOL CHEM, V250, P5400; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HAYES BK, 1993, J BIOL CHEM, V268, P16155; IZUMI J, 1994, J BIOCHEM-TOKYO, V116, P524, DOI 10.1093/oxfordjournals.jbchem.a124556; KIRBY SL, 1991, J CELL PHYSIOL, V148, P116, DOI 10.1002/jcp.1041480114; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; MANZI A, 1995, J BIOL CHEM, V270, P9154, DOI 10.1074/jbc.270.16.9154; ROBINSON HC, 1975, BIOCHEM J, V148, P25, DOI 10.1042/bj1480025; ROBINSON JA, 1981, BIOCHEM J, V194, P839, DOI 10.1042/bj1940839; ROTH J, 1991, J ELECTRON MICR TECH, V17, P121, DOI 10.1002/jemt.1060170202; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SANT AJ, 1985, J EXP MED, V162, P1916, DOI 10.1084/jem.162.6.1916; SJOBERG ER, 1992, J BIOL CHEM, V267, P16200; SOBUE M, 1987, BIOCHEM J, V241, P591, DOI 10.1042/bj2410591; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; TAKAGAKI K, 1991, J BIOCHEM-TOKYO, V109, P514, DOI 10.1093/oxfordjournals.jbchem.a123413; UHLINHANSEN L, 1993, J BIOL CHEM, V268, P17370; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295	32	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9164	9168		10.1074/jbc.270.16.9164	http://dx.doi.org/10.1074/jbc.270.16.9164			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721831	hybrid			2022-12-25	WOS:A1995QU08900019
J	ADNANE, J; SHAO, ZH; ROBBINS, PD				ADNANE, J; SHAO, ZH; ROBBINS, PD			THE RETINOBLASTOMA SUSCEPTIBILITY GENE-PRODUCT REPRESSES TRANSCRIPTION WHEN DIRECTLY BOUND TO THE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DIRECT BINDING; CDC2 KINASE; RB PROTEIN; T-ANTIGEN; C-MYC; E2F; PHOSPHORYLATION; EXPRESSION; ACTIVATION	Rb represses E2F-mediated transcription in part by blocking the trans-activation domain of E2F. In addition, Rb can convert an E2F binding site from a positive to a negative element. To examine the effect of a Rb-DNA bound complex on transcription, full-length Rb was fused to the DNA binding domain of GAL4. Here, we report that GAL4-Rb can repress transcription mediated by either Sp1, AP-1, or p53, dependent upon the presence of both the GAL4 DNA binding domain and GAL4 binding sites. Moreover, GAL4-Rb inhibited the activity of the herpes simplex virus tk promoter from GAL4 binding sites located at a distance from the promoter. In contrast, GAL4-Rb was unable to repress basal transcription. Cotransfection of specific cyclins and cyclin dependent kinases or SV40 T-antigen abolished the repressive activity of GAL4-Rb. The domains of Rb involved in mediating the repression of transcription were mapped to regions that are overlapping, but not identical, to those required for the interaction with E2F. We propose that Rb can function as a general repressor of transcription when bound to the promoter region.	UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA055227] Funding Source: NIH RePORTER; NCI NIH HHS [CA55227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARLOW E, 1988, ANTIBODIES LABORATOR; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1993, GENE CHROMOSOME CANC, V6, P124, DOI 10.1002/gcc.2870060211; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KATO J, 1993, GENE DEV, V7, P331; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MADDEN SL, 1993, ONCOGENE, V8, P1713; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J, 1989, MOL CLONING LABORATO; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAO Z, 1995, IN PRESS P NATL ACAD; SRINIVASAN A, 1989, J VIROL, P5459; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YU DH, 1992, J BIOL CHEM, V267, P10203	49	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8837	8843		10.1074/jbc.270.15.8837	http://dx.doi.org/10.1074/jbc.270.15.8837			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721791	hybrid			2022-12-25	WOS:A1995QT44800069
J	CATERINA, MJ; DEVREOTES, PN; BORLEIS, J; HERELD, D				CATERINA, MJ; DEVREOTES, PN; BORLEIS, J; HERELD, D			AGONIST-INDUCED LOSS OF LIGAND-BINDING IS CORRELATED WITH PHOSPHORYLATION OF CAR1, A G-PROTEIN-COUPLED CHEMOATTRACTANT RECEPTOR FROM DICTYOSTELIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE CAMP RECEPTORS; CYCLIC-AMP; CONCENTRATION-DEPENDENCE; KINASE ACTIVATION; DOWN-REGULATION; DISCOIDEUM; DESENSITIZATION; INTERNALIZATION; AGGREGATION; INHIBITORS	The parallel agonist-induced phosphorylation, alteration in electrophoretic mobility, and loss of ligand binding of a guanine nucleotide-binding regulatory protein (G protein)-coupled chemoattractant receptor from Dictyostelium (cAR1) depend upon a cluster of five C-terminal domain serine residues (Caterina, M. J., Hereld, D., and Devreotes, P. N. (1995) J. Biol. Chem. 270, 4418-4423). Analysis of mutants lacking combinations of these serines revealed that either Ser(303) or Ser(304) is required; mutants lacking both serines are defective in all of these responses. Interestingly, several mutants, in eluding those substituted at only Ser(299), Ser(302), or Ser(303) or at non-serine positions within the third cytoplasmic loop, displayed an unstable mobility shift; the alteration was rapidly reversed upon cAMP removal. These mutants also exhibited subnormal extents of loss of ligand binding, which is assessed after removal of the ligand. For the wild-type receptor, we found that the stability of phosphorylation depends upon the concentration and duration of agonist pretreatment. This suggests that, following phosphorylation of Ser(303) or Ser(304), cAR1 undergoes a further transition (EC(50) approximate to 140 nM, t(1/2) approximate to 4 min) to a relatively phosphatase resistant state. We used this insight to show that, under all conditions tested, the extent of loss of binding is correlated with the fraction of cAR1 in the altered mobility form. We discuss possible relationships between cAR1 phosphorylation and loss of ligand binding.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034933] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34933, GM07309] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENOVIC JL, 1990, BRIT J CLIN PHARMACO, V30, pS3, DOI 10.1111/j.1365-2125.1990.tb05462.x; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BRENNER M, 1984, DEV BIOL, V101, P136, DOI 10.1016/0012-1606(84)90124-6; CATERINA MJ, 1994, J BIOL CHEM, V269, P1523; CATERINA MJ, 1995, J BIOL CHEM, V270, P4418, DOI 10.1074/jbc.270.9.4418; CHEN CY, 1993, J BIOL CHEM, V268, P7825; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; DEVREOTES P, 1989, TRENDS GENET, V5, P242, DOI 10.1016/0168-9525(89)90095-4; DEVREOTES PN, 1985, J BIOL CHEM, V260, P6378; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HENDERSON EJ, 1975, J BIOL CHEM, V250, P4730; HERELD D, 1994, J BIOL CHEM, V269, P7036; JULIANI MH, 1981, J BIOL CHEM, V256, P613; KLEIN C, 1977, CELL, V10, P329, DOI 10.1016/0092-8674(77)90227-6; KLEIN P, 1985, J BIOL CHEM, V260, P1757; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MORO O, 1993, J BIOL CHEM, V268, P22273; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; TSUGA H, 1994, J BIOL CHEM, V269, P3252; VANHAASTERT PJM, 1987, J BIOL CHEM, V262, P7700; VANHAASTERT PJM, 1985, BIOCHIM BIOPHYS ACTA, V845, P254, DOI 10.1016/0167-4889(85)90184-3; VANHAASTERT PJM, 1984, BIOCHEM BIOPH RES CO, V124, P597, DOI 10.1016/0006-291X(84)91596-1; VANHAASTERT PJM, 1992, MOL BIOL CELL, V3, P603, DOI 10.1091/mbc.3.6.603; VAUGHAN RA, 1988, J BIOL CHEM, V263, P14538; WANG M, 1988, DEV BIOL, V128, P72, DOI 10.1016/0012-1606(88)90268-0; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; YU SS, 1993, J BIOL CHEM, V268, P337	32	39	40	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8667	8672		10.1074/jbc.270.15.8667	http://dx.doi.org/10.1074/jbc.270.15.8667			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721769	hybrid			2022-12-25	WOS:A1995QT44800047
J	HYDER, SM; NAWAZ, Z; CHIAPPETTA, C; YOKOYAMA, K; STANCEL, GM				HYDER, SM; NAWAZ, Z; CHIAPPETTA, C; YOKOYAMA, K; STANCEL, GM			THE PROTOONCOGENE C-JUN CONTAINS AN UNUSUAL ESTROGEN-INDUCIBLE ENHANCER WITHIN THE CODING SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; RAT UTERINE CELLS; RESPONSE ELEMENT; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; 3'-FLANKING REGION; NUCLEAR RECEPTORS; FOS PROTOONCOGENE; UTERUS; DNA	Estrogens have previously been shown to induce c-jun mRNA levels in target cells during hormone induced proliferation, and this appears to be a primary hormonal response involving transcriptional activation. In this report we have now identified an estrogen dependent enhancer within the coding sequence of c-jun. This element has the sequence GCAGAnnnTGACC which is identical to the consensus estrogen response element GGTCAnnnTGACC in the second half site, but varies considerably in the first half site. Synthetic oligodeoxynucleotides containing this jun sequence bind the estrogen receptor in cell-free studies using a competitive band shift assay with the consensus element. The jun element also confers hormone inducibility to re porter plasmids in yeast and mammalian based transcriptional systems. Structure-function studies illustrate that the TGACC half-site and its immediate flanking dinucleotides, but not the GCAGA half-site, are required for estrogen receptor binding. In contrast, both the GCAGA and TGACC half-sites are obligatory for hormone inducible transcriptional activation. These results suggest a model in which the estrogen receptor functions as a heterodimer to regulate transcription of the c-jun protooncogene. Coupled with reports of estrogen response elements in c-fos and estrogenic induction of c-fos and c-jun in vivo, these findings also support a role for AP-1 components as early response genes in estrogen-induced proliferation.	UNIV TEXAS,SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,HOUSTON,TX 77225; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; RIKEN,TSUKUBA LIFE SCI CTR,IBARAKI,OSAKA 305,JAPAN	University of Texas System; Baylor College of Medicine; RIKEN	HYDER, SM (corresponding author), UNIV TEXAS,SCH MED,DEPT PHARMACOL,POB 20708,HOUSTON,TX 77225, USA.				NICHD NIH HHS [HD-08615] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANOLIK JH, 1993, J STEROID BIOCHEM, V46, P713, DOI 10.1016/0960-0760(93)90312-K; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BIGSBY RM, 1994, ENDOCRINOLOGY, V134, P1820, DOI 10.1210/en.134.4.1820; BURCH JBE, 1988, MOL CELL BIOL, V8, P1123, DOI 10.1128/MCB.8.3.1123; CHIAPPETTA C, 1992, J STEROID BIOCHEM, V41, P113, DOI 10.1016/0960-0760(92)90037-J; CICATIELLO L, 1992, J STEROID BIOCHEM, V41, P523, DOI 10.1016/0960-0760(92)90377-U; CLARET FX, 1994, J BIOL CHEM, V269, P14047; CURTIS SW, 1990, MOL ENDOCRINOL, V4, P276, DOI 10.1210/mend-4-2-276; DANA SL, 1994, MOL ENDOCRINOL, V8, P1193, DOI 10.1210/me.8.9.1193; ELLISTON JF, 1990, J BIOL CHEM, V265, P11517; FURLOW JD, 1990, ENDOCRINOLOGY, V127, P1028, DOI 10.1210/endo-127-3-1028; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GORSKI J, 1993, BIOL REPROD, V48, P8, DOI 10.1095/biolreprod48.1.8; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HAWA NS, 1994, ENDOCRINOLOGY, V135, P1, DOI 10.1210/en.135.1.1; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hyder Salman M., 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P55; HYDER SM, 1994, BIOTECHNIQUES, V17, P478; HYDER SM, 1991, GENE, V105, P281, DOI 10.1016/0378-1119(91)90164-7; HYDER SM, 1992, J BIOL CHEM, V267, P18047; HYDER SM, 1989, J STEROID BIOCHEM, V33, P965, DOI 10.1016/0022-4731(89)90247-1; HYDER SM, 1994, J STEROID BIOCHEM, V48, P69, DOI 10.1016/0960-0760(94)90252-6; INOUE S, 1991, NUCLEIC ACIDS RES, V19, P4091, DOI 10.1093/nar/19.15.4091; ITAO M, 1983, J BACTERIOL, V153, P163; KANEKO KJ, 1993, MOL ENDOCRINOL, V7, P879, DOI 10.1210/me.7.7.879; KIRKLAND JL, 1979, BIOL REPROD, V21, P269, DOI 10.1095/biolreprod21.2.269; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; KITABAYASHI I, 1990, NUCLEIC ACIDS RES, V18, P3400, DOI 10.1093/nar/18.11.3400; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KOJI T, 1993, ENDOCRINOLOGY, V132, P382, DOI 10.1210/en.132.1.382; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LANNIGAN DA, 1993, MOL CELL ENDOCRINOL, V94, P47, DOI 10.1016/0303-7207(93)90050-T; LOOSEMITCHELL DS, 1988, MOL ENDOCRINOL, V2, P946, DOI 10.1210/mend-2-10-946; LUCKOW B, 1984, NUCLEIC ACIDS RES, V15, P5490; MAK P, 1989, J BIOL CHEM, V264, P21613; Maniatis T., 1982, MOL CLONING; MCDONNELL DP, 1991, J STEROID BIOCHEM, V39, P291, DOI 10.1016/0960-0760(91)90038-7; MOENLE CM, 1994, GENETICS, V115, P255; MURDOCH FE, 1990, BIOCHEMISTRY-US, V29, P8377, DOI 10.1021/bi00488a026; NAWAZ Z, 1993, MOL CARCINOGEN, V7, P76, DOI 10.1002/mc.2940070204; NEPHEW KP, 1994, ENDOCRINOLOGY, V134, P1827, DOI 10.1210/en.134.4.1827; PERSICO E, 1990, BIOCHEM BIOPH RES CO, V171, P287, DOI 10.1016/0006-291X(90)91390-E; PHAM TA, 1991, J BIOL CHEM, V266, P18179; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SIRBASKU DA, 1976, ENDOCRINOLOGY, V98, P1260, DOI 10.1210/endo-98-5-1260; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WEBB DK, 1990, BIOCHEM BIOPH RES CO, V168, P721, DOI 10.1016/0006-291X(90)92381-9; WEBB DK, 1993, ENDOCRINOLOGY, V133, P20, DOI 10.1210/en.133.1.20; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; WEISZ A, 1988, MOL ENDOCRINOL, V2, P816, DOI 10.1210/mend-2-9-816; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541	57	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8506	8513		10.1074/jbc.270.15.8506	http://dx.doi.org/10.1074/jbc.270.15.8506			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721748	hybrid			2022-12-25	WOS:A1995QT44800024
J	SHIRAISHI, M; SEKIYA, T				SHIRAISHI, M; SEKIYA, T			MUTATIONS IN AN ALU REPEATED SEQUENCE ASSOCIATED WITH THE DXS43 LOCUS IN HUMAN SMALL-CELL LUNG CANCERS	ONCOGENE			English	Note						HUMAN SMALL CELL LUNG CANCER; X CHROMOSOME; ALU REPEATED SEQUENCE; POINT MUTATION	CARCINOMAS; GENE; DNA	Point mutations in an Alu repeated sequence associated with the DXS43 locus were identified in two out of 10 human small cell lung cancers. Since these aberrations were identified in DNA from both metastatic lesions and primary lesions from the same patient, they would appear to have occurred at a relatively early stage. Although this sequence is not apparently associated with known genes, these tumor-specific mutations occurred at an early stage may play an important role in tumorigenesis.			SHIRAISHI, M (corresponding author), NATL CANC CTR, RES INST, DIV ONCOGENE, CHUO KU, 1-1 TSUKIJI 5 CHOME, TOKYO 104, JAPAN.							AUSTIN GE, 1993, LEUKEMIA, V7, P1445; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; IIZUKA M, 1995, INPRESS GENES CHROMO; SHIRAISHI M, 1987, JPN J CANCER RES, V78, P1302; SHIRAISHI M, 1989, CANCER RES, V49, P6474; SHIRAISHI M, 1989, JPN J CANCER RES, V80, P924, DOI 10.1111/j.1349-7006.1989.tb01627.x	8	3	3	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1453	1454						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731698				2022-12-25	WOS:A1995QR65100025
J	BRUCE, C; DAVIDSON, WS; KUSSIE, P; LUNDKATZ, S; PHILLIPS, MC; GHOSH, R; TALL, AR				BRUCE, C; DAVIDSON, WS; KUSSIE, P; LUNDKATZ, S; PHILLIPS, MC; GHOSH, R; TALL, AR			MOLECULAR DETERMINANTS OF PLASMA CHOLESTERYL ESTER TRANSFER PROTEIN-BINDING TO HIGH-DENSITY-LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; LIPID TRANSFER PROTEIN; CELL-DERIVED CHOLESTEROL; PARTICLES; ACYLTRANSFERASE; LECITHIN; CHARGE; CONFORMATION; PURIFICATION; METABOLISM	The plasma cholesteryl ester transfer protein (CETP) mediates the transfer of neutral lipids between lipoproteins and is associated with high density lipoproteins (HDL), To understand the mechanism of interaction of CETP with HDL, we studied the binding of pure recombinant CETP to 1-palmitoyl-2-oleoylphosphatidylcholine (POPC)/apoA-I discoidal particles, Separating bound from free CETP using native gradient gel electrophoresis, complexes of CETP with 10-nm hydrodynamic diameter discoidal particles migrated with a diameter of 12-16 nm, compared with similar to 7.5 nm for CETP, At lower ratios of CETP to discs, CETP bound to discs without displacement of apoA-I. CETP alone was unable to generate discoidal complexes, Cross-linking and fluorescence resonance energy transfer experiments indicated that CETP bound to discs as monomers, Cross-linking of CETP to apoA-I in discs suggested proximity of apoA-I and CETP, By negative-stain electron microscopy, discoidal complexes containing CETP and CETP monoclonal antibody showed localization of antibody molecules to the disc edge, suggesting that CETP was bound to the disc edge, The binding of CETP to discs of different composition or size was studied, Discs (10-nm Stokes diameter) prepared with either apoA-I or apoA-II had a similar K-d (120 nM), Inclusion of 1 mol % cholesteryl oleate, 5 mol % cholesterol, or 6 mol % phosphatidylinositol increased the binding affinity of CETP 3-10 times (20-30 nar), In comparison, plasma HDL(3) had a K-d of similar to 450 nM, For POPC/apoA-I discs, 10-nm discs bound CETP with much higher affinity than smaller 7.8-nm discs (K-d = 1-2 mu M), 7.7-nm hydrodynamic diameter POPC/apoA-I spherical particles containing either triolein or cholesteryl oleate in their core bound CETP with higher affinity (K-d = 50-100 mu M) than 7.8-nm POPC/apoA-I discs, Thus, CETP appears to bind to the perimeter of discoidal particles, possibly in a process in which flexible segments in apoA-I or apoA-II accommodate CETP at the disc edge, The binding of CETP to HDL is markedly influenced by overall particle size and shape and by lipid composition, and the increased binding affinity for cholesterol- and cholesteryl ester containing discs suggests a higher affinity of CETP for nascent than mature HDL.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,DIV MOLEC MED,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; MED COLL PENN,DEPT BIOCHEM,PHILADELPHIA,PA 19129	Columbia University; Columbia University; Drexel University			Tall, Alan/AAT-8528-2021	Phillips, Michael/0000-0002-7147-8007; Bruce, Can/0000-0002-3101-1250; Davidson, William/0000-0003-2756-2989				BANKA CL, 1994, J BIOL CHEM, V269, P10288; BANKA CL, 1991, J BIOL CHEM, V266, P23886; CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CLAY MA, 1992, BIOCHIM BIOPHYS ACTA, V1124, P52, DOI 10.1016/0005-2760(92)90125-F; DAVIDSON WS, 1994, J BIOL CHEM, V269, P8859; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; EISENBERG S, 1984, J LIPID RES, V25, P1017; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; GREEN PHR, 1978, J CLIN INVEST, V61, P528, DOI 10.1172/JCI108963; GUYARDDANGREMON.V, 1994, J LIPID RES, V35, P982; HAMILTON RL, 1976, J CLIN INVEST, V58, P667, DOI 10.1172/JCI108513; HAYEK T, 1992, J CLIN INVEST, V90, P505, DOI 10.1172/JCI115887; HESLER CB, 1989, J BIOL CHEM, V264, P11317; HESLER CB, 1987, J BIOL CHEM, V262, P2275; JOHNSON DA, 1984, J BIOL CHEM, V259, P5717; JOHNSON FL, 1986, J LIPID RES, V27, P537; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; KATO H, 1989, J BIOL CHEM, V264, P4082; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; MARCEL YL, 1990, J CLIN INVEST, V85, P10, DOI 10.1172/JCI114397; MENG QH, 1993, J BIOL CHEM, V268, P16966; MORTON RE, 1990, J LIPID RES, V31, P1559; MORTON RE, 1981, J BIOL CHEM, V256, P1992; MORTON RE, 1988, J BIOL CHEM, V263, P12235; MOULIN P, 1994, J LIPID RES, V35, P793; MUSLINER TA, 1991, J LIPID RES, V32, P917; NISHIDA HI, 1993, J BIOL CHEM, V268, P16352; OHNISHI T, 1994, BIOCHEMISTRY-US, V33, P6093, DOI 10.1021/bi00186a008; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; QUINET E, 1993, J BIOL CHEM, V268, P16891; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; RYE KA, 1989, J LIPID RES, V30, P335; SAMMETT D, 1985, J BIOL CHEM, V260, P6687; SEGREST JP, 1992, J LIPID RES, V33, P141; SPARKS DL, 1993, J BIOL CHEM, V268, P23250; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; SWENSON TL, 1989, J BIOL CHEM, V264, P14318; TAKAHASHI K, 1993, J CLIN INVEST, V92, P2060, DOI 10.1172/JCI116802; TALL A, 1987, J CLIN INVEST, V79, P1217, DOI 10.1172/JCI112940; TALL AR, 1977, J BIOL CHEM, V252, P4701; TALL AR, 1993, J LIPID RES, V34, P1255; TALL AR, 1977, NATURE, V265, P163, DOI 10.1038/265163a0; WALD JH, 1990, J BIOL CHEM, V265, P20037; WANG SK, 1995, J BIOL CHEM, V270, P612, DOI 10.1074/jbc.270.2.612; WEINBERG RB, 1994, J BIOL CHEM, V269, P29588	47	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11532	11542		10.1074/jbc.270.19.11532	http://dx.doi.org/10.1074/jbc.270.19.11532			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744792	hybrid			2022-12-25	WOS:A1995QX86500072
J	SAKAUE, H; HARA, K; NOGUCHI, T; MATOZAKI, T; KOTANI, K; OGAWA, W; YONEZAWA, K; WATERFIELD, MD; KASUGA, M				SAKAUE, H; HARA, K; NOGUCHI, T; MATOZAKI, T; KOTANI, K; OGAWA, W; YONEZAWA, K; WATERFIELD, MD; KASUGA, M			RAS-INDEPENDENT AND WORTMANNIN-SENSITIVE ACTIVATION OF GLYCOGEN-SYNTHASE BY INSULIN IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR SUBSTRATE-1; VACCINIA VIRUS; 70K-S6 KINASE; PHOSPHORYLATION; STIMULATION; INHIBITION; IRS-1; SHC	Activation of glycogen synthase is one of the major metabolic events triggered by exposure of cells to insulin. The molecular mechanism by which insulin activates glycogen synthase was investigated. The possible role of Ras and mitogen-activated protein kinase cascade was investigated with a stable cell line, CHO-IR-C/S 46, that overexpresses insulin receptors and a catalytically inactive SH-PTP 2 protein phosphatase and in which insulin does not induce the formation of the Ras-GTP complex or the subsequently activation of the mitogen-activated protein kinase cascade. Insulin activated glycogen synthase in this cell line to a similar extent as in parental CHO-IR cells, The importance of heteromeric phosphoinositide (PI) 3-kinase in insulin activation of glycogen synthase was examined in a stable cell line, CHO-IR/Delta p85, that overexpresses insulin receptors and a dominant negative mutant (Delta p85) of the 85-kDa subunit of PI-3 kinase that lacks the binding site for the catalytic 110-kDa subunit. Insulin-dependent activation of PI-3 kinase and glucose transport, but not the formation of the Ras-GTP complex, are markedly attenuated in this cell line. In CHO-IR/Delta p85 cells, insulin activated glycogen synthase to a similar extent as in parental CRO-IR cells. The failure of overproduction of the mutant (Delta p85) protein to inhibit insulin activation of glycogen synthase was also confirmed by transient expression in Rat 1 cells with the use of a recombinant vaccinia virus. However, wortmannin abolished insulin activation of glycogen synthase in all cell lines. These data suggest the existence of a Ras-independent and wortmannin-sensitive pathway for activation of glycogen synthase by insulin,	KOBE UNIV, SCH MED, DEPT INTERNAL MED 2, CHUO KU, KOBE 650, JAPAN; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UNIV LONDON UNIV COLL, DEPT BIOCHEM & MOLEC BIOL, LONDON WC1E 6BT, ENGLAND	Kobe University; Ludwig Institute for Cancer Research; University of London; University College London			Sakaue, Hiroshi/ABE-2337-2021; OGAWA, Wataru/AAQ-9586-2020	Sakaue, Hiroshi/0000-0002-2468-2363; 				AHN NG, 1990, J BIOL CHEM, V265, P11495; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CALVO V, 1992, P NATL ACAD SCI USA, V89, P75741; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; EAGAN SE, 1993, NATURE, V365, P781; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARA K, 1995, BIOCHEM BIOPH RES CO, V208, P735, DOI 10.1006/bbrc.1995.1399; HOSHIKAWA N, 1991, J GEN VIROL, V72, P2509, DOI 10.1099/0022-1317-72-10-2509; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LIN FA, 1994, J BIOL CHEM, V269, P1255; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OKADA T, 1994, J BIOL CHEM, V269, P3568; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUGIMOTO M, 1985, MICROBIOL IMMUNOL, V29, P421, DOI 10.1111/j.1348-0421.1985.tb00843.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; YANO H, 1993, J BIOL CHEM, V268, P25846; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	42	77	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11304	11309		10.1074/jbc.270.19.11304	http://dx.doi.org/10.1074/jbc.270.19.11304			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744767	hybrid			2022-12-25	WOS:A1995QX86500044
J	DYCK, JRB; FLIEGEL, L				DYCK, JRB; FLIEGEL, L			SPECIFIC ACTIVATION OF THE NA+/H+ EXCHANGER GENE DURING NEURONAL DIFFERENTIATION OF EMBRYONAL CARCINOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH; RETINOIC ACID; TRANSCRIPTION FACTOR; HL-60 CELLS; PHORBOL ESTER; AP-2; ACIDIFICATION; PROLIFERATION; LYMPHOCYTES; FIBROBLASTS	We examined the regulation of the Na+/H+ exchanger gene during differentiation of the pig mouse embryonal carcinoma cells, Treatment of P19 cells with retinoic acid induces the development of neurons, astroglia, and microglia cells, Upon retinoic acid induced differentiation of P19 cells, there was an early and rapid 10-fold increase in NHE1 transcription, A proximal cis-acting AP-2 site of the NHE1 promoter was sufficient for stimulation of transcription of the gene by differentiation. Bandshift experiments demonstrated that in retinoic acid-treated cells there was an elevated level of AP-2 transcription factor binding to the AP-2 consensus site of the Na+/H+ exchanger gene, In the differentiation defective mutant RAC65, the effect of differentiation on Na+/H+ exchanger gene expression was reduced by 60%. Examination of Na+/H+ exchanger activity showed that retinoic acid treated P19 cells recovered from an acid load at a rate approximately three times greater than untreated cells. The increases in gene expression and protein activity preceded major changes in cell morphology, suggesting that the initiation of differentiation is linked to NHE1 gene expression, Our findings show for the first time that the NHE1 gene is activated early in cell differentiation and that this activation may play an important role in the process of neuronal cell differentiation.	UNIV ALBERTA,FAC MED,DEPT PEDIAT,MRC,MOLEC BIOL MEMBRANES GRP,EDMONTON,AB T6G 2S2,CANADA	University of Alberta				Dyck, Jason/0000-0002-7045-2884				ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; ALVAREZ J, 1989, EUR J BIOCHEM, V183, P709, DOI 10.1111/j.1432-1033.1989.tb21102.x; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; BIERMAN AJ, 1987, J BIOL CHEM, V262, P9621; BISHOP JF, 1990, FEBS LETT, V264, P125, DOI 10.1016/0014-5793(90)80781-D; BORON WF, 1983, J GEN PHYSIOL, V81, P29, DOI 10.1085/jgp.81.1.29; CHAILLET JR, 1985, J GEN PHYSIOL, V86, P765, DOI 10.1085/jgp.86.6.765; CHAMBARD JC, 1986, EXP CELL RES, V164, P282, DOI 10.1016/0014-4827(86)90029-7; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DYCK JRB, 1995, J BIOL CHEM, V270, P1375, DOI 10.1074/jbc.270.3.1375; FLIEGEL L, 1993, BIOCHEM J, V296, P273, DOI 10.1042/bj2960273; FLIEGEL L, 1993, BIOCHEM J, V289, P101, DOI 10.1042/bj2890101; GRINSTEIN S, 1983, J GEN PHYSIOL, V82, P619, DOI 10.1085/jgp.82.5.619; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAZAV P, 1989, CANCER RES, V49, P72; JONESVILLENEUVE EV, 1993, MOL CELL BIOL, V3, P2271; KOLYADA AY, 1994, BBA-GENE STRUCT EXPR, V1217, P54; LADOUX A, 1987, J BIOL CHEM, V262, P811; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MAIDORN RP, 1993, BRIT J CANCER, V67, P297, DOI 10.1038/bjc.1993.56; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; PHILIPP J, 1994, DEV BIOL, V165, P602, DOI 10.1006/dbio.1994.1279; PIPKIN J L, 1991, Applied and Theoretical Electrophoresis, V2, P17; POUYSSEGUR J, 1985, TRENDS BIOCHEM SCI, V10, P453, DOI 10.1016/0968-0004(85)90030-1; POUYSSEGUR J, 1985, FEBS LETT, V190, P115, DOI 10.1016/0014-5793(85)80439-7; PRATT CMA, 1990, MOL CELL BIOL, V10, P6446; RAC GN, 1992, J CELL PHYSL, V151, P361; RAO GN, 1993, AM J PHYSIOL, V264, pC1278, DOI 10.1152/ajpcell.1993.264.5.C1278; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMITH LL, 1988, J BIOL CHEM, V263, P7359; SPECTOR NL, 1994, FEBS LETT, V337, P184, DOI 10.1016/0014-5793(94)80270-X; STARNAUD R, 1993, MOL CELL BIOL, V13, P1590, DOI 10.1128/MCB.13.3.1590; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; VAIRO G, 1993, CELL GROWTH DIFFER, V4, P461; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557	37	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10420	10427		10.1074/jbc.270.18.10420	http://dx.doi.org/10.1074/jbc.270.18.10420			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737975	hybrid			2022-12-25	WOS:A1995QW60100013
J	KIM, JS; SOUCEK, J; MATOUSEK, J; RAINES, RT				KIM, JS; SOUCEK, J; MATOUSEK, J; RAINES, RT			STRUCTURAL BASIS FOR THE BIOLOGICAL-ACTIVITIES OF BOVINE SEMINAL RIBONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CRYSTAL-STRUCTURE; RNASE; INVITRO; PLASMA; GROWTH; FLUID; CELLS; TUMOR	Bovine seminal ribonuclease (BS-RNase) is a homolog of RNase A with special biological properties that include specific antitumor, aspermatogenic, and immunosuppressive activities. Unlike RNase A, BS-RNase is a dimer cross-linked by disulfide bonds between Cys(31) of one subunit and Cys(32) Of the other. At equilibrium, this dimer is a mixture of two distinct quaternary forms, M=M and MxM. The conversion of M=M to MxM entails the exchange of NH2-terminal alpha-helices between subunits. Here, the cytotoxic activities of purified MxM were shown to be greater than those of purified M=M, despite extensive equilibration of M=M and MxM during the time course of the assays. Replacing Cys(31) or Cys(32) with a serine residue did not compromise the enzymatic activity of dimeric BS-RNase, but reduced both the fraction of MxM at equilibrium and the cytotoxicity. We conclude that the MxM form is responsible for the special biological properties of BS-RNase. Since cytosolic ribonuclease inhibitor binds tightly to monomeric but not dimeric BS-RNase and only the MxM form can remain dimeric in the reducing environment of the cytosol, we propose that BS-RNase has evolved its MxM form to retain its lethal enzymatic activity in vivo.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; INST HEMATOL & BLOOD TRANSFUS,DEPT CELL PHYSIOL,CR-12820 PRAGUE 2,CZECH REPUBLIC; INST ANIM PHYSIOL & GENET,CR-27721 LIBECHOV,CZECH REPUBLIC	University of Wisconsin System; University of Wisconsin Madison; Institute of Hematology Prague; Czech Academy of Sciences; Institute of Animal Physiology & Genetics of the Czech Academy of Sciences			Raines, Ronald T./A-5009-2013; KIM, Jin-Soo/M-6918-2013	Raines, Ronald T./0000-0001-7164-1719; KIM, Jin-Soo/0000-0003-4847-1306	NIGMS NIH HHS [GM-44783] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044783] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BARTHOLEYNS J, 1976, P NATL ACAD SCI USA, V73, P573, DOI 10.1073/pnas.73.2.573; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; Berger S L, 1979, Methods Enzymol, V58, P486; BORCHERT TV, 1994, P NATL ACAD SCI USA, V91, P1515, DOI 10.1073/pnas.91.4.1515; BREITMAN TR, 1980, P NATL ACAD SCI USA, V71, P2936; BREUKELMAN HJ, 1993, RIBONUCLEASES CHEM B; CRESTFIELD A M, 1962, Arch Biochem Biophys, VSuppl 1, P217; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; DALESSIO G, 1975, BIOCHEMISTRY-US, V14, P1116, DOI 10.1021/bi00677a004; DALESSIO G, 1991, TRENDS BIOCHEM SCI, V16, P104, DOI 10.1016/0968-0004(91)90042-T; DALESSIO G, 1972, EUR J BIOCHEM, V26, P153, DOI 10.1111/j.1432-1033.1972.tb01751.x; DENIGRIS M, 1993, BIOCHEM BIOPH RES CO, V193, P155, DOI 10.1006/bbrc.1993.1603; DIDONATO A, 1994, J BIOL CHEM, V269, P17394; DOSTAL J, 1973, J REPROD FERTIL, V33, P263, DOI 10.1530/jrf.0.0330263; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JAMES K, 1984, IMMUNOL TODAY, V5, P357, DOI 10.1016/0167-5699(84)90079-3; KIM EE, 1992, BIOCHEMISTRY-US, V31, P12304, DOI 10.1021/bi00164a004; KIM JS, 1993, J BIOL CHEM, V268, P17392; KIM JS, 1994, EUR J BIOCHEM, V224, P109, DOI 10.1111/j.1432-1033.1994.tb20001.x; KIM JS, 1993, PROTEIN SCI, V2, P348; KIM JS, 1995, IN PRESS BIOCH J; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KUNITZ M, 1946, J BIOL CHEM, V164, P563; LACCETTI P, 1992, CANCER RES, V52, P4582; LIBONATI M, 1976, EUR J BIOCHEM, V69, P445, DOI 10.1111/j.1432-1033.1976.tb10929.x; LIBONATI M, 1969, EUR J BIOCHEM, V8, P81, DOI 10.1111/j.1432-1033.1969.tb00498.x; MANCHENO JM, 1994, BIOCHEM BIOPH RES CO, V199, P119, DOI 10.1006/bbrc.1994.1202; MATOUSEK J, 1994, ANIM GENET, V25, P45, DOI 10.1111/j.1365-2052.1994.tb00402.x; MATOUSEK J, 1973, EXPERIENTIA, V29, P858, DOI 10.1007/BF01946329; MATOUSEK J, 1992, ANIMAL GENET S1, V23, P46; MAZZARELLA L, 1987, GAZZ CHIM ITAL, V117, P91; MURTHY BS, 1992, BIOCHEM J, V281, P343, DOI 10.1042/bj2810343; NEWTON DL, 1994, J NEUROSCI, V14, P538; PICCOLI R, 1992, P NATL ACAD SCI USA, V89, P1870, DOI 10.1073/pnas.89.5.1870; PICCOLI R, 1988, BIOCHEM J, V253, P329, DOI 10.1042/bj2530329; PICCOLI R, 1993, RIBONUCLEASES CHEM B; PICCOLI R, 1983, J BIOL CHEM, V259, P693; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V26, P502, DOI 10.1016/0006-3002(57)90096-3; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; SMITH GK, 1978, BIOCHEMISTRY-US, V17, P2633, DOI 10.1021/bi00606a027; SOUCEK J, 1983, FOLIA BIOL-PRAGUE, V29, P250; SOUCEK J, 1986, NAT IMMUN CELL GROW, V5, P250; SOUCEK J, 1993, RIBONUCLEASES CHEM B; SUZUKI H, 1987, BIOL CHEM H-S, V368, P1305, DOI 10.1515/bchm3.1987.368.2.1305; TAMBURRINI M, 1989, J PROTEIN CHEM, V8, P719, DOI 10.1007/BF01024897; TAMBURRINI M, 1990, EUR J BIOCHEM, V190, P145, DOI 10.1111/j.1432-1033.1990.tb15557.x; VESCIA S, 1980, CANCER RES, V40, P3740; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; YOULE RJ, 1993, CRIT REV THER DRUG, V10, P1	52	81	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10525	10530		10.1074/jbc.270.18.10525	http://dx.doi.org/10.1074/jbc.270.18.10525			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737987	hybrid			2022-12-25	WOS:A1995QW60100027
J	OLSON, ST; STEPHENS, AW; HIRS, CHW; BOCK, PE; BJORK, I				OLSON, ST; STEPHENS, AW; HIRS, CHW; BOCK, PE; BJORK, I			KINETIC CHARACTERIZATION OF THE PROTEINASE BINDING DEFECT IN A REACTIVE-SITE VARIANT OF THE SERPIN, ANTITHROMBIN - ROLE OF THE P1' RESIDUE IN TRANSITION-STATE STABILIZATION OF ANTITHROMBIN-PROTEINASE COMPLEX-FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTION; CATALYZED PROTEASE INACTIVATION; FACTOR-XA; ALPHA-THROMBIN; ANTI-THROMBIN; BOND LOOP; HEPARIN ACCELERATION; SUBSTRATE PROPERTIES; TARGET PROTEINASES; TRANSIENT KINETICS	To elucidate the role of the P1' residue of the serpin, antithrombin (AT), in proteinase inhibition, the source of the functional defect in a natural Ser-394 --> Leu variant, AT-Denver, was investigated. AT-Denver inhibited thrombin, Factor Ma, plasmin, and Factor Xa with second order rate constants that were 430-, 120-, 40-, and 7-fold slower, respectively, than those of native AT, consistent with an altered specificity of the variant inhibitor for its target proteinases. AT-Denver inhibited thrombin and Factor Xa with nearly equimolar stoichiometries and formed SDS-stable complexes with these proteinases, indicating that the diminished inhibitor activity was not due to an enhanced turnover of the inhibitor as a substrate, Binding and kinetic studies showed that heparin binding to AT-Denver as well as heparin accelerations of AT-Denver-proteinase reactions were normal, consistent with the P1' mutation not affecting the heparin activation mechanism. Resolution of the two-step reaction of AT-Denver with thrombin revealed that the majority of the defective function was localized in the second reaction step and resulted from a 190-fold decreased rate constant for conversion of a noncovalent proteinase-inhibitor encounter complex to a stable, covalent complex, Little or no effects of the mutation on the binding constant for encounter complex formation or on the rate constant for stable complex dissociation were evident, These results support a role for the P1' residue of antithrombin in transition-state stabilization of a substrate-like attack of the proteinase on the inhibitor-reactive bond following the formation of a proteinase-inhibitor encounter complex but prior to the conformational change leading to the trapping of proteinase in a stable, covalent complex. Such a role indicates that the P1' residue does not contribute to thermodynamic stabilization of AT-proteinase complexes and instead favors a kinetic stabilization of these complexes by a suicide substrate reaction mechanism.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; VANDERBILT UNIV,DEPT PATHOL,NASHVILLE,TN 37232; SWEDISH UNIV AGR SCI,DEPT VET MED CHEM,S-75123 UPPSALA,SWEDEN	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Vanderbilt University; Swedish University of Agricultural Sciences	OLSON, ST (corresponding author), UNIV ILLINOIS,CTR MOLEC BIOL ORAL DIS,RM 530E,DENT M-C 860,801 S PAULINA ST,CHICAGO,IL 60612, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039888, R37HL039888, R29HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-02832, HL-39888] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSTIN RC, 1991, BLOOD, V77, P2185; BARLOW GH, 1969, J BIOL CHEM, V244, P1138; BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1982, J BIOL CHEM, V257, P2406; BJORK I, 1992, J BIOL CHEM, V267, P19047; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; BJORK I, 1981, FEBS LETT, V126, P257, DOI 10.1016/0014-5793(81)80255-4; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, EUR J BIOCHEM, V204, P423; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CASO R, 1991, BRIT J HAEMATOL, V77, P87, DOI 10.1111/j.1365-2141.1991.tb07953.x; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DANIELSSON A, 1983, BIOCHEM J, V213, P345, DOI 10.1042/bj2130345; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; EMPIE MW, 1982, BIOCHEMISTRY-US, V21, P2274, DOI 10.1021/bi00539a002; ENGH RA, 1990, PROTEIN ENG, V3, P469, DOI 10.1093/protein/3.6.469; ERDJUMENT H, 1989, THROMB RES, V54, P613, DOI 10.1016/0049-3848(89)90127-8; ERDJUMENT H, 1988, J BIOL CHEM, V263, P5589; ERDJUMENT H, 1988, THROMB HAEMOSTASIS, V60, P471; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FISH WW, 1979, EUR J BIOCHEM, V101, P31, DOI 10.1111/j.1432-1033.1979.tb04212.x; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; JESTY J, 1979, J BIOL CHEM, V254, P44; JORDAN RE, 1980, J BIOL CHEM, V255, P81; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DA, 1989, BRIT J HAEMATOL, V71, P91, DOI 10.1111/j.1365-2141.1989.tb06280.x; LANE DA, 1989, J BIOL CHEM, V264, P10200; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; OWEN MC, 1988, FEBS LETT, V231, P317, DOI 10.1016/0014-5793(88)80841-X; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; READ RJ, 1986, PROTEINASE INHIBITOR, P301; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SAMBRANO JE, 1986, J CLIN INVEST, V77, P887, DOI 10.1172/JCI112386; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEPHENS AW, 1988, J BIOL CHEM, V263, P15849; STEPHENS AW, 1987, J BIOL CHEM, V262, P1044; THEUNISSEN HJM, 1993, J BIOL CHEM, V268, P9035	56	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9717	9724		10.1074/jbc.270.17.9717	http://dx.doi.org/10.1074/jbc.270.17.9717			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730349	hybrid			2022-12-25	WOS:A1995QV41700007
J	MALABARBA, MG; KIRKEN, RA; RUI, H; KOETTNITZ, K; KAWAMURA, M; OSHEA, JJ; KALTHOFF, FS; FARRAR, WL				MALABARBA, MG; KIRKEN, RA; RUI, H; KOETTNITZ, K; KAWAMURA, M; OSHEA, JJ; KALTHOFF, FS; FARRAR, WL			ACTIVATION OF JAR3, BUT NOT JAK1, IS CRITICAL TO INTERLEUKIN-4 (IL4) STIMULATED PROLIFERATION AND REQUIRES A MEMBRANE-PROXIMAL REGION OF IL4 RECEPTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SIGNAL-TRANSDUCTION; NATURAL-KILLER-CELLS; TYROSINE KINASE; FUNCTIONAL COMPONENT; CHAIN; IL-2; LINE; IDENTIFICATION	The tyrosine kinases JAK1 and JARS have been shown to undergo tyrosine phosphorylation in response to interleukin-2 (IL), IL4, IL7, and IL9, cytokines which share the common IL2 receptor gamma-chain (IL2R gamma), and evidence has been found for a preferential coupling of JAK3 to IL2R gamma and JAK1 to IL2R beta. Here we show, using human premyeloid TF-1 cells, that IL4 stimulates JAK3 to a larger extent than JAK1, based upon three different evaluation criteria. These include a more vigorous tyrosine phosphorylation of JAK3 as measured by anti-phosphotyrosine immunoblotting, a more marked activation of JAK3 as determined by in vitro tyrosine kinase assays and a more manifest presence of JAK3 in activated IL4-receptor complexes. These observations suggest that IL4 receptor signal transduction does not depend on equimolar heterodimerization of JAK1 and JAK3 following IL4-induced heterodimerization of IL4R alpha and IL2R gamma. Indeed, when human IL4R alpha was stably expressed in mouse BA/F3 cells, robust IL4-induced proliferation and JAK3 activation occurred without detectable involvement of JAK1, JAK2, or TYK2. The present study suggests that JAK1 plays a subordinate role in IL4 receptor signaling, and that in certain cells exclusive JARS activation may mediate IL4-induced cell growth. Moreover, mutational analysis of human IL4R alpha showed that a membrane-proximal cytoplasmic region was critical for JARS activation, while the I4R motif was not, which is compatible with a role of JARS upstream of the recruitment of the insulin receptor substrate-1/4PS signaling proteins by IL4 receptors.	NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702; SANDOZ GMBH,RES INST,A-1235 VIENNA,AUSTRIA; NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,EXPTL IMMUNOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Novartis; Sandoz; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	MALABARBA, MG (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702, USA.		Malabarba, Maria Grazia/L-4805-2015	Malabarba, Maria Grazia/0000-0002-9457-2047	FIC NIH HHS [5FO5 TWO4300-02] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004300] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ASAO H, 1994, FEBS LETT, V351, P201, DOI 10.1016/0014-5793(94)00831-0; DASILVA L, 1994, J BIOL CHEM, V269, P18267; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HAN X, 1988, LYMPHOKINE RES, V141, P227; HARADA N, 1992, J BIOL CHEM, V267, P22752; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KARRAY S, 1988, J EXP MED, V168, P85, DOI 10.1084/jem.168.1.85; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KIRKEN RA, 1993, J BIOL CHEM, V268, P22765; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; KITAMURA T, 1991, INT IMMUNOL, V3, P571, DOI 10.1093/intimm/3.6.571; KOETTNITZ K, 1993, EUR J IMMUNOL, V23, P988, DOI 10.1002/eji.1830230437; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NAGLER A, 1988, J IMMUNOL, V141, P2349; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PAUL WE, 1991, BLOOD, V77, P1859; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SELDIN DC, 1994, P NATL ACAD SCI USA, V91, P2140, DOI 10.1073/pnas.91.6.2140; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TORIGOE T, 1992, CYTOKINE, V4, P369, DOI 10.1016/1043-4666(92)90080-B; VOSS SD, 1992, J EXP MED, V176, P531, DOI 10.1084/jem.176.2.531; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	37	59	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9630	9637		10.1074/jbc.270.16.9630	http://dx.doi.org/10.1074/jbc.270.16.9630			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721895	hybrid			2022-12-25	WOS:A1995QU08900084
J	MARCILLA, A; RIVEROLEZCANO, OM; AGARWAL, A; ROBBINS, KC				MARCILLA, A; RIVEROLEZCANO, OM; AGARWAL, A; ROBBINS, KC			IDENTIFICATION OF THE MAJOR TYROSINE KINASE SUBSTRATE IN SIGNALING COMPLEXES FORMED AFTER ENGAGEMENT OF FC-GAMMA RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION; PROTEIN; CELLS; P72(SYK); ONCOGENE; CBL	We have recently identified the protein product of the c-cbl proto oncogene as an SH3 binding protein expressed in macrophages. To investigate the possibility that p120(c-cbl) is involved in signaling pathways initiated by cell surface receptors for IgG (Fc gamma R), lysates of HL60 cells were examined for tyrosine phosphorylation of p120(c-cbl) upon Fc gamma R engagement. Our findings demonstrate that p120(c-cbl) is tyrosine-phosphorylated upon Fc gamma R engagement and that this molecule represents the major tyrosine kinase substrate in this signaling pathway. Protein complexes containing p120(c-cbl), p72(syk), and p56(lyn) were observed either in resting or activated cells. In vitro studies showed that the direct association between p120(c-cbl) and p56(lyn) was mediated by the SH3 domain of p56(lyn).	NIDR, CELLULAR DEV & ONCOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Rivero-Lezcano, Octavio Miguel/J-9089-2015; marcilla, antonio/F-9996-2010	Rivero-Lezcano, Octavio Miguel/0000-0002-8793-0731; marcilla, antonio/0000-0003-0004-0531				AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EISEMAN E, 1992, NATURE, V355, P78; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KIHARA H, 1994, J BIOL CHEM, V269, P22427; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RIVEROLEZCANO OM, 1994, FEBS LETT, V338, P183, DOI 10.1016/0014-5793(94)80361-7; SONGYANG Z, CELL, V72, P767; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	23	129	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9115	9120		10.1074/jbc.270.16.9115	http://dx.doi.org/10.1074/jbc.270.16.9115			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721825	hybrid			2022-12-25	WOS:A1995QU08900013
J	METZGER, D; ALI, S; BORNERT, JM; CHAMBON, P				METZGER, D; ALI, S; BORNERT, JM; CHAMBON, P			CHARACTERIZATION OF THE AMINO-TERMINAL TRANSCRIPTIONAL ACTIVATION FUNCTION OF THE HUMAN ESTROGEN-RECEPTOR IN ANIMAL AND YEAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; MAMMALIAN-CELLS; GENE-EXPRESSION; GLUCOCORTICOID RECEPTORS; TRANS-ACTIVATOR; DOMAINS; GAL4; REGION; TRANSACTIVATION; DROSOPHILA	We have previously reported that the transcriptional activation function AF-1, located in the A/B region of the human estrogen receptor, exhibits cell type and promoter context specificity in both animal cells and yeast. To further characterize AF-1, we have constructed a number of deletion mutants spanning the A/B region in the context of either the whole human estrogen receptor or the A/B region linked to the GAL4 DNA binding do main, and tested their transcriptional activity in chicken embryo fibroblasts and in yeast cells, two cell types in which AF-1 efficiently activates transcription on its own. Additionally, we utilized HeLa cells in which AF-1 is poorly active but can synergize with the transcriptional activation function AF-2 located in the hormone binding domain. We show that in animal cells the ''independent'' activity of AF-1 is embodied in a rather hydrophobic proline-rich 99-amino acid activating domain (amino acids 51-149), whereas amino acids 51-93 and 102-149 can independently synergize with AF-2. Interestingly, in yeast, three discrete activating domains (amino acids 1-62, 80-113, and 118-149) are almost as active on their own as the whole A/B region, indicating that multiple activating domains can operate independently in yeast. Our study also demonstrates that, within the context of the whole human estrogen receptor, the same AF-1 activating domains are ''induced'' by either estradiol or 4-hydroxytamoxifen.	UNIV STRASBOURG 1, COLL FRANCE,INST GENET & BIOL MOLEC & CELLULAIRE, CNRS,INSERM, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			; Ali, Simak/M-6912-2018	Coombes, Raoul Charles/0000-0002-4811-1100; Metzger, Daniel/0000-0002-5555-046X; Ali, Simak/0000-0002-1320-0816				ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; Carey M, 1991, CURR OPIN CELL BIOL, V3, P452, DOI 10.1016/0955-0674(91)90073-8; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FISHER JA, 1988, NATURE, V332, P853; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GILL G, 1990, P NATL ACAD SCI USA, V87, P2127, DOI 10.1073/pnas.87.6.2127; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GILL G, 1987, CELL, V51, P12; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HAM J, 1992, FEBS LETT, V307, P81, DOI 10.1016/0014-5793(92)80906-W; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Kastner P., 1994, Vitamin A in health and disease., P189; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEES JA, 1989, J STEROID BIOCHEM, V34, P33, DOI 10.1016/0022-4731(89)90063-0; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; MA J, 1988, NATURE, V334, P631, DOI 10.1038/334631a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Mangelsdorf David J., 1994, P319; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MEYER ME, 1992, J BIOL CHEM, V267, P10882; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PHAM TA, 1992, MOL ENDOCRINOL, V6, P1043, DOI 10.1210/me.6.7.1043; PONGLIKITMONGKOL M, 1988, EMBO J, V7, P3385, DOI 10.1002/j.1460-2075.1988.tb03211.x; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SEGRAVES WA, 1991, CELL, V67, P225, DOI 10.1016/0092-8674(91)90172-U; SEIPEL K, 1994, BIOL CHEM H-S, V375, P463, DOI 10.1515/bchm3.1994.375.7.463; SENTENAC A, 1990, ANNU REV BIOCHEM, V459, P711; SILVER PA, 1988, GENE DEV, V2, P707, DOI 10.1101/gad.2.6.707; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WHITE JH, 1988, COLD SPRING HARB SYM, V53, P819, DOI 10.1101/SQB.1988.053.01.093; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	77	203	203	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9535	9542		10.1074/jbc.270.16.9535	http://dx.doi.org/10.1074/jbc.270.16.9535			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721882	hybrid			2022-12-25	WOS:A1995QU08900071
J	ZOLKIEWSKA, A; MOSS, J				ZOLKIEWSKA, A; MOSS, J			PROCESSING OF ADP-RIBOSYLATED INTEGRIN ALPHA-7 IN SKELETAL-MUSCLE MYOTUBES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; PROTEINS; GLYCOHYDROLASE; RECEPTOR; SURFACE; ANCHOR	Integrin alpha 7 is a major substrate in skeletal muscle cells for the cell surface, glycosylphosphatidylinositol-anchored, arginine-specific ADP-ribosyltransferase. Since ADP-ribosylarginine hydrolase, the enzyme responsible for cleavage of the ADP-ribosylarginine bond and a component with the transferase of a putative ADP-ribosylation cycle, is cytosolic, the processing of ADP-ribosylated integrin alpha 7 was investigated. Following incubation of differentiated mouse C2C12 myoblasts with [adenylate-P-32]NAD and analysis by SDS-polyacrylamide gel electrophoresis under reducing conditions, two [P-32]ADP-ribosylated forms of integrin alpha 7 were resolved, By pulse chase and purification of the radio labeled proteins on a laminin affinity column, it was demonstrated that a 105-kDa ADP-ribosylated form originated from a mono ADP-ribosylated 102-kDa form and represented integrin alpha 7 modified at more than one site, The additional site(s) of modification, utilized at higher NAD concentrations, were located in the 63-kDa N-terminal segment of integrin alpha 7. Both [P-32]ADP-ribosylated integrins were loosely associated with the cytoskeleton, bound to laminin affinity columns, and immunoprecipitated with antibodies to integrin beta 1. P-32 label was rapidly removed from [P-32]ADP-ribosylated integrin alpha 7 at either site of modification, a process inhibited by free ADP-ribose or p-nitrophenylthymidine-5'-monophosphate, an alternative substrate of 5'-nucleotide phosphodiesterase. The processed integrin alpha 7 was unavailable for subsequent ADP-ribosylation, although the amount of surface integrin alpha 7 remained constant, During the processing, no loss of label was observed from integrin alpha 7 radiolabeled with [C-14]NAD, containing C-14 in the nicotinamide proximal ribose, consistent with degradation of the ADP-ribose moiety by a cell surface 5'-nucleotide phosphodiesterase, Thus, cell surface ADP-ribosylation, in contrast to intracellular ADP-ribosylation, is not readily reversed by ADP-ribosylarginine hydrolase and seems to operate outside the postulated ADP-ribosylation cycle.			ZOLKIEWSKA, A (corresponding author), NHLBI,PULM CRIT CARE MED BRANCH,BLDG 10,RM 5N307,10 CTR RD,MSC 1434,BETHESDA,MD 20892, USA.							COLLO G, 1993, J BIOL CHEM, V268, P19019; FUKZAWA H, 1989, BIOCHIM BIOPHYS ACTA, V991, P272; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO R, 1994, CANCER METAST REV, V13, P25, DOI 10.1007/BF00690416; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KONTANI K, 1993, J BIOL CHEM, V268, P16895; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; MOSS J, 1992, J BIOL CHEM, V267, P10481; MULLER HM, 1983, BIOCHEM J, V212, P459, DOI 10.1042/bj2120459; NAKABAYASHI T, 1993, J BIOCHEM-TOKYO, V99, P703; OKAZAKI IJ, 1994, BIOCHEMISTRY-US, V33, P12828, DOI 10.1021/bi00209a014; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROMANO C, 1987, J NEUROSCI, V7, P1300; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SJAASTAD MD, 1994, P NATL ACAD SCI USA, V91, P8214, DOI 10.1073/pnas.91.17.8214; SONG WK, 1993, J CELL SCI, V106, P1139; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; VANDERMARK H, 1991, J BIOL CHEM, V266, P23593; WILLIAMSON KC, 1990, ADP RIBOSYLATING TOX, P151; ZIOBER BL, 1993, J BIOL CHEM, V268, P26773; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273; ZOLKIEWSKA A, 1994, P NATL ACAD SCI USA, V138, P107	29	56	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9227	9233		10.1074/jbc.270.16.9227	http://dx.doi.org/10.1074/jbc.270.16.9227			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721841	hybrid			2022-12-25	WOS:A1995QU08900029
J	VOLCHUK, A; SARGEANT, R; SUMITANI, S; LIU, Z; HE, LJ; KLIP, A				VOLCHUK, A; SARGEANT, R; SUMITANI, S; LIU, Z; HE, LJ; KLIP, A			CELLUBREVIN IS A RESIDENT PROTEIN OF INSULIN-SENSITIVE GLUT4 GLUCOSE-TRANSPORTER VESICLES IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; PLASMA-MEMBRANE; SUBCELLULAR TRAFFICKING; TETANUS-TOXIN; VAMP FAMILY; COMPARTMENTS; EXPRESSION; TRANSLOCATION; LOCALIZATION; RECEPTORS	Insulin stimulates glucose transport in muscle and fat cells by inducing translocation of GLUT4 glucose transporters from a storage site to the cell surface. The mechanism of this translocation and the identity of the storage site are unknown, but it has been hypothesized that transporters recycle between an insulin-sensitive pool, endosomes, and the cell surface. Upon cell homogenization and fractionation, the storage site migrates with Light microsomes (LDM) separate from the plasma membrane fraction (PM). Cellubrevin is a recently identified endosomal protein that may be involved in the reexocytosis of recycling endosomes. Here we describe that cellubrevin is expressed in 3T3-L1 adipocytes and is more abundant in the LDM than in the PM. Cellubrevin was markedly induced during differentiation of 3T3-L1 fibroblasts into adipocytes, in parallel with GLUT4, and the development of insulin regulated traffic. In response to insulin, the cellubrevin content decreased in the LDM and increased in the PM, suggesting translocation akin to that of the GLUT4 glucose transporter. Vesicle-associated membrane protein 2 (VAMP-2)/synaptobrevin-II, a protein associated with regulated exocytosis in secretory cells, also redistributed in response to insulin. Both cellubrevin and VAMP-2 were susceptible to cleavage by tetanus toxin. Immunopurified GLUT4-containing vesicles contained cellubrevin and VAMP-2, and immunopurified cellubrevin-containing vesicles contained GLUT4 protein, but undiscernible amounts of VAMP-2. These observations suggest that cellubrevin and VAMP-2 are constituents of the insulin-regulated pathway of membrane traffic. These results are the first demonstration that cellubrevin is present in a regulated intracellular compartment. We hypothesize that cellubrevin and VAMP-2 may be present in different subsets of GLUT4-containing vesicles.	HOSP SICK CHILDREN, DIV CELL BIOL, TORONTO, ON M5G 1X8, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BRAND SH, 1991, J BIOL CHEM, V266, P18949; BRAUN JEA, 1994, J BIOL CHEM, V269, P5328; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CHAKRABARTI R, 1994, J BIOL CHEM, V269, P7926; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; CORVERA S, 1989, J BIOL CHEM, V264, P10133; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1993, J BIOL CHEM, V268, P9187; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GAISANO HY, 1994, J BIOL CHEM, V269, P19110; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; HANEY PM, 1991, J CELL BIOL, V114, P689, DOI 10.1083/jcb.114.4.689; HUDSON AW, 1993, J CELL BIOL, V122, P579, DOI 10.1083/jcb.122.3.579; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; LIENHARD GE, 1989, INT CONGR SER, V866, P313; MARTIN S, 1994, BIOCHEM J, V300, P743, DOI 10.1042/bj3000743; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; NISHIMURA H, 1993, J BIOL CHEM, V268, P19246; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; SATOH S, 1993, J BIOL CHEM, V268, P17820; SHIBASAKI Y, 1992, BIOCHEM J, V281, P829, DOI 10.1042/bj2810829; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; TANNER LI, 1987, J BIOL CHEM, V262, P8975; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; TRIMBLE WS, 1993, J PHYSIOLOGY-PARIS, V87, P107, DOI 10.1016/0928-4257(93)90004-D; VOLCHUK A, 1994, BIOCHEM J, V304, P139, DOI 10.1042/bj3040139; WELLER U, 1989, EUR J BIOCHEM, V182, P649, DOI 10.1111/j.1432-1033.1989.tb14874.x; YANG J, 1993, J BIOL CHEM, V268, P4600; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	47	125	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8233	8240		10.1074/jbc.270.14.8233	http://dx.doi.org/10.1074/jbc.270.14.8233			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713930	hybrid			2022-12-25	WOS:A1995QR52600069
J	HART, AH; CORRICK, CM; TYMMS, MJ; HERTZOG, PJ; KOLA, I				HART, AH; CORRICK, CM; TYMMS, MJ; HERTZOG, PJ; KOLA, I			HUMAN ERG IS A PROTOONCOGENE WITH MITOGENIC AND TRANSFORMING ACTIVITY	ONCOGENE			English	Article						ETS; TRANSCRIPTION FACTORS; TUMOR; CHROMOSOME 21; CHROMOSOME TRANSLOCATION	ETS-RELATED GENE; DNA-BINDING; TRANSCRIPTION FACTOR; LEUKEMIA-VIRUS; DOWN-SYNDROME; C-ETS-1 PROTOONCOGENE; FLI-1 GENE; FAMILY; EXPRESSION; SEQUENCE	The ETS related gene, ERG, is one of 20 or more genes belonging to the ETS family of transcription factors, Translocation of the ERG gene t(21;22) results in the chimeric fusion transcript seen in approximately 10% of Ewings sarcomas, In addition, recent studies have shown that a reciprocal translocation t(21;16) of ERG gives rise to two aberrant transcripts seen in some forms of acute myeloid leukaemia. ln vitro studies have linked the up regulation of ERG expression with stromal cell independence in erythroleukemic clones and shown that the ERG related genes ETS1 and ETS2 have mitogenic and transforming activity when overexpressed in NIH3T3 cells, Interestingly ERGB/FLI-1, which is also involved in Ewings sarcoma translocations and shares a very high sequence identity with ERG has been reported to be unable to transform NIH3T3 cells, In this study we investigate the effects of overexpression of ERG on cell proliferation, factor dependence, growth in soft agar and tumorigenesis in nude mice, An ERG expression construct with the human ERG2 cDNA driven by the sheep metallothionein la promoter (sMTERG) was transfected into NIH3T3 cells. Clonal cell lines overexpressing ERG were established. The cell lines became morphologically altered, grew in low serum and serum free media and gave rise to colonies in soft agar suspension. Furthermore, we demonstrate that after subcutaneous injection these clones grow as solid tumors in nude mice, These data demonstrate that c-ERG is a proto-oncogene capable of transforming NM3T3 cells. Therefore, overexpression or inappropriate expression of ERG may contribute to oncogenesis.	MONASH UNIV, MONASH MED CTR, INST REPROD & DEV, MOLEC EMBRYOL & BIRTH DEFECTS LAB, CLAYTON, VIC 3168, AUSTRALIA	Monash University			Hart, Adam/C-1196-2011; Kola, Ismail/C-5254-2013; Hertzog, Paul/I-7053-2013	Hart, Adam/0000-0001-8129-3877; Hertzog, Paul/0000-0002-1373-8472				ASCIONE R, 1992, INT J ONCOL, V1, P631; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; CHEN ZQ, 1990, SCIENCE, V250, P1416, DOI 10.1126/science.2255913; DEHAAN JB, 1992, MOL BRAIN RES, V13, P179, DOI 10.1016/0169-328X(92)90025-7; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; ISELIUS L, 1990, HUM GENET, V85, P477; JOHNS TG, 1992, J NATL CANCER I, V84, P1185, DOI 10.1093/jnci/84.15.1185; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KOLA I, 1989, REPROD FERT DEVELOP, V1, P81, DOI 10.1071/RD9890081; KORENBERG JR, 1990, AM J HUM GENET, V47, P236; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1993, J VIROL, V67, P610, DOI 10.1128/JVI.67.1.610-612.1993; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LOVELAND BE, 1992, BIOCHEM INT, V27, P501; Maniatis T., 1982, MOL CLONING; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MURAKAMI K, 1993, ONCOGENE, V8, P1559; NIBBS RJB, 1993, MOL CELL BIOL, V13, P5582, DOI 10.1128/MCB.13.9.5582; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OHNO T, 1993, CANCER RES, V53, P5859; PETERSON MG, 1986, EUR J BIOCHEM, V160, P579, DOI 10.1111/j.1432-1033.1986.tb10077.x; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRIBYL LJ, 1991, ONCOGENE, V56, P1175; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; ROBISON LL, 1992, LEUKEMIA, V6, P5; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TOPOL LZ, 1992, CANCER LETT, V67, P71, DOI 10.1016/0304-3835(92)90010-S; TYMMS M, 1995, IN VITRO TRANSCRIPTI, P31; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERNERT N, 1992, AM J PATHOL, V140, P119; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	58	50	55	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1423	1430						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731694				2022-12-25	WOS:A1995QR65100021
J	PILZ, RB; SUHASINI, M; IDRISS, S; MEINKOTH, JL; BOSS, GR				PILZ, RB; SUHASINI, M; IDRISS, S; MEINKOTH, JL; BOSS, GR			NITRIC-OXIDE AND CGMP ANALOGS ACTIVATE TRANSCRIPTION FROM AP-1-RESPONSIVE PROMOTERS IN MAMMALIAN-CELLS	FASEB JOURNAL			English	Article						GENE TRANSCRIPTION; CELL BIOLOGY; SIGNAL TRANSDUCTION PATHWAY; TRANSFECTED CELL LINES	C-JUN; PROTEIN-KINASE; FOS; GENE; SEQUENCES; CALCIUM	Nitric oxide (NO) increases cytosolic guanylate cyclase activity and thereby activates the cGMP signal transduction pathway, The cAMP and Ca2+-phospholipid signal transduction pathways activate transcription factors that bind to the cAMP response element (CRE) and phorbol ester response element (TRE), respectively, Little is known about transcriptional regulation of gene expression by NO/cGMP, In transient and stable transfection experiments and in microinjection studies we found that three different NO-releasing agents and two membrane-permeable cGMP analogs activated TRE-regulated but not CRE-regulated reporter genes in rodent fibroblast and epithelial cell lines, Activation of TRE regulated genes by NO-releasing agents and cGMP analogs appeared to be mediated by the AP-1 (Jun/Fos) transcription factor complex because we observed increased DNA binding of AP-1 and increased junB and c-fos mRNA in cells treated with these agents, The mechanism of gene activation by NO/cGMP was distinct from that used by phorbol esters and cAMP because it was not associated with c-jun mRNA induction and was not observed with CRE-containing promoters.	UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego			Meinkoth, Judy L/G-2900-2010	Boss, Gerry/0000-0002-9758-8714	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049360] Funding Source: NIH RePORTER; NCI NIH HHS [CA01538] Funding Source: Medline; NIDDK NIH HHS [DK45696] Funding Source: Medline; NIGMS NIH HHS [GM49360] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BOSS GR, 1989, P NATL ACAD SCI USA, V86, P7174, DOI 10.1073/pnas.86.18.7174; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; CORBIN JD, 1990, ADV SEC MESS PHOSPH, V24, P411; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; GARG UC, 1991, J BIOL CHEM, V266, P9; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; HABY C, 1994, J NEUROCHEM, V62, P496; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HOUSE C, 1987, J BIOL CHEM, V262, P772; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; MARGRINAT G, 1992, BLOOD, V88, P1880; MATHEWS WR, 1993, J PHARMACOL EXP THER, V267, P1529; MEINKOTH J, 1990, CIBA F SYMP, V150, P47; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PILZ RB, 1992, J BIOL CHEM, V267, P16161; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Scholtholt J, 1985, CLIN PHARM ANTIANGIN, P365; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TAKASHIBA S, 1993, GENE, V131, P307, DOI 10.1016/0378-1119(93)90314-S	33	177	178	2	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1995	9	7					552	558		10.1096/fasebj.9.7.7737465	http://dx.doi.org/10.1096/fasebj.9.7.7737465			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX148	7737465				2022-12-25	WOS:A1995QX14800014
J	PRASAD, KSS; JORDAN, JE; KOURY, MJ; BONDURANT, MC; BRANDT, SJ				PRASAD, KSS; JORDAN, JE; KOURY, MJ; BONDURANT, MC; BRANDT, SJ			ERYTHROPOIETIN STIMULATES TRANSCRIPTION OF THE TAL1/SCL GENE AND PHOSPHORYLATION OF ITS PROTEIN PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; T-CELL LEUKEMIA; ERYTHROID PROGENITOR CELLS; DNA-BINDING; ENHANCER-BINDING; MESSENGER-RNA; TAL-1 GENE; SCL GENE; EXPRESSION; MYOD	Activation of the TAL1 (or SCL) gene, originally identified through its involvement by a recurrent chromosomal translocation, is the most frequent molecular lesion recognized in T-cell acute lymphoblastic leukemia. The protein products of this gene contain the basic-helix-loop-helix motif characteristic of a large family of transcription factors that bind to the canonical DNA sequence CANNTG as protein heterodimers. TAL1 expression by erythroid cells in vivo and in chemical-induced erythroleukemia cell lines in vitro suggested the gene might regulate aspects of erythroid differentiation. Since the terminal events of erythropoiesis are controlled by the glycoprotein hormone erythropoietin (Epo), we investigated whether the expression or activity of the TAL1 gene and its protein products were affected by Epo in splenic erythroblasts from mice infected with an anemia-inducing strain of Friend virus (FVA cells), Epo elicited a rapid, dose-related increase in TALI mRNA by increasing transcription of the gene and stabilizing one of its mRNAs, An Epo-inducible TAL1 DNA binding activity was identified in FVA cell nuclear extracts that subsequently decayed despite accumulating mRNA and protein. Induction of DNA binding activity was associated temporally with Epo-induced phosphorylation of nuclear TAL1 protein. These results indicate that Epo acts at both transcriptional and posttranscriptional levels on the TAL1 locus in Friend virus-induced erythroblasts and establish a link between Epo signaling mechanisms and a member of a family of transcription factors involved in the differentiation of diverse cell lineages.	VANDERBILT UNIV,MED CTR,DEPT MED,DIV HEMATOL,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT CELL BIOL,DIV HEMATOL,NASHVILLE,TN 37232; DEPT VET AFFAIRS MED CTR,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System					NHLBI NIH HHS [R29HL49118] Funding Source: Medline; NIDDK NIH HHS [R01 DK31513] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031513] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEGLEY CG, 1994, GENE, V138, P93, DOI 10.1016/0378-1119(94)90787-0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERNARD O, 1991, ONCOGENE, V6, P1477; BONDURANT MC, 1985, MOL CELL BIOL, V5, P675, DOI 10.1128/MCB.5.4.675; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHENG JT, 1993, ONCOGENE, V8, P677; CHIBA T, 1993, P NATL ACAD SCI USA, V90, P11593, DOI 10.1073/pnas.90.24.11593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS MA, 1994, ONCOGENE, V9, P3013; DANDREA AD, 1992, BIOCHIM BIOPHYS ACTA, V1114, P31, DOI 10.1016/0304-419X(92)90004-I; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELWOOD NJ, 1994, LEUKEMIA, V8, P106; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRO FE, 1993, J BIOL CHEM, V268, P5741; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FITZGERALD TJ, 1991, BLOOD, V78, P2686; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; GARRELL J, 1991, BIOESSAYS, V13, P493, DOI 10.1002/bies.950131002; GOLDFARB AN, 1994, LEUKEMIA LYMPHOMA, V12, P157, DOI 10.3109/10428199409059586; GOLDFARB AN, 1992, BLOOD, V80, P2858; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; HARLOW E, 1988, ANTIBODIES LABORATOR; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HSU HL, 1994, MOL CELL BIOL, V91, P3181; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HWANG LY, 1993, ONCOGENE, V8, P3043; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KELLEY LL, 1993, BLOOD, V82, P2340; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KOURY MJ, 1982, J CELL PHYSL, V121, P526; KOURY ST, 1989, J CELL BIOL, V109, P3005, DOI 10.1083/jcb.109.6.3005; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LECOINTE N, 1994, ONCOGENE, V9, P2623; LEONARD M, 1993, BLOOD, V82, P1071; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MOUTHON MA, 1993, BLOOD, V81, P647; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; QUINN CO, 1990, J BIOL CHEM, V265, P22342; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SPIVAK JL, 1991, BLOOD, V77, P1228; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VISVADER J, 1991, ONCOGENE, V6, P187; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WADMAN IA, 1994, ONCOGENE, V9, P3713; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WICKREMA A, 1991, BLOOD, V78, P2269, DOI 10.1182/blood.V78.9.2269.bloodjournal7892269	68	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11603	11611		10.1074/jbc.270.19.11603	http://dx.doi.org/10.1074/jbc.270.19.11603			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744799	hybrid			2022-12-25	WOS:A1995QX86500081
J	TERRY, MJ; MCDOWELL, MT; LAGARIAS, JC				TERRY, MJ; MCDOWELL, MT; LAGARIAS, JC			(3Z)-PHYTOCHROMOBILIN AND (3E)-PHYTOCHROMOBILIN ARE INTERMEDIATES IN THE BIOSYNTHESIS OF THE PHYTOCHROME CHROMOPHORE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIVERDIN-IX-ALPHA; DIMETHYL ESTER; BILE-PIGMENTS; PHYCOBILINS; EXPRESSION; FORM	Using a high performance liquid chromatography (HPLC)-based assay, we have demonstrated that isolated oat etioplasts convert the linear tetrapyrrole biliverdin IX alpha to (3E)-phytochromobilin, the proposed precursor of the chromophore of the plant photoreceptor phytochrome. In addition to (3E)-phytochromobilin, the synthesis of a second phytochromobilin was detected by its ability to functionally assemble with recombinant oat apophytochrome A. The structure of this new pigment has been determined to be the 3Z isomer of phytochromobilin by absorption and H-1 NMR spectroscopy. Like (3E)-phytochromobilin, assembly of HPLC-purified (3Z)-phytochromobilin with apophytochrome yielded a holoprotein that is spectrally indistinguishable from native oat phytochrome A. However, the postchromato-graphic conversion of (3Z)- to (3E)-phytochromobilin appears to be responsible for this result. Kinetic HPLC analyses have demonstrated that (3Z) -phytochromobilin is synthesized prior to the 3E isomer by oat etioplasts. We therefore propose that (3Z)-phytochromobilin is the immediate product of biliverdin IX alpha reduction by the enzyme phytochromobilin synthase. This implicates the presence of an isomerase that catalyzes the conversion of (3Z)- to (3E)-phytochromobilin, the immediate precursor of the phytochrome A chromophore.	UNIV CALIF DAVIS,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis			Lagarias, John Clark/L-3139-2013; Terry, Matthew/ABE-6419-2020; Terry, Matthew/B-3000-2012	Lagarias, John Clark/0000-0002-2093-0403; Terry, Matthew/0000-0001-5002-2708; Terry, Matthew/0000-0001-5002-2708				BEALE SI, 1991, J BIOL CHEM, V266, P22328; BEALE SI, 1991, J BIOL CHEM, V266, P22333; BEALE SI, 1991, J BIOL CHEM, V266, P22341; CHAPMAN DJ, 1967, J AM CHEM SOC, V89, P976; CLACK T, 1994, PLANT MOL BIOL, V25, P413, DOI 10.1007/BF00043870; COLE WJ, 1967, J AM CHEM SOC, V89, P3643, DOI 10.1021/ja00990a055; CORNEJO J, 1992, J BIOL CHEM, V267, P14790; CRESPI HL, 1967, J AM CHEM SOC, V89, P3642, DOI 10.1021/ja00990a054; CRESPI HL, 1969, PHYTOCHEMISTRY, V8, P759, DOI 10.1016/S0031-9422(00)85848-3; ELICH TD, 1989, J BIOL CHEM, V264, P183; FURUYA M, 1993, ANNU REV PLANT PHYS, V44, P617, DOI 10.1146/annurev.pp.44.060193.003153; GOSSAUER A, 1978, J AM CHEM SOC, V100, P5928, DOI 10.1021/ja00486a053; GOSSAUER A, 1983, TETRAHEDRON, V39, P1933, DOI 10.1016/S0040-4020(01)88708-1; GROSSAUER A, 1974, LIEBIGS ANN CHEM, P1496; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KUNKEL T, 1993, EUR J BIOCHEM, V215, P587, DOI 10.1111/j.1432-1033.1993.tb18069.x; LAGARIAS JC, 1980, J AM CHEM SOC, V102, P4821, DOI 10.1021/ja00534a042; LAGARIAS JC, 1987, PHOTOCHEM PHOTOBIOL, V46, P5, DOI 10.1111/j.1751-1097.1987.tb04729.x; LI L, 1982, J BIOL CHEM, V267, P19204; MCDONAGH AF, 1980, BIOCHEM J, V189, P193, DOI 10.1042/bj1890193; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; RUDIGER W, 1983, P NATL ACAD SCI-BIOL, V80, P6244, DOI 10.1073/pnas.80.20.6244; Sage LC., 1992, PIGMENT IMAGINATION; SHARROCK RA, 1989, GENE DEV, V3, P1745, DOI 10.1101/gad.3.11.1745; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TERRY MJ, 1993, J BIOL CHEM, V268, P26099; TERRY MJ, 1991, J BIOL CHEM, V266, P22215; TERRY MJ, 1993, ARCH BIOCHEM BIOPHYS, V306, P1, DOI 10.1006/abbi.1993.1473; WELLER JP, 1980, CHEM BER-RECL, V113, P1603, DOI 10.1002/cber.19801130439	29	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11111	11118		10.1074/jbc.270.19.11111	http://dx.doi.org/10.1074/jbc.270.19.11111			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744741	Green Accepted, hybrid			2022-12-25	WOS:A1995QX86500017
J	CHUN, MY; LIN, HY; HENIS, YI; LODISH, HF				CHUN, MY; LIN, HY; HENIS, YI; LODISH, HF			ENDOTHELIN-INDUCED ENDOCYTOSIS OF CELL-SURFACE ET(A) RECEPTORS - ENDOTHELIN REMAINS INTACT AND BOUND TO THE ET(A) RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; HETEROTRIMERIC G-PROTEIN; FUNCTIONAL EXPRESSION; MEDIATED ENDOCYTOSIS; EPITHELIAL-CELLS; PLASMA-MEMBRANE; CLONING; CDNA; FAMILY; DESENSITIZATION	We demonstrate unusual features of the intracellular processing of endothelin-1 (ET-1) and its receptor ET(A), the receptor subtype that mediates contraction of vascular smooth muscle cells. First, we show that in stably transfected CHO cells expressing ET(A), binding of an ET-1 ligand induces rapid endocytosis of cell surface ET(A). Receptor endocytosis was measured both by immunofluorescence and by radioiodinated antibodies specific for ET(A). Second, we demonstrate that ET-1 remains intact for up to 2 h after endocytosis and, as judged by co-immunoprecipitation, internalized I-125-ET-1 remains bound to ET(A) receptors. We hypothesize that internalized ET-1, bound to ET(A) receptors, continues to activate a signal-transducing G protein, thus accounting for the prolonged period of contraction induced in smooth muscle cells by a single administration of ET-1.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT BIOCHEM, IL-69978 TEL AVIV, ISRAEL	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Tel Aviv University				Henis, Yoav/0000-0002-1408-3877	NHLBI NIH HHS [HL-41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ASCOLI M, 1978, J BIOL CHEM, V253, P4892; BATTISTINI B, 1993, LAB INVEST, V68, P600; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BRIDGES K, 1982, P NATL ACAD SCI-BIOL, V79, P350, DOI 10.1073/pnas.79.2.350; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DAVENPORT AP, 1989, J CARDIOVASC PHARM, V13, pS166, DOI 10.1097/00005344-198900135-00045; DEALMEIDA JB, 1994, J CELL SCI, V107, P507; DEGOUVILLE ACL, 1989, LIFE SCI, V45, P1499, DOI 10.1016/0024-3205(89)90415-3; FEHLMANN M, 1982, P NATL ACAD SCI-BIOL, V79, P5921, DOI 10.1073/pnas.79.19.5921; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; GRIENDLING KK, 1989, J BIOL CHEM, V264, P8237; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; HUGGINS JP, 1993, PHARMACOL THERAPEUT, V59, P55, DOI 10.1016/0163-7258(93)90041-B; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; INOUE Y, 1990, J PHYSIOL-LONDON, V423, P171, DOI 10.1113/jphysiol.1990.sp018017; JAMES AF, 1994, NATURE, V370, P297, DOI 10.1038/370297a0; KARNE S, 1993, J BIOL CHEM, V268, P19126; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; KLOOG Y, 1989, FEBS LETT, V253, P199, DOI 10.1016/0014-5793(89)80958-5; LEFKOWITZ RJ, 1993, ADV SEC MESS PHOSPH, V28, P1; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MARSDEN PA, 1989, BIOCHEM BIOPH RES CO, V158, P86, DOI 10.1016/S0006-291X(89)80180-9; MASUDA Y, 1989, FEBS LETT, V257, P208, DOI 10.1016/0014-5793(89)81535-2; MELLMAN I, 1992, J EXP BIOL, V172, P39; MORELAND S, 1992, BIOCHEM BIOPH RES CO, V184, P100, DOI 10.1016/0006-291X(92)91163-K; NAKAMUTA M, 1991, BIOCHEM BIOPH RES CO, V177, P34, DOI 10.1016/0006-291X(91)91944-8; OGAWA Y, 1991, BIOCHEM BIOPH RES CO, V178, P248, DOI 10.1016/0006-291X(91)91806-N; ONO K, 1994, NATURE, V370, P301, DOI 10.1038/370301a0; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; RESINK TJ, 1989, BIOCHEM BIOPH RES CO, V158, P279, DOI 10.1016/S0006-291X(89)80209-8; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STOW JL, 1993, J CELL SCI, P33; SUMNER MJ, 1992, BRIT J PHARMACOL, V107, P858, DOI 10.1111/j.1476-5381.1992.tb14537.x; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; TSAI JS, 1981, BIOCHIM BIOPHYS ACTA, V673, P259, DOI 10.1016/0304-4165(81)90334-2; VAN LF, 1980, CELL, V20, P37; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	57	94	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10855	10860		10.1074/jbc.270.18.10855	http://dx.doi.org/10.1074/jbc.270.18.10855			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738024	hybrid			2022-12-25	WOS:A1995QW60100072
J	SHEARS, SB; ALI, N; CRAXTON, A; BEMBENEK, ME				SHEARS, SB; ALI, N; CRAXTON, A; BEMBENEK, ME			SYNTHESIS AND METABOLISM OF BIS-DIPHOSPHOINOSITOL TETRAKISPHOSPHATE IN-VITRO AND IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; 3-PHOSPHATASE; PURIFICATION; TURNOVER	The pathway of synthesis and metabolism of bis-diphosphoinositol tetrakisphosphate (PP-InsP(4)-PP) was elucidated by high performance liquid chromatography using newly available H-3- and P-32-labeled substrates. Metabolites were also identified by using two purified phosphatases in a structurally diagnostic manner: tobacco ''pyrophosphatase'' (Shinshi, Ii,, Miwa, M., Kato, K., Noguchi, M. Matsushima, T., and Sugimura, T. (1976) Biochemistry 15, 2185-2190) and rat hepatic multiple inositol polyphosphate phosphatase (MIPP; Craxton, A., All, N., and Shears, S. B. (1995) Biochem. J. 305, 491-498). The demonstration that diphosphoinositol polyphosphates were hydrolyzed by MIPP provides new information on its substrate specificity, although MIPP did not metabolize significant amounts of these polyphosphates in either rat liver homogenates or intact AR4-2J cells. In liver homogenates, inositol hexakisphosphate (InsP(6)) was phosphorylated first to a diphosphoinositol pentakisphosphate (PP-InsP(5)) and then to PP-InsP(4)-PP. These kinase reactions were reversed by phosphatases, establishing two coupled substrate cycles. The two dephosphorylations were probably performed by distinct phosphatases that were distinguished by their separate positional specificities, and their different sensitivities to inhibition by F- (IC50 values of 0.03 mM and 1.4 mM against PP-InsP(5) and PP-InsP(5)-PP, respectively). In [H-3]inositol-labeled AR4-2J cells, the steady-state levels of PP-[H-3]InsP(5) and PP-[H-3]InsP(4)-PP were, respectively, 2-3 and 0.6% of the level of [H-3]InsP(6). The ongoing turnover of these polyphosphates was revealed by treatment of cells with 0.8 mM NaF for 40 min, which reduced levels of [H-3]InsP(6) by 50%, increased the levels of PP-[H-3]InsP(5) 16-fold, and increased levels of PP-[H-3]InsP(4)-PP 5-fold. A large increase in levels of PP-[H-3]InsP(5) also occurred in cells treated with 10 mM NaF, but then no significant change to levels of PP-[H-3]InsP(4)-PP were observed; there may be important differences in the control of the turnover of these two compounds.	DUPONT CO INC,DEPT MED PROD,NEN,BOSTON,MA 02118	DuPont	SHEARS, SB (corresponding author), NIEHS,CELLULAR & MOLEC PHARMACOL LAB,INOSITOL LIPID SECT,RES TRIANGLE PK,NC 27709, USA.		Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916				ALI N, 1993, J BIOL CHEM, V268, P6161; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAXTON A, 1995, BIOCHEM J, V305, P491, DOI 10.1042/bj3050491; CUNHAMELO JR, 1988, J BIOL CHEM, V263, P14245; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; GLENNON MC, 1993, BIOCHEM J, V293, P583, DOI 10.1042/bj2930583; Irvine Robin F., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P161; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JOHNSON M T, 1986, Biotechniques, V4, P64; Kirk CJ., 1990, PEPTIDE HORMONE ACTI, P151; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; NOGIMORI K, 1991, J BIOL CHEM, V266, P16499; OLIVER KG, 1992, J BIOL CHEM, V267, P21528; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; SHINSHI H, 1976, BIOCHEMISTRY-US, V15, P2185, DOI 10.1021/bi00655a024; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	19	58	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10489	10497		10.1074/jbc.270.18.10489	http://dx.doi.org/10.1074/jbc.270.18.10489			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737983	hybrid			2022-12-25	WOS:A1995QW60100022
J	GOODEMOTE, KA; MATTIE, ME; BERGER, A; SPIEGEL, S				GOODEMOTE, KA; MATTIE, ME; BERGER, A; SPIEGEL, S			INVOLVEMENT OF A PERTUSSIS-TOXIN-SENSITIVE G-PROTEIN IN THE MITOGENIC SIGNALING PATHWAYS OF SPHINGOSINE 1-PHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDIC-ACID LEVELS; SWISS 3T3 CELLS; CELLULAR PROLIFERATION; ENDOGENOUS GANGLIOSIDE; TRANSDUCTION PATHWAYS; DNA-SYNTHESIS; KINASE-C; FIBROBLASTS; SPHINGOSINE-1-PHOSPHATE; CALCIUM	Sphingosine 1-phosphate, a sphingolipid metabolite, was previously reported to increase DNA synthesis in quiescent Swiss 3T3 fibroblasts and to induce transient increases in intracellular free calcium (Zhang, H., Desai, N. N., Olivera, A., Seki, T., Brooker, G., and Spiegel, S. (1991) J. Cell Biol. 114, 155-167). Tn the present study, pretreatment of Swiss 3T3 fibroblasts with pertussis toxin reduced sphingosine l-phosphate-induced DNA synthesis. Sphingosine l-phosphate decreased cellular cAMP levels and also caused a drastic decrease in isoproterenol- and forskolin-stimulated cAMP accumulation. Pertussis toxin treatment prevented the inhibitory effect of sphingosine 1-phosphate on cAMP accumulation, suggesting that a pertussis toxin-sensitive G(i) or G(i)-like protein may be involved in sphingosine 1-phosphate-mediated inhibition of cAMP accumulation. Mitogenic concentrations of sphingosine 1-phosphate stimulated production of inositol phosphates which was inhibited by pertussis toxin, while the response to bradykinin was not affected. Furthermore, calcium release induced by sphingosine 1-phosphate, but not by bradykinin, was also attenuated by pertussis toxin treatment. However, sphingosine 1-phosphate induced phosphatidic acid accumulation was unaffected by pertussis toxin. The increase in specific DNA binding activity of activator protein-1, which was induced by treatment of quiescent Swiss 3T3 fibroblasts with sphingosine 1-phosphate, was also inhibited by pertussis toxin. These results suggest that some of the sphingosine 1-phosphate-induced signaling pathways are mediated by G proteins that are substrates for pertussis toxin.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007	Georgetown University					NCI NIH HHS [F32CA09249] Funding Source: Medline; NIGMS NIH HHS [1RO1 GM43880] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA009249] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043880] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BREITTMAYER JP, 1991, IMMUNOLOGY, V73, P134; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHAO CP, 1994, J BIOL CHEM, V269, P5849; CUI Z, 1991, J BIOL CHEM, V266, P20276; DESAI NN, 1992, J BIOL CHEM, V267, P23122; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HERMOUET S, 1993, CELL SIGNAL, V5, P215, DOI 10.1016/0898-6568(93)90072-T; HILDEBRANDT JD, 1986, FEBS LETT, V203, P87, DOI 10.1016/0014-5793(86)81442-9; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; JOHNSON JA, 1990, J BIOL CHEM, V265, P9333; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LETTERIO JJ, 1986, SCIENCE, V234, P1117, DOI 10.1126/science.3465038; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; NEER EJ, 1988, NATURE, V33, P129; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; RITCHIE T, 1992, BIOCHEM BIOPH RES CO, V186, P790, DOI 10.1016/0006-291X(92)90815-3; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SPIEGEL S, 1989, J BIOL CHEM, V264, P6766; SPIEGEL S, 1988, EXP CELL RES, V177, P414, DOI 10.1016/0014-4827(88)90474-0; Spiegel Sarah, 1993, V25, P105; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P1311, DOI 10.1515/bchm2.1973.354.2.1311; SU Y, 1994, J BIOL CHEM, V269, P16512; UI M, 1986, P163; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANVELDHOVEN PP, 1991, J BIOL CHEM, V266, P12502; ZHANG H, 1990, J BIOL CHEM, V265, P76; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZHANG H, 1990, J BIOL CHEM, V265, P21309	43	155	157	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10272	10277		10.1074/jbc.270.17.10272	http://dx.doi.org/10.1074/jbc.270.17.10272			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730331	hybrid			2022-12-25	WOS:A1995QV41700080
J	HUNYADY, L; BOR, M; BALLA, T; CATT, KJ				HUNYADY, L; BOR, M; BALLA, T; CATT, KJ			CRITICAL ROLE OF A CONSERVED INTRAMEMBRANE TYROSINE RESIDUE IN ANGIOTENSIN-II RECEPTOR ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADRENAL GLOMERULOSA CELLS; PROTEIN-COUPLED RECEPTORS; BETA-ADRENERGIC-RECEPTOR; MUTAGENESIS; SIGNAL; SEQUESTRATION; GENERATION; LIGAND; GS	The rat type 1a (AT(1a)) angiotensin II (Ang II) receptor contains a highly conserved tyrosine residue in the fifth transmembrane region that is present in most G protein-coupled receptors. The role of this amino acid in AT(1) receptor activation was analyzed in a mutant receptor (Y215F) created by replacing Tyr(215) with phenylalanine, The mutant receptor was highly expressed in transfected COS-7 cells, and its binding affinity for the peptide antagonist [Sar(1),Ile(8)]Ang II was similar to that of the wild type receptor. Although the structural integrity of the peptide ligand binding domain was preserved in the Y215F mutant receptor, its affinity for the native agonist, Ang II, was significantly reduced. Also, whereas guanosine 5'-3-O-(thio)triphosphate markedly reduced Ang II binding to the wild type receptor, it had little effect on agonist binding to the mutant receptor. Agonist-induced internalization of the mutant receptor was also impaired, and its ability to mediate inositoI phosphate responses to Ang II stimulation was abolished. The concomitant decreases in receptor internalization and G protein-mediated signaling of the Y215F mutant receptor indicate that Tyr(215) has a critical role in AT(1) receptor activation. In view of its conservation among members of the seven transmembrane domain receptor superfamily, this residue is likely to be of general importance in signal transduction from G protein-coupled receptors.	SEMMELWEIS UNIV MED,SCH MED,DEPT PHYSIOL,H-1444 BUDAPEST,HUNGARY	Semmelweis University	HUNYADY, L (corresponding author), NICHHD,ERRB,BLDG 49,RM 6A36,BETHESDA,MD 20892, USA.			Balla, Tamas/0000-0002-9077-3335				ANDERSON KM, 1993, AM J PHYSIOL, V264, pC179, DOI 10.1152/ajpcell.1993.264.1.C179; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BALLA T, 1991, J BIOL CHEM, V266, P24719; BERNSTEIN KE, 1993, AM J KIDNEY DIS, V22, P745, DOI 10.1016/S0272-6386(12)80441-0; BIHOREAU C, 1993, P NATL ACAD SCI USA, V90, P5133, DOI 10.1073/pnas.90.11.5133; BLUML K, 1994, J BIOL CHEM, V269, P11537; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; Catt KJ, 1993, CELLULAR MOL BIOL RE, P307; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; FINDLAY JBC, 1993, BIOCHEM SOC T, V21, P869, DOI 10.1042/bst0210869; HAUSDORFF WP, 1992, ASIA PAC J PHARMACOL, V7, P149; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; HUNYADY L, 1991, J BIOL CHEM, V266, P2783; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARIE J, 1994, J BIOL CHEM, V269, P20815; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SPAT A, 1991, EXP PHYSIOL, V76, P859, DOI 10.1113/expphysiol.1991.sp003550; VINSON GP, 1994, J ENDOCRINOL, V141, pR5, DOI 10.1677/joe.0.141R005; WESS J, 1993, LIFE SCI, V53, P1447, DOI 10.1016/0024-3205(93)90618-D	27	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9702	9705		10.1074/jbc.270.17.9702	http://dx.doi.org/10.1074/jbc.270.17.9702			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730346	hybrid			2022-12-25	WOS:A1995QV41700004
J	JOST, JP; SIEGMANN, M; SUN, LJ; LEUNG, R				JOST, JP; SIEGMANN, M; SUN, LJ; LEUNG, R			MECHANISMS OF DNA DEMETHYLATION IN CHICKEN EMBRYOS - PURIFICATION AND PROPERTIES OF A 5-METHYLCYTOSINE-DNA GLYCOSYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REMOVAL; CELLS	We have previously shown that in developing chicken embryos and differentiating mouse myoblasts, the demethylation of 5-metCpGs occurs through the replacement of 5-methylcytosine by cytosine (Jest, J, P, (1993) Proc, Natl. Acad. Sci, U.S.A. 90, 4685-4688; Jest, J. P, and Jest, Y. C, (1994) J. Biol, Chem, 269, 10040-10043), We have now purified over 30,000-fold a 5-methylcytosine-DNA glycosylase from Ig-day-old chicken embryos, The enzyme copurifies with a mismatch specific thymine-DNA glycosylase and an apyrimidic-endonuclease. The reaction product of the highly purified 8-methylcytosine-DNA glycosylase is 5-methylcytosine. The copurified apyrimidic-endonuclease activity cleaves 3' from the apyrimidic sugar. A 52.5-kDa peptide, isolated as a single band from preparative SDS-polyacrylamide gels, has both the 5-methylcytosine-DNA glycosylase and the mismatch-specific thymine-DNA glycosylase activities, 5 Methylcytosine-DNA glycosylase has an apparent pi of 5.5-7.5 and maximal activity between pH 6.5 and 7.5, The K-m for hemimethylated oligonucleotide substrate is 8 x 10(-8) M with a V-max of 4 x 10(-11) mol/h/mu g protein, B-Methylcytosine-DNA glycosylase binds equally well to methylated and non-methylated DNA, The enzyme reacts six times faster with the hemimethylated DNA than with the same bifilarly methylated DNA sequence, and single-stranded methylated DNA is not a substrate, The action of the enzyme is distributive.			JOST, JP (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.							Adams R. L. P., 1985, MOL BIOL DNA METHYLA; ADAMS RLP, 1990, FEBS LETT, V269, P29, DOI 10.1016/0014-5793(90)81111-Z; BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; CEDAR H, 1979, NUCLEIC ACIDS RES, V6, P2125, DOI 10.1093/nar/6.6.2125; EGAN NB, 1988, ANAL BIOCHEM, V172, P488; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HARLOW E, 1988, ANTIBODIES LABORATOR; HUGHES MJ, 1991, LABORATORY GUIDE IN, P79; JOST JP, 1994, J BIOL CHEM, V269, P10040; JOST JP, 1993, DNA METHYLATION MOL; JOST JP, 1995, IN PRESS GENE AMST; JOST JP, 1993, P NATL ACAD SCI USA, V90, P4685; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; RAZIN A, 1984, DNA METHYLATION BIOC; VAIRAPANDI M, 1993, NUCLEIC ACIDS RES, V21, P5323, DOI 10.1093/nar/21.23.5323	18	122	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9734	9739		10.1074/jbc.270.17.9734	http://dx.doi.org/10.1074/jbc.270.17.9734			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730351				2022-12-25	WOS:A1995QV41700009
J	WADE, M; BLAKE, MC; JAMBOU, RC; HELIN, K; HARLOW, E; AZIZKHAN, JC				WADE, M; BLAKE, MC; JAMBOU, RC; HELIN, K; HARLOW, E; AZIZKHAN, JC			AN INVERTED REPEAT MOTIF STABILIZES BINDING OF E2F AND ENHANCES TRANSCRIPTION OF THE DIHYDROFOLATE-REDUCTASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS-INFECTED CELLS; HUMAN MYC PROMOTER; DNA-BINDING; TRANS-ACTIVATION; E4 GENE; COOPERATIVE BINDING; COMPLEX-FORMATION; GROWTH-REGULATION; CELLULAR GENES; MESSENGER-RNA	An overlapping inverted repeat sequence that binds the eukaryotic transcription factor E2F is 100% conserved near the major transcription start sites in the promoters of three mammalian genes encoding dihydrofolate reductase, and is also found in the promoters of several other important cellular and viral genes. This element, 5' TTTCGCGCCAAA-3', is comprised of two overlapping, oppositely oriented sites which match the consensus E2F site (5'-TTT(C/G) (C/G)CGC-3'). Recent work has shown that E2F binding activity is composed of at least six related cellular polypeptides which are capable of forming DNA-binding home- and heterodimers. We have investigated the binding of cellular E2F activity and of home- and heterodimers of cloned E2F proteins to the inverted repeat E2F element. We have demonstrated that mutations in this element that abolish its inverted repeat nature, while preserving a single consensus E2F site, significantly decrease the binding stability of all of the forms of E2F tested. The rate of association of E2F-1/DP-1 heterodimers with the inverted repeat wild type site was not significantly different from those with the two single site mutated probes, Furthermore, the mutations decrease in vitro transcription and transient reporter gene expression 2-5-fold, an effect equivalent to that of abolishing E2F binding altogether. These data suggest a functional role that may explain the conservation of inverted repeat E2F elements among the DHFR promoters and several other cellular and viral promoters.	ROSWELL PK CANC INST,DEPT EXPTL THERAPEUT,BUFFALO,NY 14263; UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GENET & MOLEC BIOL,CHAPEL HILL,NC 27599; MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA	Roswell Park Cancer Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Massachusetts General Hospital			Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022	Helin, Kristian/0000-0003-1975-6097				Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; AZIZKHAN JC, 1986, BIOCHEMISTRY-US, V25, P6228, DOI 10.1021/bi00368a059; BABISS LE, 1989, J VIROL, V63, P2709, DOI 10.1128/JVI.63.6.2709-2717.1989; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1156, P125; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HARDY S, 1989, MOL CELL BIOL, V9, P4495, DOI 10.1128/MCB.9.10.4495; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; HUBER HE, 1994, J BIOL CHEM, V269, P6999; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JANSENDURR P, 1989, EMBO J, V8, P3365, DOI 10.1002/j.1460-2075.1989.tb08499.x; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MCGROGAN M, 1985, J BIOL CHEM, V260, P2307; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P425, DOI 10.1128/MCB.6.2.425; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; OUELLETTE MM, 1992, ONCOGENE, V7, P1075; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; REICHEL R, 1989, J VIROL, V63, P3643, DOI 10.1128/JVI.63.9.3643-3650.1989; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	59	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9783	9791		10.1074/jbc.270.17.9783	http://dx.doi.org/10.1074/jbc.270.17.9783			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730357	hybrid			2022-12-25	WOS:A1995QV41700016
J	GARINGO, AD; SUHASINI, M; ANDREWS, NC; PILZ, RB				GARINGO, AD; SUHASINI, M; ANDREWS, NC; PILZ, RB			CAMP-DEPENDENT PROTEIN-KINASE IS NECESSARY FOR INCREASED NF-E2.DNA COMPLEX-FORMATION DURING ERYTHROLEUKEMIA CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NF-E2; ALPHA-GLOBIN GENE; PORPHOBILINOGEN DEAMINASE GENE; ERYTHROID-SPECIFIC GENE; DOMINANT CONTROL REGION; LEUCINE ZIPPER PROTEIN; DNA-BINDING PROTEINS; LOCUS-CONTROL REGION; REGULATORY ELEMENT; NUCLEAR FACTOR	When murine erythroleukemia (MEL) cells are induced to differentiate by hexamethylene bisacetamide (HMBA), erythroid-specific genes are transcriptionally activated; however, transcriptional activation of these genes is severely impaired in cAMP dependent protein kinase (protein kinase A)-deficient MEL cells, The transcription factor NF-EB, composed of a 45-kDa (p45) and an 18-kDa (p18) subunit, is essential for enhancer activity of the globin locus control regions (LCRs), DNA binding of NF-E2 and alpha-globin LCR enhancer activity was significantly less in HMBA-treated protein kinase A-deficient cells compared to cells containing normal protein kinase A activity; DNA binding of several other transcription factors was the same in both cell types, In parental cells, HMBA treatment and/or prolonged activation of protein kinase A increased the amount of NF-E2 . DNA complexes without change in DNA binding affinity; the expression of p45 and p18 was the same under all conditions, p45 and p18 were phosphorylated by protein kinase A in vitro, but the phosphorylation did not affect NF-E2 . DNA complexes, suggesting that protein kinase A regulates NF-E2 . DNA complex formation indirectly, e,g, by altering expression of a regulatory factor(s), Thus, protein kinase A appears to be necessary for increased NF-E2 . DNA complex formation during differentiation of MEL cells and may influence erythroid-specific gene expression through this mechanism.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115	University of California System; University of California San Diego; Harvard University; Harvard Medical School; Howard Hughes Medical Institute				Andrews, Nancy/0000-0003-0243-4462	NATIONAL CANCER INSTITUTE [K08CA001548] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA01548] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELDRIDGE MG, 1992, BIOTECHNIQUES, V12, P848; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FRASER PJ, 1987, GENE DEV, V1, P855, DOI 10.1101/gad.1.8.855; FREGIEN N, 1986, GENE, V48, P1, DOI 10.1016/0378-1119(86)90346-X; GANGULY S, 1985, J BIOL CHEM, V260, P2167; GLASS DB, 1980, ANNU REV PHARMACOL, V20, P363, DOI 10.1146/annurev.pa.20.040180.002051; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PILZ RB, 1993, J BIOL CHEM, V268, P20252; PILZ RB, 1992, J BIOL CHEM, V267, P16161; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; PONDEL MD, 1992, NUCLEIC ACIDS RES, V20, P237, DOI 10.1093/nar/20.2.237; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; PROCHOWNIK EV, 1990, BLOOD, V76, P1830; RIFKIND RA, 1987, BLOOD CELLS, V13, P277; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SCHEELE JS, 1994, J BIOL CHEM, V269, P18599; SCHNEIDER R, 1986, NUCLEIC ACIDS RES, V14, P1303, DOI 10.1093/nar/14.3.1303; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHARPE JA, 1993, P NATL ACAD SCI USA, V90, P11262, DOI 10.1073/pnas.90.23.11262; SOLOMON WB, 1993, J BIOL CHEM, V268, P5089; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TUGORES A, 1994, J BIOL CHEM, V269, P30789; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; WHITELAW E, 1989, MOL CELL BIOL, V9, P241, DOI 10.1128/MCB.9.1.241; ZHANG QY, 1993, MOL CELL BIOL, V13, P2298, DOI 10.1128/MCB.13.4.2298	61	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9169	9177		10.1074/jbc.270.16.9169	http://dx.doi.org/10.1074/jbc.270.16.9169			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721832	hybrid			2022-12-25	WOS:A1995QU08900020
J	DELGADO, MD; LERGA, A; CANELLES, M; GOMEZCASARES, MT; LEON, J				DELGADO, MD; LERGA, A; CANELLES, M; GOMEZCASARES, MT; LEON, J			DIFFERENTIAL REGULATION OF MAX AND ROLE OF C-MYC DURING ERYTHROID AND MYELOMONOCYTIC DIFFERENTIATION OF K562 CELLS	ONCOGENE			English	Note						C-MYC; MAX; K562 CELLS; DIFFERENTIATION	MURINE ERYTHROLEUKEMIA-CELLS; MYELOID-LEUKEMIA CELLS; GENE-EXPRESSION; TERMINAL DIFFERENTIATION; NEGATIVE AUTOREGULATION; GROWTH-INHIBITION; PHORBOL ESTER; LINE K562; ONCOGENE; PROTEIN	The protein Max binds to c-Myc and the heterodimer c-Myc/Max seems to be the active form in vivo. While the expression of c-myc is extensively regulated, no major changes in max expression have been reported so far with respect to differentiation, We have studied the expression of c-Myc and Max during in vitro differentiation of the bipotent human myeloid leukemia K562 cell line, This cell model system allowed us to compare c-Myc and Max expression during differentiation along erythroid (induced by 1-beta-D-arabinofuranosyl-cytosine) and myelomonocytic lineages (induced by 12-0-tetradecanoylphorbol-13-acetate). We found that c-myc expression decreased as a result of both differentiating treatments, The expression level of max remained unchanged during myelomonocytic differentiation, In contrast, max mRNA and protein were dramatically down-regulated during erythroid differentiation of K562 cells, thus demonstrating that max gene is subjected to regulation during differentiation, We also studied the expression of the other two described members of the c-Myc network: mxi1 and mad. mxi1 expression increased during erythroid differentiation but was strongly downregulated during myelomonocytic differentiation of K562, mad was constitutively expressed during K562 erythroid differentiation and slightly increased during induction of the myelomonocytic pathway, We have obtained K562 sublines stably transfected with a zinc-inducible c-myc gene, In these clones the overexpression of c-Myc did not interfere with TPA-induced myelomonocytic differentiation. In contrast, erythroid differentiation was significantly inhibited upon c-myc induction despite the downregulation of endogeneous max expression, These results suggest a differential role for c-Myc in the human myeloid cell differentiation depending on the cell lineage.	UNIV CANTABRIA,FAC MED,DEPT BIOL MOLEC,E-39011 SANTANDER,SPAIN	Universidad de Cantabria			Leon, Javier/K-4615-2014; Canelles, Matilde/AAB-1011-2019; Delgado, M. Dolores/K-9056-2014	Canelles, Matilde/0000-0003-2973-609X; Delgado, M. Dolores/0000-0003-4682-4040; Leon, Javier/0000-0001-5803-0112				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BERBERICH S, 1992, ONCOGENE, V7, P775; BIRNIE GD, 1988, BRIT J CANCER, V58, P41; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHISHOLM O, 1992, ONCOGENE, V7, P1827; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cleveland J L, 1988, Oncogene Res, V3, P357; COGLIATI T, 1993, ONCOGENE, V8, P1263; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GOMEZCASARES MT, 1993, LEUKEMIA, V7, P1824; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HOFFMANLIEBERMA.B, 1991, ONCOGENE, V6, P903; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KAMANO H, 1990, LEUKEMIA RES, V14, P831, DOI 10.1016/0145-2126(90)90171-5; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LARSSON LG, 1994, ONCOGENE, V9, P1247; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUBBERT M, 1988, BLOOD REV, V2, P121, DOI 10.1016/0268-960X(88)90034-3; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; OHMORI Y, 1993, ONCOGENE, V8, P379; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; SAMBROOK F, 1989, MOL CLONING LABORATO; SHEN WF, 1992, EMBO J, V11, P983, DOI 10.1002/j.1460-2075.1992.tb05137.x; SIEBERT PD, 1985, J BIOL CHEM, V260, P3868; TONINI GP, 1987, CANCER RES, V47, P4544; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	42	62	64	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1659	1665						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731722				2022-12-25	WOS:A1995QU68100024
J	CHAMPAGNE, DE; NUSSENZVEIG, RH; RIBEIRO, JMC				CHAMPAGNE, DE; NUSSENZVEIG, RH; RIBEIRO, JMC			PURIFICATION, PARTIAL CHARACTERIZATION, AND CLONING OF NITRIC OXIDE-CARRYING HEME-PROTEINS (NITROPHORINS) FROM SALIVARY-GLANDS OF THE BLOODSUCKING INSECT RHODNIUS-PROLIXUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HEMOGLOBIN	Four nitric oxide (NO) carrying proteins have been isolated from salivary glands of the blood-sucking insect Rhodnius prolixus. These have been given the collective name ''nitrophorins,'' and individual proteins are designated NP1-NP4 in order of their relative abundance in the glands. All four reversibly bind NO; spectral shifts associated with NO binding indicate the interaction of NO with an Fe(III) heme. Physical properties, amino acid composition, and amino-terminal sequences of the nitrophorins are reported. The most abundant nitrophorin was cloned, and its sequence was determined.	UNIV ARIZONA,CTR INSECT SCI,TUCSON,AZ 85721	University of Arizona	CHAMPAGNE, DE (corresponding author), UNIV ARIZONA,DEPT ENTOMOL,TUCSON,AZ 85721, USA.			Ribeiro, Jose/0000-0002-9107-0818	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018694, R29AI035591, R01AI035591, R37AI018694] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-35591, AI-18694] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTOINE M, 1987, GENE, V56, P41, DOI 10.1016/0378-1119(87)90156-9; Antonini E., 1971, FRONTIERS BIOL, V21; CHAMPAGNE DE, UNPUB; Dickerson R.E., 1983, HEMOGLOBIN; GARLICK RL, 1982, J BIOL CHEM, V257, P9005; IMAMURA T, 1972, J BIOL CHEM, V247, P2785; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; RIBEIRO JMC, 1990, BRIT J PHARMACOL, V101, P932, DOI 10.1111/j.1476-5381.1990.tb14183.x; RIBEIRO JMC, 1993, SCIENCE, V260, P539, DOI 10.1126/science.8386393; RIBEIRO JMC, 1987, ANNU REV ENTOMOL, V32, P463, DOI 10.1146/annurev.en.32.010187.002335; RIGGS AF, 1991, AM ZOOL, V31, P535; RUNNEGAR B, 1984, J MOL EVOL, V2, P33; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; SUZUKI T, 1986, J BIOL CHEM, V261, P9257; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; VINOGRADOV SN, 1985, COMP BIOCHEM PHYS B, V82, P1, DOI 10.1016/0305-0491(85)90120-8; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	18	146	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8691	8695		10.1074/jbc.270.15.8691	http://dx.doi.org/10.1074/jbc.270.15.8691			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721773	hybrid			2022-12-25	WOS:A1995QT44800051
J	MANJI, SS; ZHOU, H; FINDLAY, DM; MARTIN, TJ; NG, KW				MANJI, SS; ZHOU, H; FINDLAY, DM; MARTIN, TJ; NG, KW			TUMOR-NECROSIS-FACTOR-ALPHA FACILITATES NUCLEAR ACTIONS OF RETINOIC ACID TO REGULATE EXPRESSION OF THE ALKALINE-PHOSPHATASE GENE IN PREOSTEOBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CELLS-INVITRO; BONE-RESORPTION; RAT; DIFFERENTIATION; INTERLEUKIN-1; PROLIFERATION; OSTEOBLASTS; MECHANISMS; INTERFERON	This study examines the molecular mechanisms of interaction between tumor necrosis factor alpha (TNF alpha) and retinoic acid on the expression of the alkaline phosphatase gene by rat clonal preosteoblastic cells. In this cell line, alkaline phosphatase mRNA was not constitutively expressed but was progressively induced by treatment with 1 mu M retinoic acid, detectable by 6 h. Combining retinoic acid with 0.6 nM TNF alpha resulted in alkaline phosphatase mRNA appearing by 2 h, as well as enhanced expression above that observed with retinoic acid alone at 6, 12, and 24 h, Nuclear run-on analysis showed constitutive transcription of the alkaline phosphatase gene in control and TNF alpha-treated cells, At 4 h, retinoic acid, alone or combined with TNF alpha, increased alkaline phosphatase gene transcriptional rate by 2-fold. However, at 24 h, while no retinoic acid effect was retained, retinoic acid plus TNF alpha resulted in a 5-fold increase in alkaline phosphatase transcriptional rate. Examination of the distribution of nuclear alkaline phosphatase mRNA demonstrated that pre-spliced precursor mRNA was localized to the nuclear matrix in control and all treatment groups, Retinoic acid caused a time-dependent accumulation of mature, spliced alkaline phosphatase mRNA located in the non-matrix and cytoplasmic fractions, implying a post-transcriptional action of retinoic acid in nuclear processing and nucleocytoplasmic transport, Adding TNF alpha with retinoic acid greatly enhanced this effect, which was observed after 4 h, prior to any detectable interaction between TNF alpha and retinoic acid on gene transcription, In sharp contrast, only a negligible mount of nuclear processing occurred in control and TNF alpha-treated cells, This study reveals distinct interactions between TNF alpha and retinoic acid at post transcriptional as well as transcriptional levels to regulate expression of the alkaline phosphatase gene in preosteoblasts.	UNIV MELBOURNE, ST VINCENTS HOSP, DEPT MED, FITZROY, VIC 3065, AUSTRALIA	St Vincent's Hospital Melbourne; University of Melbourne				Zhou, Hong/0000-0001-5899-9660				AGGARWAL BB, 1992, TUMOR NECROSIS FACTO; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BERTOLINI DR, 1986, NATURE, V319, P516, DOI 10.1038/319516a0; CAMPBELL DJ, 1986, J CLIN INVEST, V78, P31, DOI 10.1172/JCI112566; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Favaloro J, 1980, Methods Enzymol, V65, P718; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GOWEN M, 1988, ARTHRITIS RHEUM, V31, P1500, DOI 10.1002/art.1780311206; GREEN AR, 1989, LANCET, V1, P705; ISHIMI Y, 1990, J IMMUNOL, V145, P3297; JAATTELA M, 1991, LAB INVEST, V64, P724; JARROUS N, 1994, J BIOL CHEM, V269, P23141; LEPPARD KN, 1989, EMBO J, V8, P2329, DOI 10.1002/j.1460-2075.1989.tb08360.x; LITTLEWOOD AJ, 1991, ENDOCRINOLOGY, V129, P1513, DOI 10.1210/endo-129-3-1513; MUNDY GR, 1993, PHYSL PHARM BONE, P185; NG KW, 1988, J BONE MINER RES, V3, P53; NG KW, 1989, J MOL ENDOCRINOL, V3, P57, DOI 10.1677/jme.0.0030057; NG KW, 1989, MOL ENDOCRINOL, V3, P2079, DOI 10.1210/mend-3-12-2079; PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; Sambrook J, 1989, MOL CLONING LABORATO; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; THIEDE MA, 1988, P NATL ACAD SCI USA, V85, P319, DOI 10.1073/pnas.85.2.319; THOMSON BM, 1987, J IMMUNOL, V138, P775; TOH Y, 1989, EUR J BIOCHEM, V182, P231, DOI 10.1111/j.1432-1033.1989.tb14822.x; TRINCHIERI G, 1987, CANCER RES, V47, P2236; TRINCHIERI G, 1987, BLOOD, V69, P1218; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VILCEK J, 1991, J BIOL CHEM, V266, P7313; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818; ZHOU H, 1993, J CELL PHYSIOL, V155, P112, DOI 10.1002/jcp.1041550115; ZHOU H, 1991, J BONE MINER RES, V6, P767; ZHOU H, 1994, J BIOL CHEM, V269, P22433	34	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8958	8962		10.1074/jbc.270.15.8958	http://dx.doi.org/10.1074/jbc.270.15.8958			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721805	hybrid			2022-12-25	WOS:A1995QT44800084
J	JOHNSTON, JA; JOHNSON, ES; WALLER, PRH; VARSHAVSKY, A				JOHNSTON, JA; JOHNSON, ES; WALLER, PRH; VARSHAVSKY, A			METHOTREXATE INHIBITS PROTEOLYSIS OF DIHYDROFOLATE-REDUCTASE BY THE N-END RULE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; SHORT-LIVED PROTEIN; SACCHAROMYCES-CEREVISIAE; DEGRADATION SIGNAL; PRECURSOR PROTEIN; UBIQUITIN; TRANSLOCATION; MITOCHONDRIA; GENES; RECOGNITION	The N-end rule relates the in vivo half-life of a protein to the identity of its N-terminal residue. In eukaryotes, the N-end rule pathway is a ubiquitin-dependent, proteasome-based system that targets and processively degrades proteins bearing certain N-terminal residues. Arg-DHFR, a modified dihydrofolate reductase bearing an N-terminal arginine (destabilizing residue in the N-end rule), is short lived in ATP-supplemented reticulocyte extract. It is shown here that methotrexate, which is a folic acid analog and high affinity ligand of DHFR, inhibits the degradation but not ubiquitination of Arg-DHFR by the N-end rule pathway. The degradation of other N-end rule substrates is not affected by methotrexate. We discuss implications of these results for the mechanism of proteasome-mediated protein degradation.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology				Johnston, Jennifer/0000-0002-4867-9230	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039520, R01DK039520, R56DK039520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031530] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39520] Funding Source: Medline; NIGMS NIH HHS [GM31530] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARKOWITZ RA, 1992, EMBO J, V12, P243; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; Creighton T.E., 1992, PROTEINS STRUCTURES; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; EILERS M, 1988, CELL, V52, P481, DOI 10.1016/0092-8674(88)90458-8; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FINLEY D, 1992, MOL CELLULAR BIOL YE, V2, P539; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; GOLDBERG AL, 1992, NATURE, V375, P375; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILL CP, 1993, P NATL ACAD SCI USA, V90, P4136, DOI 10.1073/pnas.90.9.4136; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; HUBBARD SJ, 1994, PROTEIN SCI, V3, P757; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1992, THESIS MIT CAMBRIDGE; LUPAS A, 1995, IN PRESS ENZYME PROT; MADURA K, 1993, J BIOL CHEM, V268, P12046; MATTHEWS DA, 1985, J BIOL CHEM, V260, P392; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REISS Y, 1988, J BIOL CHEM, V263, P2693; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VARSHAVSKY A, 1991, CELL, V64, P13, DOI 10.1016/0092-8674(91)90202-A; VESTWEBER D, 1988, EMBO J, V7, P1147, DOI 10.1002/j.1460-2075.1988.tb02924.x; VIERSTRA RD, 1993, ANNU REV PLANT PHYS, V44, P385, DOI 10.1146/annurev.pp.44.060193.002125; WIENHUES U, 1991, J CELL BIOL, V115, P1601, DOI 10.1083/jcb.115.6.1601	46	103	107	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8172	8178		10.1074/jbc.270.14.8172	http://dx.doi.org/10.1074/jbc.270.14.8172			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713922	Green Accepted, hybrid			2022-12-25	WOS:A1995QR52600061
J	LALA, AK; RAJA, SM				LALA, AK; RAJA, SM			PHOTOLABELING OF A PORE-FORMING TOXIN WITH THE HYDROPHOBIC PROBE 2-[H-3]DIAZOFLUORENE - IDENTIFICATION OF MEMBRANE-INSERTED SEGMENTS OF STAPHYLOCOCCUS-AUREUS ALPHA-TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; LIPOSOME MEMBRANE; 3-DIMENSIONAL STRUCTURE; CHANNEL; PROTEINS; HEMOLYSIN; PURIFICATION; PENETRATION; RESOLUTION; PHOTOLYSIS	The identification of membrane-inserted segments of pore-forming soluble proteins is crucial to understanding the action of these proteins at the molecular level. A distinct member of this class of proteins is alpha-toxin, a 293-amino acid long 33-kDa hemolytic toxin secreted by Staphylococcus aureus that can form pores in both artificial and natural membranes, We have studied the interaction of alpha-toxin with single bilayer vesicles prepared from asolectin using a hydrophobic photoactivable reagent, 2-[H-3]diazofluorene ([H-3]DAF) (Pradhan, D., and Lala, A. K. (1987) J, Biol, Chem, 262, 8242-8251), This reagent readily partitions into the membrane hydrophobic core and on photolysis labels the lipid and protein segments that penetrate the membrane. Current models on the mode of action of alpha-toxin indicate that, on interaction with membranes, alpha-toxin forms an oligomer, which represents the active pore. Ln keeping with these models, we observe that [H-3]DAF photolabels the membrane-bound alpha-toxin oligomer. Cyanogen bromide fragmentation of [H-3]DAF-labeled alpha-toxin gave several fragments, which were subjected to Edman degradation, We could thus sequence residues 1-19, 35-60, 114-139, 198-231, and 235-258, Radioactive analysis and phenylthiohydantoin-derivative analysis during sequencing permitted analysis of DAF insertion sites, The results obtained indicated that the N and C termini (residues 235-258) have been extensively labeled. The putative pore-forming glycine-rich central hinge region was poorly labeled, indicating that the apposing side of the lumen of the pore does not form the lipid-protein interface, The DAF labeling pattern indicated that the major structural motif in membrane-bound alpha-toxin was largely beta-sheet.	INDIAN INST TECHNOL, DEPT CHEM, BIOMEMBRANE LAB, BOMBAY 400076, MAHARASHTRA, INDIA	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay								ALLEN TM, 1980, BIOCHIM BIOPHYS ACTA, V597, P418, DOI 10.1016/0005-2736(80)90118-2; AMES BN, 1960, J BIOL CHEM, V235, P769; ANJANEYULU PSR, 1984, P INDIAN AS-CHEM SCI, V93, P1229; ANJANEYULU PSR, 1984, INDIAN J CHEM B, V23, P802; BHAKDI S, 1981, P NATL ACAD SCI-BIOL, V78, P5475, DOI 10.1073/pnas.78.9.5475; BHAKDI S, 1989, INFECT IMMUN, V57, P3512, DOI 10.1128/IAI.57.11.3512-3519.1989; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BRUNNER J, 1989, FEBS LETT, V257, P369, DOI 10.1016/0014-5793(89)81574-1; BRUNNER J, 1989, METHOD ENZYMOL, V172, P628; BRUNNER J, 1981, TRENDS BIOCHEM SCI, V6, P44, DOI 10.1016/0968-0004(81)90017-7; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; BUCKELEW AR, 1971, BIOCHIM BIOPHYS ACTA, V233, P7, DOI 10.1016/0005-2736(71)90352-X; CEUNEBROECK JCV, 1986, BIOCHEM BIOPH RES CO, V138, P604; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DUMONT ME, 1988, J BIOL CHEM, V263, P2087; FORTI S, 1989, EUR J BIOCHEM, V181, P767, DOI 10.1111/j.1432-1033.1989.tb14790.x; FREER JH, 1968, J BACTERIOL, V95, P1153, DOI 10.1128/JB.95.3.1153-1168.1968; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828; GRASSE PB, 1983, J AM CHEM SOC, V105, P6833, DOI 10.1021/ja00361a014; GRAY GS, 1984, INFECT IMMUN, V46, P615, DOI 10.1128/IAI.46.2.615-618.1984; GROSS E, 1962, J BIOL CHEM, V237, P1856; HARSHMAN S, 1989, J BIOL CHEM, V264, P14978; HARSHMAN S, 1988, METHOD ENZYMOL, V165, P3; IKIGAI H, 1987, J BIOL CHEM, V262, P2150; IKIGAI H, 1985, BIOCHEM BIOPH RES CO, V130, P175, DOI 10.1016/0006-291X(85)90398-5; JAP BK, 1991, NATURE, V350, P167, DOI 10.1038/350167a0; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KEHOE M, 1983, INFECT IMMUN, V41, P1105, DOI 10.1128/IAI.41.3.1105-1111.1983; KOCHI SK, 1994, BIOCHEMISTRY-US, V33, P2604, DOI 10.1021/bi00175a032; KREBS J, 1984, BIOCHEMISTRY-US, V23, P400, DOI 10.1021/bi00298a002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALA AK, 1990, BIOTECHNOL APPL BIOC, V12, P586; LALA AK, 1990, PURE APPL CHEM, V62, P1453, DOI 10.1351/pac199062071453; LALA AK, 1992, J BIOL CHEM, V267, P19914; LEAR JD, 1987, J BIOL CHEM, V262, P6500; LIND I, 1987, ANAL BIOCHEM, V164, P84, DOI 10.1016/0003-2697(87)90371-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENESTRINA G, 1986, J MEMBRANE BIOL, V90, P177, DOI 10.1007/BF01869935; Montecucco C., 1988, METHOD ENZYMOL, V165, P347; MOZDZANOWSKI J, 1992, ANAL BIOCHEM, V207, P11, DOI 10.1016/0003-2697(92)90492-P; OLOFSSON A, 1990, J MOL BIOL, V214, P299, DOI 10.1016/0022-2836(90)90162-F; OLOFSSON A, 1988, J ULTRA MOL STRUCT R, V100, P194, DOI 10.1016/0889-1605(88)90026-2; PALMER M, 1993, J BIOL CHEM, V268, P11959; PALMER M, 1993, J BIOL CHEM, V268, P11963; PRADHAN D, 1987, J BIOL CHEM, V262, P8242; RUZICKA J, 1992, J AM CHEM SOC, V114, P897, DOI 10.1021/ja00029a016; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; THELESTAM M, 1988, TOXICON, V26, P51, DOI 10.1016/0041-0101(88)90137-7; THELESTAM M, 1983, BIOCHEM BIOPH RES CO, V111, P444, DOI 10.1016/0006-291X(83)90326-1; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; TOMITA T, 1992, BIOCHIM BIOPHYS ACTA, V1104, P325, DOI 10.1016/0005-2736(92)90047-P; TOMITA T, 1993, BIOCHIM BIOPHYS ACTA, V1145, P51, DOI 10.1016/0005-2736(93)90380-I; TOMITA T, 1992, J BIOL CHEM, V267, P13391; WALKER B, 1993, J BIOL CHEM, V268, P5285; WALKER B, 1992, J BIOL CHEM, V267, P10902; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1994, PROTEIN ENG, V7, P655, DOI 10.1093/protein/7.5.655; WARD RJ, 1994, BIOCHEMISTRY-US, V33, P7477, DOI 10.1021/bi00189a056; WATANABE M, 1987, BIOCHIM BIOPHYS ACTA, V898, P257, DOI 10.1016/0005-2736(87)90065-4; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009	63	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11348	11357		10.1074/jbc.270.19.11348	http://dx.doi.org/10.1074/jbc.270.19.11348			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744772	hybrid			2022-12-25	WOS:A1995QX86500049
J	SALEEM, A; KHARBANDA, S; YUAN, ZM; KUFE, D				SALEEM, A; KHARBANDA, S; YUAN, ZM; KUFE, D			MONOCYTE COLONY-STIMULATING FACTOR STIMULATES BINDING OF PHOSPHATIDYLINOSITOL 3-KINASE TO GRB2-CENTER-DOT-SOS COMPLEXES IN HUMAN MONOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; FMS PROTO-ONCOGENE; SIGNAL-TRANSDUCTION; CSF-1 RECEPTOR; FACTOR-I; INSULIN STIMULATION; GROWTH-FACTOR; SH3 DOMAIN; RAS	Monocyte colony-stimulating factor (M-CSF) is required for the proliferation of mononuclear phagocytes. The activated M-CSF receptor associates with phosphatidylinositol 3-kinase (PI 3-kinase). In the present studies, we demonstrate that M-CSF also induces direct interaction of PI 3-kinase (p85 alpha subunit) with the SH2/SH3 adaptor protein Grb2. Tyrosine-phosphorylated PI 3-kinase interacts with the SH2 domain of Grb2. A pYRNE (pY408) site in PI 3-kinase is potentially involved in this interaction. The results also demonstrate that the PI 3-kinase . Grb2 complex associates with the guanine nucleotide exchange protein Sos. Since Sos binds to the SH3 domains of Grb2 and thereby associates with Pas at the cell membrane, formation of the PI 3-kinase . Grb2 . Sos complex provides a potential mechanism for growth factor-induced interactions of PI 3-kinase and Pas.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NCI NIH HHS [CA42802] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; KARNITZ LM, 1994, J EXP MED, V179, P1799, DOI 10.1084/jem.179.6.1799; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SJOLANDER A, 1992, BIOCHEM BIOPH RES CO, V169, P1503; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUNG CK, 1994, J BIOL CHEM, V269, P12503; SUSA M, 1992, J BIOL CHEM, V267, P6905; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597	32	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10380	10383		10.1074/jbc.270.18.10380	http://dx.doi.org/10.1074/jbc.270.18.10380			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737969				2022-12-25	WOS:A1995QW60100006
J	FRANTZ, JD; GILBERT, W				FRANTZ, JD; GILBERT, W			A YEAST GENE-PRODUCT, G4P2, WITH A SPECIFIC AFFINITY FOR QUADRUPLEX NUCLEIC-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TELOMERIC DNA; GENOMIC RNA; PROTEIN; SEQUENCE; OLIGONUCLEOTIDE; DIMERIZATION; EXPRESSION; MUTATIONS; REGION	G4 nucleic acids are quadruplex structures involving guanine-rich sequences that form in vitro under moderate conditions. Experimental evidence exists supporting biological functions for these elements; however, direct demonstration of G4 nucleic acids in vivo has not yet been achieved, Here we purify and characterize a yeast protein, G4p2, which has a specific affinity for G4 nucleic acids, G4p2 binds equivalently to RNA and DNA in G4 form. The K-eq for G4p2 binding to a G4 DNA oligomer is 2.2 x 10(8) M(-1) under near physiological conditions, We have cloned and sequenced the gene encoding G4p2 and have shown it to be identical to MPT4 and STO1, MPT4 was isolated in a screen for multicopy suppressors of staurosporine sensitivity in POP2 cells, Pop2 is a complex regulatory factor that participates, in part, in the repression of certain genes in the absence of glucose (Sakai, A., Chibazakura, T., Shimizu, Y., and Hishinuma, F. (1992) Nucleic Acids Res. 20, 6227-6233), STO1 was isolated as a multicopy suppressor of TOM1, an uncharacterized mutation that leads to temperature sensitive cell cycle arrest at the G2/M boundary, Suppression of these mutations by G4p2 indicate this G4 nucleic acid binding protein may function in signal transduction pathways regulated by protein kinases, which control carbon source utilization, and in cell cycle progression.			FRANTZ, JD (corresponding author), HARVARD UNIV, BIOL LABS, DEPT MOLEC & CELLULAR BIOL, 16 DIVIN AVE, CAMBRIDGE, MA 02138 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041895] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41895] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AWANG G, 1993, BIOCHEMISTRY-US, V32, P11453, DOI 10.1021/bi00093a024; DAVIS TN, 1987, METHOD ENZYMOL, V139, P248; DYKSTRA CC, 1991, MOL CELL BIOL, V11, P2583, DOI 10.1128/MCB.11.5.2583; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; GALLAGHER SR, 1992, CURRENT PROTOCOLS MO, V2; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; HAMMONDKOSACK MCU, 1992, NUCLEIC ACIDS RES, V20, P231, DOI 10.1093/nar/20.2.231; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KIM J, 1991, NATURE, V351, P331, DOI 10.1038/351331a0; KIM JM, 1990, GENETICS, V126, P799; KOVALCHUKE O, 1994, FASEB J, V8, pA1307; LARIMER FW, 1990, GENE, V95, P85, DOI 10.1016/0378-1119(90)90417-P; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; LIU ZP, 1994, CELL, V77, P1083, DOI 10.1016/0092-8674(94)90447-2; MAIDAK BL, 1994, NUCLEIC ACIDS RES, V22, P3485, DOI 10.1093/nar/22.17.3485; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; SAKAI A, 1992, NUCLEIC ACIDS RES, V20, P6227, DOI 10.1093/nar/20.23.6227; SEN D, 1992, BIOCHEMISTRY-US, V31, P65, DOI 10.1021/bi00116a011; SEN D, 1992, METHOD ENZYMOL, V211, P191; Sen D, 1991, CURR OPIN STRUC BIOL, V1, P435, DOI 10.1016/0959-440X(91)90044-T; SMITH DB, 1992, CURRENT PROTOCOLS MO, V2; SNYDER M, 1986, P NATL ACAD SCI USA, V83, P730, DOI 10.1073/pnas.83.3.730; SORGER PK, 1989, PROTEIN FUNCTION PRA, P199; Sundquist W. I., 1991, Nucleic Acids and Molecular Biology, V5, P1; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TAKEDA J, 1989, FEBS LETT, V247, P41, DOI 10.1016/0014-5793(89)81236-0; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; WILLIAMSON JR, 1994, ANNU REV BIOPH BIOM, V23, P703, DOI 10.1146/annurev.bb.23.060194.003415; WILLIAMSON JR, 1993, CURR OPIN STRUC BIOL, V3, P357, DOI 10.1016/S0959-440X(05)80106-X; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3	36	63	66	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9413	9419		10.1074/jbc.270.16.9413	http://dx.doi.org/10.1074/jbc.270.16.9413			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721866	hybrid			2022-12-25	WOS:A1995QU08900055
J	KOUNNAS, MZ; CHAPPELL, DA; WONG, H; ARGRAVES, WS; STRICKLAND, DK				KOUNNAS, MZ; CHAPPELL, DA; WONG, H; ARGRAVES, WS; STRICKLAND, DK			THE CELLULAR INTERNALIZATION AND DEGRADATION OF HEPATIC LIPASE IS MEDIATED BY LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN AND REQUIRES CELL-SURFACE PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; TRIGLYCERIDE LIPASE; RAT-LIVER; BINDING; HYDROLYSIS; PLASMA; CHYLOMICRONS; ACCUMULATION; CATABOLISM; INHIBITION	Hepatic lipase (HL) and lipoprotein lipase (LpL) are structurally related lipolytic enzymes that have distinct functions in lipoprotein catabolism. In addition to its lipolytic activity, LpL binds to very low density lipoproteins and promotes their interaction with the low density lipoprotein receptor-related protein (LRP) (Chappell, D. A., Fry, G. L., Waknitz, M. A., Muhonen, L. E., Pladet M. W., Iverius, P. H., and Strickland, D. K. (1993) J. Biol. Chem. 268, 14168-14175). In vitro binding assays revealed that HL also binds to purified LRP with a K-D of 52 nM. Its binding to LRP is inhibited by the 39-kDa receptor associated protein (RAP), a known LRP antagonist, and by heparin. I-125-Labeled HL is rapidly internalized and degraded by HepG2 cell lines, and approximately 70% of the cellular internalization and degradation is blocked by either exogenously added RAP or anti LRP IgG. Mouse fibroblasts that lack LRP display a greatly diminished capacity to internalize and degrade HL when compared to control fibroblasts. These data indicate that LRP-mediated cellular uptake of HL accounts for a substantial portion of the internalization of this molecule. Proteoglycans have been shown to participate in the clearance of LpL, and consequently a role for proteoglycans in HL clearance pathway was also investigated. Chinese hamster ovary cell lines that are deficient in proteoglycan biosynthesis were unable to internalize or degrade I-125-HL despite the fact that these cells express LRP. Thus, the initial binding of HL to cell surface proteoglycans is an obligatory step for the delivery of the enzyme to LRP for endocytosis. A small, but significant, amount of I-125-HL was internalized in LRP deficient cells indicating that an LRP independent pathway for HL internalization does exist. This pathway could involve cell surface proteoglycans, the LDL receptor, or some other unidentified surface protein.	AMER RED CROSS,DEPT BIOCHEM,JEROME H HOLLAND LAB,ROCKVILLE,MD 20855; UNIV IOWA,COLL MED,DEPT MED,IOWA CITY,IA 52242; UNIV CALIF LOS ANGELES,VET ADM WADSWORTH MED CTR,LIPID RES LAB,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90073	American Red Cross; University of Iowa; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049264] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50787, HL49264] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BELCHER JP, 1988, CIRCULATION, V11, P145; BENZEEV O, 1987, BIOCHIM BIOPHYS ACTA, V919, P13, DOI 10.1016/0005-2760(87)90212-8; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CHANG SY, 1993, BIOCHEM J, V293, P745, DOI 10.1042/bj2930745; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; DAGGY BP, 1986, BIOCHIM BIOPHYS ACTA, V877, P252, DOI 10.1016/0005-2760(86)90302-4; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; ESKO JD, 1986, J BIOL CHEM, V261, P5725; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; FELTS JM, 1975, BIOCHEM BIOPH RES CO, V66, P1467, DOI 10.1016/0006-291X(75)90524-0; GOLDBERG IJ, 1982, J CLIN INVEST, V70, P1184, DOI 10.1172/JCI110717; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; HEGELE RA, 1993, ARTERIOSCLER THROMB, V13, P720, DOI 10.1161/01.ATV.13.5.720; HERZ J, 1991, J BIOL CHEM, V266, P21232; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; HORNICK CA, 1992, J BIOL CHEM, V267, P3396; HUFF MW, 1993, ARTERIOSCLER THROMB, V13, P1282, DOI 10.1161/01.ATV.13.9.1282; JENSEN GL, 1982, BIOCHIM BIOPHYS ACTA, V710, P464, DOI 10.1016/0005-2760(82)90130-8; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1994, J BIOL CHEM, V269, P13429; KOMAROMY MC, 1991, J LIPID RES, V32, P963; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KUUSI T, 1979, BIOCHEM J, V181, P245, DOI 10.1042/bj1810245; KUUSI T, 1979, FEBS LETT, V104, P384, DOI 10.1016/0014-5793(79)80858-3; LABODA HM, 1986, BIOCHIM BIOPHYS ACTA, V876, P233, DOI 10.1016/0005-2760(86)90279-1; MARTEAU C, 1988, LIFE SCI, V42, P533, DOI 10.1016/0024-3205(88)90094-X; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MIKHAILENKO I, 1995, IN PRESS J BIOL CHEM, V270; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NILSSON A, 1987, J LIPID RES, V28, P510; NILSSONEHLE P, 1980, ANNU REV BIOCHEM, V49, P667, DOI 10.1146/annurev.bi.49.070180.003315; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; Olivecrona T, 1990, CURR OPIN LIPIDOL, V1, P222; SHAFI S, 1994, J LIPID RES, V35, P709; SHIRAI K, 1981, BIOCHEM BIOPH RES CO, V100, P591, DOI 10.1016/S0006-291X(81)80217-3; STRICKLAND DK, 1994, FIBRINOLYSIS, V8, P204, DOI 10.1016/0268-9499(94)90718-8; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	53	113	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9307	9312		10.1074/jbc.270.16.9307	http://dx.doi.org/10.1074/jbc.270.16.9307			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721852	hybrid			2022-12-25	WOS:A1995QU08900040
J	LADU, MJ; PEDERSON, TM; FRAIL, DE; REARDON, CA; GETZ, GS; FALDUTO, MT				LADU, MJ; PEDERSON, TM; FRAIL, DE; REARDON, CA; GETZ, GS; FALDUTO, MT			PURIFICATION OF APOLIPOPROTEIN-E ATTENUATES ISOFORM-SPECIFIC BINDING TO BETA-AMYLOID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALZHEIMER-DISEASE; CLEAVAGE; PROTEIN; ALLELE; NERVE	Apolipoprotein E (apoE), particularly the e4 allele, is genetically linked to the incidence of Alzheimer's disease. In vitro, apoE has been shown to bind beta-amyloid (A beta), an amyloidogenic peptide that aggregates to form the primary component of senile plaques. In previous work, we demonstrated that apoE3 from tissue culture medium binds to A beta with greater avidity than apoE4 (LaDu, M. J., Falduto, M. T., Manelli, A. M., Reardon, C. A., Getz, G, S., and Frail, D. E. (1994) J. Biol. Chem. 269, 23403-23406). This is in contrast to data using purified apoE isoforms as substrate for A beta (Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L.-M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., and Roses, A. D. (1993) Proc. Natl. Acad. Sci. U.S. A. 90, 8098-8102). Here we resolve this apparent discrepancy by demonstrating that the preferential binding of A beta to apoE3 is attenuated and even abolished with purification, a process that includes delipidation and denaturation. We compared the A beta binding capacity of unpurified apoE isoforms from both tissue culture medium and intact human very low density lipoproteins with that of apoE purified from these two sources. The interaction of human A beta-(1-40)-peptide and apoE was analyzed by nonreducing SDS-polyacrylamide gel electrophoresis followed by Western immunoblotting for either A beta or apoE immunoreactivity. While the level of the apoE3 . A beta complex was similar to 20-fold greater compared with the apoE4 . A beta complex in unpurified conditioned medium, apoE3 and apoE4 purified from this medium bound to A beta with comparable avidity. Moreover, using endogenous apoE on very low density lipoproteins from plasma of apoE3/3 and apoE4/4 homozygotes, apoE3 was again a better substrate for A beta than apoE4. However, apoE purified from these plasma lipoproteins exhibited little isoform specificity in binding to A beta. These results suggest that native preparations of apoE may be a more physiologically relevant substrate for A beta binding than purified apoE and further underscore the importance of subtle differences in apoE conformation to its biological activity.	ABBOTT LABS,DIV PHARMACEUT PROD,ABBOTT PK,IL 60064	Abbott Laboratories	LADU, MJ (corresponding author), UNIV CHICAGO,DEPT PATHOL MC6079,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.			LaDu, Mary Jo/0000-0003-2141-1450	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL015062, F32HL008833] Funding Source: NIH RePORTER; NHLBI NIH HHS [1F32 HL08833-01, HL15062] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; HIXSON JE, 1990, J LIPID RES, V31, P545; Innerarity T L, 1986, Methods Enzymol, V129, P542; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; RALL SC, 1986, METHOD ENZYMOL, V128, P273; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Weisgraber K H, 1986, Methods Enzymol, V129, P145; WHITSON JS, 1994, BIOCHEM BIOPH RES CO, V199, P163, DOI 10.1006/bbrc.1994.1209; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423	23	170	175	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9039	9042		10.1074/jbc.270.16.9039	http://dx.doi.org/10.1074/jbc.270.16.9039			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721816	hybrid			2022-12-25	WOS:A1995QU08900004
J	LINDSEY, S; HARWOOD, HJ				LINDSEY, S; HARWOOD, HJ			INHIBITION OF MAMMALIAN SQUALENE SYNTHETASE-ACTIVITY BY ZARAGOZIC ACID A IS A RESULT OF COMPETITIVE-INHIBITION FOLLOWED BY MECHANISM-BASED IRREVERSIBLE INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESQUALENE PYROPHOSPHATE; CHOLESTEROL-BIOSYNTHESIS; DISSOCIATION-CONSTANTS; STRUCTURE ELUCIDATION; AMMONIUM ANALOGS; POTENT INHIBITOR; RAT-LIVER; SYNTHASE; ENZYME; DIPHOSPHATE	Squalene synthetase (SQS, EC 2.5.1.21) catalyzes the first committed step in the formation of cholesterol and thus represents an ideal site for selectively inhibiting sterol formation. Previous studies have demonstrated that the fungal metabolite, zaragozic acid A (ZGA-A), inhibits SQS activity by mimicking the substrate farnesyl pyrophosphate, the reaction intermediate presqualene pyrophosphate, or both, through a process that confers increased apparent potency in the presence of reduced enzyme concentrations, an observation consist ent with either tight binding reversible competitive inhibition or mechanism-based irreversible inactivation. The studies outlined in this report provide multiple lines of evidence indicating that ZGA-A acts as a mechanism-based irreversible inactivator of SQS. 1) Inhibition of SQS by ZGA-A is dependent on the [SQS] present in the incubation reaction, and this inhibition is time dependent and follows pseudo-first order reaction kinetics, exhibiting hobs values that range between 2 x 10(-4)/s and 23 x 10(-4)/s for [ZGA-A] within the log-linear range of the inhibition curve, and a bimolecular rate constant of 2.3 x 10(5) M(-1) s(-1). 2) SQS activity is titratable by ZGA-A, such that for each [ZGA-A] evaluated, inactivation exhibits a threshold [SQS] whereby enzyme activity at lower [SQS] is totally inhibited. 3) Time dependent inactivation exhibits saturation kinetics with a K-m for the process of 2.5 nM, which is approximately equal to the IC50 for SQS inhibition under these conditions, suggesting that inactivation results from selective modification of a functional group of the enzyme active center rather than from a nonspecific bimolecular reaction mechanism and that most, if not all of the inhibition results from irreversible inactivation. 4) Saturable, time-dependent inactivation occurs with similar inactivation kinetics for both the microsomal and trypsin-solubilized forms of the enzyme, indicating that irreversible inactivation by ZGA-A is not a consequence of membrane modification but is a direct effect of the inhibitor on the enzyme. 5) Inactivation is biphasic, exhibiting a rapid (''burst'') phase followed by a second, pseudo-first order phase, similar to that previously noted for irreversible inactivators in other enzyme systems, and occurs even in the presence of 5 mM concentrations of the nucleophylic scavenger dithiothreitol, suggesting that the reaction between ZGA-A and SQS occurs at or near the active center prior to diffusion of reactive species out of the catalytic cleft. 6) Inactivation can be prevented through competition with the substrate, farnesyl pyrophosphate, further identifying the active center as the site of modification. 7) The inhibitory effects of ZGA-A cannot be reversed either by lowering the [ZGA-A] to noninhibitory levels by dilution or by removal of unreacted ZGA-A from the enzyme by repetitive centrifugation, suggesting that enzyme modification is covalent. 8) The alpha,beta-unsaturated carbonyl moiety of ZGA-A, which is similar to related Michael acceptor moieties present in a variety of mechanism-based inactivators identified in other enzyme systems, appears to be required for eliciting the time dependent irreversible inactivation of SQS by ZGA-A and related alpha,beta-unsaturated carbonyl-containing analogs. 9) Observations similar to those described above were not noted for any of a number of other competitive inhibitors of SQS from a variety of diverse structural classes, whose K-i values for SQS inhibition ranged from 3 to 700 nM, suggesting that the mechanism-based irreversible inactivation of SQS by ZGA-A appears to be specific to this class of compounds rather than to inhibition of SQS per se. These observations strongly suggest that inhibition of SQS by ZGA-A and related analogs occurs through a mechanism-based irreversible inactivation process, presumably with formation of a covalent ZGA-A-SQS adduct that is catalytically incompetent. ZGA-A and related analogs may thus serve as useful tools for probing the substrate binding sites and catalytic reaction centers within the active center of SQS and for further evaluating the unique catalytic mechanisms of this important enzyme.	PFIZER INC,PFIZER CENT RES,DEPT METAB DIS,GROTON,CT 06340	Pfizer								AGNEW WS, 1985, METHOD ENZYMOL, V110, P359; AMIN D, 1992, J LIPID RES, V33, P1657; ATOR MA, 1990, ENZYMES, V19, P213; BAXTER A, 1992, J BIOL CHEM, V267, P11705; BAZAES S, 1987, CHEM MODIFICATION EN, P35; BERGSTROM JD, 1993, P NATL ACAD SCI USA, V90, P80, DOI 10.1073/pnas.90.1.80; BEYTIA E, 1973, J BIOL CHEM, V248, P1856; BILLER SA, 1988, J MED CHEM, V31, P1869, DOI 10.1021/jm00118a001; BILLER SA, 1991, J MED CHEM, V34, P1912, DOI 10.1021/jm00110a024; BILLER SA, 1991, J AM CHEM SOC, V113, P8522, DOI 10.1021/ja00022a050; BROCKLEHURST K, 1979, BIOCHEM J, V181, P775, DOI 10.1042/bj1810775; BROWN GR, 1993, Patent No. 9313096; BROWN MS, 1980, J LIPID RES, V21, P505; BRUENGER E, 1986, BIOCHIM BIOPHYS ACTA, V876, P500, DOI 10.1016/0005-2760(86)90037-8; CAPSON TL, 1988, J ORG CHEM, V53, P5903, DOI 10.1021/jo00260a019; CARDEMIL E, 1987, CHEM MODIFICATIONS E, P23; CIOSEK CP, 1993, J BIOL CHEM, V268, P24832; COLEMAN RF, 1990, ENZYMES, V19, P283; CONNOLLY BA, 1979, EUR J BIOCHEM, V93, P375, DOI 10.1111/j.1432-1033.1979.tb12833.x; COPP LJ, 1987, BIOCHEMISTRY-US, V26, P169, DOI 10.1021/bi00375a024; COREY EJ, 1976, J AM CHEM SOC, V98, P1291, DOI 10.1021/ja00421a056; DAWSON MJ, 1992, J ANTIBIOT, V45, P639, DOI 10.7164/antibiotics.45.639; de Montellano P R, 1977, J Med Chem, V20, P243; DEMONTELLANO PRO, 1977, BIOCHEMISTRY-US, V16, P2680; DEWAR MJS, 1987, TETRAHEDRON, V43, P2661, DOI 10.1016/S0040-4020(01)86871-X; DIXON M, 1972, BIOCHEM J, V129, P197, DOI 10.1042/bj1290197; DUFRESNE C, 1992, TETRAHEDRON, V48, P10221, DOI 10.1016/S0040-4020(01)88327-7; FAUST JR, 1979, P NATL ACAD SCI USA, V76, P5018, DOI 10.1073/pnas.76.10.5018; FERSHT A, 1985, ENZYME STRUCTURE MEC, P121; FERSHT A, 1985, ENZYME STRUCTURE MEC, P248; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HARWOOD HJ, 1995, ANAL BIOCHEM, V226, P268, DOI 10.1006/abio.1995.1225; HARWOOD HJ, 1993, J LIPID RES, V34, P377; HASUMI K, 1993, J ANTIBIOT, V46, P689, DOI 10.7164/antibiotics.46.689; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; KELLER RK, 1993, BIOCHIM BIOPHYS ACTA, V1170, P204, DOI 10.1016/0005-2760(93)90072-H; KELLER RK, 1987, J BIOL CHEM, V261, P12053; KIICK DM, 1984, BIOCHEMISTRY-US, V23, P5454, DOI 10.1021/bi00318a012; KOYAMA T, 1980, BIOCHIM BIOPHYS ACTA, V617, P218; LINDSEY S, 1994, FASEB J, V8, pA1285; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MCKENZIE TL, 1992, J BIOL CHEM, V267, P21368; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; NESS GC, 1994, ARCH BIOCHEM BIOPHYS, V311, P277, DOI 10.1006/abbi.1994.1238; OEHLSCHLAGER AC, 1991, J ORG CHEM, V56, P3856, DOI 10.1021/jo00012a016; PANINI SR, 1985, REGULATION HMG COA R, P149; PISZKIEWICZ D, 1977, KINETICS CHEM ENZYME, P79; PLAPP BV, 1982, METHOD ENZYMOL, V87, P469; POPJAK G, 1979, MOL CELL BIOCHEM, V27, P97; Poulter C, 1981, BIOSYNTHESIS ISOPREN, P413; POULTER CD, 1990, ACCOUNTS CHEM RES, V23, P70, DOI 10.1021/ar00171a003; POULTER CD, 1989, J AM CHEM SOC, V111, P3734, DOI 10.1021/ja00192a036; PRASHAD M, 1993, J MED CHEM, V36, P1501, DOI 10.1021/jm00062a026; PRASHAD M, 1993, EUR J MED CHEM, V28, P527, DOI 10.1016/0223-5234(93)90022-7; QUESNEYHUNEEUS V, 1983, J BIOL CHEM, V258, P378; Rando R R, 1977, Methods Enzymol, V46, P28; RENOSTO F, 1985, J BIOL CHEM, V260, P1903; RILLING HC, 1985, BIOCHEM SOC T, V13, P997, DOI 10.1042/bst0130997; ROBINSON GW, 1993, MOL CELL BIOL, V13, P2706, DOI 10.1128/MCB.13.5.2706; ROGERS DH, 1980, ANAL BIOCHEM, V101, P107, DOI 10.1016/0003-2697(80)90047-0; SANDIFER RM, 1982, J AM CHEM SOC, V104, P7376, DOI 10.1021/ja00389a106; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; SEGEL IH, 1976, BIOCH CALCULATIONS, P257; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; SIDEBOTTOM PJ, 1992, J ANTIBIOT, V45, P648, DOI 10.7164/antibiotics.45.648; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEIGER A, 1992, J ORG CHEM, V57, P3444, DOI 10.1021/jo00038a038; TAIT RM, 1992, ANAL BIOCHEM, V203, P310, DOI 10.1016/0003-2697(92)90318-2; WALSH CT, 1984, ANNU REV BIOCHEM, V53, P493, DOI 10.1146/annurev.bi.53.070184.002425; WASHBURN W N, 1977, Tetrahedron Letters, V18, P1555, DOI 10.1016/S0040-4039(01)93101-6; WESTKAEMPER RB, 1983, BIOCHEMISTRY-US, V22, P3256, DOI 10.1021/bi00282a034	72	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9083	9096		10.1074/jbc.270.16.9083	http://dx.doi.org/10.1074/jbc.270.16.9083			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721822				2022-12-25	WOS:A1995QU08900010
J	MOASSER, MM; REUTER, VE; DMITROVSKY, E				MOASSER, MM; REUTER, VE; DMITROVSKY, E			OVEREXPRESSION OF THE RETINOIC ACID RECEPTOR-GAMMA DIRECTLY INDUCES TERMINAL DIFFERENTIATION OF HUMAN EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article						RETINOIC ACID; DIFFERENTIATION; EMBRYONAL CARCINOMA; EPISOMAL VECTOR; RAR-GAMMA	ACUTE PROMYELOCYTIC LEUKEMIA; TERATOCARCINOMA STEM-CELLS; EPSTEIN-BARR VIRUS; GRANULOCYTIC DIFFERENTIATION; NUCLEAR RECEPTORS; EXPRESSION; ALPHA; GENE; MOUSE; ISOFORMS	All-trans retinoic acid (RA) exerts profound effects on the growth and differentiation of normal, embryonic, and malignant cells. The effects of RA are mediated through multiple members of the retinoic acid receptor (RAR) and retinoid X receptor (RXR) families of nuclear transcription factors, The RARs and RXRs exhibit specific patterns of expression during development and in adult tissues suggesting tissue or cell-type specific functions. Using NTera2/clone D1 (NT2/D1) human embryonal carcinoma cells as a model, we report that the RA induced terminal differentiation of these cells into a neuronal phenotype is characterized by an increase in expression of RAR alpha, RAR beta, RAR gamma, and a slight induction of RXR alpha. TO study the role of these receptors in the differentiation process we individually overexpressed RAR alpha, beta, gamma and RXR alpha in NT2/D1 cells by cDNA transfection. Using induced cDNA expression by episomal vector amplification we show that RAR gamma overexpression causes the terminal mesenchymal differentiation of these cells,while over-expresssion of RAR alpha, beta and RXR alpha has no observed maturation or growth inhibitory effects. Over-expression of these receptors in the derived RA resistant subclone NT2/D1-R1 showed phenotypic changes characteristic of RA response in RAR gamma transfectants. These studies indicate that of the retinoid receptors expressed in RA-treated NT2/D1 cells, it is the upregulation of RAR gamma that specifically induces the terminal differentiation of these cells.	MEM HOSP,DEPT MED,MOLEC MED LAB,NEW YORK,NY 10021; MEM HOSP,DEPT PATHOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,DEPT MOLEC PHARMACOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,THERAPEUT PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [1R01-CA54494-03, T32-CA-09512-10] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009512, R01CA054494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1987, J CELL BIOCHEM, V35, P321, DOI 10.1002/jcb.240350407; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1981, BLOOD, V57, P1000; CANFIELD V, 1990, MOL CELL BIOL, V10, P1367, DOI 10.1128/MCB.10.4.1367; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MADER S, 1993, J BIOL CHEM, V268, P591; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANIATIS T, 1989, COLD SPRING HARBOR L; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MERRIMAN RL, 1979, CANCER RES, V39, P1661; MOASSER MM, 1994, ONCOGENE, V9, P833; MOON RC, 1983, CANCER RES, V43, P24696; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SAMANIEGO F, 1990, GENE CHROMOSOME CANC, V1, P289, DOI 10.1002/gcc.2870010406; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x	41	49	49	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1537	1543						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731708				2022-12-25	WOS:A1995QU68100009
J	BOHM, GA; PFLEIDERER, W; BOGER, P; SCHERER, S				BOHM, GA; PFLEIDERER, W; BOGER, P; SCHERER, S			STRUCTURE OF A NOVEL OLIGOSACCHARIDE-MYCOSPORINE-AMINO ACID ULTRAVIOLET A/B SUNSCREEN PIGMENT FROM THE TERRESTRIAL CYANOBACTERIUM NOSTOC COMMUNE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UV; GLYCOSIDES; EXPOSURE	Water-soluble UV-A/B-absorbing pigments are secreted by cells of the cosmopolitan terrestrial cyanobacterium Nostoc commune. The pigments constitute a complex mixture of monomers with molecular masses of up to 1801 Da. Two different chromophores with absorption maxima at 312 and 335 nm are linked to different amino acids and to oligosaccharides consisting of galactose, glucose, xylose, glucuronic acid, and glucosamine. The 335 nm chromophore is a 1,3-diaminocyclohexen derivative, while the chromophore with an absorption maximum at 312 nm is most likely a 3-aminocyclohexen-1-one derivative. These UV-inducible substances are the first mycosporines to be described covalently linked to oligosaccharides. The pigments are located in the extracellular glycan sheath of Nostoc colonies, where they form complexes of extremely high molecular mass that are attached noncovalently to the glycan sheath. Pigments occur in concentrations that permit the cells to attenuate a significant part of incident UV-B radiation.	TECH UNIV MUNICH,INST MIKROBIOL,D-85350 FREISING,GERMANY; UNIV KONSTANZ,FAK CHEM,D-78434 CONSTANCE,GERMANY; UNIV KONSTANZ,LEHRSTUHL PHYSIOL & BIOCHEM PFLANZEN,D-78434 CONSTANCE,GERMANY	Technical University of Munich; University of Konstanz; University of Konstanz			Scherer, Siegfried/I-1320-2013	Scherer, Siegfried/0000-0002-0394-9890				AGRAWAL PK, 1992, PHYTOCHEMISTRY, V31, P3307, DOI 10.1016/0031-9422(92)83678-R; BOCK K, 1984, ADV CARBOHYD CHEM BI, V42, P193, DOI 10.1016/S0065-2318(08)60125-0; CHIOCCARA F, 1980, B SOC CHIM BELG, V89, P1101; DILL K, 1985, ADV CARBOHYD CHEM BI, V43, P1, DOI 10.1016/S0065-2318(08)60066-9; FOSTER AB, 1957, J CHEM SOC, P81, DOI 10.1039/jr9570000081; FRANSSON LA, 1984, MOL BIOPHYSICS EXTRA, P95; GARCIAPICHEL F, 1993, APPL ENVIRON MICROB, V59, P163, DOI 10.1128/AEM.59.1.163-169.1993; GARCIAPICHEL F, 1993, APPL ENVIRON MICROB, V59, P170, DOI 10.1128/AEM.59.1.170-176.1993; GAUCH R, 1979, J CHROMATOGR, V174, P195, DOI 10.1016/S0021-9673(00)87050-8; GORIN PAJ, 1975, CAN J CHEM, V53, P1212, DOI 10.1139/v75-168; HILL DR, 1994, J BIOL CHEM, V269, P7726; ITO S, 1977, TETRAHEDRON LETT, P2429; KARENTZ D, 1991, MAR BIOL, V108, P157, DOI 10.1007/BF01313484; PLACK PA, 1981, BIOCHEM J, V199, P741, DOI 10.1042/bj1990741; POST A, 1993, AQUAT BOT, V45, P231, DOI 10.1016/0304-3770(93)90023-P; POTTS M, 1994, MICROBIOL REV, V58, P755, DOI 10.1128/MMBR.58.4.755-805.1994; REBERS PA, 1986, CARBOHYD RES, V153, P132, DOI 10.1016/S0008-6215(00)90202-7; SCHERER S, 1991, MICROBIAL ECOL, V22, P271, DOI 10.1007/BF02540229; SCHERER S, 1988, PLANT PHYSIOL, V88, P1055, DOI 10.1104/pp.88.4.1055; SCHERER S, 1989, J BIOL CHEM, V264, P12546; SHIBATA K, 1969, PLANT CELL PHYSIOL, V10, P325; SPIRO MJ, 1992, ANAL BIOCHEM, V204, P152, DOI 10.1016/0003-2697(92)90155-Z; TAKANO S, 1979, CHEM LETT, P419, DOI 10.1246/cl.1979.419; TAKANO S, 1978, TETRAHEDRON LETT, P4909; WAKABAYASHI K, 1974, CARBOHYD RES, V35, P3, DOI 10.1016/S0008-6215(00)84828-4	25	127	135	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8536	8539		10.1074/jbc.270.15.8536	http://dx.doi.org/10.1074/jbc.270.15.8536			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721752	hybrid			2022-12-25	WOS:A1995QT44800028
J	BONSCH, D; KAMMER, W; LISCHKE, A; FRIEDRICH, K				BONSCH, D; KAMMER, W; LISCHKE, A; FRIEDRICH, K			SPECIES-SPECIFIC AGONIST-ANTAGONIST ACTIVITIES OF HUMAN INTERLEUKIN-4 VARIANTS SUGGEST DISTINCT LIGAND-BINDING PROPERTIES OF HUMAN AND MURINE COMMON RECEPTOR-GAMMA CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR RECEPTOR; GROWTH-HORMONE RECEPTOR; SIGNAL-TRANSDUCTION; CELL-LINES; CYTOPLASMIC DOMAIN; MOUSE; ESTABLISHMENT; SUPERFAMILY; MUTAGENESIS; ACTIVATION	Interleukin-4 (IL-4) is a pleiotropic cytokine eliciting various responses in target cells upon binding to its receptor. Activation of the IL-4 receptor probably involves interaction of the ligand with both the IL-4 receptor alpha subunit (IL-4R alpha) and the common gamma chain (c gamma). Although human and murine IL-4 receptor alpha chains are specific for IL-4 from the same species, murine c gamma can form a signal-competent complex with human IL-4R alpha (hIL-4R alpha) and human IL-4 (hIL-4). We have generated a hIL-4 responsive murine myeloid cell line (FDC-4G) expressing a chimera comprising the extracellular domain of human IL-4R alpha and the intracellular domain of human granulocyte colony-stimulating factor receptor (hG-CSFR). This hybrid receptor was shown to form a complex with hIL-4 and the murine c gamma-chain. Biological activities of human IL-4 variants on murine FDC-4G cells and on the human erythroleukemic cell line TF-1 displayed a strikingly different pattern. Single amino acid replacements at two different positions in the C-terminal helix of hIL-4, the region of the previously defined ''signaling site,'' lead to an inverse agonist/antagonist behavior of the resulting cytokines in the two cellular systems. From these findings we conclude that upon formation of the activated IL-4 receptor complex murine and human c gamma interact with hIL-4 in a geometrically different fashion.	UNIV WURZBURG,THEODOR BOVERI INST BIOWISSENSCH BIOZENTRUM,D-97074 WURZBURG,GERMANY	University of Wurzburg								BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; CABRILLAT H, 1987, BIOCHEM BIOPH RES CO, V149, P995, DOI 10.1016/0006-291X(87)90507-9; CARR C, 1991, BIOCHEMISTRY-US, V30, P1515, DOI 10.1021/bi00220a011; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Duschl A, 1992, Eur Cytokine Netw, V3, P97; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; HARADA N, 1992, J BIOL CHEM, V267, P22752; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOETTNITZ K, 1993, EUR J IMMUNOL, V23, P988, DOI 10.1002/eji.1830230437; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; KRUSE N, 1991, FEBS LETT, V286, P58, DOI 10.1016/0014-5793(91)80939-Z; KUMAKI S, 1993, BIOCHEM BIOPH RES CO, V193, P356, DOI 10.1006/bbrc.1993.1631; MATSUDA T, 1994, BLOOD, V83, P3457; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MORRISON BW, 1992, J BIOL CHEM, V267, P11957; MULLER T, 1994, J MOL BIOL, V237, P423, DOI 10.1006/jmbi.1994.1245; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; OHARE K, 1981, P NATL ACAD SCI-BIOL, V78, P1527, DOI 10.1073/pnas.78.3.1527; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAKAMAKI K, 1993, J BIOL CHEM, V268, P15833; Sambrook J, 1989, MOL CLONING LABORATO; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	39	22	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8452	8457		10.1074/jbc.270.15.8452	http://dx.doi.org/10.1074/jbc.270.15.8452			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721740	hybrid			2022-12-25	WOS:A1995QT44800016
J	DOKTYCZ, MJ; MORRIS, MD; DORMADY, SJ; BEATTIE, KL				DOKTYCZ, MJ; MORRIS, MD; DORMADY, SJ; BEATTIE, KL			OPTICAL MELTING OF 128-OCTAMER DNA DUPLEXES - EFFECTS OF BASE-PAIR LOCATION AND NEAREST NEIGHBORS ON THERMAL-STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE DETERMINATION; PRIMER WALKING; HYBRIDIZATION; HEXAMERS; STACKING; OLIGONUCLEOTIDES; STRATEGY; LIBRARY; STRINGS; CURVES	The use of short oligonucleotide probes is finding increased application in DNA sequencing and genome characterization techniques, but a lack of knowledge of the hybridization properties of short duplexes hinders their use. Melting data were acquired on 128 DNA duplexes based on the length proposed in sequencing by hybridization procedures and formed from the general sequences 5'-XYZTGGAC-3', 5'-GTCCAXYZ-3', 5'-GCXYZGAC-3', and 5'-GTCXYZGC-3' where X, Y, and Z are either A, T, G, or C. These molecules were designed to elucidate the effects of location and nearest neighbor stacking on the stability of base pairing in short DNA duplexes. The type of base pairs present had a major effect on stability, but was insufficient to predict stability without the inclusion of nearest-neighbor terms. Furthermore, the addition of information on position, or distance from the end, of the nearest-neighbor doublets led to statistically better fitting of the melting data. However, the positionally dependent stabilization differences are small compared with the contributions of base pairing and stacking.	OAK RIDGE NATL LAB,DIV MATH & COMP SCI,OAK RIDGE,TN 37831; HOUSTON ADV RES CTR,DNA TECHNOL LAB,THE WOODLANDS,TX 77831	United States Department of Energy (DOE); Oak Ridge National Laboratory	DOKTYCZ, MJ (corresponding author), OAK RIDGE NATL LAB,DIV HLTH SCI RES,OAK RIDGE,TN 37831, USA.		Doktycz, Mitchel J/A-7499-2011	Doktycz, Mitchel J/0000-0003-4856-8343	NHGRI NIH HHS [1 P20 HG00666] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AZHIKINA T, 1993, P NATL ACAD SCI USA, V90, P11460, DOI 10.1073/pnas.90.24.11460; BAINS W, 1988, J THEOR BIOL, V135, P303, DOI 10.1016/S0022-5193(88)80246-7; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; DELCOURT SG, 1991, J BIOL CHEM, V266, P15160; DOKTYCZ MJ, 1992, BIOPOLYMERS, V32, P849, DOI 10.1002/bip.360320712; DRMANAC R, 1993, SCIENCE, V260, P1649, DOI 10.1126/science.8503011; DRMANAC R, 1989, GENOMICS, V4, P114; DRMANAC R, 1992, ELECTROPHORESIS, V13, P566, DOI 10.1002/elps.11501301115; FODOR SPA, 1993, NATURE, V364, P555, DOI 10.1038/364555a0; GOLDSTEIN RF, 1992, BIOPOLYMERS, V32, P1679, DOI 10.1002/bip.360321210; GOTOH O, 1981, BIOPOLYMERS, V20, P1033, DOI 10.1002/bip.1981.360200513; KACZOROWSKI T, 1994, ANAL BIOCHEM, V221, P127, DOI 10.1006/abio.1994.1388; KIELECZAWA J, 1992, SCIENCE, V258, P1787, DOI 10.1126/science.1465615; KOTLER LE, 1993, P NATL ACAD SCI USA, V90, P4241, DOI 10.1073/pnas.90.9.4241; LEIJON M, 1992, NUCLEIC ACIDS RES, V20, P5339, DOI 10.1093/nar/20.20.5339; LYSOV YP, 1988, DOKL AKAD NAUK SSSR, V303, P1508; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; MIRZABEKOV AD, 1994, TRENDS BIOTECHNOL, V12, P27, DOI 10.1016/0167-7799(94)90008-6; ORNSTEIN RL, 1983, BIOPOLYMERS, V22, P1979, DOI 10.1002/bip.360220811; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; Snedecor GW, 1967, STATISTICAL METHODS, P285; SOUTHERN EM, 1992, GENOMICS, V13, P1008, DOI 10.1016/0888-7543(92)90014-J; STREZOSKA Z, 1991, P NATL ACAD SCI USA, V88, P10089, DOI 10.1073/pnas.88.22.10089; STUDIER FW, 1989, P NATL ACAD SCI USA, V86, P6917, DOI 10.1073/pnas.86.18.6917; SZYBALSKI W, 1990, GENE, V90, P177, DOI 10.1016/0378-1119(90)90458-4; VOLOGODSKII AV, 1984, J BIOMOL STRUCT DYN, V2, P131, DOI 10.1080/07391102.1984.10507552; WARTELL RM, 1985, PHYS REP, V126, P67, DOI 10.1016/0370-1573(85)90060-2; WETMUR JG, 1991, CRIT REV BIOCHEM MOL, V26, P227, DOI 10.3109/10409239109114069	28	70	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8439	8445		10.1074/jbc.270.15.8439	http://dx.doi.org/10.1074/jbc.270.15.8439			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721738	hybrid			2022-12-25	WOS:A1995QT44800014
J	ONG, OC; YAMANE, HK; PHAN, KB; FONG, HKW; BOK, D; LEE, RH; FUNG, BKK				ONG, OC; YAMANE, HK; PHAN, KB; FONG, HKW; BOK, D; LEE, RH; FUNG, BKK			MOLECULAR-CLONING AND CHARACTERIZATION OF THE G-PROTEIN GAMMA-SUBUNIT OF CONE PHOTORECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; ROD OUTER SEGMENTS; BETA-SUBUNIT; CYCLIC-GMP; SIGNAL TRANSDUCTION; RETINAL ROD; CDNA CLONE; AMINO-ACID; 3RD FORM; SEQUENCE	The phototransduction process in cones has been pro posed to involve a G protein that couples the signal from light-activated visual pigment to the effector cyclic GMP phosphodiesterase. Previously, we have identified and purified a G beta gamma complex composed of a G beta(3) isoform and an immunochemically distinct G gamma subunit (G gamma(8)) from bovine retinal cones (Fung, B. K.-K., Lieberman, B. S., and Lee, R. H. (1992) J. Biol. Chem. 267, 24782-24788; Lee, R. H., Lieberman, B, S., Yamane, H. K., Bok, D., and Fung, B. K.-K. (1992a) J. Biol. Chem. 267, 24776-24781). Based on the partial amino acid sequence of this cone G gamma(8), we screened a bovine retinal cDNA library and isolated a cDNA clone encoding G gamma(8). The cDNA insert of this clone includes an open reading frame of 207 bases encoding a 69-amino acid protein. The predicted protein sequence of G gamma(8) shares a high degree of sequence identity (68%) with the G gamma (G gamma(1)) subunit of rod transducin. Similar to rod G gamma(1), it terminates in a CIIS motif that is the site for post-translational modification by farnesylation. Messenger RNA for G gamma(8) is present at a high level in the retina and at a very low level in the lung, but is undetectable in other tissues. Immunostaining of bovine retinal sections with an antipeptide antibody against the N-terminal region of G gamma(8) further shows a differential localization of G gamma(8) to cones with a pattern indistinguishable from that of G beta(3). This finding suggests that G beta(3) gamma(8) is a component of cone transducin involved in cone phototransduction and color vision.	UNIV CALIF LOS ANGELES,SCH MED,JULES STEIN EYE INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROBIOL,LOS ANGELES,CA 90024; VET ADM MED CTR,MOLEC NEUROL LAB,SEPULVEDA,CA 91343; UNIV SO CALIF,SCH MED,DOHENY EYE INST,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT OPHTHALMOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); Doheny Eye Institute; University of Southern California; University of Southern California; University of Southern California					NATIONAL EYE INSTITUTE [R37EY000444, R01EY009936, R01EY005895, R01EY000444] Funding Source: NIH RePORTER; NEI NIH HHS [EY05895, EY 00444, EY09936] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COBBS WH, 1985, NATURE, V317, P64, DOI 10.1038/317064a0; EIDE B, 1987, BIOCHEM BIOPH RES CO, V148, P1398, DOI 10.1016/S0006-291X(87)80287-5; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1992, J BIOL CHEM, V267, P24782; FUNG BKK, 1994, METHOD ENZYMOL, V237, P509; FUNG BKK, 1983, J BIOL CHEM, V258, P495; FUNG BKK, 1986, PROG RETIN RES, V6, P151; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAYNES L, 1985, NATURE, V317, P61, DOI 10.1038/317061a0; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JIANG MS, 1991, P NATL ACAD SCI USA, V88, P3907, DOI 10.1073/pnas.88.9.3907; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LEE RH, 1992, J BIOL CHEM, V267, P24776; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1992, J BIOL CHEM, V267, P25104; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LOLLEY RN, 1990, FASEB J, V4, P3001, DOI 10.1096/fasebj.4.12.1697545; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NAKATANI K, 1986, Investigative Ophthalmology and Visual Science, V27, P300; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; PUGH EN, 1986, VISION RES, V26, P1613, DOI 10.1016/0042-6989(86)90051-9; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; STRYER L, 1991, J BIOL CHEM, V266, P10711; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1993, ANN REV PHARM TOXICO, V32, P201; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936; YAU KW, 1994, INVEST OPHTH VIS SCI, V35, P9	58	80	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8495	8500		10.1074/jbc.270.15.8495	http://dx.doi.org/10.1074/jbc.270.15.8495			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721746	hybrid			2022-12-25	WOS:A1995QT44800022
J	RIGLER, MN; ROMANO, LJ				RIGLER, MN; ROMANO, LJ			DIFFERENCES IN THE MECHANISM OF STIMULATION OF T7 DNA-POLYMERASE BY 2 BINDING MODES OF ESCHERICHIA-COLI SINGLE-STRANDED DNA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 DEOXYRIBONUCLEIC-ACID; GENE-4 PROTEIN; REPLICATION FORK; T7-DNA POLYMERASE; SSDNA COMPLEXES; RECA-PROTEIN; INVITRO; SSB; GENE-4-PROTEIN; OPERATIVITY	Escherichia coli single-stranded DNA-binding protein (Eco SSB) has been shown previously to display several DNA binding modes depending on the ionic conditions. To determine what effect these various binding modes have on DNA replication, we have studied DNA synthesis by the T7 DNA polymerase under ionic conditions where Eco SSB interacts with either 72 or 91 nucleotides of M13 DNA. These forms presumably correspond to the previously described (SSB)(56) land (SSB)(65) (Lohman and Ferrari, 1994) that were determined using the binding of SSB to homopolymers. Here we report the stimulation induced by (SSB)(91) to be 4-fold greater than that produced by (SSB)(72) under conditions where the template is in large excess. Surprisingly, when the polymerase level is raised so that it is in molecular excess, (SSB)(91) no longer stimulates synthesis while (SSB)(72) affords a 4-fold stimulation, which is the same level of stimulation as when the template was mi excess. Both SSB forms increase the rate of DNA synthesis and were found to stimulate synthesis by relieving template secondary structures. However, (SSB)(72) specifically increases strand displacement synthesis, while (SSB)(91) stimulates synthesis by increasing the affinity of the polymerase for the template.	WAYNE STATE UNIV,DEPT CHEM,DETROIT,MI 48202	Wayne State University					NATIONAL CANCER INSTITUTE [R01CA035451, R01CA040605] Funding Source: NIH RePORTER; NCI NIH HHS [CA40605, CA35451] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALATOSSAVA T, 1985, J BACTERIOL, V162, P413, DOI 10.1128/JB.162.1.413-419.1985; BANERJEE SK, 1990, J BACTERIOL, V172, P2105, DOI 10.1128/jb.172.4.2105-2112.1990; BROWN WC, 1989, J BIOL CHEM, V264, P6748; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; BUJALOWSKI W, 1988, J BIOL CHEM, V263, P4629; BUJALOWSKI W, 1989, J MOL BIOL, V207, P249, DOI 10.1016/0022-2836(89)90454-3; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P7799, DOI 10.1021/bi00372a003; CAMERON IL, 1980, CANCER RES, V40, P143; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; ENGLER MJ, 1983, J BIOL CHEM, V258, P1165; EPEL D, 1982, IONS CELL PROLIFERAT, P327; EPSTEIN W, 1965, J GEN PHYSIOL, V49, P221, DOI 10.1085/jgp.49.2.221; FULLER CW, 1985, J BIOL CHEM, V260, P3197; GREIPEL J, 1987, BIOPHYS CHEM, V26, P149, DOI 10.1016/0301-4622(87)80018-2; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; GRIFFITH JD, 1984, COLD SPRING HARB SYM, V49, P553, DOI 10.1101/SQB.1984.049.01.062; HAYES RC, 1983, GENE, V21, P1, DOI 10.1016/0378-1119(83)90141-5; HUBER HE, 1987, J BIOL CHEM, V262, P16224; Kowalczykowski S.C., 1981, ENZYMES, V14, P373; KRAUSS G, 1981, BIOCHEMISTRY-US, V20, P53246; KUHN A, 1985, J BACTERIOL, V163, P906, DOI 10.1128/JB.163.3.906-912.1985; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; LOHMAN TM, 1986, J MOL BIOL, V187, P603, DOI 10.1016/0022-2836(86)90338-4; LOHMAN TM, 1988, TRENDS BIOCHEM SCI, V13, P250; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Lohman TM., 1990, BIOL NONSPECIFIC DNA, P131; LUSK JE, 1968, J BIOL CHEM, V243, P2618; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MCCLELLAND M, 1988, NUCLEIC ACIDS RES, V16, P364, DOI 10.1093/nar/16.1.364; MEASURES JC, 1975, NATURE, V257, P398, DOI 10.1038/257398a0; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MORRICAL SW, 1990, BIOCHEMISTRY-US, V29, P837, DOI 10.1021/bi00455a034; MUNIYAPPA K, 1990, NUCLEIC ACIDS RES, V18, P3967, DOI 10.1093/nar/18.13.3967; MYERS TW, 1988, J BIOL CHEM, V263, P17006; NAKAI H, 1986, J BIOL CHEM, V261, P5217; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9831; NAKAI H, 1988, J BIOL CHEM, V263, P9818; Record M T Jr, 1985, Adv Biophys, V20, P109; RICHARDSON CC, 1971, PROCEDURES NUCLEIC A, V2, P815; RICHARDSON CC, 1983, REPLICATION VIRAL CE, P163; RICHEY B, 1987, J BIOL CHEM, V262, P7157; ROMANO LJ, 1979, J BIOL CHEM, V254, P476; ROMANO LJ, 1979, J BIOL CHEM, V254, P483; Sambrook J, 1989, MOL CLONING LABORATO; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; STEINHARDT RA, 1982, IONS CELL PROLIFERAT, P311; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1989, J BIOL CHEM, V264, P6447; WEINER JH, 1975, J BIOL CHEM, V250, P1972	54	6	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8910	8919		10.1074/jbc.270.15.8910	http://dx.doi.org/10.1074/jbc.270.15.8910			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721799	hybrid			2022-12-25	WOS:A1995QT44800078
J	SIDDIQI, AR; SMITH, JL; ROSS, AH; QUO, RG; SYMONS, M; EXTON, JH				SIDDIQI, AR; SMITH, JL; ROSS, AH; QUO, RG; SYMONS, M; EXTON, JH			REGULATION OF PHOSPHOLIPASE-D IN HL-60 CELLS - EVIDENCE FOR A CYTOSOLIC PHOSPHOLIPASE-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; ADP-RIBOSYLATION; PHOSPHATIDIC-ACID; CHOLERA-TOXIN; GROWTH-FACTOR; HL-60 GRANULOCYTES; ENDOTHELIAL-CELLS; 3T3 CELLS; RAT-BRAIN; ACTIVATION	Phospholipase D (PLD) activity that was stimulated by guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) was detected in cytosol and membranes of HL60 cells. GTP gamma S-stimulated PLD activity was detected in the membranes when exogenous labeled phosphatidylcholine was used in the presence of phosphatidylethanolamine and phosphatidylinositol 4,5-bisphosphate, but not when [H-3]myristic acid labeled endogenous substrate was used. Cytosolic PLD co-chromatographed with small GTP-binding proteins on anion exchange columns, but subsequent chromatography separated these. Reconstitution studies demonstrated ADP ribosylation factor (ARF) as a regulator of cytosolic PLD, whereas the Rho proteins RhoA and CDC42Hs were ineffective. The cytosolic enzyme showed very little activity in the absence of GTP gamma S and was stimulated by 2 mM Ca2+, whereas the membrane enzyme had significant basal activity and was inhibited by Ca2+. Rho-specific GDP dissociation inhibitor inhibited GTP gamma S stimulation of membrane PLD activity in the presence and absence of cytosol. The stimulation in GDP dissociation inhibitor-treated membranes could be partially recovered by the addition of recombinant Rho proteins (RhoA, Rac1, CDC42Hs). RhoA and Rac1 were also stimulatory in untreated membranes. However, Western blot analysis of membranes showed the presence of RhoA, but not Rac1 or CDC42Hs, suggesting that RhoA was the endogenous small GTP-binding protein involved in GTP-dependent PLD activity in membranes in the absence of cytosol. ARF also stimulated the membrane PLD in the presence of GTP gamma S, and the combination of RhoA and ARF showed a synergistic effect. These results show the presence of ARF-dependent PLD activity in both cytosol and membranes. The membranes contain another PLD activity for which the endogenous regulator appears to be RhoA. The data suggest the existence of at least two different PLD isozymes in HL60 cells.	VANDERBILT UNIV, SCH MED, HOWARD HUGHES MED INST, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT PHYSIOL & MOLEC BIOPHYS, NASHVILLE, TN 37232 USA; ONYX PHARMACEUT, RICHMOND, CA 94806 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University								ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; Bligh E., 1959, CAN J BIOCH PHYSL, V37, P11; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOUGSKI MS, 1993, NATURE, V366, P643; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHALIFOUR RJ, 1980, BIOCHEM BIOPH RES CO, V96, P742, DOI 10.1016/0006-291X(80)91417-5; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DAWSON RMC, 1967, BIOCHEM J, V102, P205, DOI 10.1042/bj1020205; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GENY B, 1992, EUR J BIOCHEM, V215, P389; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; KONDO T, 1992, J BIOL CHEM, V267, P23609; LEONARD D, 1992, J BIOL CHEM, V267, P22860; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MOSS J, 1991, METHOD ENZYMOL, V195, P243; MURAYAMA Y, 1989, J BIOL CHEM, V262, P12463; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SIDDIQUI RA, 1992, J BIOL CHEM, V267, P5755; TSAI SC, 1988, J CELL BIOL, V107, P4017; WANG P, 1991, J BIOL CHEM, V266, P14877; XIE MS, 1991, BIOCHEM J, V278, P81, DOI 10.1042/bj2780081; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZHANG H, 1990, J BIOL CHEM, V265, P21309	37	151	151	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8466	8473		10.1074/jbc.270.15.8466	http://dx.doi.org/10.1074/jbc.270.15.8466			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721742	hybrid			2022-12-25	WOS:A1995QT44800018
J	HSU, DS; KIM, ST; SUN, Q; SANCAR, A				HSU, DS; KIM, ST; SUN, Q; SANCAR, A			STRUCTURE AND FUNCTION OF THE UVRB PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; POLYMERASE-III HOLOENZYME; ESCHERICHIA-COLI UVRB; (A)BC EXCINUCLEASE; DNA PHOTOLYASE; ACTIVE-SITE; 5' INCISION; COMPLEX; ATP; MECHANISM	UvrB plays a central role in (A)BC excinuclease. To identify the regions of UvrB which are involved in interacting with UvrA, UvrC, and DNA, deletion mutants, point mutants, and various fusion forms of UvrB were constructed and characterized. We found that the region encompassing amino acid residues 115-250 of UvrB binds to UvrA, while the region encompassing amino acid residues 547-673 binds to both UvrA and UvrC. In addition, the region between these two domains, which contains the helicase motifs II-VI, was found to be involved in binding to DNA. Within this DNA-binding region, two point mutants, E265A and E338A, were found to be unable to bind DNA while two residues, Phe-365 and Phe-496, were identified to interact with DNA. Furthermore, fluorescence quenching studies with mutants F365W and F496W and repair of thymine cyclobutane dimers by photoinduced electron transfer by these mutants suggest that residues Phe-365 and Phe-496 interact with DNA most likely through stacking interactions.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine								ARIKAN E, 1986, NUCLEIC ACIDS RES, V14, P2637, DOI 10.1093/nar/14.6.2637; BACKENDORF C, 1986, NUCLEIC ACIDS RES, V14, P2877, DOI 10.1093/nar/14.7.2877; CRUTE JJ, 1983, J BIOL CHEM, V258, P1344; FERRARI ME, 1994, J MOL BIOL, V236, P106, DOI 10.1006/jmbi.1994.1122; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; HELENE C, 1977, PHOTOCHEM PHOTOBIOL, V52, P789; HSU DS, 1994, J MOL BIOL, V241, P645, DOI 10.1006/jmbi.1994.1541; HUANG CC, 1981, J BIOL CHEM, V256, P4087; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; KIM ST, 1992, P NATL ACAD SCI USA, V89, P900, DOI 10.1073/pnas.89.3.900; KIM ST, 1990, PHOTOCHEM PHOTOBIOL, V52, P789, DOI 10.1111/j.1751-1097.1990.tb08683.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; KWONSHIN O, 1987, J BIOL CHEM, V262, P2121; LI YF, 1993, P NATL ACAD SCI USA, V90, P4389, DOI 10.1073/pnas.90.10.4389; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LIN JJ, 1992, J BIOL CHEM, V267, P17688; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; NOSSAL NG, 1984, BACTERIOPHAGE T, V4, P71; ORREN DK, 1992, J BIOL CHEM, V267, P780; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; PHILLIPS AM, 1994, THESIS U N CAROLINA; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SANDERS GM, 1994, P NATL ACAD SCI USA, V91, P7703, DOI 10.1073/pnas.91.16.7703; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; SHI Q, 1992, J MOL BIOL, V226, P425, DOI 10.1016/0022-2836(92)90957-L; SVOBODA DL, 1993, J BIOL CHEM, V268, P10694; THOMAS DC, 1985, J BIOL CHEM, V260, P9875; VANHOUTEN B, 1987, J BIOL CHEM, V262, P13180; VISSE R, 1992, J BIOL CHEM, V267, P6736; VISSE R, 1994, BIOCHEMISTRY-US, V33, P1804, DOI 10.1021/bi00173a025; VISSE R, 1994, BIOCHEMISTRY-US, V33, P9881, DOI 10.1021/bi00199a009	37	67	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8319	8327		10.1074/jbc.270.14.8319	http://dx.doi.org/10.1074/jbc.270.14.8319			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713940	hybrid, Green Published			2022-12-25	WOS:A1995QR52600079
J	KUWABARA, K; PINSKY, DJ; SCHMIDT, AM; BENEDICT, C; BRETT, J; OGAWA, S; BROEKMAN, MJ; MARCUS, AJ; SCIACCA, RR; MICHALAK, M; WANG, F; PAN, YC; GRUNFELD, S; PATTON, S; MALINSKI, T; STERN, DM; RYAN, J				KUWABARA, K; PINSKY, DJ; SCHMIDT, AM; BENEDICT, C; BRETT, J; OGAWA, S; BROEKMAN, MJ; MARCUS, AJ; SCIACCA, RR; MICHALAK, M; WANG, F; PAN, YC; GRUNFELD, S; PATTON, S; MALINSKI, T; STERN, DM; RYAN, J			CALRETICULIN, AN ANTITHROMBOTIC AGENT WHICH BINDS TO VITAMIN-K-DEPENDENT COAGULATION-FACTORS, STIMULATES ENDOTHELIAL NITRIC-OXIDE PRODUCTION, AND LIMITS THROMBOSIS IN CANINE CORONARY-ARTERIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; GAMMA-CARBOXYGLUTAMIC ACID; TUMOR NECROSIS FACTOR; HUMAN FACTOR-IX; FACTOR-X; HIGH-AFFINITY; CELL-SURFACE; FACTOR-VA; ESCHERICHIA-COLI; TISSUE FACTOR	Coagulation Factor IX/IXa has been shown to bind to cellular surfaces, and Factor IXa expresses its procoagulant activity by assembling into the intrinsic Factor X activating complex (Factors IXa/VIIIa/X), which also forms on membrane surfaces. This led us to identify cellular proteins which bind Factor IX/IXa; an approximate to 55-kDa polypeptide was purified to homogeneity from bovine lung extracts based on its capacity to bind I-125-Factor IX in a dose-dependent and saturable manner. From protein sequence data of the amino terminus and internal peptides, the approximate to 55-kDa polypeptide was identified as calreticulin, a previously identified intracellular calcium binding protein. Recombinant calreticulin bound vitamin K-dependent coagulation factors, I-125-Factor IX, I-125-Factor X, and I-125-prothrombin (K-d values of approximate to 2.7, 3.2, and 8.3 nM, respectively), via interaction with its C-domain, although it did not affect the coagulant properties of these proteins. I-125-Calreticulin also bound to endothelial cells in vitro (K-d approximate to 7.4 nM), and mouse infusion studies showed an initial rapid phase of clearance in which calreticulin could be localized on the vascular endothelium. Exposure of endothelial cells to calreticulin led to dose-dependent, immediate, and sustained increase in the production of nitric oxide, as measured using a porphyrinic microsensor. In a canine electrically induced thrombosis model, intracoronary infusion of calreticulin (n = 7) prevented occlusion of the left circumflex coronary artery in a dose-dependent manner compared with vehicle-treated controls (n = 5). These results indicate that calreticulin interacts with the endothelium to stimulate release of nitric oxide and inhibit clot formation.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT PHYSIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; UNIV TEXAS, HLTH SCI CTR, DEPT MED, HOUSTON, TX 77225 USA; CORNELL UNIV, COLL MED, DEPT MED, NEW YORK, NY 10010 USA; CORNELL UNIV, COLL MED, DEPT PATHOL, NEW YORK, NY 10010 USA; DEPT VET AFFAIRS, MED CTR, NEW YORK, NY 10010 USA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2E1, CANADA; HOFFMANN LA ROCHE INC, ROCHE RES CTR, NUTLEY, NJ 07110 USA; OAKLAND UNIV, DEPT CHEM, ROCHESTER, MI 48309 USA	Columbia University; Columbia University; University of Texas System; University of Texas Health Science Center Houston; Cornell University; Cornell University; University of Alberta; Roche Holding; Oakland University					NHLBI NIH HHS [HL42833, HL34625] Funding Source: Medline; NIA NIH HHS [AG00602] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034625, R01HL042833] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1989, J CLIN INVEST, V84, P824, DOI 10.1172/JCI114242; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BAUW G, 1989, P NATL ACAD SCI USA, V86, P7701, DOI 10.1073/pnas.86.20.7701; BENEDICT CR, 1991, J CLIN INVEST, V88, P1760, DOI 10.1172/JCI115495; BENEDICT CR, 1986, CIRC RES, V58, P58, DOI 10.1161/01.RES.58.1.58; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; COLLINS JH, 1989, BIOCHEM BIOPH RES CO, V164, P575, DOI 10.1016/0006-291X(89)91758-0; DAVID GS, 1974, BIOCHEMISTRY-US, V13, P1014, DOI 10.1021/bi00702a028; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; DOWNING MR, 1975, J BIOL CHEM, V250, P8897; ESMON NL, 1982, J BIOL CHEM, V257, P859; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P4882, DOI 10.1021/bi00776a002; FUJIKAWA K, 1973, BIOCHEMISTRY-US, V12, P4938, DOI 10.1021/bi00748a019; GITEL SN, 1977, P NATL ACAD SCI USA, V74, P3028, DOI 10.1073/pnas.74.7.3028; GUREWICH V, 1979, THROMB RES, V14, P931, DOI 10.1016/0049-3848(79)90011-2; HEIMARK RL, 1983, BIOCHEM BIOPH RES CO, V111, P723, DOI 10.1016/0006-291X(83)90365-0; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUNKAPILLER MW, 1986, METHODS PROTEIN MICR, P315; KLOTZ IM, 1984, J BIOL CHEM, V259, P60; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI J, 1993, J PHARMACOL EXP THER, V267, P371; LOLLAR P, 1980, J BIOL CHEM, V255, P279; LONDON F, 1992, CIRCULATION S1, V86, P1855; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1991, J BIOL CHEM, V266, P7155; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; RAPAPORT S, 1990, PHYSL BASIS MED PRAC, P385; RIMON S, 1987, J BIOL CHEM, V262, P6023; ROKEACH LA, 1991, J IMMUNOL, V147, P3031; ROSING J, 1980, J BIOL CHEM, V255, P274; RYAN J, 1989, J BIOL CHEM, V264, P20283; RYAN J, 1992, BLOOD, V80, P966; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPADY DK, 1983, P NATL ACAD SCI-BIOL, V80, P3499, DOI 10.1073/pnas.80.11.3499; STERN D, 1985, P NATL ACAD SCI USA, V82, P2523, DOI 10.1073/pnas.82.8.2523; STERN DM, 1986, J BIOL CHEM, V261, P713; STERN DM, 1984, P NATL ACAD SCI-BIOL, V81, P913, DOI 10.1073/pnas.81.3.913; STERN DM, 1985, J BIOL CHEM, V260, P6717; STERN DM, 1987, BRIT J HAEMATOL, V66, P227, DOI 10.1111/j.1365-2141.1987.tb01303.x; SUEYOSHI T, 1991, THROMB RES, V63, P569, DOI 10.1016/0049-3848(91)90184-X; THOMPSON AR, 1986, BLOOD, V67, P565; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; TOOMEY JR, 1992, BIOCHEMISTRY-US, V31, P1806, DOI 10.1021/bi00121a031; TRACY PB, 1981, J BIOL CHEM, V256, P743; VAN PN, 1989, J BIOL CHEM, V264, P17494; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433	51	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8179	8187		10.1074/jbc.270.14.8179	http://dx.doi.org/10.1074/jbc.270.14.8179			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713923	hybrid			2022-12-25	WOS:A1995QR52600062
J	COLOMBEL, M; RADVANYI, F; BLANCHE, M; ABBOU, C; BUTTYAN, R; DONEHOWER, LA; CHOPIN, D; THIERY, JP				COLOMBEL, M; RADVANYI, F; BLANCHE, M; ABBOU, C; BUTTYAN, R; DONEHOWER, LA; CHOPIN, D; THIERY, JP			ANDROGEN SUPPRESSED APOPTOSIS IS MODIFIED IN P53 DEFICIENT MICE	ONCOGENE			English	Article						APOPTOSIS; GENE, P53; PROSTATE, GLAND; CELL CYCLE; CASTRATION EFFECT; DNA FRAGMENTATION	WILD-TYPE P53; RAT PROSTATE; CELL-CYCLE; DNA; DEATH; INVOLUTION; INDUCTION; GLAND; GENE	Several in vitro studies have provided evidence that the tumor suppressor protein, p53, is involved in the cell death process referred to as apoptosis, The recent development of p53 knock-out mice has enabled further investigation into the function of p53 for apoptosis, in vivo. Radiation-induced apoptosis is suppressed in such mice, yet other forms of apoptosis do not seem to be significantly affected, In this report, we present evidence that such male p53 nullizygous mice have less apoptosis in the prostate glands associated,vith the first 4 days following castration, Ventral prostate glands were obtained from normal, heterozygous p53-null and p53 nullizygous mice at daily intervals after castration, These tissues were stained for apoptosis with the use of the irt situ end labeling method and apoptotic bodies were quantified by microscopy, Although labeled apoptotic bodies were observed in post-castrated tissues from all of these genetic variant mice, the onset of apoptosis was delayed and the occurrence of apoptosis was significantly reduced in the p53 nullizygous mice when compared to normal controls, Heterozygous p53-null mice were intermediate for these criteria, Examination of the internucleosomal DNA fragmentation pattern at 2 days of castration supports a significant diminution of prostate cell apoptosis in nullizygous p53 mice, Additionally, large nucleated and multinucleated cells were detected in the prostate epithelium of noncastrated p53 nullizygous mice and these abnormal cells were increased after castration, Flow cytometric analysis of these tissues confirmed a high number of 4C and 8C DNA content cells in the p53 nullizygous prostates and their frequency was increased by castration, In concordance with an earlier study, we conclude that functional p53 protein is not essential for prostate epithelial cells to undergo catration-induced apoptosis, However, wild-type p53 does appear to enhance this process, especially in the early period following castration, and this protein may regulate an aberrant prostate cell cycling activity that follows castration.	CNRS, URA 1337, PARIS, FRANCE; ECOLE NORMALE SUPER, F-75230 PARIS 05, FRANCE; COLUMBIA UNIV, PRESBYTERIAN HOSP, DEPT UROL, NEW YORK, NY 10032 USA; BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Columbia University; NewYork-Presbyterian Hospital; Baylor College of Medicine	COLOMBEL, M (corresponding author), CHU HENRI MONDOR, SERV UROL, ETUD TUMEURS UROL GRP, F-94010 CRETEIL, FRANCE.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; colombel, marc/0000-0002-0152-8021; Radvanyi, Francois/0000-0002-5696-6424				BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CASEY G, 1991, ONCOGENE, V6, P1791; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLOMBEL M, 1992, CANCER RES, V52, P4313; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; KATZ AE, 1989, CANCER RES, V49, P5889; KERR JFR, 1973, VIRCHOWS ARCH B, V13, P87; KIPRIANOU N, 1990, CANCER RES, V50, P3748; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARIE D, 1993, BIOL CELL, V78, P41, DOI 10.1016/0248-4900(93)90113-S; MERRITT AJ, 1994, CANCER RES, V54, P614; RAMVQVIST T, 1993, ONCOGENE, V8, P1495; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STRANGE R, 1992, DEVELOPMENT, V115, P49; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHANG XJ, 1994, BIOCHEM BIOPH RES CO, V198, P1189, DOI 10.1006/bbrc.1994.1168	21	55	55	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1269	1274						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731676				2022-12-25	WOS:A1995QR65100002
J	YANG, JJ; KANG, JS; KRAUSS, RS				YANG, JJ; KANG, JS; KRAUSS, RS			TRANSFORMATION-RESTORING FACTOR - A LOW-MOLECULAR-WEIGHT SECRETED FACTOR REQUIRED FOR ANCHORAGE-INDEPENDENT GROWTH OF ONCOGENE-RESISTANT MUTANT-CELL LINES	ONCOGENE			English	Article						CELLULAR TRANSFORMATION; GENETIC REVERTANT; RAS ONCOGENE; GROWTH FACTORS; SIGNAL TRANSDUCTION	ACTIVATED PROTEIN-KINASE; H-RAS ONCOGENE; SIGNAL-TRANSDUCTION; MAP KINASES; NUDE MICE; PHOSPHORYLATION; TUMORIGENICITY; FIBROBLASTS; EXPRESSION; REVERTANTS	We have previously described two independent mutant rat fibroblast cell lines that fail to form colonies in soft agar when infected with a v-H-ras-expressing retrovirus, yet still undergo transformation-related morphological alterations in response to this oncogene, We report here that conditioned medium (CM) from non-transformed rat fibroblasts contains an activity that specifically corrects this defect in the mutant cell lines, rendering them capable of anchorage-independent growth in response to uas, The major activity in CM, designated transformation-restoring factor (TRF), is similar to 1300 molecular weight, lipid insoluble, and heat, protease, acid and base stable, Latent activity, distinct from TRF, is also present in CM; several lines of evidence indicate that transforming growth factor (TGF) beta is responsible for this activity, TRF, however, cannot substitute for TGF beta in the phenotypic transformation of NRK cells, TRF activity is decreased in CM of control cells transformed by uas and this response to ras is retained by the mutant cell lines, We propose that whereas wild-type cells transformed by ras may constitutively activate a TRF-regulated pathway, thus becoming independent of TRF for growth in soft agar, these mutants have acquired dependence on an exogenous supply of TRF for this aspect of the transformed phenotype, Cellular activities regulated, directly or indirectly, by TRF may be effecters of the anchorge-independent growth property that is a hallmark of transformed rodent fibroblasts.	MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai					NATIONAL CANCER INSTITUTE [R01CA059474, R29CA059474] Funding Source: NIH RePORTER; NCI NIH HHS [CA59474] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANZANO MA, 1983, P NATL ACAD SCI-BIOL, V80, P6264, DOI 10.1073/pnas.80.20.6264; ANZANO MA, 1982, CANCER RES, V42, P4776; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLBURN NH, 1978, CANCER RES, V38, P624; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; EAGLE H, 1960, P NATL ACAD SCI USA, V46, P427, DOI 10.1073/pnas.46.4.427; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GWATKIN RB, 1960, NATURE, V186, P984, DOI 10.1038/186984a0; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HSIAO WLW, 1987, MOL CELL BIOL, V7, P3380, DOI 10.1128/MCB.7.10.3380; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAUSS RS, 1992, MOL CELL BIOL, V12, P3117, DOI 10.1128/MCB.12.7.3117; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; PICKART L, 1973, NATURE-NEW BIOL, V243, P85; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SETH A, 1992, J BIOL CHEM, V267, P24796; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SHODELL M, 1973, NATURE-NEW BIOL, V243, P83; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	35	5	5	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1291	1299						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731679				2022-12-25	WOS:A1995QR65100005
J	LI, L; MATTHEWS, KS				LI, L; MATTHEWS, KS			CHARACTERIZATION OF MUTANTS AFFECTING THE KRK SEQUENCE IN THE CARBOXYL-TERMINAL DOMAIN OF LAC REPRESSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; OPERATOR DNA COMPLEX; LACTOSE REPRESSOR; PHENOTYPIC SELECTION; PROTEIN; BINDING; MUTATIONS; CLONING	The lac repressor carboxyl-terminal region is required for tetramer assembly and protein stability. To further investigate this region, especially the unusual sequence KRK, four deletion mutants eliminating the carboxyl-terminal 34, 35, 36, and 39 amino acids and five substitution mutants at the position of Arg-326, R326K, R326A, R326E, R326L, and R326W, were constructed using site specific mutagenesis. The -34-amino-acid (aa) mutant, missing the most carboxyl-proximal lysine from the KRK sequence, exhibited lower affinity for both operator and inducer and lower protein stability than dimeric proteins studied previously. The -35-aa mutant with RK missing, as well as -36 aa and -39 aa, for which the entire KRK sequence was deleted, yielded inactive polypeptides that could be detected only by monoclonal antibody for lac repressor. In the Arg-326 mutant proteins, operator binding affinity was decreased by similar to 6-fold, the shift in inducer binding at elevated pH was diminished, and protein stability was decreased. Dramatic decreases in protein expression and stability occurred with substitution at position 326 by glutamate, leucine, or tryptophan. These results suggest that Arg 326 plays an important role in the formation of the proper tertiary structure necessary for inducer and operator affinity and for protein stability.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER K, 1972, NATURE, V237, P322, DOI 10.1038/237322a0; ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; ALBERTI S, 1991, NEW BIOL, V3, P57; BARKLEY MD, 1975, BIOCHEMISTRY-US, V14, P1700, DOI 10.1021/bi00679a024; BATTEIGER B, 1982, J IMMUNOL METHODS, V55, P297, DOI 10.1016/0022-1759(82)90089-8; BETZ JL, 1986, GENE, V42, P283, DOI 10.1016/0378-1119(86)90232-5; BOURGEOIS S, 1971, METHODS ENZYMOLOGY D, V21, P491; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENOWITZ M, 1991, J BIOL CHEM, V266, P1281; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P22206; CHANG WI, 1994, BIOCHEMISTRY-US, V33, P3607, DOI 10.1021/bi00178a018; CHANG WI, 1993, J BIOL CHEM, V268, P17613; CHEN J, 1994, J BIOL CHEM, V269, P12482; CHEN J, 1992, J BIOL CHEM, V267, P13843; CHEN J, 1994, BIOCHEMISTRY-US, V33, P1234, DOI 10.1021/bi00171a025; CHEN J, 1994, BIOCHEMISTRY-US, V33, P8728, DOI 10.1021/bi00195a014; CHEN J, 1993, THESIS RICE U; CULARD F, 1981, NUCLEIC ACIDS RES, V9, P5175, DOI 10.1093/nar/9.19.5175; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; HAMADA F, 1973, J BIOCHEM, V73, P1299, DOI 10.1093/oxfordjournals.jbchem.a130204; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; JOBE A, 1972, J MOL BIOL, V72, P139, DOI 10.1016/0022-2836(72)90075-7; KISTERSWOIKE B, 1991, EUR J BIOCHEM, V198, P411, DOI 10.1111/j.1432-1033.1991.tb16030.x; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEHMING N, 1990, EMBO J, V9, P615, DOI 10.1002/j.1460-2075.1990.tb08153.x; LEHMING N, 1988, P NATL ACAD SCI USA, V85, P9747; LIN SY, 1975, BIOCHEM BIOPH RES CO, V62, P704, DOI 10.1016/0006-291X(75)90456-8; MATTHEWS KS, 1979, J BIOL CHEM, V254, P3348; MATTHEWS KS, 1987, DNA PROTEIN INTERACT, P13; Miller J. H., 1980, OPERON; MILLER JH, 1979, J MOL BIOL, V131, P249, DOI 10.1016/0022-2836(79)90075-5; MILLER JH, 1979, J MOL BIOL, V131, P191, DOI 10.1016/0022-2836(79)90073-1; Muller-Hill B, 1975, Prog Biophys Mol Biol, V30, P227; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; OGATA RT, 1978, P NATL ACAD SCI USA, V75, P5851, DOI 10.1073/pnas.75.12.5851; OGORMAN RB, 1980, J BIOL CHEM, V255, P107; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; PLATT T, 1973, J BIOL CHEM, V248, P110; RIGGS AD, 1968, J MOL BIOL, V34, P361, DOI 10.1016/0022-2836(68)90260-X; ROYER CA, 1990, BIOCHEMISTRY-US, V29, P4959, DOI 10.1021/bi00472a028; SAMS CF, 1985, J BIOL CHEM, V260, P1185; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; SCHUMACHER MA, 1993, J BIOL CHEM, V268, P12282; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; WHITSON PA, 1986, BIOCHEMISTRY-US, V25, P3845, DOI 10.1021/bi00361a016; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428	51	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10640	10649		10.1074/jbc.270.18.10640	http://dx.doi.org/10.1074/jbc.270.18.10640			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738001	hybrid			2022-12-25	WOS:A1995QW60100044
J	CHAUVAUX, S; SOUCHON, H; ALZARI, PM; CHARIOT, P; BEGUIN, P				CHAUVAUX, S; SOUCHON, H; ALZARI, PM; CHARIOT, P; BEGUIN, P			STRUCTURAL AND FUNCTIONAL-ANALYSIS OF THE METAL-BINDING SITES OF CLOSTRIDIUM-THERMOCELLUM ENDOGLUCANASE CELD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUPLICATED SEGMENT; ESCHERICHIA-COLI; CELLULASE; SEQUENCES; FAMILIES; RESIDUES; PROTEINS; DOMAINS	Crystallographic analysis indicated that Clostridium thermocellum endoglucanase CelD contained three Ca2+-binding sites, termed A, B, and C, and one Zn2+ binding site, The protein contributed five, six, and three of the coordinating oxygen atoms present at sites A, B, and C, respectively, Proteins altered by mutation in site A (CelD(D246A)), B (CelD(D361A)), or C (CelD(D523A)) were compared with wild type CelD, The Ca2+-binding isotherm of wad type CelD was compatible with two high affinity sites (K-alpha = 2 x 10(6) M(-1)) and one low affinity site (K alpha < 10(5) M(-1)), The Ca2+-binding isotherms of the mutated proteins showed that sites A and B were the two high affinity sites and that site C was the low affinity site, Atomic absorption spectrometry confirmed the presence of one tightly bound Zn2+ atom per CelD molecule, The inactivation rate of CelD at 75 degrees C was decreased 1.9-fold upon increasing the Ca2+ concentration from 2 x 10(-5) to 10(-3) M. The K-m of CelD was decreased 1.8-fold upon increasing the Ca2+ concentration from 5 x 10(-6) to 10(-4) M. Over similar ranges of concentration, Ca2+ did not affect the thermostability nor the kinetic properties of Cell)D-523A. These findings suggest that Ca2+ binding to site C stabilizes the active conformation of CelD in agreement with the close vicinity of site C to the catalytic center.	INST PASTEUR,UNITE PHYSIOL CELLULAIRE,F-75724 PARIS 15,FRANCE; INST PASTEUR,DEPT BIOTECHNOL,CNRS,URA 1300,F-75724 PARIS 15,FRANCE; INST PASTEUR,UNITE IMMUNOL STRUCT,F-75724 PARIS 15,FRANCE; INST PASTEUR,DEPT IMMUNOL,CNRS,URA 359,F-75724 PARIS 15,FRANCE; HOP HENRI MONDOR,PHARMACOL & TOXICOL SERV,F-94010 CRETEIL,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP			Chariot, Patrick/H-6384-2019	Chariot, Patrick/0000-0001-5556-8814; Beguin, Pierre/0000-0002-5372-6281; Alzari, Pedro/0000-0002-4233-1903				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUVAUX S, 1992, J BIOL CHEM, V267, P4472; CHAUVAUX S, 1990, BIOCHEM J, V265, P261, DOI 10.1042/bj2650261; Gibson T., 1984, STUDIES EPSTEIN BARR; GILKES NR, 1991, MICROBIOL REV, V55, P303, DOI 10.1128/MMBR.55.2.303-315.1991; HENRISSAT B, 1989, GENE, V81, P83, DOI 10.1016/0378-1119(89)90339-9; HENRISSAT B, 1993, GENE, V125, P199, DOI 10.1016/0378-1119(93)90329-2; JOLIFF G, 1986, BIO-TECHNOL, V4, P896, DOI 10.1038/nbt1086-896; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMED R, 1983, J BACTERIOL, V156, P828, DOI 10.1128/JB.156.2.828-836.1983; Lamed R, 1983, BIOTECHNOL BIOENG S, V13, P163; Maniatis T., 1982, MOL CLONING; MERET S, 1971, CLIN CHEM, V17, P369; TOKATLIDIS K, 1991, FEBS LETT, V291, P185, DOI 10.1016/0014-5793(91)81279-H; TOKATLIDIS K, 1991, FEBS LETT, V282, P205, DOI 10.1016/0014-5793(91)80478-L; TOKATLIDIS K, 1993, PROTEIN ENG, V6, P947, DOI 10.1093/protein/6.8.947; TOMME P, 1991, J BIOL CHEM, V266, P10313; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	21	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9757	9762		10.1074/jbc.270.17.9757	http://dx.doi.org/10.1074/jbc.270.17.9757			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730353	Green Published, hybrid			2022-12-25	WOS:A1995QV41700012
J	LU, S; SAYDAK, M; GENTILE, V; STEIN, JP; DAVIES, PJA				LU, S; SAYDAK, M; GENTILE, V; STEIN, JP; DAVIES, PJA			ISOLATION AND CHARACTERIZATION OF THE HUMAN TISSUE TRANSGLUTAMINASE GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG LIVER TRANSGLUTAMINASE; BLOOD-COAGULATION FACTOR; CROSS-LINKED ENVELOPE; AMINO-ACID SEQUENCE; HUMAN FACTOR-XIII; KERATINOCYTE TRANSGLUTAMINASE; TERMINAL DIFFERENTIATION; EXPRESSION; LINKING; SUBUNIT	Tissue transglutaminase belongs to a family of calcium-dependent enzymes, the transglutaminases that catalyze the covalent cross-linking of specific proteins by the formation of epsilon(gamma-glutamyl)lysine isopeptide bonds, The goal of this study has been the isolation and characterization of the human tissue transglutaminase gene promoter, Genomic DNA clones, spanning the 5' region of the gene, were isolated and the structure of the 5'-end of the human tissue transglutaminase gene was deter mined, 1.74 kilobases of flanking DNA were sequenced and were found to contain a TATA box element (TATAA), a CAAT box element (GGACAAT), a series of potential transcription factor-binding sites (AP1, SP1, interleukin-6 response element), and a glucocorticoid response elements, Transient transfection experiments showed that this DNA fragment included a functional promoter, which is constitutively active in multiple cell types.	UNIV TEXAS,SCH MED,DEPT PHARMACOL,HOUSTON,TX 77225; SYRACUSE UNIV,DEPT PHARMACOL,SYRACUSE,NY 13210	University of Texas System; Syracuse University			Gentile, Vittorio/A-3045-2008; Gentile, Vittorio/N-1685-2019	Gentile, Vittorio/0000-0001-7792-8294; Gentile, Vittorio/0000-0001-7792-8294	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027078] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27078] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; BOWNESS JM, 1987, J BIOL CHEM, V262, P1022; CHANG TC, 1990, J BIOL CHEM, V265, P8176; CHIOCCA EA, 1988, J BIOL CHEM, V263, P11584; FESUS L, 1992, IMMUNOL TODAY, V13, pA16, DOI 10.1016/0167-5699(92)90059-G; Fesus L, 1988, Adv Exp Med Biol, V231, P119; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GENTILE V, 1991, J BIOL CHEM, V266, P478; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRUNDMANN U, 1986, P NATL ACAD SCI USA, V83, P8024, DOI 10.1073/pnas.83.21.8024; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P6900, DOI 10.1021/bi00370a025; ICHINOSE A, 1988, P NATL ACAD SCI USA, V85, P5829, DOI 10.1073/pnas.85.16.5829; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; KINSELLA MG, 1990, J BIOL CHEM, V265, P17891; KORSGREN C, 1991, P NATL ACAD SCI USA, V88, P4840, DOI 10.1073/pnas.88.11.4840; MARTINEZ J, 1989, J BIOL CHEM, V264, P20502; MOORE WT, 1984, J BIOL CHEM, V259, P2794; MURTAUGH MP, 1984, J EXP MED, V159, P114, DOI 10.1084/jem.159.1.114; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PHILLIPS MA, 1993, BIOCHEMISTRY-US, V32, P11057, DOI 10.1021/bi00092a015; PHILLIPS MA, 1992, J BIOL CHEM, V267, P2282; RICE RH, 1978, J CELL BIOL, V76, P705, DOI 10.1083/jcb.76.3.705; Sambrook J., 1989, MOL CLONING; SLIFE CW, 1986, J BIOL CHEM, V261, P3452; SUNG LPA, 1992, BLOOD, V79, P2763; SUTO N, 1993, J BIOL CHEM, V268, P7469; SUTO N, 1993, BIOCHIM BIOPHYS ACTA, V1172, P319, DOI 10.1016/0167-4781(93)90221-X; TAKAHASHI N, 1986, P NATL ACAD SCI USA, V83, P8019, DOI 10.1073/pnas.83.21.8019; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858	36	88	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9748	9756		10.1074/jbc.270.17.9748	http://dx.doi.org/10.1074/jbc.270.17.9748			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730352	hybrid			2022-12-25	WOS:A1995QV41700011
J	MUROPASTOR, AM; MALOY, S				MUROPASTOR, AM; MALOY, S			PROLINE DEHYDROGENASE-ACTIVITY OF THE TRANSCRIPTIONAL REPRESSOR PUTA IS REQUIRED FOR INDUCTION OF THE PUT OPERON BY PROLINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; MEMBRANE ASSOCIATION; ESCHERICHIA-COLI; PROTEIN; GENE; SEQUENCES; EXPRESSION; INVITRO; ACID; LAC)	The proline utilization (put) operon from Salmonella typhimurium consists of the putP gene, encoding a proline transporter, and the putA gene, encoding an enzyme with both proline dehydrogenase and 1-pyrroline-5-carboxylate dehydrogenase activities. In addition to these two enzymatic activities, the PutA protein is a transcriptional repressor that regulates the expression of putP and putA in response to the availability of proline, We report the isolation of super-repressor mutants of PutA that decrease expression from the putA promoter in the presence or absence of proline. None of the mutants exhibited increased affinity for the DNA in the put regulatory region in vitro, Although DNA binding by wildtype PutA was prevented by the addition of proline and an artificial electron acceptor, DNA binding by the two strongest super-repressors was not prevented under identical conditions. The proline dehydrogenase activity of the purified mutant proteins showed altered kinetic properties (increased K-m(Pro), reduced V-max, or a completely null phenotype). The observation that these mutations simultaneously affect induction by proline and proline dehydrogenase activity suggests that a single proline-binding site is involved in both proline dehydrogenase activity and induction of the expression of the put operon. Furthermore, the results indicate that the proline dehydrogenase activity of PutA is essential for induction of the put operon by proline.	UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign			Muro-Pastor, Alicia M/Q-3157-2019; Maloy, Stanley/AAA-7095-2019; Muro-Pastor, Alicia M/A-4445-2015	Muro-Pastor, Alicia M/0000-0003-2503-6336; Maloy, Stanley/0000-0001-9900-4367; Muro-Pastor, Alicia M/0000-0003-2503-6336	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034715] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34715] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSON JLA, 1983, EUR J BIOCHEM, V134, P77, DOI 10.1111/j.1432-1033.1983.tb07533.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN ED, 1992, J BIOL CHEM, V267, P13086; BROWN ED, 1993, J BIOL CHEM, V268, P8972; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; CASTILHO BA, 1984, J BACTERIOL, V158, P488, DOI 10.1128/JB.158.2.488-495.1984; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DESPICER PO, 1993, P NATL ACAD SCI USA, V90, P4295, DOI 10.1073/pnas.90.9.4295; DESPICER PO, 1991, J BACTERIOL, V173, P211, DOI 10.1128/jb.173.1.211-219.1991; EKENA K, 1990, MOL GEN GENET, V220, P492, DOI 10.1007/BF00391761; GAY P, 1983, J BACTERIOL, V153, P1424, DOI 10.1128/JB.153.3.1424-1431.1983; GRAHAM SB, 1984, J BIOL CHEM, V259, P2656; GUTTERSON NI, 1983, P NATL ACAD SCI-BIOL, V80, P4894, DOI 10.1073/pnas.80.16.4894; HAHN DR, 1988, MOL GEN GENET, V213, P125, DOI 10.1007/BF00333408; HUGHES KT, 1985, GENETICS, V109, P263; LEE EC, 1990, J BACTERIOL, V172, P1529, DOI 10.1128/jb.172.3.1529-1538.1990; LING MF, 1994, J MOL BIOL, V243, P950, DOI 10.1006/jmbi.1994.1696; MALOY S, 1993, J BACTERIOL, V175, P307, DOI 10.1128/JB.175.2.307-316.1993; MALOY S, 1989, EXPT TECHNIQUES BACT; MALOY SR, 1983, J BACTERIOL, V154, P561, DOI 10.1128/JB.154.2.561-568.1983; MALOY SR, 1987, ESCHERICHIA COLI SAL, V2, P1513; MENZEL R, 1981, J BIOL CHEM, V256, P9755; MENZEL R, 1981, J BIOL CHEM, V256, P9762; MEZL VA, 1976, ANAL BIOCHEM, V74, P430, DOI 10.1016/0003-2697(76)90223-2; MUROPASTOR AM, 1995, BIOTECHNIQUES, V18, P386; RATZKIN B, 1978, J BACTERIOL, V133, P744, DOI 10.1128/JB.133.2.744-754.1978; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRECKER HJ, 1957, J BIOL CHEM, V225, P825; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WHITFIELD HJ, 1973, J BACTERIOL, V116, P54, DOI 10.1128/JB.116.1.54-58.1973	31	40	42	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9819	9827		10.1074/jbc.270.17.9819	http://dx.doi.org/10.1074/jbc.270.17.9819			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730362	hybrid			2022-12-25	WOS:A1995QV41700021
J	TRON, T; YANG, MJ; DICK, FA; SCHMITT, ME; TRUMPOWER, BL				TRON, T; YANG, MJ; DICK, FA; SCHMITT, ME; TRUMPOWER, BL			QSR1, AN ESSENTIAL YEAST GENE WITH A GENETIC-RELATIONSHIP TO A SUBUNIT OF THE MITOCHONDRIAL CYTOCHROME BC(1) COMPLEX, IS HOMOLOGOUS TO A GENE IMPLICATED IN EUKARYOTIC CELL-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BC1 COMPLEX; NUCLEOTIDE-SEQUENCE; ELECTRON-TRANSFER; PROTEIN; BINDING; SUPPRESSOR; REDUCTASE; MUTANTS; SITES	Subunit 6 of the mitochondrial cytochrome bc(1) complex regulates the activity of the bc(1) complex in Saccharomyces cerevisiae but is not essential for respiration. To test whether QCR6, the nuclear gene which encodes subunit 6, might be functionally redundant with any other gene(s), we screened for mutations in yeast genes which are essential when the otherwise non-essential QCR6 is deleted from the yeast chromosome. We obtained such quinol-cytochrome c reductase subunit-requiring mutants in two complementation groups, which we named qsr1 and qsr2. The qsr mutants require QCR6 for viability on fermentable and non-fermentable carbon sources, indication that QCR6 is covering lethal mutations in qsr1 and qsr2, even when the yeast do not require respiration. QSR1 was cloned by rescuing the synthetic lethality of a qsr1-1 mutant. QSR1 encodes a 25.4-kDa protein which is 65% identical to a protein encoded by QM, a highly conserved human gene which has been implicated in tumorigenesis. In mammals QM is down-regulated during adipocyte, kidney, and heart differentiation, and in Nicotiana the homolog of QM is also down-regulated during differentiation. When one chromosomal copy of QSR1 was deleted in a diploid yeast strain, haploid spores derived therefrom and carrying the deletion were unable to grow on fermentable or non-fermentable carbon sources. Although QCR6 allows the qsr1-1 mutant to grow, it will not substitute for QSR1, since the deletion of QSR1 is lethal even if QCR6 is present. These results indicate a novel genetic relationship between a subunit of the mitochondrial respiratory chain and an essential gene in yeast which is homologous to a gene implicated in differentiation in other eukaryotes.	DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA	Dartmouth College					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 20379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; BROWN TA, 1995, J BACTERIOL, V177, P1380, DOI 10.1128/jb.177.5.1380-1382.1995; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DOWDY SF, 1991, NUCLEIC ACIDS RES, V19, P5763, DOI 10.1093/nar/19.20.5763; EISINGER DP, 1993, BIOCHEM BIOPH RES CO, V196, P1227, DOI 10.1006/bbrc.1993.2383; FARMER AA, 1994, HUM MOL GENET, V3, P723, DOI 10.1093/hmg/3.5.723; Hanahan D., 1985, DNA CLONING; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KIM CH, 1990, FEBS LETT, V266, P78, DOI 10.1016/0014-5793(90)81511-L; KIM CH, 1987, J BIOL CHEM, V262, P8103; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; KRIAUCIUNAS A, 1989, BIOCHIM BIOPHYS ACTA, V976, P70, DOI 10.1016/S0005-2728(89)80190-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LUNDIN M, 1994, MOL CELL BIOL, V14, P1979, DOI 10.1128/MCB.14.3.1979; MARTY I, 1993, PLANT J, V4, P265, DOI 10.1046/j.1365-313X.1993.04020265.x; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RIVERAMADRID R, 1993, PLANT PHYSIOL, V102, P329, DOI 10.1104/pp.102.1.329; ROBERTSON DE, 1993, BIOCHEMISTRY-US, V32, P1310, DOI 10.1021/bi00056a016; SAKAI A, 1990, MOL CELL BIOL, V10, P4130, DOI 10.1128/MCB.10.8.4130; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SCHMITT ME, 1990, J BIOL CHEM, V265, P17005; SCHMITT ME, 1990, THESIS DARTMOUTH COL; SCHOPPINK PJ, 1988, EUR J BIOCHEM, V173, P115, DOI 10.1111/j.1432-1033.1988.tb13974.x; SCHULTE U, 1989, NATURE, V339, P147, DOI 10.1038/339147a0; SIEDOW JN, 1978, J BIOL CHEM, V253, P2392; STABEN C, 1986, J BIOL CHEM, V261, P4629; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; VANLOON APGM, 1984, EMBO J, V3, P1039, DOI 10.1002/j.1460-2075.1984.tb01924.x; YANG MJ, 1994, J BIOL CHEM, V269, P1270; YANG XH, 1986, J BIOL CHEM, V261, P2282; 1991, PROGRAM MANUAL GCG P	40	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9961	9970		10.1074/jbc.270.17.9961	http://dx.doi.org/10.1074/jbc.270.17.9961			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730379	hybrid			2022-12-25	WOS:A1995QV41700041
J	DATTANI, MT; HINDMARSH, PC; BROOK, CGD; ROBINSON, ICAF; KOPCHICK, JJ; MARSHALL, NJ				DATTANI, MT; HINDMARSH, PC; BROOK, CGD; ROBINSON, ICAF; KOPCHICK, JJ; MARSHALL, NJ			G120R, A HUMAN GROWTH-HORMONE ANTAGONIST, SHOWS ZINC-DEPENDENT AGONIST AND ANTAGONIST ACTIVITY ON NB2 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR DOMAIN; PROLACTIN RECEPTOR; BINDING; ENHANCEMENT; BIOASSAY; DESIGN; SYSTEM	Substitution of arginine for glycine at position 120 in native 22-kDa human growth hormone (hGH) results in an analogue, G120R, which is unable to dimerize the GH receptor and is widely used to probe the molecular mechanism of action of hGH, When acting on human GH receptors, G120R antagonizes several biological effects of hGH, but is itself inactive as an agonist, It has been reported that this mutant also antagonizes hGH activation of the rat or human prolactin (PRL) receptor in cell-based assays, with no agonist activity, We have now tested this mutant in a sensitive MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)-ESTA (eluted stain assay) bioassay using rat PRL receptors in the Nb2 cell Line. We confirm that G120R acts as an efficient antagonist of native hGH, but show that it can also act as an agonist to generate intracellular signals leading to metabolic activation and proliferation of Nb2 cells, We have demonstrated an unusual sensitivity to the presence of zinc (Zn2+). In the absence of added Zn2+, G120R shows weak but full agonist activity in the bioassay, and this can be blocked by co incubation with recombinant hGH binding protein, G120R can therefore be utilized to discriminate between the molecular mechanisms of hGH interactions with its somatogenic and lactogenic receptors, Future studies with G120R in the rat may need to take account of its significant agonist effects on PRL receptors.	MIDDLESEX HOSP,ENDOCRINE UNIT,LONDON W1N 8AA,ENGLAND; MIDDLESEX HOSP,DIV MOLEC PATHOL,LONDON W1N 8AA,ENGLAND; NATL INST MED RES,LONDON NW7 1AA,ENGLAND; OHIO UNIV,EDISON BIOTECHNOL INST,ATHENS,OH 45701	University of London; University College London; University of London; University College London; MRC National Institute for Medical Research; University System of Ohio; Ohio University			Hindmarsh, P C/C-4964-2008; DATTANI, MEHUL/C-5401-2008					BANGHAM DR, 1985, MOL CELL ENDOCRINOL, V42, P269, DOI 10.1016/0303-7207(85)90058-9; CHEN WY, 1994, J BIOL CHEM, V269, P15892; CHEN WY, 1991, J BIOL CHEM, V266, P2252; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CHEN WY, 1990, P NATL ACAD SCI USA, V8, P5061; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DATTANI MT, 1993, ENDOCRINOLOGY, V133, P2803, DOI 10.1210/en.133.6.2803; DATTANI MT, 1994, J ENDOCRINOL, V140, P445, DOI 10.1677/joe.0.1400445; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EALEY PA, 1988, J MOL ENDOCRINOL, V1, pR1, DOI 10.1677/jme.0.001R001; EALEY PA, 1994, IN PRESS GROWTH REGU; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1990, J BIOL CHEM, V265, P3111; IIONDO MM, 1994, ENDOCRINOLOGY, V134, P2397; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MARSHALL NJ, 1995, IN PRESS GROWTH REGU; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; WELLS JA, 1993, RECENT PROG HORM RES, V48, P253	21	37	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9222	9226		10.1074/jbc.270.16.9222	http://dx.doi.org/10.1074/jbc.270.16.9222			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721840	hybrid			2022-12-25	WOS:A1995QU08900028
J	HUANG, T; CAMPBELL, JL				HUANG, T; CAMPBELL, JL			AMPLIFICATION OF A CIRCULAR EPISOME CARRYING AN INVERTED REPEAT OF THE DFR1 LOCUS AND ADJACENT AUTONOMOUSLY REPLICATING SEQUENCE ELEMENT OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE GENE; LINEARIZED PLASMID DNA; WILD-TYPE P53; CELL-CYCLE; MOLECULAR DISSECTION; COPPER RESISTANCE; MAMMALIAN-CELLS; DIMER PLASMIDS; DOUBLE MINUTES; YEAST	Lack of suitable amplification markers has hindered the use of the yeast system for investigating the mechanism of gene amplification in a eukaryote with a simple genome and well defined genetic system. Recently, methotrexate has been used to select for Saccharomyces cerevisiae mutants with de novo amplification of the dihydrofolate reductase gene (DFR1) (Huang, T. (1993) In Vivo Disruption and de Novo Amplification of the DFR1 Gene Encoding Dihydrofolate Reductase in Saccharomyces cerevisiae. Ph. D. thesis, University of Alberta, Edmonton, Canada). We report here the detailed structure of a DFR1 episome amplified in methotrexate-resistant strain 25-1. The extrachromosomal DNA is found predominantly as a single 11-kilobase circular molecule. It consists of a 5.5-kilobase inverted duplication that contains the DFR1 locus and adjacent ARS (autonomously replicating sequence) element. This molecular configuration mimics the inferred structure of double minute chromosomes observed in a number of mammalian amplification systems and suggests that mechanisms that generate amplified DNAs are conserved from yeast to mammals.	CALTECH,BRAUN LABS,PASADENA,CA 91125	California Institute of Technology					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047281, R01GM025508] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 25508, GM 47281] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALADJEM MI, 1992, MUTAT RES, V276, P339, DOI 10.1016/0165-1110(92)90020-A; BARCLAY BJ, 1988, GENE, V63, P175, DOI 10.1016/0378-1119(88)90523-9; BURHANS WC, 1986, P NATL ACAD SCI USA, V83, P7790, DOI 10.1073/pnas.83.20.7790; CARROLL SM, 1993, MOL CELL BIOL, V13, P2971, DOI 10.1128/MCB.13.5.2971; COWELL JK, 1982, ANNU REV GENET, V16, P21, DOI 10.1146/annurev.ge.16.120182.000321; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DORSEY M, 1992, GENETICS, V132, P943; DORSEY MJ, 1993, CURR GENET, V23, P392, DOI 10.1007/BF00312624; FAKHARZADEH SS, 1993, GENOMICS, V15, P283, DOI 10.1006/geno.1993.1058; FLING ME, 1988, GENE, V63, P165, DOI 10.1016/0378-1119(88)90522-7; FOGEL S, 1982, P NATL ACAD SCI-BIOL, V79, P5342, DOI 10.1073/pnas.79.17.5342; FOGEL S, 1983, CURR GENET, V7, P347, DOI 10.1007/BF00445874; FRIED M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P143, DOI 10.1016/0167-4781(91)90095-4; HAMLIN JL, 1992, MUTAT RES, V276, P179, DOI 10.1016/0165-1110(92)90007-V; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HEINTZ NH, 1983, NATURE, V302, P439, DOI 10.1038/302439a0; HUANG T, 1992, GENE, V121, P167, DOI 10.1016/0378-1119(92)90177-Q; HUANG T, 1993, THESIS U ALBERTA EMO; HYRIEN O, 1988, EMBO J, V7, P407, DOI 10.1002/j.1460-2075.1988.tb02828.x; KUNES S, 1990, GENETICS, V124, P67; KUNES S, 1984, COLD SPRING HARB SYM, V49, P617, DOI 10.1101/SQB.1984.049.01.070; KUNES S, 1985, J MOL BIOL, V184, P375, DOI 10.1016/0022-2836(85)90288-8; LAGOSKY PA, 1987, NUCLEIC ACIDS RES, V15, P10355, DOI 10.1093/nar/15.24.10355; LAVI S, 1981, P NATL ACAD SCI-BIOL, V78, P6144, DOI 10.1073/pnas.78.10.6144; LEE FJS, 1992, BIOTECHNIQUES, V12, P677; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Maniatis T., 1982, MOL CLONING; Morelle G, 1989, FOCUS, V11, P7; NATH K, 1984, CURR GENET, V8, P265, DOI 10.1007/BF00419723; NONET GH, 1993, GENOMICS, V15, P543, DOI 10.1006/geno.1993.1107; PASSANANTI C, 1987, EMBO J, V6, P1697, DOI 10.1002/j.1460-2075.1987.tb02420.x; PELLEGRINI S, 1984, CELL, V36, P943, DOI 10.1016/0092-8674(84)90044-8; SCHIMKE RT, 1986, CANCER, V57, P1912, DOI 10.1002/1097-0142(19860515)57:10<1912::AID-CNCR2820571004>3.0.CO;2-O; Sherman F., 1986, METHODS YEAST GENETI; SIEDE W, 1993, P NATL ACAD SCI USA, V90, P7985, DOI 10.1073/pnas.90.17.7985; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; WAHL GM, 1989, CANCER RES, V49, P21; WALTON JD, 1986, CELL, V46, P857, DOI 10.1016/0092-8674(86)90067-X; WINDLE BE, 1992, MUTAT RES, V276, P199, DOI 10.1016/0165-1110(92)90009-X; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	44	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9607	9614		10.1074/jbc.270.16.9607	http://dx.doi.org/10.1074/jbc.270.16.9607			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721892	hybrid			2022-12-25	WOS:A1995QU08900081
J	TENNEY, DJ; SHEAFFER, AK; HURLBURT, WW; BIFANO, M; HAMATAKE, RK				TENNEY, DJ; SHEAFFER, AK; HURLBURT, WW; BIFANO, M; HAMATAKE, RK			SEQUENCE-DEPENDENT PRIMER SYNTHESIS BY THE HERPES-SIMPLEX VIRUS HELICASE-PRIMASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ORIGIN-BINDING PROTEIN; REPLICATION ORIGIN; TEMPLATE SEQUENCE; INITIATION SITES; GENE-PRODUCTS; UL8 PROTEIN; TYPE-1; POLYMERASE; BACTERIOPHAGE-T4	The herpes simplex virus helicase-primase complex, a heterotrimer of the UL5, UL8, and UL52 proteins, displays a single predominant site of primer synthesis on phi X174 virion DNA (Tenney, D, J,, Hurlburt, W, W., Micheletti, P, M,, Bifano, M,, and Hamatake, R, K, (1994) J, Biol, Chem, 269, 5030-5035), This site was mapped and found to be deoxycytosine-rich, directing the synthesis of a primer initiating with several guanine residues, The size and sequence requirements for primer synthesis were determined using oligonucleotides containing variations of the predominant template, Although the efficiency of primer synthesis on oligonucleotides was influenced by template size, it was absolutely dependent on nucleotide sequence, Conversely, the ATPase activity on oligonucleotide templates was dependent on template size rather than nucleotide sequence, Furthermore, only oligonucleotides containing primase templates were inhibitory in a coupled primase-polymerase assay using phi X174 DNA as template, suggesting that primer synthesis or primase turnover is rate-limiting, Additionally, stimulation of helicase-primase by the UL8 component and that by the ICP8 protein were shown to differ mechanistically using different templates: the UL8 component stimulated the rate of primer synthesis on phi X174 virion DNA and oligonucleotide templates, while ICP8 stimulation occurred only on phi X174 virion DNA.			TENNEY, DJ (corresponding author), BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,DEPT VIROL,5 RES PKWY,WALLINGFORD,CT 06492, USA.			Sheaffer, Amy/0000-0002-4776-4679				CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CALDER JM, 1992, J GEN VIROL, V73, P531, DOI 10.1099/0022-1317-73-3-531; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1990, BIOCHEMISTRY-US, V29, P1791, DOI 10.1021/bi00459a018; CHALLBERG MD, 1991, SEMIN VIROL, V2, P247; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1991, J BIOL CHEM, V266, P21252; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; DRACHEVA S, 1994, IN PRESS J BIOL CHEM; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HAMATAKE RK, 1993, J GEN VIROL, V74, P2181, DOI 10.1099/0022-1317-74-10-2181; HAZUDA DJ, 1992, J BIOL CHEM, V267, P14309; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; HIASA H, 1989, GENE, V84, P9, DOI 10.1016/0378-1119(89)90133-9; HINTON DM, 1987, J BIOL CHEM, V262, P10873; KLINEDINST DK, 1994, J VIROL, V68, P3693, DOI 10.1128/JVI.68.6.3693-3701.1994; KORNBERG A, 1992, DNA REPLICATION, P275; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LIU CC, 1981, J BIOL CHEM, V256, P2813; LOCKSHON D, 1988, MOL CELL BIOL, V8, P4018, DOI 10.1128/MCB.8.10.4018; MCLEAN GW, 1994, J GEN VIROL, V75, P2699, DOI 10.1099/0022-1317-75-10-2699; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; NOSSAL NG, 1987, J BIOL CHEM, V262, P10879; ODONNELL ME, 1987, J BIOL CHEM, V262, P4260; PARRY ME, 1993, J GEN VIROL, V74, P607, DOI 10.1099/0022-1317-74-4-607; RUYECHAN WT, 1983, J VIROL, V46, P661, DOI 10.1128/JVI.46.2.661-666.1983; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SHERMAN G, 1992, J VIROL, V66, P4884, DOI 10.1128/JVI.66.8.4884-4892.1992; SKALITER R, 1994, P NATL ACAD SCI USA, V91, P10665, DOI 10.1073/pnas.91.22.10665; SWART JR, 1993, J BIOL CHEM, V268, P12970; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TENNEY DJ, 1994, J BIOL CHEM, V269, P5030; WELLER SK, 1991, HERPESVIRUS TRANSCRI, P105; YAMAGUCHI M, 1985, MOL CELL BIOL, V5, P1170, DOI 10.1128/MCB.5.5.1170; YODA KY, 1988, NUCLEIC ACIDS RES, V16, P6531, DOI 10.1093/nar/16.14.6531; ZHU L, 1992, J VIROL, V66, P469, DOI 10.1128/JVI.66.1.469-479.1992	39	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9129	9136		10.1074/jbc.270.16.9129	http://dx.doi.org/10.1074/jbc.270.16.9129			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721827				2022-12-25	WOS:A1995QU08900015
J	WOOD, TJJ; SLIVA, D; LOBIE, PE; PIRCHER, TJ; GOUILLEUX, F; WAKAO, H; GUSTAFSSON, JA; GRONER, B; NORSTEDT, G; HALDOSEN, LA				WOOD, TJJ; SLIVA, D; LOBIE, PE; PIRCHER, TJ; GOUILLEUX, F; WAKAO, H; GUSTAFSSON, JA; GRONER, B; NORSTEDT, G; HALDOSEN, LA			MEDIATION OF GROWTH HORMONE-DEPENDENT TRANSCRIPTIONAL ACTIVATION BY MAMMARY-GLAND FACTOR STAT-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE RECEPTOR SUPERFAMILY; DNA-BINDING PROTEINS; PROLACTIN RECEPTOR; EXPRESSION; CELLS; CLONING; FAMILY; LIVER	Previous observations have shown that binding of growth hormone to its receptor leads to activation of transcription factors via a mechanism involving phosphorylation on tyrosine residues. In order to establish whether the prolactin-activated transcription factor Stat 5 (mammary gland factor) is also activated by growth hormone, nuclear extracts were prepared from COS-7 cells transiently expressing transfected Stat 5 and growth hormone receptor cDNA. Gel electrophoresis mobility shift analyses revealed the growth hormone-dependent presence of specific DNA-binding proteins in these extracts, The complexes formed could be supershifted by polyclonal anti-Stat 5 antiserum. In other experiments nuclear extracts from growth hormone-treated Chinese hamster ovary cells stably expressing transfected growth hormone receptor cDNA and liver from growth hormone-treated hypophysectomized rats were used for gel electrophoresis mobility shift analyses. These also revealed the presence of specific DNA-binding proteins sharing antigenic determinants with Stat 5. Stat 5 cDNA was shown to be capable of complementing the growth hormone-dependent activation of transcription of a reporter gene in the otherwise unresponsive COS-7 cell line. This complementation was dependent on the presence of Stat 5 tyrosine 694, suggesting a role for phosphorylation of this residue in growth hormone-dependent activation of DNA-binding and transcription.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; INST EXPTL CANC RES, TUMOR BIOL CTR, D-79106 FREIBURG, GERMANY	Friedrich Miescher Institute for Biomedical Research	WOOD, TJJ (corresponding author), KAROLINSKA INST, NOVUM, DEPT MED NUTR, S-14157 HUDDINGE, SWEDEN.		WAKAO, Hiroshi/A-4242-2012	Gouilleux, Fabrice/0000-0001-6047-1718				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BARBER MC, 1992, J ENDOCRINOL, V135, P195, DOI 10.1677/joe.0.1350195; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; FELDMAN M, 1993, ENDOCRINOLOGY, V133, P1602, DOI 10.1210/en.133.4.1602; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PLAUT K, 1993, ENDOCRINOLOGY, V133, P1843, DOI 10.1210/en.133.4.1843; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SHIU RPC, 1979, CANCER RES, V39, P4381; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SILVA CM, 1994, J BIOL CHEM, V269, P27532; SLIVA D, 1994, J BIOL CHEM, V269, P26208; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG XZ, 1994, P NATL ACAD SCI USA, V91, P1391, DOI 10.1073/pnas.91.4.1391; WARREN WC, 1993, MOL CELL ENDOCRINOL, V98, P27, DOI 10.1016/0303-7207(93)90232-9; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	44	158	162	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9448	9453		10.1074/jbc.270.16.9448	http://dx.doi.org/10.1074/jbc.270.16.9448			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721871	Green Published, hybrid			2022-12-25	WOS:A1995QU08900060
J	FELLER, SM; KNUDSEN, B; HANAFUSA, H				FELLER, SM; KNUDSEN, B; HANAFUSA, H			CELLULAR PROTEINS BINDING TO THE FIRST SRC HOMOLOGY-3 (SH3) DOMAIN OF THE PROTOONCOGENE PRODUCT C-CRK INDICATE CRK-SPECIFIC SIGNALING PATHWAYS	ONCOGENE			English	Article						CRK; SH3; SIGNAL TRANSDUCTION; CRKL; BLOT ASSAY	GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; PHOSPHOTYROSINE-CONTAINING PROTEINS; ADAPTER PROTEIN; CYTOPLASMIC PROTEIN; SARCOMA-VIRUS; V-CRK; RAS; GRB2; IDENTIFICATION	The widely expressed c-Crk protein, composed of one SH2 and two SH3 domains, lacks an apparent catalytic domain, suggesting that it functions through the formation of specific complexes with other proteins. Bacterially expressed c-Crk formed in vitro highly stable complexes via the first SH3 domain [SH3(N)]. Most prominent were a 185 kDa protein of unknown identity (p185), Sos- immunoreactive bands of 170 kDa (p170) and 145 to 155 kDa bands, corresponding to the recently cloned C3G protein. p170 also bound to Ash/Grb2 and Nck while p185 and C3G bound only to Crk, Additional Crk binding proteins were found in hematopoietic cells, particularly the myeloid-monocytic lineage. The protein binding properties of Crk were subsequently compared to CRKL, the product of a homologous but distinct gene, and found to be very similar. The binding of two guanine nucleotide exchange factors, Sos and C3G, to Crk and CRKL indicates that Ras or related proteins likely play a role in signaling through Crk family proteins.			FELLER, SM (corresponding author), ROCKEFELLER UNIV, MOLEC ONCOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.							ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, IN PRESS J BIOL CHEM; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1992, BIOCHEMISTRY-US, V31, P3044, DOI 10.1021/bi00127a003; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, IN PRESS METH ENZYMO; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, STRUCT BIOL, V1, P221; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SECHLER JMG, 1989, J IMMUNOL METHODS, V119, P277, DOI 10.1016/0022-1759(89)90407-9; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SUDOL M, 1994, ONCOGENE, V9, P2145; TANAKA S, 1993, JPN J CANCER RES, V84, P279, DOI 10.1111/j.1349-7006.1993.tb02868.x; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TSUCHIE H, 1989, ONCOGENE, V4, P1281; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	70	111	113	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1465	1473						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731701				2022-12-25	WOS:A1995QU68100001
J	ISHIOKA, C; ENGLERT, C; WINGE, P; YAN, YX; ENGELSTEIN, M; FRIEND, SH				ISHIOKA, C; ENGLERT, C; WINGE, P; YAN, YX; ENGELSTEIN, M; FRIEND, SH			MUTATIONAL ANALYSIS OF THE CARBOXY-TERMINAL PORTION OF P53 USING BOTH YEAST AND MAMMALIAN-CELL ASSAYS IN-VIVO	ONCOGENE			English	Article						P53; CELL CYCLE ARREST; TUMOR SUPPRESSOR GENE	WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; GENE AMPLIFICATION; PROTEIN; APOPTOSIS; CANCER; LINE; TRANSFORMATION	Increasing evidence indicates that p53 is a transcriptional tuans-activator through its sequence-specific DNA binding domain. Tumor-derived p53 mutations disrupt the tuans-activation ability mainly due to loss of its sequence-specific DNA binding, Using both yeast and mammalian cell assays, the effect of p53 mutations in the carboxy terminal portion was investigated in order to address how p53 mutations outside of the DNA binding domain affect p53 function, The p53 cDNA in the carboxy-terminus was randomly mutagenized by error-prone polymerase chain reactions and the amplified cDNA was screened for the ability to trans-activate using a yeast assay, Four p53 mutations, including two missense and two nonsense mutations located in the carboxy-terminal oligomerization domain, were further analysed for trans-activation, cell cycle arrest and colony formation in a human osteosarcoma cell line, Saos-2. These functional properties of p53 were disrupted by the missense mutations. Surprisingly, one of the nonsense mutations disrupts the trans-activation function and the ability to G1 arrest but shows a strong inhibition of colony formation, These results confirm that mutations in the oligomerization domain can inactivate p53 function and also indicate that p53-mediated cell growth inhibition does not necessarily depend on the ability to arrest cell cycle.	MASSACHUSETTS GEN HOSP,CTR CANC,DIV MOLEC GENET,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; CHILDRENS HOSP,DANA FARBER INST,DIV HEMATOL ONCOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	ISHIOKA, C (corresponding author), TOHOKU UNIV,INST DEV AGING & CANC,DEPT CLIN ONCOL,SENDAI,MIYAGI 980,JAPAN.							AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DAMICO D, 1992, ONCOGENE, V7, P339; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FREBOURG T, 1992, CANCER RES, V52, P6976; FREBOURG T, 1994, CANCER RES, V54, P878; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NISHIDA N, 1993, CANCER RES, V53, P368; OKAMOTO A, 1991, CANCER RES, V51, P5632; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Reed Michael, 1993, Gene Expression, V3, P95; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; YAMADA Y, 1991, CANCER RES, V51, P5800; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	57	83	85	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1485	1492						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731702				2022-12-25	WOS:A1995QU68100003
J	BERGANTINO, E; DAINESE, P; CEROVIC, Z; SECHI, S; BASSI, R				BERGANTINO, E; DAINESE, P; CEROVIC, Z; SECHI, S; BASSI, R			A POSTTRANSLATIONAL MODIFICATION OF THE PHOTOSYSTEM-II SUBUNIT CP29 PROTECTS MAIZE FROM COLD STRESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-A/B-PROTEINS; CHLOROPLAST PSBA GENE; CYTOCHROME-BF COMPLEX; THYLAKOID MEMBRANES; CHLAMYDOMONAS-REINHARDTII; LATERAL REDISTRIBUTION; ELECTRON-TRANSPORT; INVIVO DEGRADATION; STATE TRANSITIONS; BINDING PROTEINS	The resistance of maize plants to cold stress has been associated with the appearance of a new chlorophyll a/b binding protein in the thylakoid membrane following chilling treatment in the light. The cold-induced protein has been isolated, characterized by amino acid sequencing, and pulse labeled with radioactive precursors, showing that it is the product of post-translational modification by phosphorylation of the minor chlorophyll a/b protein CP29 rather than the product of a cold-regulated gene or an unprocessed CP29 precursor. We show here that the CP29 kinase activity displays unique characteristics differing from previously described thylakoid kinases and is regulated by the redox state of a quinonic site. Finally, we show that maize plants unable to perform phosphorylation have enhanced sensitivity to cold-induced photoinhibition.	UNIV PADUA,DIPARTIMENTO BIOL,I-35121 PADUA,ITALY; CTR UNIV PARIS SUD,UTILISAT RAYONNEMENT ELECTROMAGNET LAB,F-91405 ORSAY,FRANCE; NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892; UNIV VERONA,FAC SCI MATEMAT FIS & NAT,I-37134 VERONA,ITALY	University of Padua; UDICE-French Research Universities; Universite Paris Saclay; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Verona				bassi, roberto/0000-0002-4140-8446				ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; BARBATO R, 1992, FEBS LETT, V309, P165, DOI 10.1016/0014-5793(92)81087-3; BARBATO R, 1992, J CELL BIOL, V119, P325, DOI 10.1083/jcb.119.2.325; BASSI R, 1987, J BIOL CHEM, V262, P13333; BASSI R, 1988, BIOCHIM BIOPHYS ACTA, V935, P152, DOI 10.1016/0005-2728(88)90212-5; BASSI R, 1988, BIOCHIM BIOPHYS ACTA, V936, P29, DOI 10.1016/0005-2728(88)90248-4; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; BASSI R, 1992, EUR J BIOCHEM, V204, P317, DOI 10.1111/j.1432-1033.1992.tb16640.x; BENNETT J, 1988, EUR J BIOCHEM, V171, P95, DOI 10.1111/j.1432-1033.1988.tb13763.x; BENNETT J, 1979, FEBS LETT, V103, P342, DOI 10.1016/0014-5793(79)81358-7; BENNETT J, 1991, ANNU REV PLANT PHYS, V42, P281, DOI 10.1146/annurev.pp.42.060191.001433; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BOYER SK, 1988, NUCLEIC ACIDS RES, V16, P8184, DOI 10.1093/nar/16.16.8184; CARLBERG I, 1992, BIOCHIM BIOPHYS ACTA, V1099, P111, DOI 10.1016/0304-4173(92)90015-7; COUGHLAN SJ, 1988, BIOCHIM BIOPHYS ACTA, V933, P413, DOI 10.1016/0005-2728(88)90076-X; Dainese P., 1992, RES PHOTOSYNTHESIS, VII, P13; DEMMIGADAMS B, 1990, BIOCHIM BIOPHYS ACTA, V1020, P1, DOI 10.1016/0005-2728(90)90088-L; DIPAOLO ML, 1990, PLANTA, V181, P275, DOI 10.1007/BF00195877; DUNAHAY TG, 1984, BIOCHIM BIOPHYS ACTA, V764, P179, DOI 10.1016/0005-2728(84)90027-6; EFIMOV VA, 1988, NUCLEIC ACIDS RES, V16, P5685, DOI 10.1093/nar/16.12.5685; FRID D, 1992, J BIOL CHEM, V267, P25908; GAL A, 1988, J BIOL CHEM, V263, P7785; GAL A, 1990, J BIOL CHEM, V265, P19742; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; GREER DH, 1986, PLANTA, V168, P253, DOI 10.1007/BF00402971; HAYDEN DB, 1986, BIOCHIM BIOPHYS ACTA, V851, P86, DOI 10.1016/0005-2728(86)90251-3; HAYDEN DB, 1988, PHOTOSYNTH RES, V15, P257, DOI 10.1007/BF00047357; HODGES M, 1989, BIOCHIM BIOPHYS ACTA, V974, P289, DOI 10.1016/S0005-2728(89)80246-4; KRAUSE GH, 1988, PHYSIOL PLANTARUM, V74, P566, DOI 10.1111/j.1399-3054.1988.tb02020.x; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTOO AK, 1984, P NATL ACAD SCI-BIOL, V81, P1380, DOI 10.1073/pnas.81.5.1380; METZ JG, 1983, PLANT PHYSIOL, V73, P452, DOI 10.1104/pp.73.2.452; MORISHIGE DT, 1992, PLANT PHYSIOL, V98, P238, DOI 10.1104/pp.98.1.238; OQUIST G, 1987, TOPICS PHOTOSYNTHESI, V9, P67; PETER GF, 1991, J BIOL CHEM, V266, P16745; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; RICH PR, 1991, BIOCHIM BIOPHYS ACTA, V1058, P312, DOI 10.1016/S0005-2728(05)80252-X; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; SANTINI C, 1994, EUR J BIOCHEM, V221, P307, DOI 10.1111/j.1432-1033.1994.tb18742.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P403, DOI 10.1111/j.1432-1033.1988.tb14389.x; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; VALLON O, 1991, P NATL ACAD SCI USA, V88, P8262, DOI 10.1073/pnas.88.18.8262; WOLLMAN FA, 1988, BIOCHIM BIOPHYS ACTA, V933, P85, DOI 10.1016/0005-2728(88)90058-8	47	102	105	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8474	8481		10.1074/jbc.270.15.8474	http://dx.doi.org/10.1074/jbc.270.15.8474			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721743	hybrid			2022-12-25	WOS:A1995QT44800019
J	POON, PH; MORRISON, SL; SCHUMAKER, VN				POON, PH; MORRISON, SL; SCHUMAKER, VN			STRUCTURE AND FUNCTION OF SEVERAL ANTIDANSYL CHIMERIC ANTIBODIES FORMED BY DOMAIN INTERCHANGES BETWEEN HUMAN-IGM AND MOUSE IGG2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT-MEDIATED LYSIS; MU-HEAVY-CHAIN; ELECTROPHORETIC TRANSFER; SEGMENTAL FLEXIBILITY; POLYACRYLAMIDE GELS; BINDING; MECHANISM; PROTEINS; CELLS; CLQ	Two pairs of chimeric, domain-switched immunoglobulins with identical murine, anti-dansyl (5-dimethylaminonaphthalene-1-sulfonyl) variable domains have been generated, employing as parent antibodies a human IgM and a mouse IgG2b. The first pair of chimeric antibodies mu mu gamma mu and gamma gamma mu gamma was generated by switching the C mu 3 and C gamma 2 domains between IgM and IgG2b. The second pair of chimeras mu mu gamma gamma and gamma gamma mu mu were formed by switching both C mu 3 and C mu 4 with C gamma 2 and C gamma 3. SDS-polyacrylamide gel electrophoresis and analytical ultracentrifugation showed that over half (57 and 71%) of the two chimeric antibodies possessing the C mu 4 domain and tail piece formed disulfide-linked IgM-like polymers. In contrast, the two chimeric antibodies lacking the C mu 4 domain were almost entirely monomeric. Both monomeric chimeras had reduced ability to activate complement. The chimera gamma gamma mu gamma had no activity under any of the assay conditions, whereas mu mu gamma gamma caused only a small amount of cell lysis but was fully active in consuming complement at 4 degrees C. The polymeric chimera gamma gamma mu mu was much less active than IgM, bound C (1) over bar weakly and caused some cell lysis but consumed little complement with soluble antigen. The polymeric chimera mu mu gamma mu bound C (1) over bar strongly and was the most active antibody in all assays, even more active than the parental IgG2b and IgM antibodies; it was the only antibody that exhibited antigen-independent activity. The results suggest that C mu 3 alone does not constitute the complement binding site in IgM but requires both C mu(1-2) and C mu(4) for full activity.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	POON, PH (corresponding author), UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, 405 HILGARD AVE, LOS ANGELES, CA 90024 USA.				NCI NIH HHS [CA 16858] Funding Source: Medline; NIAID NIH HHS [AI 29470] Funding Source: Medline; NIGMS NIH HHS [GM 13914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029470, R37AI029470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM013914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASE A, 1991, J IMMUNOL METHODS, V136, P185, DOI 10.1016/0022-1759(91)90005-Z; ARYA S, 1994, J IMMUNOL, V152, P1206; BAKER MD, 1986, J IMMUNOL, V137, P1724; BEALE D, 1976, Q REV BIOPHYS, V9, P135, DOI 10.1017/S0033583500002390; BORSOS T, 1965, J IMMUNOL, V94, P510; BORSOS T, 1965, SCIENCE, V150, P505, DOI 10.1126/science.150.3695.505; BOULIANNE GL, 1984, NATURE, V312, P643, DOI 10.1038/312643a0; BUBB MO, 1978, IMMUNOLOGY, V34, P449; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEN FH, 1994, FASEB J, V8, pA767; CUNNIFF RV, 1968, J IMMUNOL, V100, P7; DANGL JL, 1986, THESIS STANFORD U; DAVIS AC, 1989, J IMMUNOL, V143, P1352; DAVIS AC, 1988, EUR J IMMUNOL, V18, P1001, DOI 10.1002/eji.1830180705; DAVIS AC, 1989, EMBO J, V8, P2519, DOI 10.1002/j.1460-2075.1989.tb08389.x; DEISENHOFER J, 1976, H-S Z PHYSIOL CHEM, V357, P1421, DOI 10.1515/bchm2.1976.357.2.1421; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; EDMUNDSON AB, 1975, BIOCHEMISTRY-US, V14, P3953, DOI 10.1021/bi00689a005; FEINSTEIN A, 1966, J PHYSIOL-LONDON, V186, pP64; FEINSTEIN A, 1969, NATURE, V224, P1307, DOI 10.1038/2241307a0; FEINSTEIN A, 1983, PROTEIN CONFORMATION, P47; GEE AP, 1981, MOL IMMUNOL, V18, P609, DOI 10.1016/0161-5890(81)90031-6; HANSON DC, 1985, J BIOL CHEM, V260, P3576; Hardy RR, 1986, HDB EXPT IMMUNOLOGY, V1; HOEKZEMA R, 1988, MOL IMMUNOL, V25, P485, DOI 10.1016/0161-5890(88)90169-1; HUGHESJONES NC, 1983, EUR J IMMUNOL, V13, P635, DOI 10.1002/eji.1830130806; HURST MM, 1975, J EXP MED, V142, P1322, DOI 10.1084/jem.142.5.1322; ISHIZAKA T, 1968, J IMMUNOL, V100, P1145; JOHNSON BJ, 1976, J IMMUNOL, V117, P1491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Metzger H, 1974, Adv Immunol, V18, P169, DOI 10.1016/S0065-2776(08)60310-7; Metzger H, 1978, Contemp Top Mol Immunol, V7, P119; NORDERHAUG L, 1991, EUR J IMMUNOL, V21, P2379, DOI 10.1002/eji.1830211013; OI VT, 1984, NATURE, V307, P136, DOI 10.1038/307136a0; POON PH, 1985, J BIOL CHEM, V260, P9357; POON PH, 1991, J BIOL CHEM, V266, P5723; PRUUL H, 1978, IMMUNOCHEMISTRY, V15, P721, DOI 10.1016/0161-5890(78)90099-8; SCHNEIDER WP, 1987, PROTEINS, V2, P81, DOI 10.1002/prot.340020203; SCHUMAKER VN, 1976, BIOCHEMISTRY-US, V15, P5175, DOI 10.1021/bi00668a035; SCHUMAKER VN, 1957, BIOCHIM BIOPHYS ACTA, V23, P628, DOI 10.1016/0006-3002(57)90386-4; SHIN SU, 1989, METHOD ENZYMOL, V178, P459; SHOPES B, 1990, J IMMUNOL, V145, P3842; SIEGEL RC, 1981, BIOCHEMISTRY-US, V20, P192, DOI 10.1021/bi00504a032; SMITH RIF, 1994, BIO-TECHNOL, V12, P683, DOI 10.1038/nbt0794-683; Stollar B D, 1978, Methods Cell Biol, V18, P105; TAN LK, 1991, P NATL ACAD SCI USA, V88, P5066; TAO MH, 1991, J EXP MED, V173, P1025, DOI 10.1084/jem.173.4.1025; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERZEE JS, 1986, MOL IMMUNOL, V23, P669, DOI 10.1016/0161-5890(86)90105-7; WEBER G, 1952, BIOCHEM J, V51, P155, DOI 10.1042/bj0510155; WEETALL M, 1990, J IMMUNOL, V145, P3849; WRIGHT JF, 1988, J BIOL CHEM, V263, P11221; ZICCARDI RJ, 1986, J IMMUNOL, V136, P3378	53	12	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8571	8577		10.1074/jbc.270.15.8571	http://dx.doi.org/10.1074/jbc.270.15.8571			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721758	hybrid			2022-12-25	WOS:A1995QT44800034
J	SHAPIRO, LH				SHAPIRO, LH			MYB AND ETS PROTEINS COOPERATE TO TRANSACTIVATE AN EARLY MYELOID GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN ERYTHROID-CELLS; HUMAN C-MYB; V-MYB; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; HEMATOPOIETIC DIFFERENTIATION; ERYTHROLEUKEMIA-CELLS; FUNCTIONAL DOMAINS; LEUKEMIA-VIRUS; EXPRESSION	The earliest progenitor cell committed to the granulocyte/monocyte developmental pathway can be identified by the appearance of a 150-kDa glycoprotein on the cell surface (CD13/aminopeptidase N (CD13/APN), EC 3.4.11.2). A 455-base pair genomic fragment from the CD13/APN gene containing a Myb consensus-binding site as well as three potential Ets-binding sites was found to regulate tissue-appropriate expression of reporter genes in hematopoietic cell lines. Transactivation experiments with plasmids expressing either a full-length or truncated Myb protein and the full-length Ets-1 or Ets-2 protein demonstrated that these proteins cooperate to positively regulate CD13/APN gene expression. This cooperation is synergistic, as levels of transcriptional activity produced by Myb and Ets in combination were higher than those expected from a purely additive effect. Mutation of the Myb consensus-binding site completely abolished CD13/APN promoter activity in myeloid cells. Introduction of a dominant interfering Myb allele disrupted the ability of endogenous c-Myb in myeloid cells to transactivate the CD13/APN construct. Other myeloid cell-expressed Ets family members (PU.1, Fli-1, and Elf-1) failed to produce a cooperative transactivating effect when combined with the Myb expression construct. These data contrast with previous studies indicating that full-length c-Myb is unable to positively cooperate with Ets proteins in the regulation of myeloid genes. Because intact c-Myb and Ets-g proteins, both endogenously expressed in myeloid cells, act synergistically to transactivate the CD13/APN promoter, this gene may represent a physiological target for dissection of the roles of these transcription factors in normal and malignant myelopoiesis.			SHAPIRO, LH (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, 332 N LAUDERDALE ST, MEMPHIS, TN 38101 USA.				NATIONAL CANCER INSTITUTE [R01CA042804] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-42804] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARUFFO A, 1988, CURRENT PROTOCOLS MO; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FAVIER, 1994, ONCOGENE, V0009; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRIFFIN J D, 1983, International Journal of Cell Cloning, V1, P33; GRIFFIN JD, 1981, J CLIN INVEST, V68, P932, DOI 10.1172/JCI110348; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HOGG N, 1987, LEUCOCYTE TYPING, V3, P576; HU YL, 1991, ONCOGENE, V6, P1549; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KUEHL WM, 1988, CURR TOP MICROBIOL, V141, P318; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LEMONS RS, 1978, CELL, V14, P995, DOI 10.1016/0092-8674(78)90353-7; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MELOTTI P, 1994, J BIOL CHEM, V269, P25303; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NOMURA T, 1993, J BIOL CHEM, V268, P21914; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; ORKIN SH, 1992, BLOOD, V80, P575; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAMSAY RG, 1991, ONCOGENE, V6, P1875; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SHAPIRO LH, 1991, J BIOL CHEM, V266, P11999; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; ULRICH MJ, 1990, BLOOD, V75, P990; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	67	92	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8763	8771		10.1074/jbc.270.15.8763	http://dx.doi.org/10.1074/jbc.270.15.8763			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721782	hybrid			2022-12-25	WOS:A1995QT44800060
J	YU, GY; DESCHENES, RJ; FASSLER, JS				YU, GY; DESCHENES, RJ; FASSLER, JS			THE ESSENTIAL TRANSCRIPTION FACTOR, MCM1, IS A DOWNSTREAM TARGET OF SLN1, A YEAST 2-COMPONENT REGULATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; 2-COMPONENT REGULATORS; DNA-BINDING; GENE FUSIONS; ALPHA-FACTOR; 2ND PROTEIN; MAINTENANCE; POLYPEPTIDE; SUPPRESSOR; SUFFICIENT	In a search for mutants exhibiting altered activity of the yeast transcription factor, Mcm1, we have identified the SLN1 gene, whose product is highly related to bacterial two-component sensor-regulator proteins. sln1 alleles identified in our screen increased Mcm1p-mediated transcriptional activation, while deletion of the SLN1 locus severely reduced Mcm1p activity. Our data establish that Mcm1p is a downstream target of the Sln1 signaling pathway. Yeast Sln1p was recently shown to be involved in osmoregulation and to depend on the Hog1 MAP kinase (Maeda, T., Wurgler-Murphy, S., and Saito, H. (1994) Nature 369, 242-245). We show that SLN1-mediated regulation of Mcm1p activity is independent of the Hog1 MAP kinase, and suggest that the role of SLN1 is not restricted to osmoregulation.	UNIV IOWA,GENET PHD PROGRAM,IOWA CITY,IA 52242; UNIV IOWA,DEPT BIOL SCI,IOWA CITY,IA 52242; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa			Deschenes, Robert J/E-4926-2010	Deschenes, Robert J/0000-0001-8325-4257				AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; BENDER A, 1987, CELL, V50, P681, DOI 10.1016/0092-8674(87)90326-6; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BROWN JL, 1993, J BACTERIOL, V175, P6908, DOI 10.1128/jb.175.21.6908-6915.1993; BRUHN L, 1994, MOL CELL BIOL, V14, P2534, DOI 10.1128/MCB.14.4.2534; BRUHN L, 1992, MOL CELL BIOL, V12, P3563, DOI 10.1128/MCB.12.8.3563; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; FASSLER JS, 1988, GENETICS, V118, P203; FASSLER JS, 1989, MOL CELL BIOL, V12, P5602; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GUAN KL, 1992, J BIOL CHEM, V267, P10024; GUARENTE L, 1981, P NATL ACAD SCI USA, V73, P2199; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; KUO MH, 1994, MOL CELL BIOL, V14, P348, DOI 10.1128/MCB.14.1.348; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LARSON GP, 1983, GENE, V22, P31, DOI 10.1016/0378-1119(83)90061-6; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Miller J.H., 1972, EXPT MOL GENETICS; OTA IM, 1992, P NATL ACAD SCI USA, V89, P2355, DOI 10.1073/pnas.89.6.2355; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Sherman F., 1978, METHODS YEAST GENETI; STOCK JB, 1993, J CELL BIOCHEM, V51, P41; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; YU GY, 1993, MOL CELL BIOL, V13, P63, DOI 10.1128/MCB.13.1.63	34	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8739	8743		10.1074/jbc.270.15.8739	http://dx.doi.org/10.1074/jbc.270.15.8739			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721779	hybrid			2022-12-25	WOS:A1995QT44800057
J	DAVID, E; GARCIA, AD; HEARING, P				DAVID, E; GARCIA, AD; HEARING, P			INTERACTION OF EF-C/RFX-1 WITH THE INVERTED REPEAT OF VIRAL ENHANCE REGIONS IS REQUIRED FOR TRANSACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; B VIRUS ENHANCER; FACTOR EF-C; NUCLEAR FACTOR; FUNCTIONAL-ORGANIZATION; SV40 ENHANCER; FACTOR EF-1A; PROMOTER; SITE; ELEMENT	The hepatitis B virus (HBV) and polyomavirus (Py) enhancer regions contain multiple cis-acting elements that contribute to enhancer activity, The EF-C binding site was previously shown to be an important functional component of each enhancer region. EF-C is a ubiquitous binding activity that interacts with an inverted repeat sequence in the HBV and Py enhancer regions. Although the EF-C binding site is required for optimal enhancer function, the EF-C site does not possess intrinsic enhancer activity when assayed in the absence of flanking elements. With both the HBV and Py enhancer regions, EF-C stimulates the activity of adjacent enhancer elements in a synergistic manner. EF-C corresponds to RFX-1, a protein that binds to a conserved and functionally important site in major histocompatibility complex (MHC) class II antigen promoter regions. Interestingly, the RFX-I binding site in MHC class II promoters only contains an EF-C half-site, maintaining one arm of the inverted repeat in an EF-C binding site. We have investigated the binding of purified EF-C and RFX-1 to sites in the Py and HBV enhancer regions that carry mutations that either disrupt one arm of the EF-C inverted repeat, or alter the spacing between the repeats. Our results show that the interaction of EF-C and RFX-1 with an intact inverted repeat is required for functional activity of these viral enhancer regions. Chemical footprinting and modification interference assays show that the interaction of EF-C and RFX-1 with the DRA MHC class II promoter truly represents half-site interaction, and that this binding is unstable. In contrast, the binding of EF-C and RFX-1 to the viral inverted repeats is stable. These results suggest that an additional activity may be required to stabilize EF-C/RFX-1 interaction with the MHC class II promoter, and that viral enhancer regions have evolved high affinity binding sites to sequester dimeric EF-C/RFX-1.	SUNY STONY BROOK, HLTH SCI CTR, DEPT MOLEC GENET & MICROBIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [T32CA009176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029427] Funding Source: NIH RePORTER; NCI NIH HHS [CA09176] Funding Source: Medline; NIAID NIH HHS [AI29427] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOLWIG GM, 1992, NUCLEIC ACIDS RES, V20, P6555, DOI 10.1093/nar/20.24.6555; BOLWIG GM, 1991, J VIROL, V65, P1884, DOI 10.1128/JVI.65.4.1884-1892.1991; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3683, DOI 10.1128/MCB.10.7.3683; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GARCIA AD, 1991, VIROLOGY, V182, P857, DOI 10.1016/0042-6822(91)90629-P; GARCIA AD, 1993, J VIROL, V67, P3940, DOI 10.1128/JVI.67.7.3940-3950.1993; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HUANG LH, 1984, NATURE, V308, P293, DOI 10.1038/308293a0; KHAN R, 1988, J BIOL CHEM, V263, P14374; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIOU HC, 1988, SCIENCE, V242, P69, DOI 10.1126/science.3140376; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; OSTAPCHUK P, 1986, P NATL ACAD SCI USA, V83, P8550, DOI 10.1073/pnas.83.22.8550; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; SAFRANY G, 1993, GENE, V132, P279, DOI 10.1016/0378-1119(93)90208-K; SANCHEZ CH, 1992, MOL CELL BIOL, V12, P4076, DOI 10.1128/MCB.12.9.4076; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; SUPAKAR PC, 1989, NUCLEIC ACIDS RES, V17, P8611, DOI 10.1093/nar/17.21.8611; VOLIVA CF, 1992, MOL CELL BIOL, V12, P2383, DOI 10.1128/MCB.12.5.2383; ZHANG XY, 1993, MOL CELL BIOL, V13, P6810, DOI 10.1128/MCB.13.11.6810; ZHANG XY, 1990, NUCLEIC ACIDS RES, V18, P6253, DOI 10.1093/nar/18.21.6253	25	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8353	8360		10.1074/jbc.270.14.8353	http://dx.doi.org/10.1074/jbc.270.14.8353			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713944	hybrid			2022-12-25	WOS:A1995QR52600083
J	BOUVERET, E; DEROUICHE, R; RIGAL, A; LLOUBES, R; LAZDUNSKI, C; BENEDETTI, H				BOUVERET, E; DEROUICHE, R; RIGAL, A; LLOUBES, R; LAZDUNSKI, C; BENEDETTI, H			PEPTIDOGLYCAN-ASSOCIATED LIPOPROTEIN-TOLB INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; CELL-ENVELOPE INTEGRITY; MEMBRANE TOPOLOGY; OUTER-MEMBRANE; TONB PROTEIN; SALMONELLA-TYPHIMURIUM; PERIPLASMIC PROTEINS; ENERGY TRANSDUCTION; CROSS-LINKING; GROUP-A	TolA, B, -Q, and -R proteins are involved in maintaining the cell envelope integrity of Escherichia coli; they have been parasitized by the group A colicins and the single strand DNA of some filamentous bacteriophages to permit them to enter the cells, TolA and TolR are anchored to the inner membrane by a single transmembrane domain, TolQ is an integral membrane protein with three transmembrane segments, and TolB has re cently been found to be periplasmic although it is partially membrane-associated The latter result suggests that TolB might interact with membrane proteins, Other lines of evidence favor the existence of a Tol complex, To further characterize this complex, we investigated which proteins interact with TolB, For this purpose, two different methods were used, First, we took advantage of the existence of a tagged TolB (TolBep) to perform immunoprecipitation under native conditions in order to preserve the putative associations of TolBep with other proteins, Secondly, in vivo cross-linking experiments with formaldehyde were performed, These two approaches led to the same result and demonstrated for the first time that a component of the Tol system, TolB, interacts with a protein located in the outer membrane, the peptidoglycan-associated lipoprotein.	CNRS,INGN & DYNAM SYST MEMBRANAIRES LAB,F-13402 MARSEILLE 20,FRANCE	Centre National de la Recherche Scientifique (CNRS)				LLOUBES, Roland/0000-0002-9520-1053; Bouveret, Emmanuelle/0000-0001-5511-6375				BENEDETTI H, 1991, EMBO J, V10, P1989, DOI 10.1002/j.1460-2075.1991.tb07728.x; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; BOURDINEAUD JP, 1989, J BACTERIOL, V171, P2458, DOI 10.1128/jb.171.5.2458-2465.1989; BRAUN V, 1989, J BACTERIOL, V171, P6387, DOI 10.1128/jb.171.11.6387-6390.1989; BRAUN V, 1991, BIOL MET, V4, P14, DOI 10.1007/BF01135552; CHEN R, 1987, EUR J BIOCHEM, V163, P73, DOI 10.1111/j.1432-1033.1987.tb10738.x; DAVIES JK, 1975, J BACTERIOL, V123, P102, DOI 10.1128/JB.123.1.102-117.1975; DEICH RA, 1988, J BACTERIOL, V170, P489, DOI 10.1128/jb.170.2.489-498.1988; DEROUICHE R, 1995, J BIOL CHEM, V270, P11078, DOI 10.1074/jbc.270.19.11078; EICKHELMERICH K, 1989, J BACTERIOL, V171, P5117, DOI 10.1128/jb.171.9.5117-5126.1989; FISCHER E, 1989, J BACTERIOL, V171, P5129; FOGNINILEFEBVRE N, 1987, MOL GEN GENET, V209, P391, DOI 10.1007/BF00329670; GELI V, 1993, FEMS MICROBIOL LETT, V109, P335; GORVEL JP, 1985, CELL TISSUE RES, V239, P241, DOI 10.1007/BF00214925; GUIHARD G, 1994, J BIOL CHEM, V269, P5874; HANNAVY K, 1990, J MOL BIOL, V216, P897, DOI 10.1016/S0022-2836(99)80009-6; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ISNARD M, 1994, J BACTERIOL, V176, P6392, DOI 10.1128/jb.176.20.6392-6396.1994; JASKULA JC, 1994, J BACTERIOL, V175, P2326; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KAMPFENKEL K, 1993, J BACTERIOL, V175, P4485, DOI 10.1128/JB.175.14.4485-4491.1993; KAMPFENKEL K, 1992, J BACTERIOL, V174, P5485, DOI 10.1128/JB.174.16.5485-5487.1992; KAMPFENKEL K, 1992, J BIOL CHEM, V268, P6050; KARLSSON M, 1993, MOL MICROBIOL, V8, P379, DOI 10.1111/j.1365-2958.1993.tb01581.x; KLEBBA PE, 1993, J BIOENERG BIOMEMBR, V25, P603; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN RA, 1994, MOL MICROBIOL, V13, P627, DOI 10.1111/j.1365-2958.1994.tb00457.x; LAZZARONI JC, 1981, J BACTERIOL, V145, P1351, DOI 10.1128/JB.145.3.1351-1358.1981; LAZZARONI JC, 1995, J MOL BIOL, V246, P1, DOI 10.1006/jmbi.1994.0058; LAZZARONI JC, 1992, MOL MICROBIOL, V6, P735, DOI 10.1111/j.1365-2958.1992.tb01523.x; LAZZARONI JC, 1989, MOL GEN GENET, V218, P460, DOI 10.1007/BF00332410; LEDUC M, 1992, J BACTERIOL, V174, P7982, DOI 10.1128/JB.174.24.7982-7988.1992; Maniatis T, 1989, DECONTAMINATION DILU; MILLER JH, 1992, LABORATORY MANUAL HD; MIZUNC T, 1981, J BIOCHEM-TOKYO, V175, P6059; MIZUNO T, 1979, J BIOCHEM-TOKYO, V86, P991, DOI 10.1093/oxfordjournals.jbchem.a132631; MULLER MM, 1993, J BACTERIOL, V175, P6059, DOI 10.1128/JB.175.18.6059-6061.1993; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; POSTLE K, 1988, J BIOL CHEM, V263, P11000; POSTLE K, 1993, J BIOENERG BIOMEMBR, V25, P591; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; ROOF SK, 1991, J BACTERIOL, V173, P5554, DOI 10.1128/jb.173.17.5554-5557.1991; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKARE JT, 1991, MOL MICROBIOL, V5, P2883, DOI 10.1111/j.1365-2958.1991.tb01848.x; SKARE JT, 1993, J BIOL CHEM, V268, P16302; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIANNEY A, 1994, J BACTERIOL, V176, P822, DOI 10.1128/jb.176.3.822-829.1994; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x	50	110	112	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11071	11077		10.1074/jbc.270.19.11071	http://dx.doi.org/10.1074/jbc.270.19.11071			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744736	hybrid			2022-12-25	WOS:A1995QX86500011
J	BROCKMANN, D; BURY, C; KRONER, G; KIRCH, HC; ESCHE, H				BROCKMANN, D; BURY, C; KRONER, G; KIRCH, HC; ESCHE, H			REPRESSION OF THE C-JUN TRANSACTIVATION FUNCTION BY THE ADENOVIRUS-TYPE-12 E1A 52R PROTEIN CORRELATES WITH THE INHIBITION OF PHOSPHORYLATION OF THE C-JUN ACTIVATION DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; MESSENGER-RNAS; GENE-PRODUCT; NEGATIVE REGULATOR; LEUCINE ZIPPERS; ACTING FACTOR; AP-1 ACTIVITY; PRIMARY-CELLS; 5 DNA; FOS	The early region 1A 52R polypeptide, a protein expressed exclusively by the in vivo oncogenic adenovirus subtype 12, represses the trans-activating function of the cellular transcription factor complex AP-1 consisting of c-Jun-c-Jun homodimers. In this report we demonstrate that the repression in vivo correlates with a direct physical interaction of the adenovirus protein with c-Jun in vitro. Interestingly, the 52R protein binds to the bZIP domain of c-Jun essential for dimerization and DNA binding but not to the c-dun activation domain. This interaction does not prevent the promoter binding of c-Jun/AP-1. Moreover, the physical association between c-Jun and the TATA box-binding protein TBP is not disturbed by the 52R polypeptide. In fact, we show evidence that down-regulation of c-Jun activity by the adenoviral protein is due to the inhibition of phosphorylation of the c-Jun trans-activation domain. In vivo phosphorylation of the c-Jun activation domain is necessary for the interaction of c-Jun with specific cofactors such as CBP and therefore a prerequisite for the activation of target genes. Due to these results we propose a model in which the 52R protein represses the trans-activating function of c-Jun by preventing its phosphorylation through a specific kinase necessary for the activation of the cellular transcription factor.			BROCKMANN, D (corresponding author), UNIV ESSEN GESAMTHSCH, INST MOLEC BIOL CANC RES, HUFELANDSTR 55, D-45122 ESSEN, GERMANY.							Abate C, 1990, Semin Cancer Biol, V1, P19; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMANN D, 1994, VIROLOGY, V198, P717, DOI 10.1006/viro.1994.1085; BROCKMANN D, 1990, VIROLOGY, V179, P585, DOI 10.1016/0042-6822(90)90125-B; BROCKMANN D, 1993, LIFE SCI ADV, V12, P13; BYRD PJ, 1988, ONCOGENE, V2, P477; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUEBNER RJ, 1962, P NATL ACAD SCI USA, V48, P2051, DOI 10.1073/pnas.48.12.2051; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; JELINEK T, 1994, J VIROL, V68, P888, DOI 10.1128/JVI.68.2.888-896.1994; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; JOCHEMSEN H, 1982, VIROLOGY, V122, P15, DOI 10.1016/0042-6822(82)90373-7; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KARIN M, 1991, HORMONAL CONTROL REG, P235; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; Maniatis T., 1982, MOL CLONING; MEIJER I, 1992, CELL IMMUNOL, V145, P56, DOI 10.1016/0008-8749(92)90312-D; MUKAI N, 1972, AM J PATHOL, V69, P331; MURPHY M, 1987, VIROLOGY, V159, P49, DOI 10.1016/0042-6822(87)90346-1; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OPALKA B, 1992, INTERVIROLOGY, V33, P211, DOI 10.1159/000150253; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PERRICAUDET M, 1980, NATURE, V288, P174, DOI 10.1038/288174a0; POPE JH, 1964, J EXP MED, V120, P577, DOI 10.1084/jem.120.4.577; Ransone Lynn J., 1993, Gene Expression, V3, P37; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; RON D, 1992, BIOTECHNIQUES, V13, P866; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAMBUCETTI LC, 1986, GENE, V43, P69, DOI 10.1016/0378-1119(86)90009-0; SAWADA Y, 1980, J VIROL, V36, P639, DOI 10.1128/JVI.36.3.639-651.1980; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHARP PM, 1988, NUCLEIC ACIDS RES, V16, P8207, DOI 10.1093/nar/16.17.8207; SHENK T, 1991, ADV CANCER RES, V57, P47; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TELLING GC, 1994, J VIROL, V68, P877, DOI 10.1128/JVI.68.2.877-887.1994; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; YAMITHEZI A, 1994, ONCOGENE, V9, P1065; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	69	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10754	10763		10.1074/jbc.270.18.10754	http://dx.doi.org/10.1074/jbc.270.18.10754			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738014	hybrid			2022-12-25	WOS:A1995QW60100058
J	DUBOIS, CM; LAPRISE, MH; BLANCHETTE, F; GENTRY, LE; LEDUC, R				DUBOIS, CM; LAPRISE, MH; BLANCHETTE, F; GENTRY, LE; LEDUC, R			PROCESSING OF TRANSFORMING GROWTH-FACTOR-BETA-1 PRECURSOR BY HUMAN FURIN CONVERTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY DISEASE; BINDING-PROTEIN; HUMAN-PLATELETS; CELL-LINES; FACTOR-BETA-1; EXPRESSION; ACTIVATION; PROLIFERATION; ENDOPROTEASE; INHIBITION	Proteolytic processing of the transforming growth factor beta precursor (pro-TGF beta) is an essential step in the formation of the biologically active TGF beta homodimeric protein (TGF beta). The 361-amino-acid precursor pro-TGF beta 1 has within its primary structure the R-H-R-R processing signal found in many constitutively secreted precursor proteins and potentially recognized by members of the mammalian convertase family of endoproteases. To determine whether cleavage of pro-TGF beta 1 can be achieved by the furin convertase in vitro, purified precursor was incubated in the presence of a truncated/secreted form of the enzyme. Immunoblots showed that the 55-kDa pro-TGF beta 1 was converted into the 44 and 12.5 kDa bands corresponding to the proregion and the mature monomer, respectively. Treatment of pro-TGF beta 1 with furin resulted in a 5-fold increase in the production of biologically active TGF beta 1. Furthermore, when expressed in the furin-deficient LoVo cells, no processing of pro-TGF beta 1 was observed. In contrast, efficient processing was oberved when pro-TGF beta 1 was coexpressed with the furin convertase. Collectively, these results provide evidence that in our experimental systems the TGF beta 1 precursor is efficiently and correctly processed by human furin thus permitting release of the biologically active peptide.	MED COLL OHIO, DEPT BIOCHEM, TOLEDO, OH 43699 USA		DUBOIS, CM (corresponding author), UNIV SHERBROOKE, FAC MED, DEPT PEDIAT, DIV IMMUNOL, 3001 N 12TH AVE, SHERBROOKE, PQ J1H 5N4, CANADA.				PHS HHS [A60848] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; ASSOIAN RK, 1978, J BIOL CHEM, V235, P1357; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; BRUNNER AM, 1989, J BIOL CHEM, V264, P13660; CHAN SJ, 1992, P NATL ACAD SCI USA, V89, P6678, DOI 10.1073/pnas.89.15.6678; CHILDS CB, 1982, P NATL ACAD SCI-BIOL, V79, P5312, DOI 10.1073/pnas.79.17.5312; CREEMERS JWM, 1993, FEBS LETT, V336, P65, DOI 10.1016/0014-5793(93)81610-C; CZARNIECKI CW, 1988, J IMMUNOL, V140, P4217; DERYNCK R, 1986, J BIOL CHEM, V261, P4377; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DUBOIS CM, 1990, J EXP MED, V172, P737, DOI 10.1084/jem.172.3.737; EBERT EC, 1987, J IMMUNOL, V138, P2161; GENTRY LE, 1987, MOL CELL BIOL, V7, P3418, DOI 10.1128/MCB.7.10.3418; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GOEY H, 1989, J IMMUNOL, V143, P877; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Hruby D E, 1986, Methods Enzymol, V124, P295; JACOBSEN SEW, 1991, BLOOD, V77, P1706; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KEHRL JH, 1986, J IMMUNOL, V137, P3855; KELLER JR, 1988, J EXP MED, V168, P737, DOI 10.1084/jem.168.2.737; KELLER JR, 1989, J CELL BIOCHEM, V39, P175, DOI 10.1002/jcb.240390209; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; KONDAIAH P, 1990, J BIOL CHEM, V265, P1089; KULKARNI AB, 1993, AM J PATHOL, V143, P3; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAWRENCE D, 1985, BIOCHEM BIOPH RES CO, V133, P1026, DOI 10.1016/0006-291X(85)91239-2; LEDUC R, 1992, J BIOL CHEM, V267, P14304; LEDUC R, 1990, J CELL BIOL, V11, P338; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIYAZONO K, 1992, J BIOL CHEM, V267, P5668; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MOSES HL, 1985, CANCER CELL, V3, P65; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; PIRCHER R, 1986, BIOCHEM BIOPH RES CO, V136, P30, DOI 10.1016/0006-291X(86)90872-7; RAPP UR, 1983, J CELL BIOCHEM, V21, P29, DOI 10.1002/jcb.240210105; REHEMTULLA A, 1993, BIOCHEMISTRY-US, V32, P11586, DOI 10.1021/bi00094a015; RISTOW HJ, 1986, P NATL ACAD SCI USA, V83, P5531, DOI 10.1073/pnas.83.15.5531; ROBERTS AB, 1983, FED PROC, V42, P2621; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; ROBERTSON BJ, 1993, J BIOL CHEM, V268, P24274; ROOK AH, 1986, J IMMUNOL, V136, P3916; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHWARZ LC, 1990, ANN NY ACAD SCI, V593, P315, DOI 10.1111/j.1749-6632.1990.tb16129.x; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; SHA X, 1989, MOL ENDOCRINOL, V3, P1090, DOI 10.1210/mend-3-7-1090; SHARPLES K, 1987, DNA-J MOLEC CELL BIO, V6, P239, DOI 10.1089/dna.1987.6.239; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STRASSMANN G, 1988, J IMMUNOL, V140, P2645; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; TUCKER RF, 1984, P NATL ACAD SCI-BIOL, V81, P6757, DOI 10.1073/pnas.81.21.6757; TURNER M, 1991, EUR J IMMUNOL, V21, P1635, DOI 10.1002/eji.1830210708; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; WAHL SM, 1988, J IMMUNOL, V140, P3026; WAHL SM, 1988, J EXP MED, V168, P1403, DOI 10.1084/jem.168.4.1403; WALKER JA, 1994, J VIROL, V68, P1213, DOI 10.1128/JVI.68.2.1213-1218.1994	74	328	344	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10618	10624		10.1074/jbc.270.18.10618	http://dx.doi.org/10.1074/jbc.270.18.10618			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737999	hybrid			2022-12-25	WOS:A1995QW60100041
J	ZIEGELHOFFER, T; LOPEZBUESA, P; CRAIG, EA				ZIEGELHOFFER, T; LOPEZBUESA, P; CRAIG, EA			THE DISSOCIATION OF ATP FROM HSP70 OF SACCHAROMYCES-CEREVISIAE IS STIMULATED BY BOTH YDJ1P AND PEPTIDE-SUBSTRATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; BINDING-SPECIFICITY; UNFOLDED PROTEINS; DNAJ; AFFINITY; GROEL; GRPE; TRANSLOCATION; POLYPEPTIDES; CHAPERONES	hsp70 proteins of both eukaryotes and prokaryotes possess both ATPase and peptide binding activities, These two activities are crucial for the chaperone activity of hsp70 proteins, The activity of DnaK, the primary hsp70 of Escherichia coli, is modulated by the GrpE and DnaJ proteins, In the yeast Saccharomyces cerevisiae, the predominant cytosolic hsp70, Ssa1p, interacts with a DnaJ homologue, Ydj1p, In order to better understand the function of the Ssa1p/Ydj1p chaperone, the effects of polypeptide substrates and Ydj1p on Ssa1p ATPase activity were assessed using a combination of steady-state kinetic analysis and single turnover substrate hydrolysis experiments, Polypeptide substrates and Ydj1p both serve to stimulate ATPase activity of Ssa1p, The two types of effector are biochemically distinct, each conferring a characteristic K+ dependence on Ssa1p ATPase activity, However, in single turnover ATP hydrolysis experiments, both polypeptide substrates and Ydj1p destabilized the ATP . Ssa1p complex through a combination of accelerated hydrolysis of bound ATP and accelerated release of ATP from Ssa1p, The acceleration of ATP release by Ydj1p is a previously unidentified function of a DnaJ homologue, In the case of Ydj1p-stimulated Ssa1p, steady-state ATPase activity is increased less than g-fold at physiological K+ concentrations, despite a 15-fold increase in the hydrolysis of bound ATP, The primary effect of Ydj1p appears to be to disfavor an ATP form of Ssa1p, On the other hand, peptide stimulation of Ssa1p ATPase activity was enhanced at physiological K+ concentrations, supporting the idea that cycles of ATP hydrolysis play an important role in the interaction of hsp70 with polypeptide substrates, The enhanced ATP dissociation caused by both polypeptide substrates and Ydj1p may play a role in the regulation of Ssa1p chaperone activity by altering the relative abundance of ATP- and ADP-bound forms.	UNIV WISCONSIN,DEPT BIOMOLEC CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [5 R01 GM31107, 5 F32 GM14394] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014394, R01GM031107] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON DE, 1965, J BIOL CHEM, V240, P757; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOORSTEIN WR, 1994, J MOL EVOL, V38, P1; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CEGIELSKA A, 1989, J BIOL CHEM, V264, P21122; CHAPMAN C, 1969, BIOCHEM J, V111, P609, DOI 10.1042/bj1110609; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; CYR DM, 1994, J BIOL CHEM, V269, P9798; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; FINDLY RC, 1983, SCIENCE, V219, P1223, DOI 10.1126/science.6828852; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GRECO WR, 1982, COMPUT BIOMED RES, V15, P39, DOI 10.1016/0010-4809(82)90051-9; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1993, P NATL ACAD SCI USA, V90, P11019, DOI 10.1073/pnas.90.23.11019; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; MUKAI H, 1993, GENE, V132, P57; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PRASAD K, 1994, J BIOL CHEM, V269, P6931; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SHIRAYAMA M, 1993, MOL GEN GENET, V240, P323, DOI 10.1007/BF00280382; STONE DE, 1990, MOL CELL BIOL, V10, P1622, DOI 10.1128/MCB.10.4.1622; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WANG TF, 1993, J BIOL CHEM, V268, P26049; WETZSTEIN M, 1992, J BACTERIOL, V174, P3300, DOI 10.1128/jb.174.10.3300-3310.1992; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; [No title captured]	43	80	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10412	10419		10.1074/jbc.270.18.10412	http://dx.doi.org/10.1074/jbc.270.18.10412			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737974	hybrid			2022-12-25	WOS:A1995QW60100012
J	HSU, K; CHANG, DY; MARAIA, RJ				HSU, K; CHANG, DY; MARAIA, RJ			HUMAN SIGNAL RECOGNITION PARTICLE (SRP) ALU-ASSOCIATED PROTEIN ALSO BINDS ALU INTERSPERSED REPEAT SEQUENCE RNAS - CHARACTERIZATION OF HUMAN SRP9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							7SL RNA; SECONDARY STRUCTURE; MESSENGER-RNA; REPETITIVE SEQUENCES; 7SL-RNA COMPONENT; CYTOPLASMIC RNAS; HUMAN GENOME; GENE; EXPRESSION; ELEMENTS	Nearly 1 million interspersed Alu elements reside in the human genome. Alu retrotransposition is presumably mediated by full-length Alu transcripts synthesized by RNA polymerase III, while some polymerase III-synthesized Alu transcripts undergo 3'-processing and accumulate as small cytoplasmic (sc) RNAs of unknown function. Interspersed Alu sequences also reside in the untranslated regions of some mRNAs. The Alu sequence is related to a portion of the 7SL RNA component of signal recognition particle (SRP), This region of 7SL RNA together with 9- and 14-kDa polypeptides (SRP9/14) regulates translational elongation of ribosomes engaged by SRP. Here we characterize human (h) SRP9 and show that it, together with hSRP14 (SRP9/14), forms the activity previously identified as Alu RNA-binding protein (REP), The primate-specific C-terminal tail of hSRP14 does not appreciably affect binding to scAlu RNA. K-d values for three Alu-homologous scRNAs were determined using Alu REP (SRP9/14) purified from HeLa cells. The Alu region of 7SL, scAlu, and scB1 RNAs exhibited K-d values of 203 pM, 318 pM, and 1.8 nM, respectively, Finally, Alu REP can bind with high affinity to synthetic mRNAs that contain interspersed Alus in their untranslated regions.	NICHHD,MOLEC GROWTH REGULAT LAB,BETHESDA,MD 20892; NIH,HOWARD HUGHES MED INST,RES SCHOLARS PROGRAM,HHMI,BETHESDA,MD 20817	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA			Maraia, Richard/ABC-1442-2020	Maraia, Richard/0000-0002-5209-0066				ADENIYIJONES S, 1985, NATURE, V317, P81, DOI 10.1038/317081a0; ANNWEILER A, 1991, NUCLEIC ACIDS RES, V19, P3750, DOI 10.1093/nar/19.13.3750; BOVIA F, 1994, NUCLEIC ACIDS RES, V22, P2028, DOI 10.1093/nar/22.11.2028; CHANG DY, 1993, J BIOL CHEM, V268, P6423; CHANG DY, 1994, MOL CELL BIOL, V14, P3949, DOI 10.1128/MCB.14.6.3949; CHANG DY, 1995, MOL CELL BIOL, P2109; DEININGER PL, 1993, EVOL BIOL, V27, P157; ECONOMOUPACHNIS A, 1985, NUCLEIC ACIDS RES, V13, P8379, DOI 10.1093/nar/13.23.8379; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GIORDANO T, 1990, NUCLEIC ACIDS RES, V18, P4627, DOI 10.1093/nar/18.15.4627; GUNDELFINGER ED, 1983, NUCLEIC ACIDS RES, V11, P7363, DOI 10.1093/nar/11.21.7363; GUNDELFINGER ED, 1984, EMBO J, V3, P2325, DOI 10.1002/j.1460-2075.1984.tb02134.x; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; JAGADEESWARAN P, 1981, CELL, V26, P141, DOI 10.1016/0092-8674(81)90296-8; JANIAK F, 1992, BIOCHEMISTRY-US, V31, P5830, DOI 10.1021/bi00140a019; JELINEK WR, 1982, ANNU REV BIOCHEM, V51, P813, DOI 10.1146/annurev.bi.51.070182.004121; KRAMEROV DA, 1979, NUCLEIC ACIDS RES, V6, P697, DOI 10.1093/nar/6.2.697; KRAMEROV DA, 1982, NUCLEIC ACIDS RES, V10, P7477, DOI 10.1093/nar/10.23.7477; LABUDA D, 1991, J MOL EVOL, V32, P405, DOI 10.1007/BF02101280; LARSEN N, 1991, NUCLEIC ACIDS RES, V19, P209, DOI 10.1093/nar/19.2.209; LEHRMAN MA, 1987, J BIOL CHEM, V262, P3354; LOWREY DM, 1989, P NATL ACAD SCI USA, V86, P247, DOI 10.1073/pnas.86.1.247; MARAIA R, 1988, MOL CELL BIOL, V8, P4433, DOI 10.1128/MCB.8.10.4433; MARAIA RJ, 1993, MOL CELL BIOL, V13, P4233, DOI 10.1128/MCB.13.7.4233; MARAIA RJ, 1991, NUCLEIC ACIDS RES, V19, P5695, DOI 10.1093/nar/19.20.5695; MATERA AG, 1990, MOL CELL BIOL, V10, P5424, DOI 10.1128/MCB.10.10.5424; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; MURATANI K, 1991, P NATL ACAD SCI USA, V88, P11315, DOI 10.1073/pnas.88.24.11315; MYEROWITZ R, 1987, J BIOL CHEM, V262, P15396; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; PAN J, 1981, NUCLEIC ACIDS RES, V9, P1151; PANACCIO M, 1987, P NATL ACAD SCI USA, V84, P6874, DOI 10.1073/pnas.84.19.6874; PANNING B, 1993, MOL CELL BIOL, V13, P3231, DOI 10.1128/MCB.13.6.3231; PANNING B, 1994, VIROLOGY, V202, P408, DOI 10.1006/viro.1994.1357; ROUYER F, 1987, CELL, V51, P417, DOI 10.1016/0092-8674(87)90637-4; Schmid C, 1992, CURR OPIN GENET DEV, V2, P874, DOI 10.1016/S0959-437X(05)80110-8; SCHMID CW, 1990, CHROMOSOMES EUKARYOT, P3; SCHMID CW, 1985, MOL EVOLUTIONARY GEN, P323; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIEGEL V, 1988, TRENDS BIOCHEM SCI, V13, P314, DOI 10.1016/0968-0004(88)90127-2; SIEGEL V, 1986, NATURE, V320, P81, DOI 10.1038/320081a0; SINGER MF, 1982, CELL, V28, P433, DOI 10.1016/0092-8674(82)90194-5; SINNETT D, 1991, J BIOL CHEM, V266, P8675; SRIVASTAVA R, 1987, P NATL ACAD SCI USA, V84, P4224, DOI 10.1073/pnas.84.12.4224; STOPPALYONNET D, 1990, P NATL ACAD SCI USA, V87, P1551, DOI 10.1073/pnas.87.4.1551; STRUB K, 1990, MOL CELL BIOL, V10, P777, DOI 10.1128/MCB.10.2.777; STRUB K, 1989, P NATL ACAD SCI USA, V86, P9747, DOI 10.1073/pnas.86.24.9747; STRUB K, 1991, MOL CELL BIOL, V11, P3949, DOI 10.1128/MCB.11.8.3949; STRUB K, 1993, TRANSLATIONAL APPARATUS, P635; ULLU E, 1985, NATURE, V318, P371, DOI 10.1038/318371a0; ULLU E, 1984, EMBO J, V3, P3303, DOI 10.1002/j.1460-2075.1984.tb02294.x; ULLU E, 1984, NATURE, V312, P171, DOI 10.1038/312171a0; VANARSDELL SW, 1981, CELL, V26, P11, DOI 10.1016/0092-8674(81)90028-3; VIDAL F, 1993, P NATL ACAD SCI USA, V90, P208, DOI 10.1073/pnas.90.1.208; VIDAUD D, 1989, EUR J HUM GENET, V1, P30; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WALTER P, 1983, CELL, V34, P525, DOI 10.1016/0092-8674(83)90385-9; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; WEINER AM, 1980, CELL, V22, P209, DOI 10.1016/0092-8674(80)90169-5; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; ZWIEB C, 1985, NUCLEIC ACIDS RES, V13, P6105, DOI 10.1093/nar/13.17.6105	63	44	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10179	10186		10.1074/jbc.270.17.10179	http://dx.doi.org/10.1074/jbc.270.17.10179			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730321	hybrid			2022-12-25	WOS:A1995QV41700068
J	KOMISSAROV, AA; ROMANOVA, DV; DEBABOV, VG				KOMISSAROV, AA; ROMANOVA, DV; DEBABOV, VG			COMPLETE INACTIVATION OF ESCHERICHIA-COLI URIDINE PHOSPHORYLASE BY MODIFICATION OF ASP(5) WITH WOODWARDS REAGENT-K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; MOLECULAR-PROPERTIES; CARBOXYL GROUPS; ACTIVE-SITE; ENZYME; CRYSTALLIZATION; QUANTITATION; RESOLUTION; PROTEINS; SEQUENCE	Woodward's reagent K (WRK) completely inactivated Escherichia coli uridine phosphorylase by reversible binding in the active site (K-i = 0.07 mM) with subsequent modification of a carboxyl (k(2) = 1.2 min(-1)). Neither substrate alone protected uridine phosphorylase from inactivation. The presence of phosphate did not affect the K-i and k(2) values. The addition of uracil or uridine led to a significant increase of both K-i (to 2.5 or 2.1 mM, respectively) and k(2) (to 6.1 or 4.8 min(-1), respectively) values. Thus, WRK could react in accordance with slow (high affinity) and fast (low affinity) mechanisms. Combined addition of phosphate and uracil completely protected uridine phosphorylase. Tryptic digestion yielded a single modified peptide (Ser(4)-Asp(WRK)-Val-Phe-His-Leu-Gly-Leu-Thr-Lys(13)). Treatment of the modified enzyme with hydroxylamine led to removal of the bulky WRK residue and replacement of the Asp(5) carboxyl by a hydroxamic group. The enzyme thus obtained recovered about 10% of initial specific activity, whereas its substrate binding ability changed only moderately; the K-m values for phosphate and uridine were changed from 5.1 and 0.19 mM (or 7.3 and 0.14 mM according to Leer et al. (Leer, J. C., Hammer-Jespersen, K., and M. Schwartz (1977) Eur. J. Biochem. 75, 217-224)) to 22.6 and 0.12 mM, respectively. The hydroxamic enzyme had higher thermostability than the native enzyme. The results obtained demonstrated the importance of the carboxyl at position 5. The loss of activity after selective group replacement is due to impaired stabilization of the transition state rather than to a decline in substrate affinity or change of the active site structure.	RUSSIAN FEDERAT GNII GENET,STATE SCI CTR,MOSCOW 113545,RUSSIA									BOSE R, 1974, BIOCHEMISTRY-US, V13, P2051, DOI 10.1021/bi00707a008; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAKE AJ, 1974, J BIOL CHEM, V249, P5452; BRYKUN IA, 1989, GENETIKA+, V25, P1717; COOK WJ, 1987, J BIOL CHEM, V262, P2852; DRABIKOWSKA AK, 1990, BIOCHEM J, V270, P319, DOI 10.1042/bj2700319; EALICK SE, 1990, J BIOL CHEM, V265, P1812; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; IIGO M, 1990, BIOCHEM PHARMACOL, V39, P1247; KOMISSAROV AA, 1994, BBA-PROTEIN STRUCT M, V1205, P54, DOI 10.1016/0167-4838(94)90091-4; KOMISSAROV AA, 1994, FEBS LETT, V355, P192, DOI 10.1016/0014-5793(94)01204-0; KOMISSAROV AA, 1993, PHARM WORLD SCI F, V15, P20; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEER JC, 1977, EUR J BIOCHEM, V75, P217, DOI 10.1111/j.1432-1033.1977.tb11520.x; Magni G, 1978, Methods Enzymol, V51, P290; MIKHAILOV AM, 1992, BIOCHEM INT, V26, P607; MOOSER G, 1991, J BIOL CHEM, V266, P8916; NAGUIB FNM, 1987, BIOCHEM PHARMACOL, V36, P2195, DOI 10.1016/0006-2952(87)90150-X; PETRA PH, 1971, BIOCHEMISTRY-US, V10, P3163, DOI 10.1021/bi00793a001; Raznikov A V, 1992, Biokhimiia, V57, P1902; SCHWARTZ PM, 1985, BIOCHEM PHARMACOL, V34, P3585, DOI 10.1016/0006-2952(85)90737-3; SINHA U, 1985, ANAL BIOCHEM, V151, P327, DOI 10.1016/0003-2697(85)90183-6; TISHKOV VI, 1983, BIOORG KHIM+, V9, P1341; TSUPRUN V L, 1991, Biokhimiya, V56, P930; VERES Z, 1988, EUR J BIOCHEM, V178, P173, DOI 10.1111/j.1432-1033.1988.tb14441.x; VITA A, 1986, INT J BIOCHEM, V18, P431, DOI 10.1016/0020-711X(86)90185-0; WALTER MR, 1990, J BIOL CHEM, V265, P14016; WALTON L, 1989, NUCLEIC ACIDS RES, V17, P6741, DOI 10.1093/nar/17.16.6741	28	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10050	10055		10.1074/jbc.270.17.10050	http://dx.doi.org/10.1074/jbc.270.17.10050			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730307	hybrid			2022-12-25	WOS:A1995QV41700052
J	BENBARUCH, A; BENGALI, KM; BIRAGYN, A; JOHNSTON, JJ; WANG, JM; KIM, J; CHUNTHARAPAI, A; MICHIEL, DF; OPPENHEIM, JJ; KELVIN, DJ				BENBARUCH, A; BENGALI, KM; BIRAGYN, A; JOHNSTON, JJ; WANG, JM; KIM, J; CHUNTHARAPAI, A; MICHIEL, DF; OPPENHEIM, JJ; KELVIN, DJ			INTERLEUKIN-8 RECEPTOR-BETA - THE ROLE OF THE CARBOXYL-TERMINUS IN SIGNAL-TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; NEUTROPHIL-ACTIVATING PEPTIDE-2; GROWTH-STIMULATORY ACTIVITY; PROTEIN-COUPLED RECEPTORS; CHEMOTACTIC RECEPTOR; FUNCTIONAL EXPRESSION; AMINO TERMINUS; CLONING; LIGAND; IDENTIFICATION	Two interleukin-8 (IL-8) receptors, alpha and beta, have been identified and cloned. Both receptors are thought to transduce signals by coupling to GTP-binding proteins. The aim of this study is to determine whether the carboxyl terminus (C') of IL-8 receptor beta (IL-8R beta) is involved in signaling in response to IL-8. We have constructed a number of IL-8R beta genes that encode truncated forms of the IL-8R beta. The deletions consisted of amino acids 349-355, 336-355, 325-355, and 317-355 (termed beta 2, beta 3, beta 4, and beta 5, respectively). 293 human embryonic kidney cells were transfected with the wild type IL-8R beta (beta 1) and with these mutants. Cells transfected with the mutated receptors expressed the receptors and bound IL-8 with the same high affinity as cells transfected with the wild type receptor. The capacity of the mutated receptors to convey functional signals was evaluated by comparing the chemotaxis index of cells expressing the C' truncated receptors to the index of cells expressing the wild type receptor. The results indicate that while cells expressing beta 1, beta 2, beta 3, and beta 4 were chemoattracted in response to IL-8, cells expressing beta 5 did not migrate in response to IL-8 stimulation. Therefore, the data suggest that amino acids 317-324 are involved in signaling by IL-8R beta.	NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP,FREDERICK,MD 21702; NCI,BIOL RESPONSE MODIFIERS PROGRAM,PRECLIN EVALUAT LAB,FREDERICK,MD 21702; NCI,BIOL RESPONSE MODIFIERS PROGRAM,EXPTL IMMUNOL LAB,FREDERICK,MD 21702; GENENTECH INC,S SAN FRANCISCO,CA 94080	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Roche Holding; Genentech	BENBARUCH, A (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702, USA.							AHUJA SK, 1993, J BIOL CHEM, V268, P20691; ALI H, 1993, J BIOL CHEM, V268, P24247; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BOMMAKANTI RK, 1993, J LEUKOCYTE BIOL, V54, P572, DOI 10.1002/jlb.54.6.572; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHUNTHARAPAI A, 1994, J IMMUNOL, V152, P1783; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GROB PM, 1990, J BIOL CHEM, V265, P8311; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; JOSHIA SM, 1994, BIOCHEM BIOPH RES CO, V199, P626; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUPPER RW, 1992, BIOCHEM J, V282, P429, DOI 10.1042/bj2820429; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE J, 1992, J BIOL CHEM, V267, P16283; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEONG SR, 1994, J BIOL CHEM, V269, P19343; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; MOSER B, 1991, J BIOL CHEM, V266, P10666; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PARRUTI G, 1993, J BIOL CHEM, V268, P9753; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REMES JJ, 1993, EXP CELL RES, V209, P26, DOI 10.1006/excr.1993.1280; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SHAPIRO RA, 1993, J BIOL CHEM, V268, P21734; SPRENGER H, 1994, J BIOL CHEM, V269, P11065; TAKANO T, 1994, J BIOL CHEM, V269, P22453; WEISS ER, 1988, FASEB J, V2, P2841, DOI 10.1096/fasebj.2.13.3139484; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	46	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9121	9128		10.1074/jbc.270.16.9121	http://dx.doi.org/10.1074/jbc.270.16.9121			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721826	hybrid			2022-12-25	WOS:A1995QU08900014
J	JOHANSON, K; APPELBAUM, E; DOYLE, M; HENSLEY, P; ZHAO, B; ABDELMEGUID, SS; YOUNG, P; COOK, R; CARR, S; MATICO, R; CUSIMANO, D; DUL, E; ANGELICHIO, M; BROOKS, I; WINBORNE, E; MCDONNELL, P; MORTON, T; BENNETT, D; SOKOLOSKI, T; MCNULTY, D; ROSENBERG, M; CHAIKEN, I				JOHANSON, K; APPELBAUM, E; DOYLE, M; HENSLEY, P; ZHAO, B; ABDELMEGUID, SS; YOUNG, P; COOK, R; CARR, S; MATICO, R; CUSIMANO, D; DUL, E; ANGELICHIO, M; BROOKS, I; WINBORNE, E; MCDONNELL, P; MORTON, T; BENNETT, D; SOKOLOSKI, T; MCNULTY, D; ROSENBERG, M; CHAIKEN, I			BINDING INTERACTIONS OF HUMAN INTERLEUKIN-5 WITH ITS RECEPTOR-ALPHA SUBUNIT - LARGE-SCALE PRODUCTION, STRUCTURAL, AND FUNCTIONAL, STUDIES OF DROSOPHILA-EXPRESSED RECOMBINANT PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; EOSINOPHIL DIFFERENTIATION FACTOR; HUMAN GROWTH-HORMONE; MOLECULAR-CLONING; GM-CSF; BIOLOGICAL-ACTIVITY; CRYSTAL-STRUCTURE; AFFINITY BINDING; IL-5 RECEPTORS; CELLS	Human interleukin 5 (hIL5) and soluble forms of its receptor alpha subunit were expressed in Drosophila cells and purified to homogeneity, allowing a detailed structural and functional analysis, B cell proliferation confirmed that the hIL5 was biologically active. Deglycosylated hTL5 remained active, while similarly deglycosylated receptor alpha subunit lost activity. The crystal structure of the deglycosylated hIL5 was determined to 2.6-Angstrom resolution and found to be similar to that of the protein produced in Escherichia coli. Human IL5 was shown by analytical ultracentrifugation to form a 1:1 complex with the soluble domain of the hIL5 receptor alpha subunit (shIL5R alpha). Additionally, the relative abundance of ligand and receptor in the hIL5 . shIL5R alpha complex was determined to be 1:1 by both titration calorimetry and SDS-polyacrylamide gel electrophoresis analysis of dissolved cocrystals of the complex. Titration microcalorimetry yielded equilibrium dissociation constants of 3.1 and 2.0 nM, respectively, for the binding of hIL5 to shIL5R alpha and to a chimeric form of the receptor containing shIL5R alpha fused to the immunoglobulin Fc domain (shIL5R alpha-Fc). Analysis of the binding thermodynamics of IL5 and its soluble receptor indicates that conformational changes are coupled to the binding reaction, Kinetic analysis using surface plasmon resonance yielded data consistent with the K-d values from calorimetry and also with the possibility of conformational isomerization in the interaction of hIL5 with the receptor alpha subunit, Using a radioligand binding assay, the affinity of hIL5 with full-length hIL5R alpha in Drosophila membranes was found to be 6 nM, in accord with the affinities measured for the soluble receptor forms, Hence, most of the binding energy of the alpha receptor is supplied by the soluble domain. Taken with other aspects of hIL5 structure and biological activity, the data obtained allow a prediction for how 1:1 stoichiometry and conformational change can lead to the formation of hIL5-receptor alpha beta complex and signal transduction.	SMITHKLINE BEECHAM PHARMACEUT, DEPT MOLEC IMMUNOL, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT PROT BIOCHEM, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT GENE EXPRESS SCI, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT PHYS & STRUCT CHEM, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT PHARMACOL TECHNOL, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DIV BIOPHARMACEUT, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT MACROMOLEC SCI, KING OF PRUSSIA, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline			Brooks, Ian/AAI-2571-2021; Brooks, Ian/E-7052-2010; Carr, Steven A./AAH-8366-2019	Doyle, Michael/0000-0003-4569-6315; Brooks, Ian/0000-0002-3793-3635				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ANGELICHIO ML, 1991, NUCLEIC ACIDS RES, V19, P5037, DOI 10.1093/nar/19.18.5037; ANUMULA KR, 1989, GLYCOCONJUGATE J, V6, P414; BASTEN A, 1970, J EXP MED, V131, P1288, DOI 10.1084/jem.131.6.1288; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; BOULAY JL, 1992, J BIOL CHEM, V267, P20525; BROOKS I, 1994, METHOD ENZYMOL, V240, P459; BROOKS I, 1994, MODERN ANAL ULTRACEN, P15; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CAMPBELL HD, 1987, P NATL ACAD SCI USA, V84, P6629, DOI 10.1073/pnas.84.19.6629; CHIHARA J, 1990, J EXP MED, V172, P1347, DOI 10.1084/jem.172.5.1347; Christensen J.J., 1976, HDB PROTON IONIZATIO; CLUTTERBUCK E, 1987, EUR J IMMUNOL, V17, P1743, DOI 10.1002/eji.1830171210; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; CULP JS, 1991, BIO-TECHNOL, V9, P173, DOI 10.1038/nbt0291-173; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; DEVOS R, 1993, J BIOL CHEM, V268, P6581; FISHER RJ, 1994, PROTEIN SCI, V3, P257; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HSIEH P, 1984, J BIOL CHEM, V259, P2375; JANIN J, 1990, J BIOL CHEM, V265, P16027; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KODAMA S, 1991, BIOCHEM BIOPH RES CO, V178, P514, DOI 10.1016/0006-291X(91)90137-V; KOIKE M, 1994, INT ARCH ALLERGY IMM, V104, P1, DOI 10.1159/000236702; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; LAYTON MJ, 1994, J BIOL CHEM, V269, P17048; LOPEZ AF, 1990, J CELL PHYSIOL, V145, P69, DOI 10.1002/jcp.1041450111; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCKENZIE ANJ, 1991, EMBO J, V10, P1193, DOI 10.1002/j.1460-2075.1991.tb08060.x; MCKENZIE ANJ, 1992, CHEM IMMUNOL, V51, P135; McPherson A Jr, 1976, Methods Biochem Anal, V23, P249, DOI 10.1002/9780470110430.ch4; METCALF D, 1974, J CELL PHYSIOL, V84, P275, DOI 10.1002/jcp.1040840214; MIGITA M, 1991, CELL IMMUNOL, V133, P484, DOI 10.1016/0008-8749(91)90120-Z; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MITA S, 1988, J EXP MED, V168, P863, DOI 10.1084/jem.168.3.863; Mitchell Diane L., 1993, Biochemical Society Transactions, V21, p332S; Morton Thomas A., 1994, Journal of Molecular Recognition, V7, P47, DOI 10.1002/jmr.300070107; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; PROUDFOOT AEI, 1990, BIOCHEM J, V270, P357, DOI 10.1042/bj2700357; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; ROBERT CH, 1989, BIOPOLYMERS, V28, P1705, DOI 10.1002/bip.360281006; RONCO LV, 1994, J BIOL CHEM, V269, P277; SANDERSON CJ, 1985, J EXP MED, V162, P60, DOI 10.1084/jem.162.1.60; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SHATZMAN A, 1990, CURRENT PROTOCOLS MO, V11; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; TANABE T, 1987, J BIOL CHEM, V262, P16580; TANFORD C, 1980, HYDROPHOBIC EFFECT; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; VANDERSTRATEN A, 1989, CURR METHODS MOL BIO, V1, P1; WARREN DJ, 1985, IMMUNOLOGY, V54, P615; WELLS JA, 1993, ANNU REV BIOPH BIOM, V22, P329, DOI 10.1146/annurev.bb.22.060193.001553; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wyman J, 1990, BINDING LINKAGE FUNC	66	85	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9459	9471		10.1074/jbc.270.16.9459	http://dx.doi.org/10.1074/jbc.270.16.9459			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721873	hybrid			2022-12-25	WOS:A1995QU08900062
J	PFEIFER, A; NURNBERG, B; KAMM, S; UHDE, M; SCHULTZ, G; RUTH, P; HOFMANN, F				PFEIFER, A; NURNBERG, B; KAMM, S; UHDE, M; SCHULTZ, G; RUTH, P; HOFMANN, F			CYCLIC GMP-DEPENDENT PROTEIN-KINASE BLOCKS PERTUSSIS-TOXIN-SENSITIVE HORMONE-RECEPTOR SIGNALING PATHWAYS IN CHINESE-HAMSTER OVARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NUCLEOTIDE-BINDING-PROTEINS; GROWTH FACTOR-II; TYROSINE PHOSPHORYLATION; NITRIC-OXIDE; CA2+ CURRENT; MOLECULAR-CLONING; CALCIUM INFLUX; ALPHA-SUBUNIT; RAT AORTA	cGMP-dependent protein kinase (cGMP kinase) has been implicated in the regulation of the cytosolic calcium level ([Ca2+](i)). In Chinese hamster ovary (CHO) cells stably transfected with the cGMP kinase I alpha (CHO-cGK cells), cGMP kinase suppressed the thrombin-induced increase in inositol 1,4,5-trisphosphate and [Ca2+](i) (Ruth, P,, Wang, G.-X., Boekhoff, I., May, B,, Pfeifer, A., Penner, R., Korth, M,, Breer, H,, and Hofmann, F, (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 2623-2627), Cholecystokinin activated intracellular calcium release via a pertussis toxin (PTX)-insensitive pathway in CHO-cGK cells. cGMP kinase did not attenuate the CCK stimulated [Ca2+](i). In contrast, cGMP kinase suppressed calcium influx stimulated by insulinlike growth factors 1 and 2 (IGF-1 and IGF-2) via PTX-sensitive pathways. The effects of PTX and cGMP kinase on [Ca2+](i) were not additive. 8-Bromo-cGMP had no effect on [Ca2+](i) stimulated by IGF-1 or IGF-2 in wild type CHO cells, These results suggested that cGMP kinase inhibited the different signaling pathways by the phosphorylation of a PTX-sensitive G protein. cGMP kinase phosphorylated the alpha subunits of G(i1), G(i2), and G(i3) in vitro. Phosphorylation stoichiometry was 0.4 mol of phosphate/mol of G(alpha i1) after reconstitution of heterotrimeric G(i1) in phospholipid vesicles. The alpha subunit of G(i) was also phosphorylated in vivo, These results show that cGMP kinase blocks transduction of distinct hormone pathways that signal via PTX-sensitive G(i) proteins.	FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, INST PHARMAKOL, D-14195 BERLIN, GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	PFEIFER, A (corresponding author), TECH UNIV MUNICH, INST PHARMAKOL & TOXIKOL, BIEDERSTEINER STR 29, D-80802 MUNICH, GERMANY.			Nurnberg, Bernd/0000-0002-5995-6555				ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BAFFY G, 1994, J BIOL CHEM, V269, P8483; BARNETT R, 1990, AM J PHYSIOL, V258, pC37, DOI 10.1152/ajpcell.1990.258.1.C37; BRAY P, 1987, P NATL ACAD SCI USA, V84, P5115, DOI 10.1073/pnas.84.15.5115; CODINA J, 1991, METHOD ENZYMOL, V195, P177; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARHAMMER R, 1994, BIOCHEM J, V303, P135, DOI 10.1042/bj3030135; HIRATA M, 1990, J BIOL CHEM, V265, P1268; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; HUNG DT, 1992, J BIOL CHEM, V267, P20831; ISHIKAWA T, 1993, CIRC RES, V73, P1128, DOI 10.1161/01.RES.73.6.1128; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KEILBACH A, 1992, EUR J BIOCHEM, V208, P467, DOI 10.1111/j.1432-1033.1992.tb17209.x; KOGA T, 1994, J BIOL CHEM, V269, P11640; KOJIMA I, 1988, J BIOL CHEM, V263, P16561; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; LANDGRAF W, 1989, EUR J BIOCHEM, V181, P643, DOI 10.1111/j.1432-1033.1989.tb14771.x; LAW SF, 1993, J BIOL CHEM, V268, P10721; LIGHT DB, 1990, NATURE, V344, P336, DOI 10.1038/344336a0; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LINCOLN TM, 1991, SEC MESS PHOSPHOPROT, V13, P99; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LUTZ MP, 1993, J BIOL CHEM, V268, P11119; MENOZZI D, 1991, J BIOL CHEM, V266, P10385; MERY PF, 1993, J BIOL CHEM, V268, P26286; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; NURNBERG B, 1994, BIOCHEM J, V300, P387; OFFERMANNS S, 1993, BIOCHEM J, V290, P27, DOI 10.1042/bj2900027; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OKAMOTO T, 1991, J BIOL CHEM, V266, P1085; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; ONO K, 1991, J PHYSIOL-LONDON, V443, P387, DOI 10.1113/jphysiol.1991.sp018839; PARK DJ, 1992, J BIOL CHEM, V267, P1496; RAPOPORT RM, 1986, CIRC RES, V58, P407, DOI 10.1161/01.RES.58.3.407; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; ROSENTHAL W, 1986, EUR J BIOCHEM, V158, P255, DOI 10.1111/j.1432-1033.1986.tb09745.x; RUTH P, 1993, P NATL ACAD SCI USA, V90, P2623, DOI 10.1073/pnas.90.7.2623; RUTH P, 1991, EUR J BIOCHEM, V202, P1339, DOI 10.1111/j.1432-1033.1991.tb16509.x; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; SPICHER K, 1991, BIOCHEM BIOPH RES CO, V175, P473, DOI 10.1016/0006-291X(91)91588-4; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; STRASSHEIM D, 1994, J BIOL CHEM, V269, P14307; TANIGUCHI J, 1993, PFLUG ARCH EUR J PHY, V423, P167, DOI 10.1007/BF00374390; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WEISS RH, 1992, J BIOL CHEM, V267, P5608; WINITZ S, 1994, J BIOL CHEM, V269, P1889	53	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9052	9059		10.1074/jbc.270.16.9052	http://dx.doi.org/10.1074/jbc.270.16.9052			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721818	hybrid			2022-12-25	WOS:A1995QU08900006
J	LETOURNEUR, O; SECHI, S; WILLETTEBROWN, J; ROBERTSON, MW; KINET, JP				LETOURNEUR, O; SECHI, S; WILLETTEBROWN, J; ROBERTSON, MW; KINET, JP			GLYCOSYLATION OF HUMAN TRUNCATED FC-EPSILON-RI ALPHA-CHAIN IS NECESSARY FOR EFFICIENT FOLDING IN THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; EPIDERMAL LANGERHANS CELLS; IMMUNOGLOBULIN-E; IGE RECEPTOR; TRANSFECTED CELLS; SUBUNIT; RAT; EXPRESSION; BINDING; PROTEIN	The high affinity immunoglobulin E (IgE) receptor is an alpha beta gamma(2) tetrameric complex. The truncated extracellular segment (alpha t) of the heavily glycosylated alpha chain is sufficient for high affinity binding of IgE. Here we have expressed various alpha t mutants in eukaryotic and prokaryotic cells to analyze the role of glycosylation in the folding, stability, and secretion of alpha t. All seven N-linked glycosylation sites in alpha t are glycosylated and their mutations have an additive effect on the folding and secretion of alpha t. Mutation of the seven N-glycosylation sites (Delta 1-7 alpha t) induces misfolding and retention of alpha t in the endoplasmic reticulum. Similarly, tunicamycin treatment reduces substantially the folding efficiency of wild-type alpha t. In contrast, no difference in folding efficiency is detected between wild-type alpha t and Delta 1-7 alpha t expressed in Escherichia coli. In addition, maturation of N-linked oligosaccharides and addition of O-linked carbohydrates are not required for either the transport or the IgE-binding function of alpha t. Furthermore, complete enzymatic deglycosylation does not affect the stability and the IgE-binding capacity of alpha t. Therefore, glycosylation is not intrinsically necessary for proper folding of alpha t but is required for folding in the endoplasmic reticulum. Our data are compatible with the concept that specific interactions between N-linked oligosaccharides and the folding machinery of the endoplasmic reticulum are necessary for efficient folding of alpha t in eukaryotic cells.	NIAID, MOLEC ALLERGY & IMMUNOL SECT, ROCKVILLE, MD 20852 USA; MRC, CTR PROT ENGN, CAMBRIDGE CB2 2QH, ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Cambridge								ARGOS P, 1987, J MOL BIOL, V197, P331, DOI 10.1016/0022-2836(87)90127-6; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BLANK U, 1991, J BIOL CHEM, V266, P2639; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; HAKIMI J, 1990, J BIOL CHEM, V265, P22079; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOGARTH PM, 1992, IMMUNOL REV, V125, P21, DOI 10.1111/j.1600-065X.1992.tb00623.x; KINET JP, 1987, BIOCHEMISTRY-US, V26, P4605, DOI 10.1021/bi00389a002; KINET JP, 1990, CURR OPIN IMMUNOL, V2, P499, DOI 10.1016/0952-7915(90)90002-X; KOCHAN J, 1988, NUCLEIC ACIDS RES, V16, P3584, DOI 10.1093/nar/16.8.3584; LACROIX EL, 1993, MOL IMMUNOL, V30, P321, DOI 10.1016/0161-5890(93)90060-O; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; MALLAMACI MA, 1993, J BIOL CHEM, V268, P22076; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; RA C, 1989, J BIOL CHEM, V264, P15323; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; SHIMIZU A, 1988, P NATL ACAD SCI USA, V85, P1907, DOI 10.1073/pnas.85.6.1907; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353	29	92	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8249	8256		10.1074/jbc.270.14.8249	http://dx.doi.org/10.1074/jbc.270.14.8249			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713932	hybrid			2022-12-25	WOS:A1995QR52600071
J	CHIAPPETTA, G; BANDIERA, A; BERLINGIERI, MT; VISCONTI, R; MANFIOLETTI, G; BATTISTA, S; MARTINEZTELLO, FJ; SANTORO, M; GIANCOTTI, V; FUSCO, A				CHIAPPETTA, G; BANDIERA, A; BERLINGIERI, MT; VISCONTI, R; MANFIOLETTI, G; BATTISTA, S; MARTINEZTELLO, FJ; SANTORO, M; GIANCOTTI, V; FUSCO, A			THE EXPRESSION OF THE HIGH-MOBILITY GROUP HMGI (Y) PROTEINS CORRELATES WITH THE MALIGNANT PHENOTYPE OF HUMAN THYROID NEOPLASIAS	ONCOGENE			English	Article						HMGI (Y) PROTEINS; THYROID; CARCINOMAS; TUMOR MARKER; IMMUNOHISTOCHEMISTRY	NUCLEAR PROTEINS; HISTONE H1; CELLS; BINDING; MOUSE; GENE; DNA; TRANSFORMATION; CARCINOMAS; SEQUENCE	High Mobility Group I(HMGI) proteins are nuclear proteins involved in the regulation of chromatin structure and function, Elevated expression of the HMGI proteins (HMGI, HMGY and HMGI-C) has been correlated with the presence of a highly malignant phenotype in epithelial and fibroblastic rat thyroid cells, and in several experimental carcinomas, Here, we demonstrate that HMGI and HMGY proteins are expressed in human thyroid carcinomas and thyroid carcinoma cell lines, but not in adenomas, goiters, normal thyroid tissues and cells, These results indicate a correlation between HMGI and HMGY expression and the malignant phenotype of thyroid neoplasias, suggesting that these proteins may be used as markers in thyroid cancer.	UNIV REGGIO CALABRIA, FAC MED & CHIRURG, DIPARTIMENTO MED SPERIMENTALE & CLIN, I-88100 CATANZARO, ITALY; IST NAZL TUMORI, FDN SENATORE PASCALE, I-80131 NAPLES, ITALY; UNIV TRIESTE, DIPARTIMENTO BIOCHIM BIOFIS & CHIM MACROMOLEC, I-34127 TRIESTE, ITALY; UNIV NAPLES, FAC MED & CHIRURG, CNR, CTR ENDOCRINOL ONCOL SPERIMENTALE, I-80131 NAPLES, ITALY; UNIV COMPLUTENSE MADRID, HOSP UNIV 12 OCTUBRE, DEPT PATHOL, E-28041 MADRID, SPAIN	Universita Mediterranea di Reggio Calabria; IRCCS Fondazione Pascale; University of Trieste; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Complutense University of Madrid; Hospital Universitario 12 de Octubre			Visconti, Roberta/C-5299-2009	MANFIOLETTI, GUIDALBERTO/0000-0001-7913-2601; Visconti, Roberta/0000-0001-7613-3801; Fusco, Alfredo/0000-0003-3332-5197				BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947; ESTOUR B, 1989, VIRCHOWS ARCH B, V57, P167, DOI 10.1007/BF02899078; FABIEN N, 1994, CANCER, V73, P2206, DOI 10.1002/1097-0142(19940415)73:8<2206::AID-CNCR2820730828>3.0.CO;2-M; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; GIANCOTTI V, 1993, EUR J BIOCHEM, V213, P825, DOI 10.1111/j.1432-1033.1993.tb17825.x; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MARTINEZTELLO FJ, 1993, CANCER-AM CANCER SOC, V71, P4022, DOI 10.1002/1097-0142(19930615)71:12<4022::AID-CNCR2820711236>3.0.CO;2-O; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; RAM TG, 1993, CANCER RES, V53, P2655; REEVES R, 1990, J BIOL CHEM, V265, P8573; SANTORO M, 1990, ONCOGENE, V5, P1595; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; TAMIMI Y, 1993, CANCER RES, V53, P5512; TANAKA J, 1987, VIROLOGY, V161, P62, DOI 10.1016/0042-6822(87)90171-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WINTER E, 1989, EMBO J, V8, P1867, DOI 10.1002/j.1460-2075.1989.tb03583.x; YANGYEN HF, 1988, MOL CELL BIOL, V8, P3406, DOI 10.1128/MCB.8.8.3406; ZEKI K, 1993, J CLIN ENDOCR METAB, V76, P127, DOI 10.1210/jc.76.1.127; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; [No title captured]	34	190	191	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1307	1314						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731681				2022-12-25	WOS:A1995QR65100007
J	HENIN, N; VINCENT, MF; GRUBER, HE; VANDENBERGHE, G				HENIN, N; VINCENT, MF; GRUBER, HE; VANDENBERGHE, G			INHIBITION OF FATTY-ACID AND CHOLESTEROL-SYNTHESIS BY STIMULATION OF AMP-ACTIVATED PROTEIN-KINASE	FASEB JOURNAL			English	Article						ACETYL-COA CARBOXYLASE; HMG-COA REDUCTASE; AICARIBOSIDE; ZMP	ACETYL-COA CARBOXYLASE; ISOLATED RAT HEPATOCYTES; COENZYME-A REDUCTASE; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; 5-AMINO-4-IMIDAZOLECARBOXAMIDE RIBOSIDE; REVERSIBLE PHOSPHORYLATION; CYCLIC-AMP; INACTIVATION; PURIFICATION; LIPOGENESIS	AMP-activated protein kinase is a multisubstrate protein kinase that, in liver, inactivates both acetyl-CoA carboxylase, the rate-limiting enzyme of fatty acid synthesis, and 3-hydroxy-3-methyl-glutaryl-CoA reductase, the rate-limiting enzyme of cholesterol synthesis, AICAR (5-amino 4-imidazolecarboxamide ribotide, ZMP) was found to stimulate up to 10-fold rat liver AMP-activated protein kinase, with a half-maximal effect at approximately 5 mM. In accordance with previous observations, addition to suspensions of isolated rat hepatocytes of 50-500 mu M AICAriboside, the nucleoside corresponding to ZMP, resulted in the accumulation of millimolar concentrations of the latter. This was accompanied by a dose-dependent inactivation of both acetyl-CoA carboxylase and 3-hydroxy-3-methylglutaryl-CoA reductase. Addition of 50-500 mu M AICAriboside to hepatocyte suspensions incubated in the presence of various substrates, including glucose and lactate/pyruvate, caused a parallel inhibition of both fatty acid and cholesterol synthesis, With lactate/pyruvate (10/1 mM), half-maximal inhibition was obtained at approximately 100 mu M, and near-complete inhibition at 500 mu M AICAriboside. These findings open new perspectives for the simultaneous control of triglyceride and cholesterol synthesis by pharmacological stimulators of AMP-activated protein kinase.	INT INST CELLULAR & MOLEC PATHOL,PHYSIOL CHEM LAB,B-1200 BRUSSELS,BELGIUM; UNIV LOUVAIN,SCH MED,B-1200 BRUSSELS,BELGIUM; GENSIA INC,SAN DIEGO,CA 92121	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								BEG ZH, 1981, CURR TOP CELL REGUL, V20, P139; BEG ZH, 1985, J BIOL CHEM, V260, P1682; BIJLEVELD C, 1987, BIOCHIM BIOPHYS ACTA, V918, P274, DOI 10.1016/0005-2760(87)90231-1; BROWN MS, 1975, J BIOL CHEM, V250, P2502; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CARLING D, 1994, J BIOL CHEM, V269, P11442; COHEN P, 1991, BIOCHIM BIOPHYS ACTA, V1094, P292, DOI 10.1016/0167-4889(91)90089-G; DAVIES SP, 1994, EUR J BIOCHEM, V223, P351, DOI 10.1111/j.1432-1033.1994.tb19001.x; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; DAVIES SP, 1972, EUR J BIOCHEM, V203, P615; EASOM RA, 1984, BIOCHEM J, V220, P739, DOI 10.1042/bj2200739; EVANS RD, 1990, BIOCHEM J, V269, P269, DOI 10.1042/bj2690269; GEELEN MJH, 1991, BIOCHEM BIOPH RES CO, V180, P525, DOI 10.1016/S0006-291X(05)81096-4; GIBBONS GF, 1979, BIOCHEM J, V177, P255, DOI 10.1042/bj1770255; GIBBONS GF, 1986, BIOCHEM J, V239, P617, DOI 10.1042/bj2390617; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HARDIE DG, 1992, BIOCHIM BIOPHYS ACTA, V1123, P231, DOI 10.1016/0005-2760(92)90001-C; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HARRIS RA, 1975, ARCH BIOCHEM BIOPHYS, V169, P168, DOI 10.1016/0003-9861(75)90330-6; HAVEL RJ, 1988, J CLIN INVEST, V81, P1653, DOI 10.1172/JCI113501; JAVAUX F, 1995, BIOCHEM J, V305, P913, DOI 10.1042/bj3050913; KENNELLY PJ, 1985, J LIPID RES, V26, P903; KIM KH, 1983, CURR TOP CELL REGUL, V22, P143; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; LINN TC, 1981, ARCH BIOCHEM BIOPHYS, V209, P613, DOI 10.1016/0003-9861(81)90320-9; LOPESVIRELLA MF, 1987, DIABETES METAB REV, V3, P691, DOI 10.1002/dmr.5610030305; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; NISHINA PM, 1990, J NUTR, V120, P668, DOI 10.1093/jn/120.7.668; SABINA RL, 1984, SCIENCE, V223, P1193, DOI 10.1126/science.6199843; SULLIVAN JE, 1994, BIOCHEM BIOPH RES CO, V200, P1551, DOI 10.1006/bbrc.1994.1627; TIPPER JP, 1982, BIOCHIM BIOPHYS ACTA, V715, P162, DOI 10.1016/0304-4165(82)90354-3; VINCENT MF, 1991, DIABETES, V40, P1259, DOI 10.2337/diabetes.40.10.1259; VINCENT MF, 1992, BIOCHEM J, V281, P267, DOI 10.1042/bj2810267; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WEEKES J, 1994, EUR J BIOCHEM, V219, P751, DOI 10.1111/j.1432-1033.1994.tb18554.x	36	217	233	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1995	9	7					541	546		10.1096/fasebj.9.7.7737463	http://dx.doi.org/10.1096/fasebj.9.7.7737463			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	QX148	7737463				2022-12-25	WOS:A1995QX14800012
J	JARIELENCONTRE, I; PARIAT, M; MARTIN, F; CARILLO, S; SALVAT, C; PIECHACZYK, M				JARIELENCONTRE, I; PARIAT, M; MARTIN, F; CARILLO, S; SALVAT, C; PIECHACZYK, M			UBIQUITINYLATION IS NOT AN ABSOLUTE REQUIREMENT FOR DEGRADATION OF C-JUN PROTEIN BY THE 26-S PROTEASOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; ORNITHINE DECARBOXYLASE; FOS; FIBROBLASTS; COMPLEXES; ONCOGENE; CALPAIN; GROWTH; SYSTEM; TRANSFORMATION	Degradation of rapidly turned over cellular proteins is commonly thought to be energy dependent, to require tagging of protein substrates by multi-ubiquitin chains, and to involve the 26 S proteasome, which is the major neutral proteolytic activity in both the cytosol and the nucleus, The c-Jun oncoprotein is very unstable in vivo, Using cell-free degradation assays, we show that ubiquitinylation, along with other types of tagging, is not an absolute prerequisite for ATP dependent degradation of c-Jun by the 26 S proteasome. This indicates that a protein may bear intrinsic structural determinants allowing its selective recognition and breakdown by the 26 S proteasome. Moreover, taken together with observations by different groups, our data point to the notion of the existence of multiple degradation pathways operating on c-Jun.	INSERM, U249, INST MOLEC GENET, CNRS, UMR 9942, F-34033 MONTPELLIER 01, FRANCE; INSERM, U249, CTR RECH BIOCHIM MACROMOLEC, CNRS, UMR 9008, F-34033 MONTPELLIER 01, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			PIECHACZYK, Marc/E-7896-2013	PIECHACZYK, Marc/0000-0003-1367-2597				ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; Angel P. E., 1994, FOS JUN FAMILIES TRA; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CARILLO S, 1994, ONCOGENE, V9, P1679; CHANG LMS, 1982, J BIOL CHEM, V257, P5700; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DESA MFG, 1988, J CELL SCI, V89, P151; GROPPER R, 1991, J BIOL CHEM, V266, P3602; HARLOW E, 1988, ANTIBODIES; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MAKI M, 1989, J BIOL CHEM, V264, P18866; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MORGAN IM, 1993, ONCOGENE, V8, P1135; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAWADA H, 1993, FEBS LETT, V335, P207, DOI 10.1016/0014-5793(93)80731-9; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; TANAKA K, 1988, J BIOL CHEM, V263, P16209; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; UGAI S, 1993, J BIOCHEM, V113, P754, DOI 10.1093/oxfordjournals.jbchem.a124116; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092	40	131	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11623	11627		10.1074/jbc.270.19.11623	http://dx.doi.org/10.1074/jbc.270.19.11623			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744802	Green Published, hybrid			2022-12-25	WOS:A1995QX86500084
J	HO, V; ACQUAVIVA, A; DUH, E; BUNN, HF				HO, V; ACQUAVIVA, A; DUH, E; BUNN, HF			USE OF A MARKED ERYTHROPOIETIN GENE FOR INVESTIGATION OF ITS CIS-ACTING ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; MESSENGER-RNA LEVELS; BINDING-PROTEIN; TRANSCRIPTIONAL ENHANCER; HYPOXIA; EXPRESSION; CLONING; DEGRADATION; SEQUENCES; HOMOLOGY	To examine the function of conserved noncoding regions in the erythropoietin (Epo) gene, we have prepared clones and pools of Hep3B cells stably transfected with a marked 4.1-kilobase Epo gene and deletions thereof, The marked transcripts had single base substitutions at three sites in the coding portion of Exon 5, enabling them to be distinguished from endogenous Epo mRNA by ribonuclease protection and competitive polymerase chain reaction. The basal expression and hypoxic induction of the marked Epo gene that had no deletions were indistinguishable from that of the endogenous Epo gene. Likewise, deletion of conserved intervening sequence 1 had minimal effect on hypoxic induction, In contrast, a 3'-deletion that included the conserved S'-enhancer element resulted in a substantial, but not complete, suppression of hypoxic induction while a 3' deletion downstream of the enhancer resulted in enhancement, A 188-base pair deletion of a conserved 3'-untranslated region in Exon 5 had minimal effect on hypoxic induction, However, the truncated Epo mRNA had a markedly prolonged half life (15 h) in comparison to the endogenous Epo mRNA (2.0 h) or the marked full-length Epo mRNA (2.1 h), Further deletions in the 3'-UTR showed that a relatively small region of approximately 50 bases is responsible for the relatively rapid turnover of Epo mRNA. These experiments provide information on cis-acting elements of the Epo gene that cannot be obtained from conventional reporter gene transfection experiments.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041234] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK41234] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK I, 1993, BLOOD, V82, P704; BECK I, 1991, J BIOL CHEM, V266, P15563; BERU N, 1986, MOL CELL BIOL, V6, P2571, DOI 10.1128/MCB.6.7.2571; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BONDURANT MC, 1986, MOL CELL BIOL, V6, P2731, DOI 10.1128/MCB.6.7.2731; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CLEVELAND DW, 1985, ANNU REV BIOCHEM, V54, P331, DOI 10.1146/annurev.bi.54.070185.001555; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; FANDREY J, 1993, BLOOD, V81, P617; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GALSON DL, 1993, BLOOD, V82, P3321; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GOLDBERG MA, 1991, BLOOD, V77, P271; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; IMAGAWA S, 1991, BLOOD, V77, P278; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MCDONALD JD, 1986, MOL CELL BIOL, V6, P842, DOI 10.1128/MCB.6.3.842; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; SCHUSTER SJ, 1989, BLOOD, V73, P13; SCHUSTER SJ, 1987, BLOOD, V70, P316; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHOEMAKER CB, 1986, MOL CELL BIOL, V6, P849, DOI 10.1128/MCB.6.3.849; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230	33	23	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10084	10090		10.1074/jbc.270.17.10084	http://dx.doi.org/10.1074/jbc.270.17.10084			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730312	hybrid			2022-12-25	WOS:A1995QV41700057
J	ICHINOSE, H; OHYE, T; MATSUDA, Y; HORI, T; BLAU, N; BURLINA, A; ROUSE, B; MATALON, R; FUJITA, K; NAGATSU, T				ICHINOSE, H; OHYE, T; MATSUDA, Y; HORI, T; BLAU, N; BURLINA, A; ROUSE, B; MATALON, R; FUJITA, K; NAGATSU, T			CHARACTERIZATION OF MOUSE AND HUMAN GTP CYCLOHYDROLASE-I GENES - MUTATIONS IN PATIENTS WITH GTP CYCLOHYDROLASE-I DEFICIENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TETRAHYDROBIOPTERIN; CELLS; HYPERPHENYLALANINEMIA; COFACTOR; MUTANT; GAMMA; HPH-1; BIOSYNTHESIS; MACROPHAGES	GTP cyclohydrolase I is the first and rate-limiting enzyme for the biosynthesis of tetrahydrobiopterin in mammals. Previously, we reported three species of human GTP cyclohydrolase I cDNA in a human liver cDNA library (Togari, A., Ichinose, H., Matsumoto, S., Fujita, IC., and Nagatsu, T. (1992) Biochem. Biophys. Res. Commun. 187, 359-365). Furthermore, very recently, we found that the GTP cyclohydrolase I gene is causative for hereditary progressive dystonia with marked diurnal fluctuation, also known as DOPA-responsive dystonia (Ichinose, H., Ohye, T., Takahashi, E., Seki, N., Hori, T., Segawa, M., Nomura, Y., Endo, K., Tanaka, H., Tsuji, S., Fujita, K., and Nagatsu, T. (1994) Nature Genetics 8, 236-242). To clarify the mechanisms that regulate transcription of the GTP cyclohydrolase I gene and to generate multiple species of mRNA, we isolated genomic DNA clones for the human and mouse GTP cyclohydrolase I genes. Structural analysis of the isolated clones revealed that the GTP cyclohydrolase I gene is encoded by a single copy gene and is composed of six exons spanning similar to 30 kilobases. We sequenced all exon/intron boundaries of the human and mouse genes. Structural analysis also demonstrated that the heterogeneity of GTP cyclohydrolase I mRNA is caused by an alternative usage of the splicing acceptor site at the sixth exon. The transcription start site of the mouse GTP cyclohydrolase I gene and the 5'-flanking sequences of the mouse and human genes were deter mined. We performed regional mapping of the mouse gene by fluorescence in situ hybridization, and the mouse GTP cyclohydrolase I gene was assigned to region C2-3 of mouse chromosome 14. We identified missense mutations in patients with GTP cyclohydrolase I deficiency and expressed mutated enzymes in Escherichia coli to confirm alterations in the enzyme activity.	FUJITA HLTH UNIV,INST COMPREHENS MED SCI,TOYOAKE,AICHI 47011,JAPAN; NATL INST RADIOL SCI,DIV GENET,CHIBA 263,JAPAN; UNIV ZURICH,DEPT PEDIAT,DIV CLIN CHEM,CH-8032 ZURICH,SWITZERLAND; UNIV PADUA,DEPT PEDIAT,I-35128 PADUA,ITALY; MIAMI CHILDRENS HOSP,RES INST,MIAMI,FL 33155; UNIV TEXAS,MED BRANCH,DEPT PEDIAT,GALVESTON,TX 77550	Fujita Health University; National Institutes for Quantum Science & Technology; University of Zurich; University of Padua; University of Texas System; University of Texas Medical Branch Galveston			Ichinose, Hiroshi/D-8986-2015	Ichinose, Hiroshi/0000-0001-6008-6860; Blau, Nenad/0000-0003-4347-3230				BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BLAU N, 1985, CLIN CHIM ACTA, V148, P47, DOI 10.1016/0009-8981(85)90299-2; BLAU N, 1995, IN PRESS J PEDIATR; BODE VC, 1988, GENETICS, V118, P299; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; DALTON S, 1988, EMBO J, V7, P49, DOI 10.1002/j.1460-2075.1988.tb02782.x; DHONDT JL, 1985, J PEDIATR-US, V106, P954, DOI 10.1016/S0022-3476(85)80251-1; GUTLICH M, 1992, BIOCHIM BIOPHYS ACTA, V1171, P133, DOI 10.1016/0167-4781(92)90112-D; GUTLICH M, 1994, BIOCHEM J, V302, P215, DOI 10.1042/bj3020215; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; ICHINOSE H, 1994, NAT GENET, V8, P236, DOI 10.1038/ng1194-236; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; KAUFMAN S, 1959, J BIOL CHEM, V234, P2677; KWON NS, 1989, J BIOL CHEM, V264, P20496; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LOVENBERG W, 1967, SCIENCE, V155, P217, DOI 10.1126/science.155.3759.217; MATALON R, 1984, Pediatric Research, V18, p223A, DOI 10.1203/00006450-198404001-00781; MATSUDA Y, 1992, CYTOGENET CELL GENET, V61, P282, DOI 10.1159/000133423; MCDONALD JD, 1988, PEDIATR RES, V23, P63, DOI 10.1203/00006450-198801000-00014; MCDONALD JD, 1988, J NEUROCHEM, V50, P655, DOI 10.1111/j.1471-4159.1988.tb02961.x; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NAYLOR EW, 1987, PEDIATRICS, V79, P374; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NIEDERWIESER A, 1984, EUR J PEDIATR, V141, P203; NOMURA T, 1993, BIOCHEM BIOPH RES CO, V191, P523, DOI 10.1006/bbrc.1993.1249; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOEDON G, 1987, EUR J BIOCHEM, V166, P303, DOI 10.1111/j.1432-1033.1987.tb13515.x; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5864, DOI 10.1073/pnas.86.15.5864; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; TOGARI A, 1992, BIOCHEM BIOPH RES CO, V187, P359, DOI 10.1016/S0006-291X(05)81501-3; WERNER ER, 1990, J BIOL CHEM, V265, P3189; WERNERFELMAYER G, 1993, FEBS LETT, V322, P223, DOI 10.1016/0014-5793(93)81574-J; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x; ZIEGLER I, 1993, J BIOL CHEM, V268, P12544	36	136	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10062	10071		10.1074/jbc.270.17.10062	http://dx.doi.org/10.1074/jbc.270.17.10062			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730309	hybrid			2022-12-25	WOS:A1995QV41700054
J	SUNDARAM, SK; FAN, JH; LEV, M				SUNDARAM, SK; FAN, JH; LEV, M			A NEUTRAL GALACTOCEREBROSIDE SULFATE SULFATIDASE FROM MOUSE-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFOTRANSFERASE ACTIVITY; VITAMIN-K; RAT-BRAIN; 3-KETODIHYDROSPHINGOSINE SYNTHETASE; BACTEROIDES-MELANINOGENICUS; PARTIAL-PURIFICATION; CERAMIDE; SPHINGOMYELINASE; LIVER	We have described an enzyme in brain that catabolizes galactocerebroside sulfatide with a pH optimum of 7.2. To our knowledge, this is the first description of a catabolic enzyme for sulfatide at a neutral pH, Activity at a neutral pH implies a non-lysosomal location for this sulfatidase. Galactocerebroside sulfate sulfatidase (n-sulfatidase) activity was not apparent in crude microsomal extracts acid was detected following partial purification of the enzyme, This enzyme, n-sulfatidase, differs from other arylsulfatases in its M(r), inability to bind to concanavalin A, and substrate specificity; n-sulfatidase was unable to hydrolyze p-nitrocatechol sulfate or estrone sulfate, The molecular mass of n-sulfatidase obtained by Sephacryl S-200 chromatography was 72 kDa, and the active fraction from this procedure was purified >600-fold by isoelectric focusing. Following SDS polyacrylamide gel electrophoresis, two bands were obtained with apparent molecular masses of 58 and 66 kDa, Enzyme activity was regenerated from both of these bands, with the 66-kDa band showing greater activity, The K-m of the sulfatidase was determined as 5.8 x 10(-5) M. The pI of n-sulfatidase was 7.7 in contrast to the pI of 4.9 for the sulfotransferase. No requirement was found for Mg2+ or ATP for sulfatidase activity; vitamin K-1 enhanced sulfatidase activity approximately 3.3-fold. Therefore, this enzyme may have a role in the pathogenesis of metachromatic leukodystrophy in which sulfatides accumulate in the nervous and other tissues and in myelination since sulfatides are an important component of myelin.	CUNY,SCH MED,SOPHIE DAVIES SCH BIOMED EDUC,DEPT MICROBIOL,NEW YORK,NY 10031	City University of New York (CUNY) System					NCRR NIH HHS [RR03060] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BRATTAIN MG, 1977, BIOCHEM J, V163, P247, DOI 10.1042/bj1630247; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; CUMAR FA, 1968, J BIOL CHEM, V243, P3807; DYER CA, 1990, J CELL BIOL, V111, P625, DOI 10.1083/jcb.111.2.625; DYER CA, 1991, J NEUROSCI RES, V711, P699; FARRELL DF, 1971, J BIOL CHEM, V246, P4694; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; HANNUN YA, 1993, ADV LIPID RES, V25, P27; IWAMORI M, 1976, ARCH BIOCHEM BIOPHYS, V174, P199, DOI 10.1016/0003-9861(76)90339-8; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LEV M, 1973, ARCH BIOCHEM BIOPHYS, V157, P500, DOI 10.1016/0003-9861(73)90668-1; LEV M, 1981, ARCH BIOCHEM BIOPHYS, V212, P424, DOI 10.1016/0003-9861(81)90384-2; LEV M, 1972, J LIPID RES, V13, P364; LEV M, 1993, T AM SOC NEUROCHEM, V24, P185; LISTER MD, 1993, BIOCHIM BIOPHYS ACTA, V1165, P314, DOI 10.1016/0005-2760(93)90142-V; MCALARNEY T, 1994, J NEUROSCI RES, V37, P453, DOI 10.1002/jnr.490370404; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; PHILLIPS NC, 1976, BIOCHEM J, V153, P579, DOI 10.1042/bj1530579; RAGHAVAN SS, 1981, J NEUROCHEM, V36, P724, DOI 10.1111/j.1471-4159.1981.tb01648.x; SHAPIRO LJ, 1989, METABOLIC BASIS INHE, P1965; SUNDARAM KS, 1992, J BIOL CHEM, V267, P24041; SUNDARAM KS, 1990, ARCH BIOCHEM BIOPHYS, V277, P109, DOI 10.1016/0003-9861(90)90557-F; SUNDARAM KS, 1990, BIOCHEM BIOPH RES CO, V169, P927, DOI 10.1016/0006-291X(90)91982-X; SUNDARAM KS, 1988, J LIPID RES, V29, P1475; TAYLOR T, 1987, BIOCHIM BIOPHYS ACTA, V913, P131, DOI 10.1016/0167-4838(87)90321-9; TENNEKOON G, 1978, J NEUROCHEM, V31, P329, DOI 10.1111/j.1471-4159.1978.tb12466.x; VOS JP, 1994, BBA-LIPID LIPID MET, V1211, P125, DOI 10.1016/0005-2760(94)90262-3	32	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10187	10192		10.1074/jbc.270.17.10187	http://dx.doi.org/10.1074/jbc.270.17.10187			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730322	hybrid			2022-12-25	WOS:A1995QV41700069
J	WEDLER, FC; LEY, BW; LEE, BH; OLEARY, MH; KANTROWITZ, ER				WEDLER, FC; LEY, BW; LEE, BH; OLEARY, MH; KANTROWITZ, ER			L-ASPARTATE ASSOCIATION CONTRIBUTES TO RATE LIMITATION AND INDUCTION OF THE T-]R TRANSITION IN ESCHERICHIA-COLI ASPARTATE TRANSCARBAMOYLASE - EQUILIBRIUM EXCHANGES AND KINETIC ISOTOPE EFFECTS WITH A V-MAX-ENHANCED MUTANT, ASP-236-]ALA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTATION; HETEROTROPIC INTERACTIONS; CATALYTIC SUBUNITS; RESIDUES 230-245; CARBAMOYLTRANSFERASE; MECHANISM; ENZYME; CHAIN; C-13; CTP	Equilibrium isotope exchange kinetics (EIEK) and kinetic isotope effects have been used to determine the mechanistic basis for the altered kinetic characteristics of a mutant version of Escherichia coli aspartate trans carbamoylase in which Asp-236 of the catalytic chain is replaced by alanine (Asp 236 --> Ale), The [C-14]Asp reversible arrow N-carbamyl-L-aspartate (CAsp) and [C-14]CP reversible arrow CAsp exchange rates, observed as a function of various reactant-product pairs, exhibited dramatic increases in maximal rates, along with decreases in substrate half-saturation values and cooperativity, The carbon kinetic isotope effect, C-13 versus C-12 at the carbonyl group of carbamoyl phosphate, for the Asp-236 --> Ala enzyme decreased toward unity as [Asp] increased, as observed for the wildtype enzyme, Both the kinetic isotope effects and EIEK results indicate that the Asp-236 --> Ala enzyme operates by the same ordered kinetic mechanism as the wild-type enzyme, Although activation effects by ATP and N-phosphonacetyl-L-aspartate are lost, inhibition by CTP was apparent in equilibrium exchanges, Simulation of the EIEK data indicated that the best fit to the observed changes in saturation curves was obtained by preferentially increasing the rate of the T --> R transition, k(T-->R), thereby destabilizing the T-state and increasing the equilibrium constant for the T reversible arrow R transition, A multistep model for Asp binding to aspartate transcarbamoylase is proposed, in which Asp induces the initial conformational changes that in turn trigger the T --> R transition, followed by stepwise filling of the remaining active sites.	BOSTON COLL, MERKERT CHEM CTR, DEPT CHEM, CHESTNUT HILL, MA 02167 USA; PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, ALTHOUSE LAB, UNIVERSITY PK, PA 16802 USA; UNIV NEBRASKA, DEPT BIOCHEM, LINCOLN, NE 68583 USA	Boston College; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Nebraska System; University of Nebraska Lincoln					NIGMS NIH HHS [GM43043, GM26237] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043043, R01GM026237] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN CM, 1964, BIOCHEMISTRY-US, V3, P1238, DOI 10.1021/bi00897a010; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BOYER PD, 1978, ACCOUNTS CHEM RES, V11, P218, DOI 10.1021/ar50125a007; FOOTE J, 1985, J MOL BIOL, V186, P175, DOI 10.1016/0022-2836(85)90267-0; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1962, J BIOL CHEM, V237, P891; GOUAUX JE, 1990, BIOCHEMISTRY-US, V29, P7702, DOI 10.1021/bi00485a020; GOUAUX JE, 1988, P NATL ACAD SCI USA, V85, P4205, DOI 10.1073/pnas.85.12.4205; HSUANYU Y, 1989, BIOCHIM BIOPHYS ACTA, V995, P54, DOI 10.1016/0167-4838(89)90232-X; HSUANYU Y, 1987, ARCH BIOCHEM BIOPHYS, V259, P316, DOI 10.1016/0003-9861(87)90498-X; HSUANYU Y, 1988, BIOCHIM BIOPHYS ACTA, V957, P455, DOI 10.1016/0167-4838(88)90236-1; HSUANYU YC, 1989, J BIOL CHEM, V264, P17259; JACOBSON GR, 1973, ENZYMES, V9, P225; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; KIM KH, 1987, J MOL BIOL, V196, P853, DOI 10.1016/0022-2836(87)90410-4; KNOWLES JR, 1977, ACCOUNTS CHEM RES, V10, P105, DOI 10.1021/ar50112a001; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; LADJIMI MM, 1985, J MOL BIOL, V186, P715, DOI 10.1016/0022-2836(85)90391-2; LIPSCOMB WN, 1994, ADV ENZYMOL RAMB, V68, P67; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIDDLETON SA, 1986, P NATL ACAD SCI USA, V83, P5866, DOI 10.1073/pnas.83.16.5866; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NEWTON CJ, 1990, P NATL ACAD SCI USA, V87, P2309, DOI 10.1073/pnas.87.6.2309; Northrop D. B., 1977, ISOTOPE EFFECTS ENZY, P122; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; PARMENTIER LE, 1992, BIOCHEMISTRY-US, V31, P6577, DOI 10.1021/bi00143a030; PARMENTIER LE, 1992, BIOCHEMISTRY-US, V31, P6598, DOI 10.1021/bi00143a033; PARMENTIER LE, 1992, BIOCHEMISTRY-US, V31, P6570, DOI 10.1021/bi00143a029; PASTRALANDIS SC, 1978, J BIOL CHEM, V253, P4624; PORTER RW, 1969, J BIOL CHEM, V244, P1846; PURICH DL, 1980, METHOD ENZYMOL, V64, P3; RAY WJ, 1983, BIOCHEMISTRY-US, V22, P4625, DOI 10.1021/bi00289a003; STEVENS RC, 1991, PROTEIN ENG, V4, P391, DOI 10.1093/protein/4.4.391; TAUC P, 1982, J MOL BIOL, V155, P155, DOI 10.1016/0022-2836(82)90442-9; WALDROP GL, 1992, BIOCHEMISTRY-US, V31, P6585, DOI 10.1021/bi00143a031; WALDROP GL, 1992, BIOCHEMISTRY-US, V31, P6592, DOI 10.1021/bi00143a032; WEDLER FC, 1994, ANAL BIOCHEM, V218, P449, DOI 10.1006/abio.1994.1205; WEDLER FC, 1989, J BIOL CHEM, V264, P17266; WEDLER FC, 1995, IN PRESS METHODS ENZ; WILD JR, 1989, P NATL ACAD SCI USA, V86, P46, DOI 10.1073/pnas.86.1.46	42	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9725	9733		10.1074/jbc.270.17.9725	http://dx.doi.org/10.1074/jbc.270.17.9725			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730350	hybrid			2022-12-25	WOS:A1995QV41700008
J	BARBACCI, EG; GUARINO, BC; STROH, JG; SINGLETON, DH; ROSNACK, KJ; MOYER, JD; ANDREWS, GC				BARBACCI, EG; GUARINO, BC; STROH, JG; SINGLETON, DH; ROSNACK, KJ; MOYER, JD; ANDREWS, GC			THE STRUCTURAL BASIS FOR THE SPECIFICITY OF EPIDERMAL GROWTH-FACTOR AND HEREGULIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND; DIFFERENTIATION; PROTEINS	Heregulin is a ligand for the erbB3 and erbB4 receptors, with a region of high homology to epidermal growth factor (EGF). Despite this homology, these ligands bind to their corresponding receptors with great specificity. We report here the synthesis of heregulin beta 177-241 and show that a region consisting of amino acids 177-226 is sufficient both for binding and stimulation of receptor phosphorylation. Studies of chimeric EGF/heregulin peptides revealed that amino acids 177-181 of heregulin provide the specificity for binding to the heregulin receptor. The substitution of amino acids 177-181 of heregulin for the N terminus of EGF produced a unique bifunctional agonist that binds with high affinity to both the EGF receptor and the heregulin receptor.	PFIZER INC,CENT RES,GROTON,CT 06340	Pfizer								CARPENTER G, 1991, PEPTIDE GROWTH FACTO, V1, P69; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DEFEOJONES D, 1988, MOL CELL BIOL, V8, P2999, DOI 10.1128/MCB.8.8.2999; ENGLER DA, 1992, J BIOL CHEM, V267, P2274; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MATSUNAMI RK, 1991, J CELL BIOCHEM, V46, P242, DOI 10.1002/jcb.240460307; NAGATA K, 1994, EMBO J, V13, P3517, DOI 10.1002/j.1460-2075.1994.tb06658.x; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; SHIN SY, 1994, LIFE SCI, V55, P131; SIMPSON RJ, 1985, EUR J BIOCHEM, V153, P629, DOI 10.1111/j.1432-1033.1985.tb09346.x; SLOWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TADAKI DK, 1991, FASEB J, V5, pA1183; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	24	99	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9585	9589		10.1074/jbc.270.16.9585	http://dx.doi.org/10.1074/jbc.270.16.9585			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721889	hybrid			2022-12-25	WOS:A1995QU08900078
J	OXFORD, JT; DOEGE, KJ; MORRIS, NP				OXFORD, JT; DOEGE, KJ; MORRIS, NP			ALTERNATIVE EXON SPLICING WITHIN THE AMINO-TERMINAL NONTRIPLE-HELICAL DOMAIN OF THE RAT PRO-ALPHA-1(XI) COLLAGEN CHAIN GENERATES MULTIPLE FORMS OF THE MESSENGER-RNA TRANSCRIPT WHICH EXHIBIT TISSUE-DEPENDENT VARIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE-RICH PROTEIN; XI COLLAGEN; NH2-TERMINAL DOMAIN; V COLLAGEN; DIFFERENTIAL EXPRESSION; MESSENGER-RNA; TRIPLE HELIX; 5' END; CARTILAGE; FIBRILS	Type XI collagen is an integral, although minor component of cartilage collagen fibrils, We have established that alternative exon usage is a mechanism for increasing structural diversity within the amino-terminal non-triple helical domain of the pro-alpha 1 (XI) collagen gene. cDNA clones spanning the amino-terminal domain were selected from a rat chondrosarcoma library, and were shown to contain two major sequence differences from the previously reported human sequence. The first difference was the replacement of sequence encoding an acidic domain of 39 amino acids in length by a sequence encoding a 51-amino acid basic domain with a predicted pI of 11.9. The second difference was the absence of a sequence that would translate into a highly acidic 85-amino acid sequence downstream from the first variation. These two changes, expressed together, result in the replacement of most of the acidic domain with one that is smaller and basic. These two sequence differences serve to identify subdomains of a variable region, designated V1 and V2, respectively. V1a is defined as the acidic 39 amino acid sequence element and V1b is defined as the 51-amino acid basic sequence. Analysis of genomic DNA revealed that both V1a and V1b are encoded by separate adjacent exons in the rat genome and V2 is also encoded in a single exon downstream. Analysis of mRNA from cartilage derived sources revealed a complex pattern of alpha 1 (XI) transcript expression due to differential exon usage. In non-cartilage sources, the pattern is less complex; the most prevalent form is the one containing the two acidic sequences, V1a and V2.	SHRINERS HOSP CRIPPLED CHILDRENS,DEPT BIOCHEM & MOLEC BIOL,RES DEPT,PORTLAND UNIT,PORTLAND,OR 97201; SHRINERS HOSP CRIPPLED CHILDRENS,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201				Oxford, Julia Thom/AAH-2842-2019	Oxford, Julia Thom/0000-0002-4850-3569	NIGMS NIH HHS [GM-39862] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039862] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BACHINGER HP, 1991, INT J BIOL MACROMOL, V13, P152, DOI 10.1016/0141-8130(91)90040-2; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BOYD CD, 1993, MATRIX, V13, P457, DOI 10.1016/S0934-8832(11)80112-5; BURGESON RE, 1988, ANNU REV CELL BIOL, V4, P551, DOI 10.1146/annurev.cb.04.110188.003003; BURGESON RE, 1971, BIOCHEM BIOPH RES CO, V87, P1124; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P1367, DOI 10.1002/bip.360280803; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DOEGE K, 1987, J BIOL CHEM, V262, P17757; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; EYRE D, 1987, STRUCTURE FUNCTION C, P81; FURUTO DK, 1983, ARCH BIOCHEM BIOPHYS, V226, P604, DOI 10.1016/0003-9861(83)90329-6; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOLMES DF, 1993, J BIOL CHEM, V268, P15758; HORTON WE, 1988, EXP CELL RES, V178, P457, DOI 10.1016/0014-4827(88)90414-4; Keene D. R., 1993, Molecular Biology of the Cell, V4, p289A; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; KUHN K, 1987, STRUCTURE FUNCTION C, P1; LEES JF, 1994, J BIOL CHEM, V269, P24354; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; MORRIS NP, 1990, J BIOL CHEM, V265, P10081; NAH HD, 1992, J BIOL CHEM, V267, P22581; NAH HD, 1991, J BIOL CHEM, V266, P23446; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; OXFORD JT, 1994, EXP CELL RES, V213, P28, DOI 10.1006/excr.1994.1169; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; PETIT B, 1993, HISTOCHEMISTRY, V100, P231, DOI 10.1007/BF00269096; PIERARD GE, 1986, COLLAGEN REL RES, V6, P481; RAMIREZ F, 1990, ANN NY ACAD SCI, V580, P74, DOI 10.1111/j.1749-6632.1990.tb17919.x; ROMANIC AM, 1991, J BIOL CHEM, V266, P12703; RYAN MC, 1990, J BIOL CHEM, V265, P10334; Sambrook J, 1989, MOL CLONING LABORATO; SANDBERG MM, 1993, BIOCHEM J, V294, P595, DOI 10.1042/bj2940595; SANDELL LJ, 1994, DEV DYNAM, V199, P129, DOI 10.1002/aja.1001990206; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SANDELL LJ, 1990, EXTRACELLULAR MATRIX, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEGMILL.R, 1972, J ULTRA MOL STRUCT R, V38, P288, DOI 10.1016/S0022-5320(72)90006-8; SEEGMILLER R, 1971, J CELL BIOL, V48, P580, DOI 10.1083/jcb.48.3.580; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SMITH BD, 1975, ARCH BIOCHEM BIOPHYS, V166, P181, DOI 10.1016/0003-9861(75)90378-1; THOM JR, 1991, J BIOL CHEM, V266, P7262; TRUEB J, 1992, BIOCHIM BIOPHYS ACTA, V1171, P97, DOI 10.1016/0167-4781(92)90145-P; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WALCHLI C, 1993, EUR J BIOCHEM, V212, P483, DOI 10.1111/j.1432-1033.1993.tb17685.x; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; ZHANG RZ, 1994, GENOMICS, V22, P425, DOI 10.1006/geno.1994.1404; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486; 1991, PROGRAM MANUAL GCG P	58	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9478	9485		10.1074/jbc.270.16.9478	http://dx.doi.org/10.1074/jbc.270.16.9478			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721875	hybrid			2022-12-25	WOS:A1995QU08900064
J	RAMAGE, P; CHENEVAL, D; CHVEI, M; GRAFF, P; HEMMIG, R; HENG, R; KOCHER, HP; MACKENZIE, A; MEMMERT, K; REVESZ, L; WISHART, W				RAMAGE, P; CHENEVAL, D; CHVEI, M; GRAFF, P; HEMMIG, R; HENG, R; KOCHER, HP; MACKENZIE, A; MEMMERT, K; REVESZ, L; WISHART, W			EXPRESSION, REFOLDING, AND AUTOCATALYTIC PROTEOLYTIC PROCESSING OF THE INTERLEUKIN-1-BETA CONVERTING-ENZYME PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; PROTEASE; REQUIRES; SEQUENCE; PROTEINS	The interleukin-1 beta p-converting enzyme is a heterodimeric cysteine protease that is produced as a 45-kDa precursor, The full-length precursor form of the enzyme was expressed in Escherichia coli as insoluble inclusion bodies. Following solubilization and refolding of the 45-kDa protein, autoproteolytic conversion to a heterodimeric form containing 10- and 20-kDa subunits was observed. This enzyme had catalytic activity against both natural (interleukin-1 beta precursor) and synthetic peptide substrates. The inclusion of a specific inhibitor (SDZ 223-941) of the converting enzyme in the refolding mixture prevented proteolytic processing to the 10-/20 kDa form. Similarly, refolding under nonreducing conditions also prevented processing. Time course experiments showed that the 10-kDa subunit was released from the 45-kDa precursor before the 20-kDa subunit, implying that the N-terminal portion of the precursor is released last and may play a regulatory role,	SANDOZ PHARMA LTD,DEPT BONE & JOINT,CH-4002 BASEL,SWITZERLAND; SANDOZ PHARMA LTD,DEPT SIGNAL TRANSDUCT,CH-4002 BASEL,SWITZERLAND	Novartis; Sandoz; Novartis; Sandoz	RAMAGE, P (corresponding author), SANDOZ PHARMA LTD,DEPT BIOTECHNOL,CH-4002 BASEL,SWITZERLAND.							BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLACK RA, 1988, J BIOL CHEM, V263, P9437; CAPUTO A, 1994, STRUCT BIOL, V1, P364; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; HAZUDA D, 1989, J BIOL CHEM, V264, P1689; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KRONHEIM SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P698, DOI 10.1016/0003-9861(92)90629-B; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; SHIVELY JE, 1987, ANAL BIOCHEM, V163, P517, DOI 10.1016/0003-2697(87)90257-0; SLEATH PR, 1990, J BIOL CHEM, V365, P14526; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG XM, 1994, GENE, V145, P273; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0	21	102	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9378	9383		10.1074/jbc.270.16.9378	http://dx.doi.org/10.1074/jbc.270.16.9378			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721861	hybrid			2022-12-25	WOS:A1995QU08900050
J	SHERMAN, PM; LAWRENCE, DA; VERHAMME, IM; PAIELLI, D; SHORE, JD; GINSBURG, D				SHERMAN, PM; LAWRENCE, DA; VERHAMME, IM; PAIELLI, D; SHORE, JD; GINSBURG, D			IDENTIFICATION OF TISSUE-TYPE PLASMINOGEN ACTIVATOR-SPECIFIC PLASMINOGEN-ACTIVATOR INHIBITOR-1 MUTANTS - EVIDENCE THAT 2ND SITES OF INTERACTION CONTRIBUTE TO TARGET SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE DEFICIENT MICE; HEPARIN COFACTOR-II; REACTIVE SITE; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; ANTITHROMBIN-III; DIRECTED MUTAGENESIS; SERINE PROTEASES; ALPHA-THROMBIN; VITRONECTIN	Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of the plasminogen activators (PAs), tis sue-type plasminogen activator (tPA), and urokinase-type plasminogen activator (uPA). A library of PAL-1 mutants containing substitutions at the P-1 and P-1' positions was screened for functional activity against tPA and thrombin. Several PAI-1 variants that were inactive against uPA in a previous study (Sherman, P. M., Lawrence, D. A., Yang, A. Y., Vandenberg, E. T., Paielli, D., Olson, S. T., Shore, J. D., and Ginsburg, D. (1992) J. Biol. Chem. 267, 7588-7595) had significant inhibitory activity toward tPA. This set of tPA specific PAI-1 mutants contained a wide range of amino acid substitutions at P-1 including Asn, Gin, His, Ser, Thr, Leu, Met, and all the aromatic amino acids. This group of mutants also demonstrated a spectrum of substitutions at P-1'. Kinetic analyses of selected variants identified P(1)Tyr and P(1)His as the most efficient tPA-specific inhibitors, with second order rate constants (k(i)) of 4.0 x 10(5) M(-1) s(-1) and 3.6 x 10(5) M(-1) s(-1), respectively. Additional PA specific PAI-1 variants containing substitutions at P-3 through P-1' were constructed. P(3)Tyr-P(2)Ser-P(1)Lys-P-1'Trp and P(3)Tyr-P(2)Ser-P(1)Tyr-P-1'Met had k(i) values of 1.7 x 10(6) M(-1) s(-1) and 2.5 x 10(6) M(-1) s(-1) against tPA, respectively, but both were inactive against uPA. In contrast, P(2)Arg-P(1)Lys-P-1'Ala inhibited uPA 74-fold more rapidly than tPA. The mutant PAI-1 Library was also screened for inhibitory activity toward thrombin in the presence and absence of the cofactor heparin. While wild-type PAI-1 and several P(1)Arg variants inhibited thrombin in the absence of heparin, a number of variants were thrombin inhibitors only in the presence of heparin. These results demonstrate the importance of the reactive center residues in determining PAI-1 target specificity and suggest that second sites of interaction between inhibitors and proteases can also contribute to target specificity. Finally, the PA-specific mutants described here should provide novel reagents for dissecting the physiological role of PAI-1 both in vitro and in vivo.	UNIV MICHIGAN,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; HENRY FORD HOSP,DIV BIOCHEM RES,DETROIT,MI 48202	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Henry Ford Health System; Henry Ford Hospital				Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049184, F32HL008572, R01HL045930] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 49184, HL 45930A, HL 08572] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS DS, 1991, J BIOL CHEM, V266, P8476; ALBERTY RA, 1979, PHYSICAL CHEM, P482; AULAK KS, 1988, BIOCHEM J, V253, P615, DOI 10.1042/bj2530615; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHANG AC, 1991, BIOCHEM BIOPH RES CO, V177, P1198, DOI 10.1016/0006-291X(91)90668-W; CHMIELEWSKA J, 1988, BIOCHEM J, V251, P327, DOI 10.1042/bj2510327; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; EHRLICH HJ, 1992, J BIOL CHEM, V267, P11606; EHRLICH HJ, 1991, BIOCHEMISTRY-US, V30, P1021, DOI 10.1021/bi00218a020; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; ERDJUMENT H, 1988, J BIOL CHEM, V263, P5589; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; GEBBINK RK, 1993, BIOCHEMISTRY-US, V32, P1675, DOI 10.1021/bi00057a035; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; HEKMAN CM, 1988, ARCH BIOCHEM BIOPHYS, V262, P199, DOI 10.1016/0003-9861(88)90182-8; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOLMES WE, 1987, BIOCHEMISTRY-US, V26, P5133, DOI 10.1021/bi00390a036; HORREVOETS AJG, 1993, J BIOL CHEM, V268, P779; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JALLAT S, 1986, PROTEIN ENG, V1, P29, DOI 10.1093/protein/1.1.29; KEIJER J, 1991, BLOOD, V78, P1254; KEIJER J, 1991, J BIOL CHEM, V266, P10700; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LAWRENCE DA, 1995, MOL BASIS THROMBOSIS, P517; LEVIN EG, 1987, BLOOD, V70, P1090; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOSKUTOFF DJ, 1991, FIBRINOLYSIS, V5, P197, DOI 10.1016/0268-9499(91)90001-K; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; MOUREY L, 1990, BIOCHIMIE, V72, P599, DOI 10.1016/0300-9084(90)90123-X; NASKI MC, 1993, J BIOL CHEM, V268, P12367; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PATSTON PA, 1994, BLOOD, V84, P1164; PATSTON PA, 1990, J BIOL CHEM, V265, P10786; PHILLIPS JE, 1994, J BIOL CHEM, V269, P16696; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SHUBEITA HE, 1990, J BIOL CHEM, V265, P18379; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; STEPHENS AW, 1988, J BIOL CHEM, V263, P15849; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEUNISSEN HJM, 1993, J BIOL CHEM, V268, P9035; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WIMAN B, 1978, EUR J BIOCHEM, V84, P573, DOI 10.1111/j.1432-1033.1978.tb12200.x; YORK JD, 1991, J BIOL CHEM, V266, P8495	62	26	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9301	9306		10.1074/jbc.270.16.9301	http://dx.doi.org/10.1074/jbc.270.16.9301			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721851	hybrid			2022-12-25	WOS:A1995QU08900039
J	STANFORD, CM; JACOBSON, PA; EANES, ED; LEMBKE, LA; MIDURA, RJ				STANFORD, CM; JACOBSON, PA; EANES, ED; LEMBKE, LA; MIDURA, RJ			RAPIDLY FORMING APATITIC MINERAL IN AN OSTEOBLASTIC CELL-LINE (UMR-106-01 BSP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENIC-SARCOMA CELLS; NODULES FORMED INVITRO; BONE SIALOPROTEIN BSP; PARATHYROID-HORMONE; BETA-GLYCEROPHOSPHATE; ALKALINE-PHOSPHATASE; BREFELDIN-A; INORGANIC PYROPHOSPHATE; X COLLAGEN; RAT	This study evaluated a rapid biomineralization phenomenon exhibited by an osteoblastic cell line, UMR 106-01 BSP, when treated with either organic phosphates [beta-glycerophosphate (beta-GP), Ser-P, or Thr-P], inorganic phosphate (P-i), or calcium. In a dose-dependent manner, these agents (2-10 mM) stimulated confluent cultures to deposit mineral in the cell layer (ED(50) of similar to 4.6 mM for beta-GP (30 +/- 2 nmol Ca2+/mu g DNA) and similar to 3.8 mM (29 +/- 2 nmol Ca2+/mu g DNA) for P-i) with a plateau in mineral formation by 20 h (ET(50) approximate to 12-15 h). beta-GP or P-i treatment yielded mineral crystals having an x-ray diffraction pattern similar to normal human bone, Alizarin red-S histology demonstrated calcium mineral deposition in the extracellular matrix and what appeared to be intracellular paranuclear staining. Electron microscopy revealed small, needle-like crystals associated with fibrillar, extracellular matrix deposits and intracellular spherical structures. Mineral formation was inhibited by levamisole (ED(50) approximate to 250 mu M), pyrophosphate (ED(50) approximate to 1-10 mu M), actinomycin C-1 (500 ng/ml), cycloheximide (50 mu g/ml), or brefeldin A (1 mu g/ml). These results indicate that UMR 106-01 BSP cells form a bio apatitic mineralized matrix upon addition of supplemental phosphate. This process involves alkaline phosphatase activity, ongoing RNA and protein synthesis, as well as Golgi-mediated processing and secretion.	UNIV IOWA,COLL DENT,DOW INST DENT RES,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT ORTHOPAED SURG,IOWA CITY,IA 52242; NIDR,BONE RES BRANCH,BETHESDA,MD 20892	University of Iowa; University of Iowa; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Eanes, Edward/AAM-9298-2021		NCRR NIH HHS [2 SO7 RR05313-31] Funding Source: Medline; NIAMS NIH HHS [AR-0705] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005313] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; ANDERSON HC, 1969, J CELL BIOL, V41, P59, DOI 10.1083/jcb.41.1.59; BELLOWS CG, 1986, CALCIFIED TISSUE INT, V38, P143, DOI 10.1007/BF02556874; BELLOWS CG, 1991, BONE MINER, V14, P27, DOI 10.1016/0169-6009(91)90100-E; BERESFORD JN, 1993, AM J MED GENET, V45, P163, DOI 10.1002/ajmg.1320450205; BERNARD GW, 1969, AM J ANAT, V125, P271, DOI 10.1002/aja.1001250303; BIANCO P, 1993, J HISTOCHEM CYTOCHEM, V41, P193, DOI 10.1177/41.2.8419459; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; Bonucci E, 1971, Clin Orthop Relat Res, V78, P108, DOI 10.1097/00003086-197107000-00010; BONUCCI E, 1967, J ULTRA MOL STRUCT R, V20, P33, DOI 10.1016/S0022-5320(67)80034-0; Bonucci E., 1992, CALCIFICATION BIOL S, P19; CALABRO A, 1994, J BIOL CHEM, V269, P22771; CASSERBETTE M, 1990, CALCIFIED TISSUE INT, V46, P46, DOI 10.1007/BF02555824; CHEN JK, 1992, J BONE MINER RES, V7, P987; CHRISTOFFERSEN J, 1991, ANAT RECORD, V230, P435, DOI 10.1002/ar.1092300402; EANES ED, 1992, CALCIFICATION BIOL S, P1; ECAROTCHARRIER B, 1988, BONE, V9, P147, DOI 10.1016/8756-3282(88)90004-X; FORREST SM, 1985, CALCIFIED TISSUE INT, V37, P51, DOI 10.1007/BF02557679; Glimcher M. J., 1968, TREATISE COLLAGEN  B, VII, P68; GLIMCHER MJ, 1984, PHILOS T R SOC B, V304, P479, DOI 10.1098/rstb.1984.0041; Glimcher MJ, 1976, HDB PHYSL ENDOCRINOL, P25, DOI 10.1136/bmj.2.6038.761-a; GLIMCHER MJ, 1981, CHEM BIOL MINERALIZE, P617; GRONOWICZ G, 1989, J BONE MINER RES, V4, P313; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; HUNTER GK, 1994, BIOCHEM J, V302, P175, DOI 10.1042/bj3020175; HUNZIKER W, 1992, FEBS LETT, V307, P93, DOI 10.1016/0014-5793(92)80908-Y; KATOH Y, 1991, BONE, V12, P59, DOI 10.1016/8756-3282(91)90001-Y; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Klug H.P, 1974, X RAY DIFFRACTION PR, Vsecond; LEBOY PS, 1989, J BIOL CHEM, V264, P17281; MARTIN TJ, 1979, CLIN ORTHOP RELAT R, V140, P247; MARTIN TJ, 1985, CHEM BIOL MINERALIZE, P311; MCGEERUSSELL SM, 1958, J HISTOCHEM CYTOCHEM, V6, P22, DOI 10.1177/6.1.22; MCQUILLAN DJ, 1991, BIOCHEM J, V277, P199, DOI 10.1042/bj2770199; MCQUILLAN DJ, 1992, BIOCHEM J, V285, P25, DOI 10.1042/bj2850025; MIDURA RJ, 1994, J BIOL CHEM, V269, P13200; MIDURA RJ, 1990, J BIOL CHEM, V265, P5285; MURPHY J, 1962, ANAL CHIM ACTA, V47, P31; PARTRIDGE NC, 1980, FEBS LETT, V115, P139, DOI 10.1016/0014-5793(80)80744-7; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo-108-1-220; PARTRIDGE NC, 1983, CANCER RES, V43, P4308; PARTRIDGE NC, 1989, MOL ENDOCRINOL, V3, P232, DOI 10.1210/mend-3-2-232; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P213, DOI 10.1210/endo-108-1-213; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PUCHTLER H, 1969, J HISTOCHEM CYTOCHEM, V17, P110, DOI 10.1177/17.2.110; ROBEY PG, 1992, DISORDERS BONE MINER, P241; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P1425, DOI 10.1210/me.6.9.1425; SELA J, 1992, CALCIFICATION BIOL S, P74; SODEK J, 1992, BIOL MECHANISMS TOOT, P127; TENENBAUM HC, 1987, BONE MINER, V3, P13; TENENBAUM HC, 1989, CELL TISSUE RES, V257, P555, DOI 10.1007/BF00221466; TENENBAUM HC, 1992, BONE, V13, P249, DOI 10.1016/8756-3282(92)90205-B; THOMAS JT, 1990, J CELL SCI, V95, P639; UNDERWOOD JCE, 1979, EUR J CANCER, V15, P1151, DOI 10.1016/0014-2964(79)90131-2; WU LNY, 1989, J BIOL CHEM, V264, P21346; ZIMMERMANN B, 1992, CALCIFIED TISSUE INT, V51, P54, DOI 10.1007/BF00296218; ZIMMERMANN B, 1988, CELL DIFFER DEV, V25, P145, DOI 10.1016/0922-3371(88)90007-X	57	390	406	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9420	9428		10.1074/jbc.270.16.9420	http://dx.doi.org/10.1074/jbc.270.16.9420			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721867	hybrid			2022-12-25	WOS:A1995QU08900056
J	COLLINS, N; MCMANUS, R; WOOSTER, R; MANGION, J; SEAL, S; LAKHANI, SR; ORMISTON, W; DALY, PA; FORD, D; EASTON, DF; STRATTON, MR				COLLINS, N; MCMANUS, R; WOOSTER, R; MANGION, J; SEAL, S; LAKHANI, SR; ORMISTON, W; DALY, PA; FORD, D; EASTON, DF; STRATTON, MR			CONSISTENT LOSS OF THE WILD-TYPE ALLELE IN BREAST CANCERS FROM A FAMILY LINKED TO THE BRCA2 GENE ON CHROMOSOME 13Q12-13	ONCOGENE			English	Note						BREAST CANCER; GENETICS; LOSS OF HETEROZYGOSITY	RETINOBLASTOMA; HETEROZYGOSITY; CARCINOMA; REGION	A small proportion of breast cancer is attributable to the inheritance of dominant, high penetrance susceptibility genes. One of these genes, BRCA2, has recently been localised by genetic linkage analysis to chromosome 13q12-13, This is a region known to exhibit loss of heterozygosity in 20-40% sporadic breast cancers, In this study, we have examined cancers from a family showing strong evidence of linkage to BRCA2. LOH was seen in seven out of eight informative cancers, In all cases the allele lost was the wild type allele that does not segregate with the disease in the family. The data suggest that both alleles of BRCA2 are inactivated in cancers, the pattern expected of a recessive oncogene or tumour suppressor gene.	ROYAL MARSDEN HOSP,MOLEC CARCINOGENESIS SECT,SUTTON SM2 5NG,SURREY,ENGLAND; ROYAL MARSDEN HOSP,INST CANC RES,EPIDEMIOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND; ROYAL MARSDEN HOSP,DEPT HISTOPATHOL,SUTTON SM2 5NG,SURREY,ENGLAND; UNIV DUBLIN TRINITY COLL,DEPT GENET,DUBLIN 2,IRELAND; UNIV IRELAND TRINITY COLL,ST JAMES HOSP,SCH MED,DEPT MED,DUBLIN 8,IRELAND	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Trinity College Dublin; Trinity College Dublin			McManus, Ross/AAE-9236-2020; Lakhani, Sunil/I-1970-2018	McManus, Ross/0000-0002-0529-9617; Lakhani, Sunil/0000-0003-4067-2760				CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; DENG G, 1994, CANCER RES, V54, P499; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; GERSDORFSTEICHE.E, 1994, AM J HUM GENET, V55, P870; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; KELSELL DP, 1993, HUM MOL GENET, V2, P1823; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; STRATTON MR, 1994, NAT GENET, V7, P103, DOI 10.1038/ng0594-103; STRATTON MR, 1995, IN PRESS J PATHOL; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	14	217	219	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1673	1675						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731724				2022-12-25	WOS:A1995QU68100026
J	CHUNG, DC; BRAND, SJ; TILLOTSON, LG				CHUNG, DC; BRAND, SJ; TILLOTSON, LG			MUTUALLY EXCLUSIVE INTERACTIONS BETWEEN FACTORS BINDING TO ADJACENT SP1 AND AT-RICH ELEMENTS REGULATE GASTRIN GENE-TRANSCRIPTION IN INSULINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; DEVELOPMENTAL EXPRESSION; ACCURATE TRANSCRIPTION; PROMOTER; PROTEINS; ENHANCER; LINES; SITE; NESIDIOBLASTOSIS; HOMEODOMAIN	The gastrin gene is transiently expressed in fetal pancreatic islets during islet neogenesis but then switched off after birth when islet cells become fully differentiated. Previous studies identified a cis-regulatory sequence between -109 and -75 in the human gastrin promoter which binds islet cell-specific activators and a nonspecific repressor and thus may act as a molecular switch. The present study identified another cis-regulatory sequence ((-163)ACACTAAATGAAAGGGCGGGGCAG(-140)) which bound two islet nuclear proteins in a mutually exclusive manner, as defined by gel shift competition, methylation interference, and DNase I footprinting assays. The general transactivator Sp1 recognized the downstream GGGCGGGG sequence, but Sp1 binding was prevented when another islet factor bound to the adjacent AT-rich sequence (CTAAATGA). This gastrin AT-rich element is nearly identical to the binding site (ATAAATGA) for the islet-specific transcription factor beta TF-1. However, the gastrin AT-binding factor appeared to differ from beta TF-1 in its gel mobility shift pattern. Transfections of rat insulinoma cells revealed that mutations which blocked binding to the AT-rich element but allowed Sp1 binding up-regulated transcriptional activity. These results suggest that the gastrin AT-binding factor blocks transactivation by Sp1 and may have a role in the repression of gastrin transcription seen at the end of islet differentiation.	MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	CHUNG, DC (corresponding author), MASSACHUSETTS GEN HOSP, GASTROINTESTINAL UNIT, JACKSON 7, BOSTON, MA 02114 USA.				NIDDK NIH HHS [DK42147, DK01410, DK07191] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007191, R01DK042147] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN AS, 1988, CURRENT PROTOCOLS MO, V2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND SJ, 1984, NATURE, V309, P456, DOI 10.1038/309456a0; BRAND SJ, 1993, GASTRIN, P73; BRAND SJ, 1988, J BIOL CHEM, V263, P5341; BRAND SJ, 1988, J BIOL CHEM, V263, P16597; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DEMEDIUK B H, 1992, Gastroenterology, V102, pA728; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GEGENHEIMER P, 1990, METHOD ENZYMOL, V182, P714; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HERR W, 1992, TRANSCRIPTIONAL REGU, V1, P1103; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; KRASINSKI SD, 1991, MOL ENDOCRINOL, V5, P433, DOI 10.1210/mend-5-3-433; KRUSE F, 1993, GENE DEV, V7, P774, DOI 10.1101/gad.7.5.774; LARSSON LI, 1976, NATURE, V262, P609, DOI 10.1038/262609a0; LARSSON LI, 1973, VIRCHOWS ARCH A, V360, P305, DOI 10.1007/BF00548351; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LI RS, 1994, J BIOL CHEM, V269, P7941; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MERCHANT J, 1994, GASTROENTEROLOGY, V106, pA827; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; Pictet R., 1972, HDB PHYSIOLOGY     7, V1, P25; SACCHI TB, 1985, VIRCHOWS ARCH B, V48, P261, DOI 10.1007/BF02890134; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; TILLOTSON LG, 1994, J BIOL CHEM, V269, P2234; WANG TC, 1990, J BIOL CHEM, V265, P8908; WANG TC, 1992, YALE J BIOL MED, V65, P705; WHEELER MB, 1992, MOL CELL BIOL, V12, P3531, DOI 10.1128/MCB.12.8.3531; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; YU CY, 1990, MOL CELL BIOL, V10, P282, DOI 10.1128/MCB.10.1.282; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x	47	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8829	8836		10.1074/jbc.270.15.8829	http://dx.doi.org/10.1074/jbc.270.15.8829			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721790	hybrid			2022-12-25	WOS:A1995QT44800068
J	HUSSAIN, MM; INNERARITY, TL; BRECHT, WJ; MAHLEY, RW				HUSSAIN, MM; INNERARITY, TL; BRECHT, WJ; MAHLEY, RW			CHYLOMICRON METABOLISM IN NORMAL, CHOLESTEROL-FED, AND WATANABE HERITABLE HYPERLIPIDEMIC RABBITS - SATURATION OF THE SEQUESTRATION STEP OF THE REMNANT CLEARANCE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; APOLIPOPROTEIN-E; LDL-RECEPTOR; WHHL RABBITS; PROTEIN-ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMA-LIPOPROTEINS; RETINYL PALMITATE; CULTURED-CELLS; MESSENGER-RNA; BONE-MARROW	The plasma clearance of radiolabeled chylomicrons was compared in normal, cholesterol-fed, and Watanabe heritable hyperlipidemic (WHHL) rabbits. Chylomicron clearance was rapid in normal rabbits but was significantly retarded in cholesterol-fed and WHHL rabbits. At 40 min after the injection of chylomicrons, 14-17% of the injected dose remained in the plasma of normal rabbits, whereas similar to 40-50% of the injected dose remained in the plasma of cholesterol-fed and WHHL rabbits. The differences were reflected in the reduced plasma clearance by the liver and bone marrow of the cholesterol-fed and WHHL rabbits. The hyperlipidemic rabbits expressed normal levels of low density lipoprotein (LDL) receptor-related protein/alpha(2)-macroglobulin receptor in the liver, In contrast, the hepatic levels of LDL receptors were lower in hyperlipidemic rabbits; as expected, they were significantly lower in WHHL rabbits compared with normal and cholesterol-fed rabbits. Furthermore, it was demonstrated that lipoproteins accumulating in the plasma of the hyperlipidemic rabbits competed for and retarded the clearance of chylomicrons from the plasma. Competition was demonstrated by cross-circulation of normal and cholesterol-fed or normal and WHHL rabbits, in which the rapid influx of plasma containing the accumulated plasma lipoproteins from cholesterol-fed or WHHL rabbits was shown to impair the uptake of chylomicrons by the liver and bone marrow of normal rabbits. These observations were extended by infusing isolated lipoproteins into normal rabbits. The rabbit d < 1.02 g/ml (remnant) fraction and the canine cholesterol rich high density lipoproteins (HDL) with apolipoprotein E (HDL(c)) inhibited chylomicron clearance, whereas human LDL and HDL from humans and rabbits did not, We conclude that the low LDL receptor activity in the cholesterol-fed and WHHL rabbits may contribute, at least in part, to the impaired clearance by decreasing remnant uptake and causing the accumulation of chylomicron and/or very low density lipoprotein remnants, The accumulated remnant lipoproteins then compete for and saturate the mechanism responsible for the initial rapid clearance of chylomicrons from the plasma, We speculate that saturation of the initial rapid clearance may occur at the sequestration step, which involves the binding of remnants to heparan sulfate proteoglycans in the space of Disse.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL 41633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAUMONT JL, 1990, ATHEROSCLEROSIS, V85, P103, DOI 10.1016/0021-9150(90)90102-O; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; CHOI SY, 1993, J BIOL CHEM, V268, P15804; CLARK SB, 1982, J LIPID RES, V23, P28; CLAY MA, 1989, BIOCHIM BIOPHYS ACTA, V1002, P173, DOI 10.1016/0005-2760(89)90284-1; DEMACKER PNM, 1992, BIOCHEM J, V285, P641, DOI 10.1042/bj2850641; FAINARU M, 1988, ARTERIOSCLEROSIS, V8, P130, DOI 10.1161/01.ATV.8.2.130; FAINARU M, 1982, J LIPID RES, V23, P702; FAN JL, 1994, CIRCULATION, V90, P289; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; FOX JC, 1987, J BIOL CHEM, V262, P7014; GOLDSTEIN JL, 1983, NEW ENGL J MED, V309, P288, DOI 10.1056/NEJM198308043090507; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAVEL RJ, 1989, ARTERIOSCLER, V9, P33; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HUETTINGER M, 1984, J CLIN INVEST, V74, P1017, DOI 10.1172/JCI111469; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; HUSSAIN MM, 1989, J BIOL CHEM, V264, P17931; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1994, J BIOL CHEM, V269, P13429; JI ZS, 1993, J BIOL CHEM, V268, P10160; KANE JP, 1983, ARTERIOSCLEROSIS, V3, P47, DOI 10.1161/01.ATV.3.1.47; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRISETHERTON PM, 1980, J LIPID RES, V21, P435; LOWRY OH, 1951, J BIOL CHEM, V13, P265; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1989, J CLIN INVEST, V83, P2125, DOI 10.1172/JCI114126; MAHLEY RW, 1980, J LIPID RES, V21, P970; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1977, AM J PATHOL, V87, P205; MAHLEY RW, 1994, METABOLIC BASES INHE, P1953; MAMO JCL, 1991, BIOCHIM BIOPHYS ACTA, V1081, P241, DOI 10.1016/0005-2760(91)90277-O; MELCHIOR GW, 1981, J LIPID RES, V22, P598; MISTRY P, 1981, J CLIN INVEST, V67, P493, DOI 10.1172/JCI110058; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; PRINCE H, 1982, Q J EXP PHYSIOL CMS, V67, P87, DOI 10.1113/expphysiol.1982.sp002628; REDGRAVE TG, 1973, BIOCHEM J, V136, P109, DOI 10.1042/bj1360109; REDGRAVE TG, 1976, ATHEROSCLEROSIS, V24, P501, DOI 10.1016/0021-9150(76)90142-8; REDGRAVE TG, 1977, METABOLISM, V26, P493, DOI 10.1016/0026-0495(77)90093-2; ROSS AC, 1977, J LIPID RES, V18, P169; RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839; SHAFI S, 1994, J LIPID RES, V35, P709; SHERRILL BC, 1980, J BIOL CHEM, V255, P1804; SORCITHOMAS M, 1989, J BIOL CHEM, V264, P9039; SPADY DK, 1985, P NATL ACAD SCI USA, V82, P4526, DOI 10.1073/pnas.82.13.4526; SULTAN F, 1990, BIOCHIM BIOPHYS ACTA, V1042, P150, DOI 10.1016/0005-2760(90)90071-5; THOMPSON KH, 1983, J NUTR, V113, P2002, DOI 10.1093/jn/113.10.2002; WARREN RJ, 1991, J LIPID RES, V32, P1333; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194	58	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8578	8587		10.1074/jbc.270.15.8578	http://dx.doi.org/10.1074/jbc.270.15.8578			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721759	hybrid			2022-12-25	WOS:A1995QT44800035
J	PAULL, TT; JOHNSON, RC				PAULL, TT; JOHNSON, RC			DNA LOOPING BY SACCHAROMYCES-CEREVISIAE HIGH-MOBILITY GROUP PROTEINS NHP6A/B - CONSEQUENCES FOR NUCLEOPROTEIN COMPLEX ASSEMBLY AND CHROMATIN CONDENSATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-LIKE PROTEINS; ESCHERICHIA-COLI CHROMOSOME; SITE-SPECIFIC RECOMBINATION; LACKING HU PROTEIN; RNA POLYMERASE-II; FIS PROTEIN; DROSOPHILA-MELANOGASTER; BACTERIOPHAGE-LAMBDA; YEAST MITOCHONDRIA; MOLECULAR-DYNAMICS	The formation of higher order protein . DNA structures often requires bending of DNA strands between specific sites, a process that can be facilitated by the action of nonspecific DNA-binding proteins which serve as assembly factors. A model for this activity is the formation of the invertasome, an intermediate structure created in the Hin-mediated site-specific DNA inversion reaction, which is stimulated by the prokaryotic nucleoid-associated protein HU. Previously, we have shown that the mammalian HMG1/2 proteins substitute for HU in this system and display efficient DNA wrapping activity in vitro. In the present work, we isolate the primary sources of assembly factor activity in Saccharomyces cerevisiae, as measured by the ability to stimulate invertasome formation, and show that these are the previously identified NHP6A/B proteins. NHP6A/B have comparable or greater activity in DNA binding, bending, and supercoiling with respect to HU and HMG1 and appear to form more stable protein . DNA complexes. In addition, expression of NHPA in mutant Escherichia coli cells lacking HU and Fis restores normal morphological appearance to these cells, specifically in nucleoid condensation and segregation. From these data we predict diverse architectural roles for NHP6A/B in manipulating chromosome structure and promoting the assembly of multicomponent protein . DNA complexes.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles				Paull, Tanya/0000-0002-2991-651X	NIGMS NIH HHS [GM38509] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038509, R37GM038509] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; BALL CA, 1991, J BACTERIOL, V173, P4027, DOI 10.1128/jb.173.13.4027-4031.1991; Bellomy G R, 1990, Prog Nucleic Acid Res Mol Biol, V39, P81, DOI 10.1016/S0079-6603(08)60624-8; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BONNEFOY E, 1991, EMBO J, V10, P687, DOI 10.1002/j.1460-2075.1991.tb07998.x; BROYLES SS, 1986, J MOL BIOL, V187, P47, DOI 10.1016/0022-2836(86)90405-5; BUTLER AP, 1985, J BIOL CHEM, V260, P613; CARON F, 1979, P NATL ACAD SCI USA, V76, P4265, DOI 10.1073/pnas.76.9.4265; COSTIGAN C, 1994, MOL CELL BIOL, V14, P2391, DOI 10.1128/MCB.14.4.2391; CROTHERS DM, 1993, CURR BIOL, V3, P675, DOI 10.1016/0960-9822(93)90065-V; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; DRI AM, 1991, J BACTERIOL, V173, P2852, DOI 10.1128/JB.173.9.2852-2863.1991; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FILUTOWICZ M, 1992, J BACTERIOL, V174, P398, DOI 10.1128/jb.174.2.398-407.1992; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GILLE H, 1991, NUCLEIC ACIDS RES, V19, P4167, DOI 10.1093/nar/19.15.4167; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GOODMAN SD, 1992, P NATL ACAD SCI USA, V89, P11910, DOI 10.1073/pnas.89.24.11910; GROSSCHEDL R, 1984, TRENDS GENET, V10, P94; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HAYKINSON MJ, 1993, EMBO J, V12, P2503, DOI 10.1002/j.1460-2075.1993.tb05905.x; HILLYARD DR, 1990, J BACTERIOL, V172, P5402, DOI 10.1128/jb.172.9.5402-5407.1990; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; HODGESGARCIA Y, 1989, J BIOL CHEM, V264, P14621; HUISMAN O, 1989, J BACTERIOL, V171, P3704, DOI 10.1128/jb.171.7.3704-3712.1989; HWANG DS, 1992, J BIOL CHEM, V267, P23083; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; JOHNSON RC, 1985, CELL, V41, P781, DOI 10.1016/S0092-8674(85)80059-3; Johnson RC, 1991, CURR OPIN GENET DEV, V1, P404, DOI 10.1016/S0959-437X(05)80307-7; KAO LR, 1993, P NATL ACAD SCI USA, V90, P5598, DOI 10.1073/pnas.90.12.5598; KOHLSTAEDT LA, 1994, BIOCHEMISTRY-US, V33, P570, DOI 10.1021/bi00168a023; KOLODRUBETZ D, 1988, FEBS LETT, V238, P175, DOI 10.1016/0014-5793(88)80251-5; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LANDSMAN D, 1991, MOL CELL BIOL, V11, P4483, DOI 10.1128/MCB.11.9.4483; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LAVOIE BD, 1994, J BIOL CHEM, V269, P15571; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LILLEY DMJ, 1992, NATURE, V357, P282, DOI 10.1038/357282a0; Maniatis T., 1982, MOL CLONING; MAY R, 1971, Z ALLG MIKROBIOL, V11, P131, DOI 10.1002/jobm.3630110208; MEGRAW TL, 1993, J BIOL CHEM, V268, P12758; METZLER WJ, 1990, J MOL BIOL, V214, P711, DOI 10.1016/0022-2836(90)90288-W; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; NER SS, 1993, NUCLEIC ACIDS RES, V21, P4369, DOI 10.1093/nar/21.18.4369; NER SS, 1994, TRENDS BIOCHEM SCI, V19, P185, DOI 10.1016/0968-0004(94)90017-5; NER SS, 1994, EMBO J, V13, P1817, DOI 10.1002/j.1460-2075.1994.tb06450.x; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PETTIJOHN DE, 1988, J BIOL CHEM, V263, P12793; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; ROUVIEREYANIV J, 1979, CELL, V17, P265, DOI 10.1016/0092-8674(79)90152-1; SCHMITZ U, 1993, J MOL BIOL, V234, P373, DOI 10.1006/jmbi.1993.1593; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; SHELLMAN VL, 1991, J BACTERIOL, V173, P3047, DOI 10.1128/JB.173.10.3047-3059.1991; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; TREMETHICK DJ, 1988, NUCLEIC ACIDS RES, V16, P11107, DOI 10.1093/nar/16.23.11107; WAGNER CR, 1992, MOL CELL BIOL, V12, P1915, DOI 10.1128/MCB.12.5.1915; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713	71	90	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8744	8754		10.1074/jbc.270.15.8744	http://dx.doi.org/10.1074/jbc.270.15.8744			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721780	hybrid			2022-12-25	WOS:A1995QT44800058
J	RASCHELLA, G; NEGRONI, A; SALA, A; PUCCI, S; ROMEO, A; CALABRETTA, B				RASCHELLA, G; NEGRONI, A; SALA, A; PUCCI, S; ROMEO, A; CALABRETTA, B			REQUIREMENT OF B-MYB FUNCTION FOR SURVIVAL AND DIFFERENTIATIVE POTENTIAL OF HUMAN NEUROBLASTOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEURO-BLASTOMA; C-MYB; N-MYC; MORPHOLOGICAL-DIFFERENTIATION; MYELOID-LEUKEMIA; NERVOUS-SYSTEM; CDNA CLONES; A-MYB; EXPRESSION; PROLIFERATION	The B-myb gene belongs to a family of transcription factors that also includes A-myb and c-myb. B-myb is expressed in many cell types including human neuroblastoma cells. Here we demonstrate that B-myb expression is down-regulated during retinoic acid-induced neural and glial differentiation of neuroblastoma cells. This modulation is an early event, is maintained at late times of induction, and is in part regulated at the transcriptional level. Constitutive expression of B-myb prevents retinoic acid-induced neural differentiation as reflected by morphological features and the expression of (or lack of) biochemical markers associated with the undifferentiated phenotype. Furthermore, the expression of antisense B-myb transcripts does not allow the rescue of viable cells, suggesting an important role for B-myb in the survival of neuroblastoma cells. These results indicate that B-myb plays a functional role in the differentiative potential of neuroblastoma cells, raising the possibility that this gene is one of the nuclear regulators in the cascade of events leading to cellular differentiation.	THOMAS JEFFERSON UNIV,DEPT MICROBIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT MICROBIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University			Negroni, Anna/GLS-2306-2022; sala, arturo/C-4959-2008; Pucci, Sabina/J-2542-2012	Negroni, Anna/0000-0002-2273-8837; Sala, Arturo/0000-0002-2841-7866; Pucci, Sabina/0000-0002-2418-6482				ABEMAYOR E, 1989, ENVIRON HEALTH PERSP, V80, P3, DOI 10.2307/3430727; ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ARSURA M, 1992, BLOOD, V79, P2708; BARLETTA C, 1991, CANCER RES, V51, P3821; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BIEDLER JL, 1978, CANCER RES, V38, P3751; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICCARONE V, 1989, CANCER RES, V49, P219; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DELPECH B, 1978, BRIT J CANCER, V37, P33, DOI 10.1038/bjc.1978.5; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRIFFIN CA, 1985, CANCER RES, V45, P272; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HELMAN LJ, 1987, P NATL ACAD SCI USA, V84, P2336, DOI 10.1073/pnas.84.8.2336; HINO T, 1989, INT J CANCER, V44, P286, DOI 10.1002/ijc.2910440217; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; LATCHMAN DS, 1991, EUKARYOTIC TRANSCRIP; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RASCHELLA G, 1992, CANCER RES, V52, P4221; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sambrook J, 1989, MOL CLONING LABORATO; SCARPA S, 1987, AM J PATHOL, V129, P74; SCHWAB M, 1992, BIOCHIM BIOPHYS ACTA, V1114, P43, DOI 10.1016/0304-419X(92)90005-J; SEEGER RC, 1982, J IMMUNOL, V128, P983; SHEA TB, 1988, DEV BRAIN RES, V43, P97, DOI 10.1016/0165-3806(88)90155-1; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SPENCE MA, 1989, CYTOGENET CELL GENET, V51, P149, DOI 10.1159/000132790; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TORELLI G, 1987, CANCER RES, V47, P5266; TSOKOS M, 1987, AM J PATHOL, V128, P484; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WEISS SW, 1983, LAB INVEST, V49, P299; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	51	70	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8540	8545		10.1074/jbc.270.15.8540	http://dx.doi.org/10.1074/jbc.270.15.8540			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721753	hybrid			2022-12-25	WOS:A1995QT44800029
J	SINGH, P; OWLIA, A; ESPEIJO, R; DAI, BS				SINGH, P; OWLIA, A; ESPEIJO, R; DAI, BS			NOVEL GASTRIN RECEPTORS MEDIATE MITOGENIC EFFECTS OF GASTRIN AND PROCESSING INTERMEDIATES OF GASTRIN ON SWISS 3T3 FIBROBLASTS - ABSENCE OF DETECTABLE CHOLECYSTOKININ (CCK)-A AND CCK-B RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE COLON CANCER; AFFINITY CROSS-LINKING; CARCINOMA CELL-LINES; MUCOSAL MEMBRANES; TYROSINE KINASES; BINDING-PROTEIN; RAT PANCREAS; GUINEA-PIGS; GROWTH; EXPRESSION	We have reported previously mitogenic effects of gastrin on several immortalized and neoplastic cell lines, including Swiss 3T3 fibroblasts. Receptor subtypes, cholecystokinin (CCK)-A and CCK-B, for a closely related peptide, cholecystokinin, were recently cloned. These studies were undertaken to investigate if CCK-A- and CCK-B receptors were perhaps mediating the mitogenic effects of gastrin on Swiss 3T3 cells. Receptor antagonists that inhibit the biological effects and binding of peptides to the CCK-A (L-364,718 (L18)) and CCK-B (L-365,260 (L60)) receptors were ineffective toward inhibiting the binding and proliferative effects of gastrin on Swiss 3T3 cells. Radiolabeled L18 and L60 demonstrated no binding to the cells, indicating that CCK-A and CCK-B receptors may be absent on Swiss 3T3 cells. Radiolabeled CCK-8, gastrin, L18, and L60, on the other hand, demonstrated specific binding to a pancreatic cancer cell line (AR42J cells) (used as a positive control). In cross-linking studies the molecular mass of the major band of gastrin receptors (GR) on Swiss 3T3 cells was determined to be similar to 45 kDa. The mitogenic potency of 0.1-1.0 nM gastrin-like peptides on Swiss 3T3 cells was in the order of G1-17 greater than or equal to G1-17-Gly > G5-17 greater than or equal to G5-17-Gly > G2-17 > CCK-8-Gly greater than or equal to G1-17-Lys greater than or equal to CCK-8. The relative binding affinity of the peptides (based on the dose dependent inhibition of binding of I-125-G1-17 to Swiss 3T3 cells) was similar to the relative mitogenic potency of the peptides as given above. Furthermore, G1-17-Gly was equally effective as G1-17 in displacing the binding of I-125-G1-17 to the 45-kDa GR from the Swiss 3T3 cells. Based on these studies it became evident that the novel gastrin preferring GR, expressed by Swiss 3T3 cells, binds and mediates the mitogenic effects of not only the mature (amidated) forms of gastrin-like peptides but also binds and meditates the mitogenic effects of glycine-extended forms of gastrin-like peptides. Possible mRNA expression of CCK-A and CCK-B receptor subtypes by gastrin-responsive rodent intestinal and fibroblast cell lines (Swiss 3T3, IEC-6, CA) was measured by the methods of Northern blot analysis and reverse transcriptase-polymerase chain reaction. mRNA from rat pancreas, AR42J cells, and rat antrum served as positive controls. We were unable to detect CCK-A and CCK-B receptor mRNA in the three cell lines by both the methods. The positive control samples, on the other hand, gave the expected results. Thus the three gastrin-responsive rodent cell lines examined in this study lacked CCK-A and CCK-B receptors, but were positive for the gastrin preferring GR that demonstrated physicochemical and pharmacological attributes distinct from CCK-A and CCK-B receptors. Since colon cancers are known to express high concentrations of non-amidated gastrin-like peptides, a possible autocrine role of glycine extended forms of gastrin becomes a highly relevant clinical question in the light of the presence of novel GR on the fibroblast and intestinal cell lines.			SINGH, P (corresponding author), UNIV TEXAS, MED BRANCH, DEPT ANAT & NEUROSCI, 10138 MED RES BLDG, 1043, GALVESTON, TX 77555 USA.				NATIONAL CANCER INSTITUTE [R01CA038651] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38651] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDWIN GS, 1986, J BIOL CHEM, V261, P2252; BLACKMORE M, 1994, INT J CANCER, V57, P385, DOI 10.1002/ijc.2910570316; BLACKMORE M, 1992, BRIT J CANCER, V66, P32, DOI 10.1038/bjc.1992.212; CHICONE L, 1989, BIOCHEM BIOPH RES CO, V164, P512, DOI 10.1016/0006-291X(89)91749-X; DAI B, 1992, GASTROENTEROLOGY, V102, pA352; ELLISON BJ, 1992, CANCER RES, V53, P667; ESPEIJO R, 1992, FEB C GASTR DAN POIN; ESPEJO R, 1992, Gastroenterology, V102, pA354; GUO YS, 1989, J STEROID BIOCHEM, V33, P459, DOI 10.1016/0022-4731(89)90337-3; GUO YS, 1990, IN VITRO CELL DEV B, V26, P871; GUO YS, 1992, GASTROENTEROLOGY, V102, P1101; HADJIIVANOVA C, 1992, EUR J BIOCHEM, V204, P273, DOI 10.1111/j.1432-1033.1992.tb16634.x; HOOSEIN NM, 1988, CANCER RES, V48, P7179; ISHIZUKA J, 1994, CANCER RES, V54, P2129; ITO M, 1993, J BIOL CHEM, V268, P18300; JENSEN RT, 1994, ANN NY ACAD SCI, V713, P88, DOI 10.1111/j.1749-6632.1994.tb44055.x; Johnson L.R, 1981, PHYSL GASTROINTESTIN, V1, P169; LALLEMENT JC, 1994, EUR J PHARM-MOLEC PH, V267, P297, DOI 10.1016/0922-4106(94)90154-6; LEE YM, 1993, J BIOL CHEM, V268, P8164; LEMEUTH V, 1993, ENDOCRINOLOGY, V133, P1182, DOI 10.1210/en.133.3.1182; MAJUMDAR APN, 1990, AM J PHYSIOL, V259, pG626, DOI 10.1152/ajpgi.1990.259.4.G626; MAJUMDAR APN, 1992, PEPTIDES, V13, P795, DOI 10.1016/0196-9781(92)90189-A; MATSUMOTO M, 1987, AM J PHYSIOL, V252, pG143, DOI 10.1152/ajpgi.1987.252.1.G143; MAUSS S, 1994, ANTICANCER RES, V14, P215; NAKATA H, 1992, BIOCHEM BIOPH RES CO, V187, P1151, DOI 10.1016/0006-291X(92)91317-J; NARAYAN S, 1990, CANCER RES, V50, P6772; NARAYAN S, 1992, MOL CELL BIOCHEM, V112, P163; NARAYAN S, 1992, CELL GROWTH DIFFER, V3, P111; PEARSON RK, 1987, J BIOL CHEM, V262, P13850; POVOSKI SP, 1993, CANCER RES, V53, P3925; RAMANI N, 1989, ENDOCRINOLOGY, V124, P1881, DOI 10.1210/endo-124-4-1881; REHFELD JF, 1992, ADV CLIN CHEM, V29, P239, DOI 10.1016/S0065-2423(08)60226-7; RIVARD N, 1994, AM J PHYSIOL, V266, pG62, DOI 10.1152/ajpgi.1994.266.1.G62; SETHI T, 1993, CANCER RES, V53, P5208; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; SILVENTE-POIROT S, 1993, EUR J BIOCHEM, V212, P529, DOI 10.1111/j.1432-1033.1993.tb17690.x; SINGH P, 1994, AM J PHYSIOL, V267, pG235, DOI 10.1152/ajpgi.1994.267.2.G235; SINGH P, 1994, AM J PHYSIOL, V266, pG459, DOI 10.1152/ajpgi.1994.266.3.G459; SINGH P, 1987, CANCER RES, V47, P5000; SINGH P, 1987, Surgical Forum (Chicago), V38, P171; SINGH P, 1994, AM J PHYSIOL-GASTR L, V267, pG608, DOI 10.1152/ajpgi.1994.267.4.G608; SINGH P, 1985, AM J PHYSIOL, V249, pG761, DOI 10.1152/ajpgi.1985.249.6.G761; SIRINEK KR, 1985, AM J SURG, V149, P35, DOI 10.1016/S0002-9610(85)80006-4; SMITH JP, 1994, AM J PHYSIOL, V266, pR277, DOI 10.1152/ajpregu.1994.266.1.R277; TALKAD VD, 1994, P NATL ACAD SCI USA, V91, P1868, DOI 10.1073/pnas.91.5.1868; THUMWOOD CM, 1991, EXP CELL RES, V192, P189, DOI 10.1016/0014-4827(91)90174-S; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; WATSON S, 1994, G PROTEIN LINKED REC, P1; WEINSTOCK J, 1988, CANCER RES, V48, P932; YASSIN RR, 1991, PEPTIDES, V12, P63, DOI 10.1016/0196-9781(91)90168-O; YU DH, 1990, AM J PHYSIOL, V258, pG86, DOI 10.1152/ajpgi.1990.258.1.G86; ZACHARY I, 1987, J BIOL CHEM, V262, P3947; ZHOU WG, 1992, CANCER RES, V52, P6905	53	128	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8429	8438		10.1074/jbc.270.15.8429	http://dx.doi.org/10.1074/jbc.270.15.8429			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721737	hybrid			2022-12-25	WOS:A1995QT44800013
J	TAKAHASHI, S; CHING, YC; WANG, JL; ROUSSEAU, DL				TAKAHASHI, S; CHING, YC; WANG, JL; ROUSSEAU, DL			MICROSECOND GENERATION OF OXYGEN-BOUND CYTOCHROME-C-OXIDASE BY RAPID SOLUTION MIXING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ELECTRON-TRANSFER; DIOXYGEN REDUCTION; INTERMEDIATE; TEMPERATURE; MECHANISM; SPECTROSCOPY; RESONANCE; COMPLEX; FERRYL; FLOW	Current understanding of the oxygen reduction and proton translocation processes in cytochrome c oxidase is largely derived from the data obtained by a nonphysiological method for initiating the catalytic reaction: photolyzing carbon monoxide (CO) from the CO-inhibited enzyme in the presence of oxygen (O-2). However, considerable evidence suggests that the use of CO introduces artifacts into the reaction mechanism. We have therefore developed a rapid solution mixer with a mixing time of 20 mu s to study the catalytic reaction by directly mixing the enzyme with O-2 without using CO. Unexpectedly, the resonance Raman scattering detected for the first 120 mu s after the mixing show that the CO influences neither the structure of the primary oxy-intermediate, its rate of decay, nor the rate of oxidation of cytochrome a. This implies that CO has an effect on the later stages of the catalytic process, which may involve the proton translocation steps, and calls for the re-examination of the catalytic process by using the direct mixing method. In addition, these results demonstrate the feasibility of using the rapid mixing device for the study of biological reactions in the microsecond time domain.	AT&T BELL LABS, MURRAY HILL, NJ 07974 USA	AT&T; Nokia Corporation; Nokia Bell Labs					NIGMS NIH HHS [GM-48714] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048714] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBEN JO, 1981, P NATL ACAD SCI-BIOL, V78, P234, DOI 10.1073/pnas.78.1.234; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BLAIR DF, 1985, J AM CHEM SOC, V107, P7389, DOI 10.1021/ja00311a029; BRUNORI M, 1988, ADV INORG BIOCHEM, V7, P93; BRUNORI M, 1979, J BIOL CHEM, V254, P769; CHANCE B, 1975, J BIOL CHEM, V250, P9226; CHANCE B, 1974, TECHNIQUES CHEM IN 2, P5; CLORE GM, 1980, BIOCHEM J, V185, P139, DOI 10.1042/bj1850139; EINARSDOTTIR O, 1993, BIOCHEMISTRY-US, V32, P12013, DOI 10.1021/bi00096a011; FINDSEN EW, 1987, J AM CHEM SOC, V109, P5367, DOI 10.1021/ja00252a011; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; HAN S, 1990, P NATL ACAD SCI USA, V87, P8408, DOI 10.1073/pnas.87.21.8408; HAN S, 1990, P NATL ACAD SCI USA, V87, P2491, DOI 10.1073/pnas.87.7.2491; HAN SH, 1990, BIOCHEMISTRY-US, V29, P1380, DOI 10.1021/bi00458a006; HAN SH, 1990, J AM CHEM SOC, V112, P9445, DOI 10.1021/ja00182a001; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; HILL BC, 1984, BIOCHEM J, V218, P913, DOI 10.1042/bj2180913; HILL BC, 1986, BIOCHIM BIOPHYS ACTA, V853, P91, DOI 10.1016/0304-4173(86)90006-6; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; LODDER AL, 1994, BBA-BIOENERGETICS, V1186, P67, DOI 10.1016/0005-2728(94)90136-8; MORGAN JE, 1989, BIOCHEMISTRY-US, V28, P6975, DOI 10.1021/bi00443a030; OGURA T, 1990, J AM CHEM SOC, V112, P5630, DOI 10.1021/ja00170a032; OGURA T, 1993, J AM CHEM SOC, V115, P8527, DOI 10.1021/ja00072a002; OLIVEBERG M, 1992, BIOCHEMISTRY-US, V31, P3560, DOI 10.1021/bi00129a002; ORII Y, 1988, ANN NY ACAD SCI, V550, P105, DOI 10.1111/j.1749-6632.1988.tb35327.x; PAENG KJ, 1994, ANAL SCI, V10, P157, DOI 10.2116/analsci.10.157; PAENG KJ, 1989, THESIS MARQUETTE U M; POWERS L, 1981, BIOPHYS J, V34, P465, DOI 10.1016/S0006-3495(81)84863-1; REGENFUSS P, 1985, REV SCI INSTRUM, V56, P283, DOI 10.1063/1.1138345; REGENFUSS P, 1987, BIOPHYS CHEM, V26, P83, DOI 10.1016/0301-4622(87)80010-8; ROUSSEAU DL, 1992, J RAMAN SPECTROSC, V23, P551, DOI 10.1002/jrs.1250231007; SCOTT RA, 1989, ANNU REV BIOPHYS BIO, V18, P137, DOI 10.1146/annurev.bb.18.060189.001033; VAROTSIS C, 1993, P NATL ACAD SCI USA, V90, P237, DOI 10.1073/pnas.90.1.237; VAROTSIS C, 1990, BIOCHEMISTRY-US, V29, P7357, DOI 10.1021/bi00484a001; VAROTSIS C, 1989, J AM CHEM SOC, V111, P6439, DOI 10.1021/ja00198a075; VAROTSIS C, 1990, J AM CHEM SOC, V112, P1297, DOI 10.1021/ja00159a091; VAROTSIS C, 1990, J BIOL CHEM, V265, P11131; VERKHOVSKY MI, 1994, BIOCHEMISTRY-US, V33, P3079, DOI 10.1021/bi00176a042; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; YOSHIKAWA S, 1977, J BIOL CHEM, V252, P5498	40	46	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8405	8407		10.1074/jbc.270.15.8405	http://dx.doi.org/10.1074/jbc.270.15.8405			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721733	hybrid			2022-12-25	WOS:A1995QT44800009
J	LOSCH, A; KOCHBRANDT, C				LOSCH, A; KOCHBRANDT, C			DITHIOTHREITOL TREATMENT OF MADIN-DARBY CANINE KIDNEY-CELLS REVERSIBLY BLOCKS EXPORT FROM THE ENDOPLASMIC-RETICULUM BUT DOES NOT AFFECT VECTORIAL TARGETING OF SECRETORY PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; VIRUS-G-PROTEIN; GLYCOPROTEIN COMPLEX; BINDING; PATHWAY; OLIGOMERIZATION; HEMAGGLUTININ; BIOSYNTHESIS; POLYPEPTIDE; DEGRADATION	Addition of dithiothreitol (DTT) to the culture me medium of Madin-Darby canine kidney (MDCK) cells blocks transport of newly synthesized gp80 (clusterin, apolipoprotein J), a soluble marker protein for apical exocytosis in this epithelial cell line, In cells treated with DTT during pulse labeling, gp80 is retained in the endoplasmic reticulum, After removal of the reducing agent, gp80 is posttranslationally oxidized and secreted at the apical surface of MDCK cell monolayers, This demonstrates that when folded and oxidized posttranslationally, gp80 can acquire a conformation that exhibits sorting signals for vectorial targeting, In the continuous presence of DTT, the transepithelial electrical resistance of filter grown monolayers is maintained for several hours, indicating the presence of functionally intact tight junctions. Under the same conditions, transport competent forms of gp80 mature within the Golgi complex and are secreted predominantly at the apical surface of MDCK monolayers, Furthermore, another secretory protein, the osteopontin derived 20-kDa polypeptide, is targeted to the apical plasma membrane domain in the continuous presence of DTT, These re suits suggest that the apical sorting machinery in MDCK cells functions independent of the redox state of the secretory pathway.	UNIV MAINZ, INST BIOCHEM, D-55099 MAINZ, GERMANY	Johannes Gutenberg University of Mainz								BERGMAN LW, 1979, J BIOL CHEM, V254, P8869; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CHOIMIURA NH, 1992, J BIOCHEM, V112, P557, DOI 10.1093/oxfordjournals.jbchem.a123938; CLAUDE P, 1978, J MEMBRANE BIOL, V39, P219, DOI 10.1007/BF01870332; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; HARTMANN K, 1991, J BIOL CHEM, V266, P9924; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JENNE DE, 1992, TRENDS BIOCHEM SCI, V16, P27; KIRSZBAUM L, 1992, FEBS LETT, V297, P70, DOI 10.1016/0014-5793(92)80330-J; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LODISH HF, 1993, J BIOL CHEM, V268, P20598; LOUVARD D, 1980, P NATL ACAD SCI-BIOL, V77, P4132, DOI 10.1073/pnas.77.7.4132; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PETERS T, 1982, J BIOL CHEM, V257, P8847; PICCIONI R, 1982, METHODS CHLOROPLAST, P985; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; ULLRICH O, 1991, J BIOL CHEM, V266, P3518; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; WADA I, 1994, J BIOL CHEM, V269, P7464	41	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11543	11548		10.1074/jbc.270.19.11543	http://dx.doi.org/10.1074/jbc.270.19.11543			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744793	hybrid			2022-12-25	WOS:A1995QX86500073
J	ALMUSTAFA, J; SYKORA, M; KINCAID, JR				ALMUSTAFA, J; SYKORA, M; KINCAID, JR			RESONANCE RAMAN INVESTIGATION OF CYANIDE LIGATED BEEF-LIVER AND ASPERGILLUS-NIGER CATALASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; IRON-CARBON BOND; HORSERADISH-PEROXIDASE; 3-DIMENSIONAL STRUCTURE; LIGAND VIBRATIONS; SPECTRA; SPECTROSCOPY; RESOLUTION; NADPH; MOLECULES	Resonance Raman spectroscopy has been used to investigate the properties of cyanide-bound beef liver catalase (BLC) and Aspergillus niger catalase (ANC) in the pH range 4.9-11.5. Evidence has been obtained for the binding of cyanide to both BLC and ANC in two binding geometries. The first conformer, exhibiting the nu[Fe-CN] stretching mode at a higher frequency than the delta[Fe-C-N] bending mode, exists as an essentially linear Fe-C-N linkage. For both BLC-CN and ANC-CN, the nu[Fe-CN] and delta[Fe-C-N] frequencies of this conformer were practically identical and observed at similar to 434 and similar to 413 cm(-1), respectively. The second conformer exhibits a nu[Fe-CN] mode at lower frequency than the delta[Fe-C-N] mode, and is thus characteristic of a bent Fe-C-N linkage. The nu[Fe-CN] and delta[Fe-C-N] modes were identified at 349 and 445 cm(-1), respectively, for BLC-CN, and at 350 and 456 cm(-1), respectively, for ANC-CN. The two conformers persist in the pH range 4.9-11.5. Furthermore, upon raising the pH to 11.5, the nu[Fe-CN] mode of the linear conformer of BLC-CN downshifts to 429 cm(-1) while that of the bent conformer remains unchanged. The observed pH-dependent shift is attributed to the deprotonation of a distal-side amino acid residue, probably a distal histidine, The Fe-C-N axial vibrations of the two conformers identified for ANC-CN did not show any significant pH-dependent shifts, indicating a more stable hydrogen bonding interaction relative to BLC-CN.			ALMUSTAFA, J (corresponding author), MARQUETTE UNIV,DEPT CHEM,MILWAUKEE,WI 53233, USA.		Sykora, Milan/N-5743-2019	Sykora, Milan/0000-0002-1747-0709	NIDDK NIH HHS [DK 35153] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035153] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMUSTAFA J, 1994, BIOCHEMISTRY-US, V33, P2191, DOI 10.1021/bi00174a028; BANCI L, 1991, INORG CHEM, V30, P4510, DOI 10.1021/ic00024a010; BELAL R, 1989, NEW J CHEM, V13, P853; BROWETT WR, 1979, BIOCHIM BIOPHYS ACTA, V577, P291, DOI 10.1016/0005-2795(79)90033-3; CHANCE B, 1952, J BIOL CHEM, V194, P483; CHUANG WJ, 1988, J INORG BIOCHEM, V34, P201, DOI 10.1016/0162-0134(88)85030-X; CHUANG WJ, 1992, J BIOL CHEM, V267, P13293; CHUANG WJ, 1989, J BIOL CHEM, V264, P14209; EGLINTON DG, 1983, BIOCHIM BIOPHYS ACTA, V742, P648, DOI 10.1016/0167-4838(83)90284-4; EVANGELISTAKIRK.R, 1986, BIOCHEMISTRY-US, V25, P4420; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FITA I, 1985, P NATL ACAD SCI USA, V82, P1604, DOI 10.1073/pnas.82.6.1604; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; GALSTON AW, 1957, ACTA CHEM SCAND, V5, P781; HAN SW, 1989, BIOCHEMISTRY-US, V28, P5477, DOI 10.1021/bi00439a024; HERBERT D, 1948, BIOCHEM J, V43, P193, DOI 10.1042/bj0430193; HU SH, 1992, FEBS LETT, V314, P293, DOI 10.1016/0014-5793(92)81492-5; HU SZ, 1993, BIOCHEMISTRY-US, V32, P10125, DOI 10.1021/bi00089a031; KERR EA, 1984, FEBS LETT, V178, P31, DOI 10.1016/0014-5793(84)81233-8; KIKUCHITORII K, 1982, J BIOCHEM, V92, P1449, DOI 10.1093/oxfordjournals.jbchem.a134069; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; KIRKMAN HN, 1987, J BIOL CHEM, V262, P660; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; LOPEZGARRIGA JJ, 1990, BIOCHEMISTRY-US, V29, P9387, DOI 10.1021/bi00492a012; MARGOLIASH E, 1971, BIOCHEM J, V74, P339; MURSHUDOV GN, 1992, FEBS LETT, V312, P127, DOI 10.1016/0014-5793(92)80919-8; MURTHY MRN, 1981, J MOL BIOL, V152, P465, DOI 10.1016/0022-2836(81)90254-0; NAGAI M, 1989, BIOCHEMISTRY-US, V28, P2418, DOI 10.1021/bi00432a012; POULOS TL, 1987, ADV INORG BIOCHEM, V7, P1; RAJANI C, 1995, IN PRESS J RAMAN SPE; ROBERT A, 1991, INORG CHEM, V30, P706, DOI 10.1021/ic00004a021; SAKURADA J, 1986, J BIOL CHEM, V261, P9657; SCHONBAUM GR, 1976, ENZYMES, V13, P263; SCOTT DON, 1960, ENZYMOLOGIA, V22, P229; SHARMA KD, 1989, J BIOL CHEM, V264, P12772; Spiro, 1988, BIOL APPL RAMAN SPEC, P1; Sumner JB, 1937, J BIOL CHEM, V121, P417; TANAKA T, 1987, BIOPHYS J, V52, P801, DOI 10.1016/S0006-3495(87)83274-5; TEROAKA J, 1981, J BIOL CHEM, V256, P3969; THANABAL V, 1988, J AM CHEM SOC, V110, P3027, DOI 10.1021/ja00218a005; UNO T, 1988, INORG CHEM, V27, P3215, DOI 10.1021/ic00291a035; UNO T, 1987, J BIOL CHEM, V262, P4549; VAINSHTEIN BK, 1986, J MOL BIOL, V188, P49, DOI 10.1016/0022-2836(86)90479-1; YU NT, 1984, P NATL ACAD SCI-BIOL, V81, P5106, DOI 10.1073/pnas.81.16.5106; YU NT, 1988, BIOL APPLICATIONS RA, P39	45	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10449	10460		10.1074/jbc.270.18.10449	http://dx.doi.org/10.1074/jbc.270.18.10449			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737979	hybrid			2022-12-25	WOS:A1995QW60100017
J	BIDWAI, AP; REED, JC; GLOVER, CVC				BIDWAI, AP; REED, JC; GLOVER, CVC			CLONING AND DISRUPTION OF CKB1, THE GENE ENCODING THE 38-KDA BETA-SUBUNIT OF SACCHAROMYCES-CEREVISIAE CASEIN KINASE-II (CKII) - DELETION OF CKII REGULATORY SUBUNITS ELICITS A SALT-SENSITIVE PHENOTYPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; DROSOPHILA-MELANOGASTER; CAENORHABDITIS-ELEGANS; CELLULAR-REGULATION; ESCHERICHIA-COLI; SHUTTLE VECTORS; PROTEIN-KINASE; YEAST; CALMODULIN; PHOSPHORYLATION	Saccharomyces cerevisiae casein kinase II (CKII) contains two distinct catalytic (alpha and alpha') and regulatory (beta and beta') subunits, We report here the isolation and disruption of the gene, CKB1, encoding the 38-kDa beta subunit. The predicted Ckb1 sequence includes the N-terminal autophosphorylation site, internal acidic domain, and potential metal binding motif (CPX(3)C-X(22)-CPXC) present in other beta subunits but is unique in that it contains two additional autophosphorylation sites as well as a 30-amino-acid acidic insert. CKB1 is located on the left arm of chromosome VII, approximately 33 kilobases from the centromere and does not correspond to any previously characterized genetic locus. Haploid and diploid strains lacking either or both beta subunit genes are viable, demonstrating that the regulatory subunit of CKII is dispensable in S. cerevisiae. Such strains exhibit wild type behavior with regard to growth on both fermentable and nonfermentable carbon sources, mating, sporulation, spore germination, and resistance to heatshock and nitrogen starvation, but are salt sensitive. Salt sensitivity is specific for NaCl and LiCl and is not observed with KCI or agents which increase osmotic pressure alone, These data suggest a role for CKII in ion homeostasis in S. cerevisiae.	UNIV GEORGIA, DEPT BIOCHEM & MOLEC BIOL, ATHENS, GA 30602 USA	University System of Georgia; University of Georgia				Bidwai, Ashok/0000-0002-4297-5629	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033237] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33237] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BIDWAI AP, 1994, ARCH BIOCHEM BIOPHYS, V309, P348, DOI 10.1006/abbi.1994.1123; BIDWAI AP, 1993, ARCH BIOCHEM BIOPHYS, V300, P265, DOI 10.1006/abbi.1993.1037; BOLDYREFF B, 1993, EUR J BIOCHEM, V218, P515, DOI 10.1111/j.1432-1033.1993.tb18404.x; BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; BOLDYREFF B, 1994, J BIOL CHEM, V269, P4827; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; CHOWDHURY S, 1992, J CELL BIOL, V118, P561, DOI 10.1083/jcb.118.3.561; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; COLLINGE MA, 1994, PLANT MOL BIOL, V25, P649, DOI 10.1007/BF00029603; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; FELSENSTEIN J, 1982, Q REV BIOL, V57, P379, DOI 10.1086/412935; GLOVER CVC, 1983, J BIOL CHEM, V258, P3258; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P77; HANNA DE, 1991, THESIS U GEORGIA ATH; HU E, 1990, J BIOL CHEM, V265, P20609; HU ED, 1990, J BIOL CHEM, V265, P5072; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; ISSINGER OG, 1992, BIOCHEMISTRY-US, V31, P6098, DOI 10.1021/bi00141a020; LIN WJ, 1991, J BIOL CHEM, V266, P5664; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LIVAK KJ, 1990, GENETICS, V124, P303; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MEGGIO F, 1983, FEBS LETT, V162, P235, DOI 10.1016/0014-5793(83)80762-5; MEGGIO F, 1987, FEBS LETT, V215, P241, DOI 10.1016/0014-5793(87)80154-0; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; MORTIMER RK, 1992, YEAST, V8, P817, DOI 10.1002/yea.320081002; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; REED JC, 1994, J BIOL CHEM, V269, P18192; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROUSSOU I, 1994, MOL CELL BIOL, V14, P576, DOI 10.1128/MCB.14.1.576; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SKALA J, 1991, YEAST, V7, P651, DOI 10.1002/yea.320070614; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; TEITZ T, 1990, MUTAT RES, V236, P85, DOI 10.1016/0921-8777(90)90036-5; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WELCH MD, 1993, GENETICS, V135, P265; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359; ZALKIN H, 1982, J BIOL CHEM, V257, P1491	47	75	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10395	10404		10.1074/jbc.270.18.10395	http://dx.doi.org/10.1074/jbc.270.18.10395			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737972				2022-12-25	WOS:A1995QW60100010
J	LEE, GJ; POKALA, N; VIERLING, E				LEE, GJ; POKALA, N; VIERLING, E			STRUCTURE AND IN-VITRO MOLECULAR CHAPERONE ACTIVITY OF CYTOSOLIC SMALL HEAT-SHOCK PROTEINS FROM PEA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CRYSTALLIN; CITRATE SYNTHASE; EXPRESSION; PHOSPHORYLATION; RESISTANCE; PLANTS; FAMILY; TOMATO; HSP27; GENES	Plants synthesize several classes of small heat shock proteins ranging in size from 15 to 30 kDa. Two conserved classes, designated class I and class II, are localized to the cytosol. Recombinant HSP18.1 and HSP17.7, representing class I and class II proteins from pea, respectively, were expressed in Escherichia coli and purified. Non-denaturing polyacrylamide gel electrophoresis and electron microscopy demonstrated that the purified proteins formed discretely sized, high molecular weight complexes. Sedimentation equilibrium analytical ultracentrifugation revealed that the HSP18.1 and HSP17.7 complexes were composed of approximately 12 subunits. Both proteins were able to enhance the refolding of chemically denatured citrate synthase and lactate dehydrogenase at stoichiometric levels in an ATP-independent manner. Furthermore, HSP18.1 and HSP17.7 prevented aggregation of citrate synthase at 45 degrees C and irreversible inactivation of citrate synthase at 38 degrees C. HSP18.1 also suppressed aggregation of lactate dehydrogenase at 55 degrees C. These findings demonstrate that HSP18.1 and HSP17.7 can function as molecular chaperones in vitro.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute	LEE, GJ (corresponding author), UNIV ARIZONA, DEPT BIOCHEM, LIFE SCI S, TUCSON, AZ 85721 USA.		Pokala, Navin/AAH-5719-2019	Pokala, Navin/0000-0003-2323-6190; Vierling, Elizabeth/0000-0002-0066-4881				ANDERSSON LO, 1972, FEBS LETT, V20, P199, DOI 10.1016/0014-5793(72)80793-2; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; BERGER EM, 1983, EXP CELL RES, V147, P437, DOI 10.1016/0014-4827(83)90225-2; BLOXHAM DP, 1980, BIOCHEMISTRY-US, V19, P3979, DOI 10.1021/bi00558a014; BOUCHARD RA, 1990, GENOME, V33, P68, DOI 10.1139/g90-012; CHEN Q, 1994, J BIOL CHEM, V269, P13216; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; DEROCHER AE, 1994, PLANT J, V5, P93, DOI 10.1046/j.1365-313X.1994.5010093.x; DEROCHER AE, 1991, PLANT PHYSIOL, V96, P1038, DOI 10.1104/pp.96.4.1038; DIETRICH PS, 1991, PLANT PHYSIOL, V96, P1268, DOI 10.1104/pp.96.4.1268; FRAY RG, 1990, NUCLEIC ACIDS RES, V18, P7148, DOI 10.1093/nar/18.23.7148; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; HELM KW, 1993, MOL CELL BIOL, V13, P238, DOI 10.1128/MCB.13.1.238; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HERNANDEZ LD, 1993, PLANT PHYSIOL, V101, P1209, DOI 10.1104/pp.101.4.1209; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KANDROR O, 1994, J BIOL CHEM, V269, P23575; KATO K, 1994, J BIOL CHEM, V269, P11274; KORNBERG A, 1955, METHOD ENZYMOL, V1, P441, DOI 10.1016/0076-6879(55)01072-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1992, J BIOL CHEM, V267, P794; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LAUZON LM, 1990, NUCLEIC ACIDS RES, V18, P4274, DOI 10.1093/nar/18.14.4274; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LENNE C, 1994, PLANT PHYSIOL, V105, P1255, DOI 10.1104/pp.105.4.1255; MANSFIELD MA, 1987, PLANT PHYSIOL, V84, P1007, DOI 10.1104/pp.84.4.1007; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; NOVER L, 1984, EUR J BIOCHEM, V139, P303, DOI 10.1111/j.1432-1033.1984.tb08008.x; OCHOA S, 1957, BIOCHEM PREP, V5, P19; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PLESOFSKYVIG N, 1992, J MOL EVOL, V35, P537, DOI 10.1007/BF00160214; ROLLET E, 1992, BIOCHEM BIOPH RES CO, V185, P116, DOI 10.1016/S0006-291X(05)80963-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; VIERLING E, 1991, ANNU REV PLANT PHYS, V42, P579, DOI 10.1146/annurev.pp.42.060191.003051; WANG Z, 1992, PROTEIN SCI, V1, P522	47	266	287	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10432	10438		10.1074/jbc.270.18.10432	http://dx.doi.org/10.1074/jbc.270.18.10432			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737977	hybrid			2022-12-25	WOS:A1995QW60100015
J	PROSSNITZ, ER; SCHREIBER, RE; BOKOCH, GM; YE, RD				PROSSNITZ, ER; SCHREIBER, RE; BOKOCH, GM; YE, RD			BINDING OF LOW-AFFINITY N-FORMYL PEPTIDE RECEPTORS TO G-PROTEIN - CHARACTERIZATION OF A NOVEL INACTIVE RECEPTOR INTERMEDIATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; ADENYLATE-CYCLASE; RECONSTITUTION; FLUORESCENCE; COMPLEX; LIGAND; CDNA	G protein-coupled seven-transmembrane-containing receptors, such as the N-formyl peptide receptor (FPR) of neutrophils, likely undergo a conformational change upon binding of ligand, which enables the receptor to transmit a signal to G proteins. We have examined the functional significance of numerous conserved charged amino acid residues proposed to be located within or near the transmembrane domains. Whereas the wild type FPR exhibits a K-d for an agonist of 1-3 nM, which is reduced to similar to 40 nM in the presence of guanosine 5'-3-O-(thio)triphosphate (GTP gamma S)) substitution of either Asp(71) or Arg(123) resulted in mutant receptors that bound ligand with only low affinity (K-d = 30-50 niM) independent of GTP gamma S. In contrast, substitution of Arg(163), predicted to be located at a similar depth within the membrane as Asp(71), had no effect on ligand binding. Replacement of residues Arg(309)-Glu(310)-Arg(311) resulted in an FPR with intermediate ligand binding characteristics. Functional analysis of the mutant receptors revealed that substitution of either Asp(71) or Arg(123) resulted in a mutant receptor that was unable to mediate calcium mobilization, whereas replacement of residues Arg(309)-Glu(310)-Arg(311) yielded a receptor with an EC(50) of 50 nM, compared with 0.5 nM for the wild type FPR. In order to determine the point of the defect in signal transduction, we performed reconstitution of the solubilized receptors with purified G proteins. The wild type FPR displayed a K-d for G protein of similar to 0.6 mu M compared with the Arg(309)/Glu(310)/Arg(311) mutant with a K-d of approximately 30 mu M. A Significant physical interaction between the Asp(71) or Arg(123) mutants and G protein was not observed. The implications of these findings for signal transduction mechanisms are discussed.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	PROSSNITZ, ER (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, IMM12, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Ye, Richard/O-5223-2016; Prossnitz, Eric R./B-4543-2008; Ye, Richard/ABF-2413-2020	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Prossnitz, Eric/0000-0001-9190-8302	NIAID NIH HHS [AI33503, AI36357] Funding Source: Medline; NIGMS NIH HHS [GM46572] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033503, R01AI036357, R29AI036357, R56AI033503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046572] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RA, 1986, BIOCHIM BIOPHYS ACTA, V882, P271, DOI 10.1016/0304-4165(86)90248-5; ALLEN RA, 1987, PHARMACOL THERAPEUT, V33, P333, DOI 10.1016/0163-7258(87)90070-2; BOMMAKANTI RK, 1992, J BIOL CHEM, V267, P7576; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DELEAN A, 1980, J BIOL CHEM, V255, P7108; FAY SP, 1991, BIOCHEMISTRY-US, V30, P5066, DOI 10.1021/bi00234a033; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; POSNER RG, 1994, MOL PHARMACOL, V45, P65; PROBST WC, 1992, DNA CELL BIOL, P11; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; SAMAMA P, 1993, J BIOL CHEM, V268, P5066; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHREIBER RE, 1993, J LEUKOCYTE BIOL, V53, P470, DOI 10.1002/jlb.53.4.470; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	24	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10686	10694		10.1074/jbc.270.18.10686	http://dx.doi.org/10.1074/jbc.270.18.10686			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738006	hybrid			2022-12-25	WOS:A1995QW60100050
J	TONG, GX; TANEN, MR; BAGCHI, MK				TONG, GX; TANEN, MR; BAGCHI, MK			LIGAND MODULATES THE INTERACTION OF THYROID-HORMONE RECEPTOR-BETA WITH THE BASAL TRANSCRIPTION MACHINERY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; RETINOIC ACID RECEPTORS; RESPONSE ELEMENTS; X-RECEPTOR; PROGESTERONE-RECEPTOR; PREINITIATION COMPLEX; NUCLEAR RECEPTORS; ENHANCES BINDING; ONCOGENE PRODUCT; GENE-EXPRESSION	We investigated the molecular mechanisms underlying the transcriptional silencing and the hormone-induced activation of target genes by thyroid hormone receptor beta (TR-beta). We developed a cell-free transcription system containing HeLa cell nuclear extracts in which unliganded human TR-beta represses basal transcription from a promoter bearing thyroid hormone response elements. Binding of hormonal ligand to the receptor reverses this transcriptional silencing. Specific binding of TR-beta to the thyroid hormone response element at the target promoter is crucial for silencing. Studies employing TR-beta mutants indicate that the silencing activity is located within the C-terminal rather than the N-terminal domain of the receptor. Our studies reveal further that unliganded TR-beta inhibits the assembly of a functional transcription preinitiation complex (PIC) at the target promoter. We postulate that interaction with TR-beta impairs the function(s) of one or more assembling transcriptional complexes during the multistep assembly of a PIC. Consistent with this hypothesis, we observe that, in the absence of thyroid hormone, TR-beta or a heterodimer of TR-beta and retinoid-X-receptor undergoes direct protein-protein interactions with the transcription factor IIB-TATA binding protein complex, an early intermediate during PIC assembly. Binding of hormone to TR-beta dramatically reduces the interaction between the receptor and the transcription factor IIB-TATA binding protein complex. We propose that the role of ligand is to facilitate the assembly of functional PICs at the target promoter by reducing nonproductive interactions between TR-beta and the initiation factors.	POPULAT COUNCIL,NEW YORK,NY 10021; UNIV ROCHESTER,NEW YORK,NY 10021	Population Council; University of Rochester								AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BAGCHI MK, 1990, J BIOL CHEM, V265, P5129; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BRENT G A, 1989, New Biologist, V1, P329; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; Drapkin R, 1993, CURR OPIN CELL BIOL, V5, P469, DOI 10.1016/0955-0674(93)90013-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLORES O, 1992, J BIOL CHEM, V267, P2786; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; JOHNSON FB, 1992, GENE DEV, V7, P1400; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LEE IJ, 1994, P NATL ACAD SCI USA, V91, P1647, DOI 10.1073/pnas.91.5.1647; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; SAMUELS HH, 1988, J CLIN INVEST, V81, P957, DOI 10.1172/JCI113449; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SUEN CS, 1993, MOL CELL BIOL, V13, P1719, DOI 10.1128/MCB.13.3.1719; TAKEDA K, 1992, J CLIN ENDOCR METAB, V74, P49, DOI 10.1210/jc.74.1.49; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TONEY JH, 1993, BIOCHEMISTRY-US, V32, P2, DOI 10.1021/bi00052a001; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; USALA SJ, 1991, MOL ENDOCRINOL, V5, P327, DOI 10.1210/mend-5-3-327; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	64	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10601	10611		10.1074/jbc.270.18.10601	http://dx.doi.org/10.1074/jbc.270.18.10601			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737997	hybrid			2022-12-25	WOS:A1995QW60100039
J	ZGOMBICKNIGHT, M; ANG, HL; FOGLIO, MH; DUESTER, G				ZGOMBICKNIGHT, M; ANG, HL; FOGLIO, MH; DUESTER, G			CLONING OF THE MOUSE CLASS-IV ALCOHOL-DEHYDROGENASE (RETINOL DEHYDROGENASE) CDNA AND TISSUE-SPECIFIC EXPRESSION PATTERNS OF THE MURINE ADH GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT FORMALDEHYDE DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; ENZYMATIC-PROPERTIES; MOLECULAR ANALYSIS; HUMAN STOMACH; LIVER; ACID; PURIFICATION; ISOZYMES; PROTEIN	Humans possess five classes of alcohol dehydrogenase (ADH), including forms able to oxidize ethanol or formaldehyde as part of a defense mechanism, as well as forms acting as retinol dehydrogenases in the synthesis of the regulatory ligand retinoic acid. However, the mouse has previously been shown to possess only three forms of ADH. Hybridization analysis of mouse genomic DNA using cDNA probes specific for each of the five classes of human ADH has now indicated that mouse DNA cross-hybridizes to only classes I, III, and IV. With human class II or class V ADH cDNA probes, hybridization to mouse genomic DNA was very weak or undetectable, suggesting either a lack of these genes in the mouse or a high degree of mutational divergence relative to the human genes. cDNAs for murine ADH classes I and III have previously been cloned, and we now report the cloning of a full-length mouse class IV ADH cDNA In Northern blot analyses, mouse class TV ADH mRNA was abundant in the stomach, eye, skin, and ovary, thus correlating with the expression pattern for the mouse Adh-3 gene previously determined by enzyme analysis. In situ hybridization studies on mouse stomach indicated that class IV ADH transcripts were abundant in the mucosal epithelium but absent from the muscular layer. Comparison of the expression patterns for all three mouse ADH genes indicated that class III was expressed ubiquitously, whereas classes I and IV were differentially expressed in an overlapping set of tissues that all contain a large component of epithelial cells. This expression pattern is consistent with the ability of classes I and IV to oxidize retinol for the synthesis of retinoic acid known to regulate epithelial cell differentiation. The results presented here indicate that the mouse has a simpler ADH gene family than the human but has conserved class IV ADH previously shown to be a very active retinol dehydrogenase in humans.	LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NIAAA NIH HHS [AA07261] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007261] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALGAR EM, 1983, EUR J BIOCHEM, V137, P139, DOI 10.1111/j.1432-1033.1983.tb07807.x; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; Blaner William S., 1994, P229; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; BOLEDA MD, 1989, ARCH BIOCHEM BIOPHYS, V274, P74, DOI 10.1016/0003-9861(89)90416-5; CECI JD, 1987, GENE, V59, P171, DOI 10.1016/0378-1119(87)90325-8; CECI JD, 1986, GENE, V41, P217, DOI 10.1016/0378-1119(86)90101-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONNOR MJ, 1987, BIOCHEM J, V244, P489, DOI 10.1042/bj2440489; CONNOR MJ, 1988, CANCER RES, V48, P7038; CRABB DW, 1989, GENOMICS, V5, P906, DOI 10.1016/0888-7543(89)90133-X; DANIELSSON O, 1994, P NATL ACAD SCI USA, V91, P4980, DOI 10.1073/pnas.91.11.4980; DANIELSSON O, 1992, P NATL ACAD SCI USA, V89, P9247, DOI 10.1073/pnas.89.19.9247; DE LUCA LM, 1991, FASEB J, V5, P2924; DERR RF, 1994, BIOCHEM ARCH, V10, P59; DUESTER G, 1986, J BIOL CHEM, V261, P2027; EDENBERG HJ, 1985, P NATL ACAD SCI USA, V82, P2262, DOI 10.1073/pnas.82.8.2262; ESTONIUS M, 1993, EUR J BIOCHEM, V215, P497, DOI 10.1111/j.1432-1033.1993.tb18059.x; GIRI PR, 1989, BIOCHEM BIOPH RES CO, V164, P453, DOI 10.1016/0006-291X(89)91741-5; HOLMES RS, 1978, COMP BIOCHEM PHYS B, V61, P339, DOI 10.1016/0305-0491(78)90134-7; HOLMES RS, 1977, GENETICS, V87, P709; HOOG JO, 1987, BIOCHEMISTRY-US, V26, P1926, DOI 10.1021/bi00381a021; HOOG JO, 1986, EUR J BIOCHEM, V159, P215, DOI 10.1111/j.1432-1033.1986.tb09855.x; HOOG JO, 1991, ADV EXP MED BIOL, V284, P285; HOOG JO, 1995, IN PRESS ADV EXP MED; Hur M W, 1992, DNA Seq, V3, P167, DOI 10.3109/10425179209034012; HUR MW, 1992, GENE, V121, P305, DOI 10.1016/0378-1119(92)90135-C; JORNVALL H, 1987, P NATL ACAD SCI USA, V84, P2580, DOI 10.1073/pnas.84.9.2580; JULIA P, 1987, EUR J BIOCHEM, V162, P179, DOI 10.1111/j.1432-1033.1987.tb10559.x; KAISER R, 1993, P NATL ACAD SCI USA, V90, P11222, DOI 10.1073/pnas.90.23.11222; KOIVUSALO M, 1989, FEBS LETT, V257, P105, DOI 10.1016/0014-5793(89)81797-1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREBS HA, 1970, BIOCHEM J, V118, P635, DOI 10.1042/bj1180635; LEVITT MD, 1994, AM J PHYSIOL, V267, pG452, DOI 10.1152/ajpgi.1994.267.3.G452; LIM RT, 1993, ALCOHOL CLIN EXP RES, V17, P1337, DOI 10.1111/j.1530-0277.1993.tb05250.x; MATSUO Y, 1990, AM J HUM GENET, V46, P85; MORENO A, 1991, J BIOL CHEM, V266, P1128; PARES X, 1994, P NATL ACAD SCI USA, V91, P1893, DOI 10.1073/pnas.91.5.1893; PARES X, 1992, FEBS LETT, V303, P69, DOI 10.1016/0014-5793(92)80479-Z; PARES X, 1990, FEBS LETT, V277, P115, DOI 10.1016/0014-5793(90)80822-Z; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; ROUT UK, 1991, BIOL NEONATE, V59, P93; Sambrook J, 1989, MOL CLONING LABORATO; SATRE MA, 1994, J BIOL CHEM, V269, P15606; STONE CL, 1993, ALCOHOL CLIN EXP RES, V17, P911, DOI 10.1111/j.1530-0277.1993.tb00863.x; VONBAHRLINDSTROM H, 1991, GENE, V103, P269, DOI 10.1016/0378-1119(91)90285-J; WANG B, 1992, BIOTECHNIQUES, V13, P527; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; YASUNAMI M, 1991, P NATL ACAD SCI USA, V88, P7610, DOI 10.1073/pnas.88.17.7610; YIN SJ, 1993, ALCOHOL CLIN EXP RES, V17, P376, DOI 10.1111/j.1530-0277.1993.tb00779.x; YIN SJ, 1990, BIOCHEM INT, V22, P829; YOKOYAMA S, 1994, FEBS LETT, V351, P411, DOI 10.1016/0014-5793(94)00895-7; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P4305, DOI 10.1074/jbc.270.9.4305; ZHANG K, 1987, GENE, V57, P27, DOI 10.1016/0378-1119(87)90173-9; ZHENG YW, 1993, J BIOL CHEM, V268, P24933	56	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10868	10877						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738026	hybrid			2022-12-25	WOS:A1995QW60100074
J	CHALOVICH, JM; CHEN, YD; DUDEK, R; LUO, H				CHALOVICH, JM; CHEN, YD; DUDEK, R; LUO, H			KINETICS OF BINDING OF CALDESMON TO ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; ACTOMYOSIN ATPASE ACTIVITY; CHICKEN GIZZARD CALDESMON; MYOSIN SUBFRAGMENT-1; SKELETAL-MUSCLE; THIN-FILAMENTS; TROPOMYOSIN; INHIBITION; CALMODULIN; DOMAIN	The time course of interaction of caldesmon with actin may be monitored by fluorescence changes that occur upon the binding of 12-(N-methyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))-labeled caldesmon to actin or to acrylodan actin. The concentration dependence of the observed rate of caldesmon-actin binding was analyzed to a first approximation as a single-step reaction using a Monte Carlo simulation. The derived association and dissociation rates were 10(7) M(-1) S-1 and 18.2 S-1, respectively. Smooth muscle tropomyosin enhances the binding of caldesmon to actin, and this was found to be due to a reduction in the rate of dissociation to 6.3 S-1. There is no evidence from this study for a different mechanism of binding in the presence of tropomyosin. The floor escence changes that occurred with the binding of 12(N-methhyl-N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl))-labeled caldesmon to actin or actin-tropomyosin were reversed by the addition of myosin subfragment 1 as predicted by a competitive binding mechanism.	E CAROLINA UNIV,SCH MED,DEPT ANAT,GREENVILLE,NC 27858; NIDDK,PHYS CHEM LAB,BETHESDA,MD 20892	University of North Carolina; East Carolina University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	CHALOVICH, JM (corresponding author), E CAROLINA UNIV,SCH MED,DEPT BIOCHEM,GREENVILLE,NC 27858, USA.			Chalovich, Joseph/0000-0002-1243-4055	NIAMS NIH HHS [R01 AR035216, AR35216, AR40540] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040540, R01AR035216] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRENNER B, 1991, P NATL ACAD SCI USA, V88, P5739, DOI 10.1073/pnas.88.13.5739; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CHALOVICH JM, 1992, J BIOL CHEM, V267, P16644; CHEN YD, 1992, BIOPHYS J, V63, P1063, DOI 10.1016/S0006-3495(92)81687-9; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; FUJII T, 1987, J BIOL CHEM, V262, P2757; FUJII T, 1988, J BIOCHEM-TOKYO, V104, P734, DOI 10.1093/oxfordjournals.jbchem.a122542; GRACEFFA P, 1992, BIOCHIM BIOPHYS ACTA, V1120, P205, DOI 10.1016/0167-4838(92)90271-E; GRACEFFA P, 1987, FEBS LETT, V218, P139, DOI 10.1016/0014-5793(87)81034-7; Hayat MA, 1972, PRINCIPLES TECHNIQUE, V2; HEGMANN TE, 1991, CELL MOTIL CYTOSKEL, V20, P109, DOI 10.1002/cm.970200204; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; MARSTON SB, 1993, J BIOL CHEM, V268, P12317; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; NGAI PK, 1985, BIOCHEM J, V230, P695, DOI 10.1042/bj2300695; PFITZER G, 1993, P NATL ACAD SCI USA, V90, P5904, DOI 10.1073/pnas.90.13.5904; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SMITH CWJ, 1985, FEBS LETT, V184, P115, DOI 10.1016/0014-5793(85)80665-7; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; TRAYER HR, 1988, BIOCHEMISTRY-US, V27, P5718, DOI 10.1021/bi00415a049; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WALKER G, 1989, J BIOL CHEM, V264, P496; WATSON MH, 1990, BIOCHIM BIOPHYS ACTA, V1054, P103, DOI 10.1016/0167-4889(90)90211-U; WEGNER A, 1979, J MOL BIOL, V131, P839, DOI 10.1016/0022-2836(79)90204-3; WILLIAMS DL, 1984, BIOCHEMISTRY-US, V23, P4150, DOI 10.1021/bi00313a022; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0	32	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9911	9916		10.1074/jbc.270.17.9911	http://dx.doi.org/10.1074/jbc.270.17.9911			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730374	Green Submitted, Green Accepted			2022-12-25	WOS:A1995QV41700034
J	WOOLKALIS, MJ; DEMELFI, TM; BLANCHARD, N; HOXIE, JA; BRASS, LF				WOOLKALIS, MJ; DEMELFI, TM; BLANCHARD, N; HOXIE, JA; BRASS, LF			REGULATION OF THROMBIN RECEPTORS ON HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTACYCLIN PRODUCTION; PHOSPHOINOSITIDE HYDROLYSIS; HOMOLOGOUS DESENSITIZATION; PROTEOLYTIC MECHANISM; CALCIUM-CONCENTRATION; MOBILIZATION; ACTIVATION; PLATELETS; CLONING	Activated thrombin receptors on human umbilical vein endothelial cells rapidly undergo homologous desensitization, leaving the cells unable to respond to thrombin. The present studies examine the fate of activated thrombin receptors on endothelial cells and the mechanisms that restore intact receptors to the cell surface. The results show that: 1) at biologically relevant concentrations, thrombin rapidly cleaves all of its receptors on the cell surface, 2) The cleaved receptors are cleared from the cell surface in a two-phase process, with 60% being internalized within 10 min, the remainder requiring several hours, 3) The restoration of intact, thrombin-responsive receptors on the cell surface initially occurs from an intracellular pool of receptors in a process that is independent of protein synthesis, 4) Recycling of cleaved receptors either does not occur on endothelial cells or is masked by receptor clearance, 5) Subconfluent endothelial cells re-express intact receptors on the cell surface at a slower rate than confluent cells, 6) The agonist peptide, SFLLRN, also causes receptor internalization, although at concentrations greater than those required for receptor activation and desensitization. These results are distinctly different from those observed with megakaryoblastic cell lines, where >90% of the activated thrombin receptors are internalized rapidly, up to 40% of the cleaved receptors are recycled, and no intracellular pool of intact receptors has been detected, Since the primary structure of the thrombin receptor is the same in all the cell types studied, these results demonstrate that there can be substantial differences between cell types in the mechanisms involved in the clearance of activated receptors and the re-expression on the cell surface of intact receptors capable of responding to thrombin.	UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	WOOLKALIS, MJ (corresponding author), THOMAS JEFFERSON UNIV,DEPT PHYSIOL,1020 LOCUST ST,PHILADELPHIA,PA 19107, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049987, P01HL040387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40387, HL49987] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BRASS LF, 1992, J BIOL CHEM, V267, P6044; BRASS LF, 1994, J BIOL CHEM, V289, P2943; BROCK TA, 1988, J CELL PHYSIOL, V136, P54, DOI 10.1002/jcp.1041360107; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; FOSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788; GOLIGORSKY MS, 1989, J BIOL CHEM, V264, P16771; GREEN SA, 1994, J BIOL CHEM, V269, P26215; HALLAM TJ, 1988, BIOCHEM J, V251, P243, DOI 10.1042/bj2510243; HEIN L, 1994, J BIOL CHEM, V269, P27719; HORVAT R, 1995, IN PRESS J CELL SCI; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUANG EM, 1987, BIOCHEM J, V242, P11, DOI 10.1042/bj2420011; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; JONES LG, 1989, MOL PHARMACOL, V36, P142; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; PARIS S, 1988, J BIOL CHEM, V263, P11250; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	25	100	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9868	9875		10.1074/jbc.270.17.9868	http://dx.doi.org/10.1074/jbc.270.17.9868			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730369				2022-12-25	WOS:A1995QV41700028
J	FEUERSTEIN, N; HUANG, D; PRYSTOWSKY, MB				FEUERSTEIN, N; HUANG, D; PRYSTOWSKY, MB			RAPAMYCIN SELECTIVELY BLOCKS INTERLEUKIN-2-INDUCED PROLIFERATING CELL NUCLEAR ANTIGEN GENE-EXPRESSION IN T-LYMPHOCYTE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P34CDC2 KINASE ACTIVATION; ELEMENT-BINDING PROTEIN; DNA POLYMERASE-DELTA; MESSENGER-RNA LEVELS; P70 S6 KINASE; MATRIX PROTEIN; TRANSCRIPTIONAL ACTIVATION; MOLECULAR-CLONING; AUXILIARY PROTEIN; ESCHERICHIA-COLI	The macrolide rapamycin arrests T lymphocytes stimulated by interleukin-2 (IL-2) at G(1)/S. We have recently found that IL-2 induced an increase in the binding of discrete transcription factors of the ATF/cAMP-responsive element binding factor (CREB) family at G(1)/S, and that this effect was inhibited by rapamycin (Feuerstein, N., Huang, D., Hinrichs, S. H., Orten, D. J., Aiyar, N., and Prystowsky, M. B. (1995) J. Immunol, 154, 68-79), We now show, by using high resolution two-dimensional gel electrophoresis, that rapamycin inhibited selectively the synthesis of three discrete IL-2-induced soluble proteins (35 kDa/pI similar to 5, 68 kDa/pI similar to 4, 110 kDa/pI similar to 4.3), Analysis of nuclear proteins demonstrated that rapamycin selectively blocked the expression of proliferating cell nuclear antigen (PCNA), an obligate cofactor of DNA polymerase-delta, an important component for DNA replication, Rapamycin inhibited the IL-2-induced PCNA mRNA, and the murine PCNA promoter activity in IL-2-stimulated cells, Inducible CRE-binding proteins were shown previously to be required for PCNA promoter activity in IL-2-stimulated T lymphocytes, Using DNA binding gel mobility shift assay we demonstrated that rapamycin potently inhibited the binding of CREB/ATF transcription factors to CRE elements in the murine proximal PCNA promoter, These results suggest that PCNA is a preferred target in a rapamycin-sensitive transduction pathway, and that the mechanism by which rapamycin inhibits PCNA gene expression may involve the inhibition of the interaction of CREB/ATF transcription factors with CRE elements in the proximal PCNA promoter.	ALBERT EINSTEIN COLL MED,BRONX,NY 10467	Yeshiva University; Albert Einstein College of Medicine	FEUERSTEIN, N (corresponding author), MED COLL PENN,CGR RM 245,2900 QUEEN LN,PHILADELPHIA,PA 19129, USA.				NCI NIH HHS [R29-CA48667] Funding Source: Medline; NIA NIH HHS [AG00378] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA048667] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER A, 1992, NUCLEIC ACIDS RES, V20, P1769; ALBERS MW, 1993, J BIOL CHEM, V268, P22825; ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLEVENGER CV, 1992, ENDOCRINOLOGY, V130, P3216, DOI 10.1210/en.130.6.3216; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DUNMONT FJ, 1990, J IMMUNOL, V144, P251; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; FEUERSTEIN N, 1995, J IMMUNOL, V154, P68; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GLOSEBROOK AL, 1980, J EXP MED, V151, P876; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HUANG DY, 1994, MOL CELL BIOL, V14, P4233, DOI 10.1128/MCB.14.6.4233; JASKULSKI D, 1988, J BIOL CHEM, V263, P10175; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LIU F, 1993, J BIOL CHEM, V268, P6714; MATHEWS MB, 1989, GROWTH CONTROL CELL, P89; MATSUMOTO K, 1987, EMBO J, V6, P637, DOI 10.1002/j.1460-2075.1987.tb04802.x; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MOORE KS, 1987, J BIOL CHEM, V262, P8447; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MORICE WG, 1993, J BIOL CHEM, V268, P3734; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; OTTAVIO L, 1990, MOL CELL BIOL, V10, P303, DOI 10.1128/MCB.10.1.303; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; ROSENBERG SA, 1984, SCIENCE, V223, P1412, DOI 10.1126/science.6367046; SABATH DE, 1986, P NATL ACAD SCI USA, V83, P4739, DOI 10.1073/pnas.83.13.4739; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHIPMAN PM, 1988, J CELL BIOCHEM, V38, P189, DOI 10.1002/jcb.240380306; SHIPMANAPPASAMY P, 1990, J BIOL CHEM, V265, P19180; SHIPMANAPPASAMY P, 1991, J DNA SEQUENCING MAP, V2, P181; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; TAN CK, 1986, J BIOL CHEM, V261, P2310; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANG A, 1984, SCIENCE, V224, P1431, DOI 10.1126/science.6427925; WONG RL, 1987, CELL IMMUNOL, V110, P443, DOI 10.1016/0008-8749(87)90137-7; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	58	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9454	9458		10.1074/jbc.270.16.9454	http://dx.doi.org/10.1074/jbc.270.16.9454			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721872	hybrid			2022-12-25	WOS:A1995QU08900061
J	OGAWA, Y; AIZAWA, S; SHIRAKAWA, H; YOSHIDA, M				OGAWA, Y; AIZAWA, S; SHIRAKAWA, H; YOSHIDA, M			STIMULATION OF TRANSCRIPTION ACCOMPANYING RELAXATION OF CHROMATIN STRUCTURE IN CELLS OVEREXPRESSING HIGH-MOBILITY GROUP-1 PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG CHROMOSOMAL-PROTEINS; SINGLE-STRANDED-DNA; RNA POLYMERASE-II; NUCLEOTIDE-SEQUENCE; PREFERENTIAL AFFINITY; BOVINE PAPILLOMAVIRUS; MELTING TEMPERATURE; SUPERCOILED DNA; MESSENGER-RNA; PIG THYMUS	We developed murine C-127 cell lines that stationarily overexpress high mobility group (HMG) proteins 1 and 2 by transfecting them with the bovine papilloma virus plasmid carrying their respective cDNA sequences, Using these cell lines, we examined the effects of these HMG proteins on the modulation of chromatin structure that accompanied transcription, The levels of HMG1 mRNA and protein in cells overexpressing HMG1 protein were enhanced about 7- and 3-fold, respectively, in comparison with control cells, whereas those in cells overexpressing HMG1 protein were enhanced about 17- and 9-fold, The expression of reporter genes transfected into the cells was enhanced approximately 2-fold in cells overexpressing HMG1, but not HMG2, in comparison with those in control cells, irrespective of the sources of the genes and promoters, The minichromosome derived from the reporter plasmid in cells overexpressing HMG1 protein was more susceptible to micrococcal nuclease digestion than those in cells overexpressing HMG2 protein and control cells, The enhanced accessibility to micrococcal nuclease was not restricted to the expressing gene and promoter but involved the entire minichromosome, suggesting that the enhancement of gene expression resulted from changes in the condensation of the entire minichromosomal region by HMG1 protein, Minichromosomes in cells overexpressing HMG contained enhanced amounts of the respective HMG proteins and simultaneously reduced amounts of histone His. These results suggest that HMG1 and -2 proteins have different functions in the modulation of chromatin structure, and that HMG1 protein may sustain the structure of the respective gene to ensure that its activity as a template is expressed fully, These observations on the modulation of chromatin structure accompanying gene transcription in cells overexpressing HMG protein may provide important information on the function of these proteins.	SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,NODA,CHIBA 278,JAPAN	Tokyo University of Science			Shirakawa, Hitoshi/D-1406-2009	SHIRAKAWA, HITOSHI/0000-0002-4828-5274				AIZAWA S, 1994, BIOCHEMISTRY-US, V33, P14690, DOI 10.1021/bi00253a006; AYUSAWA D, 1986, J MOL BIOL, V190, P559, DOI 10.1016/0022-2836(86)90241-X; BEATRIZ LW, 1978, NUCLEIC ACIDS RES, V5, P4155; BIDNEY DL, 1978, BIOCHEM BIOPH RES CO, V85, P1211, DOI 10.1016/0006-291X(78)90671-X; BONNEANDREA C, 1984, EMBO J, V3, P1193, DOI 10.1002/j.1460-2075.1984.tb01950.x; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; BUTLER JL, 1984, P NATL ACAD SCI-BIOL, V81, P2475, DOI 10.1073/pnas.81.8.2475; EINCK L, 1985, EXP CELL RES, V156, P295, DOI 10.1016/0014-4827(85)90539-7; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUKUNAGA R, 1984, P NATL ACAD SCI-BIOL, V81, P5086, DOI 10.1073/pnas.81.16.5086; GE H, 1994, J BIOL CHEM, V269, P17136; GIRI C, 1987, J BIOL CHEM, V262, P9839; GOODWIN GH, 1978, BIOCHIM BIOPHYS ACTA, V519, P279, DOI 10.1016/0005-2787(78)90081-3; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMADA H, 1985, BIOCHEMISTRY-US, V24, P1428, DOI 10.1021/bi00327a022; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; ISACKSON PJ, 1979, J BIOL CHEM, V254, P5569; Johns EW, 1982, HMG CHROMOSOMAL PROT; JOSE M, 1987, EUR J BIOCHEM, V163, P347, DOI 10.1111/j.1432-1033.1987.tb10806.x; KLEINSCHMIDT JA, 1983, J CELL BIOL, V97, P838, DOI 10.1083/jcb.97.3.838; LAITINEN J, 1990, J CELL BIOL, V111, P9, DOI 10.1083/jcb.111.1.9; LANDSMAN D, 1991, MOL CELL BIOL, V11, P4483, DOI 10.1128/MCB.11.9.4483; LAW MF, 1983, MOL CELL BIOL, V3, P2110, DOI 10.1128/MCB.3.11.2110; LEWIS SA, 1985, J CELL BIOL, V101, P852, DOI 10.1083/jcb.101.3.852; LUSKY M, 1984, CELL, V36, P391, DOI 10.1016/0092-8674(84)90232-0; MAKIGUCHI K, 1984, J BIOCHEM-TOKYO, V95, P423, DOI 10.1093/oxfordjournals.jbchem.a134623; MAREKOV LN, 1984, BIOCHEM BIOPH RES CO, V120, P782, DOI 10.1016/S0006-291X(84)80175-8; MASUJI H, 1974, ACTA MED OKAYAMA, V28, P281; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; OUDET P, 1989, METHOD ENZYMOL, V170, P15; SAMBROOK J, 1985, EMBO J, V4, P91, DOI 10.1002/j.1460-2075.1985.tb02322.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT A, 1985, NATURE, V314, P286, DOI 10.1038/314286a0; SCOVELL WM, 1987, BIOCHEM BIOPH RES CO, V142, P826, DOI 10.1016/0006-291X(87)91488-4; SEYEDIN SM, 1979, J BIOL CHEM, V254, P1264; SHIRAKAWA H, 1990, BIOCHEMISTRY-US, V29, P4419, DOI 10.1021/bi00470a022; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; STELZER G, 1994, MOL CELL BIOL, V14, P4712, DOI 10.1128/MCB.14.7.4712; STROS M, 1987, EUR J BIOCHEM, V162, P111, DOI 10.1111/j.1432-1033.1987.tb10549.x; TENG CS, 1979, BIOCHEM J, V181, P585, DOI 10.1042/bj1810585; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; TREMETHICK DJ, 1988, NUCLEIC ACIDS RES, V16, P11107, DOI 10.1093/nar/16.23.11107; TSUDA K, 1988, BIOCHEMISTRY-US, V27, P6159, DOI 10.1021/bi00416a050; van Holde KE., 1989, SPRINGER SERIES MOL; VIDALI G, 1977, CELL, V12, P409, DOI 10.1016/0092-8674(77)90117-9; WAGA S, 1990, J BIOL CHEM, V265, P19424; WAGA S, 1989, BIOCHIM BIOPHYS ACTA, V1007, P209, DOI 10.1016/0167-4781(89)90041-9; WAGA S, 1988, BIOCHEM BIOPH RES CO, V153, P334, DOI 10.1016/S0006-291X(88)81227-0; WATT F, 1988, NUCLEIC ACIDS RES, V16, P1471, DOI 10.1093/nar/16.4.1471; YOSHIDA M, 1984, J BIOCHEM-TOKYO, V95, P117, DOI 10.1093/oxfordjournals.jbchem.a134573	51	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9272	9280		10.1074/jbc.270.16.9272	http://dx.doi.org/10.1074/jbc.270.16.9272			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721847				2022-12-25	WOS:A1995QU08900035
J	YLANNE, J; HUUSKONEN, J; OTOOLE, TE; GINSBERG, MH; VIRTANEN, I; GAHMBERG, CG				YLANNE, J; HUUSKONEN, J; OTOOLE, TE; GINSBERG, MH; VIRTANEN, I; GAHMBERG, CG			MUTATION OF THE CYTOPLASMIC DOMAIN OF THE INTEGRIN BETA(3) SUBUNIT - DIFFERENTIAL-EFFECTS ON CELL SPREADING, RECRUITMENT TO ADHESION PLAQUES, ENDOCYTOSIS, AND PHAGOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PLATELET GPIIB-IIIA; FIBRONECTIN RECEPTOR; EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; LIGAND-BINDING; MOLECULES CD11; ALPHA-ACTININ; PROTEIN; MODULATION	The cytoplasmic domain of the beta subunit of the alpha(IIb)beta(3) integrin is required for cell spreading on fibrinogen, Here we report that deletion of six amino acids from the COOH terminus of the beta(3) (I(757)TYRGT) totally abolished cell spreading and formation of adhesion plaques, whereas retaining Ile(757) partially preserved these functions, We further found that substitution of Tyr(747) with Ala also abolished alpha(IIb)beta(3)-mediated cell spreading. The effects of these and other mutations on additional functions of alpha(IIb)beta(3) were also studied. Progressive truncations of beta(3), in which stop codons were inserted at amino acid positions 759-756, caused partial defects in the recruitment of alpha(IIb)beta(3) to preestablished adhesion plaques and a gradual decrease in the ability of alpha(IIb)beta(3) to mediate internalization of fibrinogen-coated particles, The Tyr(747) --> Ala substitution mutant was almost totally inactive in both of these assays, Point mutations at Tyr(769), and at a conserved area close to the transmembrane domain of beta(3), decreased integrin recruitment to preestablished adhesion plaques but allowed alpha(IIb)beta(3)-mediated formation of these structures and partial cell spreading, Deletion of the cytoplasmic domain of beta(3) did not affect the constitutive endocytosis of alpha(IIb)beta(3).	UNIV HELSINKI, DEPT ANAT, SF-00014 HELSINKI, FINLAND; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA USA	University of Helsinki; Scripps Research Institute	YLANNE, J (corresponding author), UNIV HELSINKI, DEPT BIOSCI, DIV BIOCHEM, POB 5, UNIONINKATU 35, SF-00014 HELSINKI, FINLAND.		Gahmberg, Carl/AAE-1876-2019; O'Toole, Timothy/I-4172-2013	Ylanne, Jari/0000-0003-4627-021X; Gahmberg, Carl/0000-0001-9892-9296	NHLBI NIH HHS [HL28235, HL48728] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028235, P01HL048728] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ARNAOUT MA, 1990, BLOOD, V75, P1037; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FATH KR, 1989, J CELL SCI, V92, P67; GBARAH A, 1991, INFECT IMMUN, V59, P4524, DOI 10.1128/IAI.59.12.4524-4530.1991; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HOGG N, 1991, CHEM IMMUNOL, V50, P1; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Isberg Ralph R., 1994, Trends in Microbiology, V2, P10, DOI 10.1016/0966-842X(94)90338-7; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; PATARROYO M, 1990, IMMUNOL REV, V114, P67, DOI 10.1111/j.1600-065X.1990.tb00562.x; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sambrook J, 1989, MOL CLONING LABORATO; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAPLEY P, 1989, ONCOGENE, V4, P325; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; YLANNE J, 1989, INT J CANCER, V43, P1126, DOI 10.1002/ijc.2910430628; YLANNE J, 1988, BLOOD, V72, P1478	51	122	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9550	9557						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721884				2022-12-25	WOS:A1995QU08900073
J	VALENZUELA, DM; ROJAS, E; GRIFFITHS, JA; COMPTON, DL; GISSER, M; IP, NY; GOLDFARB, M; YANCOPOULOS, GD				VALENZUELA, DM; ROJAS, E; GRIFFITHS, JA; COMPTON, DL; GISSER, M; IP, NY; GOLDFARB, M; YANCOPOULOS, GD			IDENTIFICATION OF FULL-LENGTH AND TRUNCATED FORMS OF EHK-3, A NOVEL MEMBER OF THE EPH RECEPTOR TYROSINE KINASE FAMILY	ONCOGENE			English	Article						RECEPTOR TYROSINE KINASE; EPH GENE FAMILY; EHK-3; NEURAL EXPRESSION	RAT TRKC; PROTEIN; GENE; ENCODES; NEUROTROPHIN-3; HINDBRAIN; MOUSE	Factors that bind and activate receptor tyrosine kinases are known to play key roles during development and in the adult, The Eph-related receptors constitute the largest known family of receptor tyrosine kinases, Members of the Eph family exhibit intriguing patterns of expression in the embryo, implicating them in a variety of developmental processes, and their expression is often restricted to particular subpopulations of postmitotic neurons in the adult, We describe the identification and characterization of a novel member of the Eph receptor family, which we have termed Ehk-3 for Eph Homologous Kinase 3, Ehk-3 displays all the major structural features shared by other members of the Eph family, including a cysteine-rich region and tandem fibronectin type-III domains in its extracellular portion, Ehk-3 is expressed in two forms in a developmentally-regulated fashion: a conventional full-length version containing the intracellular tyrosine kinase domain, as well as a truncated form that lacks this domain, Both forms of Ehk-3 are quite restricted to the nervous system in the adult, but Ehk-3 is more widely expressed in the embryo, suggesting that Ehk-3 mediates different functions during development and in the adult.			VALENZUELA, DM (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.							BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; FROHMAN MA, 1990, PCR PROTOCOLS; GILARDIHEBENSTREIT, 1992, ONCOGENE, V7, P2499; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NIETO MA, 1992, DEVELOPMENT, V116, P1137; SAJJADI FG, 1991, NEW BIOL, V3, P769; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9	21	49	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1573	1580						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731712				2022-12-25	WOS:A1995QU68100013
J	LAMANDE, SR; CHESSLER, SD; GOLUB, SB; BYERS, PH; CHAN, D; COLE, WG; SILLENCE, DO; BATEMAN, JF				LAMANDE, SR; CHESSLER, SD; GOLUB, SB; BYERS, PH; CHAN, D; COLE, WG; SILLENCE, DO; BATEMAN, JF			ENDOPLASMIC RETICULUM-MEDIATED QUALITY-CONTROL OF TYPE-I COLLAGEN PRODUCTION BY CELLS FROM OSTEOGENESIS IMPERFECTA PATIENTS WITH MUTATIONS IN THE PRO-ALPHA-1(I) CHAIN CARBOXYL-TERMINAL PROPEPTIDE WHICH IMPAIR SUBUNIT ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; PROTEIN DISULFIDE ISOMERASE; BINDING-PROTEIN; FRAMESHIFT MUTATION; LUNG FIBROBLASTS; MESSENGER-RNA; BREFELDIN-A; PROCOLLAGEN; GENE; ASSOCIATION	A heterozygous single base change in exon 49 of COL1A1, which converted the codon for pro alpha 1(I) carboxyl-terminal propeptide residue 94 from tryptophan (TGG) to cysteine (TGT) was identified in a baby with lethal osteogenesis imperfecta (OI64). The C-propeptide mutations in OI64 and in another lethal osteogenesis imperfecta cell strain (OI26), which has a frameshift mutation altering the sequence of the carboxyl-terminal half of the propeptide (Bateman, J. F., Lamande, S. R., Dahl, H.-H. M., Chan, D., Mascara, T. and Cole, W. G. (1989) J. Biol. Chem. 264, 10960-10964), disturbed procollagen folding and retarded ri,he formation of disulfide-linked trimers. Although assembly was delayed, the presence of slowly migrating, overmodified alpha 1(I) and alpha 2(I) chains indicated that mutant pro alpha 1(I) could associate with normal pro alpha 1(I) and pro alpha 2(I) to form pepsin-resistant triple-helical molecules, a proportion of which were secreted. Further evidence of the aberrant folding of mutant procollagen in OI64 and OI26 was provided by experiments demonstrating that the endoplasmic reticulum resident molecular chaperone BiP, which binds to malfolded proteins, was specifically bound to type I procollagen and was coimmunoprecipitated in the osteogenesis imperfecta cells but not control cells. Experiments with brefeldin A, which inhibits protein export from the endoplasmic reticulum, demonstrated that unassembled mutant pro alpha 1(I) chains were selectively degraded within the endoplasmic reticulum resulting in reduced collagen production by the osteogenesis imperfecta cells. This biosynthetic deficiency was reflected in the inability of OI64 and OI26 cells to produce a substantial in vitro collagenous matrix when grown in the continuous presence of ascorbic acid to allow collagen matrix formation. Both these carboxyl-terminal propeptide mutants showed a marked reduction in collagen accumulation to 20% (or less) of control cultures, comparable to the reduced collagen content of tissues from OI26.	UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT PAEDIAT,ORTHOPAED MOLEC BIOL RES UNIT,PARKVILLE,VIC 3052,AUSTRALIA; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; CHILDRENS HOSP,DEPT GENET,CAMPERDOWN,NSW 2050,AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			; Chan, Danny/C-4203-2009	Lamande, Shireen/0000-0003-2938-2711; Byers, Peter H./0000-0001-7786-7030; Bateman, John/0000-0001-8542-0730; Chan, Danny/0000-0003-3824-5778				BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; BARILE FA, 1990, ARCH BIOCHEM BIOPHYS, V276, P125, DOI 10.1016/0003-9861(90)90018-T; Bateman J F, 1988, Ann N Y Acad Sci, V543, P95, DOI 10.1111/j.1749-6632.1988.tb55321.x; BATEMAN JF, 1989, J BIOL CHEM, V264, P10960; BATEMAN JF, 1986, BIOCHEM J, V240, P699, DOI 10.1042/bj2400699; BATEMAN JF, 1988, ANAL BIOCHEM, V168, P171, DOI 10.1016/0003-2697(88)90025-5; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; BATEMAN JF, 1994, MATRIX BIOL, V14, P251, DOI 10.1016/0945-053X(94)90189-9; BECKERANDRE M, 1989, NUCLEIC ACIDS RES, V17, P9437, DOI 10.1093/nar/17.22.9437; BERG RA, 1973, BIOCHEMISTRY-US, V12, P3395, DOI 10.1021/bi00742a005; BERG RA, 1980, P NATL ACAD SCI-BIOL, V77, P4746, DOI 10.1073/pnas.77.8.4746; BERG RA, 1984, BIOCHEMISTRY-US, V23, P2143; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P1139, DOI 10.1021/bi00274a023; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; CHAN D, 1990, BIOCHEM J, V269, P175, DOI 10.1042/bj2690175; CHESSLER SD, 1992, J BIOL CHEM, V267, P7751; CHESSLER SD, 1993, J BIOL CHEM, V268, P18218; CHESSLER SD, 1993, J BIOL CHEM, V268, P18226; COLE WG, 1990, J MED GENET, V27, P545, DOI 10.1136/jmg.27.9.545; COLE WG, 1981, BIOCHEM J, V197, P377, DOI 10.1042/bj1970377; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; Fisher L. W., 1989, CONNECT TISSUE RES, V21, P43; FISHER LW, 1987, J BIOL CHEM, V262, P13457; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Higuchi R, 1989, PCR TECHNOLOGY PRINC, P31; JIMENEZ SA, 1978, J BIOL CHEM, V253, P1420; KAO WWY, 1977, J BIOL CHEM, V252, P8391; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOSEN PA, 1982, BIOCHEMISTRY-US, V21, P4278, DOI 10.1021/bi00261a016; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NOIVA R, 1992, J BIOL CHEM, V267, P3553; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PIHLAJANIEMI T, 1984, J BIOL CHEM, V259, P2941; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; RIPLEY CR, 1993, J BIOL CHEM, V268, P3677; SILLENCE DO, 1979, J MED GENET, V16, P101, DOI 10.1136/jmg.16.2.101; STARMAN BJ, 1989, J CLIN INVEST, V84, P1206, DOI 10.1172/JCI114286; WAKE SA, 1985, BIOCHEM J, V228, P425, DOI 10.1042/bj2280425; WILLING MC, 1990, J CLIN INVEST, V85, P282, DOI 10.1172/JCI114424; WU H, 1990, MOL CELL BIOL, V10, P1452, DOI 10.1128/MCB.10.4.1452	50	120	120	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8642	8649		10.1074/jbc.270.15.8642	http://dx.doi.org/10.1074/jbc.270.15.8642			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721766	hybrid			2022-12-25	WOS:A1995QT44800043
J	LEE, CH; MURAKAMI, T; SIMONDS, WF				LEE, CH; MURAKAMI, T; SIMONDS, WF			IDENTIFICATION OF A DISCRETE REGION OF THE G-PROTEIN GAMMA-SUBUNIT CONFERRING SELECTIVITY IN BETA-GAMMA COMPLEX-FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; INFECTED INSECT CELLS; LIMITED PROTEOLYSIS; COILED-COIL; TRANSDUCIN; DIMERS; PURIFICATION; EXPRESSION; SEQUENCE; BRAIN	The identification of multiple G protein beta and gamma subunit subtypes suggests a potential diversity of beta gamma heterodimers, which may contribute to the specificity of signal transduction between receptors and effecters. The assembly of beta and gamma subtypes is selective. For example, gamma(1) can assemble with beta(1) but not with beta(2), whereas gamma(2) assembles with both beta isoforms. To identify the structural features of the beta and gamma subunits governing selectivity in heterodimer assembly, a series of nonisoprenylated chimeras of gamma(1) and gamma 2 was constructed, and their interaction with beta(1) and beta(2) was assessed by their ability to direct beta expression to the cytosol in cotransfected COS cells. All of the gamma(1)/gamma(2) chimeras were capable of interacting with beta(1) as judged by the cotransfection assay. Chimeras containing gamma(2) sequence near the middle of the molecule between two conserved sequence motifs were capable of interacting as well with beta(2). Among 12 divergent residues in this region, it was found that replacement of three consecutive amino acids in gamma(1), Glu-Glu-Phe (residues 38-40), with the three corresponding amino acids of gamma(2), Ala-Asp-Leu (residues 35-37), conferred the ability to assemble with beta(2). The reciprocal chimera containing Glu-Glu-Phe in the context of gamma(2) failed to assemble with beta(2). The last residue of this triplet is occupied by a leucine in all known mammalian gamma subunits except gamma(1) and appears to be a key determinant of the ability of a gamma subunit to assemble with beta(2). This locus maps to a region of predicted alpha-helical structure in the gamma subunit, likely to represent a point of physical contact with the beta subunit.	NIDDK,METAB DIS BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BUBIS J, 1990, J BIOL CHEM, V265, P12995; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIETRICH A, 1994, EUR J BIOCHEM, V219, P171, DOI 10.1111/j.1432-1033.1994.tb19927.x; DIETRICH A, 1992, FEBS LETT, V313, P220, DOI 10.1016/0014-5793(92)81195-R; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FUNG BKK, 1992, J BIOL CHEM, V267, P24782; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; GRABER SG, 1992, J BIOL CHEM, V267, P13123; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PRONIN AN, 1993, FEBS LETT, V328, P89, DOI 10.1016/0014-5793(93)80971-V; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROBISHAW JD, 1992, BIOCHEM J, V286, P677, DOI 10.1042/bj2860677; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SPIEGEL AM, 1994, G PROTEINS, P1; SPRING DJ, 1994, J BIOL CHEM, V269, P22882; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; TAO L, 1993, EXP EYE RES, V56, P497, DOI 10.1006/exer.1993.1063; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8628, DOI 10.1021/bi00084a034; UEDA N, 1994, J BIOL CHEM, V269, P4388; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571	52	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8779	8784		10.1074/jbc.270.15.8779	http://dx.doi.org/10.1074/jbc.270.15.8779			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721784	hybrid			2022-12-25	WOS:A1995QT44800062
J	MACDONALD, GM; STEENHUIS, JJ; BARRY, BA				MACDONALD, GM; STEENHUIS, JJ; BARRY, BA			A DIFFERENCE FOURIER-TRANSFORM INFRARED SPECTROSCOPIC STUDY OF CHLOROPHYLL OXIDATION IN HYDROXYLAMINE-TREATED PHOTOSYSTEM-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; ELECTRON-PARAMAGNETIC RESONANCE; PRIMARY QUINONE ACCEPTOR; NORMAL MODE DESCRIPTIONS; WATER-OXIDIZING COMPLEX; RHODOBACTER-SPHAEROIDES; REACTION CENTERS; RHODOPSEUDOMONAS-VIRIDIS; SPINACH-CHLOROPLASTS; EPR CHARACTERIZATION	In oxygenic photosynthesis, photosystem II is the chlorophyll-containing reaction center that carries out the light-induced transfer of electrons from water to plastoquinone. Fourier transform infrared spectroscopy can be used to obtain information about the structural changes that accompany electron transfer in photosystem II. The vibrational difference spectrum associated with the reduction of photosystem II acceptor quinones is of interest. Previously, a high concentration of the photosystem II donor, hydroxylamine, has been used to obtain a spectrum attributed to Q(A-) - Q(A) (Berthomieu, C., Nabedryk, E., Mantele, W. and Breton, J. FEBS Lett. (1990) 269, 363). Here, we use electron paramagnetic resonance, Fourier transform infrared spectroscopy, and N-15 isotopic labeling to show that the difference infrared spectrum, obtained under these conditions, also exhibits a contribution from the oxidation of chlorophyll.	UNIV MINNESOTA,DEPT BIOCHEM,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043273, T32GM008277] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43273, GM08277] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAGA C, 1993, BIOCHIM BIOPHYS ACTA, V1142, P36, DOI 10.1016/0005-2728(93)90081-P; ARNON DI, 1988, P NATL ACAD SCI USA, V85, P9524, DOI 10.1073/pnas.85.24.9524; BABCOCK GT, 1983, BIOCHIM BIOPHYS ACTA, V723, P276, DOI 10.1016/0005-2728(83)90127-5; BARRY BA, 1987, P NATL ACAD SCI USA, V84, P7099, DOI 10.1073/pnas.84.20.7099; BARRY BA, 1993, PHOTOCHEM PHOTOBIOL, V57, P179, DOI 10.1111/j.1751-1097.1993.tb02275.x; BERNARD MT, 1995, J BIOL CHEM, V270, P1589, DOI 10.1074/jbc.270.4.1589; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BERTHOMIEU C, 1992, BIOCHEMISTRY-US, V31, P11460, DOI 10.1021/bi00161a026; BERTHOMIEU C, 1990, FEBS LETT, V269, P363, DOI 10.1016/0014-5793(90)81194-S; BERTHOMIEU C, 1992, RES PHOTOSYNTHESIS, V2, P53; BOLDT NJ, 1987, J AM CHEM SOC, V109, P2284, DOI 10.1021/ja00242a009; BOUGES B, 1971, BIOCHIM BIOPHYS ACTA, V234, P103, DOI 10.1016/0005-2728(71)90135-6; BOUGESBOCQUET B, 1973, BIOCHIM BIOPHYS ACTA, V292, P772, DOI 10.1016/0005-2728(73)90024-8; BUSER CA, 1992, BIOCHEMISTRY-US, V31, P11441, DOI 10.1021/bi00161a024; BUSER CA, 1992, BIOCHEMISTRY-US, V31, P11449, DOI 10.1021/bi00161a025; BUSER CA, 1990, BIOCHEMISTRY-US, V29, P8977, DOI 10.1021/bi00490a014; CANAANI O, 1990, P NATL ACAD SCI USA, V87, P9295, DOI 10.1073/pnas.87.23.9295; CHENIAE GM, 1971, PLANT PHYSIOL, V47, P568, DOI 10.1104/pp.47.4.568; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; DEPAULA JC, 1986, BIOCHEMISTRY-US, V25, P6487, DOI 10.1021/bi00369a022; DEPAULA JC, 1985, BIOCHEMISTRY-US, V24, P8114, DOI 10.1021/bi00348a042; DEROSE VJ, 1991, BIOCHEMISTRY-US, V30, P1335, DOI 10.1021/bi00219a025; DONOHOE RJ, 1988, PHOTOCHEM PHOTOBIOL, V48, P531, DOI 10.1111/j.1751-1097.1988.tb02857.x; EVANS MCW, 1982, BIOCHIM BIOPHYS ACTA, V682, P97, DOI 10.1016/0005-2728(82)90123-2; GHANOTAKIS DF, 1983, FEBS LETT, V153, P231, DOI 10.1016/0014-5793(83)80154-9; GRESE RP, 1990, J AM SOC MASS SPECTR, V1, P72, DOI 10.1016/1044-0305(90)80008-B; HEBER U, 1979, BIOCHIM BIOPHYS ACTA, V546, P292, DOI 10.1016/0005-2728(79)90047-1; HOFF AJ, 1987, PHOTOSYNTHESIS NEW C, V15, P97; HOGANSON CW, 1989, BIOCHEMISTRY-US, V28, P1448, DOI 10.1021/bi00430a004; KRETSCHMANN H, 1991, BIOCHIM BIOPHYS ACTA, V1059, P208, DOI 10.1016/S0005-2728(05)80205-1; LEONHARD M, 1993, BIOCHEMISTRY-US, V32, P4532, DOI 10.1021/bi00068a007; MACDONALD GM, 1992, BIOCHEMISTRY-US, V31, P9848, DOI 10.1021/bi00155a043; MACDONALD GM, 1993, P NATL ACAD SCI USA, V90, P11024, DOI 10.1073/pnas.90.23.11024; MACDONALD GM, 1994, BIOCHEMISTRY-US, V33, P4393, DOI 10.1021/bi00180a037; MANTELE WG, 1988, P NATL ACAD SCI USA, V85, P8468, DOI 10.1073/pnas.85.22.8468; MESSINGER J, 1991, BIOCHEMISTRY-US, V30, P7852, DOI 10.1021/bi00245a027; METZ JG, 1989, BIOCHEMISTRY-US, V28, P6960, DOI 10.1021/bi00443a028; MILLER AF, 1991, BIOCHIM BIOPHYS ACTA, V1056, P1, DOI 10.1016/S0005-2728(05)80067-2; NABEDRYK E, 1990, BIOCHEMISTRY-US, V29, P3242, DOI 10.1021/bi00465a015; NABEDRYK E, 1990, FEBS LETT, V266, P59, DOI 10.1016/0014-5793(90)81506-J; NABEDRYK E, 1992, BIOCHEMISTRY-US, V31, P10852, DOI 10.1021/bi00159a028; NOGUCHI T, 1993, BIOCHIM BIOPHYS ACTA, V1143, P333, DOI 10.1016/0005-2728(93)90205-T; NOGUCHI T, 1992, BIOCHEMISTRY-US, V31, P5953, DOI 10.1021/bi00141a001; NOREN GH, 1991, BIOCHEMISTRY-US, V30, P3943, DOI 10.1021/bi00230a020; NOREN GH, 1992, BIOCHEMISTRY-US, V31, P3335, DOI 10.1021/bi00128a005; NUGENT JHA, 1981, FEBS LETT, V124, P241, DOI 10.1016/0014-5793(81)80146-9; PALANIAPPAN V, 1993, J AM CHEM SOC, V115, P12035, DOI 10.1021/ja00078a048; PETERSEN J, 1990, BIOCHEMISTRY-US, V29, P3226, DOI 10.1021/bi00465a012; RADMER R, 1982, FEBS LETT, V144, P162, DOI 10.1016/0014-5793(82)80592-9; RIGBY SEJ, 1994, BIOCHEMISTRY-US, V33, P10043, DOI 10.1021/bi00199a031; ROGNER M, 1990, J BIOL CHEM, V265, P6189; RUTHERFORD AW, 1983, FEBS LETT, V154, P328, DOI 10.1016/0014-5793(83)80176-8; RUTHERFORD AW, 1984, BIOCHIM BIOPHYS ACTA, V767, P168, DOI 10.1016/0005-2728(84)90092-6; SIVARAJA M, 1988, BIOCHEMISTRY-US, V27, P3467, DOI 10.1021/bi00409a051; THIBODEAU DL, 1990, BIOCHIM BIOPHYS ACTA, V1020, P253, DOI 10.1016/0005-2728(90)90155-W; THOMPSON LK, 1988, BIOCHEMISTRY-US, V27, P6653, DOI 10.1021/bi00418a002; WERTZ JE, 1986, ELECTRON SPIN RESON, P462; YOCUM CF, 1981, P NATL ACAD SCI-BIOL, V78, P7507, DOI 10.1073/pnas.78.12.7507	59	35	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8420	8428		10.1074/jbc.270.15.8420	http://dx.doi.org/10.1074/jbc.270.15.8420			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721736	hybrid			2022-12-25	WOS:A1995QT44800012
J	EKSTRAND, AJ; LIU, L; HE, J; HAMID, ML; LONGO, N; COLLINS, VP; JAMES, CD				EKSTRAND, AJ; LIU, L; HE, J; HAMID, ML; LONGO, N; COLLINS, VP; JAMES, CD			ALTERED SUBCELLULAR LOCATION OF AN ACTIVATED AND TUMOR-ASSOCIATED EPIDERMAL GROWTH-FACTOR RECEPTOR	ONCOGENE			English	Note						GLIO BLASTOMA; TYROSINE KINASE; ONCOGENE; ENDOPLASMIC RETICULUM; EGF-BINDING; CONFOCAL MICROSCOPY	AVIAN ERYTHROBLASTOSIS VIRUS; HUMAN-BRAIN-TUMORS; PROTEIN KINASE-C; B GENE-PRODUCT; EGF RECEPTOR; SIGNAL TRANSDUCTION; HUMAN GLIOBLASTOMAS; PLASMA-MEMBRANE; HUMAN GLIOMAS; CELL-SURFACE	The epidermal growth factor (EGF) receptor is a membrane bound tyrosine kinase whose activity is initiated by ligand binding, The malignant brain tumour glioblastoma frequently shows amplification and rearrangements of the EGF receptor gene that are associated with the synthesis of a constitutively activated tyrosine kinase, lacking amino acids 6-273 near the protein's N-terminus, When expressed in Chinese hamster ovary (CHO) cells, this mutant receptor (p140(EGFR)) displays ligand-independent tyrosine kinase activity, stimulates DNA synthesis, and promotes cell proliferation, Here, we investigate the subcellular location of p140(EGFR) in CHO cell transfectants as web as in human glioblastoma tumours, p140(EGFR) had an intracellular location that contrasted sharply with the plasma membrane location of the wild-type EGF receptor, Endoglycosidase H sensitivity analysis and the pattern of p140(EGFR) immunoreactivity suggested that the aberrant tyrosine kinase resided primarily in the endoplasmic reticulum, The half-life of p140(EGFR) in, the endoplasmic reticulum was extended several-fold over that of the ligand-activated wild-type receptor, The altered subcellular location of p140(EGFR) in combination with its prolonged half-life suggest that this activated tyrosine kinase may escape the regulatory mechanisms utilized for the attenuation of wild-type receptor signaling, Therefore, the previously reported growth stimulatory property of the ligand-independent p140(EGFR) may be attributed to a sustained tyrosine kinase activity resulting from an altered subcellular location.	EMORY UNIV, SCH MED, DEPT NEUROSURG, MOLEC NEUROONCOL LAB, ATLANTA, GA 30322 USA; KAROLINSKA HOSP, LUDWIG INST CANC RES, S-17176 STOCKHOLM, SWEDEN; KAROLINSKA HOSP, DEPT PATHOL & ONCOL, S-17176 STOCKHOLM, SWEDEN; EMORY UNIV, SCH MED, DEPT PEDIAT, DIV MED GENET, ATLANTA, GA 30322 USA	Emory University; Karolinska Institutet; Karolinska University Hospital; Ludwig Institute for Cancer Research; Karolinska Institutet; Karolinska University Hospital; Emory University			James, Charles D/E-2721-2012	James, Charles D/0000-0002-1027-203X	NATIONAL CANCER INSTITUTE [R01CA055728] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55728] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BOHMER FD, 1993, FEBS LETT, V331, P276, DOI 10.1016/0014-5793(93)80352-U; BOWEN S, 1991, J BIOL CHEM, V266, P1162; COCHET C, 1984, J BIOL CHEM, V259, P2553; CUMMINGS RD, 1985, J BIOL CHEM, V260, P1944; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DUNPHY WG, 1983, J CELL BIOL, V97, P270, DOI 10.1083/jcb.97.1.270; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; FAURE R, 1992, J BIOL CHEM, V267, P11215; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FOOD MR, 1994, J BIOL CHEM, V269, P3034; GILMORE T, 1985, CELL, V40, P609, DOI 10.1016/0092-8674(85)90209-0; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HAYMAN MJ, 1984, NATURE, V309, P460, DOI 10.1038/309460a0; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MAYES ELV, 1984, EMBO J, V3, P531, DOI 10.1002/j.1460-2075.1984.tb01842.x; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISTER M, 1988, CANCER RES, V48, P3910; PRIVALSKY ML, 1984, VIROLOGY, V135, P356, DOI 10.1016/0042-6822(84)90192-2; SCHATZMAN RC, 1986, MOL CELL BIOL, V6, P1329, DOI 10.1128/MCB.6.4.1329; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; YAMAZAKI H, 1990, JPN J CANCER RES, V81, P773, DOI 10.1111/j.1349-7006.1990.tb02644.x	39	43	47	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1455	1460						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731699				2022-12-25	WOS:A1995QR65100026
J	HIGASHINO, F; YOSHIDA, K; NOUMI, T; SEIKI, M; FUJINAGA, K				HIGASHINO, F; YOSHIDA, K; NOUMI, T; SEIKI, M; FUJINAGA, K			ETS-RELATED PROTEIN E1A-F CAN ACTIVATE 3 DIFFERENT MATRIX METALLOPROTEINASE GENE PROMOTERS	ONCOGENE			English	Note						ETS; MMP; INVASION; TRANSCRIPTION	COLLAGENASE GENE; MAMMALIAN-CELLS; ONCOGENE FAMILY; BINDING-SITES; EXPRESSION; PEA3; FOS; AP-1; TRANSCRIPTION; ELEMENTS	An Ets-related E1A-F has been characterized as an enhancer-binding protein for the adenovirus E1A gene, Here we show, in transient expression assays, that E1A-F can activate three different subclasses of the matrix metalloproteinase gene promoters, Expressions of the chloramphenicol acetyltransferase (CAT) reporter gene under the control of stromelysin, type I collagenase and 92 kD type IV collagenase promoters were increased approximately 10- to 20-fold by co-transfection with the E1A-F expression vector. Activation levels were as much high as those obtained by exogenous expression of AP-1 transcription factor. These results suggest that EIA-F positively regulates transcriptions from matrix metalloproteinase genes that are associated with invasion and metastasis of tumor cells.	SAPPORO MED UNIV, SCH MED, CANC RES INST, DEPT BIOL MOLEC, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN; OKAYAMA UNIV, FAC ENGN SCI, DEPT BIOTECHNOL, OKAYAMA 700, JAPAN; KANAZAWA UNIV, CANC RES INST, DEPT MOLEC ONCOL & VIROL, KANAZAWA, ISHIKAWA 920, JAPAN	Sapporo Medical University; Okayama University; Kanazawa University			Higashino, Fumihiro/F-8510-2012; Seiki, Motoharu/K-9443-2015					ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1989, NATURE, V284, P67; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; NAKAJIMA M, 1987, CANCER RES, V47, P4869; NERLOV C, 1991, ONCOGENE, V6, P1583; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; POWELL WC, 1993, CANCER RES, V53, P417; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SATO H, 1993, ONCOGENE, V8, P395; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YOSHIDA K, 1989, NUCLEIC ACIDS RES, V17, P10015, DOI 10.1093/nar/17.23.10015	29	149	153	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1461	1463						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731700				2022-12-25	WOS:A1995QR65100027
J	YAMAMORI, B; KURODA, S; SHIMIZU, K; FUKUI, K; OHTSUKA, T; TAKAI, Y				YAMAMORI, B; KURODA, S; SHIMIZU, K; FUKUI, K; OHTSUKA, T; TAKAI, Y			PURIFICATION OF A RAS-DEPENDENT MITOGEN-ACTIVATED PROTEIN-KINASE KINASE KINASE FROM BOVINE BRAIN CYTOSOL AND ITS IDENTIFICATION AS A COMPLEX OF B-RAF AND 14-13-3-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; XENOPUS-OOCYTES; DOWNSTREAM; DEFINITION; EXPRESSION; INVITRO; C-RAF-1; REGION; FAMILY	We previously purified a protein factor, named REKS (Ras-dependent Extracellular Signal-regulated Kinase (ERK)/mitogen-activated protein kinase Kinase (MEK) Stimulator), from Xenopus eggs by use of a cell-free assay system in which recombinant GTP gamma S (guanosine 5'-(3-O-thio)triphosphate) -Ki-Ras activates recombinant MEK. By use of this assay system, we purified here bovine REKS to near homogeneity from the cytosol fraction of bovine brain by successive chromatographies of Mono S, Mono Q, GTP gamma S-glutathione S-transferase-Ha-Ras-coupled glutathione-agarose, and Mono Q columns. It was composed of three proteins with masses of about 95, 32, and 30 kDa as estimated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The 95-, 32-, and 30-kDa proteins were identified by immunoblot analysis to be B-Raf protein kinase, 14-3-3 protein, and 14-3-3 protein, respectively. Moreover, the REKS activity was specifically immunoprecipitated by an anti-B-Raf antibody. Bovine REKS was activated by lipid-modified GTP gamma S-Ki-Ras far more effectively than by a lipid-unmodified one. Lipid-modified GDP-Ki-Ras was inactive. Exogenous addition of 14-3-3 proteins stimulated further the REKS activity both in the presence and absence of GTP gamma S-Ki-Ras. These results indicate that at least one of the direct targets of Ras is B-Raf complexed with 14-3-3 proteins in bovine brain.	OSAKA UNIV,SCH MED,DEPT MOLEC BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)			KURODA, SHINYA/G-4961-2014					AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CATLING AD, 1994, J BIOL CHEM, V269, P30014; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; ITOH T, 1993, J BIOL CHEM, V268, P3025; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KURODA S, 1995, J BIOL CHEM, V270, P2460, DOI 10.1074/jbc.270.6.2460; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STORM SM, 1990, ONCOGENE, V5, P345; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	45	97	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11723	11726		10.1074/jbc.270.20.11723	http://dx.doi.org/10.1074/jbc.270.20.11723			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744815	hybrid			2022-12-25	WOS:A1995QY73600006
J	SHIN, HJ; RHO, HM				SHIN, HJ; RHO, HM			RELEASE OF THE HEPATITIS-B VIRUS-ASSOCIATED DNA-POLYMERASE FROM THE VIRAL PARTICLE BY THE PROTEOLYTIC CLEAVAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PUTATIVE REVERSE-TRANSCRIPTASE; NUCLEOTIDE-SEQUENCE; READING FRAME; PROTEIN; GENE; REPLICATION; STRAND; MUTATIONS; PRIMER; GENOME	Previous efforts for biochemical study of the human hepatitis B virus (HBV) DNA polymerase have been limited by its tight association with viral nucleocapsids, We report here that the soluble DNA polymerase from HBV particles was obtained by low pH treatment of the viral particles followed by incubation with small amounts of subtilisin, By these treatments, the similar to 100-kDa band in the activity gel assay was gradually converted to similar to 70 kDa, which subsequently showed reverse transcriptase activity on several exogenous templates. The single similar to 70-kDa active band, which did not show any DNA polymerase activity in endogenous reaction, was eluted through DEAE-Sepharose chromatography, These results suggest that the similar to 100-kDa protein, most likely the product of HBV Pol open reading frame, is tightly associated with viral nucleocapsids, and the similar to 70-kDa protein, the proteolytic cleavage product of similar to 100-kDa enzyme, is solubilized from viral particles as an active enzyme on exogenous templates.	SEOUL NATL UNIV,COLL NAT SCI,DEPT MOLEC BIOL,SEOUL 151742,SOUTH KOREA; SEOUL NATL UNIV,COLL NAT SCI,CELL DIFFERENTIAT RES CTR,SEOUL 151742,SOUTH KOREA	Seoul National University (SNU); Seoul National University (SNU)								BAVAND M, 1989, J VIROL, V63, P1019, DOI 10.1128/JVI.63.2.1019-1021.1989; BAVAND MR, 1988, J VIROL, V62, P626, DOI 10.1128/JVI.62.2.626-628.1988; CHANG LJ, 1990, J VIROL, V64, P5553, DOI 10.1128/JVI.64.11.5553-5558.1990; CHANG LJ, 1989, NATURE, V337, P364, DOI 10.1038/337364a0; FARUQI AF, 1991, VIROLOGY, V183, P764, DOI 10.1016/0042-6822(91)91007-4; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GERLICH WH, 1980, CELL, V21, P801, DOI 10.1016/0092-8674(80)90443-2; GRANDGENETT DP, 1975, J VIROL, V15, P526, DOI 10.1128/JVI.15.3.526-533.1975; Heermann KH, 1991, MOL BIOL HEPATITIS B, P109; KAPLAN PM, 1973, J VIROL, V12, P995, DOI 10.1128/JVI.12.5.995-1005.1973; KIM SH, 1992, J GEN VIROL, V73, P2421, DOI 10.1099/0022-1317-73-9-2421; KIM SK, 1994, J GEN VIROL, V75, P917, DOI 10.1099/0022-1317-75-4-917; LEE HJ, 1993, BIOTECHNOL LETT, V15, P821; LI JS, 1989, J VIROL, V63, P4965, DOI 10.1128/JVI.63.11.4965-4968.1989; LIEN JM, 1986, J VIROL, V57, P229, DOI 10.1128/JVI.57.1.229-236.1986; MACK DH, 1988, J VIROL, V62, P4786, DOI 10.1128/JVI.62.12.4786-4790.1988; MANDART E, 1984, J VIROL, V49, P782, DOI 10.1128/JVI.49.3.782-792.1984; MOLNARKIMBER KL, 1983, J VIROL, V45, P165, DOI 10.1128/JVI.45.1.165-172.1983; OBERHAUS SM, 1993, J VIROL, V67, P6558, DOI 10.1128/JVI.67.11.6558-6566.1993; OU JH, 1990, J VIROL, V64, P4578, DOI 10.1128/JVI.64.9.4578-4581.1990; RADZIWILL G, 1988, VIROLOGY, V163, P123, DOI 10.1016/0042-6822(88)90239-5; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; RHO HM, 1989, NUCLEIC ACIDS RES, V17, P2124, DOI 10.1093/nar/17.5.2124; RHO HM, 1979, VIROLOGY, V99, P192, DOI 10.1016/0042-6822(79)90054-0; RHO HM, 1980, CANCER LETT, V10, P207, DOI 10.1016/0304-3835(80)90073-7; SCHLICHT HJ, 1989, CELL, V56, P85, DOI 10.1016/0092-8674(89)90986-0; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; Temin H M, 1972, Adv Virus Res, V17, P129, DOI 10.1016/S0065-3527(08)60749-6; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TOH H, 1983, NATURE, V305, P827, DOI 10.1038/305827a0; WANG GH, 1993, J VIROL, V67, P6507, DOI 10.1128/JVI.67.11.6507-6512.1993; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WEBER M, 1994, J VIROL, V68, P2994, DOI 10.1128/JVI.68.5.2994-2999.1994; WILL H, 1986, SCIENCE, V231, P594, DOI 10.1126/science.2418501; ZOULIM F, 1994, J VIROL, V68, P6, DOI 10.1128/JVI.68.1.6-13.1994	35	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11047	11050		10.1074/jbc.270.19.11047	http://dx.doi.org/10.1074/jbc.270.19.11047			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744734	hybrid			2022-12-25	WOS:A1995QX86500007
J	HAMAZAKI, H				HAMAZAKI, H			CA2+-DEPENDENT BINDING OF HUMAN SERUM AMYLOID-P COMPONENT TO ALZHEIMERS BETA-AMYLOID PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEPARAN-SULFATE; DISEASE; PROTEIN; CDNA; LOCALIZATION; DEPOSITS; PRECURSOR; PLAQUES; GENE	Serum amyloid P component (SAP), a normal glyco protein, is universally found in amyloid deposits, including cerebrovascular amyloid of Alzheimer's disease. This paper describes the Ca2+-dependent binding of human SAP to Alzheimer's beta-amyloid peptide (A beta). I-125-SAP binds to synthetic human A beta-(1-40) immobilized on microtiter plates at a dissociation constant of 6.0 x 10(-9) M in 0.01 M Tris-HCl, 0.15 M NaCl, pH 7.5, containing 2 mM Ca2+, 1% bovine serum albumin, and 0.05% Tween 20. Binding inhibition assay has shown that soluble A beta-(1-40) and A beta-(1-28) also bind to SAP. Since SAP is resistant to proteases in the presence of calcium, the Ca2+-dependent binding of SAP to soluble A beta and to beta-amyloid fibrils would give pathological effects on fibril formation and persistence of beta-amyloid in Alzheimer's disease.			HAMAZAKI, H (corresponding author), KITASATO UNIV,SCH MED,DEPT BIOL,SAGAMIHARA,KANAGAWA 228,JAPAN.							ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; BALTZ ML, 1986, CLIN EXP IMMUNOL, V66, P691; BUSH AI, 1994, J BIOL CHEM, V269, P12152; CORIA F, 1988, LAB INVEST, V58, P454; DALFERES ER, 1967, ARCH BIOCHEM BIOPHYS, V118, P284, DOI 10.1016/0003-9861(67)90350-5; EIKELENBOOM P, 1982, ACTA NEUROPATHOL, V57, P239, DOI 10.1007/BF00685397; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAMAZAKI H, 1987, J BIOL CHEM, V262, P1456; HAMAZAKI H, 1994, BIOCHEM BIOPH RES CO, V205, P1172, DOI 10.1006/bbrc.1994.2789; HAUPT H, 1972, H-S Z PHYSIOL CHEM, V353, P1841, DOI 10.1515/bchm2.1972.353.2.1841; HAWKINS PN, 1988, J EXP MED, V167, P903, DOI 10.1084/jem.167.3.903; HAWKINS PN, 1990, NEW ENGL J MED, V323, P508, DOI 10.1056/NEJM199008233230803; ISHII T, 1984, ACTA NEUROPATHOL, V36, P296; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KINOSHITA CM, 1992, PROTEIN SCI, V1, P700, DOI 10.1002/pro.5560010602; LADROR US, 1994, J BIOL CHEM, V269, P18422; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MANTZOURANIS EC, 1985, J BIOL CHEM, V260, P7752; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; NELSON SR, 1991, LANCET, V338, P335, DOI 10.1016/0140-6736(91)90478-8; OHNISHI S, 1986, J BIOCHEM-TOKYO, V100, P849, DOI 10.1093/oxfordjournals.jbchem.a121797; PENNOCK CA, 1968, NATURE, V217, P753, DOI 10.1038/217753a0; PEPYS MB, 1977, LANCET, V1, P1029; PEPYS MB, 1979, CLIN EXP IMMUNOL, V38, P284; PEPYS MB, 1988, Q J MED, V67, P283; PINTERIC L, 1979, CAN J BIOCHEM CELL B, V57, P727, DOI 10.1139/o79-091; PRELLI F, 1985, J BIOL CHEM, V260, P2895; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROZEMULLER JM, 1989, J NEUROPATH EXP NEUR, V48, P674, DOI 10.1097/00005072-198911000-00009; SCHWARZMAN AL, 1994, P NATL ACAD SCI USA, V91, P8368, DOI 10.1073/pnas.91.18.8368; SKINNER M, 1980, AMYLOID AMYLOIDOSIS, P384; SNOW AD, 1987, LAB INVEST, V56, P120; SNOW AD, 1988, AM J PATHOL, V133, P456; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; WOOD SP, 1988, J MOL BIOL, V202, P169, DOI 10.1016/0022-2836(88)90529-3	38	61	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10392	10394		10.1074/jbc.270.18.10392	http://dx.doi.org/10.1074/jbc.270.18.10392			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737971	hybrid			2022-12-25	WOS:A1995QW60100009
J	LEFEBVRE, P; GAUB, MP; TAHAYATO, A; ROCHETTEEGLY, C; FORMSTECHER, P				LEFEBVRE, P; GAUB, MP; TAHAYATO, A; ROCHETTEEGLY, C; FORMSTECHER, P			PROTEIN PHOSPHATASE-1 AND PHOSPHATASE-2A REGULATE THE TRANSCRIPTIONAL AND DNA-BINDING ACTIVITIES OF RETINOIC ACID RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; THYROID-HORMONE; GENE-EXPRESSION; X-RECEPTOR; SIGNALING PATHWAYS; OKADAIC ACID; GLUCOCORTICOID RECEPTOR; RESPONSIVE ELEMENT; ESTROGEN-RECEPTOR; CATALYTIC SUBUNIT	To determine which factors may regulate the DNA binding and transcriptional properties of retinoic acid receptors (RARs and RXRs), we investigated the sensitivity of reporter genes bearing various retinoic acid response elements (RAREs) to protein phosphatases (PPases) inhibition. PPases inhibition by okadaic acid led to an increase of the reporter genes activity in a RARE-dependent and ligand-independent manner and was dependent on the type of response element used. Overexpression of protein phosphatases 2A and 1 (PP2A and PP1) decreased the inducibility of the reporter genes tested. Nuclear extracts from okadaic acid-treated COS cells displayed an 2-5-fold increased level of receptor binding to RAREs in vitro, suggesting that PPases inhibition increased the DNA binding activity of retinoid receptors. Treatment of receptors extracted from COS cells by alkaline phosphatase and partially purified PP1 and PP2A decreased their DNA binding activity, but heterodimers bound to DNA were not sensitive to phosphatase treatment. Reconstitution experiments showed that phosphorylation of both receptors increased the DNA binding activity of RXR/RAR heterodimers. Taken together, these data show that the modulation of the phosphorylation state of RARs and RXRs represents an other level of regulation of the retinoid signaling pathway.	INST GENET & BIOL MOLEC & CELLULAIRE, INSERM, U184, GENET MOLEC EUCARYOTES LAB, CNRS, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	LEFEBVRE, P (corresponding author), FAC MED LILLE 1, INSERM, BIOCHIM STRUCT LAB, CJF 92-03, 1 PL VERDUN, F-59045 LILLE, FRANCE.		Lefebvre, Philippe/F-2685-2010	Lefebvre, Philippe/0000-0002-9366-5129				ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Ausubel FM, 1991, CURRENT PROTOCOLS MO; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BHAT MK, 1994, P NATL ACAD SCI USA, V91, P7927, DOI 10.1073/pnas.91.17.7927; BOURGUET W, 1992, BIOCHEM BIOPH RES CO, V187, P711, DOI 10.1016/0006-291X(92)91253-M; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GLASS CK, 1991, DNA CELL BIOL, V10, P623, DOI 10.1089/dna.1991.10.623; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HUGGENVIK JI, 1993, MOL ENDOCRINOL, V7, P543, DOI 10.1210/me.7.4.543; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; KEAVENEY M, 1993, NATURE, V365, P562, DOI 10.1038/365562a0; KIM YH, 1993, J BIOL CHEM, V268, P18513; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KURET J, 1986, FEBS LETT, V203, P197, DOI 10.1016/0014-5793(86)80741-4; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MASON SA, 1993, J BIOL CHEM, V268, P21501; MOYER ML, 1993, J BIOL CHEM, V268, P22933; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; PETKOVICH M, 1992, ANNU REV NUTR, V12, P443, DOI 10.1146/annurev.nu.12.070192.002303; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; SCHONTHAL A, 1992, NEW BIOL, V4, P16; SILBERMAN SR, 1984, J BIOL CHEM, V259, P2913; SOMERS JP, 1992, MOL ENDOCRINOL, V6, P26, DOI 10.1210/me.6.1.26; SRINIVASAN M, 1994, J BIOL CHEM, V269, P12514; SUGAWARA A, 1994, J BIOL CHEM, V269, P433; TAHAYATO A, 1993, MOL ENDOCRINOL, V7, P1642, DOI 10.1210/me.7.12.1642; TAWARA I, 1993, FEBS LETT, V321, P224, DOI 10.1016/0014-5793(93)80113-9; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1993, TRENDS ENDOCRIN MET, V4, P156, DOI 10.1016/1043-2760(93)90105-N; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	62	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10806	10816		10.1074/jbc.270.18.10806	http://dx.doi.org/10.1074/jbc.270.18.10806			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738017	hybrid			2022-12-25	WOS:A1995QW60100065
J	DOBI, A; DAMERON, CT; HU, S; HAMER, D; WINGE, DR				DOBI, A; DAMERON, CT; HU, S; HAMER, D; WINGE, DR			DISTINCT REGIONS OF CU(I)-CENTER-DOT-ACE1 CONTACT 2 SPATIALLY-RESOLVED DNA MAJOR GROOVE SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECO RI ENDONUCLEASE; CUP2 GENE-PRODUCT; YEAST METALLOTHIONEIN; TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; BINDING PROTEIN; EXPRESSION; COPPER; ACE1	The interaction between the Cu(I). ACE1 (CuACE1) transcription factor and its DNA binding site in the yeast metallothionein gene was studied by systematically altering the DNA sequence through base substitution, modification, and deletions as well as by altering the protein structure through chemical modification. We show here that CuACE1 is comprised of two distinct domains that contact DNA through minor groove interactions located between two major groove interaction sites. The minor groove interactions are shown to be critical for formation of a stable CuACE1 . DNA complex, The NH2-terminal segment of ACEI is shown to contact the 5'-most distal major groove site.	NCI, BIOCHEM LAB, BETHESDA, MD 20892 USA; UNIV UTAH, HLTH SCI CTR, SALT LAKE CITY, UT 84132 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Utah System of Higher Education; University of Utah								BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; BUCHMAN C, 1989, MOL CELL BIOL, V9, P4091, DOI 10.1128/MCB.9.9.4091; BUCHMAN C, 1990, MOL CELL BIOL, V10, P4778, DOI 10.1128/MCB.10.9.4778; CARRI MT, 1991, FEBS LETT, V278, P263, DOI 10.1016/0014-5793(91)80131-L; DAMERON CT, 1991, P NATL ACAD SCI USA, V88, P6127, DOI 10.1073/pnas.88.14.6127; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; FURST P, 1989, P NATL ACAD SCI USA, V86, P5267, DOI 10.1073/pnas.86.14.5267; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HU S, 1990, New Biologist, V2, P544; HUIBREGTSE JM, 1989, P NATL ACAD SCI USA, V86, P65, DOI 10.1073/pnas.86.1.65; Imbert J, 1990, Adv Inorg Biochem, V8, P139; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; LU AL, 1981, J BIOL CHEM, V256, P3200; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MEHRA RK, 1991, J CELL BIOCHEM, V45, P30, DOI 10.1002/jcb.240450109; NAKAGAWA KH, 1991, J AM CHEM SOC, V113, P3621, DOI 10.1021/ja00009a075; SCHEIT KH, 1967, BIOCHIM BIOPHYS ACTA, V149, P344, DOI 10.1016/0005-2787(67)90162-1; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; THORVALDSEN JL, 1994, BIOCHEMISTRY-US, V33, P9566, DOI 10.1021/bi00198a024; THORVALDSEN JL, 1993, J BIOL CHEM, V268, P12512; WELCH J, 1989, EMBO J, V8, P255, DOI 10.1002/j.1460-2075.1989.tb03371.x; Winge D R, 1994, Adv Inorg Biochem, V10, P1; WINGE DR, 1985, J BIOL CHEM, V260, P4464; ZHOU PB, 1992, MOL CELL BIOL, V12, P3766, DOI 10.1128/MCB.12.9.3766; ZHOU PB, 1991, P NATL ACAD SCI USA, V88, P6112, DOI 10.1073/pnas.88.14.6112	34	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10171	10178		10.1074/jbc.270.17.10171	http://dx.doi.org/10.1074/jbc.270.17.10171			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730320	hybrid			2022-12-25	WOS:A1995QV41700067
J	LEE, SL; TOURTELLOTTE, LC; WESSELSCHMIDT, RL; MILBRANDT, J				LEE, SL; TOURTELLOTTE, LC; WESSELSCHMIDT, RL; MILBRANDT, J			GROWTH AND DIFFERENTIATION PROCEEDS NORMALLY IN CELLS DEFICIENT IN THE IMMEDIATE-EARLY GENE NGFI-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR EGR-1; EMBRYONAL CARCINOMA-CELLS; FINGER-ENCODING GENE; STEM-CELLS; C-FOS; ES CELLS; EXPRESSION; PROTEIN; RAT; PROTOONCOGENE	NGFI-A (also known as EGR-1, zif/268, and Krox-24) is a zinc finger transcription factor induced in many cell types by a variety of growth and differentiation stimuli, To determine if NGFI-A plays a requisite role in these processes, we used homologous recombination to mutate both alleles of NGFI-A in embryonic stem (ES) cells and examined its effect on growth and differentiation. We find that ES cells lacking NGFI-A exhibit similar growth rates and serum-induced gene expression profiles compared to wild-type parental cells. They are capable of differentiating into neurons, cardiac myocytes, chondrocytes, and squamous epithelium, Chimeric mice were generated from targeted ES cells, and their progeny were crossed to produce homozygous mutant mice, Growth and histological analyses of mice lacking NGFI-A confirm the finding in ES cells that NGFI-A is not required for many of the processes associated with its expression and suggest that the function of NGFI-A is either more subtle in vivo or masked by redundant expression provided by other gene family members such as NGFI-C, Krox-20, or EGR3.	WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA; JEWISH HOSP ST LOUIS, DEPT MED, DIV BONE MARROW TRANSPLANTAT, ST LOUIS, MO 63110 USA; JEWISH HOSP ST LOUIS, DEPT GENET, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Barnes-Jewish Hospital; Barnes-Jewish Hospital	LEE, SL (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA.			Milbrandt, Jeffrey/0000-0002-5477-7689	NCI NIH HHS [P01 CA53514] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHAVRIER P, 1988, MOL CELL BIOL, V8, P1319, DOI 10.1128/MCB.8.3.1319; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; CROSBY SD, 1992, P NATL ACAD SCI USA, V89, P4739, DOI 10.1073/pnas.89.10.4739; DAY ML, 1990, J BIOL CHEM, V265, P15253; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; FIELD SJ, 1992, P NATL ACAD SCI USA, V89, P9306, DOI 10.1073/pnas.89.19.9306; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HILBERG F, 1992, ONCOGENE, V7, P2371; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KHARBANDA S, 1991, J CLIN INVEST, V88, P571, DOI 10.1172/JCI115341; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; LANOIX J, 1991, CELL GROWTH DIFFER, V2, P391; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; ROBBINS J, 1990, J BIOL CHEM, V265, P11905; ROBERTSON E, 1987, TERATOCARCINOMA EMBR; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WATSON MA, 1990, DEVELOPMENT, V110, P173	38	161	163	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9971	9977		10.1074/jbc.270.17.9971	http://dx.doi.org/10.1074/jbc.270.17.9971			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730380	hybrid			2022-12-25	WOS:A1995QV41700042
J	PAPP, B; BYRN, RA				PAPP, B; BYRN, RA			STIMULATION OF HIV EXPRESSION BY INTRACELLULAR CALCIUM-PUMP INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL CLONE; NF-KAPPA-B; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; CA2+ STORES; THYMIC LYMPHOCYTES; TUMOR PROMOTER; THAPSIGARGIN; CA-2+	We have studied the role of intracellular calcium sequestration on human immunodeficiency virus (HIV) production by latently infected T-lymphocytic cells. Inhibition of the sarco-endoplasmic reticulum-type calcium transport ATPases by thapsigargin or cyclopiazonic acid induced activation of HIV production in the GEM-derived ACH-S cells. An approximately 50% depletion of the thapsigargin-sensitive calcium pools as measured fluorimetrically of Indo-loaded cells fully activated virus production. Viral activation was manifest by increases in soluble viral core p24 production, increases in cellular immunofluorescent staining for viral antigens, and increased viral transcription as measured by HIV long terminal repeat-directed expression of the chloramphenicol acetyltransferase reporter gene. Virus induction could be blocked in a dose dependent manner by the calcium channel blocker econazole. Virus production by the Jurkat-derived HIV-l-inducible J1.1 cells was not significantly stimulated by thapsigargin. These data indicate that intracellular calcium pool function is involved in the control of the transcription of proviral HIV in a cell type-specific manner within the T-Iymphoid lineage and that AGH-2 cells represent a useful model for the study of calcium dependent activation of the transcription of proviral HIV.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,HEMATOL ONCOL RES LAB,BOSTON,MA 02215	Harvard University; Harvard Medical School								BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BUTERA ST, 1994, J VIROL, V68, P2726, DOI 10.1128/JVI.68.4.2726-2730.1994; COMBETTES L, 1994, SCIENCE, V265, P818; DONNADIEU E, 1992, J BIOL CHEM, V267, P25864; EMBERTSON J, 1993, P NATL ACAD SCI USA, V90, P357; EMBERTSON J, 1993, NATURE, V362, P359; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FINCH EA, 1994, SCIENCE, V265, P813, DOI 10.1126/science.265.5173.813-a; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GRAZIOSI C, 1993, AIDS, V7, pS53, DOI 10.1097/00002030-199311002-00012; GRINSTEIN S, 1989, B NEW YORK ACAD MED, V65, P69; GROVER AK, 1992, CELL CALCIUM, V13, P9, DOI 10.1016/0143-4160(92)90025-N; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTHEIL JC, 1994, J BIOL CHEM, V269, P7976; HASELTINE WA, 1991, FASEB J, V5, P2349, DOI 10.1096/fasebj.5.10.1829694; HAVERSTICK DM, 1993, MOL BIOL CELL, V4, P173, DOI 10.1091/mbc.4.2.173; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; INO M, 1990, J GEN PHYSIOL, V95, P1103; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; LI WWF, 1993, J BIOL CHEM, V268, P12003; MACLENNAN DH, 1992, ANN NY ACAD SCI, V671, P1, DOI 10.1111/j.1749-6632.1992.tb43779.x; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MASON MJ, 1993, AM J PHYSIOL, V264, pC654, DOI 10.1152/ajpcell.1993.264.3.C654; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; NORDSTROM T, 1992, EXP CELL RES, V202, P487, DOI 10.1016/0014-4827(92)90103-F; NYE KE, 1991, AIDS, V5, P413, DOI 10.1097/00002030-199104000-00009; NYE KE, 1990, AIDS, V4, P41, DOI 10.1097/00002030-199001000-00006; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PAPP B, 1994, AIDS RES HUM RETROV, V10, P775, DOI 10.1089/aid.1994.10.775; PAPP B, 1991, J BIOL CHEM, V266, P14593; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; PEREZ VL, 1991, J IMMUNOL, V147, P3145; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SARKADI B, 1991, J MEMBRANE BIOL, V123, P9, DOI 10.1007/BF01993958; SCHAEFER A, 1994, J BIOL CHEM, V269, P8786; SCHENTAL A, 1991, P NATL ACAD SCI USA, V88, P7096; SCHWARTZ O, 1988, AIDS RES HUM RETROV, V4, P441, DOI 10.1089/aid.1988.4.441; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAO JG, 1992, J BIOL CHEM, V267, P24972; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; THASTRUP O, 1987, BIOCHEM BIOPH RES CO, V142, P654, DOI 10.1016/0006-291X(87)91464-1; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; ZEIRA M, 1990, AIDS RES HUM RETROV, V6, P629, DOI 10.1089/aid.1990.6.629; ZHANG BX, 1993, J BIOL CHEM, V268, P10997; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295; [No title captured]	63	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10278	10283		10.1074/jbc.270.17.10278	http://dx.doi.org/10.1074/jbc.270.17.10278			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730332	hybrid			2022-12-25	WOS:A1995QV41700081
J	TESSON, F; LIMONBOULEZ, I; URBAN, P; PUYPE, M; VANDEKERCKHOVE, J; COUPRY, I; POMPON, D; PARINI, A				TESSON, F; LIMONBOULEZ, I; URBAN, P; PUYPE, M; VANDEKERCKHOVE, J; COUPRY, I; POMPON, D; PARINI, A			LOCALIZATION OF I-2-IMIDAZOLINE BINDING-SITES ON MONOAMINE OXIDASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-3 IDAZOXAN BINDING; GUANIDINIUM-RECEPTIVE SITES; VENTROLATERAL MEDULLA; RABBIT KIDNEY; RAT-BRAIN; IMIDAZOLINE; MEMBRANES; CELLS; ALPHA-2-ADRENOCEPTORS; EXPRESSION	Imidazoline binding sites (IBS) were proposed to be responsible for some of the pharmacological and therapeutic activities of imidazoline and related compounds and have been classified into two subtypes, I1BS and I2BS, Convergent studies attribute a role in central blood pressure regulation to the I1BS. In contrast, the function of I2BS remains unknown. In the present study, by combining biochemical and molecular biology approaches, we show that 1) microsequencing of I2BS purified from rabbit kidney mitochondria allowed the recovery of four peptide sequence stretches displaying up to 85.7% similarity with human, rat, and bovine monoamine oxidases (MAO)-A and -B; 2) I2BS and MAO displayed identical biophysical characteristics as their activities, measured by [H-3]idazoxan binding and [C-14]tyramine oxidation, respectively, could not be separated using various chromatographic procedures; and 3) heterologous expression of human placenta MAO-A and human liver MAO-B in yeast, inherently devoid of I2BS and MAO activities, led to the coexpression of [H-9]idazoxan binding sites displaying ligand-recognition properties typical of I2BS. These results show definitely that I2BS is located on both MAO-A and -B. The fact that I2BS ligands inhibited MAO activity independently of the interaction with the catalytic region suggests that I2BS might be a previously unknown MAO regulatory site.	CHU RANGUEIL,INST LOUIS BUGNARD,INSERM,U388,F-31054 TOULOUSE,FRANCE; CTR GENET MOLEC,CNRS,UPR 2420,F-91198 GIF SUR YVETTE,FRANCE; STATE UNIV GHENT,PHYSIOL CHEM LAB,B-9000 GHENT,BELGIUM	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Ghent University			COUPRY, Isabelle/L-4900-2014; Tesson, Frederique/A-3218-2013; Limon, Isabelle/P-2750-2017; Limon, Isabelle/AAJ-6169-2020	Limon, Isabelle/0000-0002-8773-6971; Limon, Isabelle/0000-0002-8773-6971; Parini, Angelo/0000-0002-9848-8838; Urban, Philippe/0000-0003-0557-839X				ATLAS D, 1994, SCIENCE, V266, P462, DOI 10.1126/science.7939689; BAUW G, 1987, P NATL ACAD SCI USA, V84, P4806, DOI 10.1073/pnas.84.14.4806; BAUW G, 1988, J PROTEIN CHEM, V7, P194; BOUSQUET P, 1984, J PHARMACOL EXP THER, V230, P232; BRICCA G, 1994, EUR J PHARM-MOLEC PH, V266, P25, DOI 10.1016/0922-4106(94)90205-4; COUPRY I, 1987, BIOCHEM BIOPH RES CO, V147, P1055, DOI 10.1016/S0006-291X(87)80177-8; COUPRY I, 1990, J PHARMACOL EXP THER, V252, P293; DIAMANT S, 1992, BRIT J PHARMACOL, V106, P101, DOI 10.1111/j.1476-5381.1992.tb14300.x; DOXEY JC, 1983, BRIT J PHARMACOL, V78, P489, DOI 10.1111/j.1476-5381.1983.tb08809.x; ERNSBERGER P, 1990, J PHARMACOL EXP THER, V253, P408; ERNSBERGER P, 1987, EUR J PHARMACOL, V134, P1, DOI 10.1016/0014-2999(87)90125-7; GHIKA J, 1991, NEUROLOGY, V41, P986, DOI 10.1212/WNL.41.7.986; JACKSON HC, 1991, PSYCHOPHARMACOLOGY, V105, P558, DOI 10.1007/BF02244380; LI G, 1994, SCIENCE, V263, P966, DOI 10.1126/science.7906055; LIMON I, 1992, J BIOL CHEM, V267, P21645; MALLARD NJ, 1992, BRIT J PHARMACOL, V106, P1019, DOI 10.1111/j.1476-5381.1992.tb14450.x; MICHEL MC, 1992, TRENDS PHARMACOL SCI, V13, P369; OLMOS G, 1993, BRIT J PHARMACOL, V108, P597, DOI 10.1111/j.1476-5381.1993.tb12848.x; REGUNATHAN S, 1993, BIOCHEM PHARMACOL, V45, P1667, DOI 10.1016/0006-2952(93)90308-J; RENOUARD A, 1993, BRIT J PHARMACOL, V109, P625, DOI 10.1111/j.1476-5381.1993.tb13618.x; RILEY LA, 1991, BIOCHEM PHARMACOL, V42, P1953, DOI 10.1016/0006-2952(91)90595-V; RUIZ J, 1993, NEUROSCI LETT, V160, P109, DOI 10.1016/0304-3940(93)90925-B; SASTRE M, 1993, J NEUROCHEM, V61, P881, DOI 10.1111/j.1471-4159.1993.tb03599.x; SINGER TP, 1993, MONOAMINE OXIDASE BA, P23; TESSON F, 1992, EUR J PHARMACOL, V219, P335, DOI 10.1016/0014-2999(92)90316-V; TESSON F, 1991, J BIOL CHEM, V266, P155; TIMMERMANS PBMWM, 1982, J MED CHEM, V25, P1389, DOI 10.1021/jm00354a001; URBAN P, 1990, BIOCHIMIE, V72, P463, DOI 10.1016/0300-9084(90)90070-W; URBAN P, 1991, FEBS LETT, V286, P142, DOI 10.1016/0014-5793(91)80960-B; VENAULT P, 1993, LIFE SCI, V52, P639, DOI 10.1016/0024-3205(93)90455-C; WENDT RL, 1980, PHARM ANTIHYPERTENSI, P99; WEYLER W, 1989, PHARMACOL THERAPEUT, V47, P391	32	176	177	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9856	9861		10.1074/jbc.270.17.9856	http://dx.doi.org/10.1074/jbc.270.17.9856			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730367	hybrid			2022-12-25	WOS:A1995QV41700026
J	WANG, F; KAN, M; XU, JM; YAN, GC; MCKEEHAN, WL				WANG, F; KAN, M; XU, JM; YAN, GC; MCKEEHAN, WL			LIGAND-SPECIFIC STRUCTURAL DOMAINS IN THE FIBROBLAST GROWTH-FACTOR RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE EPITHELIAL-CELLS; 3-DIMENSIONAL STRUCTURE; SIGNAL-TRANSDUCTION; BINDING; KINASE; VARIANTS; HEPARIN; REGION; GENES; SITE	Two tandem immunoglobulin-like disulfide loops (Loops II and III) linked by a short connecting sequence in the ectodomain of the fibroblast growth factor receptor kinase compose the binding sites for glycosaminoglycan and fibroblast growth factor (FGF) ligands. Alternate splicing of exons IIIb and IIIc coding for the COOH-terminal half of Loop III confers high affinity for FGF-7 or FGF-2, respectively, on the fibroblast growth factor receptor ectodomain without effect on the binding of FGF-1, Here we show that a 139-amino acid fragment composed of Loop II, the inter-loop II/III sequence, and a short segment of the NH2 terminus of Loop III is sufficient and near the minimal requirement for binding of FGF-1, FGF-2, and FGF-7, Extension of the fragment by five additional highly conserved residues (SD(P/A)QP) within a distinct constitutive structural domain (fl1) in Loop III restricts the binding of FGF-7 without effect on FGF-1 and FGF-2. Since the presence of exon IIIc in the full-length ectodomain does not change this ligand binding profile, we suggest that alternately spliced exon IIIc plays no active role in binding of the three ligands. In contrast, exon IIIb actively abrogates the restriction on the binding of FGF-7 and concurrently lowers the affinity for FGF-2.	TEXAS A&M UNIV, ALBERT B ALKEK INST BIOSCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, HOUSTON, TX 77030 USA	Texas A&M University System					NCI NIH HHS [CA59971] Funding Source: Medline; NIDDK NIH HHS [DK35310, DK38639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035310, P01DK038639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; BOTTARO DP, 1993, J BIOL CHEM, V268, P9180; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOU JZ, 1992, J BIOL CHEM, V267, P17804; HOU JZ, 1993, PROTEIN SCI, V2, P86; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAN M, 1991, METHOD ENZYMOL, V198, P158; KAN M, 1992, IN VITRO CELL DEV-AN, V28A, P515; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; MATSUZAKI K, 1993, J BIOL CHEM, V268, P12719; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SEDDON AP, 1995, BIOCHEMISTRY-US, V34, P731, DOI 10.1021/bi00003a004; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; XU JM, 1992, J BIOL CHEM, V267, P17792; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; YAN GC, 1993, BIOCHEM BIOPH RES CO, V194, P512, DOI 10.1006/bbrc.1993.1849; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	32	88	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10222	10230		10.1074/jbc.270.17.10222	http://dx.doi.org/10.1074/jbc.270.17.10222			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730326	hybrid			2022-12-25	WOS:A1995QV41700074
J	ZHONG, JM; CHENHWANG, MC; HWANG, YW				ZHONG, JM; CHENHWANG, MC; HWANG, YW			SWITCHING NUCLEOTIDE SPECIFICITY OF HA-RAS P21 BY A SINGLE AMINO-ACID SUBSTITUTION AT ASPARTATE-119	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-TU; BINDING DOMAIN; MOLECULAR MECHANISM; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; TERMINAL DOMAIN; PROTEINS; GDP; EXCHANGE; MUTANTS	We examined c-Ha-Ras harboring an aspartate to asparagine substitution at position 119 (mutation D119N). The Asp-119 is part of the conserved NKXD motif shared by members of the regulatory GTPase family, This asparagine residue has been proposed to participate in direct bonding to the guanine ring and to determine the guanine-nucleotide binding specificity, The D119N mutation was found to alter nucleotide specificity of Ha-Ras from guanine to xanthine, an observation that directly supports the essential role of hydrogen bonding between the side chain of the aspartic acid residue and the guanine ring in nucleotide binding specificity, Resides nucleotide binding specificity, the D119N mutation has little or no effect on the interaction of Ha-Ras with SDC25C, SOS1, GAP, or Raf, Neither does it affect the hydrolysis of nucleotide triphosphate. Like xanthine-nucleotide-specific EF-Tu, xanthine-nucleotide-specific Ras and related proteins will be useful tools for elucidating cellular systems containing multiple regulatory GTPases.	NEW YORK STATE INST BASIC RES DEV DISABIL,DEPT MOLEC BIOL,STATEN ISL,NY 10314; CUNY,IBR,CSI,CTR DEV NEUROSCI,NEW YORK,NY 10021; CUNY,GRAD PROGRAM BIOL,NEW YORK,NY 10021	Institute for Basic Research in Developmental Disabilities; City University of New York (CUNY) System; Institute for Basic Research in Developmental Disabilities; City University of New York (CUNY) System					NCI NIH HHS [CA53782] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053782] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; Crystal R G, 1974, Methods Enzymol, V30, P101; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; HWANG YW, 1993, J BIOL CHEM, V268, P24692; HWANG YW, 1987, J BIOL CHEM, V262, P13081; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KANG C, 1994, J BIOL CHEM, V269, P24046; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAMBRIGHT DG, 1994, NATURE, V360, P621; LIU BX, 1993, ONCOGENE, V8, P8081; MANNE V, 1984, P NATL ACAD SCI-BIOL, V81, P6953, DOI 10.1073/pnas.81.22.6953; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOODIE SA, 1993, SCIENCE, V260, P1588; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SUNG YJ, 1995, BIOCHEMISTRY-US, V34, P3470, DOI 10.1021/bi00010a040; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEIJLAND A, 1994, BIOCHEMISTRY-US, V33, P10711, DOI 10.1021/bi00201a019; WEIJLAND A, 1994, TRENDS BIOCHEM SCI, V19, P188, DOI 10.1016/0968-0004(94)90018-3; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	38	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10002	10007		10.1074/jbc.270.17.10002	http://dx.doi.org/10.1074/jbc.270.17.10002			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730301	hybrid			2022-12-25	WOS:A1995QV41700046
J	AGGELER, R; HAUGHTON, MA; CAPALDI, RA				AGGELER, R; HAUGHTON, MA; CAPALDI, RA			DISULFIDE BOND FORMATION BETWEEN THE COOH-TERMINAL DOMAIN OF THE BETA-SUBUNITS AND THE GAMMA-SUBUNITS AND EPSILON-SUBUNITS OF THE ESCHERICHIA-COLI F1-ATPASE - STRUCTURAL IMPLICATIONS AND FUNCTIONAL CONSEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1 ADENOSINE-TRIPHOSPHATASE; ATP SYNTHASE; CRYOELECTRON MICROSCOPY; CATALYTIC SITES; CROSS-LINKING; F1-ATPASE; BINDING; HYDROLYSIS; AUROVERTIN; NUCLEOTIDE	A set of mutants of the Escherichia coli F1F0-type ATPase has been generated by site-directed mutagenesis as follows: beta E381C, beta S383C, beta E381C/epsilon S108C, and beta S383C/epsilon S108C. Treatment of ECF(1) isolated from any of these mutants with CuCl2 induces disulfide bond formation, For the single mutants, beta E381C and beta S383C, a disulfide bond is formed in essentially 100% yield between a beta subunit and the gamma subunit, probably at Cys(87) based on the recent structure determination of F-1 (Abrahams, J, P,, Leslie, A, G, W,, Lutter, R,, and Walker, J, E, (1994) Nature 370, 621-628). In the double mutants, two disulfide bonds are formed, again in essentially full yield, one between beta and gamma, the other between a beta and the epsilon subunit via Cys(108), The same two cross-links are produced with CuCl2 treatment of ECF(1)F(0) isolated from either of the double mutants, These results show that the parts of gamma around residue 87 (a short alpha-helix) and the epsilon subunit interact with different beta subunits. The yield of covalent linkage of beta to gamma is nucleotide dependent and highest in ATP and much lower with ADP in catalytic sites, The yield of covalent linkage of beta to epsilon is also nucleotide dependent but in this case is highest in ADP and much lower in ATP, Disulfide bond formation between either beta and gamma, or beta and epsilon inhibits the ATPase activity of the enzyme in proportion to the yield of the cross-linked product, Chemical modification of the Cys at either position 381 or 383 of the beta subunit inhibits ATPase activity in a manner that appears to be dependent on the size of the modifying reagent, These results are as expected if movements of the catalytic site containing beta subunits relative to the gamma and epsilon subunits are an essential part of the cooperativity of the enzyme.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403	University of Oregon			Haughton, Margaret/F-8033-2010		NHLBI NIH HHS [HL 24526] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1993, J BIOL CHEM, V268, P14576; AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; AGGELER R, 1993, J BIOL CHEM, V268, P20831; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1987, BIOCHEMISTRY-US, V26, P7107, DOI 10.1021/bi00396a036; Battey, 1986, BASIC METHODS MOL BI; Boyer P.D., 1981, PRESENT STATUS BINDI, P231; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRAGG PD, 1986, BIOCHIM BIOPHYS ACTA, V851, P385, DOI 10.1016/0005-2728(86)90075-7; BRUNNER J, 1978, J BIOL CHEM, V253, P7538; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; CROSS RL, 1988, J BIOENERG BIOMEMBR, V20, P395, DOI 10.1007/BF00762200; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNN SD, 1987, BIOCHEMISTRY-US, V26, P4488, DOI 10.1021/bi00388a047; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, BIOCHEMISTRY-US, V9, P4620; LOTSCHER HR, 1984, BIOCHEM BIOPH RES CO, V121, P331; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; Maniatis T., 1982, MOL CLONING; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; TOZER RG, 1986, EUR J BIOCHEM, V161, P513, DOI 10.1111/j.1432-1033.1986.tb10472.x; TURINA P, 1994, J BIOL CHEM, V269, P13465; TURINA P, 1994, BIOCHEMISTRY-US, V33, P14275, DOI 10.1021/bi00251a040; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; WILKENS S, 1994, FEBS LETT, V354, P37, DOI 10.1016/0014-5793(94)01059-5; WISE JG, 1981, J BIOL CHEM, V256, P383	36	124	124	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9185	9191		10.1074/jbc.270.16.9185	http://dx.doi.org/10.1074/jbc.270.16.9185			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721834	hybrid			2022-12-25	WOS:A1995QU08900022
J	BRUSS, M; HAMMERMANN, R; BRIMIJOIN, S; BONISCH, H				BRUSS, M; HAMMERMANN, R; BRIMIJOIN, S; BONISCH, H			ANTIPEPTIDE ANTIBODIES CONFIRM THE TOPOLOGY OF THE HUMAN NOREPINEPHRINE TRANSPORTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC-ACID TRANSPORTER; BRAIN GABA TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; DOPAMINE TRANSPORTERS; MAMMALIAN-CELLS; EXPRESSION; CLONING; NORADRENALINE	We have raised polyclonal antibodies (N6-28, L211-226, L371-384, and C590-607) against peptides corresponding to hydrophilic sequences of the human norepinephrine transporter (hNET). The antisera immuno precipitated the [S-35]Met-labeled hNET. Antiserum L211-226, directed against a sequence of the putative second (large) extracellular loop of hNET, also immunoprecipitated the human dopamine transporter. Antisera N6-28 and C590-607, raised against a hNET peptide region of the N and the C termini, respectively, recognized a 58-kDa protein from transfected COS-7 cells expressing the hNET. This 58-kDa species represents a functional, glycosylated form of the hNET and not a degradation product, Tunicamycin treatment of transfected COS-7 cells as well as peptide-N-glycosidase F digestion of the transporter converted the 58-kDa species to a 50-kDa form, indicating that the latter represents the hNET core protein. In indirect immunofluorescence studies, our antisera confirmed the originally proposed topology of hNET, Antisera N6-28 and C590-607 detected hNET only in permeabilized cells, In contrast, antisera L211-226 and L371-384 directed against peptide sequences of the second and fourth putative extracellular loop displayed fluorescence signals with the intact cells.	UNIV BONN, INST PHARMAKOL & TOXIKOL, D-53113 BONN, GERMANY; MAYO CLIN & MAYO FDN, DEPT PHARMACOL, ROCHESTER, MN 55905 USA	University of Bonn; Mayo Clinic								AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, V2; BENDAHAN A, 1993, FEBS LETT, V318, P41, DOI 10.1016/0014-5793(93)81323-R; BONISCH H, 1994, ANN NY ACAD SCI, V733, P193, DOI 10.1111/j.1749-6632.1994.tb17269.x; BONISCH H, 1990, J NEUR TR S, P413; BONISCH H, 1991, ADV BIOSCI, V82, P139; Doolittle R. F., 1986, URFS ORFS PRIMER ANA; FRIEDRICH U, 1986, N-S ARCH PHARMACOL, V333, P246, DOI 10.1007/BF00512937; GIROS B, 1992, MOL PHARMACOL, V42, P383; GRIGORIADIS DE, 1989, J NEUROSCI, V9, P2664; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HOWARD BD, 1990, J NEUROSCI RES, V26, P149, DOI 10.1002/jnr.490260204; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; LAEMMLI UK, 1970, NATURE, V4, P680, DOI DOI 10.1038/227680A0; LEW R, 1992, BRAIN RES, V584, P266, DOI 10.1016/0006-8993(92)90905-O; LINGEN B, 1994, FEBS LETT, V342, P235, DOI 10.1016/0014-5793(94)80508-3; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; PATEL A, 1993, J NEUROCHEM, V61, P496; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; SALLEE FR, 1989, FEBS LETT, V256, P219, DOI 10.1016/0014-5793(89)81752-1; TATE CG, 1994, J BIOL CHEM, V269, P26303; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; WARRALL M, 1994, BIOCHEM J, V297, P425; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZHU JH, 1992, NEUROCHEM INT, V21, P521, DOI 10.1016/0197-0186(92)90083-4	28	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9197	9201						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721836				2022-12-25	WOS:A1995QU08900024
J	LEE, HC; AARHUS, R; GRAEFF, RM				LEE, HC; AARHUS, R; GRAEFF, RM			SENSITIZATION OF CALCIUM-INDUCED CALCIUM-RELEASE BY CYCLIC ADP-RIBOSE AND CALMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; AMINO-ACID-SEQUENCE; INOSITOL TRISPHOSPHATE; CA2+ RELEASE; MICROSOMES; METABOLITE; NAD+	Cyclic ADP-ribose (cADPR) is emerging as an endogenous regulator of Ca2+-induced Ca2+ release (CICR), and we have recently demonstrated that its action is mediated by calmodulin (CaM) (Lee, H. C,, Aarhus, R,, Graeff, R., Gurnack, M. E,, and Walseth, T. F. (1994) Nature 370, 307-309). In this study we show by immunoblot analyses that the protein factor in sea urchin eggs responsible for conferring cADPR sensitivity to egg microsomes was CaM. This was further supported by the fact that bovine CaM was equally effective as the egg factor. In contrast, plant CaM was only partially active even at 10-20-fold higher concentrations. This exquisite specificity was also shown by binding studies using I-125-labeled bovine CaM. The effectiveness of various CaMs (bovine > spinach > wheat germ) in competing for the binding sites was identical to their potency in conferring cADPR sensitivity to the microsomes. A comparison between bovine and wheat germ CaM in competing for the sites suggests only 10-14% of the total binding was crucial for the activity, Depending on the CaM concentration, the sensitivity of the microsomes to cADPR could be changed by several orders of magnitude. The requirement for CaM could be alleviated by raising the divalent cation concentration with Sr2+. Results showed that CaM, cADPR, and caffeine all act synergistically to increase the divalent cation sensitivity of the CICR mechanism, The combined action of any of the three agonists was sufficient to sensitize the mechanism so much that even the nanomolar concentration of ambient Ca2+ was enough to activate the release. Unlike the CICR mechanism, the microsomal inositol 1,4,5-trisphosphate-sensitive Ca2+ release showed no dependence on CaM. Using an antagonist of CaM, W7, it was demonstrated that the cADPR(-) but not the inositol 1,4,5-trisphosphate-dependent release mechanism could be blocked in live sea urchin eggs, These results indicate cADPR can function as a physiological modulator of CICR and, together with CaM, can alter the sensitivity of the release mechanism to divalent cation by several orders of magnitude.			LEE, HC (corresponding author), UNIV MINNESOTA,DEPT PHYSIOL,LYON LAB 6182,MINNEAPOLIS,MN 55455, USA.		Graeff, Richard Milton/B-3425-2011; Lee, Hon Cheung/C-4329-2009		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032040, R01HD017484] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17484, HD32040] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; HARDY DO, 1988, J MOL BIOL, V199, P223, DOI 10.1016/0022-2836(88)90392-0; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; HULEN D, 1991, CELL MOTIL CYTOSKEL, V18, P113, DOI 10.1002/cm.970180206; LEE HC, 1994, NEWS PHYSIOL SCI, V9, P134; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEE HC, 1993, J BIOL CHEM, V268, P293; LEE HC, 1991, J BIOL CHEM, V266, P2276; LUKAS TJ, 1984, PLANT PHYSIOL, V75, P788, DOI 10.1104/pp.75.3.788; PRESTON RR, 1991, ANNU REV PHYSIOL, V53, P309, DOI 10.1146/annurev.ph.53.030191.001521; TODA H, 1985, J BIOCHEM-TOKYO, V98, P833, DOI 10.1093/oxfordjournals.jbchem.a135342; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WATTERSON DM, 1980, J BIOL CHEM, V255, P962; YANG HC, 1994, BIOCHEMISTRY-US, V33, P518, DOI 10.1021/bi00168a017	23	110	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9060	9066		10.1074/jbc.270.16.9060	http://dx.doi.org/10.1074/jbc.270.16.9060			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721819				2022-12-25	WOS:A1995QU08900007
J	SNUDDEN, DK; SMITH, PR; LAI, D; NG, MH; GRIFFIN, BE				SNUDDEN, DK; SMITH, PR; LAI, D; NG, MH; GRIFFIN, BE			ALTERATIONS IN THE STRUCTURE OF THE EBV NUCLEAR ANTIGEN, EBNA1, IN EPITHELIAL-CELL TUMORS	ONCOGENE			English	Article						NASOPHARYNGEAL CARCINOMA; MUTATIONS; DNA BINDING; EPSTEIN-BARR VIRUS	EPSTEIN-BARR-VIRUS; NASOPHARYNGEAL CARCINOMA; DNA-BINDING; BURKITT-LYMPHOMA; EXPRESSION; PROTEIN; REPLICATION; TRANSCRIPTION; SEQUENCE; PROMOTER	The EBV nuclear antigen, EBNA1, is the only viral protein consistently expressed in all virus-infected cells. It is required in trans for viral replication, maintenance of EBV extrachromosomal episomes, and transcriptional transactivation in latently-infected B-cells. It binds RNA suggestive of a regulatory role in post-transcriptional events and in transgenic mice, it is tumorigenic. In RNase protection studies relating to the EBV-associated tumour, nasopharyngeal carcinoma (NPC), we show that a C-terminal EBNA1 RNA probe from the prototype B95-8 marmoset strain can protect its own mRNA from enzymatic digestion, but does not fully protect EBNA1 mRNA from NPC cells. This finding is consistent with changes in the coding region for the antigen. We thus determined the sequences of EBNA1 genes derived from an NPC xenograft and numerous patient biopsies and identified a number of mutations in the gene in these human cells, relative to B95-8. Many of the nucleotide changes would lead to non-conservative amino acid alterations in apparently functionally significant regions of the protein. We show that although some of the mutations lie in regions designated as critical to DNA binding, they have negligible effect on this property of EBNA1. The basic regions in EBNA1 that may bind to RNA, at least in vitro, are exempt from mutation. Thus, unless the alterations are 'silent', which for such a critical viral function seems unlikely, they may relate to as yet unmapped viral activities, such as a role in tumorigenesis and the ability of EBNA1 to evade the cellular immune system, or be associated with the ability of the antigen to regulate gene transcription.	ROYAL POSTGRAD MED SCH,DEPT VIROL,LONDON W12 0NN,ENGLAND; CHINESE UNIV HONG KONG,DEPT MICROBIOL,HONG KONG,HONG KONG; QUEEN MARYS HOSP,DEPT MICROBIOL,HONG KONG,HONG KONG	Imperial College London; Chinese University of Hong Kong								ABDELHAMID M, 1992, VIROLOGY, V190, P168, DOI 10.1016/0042-6822(92)91202-6; AMBINDER RF, 1990, J VIROL, V64, P2369, DOI 10.1128/JVI.64.5.2369-2379.1990; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; CHEN HL, 1992, VIROLOGY, V191, P193, DOI 10.1016/0042-6822(92)90181-N; CHEN ML, 1992, ONCOGENE, V7, P2131; CHEN MR, 1994, VIROLOGY, V205, P486, DOI 10.1006/viro.1994.1669; CHITTENDEN T, 1989, J VIROL, V63, P3016, DOI 10.1128/JVI.63.7.3016-3025.1989; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; GILLIGAN K, 1990, J VIROL, V64, P4948, DOI 10.1128/JVI.64.10.4948-4956.1990; HEARING J, 1992, J VIROL, V66, P694, DOI 10.1128/JVI.66.2.694-705.1992; HEARING JC, 1985, VIROLOGY, V145, P105; HITT MM, 1989, EMBO J, V8, P2639, DOI 10.1002/j.1460-2075.1989.tb08404.x; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; INOUE N, 1991, VIROLOGY, V182, P84, DOI 10.1016/0042-6822(91)90651-Q; JONES CH, 1989, J VIROL, V63, P101, DOI 10.1128/JVI.63.1.101-110.1989; KHANNA R, 1992, J EXP MED, V176, P169, DOI 10.1084/jem.176.1.169; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFEMINA RL, 1989, VIROLOGY, V172, P584, DOI 10.1016/0042-6822(89)90201-8; LUNG ML, 1990, VIROLOGY, V177, P44, DOI 10.1016/0042-6822(90)90458-4; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; POLVINOBODNAR M, 1988, NUCLEIC ACIDS RES, V16, P3415, DOI 10.1093/nar/16.8.3415; POLVINOBODNAR M, 1992, VIROLOGY, V187, P591, DOI 10.1016/0042-6822(92)90461-W; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; ROTH G, 1994, BLOOD, V84, P582, DOI 10.1182/blood.V84.2.582.bloodjournal842582; ROWE DT, 1986, EMBO J, V5, P2599, DOI 10.1002/j.1460-2075.1986.tb04540.x; Sambrook J, 1989, MOL CLONING LABORATO; SAMPLE J, 1992, J VIROL, V66, P4654, DOI 10.1128/JVI.66.8.4654-4661.1992; SAMPLE J, 1991, P NATL ACAD SCI USA, V88, P6343, DOI 10.1073/pnas.88.14.6343; SCHAEFER BC, 1991, P NATL ACAD SCI USA, V88, P6550, DOI 10.1073/pnas.88.15.6550; SHAH WA, 1992, J VIROL, V66, P3355, DOI 10.1128/JVI.66.6.3355-3362.1992; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH PR, 1993, J VIROL, V67, P3217, DOI 10.1128/JVI.67.6.3217-3225.1993; SMITH PR, 1991, NUCLEIC ACIDS RES, V19, P2435, DOI 10.1093/nar/19.9.2435; SMITH PR, 1992, J VIROL, V66, P706, DOI 10.1128/JVI.66.2.706-714.1992; SNUDDEN DK, 1994, EMBO J, V13, P4840, DOI 10.1002/j.1460-2075.1994.tb06810.x; SPECK SH, 1989, ADV VIRAL ONCOL, P133; SUGDEN B, 1989, J VIROL, V63, P2644, DOI 10.1128/JVI.63.6.2644-2649.1989; TRIVEDI P, 1994, EUR J CANCER, V30A, P84, DOI 10.1016/S0959-8049(05)80024-3; Wilson J B, 1992, Curr Top Microbiol Immunol, V182, P375; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YATES JL, 1985, NATURE, V318, P812; YATES JL, 1988, CANCER CELL, V6, P197; ZHANG CX, 1993, J GEN VIROL, V74, P509, DOI 10.1099/0022-1317-74-3-509	48	69	71	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1545	1552						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731709				2022-12-25	WOS:A1995QU68100010
J	ALBLAS, J; VANETTEN, I; KHANUM, A; MOOLENAAR, WH				ALBLAS, J; VANETTEN, I; KHANUM, A; MOOLENAAR, WH			C-TERMINAL TRUNCATION OF THE NEUROKININ-2 RECEPTOR CAUSES ENHANCED AND SUSTAINED AGONIST-INDUCED SIGNALING - ROLE OF RECEPTOR PHOSPHORYLATION IN SIGNAL ATTENUATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE-K RECEPTOR; HAMSTER OVARY CELLS; TACHYKININ RECEPTORS; A RECEPTOR; DESENSITIZATION; EXPRESSION; CLONING; KINASE; CDNA; LOCALIZATION	The G protein-linked receptor for neurokinin A (NKA) couples to stimulation of phospholipase C and, in some cells, adenylyl cyclase. We have examined the function of the C-terminal cytoplasmic domain in receptor signaling and desensitization. We constructed C-terminal deletion mutants of the human NK-2 receptor (epitope tagged) to remove potential Ser/Thr phosphorylation sites, and expressed them in both mammalian and insect cells, When activated, truncated receptors mediate stronger and more prolonged phosphoinositide hydrolysis than wild-type receptor; however, the amplitude and kinetics of the NKA-induced rise in cytosolic Ca2+ remain unaltered, Protein kinase C (PKC)-activating phorbol ester abolishes wild-type receptor signaling but not mutant receptor signaling. Mutant receptors also mediate enhanced and prolonged cAMP generation, at least in part via PKC activation, When expressed in COS cells or Sf9 insect cells, the wild-type receptor is phosphorylated; receptor phosphorylation increases after addition of either NKA or phorbol ester, In contrast, mutant receptors are not phosphorylated by either treatment. Our results suggest that C-terminal Ser/Thr phosphorylation sites in the NK-2 receptor have a critical role in both homologous and heterologous desensitization, Removal of these phosphorylation sites results in a receptor that mediates sustained activation of signaling pathways and is insensitive to inhibition by PKC.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Alblas, Jacqueline/0000-0002-2996-9697				AHARONY D, 1993, MOL PHARMACOL, V44, P356; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; BRASS LF, 1992, J BIOL CHEM, V267, P6044; CYR CR, 1993, J BIOL CHEM, V268, P26071; DEBERNARDI MA, 1992, P NATL ACAD SCI USA, V88, P9257; DEBLASI A, 1989, TRENDS PHARMACOL SCI, V10, P227, DOI 10.1016/0165-6147(89)90266-6; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EISTETTER HE, 1993, J CELL BIOCHEM, V522, P84; EISTETTER HR, 1991, CELL REGUL, V2, P767, DOI 10.1091/mbc.2.10.767; GERARD NP, 1990, J BIOL CHEM, V265, P20455; INGLESE J, 1993, J BIOL CHEM, V268, P23735; ISHII K, 1994, J BIOL CHEM, V269, P1125; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JALINK K, 1990, J BIOL CHEM, V265, P12232; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENT RB, 1987, SCIENCE, V237, P901, DOI 10.1126/science.3039660; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KRIS RM, 1991, CELL GROWTH DIFFER, V2, P15; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; MANTYH PW, 1989, J NEUROSCI, V9, P258; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; NEWTON AC, 1993, TRENDS BIOCHEM SCI, V18, P275, DOI 10.1016/0968-0004(93)90032-I; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SAVARESE TM, 1992, BIOCHEM J, V283, P1; STRADER CD, 1987, CELL, V49, P855, DOI 10.1016/0092-8674(87)90623-4; TAKANO T, 1994, J BIOL CHEM, V269, P22453; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TILLY BC, 1987, BIOCHEM J, V244, P129, DOI 10.1042/bj2440129; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; YOKOTA Y, 1992, EMBO J, V11, P3585, DOI 10.1002/j.1460-2075.1992.tb05442.x	34	70	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8944	8951		10.1074/jbc.270.15.8944	http://dx.doi.org/10.1074/jbc.270.15.8944			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721803	hybrid			2022-12-25	WOS:A1995QT44800082
J	MALDONADO, AM; PORTILLO, F				MALDONADO, AM; PORTILLO, F			GENETIC-ANALYSIS OF THE FLUORESCEIN ISOTHIOCYANATE BINDING-SITE OF THE YEAST PLASMA-MEMBRANE H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SACCHAROMYCES-CEREVISIAE; SARCOPLASMIC-RETICULUM; DIRECTED MUTAGENESIS; ACTIVE-SITE; LABELED PEPTIDE; DNA; PURIFICATION; DOMAIN; GROWTH	The highly conserved motif of Saccharomyces cerevisiae H+-ATPase (474)KGAP has been proposed to participate in the formation of the phosphorylated intermediate during the catalytic cycle (Portillo, F., and Serrano, R. (1988) EMBO J. 7, 1793-1798), In addition, Lys-474 is the FITC binding site of the yeast enzyme (Portillo, F. and Serrano, R. (1989) Eur. J. Biochem. 186, 501-507). We have performed an intragenic suppressor analysis of the K474R mutation to identify the interacting regions involved in these functions. Random in vitro mutagenesis of the K474R allele resulted in seven suppressor (second-site) mutations. One mutation (V396I), located 18 residues away from the Asp-378 residue, which is phosphorylated during catalysis, is allele-specific. This provides genetic evidence of a direct interaction between the KGAP motif and the phosphorylation domain during the catalytic cycle. Three mutations (V484I, V484I/E485K, and E485K/E486K) are located near Lys-474 and may compense the structural alteration introduced by the K474R mutation. Two substitutions at the end of the predicted transmembrane stretch 2 (A165V and V169I/D170N) and another in the predicted ATP binding domain (P536L) may act as allele-nonspecific suppressors, as they are also able to suppress a mutation at the enzyme's carboxyl terminus.	CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN; UNIV AUTONOMA MADRID, FAC MED, DEPT BIOQUIM, E-28029 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid			Mary, Ana/AAA-2822-2019	Mary, Ana/0000-0002-9357-012X; Portillo Perez, Francisco/0000-0003-4922-346X				BLANPAIN JP, 1992, J BIOL CHEM, V267, P3735; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPIEAUX E, 1993, J BIOL CHEM, V268, P21895; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; ERASO P, 1987, FEBS LETT, V224, P193, DOI 10.1016/0014-5793(87)80446-5; ERASO P, 1994, J BIOL CHEM, V269, P10393; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; FILOTEO AG, 1987, J BIOL CHEM, V262, P6526; Freeman E. R., 1971, Computer designer's conference and exhibition (abstracts); GABER RF, 1992, INT REV CYTOL, V137A, P299; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GOFFEAU A, 1990, MONOVALENT CATIONS B, P155; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HARRIS S, 1993, GENETICS, V135, P5; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOSEPHSON L, 1977, BIOCHEMISTRY-US, V16, P4572, DOI 10.1021/bi00640a006; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MONK BC, 1991, J BIOL CHEM, V266, P18097; NA SQ, 1993, J BIOL CHEM, V268, P11792; NIGGLI V, 1979, J BIOL CHEM, V254, P9955; PARDO JP, 1988, J BIOL CHEM, V263, P18664; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PICK U, 1982, J BIOL CHEM, V257, P6120; PORTILLO F, 1989, EUR J BIOCHEM, V186, P501, DOI 10.1111/j.1432-1033.1989.tb15235.x; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; Rose MD., 1990, METHODS YEAST GENETI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1986, FEBS LETT, V208, P143, DOI 10.1016/0014-5793(86)81549-6; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; SERRANO R, 1985, PLASMA MEMBRANE ATPA; Serrano R, 1991, MOL CELLULAR BIOL YE, P523; SHORTLE D, 1985, GENETICS, V110, P539; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; THOMAS W, 1991, GENETICS, V128, P703; VARA F, 1983, J BIOL CHEM, V258, P5334; WACH A, 1991, EUR J BIOCHEM, V201, P91, DOI 10.1111/j.1432-1033.1991.tb16260.x; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309; [No title captured]	48	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8655	8659		10.1074/jbc.270.15.8655	http://dx.doi.org/10.1074/jbc.270.15.8655			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721767	hybrid			2022-12-25	WOS:A1995QT44800045
J	SOMERSALO, K; CARPEN, O; SAKSELA, E; GAHMBERG, CG; NORTAMO, P; TIMONEN, T				SOMERSALO, K; CARPEN, O; SAKSELA, E; GAHMBERG, CG; NORTAMO, P; TIMONEN, T			ACTIVATION OF NATURAL-KILLER-CELL MIGRATION BY LEUKOCYTE INTEGRIN-BINDING PEPTIDE FROM INTRACELLULAR ADHESION MOLECULE-2 (ICAM-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; LARGE GRANULAR LYMPHOCYTES; CD4+ T-CELLS; INTERCELLULAR-ADHESION; ENDOTHELIAL-CELL; MONOCLONAL-ANTIBODY; HUMAN-NEUTROPHILS; PHOSPHOLIPASE C-GAMMA-1; COSTIMULATORY SIGNAL; ALLOGRAFT-REJECTION	Intracellular adhesion molecule-2 (ICAM-2), one of the ligands of CD11a/CD18 (LFA-1), is mainly expressed on endothelial and hematopoietic cells. The biological significance of ICAM-2 has remained unclear. Previous findings have shown that a peptide from ICAM-2, spanning residues 21-42 from the first immunoglobulin domain, enhances natural killer (NK) cell cytotoxicity and induces T cell aggregation, We have now studied the effect of the same ICAM-2 peptide on NK cell migration in the Boyden chamber assay. The peptide significantly increased NK cell migration up to 215 +/- 21%, as compared to migration of control cells (100%), and the induction was inhibited by anti-CD11a monoclonal antibodies. The ICAM-2 peptide also induced polymerization of F-actin at the leading edge of migratory Nh cells. Crosslinking of CD11a/CD18 receptors with anti-CD11a or anti-CD18 monoclonal antibodies and secondary antibodies resulted in receptor recycling, increased migration, and actin polymerization, but led to slight inhibition of cytotoxicity. The ICAM-2 peptide did not induce such a receptor recycling. Phosphotyrosine immunoblotting experiments showed that the ICAM-2 peptide increased the phosphorylation of 150- and 35-kDa proteins. During cross-linking with antibodies, only the 150-kDa protein showed increased phosphorylation. The results show that depending on the type of CD11a/CD18 receptor ligation different kinds of signals are transduced in NK cells. These signals may either trigger only locomotion, or both locomotion and cytotoxicity. Based on these findings, a major function for ICAM-2 on endothelium may be triggering of migration of adhering leukocytes.	HELSINKI UNIV, DEPT BIOCHEM, SF-00014 HELSINKI, FINLAND	Finland National Institute for Health & Welfare; University of Helsinki	SOMERSALO, K (corresponding author), HELSINKI UNIV, DEPT PATHOL, POB 21, HAARTMANINKATU 3, SF-00014 HELSINKI, FINLAND.		Gahmberg, Carl/AAE-1876-2019	Gahmberg, Carl/0000-0001-9892-9296				AKELLA R, 1992, EUR J IMMUNOL, V22, P1069, DOI 10.1002/eji.1830220429; ALLAVENA P, 1991, J EXP MED, V173, P439, DOI 10.1084/jem.173.2.439; ARFORS KE, 1987, BLOOD, V69, P338; AXELSSON LG, 1981, J IMMUNOL METHODS, V46, P251, DOI 10.1016/0022-1759(81)90141-1; BIANCHI G, 1993, J IMMUNOL, V151, P5135; CARPEN O, 1991, J CELL BIOL, V115, P861, DOI 10.1083/jcb.115.3.861; CARPEN O, 1982, J IMMUNOL, V128, P2691; CARPEN O, 1983, J IMMUNOL, V131, P2695; CARTER SB, 1965, NATURE, V208, P1183, DOI 10.1038/2081183a0; CATERINA MJ, 1991, FASEB J, V5, P3078, DOI 10.1096/fasebj.5.15.1743439; CHATILA TA, 1989, J CELL BIOL, V109, P3435, DOI 10.1083/jcb.109.6.3435; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DAMLE NK, 1992, J IMMUNOL, V148, P665; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DOBOS GJ, 1992, J IMMUNOL, V149, P609; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FISCHER A, 1985, J CLIN INVEST, V76, P2385, DOI 10.1172/JCI112251; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; GORSKI A, 1994, IMMUNOL TODAY, V15, P251, DOI 10.1016/0167-5699(94)90002-7; HAKKERT BC, 1990, EUR J IMMUNOL, V20, P2775, DOI 10.1002/eji.1830201236; HEDMAN H, 1992, J IMMUNOL, V149, P2295; HERMANOWSKIVOSATKA A, 1992, CELL, V68, P341, DOI 10.1016/0092-8674(92)90475-R; JAASKELAINEN J, 1992, J IMMUNOL, V149, P260; JACKSON AM, 1992, IMMUNOLOGY, V76, P286; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KUHLMAN P, 1991, J IMMUNOL, V137, P2395; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPETER ER, 1992, DIABETES, V41, P1668, DOI 10.2337/diabetes.41.12.1668; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LI R, 1993, J BIOL CHEM, V268, P17513; LI R, 1993, J BIOL CHEM, V268, P21474; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARBOE CC, 1983, CLIN IMMUNOL IMMUNOP, V27, P141, DOI 10.1016/0090-1229(83)90063-6; MCVICAR DW, 1994, EUR J IMMUNOL, V24, P165, DOI 10.1002/eji.1830240125; MELERO I, 1993, EUR J IMMUNOL, V23, P1859, DOI 10.1002/eji.1830230819; MIRON S, 1992, CELL IMMUNOL, V144, P182, DOI 10.1016/0008-8749(92)90235-H; NEMLANDER A, 1983, EUR J IMMUNOL, V13, P348, DOI 10.1002/eji.1830130415; NORTAMO P, 1988, SCAND J IMMUNOL, V28, P537, DOI 10.1111/j.1365-3083.1988.tb01485.x; NORTAMO P, 1991, EUR J IMMUNOL, V21, P2629, DOI 10.1002/eji.1830211049; NORTAMO P, 1991, J IMMUNOL, V146, P2530; OPPENHEIMERMARKS N, 1990, J IMMUNOL, V145, P140; PARDI R, 1989, J IMMUNOL, V143, P3157; PEREZ HD, 1986, J IMMUNOL, V136, P1803; PRIETO J, 1988, IMMUNOLOGY, V63, P631; RENKONEN R, 1992, AM J PATHOL, V140, P763; ROBERTSON MJ, 1990, BLOOD, V76, P2421; ROEP BO, 1994, LANCET, V343, P1590, DOI 10.1016/S0140-6736(94)93055-4; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; SETH R, 1991, LANCET, V338, P83, DOI 10.1016/0140-6736(91)90077-3; SHIMIZU Y, 1993, J IMMUNOL, V151, P4106; SOMERSALO K, 1992, J IMMUNOL, V149, P590; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAHLS AK, 1989, SCAND J IMMUNOL, V29, P211, DOI 10.1111/j.1365-3083.1989.tb01118.x; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TAFFS RE, 1991, J IMMUNOL, V147, P722; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TIMONEN T, 1981, J EXP MED, V153, P569, DOI 10.1084/jem.153.3.569; TIMONEN T, 1990, INT J CANCER, V46, P1035, DOI 10.1002/ijc.2910460615; TIMONEN T, 1980, J IMMUNOL METHODS, V36, P285, DOI 10.1016/0022-1759(80)90133-7; TIMONEN T, 1988, J IMMUNOL, V141, P1041; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; VANSEVENTER GA, 1992, J IMMUNOL, V149, P3872; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; VANSEVENTER GA, 1991, EUR J IMMUNOL, V21, P1711, DOI 10.1002/eji.1830210719	73	33	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8629	8636		10.1074/jbc.270.15.8629	http://dx.doi.org/10.1074/jbc.270.15.8629			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721764	hybrid			2022-12-25	WOS:A1995QT44800041
J	TIAN, WD; WELLS, AV; CHAMPION, PM; DIPRIMO, C; GERBER, N; SLIGAR, SG				TIAN, WD; WELLS, AV; CHAMPION, PM; DIPRIMO, C; GERBER, N; SLIGAR, SG			MEASUREMENTS OF CO GEMINATE RECOMBINATION IN CYTOCHROMES P450 AND P420	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; RESONANCE RAMAN INVESTIGATIONS; CARBON-MONOXIDE BINDING; RAT-LIVER MICROSOMES; RELAXATION DYNAMICS; CRYSTAL-STRUCTURE; DISTAL HISTIDINE; MYOGLOBIN; SUBSTRATE; COMPLEX	The kinetics of CO geminate recombination in cytochrome P450(cam) are studied at room temperature subsequent to laser photolysis. The geminate rebinding kinetics of P450 are strongly affected by the presence of the camphor substrate, We observe a similar to 2% geminate yield for substrate-bound P450 and a 90% geminate yield when the substrate is absent. The drastic difference in the geminate kinetics suggests that the presence of camphor significantly alters the CO rebinding and escape rates by modifying the heme pocket environment. Two geminate phases and two bimolecular rebinding phases in the substrate free protein were observed, which could arise from slowly interconverting protein conformations. When the temperature or the viscosity of the solution is changed, the fast geminate rate remains the same, whereas the slow geminate rate and the two bimolecular rates change significantly. The geminate rebinding yield of substrate-free P420 is smaller than that of substrate free P450, but its geminate rebinding rate is faster, This demonstrates that in the absence of substrate, CO escapes from the pocket of P420 much more rapidly than from P450 and suggests that the distal pocket environment is altered in the P420 form.	UNIV ILLINOIS, DEPT BIOCHEM CHEM & BIOPHYS, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	TIAN, WD (corresponding author), NORTHEASTERN UNIV, DEPT PHYS, BOSTON, MA 02115 USA.		Di primo, Carmelo/M-6984-2018	Di primo, Carmelo/0000-0002-0509-8399	NIADDK NIH HHS [AM35090] Funding Source: Medline; NIGMS NIH HHS [GM31756] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM035090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031756, R01GM031756] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANGCHAROENPAURPONG O, 1987, J CHEM PHYS, V87, P4273, DOI 10.1063/1.452885; CHAMPION PM, 1988, BIOL APPLICATIONS RA, V3, P249; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; DEBEY P, 1973, FEBS LETT, V35, P86, DOI 10.1016/0014-5793(73)80583-6; DEBRUNNER PG, 1978, MET IONS BIOL SYST, V7, P241; DIPRIMO C, 1990, J BIOL CHEM, V265, P5361; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; GIBSON QH, 1989, J BIOL CHEM, V264, P20155; GRAY RD, 1982, J BIOL CHEM, V257, P1086; Gunsalus I C, 1978, Methods Enzymol, V52, P166; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; HOA GHB, 1989, BIOCHEMISTRY-US, V28, P651; JUNG C, 1992, BIOCHEMISTRY-US, V31, P12855, DOI 10.1021/bi00166a021; KOLEY AP, 1994, BIOCHEMISTRY-US, V33, P2484, DOI 10.1021/bi00175a017; LAMBRIGHT DG, 1991, CHEM PHYS, V158, P249, DOI 10.1016/0301-0104(91)87069-8; Martinis S. A., 1990, THESIS U ILLINOIS UR; MCKINNIE RE, 1981, J BIOL CHEM, V256, P8928; MIURA Y, 1991, BIOCHEMISTRY-US, V30, P3395, DOI 10.1021/bi00228a006; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; OERTLE M, 1985, P NATL ACAD SCI USA, V82, P4900, DOI 10.1073/pnas.82.15.4900; OKEEFE DH, 1978, BIOCHEMISTRY-US, V17, P5845, DOI 10.1021/bi00619a036; OLSON JS, 1988, NATURE, V336, P265, DOI 10.1038/336265a0; PETERSON JA, 1972, ARCH BIOCHEM BIOPHYS, V151, P427, DOI 10.1016/0003-9861(72)90518-8; POULOS TL, 1985, J BIOL CHEM, V260, P6122; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; QUILLIN M L, 1992, Biophysical Journal, V61, pA466; SHIMADA H, 1979, FEBS LETT, V98, P290, DOI 10.1016/0014-5793(79)80202-1; SHIMIZU T, 1991, BIOCHEMISTRY-US, V30, P4659, DOI 10.1021/bi00233a004; SHIRO Y, 1994, BIOCHEMISTRY-US, V33, P8673, DOI 10.1021/bi00195a007; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; TIAN WD, 1993, J MOL BIOL, V233, P155, DOI 10.1006/jmbi.1993.1491; TIAN WD, 1992, PHYS REV LETT, V68, P408, DOI 10.1103/PhysRevLett.68.408; UNO T, 1985, J BIOL CHEM, V260, P2023; WELLS AV, 1992, BIOCHEMISTRY-US, V31, P4384, DOI 10.1021/bi00133a002; WLETH VL, 1940, SOLUBILITIES INORGAN, V1, P217	36	25	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8673	8679		10.1074/jbc.270.15.8673	http://dx.doi.org/10.1074/jbc.270.15.8673			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721770	hybrid			2022-12-25	WOS:A1995QT44800048
J	VOURETCRAVIARI, V; GRALL, D; CHAMBARD, JC; RASMUSSEN, UB; POUYSSEGUR, J; VANOBBERGHENSCHILLING, E				VOURETCRAVIARI, V; GRALL, D; CHAMBARD, JC; RASMUSSEN, UB; POUYSSEGUR, J; VANOBBERGHENSCHILLING, E			POSTTRANSLATIONAL AND ACTIVATION-DEPENDENT MODIFICATIONS OF THE G-PROTEIN-COUPLED THROMBIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PLATELET ACTIVATION; MOLECULAR-CLONING; ALPHA-THROMBIN; GROWTH-FACTOR; DOMAIN; EXPRESSION; ANTIBODIES; MECHANISMS; PEPTIDES	The purpose of the present study was to analyze the post-translational and activation-dependent modifications of the G protein coupled thrombin receptor. A human receptor cDNA was engineered to encode an epitope tag derived from the vesicular stomatitis virus glycoprotein at the COOH terminus of the receptor and expressed in human embryonic kidney 293 cells. We show here that the mature receptor is a glycosylated protein with an apparent molecular mass ranging from 68 to 80 kDa by SDS-polyacrylamide gel electrophoresis. Removal of asparagine-linked oligosaccharides with N-glycosidase F leads to the appearance of a 36-40-kDa receptor species. The current model for receptor activation by thrombin involves specific hydrolysis of the arginine-4l/serine-42 (Arg-41/Ser-42) peptide bond. Cleavage of the receptor by thrombin was demonstrated directly by Western analyses performed on membranes and glycoprotein-enriched lysates from transfected cells. Whereas thrombin treatment of cells results in increased mobility of the receptor in SDS-polyacrylamide gel electrophoresis, we found that their treatment with the thrombin receptor agonist peptide leads to a decrease in thrombin receptor mobility due, in part, to phosphorylation. The serine proteases trypsin and plasmin also cleave and activate the receptor similar to thrombin, whereas chymotrypsin cleaves the receptor at a site distal to Arg-41, thus rendering it unresponsive to thrombin while still responsive to thrombin receptor agonist peptide.	CTR BIOCHIM,CNRS,UMR 134,F-06108 NICE 2,FRANCE; TRANSGENE SA,F-67082 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Transgene SA			Van Obberghen-Schilling, Ellen/Q-4372-2019; Van Obberghen-Schilling, Ellen/O-1581-2016	Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; Van Obberghen-Schilling, Ellen/0000-0003-2961-0059; CHAMBARD, Jean Claude/0000-0003-4722-2308				BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BRASS LF, 1993, THROMB HAEMOSTASIS, V70, P217; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CHEN J, 1994, J BIOL CHEM, V269, P16041; HUNG DT, 1992, J CLIN INVEST, V89, P1350, DOI 10.1172/JCI115721; HUNG DT, 1992, J CLIN INVEST, V89, P444, DOI 10.1172/JCI115604; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; LANDOLTMARTICOR.C, 1994, BIOCHEM J, V302, P253; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MCGOWAN EB, 1986, J BIOL CHEM, V261, P739; MORI S, 1992, J BIOL CHEM, V267, P6429; Rasmussen JR., 1992, CURR OPIN STRUC BIOL, V2, P682; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; TAM SW, 1980, J BIOL CHEM, V255, P6626; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P4813, DOI 10.1074/jbc.270.9.4813; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	28	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8367	8372		10.1074/jbc.270.14.8367	http://dx.doi.org/10.1074/jbc.270.14.8367			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713946	hybrid			2022-12-25	WOS:A1995QR52600085
J	HASEGAWA, Y; TAKEDA, S; ICHII, S; KOIZUMI, K; MARUYAMA, M; FUJII, A; OHTA, H; NAKAJIMA, T; OKUDA, M; BABA, S; NAKAMURA, Y				HASEGAWA, Y; TAKEDA, S; ICHII, S; KOIZUMI, K; MARUYAMA, M; FUJII, A; OHTA, H; NAKAJIMA, T; OKUDA, M; BABA, S; NAKAMURA, Y			DETECTION OF K-RAS MUTATIONS IN DNAS ISOLATED FROM FECES OF PATIENTS WITH COLORECTAL TUMORS BY MUTANT-ALLELE-SPECIFIC AMPLIFICATION (MASA)	ONCOGENE			English	Article						FECES; COLORECTAL CANCER; GENETIC DIAGNOSIS; K-RAS; MASA (MUTATED ALLELE SPECIFIC AMPLIFICATION	POLYMERASE CHAIN-REACTION; CANCER	K-ras mutations are found in approximately half of all colorectal tumors examined, To explore the possibility of detecting mutated K-ras rapidly and efficiently in DNAs isolated from fecal material, we applied the mutant allele specific amplification (MASA)-PCR method to DNA from feces of patients with colorectal tumors, Among 55 colorectal adenocarcinomas or adenomas examined, 19 were found to carry K-ras mutations in codons 12 or 13, We were able to PCR-amplify DNAs isolated from feces of 15 of these 19 patients, but in only three of the fecal samples, we were able to detect the K-ras mutations corresponding to tumor DNA by MASA and ethidium-bromide staining of the gel, The carcinomas in these three cases were more than 40 mm x 40 mm in size and located in the sigmoid colon or rectum, However, we identified the K-ras mutations in fecal DNAs of additional seven patients by MASA when the gels were blotted and probed with a radio-labeled oligonncleotide; the tumors in those patients had arisen in the distal half of the colon and the smallest of these tumors was only 7 mm x 5 mm, No K-ras mutations were detectable in feces of the remaining five cases, whose tumors were relatively small and/or located in the proximal region, The results suggested that the MASA-PCR system has potential for development as a simple, rapid and noninvasive method for diagnosing the presence of colorectal tumors that carry mutant K-ras alleles, particularly tumors located in the distal colon.	JAPANESE FDN CANC RES, INST CANC, DEPT BIOCHEM, TOSHIMA KU, TOKYO 170, JAPAN; JAPANESE FDN CANC RES, INST CANC, DEPT INTERNAL MED, TOSHIMA KU, TOKYO 170, JAPAN; JAPANESE FDN CANC RES, INST CANC, DEPT SURG, TOSHIMA KU, TOKYO 170, JAPAN; EISAI & CO LTD, TSUKUBA RES LABS, IBARAKI, OSAKA, JAPAN; HAMAMATSU MED UNIV, DEPT SURG 2, SHIZUOKA, JAPAN	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Eisai Co Ltd; Hamamatsu University School of Medicine								AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; BOS JL, 1989, CANCER RES, V49, P4682; EHLEN T, 1989, BIOCHEM BIOPH RES CO, V160, P441, DOI 10.1016/0006-291X(89)92452-2; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; OKAYAMA H, 1989, J LAB CLIN MED, V114, P105; RANSOHOFF DF, 1993, JAMA-J AM MED ASSOC, V269, P1278, DOI 10.1001/jama.269.10.1278; SATO T, 1990, CANCER RES, V50, P7184; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; STORK P, 1991, ONCOGENE, V6, P857; TAKEDA S, 1993, HUM MUTAT, V2, P112, DOI 10.1002/humu.1380020209; TOBI M, 1994, J NATL CANCER I, V86, P1007; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757	12	92	114	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1441	1445						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731696				2022-12-25	WOS:A1995QR65100023
J	SANCHEZGARCIA, I; AXELSON, H; RABBITTS, TH				SANCHEZGARCIA, I; AXELSON, H; RABBITTS, TH			FUNCTIONAL DIVERSITY OF LIM PROTEINS - AMINO-TERMINAL ACTIVATION DOMAINS IN THE ONCOGENIC PROTEINS RBTN1 AND RBTN2	ONCOGENE			English	Article						LIM DOMAIN; LEUKEMIA; TRANSCRIPTION; ACTIVATION DOMAIN	EXPRESSION VECTOR; MAMMALIAN-CELLS; DNA-BINDING; GENE; MOTIF; YEAST; DIFFERENTIATION; HOMEODOMAIN; ENCODES; ELEGANS	The RBTN1 and RBTN2 genes are activated by distinct translocations involving chromosome 11 in some T cell acute leukaemias. The RBTN proteins belong to the LIM family which comprises proteins with one, two or three cysteine-rich LIM domains, sometimes together with homeodomains or protein kinase domains. The RBTN1 and RBTN2 proteins comprise only tandem LIM domains. We report that RBTN1 and RBTN2 proteins are capable of supporting transcriptional transactivation of specific reporter genes in transfection assays. The results, using intact proteins or fusions with the homeodomain of the heterologous protein Isl-1, show that this transcriptional activation ability resides in the NH2-terminal parts of both proteins. The use of yeast assays with RBTN2 shows that RBTN2 forms homodimers and that the NH2-terminal 27 amino acids are sufficient to facilitate transcriptional transactivation. These data expand the functional diversity of the LIM-domain protein family and they augment the previously defined relationship between chromosomal translocations and transcriptional activation.			SANCHEZGARCIA, I (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.		SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905				BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MIZUNO K, 1994, ONCOGENE, V9, P1605; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOUTHON MA, 1993, BLOOD, V81, P647; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RABBITTS TH, 1990, NATURE, V346, P418, DOI 10.1038/346418a0; REDDY ESP, 1986, GENE ANAL TECH, V3, P41; Rose MD., 1990, METHODS YEAST GENETI; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SANCHEZGARCIA I, 1993, SEMIN CANCER BIOL, V4, P349; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WADMAN IA, 1994, ONCOGENE, V9, P3713; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WU RY, 1994, J BIOL CHEM, V269, P25085; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	46	20	21	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1301	1306						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731680				2022-12-25	WOS:A1995QR65100006
J	KRNACIK, MJ; LI, S; LIAO, J; ROSEN, JM				KRNACIK, MJ; LI, S; LIAO, J; ROSEN, JM			POSITION-INDEPENDENT EXPRESSION OF WHEY ACIDIC PROTEIN TRANSGENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; HIGH-LEVEL EXPRESSION; CASEIN GENE-EXPRESSION; MICE; REGION; ENHANCER; CELLS; ASSAY; TRANSCRIPTION; ORGANIZATION	The expression of a 3-kilobase genomic rat whey acidic protein (WAP) clone (-949/+2020) in transgenic mice has been demonstrated previously to be copy number dependent and independent of the site of integration (Dale, T., Krnacik, M. J., Schmidhauser, C., Yang, C. Q.-L., Bissell, M. J., and Rosen, J. M. (1992) Mol. Cell. Biol, 12, 905-914), The present study demonstrated that position-independent expression of the rat WAP -949/ +2020 transgene was dependent on transgene spacing, Position-independent expression also was inhibited by an internal replacement of 49 base pair within the conserved GC-rich 3'-untranslated region (3'-UTR) with an identically sized nonspecific DNA sequence, Using electrophoretic mobility shift assays, nuclear factors isolated from mouse and human cells were shown to associate specifically with the rWAP 3'-UTR DNA, but not with the 3'-UTR containing the internal replacement or specific point mutations, Since a single copy of the 3'UTR inserted 5' of the promoter could not rescue the 3'-UTR deletion, the 3'-UTR element does not appear to be functioning as either a classic enhancer or insulator element, However, the level of expression of rWAP transgenes was correlated with transgene association with the chromosomal scaffold in vivo.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine					NCI NIH HHS [CA 16303] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016303, R37CA016303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1990, J CELL BIOL, V111, P1197, DOI 10.1083/jcb.111.3.1197; ALTIOK S, 1994, MOL CELL BIOL, V14, P6004, DOI 10.1128/MCB.14.9.6004; ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BAYNA EM, 1990, NUCLEIC ACIDS RES, V18, P2977, DOI 10.1093/nar/18.10.2977; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; BURDON T, 1991, J BIOL CHEM, V266, P6909; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; CHAMBERLAIN JW, 1991, MOL CELL BIOL, V11, P3564, DOI 10.1128/MCB.11.7.3564; CHEN LH, 1989, CELL REGUL, V1, P45, DOI 10.1091/mbc.1.1.45; CHUNG JH, 1994, CELL, V74, P505; CIEJEK EM, 1984, NATURE, V306, P607; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DALE TC, 1992, MOL CELL BIOL, V12, P905, DOI 10.1128/MCB.12.3.905; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DOPPLER W, 1991, MOL ENDOCRINOL, V5, P1624, DOI 10.1210/mend-5-11-1624; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GREENBERG NM, 1991, P NATL ACAD SCI USA, V88, P8327, DOI 10.1073/pnas.88.19.8327; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HOBBS AA, 1982, J BIOL CHEM, V257, P3598; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEE KF, 1988, NUCLEIC ACIDS RES, V16, P1027, DOI 10.1093/nar/16.3.1027; LI S, 1995, MOL CELL BIOL, V15, P2063; LI S, 1994, J BIOL CHEM, V269, P14235; MCKENZIE RM, 1978, J DAIRY SCI, V61, P723, DOI 10.3168/jds.S0022-0302(78)83639-X; MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943, DOI 10.1073/pnas.89.15.6943; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; REITMAN M, 1993, MOL CELL BIOL, V13, P3990, DOI 10.1128/MCB.13.7.3990; ROBINSON SI, 1982, CELL, V28, P99, DOI 10.1016/0092-8674(82)90379-8; Sambrook J, 1989, MOL CLONING LABORATO; SPECTOR DL, 1993, BIOCHEM SOC T, V21, P918, DOI 10.1042/bst0210918; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; VILOTTE JL, 1989, EUR J BIOCHEM, V186, P43, DOI 10.1111/j.1432-1033.1989.tb15175.x; WHITELAW CB, 1992, BIOCHEM J, V285, P31; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901	42	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11119	11129		10.1074/jbc.270.19.11119	http://dx.doi.org/10.1074/jbc.270.19.11119			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744742	hybrid			2022-12-25	WOS:A1995QX86500018
J	GIARDINA, C; LIS, JT				GIARDINA, C; LIS, JT			SODIUM-SALICYLATE AND YEAST HEAT-SHOCK GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROMOTER; ASPIRIN; ACTIVATION; EXPRESSION; RESISTANCE; INVIVO; CELLS; DRUGS; ACID	The anti-inflammatory drug sodium salicylate modulates the activity of specific transcription factors in humans. Here we show that salicylate and sorbate, another organic acid, stimulate DNA binding by yeast heat shock transcription factor (HSF) in vivo. Surprisingly, salicylate inhibits heat shock gene transcription even in cells induced by a prior heat shock. This inhibition of transcription occurs at a step after HSF and transcription factor IID binding but before promoter melting by RNA polymerase. Salicylate appears to generate a tight binding but activation-impotent HSF by cytoplasmic acidification, since inhibiting proton efflux from cells triggers this same DNA binding and inhibition of heat shock gene expression.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025232, R01GM025232] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON S, 1985, P NATL ACAD SCI USA, V82, P7227, DOI 10.1073/pnas.82.21.7227; ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; CHENG LL, 1994, MICROBIOL-SGM, V140, P1085, DOI 10.1099/13500872-140-5-1085; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; DELANEY TP, 1994, SCIENCE, V266, P1247, DOI 10.1126/science.266.5188.1247; FERREIRA SH, 1974, ANNU REV PHARMACOL, V14, P57, DOI 10.1146/annurev.pa.14.040174.000421; GIARDINA C, 1993, SCIENCE, V261, P759, DOI 10.1126/science.8342041; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KREBS HA, 1983, BIOCHEM J, V214, P657, DOI 10.1042/bj2140657; LEE MS, 1991, EMBO J, V10, P607, DOI 10.1002/j.1460-2075.1991.tb07988.x; LINDQUIST S, 1988, ANNU REV GENET, V55, P1151; MACILWAIN C, 1993, NATURE, V364, P369; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MORIMOTO RI, 1990, BIOL HEAT SHOCK PROT, P417; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; PANARETOU B, 1990, J GEN MICROBIOL, V136, P1763, DOI 10.1099/00221287-136-9-1763; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84	26	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10369	10372		10.1074/jbc.270.18.10369	http://dx.doi.org/10.1074/jbc.270.18.10369			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737966	hybrid			2022-12-25	WOS:A1995QW60100003
J	BRENNAN, J; TAKEI, F; WONG, S; MAGER, DL				BRENNAN, J; TAKEI, F; WONG, S; MAGER, DL			CARBOHYDRATE-RECOGNITION BY A NATURAL-KILLER-CELL RECEPTOR, LY-49C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTEGRAL MEMBRANE-PROTEINS; MAJOR HISTOCOMPATIBILITY ANTIGENS; CLASS-I; ANIMAL LECTINS; MULTIGENE FAMILY; MOUSE NKR-P1; GENE-COMPLEX; IDENTIFICATION; REJECTION; MOLECULE	Ly-49 represents a family of type II transmembrane proteins containing C-type lectin domains. At least two members of the Ly-49 family, namely Ly-49A and Ly-49C, are expressed by distinct subsets of natural killer cells and bind to class I major histocompatibility complex antigens on the surface of target cells. In this report we have established that Ly-49C mediates carbohydrate recognition. The sulfated glycans fucoidan, lambda-carrageenan, and dextran sulfate were found to be potent inhibitors of Ly-49C-mediated cell adhesion, whereas other polysaccharides of similar size, charge, or sulfate content were noninhibitory. Ah of the polysaccharides which inhibited Ly-49C adhesion also blocked the binding of the antibody 5E6 to Ly-49C-expressing COS cells, confirming the direct protein-carbohydrate interaction. The enzymatic removal of specific carbohydrates from the target cell surface has shown that Ly-49C-mediated adhesion is not sialic acid-dependent, but is significantly decreased following fucosidase treatment. These results suggest an important role for carbohydrate recognition by natural killer cell receptors.	UNIV BRITISH COLUMBIA, DEPT MED GENET, VANCOUVER, BC V5Z 1L3, CANADA; UNIV BRITISH COLUMBIA, DEPT PATHOL, VANCOUVER, BC V5Z 1L3, CANADA; UNIV OXFORD, INST GLYOBIOL, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND	University of British Columbia; University of British Columbia; University of Oxford	BRENNAN, J (corresponding author), BRITISH COLUMBIA CANC AGCY, TERRY FOX LAB, 601 W 10TH AVE, VANCOUVER, BC V5Z 1L3, CANADA.			Takei, Fumio/0000-0002-3620-5046; Mager, Dixie/0000-0002-5955-2550				ALTINGMEES M, 1986, MOL IMMUNOL, V23, P847, DOI 10.1016/0161-5890(86)90070-2; BEZOUSKA K, 1994, J BIOL CHEM, V269, P16945; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; BRENNAN J, 1994, J EXP MED, V180, P2287, DOI 10.1084/jem.180.6.2287; CHAMBERS WH, 1989, J EXP MED, V169, P1373, DOI 10.1084/jem.169.4.1373; CHAMBERS WH, 1993, GLYCOBIOLOGY, V3, P9, DOI 10.1093/glycob/3.1.9; CHAN PY, 1989, J IMMUNOL, V142, P1727; CORREA I, 1995, IMMUNITY, V2, P61, DOI 10.1016/1074-7613(95)90079-9; DANIELS BF, 1994, IMMUNITY, V1, P785, DOI 10.1016/S1074-7613(94)80020-0; DANIELS BF, 1994, J EXP MED, V180, P687, DOI 10.1084/jem.180.2.687; DEANGELIS PL, 1987, J BIOL CHEM, V262, P13946; DOUGHERTY GJ, 1994, J BIOL CHEM, V269, P9074; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; GIORDA R, 1991, J IMMUNOL, V147, P1701; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; KANE KP, 1994, J EXP MED, V179, P1011, DOI 10.1084/jem.179.3.1011; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KIMBALL ES, 1983, CONTEMP TOP MOLEC IM, V9, P1; LANIER LL, 1986, J IMMUNOL, V137, P2735; LANIER LL, 1994, J IMMUNOL, V153, P2417; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MCCOY J P JR, 1991, Glycobiology, V1, P321, DOI 10.1093/glycob/1.4.321; MISRA DN, 1987, IMMUNOGENETICS, V26, P204, DOI 10.1007/BF00346513; PARISH CR, 1988, J IMMUNOL, V141, P3498; PATANKAR MS, 1993, J BIOL CHEM, V268, P21770; ROCHON YP, 1994, J IMMUNOL, V152, P1385; SENTMAN CL, 1994, J IMMUNOL, V153, P5482; SENTMAN CL, 1989, J EXP MED, V170, P191, DOI 10.1084/jem.170.1.191; SMITH HRC, 1994, J IMMUNOL, V153, P1068; SWIEDLER SJ, 1985, J BIOL CHEM, V260, P4046; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WONG S, 1991, J IMMUNOL, V147, P1417; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313, DOI 10.1016/S0065-2776(08)60645-8; YEDNOCK TA, 1987, J CELL BIOL, V104, P725, DOI 10.1083/jcb.104.3.725; YOKOYAMA WM, 1990, J IMMUNOL, V145, P2353; YOKOYAMA WM, 1989, J IMMUNOL, V143, P1379; YOKOYAMA WM, 1991, J IMMUNOL, V147, P3229; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145; YU YYL, 1992, ANNU REV IMMUNOL, V10, P189, DOI 10.1146/annurev.iy.10.040192.001201	43	73	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9691	9694		10.1074/jbc.270.17.9691	http://dx.doi.org/10.1074/jbc.270.17.9691			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730344				2022-12-25	WOS:A1995QV41700001
J	HUSAIN, I; TOMKINSON, AE; BURKHART, WA; MOYER, MB; RAMOS, W; MACKEY, ZB; BESTERMAN, JM; CHEN, JW				HUSAIN, I; TOMKINSON, AE; BURKHART, WA; MOYER, MB; RAMOS, W; MACKEY, ZB; BESTERMAN, JM; CHEN, JW			PURIFICATION AND CHARACTERIZATION OF DNA-LIGASE-III FROM BOVINE TESTES - HOMOLOGY WITH DNA-LIGASE-II AND VACCINIA DNA-LIGASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER EMBRYOS; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; DAMAGING AGENTS; STRAIN 46BR; CALF THYMUS; CELL-CYCLE; GENE; RECOMBINATION; REPLICATION	Mammalian cell nuclei contain three biochemically distinct DNA ligases. In the present study we have found high levels of DNA ligase I and DNA ligase III activity in bovine testes and have purified DNA ligase III to near homogeneity. The high level of DNA ligase III suggests a role for this enzyme in meiotic recombination. In assays measuring the fidelity of DNA joining, we detected no significant differences between DNA ligases II and III, whereas DNA ligase I was clearly a more faithful enzyme and was particularly sensitive to 3' mismatches. Amino acid sequences of peptides derived from DNA ligase III demonstrated that this enzyme, like DNA ligase II, is highly homologous with vaccinia DNA ligase. The absence of unambiguous differences between homologous peptides from DNA ligases II and III (10 pairs of peptides, 136 identical amino acids) indicates that these enzymes are either derived from a common precursor polypeptide or are encoded from the same gene by alternative splicing. Based on similarities in amino acid sequence and biochemical properties, we suggest that DNA ligases II and III. Drosophila DNA ligase II, and the DNA ligases encoded by the pox viruses constitute a distinct family of DNA ligases that perform specific roles in DNA repair and genetic recombination.	GLAXO INC,RES INST,DEPT CELL BIOL,RES TRIANGLE PK,NC 27709; GLAXO INC,RES INST,DEPT BIOANALYT & STRUCT CHEM,RES TRIANGLE PK,NC 27709; UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,INST BIOTECHNOL,SAN ANTONIO,TX 78245	GlaxoSmithKline; GlaxoSmithKline; University of Texas System; University of Texas Health San Antonio				Mackey, Zachary/0000-0002-4533-0973	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047251, R01GM047251] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47251] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUADO B, 1992, J GEN VIROL, V73, P2887, DOI 10.1099/0022-1317-73-11-2887; BARKER DG, 1985, NUCLEIC ACIDS RES, V13, P8323, DOI 10.1093/nar/13.23.8323; BARKER DG, 1987, EUR J BIOCHEM, V162, P658; BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKHART W, 1993, TECHNIQUES PROTEIN C, V4, P399; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; CHAN JYH, 1984, MUTAT RES, V131, P209, DOI 10.1016/0167-8817(84)90027-0; COLINAS RJ, 1990, VIROLOGY, V179, P267, DOI 10.1016/0042-6822(90)90295-3; CREISSEN D, 1982, NATURE, V296, P271, DOI 10.1038/296271a0; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; HENDERSON LM, 1985, P NATL ACAD SCI USA, V82, P2044, DOI 10.1073/pnas.82.7.2044; HIGASHITANI A, 1990, CELL STRUCT FUNCT, V15, P67, DOI 10.1247/csf.15.67; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; JOHNSTON LH, 1986, EXP CELL RES, V165, P541, DOI 10.1016/0014-4827(86)90606-3; KERR SM, 1991, EMBO J, V10, P4343, DOI 10.1002/j.1460-2075.1991.tb05012.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKO DD, 1990, J BIOL CHEM, V265, P12618; LEHMAN IR, 1974, SCIENCE, V186, P790; LEHMANN AR, 1988, CANCER RES, V48, P6343; LI CG, 1994, NUCLEIC ACIDS RES, V22, P632, DOI 10.1093/nar/22.4.632; LI J-H, 1989, Molecular Toxicology, V2, P1; LJUNGQUIST S, 1994, MUTAT RES, V314, P177, DOI 10.1016/0921-8777(94)90081-7; LONN U, 1989, CARCINOGENESIS, V10, P981, DOI 10.1093/carcin/10.6.981; MALKAS LH, 1990, BIOCHEMISTRY-US, V29, P6362, DOI 10.1021/bi00479a004; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PARKS RJ, 1994, VIROLOGY, V202, P642, DOI 10.1006/viro.1994.1385; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; RABIN BA, 1986, J BIOL CHEM, V261, P637; RESNICK M A, 1987, P157; ROBERTS E, 1994, J BIOL CHEM, V269, P3789; SMITH GL, 1989, NUCLEIC ACIDS RES, V17, P9021; SODERHALL S, 1976, NATURE, V260, P640, DOI 10.1038/260640a0; SODERHALL S, 1975, J BIOL CHEM, V250, P8438; SODERHALL S, 1973, BIOCHEM BIOPH RES CO, V53, P910, DOI 10.1016/0006-291X(73)90178-2; SQUIRES S, 1983, CARCINOGENESIS, V4, P565, DOI 10.1093/carcin/4.5.565; TAKAHASHI M, 1987, FEBS LETT, V213, P345, DOI 10.1016/0014-5793(87)81520-X; TEO IA, 1983, MUTAT RES, V107, P371, DOI 10.1016/0027-5107(83)90177-X; TERAOKA H, 1986, J BIOL CHEM, V261, P6888; TERAOKA H, 1982, J BIOL CHEM, V257, P4758; TOMKINSON AE, 1993, NUCLEIC ACIDS RES, V21, P5425, DOI 10.1093/nar/21.23.5425; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TOMKINSON AE, 1992, BIOCHEMISTRY-US, V31, P11762, DOI 10.1021/bi00162a013; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; YOO HY, 1992, BIOCHEM BIOPH RES CO, V186, P900, DOI 10.1016/0006-291X(92)90831-5	49	65	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9683	9690		10.1074/jbc.270.16.9683	http://dx.doi.org/10.1074/jbc.270.16.9683			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721901	hybrid			2022-12-25	WOS:A1995QU08900092
J	JOOSS, K; LAM, EWF; BYBEE, A; GIRLING, R; MULLER, R; LATHANGUE, NB				JOOSS, K; LAM, EWF; BYBEE, A; GIRLING, R; MULLER, R; LATHANGUE, NB			PROTOONCOGENIC PROPERTIES OF THE DP FAMILY OF PROTEINS	ONCOGENE			English	Article						DP/E2F; CELL CYCLE; TRANSCRIPTION; ONCOGENE	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; ADENOVIRUS-E1A PREVENTS; CELL-PROLIFERATION; COMPLEX-FORMATION; BINDING PROTEIN; CYCLIN-A; TRANSACTIVATION; P107; FIBROBLASTS	The cellular transcription factor DRTF1/E2F is implicated in the control of cellular proliferation due to its interaction with key regulators of cell cycle progression, such as the retinoblastoma tumour suppressor gene product, cyclins and cyclin-dependent kinases. DRTF1/E2F is a heterodimeric DNA binding activity which arises when a member of two distinct families of proteins, DP and E2F, interact as DP/E2F heterodimers, for example, DP-1 and E2F-1, Tn DRTF1/E2F the activity of DP-1 is under cell cycle control, possibly by phosphorylation, and in many types of cells it is a frequent, if not general DNA binding component of DRTF1/E2F. The expression of other DP proteins, such as DP-2, is tissue-restricted. Here, we show that DP-1 and DP-2 are integrated with another growth regulating pathway which involves signal transduction emanating from activated Ras protein. Thus, activated Ha-ras can co-operate with DP-1 or DP-2 in the transformation of rat embryo fibroblasts, establishing for the first time that DP proteins are endowed with proto-oncogenic activity. Moreover, an analysis of a dominant-negative and mutant DP-l proteins suggests that the primary target through which DP-1 mediates its oncogenic activity is unlikely to be due to the regulation of E2F site-transcription, suggesting an E2F-independent effector function for DP-1, These results therefore establish DP genes as proto-oncogenes and thus argue that deregulating the normal control of DP protein activity will be important in promoting aberrant cellular proliferation.	NATL INST MED RES, MRC, EUKARYOT MOLEC GENET LAB, LONDON NW7 1AA, ENGLAND; UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	MRC National Institute for Medical Research; Philipps University Marburg			Lam, Eric W-F/AAW-8566-2020; Müller, Rolf/L-4997-2016	Lam, Eric W-F/0000-0003-1274-3576; Müller, Rolf/0000-0003-3339-4248				BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BANDARA LR, 1992, J CELL SCI, P77; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GIRLING R, 1994, MOL BIOL CELL, V5, P1081, DOI 10.1091/mbc.5.10.1081; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kouzarides Tony, 1993, Trends in Cell Biology, V3, P211, DOI 10.1016/0962-8924(93)90113-F; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LOVEC H, 1994, ONCOGENE, V9, P323; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; NEVINS JR, 1992, SCIENCE, V258, P424; OCONNOR RJ, 1994, J VIROL, V68, P6848, DOI 10.1128/JVI.68.11.6848-6862.1994; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; TSAI LH, 1993, ONCOGENE, V8, P1593; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	41	58	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1529	1536						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731707				2022-12-25	WOS:A1995QU68100008
J	ROSENBERG, AR; ZINDY, F; LEDEIST, F; MOULY, H; METEZEAU, P; BRECHOT, C; LAMAS, E				ROSENBERG, AR; ZINDY, F; LEDEIST, F; MOULY, H; METEZEAU, P; BRECHOT, C; LAMAS, E			OVEREXPRESSION OF HUMAN CYCLIN-A ADVANCES ENTRY INTO S-PHASE	ONCOGENE			English	Article						CELL CYCLE; CYCLIN A; G1-S TRANSITION; S-PHASE CONTROL; SCANNING LASER CYTOMETRY	HUMAN CELL-CYCLE; SEA-URCHIN EGGS; DNA-REPLICATION; PROTEIN-KINASE; MESSENGER-RNA; MAMMALIAN FIBROBLASTS; TRANSCRIPTION FACTOR; VIRAL ONCOPROTEINS; RESTRICTION POINT; DEPENDENT KINASES	Cyclin A is a cell cycle regulatory protein that functions in mitotic and S-phase control in mammalian cells. Using a genomic construction corresponding to the human cyclin A gene under the control of its own promoter, we have established stable transfectants overexpressing cyclin A protein, Experiments assisted by laser scanning image cytometry showed that this overexpression begins from late G1 phase onwards and is therefore cell cycle-regulated in this model. We demonstrated that this overexpression advances entry into S phase, leading to a contraction of the overall cell generation time. These results provide evidence that cyclin A can be a rate-limiting factor with respect to the control of the transition to S phase in mammalian cells.	CHU NECKER ENFANTS MALAD, INSERM, U132, F-75743 PARIS 15, FRANCE; INST PASTEUR, CYTOMETRIE ANALYT & PREPARAT LAB, UNITE BIOCHIM CELLULAIRE, F-75724 PARIS 15, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	ROSENBERG, AR (corresponding author), INST NECKER, INSERM, U370, 156 RUE VAUGIRARD, F-75730 PARIS 15, FRANCE.		Lamas, Eugenia/L-9654-2018	Lamas, Eugenia/0000-0001-7677-9442; Rosenberg, Arielle/0000-0003-2085-8146				ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BATES S, 1994, ONCOGENE, V9, P71; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; DOU QP, 1993, CANCER RES, V53, P1493; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HUNT T, 1991, NATURE, V350, P462, DOI 10.1038/350462a0; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JIANG W, 1993, ONCOGENE, V8, P3447; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEVINS JR, 1992, SCIENCE, V258, P424; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SOBCZAKTHEPOT J, 1993, EXP CELL RES, V206, P43, DOI 10.1006/excr.1993.1118; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WIMMEL A, 1994, ONCOGENE, V9, P995; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	59	85	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1501	1509						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731704				2022-12-25	WOS:A1995QU68100005
J	TIAN, XQ; HOLICK, MF				TIAN, XQ; HOLICK, MF			CATALYZED THERMAL-ISOMERIZATION BETWEEN PREVITAMIN-D-3 AND VITAMIN-D-3 VIA BETA-CYCLODEXTRIN COMPLEXATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PI-FACIAL SELECTIVITY; D CALCIFEROL; HUMAN-SKIN; ANALOGS; PHOTOSYNTHESIS; STABILITY; SHIFTS	To examine the effect of microenviroments on previtamin D-3 reversible arrow vitamin D-3 isomerization, we have conducted kinetic studies of the reaction in an aqueous solution of beta-cyclodextrin. Our results showed that at 5 degrees C, the forward (k(1)) and reverse (k(2)) rate constants for previtamin D-3 reversible arrow vitamin D-3 isomerization were increased by more than 40 and 600 times, respectively, compared with those in n-hexane (k(1), 8.65 x 10(-6) versus 1.76 x 10(-7) s(-1); k(2), 8.48 x 10(-6) versus 1.40 x 10(-8) s(-1)), the fastest rate of this isomerization ever reported at this temperature. Thermodynamic studies revealed that the equilibrium constant of the reaction was significantly reduced by more than 12-fold when compared to that in n-hexane at 5 degrees C, and the percentage of vitamin D-3 at equilibrium was increased as the temperature was increased in beta-cyclodextrin. When complexed with beta-cyclodextrin, the previtamin D-3 reversible arrow vitamin D-3 isomerization became endothermic (Delta H degrees reversible arrow 13.05 kJ mol(-1)) in contrast to being exothermic in other media. We propose that thermodynamically unfavorable cZc conformers of previtamin D-3 are stabilized by beta-cyclodextrin, and thus the rate of the isomerization is increased. This conformation-controlled process may play an important role in the modulation of previtamin D-3 reversible arrow vitamin D-3 endocrine system in vivo such as in the sea urchin.	BOSTON UNIV, MED CTR,DEPT MED,ENDOCRINOL RES SECT, VITAMIN D SKIN & BONE RES LAB, BOSTON, MA 02118 USA; BOSTON UNIV, MED CTR, DEPT PHYSIOL, BOSTON, MA 02118 USA	Boston University; Boston University				Holick, Michael/0000-0001-6023-9062	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036963] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR-36963] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERS E, 1992, J PHARM SCI-US, V81, P756, DOI 10.1002/jps.2600810808; BERMAN E, 1979, VITAMIN D BASIC RES, P65; BOGOSLOVSKY NA, 1988, VITAMIN D MOL CELLUL, P1021; BRESLOW R, 1984, INCLUSION COMPOUNDS, V3, P473; CASSIS EG, 1982, PHOTOCHEM PHOTOBIOL, V35, P439; CHEN ET, 1993, ANAL CHEM, V65, P2563, DOI 10.1021/ac00067a003; CURTIN ML, 1991, J AM CHEM SOC, V113, P6958, DOI 10.1021/ja00018a038; DAUBEN WG, 1988, J ORG CHEM, V53, P5376, DOI 10.1021/jo00257a039; DAUBEN WG, 1988, J ORG CHEM, V53, P5070, DOI 10.1021/jo00256a031; DORMANEN MC, 1994, BIOCHEM BIOPH RES CO, V201, P394, DOI 10.1006/bbrc.1994.1714; DUVENECK GL, 1989, J PHYS CHEM-US, V93, P7166, DOI 10.1021/j100357a028; ENAS JD, 1991, J AM CHEM SOC, V113, P1355, DOI 10.1021/ja00004a043; ESVELT RP, 1978, ARCH BIOCHEM BIOPHYS, V188, P282, DOI 10.1016/S0003-9861(78)80010-1; HANEWALD KH, 1961, RECL TRAV CHIM PAY B, V80, P1003; HAVINGA E, 1973, EXPERIENTIA, V29, P1181, DOI 10.1007/BF01935064; HOBBS RN, 1987, CHEM SCRIPTA, V27, P199; HOEGER CA, 1987, J AM CHEM SOC, V109, P4690, DOI 10.1021/ja00249a035; HOLICK MF, 1980, SCIENCE, V210, P203, DOI 10.1126/science.6251551; HOLICK MF, 1979, BIOCHEMISTRY-US, V18, P1003, DOI 10.1021/bi00573a011; Jacobs H.J.C., 1979, ADV PHOTOCHEM, V11, P305, DOI DOI 10.1002/9780470133415.CH4; LIU FY, 1990, PHARMACEUT RES, V7, P869, DOI 10.1023/A:1015973218303; MACLAUGHLIN JA, 1982, SCIENCE, V216, P1001, DOI 10.1126/science.6281884; MYLES AMC, 1994, BBA-GEN SUBJECTS, V1199, P27, DOI 10.1016/0304-4165(94)90092-2; NORMAN AW, 1993, J BIOL CHEM, V268, P13811; PITCHUMANI K, 1994, PHOTOCHEM PHOTOBIOL, V59, P399, DOI 10.1111/j.1751-1097.1994.tb05054.x; RIEKE PC, 1992, ACS SYM SER, V499, P61; SAENGER W, 1984, INCLUSION COMPOUNDS, V2, P231; SZEJTLI J, 1980, PHARMAZIE, V35, P779; Szejtli J., 1984, INCLUSION COMPOUNDS, P331; TABUSHI I, 1984, INCLUSION COMPOUNDS, V3, P445; TERENETSKAYA IP, 1992, J MOL STRUCT, V267, P93, DOI 10.1016/0022-2860(92)87015-N; TIAN XQ, 1993, J BIOL CHEM, V268, P14888; TIAN XQ, 1994, ENDOCRINOLOGY, V135, P655, DOI 10.1210/en.135.2.655; Ueno A., 1991, PHOTOCHEMISTRY ORG C, P739; WOODWARD RB, 1965, J AM CHEM SOC, V87, P2511, DOI 10.1021/ja01089a050; WU KM, 1990, J ORG CHEM, V55, P4025, DOI 10.1021/jo00300a015; YAMAMOTO JK, 1985, BIOCHEMISTRY-US, V24, P3338, DOI 10.1021/bi00334a039	37	31	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8706	8711		10.1074/jbc.270.15.8706	http://dx.doi.org/10.1074/jbc.270.15.8706			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721775	hybrid			2022-12-25	WOS:A1995QT44800053
J	HOLEVINSKY, KO; NELSON, DJ				HOLEVINSKY, KO; NELSON, DJ			SIMULTANEOUS DETECTION OF FREE-RADICAL RELEASE AND MEMBRANE CURRENT DURING PHAGOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CHRONIC GRANULOMATOUS-DISEASE; SUPEROXIDE-GENERATING-SYSTEM; HYDROGEN-PEROXIDE PRODUCTION; B-CELL LINES; HUMAN-GRANULOCYTES; POTENTIAL CHANGES; RESPIRATORY BURST; HUMAN-NEUTROPHILS; XENOPUS-OOCYTES	Stimulation of macrophages induces the ''respiratory burst'' response which is associated with the generation of superoxide (O-2(-)), a drop in cytoplasmic pH, and a pronounced depolarization of the membrane potential. The purpose of the present studies was to determine whether an increase in O-2(-) was temporally related to changes in membrane potential and transmembrane current. Release of O-2(-) at the single cell level was photometrically monitored during phagocytosis of immune complexes while simultaneously measuring whole-cell current. Membrane depolarization and the generation of a non-selective current followed an increase in O-2(-) production with a variable lag time which was correlated with the state of cellular maturation in culture. In the absence of phagocytosis, the exposure of macrophages to O-2(-) generated by a xanthine-xanthine oxidase reaction activated a non-selective current similar to that seen after phagocytosis. These results provide the first demonstration of the relationship between free radical release and the ensuing electrophysiological signaling events which are linked to particle engulfment in phagocytic cells.	UNIV CHICAGO, DEPT NEUROL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago					NIGMS NIH HHS [R01 GM36823] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036823] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGER HA, 1993, J BIOL CHEM, V268, P2037; BIGGAR WD, 1976, INFECT IMMUN, V14, P6, DOI 10.1128/IAI.14.1.6-10.1976; CHARPENTIER G, 1993, P ROY SOC B-BIOL SCI, V254, P15, DOI 10.1098/rspb.1993.0120; COMMINS LM, 1990, INFLAMMATION, V14, P705, DOI 10.1007/BF00916373; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DECHATELET LR, 1975, J INFECT DIS, V131, P443, DOI 10.1093/infdis/131.4.443; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; FOURNIER F, 1993, FEBS LETT, V317, P118, DOI 10.1016/0014-5793(93)81504-S; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANCOCK JT, 1987, BIOCHEM J, V242, P103, DOI 10.1042/bj2420103; JONES GS, 1981, J CELL PHYSIOL, V106, P75, DOI 10.1002/jcp.1041060109; KITAGAWA S, 1986, J IMMUNOL, V136, P2605; KITAGAWA S, 1984, J CLIN INVEST, V73, P1062, DOI 10.1172/JCI111291; KITAGAWA S, 1985, J IMMUNOL, V135, P3417; KORCHAK HM, 1978, P NATL ACAD SCI USA, V75, P3818, DOI 10.1073/pnas.75.8.3818; LI M, 1993, SCIENCE, V261, P1439, DOI 10.1126/science.8396273; LOEGERING DJ, 1991, BIOCHEM BIOPH RES CO, V180, P268, DOI 10.1016/S0006-291X(05)81287-2; MALY FE, 1988, J IMMUNOL, V140, P2334; MUSSON RA, 1982, J RETICULOENDOTH SOC, V31, P261; NELSON DJ, 1990, J MEMBRANE BIOL, V117, P29, DOI 10.1007/BF01871563; NEWBURGER PE, 1979, J CELL BIOL, V82, P315, DOI 10.1083/jcb.82.2.315; OIKE M, 1993, PFLUG ARCH EUR J PHY, V424, P159, DOI 10.1007/BF00374607; RYAN TC, 1990, J IMMUNOL METHODS, V130, P223, DOI 10.1016/0022-1759(90)90052-W; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHWACHA MG, 1993, J IMMUNOL, V150, P236; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEIM S, 1982, ACTA PATH MICRO IM C, V90, P179; SELIGMANN BE, 1983, J CELL PHYSIOL, V115, P105, DOI 10.1002/jcp.1041150202; SELIGMANN BE, 1980, J CLIN INVEST, V66, P493, DOI 10.1172/JCI109880; SIMCHOWITZ L, 1979, IMMUNOLOGY, V234, P2428; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TSIEN RY, 1989, METHOD CELL BIOL, V30, P127; VOLKMAN DJ, 1984, J IMMUNOL, V133, P3006; WHITIN JC, 1980, J BIOL CHEM, V255, P1874	35	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8328	8336		10.1074/jbc.270.14.8328	http://dx.doi.org/10.1074/jbc.270.14.8328			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713941	hybrid			2022-12-25	WOS:A1995QR52600080
J	BOGGS, KP; ROCK, CO; JACKOWSKI, S				BOGGS, KP; ROCK, CO; JACKOWSKI, S			LYSOPHOSPHATIDYLCHOLINE ATTENUATES THE CYTOTOXIC EFFECTS OF THE ANTINEOPLASTIC PHOSPHOLIPID 1-O-OCTADECYL-2-O-METHYL-RAC-GLYCERO-3-PHOSPHOCHOLINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LEUKEMIC-CELLS; STIMULATING FACTOR-I; ETHER LIPID ANALOGS; HAMSTER OVARY CELLS; PROTEIN-KINASE-C; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE TRANSLOCATION; PLATELET-ACTIVATING-FACTOR; ALKYL-LYSOPHOSPHOLIPIDS; HL-60 CELLS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS	A colony-stimulating factor 1-dependent cell line was used to determine the relationship between the inhibition of phospholipid synthesis and the cytotoxic activity of the antineoplastic ether lipid, 1-O-octadecyl-2-O- methyl-rac-glycero-3-phosphocholine (ET-18-OCH3), ET-18-OCH3 inhibited choline incorporation into phosphatidylcholine as well as total phospholipid synthesis, Exposure to ET-18-OCH3 at the G(1)/S boundary led to the accumulation of cells in G(2), whereas the addition of ET-18-OCH3 in the G(1) phase of the cell cycle prevented entry into the S phase. In both cases, ET-18-OCH, treatment triggered DNA fragmentation and morphological changes associated with apoptosis within 10 h, The addition of lysophosphatidylcholine provided an exogenous source of cellular phospholipid and prevented ET-18-OCH3-dependent accumulation of cells in G(2) and apoptosis, However, lysophosphatidylcholine did not overcome the ET-18-OCH3-dependent G(1) block, although the growth-arrested cells remained viable, These data indicate that restoring phosphatidylcholine synthesis by supplementation with lysophosphatidylcholine over rides the cytotoxic but not the cytostatic activity of ET-18-OCH3.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center			Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 45737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREESEN R, 1978, CANCER RES, V38, P3894; ANDREESEN R, 1979, BLOOD, V54, P519; BERDEL WE, 1991, BRIT J CANCER, V64, P208, DOI 10.1038/bjc.1991.277; BERDEL WE, 1980, EUR J CANCER, V16, P1119; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; DANIEL LW, 1987, LIPIDS, V22, P851, DOI 10.1007/BF02535543; DANIEL LW, 1993, CANCER CHEMOTHERAPY, P146; DEAN PN, 1980, CELL TISSUE KINET, V13, P299, DOI 10.1111/j.1365-2184.1980.tb00468.x; DIOMEDE L, 1993, INT J CANCER, V53, P124, DOI 10.1002/ijc.2910530123; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1981, J BIOL CHEM, V256, P7388; GEILEN CC, 1994, BBA-LIPID LIPID MET, V1211, P14, DOI 10.1016/0005-2760(94)90133-3; GEILEN CC, 1992, J BIOL CHEM, V267, P6719; HAASE R, 1991, FEBS LETT, V288, P129, DOI 10.1016/0014-5793(91)81018-4; HAMILTON JA, 1989, J CELL PHYSIOL, V141, P618, DOI 10.1002/jcp.1041410321; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEESBEEN EC, 1993, LEUKEMIA RES, V17, P143, DOI 10.1016/0145-2126(93)90059-T; HERRMANN DBJ, 1985, J NATL CANCER I, V75, P423; HOFFMAN DR, 1986, CANCER RES, V46, P5803; HOFFMAN DR, 1992, BIOCHIM BIOPHYS ACTA, V1127, P74, DOI 10.1016/0005-2760(92)90203-8; HOFMANN J, 1994, BIOCHEM BIOPH RES CO, V199, P937, DOI 10.1006/bbrc.1994.1319; IMAMURA K, 1990, EMBO J, V9, P2423, DOI 10.1002/j.1460-2075.1990.tb07418.x; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; JAMIL H, 1993, BIOCHEM J, V291, P419, DOI 10.1042/bj2910419; JAMIL H, 1990, J BIOL CHEM, V265, P4332; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; LESLIE CC, 1995, IN PRESS ADV MOL CEL; LOCK RB, 1990, CANCER RES, V50, P3761; LOCK RB, 1990, CANCER RES, V50, P3767; LOCK RB, 1992, CANCER RES, V52, P1817; MODOLELL M, 1979, CANCER RES, V39, P4681; MOLLINEDO F, 1993, BIOCHEM BIOPH RES CO, V192, P603, DOI 10.1006/bbrc.1993.1458; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; Munder P. G., 1977, IMMUNOLOGY, V7, P411; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; NOSEDA A, 1987, LIPIDS, V22, P878, DOI 10.1007/BF02535548; NOSEDA A, 1989, EXP MOL PATHOL, V50, P69, DOI 10.1016/0014-4800(89)90057-9; O'Connor P M, 1992, Semin Cancer Biol, V3, P409; OCONNER PM, 1993, CELL GROWTH DIFFER, V3, P43; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; PARKER J, 1987, J BIOL CHEM, V262, P5385; PAWELCZYK T, 1993, BIOCHEM PHARMACOL, V45, P493, DOI 10.1016/0006-2952(93)90087-D; POWIS G, 1992, CANCER RES, V52, P2835; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; RUNGE MH, 1980, J NATL CANCER I, V64, P1301, DOI 10.1093/jnci/64.6.1301; SALARI H, 1992, BIOCHEM CELL BIOL, V70, P129, DOI 10.1139/o92-019; SALARI H, 1992, BIOCHIM BIOPHYS ACTA, V1134, P81, DOI 10.1016/0167-4889(92)90030-F; SCHWARZBAUM S, 1984, J IMMUNOL, V132, P1158; SEEWALD MJ, 1990, CANCER RES, V50, P4458; TRONCHERE H, 1991, BIOCHEM BIOPH RES CO, V176, P157, DOI 10.1016/0006-291X(91)90903-K; TSAO YP, 1992, CANCER RES, V52, P1823; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; VALLARI DS, 1988, BIOCHEM BIOPH RES CO, V156, P1, DOI 10.1016/S0006-291X(88)80797-6; VALLARI DS, 1990, J BIOL CHEM, V265, P4261; VALLARI DS, 1989, BIOCHIM BIOPHYS ACTA, V1006, P250, DOI 10.1016/0005-2760(89)90204-X; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P225; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; Vogler W R, 1993, J Hematother, V2, P93, DOI 10.1089/scd.1.1993.2.93; VOGLER WR, 1991, LIPIDS, V26, P1418, DOI 10.1007/BF02536579; VOGLER WR, 1985, EXP HEMATOL, V13, P629; WESTPHAL O, 1987, LIPIDS, V22, P787, DOI 10.1007/BF02535532; WHETTON AD, 1986, EMBO J, V5, P3281, DOI 10.1002/j.1460-2075.1986.tb04640.x; WIEDER T, 1993, BIOCHEM J, V291, P561, DOI 10.1042/bj2910561; WORKMAN P, 1990, BIOCHEM PHARMACOL, V41, P319; XU XX, 1993, MOL CELL BIOL, V13, P1522, DOI 10.1128/MCB.13.3.1522	68	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11612	11618		10.1074/jbc.270.19.11612	http://dx.doi.org/10.1074/jbc.270.19.11612			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744800	hybrid			2022-12-25	WOS:A1995QX86500082
J	HERMAN, WH; SIMONSON, MS				HERMAN, WH; SIMONSON, MS			NUCLEAR SIGNALING BY ENDOTHELIN-1 - A RAS PATHWAY FOR ACTIVATION OF THE C-FOS SERUM RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GLOMERULAR MESANGIAL CELLS; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; 3T3 CELLS; RECEPTOR; FIBROBLASTS; DNA; TRANSCRIPTION; TRANSDUCTION	Endothelin-1 (ET-1) regulates gene expression and growth of vascular cells by triggering signals that link its cognate, G protein-coupled receptor in the plasma membrane to transcriptional activation of immediate early genes in the nucleus, To define the nature of these signals, we asked whether Ras proteins contribute to activation of the c-fos serum response element (SRE) by ET-1 in mesangial cells, a microvascular cell from the renal glomerulus, ET-1 stimulated Ras by increasing Ras GTP loading, Addition of ET-1 or transfection with a plasmid expressing v-Ha-Ras stimulated SRE dependent transcription, Activation of the c-fos SRE by ET-1 was blocked by a dominant negative Asn-17 c-Ha-Ras mutant, Expression of v-Ha-Ras reversed inhibition of ET-1-stimulated SRE transcriptional activity by Asn-17 c-Ha-Ras, ET-1 also stimulated kinase activity of c-Raf-1, a downstream effector in Ras signaling cascades, Activation of the c-fos SRE by transfection with a plasmid expressing constitutively activated Delta Raf-1 was consistent with a role for Ras-Raf-1 in ET-1 signaling, Interestingly, Ras dependent SRE activation in cells treated with ET-1 was blocked by point mutations in the SRE CArG DNA sequence, which binds the serum response factor, but not by mutations that inhibit binding of ternary complex factors (p62(TCF)) to the Ets DNA sequence of the SRE, Thus, Ras contributes to a nuclear signaling cascade linking ET-1 receptors to transcriptional activation through the CArG cis-element of the c-fos SRE.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT MED, DIV NEPHROL, CLEVELAND, OH 44106 USA	Case Western Reserve University					NIDDK NIH HHS [DK-46939] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046939] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BATTISTINI B, 1993, PEPTIDES, V14, P385, DOI 10.1016/0196-9781(93)90057-N; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; BENIGNI A, 1993, KIDNEY INT, V44, P440, DOI 10.1038/ki.1993.263; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DOUGLAS SA, 1994, CIRC RES, V75, P190, DOI 10.1161/01.RES.75.1.190; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FORCE T, 1991, J BIOL CHEM, V266, P6650; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LUSCHER TF, 1992, HYPERTENSION, V19, P117, DOI 10.1161/01.HYP.19.2.117; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MASAKI T, 1993, ENDOCR REV, V14, P256, DOI 10.1210/er.14.3.256; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; PRIBNOW D, 1992, MOL ENDOCRINOL, V6, P1003, DOI 10.1210/me.6.7.1003; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUBANYI GM, 1993, J CARDIOVASC PHARM, V22, pS1, DOI 10.1097/00005344-199304000-00002; SANTORO IM, 1991, MOL CELL BIOL, V11, P6296, DOI 10.1128/MCB.11.12.6296; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SIMONSON MS, 1990, METHOD ENZYMOL, V187, P544; SIMONSON MS, 1992, J BIOL CHEM, V267, P8643; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; SIMONSON MS, 1993, PHYSIOL REV, V73, P375, DOI 10.1152/physrev.1993.73.2.375; SIMONSON MS, 1994, MOL PHARMACOL, V46, P41; SIMONSON MS, 1995, IN PRESS AM J PHYSL, V265; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TREISMAN R, 1992, TRANSCRIPTIONAL REGU, P881; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WEBER H, 1994, MOL ENDOCRINOL, V8, P148, DOI 10.1210/me.8.2.148; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WINITZ S, 1993, J BIOL CHEM, V268, P19196; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	62	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11654	11661		10.1074/jbc.270.19.11654	http://dx.doi.org/10.1074/jbc.270.19.11654			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744805	hybrid			2022-12-25	WOS:A1995QX86500088
J	RAY, S; MUKHERJI, S; BHADURI, A				RAY, S; MUKHERJI, S; BHADURI, A			2 TRYPTOPHANS AT THE ACTIVE-SITE OF UDP-GLUCOSE 4-EPIMERASE FROM KLUYVEROMYCES-FRAGILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; UDPGLUCOSE 4-EPIMERASE; GALACTOSE 4-EPIMERASE; FLUORESCENCE; BINDING; DEHYDROGENASE; PROTEINS; RESIDUE; KINETICS; ENERGY	Efficient fluorescence energy transfer from aromatic residues to the pyridine moiety of the bound coenzyme (NAD) of UDP-glucose 4-epimerase from Kluyveromyces fragilis had been reported earlier (Mukherji, S., and Bhaduri, A. (1992) J, Biol, Chem, 267, 11709-11713). We have employed N-bromosuccinimide (NBS) to identify tryptophan as the exclusive aromatic donor in the energy transfer. The characteristic UV absorption spectrum associated with Trp oxidation is observed during NBS modification of two of the four Trp residues of native epimerase along with concomitant inactivation of the enzyme, Excellent correlation between the observed inactivation and abolition of fluorescence energy transfer to coenzyme from Trp in epimerase upon treatment with NBS implicates the involvement of the same two tryptophans in both catalytic activity and fluorescence energy transfer, SDS-polyacrylamide gel electrophoresis and fluorescence data preclude gross structural/conformational changes in epimerase due to NBS oxidation, The susceptible tryptophans do not reside at the substrate binding site as substrates and UMP fail to protect against NBS modification, However, failure of sodium borohydride to reduce the bound NAD in the NBS-inactivated epimerase suggests that the reactive tryptophans are close to the coenzyme. Tryptophan fluorescence lifetime values of 1.9 and 3.9 ns for the native and 3.5 ns for the NBS-modified epimerase, complemented by a linear Stern-Volmer plot (effective Stern-Volmer constant = 2.85 M(-1)) of acrylamide quenching, suggest that the two key tryptophans are buried close to an intrinsic quencher, presumably NAD.	INDIAN INST CHEM BIOL,CALCUTTA 700032,W BENGAL,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)								ALMARSSON O, 1992, J AM CHEM SOC, V114, P8702, DOI 10.1021/ja00048a055; BEECHEM JM, 1985, ANNU REV BIOCHEM, V54, P43, DOI 10.1146/annurev.biochem.54.1.43; BERTLAND AU, 1968, P NATL ACAD SCI USA, V61, P629, DOI 10.1073/pnas.61.2.629; BERTLAND AU, 1970, BIOCHEMISTRY-US, V9, P4649, DOI 10.1021/bi00826a005; BHATTACHARJEE H, 1992, J BIOL CHEM, V267, P11714; BHATTACHARYYA D, 1993, BIOCHEMISTRY-US, V32, P9726, DOI 10.1021/bi00088a027; BURKE JR, 1993, BIOCHEMISTRY-US, V32, P13220, DOI 10.1021/bi00211a034; CAPUTTO R, 1949, J BIOL CHEM, V179, P497; CLERMONT S, 1993, BIOCHEMISTRY-US, V32, P10178, DOI 10.1021/bi00089a038; CREVELING CR, 1965, BIOCHEM BIOPH RES CO, V21, P624, DOI 10.1016/0006-291X(65)90532-2; DARROW RA, 1970, J BIOL CHEM, V245, P2036; DARROW RA, 1968, BIOCHEMISTRY-US, V7, P1645, DOI 10.1021/bi00845a005; DARROW RA, 1966, P NATL ACAD SCI USA, V55, P205, DOI 10.1073/pnas.55.1.205; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; Frey P. A., 1987, PYRIDINE NUCLEOTID B, V2B, P462; GABRIEL O, 1978, TRENDS BIOCHEM SCI, V3, P193, DOI 10.1016/S0968-0004(78)91666-3; GABRIEL O, 1978, INT REV BIOCHEM, V16, P1; GABRIEL O, 1975, SUBUNIT ENZYMES, P84; GRINVALD A, 1974, ANAL BIOCHEM, V59, P583, DOI 10.1016/0003-2697(74)90312-1; HELENE C, 1969, BIOCHEM BIOPH RES CO, V37, P393, DOI 10.1016/0006-291X(69)90927-9; KONOPKA JM, 1989, BIOCHEMISTRY-US, V28, P2645, DOI 10.1021/bi00432a043; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P83; Lakowicz J. R., 1983, PRINCIPLES FLUORESCE, P259; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P342; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIATIS T, 1982, MOL CLONING LABORATO, P466; MAY JM, 1993, BIOCHEMISTRY-US, V32, P9524, DOI 10.1021/bi00088a002; MCCLURE WO, 1967, BIOCHEMISTRY-US, V6, P559, DOI 10.1021/bi00854a025; MUKHERJI S, 1986, J BIOL CHEM, V261, P4519; MUKHERJI S, 1992, J BIOL CHEM, V267, P11709; PATCHORNIK A, 1960, J AM CHEM SOC, V82, P5923, DOI 10.1021/ja01507a032; PETERMAN BF, 1979, BIOCHIM BIOPHYS ACTA, V577, P314, DOI 10.1016/0005-2795(79)90035-7; PORTER DJT, 1993, J BIOL CHEM, V268, P66; Ramachandran L.K., 1967, METHOD ENZYMOL, V11, P283; RAY M, 1980, J BIOL CHEM, V255, P777; RAY M, 1980, J BIOL CHEM, V255, P782; RAY M, 1976, EUR J BIOCHEM, V70, P319, DOI 10.1111/j.1432-1033.1976.tb11020.x; SAMANTA AK, 1983, J BIOL CHEM, V258, P1118; SHANMUGASUNDARA.T, 1988, BIOCHEMISTRY-US, V27, P6499; SIMPSON RT, 1963, BIOCHEMISTRY-US, V2, P616, DOI 10.1021/bi00903a039; Spande T.F., 1967, DETERMINATION TRYPTO, P498; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; UDENFRIEND S, 1962, FLUORESCENCE ASSAY B, V1, P249; WEBER G, 1957, NATURE, V180, P1409, DOI 10.1038/1801409a0; WIGET P, 1978, BIOPOLYMERS, V17, P167, DOI 10.1002/bip.1978.360170113	48	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11383	11390		10.1074/jbc.270.19.11383	http://dx.doi.org/10.1074/jbc.270.19.11383			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744774	hybrid			2022-12-25	WOS:A1995QX86500053
J	MERTENS, L; VANDENBOSCH, L; VERBOOMEN, H; WUYTACK, F; DESMEDT, H; EGGERMONT, J				MERTENS, L; VANDENBOSCH, L; VERBOOMEN, H; WUYTACK, F; DESMEDT, H; EGGERMONT, J			SEQUENCE AND SPATIAL REQUIREMENTS FOR REGULATED MUSCLE-SPECIFIC PROCESSING OF THE SARCOPLASMIC ENDOPLASMIC RETICULUM CA2+-ATPASE 2 GENE TRANSCRIPT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; SARCOPLASMIC-RETICULUM; SPLICE SITES; CA-2+ PUMP; CA2+ PUMP; DIFFERENTIATION; ATPASE; INTRON; EXPRESSION; DEFINITION	Expression of the muscle-specific 2a isoform of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA2) requires activation of an otherwise inefficient splicing process at the 3'-end of the primary gene transcript, The sequence and topology requirements for this regulated splicing event were studied in the BC(3)H1 myogenic cell line using a minigene containing the 3'-end of the SERCA2 gene, In undifferentiated BC(3)H1 cells, the splice process is made inefficient by the presence of a weak muscle-type 5'-donor site (5'D1) and a long terminal intron, Both optimizing the 5'D1 and decreasing the length of the muscle-specific intron, induced muscle type splicing in undifferentiated myogenic cells, Moreover, the induction of muscle-type transcripts was only observed when two competing processing sites, the polyadenylation site (pA(u)) used in non-muscle cells and the second neuronal 5'-donor site (5'D2), were weak, Indeed, making 5'D2 consensus induced neuronal-type splicing in undifferentiated myocytes and prevented the appearance of muscle-type transcripts, Similarly, replacing the polyadenylation site (pA(u)) with a strong site almost completely inhibited muscle-type splicing after myogenic differentiation. We conclude that weak processing sites and a long terminal intron are required for tissue-dependent mRNA processing of the SERCA2 transcript.			MERTENS, L (corresponding author), CATHOLIC UNIV LEUVEN,PHYSIOL LAB,CAMPUS GASTHUISBERG,B-3000 LOUVAIN,BELGIUM.		Van Den Bosch, Ludo/B-7258-2012	Mertens, Luc/0000-0001-7308-1268; Eggermont, Jan/0000-0002-8497-1159; Van Den Bosch, Ludo/0000-0003-0104-4067				ANGER M, 1994, J MOL CELL CARDIOL, V26, P539, DOI 10.1006/jmcc.1994.1064; BOBE R, 1994, J BIOL CHEM, V269, P1417; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEJAEGERE S, 1993, BIOCHIM BIOPHYS ACTA, V1173, P188, DOI 10.1016/0167-4781(93)90180-L; DELABASTIE D, 1988, FEBS LETT, V229, P45, DOI 10.1016/0014-5793(88)80794-4; DESMEDT H, 1991, J BIOL CHEM, V266, P7092; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EGGERMONT J, 1991, BIOCHEM J, V271, P649; EGGERMONT JA, 1990, BIOCHEM J, V266, P901; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; KORCZAK B, 1988, J BIOL CHEM, V263, P48133; LEVITT N, 1989, GENE DEV, V3, P1019, DOI 10.1101/gad.3.7.1019; LUKASHIN AV, 1992, NUCLEIC ACIDS RES, V20, P2511, DOI 10.1093/nar/20.10.2511; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MOORMAN A, 1994, J MOL CELL CARDIOL, V26, P90; PETERSON ML, 1986, P NATL ACAD SCI USA, V83, P8883, DOI 10.1073/pnas.83.23.8883; PLESSERS L, 1991, J NEUROSCI, V11, P650; Sambrook J, 1989, MOL CLONING LABORATO; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; STEPHENS RM, 1992, J MOL BIOL, V228, P1124, DOI 10.1016/0022-2836(92)90320-J; TIAN M, 1994, GENE DEV, V8, P1703, DOI 10.1101/gad.8.14.1703; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; TSURUSHITA N, 1987, MOL CELL BIOL, V7, P2602, DOI 10.1128/MCB.7.7.2602; VANDENBOSCH L, 1994, BIOCHEM J, V302, P559, DOI 10.1042/bj3020559; VANOOYEN A, 1979, SCIENCE, V206, P337, DOI 10.1126/science.482942; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; VERBOOMEN H, 1994, BIOCHEM J, V303, P979, DOI 10.1042/bj3030979; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; WUYTACK F, 1992, ANN NY ACAD SCI, V671, P82, DOI 10.1111/j.1749-6632.1992.tb43786.x	36	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					11004	11011		10.1074/jbc.270.18.11004	http://dx.doi.org/10.1074/jbc.270.18.11004			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738043	hybrid			2022-12-25	WOS:A1995QW60100092
J	KONIECZNY, I; MARSZALEK, J				KONIECZNY, I; MARSZALEK, J			THE REQUIREMENT FOR MOLECULAR CHAPERONES IN LAMBDA-DNA REPLICATION IS REDUCED BY THE MUTATION-PI IN LAMBDA-P GENE, WHICH WEAKENS THE INTERACTION BETWEEN LAMBDA-P PROTEIN AND DNAB HELICASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAB; SPECIALIZED NUCLEOPROTEIN STRUCTURES; HEAT-SHOCK PROTEINS; BACTERIOPHAGE-LAMBDA; O-PROTEIN; PHAGE-LAMBDA; INITIATION; ORIGIN; COMPLEX; INVITRO	During the initiation of lambda DNA replication, the host DnaB helicase is complexed with phage lambda P protein in order to be properly positioned near the ori lambda-lambda O initiation complex, However, the lambda P-DnaB interaction inhibits the activities of DnaB, Thus, the concerted action of bacterial heat shock proteins, DnaK, DnaJ, and GrpE, is required to activate the helicase. Wild-type phage lambda cannot grow on the E, coli dnaB, dnaK dnaJ, and grpE mutants, However, lambda phage with a mutation pi in the lambda P gene, is able to produce progeny in these mutants as well as in the wild-type bacteria, Purified mutant lambda pi protein reveals a much lower affinity to DnaB than wildtype lambda P, and the lambda pi-DnaB complex is unstable, Also, a very low concentration of DnaK protein is sufficient to activate the helicase in a replication system based on lambda dv dsDNA. In that system, the mutant DnaK756 protein, inactive in the lambda P-dependent replication, revealed its activity in the lambda pi-dependent reaction, The lambda O-lambda P-dependent replication system based on M13 ssDNA efficiently replicates DNA in the absence of any chaperone protein, unless lambda P is substituted by the lambda pi mutant protein, Data presented in this paper explain why lambda pi phage is able to grow on wild-type and dnaK756 bacteria.	UNIV GDANSK,DEPT BIOL MOLEC,PL-80222 GDANSK,POLAND	Fahrenheit Universities; University of Gdansk			Marszalek, Jaroslaw/F-5824-2011	Marszalek, Jaroslaw/0000-0002-6978-1189; Konieczny, Igor/0000-0002-1588-5601				ALFANO C, 1989, J BIOL CHEM, V260, P10699; ALFANO C, 1989, J BIOL CHEM, V260, P10709; ALLEN GC, 1991, J BIOL CHEM, V266, P22096; ARAI K, 1981, J BIOL CHEM, V256, P5247; BAKER TA, 1986, CELL, V54, P53; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; DODSON M, 1989, J BIOL CHEM, V264, P10719; DRAHOS DJ, 1982, J BACTERIOL, V149, P1050, DOI 10.1128/JB.149.3.1050-1063.1982; GEORGOPOULOS C, 1971, BACTERIOPHAGE LAMBDA, P191; HOFFMANN HJ, 1992, P NATL ACAD SCI USA, V89, P12108, DOI 10.1073/pnas.89.24.12108; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KLEIN A, 1980, EUR J BIOCHEM, V105, P1, DOI 10.1111/j.1432-1033.1980.tb04467.x; KLINKERT J, 1978, J VIROL, V25, P730, DOI 10.1128/JVI.25.3.730-737.1978; Kornberg A., 1992, DNA REPLICATION; LEBOWITZ JH, 1985, P NATL ACAD SCI USA, V82, P3988, DOI 10.1073/pnas.82.12.3988; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; MALLORY JB, 1990, J BIOL CHEM, V265, P13297; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MARSZALEK J, 1992, J BIOL CHEM, V267, P19334; MASAI H, 1990, J BIOL CHEM, V265, P15134; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; Pawlowicz Alicja, 1993, Acta Biochimica Polonica, V40, P29; REISER W, 1983, MOL GEN GENET, V192, P430, DOI 10.1007/BF00392186; ROBERTS JD, 1983, NUCLEIC ACIDS RES, V11, P7435, DOI 10.1093/nar/11.21.7435; SAITO H, 1977, J MOL BIOL, V113, P1, DOI 10.1016/0022-2836(77)90038-9; Sambrook J, 1989, MOL CLONING LABORATO; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SCHUSTER RC, 1980, MOL GEN GENET, V178, P429; SHERMAN MY, 1992, EMBO J, V11, P71; SZALEWSKA A, 1994, MOL MICROBIOL, V13, P469, DOI 10.1111/j.1365-2958.1994.tb00441.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TIPPESCHINDLER R, 1979, MOL GEN GENET, V168, P185, DOI 10.1007/BF00431444; TSURIMOTO T, 1981, MOL GEN GENET, V181, P325, DOI 10.1007/BF00425606; TSURIMOTO T, 1981, MOL GEN GENET, V187, P79; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; WICKNER SH, 1979, COLD SPRING HARB SYM, V43, P303, DOI 10.1101/SQB.1979.043.01.037; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P6176, DOI 10.1073/pnas.79.20.6176; YAMAMOTO T, 1987, J BIOL CHEM, V262, P7996; ZAHN K, 1985, EMBO J, V4, P3605, DOI 10.1002/j.1460-2075.1985.tb04124.x; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1993, PHILOS T ROY SOC B, V339, P271, DOI 10.1098/rstb.1993.0025; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591; ZYLICZ M, 1984, MOL GEN GENET, V196, P401, DOI 10.1007/BF00436186	49	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9792	9799		10.1074/jbc.270.17.9792	http://dx.doi.org/10.1074/jbc.270.17.9792			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730358	hybrid			2022-12-25	WOS:A1995QV41700017
J	GRUBB, GR; YUN, K; REEVE, AE; ECCLES, MR				GRUBB, GR; YUN, K; REEVE, AE; ECCLES, MR			EXCLUSION OF THE WILMS-TUMOR GENE (WT1) PROMOTER AS A SITE OF FREQUENT MUTATION IN WILMS-TUMOR	ONCOGENE			English	Note						WT1; PROMOTER; MUTATION; SCCP; WILMS TUMOR; TUMOR SUPPRESSOR GENE	DENYS-DRASH SYNDROME; DOMINANT NEGATIVE MUTATIONS; HUMAN RETINOBLASTOMA GENE; SUPPRESSOR GENE; GENITOURINARY DEVELOPMENT; EXPRESSION; KIDNEY; REGION; LOCUS; INACTIVATION	WT1 is a tumour suppressor gene expressed in a specific temporal and spatial pattern in the developing kidney. Up to 15% of Wilms tumours have point mutations in the WT1 gene coding sequence. We have now investigated whether mutations in the WT1 promoter could be associated with loss of control WT1 expression and subsequent Wilms tumour formation. Using single-strand conformational polymorphism (SSCP) analysis we analysed 39 sporadic Wilms tumours for WT1 promoter mutations. We found six linked common sequence polymorphisms and two unlinked less frequent polymorphisms which allowed us to identify four tumours with loss of heterozygosity but none with point mutations, small deletions, insertions or rearrangements. We therefore conclude that WT1 promoter mutations are unlikely to play an important role in Wilms tumorigenesis.	UNIV OTAGO, SCH MED, DEPT BIOCHEM, CANC GENET LAB, DUNEDIN, NEW ZEALAND; UNIV OTAGO, SCH MED, DEPT PATHOL, DUNEDIN, NEW ZEALAND	University of Otago; University of Otago								ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BRESLOW N, 1993, MED PEDIATR ONCOL, V21, P172, DOI 10.1002/mpo.2950210305; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Campbell C., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P541; CAMPBELL CE, 1994, ONCOGENE, V9, P583; COPPES MJ, 1993, J PEDIATR-US, V123, P673, DOI 10.1016/S0022-3476(05)80839-X; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; ECCLES MR, 1995, AM J PATHOL, V146, P40; ECCLES MR, 1994, ONCOGENE, V9, P2059; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; GESSLER M, 1994, HUM MUTAT, V3, P212, DOI 10.1002/humu.1380030307; HABER DA, 1992, CANCER SURV, V12, P105; Hastie Nicholas D., 1992, Human Molecular Genetics, V1, P293; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOFMANN W, 1993, ONCOGENE, V8, P3123; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1993, BIOCHIM BIOPHYS ACTA, V1155, P295, DOI 10.1016/0304-419X(93)90011-Z; KONIG A, 1993, HUM MOL GENET, V2, P1967; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; NORDENSKJOLD A, 1994, HUM GENET, V93, P115; OGAWA O, 1993, HUM MOL GENET, V2, P203, DOI 10.1093/hmg/2.2.203; PARK S, 1993, NAT GENET, V5, P363, DOI 10.1038/ng1293-363; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SCHNEIDER S, 1993, HUM GENET, V91, P599; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; YEGER H, 1992, CELL GROWTH DIFFER, V3, P855	45	10	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1677	1681						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731725				2022-12-25	WOS:A1995QU68100027
J	CORSI, D; GALLUZZI, L; CRINELLI, R; MAGNANI, M				CORSI, D; GALLUZZI, L; CRINELLI, R; MAGNANI, M			UBIQUITIN IS CONJUGATED TO THE CYTOSKELETAL PROTEIN ALPHA-SPECTRIN IN MATURE ERYTHROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MEMBRANE SKELETON; DEGRADATION; RESOLUTION; PATHWAY; BINDING; QUANTITATION; INVITRO; LIGASE; CYCLIN	Ubiquitination of red blood cell (RBC) proteins was investigated by encapsulation of I-125-ubiquitin into human erythrocytes using a procedure of hypotonic dialysis, isotonic resealing, and reannealing. Incubation (37 degrees C, up to 2 h) of I-125-ubiquitin-loaded cells resulted in the recovery of I-125-ubiquitin with the cytosolic proteins (9.22 +/- 0.4 mu g/ml RBC) and conjugated to membrane proteins (2.18 +/- 0.05 mu g/ml RBC). This conjugation was time-dependent, and the predominant membrane protein band that became labeled showed an apparent molecular mass of 240 kDa on SDS-polyacrylamide gel electrophoresis (PAGE). Western blotting experiments with three different anti-ubiquitin antibodies revealed that this protein is also ubiquitinated in vivo. Cell-free experiments have shown that fraction II (a DEAE-bound protein fraction eluted by 0.5 M KCl) prepared from both mature erythrocytes and reticulocytes is able to conjugate ubiquitin to this protein. Ubiquitin conjugation was ATP-dependent (K-m 0.09 mM), time-dependent, and fraction II-dependent (8 +/- 0.5 pmol of I-125-ubiquitin/h/mg of fraction II). Isolation of the major RBC membrane protein that is ubiquitinated was obtained by using biotinylated ubiquitin. Membrane proteins, once ubiquitinated with this derivative, were extracted and purified by affinity chromatography on immobilized avidin. The major components retained by the column were two peptides of molecular masses 220 and 240 kDa. Both proteins are recognized by a monoclonal anti-spectrin antibody, but only the 240-kDa component is detected by streptavidin peroxidase conjugate. That indeed the ubiquitinated membrane protein of 240-kDa is alpha-spectrin was confirmed by immunoaffinity chromatography using I-125-ubiquitin and a monoclonal anti-spectrin antibody. Antigen-antibody complexes were purified by protein A chromatography and analyzed by SDS-PAGE and autoradiography. Again two bands of 240 and 220 kDa were eluted (alpha- and beta-spectrin), but only one band corresponding to the electrophoretic mobility of alpha-spectrin was detected by autoradiography. Thus, alpha-spectrin is a substrate for the ATP-dependent ubiquitination system, suggesting that the cytoskeleton is convalently modified by ubiquitination both in reticulocytes and mature RBC.	UNIV URBINO, IST CHIM BIOL G FORNAINI, I-61029 URBINO, ITALY	University of Urbino			Magnani, Mauro/A-1919-2008; Galluzzi, Luca/G-3969-2012	Galluzzi, Luca/0000-0002-1747-526X; Crinelli, Rita/0000-0002-1235-8910; Magnani, Mauro/0000-0001-6456-6626				BALL E, 1987, CELL, V51, P221, DOI 10.1016/0092-8674(87)90149-8; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; COHEN CM, 1983, SEMIN HEMATOL, V20, P141; COOK WJ, 1992, J BIOL CHEM, V267, P15116; DeLoach J. R, 1992, USE RESEALED ERYTHRO; DUNIGAN DD, 1988, VIROLOGY, V165, P310, DOI 10.1016/0042-6822(88)90691-5; FEBER S, 1986, J BIOL CHEM, V261, P3128; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FRIED VA, 1987, P NATL ACAD SCI USA, V84, P3685, DOI 10.1073/pnas.84.11.3685; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAAS A, 1990, J BIOL CHEM, V265, P21664; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1991, ADV EXP MED BIOL, V307, P191; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HANSPAL M, 1992, SEMIN HEMATOL, V29, P305; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; KONG SK, 1992, J BIOL CHEM, V267, P14189; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNANI M, 1992, ANN NY ACAD SCI, V673, P103, DOI 10.1111/j.1749-6632.1992.tb27441.x; MAYER RJ, 1991, BIOCHIM BIOPHYS ACTA, V1089, P141, DOI 10.1016/0167-4781(91)90002-4; MORROW JS, 1980, P NATL ACAD SCI-BIOL, V77, P6592, DOI 10.1073/pnas.77.11.6592; MURTI KG, 1988, P NATL ACAD SCI USA, V85, P3019, DOI 10.1073/pnas.85.9.3019; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PICKART CM, 1988, J BIOL CHEM, V263, P12028; RECHSTEIMER M, 1988, UBIQUITIN; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; ROSSI L, 1992, BIOTECHNOL APPL BIOC, V15, P207; SATO SB, 1983, EUR J BIOCHEM, V130, P19; SOBUE K, 1981, BIOCHEM BIOPH RES CO, V100, P1063, DOI 10.1016/0006-291X(81)91931-8; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; STJOHN T, 1986, SCIENCE, V231, P845, DOI 10.1126/science.3003914; SULLIVAN ML, 1990, PLANT PHYSIOL, V94, P710, DOI 10.1104/pp.94.2.710; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	40	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8928	8935		10.1074/jbc.270.15.8928	http://dx.doi.org/10.1074/jbc.270.15.8928			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721801	hybrid			2022-12-25	WOS:A1995QT44800080
J	LIU, YS; GOROSPE, M; YANG, CL; HOLBROOK, NJ				LIU, YS; GOROSPE, M; YANG, CL; HOLBROOK, NJ			ROLE OF MITOGEN-ACTIVATED PROTEIN-KINASE PHOSPHATASE DURING THE CELLULAR-RESPONSE TO GENOTOXIC STRESS - INHIBITION OF C-JUN N-TERMINAL KINASE-ACTIVITY AND AP-1-DEPENDENT GENE ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IMMEDIATE-EARLY GENE; TYROSINE-PHOSPHATASE; GROWTH; COMPLEX; AP-1; FOS; PRODUCT; 3CH134	Irradiation of mammalian cells with short wavelength ultraviolet light (UVC) evokes a cascade of phosphorylation events leading to altered gene expression. Both the classic mitogen-activated protein (MAP) kinases and the distantly related c-Jun N-terminal kinases (JNK) contribute to the response via phosphorylation of transcription factors including AP-1. These kinases are themselves regulated via reversible phosphorylation, and several recently identified specific MAP kinase phosphatases (MKP) have been implicated in down regulating MAP kinase-dependent gene expression in response to mitogens. Here, we provide evidence that MKP-1 plays a role in regulating transcriptional activation in response to UVC as well as another genotoxic agent, methyl methanesulfonate (MMS). We further demonstrate that JNK is a likely target for MKP-1. JNK is shown to be activated by UVC and MMS treatment, while MAP kinase activation occurs only with UVC. Like JNK activation, MKP-1 mRNA is induced by both treatments, and elevated MKP-1 expression coincides with a decline in JNK activity. Constitutive expression of MKP-1 in vivo inhibits JNK activity and reduces UVC- and MMS-induced activation of AP-1-dependent reporter genes.	NIA,GENE EXPRESS & AGING SECT,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)			Liu, Yusen/E-3527-2011	Liu, Yusen/0000-0002-0994-0109				ABDELHAFIZ HAM, 1992, MOL ENDOCRINOL, V16, P2079; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLBROOK NJ, 1992, OXIDATIVE DAMAGE REP, P202; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; YAN MH, 1994, NATURE, V372, P798	37	273	278	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8377	8380		10.1074/jbc.270.15.8377	http://dx.doi.org/10.1074/jbc.270.15.8377			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721728	hybrid			2022-12-25	WOS:A1995QT44800002
J	ZHANG, XL; MATHEWS, CK				ZHANG, XL; MATHEWS, CK			NATURAL DNA PRECURSOR POOL ASYMMETRY AND BASE SEQUENCE CONTEXT AS DETERMINANTS OF REPLICATION FIDELITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							POLYMERASES; GENOME	Previous studies showed a complex relationship between nucleotide composition of a gene and the rate of the gene's evolutionary variation. We have investigated mechanisms by constructing M13 phagemids containing part of the Escherichia coli lacZ gene, in which an opal codon is flanked either by nine adenine . thymine base pairs on each side, or by nine guanine . cytosine pairs, or by its wild-type sequence context. Reversions or pseudoreversions within the opal codon yield a lacZ alpha-peptide that can undergo alpha-complementation and yield a blue plaque when plated with a chromogenic substrate. When these constructs were replicated in HeLa cell extracts, in the presence of equimolar deoxyribonucleoside triphosphate (dNTP) mixtures, reversion was near background levels in both the AT-rich and GC-rich contexts. By contrast, when the DNAs were replicated at dNTP concentrations approximating those in HeLa cell nuclei, increases over background were seen in all three contexts. Replication of the phagemids in vivo led to even higher mutation frequencies. Replication in the presence of dGMP, added to inhibit proofreading, caused extraordinarily high reversion frequencies in the GC-flanked opal codon. Apparently, dNTP concentrations approximating intracellular concentrations are mildly but significantly mutagenic, and pool asymmetries and base sequence context both contribute to the natural fidelity of DNA replication.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; NIEHS,RES TRIANGLE PK,NC 27709	Oregon State University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								BECKMAN RA, 1994, Q REV BIOPHYS, V26, P225; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1992, BIOESSAYS, V14, P303, DOI 10.1002/bies.950140503; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNZ BA, 1994, MUTAT RES, V318, P175; LEEDS JM, 1985, MOL CELL BIOL, V5, P3443, DOI 10.1128/MCB.5.12.3443; MATHEWS CK, 1992, BIOESSAYS, V14, P295, DOI 10.1002/bies.950140502; NORTH TW, 1980, J BIOL CHEM, V255, P6640; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WOLFE KH, 1989, NATURE, V337, P283, DOI 10.1038/337283a0	15	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8401	8404		10.1074/jbc.270.15.8401	http://dx.doi.org/10.1074/jbc.270.15.8401			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721732	hybrid			2022-12-25	WOS:A1995QT44800008
J	COGAN, JG; SUN, SQ; STOFLET, ES; SCHMIDT, LJ; GETZ, MJ; STRAUCH, AR				COGAN, JG; SUN, SQ; STOFLET, ES; SCHMIDT, LJ; GETZ, MJ; STRAUCH, AR			PLASTICITY OF VASCULAR SMOOTH-MUSCLE ALPHA-ACTIN GENE-TRANSCRIPTION - CHARACTERIZATION OF MULTIPLE, SINGLE-STRAND, AND DOUBLE-STRAND SPECIFIC DNA-BINDING PROTEINS IN MYOBLASTS AND FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN-BETA GENE; STROMAL MYOFIBROBLASTS; REGULATORY ELEMENTS; PROMOTER; CELLS; EXPRESSION; SEQUENCE; CIS; INTERACTS; DIFFERENTIATION	Transcriptional activity of the mouse vascular smooth muscle (VSM) alpha-actin promoter was governed by both cell type and developmental stage-specific mechanisms, A purine-rich motif (PrM) located as -181 to -176 in the promoter was absolutely required for activation in mouse AKR-2B embryonic fibroblasts and partially contributed to activation in undifferentiated mouse BC3H1 myoblasts, Transcriptional enhancer factor 1 recognized the PrM and cooperated with other promoter binding proteins to regulate serum growth factor -dependent transcription in both myoblasts and fibroblasts, Two distinct protein factors (VAC-ssBF1 and VAC-ssBF2) also were identified that bound sequence specifically to single-stranded oligonucleotide probes that spanned both the PrM and a closely positioned negative regulatory element, VAC-ssBF1 and BF2 binding activity was detected in undifferentiated myoblasts, embryonic fibroblasts, and several smooth muscle tis sues in the mouse and human, A myoblast-specific pro tein (VAC-RF1) also was detected that bound double-stranded probes containing a CArG-like sequence that previously was shown to impart strong, cell type specific repression, The binding activity of transcription en hancer factor 1, VAC-RF1, and VAC-ssBF1 was significantly diminished when confluent BC3H1 myoblasts differentiated into myocytes and expressed VSN alpha-actin mRNA after exposure to serum-free medium, The results indicated that cell type-specific control of the VSM alpha-actin gene promoter required the participation of multiple DNA binding proteins, including two that were enriched in smooth muscle and had preferential affinity for single-stranded DNA.	OHIO STATE UNIV,COLL MED,DEPT CELL BIOL NEUROBIOL & ANAT,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,BIOCHEM PROGRAM,COLUMBUS,OH 43210; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Mayo Clinic					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043370] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 43370] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BABAEV VR, 1990, AM J PATHOL, V136, P1031; BLANK RS, 1992, J BIOL CHEM, V267, P984; BOCHATONPIALLAT ML, 1992, DIFFERENTIATION, V49, P175, DOI 10.1111/j.1432-0436.1992.tb00665.x; BOCHATONPIALLAT ML, 1993, ARTERIOSCLER THROMB, V13, P1449, DOI 10.1161/01.ATV.13.10.1449; BONDJERS G, 1991, CIRCULATION, V84, P2; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; Cogan J. G., 1993, Molecular Biology of the Cell, V4, p158A; DARBY I, 1990, LAB INVEST, V63, P21; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DAVIS EC, 1993, LAB INVEST, V68, P89; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FINOCCHIARO LME, 1991, NUCLEIC ACIDS RES, V19, P4279, DOI 10.1093/nar/19.15.4279; FLINK IL, 1992, J BIOL CHEM, V267, P9917; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GAILLARD C, 1990, J MOL BIOL, V215, P245, DOI 10.1016/S0022-2836(05)80343-2; GRAY T A, 1990, Technique (Philadelphia), V2, P147; HOEFFLER WK, 1985, CELL, V41, P955, DOI 10.1016/S0092-8674(85)80076-3; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOCHER O, 1991, LAB INVEST, V65, P459; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; LAZARD D, 1993, P NATL ACAD SCI USA, V90, P999, DOI 10.1073/pnas.90.3.999; LEE SH, 1995, IN PRESS J CELL PHYS; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MIN BH, 1990, J BIOL CHEM, V265, P16667; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; QUINN JP, 1993, NUCLEIC ACIDS RES, V21, P1637, DOI 10.1093/nar/21.7.1637; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; SAPPINO AP, 1990, LAB INVEST, V63, P144; SCHURCH W, 1981, VIRCHOWS ARCH A, V391, P125, DOI 10.1007/BF00437591; SHIMIZU N, 1992, NUCLEIC ACIDS RES, V20, P1793, DOI 10.1093/nar/20.7.1793; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; Skalli O, 1988, MOL CELLULAR BIOL WO, P373; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; STRAUCH AR, 1991, J CELL PHYSIOL, V146, P337, DOI 10.1002/jcp.1041460302; TADA H, 1992, J VIROL, V66, P6885, DOI 10.1128/JVI.66.12.6885-6892.1992; TAYLOR MV, 1991, NUCLEIC ACIDS RES, V19, P2669, DOI 10.1093/nar/19.10.2669; WANG ZY, 1993, J BIOL CHEM, V268, P10681; WILKISON WO, 1990, J BIOL CHEM, V265, P477; WILLIAMS M, 1992, NUCLEIC ACIDS RES, V20, P4935, DOI 10.1093/nar/20.18.4935; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	51	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11310	11321		10.1074/jbc.270.19.11310	http://dx.doi.org/10.1074/jbc.270.19.11310			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744768	hybrid			2022-12-25	WOS:A1995QX86500045
J	SHIAO, YJ; LUPO, G; VANCE, JE				SHIAO, YJ; LUPO, G; VANCE, JE			EVIDENCE THAT PHOSPHATIDYLSERINE IS IMPORTED INTO MITOCHONDRIA VIA A MITOCHONDRIA-ASSOCIATED MEMBRANE AND THAT THE MAJORITY OF MITOCHONDRIAL PHOSPHATIDYLETHANOLAMINE IS DERIVED FROM DECARBOXYLATION OF PHOSPHATIDYLSERINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHETIC-ENZYMES; LIVER SUBCELLULAR MEMBRANES; ROUGH ENDOPLASMIC-RETICULUM; PERMEABILIZED ANIMAL-CELLS; HAMSTER OVARY CELLS; RAT-LIVER; SACCHAROMYCES-CEREVISIAE; LIPOPROTEIN SECRETION; LIPID-COMPOSITION; HEPATOCYTES	Phosphatidylserine is synthesized in both the endo plasmic reticulum and a unique membrane fraction, the mitochondria-associated membrane (MAM) (Vance, J. E. (1990) J. Biol. Chem. 265, 7248-7256). In Chinese hamster ovary cells labeled with [H-3]serine or [H-3]ethanolamine, we found that the majority of mitochondrial phosphatidylethanolamine was derived from phosphatidylserine decarboxylation. Essentially no mitochondrial phosphatidylethanolamine, especially that in the inner membrane, was imported from the endoplasmic reticulum. We tested the hypothesis that phosphatidylserine made in the endoplasmic reticulum is delivered via the MAM to mitochondria for decarboxylation to phosphatidylethanolamine. Cells were pulse-labeled with [H-3]serine and subsequently incubated either in the presence of hydroxylamine (for inhibition of phosphatidylserine decarboxylation) or under conditions for which cellular ATP had been depleted (for inhibition of phosphatidylserine import into mitochondria). In hydroxylamine-treated cells, within 2 h, the amount of radiolabeled phosphatidylserine in the MAM and mito chondria, but not microsomes, was greater than in untreated cells. Moreover, in ATP-depleted, but not in control, cells the amount of radiolabeled phosphatidylserine in the MAM approximately doubled by 3 h. These observations are consistent with the hypothesis that newly synthesized phosphatidylserine normally traverses the MAM en route to mitochondria.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,DEPT MED,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta			Shiao, Young-Ji/AAA-9647-2022	LUPO, Gabriella/0000-0002-9291-6969				ARDAIL D, 1993, J BIOL CHEM, V268, P25985; BJERVE KS, 1985, BIOCHIM BIOPHYS ACTA, V833, P396, DOI 10.1016/0005-2760(85)90096-7; COLBEAU A, 1971, BIOCHIM BIOPHYS ACTA, V249, P462, DOI 10.1016/0005-2736(71)90123-4; CUI Z, 1993, J BIOL CHEM, V268, P16655; DENNIS EA, 1972, J LIPID RES, V13, P263; FRANKE WW, 1971, PROTOPLASMA, V73, P35, DOI 10.1007/BF01286409; Hoult J.R.S., METHODS ENZYMOLOGY, P443, DOI [10.1016/0076-6879(94)34115-X, DOI 10.1016/0076-6879(94)34115-X, DOI 10.1016/0076-6879(67)10072-4]; HOVIUS R, 1992, J BIOL CHEM, V267, P16790; JELSEMA CL, 1978, J BIOL CHEM, V253, P7960; KATZ J, 1983, BIOCHEM J, V214, P795, DOI 10.1042/bj2140795; KUGE O, 1986, J BIOL CHEM, V261, P5790; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLER HR, 1955, METHOD ENZYMOL, V2, P553; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; MCMURRAY WC, 1969, BIOCHEM J, V112, P91, DOI 10.1042/bj1120091; MEIER PJ, 1981, BIOCHIM BIOPHYS ACTA, V646, P283, DOI 10.1016/0005-2736(81)90335-7; PICKETT CB, 1980, EXP CELL RES, V128, P343, DOI 10.1016/0014-4827(80)90070-1; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; SHIAO YJ, 1993, J BIOL CHEM, V268, P26085; SHORE GC, 1977, J CELL BIOL, V72, P714, DOI 10.1083/jcb.72.3.714; SIMBENI R, 1990, J BIOL CHEM, V265, P281; SNELL EE, 1977, TRENDS BIOCHEM SCI, V2, P131, DOI 10.1016/0968-0004(77)90441-8; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; VANCE JE, 1986, J BIOL CHEM, V261, P4486; VANCE JE, 1991, J LIPID RES, V32, P1971; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1991, J BIOL CHEM, V266, P8241; VANCE JE, 1988, BIOCHIM BIOPHYS ACTA, V963, P10, DOI 10.1016/0005-2760(88)90332-3; VANCE JE, 1991, J BIOL CHEM, V266, P89; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANGOLDE LM, 1974, BIOCHIM BIOPHYS ACTA, V360, P179, DOI 10.1016/0005-2760(74)90168-4; VANHEUSDEN GPH, 1990, J BIOL CHEM, V265, P4105; VOELKER DR, 1991, J BIOL CHEM, V266, P12185; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; VOELKER DR, 1990, J BIOL CHEM, V265, P14340; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921; VOELKER DR, 1991, BIOCH LIPIDS LIPOPRO, P489; YAFFE MP, 1983, BIOCHEMISTRY-US, V22, P1497, DOI 10.1021/bi00275a026; ZBOROWSKI J, 1983, FEBS LETT, V157, P179, DOI 10.1016/0014-5793(83)81141-7; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	41	190	190	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11190	11198		10.1074/jbc.270.19.11190	http://dx.doi.org/10.1074/jbc.270.19.11190			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744750	hybrid			2022-12-25	WOS:A1995QX86500027
J	YAN, SF; TRITTO, I; PINSKY, D; LIAO, H; HUANG, J; FULLER, G; BRETT, J; MAY, L; STERN, D				YAN, SF; TRITTO, I; PINSKY, D; LIAO, H; HUANG, J; FULLER, G; BRETT, J; MAY, L; STERN, D			INDUCTION OF INTERLEUKIN-6 (IL-6) BY HYPOXIA IN VASCULAR CELLS - CENTRAL ROLE OF THE BINDING-SITE FOR NUCLEAR FACTOR-IL-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-REPERFUSION INJURY; COLONY-STIMULATING FACTORS; HUMAN-ENDOTHELIAL-CELLS; SMOOTH-MUSCLE CELLS; GRANULOCYTE-MACROPHAGE; SIGNAL TRANSDUCER; LEUCINE ZIPPER; EXPRESSION; TRANSCRIPTION; ACTIVATION	The pathologic picture in ischemic tissue injury shares features with the inflammatory response, including production of proinflammatory cytokines. Hypoxia-mediated induction of interleukin-6 (IL-6), a cytokine with anti-inflammatory properties, could set in motion mechanisms limiting inflammation in ischemia, Exposure of cultured endothelial cells (ECs) to H (pO(2) approximate to 12-16 torr) increased transcription of IL-6, elevated levels of IL-6 mRNA, and induced elaboration of IL-6 antigen in a time-dependent manner, Exposure of mice to hypoxia increased IL-6 transcripts in the lung, and immuno-staining revealed a striking increase in IL-6 antigen in pulmonary vasculature. Transfection of ECs with deletion chimeric IL-6 promoter-chloramphenicol acetyltransferase (CAT) constructs showed hypoxia-mediated 9-11-fold induction with -1200/+13, -596/+13, and -225/+13 but no induction with -111/+13. Electrophoretic mobility shift assays (EMSAs) using -225/-111 as the labeled probe demonstrated enhanced binding activity in nuclear extracts of hypoxic ECs and lung; the appearance of the gel shift band was prevented by excess unlabeled probe (-225/-111), and hypoxia-mediated enhancement of the band was blocked by a probe corresponding to the nuclear factor (NF)-IL-6 site (-158/-145). The hypoxia-enhanced band on EMSA displayed a supershift with antibody to CCAAT-enhancer-binding protein beta (C/EBP-beta), but antibody to C/EBP-alpha or -delta was without effect. Transfection of ECs with a construct comprising thymidine kinase promoter, -225/-111 in either the 5' to 3' or 3' to 5' orientation, and the reporter CAT showed this region to be an enhancer (approximate to 8-fold) under hypoxia, EMSA with the NF-IL-6 probe revealed a prominent induction of binding activity with nuclear extracts from hypoxic ECs and whole lung, Constructs with -158/-145 and the CAT reporter gene showed induction when transfected into hypoxic ECs, whereas a similar construct with the NF-IL-6 motif mutationally inactivated failed to display hypoxia-induced expression. Furthermore, the tumor necrosis factor (TNF) gene, whose product contributes to ischemic pathology and contains a putative regulatory NF-IL-6 site, demonstrated enhanced binding activity for its NF-IL-B motif and induction of TNF mRNA based on analysis of hypoxic lung, These data indicate that hypoxia induces expression of IL-6, most likely a result of hypoxic activation at the NF-IL-B site, and suggest that other genes with regulatory NF-IL-6 sites may also be induced by a similar mechanism.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT PHYSIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; UNIV ALABAMA, DEPT CELL BIOL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT ANAT, BIRMINGHAM, AL 35294 USA; NEW YORK MED COLL, DEPT MICROBIOL, VALHALLA, NY 10595 USA; NEW YORK MED COLL, DEPT IMMUNOL, VALHALLA, NY 10595 USA	Columbia University; Columbia University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; New York Medical College; New York Medical College			Tritto, Isabella/Y-8881-2019	TRITTO, Isabella/0000-0003-0026-7154; Huang, James/0000-0001-5495-3577	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006, R01HL042833, R01HL042507] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21006, HL42833, HL42507] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADERKA D, 1989, J IMMUNOL, V143, P3517; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BARTALENA L, 1992, MOL ENDOCRINOL, V6, P935, DOI 10.1210/me.6.6.935; BARTON BE, 1993, INFECT IMMUN, V61, P1496, DOI 10.1128/IAI.61.4.1496-1499.1993; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BRETT J, 1993, AM J PATHOL, V143, P1699; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; COLLETTI LM, 1990, J CLIN INVEST, V85, P1936, DOI 10.1172/JCI114656; COLUCCI WS, 1985, MOL PHARMACOL, V27, P517; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GRANGER DN, 1988, AM J PHYSIOL, V255, pH1269, DOI 10.1152/ajpheart.1988.255.6.H1269; GRENETT HE, 1991, GENE, V101, P267, DOI 10.1016/0378-1119(91)90422-8; GUMKOWSKI F, 1987, BLOOD VESSELS, V24, P11; HENSEL G, 1989, LYMPHOKINE RES, V8, P347; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IKEDA U, 1991, AM J PHYSIOL, V260, pHUMUO; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; KASAHARA T, 1991, IMMUNOLOGY, V74, P60; KISHIMOTO T, 1988, ANNU REV IMMUNOL, V6, P485, DOI 10.1146/annurev.iy.06.040188.002413; KOGA S, 1992, J CLIN INVEST, V90, P1007, DOI 10.1172/JCI115913; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; MECHAM RP, 1987, SCIENCE, V237, P423, DOI 10.1126/science.3603030; METINKO AP, 1992, J CLIN INVEST, V90, P791, DOI 10.1172/JCI115953; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MEYRICK B, 1980, AM J PATHOL, V100, P151; MULLANE KM, 1990, PATHOPHYSIOLOGY SEVE, P239; NABATA T, 1990, BIOCHEM INT, V20, P445; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; OHKAWA F, 1994, AM J PHYSIOL, V266, pH898, DOI 10.1152/ajpheart.1994.266.3.H898; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; POBER JS, 1988, AM J PATHOL, V133, P426; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; Sambrook J, 1989, MOL CLONING LABORATO; SCHINDLER R, 1990, BLOOD, V75, P40; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SHREENIWAS R, 1992, J CLIN INVEST, V90, P2333, DOI 10.1172/JCI116122; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TILG H, 1994, BLOOD, V83, P113; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; ULICH TR, 1991, AM J PATHOL, V138, P1097; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YONG K, 1991, BLOOD, V77, P1675	56	314	337	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11463	11471		10.1074/jbc.270.19.11463	http://dx.doi.org/10.1074/jbc.270.19.11463			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744784	hybrid			2022-12-25	WOS:A1995QX86500063
J	BERNSTEIN, J; SHEFLER, I; ELROYSTEIN, O				BERNSTEIN, J; SHEFLER, I; ELROYSTEIN, O			THE TRANSLATIONAL REPRESSION MEDIATED BY THE PLATELET-DERIVED GROWTH-FACTOR 2/C-SIS MESSENGER-RNA LEADER IS RELIEVED DURING MEGAKARYOCYTIC DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; C-SIS GENE; MESSENGER-RNA; VACCINIA VIRUS; INITIATION FACTOR-4E; EXPRESSION SYSTEM; FACTOR-II; 5'-NONCODING SEQUENCES; 5'-UNTRANSLATED REGION; INTERNAL INITIATION	Expression of the platelet-derived growth factor 2/c-sis gene is highly restricted and controlled at multiple levels. Its structured mRNA leader, which is unusually long (1022 nucleotides), serves as a potent translational inhibitor. One of the sites of PDGF2 synthesis is megakaryocytes, implying that PDGF2 translation efficiency is modulated during megakaryocytic differentiation. To study the role of the mRNA leader as a translational cis-modulator, the hybrid T7/vaccinia cytoplasmic expression system was used to disconnect between determinants controlling transcription, alternative splicing, and mRNA stability from those controlling translation. Chimeric transcripts in which the human PDGF2/c-sis mRNA leader positioned in frame upstream of a reporter gene were used to determine whether the mRNA leader can confer variable translational efficiencies during differentiation. It is demonstrated that there is a time window during megakaryocytic differentiation of K562 cells in which the strong translational inhibition by PDGF2/c-sis mRNA leader is relieved. The time course of the translational repression relief is similar to that of PDGF2/c-sis transcriptional induction during the differentiation process. A 179-nucleotides CG-rich fragment immediately upstream of the initiator AUG codon is necessary for coffering stringent modulation of the translational efficiency. In NIH3T3 overexpressing translation initiation factor eIF4E, the inhibitory effect of the mRNA leader of c-sis is not relieved, suggesting that the changes in the translational machinery during megakaryocytic differentiation are beyond eIF4E activity. The possible involvement of a 5'-end independent translational mechanism is discussed.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT CELL RES & IMMUNOL, IL-69978 TEL AVIV, ISRAEL	Tel Aviv University				Elroy-Stein, Orna/0000-0002-3716-1540				ALITALO R, 1987, EMBO J, V6, P1213, DOI 10.1002/j.1460-2075.1987.tb02356.x; ARRICK BA, 1994, MOL CELL BIOL, V14, P619, DOI 10.1128/MCB.14.1.619; AVNI D, 1994, MOL CELL BIOL, V14, P3822, DOI 10.1128/MCB.14.6.3822; BETSHOLTZ C, 1993, BIOL PLATELET DERIVE, P11; BONTHRON DT, 1991, GENOMICS, V10, P287, DOI 10.1016/0888-7543(91)90515-G; BORMAN A, 1993, J GEN VIROL, V74, P1775, DOI 10.1099/0022-1317-74-9-1775; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; ELROYSTEIN O, 1990, P NATL ACAD SCI USA, V87, P6743, DOI 10.1073/pnas.87.17.6743; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; ELROYSTEIN O, 1991, CURRENT PROTOCOLS MO; FEN Z, 1991, ONCOGENE, V6, P953; FUERST TR, 1989, J MOL BIOL, V206, P333, DOI 10.1016/0022-2836(89)90483-X; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GIERMAN TM, 1992, VIROLOGY, V188, P934, DOI 10.1016/0042-6822(92)90557-6; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; IGARASHI H, 1987, ONCOGENE, V1, P79; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JOSHIBARVE S, 1990, J BIOL CHEM, V265, P2979; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KIM SJ, 1992, J BIOL CHEM, V267, P13702; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAROCHELLE WJ, 1993, BIOL PLATELET DERIVE, P129; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LONING F, 1991, SCIENCE, V251, P807; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MILLER KG, 1981, CELL, V27, P165, DOI 10.1016/0092-8674(81)90370-6; MIZOKAMI A, 1994, J BIOL CHEM, V269, P25655; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; MORLEY SJ, 1993, EUR J BIOCHEM, V218, P39, DOI 10.1111/j.1432-1033.1993.tb18349.x; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; RAINES EW, 1993, BIOL PLATELET DERIVE, P74; RAO CD, 1986, P NATL ACAD SCI USA, V83, P2392, DOI 10.1073/pnas.83.8.2392; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; RAO SM, 1993, J BIOL CHEM, V268, P22164; RATNER L, 1987, NUCLEIC ACIDS RES, V15, P6017, DOI 10.1093/nar/15.15.6017; RATNER L, 1989, NUCLEIC ACIDS RES, V17, P4101, DOI 10.1093/nar/17.11.4101; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROMEO DS, 1993, MOL ENDOCRINOL, V7, P759, DOI 10.1210/me.7.6.759; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHNIERLE BS, 1992, VIROLOGY, V188, P931, DOI 10.1016/0042-6822(92)90556-5; SCOTTO L, 1993, MOL CELL BIOL, V13, P3588, DOI 10.1128/MCB.13.6.3588; SHAMA S, 1995, IN PRESS GENE EXPR; SHANTZ LM, 1994, CANCER RES, V54, P2313; SONENBERG N, 1988, MICROBIOL REV, V44, P173; TUAZON PT, 1990, J BIOL CHEM, V265, P10617; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; VANDENOUWELAND AMW, 1987, NUCLEIC ACIDS RES, V15, P959, DOI 10.1093/nar/15.3.959; VANDENOUWELAND MW, 1986, NUCLEIC ACIDS RES, V14, P765, DOI 10.1093/nar/14.2.765; WAGNER RE, 1990, MOL CELL BIOL, V10, P5983; WHETTER LE, 1994, J VIROL, V68, P5253, DOI 10.1128/JVI.68.8.5253-5263.1994	67	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10559	10565		10.1074/jbc.270.18.10559	http://dx.doi.org/10.1074/jbc.270.18.10559			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737991	hybrid			2022-12-25	WOS:A1995QW60100032
J	MORITA, I; SCHINDLER, M; REGIER, MK; OTTO, JC; HORI, T; DEWITT, DL; SMITH, WL				MORITA, I; SCHINDLER, M; REGIER, MK; OTTO, JC; HORI, T; DEWITT, DL; SMITH, WL			DIFFERENT INTRACELLULAR LOCATIONS FOR PROSTAGLANDIN ENDOPEROXIDE-H SYNTHASE-1 AND SYNTHASE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SWISS 3T3 CELLS; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; INDUCIBLE CYCLOOXYGENASE; SUBCELLULAR-LOCALIZATION; ALVEOLAR MACROPHAGES; ENDOTHELIAL-CELLS; GROWTH-FACTOR; EXPRESSION	The subcellular locations of prostaglandin endoperoxide synthase-1 and -2 (PGHS-1 and -2) were determined by quantitative confocal fluorescence imaging microscopy in murine 3T3 cells and human and bovine endothelial cells using immunocytofluorescence with isozyme-specific antibodies, In all of the cell types examined, PGHS-1 immunoreactivity was found equally distributed in the endoplasmic reticulum (ER) and nuclear envelope (NE), PGHS-2 immunoreactivity was also present in the ER and NE. However, PGHS-2 staining was twice as concentrated in the NE as in the ER, A histofluorescence staining method was developed to localize cyclooxygenase/peroxidase activity. In quiescent 3T3 cells, which express only PGHS-1, histofluorescent staining was most concentrated in the perinuclear cytoplasmic region. In contrast, histochemical staining for PGHS-2 activity was about equally intense in the nucleus and in the cytoplasm, a pattern of activity staining distinct from that observed with PGHS-1, Our results indicate that there are significant differences in the subcellular locations of PGHS-1 and PGHS-2, It appears that PGHS-1 functions predominantly in the ER whereas PGHS-S may function in the ER and the NE, We speculate that PGHS-1 and PGHS-2 acting in the ER and PGHS-2 functioning in the NE represent independent prostanoid biosynthetic systems.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NIDDK NIH HHS [DK22042, DK45209] Funding Source: Medline; NIGMS NIH HHS [GM40713] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK022042, R01DK022042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040713] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; BHATTACHARYYA DK, 1995, ARCH BIOCHEM BIOPHYS, V317, P19, DOI 10.1006/abbi.1995.1130; BRANNON TS, 1994, J CLIN INVEST, V93, P2230, DOI 10.1172/JCI117220; CRAIG S, 1988, EUR J CELL BIOL, V46, P80; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FIECK A, 1992, NUCLEIC ACIDS RES, V20, P1785, DOI 10.1093/nar/20.7.1785; Gorman R R, 1978, Adv Cyclic Nucleotide Res, V9, P597; GRANTHAM JJ, 1968, J CLIN INVEST, V47, P1154, DOI 10.1172/JCI105804; HABENICHT AJR, 1985, J CLIN INVEST, V75, P1381, DOI 10.1172/JCI111839; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HERSCHMANN HR, 1991, ANN REV BIOCH, V37, P281; HSI LC, 1994, BIOCHEM BIOPH RES CO, V202, P1592, DOI 10.1006/bbrc.1994.2114; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JANSZEN FHA, 1972, ADV BIOSCI, V9, P287; JONES DA, 1993, J BIOL CHEM, V268, P9049; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LEE SH, 1992, J BIOL CHEM, V267, P25934; LIN AH, 1989, J BIOL CHEM, V264, P17379; MARCUS AJ, 1980, J CLIN INVEST, V66, P979, DOI 10.1172/JCI109967; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MORITA I, 1984, BIOCHIM BIOPHYS ACTA, V792, P304; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; OHKI S, 1979, J BIOL CHEM, V254, P829; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; OSULLIVAN MG, 1992, BIOCHEM BIOPH RES CO, V187, P1123, DOI 10.1016/0006-291X(92)91313-F; OTTO JC, 1993, J BIOL CHEM, V268, P18234; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PATRIGNANI P, 1995, IN PRESS J PHARM EXP; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PILBEAM CC, 1993, J BIOL CHEM, V268, P25643; RAZ A, 1988, J BIOL CHEM, V263, P3022; REDDY ST, 1994, J BIOL CHEM, V269, P15473; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; RIESE J, 1990, J LEUKOCYTE BIOL, V55, P476; ROBBI M, 1991, J BIOL CHEM, V266, P20498; ROLLINS TE, 1980, J BIOL CHEM, V255, P4872; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; SMITH WL, 1994, MET IONS BIOL SYST, V30, P163; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; SONNENBURG WK, 1988, J BIOL CHEM, V263, P6155; SUH KS, 1989, J CELL BIOL, V108, P811, DOI 10.1083/jcb.108.3.811; TANG BL, 1992, J BIOL CHEM, V267, P7072; TERASAKI M, 1992, J CELL SCI, V101, P315; VELASCO A, 1987, HISTOCHEM J, V19, P7, DOI 10.1007/BF01675287; WADE MH, 1993, BIOANALYTICAL INSTRU, V37, P117; [No title captured]	54	487	499	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10902	10908		10.1074/jbc.270.18.10902	http://dx.doi.org/10.1074/jbc.270.18.10902			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738031	hybrid			2022-12-25	WOS:A1995QW60100079
J	BRINI, M; MARSAULT, R; BASTIANUTTO, C; ALVAREZ, J; POZZAN, T; RIZZUTO, R				BRINI, M; MARSAULT, R; BASTIANUTTO, C; ALVAREZ, J; POZZAN, T; RIZZUTO, R			TRANSFECTED AEQUORIN IN THE MEASUREMENT OF CYTOSOLIC CA2+ CONCENTRATION ([CA2+](C)) - A CRITICAL-EVALUATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETED RECOMBINANT AEQUORIN; FREE CALCIUM; SACCHAROMYCES-CEREVISIAE; INTRACELLULAR CALCIUM; CELLS; CA-2+; CDNA; EXPRESSION; CLONING; PROTEIN	Targeted recombinant aequorins represent to date the most specific means of monitoring [Ca2+] in subcellular organelles (Rizzuto, R., Simpson, A. W. M., Brini, M., and Pozzan, T. (1992) Nature 358, 325-328; Brini, M., Murgia, M., Pasti, L., Picard, D., Pozzan, T., and Rizzuto, R. (1993) EMBO J. 12, 4813-4819; Kendall, J. Ri., Dormer, R. L., and Campbell, A. R. (1992) Biochem. Biophys. Res. Commun. 189, 1008-1016). Up until now, however, only limited attention has been paid to the use of recombinant photoproteins for measuring, in mammalian cells, the [Ca2+] in the cytoplasm, a compartment for which effective Ca2+ probes are already available. Here we describe this approach in detail, highlighting the advantages, under various experimental conditions, of using recombinant cytosolic aequorin (cytAEQ) instead of classical fluorescent indicators. We demonstrate that cytAEQ is expressed recombinantly at high levels in transiently transfected cell Lines and primary cultures as well as in stably transfected clones, and we describe a simple algorithm for converting aequorin luminescence data into [Ca2+] values. We show that although fluorescent indicators at the usual intracellular concentrations (50-100 mu M) are associated with a significant buffering of the [Ca2+](c) transients, this problem is negligible with recombinantly expressed aequorin. The large dynamic range of the photoprotein also allows an accurate estimate of the large [Ca2+](c) increases that are observed in some cell types such as neurons. Finally, cytAEQ appears to be an invaluable tool for measuring [Ca2+](c) in cotransfection experiments. In particular, we show that when cotransfected with an alpha(1)-adrenergic receptor (coupled to inositol 1,4,5-trisphosphate generation), cytAEQ faithfully monitors the subpopulation of cells expressing the receptor, whereas the signal of fura-2, at the population level, is dominated largely by that of the untransfected cells.	UNIV PADUA,DEPT BIOMED SCI,I-35121 PADUA,ITALY; UNIV PADUA,CNR,CTR STUDY MITOCHONDRIAL PHYSIOL,I-35121 PADUA,ITALY	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua			Rizzuto, Rosario/B-6312-2008; Alvarez, Javier/K-8210-2014; Brini, Marisa/K-5189-2016	Alvarez, Javier/0000-0003-0636-5521; Brini, Marisa/0000-0001-5141-0243; Rizzuto, Rosario/0000-0001-7044-5097	Telethon [495] Funding Source: Medline	Telethon(Fondazione Telethon)		ALLEN DG, 1978, NATURE, V273, P509, DOI 10.1038/273509a0; ALLEN DG, 1971, SCIENCE, V195, P996; Blinks J.R., 1978, Methods in Enzymology, V57, P292; BRINI M, 1993, EMBO J, V12, P4813, DOI 10.1002/j.1460-2075.1993.tb06170.x; BRINI M, 1994, CELL CALCIUM, V16, P259, DOI 10.1016/0143-4160(94)90089-2; BUTTON D, 1993, CELL CALCIUM, V14, P663, DOI 10.1016/0143-4160(93)90091-J; COBBOLD PH, 1980, NATURE, V285, P441, DOI 10.1038/285441a0; Cobbold PH, 1991, CELLULAR CALCIUM PRA, P55; FABIATO A, 1991, CELLULAR CALCIUM PRA, P159; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; INOUYE S, 1985, P NATL ACAD SCI USA, V82, P3154, DOI 10.1073/pnas.82.10.3154; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KENDALL JM, 1992, BIOCHEM BIOPH RES CO, V189, P1008, DOI 10.1016/0006-291X(92)92304-G; KENDALL JM, 1994, ANAL BIOCHEM, V221, P173, DOI 10.1006/abio.1994.1394; KENDALL JM, 1992, BIOCHEM BIOPH RES CO, V187, P1091, DOI 10.1016/0006-291X(92)91309-E; KNIGHT MR, 1991, FEBS LETT, V282, P405, DOI 10.1016/0014-5793(91)80524-7; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; KNIGHT MR, 1993, J CELL BIOL, V121, P83, DOI 10.1083/jcb.121.1.83; LEW PD, 1986, J CELL BIOL, V102, P2197, DOI 10.1083/jcb.102.6.2197; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MILLER AL, 1994, METHOD CELL BIOL, V40, P305; MOISESCU DG, 1977, BIOCHIM BIOPHYS ACTA, V460, P189, DOI 10.1016/0005-2728(77)90206-7; MURGIA M, 1994, CELL CALCIUM, V16, P167, DOI 10.1016/0143-4160(94)90020-5; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; PRASHER D, 1985, BIOCHEM BIOPH RES CO, V126, P1259, DOI 10.1016/0006-291X(85)90321-3; RIDGWAY EB, 1967, BIOCHEM BIOPH RES CO, V29, P229, DOI 10.1016/0006-291X(67)90592-X; RIDGWAY EB, 1977, P NATL ACAD SCI USA, V74, P623, DOI 10.1073/pnas.74.2.623; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; RIZZUTO R, 1994, METHOD CELL BIOL, V40, P339; RIZZUTO R, 1995, IN PRESS METHODS ENZ; SARAN S, 1994, FEBS LETT, V337, P43, DOI 10.1016/0014-5793(94)80626-8; SHEU YA, 1993, ANAL BIOCHEM, V209, P343, DOI 10.1006/abio.1993.1132; SHIMOMURA O, 1993, CELL CALCIUM, V14, P373, DOI 10.1016/0143-4160(93)90041-4; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; VILLALBA M, 1994, J BIOL CHEM, V269, P2468; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X	40	314	323	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9896	9903		10.1074/jbc.270.17.9896	http://dx.doi.org/10.1074/jbc.270.17.9896			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730373	hybrid			2022-12-25	WOS:A1995QV41700032
J	FORTENBERRY, SC; CHIRGWIN, JM				FORTENBERRY, SC; CHIRGWIN, JM			THE PROPEPTIDE IS NONESSENTIAL FOR THE EXPRESSION OF HUMAN CATHEPSIN-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYME PHOSPHORYLATION; PROTEIN RECOGNITION DETERMINANTS; HAMSTER KIDNEY-CELLS; ACTIVE HUMAN RENIN; PROCATHEPSIN-D; ASPARTIC PROTEINASES; PORCINE PEPSINOGEN; TARGETING SIGNAL; CRYSTAL-STRUCTURES; SITE	When the 44-amino acid propeptide of human procathepsin D was deleted by mutagenesis in vitro, the mature protein was stably expressed and secreted from transfected mammalian cells. The secreted protein was correctly folded as judged by its binding to pepstatinyl-agarose. We were unable to detect lysosomal targeting of the propeptide-deleted protein, and targeting was not restored by the substitution of the propeptides from pepsin or renin. We conclude that its propeptide is not essential for the folding of nascent cathepsin D. Efficient lysosomal targeting in mammalian cells appears to require the precursor form of the molecule.	UNIV TEXAS, HLTH SCI CTR, DEPT MED, DIV ENDOCRINOL & METAB, SAN ANTONIO, TX 78284 USA; UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA; AUDIE L MURPHY MEM VET ADM MED CTR, RES SERV, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital								AHMAD F, 1978, INT J PEPT PROT RES, V12, P155; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CHIDGEY MAJ, 1990, EUR J BIOCHEM, V190, P139, DOI 10.1111/j.1432-1033.1990.tb15556.x; CHU WN, 1990, MOL ENDOCRINOL, V4, P1905, DOI 10.1210/mend-4-12-1905; COCKETT MI, 1991, NUCLEIC ACIDS RES, V19, P319, DOI 10.1093/nar/19.2.319; CONNER GE, 1990, DNA CELL BIOL, V9, P1, DOI 10.1089/dna.1990.9.1; CONNER GE, 1992, J BIOL CHEM, V267, P21738; CONNER GE, 1989, BIOCHEMISTRY-US, V28, P3530, DOI 10.1021/bi00434a057; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; DAVIES DR, 1990, ANNU REV BIOPHYS BIO, V19, P189, DOI 10.1146/annurev.bb.19.060190.001201; DELBRUCK R, 1994, EUR J CELL BIOL, V64, P7; ERICKSON AH, 1989, J CELL BIOCHEM, V40, P31, DOI 10.1002/jcb.240400104; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FAUST PL, 1987, J CELL BIOL, V105, P1937, DOI 10.1083/jcb.105.5.1937; FOLTMANN B, 1988, BIOL CHEM H-S, V369, P311; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; FURIE B, 1991, ANN NY ACAD SCI, V614, P1; FUSEK M, 1991, FEBS LETT, V287, P160, DOI 10.1016/0014-5793(91)80040-A; GLICKMAN JN, 1993, J CELL BIOL, V123, P99, DOI 10.1083/jcb.123.1.99; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTSUCK JA, 1992, PROTEINS, V13, P1, DOI 10.1002/prot.340130102; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORST M, 1993, J BIOL CHEM, V268, P19690; HORST M, 1991, BIOCHEM J, V273, P355, DOI 10.1042/bj2730355; HSUEH WA, 1991, HYPERTENSION, V17, P469, DOI 10.1161/01.HYP.17.4.469; HUTCHINS C, 1991, CRIT REV BIOCHEM MOL, V26, P77, DOI 10.3109/10409239109081721; ISIDORO C, 1991, BIOCHEM J, V273, P363, DOI 10.1042/bj2730363; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KOELSCH G, 1994, GEBS LETT, V343, P6; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KORNFELD S, 1990, BIOCHEM SOC T, V18, P367, DOI 10.1042/bst0180367; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN XL, 1989, J BIOL CHEM, V264, P4482; LIN XL, 1993, PROTEIN SCI, V2, P1383, DOI 10.1002/pro.5560020903; METCALF P, 1993, EMBO J, V12, P1293, DOI 10.1002/j.1460-2075.1993.tb05774.x; NILSSON B, 1991, ANNU REV MICROBIOL, V45, P607; NORMAN JA, 1992, MOL PHARMACOL, V41, P53; PAIN RH, 1985, BIOCHEM SOC T, V13, P1032, DOI 10.1042/bst0131032; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; RICHO GR, 1994, J BIOL CHEM, V269, P14806; ROTHWELL V, 1993, DNA CELL BIOL, V12, P291, DOI 10.1089/dna.1993.12.291; SACHDEV D, 1991, ADV EXP MED BIOL, V309, P335; SAGHERIAN C, 1994, BIOCHEM BIOPH RES CO, V204, P135, DOI 10.1006/bbrc.1994.2436; Sambrook J, 1989, MOL CLONING LABORATO; SHINDE U, 1994, J BIOCHEM, V115, P629, DOI 10.1093/oxfordjournals.jbchem.a124386; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; TREVINO RJ, 1993, BIOTECHNIQUES, V15, P366; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VANDENHAZEL HB, 1993, J BIOL CHEM, V268, P18002	61	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9778	9782		10.1074/jbc.270.17.9778	http://dx.doi.org/10.1074/jbc.270.17.9778			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730356	hybrid			2022-12-25	WOS:A1995QV41700015
J	GUO, W; CAMPBELL, KP				GUO, W; CAMPBELL, KP			ASSOCIATION OF TRIADIN WITH THE RYANODINE RECEPTOR AND CALSEQUESTRIN IN THE LUMEN OF THE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM RELEASE CHANNEL; RABBIT SKELETAL-MUSCLE; 1,4-DIHYDROPYRIDINE RECEPTOR; BIOCHEMICAL-CHARACTERIZATION; DIHYDROPYRIDINE RECEPTORS; GLYCOPROTEIN TRIADIN; LOCALIZATION; PROTEIN; INVOLVEMENT; SUBUNITS	Triadin is a major membrane protein that is specifically localized in the junctional sarcoplasmic reticulum of skeletal muscle and is thought to play an important role in muscle excitation-contraction coupling. In order to identify the proteins in the skeletal muscle that interact with triadin, the cytoplasmic and luminal domains of triadin were expressed as glutathione S-transferase fusion proteins and immobilized to glutathione-Sepharose to form affinity columns. Using these affinity columns, we find that triadin binds specifically to the ryanodine receptor/Ca2+ release channel and the Ca2+-binding protein calsequestrin from CHAPS (3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonic acid)-solubilized skeletal muscle homogenates. The luminal but not the cytoplasmic domain of triadin-glutathione S-transferase fusion protein binds [H-3]ryanodine receptor, whereas neither the cytoplasmic nor the luminal portion of triadin binds [H-3]PN-200-100-labeled dihydropyridine receptor, In addition, the luminal domain of triadin interacts with calsequestrin in a Ca2+-dependent manner and is capable of inhibiting the reassociation of calsequestrin to the junctional face membrane. These results suggest that triadin is the previously unidentified transmembrane protein that anchors calsequestrin to the junctional region of the sarcoplasmic reticulum, and is involved in the functional coupling between calsequestrin and the ryanodine receptor/Ca2+ release channel.	UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, DEPT PHYS & BIOPHYS, IOWA CITY, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa				Campbell, Kevin/0000-0003-2066-5889				CALA SE, 1983, J BIOL CHEM, V258, P1932; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; COSTELLO B, 1986, J CELL BIOL, V103, P741, DOI 10.1083/jcb.103.3.741; FLUCHER BE, 1990, NEURON, V5, P339, DOI 10.1016/0896-6273(90)90170-K; FOSSET M, 1983, J BIOL CHEM, V258, P6086; FRANZINI.C, 1970, J CELL BIOL, V47, P488, DOI 10.1083/jcb.47.2.488; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20850; HE ZP, 1993, J BIOL CHEM, V268, P24635; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; KAWAMOTO RM, 1986, J CELL BIOL, V103, P1405, DOI 10.1083/jcb.103.4.1405; KAWASAKI T, 1994, BIOCHEM BIOPH RES CO, V199, P1120, DOI 10.1006/bbrc.1994.1347; KNUDSON CM, 1989, J BIOL CHEM, V264, P1345; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; LIU GH, 1994, J BIOL CHEM, V269, P33028; MacLennan D., 1983, CALCIUM CELL FUNCT, V4, P151; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	30	206	208	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9027	9030		10.1074/jbc.270.16.9027	http://dx.doi.org/10.1074/jbc.270.16.9027			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721813	hybrid			2022-12-25	WOS:A1995QU08900001
J	LITTLE, E; LEE, AS				LITTLE, E; LEE, AS			GENERATION OF A MAMMALIAN-CELL LINE DEFICIENT IN GLUCOSEREGULATED PROTEIN STRESS INDUCTION THROUGH TARGETED RIBOZYME DRIVEN BY A STRESS-INDUCIBLE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEIN; CALCIUM IONOPHORE A23187; ENDOPLASMIC-RETICULUM; HEAT-SHOCK; TRANSMEMBRANE PROTEIN; MALFOLDED PROTEINS; GRP78 PROMOTER; GENES; GRP94; GLYCOSYLATION	GRP94 is an endoplasmic reticulum (ER) localized glycoprotein with Ca2+ binding and protein chaperoning properties. Using a ribozyme driven by a stress-inducible promoter and targeted against grp94 mRNA, we have generated a cell line deficient in its ability to induce GRP94. The effect of the ribozyme is mediated by the cleavage of the grp94 message just downstream of the initiation codon, and not by an antisense effect, as determined by the level of intact grp94 mRNA. Unexpectedly, this cell line's ability to induce GRP78 is also impaired. Transient overexpression of recombinant human lysosomal hydrolase alpha-L-iduronidase in the ribozyme expressing cells indicates that the secretion ratio of this enzyme is reduced by about B-fold. Additionally, the ribozyme expressing cells showed increased sensitivity to Ca2+ depletion from ER caused by either A23187 or thapsigargin, an ER-Ca2+-ATPase inhibitor, but not to tunicamycin. These combined results show that the induction of GRP94 may play important roles in ER to nuclear signaling, protein sorting and secretion, and specific protection against Ca2+ depletion stress.	UNIV SO CALIF, SCH MED, DEPT BIOCHEM & MOLEC BIOL, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, NORRIS CANC CTR, LOS ANGELES, CA 90033 USA	University of Southern California; University of Southern California				Lee, Amy/0000-0002-0378-5443	NCI NIH HHS [R37 CA27607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA027607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BROSTROM MA, 1990, J BIOL CHEM, V265, P20539; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CALA SE, 1994, J BIOL CHEM, V269, P5926; Castanotto Daniela, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P331; CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; EFRAT S, 1994, P NATL ACAD SCI USA, V91, P2051, DOI 10.1073/pnas.91.6.2051; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HUTCHISON KA, 1993, ANN NY ACAD SCI, V684, P35, DOI 10.1111/j.1749-6632.1993.tb32269.x; KAKKIS ED, 1994, PROTEIN EXPRES PURIF, V5, P225, DOI 10.1006/prep.1994.1035; KANG HS, 1991, J BIOL CHEM, V266, P5643; KIM YK, 1987, J CELL PHYSIOL, V133, P553, DOI 10.1002/jcp.1041330317; KOCH G, 1986, J CELL SCI, V86, P217; KOIZUMI M, 1988, FEBS LETT, V228, P228, DOI 10.1016/0014-5793(88)80004-8; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1983, J BIOL CHEM, V258, P597; LEE AS, 1986, J CELL PHYSIOL, V129, P277, DOI 10.1002/jcp.1041290302; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LI WWF, 1993, J BIOL CHEM, V268, P12003; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; LIN AY, 1986, MOL CELL BIOL, V6, P1235, DOI 10.1128/MCB.6.4.1235; LITTLE E, 1994, GENE EXP, V4, P1; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MENORET A, 1994, INT J CANCER, V56, P400, DOI 10.1002/ijc.2910560319; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MORI K, 1993, CELL, V74, P743; NAEVE GS, 1992, CELL GROWTH DIFFER, V3, P919; NAVARRO D, 1992, VIROLOGY, V186, P99, DOI 10.1016/0042-6822(92)90064-V; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RAMAKRISHNAN M, 1995, IN PRESS DNA CELL BI; RESENDEZ E, 1986, J CELL BIOL, V103, P2145, DOI 10.1083/jcb.103.6.2145; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; ROME LH, 1978, ARCH BIOCHEM BIOPHYS, V189, P344, DOI 10.1016/0003-9861(78)90221-7; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; SUGAWARA S, 1993, CANCER RES, V53, P6001; TING J, 1988, DNA-J MOLEC CELL BIO, V7, P275, DOI 10.1089/dna.1988.7.275; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VOLPE P, 1992, P NATL ACAD SCI USA, V89, P6142, DOI 10.1073/pnas.89.13.6142; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; Wooden S.K., 1992, DNA Sequence, V3, P41, DOI 10.3109/10425179209039694; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; ZHAO JJG, 1993, NATURE, V365, P448, DOI 10.1038/365448a0	57	94	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9526	9534		10.1074/jbc.270.16.9526	http://dx.doi.org/10.1074/jbc.270.16.9526			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721881	hybrid			2022-12-25	WOS:A1995QU08900070
J	LUCERO, HA; CHOJNICKI, EWT; MANDIYAN, S; NELSON, H; NELSON, N				LUCERO, HA; CHOJNICKI, EWT; MANDIYAN, S; NELSON, H; NELSON, N			CLONING AND EXPRESSION OF A YEAST GENE ENCODING A PROTEIN WITH ATPASE ACTIVITY AND HIGH IDENTITY TO THE SUBUNIT-4 OF THE HUMAN 26-S PROTEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAT-MEDIATED TRANSACTIVATION; VACUOLAR H+-ATPASE; CONSENSUS SEQUENCE; MOLECULAR-CLONING; BINDING-PROTEIN; UBIQUITIN; COMPLEX; MODULATOR; FAMILY; DOMAIN	The cloning, expression, and biochemical character characterization of an essential gene of Saccharomyces cerevisiae that encodes for a new member of the TBP1-like subfamily of putative ATPases are described. The protein is 72% identical at the amino acid level to subunit four (S4) of the human 26 S protease and 73% identical to Schizosaccharomyces pombe MTS2 gene product. The purified, recombinant protein, designated Yhs4p, has an estimated molecular mass of 49 kDa and exhibits a Mg2+-dependent ATPase activity with nucleotide specificity and K-m for ATP similar to those exhibited by the human 26 S protease, The observed ATPase activity was reduced by 73% upon the introduction of point mutation K229Q in the ''P-loop'' domain of the ATP-binding site relative to the nonmutated form of the protein, This is the first direct biochemical evidence supporting the putative ATPase activity of a member of the TBP1-like subfamily, Furthermore, the experimental results demonstrate a regulatory function for the amino-terminal region of the molecule, The amino-terminal truncated form of Yhs4p lacking two clusters of positively charged amino acids exhibits a greater ATPase activity, The ATPase activity of both the truncated and complete forms of Yhs4p is stimulated by polyanions, Polylysine partially inhibits the ATPase activity of the aminoterminal truncated form having no observable effect on the complete protein, N-Ethylmaleimide inhibits the ATPase activity of both forms of Yhs4p. We propose that Yhs4p ATPase may play an essential role in the regulatory function of the proteolytic activity of the yeast 26 S protease.	BRISTOL MYERS SQUIBB CO, PHARMACEUT RES INST, SYRACUSE, NY 13221 USA; ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA	Bristol-Myers Squibb	LUCERO, HA (corresponding author), BOSTON UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02118 USA.							ARMON T, 1990, J BIOL CHEM, V265, P20723; BURKE M, 1990, FEBS LETT, V262, P185, DOI 10.1016/0014-5793(90)80185-L; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DUBIEL W, 1994, BIOL CHEM H-S, V375, P237, DOI 10.1515/bchm3.1994.375.4.237; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EMORI Y, 1991, MOL CELL BIOL, V11, P344, DOI 10.1128/MCB.11.1.344; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FUJII G, 1993, BIOCHIM BIOPHYS ACTA, V1216, P65, DOI 10.1016/0167-4781(93)90038-F; FUYIWARA T, 1990, J BIOL CHEM, V256, P16604; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HILT W, 1993, ENZYME PROTEIN, V47, P189, DOI 10.1159/000468678; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1986, J BIOL CHEM, V261, P2400; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA CP, 1994, J BIOL CHEM, V269, P3539; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RIVETT AJ, 1993, BIOCHEM J, V291, P1; Sambrook J, 1989, MOL CLONING LABORATO; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SENIOR AE, 1993, J BIOL CHEM, V268, P6989; Sherman F., 1983, METHODS YEAST GENETI; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TANAKA K, 1992, NEW BIOL, V4, P173; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; XIE XS, 1988, METHOD ENZYMOL, V157, P634	41	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9178	9184		10.1074/jbc.270.16.9178	http://dx.doi.org/10.1074/jbc.270.16.9178			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721833	hybrid			2022-12-25	WOS:A1995QU08900021
J	MANZI, A; SALIMATH, PV; SPIRO, RC; KEIFER, PA; FREEZE, HH				MANZI, A; SALIMATH, PV; SPIRO, RC; KEIFER, PA; FREEZE, HH			IDENTIFICATION OF A NOVEL GLYCOSAMINOGLYCAN CORE-LIKE MOLECULE .1. 500 MHZ H-1-NMR ANALYSIS USING A NANO-NMR PROBE INDICATES THE PRESENCE OF A TERMINAL ALPHA-GALNAC RESIDUE CAPPING 4-METHYLUMBELLIFERYL-BETA-D-XYLOSIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; BETA-D-XYLOSIDES; CHONDROITIN SULFATE BIOSYNTHESIS; EMBRYONIC-CHICKEN CARTILAGE; SHARK CARTILAGE; OLIGOSACCHARIDES; PROTEOGLYCANS; CHAINS; ANALOGS; H-1-NMR	beta-Xylosides compete with endogenous proteoglycan core proteins and act as alternate accepters for synthesizing protein-free glycosaminoglycan chains, Their assembly on these alternate accepters utilizes the same glycosyltransferases that make the protein-bound chains, Most studies using alternate accepters focus on the production of sulfated glycosaminoglycan chains that are thought to be the major products. However, we previously showed that labeling melanoma cells with [6-H-3]galactose in the presence of 4-methylumbelliferyl (MU) or p-nitrophenyl (pNP) beta-xylosides led to the synthesis of mostly di- to tetrasaccharide products including incomplete core structures, We have solved the structure of one of the previously unidentified products as, GalNAc alpha(1,4)GlcA beta(1,3)Gal beta(1,3)Gal beta(1,4)Xyl beta MU, based on compositional analysis by high performance liquid chromatography, fast atom bombardment, electrospray mass spectrometry, and one dimensional and two dimensional H-1 NMR spectroscopy, The novel aspect of this molecule is the presence of a terminal alpha-Gal-NAc residue at a position that is normally occupied by beta-GalNAc in chondroitin/dermatan sulfate or by alpha-GlcNAc in heparin or heparan sulfate chains. An alpha-GalNAc residue at this critical location may prevent further chain extension or influence the type of chain subsequently added to the common tetrasaccharide core.	LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, CTR CANC, GLYCOBIOL PROGRAM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, LA JOLLA, CA 92093 USA; VARIAN NMR INSTRUMENTS, PALO ALTO, CA 94304 USA; TELIOS PHARMACEUT INC, SAN DIEGO, CA 92121 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; University of California System; University of California San Diego				Freeze, Hudson/0000-0001-6316-0501	NCRR NIH HHS [1 S10 RR07273] Funding Source: Medline; PHS HHS [R01 49243, R01 38701] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR007273] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Allen H. J., 1992, GLYCOCONJUGATES COMP; BARBARA TM, 1994, J MAGN RESON SER A, V109, P265, DOI 10.1006/jmra.1994.1168; CHAI WG, 1992, EUR J BIOCHEM, V207, P973, DOI 10.1111/j.1432-1033.1992.tb17132.x; DABROWSKI J, 1987, METHOD ENZYMOL, V83, P69; DABROWSKI U, 1993, BIOCHEM BIOPH RES CO, V192, P1057, DOI 10.1006/bbrc.1993.1524; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; FRITZ TA, 1994, J BIOL CHEM, V269, P300; GALLIGANI L, 1975, J BIOL CHEM, V250, P5400; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HASE S, 1990, J BIOL CHEM, V265, P1858; IZUMI J, 1994, J BIOCHEM-TOKYO, V116, P524, DOI 10.1093/oxfordjournals.jbchem.a124556; KESSLER H, 1987, J AM CHEM SOC, V109, P607, DOI 10.1021/ja00236a063; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; MEEZAN E, 1994, J BIOL CHEM, V269, P11503; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; RIVERASAGREDO A, 1991, CARBOHYD RES, V221, P37, DOI 10.1016/0008-6215(91)80047-Q; ROBINSON HC, 1975, BIOCHEM J, V148, P25, DOI 10.1042/bj1480025; ROBINSON JA, 1981, BIOCHEM J, V194, P839, DOI 10.1042/bj1940839; RODEN L, 1994, J BIOL CHEM, V269, P11509; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; SALIMATH PV, 1995, J BIOL CHEM, V270, P9164, DOI 10.1074/jbc.270.16.9164; SHIBATA S, 1992, J BIOL CHEM, V267, P6548; SOBUE M, 1987, BIOCHEM J, V241, P591, DOI 10.1042/bj2410591; STRECKER G, 1989, GLYCOCONJUGATE J, V6, P271, DOI 10.1007/BF01047847; STRECKER G, 1992, FEBS LETT, V298, P39, DOI 10.1016/0014-5793(92)80018-C; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; TAKAGAKI K, 1991, J BIOCHEM-TOKYO, V109, P514, DOI 10.1093/oxfordjournals.jbchem.a123413; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295; PROTON NMR SPECTRA	36	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9154	9163		10.1074/jbc.270.16.9154	http://dx.doi.org/10.1074/jbc.270.16.9154			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721830	hybrid			2022-12-25	WOS:A1995QU08900018
J	WATANABE, S; ITO, Y; MIYAJIMA, A; ARAI, K				WATANABE, S; ITO, Y; MIYAJIMA, A; ARAI, K			GRANULOCYTE MACROPHAGE-COLONY-STIMULATING FACTOR-DEPENDENT REPLICATION OF POLYOMA-VIRUS REPLICON IN HEMATOPOIETIC-CELLS - ANALYSES OF RECEPTOR SIGNALS FOR REPLICATION AND TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; COMMON BETA-SUBUNIT; LARGE TUMOR-ANTIGEN; DNA-REPLICATION; ACTIVATION DOMAINS; YEAST GAL4; T-ANTIGEN; PROTEIN-A; GM-CSF; C-FOS	Granulocyte macrophage colony stimulating factor (GM-CSF) stimulates proliferation of various hemato poietic cells. Using cytoplasmic deletion mutants of the human GM-CSF receptor (hGMR) beta subunit and tyrosine kinase inhibitors, we previously showed that distinct signaling pathways of hGMR are involved in the induction of c-fos/c-jun mRNAs and of c-myc mRNA/cell proliferation. We used polyoma virus (Py) replicon to analyze the initiation of DNA replication induced by hGM-CSF in mouse BA/F3 pro-B cells expressing hGMR. hGM-CSF efficiently stimulated Py replication in the presence of Py enhancer and Py large T antigen supplied in trans. Analyses of Py enhancer mutants revealed that hGM-CSF promoted Py replication and activated transcription of the Py early promoter through the PEA3/PEBP5 region of Py enhancer. The membrane proximal region of hGMR beta subunit is required for activation of PEA3/PEBP5-dependent replication which is also required for activation of DNA synthesis in the host cells. In contrast, a more distal region which is essential for activation of c-fos and c-jun genes is required for the PEA3/PEBP5-dependent transcription of Py early promoter. These results indicate that distinct signaling pathways of hGMR are required to activate PEA3/PEBP5-dependent replication and transcription although the same enhancer is required for both activities.	UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,MINATO KU,TOKYO 108,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 606,JAPAN; DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT MOLEC BIOL,PALO ALTO,CA 94304	University of Tokyo; Kyoto University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.								ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BARU M, 1991, J VIROL, V65, P3496, DOI 10.1128/JVI.65.7.3496-3503.1991; BENNETTCOOK ER, 1991, EMBO J, V10, P959, DOI 10.1002/j.1460-2075.1991.tb08030.x; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; CAMPBELL BA, 1988, MOL CELL BIOL, V8, P1993, DOI 10.1128/MCB.8.5.1993; CAMPBELL BA, 1986, MOL CELL BIOL, V6, P2068, DOI 10.1128/MCB.6.6.2068; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COGEN B, 1978, VIROLOGY, V85, P222, DOI 10.1016/0042-6822(78)90426-9; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DEVILLIERS J, 1984, NATURE, V312, P242, DOI 10.1038/312242a0; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1993, CURR BIOL, V3, P709, DOI 10.1016/0960-9822(93)90076-Z; FANGMAN WL, 1992, CELL, V71, P363, DOI 10.1016/0092-8674(92)90505-7; FARMERIE WG, 1984, P NATL ACAD SCI USA, V68, P6919; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; FUJIMURA FK, 1981, CELL, V23, P809, DOI 10.1016/0092-8674(81)90445-1; HASSELL JA, 1986, CANCER CELL, V4, P561; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; ISHIKAWA H, 1993, ONCOGENE, V8, P2889; KANDA T, 1994, MOL CELL BIOL, V14, P2651, DOI 10.1128/MCB.14.4.2651; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kornberg A., 1992, DNA REPLICATION; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Maniatis T., 1982, MOL CLONING; MARTIN ME, 1992, MOL CELL BIOL, V12, P2213, DOI 10.1128/MCB.12.5.2213; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAJIMA A, 1987, GENE, V58, P273, DOI 10.1016/0378-1119(87)90382-9; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; MURAKAMI Y, 1990, ONCOGENE, V5, P5; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1992, J BIOL CHEM, V267, P2537; TYNDALL C, 1981, NUCLEIC ACIDS RES, V9, P6231, DOI 10.1093/nar/9.23.6231; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WANG EH, 1993, J VIROL, V67, P6788, DOI 10.1128/JVI.67.11.6788-6796.1993; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WATANABE S, 1994, INT IMMUNOL, V6, P523, DOI 10.1093/intimm/6.4.523; WATANABE S, 1991, CURR OPIN BIOTECH, V2, P227, DOI 10.1016/0958-1669(91)90015-W; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WATANABE S, 1993, MOL BIOL CELL, V4, P983, DOI 10.1091/mbc.4.10.983; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YAMAGUCHI Y, 1989, J VIROL, V63, P1040, DOI 10.1128/JVI.63.3.1040-1048.1989; ZHIGANG H, 1993, CELL, V73, P1223	57	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9615	9621		10.1074/jbc.270.16.9615	http://dx.doi.org/10.1074/jbc.270.16.9615			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721893	hybrid			2022-12-25	WOS:A1995QU08900082
J	YAMADA, M; KURACHI, Y				YAMADA, M; KURACHI, Y			SPERMINE GATES INWARD-RECTIFYING MUSCARINIC BUT NOT ATP-SENSITIVE K+ CHANNELS IN RABBIT ATRIAL MYOCYTES - INTRACELLULAR SUBSTANCE-MEDIATED MECHANISM OF INWARD RECTIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG HEART; RECTIFIER POTASSIUM CHANNEL; CELL-FREE MEMBRANE; VENTRICULAR CELLS; ACETYLCHOLINE ACTIVATION; FUNCTIONAL EXPRESSION; MAGNESIUM BLOCK; ADENOSINE; CONDUCTANCE; POLYAMINES	The effect of spermine, a low molecular mass aliphatic amine with positive charges, on the strongly inwardly rectifying muscarinic K+ (K-ACh) channel was examined in rabbit atrial myocytes. In inside-out patch membranes, the single channel current-voltage relationship of K-ACh channels activated by guanosine 5'-3-O-(thio)triphosphate became linear in the absence of intracellular Mg2+. The open probability (P-o) of the channels did not show significant voltage dependence under these conditions. Spermine specifically reduced P-o of outwardly flowing K-ACh channel currents without affecting the unitary current amplitude at depolarized potentials, but had no effect on inward K-ACh currents under hyperpolarization, This voltage dependence of P-o of K-ACh channels in the presence of spermine resembled that normally observed in the whole cell or open cell-attached configurations. Spermine (300 nM to 3 mu M) also restored the relaxation of K-ACh currents which had been lost in the inside-out configuration, The effect of spermine was concentration-dependent with IC50 of similar to 10 nM at +40 mV, The order of potency of polyamines in reducing P-o at +40 mV was spermine greater than or equal to spermidine > putrescine > ornithine; arginine had no significant effect. Intracellular Mg2+ antagonized the effect of spermine. Neither the single channel conductance nor P-o of the ATP-sensitive K+ channel, a weak inward rectifier, was affected by spermine, Because submillimolar concentrations of spermine and spermidine are available in the cytosol of most cells, these substances may be the unidentified intracellular gating factors for strong inward rectifiers such as K-ACh and I-K1 channels.	OSAKA UNIV,FAC MED,DEPT PHARMACOL 2,SUITA,OSAKA 565,JAPAN	Osaka University								ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; CIANI S, 1978, J MEMBRANE BIOL, V44, P103, DOI 10.1007/BF01976035; COLQUHOUN D, 1983, FITTING STAT ANAL SI, P191; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FINDLAY I, 1987, PFLUG ARCH EUR J PHY, V410, P313, DOI 10.1007/BF00580282; FINDLAY I, 1987, J PHYSIOL-LONDON, V391, P611, DOI 10.1113/jphysiol.1987.sp016759; GUNNING R, 1983, J PHYSIOL-LONDON, V342, P437, DOI 10.1113/jphysiol.1983.sp014861; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 1991, IONIC CHANNELS EXCIT, P127; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HORIE M, 1987, J PHYSIOL-LONDON, V387, P251, DOI 10.1113/jphysiol.1987.sp016572; HORIE M, 1989, J PHYSIOL-LONDON, V408, P313, DOI 10.1113/jphysiol.1989.sp017461; HORIE M, 1987, AM J PHYSIOL, V253, pH210, DOI 10.1152/ajpheart.1987.253.1.H210; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; KURACHI Y, 1986, PFLUG ARCH EUR J PHY, V407, P264, DOI 10.1007/BF00585301; KURACHI Y, 1986, AM J PHYSIOL, V251, pH681, DOI 10.1152/ajpheart.1986.251.3.H681; Kurachi Y., 1990, REGULATION POTASSIUM, P403; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; MATSUDA H, 1991, ANNU REV PHYSIOL, V53, P289, DOI 10.1146/annurev.ph.53.030191.001445; MORGAN DML, 1990, BIOCHEM SOC T, V18, P1080, DOI 10.1042/bst0181080; MORGAN DML, 1990, BIOCHEM SOC T, V18, P1079; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P641, DOI 10.1113/jphysiol.1984.sp015088; SCOTT RH, 1993, TRENDS NEUROSCI, V16, P153, DOI 10.1016/0166-2236(93)90124-5; SIMMONS MA, 1987, PFLUG ARCH EUR J PHY, V409, P454, DOI 10.1007/BF00583801; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WATANABE S, 1991, J BIOL CHEM, V266, P20803; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0	36	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9289	9294		10.1074/jbc.270.16.9289	http://dx.doi.org/10.1074/jbc.270.16.9289			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721849				2022-12-25	WOS:A1995QU08900037
J	DEPREZ, RHL; RIEGMAN, PHJ; GROEN, NA; WARRINGA, UL; VANBIEZEN, NA; MOLIJN, AC; BOOTSMA, D; DEJONG, PJ; MENON, AG; KLEY, NA; SEIZINGER, BR; ZWARTHOFF, EC				DEPREZ, RHL; RIEGMAN, PHJ; GROEN, NA; WARRINGA, UL; VANBIEZEN, NA; MOLIJN, AC; BOOTSMA, D; DEJONG, PJ; MENON, AG; KLEY, NA; SEIZINGER, BR; ZWARTHOFF, EC			CLONING AND CHARACTERIZATION OF MN1, A GENE FROM CHROMOSOME 22Q11, WHICH IS DISRUPTED BY A BALANCED TRANSLOCATION IN A MENINGIOMA	ONCOGENE			English	Article						22Q11; BALANCED TRANSLOCATION; CAG REPEAT; MENINGIOMA; LEUKEMIA	TUMOR-SUPPRESSOR; NEUROFIBROMATOSIS; HETEROZYGOSITY; IDENTIFICATION; CARCINOMAS; TYPE-2; BRAIN	We have isolated a gene, called MN1, which resides on chromosome 22 and which was found to be disrupted by a balanced translocation (4;22) in meningioma 32. The MN1 gene spans about 70 kb and consists of at least two large exons of approximately 4.7 kb and 2.8 kb, The MN1 cDNA codes for a protein of 1319 amino acids when the first methionine in the open reading frame is used. The MN1 cDNA contains two CAG repeats, one of which codes for a string of 28 glutamines, The t(4;22) disrupts the S-exon within the open reading frame, In meningioma 32 no expression of the MN1 mRNA is observed, These results suggest that inactivation of the MN1 gene in this tumour may contribute to its pathogenesis.	ERASMUS UNIV ROTTERDAM, DEPT PATHOL, 3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT CELL BIOL & GENET, 3000 DR ROTTERDAM, NETHERLANDS; ROSWELL PK CANC INST, DEPT HUMAN GENET, BUFFALO, NY 14263 USA; UNIV CINCINNATI, MED CTR, DEPT MOLEC GENET, CINCINNATI, OH 45267 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC GENET & CELL BIOL, PRINCETON, NJ 08543 USA	Erasmus University Rotterdam; Erasmus University Rotterdam; Roswell Park Cancer Institute; University System of Ohio; University of Cincinnati; Bristol-Myers Squibb			Riegman, Peter/GLS-0041-2022; POPOVICI, Cornel/A-2027-2009	POPOVICI, Cornel/0000-0001-8226-3127				BIEGEL JA, 1990, J NEUROSURG, V73, P710, DOI 10.3171/jns.1990.73.5.0710; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEJONG PJ, 1989, CYTOGENET CELL GENET, V51, P985; DEPREZ RHL, 1991, AM J HUM GENET, V48, P783; DEPREZ RHL, 1994, AM J HUM GENET, V54, P1022; DEPREZ RHL, 1994, GENE CHROMOSOME CANC, V9, P24; DUMANSKI JP, 1990, CANCER RES, V50, P5863; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GOYNS MH, 1984, LEUKEMIA RES, V8, P547, DOI 10.1016/0145-2126(84)90003-1; JAMES CD, 1990, GENE CHROMOSOME CANC, V2, P94, DOI 10.1002/gcc.2870020204; KHOSLA S, 1991, J CLIN INVEST, V87, P1691, DOI 10.1172/JCI115186; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LARSSON C, 1990, GENE CHROMOSOME CANC, V2, P191, DOI 10.1002/gcc.2870020305; NEWSHAM I, 1994, GENOMICS, V19, P433, DOI 10.1006/geno.1994.1091; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; PEYRARD M, 1994, HUM MOL GENET, V3, P1393, DOI 10.1093/hmg/3.8.1393; PULST SM, 1993, NEUROLOGY, V43, P2096, DOI 10.1212/WNL.43.10.2096; REY JA, 1993, CANCER GENET CYTOGEN, V66, P1, DOI 10.1016/0165-4608(93)90140-H; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUSSELL DS, 1989, PATHOLOGY TUMOURS NE, P452; RUTTLEDGE MH, 1994, GENE CHROMOSOME CANC, V10, P122, DOI 10.1002/gcc.2870100207; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; TANAKA N, 1992, GENE CHROMOSOME CANC, V5, P399, DOI 10.1002/gcc.2870050416; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; VANBIEZEN NA, 1993, GENOMICS, V15, P206, DOI 10.1006/geno.1993.1036; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VISKOCHIL D, 1990, CELL, V62, P87; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Warren S T, 1993, Curr Opin Neurobiol, V3, P752, DOI 10.1016/0959-4388(93)90149-S; ZANG KD, 1982, CANCER GENET CYTOGEN, V6, P249, DOI 10.1016/0165-4608(82)90063-2; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	35	127	129	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1521	1528						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731706				2022-12-25	WOS:A1995QU68100007
J	HITOSHI, S; KUSUNOKI, S; KANAZAWA, I; TSUJI, S				HITOSHI, S; KUSUNOKI, S; KANAZAWA, I; TSUJI, S			MOLECULAR-CLONING AND EXPRESSION OF 2 TYPES OF RABBIT BETA-GALACTOSIDE ALPHA-1,2-FUCOSYL-TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROOT GANGLION-CELLS; GDP-L-FUCOSE; HUMAN-SERUM; DETERMINANTS; PURIFICATION; TRANSFERASE; GENETICS; EMBRYOS; CDNA	Two DNA clones encoding rabbit beta-galactoside alpha 1,2-fucosyltransferase (RFT-I and RFT-II) have been isolated from a rabbit genomic DNA library. The DNA sequences revealed open reading frames coding for 373 (RFT-I) and 354 (RFT-II) amino acids, respectively. The deduced amino acid sequences of RFT-I and RFT-II showed 56% identity with each other, and that of RFT-I showed 80% identity with that of human H blood type alpha 1,2-fucosyltransferase. Northern blot analysis of embryo and adult rabbit tissues revealed that the RFT-I gene was expressed in adult brain, and that the RFT-II gene was expressed in salivary and lactating mammary glands. The identities of these enzymes were confirmed by constructing recombinant fucosyltransferases in which the N-terminal part including the cytoplasmic tail and signal anchor domain was replaced with the immunoglobulin signal peptide sequence. RFT-I expressed in COS-7 cells exhibited similar transferase activity to that of human H blood type alpha 1,2-fucosyltransferase. RFT-II expressed in COS-7 cells showed higher affinity for type 1 (Gal beta 1,3GlcNAc) and type 3 (Gal beta 1,3GalNAc) acceptors than type 2 (Gal beta 1,4GlcNAc) ones, which suggested that RFT-II was a putative secretor-type alpha 1,2-fucosyltransferase.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN; UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT NEUROL,BUNKYO KU,TOKYO 113,JAPAN	RIKEN; University of Tokyo								BEYER TA, 1980, J BIOL CHEM, V255, P5373; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FENDERSON BA, 1986, DEV BIOL, V114, P12, DOI 10.1016/0012-1606(86)90379-9; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; KELLY RJ, 1994, P NATL ACAD SCI USA, V91, P5843, DOI 10.1073/pnas.91.13.5843; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; KUSUNOKI S, 1992, NEUROSCI RES, V15, P74, DOI 10.1016/0168-0102(92)90019-9; KUSUNOKI S, 1991, NEUROSCI LETT, V126, P159, DOI 10.1016/0304-3940(91)90543-3; KUSUNOKI S, 1989, BRAIN RES, V494, P391, DOI 10.1016/0006-8993(89)90611-2; KUSUNOKI S, 1994, BBA-LIPID LIPID MET, V1214, P27, DOI 10.1016/0005-2760(94)90005-1; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEPENDU J, 1985, AM J HUM GENET, V37, P749; LEPENDU J, 1982, AM J HUM GENET, V34, P402; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; PACUSZKA T, 1976, EUR J BIOCHEM, V64, P499, DOI 10.1111/j.1432-1033.1976.tb10328.x; PEREIRA MEA, 1978, ARCH BIOCHEM BIOPHYS, V185, P108, DOI 10.1016/0003-9861(78)90149-2; PIAU JP, 1994, BIOCHEM J, V300, P623, DOI 10.1042/bj3000623; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; Sambrook J, 1989, MOL CLONING LABORATO; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; Svennerholm L, 1980, Adv Exp Med Biol, V125, P533; SZULMAN AE, 1962, J EXP MED, V115, P977, DOI 10.1084/jem.115.5.977; SZULMAN AE, 1964, J EXP MED, V119, P503, DOI 10.1084/jem.119.4.503; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Watkins W M, 1980, Adv Hum Genet, V10, P1	27	49	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8844	8850		10.1074/jbc.270.15.8844	http://dx.doi.org/10.1074/jbc.270.15.8844			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721792	hybrid			2022-12-25	WOS:A1995QT44800070
J	LANNE, B; OLSSON, BM; JOVALL, PA; ANGSTROM, J; LINDER, H; MARKLUND, BI; BERGSTROM, J; KARLSSON, KA				LANNE, B; OLSSON, BM; JOVALL, PA; ANGSTROM, J; LINDER, H; MARKLUND, BI; BERGSTROM, J; KARLSSON, KA			GLYCOCONJUGATE RECEPTORS FOR P-FIMBRIATED ESCHERICHIA-COLI IN THE MOUSE - AN ANIMAL-MODEL OF URINARY-TRACT INFECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; SMALL-INTESTINE; BACTERIAL ADHERENCE; EMBRYONIC ANTIGEN-1; STRUCTURAL-ANALYSIS; SSEA-1 DETERMINANT; HEAD GROUP; GLYCOLIPIDS; GLYCOSPHINGOLIPIDS; EXPRESSION	Glycosphingolipids were isolated;ed from kidneys, urethers, and bladders (including urethrae) of C3H/HeN mice. Binding was studied of a clinical isolate and recombinant strains of uropathogenic P-fimbriated Escherichia coli to these glycolipids. A series of receptor-active glycolipids with Gal alpha 4Gal in common, previously shown to be recognized by these bacteria, was identified by use of specific monoclonal antibodies, fast-atom bombardment and electron-impact mass spectrometry, and proton nuclear magnetic resonance spectroscopy: galabiosylceramide (Gal alpha 4Gal beta Cer), globotriaosylceramide (Gal alpha 4Gal beta 4Glc beta Cer), globoside (GalNac beta 3Gal alpha 4Gal beta-4Glc beta Cer), the Forssman glycolipid (GalNAc alpha 3GalNAc-beta 3Gal alpha 4Gal beta 4Glc beta Cer), Gal beta 4GlcNAc beta 6(Gal beta 3)GalNAc-beta 3Gal alpha 4Gal beta 4Glc beta Cer, and Gal beta 4(Fuc alpha 3)GlcNAc beta 6-(Gal beta 3)GalNAc beta 3Gal alpha 4Gal beta 4Glc beta Cer. The binding pattern for mouse kidney glycolipids differed from that for kidney glycolipids of man and monkey, In particular, the dominant 8-sugar glycolipid in the mouse was not detected in the primates. A second difference was found in the binding of E. coli to kidney glycoproteins on blots after electrophoresis; the mouse showed distinct receptor-active bands while human and monkey did not. These differences may be of relevance when using the mouse as a model for clinical urinary tract infection of man.			LANNE, B (corresponding author), GOTHENBURG UNIV, DEPT BIOCHEM MED, MEDICINAREGATAN 9A, S-41390 GOTHENBURG, SWEDEN.			Bergstrom, Jorgen/0000-0003-3255-5150				ADAMS EP, 1968, CHEM PHYS LIPIDS, V2, P147, DOI 10.1016/0009-3084(68)90018-2; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; ARONSON M, 1979, J INFECT DIS, V139, P329, DOI 10.1093/infdis/139.3.329; BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325; BJORK S, 1987, J BIOL CHEM, V262, P6758; BOCK K, 1985, J BIOL CHEM, V260, P8545; Breimer M.E., 1985, GLYCOCONJUGATE J, V2, P375; BREIMER ME, 1985, J BIOCHEM, V98, P1169, DOI 10.1093/oxfordjournals.jbchem.a135383; CLEGG S, 1982, INFECT IMMUN, V38, P739, DOI 10.1128/IAI.38.2.739-744.1982; DABROWSKI J, 1980, BIOCHEMISTRY-US, V19, P5652, DOI 10.1021/bi00565a030; DEREE JM, 1985, FEMS MICROBIOL LETT, V29, P91, DOI 10.1016/0378-1097(85)90277-0; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; GARCIA E, 1988, CURR MICROBIOL, V17, P333, DOI 10.1007/BF01570873; HAKOMORI S, 1983, HDB LIPID RES, P1; HANFLAND P, 1981, BIOCHEMISTRY-US, V20, P5310, DOI 10.1021/bi00521a034; HANSSON GC, 1982, FEBS LETT, V139, P291, DOI 10.1016/0014-5793(82)80873-9; HANSSON GC, 1988, MOL IMMUNOLOGY COMPL, P465; HOLTHOFER H, 1994, KIDNEY INT, V45, P123, DOI 10.1038/ki.1994.14; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; IWAHI T, 1983, INFECT IMMUN, V39, P1307, DOI 10.1128/IAI.39.3.1307-1315.1983; JOHNSON JR, 1984, AM J MED SCI, V307, P335; KALLENIUS G, 1981, LANCET, V2, P1369; KALLENIUS G, 1980, FEMS MICROBIOL LETT, V7, P297, DOI 10.1111/j.1574-6941.1980.tb01608.x; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P220; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P212; KARLSSON KA, 1991, CARBOHYD RES, V221, P49, DOI 10.1016/0008-6215(91)80048-R; KARLSSON KA, 1968, BIOCHIM BIOPHYS ACTA, V152, P230, DOI 10.1016/0005-2760(68)90029-5; KARLSSON KA, 1992, FEMS SYMP, V61, P115; LARSON G, 1987, CARBOHYD RES, V161, P281, DOI 10.1016/S0008-6215(00)90085-5; LEFFLER H, 1980, FEMS MICROBIOL LETT, V8, P127, DOI 10.1111/j.1574-6968.1980.tb05064.x; LEVERY SB, 1986, CARBOHYD RES, V151, P311, DOI 10.1016/S0008-6215(00)90351-3; LINDBERG FP, 1984, EMBO J, V3, P1167, DOI 10.1002/j.1460-2075.1984.tb01946.x; LINDSTEDT R, 1991, INFECT IMMUN, V59, P1086, DOI 10.1128/IAI.59.3.1086-1092.1991; LUND B, 1987, P NATL ACAD SCI USA, V84, P5898, DOI 10.1073/pnas.84.16.5898; MARCUS DM, 1970, J IMMUNOL, V104, P1530; MARKLUND BI, 1992, MOL MICROBIOL, V6, P2225, DOI 10.1111/j.1365-2958.1992.tb01399.x; MARKLUND BI, 1991, THESIS U UMEA SWEDEN; MARTENSSON E, 1966, BIOCHIM BIOPHYS ACTA, V116, P296, DOI 10.1016/0005-2760(66)90012-9; MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010; MCKIBBIN JM, 1982, J BIOL CHEM, V257, P755; MILLER KE, 1992, BIOCHEMISTRY-US, V31, P6703, DOI 10.1021/bi00144a009; Mirelman D, 1986, MICROBIAL LECTINS AG, P1; PAPPE AK, 1991, J PHYS CHEM-US, V95, P3358; PARKKINEN J, 1988, INFECT IMMUN, V56, P2623, DOI 10.1128/IAI.56.10.2623-2630.1988; POPPE L, 1990, J AM CHEM SOC, V112, P7762, DOI 10.1021/ja00177a042; SCARSDALE JN, 1986, J AM CHEM SOC, V108, P6778, DOI 10.1021/ja00281a053; SEKINE M, 1987, J BIOCHEM-TOKYO, V101, P563, DOI 10.1093/jb/101.3.563; SEKINE M, 1990, J BIOCHEM-TOKYO, V108, P103, DOI 10.1093/oxfordjournals.jbchem.a123147; SEKINE M, 1987, J BIOCHEM-TOKYO, V101, P553, DOI 10.1093/jb/101.3.553; SEKINE M, 1988, J BIOCHEM-TOKYO, V103, P722, DOI 10.1093/oxfordjournals.jbchem.a122335; STAPLETON A, 1992, J CLIN INVEST, V90, P965, DOI 10.1172/JCI115973; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; STROMBERG N, 1990, EMBO J, V9, P2001, DOI 10.1002/j.1460-2075.1990.tb08328.x; STROMBERG N, 1991, P NATL ACAD SCI USA, V88, P9340, DOI 10.1073/pnas.88.20.9340; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; SVANBORGEDEN C, 1976, LANCET, V2, P490, DOI DOI 10.1016/S0140-6736(76)90788-1; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; TENNENT JM, 1990, MOL BASIS BACTERIAL, P79; TULLUS K, 1984, J INFECT DIS, V150, P728, DOI 10.1093/infdis/150.5.728; UMESAKI Y, 1989, BIOCHIM BIOPHYS ACTA, V1001, P157; VANCE WR, 1966, BIOCHEMISTRY-US, V5, P435, DOI 10.1021/bi00866a007; Waldi D., 1962, DUNNSCHICHT CHROMATO, P496; WESTERLUND B, 1993, ZBL BAKT-INT J MED M, V278, P229; Yamakawa T., 1983, RED BLOOD CELLS DOME, P37; YANG HJ, 1971, J BIOL CHEM, V246, P1192; YANG ZT, 1994, J BIOL CHEM, V269, P14620; [No title captured]	67	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					9017	9025		10.1074/jbc.270.15.9017	http://dx.doi.org/10.1074/jbc.270.15.9017			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721812	hybrid			2022-12-25	WOS:A1995QT44800093
J	ROESLER, WJ; GRAHAM, JG; KOLEN, R; KLEMM, DJ; MCFIE, PJ				ROESLER, WJ; GRAHAM, JG; KOLEN, R; KLEMM, DJ; MCFIE, PJ			THE CAMP RESPONSE ELEMENT-BINDING PROTEIN SYNERGIZES WITH OTHER TRANSCRIPTION FACTORS TO MEDIATE CAMP RESPONSIVENESS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; CYCLIC-AMP; GENE-TRANSCRIPTION; NUCLEAR-PROTEIN; FACTOR CREB; SOMATOSTATIN GENE; HEPATOMA-CELLS; ALPHA-SUBUNIT; ALBUMIN GENE; PROMOTER	The cAMP responsiveness of the promoter for phosphoenolpyruvate carboxykinase (EC 4.1.1.32) is mediated by a synergistic interaction between a complex regulatory region, which binds liver-enriched transcription factors, and a typical cAMP response element (CRE). Although a role for the CRE-binding protein (CREB) in the cAMP-responsiveness of this promoter has been generally assumed, some uncertainty remains due to the observations that several C/EBP-related proteins bind with near equal affinity, relative to CREB, to this particular CRE. Thus, a detailed analysis of the involvement of CREB in this synergism was undertaken in HepG2 cells. Gel mobility shift assays demonstrate that a CRE probe is bound by CREB present in HepG2 cells. Furthermore, we show that a dominant repressor of CREB is able to significantly reduce the cAMP responsiveness of the PEPCK promoter in HepG2 cells. Finally, we demonstrate using a GAL4-CREB fusion protein that CREB is able to synergize with the liver-enriched factors bound upstream on the PEPCK promoter to mediate a liver-specific response to cAMP. Examination of several mutant forms of CREB allow us to conclude that the ''synergy'' domain of CREB resides within amino acid residues 83-203, and that residues 83-145 can mediate a partial synergistic response. This study establishes that CREB is able to synergize with liver-enriched transcription factors to mediate a tissue-specific response to cAMP.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206	National Jewish Health	ROESLER, WJ (corresponding author), UNIV SASKATCHEWAN,COLL MED,DEPT BIOCHEM,SASKATOON,SK S7N 0W0,CANADA.							BOKAR JA, 1988, J BIOL CHEM, V263, P19740; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; FABER S, 1993, J BIOL CHEM, V268, P24976; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HARLOW E, 1988, ANTIBODIES LABORATOR; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IYER SV, 1991, MOL CELL BIOL, V11, P4863, DOI 10.1128/MCB.11.10.4863; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIU JS, 1991, J BIOL CHEM, V266, P19095; MEISNER H, 1985, BIOCHEMISTRY-US, V24, P421, DOI 10.1021/bi00323a027; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PATEL YM, 1994, J BIOL CHEM, V269, P5619; QUINN PG, 1993, J BIOL CHEM, V268, P16999; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; ROESLER WJ, 1994, J BIOL CHEM, V269, P14276; ROESLER WJ, 1992, J BIOL CHEM, V267, P21235; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J, 1989, MOL CLONING LABORATO; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z	43	76	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8225	8232		10.1074/jbc.270.14.8225	http://dx.doi.org/10.1074/jbc.270.14.8225			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713929	hybrid			2022-12-25	WOS:A1995QR52600068
J	LENG, P; BROWN, DR; SHIVAKUMAR, CV; DEB, S; DEB, SP				LENG, P; BROWN, DR; SHIVAKUMAR, CV; DEB, S; DEB, SP			N-TERMINAL-130 AMINO-ACIDS OF MDM2 ARE SUFFICIENT TO INHIBIT P53-MEDIATED TRANSCRIPTIONAL ACTIVATION	ONCOGENE			English	Article						MDM2; P53-MEDIATED TRANSACTIVATION	WILD-TYPE P53; GENE-EXPRESSION; BINDING-SITE; CELL-GROWTH; LUNG-CANCER; PROTEIN; MUTATIONS; ONCOGENE; FORMS; DNA	The human oncoprotein MDM2 binds with the tumor suppressor p53 and inhibits p53-directed transactivation. In this report we show that deletion of 336 amino acids from the C-terminus of human MDM2 does not decrease its efficiency to bind p53 in vivo and inhibit p53-directed transactivation. Even further deletion of MDM2 from the C-terminus up to amino acid 131 does not reduce its ability to inhibit p53-mediated transactivation. Since deletion up to amino acid 131 also deletes many antigenic sites of MDM2 and the truncated protein cannot be immunoprecipitated by the antibodies available to us, two internal deletions were made to define the p53-interaction domain. Internal deletion of four amino acids beginning at 110 residue (amino acids 110 to 113) did not reduce p53-binding or inhibition of p53-directed transactivation whereas internal deletion of amino acids 60 to 65 reduces but does not abolish these activities. Sequential deletion of amino acids from the N-terminus leads to sequential destruction of p53-binding and inhibition of transactivation capability of MDM2. Fourteen amino acids can be deleted from this end without any reduction of these activities. Deletion of 28 N-terminal amino acids residues drastically reduces, but does not abolish the p53-binding ability of the protein, as well as inhibition of p53-directed transactivation. Deletion of 58 amino acids from the N-terminus of the oncoprotein abolishes its ability to bind p53 in vivo and to inhibit p53-directed transactivation. These results locate the p53-binding domain of MDM2 within amino acids 14 to 154 and inhibition of transactivation domains of MDM2 within amino acid residues 14 to 130 suggesting possible p53-independent biological functions of the 491 amino acid long oncoprotein.	UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio				Leng, Roger/0000-0001-9652-4703	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031498] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31498-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DEBS SP, 1994, ONCOGENE, V9, P1341; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JUVEN T, 1993, ONCOGENE, V8, P3411; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KERN SE, 1991, SCIENCE, V252, P49; LADANYI M, 1993, CANCER RES, V53, P16; LENG P, 1985, INT J ONCOL, V6, P251; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OTTO A, 1993, ONCOGENE, V8, P2591; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Sambrook J, 1989, MOL CLONING LABORATO; SHAY JW, 1992, MUTAT RES, V277, P163, DOI 10.1016/0165-1110(92)90003-R; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	50	50	51	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1275	1282						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731677				2022-12-25	WOS:A1995QR65100003
J	FRANCIS, MK; PHINNEY, DG; RYDER, K				FRANCIS, MK; PHINNEY, DG; RYDER, K			ANALYSIS OF THE HORMONE-DEPENDENT REGULATION OF A JUND-ESTROGEN RECEPTOR CHIMERA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; G0-TO-G1 TRANSITION; CELL-PROLIFERATION; MOUSE FIBROBLASTS; BINDING DOMAINS; FOS PROTEINS; C-JUN; TRANSFORMATION; EXPRESSION; GENE	The modular ligand-binding domains of steroid receptors have been widely used to generate protein chimeras that are ligand dependent for activity, In a similar manner, we generated a series of conditionally active JunD and c-Fos proteins by fusing their carboxyl (COOH)terminal ends with a COOH-terminal fragment of the human estrogen receptor (ER) that contains the ligand-binding domain, JunD-ER (DER) and Fos-ER (FER) chimeras with an intact leucine zipper and basic region exhibit hormone-dependent activation of activator protein-1-directed transcription in transient expression as says, One of these fusions, DER, has been examined in detail to determine its mechanism of action, Results from immunoprecipitation experiments with extracts from DER and Fos transfected cells demonstrate that Fos and DER readily form heterodimer complexes, Surprisingly, the formation of Fos:DER heterodimers, and possibly DER homodimers, is estrogen-independent. However, gel shift assays clearly demonstrate that DNA binding to AP1 sites by Fos:DER heterodimers or DER homodimers is estrogen-dependent, Moreover, in the absence of estrogen, the DER protein is an effective inhibitor of Fos-mediated transactivation, and this effect is reversed by the presence of estrogen, Our results indicate that the DER protein is a direct, hormone-reversible inhibitor of Fos and that estrogen controls the conditional positive or dominant negative activities of DER at the level of DNA binding to AP1 sites, Accordingly, clonally derived fibroblast cell lines that stably express the DER protein exhibit reduced entry into the S phase of the cell cycle when quiescent cells are serum stimulated in the absence of estrogen, This is in contrast to the estrogen-treated controls, These results support the hypothesis that AP1 is important for cell cycle progression and provide a unique approach for examining the role of AP1 in this process.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center			Phinney, Donald G/D-2155-2014	Phinney, Donald/0000-0002-8688-2619	NATIONAL CANCER INSTITUTE [P30CA006927, F32CA009219, R01CA052752] Funding Source: NIH RePORTER; NCI NIH HHS [F32CA-09219, CA-52752, CA-06927-31] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FRIEDMAN AD, 1988, NATURE, V335, P452, DOI 10.1038/335452a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; ROEMER K, 1993, P NATL ACAD SCI USA, V90, P9252, DOI 10.1073/pnas.90.20.9252; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUERMANN M, 1993, ONCOGENE, V8, P2781; STANLEY ER, 1977, CELL, V10, P35; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; VOGT PK, 1990, ADV CANCER RES, V55, P2; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	36	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11502	11513		10.1074/jbc.270.19.11502	http://dx.doi.org/10.1074/jbc.270.19.11502			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744790	hybrid			2022-12-25	WOS:A1995QX86500069
J	KATAYAMA, T; CROOKE, E				KATAYAMA, T; CROOKE, E			DNAA PROTEIN IS SENSITIVE TO A SOLUBLE FACTOR AND IS SPECIFICALLY INACTIVATED FOR INITIATION OF IN-VITRO REPLICATION OF THE ESCHERICHIA-COLI MINICHROMOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAM METHYLTRANSFERASE; CELL-CYCLE; ORIGIN; CHROMOSOME; GENE; SEQUENCE; INVITRO; BINDING; METHYLATION; PRIMOSOME	DnaA protein loses the capacity to initiate chromosomal replication when treated with a soluble cell extract, This inactivation depends upon DNA and hydrolyzable ribonucleoside triphosphate. The extract does not affect the activities of other replicative proteins or the ability of DnaA to initiate replication of single-stranded DNA that contains a DnaA-binding hairpin, indicating that the inhibitory effect is specific for the action of DnacA at oriC. Gel filtration experiments implicate a 150-kDa factor as being responsible. Mutant DnaAcos protein, which causes overinitiation in vivo, is insensitive to the inactivating factor, suggesting a requirement for this negative control in vivo. We propose that a soluble factor controls initiation through downregulation of DnaA protein.	STANFORD UNIV,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305; GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007	Stanford University; Georgetown University				Katayama, Tsutomu/0000-0001-9994-1684	NIGMS NIH HHS [R01 GM049700, GM 49700] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049700, R21GM049700] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CROOKE E, 1992, J BIOL CHEM, V267, P16779; CROOKE E, 1993, J MOL BIOL, V233, P166; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; HANSEN FG, 1977, MOL GEN GENET, V155, P219, DOI 10.1007/BF00393163; HATTMAN S, 1978, J MOL BIOL, V126, P367, DOI 10.1016/0022-2836(78)90046-3; HELMSTETTER CE, 1987, ESCHERICHIA COLI SAL, V2, P1594; HIRAGA S, 1974, MOL GEN GENET, V132, P49, DOI 10.1007/BF00268230; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1990, J BIOL CHEM, V265, P19244; KATAYAMA T, 1994, J BIOL CHEM, V269, P12698; KATAYAMA T, 1991, MOL GEN GENET, V226, P491, DOI 10.1007/BF00260663; KATAYAMA T, 1994, J BIOL CHEM, V269, P22075; KELLENBERGERGUJ.G, 1978, MOL GEN GENET, V162, P9; Kornberg A., 1992, DNA REPLICATION; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LOBNEROLESEN A, 1989, CELL, V57, P881, DOI 10.1016/0092-8674(89)90802-7; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MARINUS MG, 1975, MUTAT RES, V28, P15, DOI 10.1016/0165-1218(75)90278-5; MARINUS MG, 1983, MOL GEN GENET, V192, P288, DOI 10.1007/BF00327681; MASAI H, 1990, J BIOL CHEM, V265, P15134; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; PARADA CA, 1991, J BIOL CHEM, V266, P18895; SAKAKIBARA Y, 1982, MOL GEN GENET, V186, P87, DOI 10.1007/BF00422917; Sambrook J, 1989, MOL CLONING LABORATO; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SEUFERT W, 1987, CELL, V48, P73, DOI 10.1016/0092-8674(87)90357-6; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; STEMMER WPC, 1991, BIOTECHNIQUES, V10, P726; TIPPESCHINDLER R, 1979, MOL GEN GENET, V168, P185, DOI 10.1007/BF00431444; YUNG BYM, 1990, J BIOL CHEM, V265, P1282; ZYSKIND JW, 1992, CELL, V69, P5, DOI 10.1016/0092-8674(92)90112-P	39	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9265	9271		10.1074/jbc.270.16.9265	http://dx.doi.org/10.1074/jbc.270.16.9265			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721846	hybrid			2022-12-25	WOS:A1995QU08900034
J	PODLISNY, MB; OSTASZEWSKI, BL; SQUAZZO, SL; KOO, EH; RYDELL, RE; TEPLOW, DB; SELKOE, DJ				PODLISNY, MB; OSTASZEWSKI, BL; SQUAZZO, SL; KOO, EH; RYDELL, RE; TEPLOW, DB; SELKOE, DJ			AGGREGATION OF SECRETED AMYLOID BETA-PROTEIN INTO SODIUM DODECYL SULFATE-STABLE OLIGOMERS IN CELL-CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; CORTICAL-NEURONS; NEURITIC PLAQUES; APOLIPOPROTEIN-E; PEPTIDE; NEUROTOXICITY; BRAIN; IDENTIFICATION; LOCALIZATION	Filamentous aggregates of the 40-42-residue amyloid beta-protein (A beta) accumulate progressively in the limbic and cerebral cortex in Alzheimer's disease, where they are intimately associated with neuronal and glial cytopathology, Attempts to model this cytotoxicity in vitro using synthetic peptides have shown that monomeric A beta is relatively inert, whereas aggregated A beta reproducibly exerts a variety of neurotoxic effects, The processes that mediate the conversion of monomeric A beta into a toxic aggregated state are thus of great interest. Previous studies of this conversion have employed high concentrations (10(-5)-10(-3) M) of synthetic A beta peptides under nonbiological conditions, We report here the detection of small amounts (<10(-9) M) of SDS-stable A beta oligomers in the culture media of Chinese hamster ovary cells expressing endogenous or transfected amyloid beta-protein precursor genes, The identity of these oligomers (primarily dimers and trimers) was established by immunoprecipitation with a panel of A beta antibodies, by electrophoretic comigration with synthetic A beta oligomers, and by amino acid sequencing, The oligomeric A beta species comprised similar to 10-20% of the total immunoprecipitable A beta in these cultures. A truncated A beta species beginning at Arg 5 was enriched in the oligomers, suggesting that amino-terminal heterogeneity can influence A beta oligomerization in this system. Addition of Congo red (10 mu M) during metabolic labeling of the cells led to increased monomeric and decreased oligomeric A beta. The ability to detect and quantitate oligomers of secreted A beta peptides in cell culture should facilitate dynamic studies of the critical process of initial A beta aggregation under physiological conditions.	HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BIOPOLYMER LAB,BOSTON,MA 02115; ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	PODLISNY, MB (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE ON AGING [R35AG007911] Funding Source: NIH RePORTER; NIA NIH HHS [AG07911] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSCIGLIO J, 1993, J NEUROCHEM, V61, P1565, DOI 10.1111/j.1471-4159.1993.tb13658.x; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; CAUGHEY B, 1993, J VIROL, V67, P6270, DOI 10.1128/JVI.67.10.6270-6272.1993; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; DYRKS T, 1993, FEBS LETT, V324, P231, DOI 10.1016/0014-5793(93)81399-K; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GAMES D, 1992, NEUROBIOL AGING, V13, P569, DOI 10.1016/0197-4580(92)90057-5; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOWING E, 1994, J BIOL CHEM, V269, P10987; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HAASS C, 1994, J BIOL CHEM, V269, P17741; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; HARDY J, 1992, NAT GENET, V1, P233, DOI 10.1038/ng0792-233; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOSIK K, 1992, NEUROBIOL AGING, V13, P535, DOI 10.1016/0197-4580(92)90052-Y; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; MASLIAH E, 1993, J NEUROPATH EXP NEUR, V52, P619, DOI 10.1097/00005072-199311000-00009; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MORI H, 1992, J BIOL CHEM, V267, P17082; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PODLISNY MB, 1993, AM J PATHOL, V142, P17; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; PODLISNY MB, 1994, NEUROBIOL AGING, V15, P82; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; SCHWARZMAN AL, 1994, P NATL ACAD SCI USA, V91, P8368, DOI 10.1073/pnas.91.18.8368; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMMONS LK, 1993, MOL PHARMACOL, V15, P373; SNOW AD, 1988, AM J PATHOL, V133, P456; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; YAMAGUCHI H, 1990, BRAIN RES, V508, P320, DOI 10.1016/0006-8993(90)90416-9; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	62	327	342	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9564	9570		10.1074/jbc.270.16.9564	http://dx.doi.org/10.1074/jbc.270.16.9564			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721886	hybrid			2022-12-25	WOS:A1995QU08900075
J	HARRISON, DJ; HOOPER, ML; ARMSTRONG, JF; CLARKE, AR				HARRISON, DJ; HOOPER, ML; ARMSTRONG, JF; CLARKE, AR			EFFECTS OF HETEROZYGOSITY FOR THE RB-1(T19NEO) ALLELE IN THE MOUSE	ONCOGENE			English	Article						RB-1; TRANSGENIC; MOUSE; PITUITARY; TUMORIGENESIS; NESIDIOBLASTOSIS	RETINOBLASTOMA GENE-PRODUCT; HUMAN-BREAST-CARCINOMA; SV40 LARGE-T; CELL-CYCLE; SUSCEPTIBILITY GENE; OSTEO-SARCOMA; PROTEIN; PHOSPHORYLATION; MUTATION; BINDING	We describe the pathology of a cohort of 80 mice heterozygous for an inactive allele of the Rb-1 tumour suppressor gene. The majority of these mice developed locally invasive tumours, arising from the pituitary gland. The time of onset of overt signs of disease in mice known to have inherited their mutant allele paternally shows a small but statistically significant shift to the lower end of the spectrum, suggesting that tumorigenesis is influenced by gametic imprinting. In situ hybridisation analysis demonstrates the presence in the tumours of proopiomelanocortin mRNA, which is normally found both in corticotroph and melanotroph cells. Mice within this cohort also develop systemic defects. Most notably, there is increased siderosis in the spleen indicating the possibility of an abnormality in red blood cell turnover, This is consistent with the abnormalities of erythropoiesis described previously in homozygous R6-1-deficient mice. In addition, a proportion of mice developed liver steatosis, probably representing the end organ effects of hormonal imbalance as a direct consequence of tumour presence. A significant proportion showed C cell hyperplasia in the thyroid. The spectrum of pathology in mice differs from that in the human but does provide a useful model of site-specific tumour predisposition.			HARRISON, DJ (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANC RES CAMPAIGN LABS,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.		Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X; Armstrong, Jane/0000-0002-0524-0260				BARLOW DP, 1994, TRENDS GENET, V10, P194, DOI 10.1016/0168-9525(94)90255-0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BOWMAKER JK, 1991, VISION VISUAL DYSFUN, V2, P63; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVANEE WK, 1983, NATURE, V305, P779; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1992, NATURE, V362, P849; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FARQUHARSON MA, 1992, J CLIN PATHOL, V45, P999, DOI 10.1136/jcp.45.11.999; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELSETH A, 1992, AM J PATHOL, V140, P1071; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; HOOPER ML, 1995, IN PRESS J CELL SC S, V18; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HU NP, 1994, ONCOGENE, V9, P1021; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; JACKS T, 1992, NATURE, V359, P285; KATO J, 1993, GENE DEV, V7, P331; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MAINS RE, 1979, J BIOL CHEM, V254, P7885; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILLER RG, 1981, SURVIVAL ANAL, pCH4; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PURDIE CA, 1994, ONCOGENE, V9, P603; REIK W, 1989, NATURE, V338, P112, DOI 10.1038/338112a0; ROBERTS JL, 1980, BIOCHEM, V17, P3609; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; WANG NP, 1993, ONCOGENE, V8, P279; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WINGSTRAND KG, 1966, PITUITARY GLAND, P1; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0	44	59	59	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1615	1620						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731716				2022-12-25	WOS:A1995QU68100018
J	LOCKER, JK; OPSTELTEN, DJE; ERICSSON, M; HORZINEK, MC; ROTTIER, PJM				LOCKER, JK; OPSTELTEN, DJE; ERICSSON, M; HORZINEK, MC; ROTTIER, PJM			OLIGOMERIZATION OF A TRANS-GOLGI TRANS-GOLGI NETWORK RETAINED PROTEIN OCCURS IN THE GOLGI-COMPLEX AND MAY BE PART OF ITS RETENTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; INFLUENZA-VIRUS HEMAGGLUTININ; MEMBRANE-SPANNING DOMAIN; CORONAVIRUS-M-PROTEIN; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; LOCALIZATION; SIGNAL	The mouse hepatitis virus M protein is a triple spanning membrane glycoprotein that, when expressed independently, localizes to trans-Golgi as well as to the trans-Golgi network (TGN). Passage of this protein from the endoplasmic reticulum through the intermediate compartment to the late Golgi and TGN can be conveniently followed by analyzing its O-linked sugars. Using pulse-chase analyses we studied the oligomerization of the M protein in sucrose gradients. The Golgi and TGN forms migrated as large heterogeneous complexes, whereas the endoplasmic reticulum and intermediate compartment forms of the protein appeared to migrate as monomer. Moreover, a mutant of the M protein lacking the 22 COOH-terminal amino acids, that is transported to the plasma membrane, gave rise to similar complexes, albeit smaller in size, that persisted at the plasma membrane. We propose that the trans-Golgi/TGN retention of the MHV-M protein is governed by two mechanisms: oligomerization possibly mediated by the transmembrane domains and binding of its cytoplasmic tail to cellular factors in trans Golgi/TGN.	UNIV UTRECHT, FAC VET MED, INST VIROL, DEPT IMMUNOL & INFECT DIS, 3584 CL UTRECHT, NETHERLANDS; EUROPEAN MOLEC BIOL LAB, D-69012 HEIDELBERG, GERMANY	Utrecht University; European Molecular Biology Laboratory (EMBL)			Locker, Jacomine Krijnse/AAX-1185-2020; Locker, Jacomine Krijnse/E-1009-2016					ARMSTRONG J, 1991, J CELL SCI, V98, P567; ARMSTRONG J, 1990, J CELL SCI, V95, P191; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BURKE J, 1992, J BIOL CHEM, V267, P24433; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; COPELAND CS, 1988, CELL, V53, P197, DOI 10.1016/0092-8674(88)90381-9; DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LOCKER JK, 1992, J BIOL CHEM, V267, P21911; LOCKER JK, 1992, J BIOL CHEM, V267, P14094; LOCKER JK, 1994, J BIOL CHEM, V269, P28263; LOCKER JK, 1994, J CELL BIOL, V124, P55; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NIEMANN H, 1984, EMBO J, V3, P665, DOI 10.1002/j.1460-2075.1984.tb01864.x; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; OPSTELTEN DJE, 1994, ARCH VIROL, P319; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROTTIER PJM, 1981, J VIROL, V40, P350, DOI 10.1128/JVI.40.2.350-357.1981; ROTTIER PJM, 1986, BIOCHEMISTRY-US, V25, P1335, DOI 10.1021/bi00354a022; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SCHWEIZER A, 1994, J CELL BIOL, V126, P25, DOI 10.1083/jcb.126.1.25; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SODEIK B, 1993, J CELL BIOL, V121, P521, DOI 10.1083/jcb.121.3.521; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TANG BL, 1992, J BIOL CHEM, V267, P7072; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245	51	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8815	8821		10.1074/jbc.270.15.8815	http://dx.doi.org/10.1074/jbc.270.15.8815			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721788	Green Submitted, hybrid			2022-12-25	WOS:A1995QT44800066
J	REGAN, LM; FAY, PJ				REGAN, LM; FAY, PJ			CLEAVAGE OF FACTOR-VIII LIGHT-CHAIN IS REQUIRED FOR MAXIMAL GENERATION OF FACTOR VIIIA ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; VONWILLEBRAND FACTOR COMPLEX; PORCINE FACTOR-VIII; FACTOR-XA; PHOSPHOLIPID-VESICLES; FACTOR-IXA; C2 DOMAIN; CONFORMATIONAL SENSITIVITY; THROMBIN ACTIVATION; A1/A3-C1-C2 DIMER	Thrombin-catalyzed activation of heterodimeric factor VIII occurs by limited proteolysis, yielding subunits A1 and A2 derived from the heavy chain (HC) and A3-C1-C2 derived from the light chain (LC). The roles of these cleavages in the function of procoagulant activity are poorly understood. To determine whether LC cleavage contributes to the potentiation of factor VIII activity, factor VIII heterodimers were reconstituted from native HC and either thrombin-cleaved LC (A3-C1-C2) or intact LC and purified by Mono S chromatography. The reconstituted factor VIII form containing the A3-C1-C2 subunit had a specific activity (2 units/mu g) that was similar to 3-fold greater than that of the reconstituted factor VIII form containing native LC (0.6 units/mu g). Factor Xa generation assays using the hybrid heterodimer showed an initial rate that was unaffected by the presence of von Willebrand factor and a reduced lag time when compared with the native heterodimer. The A1/A3-C1-C2 dimer was dissociated by chelation, and the purified A1 subunit was reacted with either the A3-C1-C2 subunit or the LC in the presence of Mn2+ to reconstitute the dimer. Factor VIIIa heterotrimers were reconstituted from either A1/A3-C1-C2 or A1/LC plus the A2 subunit. The authentic factor VIIIa heterotrimer (A1/A3-C1-C2/A2) had 3-fold greater activity than the form containing the LC. However, upon reaction with thrombin, the activity of the latter form was increased to that of the factor VIIIa form containing native subunits. The incremental increase in fluorescence anisotropy of fluorescein-Phe-Phe-Arg chloromethyl ketone-modified factor IXa was markedly greater in the presence of HC/A3-C1-C2 (Delta r = 0.037) compared with HC/LC (Delta r = 0.011) and approached the value obtained with factor VIIIa (Delta r = 0.051). These results suggest that cleavage of factor VIII LC directly contributes to the potentiation of coagulant activity by modulating the conformation of the factor IXa active site.	UNIV ROCHESTER,MED CTR,SCH MED & DENT,DEPT MED,HEMATOL UNIT,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038199, P01HL030616] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30616, HL38199] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1981, BIOCHEM J, V200, P161, DOI 10.1042/bj2000161; ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BIHOREAU N, 1989, EUR J BIOCHEM, V185, P111, DOI 10.1111/j.1432-1033.1989.tb15089.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASILLAS G, 1971, COAGULATION, V4, P107; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1993, J BIOL CHEM, V268, P17861; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1990, J BIOL CHEM, V265, P6197; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; FOSTER PA, 1993, THROMB HAEMOSTASIS, V69, P1089; GILBERT GE, 1990, J BIOL CHEM, V265, P815; HAMER RJ, 1987, EUR J BIOCHEM, V167, P253, DOI 10.1111/j.1432-1033.1987.tb13331.x; HAMER RJ, 1987, EUR J BIOCHEM, V166, P36; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; KNOWLES JR, 1987, SCIENCE, V236, P1252; KOEDAM JA, 1990, EUR J BIOCHEM, V189, P229, DOI 10.1111/j.1432-1033.1990.tb15481.x; LAJMONOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P123; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; NEUENSCHWANDER P, 1988, BLOOD, V72, P1761; NORDFANG O, 1988, J BIOL CHEM, V263, P1115; OWEN WG, 1982, THROMB DIATH HAEMO, V27, P505; PIETERS J, 1989, BLOOD, V74, P1021; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; SAENKO EL, 1993, BLOOD, V82, pA339; SHIMA M, 1989, BLOOD, V74, P1612; TOOLE JJ, 1984, NATURE, V312, P330; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; WISE RJ, 1993, BLOOD, V82, pA339; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; YE J, 1991, J BIOL CHEM, V266, P23016	47	69	71	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8546	8552		10.1074/jbc.270.15.8546	http://dx.doi.org/10.1074/jbc.270.15.8546			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721754	hybrid			2022-12-25	WOS:A1995QT44800030
J	EKLUND, EA; SKALNIK, DG				EKLUND, EA; SKALNIK, DG			CHARACTERIZATION OF A GP91-PHOX PROMOTER ELEMENT THAT IS REQUIRED FOR INTERFERON-GAMMA-INDUCED TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; CHAIN GENE-EXPRESSION; LEUKEMIA CELL-LINE; ETS-RELATED PROTEIN; CYTOCHROME-B HEAVY; NADPH OXIDASE; BOX BINDING; RNA; ENHANCER; SEQUENCE	The cytochrome b(558) heavy chain (gp91-phox) is expressed nearly exclusively in terminally differentiating myelomonocytic cells, thereby providing a model to study the events of late myeloid differentiation. We describe a tissue culture assay for studying interferon gamma induction of gp91-phox expression and a cis-element in the gp91-phox promoter that is necessary but not sufficient for this activity. In vitro assays reveal two DNA-binding proteins that interact with this cis-element. One factor is restricted to hematopoietic cells, is required for an interferon gamma response, and binds to an element similar to the Ets protein family consensus, although it does not correspond to known family members. The second factor is the ubiquitous CCAAT-binding protein CP1, which is dispensable for an interferon gamma response. Single base pair mutations in the gp91-phox promoter that specifically abolish the binding of the hematopoietic-associated factor have previously been identified in chronic granulomatous disease patients (Newburger, P. E., Skalnik, D. G., Hopkins, P. J., Eklund, E. A., and Curnutte, J. T. (1994) J. Clin, Invest. 94, 1205-1211). The data reported here directly demonstrate the functional significance of the hematopoietic-associated factor for gp91-phox promoter activity and reveal the binding properties and tissue distribution of this novel DNA-binding protein.	INDIANA UNIV,SCH MED,DEPT PEDIAT,HERMAN B WELLS CTR PEDIAT RES,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis					NCI NIH HHS [CA58947] Funding Source: Medline; NHLBI NIH HHS [K08 HL03139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058947, R29CA058947] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BARKER KA, 1988, MOL CELL BIOL, V8, P2804, DOI 10.1128/MCB.8.7.2804; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; BRADLEY TR, 1982, BRIT J HAEMATOL, V51, P595, DOI 10.1111/j.1365-2141.1982.tb02823.x; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; CHOMCZYNSKI P, 1992, NUCLEIC ACIDS RES, V20, P3791, DOI 10.1093/nar/20.14.3791; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GEY GO, 1952, CANCER RES, V12, P264; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEBANOFF SJ, 1975, SEMIN HEMATOL, V12, P117; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; KOIZUMI H, 1993, MOL CELL BIOL, V13, P6690, DOI 10.1128/MCB.13.11.6690; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; Maxam A M, 1980, Methods Enzymol, V65, P499; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MINOWADA J, 1972, J NATL CANCER I, V49, P891; MURAKAMI K, 1993, ONCOGENE, V8, P1559; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; NEWBURGER PE, 1991, J BIOL CHEM, V266, P16171; NEWBURGER PE, 1994, J CLIN INVEST, V94, P1205, DOI 10.1172/JCI117437; ORKIN SH, 1989, ANNU REV IMMUNOL, V7, P277; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; REDDY ESP, 1991, ONCOGENE, V6, P2285; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT LM, 1992, BLOOD, V80, P1725; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SKALNIK DG, 1991, P NATL ACAD SCI USA, V88, P8505, DOI 10.1073/pnas.88.19.8505; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TUCKER KA, 1987, BLOOD, V70, P372; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P725; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WEAVER RF, 1979, NUCLEIC ACIDS RES, V7, P1175, DOI 10.1093/nar/7.5.1175; WOODMAN RC, 1995, BLOOD, V85, P231, DOI 10.1182/blood.V85.1.231.bloodjournal851231; WRIGHT KL, 1992, P NATL ACAD SCI USA, V89, P7601, DOI 10.1073/pnas.89.16.7601; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG LQ, 1993, ONCOGENE, V8, P1621	60	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8267	8273		10.1074/jbc.270.14.8267	http://dx.doi.org/10.1074/jbc.270.14.8267			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713934	hybrid			2022-12-25	WOS:A1995QR52600073
J	WARNE, TR; BUCHANAN, FG; ROBINSON, M				WARNE, TR; BUCHANAN, FG; ROBINSON, M			GROWTH-DEPENDENT ACCUMULATION OF MONOALKYLGLYCEROL IN MADIN-DARBY CANINE KIDNEY-CELLS - EVIDENCE FOR A ROLE IN THE REGULATION OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; DIACYLGLYCEROL; ACTIVATION; PROLIFERATION; SPHINGOSINE; ALKYLACYLGLYCEROL; DIRADYLGLYCEROLS; ALKYLGLYCEROLS; PHOSPHOLIPIDS; MACROPHAGES	1-O-Alkyl-sn-glycerol (alkylglycerol) forms the backbone of complex ether-linked glycerolipids, including biologically active lipids such as platelet-activating factor, Synthetic alkylglycerol itself possesses several potent pharmacological activities and has been shown to inhibit protein kinase C (PKC) in vitro, In spite of these properties, free alkylglycerol has been regarded only as a potential product of the inflammatory degradation of complex ether lipids rather than a natural cell constituent. To explore the possibility that endogenous alkylglycerol functions as a physiological regulator in normal cells, we measured its content, along with related monoglycerides and diglycerides, by high performance liquid chromatography and gas-liquid chromatography in Madin-Darby canine kidney (MDCK) cells, The content of free alkylglycerol increased up to 20-fold during the growth of MDCK cell cultures to a confluent density, The increase was greatest during the log phase of growth, in which the content of alkylglycerol rose from 6.0 +/- 1.3 nmol/10(8) cells in preconfluent cultures to 23.6 +/- 3.4 nmol/10(8) cells in confluent cultures, Analysis of the molecular species of alkylglycerol showed that the higher content in quiescent MDCK cells was due primarily to an increase in 1-O- octadecyl-sn-glycerol. In contrast, the levels of monoacylglycerol and the PKC activator diacylglycerol were lower in confluent, quiescent cultures than in preconfluent, proliferating cultures, A similar pattern of changes in the monoglyceride and diglyceride content was observed in interleukin-3 dependent CFTL-12 mast cells when cell proliferation was blocked by growth factor withdrawal, Growth of MDCK cells to a confluent density resulted in a decrease in particulate PKC enzyme activity to a level that was only 6% of that in proliferating cells. To explore whether the accumulation of cellular alkylglycerol contributes to growth-dependent changes in PKC activity, we examined the effects of adding alkylglycerol to the activity and subcellular distribution of the enzyme in MDCK cells, Treatment of cells with 1-O-dodecyl-sn-glycerol resulted in a decrease in the activity of membrane associated PKC activity and inhibited 12-0-tetradecanoylphorbol-13-acetate-stimulated translocation of PKC from the cytosol to the membrane fraction, Alkylglycerol was also shown to inhibit the activity of purified PKC in vitro when present at levels similar to that of the diacylglycerol activator, We propose that the accumulation of alkylglycerol during the growth of MDCK cells to a confluent density contributes to the decrease in PKC activity, The control of cellular alkyl-glycerol levels may be a novel mechanism for the regulation of cellular physiology.			WARNE, TR (corresponding author), E TENNESSEE STATE UNIV, JAMES H QUILLEN COLL MED, DEPT BIOCHEM, JOHNSON CITY, TN 37614 USA.				NATIONAL CANCER INSTITUTE [R15CA059981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038660] Funding Source: NIH RePORTER; NCI NIH HHS [CA59981] Funding Source: Medline; NIDDK NIH HHS [DK38660] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDO K, 1972, CANCER RES, V321, P125; BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; BAUMANN WJ, 1964, J ORG CHEM, V29, P3055, DOI 10.1021/jo01033a065; BLIGH EG, 1959, CAN J BIOCH PHYSL, V37, P627; BOCCKINO SB, 1989, BIOCHEM BIOPH RES CO, V164, P290, DOI 10.1016/0006-291X(89)91716-6; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; CABOT MC, 1982, BIOCHIM BIOPHYS ACTA, V713, P16, DOI 10.1016/0005-2760(82)90161-8; FARRAR WL, 1985, NATURE, V315, P235, DOI 10.1038/315235a0; FORD DA, 1989, J BIOL CHEM, V264, P13818; GODSON C, 1990, J BIOL CHEM, V265, P8369; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HANNUN YA, 1985, J BIOL CHEM, V260, P39; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; MAVIS RD, 1972, J BIOL CHEM, V247, P2835; MCNEELY TB, 1989, BIOCHEM J, V259, P601, DOI 10.1042/bj2590601; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MILOSZEWSKA J, 1986, FEBS LETT, V206, P283, DOI 10.1016/0014-5793(86)80997-8; MYHER JJ, 1989, J CHROMATOGR, V471, P187, DOI 10.1016/S0021-9673(00)94167-0; NGWENYA BZ, 1991, P SOC EXP BIOL MED, V196, P69; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PARKER J, 1987, J BIOL CHEM, V262, P5385; ROBINSON M, 1991, BIOCHIM BIOPHYS ACTA, V1085, P63, DOI 10.1016/0005-2760(91)90232-7; ROBINSON M, 1995, IN PRESS BIOCH BIOPH; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; UBERALL F, 1991, CANCER RES, V51, P5821; VANVELDHOVEN PP, 1989, ANAL BIOCHEM, V183, P177, DOI 10.1016/0003-2697(89)90186-3; VED HS, 1991, J NEUROSCI RES, V30, P353, DOI 10.1002/jnr.490300211; WARNE TR, 1991, ANAL BIOCHEM, V198, P302, DOI 10.1016/0003-2697(91)90429-W; WARNE TR, 1990, LIPIDS, V25, P748, DOI 10.1007/BF02544045; WEINSTEIN IB, 1990, ADV SEC MESS PHOSPH, V24, P307; WEISS BA, 1989, MOL PHARMACOL, V36, P317; WHATLEY RE, 1993, J BIOL CHEM, V268, P16130; WHETTON AD, 1988, P NATL ACAD SCI USA, V85, P3284, DOI 10.1073/pnas.85.10.3284; WYKLE RL, 1970, J BIOL CHEM, V245, P3047; YAMAMOTO N, 1987, CANCER RES, V47, P2008; YAMAMOTO N, 1988, CANCER RES, V48, P6044	36	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11147	11154		10.1074/jbc.270.19.11147	http://dx.doi.org/10.1074/jbc.270.19.11147			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744745	hybrid			2022-12-25	WOS:A1995QX86500021
J	PRIGMORE, E; AHMED, S; BEST, A; KOZMA, R; MANSER, E; SEGAL, AW; LIM, L				PRIGMORE, E; AHMED, S; BEST, A; KOZMA, R; MANSER, E; SEGAL, AW; LIM, L			A 68-KDA KINASE AND NADPH OXIDASE COMPONENT P67(PHOX) ARE TARGETS FOR CDC42HS AND RAC1 IN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING PROTEIN; BINDING; CHIMAERIN; P21RAC1	Cdc42Hs and Rad are members of the Ras superfamily of small molecular weight (p21) GTP binding proteins. Cdc42Hs induces filopodia formation in Swiss 3T3 fibroblasts while Rad induces membrane ruffling. Rad also activates superoxide production by the components (cytochrome b, p40(phox), p67(phox), and p47(phox)) Of the neutrophil oxidase. To isolate target proteins involved in these signaling pathways, we have probed proteins from neutrophil cytosol immobilized on nitrocellulose with Cdc42Hs labeled with [gamma-P-32]GTP. Cdc42Hs probe detected binding protein(s) of 66-68 kDa in neutrophil cytosol. Rad probe also detected the 66-68-kDa proteins, suggesting the possibility that p67(phox) may be a binding protein for both of these p21 proteins. Indeed, Cdc42Hs and Rad were found to bind specifically to purified recombinant p67(phox) but not the other oxidase components. A 68-kDa Cdc42Hs binding protein was purified from neutrophil cytosol and found to be related to the recently described p65(pak) kinase from brain. These results suggest that the p68 kinase and p67(phox) are targets for Cdc42Hs and Rad in neutrophils.	INST NEUROL,DEPT NEUROCHEM,LONDON WC1N 1PJ,ENGLAND; NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,GLAXO IMCB GRP,SINGAPORE,SINGAPORE; UNIV LONDON UNIV COLL,DEPT MED,LONDON WC1E 6JJ,ENGLAND	University of London; University College London; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of London; University College London			Manser, Edward/ABD-2301-2020; Kozma, Robert/C-6365-2013	Kozma, Robert/0000-0001-7011-5768; Segal, Anthony/0000-0001-7602-9043	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AHMED S, 1994, J BIOL CHEM, V269, P17642; AHMED S, 1993, J BIOL CHEM, V268, P10709; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; XU XM, 1993, FASEB J, V7, pA1294	22	72	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10717	10722		10.1074/jbc.270.18.10717	http://dx.doi.org/10.1074/jbc.270.18.10717			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738010	hybrid			2022-12-25	WOS:A1995QW60100054
J	YE, WL; LAFER, EM				YE, WL; LAFER, EM			CLATHRIN BINDING AND ASSEMBLY ACTIVITIES OF EXPRESSED DOMAINS OF THE SYNAPSE-SPECIFIC CLATHRIN ASSEMBLY PROTEIN AP-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLES; MONOCLONAL-ANTIBODIES; F1-20 PROTEIN; BOVINE BRAIN; PURIFICATION; CLONING; CHAINS; NP185; ORGANIZATION; ADAPTERS	We separately expressed the 58-kDa C-terminal, 42-kDa middle, 16-kDa C-terminal, and 33-kDa N-terminal regions of AP-3 (also called F1-20, AP180, NP185, and pp155), and determined their clathrin binding and assembly properties. The 58-kDa C-terminal region of AP-3 is able to bind to clathrin triskelia and assemble them into a homogeneous population of clathrin cages and will also bind to preassembled clathrin cages. The 42-kDa central region of AP-3 can bind to both clathrin triskelia and to clathrin cages, but cannot assemble clathrin triskelia into clathrin cages. The 16-kDa C-terminal region of AP-3 can bind to clathrin cages, but cannot bind to clathrin triskelia or assemble clathrin triskelia into clathrin cages. The clathrin binding activities of the 42-kDa central region and 16-kDa C-terminal region are weaker than the corresponding activity of either the 58-kDa C-terminal region or full-length AP-3. Previous efforts had mapped a clathrin binding site within the N-terminal 33 kDa of AP-3 (Murphy, d. E., Pleasure, I. T., Puszkin, S., Prasad, K., and Keen, J. H. (1991) J. Biol. Chem. 266, 4401-4408; Morris, S. A., Schro der, S., Plessmann, U., Weber, K., and Ungewickell, E. (1993) EMBO J. 12, 667-675). However, although the N-terminal 33 kDa of AP-3 is able to bind to clathrin triskelia (Murphy, J. E., Pleasure, I. T., Puszkin, S., Prasad, K., and Keen, J. H. (1991) J. Biol. Chem. 266, 4401-4408; Ye, W., and Lafer, E. M. (1995) J. Neurosci. Res. 41, 15-26), it does not promote their assembly into clathrin cages (Murphy, J. E., Pleasure, I. T., Puszkin, S., Prasad, K., and Keen, J. H. (1991) J. Biol. Chem. 266, 4401-4408; Ye, W., and Lafer, E. M. (1995) J. Neurosci. Res. 41, 15-26) or bind to preassembled clathrin cages (Ye, W., and Lafer, E. M. (1995) J. Neurosci. Res. 41, 15-26). It appears that the smallest functional unit that carries out all of the reported clathrin binding and assembly properties of AP-3, essentially as well as the full-length protein, is the 58-kDa C-terminal region.	UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOLEC MED,SAN ANTONIO,TX 78245; UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260	University of Texas System; University of Texas Health San Antonio; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh				Ye, Weilan/0000-0002-6219-3982; Lafer, Eileen/0000-0002-0493-6522	NINDS NIH HHS [R01 NS029051, NS29051] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS029051, R01NS029051] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KIRCHHAUSEN T, 1987, SCIENCE, V236, P320, DOI 10.1126/science.3563513; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; KIRCHHAUSEN T, 1987, P NATL ACAD SCI USA, V84, P8805, DOI 10.1073/pnas.84.24.8805; KIRCHHAUSEN T, 1981, CELL, V23, P755, DOI 10.1016/0092-8674(81)90439-6; KOHTZ DS, 1988, J BIOL CHEM, V263, P7418; LINDNER R, 1991, BIOCHEMISTRY-US, V30, P9097, DOI 10.1021/bi00101a027; MORRIS SA, 1990, J BIOL CHEM, V265, P3354; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; MURPHY JE, 1994, J BIOL CHEM, V269, P21346; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; PEARSE BMF, 1975, J MOL BIOL, V97, P93, DOI 10.1016/S0022-2836(75)80024-6; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PERRY DG, 1991, J HISTOCHEM CYTOCHEM, V39, P1461, DOI 10.1177/39.11.1918924; PERRY DG, 1992, J NEUROSCI RES, V33, P408, DOI 10.1002/jnr.490330307; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; PRASAD K, 1988, BIOCHEMISTRY-US, V27, P6098, DOI 10.1021/bi00416a040; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; SOUSA R, 1990, NEUROSCIENCE, V34, P403, DOI 10.1016/0306-4522(90)90149-X; SOUSA R, 1992, J NEUROSCI, V12, P2130; UNGEWICKELL E, 1981, NATURE, V289, P420, DOI 10.1038/289420a0; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x; YE W, 1995, J NEUROSCI RES, V41, P15, DOI 10.1002/jnr.490410104; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZHOU SB, 1992, J NEUROSCI, V12, P2144; ZHOU SB, 1993, J BIOL CHEM, V268, P12655	36	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10933	10939		10.1074/jbc.270.18.10933	http://dx.doi.org/10.1074/jbc.270.18.10933			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738035	Green Accepted			2022-12-25	WOS:A1995QW60100083
J	BRTVA, TR; DRUGAN, JK; GHOSH, S; TERRELL, RS; CAMPBELLBURK, S; BELL, RM; DER, CJ				BRTVA, TR; DRUGAN, JK; GHOSH, S; TERRELL, RS; CAMPBELLBURK, S; BELL, RM; DER, CJ			2 DISTINCT RAF DOMAINS MEDIATE INTERACTION WITH RAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; REGION; CELLS; P21	A key event for Res transformation involves the direct physical association between Ras and the Raf-l kinase, This interaction promotes both Raf translocation to the plasma membrane and activation of Raf kinase activity, Although substantial experimental evidence has demonstrated that Raf residues 51-131 alone are sufficient for Ras binding, conflicting observations have suggested that the Raf cysteine-rich domain (residues 139-184) may also be important for interaction with Ras, To clarify the role of the Raf cysteine rich domain in Ras-Raf binding, we have compared the ability of two distinct Raf fragments to interact with Ras using both in vitro Ras binding and in vivo Ras inhibition assays, First, we determined that both Raf sequences 2-140 and 139-186 (designated Raf-Cys) showed preferential binding to active, GTP-bound Ras in vitro, Second, we observed that Raf-Cys antagonized oncogenic Ras(Q61L)-mediated transactivation of Ras-responsive elements and focus-forming activity in NIH 3T3 cells and insulin-induced germinal vesicle breakdown in Xenopus laevis oocytes in vivo. This inhibitory activity suggests that Raf Cys can interact with Ras in vivo, Taken together, these results suggest that Ras interaction with two distinct domains of Raf-l may be important in Ras-mediated activation of Raf kinase activity.	UNIV N CAROLINA,LINEBERGER CANC RES CTR,CURRICULUM GENET & MOLEC BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER CANC RES CTR,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER CANC RES CTR,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; DUKE UNIV,CTR COMPREHENS CANC,DEPT MOLEC CANC BIOL,DURHAM,NC 27710	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University			Ghosh, Sujoy/I-3729-2017	Ghosh, Sujoy/0000-0002-7601-165X; Der, Channing/0000-0002-7751-2747; campbell, sharon/0000-0003-0311-409X	NATIONAL CANCER INSTITUTE [R01CA042978, R01CA052072, R01CA055008] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978, CA52072, CA55008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; COX AD, 1994, METHOD ENZYMOL, V238, P277; COX AD, 1994, ONCOGENE, V9, P3281; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DELOSKEY RJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P72, DOI 10.1006/abbi.1994.1210; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FINNEY RE, 1983, CURR BIOL, V3, P805; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; HAUSER CA, 1994, METHOD ENZYMOL, V238, P271; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; MILLER AF, 1993, BIOCHEMISTRY-US, V32, P7367, DOI 10.1021/bi00080a006; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; PUMIGLIA K, 1995, MOL CELL BIOL, V270, P398; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; WU M, 1990, METHODS COMPANION ME, P315; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	30	194	196	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9809	9812		10.1074/jbc.270.17.9809	http://dx.doi.org/10.1074/jbc.270.17.9809			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730360	Green Published, hybrid			2022-12-25	WOS:A1995QV41700019
J	SORENSON, MM; DASILVA, ACR; GOUVEIA, CS; SOUSA, VP; OSHIMA, W; FERRO, JA; REINACH, FC				SORENSON, MM; DASILVA, ACR; GOUVEIA, CS; SOUSA, VP; OSHIMA, W; FERRO, JA; REINACH, FC			CONCERTED ACTION OF THE HIGH-AFFINITY CALCIUM-BINDING SITES IN SKELETAL-MUSCLE TROPONIN-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I INHIBITORY PEPTIDE; PROTEOLYTIC FRAGMENTS; MECHANICAL-PROPERTIES; BIOLOGICAL-ACTIVITY; STRUCTURAL-CHANGES; THIN FILAMENT; RABBIT PSOAS; FIBERS; CALMODULIN; SUBUNITS	Mutants of each of the four divalent cation binding sites of chicken skeletal muscle troponin C (TnC) were constructed using site directed mutagenesis to convert Asp to Ala at the first coordinating position in each site. With a view to evaluating the importance of site-site interactions both within and between the N- and C-terminal domains, in this study the mutants are examined for their ability to associate with other components of the troponin-tropomyosin regulatory complex and to regulate thin filaments. The functional effects of each mutation in reconstitution assays are largely confined to the domain in which it occurs, where the unmutated site is unable to compensate for the defect, Thus the mutants of sites I and II bind to the regulatory complex but are impaired in ability to regulate tension and actomyosin ATPase activity, whereas the mutants of sites III and IV regulate activity but are unable to remain bound to thin filaments unless Ca2+ is present. When all four sites are intact, free Mg2+ causes a 50-60-fold increase in TnC's affinity for the other components of the regulatory complex, allowing it to attach firmly to thin filaments. Calcium can replace Mg2+ at a concentration ratio of 1:5000, and at this ratio the Ca2 . TnC complex is more tightly bound to the filaments than the Mg2 . TnC form, In the C-terminal mutants, higher concentrations of Ca2+ (above tension threshold) are required to effect this transformation than in the recombinant wild-type protein, suggesting that the mutants reveal an attachment mediated by Ca2+ in the N-domain sites.	UNIV SAO PAULO,INST QUIM,DEPT BIOQUIM,SAO PAULO,BRAZIL; UNIV ESTADUAL PAULISTA,DEPT TECNOL,JABATOCABAL,SP,BRAZIL	Universidade de Sao Paulo; Universidade Estadual Paulista	SORENSON, MM (corresponding author), UFRJ,ICB,DEPT BIOQUIM MED,CIDADE UNIV,BR-21941590 RIO JANEIRO,BRAZIL.		de sousa, valeria/K-7180-2012; Ferro, Jesus Aparecido A/C-8251-2013	de sousa, valeria/0000-0003-1589-0846; Ferro, Jesus Aparecido A/0000-0002-3966-1303				ALLEN TS, 1992, BIOPHYS J, V61, P399, DOI 10.1016/S0006-3495(92)81846-5; BABU A, 1988, J BIOL CHEM, V263, P15485; BABU A, 1993, J BIOL CHEM, V268, P19232; BLANCUZZI Y, 1993, BIOCHEMISTRY-US, V32, P1302, DOI 10.1021/bi00056a015; BRANDT PW, 1987, J MOL BIOL, V195, P885, DOI 10.1016/0022-2836(87)90492-X; BRANDT PW, 1984, J MOL BIOL, V180, P379, DOI 10.1016/S0022-2836(84)80010-8; BRITO RMM, 1993, J BIOL CHEM, V268, P20966; CHANDRA M, 1994, BIOCHEMISTRY-US, V33, P2961, DOI 10.1021/bi00176a028; CHANDRA M, 1994, J BIOL CHEM, V269, P14988; CHEUNG HC, 1987, BIOCHEMISTRY-US, V26, P5904, DOI 10.1021/bi00392a049; COX JA, 1981, BIOCHEM J, V195, P205, DOI 10.1042/bj1950205; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; DECLERCQ JP, 1991, J MOL BIOL, V220, P1017, DOI 10.1016/0022-2836(91)90369-H; DOTSON DG, 1993, J BIOL CHEM, V268, P24067; EASTWOOD AB, 1979, TISSUE CELL, V11, P553, DOI 10.1016/0040-8166(79)90062-4; EBASHI S, 1971, J BIOCHEM, V69, P441, DOI 10.1093/oxfordjournals.jbchem.a129486; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; GOLOSINSKA K, 1991, J BIOL CHEM, V266, P15797; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRABAREK Z, 1982, J MUSCLE RES CELL M, V13, P383; GREASER ML, 1973, J BIOL CHEM, V248, P1125; GULATI J, 1992, J BIOL CHEM, V267, P25073; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; HITCHCOCK SE, 1981, J MOL BIOL, V147, P153, DOI 10.1016/0022-2836(81)90083-8; INGRAHAM RH, 1984, J BIOL CHEM, V259, P9544; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; KRETSINGER RH, 1980, CRC CRIT REV BIOCH, V12, P119; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEAVIS PC, 1984, BIOCHEMISTRY-US, V23, P4156, DOI 10.1021/bi00313a023; LEVINE BA, 1978, BIOCHIM BIOPHYS ACTA, V535, P11, DOI 10.1016/0005-2795(78)90028-4; LI MX, 1994, BIOCHEMISTRY-US, V33, P917, DOI 10.1021/bi00170a010; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; MOSS RL, 1992, CIRC RES, V70, P865, DOI 10.1161/01.RES.70.5.865; MOSS RL, 1983, J CELL BIOL, V96, P970, DOI 10.1083/jcb.96.4.970; MOSS RL, 1985, J GEN PHYSIOL, V86, P585, DOI 10.1085/jgp.86.4.585; NEGELE JC, 1992, J BIOL CHEM, V267, P825; PAN BS, 1987, J BIOL CHEM, V262, P7839; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POTTER JD, 1975, J BIOL CHEM, V250, P4628; PUTKEY JA, 1991, J BIOL CHEM, V266, P14881; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; ROSENFELD SS, 1985, J BIOL CHEM, V260, P252; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SIN IL, 1978, BIOCHEM BIOPH RES CO, V82, P1132, DOI 10.1016/0006-291X(78)90304-2; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SMITH L, 1994, J BIOL CHEM, V269, P9857; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SUTOH K, 1980, BIOCHEMISTRY-US, V19, P1977, DOI 10.1021/bi00550a038; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; TREWHELLA J, 1989, BIOCHEMISTRY-US, V28, P1294, DOI 10.1021/bi00429a052; TRIGOGONZALEZ G, 1992, BIOCHEMISTRY-US, V31, P7009, DOI 10.1021/bi00146a001; TSUDA S, 1992, J BIOCHEM-TOKYO, V112, P665, DOI 10.1093/oxfordjournals.jbchem.a123956; VANEYK JE, 1987, BIOCHEM CELL BIOL, V65, P982; WANG CK, 1985, BIOPHYS J, V48, P727, DOI 10.1016/S0006-3495(85)83831-5; ZOT AS, 1987, ANN REV BIOPHYS CHEM, V16, P585; ZOT HG, 1982, J BIOL CHEM, V257, P7678	59	32	33	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9770	9777		10.1074/jbc.270.17.9770	http://dx.doi.org/10.1074/jbc.270.17.9770			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730355	hybrid			2022-12-25	WOS:A1995QV41700014
J	YOUSSOUFIAN, H; AUERBACH, AD; VERLANDER, PC; STEIMLE, V; MACH, B				YOUSSOUFIAN, H; AUERBACH, AD; VERLANDER, PC; STEIMLE, V; MACH, B			IDENTIFICATION OF CYTOSOLIC PROTEINS THAT BIND TO THE FANCONI-ANEMIA COMPLEMENTATION GROUP-C POLYPEPTIDE IN-VITRO - EVIDENCE FOR A MULTIMERIC COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR; INTRACELLULAR-DISTRIBUTION; GENE; REGISTRY; CELLS; FACC; RECOMBINATION; MUTATION; CLONING	The oligomeric structure of Fanconi anemia complementation group C (FACC) was investigated in mammalian cell lysates, Using an affinity-purified polyclonal antibody, FACC was immunoprecipitated from radiolabeled cell lysates and shown to form monomers of 63 kDa, Association of FACC with heterologous proteins was investigated by co-precipitation of radiolabeled proteins with a recombinant chimeric FACC molecule fused to the constant portion of the human IgG1 heavy chain (FACC gamma 1), Expression of FACC gamma 1 in FACC-dedcient Fanconi anemia (FA) lymphoblasts corrected the hypersensitivity of these cells to mitomycin C, Binding of FACC gamma 1 to protein A-agarose and incubation with radiolabeled cell lysates identified three polypeptides with molecular masses of 65, 50, and 35 kDa that were also detected on immunoblots probed with the purified FACC gamma 1 polypeptide. FACC, as well as the three FACC-binding polypeptides, co-fractionated with cytosolic and membrane extracts, Binding was specific for the FACC moiety of FACC gamma 1 and was detected in cytosolic extracts of a number of FA and non-FA mammalian cells. These results demonstrate that FACC binds directly to a family of ubiquitous cytosolic proteins and is conserved in a wide range of mammalian cells.	ROCKEFELLER UNIV,INVEST DERMATOL LAB,NEW YORK,NY 10021; UNIV GENEVA,SCH MED,DEPT GENET & MICROBIOL,CH-1211 GENEVA 4,SWITZERLAND	Rockefeller University; University of Geneva	YOUSSOUFIAN, H (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV HEMATOL ONCOL,221 LONGWOOD AVE,LMRC 620,BOSTON,MA 02115, USA.			Auerbach, Arleen/0000-0002-6911-8379	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL032987, R01HL032987] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32987] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTER BP, 1993, HEMATOLOGY INFANCY C, P216; AUER B, 1982, HUM GENET, V61, P369; AUERBACH AD, 1991, CANCER GENET CYTOGEN, V51, P1, DOI 10.1016/0165-4608(91)90002-C; AUERBACH AD, 1979, CANCER GENET CYTOGEN, V1, P21, DOI 10.1016/0165-4608(79)90006-2; AUERBACH AD, 1989, BLOOD, V73, P391; BAILLY V, 1992, P NATL ACAD SCI USA, V89, P8273, DOI 10.1073/pnas.89.17.8273; BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; BERGER NA, 1982, NATURE, V299, P271, DOI 10.1038/299271a0; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BUTTURINI A, 1994, BLOOD, V84, P1650, DOI 10.1182/blood.V84.5.1650.bloodjournal8451650; DUCKWORTHRYSIEC.G, 1985, SOMAT CELL MOLEC GEN, V11, P35; GAVISH H, 1993, HUM MOL GENET, V2, P123, DOI 10.1093/hmg/2.2.123; GIAMPIETRO PF, 1993, PEDIATRICS, V91, P1116; GIBSON RA, 1993, HUM MOL GENET, V2, P797, DOI 10.1093/hmg/2.6.797; GIBSON RA, 1993, HUM MOL GENET, V2, P35, DOI 10.1093/hmg/2.1.35; HANG B, 1993, NUCLEIC ACIDS RES, V21, P4187, DOI 10.1093/nar/21.18.4187; HARLOW E, 1988, ANTIBODIES; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KLOCKER H, 1983, EMBO J, V2, P303, DOI 10.1002/j.1460-2075.1983.tb01423.x; SAKAGUCHI K, 1991, MUTAT RES, V255, P31, DOI 10.1016/0921-8777(91)90015-H; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STRATHDEE CA, 1992, NAT GENET, V1, P196, DOI 10.1038/ng0692-196; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; VERLANDER PC, 1994, AM J HUM GENET, V54, P595; WHITNEY MA, 1993, NAT GENET, V4, P202, DOI 10.1038/ng0693-202; WUNDER E, 1981, HUM GENET, V58, P149, DOI 10.1007/BF00278700; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P6712, DOI 10.1073/pnas.91.14.6712; YOUSSOUFIAN H, 1994, P NATL ACAD SCI USA, V91, P7975, DOI 10.1073/pnas.91.17.7975; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	29	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9876	9882		10.1074/jbc.270.17.9876	http://dx.doi.org/10.1074/jbc.270.17.9876			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730370	hybrid			2022-12-25	WOS:A1995QV41700029
J	CHANG, JY; SCHINDLER, P; RAMSEIER, U; LAI, PH				CHANG, JY; SCHINDLER, P; RAMSEIER, U; LAI, PH			THE DISULFIDE FOLDING PATHWAY OF HUMAN EPIDERMAL GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-A; PROTEIN; BPTI; IDENTIFICATION	Human epidermal growth factor (EGF) contains three disulfides and 53 amino acids. Reduced/denatured EGF refolds spontaneously in vitro to acquire its native structure, The mechanism of this folding process has been elucidated by structural analysis of both acid and iodoacetate trapped intermediates, The results reveal that the folding is accompanied by a sequential flow of unfolded EGF (O-disulfide) through three groups of folding intermediates, namely 1-disulfide, 2-disulfide, and 3-disulfide (scrambled) EGF isomers, to reach the native structure. Equilibrium occurs among isomers of each class of disulfide species, and the composition of intermediates appears to be highly heterogeneous. Together, at least 27 fractions of folding intermediates have been identified, but there exist only limited numbers of well populated species which constitute more than 80% of the total intermediates found during EGF folding. Six species of such well populated intermediates have been isolated, which included two 1-S-S, two 2-S-S, and two 3-S-S scrambled species. Their disulfide structures have been identified here. Both 1-S-S isomers are found to contain non-native disulfides. One of the 2-S-S species consists of two non-native disulfides and the other admits two native disulfides, Among the six disulfides of the two scrambled species, only one is native. Together, native disulfides constitute 25% of the total disulfides found in these six well populated intermediates, These results contrast sharply to those observed with bovine pancreatic trypsin inhibitor, which has shown that well populated folding intermediates consist of exclusively native disulfides (Weissman, J, S,, and Kim, P. S, (1991) Science 253, 1386-1393). We propose that well populated folding intermediates, regardless of whether they contain native or non-native disulfides, do not necessarily represent the productive species and specify the folding pathway. Furthermore, conditions influencing the efficiency of EGF folding have been investigated, It is demonstrated here that under optimized compositions of redox agents, including the use of cysteine/cystine and protein disulfide isomerase, the in vitro folding of EGF could be achieved quantitatively within 1 min.	PROT INST INC,BROOMALL,PA 19008		CHANG, JY (corresponding author), CIBA GEIGY LTD,PHARMACEUT RES LABS,K-121,104,CH-4002 BASEL,SWITZERLAND.							ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BOERNSEN KO, 1990, CHIMIA, V44, P412; BULLEID NJ, 1993, ADV PROTEIN CHEM, V44, P125, DOI 10.1016/S0065-3233(08)60566-5; CARVER JA, 1986, FEBS LETT, V205, P77, DOI 10.1016/0014-5793(86)80869-9; CHANG JY, 1993, J BIOL CHEM, V268, P4043; CHANG JY, 1991, ANAL BIOCHEM, V197, P52, DOI 10.1016/0003-2697(91)90354-V; CHANG JY, 1994, J BIOL CHEM, V269, P22087; CHANG JY, 1994, BIOCHEM J, V300, P643, DOI 10.1042/bj3000643; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; CHATRENET B, 1992, J BIOL CHEM, V267, P3038; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1979, J MOL BIOL, V129, P411, DOI 10.1016/0022-2836(79)90504-7; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CREIGHTON TE, 1992, SCIENCE, V256, P111, DOI 10.1126/science.1373519; EPSTEIN CJ, 1963, COLD SPRING HARB SYM, V28, P439, DOI 10.1101/SQB.1963.028.01.060; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; HANIU M, 1994, INT J PEPT PROT RES, V43, P81; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KONISHI Y, 1981, BIOCHEMISTRY-US, V20, P3945, DOI 10.1021/bi00517a001; MONTELIONE GT, 1987, P NATL ACAD SCI USA, V84, P5226, DOI 10.1073/pnas.84.15.5226; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; RAMSEIER U, 1994, ANAL BIOCHEM, V221, P231, DOI 10.1006/abio.1994.1406; ROSE GD, 1979, J MOL BIOL, V134, P447, DOI 10.1016/0022-2836(79)90363-2; SAVAGE CR, 1973, J BIOL CHEM, V248, P7669; SCHERAGA HA, 1984, ADV BIOPHYS, V18, P21, DOI 10.1016/0065-227X(84)90005-4; WEISSMAN JS, 1992, SCIENCE, V256, P112, DOI 10.1126/science.256.5053.112; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	29	59	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9207	9216		10.1074/jbc.270.16.9207	http://dx.doi.org/10.1074/jbc.270.16.9207			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721838	hybrid			2022-12-25	WOS:A1995QU08900026
J	MCCARTNEY, S; LITTLE, BM; LANGEBERG, LK; SCOTT, JD				MCCARTNEY, S; LITTLE, BM; LANGEBERG, LK; SCOTT, JD			CLONING AND CHARACTERIZATION OF A-KINASE ANCHOR PROTEIN-100 (AKAP100) - A PROTEIN THAT TARGETS A-KINASE TO THE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT RII; BOVINE BRAIN; SUBCELLULAR-LOCALIZATION; CATALYTIC SUBUNIT; POTASSIUM CHANNEL; GOLGI-COMPLEX; EXPRESSION; BETA; PHOSPHORYLATION; BINDING	Differential localization of the type II cAMP-dependent protein kinase (PKA) is achieved by interaction of the regulatory subunit (RII) with A-kinase anchor proteins (AKAPs). Anchoring is a likely means to adapt PKA for regulation of cAMP-responsive events through colocalization of the kinase with preferred substrates, Using an interaction cloning strategy with an RII alpha protein probe, we have identified a 655-amino acid protein (named AKAP100), Recombinant AKAP100, expressed in Escherichia coli, binds RII alpha in a solid-phase overlay assay, The cellular and subcellular distribution of AKAP100 was analyzed by various methods. Northern blot analysis with the AKAP100 cDNA as a probe detected an 8-kilobase message in some human tissues including various brain regions; however, the message was predominately expressed in cardiac and skeletal muscle, Anti-AKAP100 antibodies confirmed expression in the rat cardiac and skeletal muscle cell lines, H9c2 and L6P, whereas immunohistochemical analysis revealed that AKAP100 was localized to the sarcoplasmic reticulum of both cell types, RII was also detected in these regions, AKAP100 was detected in preparations of RII purified from L6P cell extracts by cAMP-agarose affinity chromatography, Collectively, these results suggest that AKAP100 functions to maintain the type II PKA at the sarcoplasmic reticulum.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048231, R37GM048231] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48231] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CAI YC, 1993, J BIOL CHEM, V268, P23720; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHEIN CT, 1991, P NATL ACAD SCI USA, V88, P9578; CHEN Y, 1994, J BIOL CHEM, V269, P7839; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; CORBIN JD, 1975, J BIOL CHEM, V250, P218; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; HARPER JF, 1985, VITAM HORM, V42, P197; HATHAWAY DR, 1981, J BIOL CHEM, V256, P8183; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; JOACHIM S, 1990, EUR J CELL BIOL, V51, P76; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KAWANO S, 1992, CIRC RES, V71, P585, DOI 10.1161/01.RES.71.3.585; KREBS EG, 1979, ANNU REV BIOCHEM, V43, P923; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEISER M, 1986, J BIOL CHEM, V261, P1904; LOHMANN SM, 1984, P NATL ACAD SCI USA, V81, P4887; LORY P, 1992, BIOCHEM BIOPH RES CO, V182, P1059, DOI 10.1016/0006-291X(92)91839-I; LUO ZJ, 1990, J BIOL CHEM, V265, P21804; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1972, J BIOL CHEM, V247, P6135; RUBIN CS, 1979, J BIOL CHEM, V254, P3797; SALAVATORI S, 1990, BIOCHEM J, V267, P679; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOPTT JD, 1994, MOL ENDOCRINOL, V13, P5; SCOTT JD, 1992, NEWS PHYSIOL SCI, V7, P143; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; STOFKOHAHN RE, 1992, FEBS LETT, V302, P274, DOI 10.1016/0014-5793(92)80458-S; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUTHERLAND EW, 1972, SCIENCE, V171, P401; TAKASAGO T, 1989, J BIOCHEM-TOKYO, V106, P872, DOI 10.1093/oxfordjournals.jbchem.a122945; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH KB, 1992, J GEN PHYSIOL, V100, P847, DOI 10.1085/jgp.100.5.847	47	91	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9327	9333		10.1074/jbc.270.16.9327	http://dx.doi.org/10.1074/jbc.270.16.9327			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721854	hybrid			2022-12-25	WOS:A1995QU08900043
J	SOLIOZ, M; ODERMATT, A				SOLIOZ, M; ODERMATT, A			COPPER AND SILVER TRANSPORT BY COPB-ATPASE IN MEMBRANE-VESICLES OF ENTEROCOCCUS-HIRAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON DISEASE GENE; CANDIDATE GENE; MENKES DISEASE; CADMIUM-RESISTANCE; PROTEIN; ACTIVATION; ENCODES; BINDING	The P-type ATPase, CopB, of Enterococcus hirae is required for the copper resistance displayed by this organism and thus was postulated to be a copper pump. Using Cu-64(+) and Ag-110m(+), we here show ATP-driven copper and silver accumulation catalyzed by CopB in native inside-out membrane vesicles of E. hirae. CopB ATPase exhibited an apparent K-m for Cu+ and Ag+ of 1 mu M and for ATP of 10 mu M. Transport was maximal at pH 6 and had an apparent V-max of 0.07 nmol . min(-1). mg(-1) for both copper and silver transport. Vanadate displayed a biphasic effect on transport: maximal inhibition was observed at 40 mu M vanadate for copper transport and 60 mu M for silver transport, respectively. At higher vanadate concentrations, these inhibitions were reversed. The CopB ATPase off. hirae is thus a pump for the extrusion of monovalent copper and silver ions, with copper probably being the natural substrate.			SOLIOZ, M (corresponding author), UNIV BERN,DEPT CLIN PHARMACOL,MURTENSTR 35,CH-3010 BERN,SWITZERLAND.		Solioz, Marc/I-3162-2013	Solioz, Marc/0000-0002-7989-6721; Odermatt, Alex/0000-0002-6820-2712				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CERVANTES C, 1994, FEMS MICROBIOL REV, V14, P121, DOI 10.1016/0168-6445(94)90002-7; CHA JS, 1991, P NATL ACAD SCI USA, V88, P8915, DOI 10.1073/pnas.88.20.8915; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; FURST P, 1989, P NATL ACAD SCI USA, V86, P5267, DOI 10.1073/pnas.86.14.5267; GE ZM, 1995, MOL MICROBIOL, V15, P97, DOI 10.1111/j.1365-2958.1995.tb02224.x; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; IVEY DM, 1992, J BACTERIOL, V174, P4878, DOI 10.1128/JB.174.15.4878-4884.1992; KAHN D, 1989, J BACTERIOL, V171, P929, DOI 10.1128/jb.171.2.929-939.1989; KANAMARU K, 1994, MOL MICROBIOL, V13, P369, DOI 10.1111/j.1365-2958.1994.tb00430.x; LEBRUN M, 1994, J BACTERIOL, V176, P3040, DOI 10.1128/JB.176.10.3040-3048.1994; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; ODERMATT A, 1994, BIOCHEM BIOPH RES CO, V202, P44, DOI 10.1006/bbrc.1994.1891; ODERMATT A, 1992, ANN NY ACAD SCI, V671, P484, DOI 10.1111/j.1749-6632.1992.tb43836.x; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; ODERMATT A, 1995, J BIOL CHEM, V269, P4349; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PETRUKHIN K, 1994, HUM MOL GENET, V3, P1647, DOI 10.1093/hmg/3.9.1647; PHUNG LT, 1994, P NATL ACAD SCI USA, V91, P9651, DOI 10.1073/pnas.91.20.9651; POPE MT, 1968, Q REV CHEM SOC, V22, P527, DOI 10.1039/qr9682200527; SILVER S, 1993, MOL MICROBIOL, V10, P7, DOI 10.1111/j.1365-2958.1993.tb00898.x; SILVER S, 1989, TRENDS BIOCHEM SCI, V14, P76, DOI 10.1016/0968-0004(89)90048-0; SOLIOZ M, 1994, FEBS LETT, V346, P44, DOI 10.1016/0014-5793(94)00316-5; SOLIOZ M, 1994, J BIOL CHEM, V269, P9453; SOUNESS JE, 1985, J CYCLIC NUCL PROT, V10, P383; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TSAI KJ, 1992, J BACTERIOL, V174, P116, DOI 10.1128/jb.174.1.116-121.1992; VILSEN B, 1989, J BIOL CHEM, V264, P21024; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471	32	223	229	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9217	9221		10.1074/jbc.270.16.9217	http://dx.doi.org/10.1074/jbc.270.16.9217			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721839	hybrid			2022-12-25	WOS:A1995QU08900027
J	CLARKE, VA; PLATT, N; BUTTERS, TD				CLARKE, VA; PLATT, N; BUTTERS, TD			CLONING AND EXPRESSION OF THE BETA-N-ACETYLGLUCOSAMINIDASE GENE FROM STREPTOCOCCUS-PNEUMONIAE - GENERATION OF TRUNCATED ENZYMES WITH MODIFIED AGLYCON SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-B STREPTOCOCCI; PROTEIN-A; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; CELL-WALL; ACETYLHEXOSAMINIDASE; PURIFICATION; HOMOLOGY; PYOGENES; COMPLEX	The gene encoding a beta-N acetylglucosaminidase from Streptococcus pneumoniae has been obtained by screening an expression library for beta-N-acetylglucosaminidase activity. Clones of different nucleotide sizes each having arylglycoside activity were obtained, and DNA sequencing revealed a gene of 3933 base pairs possessing typical bacterial transcription initiation and termination sequences and terminating in an ochre stop codon. Computer analysis of the translated protein of 1311 amino acids (144,210 Da) identified a tandem repeat within which lies a sequence homologous with six other hexosaminidase gene products from a wide variety of species ranging from bacteria to humans. Also found were an amino-terminal putative secretion signal peptide and a carboxyl-terminal cell sorting/anchorage motif typically found in over 20 other Gram-positive surface proteins. The expression of an almost complete DNA clone in Escherichia coli produced a functional and authentic beta-N-acetylglucosaminidase with aglycon specificity identical to the wild-type enzyme. However, enzymes produced from truncated DNA clones show more restricted aglycon specificity and are unable to hydrolyze terminal beta 1-2GlcNAc residues from N-glycans containing a bisecting N-acetylglucosamine, The availability of these clones allows structural analyses to be made of catalytic and oligosaccharide recognition protein domains that enhance functional activity.	UNIV OXFORD,DEPT BIOCHEM,INST GLYCOBIOL,OXFORD OX1 3QU,ENGLAND; UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3QX,ENGLAND	University of Oxford; University of Oxford								ABRAHMSEN L, 1985, EMBO J, V4, P3901, DOI 10.1002/j.1460-2075.1985.tb04164.x; BECCARI T, 1992, BIOCHEM J, V285, P593, DOI 10.1042/bj2850593; BOULNOIS GJ, 1992, J GEN MICROBIOL, V138, P249, DOI 10.1099/00221287-138-2-249; BRAUN V, 1970, EUR J BIOCHEM, V13, P336, DOI 10.1111/j.1432-1033.1970.tb00936.x; BUTTERS TD, 1991, BIOCHEM J, V279, P189, DOI 10.1042/bj2790189; CANNON RD, 1994, J BACTERIOL, V176, P2640, DOI 10.1128/JB.176.9.2640-2647.1994; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE VA, 1994, INT J BIOCHROM, V1, P151; FARRELL AM, 1993, J GEN MICROBIOL, V139, P267, DOI 10.1099/00221287-139-2-267; FRITHZ E, 1989, MOL MICROBIOL, V3, P1111, DOI 10.1111/j.1365-2958.1989.tb00261.x; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GOWARD CR, 1993, TRENDS BIOCHEM SCI, V18, P136, DOI 10.1016/0968-0004(93)90021-E; GRAHAM TR, 1988, J BIOL CHEM, V263, P16823; HAANES EJ, 1989, J BACTERIOL, V171, P6397, DOI 10.1128/jb.171.12.6397-6408.1989; HUGHES RC, 1964, BIOCHEMISTRY-US, V3, P1543, DOI 10.1021/bi00898a026; JERLSTROM PG, 1991, MOL MICROBIOL, V5, P843, DOI 10.1111/j.1365-2958.1991.tb00757.x; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; LINDER TE, 1994, MICROB PATHOGENESIS, V16, P435, DOI 10.1006/mpat.1994.1043; LOEFDAHL S, 1983, P NATL ACAD SCI USA, V80, P697; MICHEL JL, 1992, P NATL ACAD SCI USA, V89, P10060, DOI 10.1073/pnas.89.21.10060; MYEROWITZ R, 1985, P NATL ACAD SCI USA, V82, P7830, DOI 10.1073/pnas.82.23.7830; ROBBINS PW, 1992, GENE, V111, P69, DOI 10.1016/0378-1119(92)90604-N; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH HE, 1992, INFECT IMMUN, V60, P2361, DOI 10.1128/IAI.60.6.2361-2367.1992; SOMERVILLE CC, 1993, P NATL ACAD SCI USA, V90, P6751, DOI 10.1073/pnas.90.14.6751; SOTOGIL RW, 1989, J BIOL CHEM, V264, P14778; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; UHLEN M, 1984, J BIOL CHEM, V259, P1695; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; YAMASHITA K, 1981, BIOCHEM BIOPH RES CO, V100, P226, DOI 10.1016/S0006-291X(81)80086-1	34	66	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8805	8814		10.1074/jbc.270.15.8805	http://dx.doi.org/10.1074/jbc.270.15.8805			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721787	hybrid			2022-12-25	WOS:A1995QT44800065
J	DATTA, PK; GHOSH, AK; JACOB, ST				DATTA, PK; GHOSH, AK; JACOB, ST			THE RNA-POLYMERASE-I PROMOTER-ACTIVATING FACTOR CPBF IS FUNCTIONALLY AND IMMUNOLOGICALLY RELATED TO THE BASIC HELIX-LOOP-HELIX-ZIPPER DNA-BINDING PROTEIN-USF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; MAJOR LATE PROMOTER; RIBOSOMAL-RNA; ENHANCER ELEMENT; FACTOR E1BF; GENE; REGION; UPSTREAM; SEQUENCE; SPACER	Analysis of the core promoter sequence of the mam malian ribosomal RNA genes revealed an E-box like sequence (CACGCTG) to which the upstream stimulatory factor (USF) binds. Because the core promoter binding factor (CPBF) binds specifically to the core promoter sequence of the ribosomal RNA gene (Liu, Z., and Jacob, S. T. (1994) J. Biol. Chem. 269, 16618-16626) and resembles USP in some respects, we explored the potential relationship between USF and CPBF. Competition electrophoretic mobility shift assay using labeled core promoter probe and several unlabeled competitor oligonucleotides showed that USF can indeed bind to the core promoter and that only those oligonucleotides with an E-box sequence could compete in the promoter-protein complex formation characteristic of CPBF. This complex formation was thermostable, a unique property of USF. Furthermore, antibodies raised against USF cross-reacted with the 44-kDa component of rat CPBF. To prove further the relationship between CPBF and USF, we examined the effects of the unlabeled USF and ribosomal gene core promoter oligonucleotides on polymerase (pol) I and pol II transcription. Both oligonucleotides inhibited rDNA transcription as well as transcription from the adenovirus major late promoter. Only the oligonucleotides that contain the E-box sequence competed in the transcription. These data indicate that the promoter sequence of mammalian ribosomal RNA gene contains an USE-binding site, that the 44-kDa polypeptide of CPBF is related to the 44/43-kDa polypeptide of human USF, and that USF or USF-related protein can transactivate both pol I and pol II promoters.	CHICAGO MED SCH, DEPT PHARMACOL & MOLEC BIOL, N CHICAGO, IL 60064 USA	Chicago Medical School				Datta, Prasun/0000-0001-5133-253X	NATIONAL CANCER INSTITUTE [R01CA031894] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31894] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DIXIT A, 1987, J BIOL CHEM, V262, P11616; DUMENCO VM, 1986, GENE, V46, P227, DOI 10.1016/0378-1119(86)90407-5; FINANCSEK I, 1982, P NATL ACAD SCI-BIOL, V79, P3092, DOI 10.1073/pnas.79.10.3092; GHOSH AK, 1994, GENE, V141, P271, DOI 10.1016/0378-1119(94)90584-3; GHOSH AK, 1993, GENE, V125, P217, DOI 10.1016/0378-1119(93)90332-W; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GRUMMT I, 1985, CELL, V43, P801, DOI 10.1016/0092-8674(85)90253-3; HARRINGTON CA, 1983, NUCLEIC ACIDS RES, V11, P3317, DOI 10.1093/nar/11.10.3317; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; HOFF CM, 1993, BIOCHEM BIOPH RES CO, V190, P747, DOI 10.1006/bbrc.1993.1112; JACOB ST, 1995, BIOCHEM J, V306, P617, DOI 10.1042/bj3060617; JI Z, 1990, MOL CELL BIOL, V10, P5177, DOI 10.1128/MCB.10.10.5177; KURL RN, 1984, P NATL ACAD SCI-BIOL, V81, P6672, DOI 10.1073/pnas.81.21.6672; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; LI JM, 1994, MOL CELL BIOL, V14, P2191, DOI 10.1128/MCB.14.3.2191; Liu Z., UNPUB; LIU ZJ, 1994, J BIOL CHEM, V269, P16618; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Niu Huifeng, 1995, Gene Expression, V4, P111; Paule Marvin R., 1993, Gene Expression, V3, P1; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; RUDLOFF U, 1994, EMBO J, V13, P2611, DOI 10.1002/j.1460-2075.1994.tb06551.x; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; SOLLNERWEBB B, 1991, TRENDS BIOCHEM SCI, V16, P58, DOI 10.1016/0968-0004(91)90025-Q	37	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8637	8641		10.1074/jbc.270.15.8637	http://dx.doi.org/10.1074/jbc.270.15.8637			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721765	hybrid			2022-12-25	WOS:A1995QT44800042
J	HEIMBERG, H; DEVOS, A; PIPELEERS, D; THORENS, B; SCHUIT, F				HEIMBERG, H; DEVOS, A; PIPELEERS, D; THORENS, B; SCHUIT, F			DIFFERENCES IN GLUCOSE-TRANSPORTER GENE-EXPRESSION BETWEEN RAT PANCREATIC ALPHA-CELLS AND BETA-CELLS ARE CORRELATED TO DIFFERENCES IN GLUCOSE-TRANSPORT BUT NOT IN GLUCOSE-UTILIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; A-CELLS; B-CELLS; SEQUENCE; GLUT-1; LIVER; HETEROGENEITY; GLUCOKINASE; GLUCAGON; ISOFORMS	Glucose exerts inverse effects upon the secretory function of islet alpha- and beta-cells, suppressing glucagon release and increasing insulin release, This diverse action may result from differences in glucose transport and metabolism between the two cell types. The present study compares glucose transport in rat alpha- and beta-cells. beta-Cells transcribed GLUT2 and, to a lesser extent, GLUT 1; alpha-cells contained GLUT1 but no GLUT2 mRNA No other GLUT-like sequences were found among cDNAs from alpha- or beta-cells. Both cell types expressed 43-kDa GLUT1 protein which was enhanced by culture. The 62-kDa beta-cell GLUT2 protein was converted to a 58-kDa protein after trypsin treatment of the cells without detectable consequences upon glucose transport kinetics. In beta-cells, the rates of glucose transport were 10-fold higher than in alpha-cells. In both cell types, glucose uptake exceeded the rates of glucose cose utilization by a factor of 10 or more. Glycolytic flux, measured as D-[5(3)H]glucose utilization, was comparable in alpha- and beta-cells between 1 and 10 mmol/liter substrate. In conclusion, differences in glucose transporter gene expression between alpha- and beta-cells can be correlated with differences in glucose transport kinetics but not with different glucose utilization rates.	FREE UNIV BRUSSELS,DIABET RES CTR,DEPT BIOCHEM,B-1090 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,DIABET RES CTR,DEPT ENDOCRINOL & METAB,B-1090 BRUSSELS,BELGIUM; UNIV LAUSANNE,INST PHARMACOL,CH-1005 LAUSANNE,SWITZERLAND	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Lausanne				Heimberg, Harry/0000-0003-1954-7375; Pipeleers, Daniel/0000-0002-6440-2485; De Vos, Anick/0000-0001-5311-1589				CHEN L, 1990, P NATL ACAD SCI USA, V87, P4088, DOI 10.1073/pnas.87.11.4088; DEVOS A, 1991, BIOCHEM INT, V24, P117; EFRAT S, 1994, P NATL ACAD SCI USA, V91, P2051, DOI 10.1073/pnas.91.6.2051; EPSTEIN PN, 1992, P NATL ACAD SCI USA, V89, P12038, DOI 10.1073/pnas.89.24.12038; GERICH JE, 1974, J CLIN INVEST, V54, P833, DOI 10.1172/JCI107823; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GORUS FK, 1984, J BIOL CHEM, V259, P1196; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; GREENBAUM CJ, 1991, J CLIN INVEST, V88, P767, DOI 10.1172/JCI115375; HASPEL HC, 1986, J BIOL CHEM, V261, P6778; HEIMBERG H, 1993, EMBO J, V12, P2873, DOI 10.1002/j.1460-2075.1993.tb05949.x; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; KATAGIRI H, 1992, J BIOL CHEM, V267, P22550; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LING Z, 1994, DIABETOLOGIA, V37, P15; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2902; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; ORCI L, 1989, SCIENCE, V245, P295, DOI 10.1126/science.2665080; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P817, DOI 10.1210/endo-117-3-817; PIPELEERS DG, 1992, DIABETES, V41, P777, DOI 10.2337/diabetes.41.7.777; RANDLE PJ, 1993, DIABETOLOGIA, V36, P269, DOI 10.1007/BF00400227; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; TAL M, 1992, J BIOL CHEM, V267, P17241; TAL M, 1992, MOL CELL BIOL, V12, P422, DOI 10.1128/MCB.12.1.422; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; THORENS B, 1993, J CELL BIOL, V123, P1687, DOI 10.1083/jcb.123.6.1687; THORENS B, 1992, INT REV CYTOL, V137A, P209; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; WERTHEIMER E, 1991, P NATL ACAD SCI USA, V88, P2525, DOI 10.1073/pnas.88.6.2525	35	118	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8971	8975		10.1074/jbc.270.15.8971	http://dx.doi.org/10.1074/jbc.270.15.8971			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721807	hybrid			2022-12-25	WOS:A1995QT44800086
J	MUKUND, S; ADAMS, MWW				MUKUND, S; ADAMS, MWW			GLYCERALDEHYDE-3-PHOSPHATE FERREDOXIN OXIDOREDUCTASE, A NOVEL TUNGSTEN-CONTAINING ENZYME WITH A POTENTIAL GLYCOLYTIC ROLE IN THE HYPERTHERMOPHILIC ARCHAEON PYROCOCCUS-FURIOSUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							IRON-SULFUR PROTEIN; ARCHAEBACTERIUM; PATHWAY; DEHYDROGENASE; ORGANISMS	The archaeon Pyrococcus furiosus grows optimally at 100 degrees C by the fermentation of carbohydrates to yield acetate, CO2, and H-2. Cell-free extracts contain very low activity of the glycolytic enzyme, glyceraldehyde-3-phosphate dehydrogenase, but extremely high activity of glyceraldehyde-3-phosphate ferredoxin oxidoreductase (GAPOR). GAPOR was purified under strictly anaerobic conditions. It is a monomeric, O-2-sensitive protein of M(r) similar to 63,000 which contains pterin and approximately 1 tungsten and 6 iron atoms per molecule. The enzyme oxidized glyceraldehyde-3-phosphate (K-m 28 mu M) to 3-phosphoglycerate and reduced P. furiosus ferredoxin (K-m 6 mu M), but it did not oxidize formaldehyde, acetaldehyde, glyceraldehyde, benzaldehyde, glucose, glucose 6-phosphate, or glyoxylate, nor did it use NAD(P) as an electron acceptor. It is proposed that GAPOR has a glycolytic role and functions in place of glyceraldehyde-3-phosphate dehydrogenase and possibly phosphoglycerate kinase.	UNIV GEORGIA,DEPT MOLEC BIOL & BIOCHEM,ATHENS,GA 30602; UNIV GEORGIA,CTR METALLOENZYME STUDIES,ATHENS,GA 30602	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia				Adams, Michael/0000-0002-9796-5014				Adams M.W.W., 1994, ENCY INORGANIC CHEM, P4284; ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; BRYANT FO, 1989, J BIOL CHEM, V264, P5070; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; JOHNSON JL, 1993, J BIOL CHEM, V268, P4848; KENGEN SWM, 1994, FEMS MICROBIOL LETT, V117, P305, DOI 10.1016/0378-1097(94)90576-2; KENGEN SWM, 1994, ARCH MICROBIOL, V161, P168, DOI 10.1007/BF00276479; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; MA K, 1994, J BACTERIOL, V176, P6509, DOI 10.1128/JB.176.21.6509-6517.1994; MA K, 1994, FEMS MICROBIOL LETT, V122, P263; MUKUND S, 1991, J BIOL CHEM, V266, P14208; MUKUND S, 1990, J BIOL CHEM, V265, P11508; MUKUND S, 1993, J BIOL CHEM, V268, P13592; NEGELEIN E, 1957, METHOD ENZYMOL, V3, P216, DOI 10.1016/S0076-6879(57)03376-5; SCHAFER T, 1992, ARCH MICROBIOL, V158, P188, DOI 10.1007/BF00290815; SCHAFER T, 1994, FEMS MICROBIOL LETT, V121, P107, DOI 10.1016/0378-1097(94)90153-8; SCHAFER T, 1993, ARCH MICROBIOL, V159, P354, DOI 10.1007/BF00290918; SCHMITZ RA, 1992, EUR J BIOCHEM, V209, P1013, DOI 10.1111/j.1432-1033.1992.tb17376.x; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; WHITE H, 1991, BIOL CHEM H-S, V372, P999, DOI 10.1515/bchm3.1991.372.2.999; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; ZWICKL P, 1990, J BACTERIOL, V172, P4329, DOI 10.1128/jb.172.8.4329-4338.1990	22	168	173	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8389	8392		10.1074/jbc.270.15.8389	http://dx.doi.org/10.1074/jbc.270.15.8389			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721730	hybrid			2022-12-25	WOS:A1995QT44800005
J	GIULIANI, C; SAJI, M; NAPOLITANO, G; PALMER, LA; TANIGUCHI, SI; SHONG, M; SINGER, DS; KOHN, LD				GIULIANI, C; SAJI, M; NAPOLITANO, G; PALMER, LA; TANIGUCHI, SI; SHONG, M; SINGER, DS; KOHN, LD			HORMONAL MODULATION OF MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I GENE-EXPRESSION INVOLVES AN ENHANCER A-BINDING COMPLEX CONSISTING OF FRA-2 AND THE P50 SUBUNIT OF NF-KAPPA-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT THYROTROPIN RECEPTOR; AUTOIMMUNE THYROID-DISEASE; HLA-DR EXPRESSION; TRANSCRIPTION FACTORS; DNA-BINDING; C-JUN; GLUCOCORTICOID RECEPTOR; EPITHELIAL-CELLS; FRTL-5 CELLS; INTERFERON	Hydrocortisone decreases major histocompatibility complex (MHC) class I gene expression in rat thyroid cells and counteracts increases induced by interferons. Using FRTL-5 cells transfected with class I promoter-reporter gene chimeras, we show that hydrocortisone action is transcriptional and mediated by an element located between 180 and 170 base pairs upstream of the start of transcription. Gel shift assays reveal that hydrocortisone causes the decrease of a specific protein-DNA complex; this same complex, referred to as Mod-1, is increased by interferon. Oligonucleotide competition assays reveal that the Mod-1 complex is associated with enhancer A of the class I gene, -180 to -170 base pairs (5'-GGGGAGTCCCC-3'), immediately upstream of the interferon response element. Antibodies to fra-2, a fos family member, and to the p50, but not the p65, subunit of NF-kappa B supershift the Mod-1 complex. We suggest that hydrocortisone decreases MHC class I gene expression by reducing the formation of Mod-1, which contains both p50 and fra-2; interferon reverses the hydrocortisone effect and increases Mod-1 formation. These observations are relevant to the molecular basis of hydrocortisone therapy in autoimmune thyroid disease and to the actions of interferon to exacerbate or induce autoimmune disease.	NIDDK,BIOCHEM & METAB LAB,CELL REGULAT SECT,BETHESDA,MD 20892; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Saji, Motoyasu/E-4007-2011; /H-7803-2012	shong, minho/0000-0002-0247-7115				AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; Ambesi Impiombato FS., 1986, United States Patent, Patent No. [US 4608341, 4608341]; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BOTTAZZO GF, 1983, LANCET, V2, P1115; BURMAN P, 1986, J CLIN ENDOCR METAB, V63, P1086, DOI 10.1210/jcem-63-5-1086; COOPER DS, 1984, NEW ENGL J MED, V311, P1353, DOI 10.1056/NEJM198411223112106; DEGROOT LJ, 1989, ENDOCR REV, V10, P537, DOI 10.1210/edrv-10-4-537; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOEBERITZ MV, 1990, EUR J IMMUNOL, V20, P35, DOI 10.1002/eji.1830200106; EHRLICH R, 1988, MOL CELL BIOL, V8, P695, DOI 10.1128/MCB.8.2.695; FEINTIMAN IS, 1988, EUR J CANCER CLIN ON, V24, P1299; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HANAFUSA T, 1983, LANCET, V2, P1111; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOKLAND M, 1986, METHOD ENZYMOL, V119, P688; HOWCROFT TK, 1993, EMBO J, V12, P3163, DOI 10.1002/j.1460-2075.1993.tb05985.x; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P1701, DOI 10.1210/me.6.10.1701; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P793, DOI 10.1210/me.6.5.793; ISOZAKI O, 1989, MOL ENDOCRINOL, V3, P1681, DOI 10.1210/mend-3-11-1681; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Kohn L D, 1992, Int Rev Immunol, V9, P135, DOI 10.3109/08830189209061788; KOHN LD, 1989, ADV EXP MED BIOL, V261, P151; KOHN LD, 1986, Patent No. 4609622; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KORBER B, 1987, P NATL ACAD SCI USA, V84, P3380, DOI 10.1073/pnas.84.10.3380; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MARTIN A, 1992, THYROID, V2, P247, DOI 10.1089/thy.1992.2.247; Maxam A M, 1980, Methods Enzymol, V65, P499; MAYET WJ, 1989, HEPATOLOGY, V10, P24, DOI 10.1002/hep.1840100106; MISAKI T, 1988, ENDOCRINOLOGY, V123, P2849, DOI 10.1210/endo-123-6-2849; MOZES E, 1993, SCIENCE, V261, P91, DOI 10.1126/science.8316860; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PLATZER M, 1987, ENDOCRINOLOGY, V121, P2087, DOI 10.1210/endo-121-6-2087; ROITT IM, 1991, ESSENTIAL IMMUNOLOGY; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SAJI M, 1992, J CLIN ENDOCR METAB, V75, P871, DOI 10.1210/jc.75.3.871; SAJI M, 1992, P NATL ACAD SCI USA, V89, P1944, DOI 10.1073/pnas.89.5.1944; SAJI M, 1990, ENDOCRINOLOGY, V127, P1867, DOI 10.1210/endo-127-4-1867; Sambrook J, 1989, MOL CLONING LABORATO; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHIRAYOSHI Y, 1988, P NATL ACAD SCI USA, V85, P5884, DOI 10.1073/pnas.85.16.5884; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; SINGER DS, 1994, J IMMUNOL, V153, P873; SINGER DS, 1993, NIH CATALYST    0815; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3; TODD I, 1985, CLIN EXP IMMUNOL, V61, P265; TODD I, 1986, ANN NY ACAD SCI, V475, P241, DOI 10.1111/j.1749-6632.1986.tb20873.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZAKARIJA M, 1988, MOL CELL ENDOCRINOL, V58, P329	57	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11453	11462		10.1074/jbc.270.19.11453	http://dx.doi.org/10.1074/jbc.270.19.11453			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744783	hybrid			2022-12-25	WOS:A1995QX86500062
J	MORITA, K; EBERT, SN; WONG, DL				MORITA, K; EBERT, SN; WONG, DL			ROLE OF TRANSCRIPTION FACTOR EGR-1 IN PHORBOL ESTER-INDUCED PHENYLETHANOLAMINE N-METHYLTRANSFERASE GENE-EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE EARLY GENES; ZINC FINGER PROTEIN; MESSENGER-RNA EXPRESSION; NMDA RECEPTOR ACTIVATION; PARALLEL UP-REGULATION; TYROSINE-HYDROXYLASE; ADRENAL-GLAND; RAT-BRAIN; MONOCYTIC DIFFERENTIATION; GROWTH-FACTORS	Transfection of PC12-variant RS1 cells with an Egr-1 expression construct has previously been shown to stimulate phenylethanolamine N-methyltransferase (PNMT) promoter activity, thus suggesting a putative role of Egr-1 as a factor regulating PNMT gene expression. To elucidate the physiological implication of this finding, the effects of phorbol la myristate 13 acetate (PMA) on PNMT promoter activity and Egr-1 expression were ex examined. PMA stimulated luciferase expression in RS1 cells transfected with a rat PNMT promoter-luciferase reporter gene construct, and also elevated both Egr-1 mRNA and Egr-1 protein levels in the untransfected cells. Further study on the concentration dependence of PMA action showed that the stimulation of luciferase expression correlated with the elevation of Egr-1 mRNA level. Finally, the stimulatory action of PMA on luciferase expression was dramatically diminished in the cells transfected with a mutant construct in which the Egr-1 binding site in PNMT promoter was mutated. These findings suggest that PMA-stimulated PNMT gene expression requires the enhancement of Egr-1 expression, thus providing further evidence for the physiological role of Egr-1 in the regulation of PNMT gene expression in the adrenergic cell.	STANFORD UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,NANCY PRITZKER LAB DEV & MOLEC NEUROBIOL,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH039437, F32MH010350] Funding Source: NIH RePORTER; NIMH NIH HHS [MH10350, MH39437] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BORDONARO M, 1994, BIOTECHNIQUES, V16, P428; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CARROLL JM, 1991, J MOL NEUROSCI, V3, P75, DOI 10.1007/BF02885528; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COLE AJ, 1990, J NEUROCHEM, V55, P1920, DOI 10.1111/j.1471-4159.1990.tb05777.x; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DAY ML, 1990, J BIOL CHEM, V265, P15253; DEFRANCO C, 1993, MOL ENDOCRINOL, V7, P365, DOI 10.1210/me.7.3.365; DUCHEMIN AM, 1992, MOL ENDOCRINOL, V6, P563, DOI 10.1210/me.6.4.563; EBERT SN, 1994, J BIOL CHEM, V269, P20885; EVINGER MJ, 1992, CELL MOL NEUROBIOL, V12, P193, DOI 10.1007/BF00712926; EVINGER MJ, 1994, J NEUROSCI, V14, P2106; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; HASS R, 1992, BIOCHEM PHARMACOL, V44, P1569, DOI 10.1016/0006-2952(92)90474-W; IWAKI K, 1990, J BIOL CHEM, V265, P13809; JAMIESON GA, 1989, J CELL PHYSIOL, V139, P262, DOI 10.1002/jcp.1041390207; KATAYAMA N, 1993, J NEUROCHEM, V60, P902, DOI 10.1111/j.1471-4159.1993.tb03235.x; KHARBANDA S, 1991, J CLIN INVEST, V88, P571, DOI 10.1172/JCI115341; KIM KT, 1993, J NEUROCHEM, V60, P946, DOI 10.1111/j.1471-4159.1993.tb03241.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LI Y, 1993, J BIOL CHEM, V268, P3563; LIM RW, 1987, ONCOGENE, V1, P263; MILBRANDT J, 1988, SCIENCE, V238, P797; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; MULLER MT, 1987, J VIROL, V61, P858, DOI 10.1128/JVI.61.3.858-865.1987; OUELLETTE AJ, 1990, J CLIN INVEST, V85, P766, DOI 10.1172/JCI114502; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SCHALLING M, 1988, P NATL ACAD SCI USA, V85, P8306, DOI 10.1073/pnas.85.21.8306; STACHOWIAK MK, 1990, BRAIN RES, V510, P277, DOI 10.1016/0006-8993(90)91378-T; STACHOWIAK MK, 1988, MOL BRAIN RES, V3, P275, DOI 10.1016/0169-328X(88)90050-2; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; THOENEN H, 1969, J PHARMACOL EXP THER, V169, P249; THOENEN H, 1970, BIOCHEM PHARMACOL, V19, P669, DOI 10.1016/0006-2952(70)90229-7; THOENEN H, 1969, NATURE, V221, P1264, DOI 10.1038/2211264a0; WAN DC, 1991, MOL BRAIN RES, V9, P103, DOI 10.1016/0169-328X(91)90135-K; WESSEL TC, 1992, MOL BRAIN RES, V15, P349, DOI 10.1016/0169-328X(92)90128-X; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; WONG DL, 1992, DEV BRAIN RES, V67, P229, DOI 10.1016/0165-3806(92)90223-J; WONG DL, 1993, MOL BRAIN RES, V18, P107, DOI 10.1016/0169-328X(93)90178-R; WORLEY PF, 1991, P NATL ACAD SCI USA, V88, P5106, DOI 10.1073/pnas.88.12.5106; WORLEY PF, 1990, PROG BRAIN RES, V86, P277; WURTMAN RJ, 1965, SCIENCE, V150, P1464, DOI 10.1126/science.150.3702.1464; WURTMAN RJ, 1966, J BIOL CHEM, V241, P2301; WURTMAN RJ, 1972, PHARMACOL REV, V24, P411	48	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11161	11167		10.1074/jbc.270.19.11161	http://dx.doi.org/10.1074/jbc.270.19.11161			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744747	hybrid			2022-12-25	WOS:A1995QX86500023
J	GRENTZMANN, G; BRECHEMIERBAEY, D; HEURGUEHAMARD, V; BUCKINGHAM, RH				GRENTZMANN, G; BRECHEMIERBAEY, D; HEURGUEHAMARD, V; BUCKINGHAM, RH			FUNCTION OF POLYPEPTIDE-CHAIN RELEASE FACTOR RF-3 IN ESCHERICHIA-COLI - RF-3 ACTION IN TERMINATION IS PREDOMINANTLY AT UGA-CONTAINING STOP SIGNALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; FACTOR-II; PROTEIN-SYNTHESIS; CODONS; TRANSLATION; SUPPRESSION; MUTATIONS; SEQUENCE; RIBOSOME; CONTEXT	Two protein release factors (RFs) showing codon specificity, RF-1 (UAG, UAA) and RF-2 (UAA, UGA), are required for polypeptide chain termination in Escherichia coli. We recently reported the localization and characterization of the gene encoding RF-3 (prfC), a third protein component previously described as stimulating termination without codon specificity, RF-3 is a GTP-binding protein that displays much sequence similarity to elongation factor EF-G. In a termination assay in vitro, RF-3 lowers the K-m for terminator trinucleotides and is thought to act in termination signal recognition. The gene prfC was identified by transposon insertion mutagenesis leading to enhanced nonsense suppression of UGA. We report here that (i) RF-3 inactivation significantly enhances the suppression of termination in vivo only at UGA-dependent stop signals; (ii) the codon dependent contribution to the stimulation of fMet release in vitro by RF-3 is significantly greater with UGA termination triplet than UAG termination triplet; (iii) RF-3 increases dramatically the affinity of RF-2 to the UGA termination complex in vitro but not that of RF-1 to the UAG termination complex; (iv) RF-3 inactivation leads to a positive feedback on the autoregulation of RF-2 synthesis in vivo, dependent on the competition between frameshifting and termination. These findings are discussed in terms of the mechanism of involvement of RF-3 in translation termination.	INST BIOL PHYSICOCHIM,CNRS,URA 1139,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS)				Buckingham, Richard/0000-0002-8567-4500; HEURGUE-HAMARD, VALERIE/0000-0003-1576-7231				BOSSI L, 1983, J MOL BIOL, V164, P73, DOI 10.1016/0022-2836(83)90088-8; BROWN CM, 1990, NUCLEIC ACIDS RES, V18, P2079, DOI 10.1093/nar/18.8.2079; BUCKINGHAM RH, 1990, RIBOSOME, P541; BUCKINGHAM RH, 1994, BIOCHIMIE, V76, P351, DOI 10.1016/0300-9084(94)90108-2; CAPECCHI MR, 1967, P NATL ACAD SCI USA, V58, P1144, DOI 10.1073/pnas.58.3.1144; CASKEY CT, 1971, P NATL ACAD SCI USA, V68, P3163, DOI 10.1073/pnas.68.12.3163; CASKEY CT, 1977, MOL MECHANISMS PROTE, P443; CASKEY CT, 1971, METHOD ENZYMOL, V20, P367; CONNOLLY DM, 1991, J BACTERIOL, V173, P1711, DOI 10.1128/jb.173.5.1711-1721.1991; CRAIGEN WJ, 1985, P NATL ACAD SCI USA, V82, P3616, DOI 10.1073/pnas.82.11.3616; CURRAN JF, 1988, J MOL BIOL, V203, P75, DOI 10.1016/0022-2836(88)90092-7; GANOZA MC, 1966, COLD SPRING HARB SYM, V31, P273, DOI 10.1101/SQB.1966.031.01.035; GESTELAND RF, 1992, SCIENCE, V257, P1640, DOI 10.1126/science.1529352; GOLDSTEIN J, 1970, Proceedings of the National Academy of Sciences of the United States of America, V65, P430, DOI 10.1073/pnas.65.2.430; GOLDSTEIN JL, 1970, P NATL ACAD SCI USA, V67, P537, DOI 10.1073/pnas.67.2.537; GRENTZMANN G, 1994, P NATL ACAD SCI USA, V91, P5848, DOI 10.1073/pnas.91.13.5848; HIRASHIMA A, 1972, J MOL BIOL, V65, P43, DOI 10.1016/0022-2836(72)90490-1; MARTIN R, 1988, J BACTERIOL, V170, P4714, DOI 10.1128/jb.170.10.4714-4717.1988; MCCAUGHAN KK, 1984, FEBS LETT, V175, P90, DOI 10.1016/0014-5793(84)80576-1; MIKUNI O, 1994, P NATL ACAD SCI USA, V91, P5798, DOI 10.1073/pnas.91.13.5798; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MILLER JH, 1983, J MOL BIOL, V164, P59, DOI 10.1016/0022-2836(83)90087-6; MILMAN G, 1969, P NATL ACAD SCI USA, V63, P183, DOI 10.1073/pnas.63.1.183; MURGOLA EJ, 1985, ANNU REV GENET, V19, P57, DOI 10.1146/annurev.genet.19.1.57; RYOJI M, 1981, P NATL ACAD SCI-BIOL, V78, P5973, DOI 10.1073/pnas.78.10.5973; Sambrook J, 1989, MOL CLONING LABORATO; SCOLNICK E, 1968, P NATL ACAD SCI USA, V61, P768, DOI 10.1073/pnas.61.2.768; SCOLNICK EM, 1969, P NATL ACAD SCI USA, V64, P1235, DOI 10.1073/pnas.64.4.1235; SORENSEN PM, 1990, BIOCHIMIE, V72, P873, DOI 10.1016/0300-9084(90)90005-2; TATE W, 1990, NUCLEIC ACIDS RES, V18, P6537, DOI 10.1093/nar/18.22.6537; TATE WP, 1990, EUR J BIOCHEM, V187, P543, DOI 10.1111/j.1432-1033.1990.tb15335.x; TATE WP, 1992, BIOCHEMISTRY-US, V31, P2443, DOI 10.1021/bi00124a001; TATE WP, 1974, ENZYMES, P87; TATE WP, 1990, RIBOSOMES PROTEIN SY, P81; TUCKER SD, 1989, BIOCHIMIE, V71, P721, DOI 10.1016/0300-9084(89)90088-6	35	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10595	10600		10.1074/jbc.270.18.10595	http://dx.doi.org/10.1074/jbc.270.18.10595			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737996	hybrid			2022-12-25	WOS:A1995QW60100038
J	GROSSMANN, ME; TINDALL, DJ				GROSSMANN, ME; TINDALL, DJ			THE ANDROGEN RECEPTOR IS TRANSCRIPTIONALLY SUPPRESSED BY PROTEINS THAT BIND SINGLE-STRANDED-DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; GENE-EXPRESSION; DOWN-REGULATION; SERTOLI CELLS; CLONING; LNCAP; RNA	The androgen receptor (AR) is a nuclear transcription factor that is essential for development of the male urogenital tract, In the current work, we have characterized the mouse androgen receptor suppressor (mARS). A single, 20-base pair, region (TCCCCCCACCCACCCCCCCT) was sufficient for suppression in chloramphenicol acetyltransferase assays. Northern analysis indicated that translational regulation is not necessary for the suppression. Analysis of the AR mRNA half-life indicated that the mARS does not affect AR RNA degradation, Gel mobility assays showed that the mARS is bound by multiple proteins that can recognize single-stranded DNA and RNA. In addition, differing proteins are expressed in distinct tissues. Purification of some of these proteins has shown that a doublet of 33 and 35 kDa binds to the G-rich strand and that a 52-kDa protein binds to the C-rich strand. Southwestern blots have confirmed that these proteins are indeed recognized by the mARS. The results of these experiments indicate that the AR 5'-untranslated region contains a suppressor element that can be bound by multiple proteins. The mARS appears to be acting either by altering transcription initiation or blocking transcription elongation. Characterization of this suppressor may provide insight into the physiological means by which the AR is regulated.	MAYO CLIN & MAYO FDN,DEPT UROL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P20CA058225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047592] Funding Source: NIH RePORTER; NCI NIH HHS [CA58225] Funding Source: Medline; NICHD NIH HHS [HD09140] Funding Source: Medline; NIDDK NIH HHS [DK47592] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTIOK S, 1994, MOL CELL BIOL, V14, P6004, DOI 10.1128/MCB.14.9.6004; BLOK LJ, 1992, ENDOCRINOLOGY, V131, P1343, DOI 10.1210/en.131.3.1343; BLOK LJ, 1992, MOL CELL ENDOCRINOL, V88, P153, DOI 10.1016/0303-7207(92)90020-7; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; FABER PW, 1991, BIOCHEM J, V278, P269, DOI 10.1042/bj2780269; GROSSMANN ME, 1994, BIOCHEMISTRY-US, V33, P14594, DOI 10.1021/bi00252a027; GROSSMANN ME, 1994, MOL ENDOCRINOL, V8, P448, DOI 10.1210/me.8.4.448; HE WW, 1990, BIOCHEM BIOPH RES CO, V171, P697, DOI 10.1016/0006-291X(90)91202-4; HENTTU P, 1993, CANCER RES, V53, P1051; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; KRONGRAD A, 1991, MOL CELL ENDOCRINOL, V76, P79, DOI 10.1016/0303-7207(91)90262-Q; KUMAR MV, 1994, NUCLEIC ACIDS RES, V22, P3693, DOI 10.1093/nar/22.18.3693; LINDZEY J, 1994, VITAM HORM, V49, P383; LINDZEY J, 1993, MOL ENDOCRINOL, V7, P1530, DOI 10.1210/me.7.12.1530; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MIZOKAMI A, 1994, MOL ENDOCRINOL, V8, P77, DOI 10.1210/me.8.1.77; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P22, DOI 10.1210/mend-4-1-22; Sambrook J, 1989, MOL CLONING LABORATO; SUPAKAR PC, 1993, J BIOL CHEM, V268, P26400; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; WOLF DA, 1993, MOL ENDOCRINOL, V7, P924, DOI 10.1210/me.7.7.924; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	23	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10968	10975		10.1074/jbc.270.18.10968	http://dx.doi.org/10.1074/jbc.270.18.10968			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738038	hybrid			2022-12-25	WOS:A1995QW60100087
J	MARTIN, DW; JESTY, J				MARTIN, DW; JESTY, J			CALCIUM STIMULATION OF PROCOAGULANT ACTIVITY IN HUMAN ERYTHROCYTES - ATP DEPENDENCE AND THE EFFECTS OF MODIFIERS OF STIMULATION AND RECOVERY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; MULTIFUNCTIONAL PROTEIN-KINASE; LIPID ASYMMETRY; PHOSPHOLIPID ASYMMETRY; TRANSBILAYER MOVEMENT; PLASMA-MEMBRANE; AMINOPHOSPHOLIPID TRANSLOCATION; BIOCHEMICAL-CHANGES; PHOSPHATIDYLSERINE; INVOLVEMENT	The human erythrocyte membrane is generally considered to have no procoagulant activity. The normal membrane is characterized as having an asymmetric distribution of phospholipid species such that negatively charged and aminophospholipids are predominantly located on the inner leaflet of the membrane bilayer. Elevation of cytoplasmic Ca2+ in erythrocytes produces an assortment of biochemical and structural responses that include diminished phospholipid asymmetry and an elevation in procoagulant activity. Maintenance of the normal asymmetric distribution of phospholipid species is believed to be largely mediated by a phospholipid translocase mechanism. We have utilized a recently developed single-step kinetic assay of procoagulant activity to investigate the mechanisms of Ca2+ stimulation of procoagulant activity and recovery from the procoagulant state upon removal of Ca2+. This study demonstrated that stimulation of procoagulant activity by elevated cytoplasmic Ca2+ is greatly diminished in ATP-depleted erythrocytes. Phospholipid translocase inhibitors failed to fully inhibit recovery from the procoagulant state after removal of Ca2+. The data indicate that recovery of endogenous lipid from a procoagulant configuration may not be entirely mediated by the phospholipid translocase. Additionally, the data are inconsistent with the phospholipid translocase mediating the Ca2+-induced elevation of procoagulant activity, although the involvement of other protein(s) is indicated.			MARTIN, DW (corresponding author), SUNY STONY BROOK, DEPT MED, DIV HEMATOL, STONY BROOK, NY 11794 USA.				NHLBI NIH HHS [HL-45955] Funding Source: Medline; NIDDK NIH HHS [DK-19185] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045955] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019185] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLAN D, 1981, BIOCHEM J, V198, P433, DOI 10.1042/bj1980433; ALLAN D, 1981, BIOCHEM J, V198, P441, DOI 10.1042/bj1980441; ALLEN DW, 1979, BIOCHIM BIOPHYS ACTA, V551, P1, DOI 10.1016/0005-2736(79)90348-1; ANDERSON DR, 1977, J BIOL CHEM, V252, P6617; BITBOL M, 1987, BIOCHIM BIOPHYS ACTA, V904, P268, DOI 10.1016/0005-2736(87)90376-2; BITBOL M, 1988, P NATL ACAD SCI USA, V85, P6783, DOI 10.1073/pnas.85.18.6783; Brown A., 1982, ATP ATPASE DETERMINA, P223; CARSON SD, 1985, COMPUT PROG BIOMED, V19, P151, DOI 10.1016/0010-468X(85)90006-6; CHANDRA R, 1987, BIOCHIM BIOPHYS ACTA, V902, P253, DOI 10.1016/0005-2736(87)90303-8; COHEN CM, 1986, J BIOL CHEM, V261, P7701; COHEN P, 1990, ADV SEC MESS PHOSPH, V24, P230; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; CONNOR J, 1990, BIOCHIM BIOPHYS ACTA, V1025, P82, DOI 10.1016/0005-2736(90)90193-R; CONNOR J, 1992, J BIOL CHEM, V267, P19412; CONNOR J, 1987, BIOCHEMISTRY-US, V26, P5099, DOI 10.1021/bi00390a031; CONNOR J, 1991, BIOCHIM BIOPHYS ACTA, V1066, P37, DOI 10.1016/0005-2736(91)90247-6; CONNOR J, 1990, BIOCHEMISTRY-US, V29, P37, DOI 10.1021/bi00453a005; DALEKE DL, 1985, BIOCHEMISTRY-US, V24, P5406, DOI 10.1021/bi00341a019; DEVAUX PF, 1992, ANNU REV BIOPH BIOM, V21, P417, DOI 10.1146/annurev.bb.21.060192.002221; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; DODSON RA, 1987, BLOOD CELLS, V12, P555; FERRELL JE, 1984, J CELL BIOL, V98, P1992, DOI 10.1083/jcb.98.6.1992; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P653, DOI 10.1016/0006-3002(58)90124-0; GASCARD P, 1989, BIOCHEM J, V264, P547, DOI 10.1042/bj2640547; GORDESKY SE, 1973, BIOCHEM BIOPH RES CO, V50, P1027, DOI 10.1016/0006-291X(73)91509-X; HAEST CWM, 1978, BIOCHIM BIOPHYS ACTA, V509, P21, DOI 10.1016/0005-2736(78)90004-4; HANSELEIT U, 1990, BIOCHIM BIOPHYS ACTA, V1029, P127; Jesty J, 1976, Methods Enzymol, V45, P95; KAHLENBERG A, 1992, CAN J BIOCHEM, V52, P803; LEW VL, 1978, CURR TOP MEMBR TRANS, V10, P217; LORAND L, 1983, J BIOL CHEM, V258, P5300; MIDDELKOOP E, 1989, BIOCHIM BIOPHYS ACTA, V981, P151, DOI 10.1016/0005-2736(89)90093-X; MORRISON SA, 1984, BLOOD, V63, P1338; MORROT G, 1989, BIOCHEMISTRY-US, V28, P3456, DOI 10.1021/bi00434a046; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; PONNAPPA BC, 1980, BIOCHIM BIOPHYS ACTA, V598, P494, DOI 10.1016/0005-2736(80)90030-9; SCHICK PK, 1976, J CLIN INVEST, V57, P1221, DOI 10.1172/JCI108390; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SULPICE JC, 1994, J BIOL CHEM, V269, P6347; TAKAI Y, 1979, J BIOCHEM-TOKYO, V86, P575, DOI 10.1093/oxfordjournals.jbchem.a132557; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TANAKA Y, 1983, J BIOL CHEM, V258, P1335; VERHOVEN B, 1992, BIOCHIM BIOPHYS ACTA, V1104, P15, DOI 10.1016/0005-2736(92)90126-7; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; ZACHOWSKI A, 1986, BIOCHEMISTRY-US, V25, P2585, DOI 10.1021/bi00357a046; ZWAAL RFA, 1975, BIOCHIM BIOPHYS ACTA, V406, P83, DOI 10.1016/0005-2736(75)90044-9	47	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10468	10474		10.1074/jbc.270.18.10468	http://dx.doi.org/10.1074/jbc.270.18.10468			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737981	hybrid			2022-12-25	WOS:A1995QW60100019
J	MUELLER, SG; SCHRAW, WP; RICHMOND, A				MUELLER, SG; SCHRAW, WP; RICHMOND, A			ACTIVATION OF PROTEIN-KINASE-C ENHANCES THE PHOSPHORYLATION OF THE TYPE-B INTERLEUKIN-8 RECEPTOR AND STIMULATES ITS DEGRADATION IN NONHEMATOPOIETIC CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR; HUMAN NEUTROPHILS; PHORBOL ESTER; MOLECULAR CHARACTERIZATION; FUNCTIONAL EXPRESSION; ADRENERGIC-RECEPTOR; PLASMODIUM-VIVAX; U937 CELL; DESENSITIZATION; CLONING	We have previously characterized the stably transfected, clonally selected human placental cell line, 3ASubE P-3, which overexpresses the type B interleukin-8 receptor (IL-8RB) and responds to the chemokine melanoma growth stimulatory activity (MGSA) with enhanced phosphorylation of this receptor, In work described here, we demonstrate that the MGSA enhanced phosphorylation of this receptor is mediated via a process involving pertussis toxin-sensitive G proteins, Furthermore, treatment of the 3ASubE P-3 cells with either 12-O-tetradecanoylphorbol 13-acetate (TPA) or 1,2-dioctanoyl-sn-glycerol (diC(8)), two different activators of protein kinase C (PKC), results in a concentration-dependent increase in the phosphorylation of the IL-8RB. Inhibition of PKC, by treatment with staurosporin (50 mM for 2 h), or down-regulation of PKC, by prolonged treatment with TPA (400 nM for 40 h) suppresses the TPA-enhanced receptor phosphorylation, but has no effect on the MGSA enhanced receptor phosphorylation, These data suggest that the isoforms of PKC that are sensitive to these manipulations may not play a role in mediating the MGSA-enhanced phosphorylation of the IL-8RB. TPA treatment also results in a time-dependent decrease in I-125-MGSA binding to the 3ASubE P-3 cells, A 30-min treatment with 400 nM TPA results in approximately a 50% decrease in binding, whereas a 2-h treatment essentially eliminates specific binding of I-125-MGSA to these cells, The TPA-induced decrease in I-125-MGSA binding is accompanied by enhanced degradation of the IL-8RB, as indicated by Western blot analysis and pulse-chase experiments, suggesting a potential role for PKC as a negative regulator of the IL-8RB, MGSA treatment (50 nM for 2 h) also stimulates receptor degradation in the 3ASubE P-3 cells, indicating that this receptor is down-regulated in response to prolonged exposure to its ligand, In similar studies conducted on the promonocytic cell line, U937, MGSA treatment of the U937 cells resulted in receptor phosphorylation, whereas PKC activation failed to significantly modulate the phosphorylation state of the IL-8RB, Treatment of the U937 cells with MGSA, TPA, or diC(8) resulted in a loss of receptor protein present in these cell types. These data imply that MGSA signaling through the IL 8RB is similar in both the non hematopoietic and hematopoietic cell types, whereas activation of PKC by TPA or diC(8) elicits different responses in these two distinct cell types.	VANDERBILT UNIV, SCH MED, DEPT MED DERMATOL, NASHVILLE, TN 37232 USA; DEPT VET AFFAIRS MED CTR, NASHVILLE, TN 37232 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	MUELLER, SG (corresponding author), VANDERBILT UNIV, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA.		Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X	NCI NIH HHS [CA 34590] Funding Source: Medline; PHS HHS [1 P30 A41943-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA034590, R01CA034590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACON KB, 1990, BIOCHEM BIOPH RES CO, V169, P1099, DOI 10.1016/0006-291X(90)92008-N; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BOZIC CR, 1994, J BIOL CHEM, V269, P29355; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; CERRETTI DP, 1993, GENOMICS, V18, P410, DOI 10.1006/geno.1993.1486; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHAUDHURI A, 1993, P NATL ACAD SCI USA, V90, P10793, DOI 10.1073/pnas.90.22.10793; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EBELING JG, 1985, P NATL ACAD SCI USA, V82, P815, DOI 10.1073/pnas.82.3.815; HARADA A, 1994, GENE, V142, P297, DOI 10.1016/0378-1119(94)90278-X; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HEPLER JR, 1988, J BIOL CHEM, V263, P7610; HOHMANN HP, 1992, J BIOL CHEM, V267, P2065; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1993, BIOCHEMISTRY-US, V32, P5733, DOI 10.1021/bi00073a002; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; JUNG TM, 1990, J IMMUNOL, V144, P3130; KELLEHER DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4316, DOI 10.1073/pnas.81.14.4316; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KUPPER RW, 1992, BIOCHEM J, V282, P429, DOI 10.1042/bj2820429; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE J, 1992, J BIOL CHEM, V267, P16283; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; MICHEL G, 1992, FEBS LETT, V305, P241, DOI 10.1016/0014-5793(92)80677-9; MORO O, 1994, J BIOL CHEM, V269, P6651; MOSER B, 1991, J BIOL CHEM, V266, P10666; MOSER B, 1993, BIOCHEM J, V294, P285, DOI 10.1042/bj2940285; MUELLER SG, 1994, J BIOL CHEM, V269, P1973; Mukaida N, 1992, Cytokines, V4, P41; MULLBERG J, 1992, BIOCHEM BIOPH RES CO, V189, P794, DOI 10.1016/0006-291X(92)92272-Y; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; RICHMOND A, 1986, J CELL PHYSIOL, V129, P375, DOI 10.1002/jcp.1041290316; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; SCHONDORF M, 1993, BIOCHEM BIOPH RES CO, V197, P549, DOI 10.1006/bbrc.1993.2514; SMITH RJ, 1992, J LEUKOCYTE BIOL, V52, P17, DOI 10.1002/jlb.52.1.17; STRASSHEIM D, 1994, J BIOL CHEM, V269, P14307; STRIETER RM, 1992, AM J PATHOL, V141, P1279; STURANI E, 1986, BIOCHEM BIOPH RES CO, V137, P343, DOI 10.1016/0006-291X(86)91216-7; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TUSCHIL A, 1992, J INVEST DERMATOL, V99, P294, DOI 10.1111/1523-1747.ep12616634; UNEMORI EN, 1993, J BIOL CHEM, V268, P1338; WALZ A, 1991, J LEUKOCYTE BIOL, V50, P279, DOI 10.1002/jlb.50.3.279; WAYS DK, 1987, CANCER RES, V47, P3344; WILKINSON SE, 1994, TRENDS PHARMACOL SCI, V15, P53, DOI 10.1016/0165-6147(94)90110-4; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	54	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10439	10448		10.1074/jbc.270.18.10439	http://dx.doi.org/10.1074/jbc.270.18.10439			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737978	hybrid			2022-12-25	WOS:A1995QW60100016
J	SOLDATOV, NM; BOURON, A; REUTER, H				SOLDATOV, NM; BOURON, A; REUTER, H			DIFFERENT VOLTAGE-DEPENDENT INHIBITION BY DIHYDROPYRIDINES OF HUMAN CA2+ CHANNEL SPLICE VARIANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CHANNEL; FUNCTIONAL EXPRESSION; MOLECULAR DIVERSITY; ALPHA-1 SUBUNIT; NITRENDIPINE; TRANSCRIPTS; BRAIN; HEART; SITE; DNA	Voltage-dependent inhibition by 1,4-dihydropyridines is a characteristic property of L-type Ca2+ channels. Six out of 50 exons of the channel alpha(1C) subunit gene are subjected to alternative splicing, thus generating channel isoform diversity. Using Xenopus oocytes as an expression system, we have found that transmembrane segment IIIS2 of human alpha(1C) subunit is involved in the control of voltage dependence of dihydropyridine action. This segment is genetically regulated through alternative splicing of exons 21/22. Site-directed mutagenesis points to two amino acids in IIIS2, which determine the difference of the splice variants in their sensitivities to dihydropyridines. This finding provides new insight into molecular mechanisms of Ca2+ channel inhibition by this important class of drugs.	UNIV BERN,DEPT PHARMACOL,CH-3010 BERN,SWITZERLAND	University of Bern				Bouron, Alexandre/0000-0003-4471-7727				BEAN BP, 1984, P NATL ACAD SCI-BIOL, V81, P6388, DOI 10.1073/pnas.81.20.6388; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; CATTERALL WA, 1986, TRENDS NEUROSCI, V9, P7, DOI 10.1016/0166-2236(86)90004-4; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CATTERALL WA, 1991, SCIENCE, V253, P1499, DOI 10.1126/science.1654596; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIEBOLD RJ, 1992, P NATL ACAD SCI USA, V89, P1497, DOI 10.1073/pnas.89.4.1497; Janis RA, 1987, ADV DRUG RES, V16, P309; KOKUBUN S, 1986, MOL PHARMACOL, V30, P571; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; REGULLA S, 1991, EMBO J, V10, P45, DOI 10.1002/j.1460-2075.1991.tb07919.x; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; SCHUURMAN R, 1991, BIOTECHNIQUES, V10, P185; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOLDATOV NM, 1992, P NATL ACAD SCI USA, V89, P4628, DOI 10.1073/pnas.89.10.4628; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; WELLING A, 1993, CIRC RES, V73, P974, DOI 10.1161/01.RES.73.5.974	24	105	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10540	10543		10.1074/jbc.270.18.10540	http://dx.doi.org/10.1074/jbc.270.18.10540			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737988	hybrid			2022-12-25	WOS:A1995QW60100029
J	SPENCER, MJ; CROALL, DE; TIDBALL, JG				SPENCER, MJ; CROALL, DE; TIDBALL, JG			CALPAINS ARE ACTIVATED IN NECROTIC FIBERS FROM MDX DYSTROPHIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; CALCIUM-DEPENDENT PROTEASE; MUSCLE-SPECIFIC CALPAIN; NEUTRAL PROTEASE; SKELETAL-MUSCLE; CA-2+-DEPENDENT PROTEASE; INTRACELLULAR CALCIUM; LIMITED AUTOLYSIS; ALPHA-ACTININ; MU-CALPAIN	Death of dystrophin-deficient muscle purportedly re suits from increases in [Ca](in) that cause the activation of calpains. We have tested whether calpains play a role in this process by assaying for changes in calpain concentration and activation in peak necrotic mdx mice (4 weeks of age) and in completely regenerated mdx mice (14 weeks of age). Biochemical fractionation and immunoblotting with epitope-specific antisera allowed measurement of the concentrations of m- and mu-calpains and the extent of autoproteolytic modification. Our findings show that total calpain concentration is elevated in both 4-week and 14-week mdx mice. This increase in concentration was shown to result primarily from a significant increase in m-calpain concentration at 4 weeks. Northern analysis demonstrated that neither m- nor mu-calpain mRNA concentrations differed between mdx and controls suggesting that the increased calpain concentration results from post-translational regulation. Immunoblotting with antibodies directed against amino-terminal peptides revealed an increase in autoproteolysis of mu-calpain, indicative of increased activation. The extent of autoproteolysis of mu-calpain returns to control levels during regeneration. This is not a consequence of increased calpastatin mRNA or protein. The findings reported here support a role for calpains in both the degenerative and regenerative aspects of mdx dystrophy.	UNIV CALIF LOS ANGELES,JERRY LEWIS NEUROMUSCULAR RES CTR,LOS ANGELES,CA 90095; UNIV MAINE,DEPT BIOCHEM,ORONO,ME 04469	University of California System; University of California Los Angeles; University of Maine System; University of Maine Orono	SPENCER, MJ (corresponding author), UNIV CALIF LOS ANGELES,DEPT PHYSIOL SCI,LOS ANGELES,CA 90095, USA.		Tidball, James/H-7970-2012	Tidball, James/0000-0003-1202-8038	NIA NIH HHS [AG-40343] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JE, 1988, J MUSCLE RES CELL M, V9, P499, DOI 10.1007/BF01738755; ASHMORE CR, 1986, EXP NEUROL, V94, P585, DOI 10.1016/0014-4886(86)90239-6; BAKKER AJ, 1993, J PHYSIOL-LONDON, V460, P1; BECKERLE MC, 1986, J CELL BIOCHEM, V30, P259, DOI 10.1002/jcb.240300307; BERTORINI TE, 1988, NEUROLOGY, V38, P609, DOI 10.1212/WNL.38.4.609; BODENSTEINER JB, 1978, NEUROLOGY, V28, P439, DOI 10.1212/WNL.28.5.439; BROWN N, 1993, FEBS LETT, V322, P65, DOI 10.1016/0014-5793(93)81112-D; BULLARD B, 1990, J MUSCLE RES CELL M, V11, P271, DOI 10.1007/BF01843580; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUSCH WA, 1972, J CELL BIOL, V52, P367, DOI 10.1083/jcb.52.2.367; CARNWATH JW, 1987, J NEUROL SCI, V80, P39, DOI 10.1016/0022-510X(87)90219-X; CARPENTER S, 1979, BRAIN, V102, P147, DOI 10.1093/brain/102.1.147; CONG JY, 1989, J BIOL CHEM, V264, P10096; CONG JY, 1993, J BIOL CHEM, V268, P25740; COOLICAN SA, 1984, J BIOL CHEM, V259, P1627; COTTIN P, 1991, BIOCHIM BIOPHYS ACTA, V1079, P139, DOI 10.1016/0167-4838(91)90118-J; CROALL DE, 1989, BIOCHEMISTRY-US, V28, P6882, DOI 10.1021/bi00443a016; CROALL DE, 1992, BIOCHIM BIOPHYS ACTA, V1121, P47, DOI 10.1016/0167-4838(92)90335-B; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; CROALL DE, 1990, INTRACELLULAR CALCIU, P103; CULLEN MJ, 1975, J NEUROL SCI, V24, P179, DOI 10.1016/0022-510X(75)90232-4; CULLEN MJ, 1988, ACTA NEUROPATHOL, V77, P69, DOI 10.1007/BF00688245; DIMARIO JX, 1991, DEV BIOL, V148, P314, DOI 10.1016/0012-1606(91)90340-9; DUNN JF, 1991, J NEUROL SCI, V103, P226, DOI 10.1016/0022-510X(91)90168-7; FOX JEB, 1987, BLOOD, V69, P537; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; FURUNO K, 1986, BIOCHEM J, V237, P859, DOI 10.1042/bj2370859; GLESBY MJ, 1988, MUSCLE NERVE, V11, P852, DOI 10.1002/mus.880110809; GOLL DE, 1991, J BIOL CHEM, V266, P8501; HATHAWAY DR, 1982, J BIOL CHEM, V257, P9072; IMAJOH S, 1986, J BIOCHEM-TOKYO, V100, P633, DOI 10.1093/oxfordjournals.jbchem.a121755; JACKSON MJ, 1985, CLIN CHIM ACTA, V147, P215, DOI 10.1016/0009-8981(85)90202-5; JOHNSON P, 1988, INT J BIOCHEM, V20, P1227, DOI 10.1016/0020-711X(88)90223-6; KAR NC, 1976, CLIN CHIM ACTA, V73, P293, DOI 10.1016/0009-8981(76)90175-3; KAY J, 1981, ACTA BIOL MED GER, V40, P1323; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WJ, 1992, BIOCHIM BIOPHYS ACTA, V1129, P251, DOI 10.1016/0167-4781(92)90500-Y; LLADOS FT, 1985, EXPERIENTIA, V76, P121; MARSHALL PA, 1989, MUSCLE NERVE, V12, P528, DOI 10.1002/mus.880120703; MAUNDER-SEWRY C A, 1979, Journal of the Neurological Sciences, V42, P337, DOI 10.1016/0022-510X(79)90167-9; MOENS P, 1993, J MUSCLE RES CELL M, V14, P446, DOI 10.1007/BF00121296; MONGINI T, 1988, NEUROLOGY, V38, P476, DOI 10.1212/WNL.38.3.476; MORANDI L, 1990, ANN NEUROL, V28, P674, DOI 10.1002/ana.410280512; OHNO S, 1987, METHOD ENZYMOL, V139, P363; RABBANI N, 1987, BIOCHEM MED METAB B, V37, P282, DOI 10.1016/0885-4505(87)90038-7; REDDY MK, 1975, J BIOL CHEM, V250, P4278; REDDY PA, 1986, CLIN CHIM ACTA, V160, P281, DOI 10.1016/0009-8981(86)90195-6; REEDY MK, 1981, J MUSCLE RES CELL M, V2, P45, DOI 10.1007/BF00712061; SAIDO TC, 1994, FEBS LETT, V346, P263, DOI 10.1016/0014-5793(94)00487-0; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; Sambrook J, 1989, MOL CLONING LABORATO; SAMIS JA, 1991, BIOCHEM J, V276, P293, DOI 10.1042/bj2760293; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; SORIMACHI H, 1992, BIOCHIM BIOPHYS ACTA, V1160, P55, DOI 10.1016/0167-4838(92)90037-E; SPENCER MJ, 1992, EXP CELL RES, V203, P107, DOI 10.1016/0014-4827(92)90045-A; Takahashi K, 1990, INTRACELLULAR CALCIU, P55; TURNER PR, 1993, J MEMBRANE BIOL, V133, P243; VERHALLEN PFJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P206, DOI 10.1016/0005-2736(87)90170-2; ZEMAN RJ, 1985, J BIOL CHEM, V260, P3619	61	172	172	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10909	10914		10.1074/jbc.270.18.10909	http://dx.doi.org/10.1074/jbc.270.18.10909			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738032	hybrid			2022-12-25	WOS:A1995QW60100080
J	VERNET, T; BERTI, PJ; DEMONTIGNY, C; MUSIL, R; TESSIER, DC; MENARD, R; MAGNY, MC; STORER, AC; THOMAS, DY				VERNET, T; BERTI, PJ; DEMONTIGNY, C; MUSIL, R; TESSIER, DC; MENARD, R; MAGNY, MC; STORER, AC; THOMAS, DY			PROCESSING OF THE PAPAIN PRECURSOR - THE IONIZATION STATE OF A CONSERVED AMINO-ACID MOTIF WITHIN THE PRO REGION PARTICIPATES IN THE REGULATION OF INTRAMOLECULAR PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL PAPAIN PRECURSOR; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PROTEOLYTIC-ENZYMES; CATHEPSIN-B; PROTEASE; YEAST; EXPRESSION; PROTEINASE; INHIBITION	The cysteine protease papain is synthesized as a 40-kDa inactive precursor with a 107-amino-acid N-terminal pro region. Although sequence conservation in the pro region is lower than in the mature proteases, a conserved motif (Gly-Xaa-Asn-Xaa-Phe-Xaa-Asp(-36), papain precursor numbering) was found within the pro region of cysteine proteases of the papain superfamily. To determinate the function to this conserved motif, we have mutagenized at random each of the 4 residues individually within the pro region of the papain precursor. Precursor mutants were expressed in yeast, screened according to their ability to be processed through either a cis or trans reaction, into mature active papain. Three classes of mutants were found. Non-functional propapain mutants of the first class are completely degraded by subtilisin indicating that they are not folded into a native state. Mutants of the second class were neutral with respect to cis and trans processing. The third class included mutants that mostly accumulated as mature papain in the yeast vacuole. They had mutations that had lost the negatively charged Asp(-36) residues and a mutation that probably introduces a positive charge, Phe(-38)His. The precursor of the Phe(-38)His mutant could be recovered by expression in a vph1 mutant yeast strain which has a vacuolar pH of about 7. The Phe(-38)His propapain mutant has an optimum pH of autoactivation about one pH unit higher than the wild type molecule. These results indicate that the electrostatic status of the conserved motif participates in the control of intramolecular processing of the papain precursor.	NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MONTREAL, PQ H4P 2R2, CANADA	National Research Council Canada			Vernet, Thierry/G-1118-2012; Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				ALJANABI J, 1972, J BIOL CHEM, V247, P4628; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; Baker E.N., 1987, BIOL MACROMOL, V3, P314; BERTI PJ, 1994, BIOCHEM J, V302, P411, DOI 10.1042/bj3020411; Brocklehurst K., 1987, HYDROLYTIC ENZYMES, P39; BROMME D, 1993, J BIOL CHEM, V268, P4832; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHANG SC, 1994, J BIOL CHEM, V269, P3548; COLL M, 1991, EMBO J, V10, P1; COONER GE, 1992, BIOCHEMISTRY-US, V31, P1142; Davis R W, 1980, Methods Enzymol, V65, P404; DENIZOT F, 1989, EUR J IMMUNOL, V19, P631, DOI 10.1002/eji.1830190409; DESMAZEAUD MJ, 1972, BIOCHIMIE, V54, P1109, DOI 10.1016/S0300-9084(72)80014-2; FABRE E, 1992, J BIOL CHEM, V267, P15049; FABRE E, 1991, J BIOL CHEM, V266, P3782; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; FUKUDA R, 1994, J BIOL CHEM, V269, P9551; FUSEK M, 1991, FEBS LETT, V287, P160, DOI 10.1016/0014-5793(91)80040-A; GERMAIN D, 1992, FEBS LETT, V299, P283, DOI 10.1016/0014-5793(92)80132-Z; HANADA K, 1978, AGR BIOL CHEM TOKYO, V42, P537, DOI 10.1080/00021369.1978.10863016; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHANSEN JT, 1968, CR TRAV LAB CARLSB, V36, P265; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KASSELL B, 1973, SCIENCE, V180, P1022, DOI 10.1126/science.180.4090.1022; KEPPLER D, 1988, CANCER RES, V48, P6855; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOGA H, 1990, J BIOCHEM-TOKYO, V108, P976, DOI 10.1093/oxfordjournals.jbchem.a123324; Kunitz M, 1936, J GEN PHYSIOL, V19, P991, DOI 10.1085/jgp.19.6.991; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACH L, 1994, J BIOL CHEM, V269, P13030; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; MCINTYRE GF, 1994, J BIOL CHEM, V269, P567; MELCHIORI A, 1992, CANCER RES, V52, P2353; MENARD R, 1991, BIOCHEMISTRY-US, V30, P8924, DOI 10.1021/bi00101a002; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANSEGUNDO B, 1982, BIOCHIM BIOPHYS ACTA, V707, P74, DOI 10.1016/0167-4838(82)90398-3; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; VANDENHAZEL HB, 1992, EUR J BIOCHEM, V207, P277; VERNET T, 1991, J BIOL CHEM, V266, P21451; VERNET T, 1990, J BIOL CHEM, V265, P16661; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; VERNET T, 1993, PROTEIN ENG, V6, P213, DOI 10.1093/protein/6.2.213; VERNET T, 1989, GENE, V77, P229, DOI 10.1016/0378-1119(89)90071-1; WETMORE DR, 1992, MOL MICROBIOL, V6, P1593, DOI 10.1111/j.1365-2958.1992.tb00884.x; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; WOOLFORD CA, 1993, J BIOL CHEM, V268, P8990; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	58	137	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10838	10846		10.1074/jbc.270.18.10838	http://dx.doi.org/10.1074/jbc.270.18.10838			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738022	hybrid			2022-12-25	WOS:A1995QW60100070
J	MARQUETTE, KA; PITTMAN, DD; KAUFMAN, RJ				MARQUETTE, KA; PITTMAN, DD; KAUFMAN, RJ			A 110-AMINO ACID REGION WITHIN THE A1-DOMAIN OF COAGULATION-FACTOR-VIII INHIBITS SECRETION FROM MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; GLUCOSE-REGULATED PROTEINS; HAMSTER OVARY CELLS; HUMAN FACTOR-V; BINDING-PROTEIN; MESSENGER-RNA; HUMAN-LIVER; CDNA; CERULOPLASMIN; CLONING	Factor VIII is the coagulation factor deficient in the X-chromosome linked bleeding disorder hemophilia A. Factor VIII is homologous to blood coagulation factor V, both having a domain structure of A1-A2-B-A3-C1-C2. Previous transfection studies demonstrated that factor VIII is 10-fold less efficiently expressed than the homologous coagulation factor, factor V, The inefficient expression correlated with interaction of the factor VIII primary translation product with the protein chaperonin BiP in the lumen of the endoplasmic reticulum, In contrast, factor V was not detected in association with BiP and was secreted efficiently, To determine whether specific amino acid sequences within factor VIII inhibit secretion, we have studied the secretion of factor VIII deletion and factor VIII/factor V chimeric proteins upon transient transfection of COS-1 monkey cells, A chimeric factor VIII protein that contained the A1- and A2-domains of factor V was secreted with a similar efficiency as wild-type factor V, whereas the complementary chimera having the A1- and A2-domains of factor VIII was secreted with low efficiency, similar to wild-type factor WI, These results suggested that sequences within the A1- and A2-domains were responsible for the low secretion efficiency of factor VIII, Secretion of A1-domain deleted factor VIII was increased approximately 10-fold compared to wild-type factor VIII or A2-domain-deleted factor VIII, Expression of the factor VIII Al-domain alone did not yield secreted protein, whereas expression of the factor VIII A2-domain alone or the factor V A1-domain or A2-domain alone directed synthesis of secreted protein,. Secretion of a hybrid in which the carboxyl-terminal 110 amino acids of the A1-domain were replaced by homologous sequences from the factor V A1-domain was also increased 10-fold compared to wild type factor VIII, however, the secreted protein was not functional and the heavy and fight chains were not associated. These results localize a 1l0-amino acid region within the Al domain that inhibits factor VIII secretion, This region is clustered with multiple short peptide se sequences that have potential to bind BiP,	HOWARD HUGHES MED INST, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, MED CTR, DEPT BIOL CHEM, ANN ARBOR, MI 48105 USA; GENET INST INC, CAMBRIDGE, MA 02140 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053777] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53777] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BONNEROT C, 1994, EMBO J, V13, P934, DOI 10.1002/j.1460-2075.1994.tb06338.x; BURKE RL, 1986, J BIOL CHEM, V261, P2574; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRIPE LD, 1992, BIOCHEMISTRY-US, V31, P3777, DOI 10.1021/bi00130a007; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HAAS IG, 1991, CURR TOP MICROBIOL, V167, P71; HELLSTERN P, 1986, THROMB HAEMOSTASIS, V56, P353; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; Kaufman Randal J., 1992, Transfusion Medicine Reviews, V6, P235, DOI 10.1016/S0887-7963(92)70174-6; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KELLY DA, 1984, BRIT J HAEMATOL, V56, P535, DOI 10.1111/j.1365-2141.1984.tb02178.x; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEWIS JH, 1985, NEW ENGL J MED, V312, P1189; LYNCH CM, 1993, HUM GENE THER, V4, P259, DOI 10.1089/hum.1993.4.3-259; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; PAN Y, 1994, BLOOD, V84, pA62; PITTMAN DD, 1994, BLOOD, V84, P4214, DOI 10.1182/blood.V84.12.4214.bloodjournal84124214; PITTMAN DD, 1992, BLOOD, V79, P389; PITTMAN DD, 1994, J BIOL CHEM, V269, P17329; PITTMAN DD, 1993, METHOD ENZYMOL, V222, P236; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; RICHARDSON JS, 1976, J MOL BIOL, V102, P221, DOI 10.1016/S0022-2836(76)80050-2; ROSENBERG HF, 1993, J BIOL CHEM, V268, P4499; RYDEN L, 1988, OXIDASES RELATED RED, P349; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P390, DOI 10.1073/pnas.81.2.390; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WION KL, 1985, NATURE, V317, P726, DOI 10.1038/317726a0; ZELECHOWSKA MG, 1985, NATURE, V317, P729, DOI 10.1038/317729a0	49	52	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10297	10303		10.1074/jbc.270.17.10297	http://dx.doi.org/10.1074/jbc.270.17.10297			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730335	hybrid			2022-12-25	WOS:A1995QV41700084
J	MCNEILL, RB; COLBRAN, RJ				MCNEILL, RB; COLBRAN, RJ			INTERACTION OF AUTOPHOSPHORYLATED CA2+ CALMODULIN-DEPENDENT PROTEIN-KINASE-II WITH NEURONAL CYTOSKELETAL PROTEINS - CHARACTERIZATION OF BINDING TO A 190-KDA POSTSYNAPTIC DENSITY PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; RABBIT SKELETAL-MUSCLE; HIGH-AFFINITY BINDING; RAT-BRAIN; CA-2+ CALMODULIN; REGULATORY SUBUNIT; MOLECULAR-CLONING; CA-2+-INDEPENDENT ACTIVITY; DENDRITIC SPINES; MUTANT MICE	Subcellular localization of Ca2+/calmodulin-dependent protein kinase II: (CaMKII) by interaction with specific anchoring proteins may be an important mechanism contributing to the regulation of CaMKII. Proteins capable of binding CaMKII were identified by the use of a gel overlay assay with recombinant mouse CaMKII alpha (mCaMKII alpha or Xenopus CaMKII beta (xCaMKII beta) P-32-auto-phosphorylated at Thr(286/287) as a probe. Numerous [P-32]CaMKII-binding proteins were identified in various whole rat tissue extracts, but binding was most prominent to forebrain proteins of 190 kDa (p190) and 140 kDa (p140), Fractionation of forebrain extracts localized p190 and p140 to a crude particulate/cytoskeletal fraction and isolated postsynaptic densities. [P-32]mCaMKII alpha-bound to p190 with an apparent K-d of 609 nM (subunit concentration) and a B-max of 7.0 pmol of mCaMKII alpha subunit bound per mg of P2 protein, as measured using the overlay assay. Binding of 100 nM [P-32]mCaMKII alpha to p190 was competed by nonradioactive mCaMKII alpha autophosphorylated on Thr(286) (EC(50%) = 200 nM), but to a much lesser extent by nonradioactive mCaMKII alpha autophosphorylated on Thr(306) (EC(50%) > 2000 nM). In addition, nonphosphorylated mCaMKII alpha was a poor competitor for [P-32]mCaMKII alpha binding to p190. The competition data indicate that Ca2+/CaM-dependent autophosphorylation at Thr(286) promotes binding to p190, whereas, Ca2+/CaM-independent autophosphorylation at Thr(306) does not enhance binding. Therefore, CaMKII may become localized to postsynaptic densities by p190 following its activation by an increase of dendritic Ca2+ concentration.	VANDERBILT UNIV, SCH MED, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	Vanderbilt University			Colbran, Roger/AAU-7708-2021	Colbran, Roger/0000-0001-7401-8244	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047973] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32DK07563-07] Funding Source: Medline; NIGMS NIH HHS [GM 47973] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CARR DW, 1992, J BIOL CHEM, V267, P13376; CHEN C, 1994, SCIENCE, V266, P291, DOI 10.1126/science.7939668; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Cohen P., 1988, MOL ASPECTS CELL REG, V5; COLBRAN RJ, 1992, NEUROCHEM INT, V21, P469, DOI 10.1016/0197-0186(92)90080-B; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; CORREIA JJ, 1987, J BIOL CHEM, V262, P17278; EDMAN CF, 1994, BBA-MOL CELL RES, V1221, P89, DOI 10.1016/0167-4889(94)90221-6; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; GOLDENRING JR, 1984, J NEUROCHEM, V42, P1077, DOI 10.1111/j.1471-4159.1984.tb12713.x; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; ITO I, 1991, NEUROSCI LETT, V121, P119, DOI 10.1016/0304-3940(91)90663-E; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KERYER G, 1993, P NATL ACAD SCI USA, V90, P5418, DOI 10.1073/pnas.90.12.5418; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LEISER M, 1986, J BIOL CHEM, V261, P1904; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LOU LL, 1989, J NEUROSCI, V9, P2020; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MAYER P, 1993, FEBS LETT, V333, P315, DOI 10.1016/0014-5793(93)80678-N; MAYER P, 1994, BIOCHEM J, V298, P757, DOI 10.1042/bj2980757; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MUKHERJI S, 1994, J BIOL CHEM, V269, P20733; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; OHTA Y, 1986, FEBS LETT, V208, P423, DOI 10.1016/0014-5793(86)81061-4; OUIMET CC, 1984, P NATL ACAD SCI-BIOL, V81, P5604, DOI 10.1073/pnas.81.17.5604; PATTON BL, 1990, J BIOL CHEM, V265, P11204; RANNELS SR, 1983, METHOD ENZYMOL, V99, P55; RICH DP, 1989, J NEUROCHEM, V53, P807, DOI 10.1111/j.1471-4159.1989.tb11777.x; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; RUNGE MS, 1981, BIOCHEMISTRY-US, V20, P175, DOI 10.1021/bi00504a029; SAHYOUN N, 1986, J BIOL CHEM, V261, P2339; SAITOH T, 1985, J CELL BIOL, V100, P835, DOI 10.1083/jcb.100.3.835; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SCHWORER CM, 1993, J BIOL CHEM, V268, P14443; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555; SUZUKI T, 1994, J NEUROCHEM, V63, P1529, DOI 10.1046/j.1471-4159.1994.63041529.x; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; TOBIMATSU T, 1989, J BIOL CHEM, V264, P17907; TOBIMATSU T, 1988, J BIOL CHEM, V263, P16082; VALLANO ML, 1985, BIOCHEM BIOPH RES CO, V130, P957, DOI 10.1016/0006-291X(85)91708-5; VALLANO ML, 1985, P NATL ACAD SCI USA, V82, P3202, DOI 10.1073/pnas.82.10.3202; WILLMUND R, 1986, P NATL ACAD SCI USA, V83, P9789, DOI 10.1073/pnas.83.24.9789	72	84	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10043	10049		10.1074/jbc.270.17.10043	http://dx.doi.org/10.1074/jbc.270.17.10043			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730306	hybrid			2022-12-25	WOS:A1995QV41700051
J	VACCARO, AM; SALVIOLI, R; BARCA, A; TATTI, M; CIAFFONI, F; MARAS, B; SICILIANO, R; ZAPPACOSTA, F; AMORESANO, A; PUCCI, P				VACCARO, AM; SALVIOLI, R; BARCA, A; TATTI, M; CIAFFONI, F; MARAS, B; SICILIANO, R; ZAPPACOSTA, F; AMORESANO, A; PUCCI, P			STRUCTURAL-ANALYSIS OF SAPOSIN-C AND SAPOSIN-B - COMPLETE LOCALIZATION OF DISULFIDE BRIDGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SPHINGOLIPID ACTIVATOR PROTEIN-1; PATHOGENIC ENTAMOEBA-HISTOLYTICA; PORE-FORMING PEPTIDE; GAUCHER DISEASE; VARIANT; PATIENT; GLUCOCEREBROSIDASE; GLUCOSYLCERAMIDASE; ASSIGNMENT	Saposins A, B, C, and D are a group of homologous glycoproteins derived from a single precursor, prosaposin, and apparently involved in the stimulation of the enzymatic degradation of sphingolipids in lysosomes, Ah saposins have six cysteine residues at similar positions, In the present study we have investigated the disulfide structure of saposins B and C using advanced mass spectrometric procedures. Electrospray analysis showed that deglycosylated saposins B and C are mainly present as 79- and 80-residue monomeric polypeptides, respectively. Fast atom bombardment mass analysis of peptide mixtures obtained by a combination of chemical and enzymatic cleavages demonstrated that the pairings of the three disulfide bridges present in each saposin are Cys(4)-Cys(77), Cys(7)-Cys(71), Cys(36)-Cys(47) for saposin B and Cys(5)-Cys(78), Cys(8)-Cys(72), Cys(36)-Cys(47) for saposin C. We have recently shown that saposin C interacts with phosphatidylserine-containing vesicles inducing destabilization of the lipid surface (Vaccaro, A. M., Tatti, M., Ciaffoni, F., Salvioli, R., Serafino, A., and Barca, A. (1994) FEBS Lett. 349, 181-186); this perturbation promotes the binding of the lysosomal enzyme glucosylceramidase to the vesicles and the reconstitution of its activity, It was presently found that the effects of saposin C on phosphatidylserine liposomes and on glucosylceramidase activity are markedly reduced when the three disulfide bonds are irreversibly disrupted, These results stress the importance of the disulfide structure for the functional properties of the saposin.	CNR,DIPARTIMENTO SCI BIOCHIM,I-00185 ROME,ITALY; CNR,CTR MOLEC BIOL,I-00185 ROME,ITALY; CNR,SERV SPETTROMETRIA MASSA,I-80131 NAPLES,ITALY; UNIV NAPLES,DIPARTIMENTO CHIM ORGAN & BIOL,I-80134 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	VACCARO, AM (corresponding author), IST SUPER SANITA,METAB & BIOCHIM PATOL LAB,VIALE REGINA ELENA 299,I-00161 ROME,ITALY.		Siciliano, Rosa Anna/G-9822-2013; Maras, Bruno/A-2020-2010; tatti, Massimo/N-1382-2017	PUCCI, Pietro/0000-0002-5885-1495; SICILIANO, ROSAANNA/0000-0002-1042-3424; AMORESANO, Angela/0000-0002-8386-655X				BAATZ JE, 1990, BIOCHEMISTRY-US, V29, P6714, DOI 10.1021/bi00480a022; BUKO AM, 1983, BIOMED MASS SPECTROM, V10, P324, DOI 10.1002/bms.1200100504; FURST W, 1990, EUR J BIOCHEM, V192, P709, DOI 10.1111/j.1432-1033.1990.tb19280.x; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GLEW RH, 1988, LAB INVEST, V58, P5; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V303, P326, DOI 10.1006/abbi.1993.1291; ITO K, 1993, EUR J BIOCHEM, V215, P171, DOI 10.1111/j.1432-1033.1993.tb18020.x; JOHANSSON J, 1991, BIOCHEMISTRY-US, V30, P6917, DOI 10.1021/bi00242a015; JOHANSSON J, 1992, FEBS LETT, V301, P165, DOI 10.1016/0014-5793(92)81239-I; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KLEINSCHMIDT T, 1987, BIOL CHEM H-S, V368, P1571, DOI 10.1515/bchm3.1987.368.2.1571; KLEINSCHMIDT T, 1988, BIOL CHEM H-S, V369, P1361, DOI 10.1515/bchm3.1988.369.2.1361; KONDOH K, 1991, BIOCHEM BIOPH RES CO, V181, P286, DOI 10.1016/S0006-291X(05)81415-9; LEIPPE M, 1992, EMBO J, V11, P3501, DOI 10.1002/j.1460-2075.1992.tb05432.x; LEIPPE M, 1991, P NATL ACAD SCI USA, V88, P7659, DOI 10.1073/pnas.88.17.7659; MORIMOTO S, 1988, BIOCHEM BIOPH RES CO, V156, P403, DOI 10.1016/S0006-291X(88)80855-6; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; MORIMOTO S, 1990, J BIOL CHEM, V265, P1933; MORRIS HR, 1985, BIOCHEM BIOPH RES CO, V126, P1122, DOI 10.1016/0006-291X(85)90302-X; MORRIS HR, 1983, BIOCHEM BIOPH RES CO, V117, P299, DOI 10.1016/0006-291X(83)91575-9; MURRAY GJ, 1985, ANAL BIOCHEM, V147, P301, DOI 10.1016/0003-2697(85)90276-3; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; PATTHY L, 1991, J BIOL CHEM, V266, P6035; POTIER M, 1988, BIOCHEM BIOPH RES CO, V155, P32, DOI 10.1016/S0006-291X(88)81045-3; PUCCI P, 1988, BIOMED ENVIRON MASS, V17, P287, DOI 10.1002/bms.1200170410; PUCCI P, 1985, BIOCHEM BIOPH RES CO, V130, P84, DOI 10.1016/0006-291X(85)90385-7; QI XY, 1994, J BIOL CHEM, V269, P16746; RAFI MA, 1993, SOMAT CELL MOLEC GEN, V19, P1, DOI 10.1007/BF01233949; SANO A, 1988, J BIOL CHEM, V263, P19597; SANO A, 1992, BIOCHIM BIOPHYS ACTA, V1120, P75, DOI 10.1016/0167-4838(92)90426-E; SCHNABEL D, 1991, FEBS LETT, V284, P57, DOI 10.1016/0014-5793(91)80760-Z; SHIFFER K, 1988, BIOCHEMISTRY-US, V27, P2689, DOI 10.1021/bi00408a008; STRAUBINGER RM, 1983, CELL, V32, P1069, DOI 10.1016/0092-8674(83)90291-X; VACCARO AM, 1993, BIOCHIM BIOPHYS ACTA, V1149, P55, DOI 10.1016/0005-2736(93)90024-T; VACCARO AM, 1994, FEBS LETT, V349, P181, DOI 10.1016/0014-5793(94)00659-8; VACCARO AM, 1993, FEBS LETT, V1, P159; VOGEL A, 1991, EUR J BIOCHEM, V200, P591, DOI 10.1111/j.1432-1033.1991.tb16222.x; WENGER DA, 1982, BIOCHIM BIOPHYS ACTA, V712, P639, DOI 10.1016/0005-2760(82)90293-4; YAMASHITA K, 1990, BIOCHEMISTRY-US, V29, P3030, DOI 10.1021/bi00464a020	40	78	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9953	9960		10.1074/jbc.270.17.9953	http://dx.doi.org/10.1074/jbc.270.17.9953			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730378				2022-12-25	WOS:A1995QV41700040
J	ZHANG, Y; WISNER, A; XIONG, YL; BON, C				ZHANG, Y; WISNER, A; XIONG, YL; BON, C			A NOVEL PLASMINOGEN-ACTIVATOR FROM SNAKE-VENOM - PURIFICATION, CHARACTERIZATION, AND MOLECULAR-CLONING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGKISTRODON-CONTORTRIX-CONTORTRIX; PROTEIN-C ACTIVATOR; AMINO-ACID-SEQUENCE; TISSUE-TYPE; MASS UROKINASE; BOTHROPS-ATROX; HUMAN-URINE; FIBRIN; IDENTIFICATION; THROMBIN	A novel plasminogen activator from Trimeresurus stejnegeri venom (TSV-PA) has been identified and purified to homogeneity. It is a single chain glycoprotein with an apparent molecular weight of 33,000 and an isoelectric point of pH 5.2. It specifically activates plasminogen through an enzymatic reaction. The activation of human native GIu-plasminogen by TSV-PA is due to a single cleavage of the molecule at the peptide bond Arg(561)-Val-(562). Purified TSV-PA, which catalyzes the hydrolysis of several tripeptide p-nitroanilide substrates, does not activate nor degrade prothrombin, factor X, or protein C and does not clot fibrinogen nor show fibrino(geno)lytic activity in the absence of plasminogen. The activity of TSV-PA was readily inhibited by phenylmethanesulfonyl fluoride and by p-nitrophenyl-p-guanidinobenzoate. Oligonucleotide primers designed on the basis of the N-terminal and the internal peptide sequences of TSV-PA were used for the amplification of cDNA fragments by polymerase chain reaction. This allowed the cloning of a full-length cDNA encoding TSV-PA from a cDNA library prepared from the venom glands. The deduced complete amino acid sequence of TSV-PA indicates that the mature TSV-PA protein is composed of 234 amino acids and contains a single potential N-gIycosylation site at Asn(1G1). The sequence of TSV-PA exhibits a high degree of sequence identity with other snake venom proteases: 66% with the protein C activator from Aghistrodon contortrix contortrix venom, 63% with batroxobin, and 60% with the factor V activator from Russell's viper venom. On the other hand, TSV-PA shows only 21-23% sequence similarity with the catalytic domains of u-PA and t-PA. Furthermore, TSV-PA lacks the sequence site that has been demonstrated to be responsible for the interaction of t-PA (KHRR) and u-PA (RRHR) with plasminogen activator inhibitor type 1.	INST PASTEUR,UNITE VENINS,F-75724 PARIS 15,FRANCE; CHINESE ACAD SCI,KUNMING INST ZOOL,KUNMING 650223,PEOPLES R CHINA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Chinese Academy of Sciences; Kunming Institute of Zoology				Zhang, Yun/0000-0002-8636-183X				AU LC, 1993, BIOCHEM J, V294, P387, DOI 10.1042/bj2940387; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLEN D, 1988, BLOOD, V71, P216; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEARAUJO AL, 1987, TOXICON, V25, P1181, DOI 10.1016/0041-0101(87)90136-X; DELROSSO M, 1985, CANCER RES, V45, P630; FISCHER BE, 1990, BIOCHIM BIOPHYS ACTA, V1041, P48, DOI 10.1016/0167-4838(90)90121-U; FROHMAN MA, 1990, AMPLIFICATIONS, V5, P11; FUKUTAKE K, 1989, HEMOSTASIS ANIMAL VE, P591; GUNZLER WA, 1982, H-S Z PHYSIOL CHEM, V363, P1155, DOI 10.1515/bchm2.1982.363.2.1155; HOFMANN H, 1987, BIOCHEMISTRY-US, V26, P772, DOI 10.1021/bi00377a018; HOFMANN H, 1987, BIOCHEMISTRY-US, V26, P780, DOI 10.1021/bi00377a019; HORREVOETS AJG, 1994, J BIOL CHEM, V269, P12639; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; ISRAEL DI, 1993, NUCLEIC ACIDS RES, V21, P2627, DOI 10.1093/nar/21.11.2627; ITOH N, 1987, J BIOL CHEM, V262, P3132; KEIJER J, 1991, BLOOD, V78, P401; KISIEL W, 1987, J BIOL CHEM, V262, P12607; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD RJ, 1982, J BIOL CHEM, V257, P9724; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; MCMULLEN BA, 1989, BIOCHEMISTRY-US, V28, P674, DOI 10.1021/bi00428a039; NAKASHIMA K, 1993, P NATL ACAD SCI USA, V90, P5964, DOI 10.1073/pnas.90.13.5964; ORTHNER CL, 1988, BIOCHEMISTRY-US, V27, P2558, DOI 10.1021/bi00407a043; PAONI NF, 1993, PROTEIN ENG, V6, P529, DOI 10.1093/protein/6.5.529; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; STEFFENS GJ, 1982, H-S Z PHYSIOL CHEM, V363, P1043, DOI 10.1515/bchm2.1982.363.2.1043; Stocker K., 1990, P97; TOKUNAGA F, 1988, J BIOL CHEM, V263, P17471; VANSEUNINGEN I, 1992, ELECTROPHORESIS, V13, P97, DOI 10.1002/elps.1150130119; WALLEN P, 1972, BIOCHIM BIOPHYS ACTA, V257, P122, DOI 10.1016/0005-2795(72)90261-9; WEITZ JI, 1988, J CLIN INVEST, V82, P1700, DOI 10.1172/JCI113783; WEITZ JI, 1990, J CLIN INVEST, V86, P203, DOI 10.1172/JCI114685; WOHL RC, 1980, J BIOL CHEM, V255, P2005; Zhang Yun, 1993, Asiatic Herpetological Research, V5, P117	42	164	186	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10246	10255		10.1074/jbc.270.17.10246	http://dx.doi.org/10.1074/jbc.270.17.10246			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730329	hybrid			2022-12-25	WOS:A1995QV41700077
J	KUNSTNER, P; GUARDIOLA, A; TAKAHASHI, Y; ROCHAIX, JD				KUNSTNER, P; GUARDIOLA, A; TAKAHASHI, Y; ROCHAIX, JD			A MUTANT STRAIN OF CHLAMYDOMONAS-REINHARDTII LACKING THE CHLOROPLAST PHOTOSYSTEM-II PSBI GENE GROWS PHOTOAUTOTROPHICALLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION CENTER COMPLEX; COMPLETE SEQUENCE; NUCLEOTIDE-SEQUENCE; DNA; ORGANIZATION; GENOME; CYTOCHROME-B-559; TRANSFORMATION; EXPRESSION	The product of the chloroplast psbI gene is associated with the photosystem II reaction center. To gain insights into the function of this polypeptide, we have disrupted its gene in Chlamydomonas reinhardtii with an aadA expression cassette that confers resistance to spectinomycin through biolistic transformation. The transformants are still able to grow photoautotrophically in dim light, but not in high light, and they remain photosensitive when grown on acetate containing medium, The amounts of photosystem II complex and oxygen evolving activity are both reduced to 10-20% of wild-type levels in these psbI-deficient mutants. It appears that the PsbI polypeptide plays a role in the stability of photosystem II and possibly also in modulating electron transport or energy transfer in this complex.	UNIV GENEVA, DEPT PLANT BIOL, CH-1211 GENEVA 4, SWITZERLAND; OKAYAMA UNIV, DEPT BIOL, OKAYAMA 700, JAPAN	University of Geneva; Okayama University	KUNSTNER, P (corresponding author), UNIV GENEVA, DEPT MOLEC BIOL, 30 QUAI ERNEST ANSERMET, CH-1211 GENEVA 4, SWITZERLAND.		Rochaix, Jean-David/ABC-5243-2020; Takahashi, Yuichiro/B-2062-2011	Takahashi, Yuichiro/0000-0001-6410-0447				ANDERSSON B., 1991, CURR TOP BIOENERG, V16, P1; BENNOUN P, 1986, PLANT MOL BIOL, V6, P151, DOI 10.1007/BF00021484; BOUDREAU E, 1994, PLANT MOL BIOL, V24, P585, DOI 10.1007/BF00023556; CHEN JC, 1990, NUCLEIC ACIDS RES, V18, P4017, DOI 10.1093/nar/18.13.4017; ERICKSON JM, 1992, PHOTOSYSTEMS STRUCTU, P101; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; HALLICK RB, 1993, NUCLEIC ACIDS RES, V21, P3537, DOI 10.1093/nar/21.15.3537; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; IKEUCHI M, 1988, FEBS LETT, V241, P99, DOI 10.1016/0014-5793(88)81039-1; IKEUCHI M, 1991, J BIOL CHEM, V266, P11111; KUCHKA MR, 1988, EMBO J, V7, P319, DOI 10.1002/j.1460-2075.1988.tb02815.x; LEU S, 1992, PLANT MOL BIOL, V18, P613, DOI 10.1007/BF00040681; MONOD C, 1994, EMBO J, V13, P2749; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; NICKELSEN J, 1994, EMBO J, V13, P3182, DOI 10.1002/j.1460-2075.1994.tb06617.x; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; PAKRASI HB, 1991, EMBO J, V10, P1619, DOI 10.1002/j.1460-2075.1991.tb07684.x; Rochaix J. D., 1988, PLANT MOL BIOL PRACT, P253; ROCHAIX JD, 1978, J MOL BIOL, V126, P597, DOI 10.1016/0022-2836(78)90011-6; Sambrook J, 1989, MOL CLONING LABORATO; SEXTON TB, 1990, CURR GENET, V17, P445, DOI 10.1007/BF00334526; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; TAKAHASHI Y, 1994, PLANT MOL BIOL, V24, P779, DOI 10.1007/BF00029859; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; TELFER A, 1990, BIOCHIM BIOPHYS ACTA, V1017, P143, DOI 10.1016/0005-2728(90)90145-T; THOMPSON LK, 1988, BIOCHEMISTRY-US, V27, P6653, DOI 10.1021/bi00418a002; TOMO T, 1993, FEBS LETT, V323, P15, DOI 10.1016/0014-5793(93)81438-6; VERMAAS W, 1993, ANNU REV PLANT PHYS, V44, P457, DOI 10.1146/annurev.pp.44.060193.002325; WEBBER AN, 1989, FEBS LETT, V242, P259, DOI 10.1016/0014-5793(89)80481-8	29	48	50	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9651	9654						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721898				2022-12-25	WOS:A1995QU08900087
J	STERNER, JM; MURATA, Y; KIM, HG; KENNETT, SB; TEMPLETON, DJ; HOROWITZ, JM				STERNER, JM; MURATA, Y; KIM, HG; KENNETT, SB; TEMPLETON, DJ; HOROWITZ, JM			DETECTION OF A NOVEL CELL-CYCLE-REGULATED KINASE-ACTIVITY THAT ASSOCIATES WITH THE AMINO-TERMINUS OF THE RETINOBLASTOMA PROTEIN IN G(2)/M PHASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLADDER-CARCINOMA CELLS; LARGE T-ANTIGEN; GENE-PRODUCT; SUSCEPTIBILITY GENE; TUMOR SUPPRESSOR; RB PROTEIN; FUNCTIONAL-ANALYSIS; CDC2 KINASE; C-MYC; BINDING	Recent genetic and functional evidence suggests that the amino terminus of the retinoblastoma (Rb) protein plays an important role in Rb-mediated growth suppression, To explore the mechanism(s) by which this portion of Rb may regulate cell growth, we have sought to characterize cellular proteins that associate with the Rb amino terminus using an in vitro protein-binding assay, Here we report that at least one such protein is a cell cycle-regulated Rb/histone H1 kinase (RbK) whose enzymatic and/or Rb association activity is most prevalent in G(2)/M phases of cells, In contrast to previously characterized cyclin-dependent and Rb-associated kinases, such as cdk1 (cdc2) and cdk2, G(2)/M RbK 1) is not depleted by incubation with p13(suc)-beads, 2) is not detected with antisera against several Rb-associated cyclins-cdks, and 3) associates with Rb via the Rb amino terminus, a region that is dispensable for interaction with other Rb-associated kinases, RbK is clearly distinct from previously characterized mitotic cdks since cyclin A-cdc2, cyclin A-cdk2, cyclin B-cdc2, and cyclin B-cdk2 did not associate with the Rb amino terminus. Coprecipitation experiments with Rb antisera confirmed the association of Rb with a RbK like kinase in metaphase-arrested cells in vivo, Interestingly, G(2)/M RbK did not appreciably associate with an analogous portion of p107, a Rb-related protein, Taken together, these data indicate that the Rb amino terminus specifically associates with a novel cell cycle-regulated kinase in late cell cycle stages.	DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710; CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,PROGRAM CELL BIOL,CLEVELAND,OH 44106	Duke University; Duke University; Case Western Reserve University; Case Western Reserve University			Templeton, Dennis J/F-7695-2011		NCI NIH HHS [CA53248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BIGNON YJ, 1990, CELL GROWTH DIFFER, V7, P647; BOEHMELT G, 1994, CELL GROWTH DIFFER, V5, P221; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DESTREE OHJ, 1992, DEV BIOL, V153, P141, DOI 10.1016/0012-1606(92)90098-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KARANTZA V, 1993, MOL CELL BIOL, V13, P6640, DOI 10.1128/MCB.13.11.6640; KATO J, 1993, GENE DEV, V7, P331; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MADREPERLA SA, 1991, CANCER RES, V51, P6381; MANCASTER MM, 1992, CANCER RES, P654; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MURATA Y, 1994, J BIOL CHEM, V269, P20674; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; NEVINS JR, 1992, SCIENCE, V258, P424; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1989, ONCOGENE, V4, P401; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1989, CANCER RES, V49, P3713; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1991, CANCER RES, V51, P4481; YOKOTA J, 1988, ONCOGENE, V3, P471; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	68	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9281	9288		10.1074/jbc.270.16.9281	http://dx.doi.org/10.1074/jbc.270.16.9281			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721848	hybrid			2022-12-25	WOS:A1995QU08900036
J	DESDOUITS, F; COHEN, D; NAIRN, AC; GREENGARD, P; GIRAULT, JA				DESDOUITS, F; COHEN, D; NAIRN, AC; GREENGARD, P; GIRAULT, JA			PHOSPHORYLATION OF DARPP-32, A DOPAMINE-REGULATED AND CAMP-REGULATED PHOSPHOPROTEIN, BY CASEIN KINASE-I IN-VITRO AND IN-VIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 3'-5'-MONOPHOSPHATE-REGULATED PHOSPHOPROTEIN; PROTEIN PHOSPHATASE INHIBITOR-1; INNERVATED BRAIN-REGIONS; RABBIT SKELETAL-MUSCLE; LARGE T-ANTIGEN; NEURONAL PHOSPHOPROTEIN; SUBSTRATE DETERMINANTS; CATALYTIC SUBUNIT; SITES; IDENTIFICATION	DARPP-32 (dopamine- and ! cAMP-regulated phosphoprotein, M(r) = 32,000) is a potent inhibitor of protein phosphatase-1 when it is phosphorylated on Thr-34 by cAMP-dependent protein kinase. DARPP-32 is highly enriched in some specific cell populations such as striatonigral neurons and choroid plexus epithelial cells. Here we show that recombinant rat DARPP-32 is phosphorylated by casein kinase I on seryl residues to a stoichiometry of approximate to 2 mol of phosphate/mol of protein. DARPP-32 is one of the best known substrates for casein kinase I (K-m = 3.4 +/- 0.3 mu M), whereas the homologous phosphatase-1 inhibitor, inhibitor-1, is not. Phosphorylation of DARPP-32 by casein kinase I does not alter its ability to inhibit protein phosphatase-1. Residues phosphorylated by casein kinase I were identified as Ser-137 and Ser-189 by site directed mutagenesis and by protein sequencing. Ser-137 and the preceding stretch of 16-18 acidic residues are conserved in DARPP-32 among all species examined, whereas Ser-189 is not. Phosphorylation of Ser-137 induces an unusual increase in DARPP-32 electrophoretic mobility in polyacrylamide gels in the presence of SDS. In striatonigral neurons, DARPP-32 is phosphorylated on Ser-137 and the stoichiometry of phosphorylation on this residue in vivo appears to be higher in the substantia nigra (axon terminals) than in the striatum (soma and dendrites). These results indicate that casein kinase I is highly active in striatonigral neurons in which it may play important roles, including in protein phosphatase-1 modulation via phosphorylation of DARPP-32.	ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, NEW YORK, NY 10021 USA	Rockefeller University	DESDOUITS, F (corresponding author), COLL FRANCE, INSERM, U114, CHAIRE NEUROPHARMACOL, 11 PL MARCELIN BERTHELOT, F-75005 PARIS, FRANCE.		Girault, Jean-Antoine/F-7518-2013	Girault, Jean-Antoine/0000-0002-7900-1705; Nairn, Angus/0000-0002-7075-0195	NIMH NIH HHS [MH-40899] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AGOSTINIS P, 1992, FEBS LETT, V305, P121, DOI 10.1016/0014-5793(92)80877-J; AGOSTINIS P, 1987, FEBS LETT, V224, P385, DOI 10.1016/0014-5793(87)80489-1; BRENE S, 1994, J NEUROSCI, V14, P985, DOI 10.1523/JNEUROSCI.14-03-00985.1994; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; CHAUHAN VPS, 1993, BIOCHIM BIOPHYS ACTA, V1177, P318, DOI 10.1016/0167-4889(93)90128-C; CHIJIWA T, 1989, J BIOL CHEM, V264, P492; COHEN P, 1988, METHOD ENZYMOL, V159, P427; DEMAGGIO AJ, 1992, P NATL ACAD SCI USA, V89, P7008, DOI 10.1073/pnas.89.15.7008; DESDOUITS F, 1995, IN PRESS P NATL ACAD; EHRLICH ME, 1990, DEV BRAIN RES, V54, P257, DOI 10.1016/0165-3806(90)90148-R; EHRLICH ME, 1990, J MOL NEUROSCI, V2, P1, DOI 10.1007/BF02896920; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; FLOYD CC, 1991, J BIOL CHEM, V266, P4987; GIRAULT JA, 1993, NEUROCHEM INT, V23, P1, DOI 10.1016/0197-0186(93)90139-V; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; GIRAULT JA, 1990, J NEUROCHEM, V55, P1772, DOI 10.1111/j.1471-4159.1990.tb04968.x; HEMMINGS HC, 1992, J NEUROCHEM, V59, P1053, DOI 10.1111/j.1471-4159.1992.tb08347.x; HEMMINGS HC, 1986, J NEUROSCI, V6, P1469; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; HUFLEJT ME, 1993, J BIOL CHEM, V268, P26712; JIANG JX, 1994, MOL BIOL CELL, V5, P363, DOI 10.1091/mbc.5.3.363; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KLIMCZAK LJ, 1993, BIOCHEM J, V293, P283, DOI 10.1042/bj2930283; KURET J, 1985, EUR J BIOCHEM, V151, P39, DOI 10.1111/j.1432-1033.1985.tb09066.x; LINK WT, 1993, NEUROSCI LETT, V151, P89, DOI 10.1016/0304-3940(93)90053-N; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MILNE DM, 1992, ONCOGENE, V7, P1361; NEYROZ P, 1993, J BIOL CHEM, V268, P24022; OUIMET CC, 1984, J NEUROSCI, V4, P111; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; SAKAGAMI H, 1994, MOL BRAIN RES, V25, P7, DOI 10.1016/0169-328X(94)90273-9; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SICILIANO JC, 1992, NEUROPROTOCOLS, V1, P185; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; UMPHRESS JL, 1992, EUR J BIOCHEM, V203, P239, DOI 10.1111/j.1432-1033.1992.tb19852.x; WALAAS SI, 1983, NATURE, V301, P69; WALAAS SI, 1984, J NEUROSCI, V4, P84; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; ZHAI LM, 1992, BIOCHEM BIOPH RES CO, V189, P944, DOI 10.1016/0006-291X(92)92295-9	51	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8772	8778		10.1074/jbc.270.15.8772	http://dx.doi.org/10.1074/jbc.270.15.8772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721783	hybrid			2022-12-25	WOS:A1995QT44800061
J	NAKANISHI, T; SHIMOARAISO, M; KUBO, T; NATORI, S				NAKANISHI, T; SHIMOARAISO, M; KUBO, T; NATORI, S			STRUCTURE-FUNCTION RELATIONSHIP OF YEAST S-II IN TERMS OF STIMULATION OF RNA-POLYMERASE-II, ARREST RELIEF, AND SUPPRESSION OF 6-AZAURACIL SENSITIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ELONGATION-FACTOR; ASCITES TUMOR-CELLS; FACTOR-SII; SACCHAROMYCES-CEREVISIAE; DEPENDENT TRANSCRIPTION; TERMINATION SITES; CALF THYMUS; DMS-II; GENE; DNA	The yeast S-II null mutant is viable, but the mutation induces sensitivity to 6-azauracil. To examine whether the region needed for stimulation of RNA polymerase II and that for suppression of 6-azauracil sensitivity in the S-II molecule could be separated, we constructed various deletion mutants of S-II and expressed them in the null mutant using the GAL1 promoter to see if the mutant proteins suppressed 6-azauracil sensitivity. We also expressed these constructs in Escherichia coli, purified the mutant proteins to homogeneity, and examined if they stimulated RNA polymerase II, We found that a mutant protein lacking the first 147 amino acid residues suppressed 6-azauracil sensitivity but that removal of 2 additional residues completely abolished the Suppression, A mutant protein lacking the first 141 residues had activity to stimulate RNA polymerase II, whereas re moval of 10 additional residues completely abolished this activity. We also examined arrest-relief activity of these mutant proteins and found that there is a good correlation between RNA polymerase II-stimulating activity and arrest-relief activity, Therefore, at least the last 168 residues of S-II are sufficient for expressing these three activities.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo				Kubo, Takeo/0000-0002-5914-5269				AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; CLARK AB, 1991, MOL CELL BIOL, V11, P2576, DOI 10.1128/MCB.11.5.2576; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; HOMMA K, 1994, J BIOL CHEM, V269, P15258; HORIKOSHI M, 1985, J BIOL CHEM, V260, P5739; HORIKOSHI M, 1984, J BIOL CHEM, V259, P608; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; JONSON TL, 1994, CELL, V77, P217; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NATORI S, 1982, MOL CELL BIOCHEM, V46, P173; QUIAN X, 1993, NATURE, V365, P277; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; SEKIMIZU K, 1982, J BIOL CHEM, V257, P2719; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUGINO A, 1988, P NATL ACAD SCI USA, V85, P3683, DOI 10.1073/pnas.85.11.3683; UENO K, 1979, NATURE, V277, P145, DOI 10.1038/277145a0; WIEST DK, 1992, J BIOL CHEM, V267, P7733; XU QH, 1994, J BIOL CHEM, V269, P3100; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	47	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8991	8995		10.1074/jbc.270.15.8991	http://dx.doi.org/10.1074/jbc.270.15.8991			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721809	hybrid			2022-12-25	WOS:A1995QT44800089
J	OLIVEIRA, CC; MCCARTHY, JEG				OLIVEIRA, CC; MCCARTHY, JEG			THE RELATIONSHIP BETWEEN EUKARYOTIC TRANSLATION AND MESSENGER-RNA STABILITY - A SHORT UPSTREAM OPEN READING FRAME STRONGLY INHIBITS TRANSLATIONAL INITIATION AND GREATLY ACCELERATES MESSENGER-RNA DEGRADATION IN THE YEAST SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DECAY; SECONDARY STRUCTURE; NONSENSE MUTATIONS; CODING REGION; CODONS; ACID; AUG; REINITIATION; EFFICIENCY; RIBOSOMES	A new strategy was developed to study the relationship between the translation and degradation of a specific mRNA in the yeast Saccharomyces cerevisiae. A series of 5'-untranslated regions (UTR) was combined with the cat gene from the bacterial transposon Tn9, allowing us to test the influence of upstream open reading frames (uORFs) on translation and mRNA stability. The 5'-UTR sequences were designed so that the minimum possible sequence alteration, a single nucleotide substitution, could be used to create a 7-codon ORF upstream of the cat gene. The uORF was translated efficiently, but at the same time inhibited translation of the cat ORF and destabilized the cat mRNA. Investigations of various derivatives of the 5'-UTR indicated that cat translation was primarily attributable to leaky scanning of ribosomes past the uORF rather than to reinitiation. Therefore, these data directly demonstrate destabilization of a specific mRNA linked to changes in translational initiation on the same transcript. In contrast to the previously proposed nonsense-mediated mRNA decay pathway, destabilization was not triggered by premature translational termination in the main ORF and was not discernibly dependent upon a reinitiation-driven mechanism. This suggests the existence of an as yet not described pathway of translation-linked mRNA degradation.	GESELL BIOTECHNOL FORSCH MBH, DEPT GENE EXPRESS, D-38124 BRAUNSCHWEIG, GERMANY	Gesellschaft fur Biotechnologische Forschung mbH			Oliveira, Carla C/F-2323-2011	Oliveira, Carla C/0000-0002-1098-9241				ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; Belasco J.G., 2012, CONTROL MESSENGER RN; BOSSIER P, 1993, J BIOL CHEM, V268, P23640; CAPONIGRO G, 1993, MOL CELL BIOL, V13, P5141, DOI 10.1128/MCB.13.9.5141; CHENG J, 1993, MOL CELL BIOL, V13, P1892, DOI 10.1128/MCB.13.3.1892; DONAHUE TF, 1990, METHODS NEYZMOL, V193, P366; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANT CM, 1994, MOL CELL BIOL, V14, P2616, DOI 10.1128/MCB.14.4.2616; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LEEDS P, 1992, MOL CELL BIOL, V12, P2165, DOI 10.1128/MCB.12.5.2165; LIEBHABER SA, 1992, J MOL BIOL, V226, P609, DOI 10.1016/0022-2836(92)90619-U; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; PARKER R, 1991, METHOD ENZYMOL, V194, P415; PELSY F, 1984, CURR GENET, V8, P277, DOI 10.1007/BF00419725; PELTZ SW, 1992, MOL CELL BIOL, V12, P5778, DOI 10.1128/MCB.12.12.5778; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; PELTZ SW, 1993, PROTEIN SYNTHESIS TA, P1; PIERRAT B, 1993, GENE, V131, P43, DOI 10.1016/0378-1119(93)90667-R; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAGLIOCCO FA, 1994, J BIOL CHEM, V269, P18630; SAMBROOK J, 1989, MOL CLONING LABOR MA; SEDMAN SA, 1990, J VIROL, V64, P453, DOI 10.1128/JVI.64.1.453-457.1990; SHERMAN F, 1986, LABORATORY COURSE MA, P117; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEVENS A, 1980, J BIOL CHEM, V255, P3080; WELLINGTON CL, 1993, MOL CELL BIOL, V13, P5034, DOI 10.1128/MCB.13.8.5034	38	96	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8936	8943		10.1074/jbc.270.15.8936	http://dx.doi.org/10.1074/jbc.270.15.8936			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721802	hybrid			2022-12-25	WOS:A1995QT44800081
J	COSTANZO, G; DIMAURO, E; NEGRI, R; PEREIRA, G; HOLLENBERG, C				COSTANZO, G; DIMAURO, E; NEGRI, R; PEREIRA, G; HOLLENBERG, C			MULTIPLE OVERLAPPING POSITIONS OF NUCLEOSOMES WITH SINGLE IN-VIVO ROTATIONAL SETTING IN THE HANSENULA-POLYMORPHA RNA-POLYMERASE-II MOX PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTORS; CHROMATIN STRUCTURE; METHANOL OXIDASE; PHO5 PROMOTER; IN-VITRO; DNASE-I; YEAST; SEQUENCE; CORE	In vivo nucleotide level mapping of nucleosomes in the promoter of the methanol oxidase (MOX) gene in the yeast Hansenula polymorpha is reported. The 4 nucleosomes analyzed are organized in families; they localize in alternative positions along a unique rotational phase, and the linker regions can be occupied by alternative nucleosomes. This organization underscores a substantial freedom of choice by histone octamers when nucleating on a promoter region.	UNIV ROMA LA SAPIENZA, DIPARTIMENTO GENET & BIOL MOLEC, FDN IST PASTEUR FDN CENCI BOLOGNETTI, I-00185 ROME, ITALY; UNIV DUSSELDORF, INST MICROBIOL, D-40225 DUSSELDORF, GERMANY	Sapienza University Rome; Heinrich Heine University Dusseldorf	COSTANZO, G (corresponding author), CNR, CTR STUDIO ACIDI NUCL, I-00185 ROME, ITALY.							ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; BLOOM KS, 1984, J CELL BIOL, V99, P1559, DOI 10.1083/jcb.99.5.1559; BUCKLE R, 1991, NUCLEIC ACIDS RES, V19, P1219, DOI 10.1093/nar/19.6.1219; BUTTINELLI M, 1993, P NATL ACAD SCI USA, V90, P9315, DOI 10.1073/pnas.90.20.9315; CARR KD, 1990, P NATL ACAD SCI USA, V87, P9300, DOI 10.1073/pnas.87.23.9300; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; COSTANZO G, 1990, J MOL BIOL, V216, P363, DOI 10.1016/S0022-2836(05)80327-4; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; GEORGEL P, 1993, J MOL BIOL, V234, P319, DOI 10.1006/jmbi.1993.1589; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GODECKE S, 1994, GENE, V139, P35, DOI 10.1016/0378-1119(94)90520-7; GODECKE S, 1991, THESIS U DUSSELDORF; GOTTSCHLING DE, 1984, CELL, V38, P501, DOI 10.1016/0092-8674(84)90505-1; HSIEH CH, 1988, CELL, V52, P535, DOI 10.1016/0092-8674(88)90466-7; LEDEBOER AM, 1985, NUCLEIC ACIDS RES, V13, P3063, DOI 10.1093/nar/13.9.3063; LEE MS, 1991, EMBO J, V10, P607, DOI 10.1002/j.1460-2075.1991.tb07988.x; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; NEGRI R, 1989, J MOL BIOL, V207, P615, DOI 10.1016/0022-2836(89)90469-5; NEGRI R, 1994, BIOPHYS CHEM, V50, P169, DOI 10.1016/0301-4622(94)85029-1; ODONOHUE MF, 1994, NUCLEIC ACIDS RES, V22, P937, DOI 10.1093/nar/22.6.937; ONEILL TE, 1993, P NATL ACAD SCI USA, V90, P6203, DOI 10.1073/pnas.90.13.6203; PATTERTON HG, 1993, J MOL BIOL, V229, P637, DOI 10.1006/jmbi.1993.1069; PENNINGS S, 1989, J MOL BIOL, V207, P183, DOI 10.1016/0022-2836(89)90449-X; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, J MOL BIOL, V216, P975, DOI 10.1016/S0022-2836(99)80015-1; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROGGENKAMP R, 1984, MOL GEN GENET, V194, P489, DOI 10.1007/BF00425563; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SATCHWELL SC, 1989, EMBO J, V8, P229, DOI 10.1002/j.1460-2075.1989.tb03368.x; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; THOMA F, 1992, BIOCHIM BIOPHYS ACTA, V1130, P1, DOI 10.1016/0167-4781(92)90455-9; Travers A., 1993, DNA PROTEIN INTERACT, P1; TRAVERS AA, 1987, PHILOS T ROY SOC B, V317, P537, DOI 10.1098/rstb.1987.0080; TRIFONOV EN, 1980, P NATL ACAD SCI-BIOL, V77, P3816, DOI 10.1073/pnas.77.7.3816; TURNELL WG, 1992, METHOD ENZYMOL, V212, P387; van Holde K.E., 1988, CHROMATIN; VANHOLDE K, 1993, NATURE, V362, P111, DOI 10.1038/362111a0; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; VEENHUIS M, 1983, ADV MICROB PHYSIOL, V24, P1, DOI 10.1016/S0065-2911(08)60384-7; VENDITTI P, 1994, BBA-GENE STRUCT EXPR, V1219, P677, DOI 10.1016/0167-4781(94)90227-5; VENDITTI S, 1994, MOL GEN GENET, V242, P100, DOI 10.1007/BF00277353; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; YENIDUNYA A, 1994, J MOL BIOL, V237, P401, DOI 10.1006/jmbi.1994.1243; ZIVANOVIC Y, 1988, J MOL BIOL, V200, P287	58	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11091	11097		10.1074/jbc.270.19.11091	http://dx.doi.org/10.1074/jbc.270.19.11091			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744739	hybrid			2022-12-25	WOS:A1995QX86500014
J	GRUNWALD, R; MEISSNER, G				GRUNWALD, R; MEISSNER, G			LUMENAL SITES AND C-TERMINUS ACCESSIBILITY OF THE SKELETAL-MUSCLE CALCIUM-RELEASE CHANNEL (RYANODINE RECEPTOR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CA-2+-INDUCED CA-2+ RELEASE; BIOCHEMICAL-CHARACTERIZATION; FUNCTIONAL-CHARACTERIZATION; POLYACRYLAMIDE GELS; EXPRESSION VECTORS; RABBIT BRAIN; PROTEIN; COMPLEX	The membrane topology of the skeletal muscle ryanodine receptor (RyR1) was investigated using site-directed antibodies directed against amino acid sequences 2804-2930, 4581-4640, 4860-4886, and 4941-5037, Ab(2804-2930) bound with identical affinity to either closed or permeabilized sarcoplasmic reticulum vesicles, confirming the cytoplasmic location of this segment. Ab(4581-4640) did not bind to closed vesicles but bound well to permeabilized vesicles, supporting a lumenal location for this segment. Ab(4860-4886) did not bind to closed vesicles but exhibited weak binding to the permeabilized vesicles, suggesting that a portion of the epitope may be exposed on the lumenal surface. The C-terminal antibody (Ab(4941-5037)) bound weakly to closed vesicles, and binding was not significantly enhanced by permeabilizing vesicles with low concentrations of non-denaturing detergent. However, the C-terminal antibodies bound efficiently to vesicles which were transiently incubated at alkaline pH or subjected to trypsinolysis, conditions where few of the vesicles were permeabilized. These results support a model for the membrane topology of the ryanodine receptor as proposed by Takeshima et al. (Takeshima, H., Nishimura, S., Matsumoto, T., Ishida, H., Kangawa, K., Minamino, N., Matsuo, H., Ueda, M., Hanaoka, M., Hirose, T., and Numa, S. (1989) Nature 339, 439-445). The results also suggest that the native conformation of the C terminus is inaccessible to antibodies.	UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill					NIAMS NIH HHS [AR18687] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018687, R37AR018687] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON K, 1989, J BIOL CHEM, V264, P1329; BRANDT NR, 1992, J MEMBRANE BIOL, V127, P35; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; CHEN SRW, 1993, J BIOL CHEM, V268, P13414; CHEN SRW, 1993, J BIOL CHEM, V268, P22642; CHOI ESH, 1990, DEV BIOL, V142, P169, DOI 10.1016/0012-1606(90)90160-K; CHU A, 1988, BIOCHEMISTRY-US, V27, P2827, DOI 10.1021/bi00408a025; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; COSTELLO B, 1986, J CELL BIOL, V103, P741, DOI 10.1083/jcb.103.3.741; DUGGAN PF, 1970, J GEN PHYSIOL, V56, P147, DOI 10.1085/jgp.56.2.147; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; FERGUSON DG, 1984, J CELL BIOL, V99, P1735, DOI 10.1083/jcb.99.5.1735; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20857; GUO LH, 1984, GENE, V29, P251, DOI 10.1016/0378-1119(84)90186-0; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HERRMANNFRANK A, 1991, PFLUG ARCH EUR J PHY, V418, P353, DOI 10.1007/BF00550873; HYMEL L, 1988, BIOCHEM BIOPH RES CO, V152, P308, DOI 10.1016/S0006-291X(88)80715-0; IINO M, 1992, BIOCHEM BIOPH RES CO, V185, P713, DOI 10.1016/0006-291X(92)91684-I; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KREBS J, 1984, BIOCHEMISTRY-US, V23, P400, DOI 10.1021/bi00298a002; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1992, BIOCHEM J, V288, P553, DOI 10.1042/bj2880553; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LILLIE SH, 1987, YEAST, V3, P63, DOI 10.1002/yea.320030202; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MARTY I, 1994, BIOCHEM J, V298, P743, DOI 10.1042/bj2980743; MCPHERSON PS, 1993, J BIOL CHEM, V268, P19785; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; MEISSNER G, 1989, J BIOL CHEM, V264, P1715; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; Mikoshiba Katsuhiko, 1994, Seminars in Cell Biology, V5, P273, DOI 10.1006/scel.1994.1033; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; OTTER T, 1987, ANAL BIOCHEM, V162, P370, DOI 10.1016/0003-2697(87)90406-4; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; RARDON DP, 1989, CIRC RES, V64, P779, DOI 10.1161/01.RES.64.4.779; SAITO A, 1989, Biophysical Journal, V55, p206A; SAITO A, 1988, J CELL BIOL, V107, P211, DOI 10.1083/jcb.107.1.211; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; SHOSHANBARMATZ V, 1988, J BIOL CHEM, V263, P16772; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1994, FEBS LETT, V337, P81, DOI 10.1016/0014-5793(94)80634-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TU Q, 1994, J GEN PHYSIOL, V103, P853, DOI 10.1085/jgp.103.5.853; XU L, 1994, P NATL ACAD SCI USA, V91, P3294, DOI 10.1073/pnas.91.8.3294; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	63	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11338	11347		10.1074/jbc.270.19.11338	http://dx.doi.org/10.1074/jbc.270.19.11338			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744771	Green Published, hybrid			2022-12-25	WOS:A1995QX86500048
J	KAISE, M; MURAOKA, A; SEVA, C; TAKEDA, H; DICKINSON, CJ; YAMADA, T				KAISE, M; MURAOKA, A; SEVA, C; TAKEDA, H; DICKINSON, CJ; YAMADA, T			GLYCINE-EXTENDED PROGASTRIN PROCESSING INTERMEDIATES INDUCE H+,K+-ATPASE ALPHA-SUBUNIT GENE-EXPRESSION THROUGH A NOVEL RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC-ACID SECRETION; CANINE PARIETAL-CELLS; SECRETAGOGUE STIMULATION; CHOLECYSTOKININ; ACCUMULATION; METABOLISM; AMIDATION; SEQUENCE; HUMANS	Biologically active amidated gastrin is synthesized by carboxyl-terminal alpha-amidation of a glycine extended progastrin post-translational processing intermediate (G-Gly). Although plasma levels of G-Gly are equivalent to those of gastrin, G-Gly has essentially no acute effect on gastric acid secretion. However, we have observed that inhibition of gastrin amidation leads to increased plasma concentrations of G-Gly and enhanced gastric acid secretion. We hypothesized, therefore, that G-Gly might have a chronic effect to increase H+,K+-ATPase expression in gastric parietal cells, In the present studies, we observed that a a-day preincubation with G-Gly significantly enhanced histamine-stimulated [C-14]aminopyrine uptake by isolated canine gastric parietal cells but acutely administered G-Gly had no effect, On Northern blot analysis, both G-Gly and gastrin dose-dependently increased H+,K+-ATPase alpha-subunit gene expression with maximal induction (225 +/- 35 and 170 +/- 29% of basal, mean +/- S.E.) achieved at concentrations of 10(-9) M G-Gly and 10(-8) M gastrin, respectively, Using an H+,K+-ATPase alpha-subunit gene-luciferase chimeric reporter construct transfected into primary cultured parietal cells, we observed that both G-Gly and gastrin increased luciferase activity in a manner similar to that obtained by Northern blot analysis, L365,260, a specific gastrin/CCKB receptor antagonist, completely reversed the stimulation of luciferase activity induced by gastrin but had no effect on G-Gly-stimulated activity, Gastrin increased [Ca2+](i), although G-Gly did not, however, genistein (a tyrosine kinase inhibitor) significantly reduced induction of luciferase activity by both G-Gly and gastrin. Specific binding of I-125-Leu(15)-G(2-17)-Gly to gastric parietal cells was dose-dependently displaced by G(2-17)-Gly but not by gastrin nor L365,260. Gastrin peptides truncated at the carboxyl-(G(1-13)) and amino terminus (G(2-17)-Gly) both induced H+,K+-ATPase alpha-subunit gene expression and inhibited I-125-Leu(15)-G(2-17)Gly binding, but were less potent than G(2-17)-Gly. These data indicate that G-Gly may have a functional role in potentiating gastric acid secretagogue action via enhanced expression of the gene responsible for Hf generation through action at a novel receptor that can be distinguished from the gastrin/CCKB receptor. Thus, both the substrate and product of the terminal progastrin processing reaction appear to have complementary functions in regulation of gastric acid secretion.	UNIV MICHIGAN,MED CTR,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PEDIAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT PHYSIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			SEVA, Catherine/O-9166-2014	SEVA, Catherine/0000-0002-4265-7372	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034306, K08DK001903, P30DK034933] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK34306, P30DK34933, K08-DK-01903] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; BEALE EG, 1992, BIOTECHNIQUES, V12, P320; BOCK MG, 1989, J MED CHEM, V32, P16; CABERO JL, 1989, ACTA PHYSIOL SCAND, V136, P301, DOI 10.1111/j.1748-1716.1989.tb08670.x; CAMPBELL VW, 1989, J BIOL CHEM, V264, P11381; CHANG RSL, 1986, P NATL ACAD SCI USA, V83, P4923, DOI 10.1073/pnas.83.13.4923; CHEW CS, 1989, AM J PHYSIOL, V256, pG254, DOI 10.1152/ajpgi.1989.256.1.G254; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICCOTOSTO GD, 1992, AM J PHYSIOL, V263, pG802, DOI 10.1152/ajpgi.1992.263.5.G802; DELVALLE J, 1989, GASTROENTEROLOGY, V97, P1159, DOI 10.1016/0016-5085(89)91685-5; DELVALLE J, 1992, AM J PHYSIOL, V262, pG420, DOI 10.1152/ajpgi.1992.262.3.G420; DICKINSON CJ, 1991, J BIOL CHEM, V266, P334; DICKINSON CJ, 1990, AM J PHYSIOL, V258, pG810, DOI 10.1152/ajpgi.1990.258.5.G810; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; HILSTED L, 1988, GASTROENTEROLOGY, V94, P96, DOI 10.1016/0016-5085(88)90615-4; HILSTED L, 1991, REGUL PEPTIDES, V36, P323, DOI 10.1016/0167-0115(91)90067-Q; HILSTED L, 1988, AM J PHYSIOL, V255, pG665, DOI 10.1152/ajpgi.1988.255.5.G665; Langone J J, 1980, Methods Enzymol, V70, P221; LUND PK, 1985, J BIOL CHEM, V260, P7609; MATSUMOTO M, 1987, AM J PHYSIOL, V252, pG315, DOI 10.1152/ajpgi.1987.252.3.G315; MCGUIGAN JE, 1972, GASTROENTEROLOGY, V62, P553; MORLEY JS, 1965, NATURE, V207, P1356, DOI 10.1038/2071356a0; MURAOKA A, 1994, GASTROENTEROLOGY, V106, pA145; PAUWELS S, 1985, GASTROENTEROLOGY, V89, P49, DOI 10.1016/0016-5085(85)90744-9; Sachs G, 1987, PHYSL GASTROINTESTIN, P865; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; SOLL AH, 1984, J CLIN INVEST, V73, P1434, DOI 10.1172/JCI111348; SOLL AH, 1980, AM J PHYSIOL, V238, pG366, DOI 10.1152/ajpgi.1980.238.4.G366; SOLL AH, 1978, J CLIN INVEST, V61, P370, DOI 10.1172/JCI108947; SONG I, 1993, BIOCHEM BIOPH RES CO, V196, P1240, DOI 10.1006/bbrc.1993.2385; SUGANO K, 1987, AM J PHYSIOL, V253, pG502, DOI 10.1152/ajpgi.1987.253.4.G502; SUGANO K, 1985, J BIOL CHEM, V260, P1724; TRACY HJ, 1964, NATURE, V204, P935, DOI 10.1038/204935a0; YAMADA T, 1993, GASTRIN, P151	35	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 12	1995	270	19					11155	11160		10.1074/jbc.270.19.11155	http://dx.doi.org/10.1074/jbc.270.19.11155			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QX865	7744746	hybrid			2022-12-25	WOS:A1995QX86500022
J	SINGH, S; AGGARWAL, BB				SINGH, S; AGGARWAL, BB			PROTEIN-TYROSINE-PHOSPHATASE INHIBITORS BLOCK TUMOR NECROSIS FACTOR-DEPENDENT ACTIVATION OF THE NUCLEAR TRANSCRIPTION FACTOR NF-KAPPA-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHENYLARSINE OXIDE; T-CELLS; SIGNAL-TRANSDUCTION; INVITRO ACTIVATION; GAMMA-INTERFERON; TNF-ALPHA; KINASE-C; PHOSPHORYLATION; BINDING	Most of the inflammatory and proviral effects of tumor necrosis factor (TNF) are mediated through the activation of the nuclear transcription factor NF-kappa B. How TNF activates NF-kappa B, however, is not well understood. We examined the role of protein phosphatases in the TNF-dependent activation of NF-kappa B. Treatment of human myeloid ML-1a cells with TNF rapidly activated (within 30 min) NF-kappa B; this effect was abolished by treating cells with inhibitors of protein-tyrosine phosphatase (PTPase), including phenylarsine oxide (PAO), pervanadate, and diamide. The inhibition was dependent on the dose and occurred whether added before or at the same time as TNF. PAO also inhibited the activation even when added 15 min after the TNF treatment of cells. In contrast to inhibitors of PTPase, okadaic acid and calyculin A, which block serine threonine phosphatase, had no effect. The effect of PTPase inhibitors was not due to the modulation of TNF receptors. Since both dithiothreitol and dimercaptopropanol reversed the inhibitory effect of PAO, critical sulfhydryl groups in the PTPase must be involved in NF-kappa B activation by TNF. PTPase inhibitors also blocked NF-kappa B activation induced by phorbol ester, ceramide, and interleukin-1 but not that activated by okadaic acid. The degradation of I kappa B protein, a critical step in NF-kappa B activation, was also abolished by the PTPase inhibitors as revealed by immunoblotting. Thus, overall, we demonstrate that PTPase is involved either directly or indirectly in the pathway leading to the activation of NF-kappa B.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CLIN IMMUNOL & BIOL THERAPY,CYTOKINE RES LAB,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Aggarwal, Bharat B/G-3388-2013					AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAJPAI A, 1993, BIOCHIM BIOPHYS ACTA, V1177, P291, DOI 10.1016/0167-4889(93)90125-9; BALLOTTI R, 1991, EXP CELL RES, V197, P300, DOI 10.1016/0014-4827(91)90436-X; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BEUTLER B, 1992, TUMOR NECROSIS FACTO, P1; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CHATURVEDI MM, 1994, LYMPHOKINE CYTOK RES, V13, P309; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DURDEN DL, 1994, EXP CELL RES, V211, P150, DOI 10.1006/excr.1994.1071; EICHER DM, 1994, J IMMUNOL, V152, P2710; ELBERG G, 1994, J BIOL CHEM, V269, P9521; EVANS GA, 1994, J BIOL CHEM, V269, P23407; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FLETCHER MC, 1993, J BIOL CHEM, V268, P23697; FROST SC, 1990, BIOCHEM J, V269, P589, DOI 10.1042/bj2690589; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GENG Y, 1993, J IMMUNOL, V151, P6692; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GIBSON AE, 1989, AM J PHYSIOL, V257, pC182, DOI 10.1152/ajpcell.1989.257.2.C182; HASSANAIN HH, 1993, ANAL BIOCHEM, V213, P162, DOI 10.1006/abio.1993.1400; HIGUCHI M, 1992, ANAL BIOCHEM, V204, P53, DOI 10.1016/0003-2697(92)90138-W; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; IIVANAINEN AV, 1990, EUR J IMMUNOL, V20, P2509, DOI 10.1002/eji.1830201123; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; KATO Y, 1992, P NATL ACAD SCI USA, V89, P8507, DOI 10.1073/pnas.89.18.8507; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KOONG AC, 1994, CANCER RES, V54, P1425; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LINK E, 1992, J BIOL CHEM, V267, P239; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MENON SD, 1993, J BIOL CHEM, V268, P26805; MONTEIRO HP, 1991, FEBS LETT, V295, P146, DOI 10.1016/0014-5793(91)81405-W; MOSS AL, 1991, J CELL PHYSIOL, V149, P313, DOI 10.1002/jcp.1041490219; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; OETKEN C, 1992, EUR J HAEMATOL, V49, P208; PEYRON JF, 1989, CELL SIGNAL, V1, P313, DOI 10.1016/0898-6568(89)90050-8; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; SANTINI F, 1993, J BIOL CHEM, V268, P22716; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; THEVENIN C, 1990, New Biologist, V2, P793; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TOTPAL K, 1992, CANCER RES, V52, P2557; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P23517; Vilcek J, 1992, TUMOR NECROSIS FACTO, P1; YANAGA F, 1993, BIOCHEM J, V298, P733	57	123	127	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10631	10639		10.1074/jbc.270.18.10631	http://dx.doi.org/10.1074/jbc.270.18.10631			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738000				2022-12-25	WOS:A1995QW60100043
J	STAFFORD, WF; MABUCHI, K; TAKAHASHI, K; TAO, T				STAFFORD, WF; MABUCHI, K; TAKAHASHI, K; TAO, T			PHYSICAL CHARACTERIZATION OF CALPONIN - A CIRCULAR-DICHROISM, ANALYTICAL ULTRACENTRIFUGE, AND ELECTRON-MICROSCOPY STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALPONIN; RAYLEIGH OPTICAL SYSTEMS; MYOSIN ATPASE ACTIVITY; THIN-FILAMENTS; MOLECULAR-WEIGHT; HEAVY-MEROMYOSIN; ACTIN; PROTEIN; PHOSPHORYLATION; TROPOMYOSIN	Calponin is a thin filament-associated smooth muscle protein that has been suggested to play a role in the regulation of smooth muscle contraction. We have used circular dichroism spectroscopy, electron microscopy, and analytical ultracentrifugation to study the physical properties of recombinant chicken gizzard alpha-calponin. The alpha-helix content of alpha-calponin was estimated from its circular dichroism spectrum to be similar to 13%. alpha-Calponin melts with a single sharp transition at similar to 57 degrees C. Rotary shadowing electron micrographs of alpha-calponin reveal diverse shapes ranging from elongated rods to collapsed coils. The lengths of the rod-shaped structures are similar to 18 nm. Analytical ultracentrifugation studies found alpha-calponin to be homogeneous with a monomer molecular mass of 31.4 kDa, and a s(20,w), value of 2.34 S. These data could be used to model alpha-calponin as a prolate ellipsoid of revolution with an axial ratio of 6.16, a length of 16.2 nn, and a diameter of 2.6 nm. Taken together, our results indicate that calponin is a flexible, elongated molecule whose contour length is sufficient to span three actin subunits along the long pitch helix of an F-actin filament.	BOSTON BIOMED RES INST, MUSCLE RES GRP, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; CTR ADULT DIS, DEPT MED, OSAKA 537, JAPAN; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Tufts University			Stafford, Walter/ABC-6553-2020		NIAMS NIH HHS [P01-AR41637] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE M, 1990, J BIOCHEM-TOKYO, V108, P835, DOI 10.1093/oxfordjournals.jbchem.a123289; ABE M, 1990, J BIOCHEM-TOKYO, V107, P507, DOI 10.1093/oxfordjournals.jbchem.a123075; ADAMS JM, 1992, ONCOGENE, V7, P611; ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; ANSEVIN AT, 1970, ANAL BIOCHEM, V34, P237, DOI 10.1016/0003-2697(70)90103-X; APPLEGATE D, 1994, J BIOL CHEM, V269, P10683; BARANY M, 1991, FEBS LETT, V279, P65, DOI 10.1016/0014-5793(91)80252-X; BARANY M, 1993, BIOCHIM BIOPHYS ACTA, V1179, P229, DOI 10.1016/0167-4889(93)90146-G; BRENNER SL, 1990, J MOL BIOL, V216, P949, DOI 10.1016/S0022-2836(99)80013-8; CHILDS TJ, 1992, BIOCHIM BIOPHYS ACTA, V1121, P41, DOI 10.1016/0167-4838(92)90334-A; DEROSIER DJ, 1972, ANAL BIOCHEM, V50, P139, DOI 10.1016/0003-2697(72)90493-9; GIMONA M, 1992, EUR J BIOCHEM, V205, P1067, DOI 10.1111/j.1432-1033.1992.tb16875.x; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GONG BJ, 1993, J BIOCHEM-TOKYO, V114, P453, DOI 10.1093/oxfordjournals.jbchem.a124197; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HORIUCHI KY, 1991, BIOCHEM BIOPH RES CO, V176, P1487, DOI 10.1016/0006-291X(91)90455-G; INIESTA A, 1988, BIOPHYS J, V54, P269, DOI 10.1016/S0006-3495(88)82956-4; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; LEHMAN W, 1991, J MUSCLE RES CELL M, V12, P221, DOI 10.1007/BF01745110; LEHRER SS, 1990, J BIOL CHEM, V265, P1134; LIN Y, 1993, J BIOCHEM-TOKYO, V113, P643, DOI 10.1093/oxfordjournals.jbchem.a124096; LIU S, 1992, Biophysical Journal, V61, pA476; MABUCHI K, 1990, J STRUCT BIOL, V103, P249, DOI 10.1016/1047-8477(90)90043-C; MABUCHI K, 1991, J STRUCT BIOL, V107, P22, DOI 10.1016/1047-8477(91)90027-T; MABUCHI K, 1994, BIOPHYS J, V66, pA197; MAKUCH R, 1991, BIOCHEM J, V280, P33, DOI 10.1042/bj2800033; MARSTON SB, 1991, FEBS LETT, V292, P179, DOI 10.1016/0014-5793(91)80862-W; NAKA M, 1990, BIOCHEM BIOPH RES CO, V171, P933, DOI 10.1016/0006-291X(90)90773-G; NISHIDA W, 1990, FEBS LETT, V268, P165, DOI 10.1016/0014-5793(90)80999-Y; NODA S, 1992, BIOCHEM BIOPH RES CO, V185, P481, DOI 10.1016/S0006-291X(05)81010-1; NORTH AJ, 1994, J CELL SCI, V107, P437; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PARKER CA, 1994, IN PRESS AM J PHYSL; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; RICHARDS EG, 1971, ANAL BIOCHEM, V41, P215, DOI 10.1016/0003-2697(71)90206-5; RICHARDS EG, 1971, ANAL BIOCHEM, V41, P189, DOI 10.1016/0003-2697(71)90205-3; RICHARDS EG, 1972, ANAL BIOCHEM, V46, P295, DOI 10.1016/0003-2697(72)90423-X; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STAFFORD WF, 1990, ARCH BIOCHEM BIOPHYS, V281, P66, DOI 10.1016/0003-9861(90)90413-S; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; SZYMANSKI PT, 1993, FEBS LETT, V331, P256, DOI 10.1016/0014-5793(93)80348-X; TAKAHASHI K, 1986, BIOCHEM BIOPH RES CO, V141, P20, DOI 10.1016/S0006-291X(86)80328-X; TAKAHASHI K, 1988, HYPERTENSION, V11, P620, DOI 10.1161/01.HYP.11.6.620; TAKAHASHI K, 1988, J HYPERTENS, V6, pS40, DOI 10.1097/00004872-198812040-00008; TAKAHASHI K, 1987, LIFE SCI, V41, P291, DOI 10.1016/0024-3205(87)90151-2; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; TAKAHASHI K, 1993, CIRCULATION, V88, P174; TAKAHASHI K, 1991, CIRCULATION S2, V84, P532; TAKEUCHI K, 1991, J BIOCHEM, V109, P311; Tanford C., 1961, PHYS CHEM MACROMOLEC; WALSH MP, 1993, AM J PHYSIOL, V265, pC1371, DOI 10.1152/ajpcell.1993.265.5.C1371; WINDER SJ, 1993, BIOCHEM J, V296, P827, DOI 10.1042/bj2960827; WINDER SJ, 1993, CELL SIGNAL, V5, P677, DOI 10.1016/0898-6568(93)90029-L; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; WINDER SJ, 1991, ADV EXP MED BIOL, V304, P37; Yphantis D, 1994, MODERN ANAL ULTRACEN, P209	60	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10576	10579		10.1074/jbc.270.18.10576	http://dx.doi.org/10.1074/jbc.270.18.10576			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737994	hybrid			2022-12-25	WOS:A1995QW60100035
J	OTERO, AS; YI, XB; GRAY, MC; SZABO, G; HEWLETT, EL				OTERO, AS; YI, XB; GRAY, MC; SZABO, G; HEWLETT, EL			MEMBRANE DEPOLARIZATION PREVENTS CELL INVASION BY BORDETELLA-PERTUSSIS ADENYLATE-CYCLASE TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HEMOLYTIC ACTIVITIES; BACILLUS-ANTHRACIS; VIRULENCE FACTORS; LIPID BILAYERS; ENTRY; TRANSLOCATION; RESOLUTION; INHIBITORS; GENE; CYAC	Adenylate cyclase toxin from Bordetella pertussis is a 177-kDa calmodulin activated enzyme that has the ability to enter eukaryotic cells and convert endogenous ATP into cAMP, Little is known, however, about the mechanism of cell entry, We now demonstrate that intoxication of cardiac myocytes by adenylate cyclase toxin is driven and controlled by the electrical potential across the plasma membrane. The steepness of the voltage dependence of intoxication is comparable with that previously observed for the activation of K+ and Na+ channels of excitable membranes. The voltage-sensitive process is downstream from toxin binding to the cell surface and appears to correspond to the translocation of the catalytic domain across the membrane.	UNIV VIRGINIA,SCH MED,DEPT MED,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia	OTERO, AS (corresponding author), UNIV VIRGINIA,SCH MED,DEPT MOLEC PHYSIOL & BIOL PHYS,JORDAN HALL,BOX 449,CHARLOTTESVILLE,VA 22908, USA.			gray, mary/0000-0003-4441-5905	NHLBI NIH HHS [HL 37127, HL 48726] Funding Source: Medline; NIAID NIH HHS [AI 18000] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL037127, R01HL037127, R01HL048726] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018000] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; BLAUSTEIN RO, 1989, P NATL ACAD SCI USA, V86, P2209, DOI 10.1073/pnas.86.7.2209; CHAUMONT F, 1990, J BIOL CHEM, V265, P16856; CHERRY J D, 1988, Pediatrics, V81, P939; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; CONFER DL, 1984, ADV CYCLIC NUCL PROT, V17, P183; EHRMANN IE, 1992, FEBS LETT, V304, P51, DOI 10.1016/0014-5793(92)80587-7; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; GENTILE F, 1990, J BIOL CHEM, V265, P10686; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; GORDON VM, 1989, J BIOL CHEM, V264, P14792; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hannavy K, 1993, CURR OPIN CELL BIOL, V5, P694, DOI 10.1016/0955-0674(93)90142-D; HANSKI E, 1985, J BIOL CHEM, V260, P5526; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; HEWLETT EL, 1993, J BIOL CHEM, V268, P7842; HEWLETT EL, 1994, HDB NATURAL TOXINS, V8, P425; Hille B., 1992, IONIC CHANNELS EXCIT, P23; HOCH DH, 1985, P NATL ACAD SCI USA, V82, P1692, DOI 10.1073/pnas.82.6.1692; HUDSON TH, 1988, J BIOL CHEM, V263, P4773; KHELEF N, 1992, MICROB PATHOGENESIS, V12, P227, DOI 10.1016/0882-4010(92)90057-U; LI YX, 1994, J GEN PHYSIOL, V104, P941, DOI 10.1085/jgp.104.5.941; MARTIN J, 1991, J BIOL CHEM, V266, P18051; MENESTRINA G, 1990, TOXICON, V28, P477, DOI 10.1016/0041-0101(90)90292-F; OTERO AD, 1993, MOL PHARMACOL, V44, P595; PEARSON RD, 1987, J IMMUNOL, V139, P2749; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SZABO G, 1994, J BIOL CHEM, V269, P22496; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; WEISS AA, 1984, J INFECT DIS, V150, P219, DOI 10.1093/infdis/150.2.219; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661	33	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9695	9697		10.1074/jbc.270.17.9695	http://dx.doi.org/10.1074/jbc.270.17.9695			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730345	hybrid			2022-12-25	WOS:A1995QV41700002
J	ROSS, SA; ZHANG, MX; SELMAN, BR				ROSS, SA; ZHANG, MX; SELMAN, BR			ROLE OF THE CHLAMYDOMONAS-REINHARDTII COUPLING FACTOR-1 GAMMA-SUBUNIT CYSTEINE BRIDGE IN THE REGULATION OF ATP SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I CF1; NUCLEAR TRANSFORMATION; NITRATE REDUCTASE; THIOL MODULATION; GENE; ACTIVATION; MUTANT; PHOTOPHOSPHORYLATION; DITHIOTHREITOL; PURIFICATION	The gamma-subunit of coupling factor 1 (CF1) contains a cysteine bridge that is thought to be involved in the redox control of enzymatic activity, In order to test the regulatory significance of this disulfide bond, genetic transformation experiments with Chlamydomonas reinhardtii were performed. C. reinhardtii strain atpC1 (nit1-305, cw 15, mt(-)), which is null for the gamma-subunit, was transformed and complemented with gamma-subunit constructs containing amino acid substitutions localized to the cysteine bridge between Cys(198) and Cys(204), Successful complementation was confirmed by phenotypic swlection, Northern blot analysis, reverse transcription polymerase chain reaction, and cDNA sequencing, CF1 ATPase activities of the soluble enzymes were measured in the presence and absence of dithiothreitol (DTT), Mutant CF1 enzymes showed no effect of DTT although increased activity was observed for the wild-type enzyme. In vitro, phenazine methosulfate dependent photophosphorylation assays revealed that wild-type CF1 exhibits a a-fold stimulation in the presence of 25 mM DTT, whereas each of the mutant enzymes has activities that are DTT independent. Growth measurements indicated that despite the absence of a regulatory disulfide/dithiol, the mutant strains grew with the same kinetics as wild type. This study provides evidence to illustrate the involvement of the gamma-subunit in the redox regulation of ATP synthesis in vivo, This work is also the first demonstration in C. reinhardtii of stable nuclear transformation using mutated genes to complement a known defect.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								DIENER DR, 1990, P NATL ACAD SCI USA, V87, P5739, DOI 10.1073/pnas.87.15.5739; FERNANDEZ E, 1989, P NATL ACAD SCI USA, V86, P6449, DOI 10.1073/pnas.86.17.6449; GABRYS H, 1994, PLANT PHYSIOL, V104, P769, DOI 10.1104/pp.104.2.769; HANGARTER RP, 1987, J BIOL CHEM, V262, P13513; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HASNAIN SE, 1985, MOL CELL BIOL, V5, P3647, DOI 10.1128/MCB.5.12.3647; JUNESCH U, 1985, BIOCHIM BIOPHYS ACTA, V809, P429, DOI 10.1016/0005-2728(85)90194-X; JUNESCH U, 1987, BIOCHIM BIOPHYS ACTA, V893, P275, DOI 10.1016/0005-2728(87)90049-1; KETCHAM SR, 1984, J BIOL CHEM, V259, P7286; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; KINDLE KL, 1989, J CELL BIOL, V109, P2589, DOI 10.1083/jcb.109.6.2589; KRAMER DM, 1990, PHOTOSYNTH RES, V26, P213, DOI 10.1007/BF00033134; MCCARTY RE, 1984, ENZYMES BIOL MEMBR, P383; MERCHANT S, 1985, PHOTOSYNTH RES, V6, P3, DOI 10.1007/BF00029044; MILLS JD, 1984, BIOCHIM BIOPHYS ACTA, V764, P93, DOI 10.1016/0005-2728(84)90145-2; MITCHELL DR, 1991, J CELL BIOL, V113, P835, DOI 10.1083/jcb.113.4.835; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; NALIN CM, 1984, J BIOL CHEM, V259, P7275; NOCTOR G, 1988, BIOCHIM BIOPHYS ACTA, V935, P53, DOI 10.1016/0005-2728(88)90107-7; ORT DR, 1992, ANNU REV PLANT PHYS, V43, P269, DOI 10.1146/annurev.pp.43.060192.001413; QUINN J, 1993, J BIOL CHEM, V268, P7832; SAGER R, 1953, ANN NY ACAD SCI, V56, P831, DOI 10.1111/j.1749-6632.1953.tb30261.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELMAN BR, 1976, J BIOENERG BIOMEMBR, V8, P143, DOI 10.1007/BF00748960; SELMANREIMER S, 1981, BIOCHEMISTRY-US, V20, P5476, DOI 10.1021/bi00522a020; SELMANREIMER S, 1986, PROGR PHOTOSYNTHESIS; SHAHAK Y, 1985, J BIOL CHEM, V260, P1459; SHAVIT N, 1980, ANNU REV BIOCHEM, V49, P111, DOI 10.1146/annurev.bi.49.070180.000551; SMART EJ, 1991, MOL CELL BIOL, V11, P5053, DOI 10.1128/MCB.11.10.5053; SMART EJ, 1993, J BIOENERG BIOMEMBR, V25, P275, DOI 10.1007/BF00762588; SODEINDE OA, 1993, P NATL ACAD SCI USA, V90, P9199, DOI 10.1073/pnas.90.19.9199; STROTMANN H, 1987, FEBS LETT, V221, P265, DOI 10.1016/0014-5793(87)80938-9; WERNER S, 1990, FEBS LETT, V126, P204; YU LM, 1988, J BIOL CHEM, V263, P19342	35	33	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					9813	9818		10.1074/jbc.270.17.9813	http://dx.doi.org/10.1074/jbc.270.17.9813			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730361	hybrid			2022-12-25	WOS:A1995QV41700020
J	SHAROM, FJ; DIDIODATO, G; YU, XH; ASHBOURNE, KJD				SHAROM, FJ; DIDIODATO, G; YU, XH; ASHBOURNE, KJD			INTERACTION OF THE P-GLYCOPROTEIN MULTIDRUG TRANSPORTER WITH PEPTIDES AND IONOPHORES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; PREDICTED TRANSMEMBRANE DOMAIN; FUNCTIONAL CONSEQUENCES; DEPENDENT TRANSPORT; MEMBRANE-VESICLES; RESISTANCE PUMP; ATPASE ACTIVITY; GENE; MUTATIONS; RECONSTITUTION	P-glycoprotein functions as an ATP-driven active efflux pump for many cytotoxic drugs. We now show that hydrophobic peptides and ionophores also interact with the multidrug transporter. Multidrug-resistant cells are cross-resistant to several hydrophobic peptides and ionophores, but not to some other membrane-active species. Linear peptides, cyclic peptides, and ionophores stimulated the ATPase activity of P-glycoprotein in plasma membrane vesicles by up to 2.5-fold. Drugs and chemosensitizers were able to block P-glycoprotein ATPase stimulation by verapamil, however, peptides and ionophores (with the exception of cyclosporine A) were unable to do so. Peptides and ionophores also effectively inhibited ATP-dependent drug transport by P-glycoprotein in plasma membrane vesicles, The median effect analysis was used to extract quantitative parameters from the drug transport inhibition data. Unlike drug substrates and cyclic peptides, linear peptides did not inhibit photoaffinity labeling of P-glycoprotein by [H-3]azidopine, Taken together, these results indicate that certain hydrophobic peptides and ionophores are P-glycoprotein substrates, however, they affect the transporter in a different manner from drugs, Linear peptides interact with P-glycoprotein at a site distinct from those for verapamil and azidopine, whereas the interaction site for cyclic peptides and ionophores appears to be linked to these sites to varying degrees. Export of hydrophobic peptides may be an important physiological function of P-glycoprotein.			SHAROM, FJ (corresponding author), UNIV GUELPH, GUELPH WATERLOO CTR GRAD WORK CHEM, DEPT CHEM & BIOCHEM, GUELPH, ON N1G 2W1, CANADA.		Excoffon, Katherine/ABC-5037-2021; Sharom, Frances/A-1613-2010	Excoffon, Katherine/0000-0003-3945-0298; Sharom, Frances/0000-0002-9521-5367				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AMES GF, 1992, FASEB J, V6, P2660, DOI 10.1096/fasebj.6.9.1377140; ASSARAF YG, 1994, EUR J BIOCHEM, V222, P813, DOI 10.1111/j.1432-1033.1994.tb18928.x; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOU TC, 1983, TRENDS PHARMACOL SCI, V4, P450, DOI 10.1016/0165-6147(83)90490-X; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; DHIR R, 1993, BIOCHEMISTRY-US, V32, P9492, DOI 10.1021/bi00087a030; Doige C A, 1991, Protein Expr Purif, V2, P256, DOI 10.1016/1046-5928(91)90081-S; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P161, DOI 10.1016/0005-2736(92)90079-2; ERTEL A, 1993, BIOPHYS J, V64, P426, DOI 10.1016/S0006-3495(93)81383-3; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; HOLLAND IB, 1990, BIOCHIMIE, V72, P131, DOI 10.1016/0300-9084(90)90138-7; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HORIO M, 1991, BIOCHIM BIOPHYS ACTA, V1061, P106, DOI 10.1016/0005-2736(91)90274-C; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; LOE DW, 1994, BBA-BIOMEMBRANES, V1190, P72, DOI 10.1016/0005-2736(94)90035-3; LOE DW, 1993, BRIT J CANCER, V68, P342, DOI 10.1038/bjc.1993.338; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1993, J BIOL CHEM, V268, P19965; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SAEKI T, 1993, J BIOL CHEM, V268, P6077; SAFA AR, 1988, P NATL ACAD SCI USA, V85, P7187, DOI 10.1073/pnas.85.19.7187; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SARKADI B, 1994, FASEB J, V8, P766, DOI 10.1096/fasebj.8.10.7914178; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SHAROM FJ, 1995, IN PRESS BIOCH J; SHIRAI A, 1994, BBA-MOL CELL RES, V1222, P400, DOI 10.1016/0167-4889(94)90047-7; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; TOPPMEYER DL, 1994, BIOCHEM PHARMACOL, V48, P609, DOI 10.1016/0006-2952(94)90292-5; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; ZHANG L, 1994, J BIOL CHEM, V269, P15973	44	102	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10334	10341		10.1074/jbc.270.17.10334	http://dx.doi.org/10.1074/jbc.270.17.10334			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730340	hybrid			2022-12-25	WOS:A1995QV41700089
J	VALGEIRSDOTTIR, S; ERIKSSON, A; NISTER, M; HELDIN, CH; WESTERMARK, B; CLAESSONWELSH, L				VALGEIRSDOTTIR, S; ERIKSSON, A; NISTER, M; HELDIN, CH; WESTERMARK, B; CLAESSONWELSH, L			COMPARTMENTALIZATION OF AUTOCRINE SIGNAL-TRANSDUCTION PATHWAYS IN SIS-TRANSFORMED NIH 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN SARCOMA-VIRUS; GROWTH-FACTOR RECEPTOR; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; FAMILY TYROSINE KINASES; PDGF BETA-RECEPTOR; V-SIS; PHOSPHORYLATION SITES; SRC FAMILY; AUTOPHOSPHORYLATION SITES; PHOSPHOLIPASE C-GAMMA-1	The transforming protein of simian sarcoma virus is homologous to the platelet-derived growth factor (PDGF) B-chain. Fibroblasts transformed with simian sarcoma virus constitutively produce a growth factor that stimulates the endogenous tyrosine kinase of PDGF receptors in an autocrine manner, Autophosphorylation of PDGF receptors upon ligand stimulation provides binding sites for Src homology 2 domains of intracellular signaling molecules, which thereby become activated, We have characterized the PDGF receptor-mediated signal transduction in NIH 3T3 cells transformed with a PDGF B-chain cDNA (Sis 3T3 cells) in the absence and presence of suramin, a polyanionic compound that quenches PDGF-induced mitogenicity and reverts the transformed phenotype of the Sis 3T3 cells, Our data show that in the presence of suramin the general level of tyrosine phosphorylation was decreased, Nevertheless, autophosphorylated receptors complexed with substrates persisted in the cells, Suramin had no effect on activation of phosphatidylinositol 3'-kinase or an tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein of Ras. On the other hand, kinase activation of Src and Raf-1, phosphorylation of protein-tyrosine phosphatase 1D/Syp and Shc, and complex formation with Grb2 were greatly diminished by suramin. A possible explanation for our findings is that different PDGF receptor-coupled signaling pathways are active in different structural or functional compartments in the cell, Those pathways that are not affected by suramin might elicit distinct cellular responses, which are not sufficient for growth and transformation.	UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital	VALGEIRSDOTTIR, S (corresponding author), BIOMED CTR,LUDWIG INST CANC RES,BOX 595,S-75124 UPPSALA,SWEDEN.							AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P3942, DOI 10.1073/pnas.89.9.3942; ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BOURASSA C, 1988, ANAL BIOCHEM, V169, P356, DOI 10.1016/0003-2697(88)90295-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1987, P NATL ACAD SCI USA, V84, P8796, DOI 10.1073/pnas.84.24.8796; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CLAESSONWELSH L, 1993, BIOL PLATELET DERIVE, V5, P31; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HERMANSON M, 1992, CANCER RES, V52, P3213; HUANG SS, 1988, J BIOL CHEM, V263, P12608; JOHNSSON A, 1986, EMBO J, V5, P1535, DOI 10.1002/j.1460-2075.1986.tb04394.x; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAROCHELLE WJ, 1993, BIOL PLATELET DERIVE, V5, P129; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; NISTER M, 1991, J BIOL CHEM, V266, P16755; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAPP UR, 1991, ONCOGENE, V6, P495; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SMITS A, 1992, AM J PATHOL, V140, P639; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VALIUS M, 1993, MOL CELL BIOL, V13, P183; VASSBOTN FS, 1994, J CELL PHYSIOL, V158, P381, DOI 10.1002/jcp.1041580221; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEIMA SM, 1990, EXP CELL RES, V186, P324, DOI 10.1016/0014-4827(90)90312-X; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; WENNSTROM S, 1994, ONCOGENE, V9, P651; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	64	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10161	10170		10.1074/jbc.270.17.10161	http://dx.doi.org/10.1074/jbc.270.17.10161			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730319	hybrid			2022-12-25	WOS:A1995QV41700066
J	KOJIMA, S; MURAMATSU, H; AMANUMA, H; MURAMATSU, T				KOJIMA, S; MURAMATSU, H; AMANUMA, H; MURAMATSU, T			MIDKINE ENHANCES FIBRINOLYTIC-ACTIVITY OF BOVINE ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-RESPONSIVE GENE; GROWTH-FACTOR-BETA; PLASMINOGEN-ACTIVATOR INHIBITOR; EMBRYONAL CARCINOMA-CELLS; RETINOIC ACID; MOLECULAR-CLONING; UP-REGULATION; VITAMIN-A; EXPRESSION; DIFFERENTIATION	A hitherto unknown function of midkine (MK) was found in the regulation of fibrinolytic activity of vascular endothelial cells. Recombinant murine MR enhanced plasminogen activator (PA)/plasmin levels in bovine aortic endothelial cells (BAECs) in a dose- and time dependent manner. After incubation with 10 ng/ml MK for 18 h, PA and plasmin levels increased 6- and 4-fold, respectively. This effect was attributed to a moderate upregulation of urokinase-type PA expression as well as to a significant down-regulation of PA inhibitor-1 (PAI-1) expression. BAECs constitutively synthesized and secreted MK and its production was enhanced 2-fold with 1 mu M retinoic acid or 10 mu M retinol. It was found that MK served as a substrate for tissue transglutaminase. In the culture medium, MK existed as a transglutaminase-mediated complex of 36 kDa. Addition of anti-MR antibody to BAEC cultures resulted in a decrease of basal PA activity and an increase of basal PAI-1 levels and attenuated the ability of retinol to enhance PA activity 50% and potentiated the ability to increase PAI-1 levels 4-fold. Furthermore, MK and basic fibroblast growth factor (bFGF) acted more than additively in enhancing PA levels. We conclude that in BAECs MK is a novel autocrine factor sustaining the fibrinolytic property. MK functions as a mediator of retinoid and cooperates with bFGF to enhance fibrinolytic activity of BAECs.	NAGOYA UNIV, SCH MED, DEPT BIOCHEM, SHOWA KU, NAGOYA, AICHI 466, JAPAN	Nagoya University	KOJIMA, S (corresponding author), INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, GENE TECHNOL & SAFETY LAB, TSUKUBA, IBARAKI 305, JAPAN.		Kojima, Soichi/N-7104-2015	Kojima, Soichi/0000-0002-5252-1612				BEACH RS, 1983, BIOCHEM BIOPH RES CO, V114, P395, DOI 10.1016/0006-291X(83)91640-6; BENDIXEN E, 1993, J BIOL CHEM, V268, P21962; BRAUNHUT SJ, 1991, MICROVASC RES, V41, P47, DOI 10.1016/0026-2862(91)90007-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECLERCK PJ, 1988, BLOOD, V71, P220; DENT MAR, 1993, EUR J NEUROSCI, V5, P633, DOI 10.1111/j.1460-9568.1993.tb00529.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Flaumenhaft R, 1993, Adv Pharmacol, V24, P51, DOI 10.1016/S1054-3589(08)60933-3; Gudas Lorraine J., 1994, P443; HALL SW, 1991, J BIOL CHEM, V266, P12329; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HORIE S, 1992, BIOCHEM J, V281, P149, DOI 10.1042/bj2810149; INADA Y, 1985, BIOCHEM BIOPH RES CO, V130, P182, DOI 10.1016/0006-291X(85)90399-7; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KOJIMA S, 1986, BIOSCIENCE REP, V6, P1029, DOI 10.1007/BF01141023; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; KOJIMA S, 1993, J CELL PHYSIOL, V155, P323, DOI 10.1002/jcp.1041550213; KOJIMA S, 1995, BIOCHEM BIOPH RES CO, V206, P468, DOI 10.1006/bbrc.1995.1066; KOJIMA S, 1986, BIOMED RES-TOKYO, V7, P155; KRATZSCHMAR J, 1993, GENE, V125, P177, DOI 10.1016/0378-1119(93)90325-W; LAAROUBI K, 1994, GROWTH FACTORS, V10, P89, DOI 10.3109/08977199409010982; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; LOSKUTOFF DJ, 1988, METHOD ENZYMOL, V163, P293; LOTTENBERG R, 1981, METHOD ENZYMOL, V80, P341; MARTIN TJ, 1993, GROWTH REGULAT, V3, P209; MARUTA H, 1993, GROWTH FACTORS, V8, P119, DOI 10.3109/08977199309046932; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MICHIKAWA M, 1993, J NEUROSCI RES, V35, P530, DOI 10.1002/jnr.490350509; MICHIKAWA M, 1993, BIOCHEM BIOPH RES CO, V192, P1312, DOI 10.1006/bbrc.1993.1559; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MULLINS DE, 1990, HDB EXPT PHARM, V95, P481; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; MURAMATSU H, 1993, DEV BIOL, V159, P392, DOI 10.1006/dbio.1993.1250; MURAMATSU H, 1994, BIOCHEM BIOPH RES CO, V203, P1131, DOI 10.1006/bbrc.1994.2300; MURAMATSU T, 1994, DEV GROWTH DIFFER, V36, P1; MURAMATSU T, 1993, INT J DEV BIOL, V37, P183; MURASE K, 1991, BIOCHEM INT, V25, P29; NARA K, 1989, J BIOL CHEM, V264, P19308; NURCOMBE V, 1992, DEVELOPMENT, V116, P1175; PAIGE K, 1991, IN VITRO CELL DEV B, V27, P151; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; Sambrook J, 1989, MOL CLONING LABORATO; SATOH J, 1993, DEV BRAIN RES, V75, P201, DOI 10.1016/0165-3806(93)90024-5; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; TOMOMURA M, 1990, J BIOL CHEM, V265, P10765; TOMOMURA M, 1990, BIOCHEM BIOPH RES CO, V171, P603, DOI 10.1016/0006-291X(90)91189-Y; TSUTSUI J, 1993, CANCER RES, V53, P1281; URIOS P, 1991, BIOCHEM BIOPH RES CO, V175, P617, DOI 10.1016/0006-291X(91)91610-O	53	125	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9590	9596		10.1074/jbc.270.16.9590	http://dx.doi.org/10.1074/jbc.270.16.9590			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721890	hybrid			2022-12-25	WOS:A1995QU08900079
J	DEVRIES, T; SRNKA, CA; PALCIC, MM; SWIEDLER, SJ; VANDENEIJNDEN, DH; MACHER, BA				DEVRIES, T; SRNKA, CA; PALCIC, MM; SWIEDLER, SJ; VANDENEIJNDEN, DH; MACHER, BA			ACCEPTOR SPECIFICITY OF DIFFERENT LENGTH CONSTRUCTS OF HUMAN RECOMBINANT ALPHA-1,3/4-FUCOSYL-TRANSFERASES - REPLACEMENT OF THE STEM REGION AND THE TRANSMEMBRANE DOMAIN OF FUCOSYL-TRANSFERASE-V BY PROTEIN-A RESULTS IN AN ENZYME WITH GDP-FUCOSE HYDROLYZING ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; ELAM-1-DEPENDENT CELL-ADHESION; DIMERIC LEX ANTIGEN; E-SELECTIN LIGAND; EMBRYONIC ANTIGEN; SUBSTRATE SPECIFICITIES; LINKED OLIGOSACCHARIDES; MONOCLONAL-ANTIBODIES; DETERMINES EXPRESSION	The acceptor specificity of recombinant full-length, membrane-bound fucosyltransferases, expressed in COS-7 cells, and soluble, protein-A chimeric forms of alpha 1,3-fucosyltransferase (Fuc-T) III, Fuc-TIV, and Fuc-TV was analyzed toward a broad panel of oligosaccharide, glycolipid, and glycoprotein substrates. Our results on the full-length enzymes confirm and extend previous studies. However, chimeric Fuc-Ts showed increased activity toward glycoproteins, whereas chimeric Fuc-TIII and Fuc-TV had a decreased activity with glycosphingolipids, compared to the full-length enzymes. Unexpectedly, chimeric Fuc-TV exhibited a GDP-fucose hydrolyzing activity. In substrates with multiple acceptor sites, the preferred site of fucosylation was identified. Fuc-TIII and Fuc-TV catalyzed fucose transfer exclusively to OH-3 of glucose in lacto-N-neotetraose and lacto-N-tetraose, respectively, as was demonstrated by H-1 MMR spectroscopy. Thin layer chromatography immunostaining revealed that FucT-IV preferred the distal GlcNAc residue in nLc(6)Cer, whereas Fuc-TV preferred the proximal GlcNAc residue. Incubation of Fuc-TIV or Fuc-TV with VI(3)NeuAcnLc(6)Cer resulted in products with the sialyl-Lewis(X) epitope as well as the VIM-2 structure. To identify polar groups on accepters that function in enzyme binding, deoxygenated substrate analogs were tested as accepters. All three Fuc-Ts had an absolute requirement for a hydroxyl at C-6 of galactose in addition to the accepting hydroxyl at C-3 or C-4 of GlcNAc.	SAN FRANCISCO STATE UNIV, DEPT CHEM & BIOCHEM, SAN FRANCISCO, CA 94132 USA; GLYCOMED INC, ALAMEDA, CA 94501 USA; UNIV ALBERTA, DEPT CHEM, EDMONTON, AB T6G 2G2, CANADA	California State University System; San Francisco State University; University of Alberta	DEVRIES, T (corresponding author), VRIJE UNIV AMSTERDAM, DEPT MED CHEM, VAN DE BOECHORSTSTR 7, 1081 BT AMSTERDAM, NETHERLANDS.				NCI NIH HHS [CA32826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BREG J, 1988, CARBOHYD RES, V183, P19, DOI 10.1016/0008-6215(88)80042-9; BUEHLER J, 1986, ANAL BIOCHEM, V158, P283, DOI 10.1016/0003-2697(86)90551-8; DAVIS LG, 1986, BASIC METHODS MOL BI, P290; DEVRIES T, 1994, BIOCHEMISTRY-US, V33, P9937, DOI 10.1021/bi00199a016; DEVRIES T, 1993, EUR J BIOCHEM, V216, P769, DOI 10.1111/j.1432-1033.1993.tb18197.x; DEVRIES T, 1992, HISTOCHEM J, V24, P761, DOI 10.1007/BF01046347; DONALD ASR, 1988, CARBOHYD RES, V178, P79, DOI 10.1016/0008-6215(88)80103-4; EASTON EW, 1993, BLOOD, V81, P2978; FEIZI T, 1987, BIOCHEM J, V245, P1; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FENDERSON BA, 1986, DEV BIOL, V114, P12, DOI 10.1016/0012-1606(86)90379-9; FOSTER CS, 1991, J BIOL CHEM, V266, P3526; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; GREEN ED, 1988, J BIOL CHEM, V263, P18253; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HANISCH FG, 1988, CARBOHYD RES, V178, P23, DOI 10.1016/0008-6215(88)80099-5; HAO YL, 1973, BIOCHIM BIOPHYS ACTA, V322, P99, DOI 10.1016/0005-2795(73)90180-3; HE PG, 1993, ARCH BIOCHEM BIOPHYS, V305, P350, DOI 10.1006/abbi.1993.1432; HINDSGAUL O, 1991, J BIOL CHEM, V266, P17858; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V274, P633, DOI 10.1016/0003-9861(89)90479-7; HOLMES EH, 1993, ARCH BIOCHEM BIOPHYS, V301, P190, DOI 10.1006/abbi.1993.1132; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; HUANG LC, 1983, BLOOD, V61, P1020; ICHIKAWA Y, 1992, J AM CHEM SOC, V114, P9283, DOI 10.1021/ja00050a007; JEZEQUELCUER M, 1993, BIOCHIM BIOPHYS ACTA, V1157, P252, DOI 10.1016/0304-4165(93)90107-J; JOHNSON PH, 1992, GLYCOCONJUGATE J, V9, P251, DOI 10.1007/BF00731137; JOHNSON PH, 1993, GLYCOCONJUGATE J, V10, P152, DOI 10.1007/BF00737712; JOHNSON PH, 1989, 10TH P INT S GLYC, P214; JOZIASSE DH, 1985, J BIOL CHEM, V260, P4941; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; LEMIEUX RU, 1985, 8TH P INT S MED CHEM, V1, P329; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; MACHER BA, 1988, J BIOL CHEM, V263, P10186; MATSUSAKO T, 1991, BIOCHEM BIOPH RES CO, V181, P1218, DOI 10.1016/0006-291X(91)92068-U; MATSUSHITA Y, 1991, EXP CELL RES, V196, P20, DOI 10.1016/0014-4827(91)90451-Y; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PAULSON JC, 1982, J BIOL CHEM, V257, P2734; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PLATZER N, 1989, CARBOHYD RES, V191, P191, DOI 10.1016/0008-6215(89)85064-5; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; ROBINSON NE, 1994, GLYCOBIOLOGY, V4, P317, DOI 10.1093/glycob/4.3.317; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNESTO A, 1992, J BIOL CHEM, V267, P2745; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STRECKER G, 1989, GLYCOCONJUGATE J, V6, P67, DOI 10.1007/BF01047891; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; TOWNSEND RR, 1989, ANAL BIOCHEM, V182, P1; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WESTRICK MA, 1983, CANCER RES, V43, P5890; WLASICHUK KB, 1993, J BIOL CHEM, V268, P13971; YOUNG WW, 1981, J BIOL CHEM, V256, P967	69	132	138	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8712	8722		10.1074/jbc.270.15.8712	http://dx.doi.org/10.1074/jbc.270.15.8712			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721776	hybrid			2022-12-25	WOS:A1995QT44800054
J	OBIRI, NI; DEBINSKI, W; LEONARD, WJ; PURI, RK				OBIRI, NI; DEBINSKI, W; LEONARD, WJ; PURI, RK			RECEPTOR FOR INTERLEUKIN-13 - INTERACTION WITH INTERLEUKIN-4 BY A MECHANISM THAT DOES NOT INVOLVE THE COMMON GAMMA-CHAIN SHARED BY RECEPTORS FOR INTERLEUKIN-2, INTERLEUKIN-4, INTERLEUKIN-7, INTERLEUKIN-9 AND INTERLEUKIN-15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN B-CELLS; FUNCTIONAL COMPONENT; IL-2 RECEPTOR; IGE SYNTHESIS; KILLER-CELLS; EXPRESSION; CYTOKINE; DIFFERENTIATION; PROLIFERATION; ACTIVATION	Interleukin 13 (IL-13) shares many biological properties with IL-4, and although the receptor for IL-4 (IL-4R) has been characterized, the expression and structure of IL-13 receptor are unknown. We report here that human renal cell carcinoma (RCC) cells express large numbers of functional IL-13R. Human B lymphocytes and monocytes expressed a very small number of IL-13R, while resting or activated human T cells expressed little or no IL-13R, IL-4 did not compete for IL-13 binding, while IL-13 competed for IL-4 binding, even though IL-4R and IL-13R are structurally distinct on human RCC cells. IL-13 cross-linked with one major protein that is similar in size to the gamma(c) subunit of IL-2, -4, -7, -9, and -15 receptors but was not recognized by anti-gamma(c) or anti-IL-4R antibodies. IL-4, on the other hand, cross linked with two major proteins, the smaller of which appears to be similar in size to IL-13R and gamma(c), but (like the IL-13R) it did not react with anti-gamma(c) antibody. Although as shown in this study and in previous studies, gamma(c) is a functional component of IL-4R in lymphoid cells, it does not appear to be associated with IL-4R on RCC cells. Even in the absence of common gamma chain IL-4 and IL-13 were able to up-regulate intracellular adhesion molecule-1 antigen on RCC cells. These data suggest that the interaction of IL-13 with IL-4R does not involve gamma(c) and IL-13R itself may be a novel subunit of the IL-4R.	US FDA,CTR BIOL EVALUAT & RES,DIV CELLULAR & GENE THERAPIES,MOLEC TUMOR BIOL LAB,BETHESDA,MD 20892; PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT SURG,DIV NEUROSURG,HERSHEY,PA 17033; PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033; NHLBI,MOLEC IMMUNOL LAB,BETHESDA,MD 20892	US Food & Drug Administration (FDA); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Leonard, Warren/AAA-1397-2022					AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; BROWN KD, 1989, J IMMUNOL, V142, P679; CARLSSON M, 1989, EUR J IMMUNOL, V19, P913, DOI 10.1002/eji.1830190519; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; DEFRANCET, 1994, J EXP MED, V179, P135; DEWIT H, 1994, BLOOD, V84, P608; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; MALEFYT RD, 1993, RES IMMUNOL, V144, P629, DOI 10.1016/S0923-2494(05)80016-1; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOGUCHI M, 1993, J BIOL CHEM, V268, P13601; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RIGLEY KP, 1991, INT IMMUNOL, V3, P197, DOI 10.1093/intimm/3.2.197; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Sambrook J, 1989, MOL CLONING LABORATO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; VOSS SD, 1992, J EXP MED, V176, P531, DOI 10.1084/jem.176.2.531; WEBB DSA, 1991, J IMMUNOL, V146, P3682; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	31	244	257	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8797	8804		10.1074/jbc.270.15.8797	http://dx.doi.org/10.1074/jbc.270.15.8797			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721786	hybrid			2022-12-25	WOS:A1995QT44800064
J	OTOOLE, TE; YLANNE, J; CULLEY, BM				OTOOLE, TE; YLANNE, J; CULLEY, BM			REGULATION OF INTEGRIN AFFINITY STATES THROUGH AN NPXY MOTIF IN THE BETA-SUBUNIT CYTOPLASMIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; AMINO-ACID-SEQUENCE; DENSITY-LIPOPROTEIN RECEPTOR; PLATELET GPIIB-IIIA; FIBRONECTIN RECEPTOR; LAMININ RECEPTOR; CELL-ADHESION; ALPHA; INTERNALIZATION; ACTIVATION	The ligand binding affinities of the integrins are regulated through their cytoplasmic domains. To identify specific residues that are involved in this process, we have generated mutants in the beta(1) and beta(3) tails and coexpressed them in Chinese hamster ovary cells with constitutively active alpha subunits. These alpha subunits are chimera of extracellular and transmembrane alpha(IIb) joined to the cytoplasmic domains of alpha(5), alpha(6A), or alpha(6B), and confer an energy-dependent high affinity state when expressed in Chinese hamster ovary cells. The affinity state of these transfectants was determined by analyzing the binding of PAC1, an antibody that specifically recognizes the activated form of the reporter group, extracellular alpha(IIb)beta(3). We have identified point mutants in several areas of the beta tails, which result in a reduced ability to bind ligand. Complete abolition of PAC1 binding was obtained with mutants in an NPXY motif found in many integrin beta subunits and implicated in the internalization of other cell surface receptors. Similar effects on PAC1 binding were observed whether coexpression was with alpha chimera containing alpha(5), alpha(6A), or alpha(6B) cytoplasmic sequences. These studies identify a novel role for the NPXY motif in the regulation of integrin binding affinity.	HELSINKI UNIV, DEPT BIOCHEM, SF-00014 HELSINKI, FINLAND	Finland National Institute for Health & Welfare; University of Helsinki	OTOOLE, TE (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA.		O'Toole, Timothy/I-4172-2013	Ylanne, Jari/0000-0003-4627-021X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48728] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BRIESEWITZ R, 1993, MOL BIOL CELL, V4, P593, DOI 10.1091/mbc.4.6.593; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHEN YP, 1994, J BIOL CHEM, V269, P18307; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CROWE DT, 1994, J BIOL CHEM, V269, P1411; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; DRUKER BJ, 1992, J VIROL, V66, P5770, DOI 10.1128/JVI.66.10.5770-5776.1992; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GINSBERG MH, 1980, BLOOD, V55, P661; GINSBERG MH, 1983, METHODS HEMATOLOGY, P158; HAYASHI Y, 1990, J CELL BIOL, V110, P75; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HOGERVORST F, 1993, J BIOL CHEM, V268, P18427; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KASSNER PD, 1993, J EXP MED, V178, P649, DOI 10.1084/jem.178.2.649; KAWAGUCHI S, 1994, MOL BIOL CELL, V5, P977, DOI 10.1091/mbc.5.9.977; KAWAGUCHI S, 1993, J BIOL CHEM, V268, P16279; KISHIMOTO TK, 1987, J CELL BIOL, V108, P703; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LUSKASHEV ME, 1994, J BIOL CHEM, V269, P18311; Maniatis T, 1989, DECONTAMINATION DILU; MCLEAN JW, 1990, J BIOLL CHEM, V265, P17216; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1989, BLOOD, V74, P14; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; RABB H, 1993, J IMMUNOL, V151, P990; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHAW LM, 1993, J CELL BIOL, V123, P1017, DOI 10.1083/jcb.123.4.1017; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; TAPLEY P, 1989, ONCOGENE, V4, P325; VANKUPPEVELT THMSM, 1989, P NATL ACAD SCI USA, V86, P5415; VIGNOUD L, 1994, BIOCHEM BIOPH RES CO, V199, P603, DOI 10.1006/bbrc.1994.1271; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; ZIMRIN AB, 1988, J CLIN INVEST, V81, P1470, DOI 10.1172/JCI113478	48	170	173	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8553	8558		10.1074/jbc.270.15.8553	http://dx.doi.org/10.1074/jbc.270.15.8553			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721755	hybrid			2022-12-25	WOS:A1995QT44800031
J	AZARYAN, AV; KRIEGER, TJ; HOOK, VYH				AZARYAN, AV; KRIEGER, TJ; HOOK, VYH			PURIFICATION AND CHARACTERISTICS OF THE CANDIDATE PROHORMONE PROCESSING PROTEASES PC2 AND PC1/3 FROM BOVINE ADRENAL-MEDULLA CHROMAFFIN GRANULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILISIN-LIKE PROTEASE; ENKEPHALIN PRECURSOR; PROPROTEIN CONVERTASES; THIOL PROTEASE; YEAST KEX2; ENZYMATIC CHARACTERIZATION; FUNCTIONAL EXPRESSION; ENDOPROTEASE FAMILY; SERINE PROTEASE; MAMMALIAN-CELLS	The prohormone-processing proteases PC1/3 and PC2 belong to the family of mammalian subtilisin-related proprotein convertases (PC) possessing homology to the yeast Kex2 protease. The presence of PC1/3 and PC2 in secretory vesicles of bovine adrenal medulla (chromaffin granules) implicates their role in the processing the precursors of enkephalin, neuropeptide Y, somatostatin, and other neuropeptides that are present in chromaffin granules. In this study, PC1/3 and PC2 were purified to apparent homogeneity from the soluble fraction of chromaffin granules by chromatography on concanavalin A-Sepharose, Sephacryl S-200, pepstatin A-agarose, and anti-PC1/3 or anti-PC2 immunoaffinity resins. PC1/3 and PC2 were monitored during purification by measuring proteolytic activities with S-35-enkephalin precursor and Boc-Arg-Val-Arg-Arg-methylcoumarin amide (MCA) substrates and by following PC1/3 and PC2 immunoreactivity with specific anti-PC1/3 and anti-PC2 sera generated in this study. Purified PC1/3 and PC2 on SDS-polyacrylamide gels each show a molecular mass of 66 kDa. PC2 in the soluble fraction of chromaffin granules was present at 5- and 10-fold higher enzyme protein and activity, respectively, compared with that of PC1/3. PC1/3 and PC2 cleaved paired basic and monobasic sites within peptide-MCA substrates, with Boc-Arg-Val-Arg-Arg-MCA and pGlu-Arg-Thr-Lys-Arg-MCA as the most effectively cleaved peptides tested. PC1/3 and PC2 showed pH optima of 6.5 and 7.0, respectively. Kinetic studies indicated apparent K-m values for hydrolysis of Boc-Arg-Val-Arg-Arg-MCA as 66 and 40 mu M, with V-max values of 255 and 353 nmol/h/mg for PC1/3 and PC2, respectively. Specificity of the PC enzymes for dibasic sites was confirmed by potent inhibition by the active site-directed peptide inhibitors (D-Tyr)-Glu-Phe-Lys-Arg-CH2Cl and Ac-Arg-Arg-Ch(2)Cl. Inhibition by EGTA and activation by Ca2+ indicated PC1/3 and PC2 as Ca2+-dependent proteases. In addition, PC enzymes were activated by dithiothreitol and inhibited by thiol-blocking reagents, p-hydroxymercuribenzoate and mercuric chloride. These results illustrate the properties of endogenous PC1/3 and PC2 as prohormone-processing enzymes.	UNIV CALIF SAN DIEGO, MED CTR, DEPT MED, SAN DIEGO, CA 92103 USA; UNIFORMED SERV UNIV HLTH SCI, DEPT BIOCHEM, BETHESDA, MD 20814 USA	University of California System; University of California San Diego; Uniformed Services University of the Health Sciences - USA								ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; Azaryan A. V., 1992, Society for Neuroscience Abstracts, V18, P269; AZARYAN AV, 1992, BIOCHEM BIOPH RES CO, V185, P398, DOI 10.1016/S0006-291X(05)80999-4; AZARYAN AV, 1994, FEBS LETT, V341, P197, DOI 10.1016/0014-5793(94)80456-7; AZARYAN AV, 1994, ARCH BIOCHEM BIOPHYS, V314, P171, DOI 10.1006/abbi.1994.1426; BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BRENNAN SO, 1994, FEBS LETT, V338, P147, DOI 10.1016/0014-5793(94)80353-6; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; CARMICHAEL SW, 1990, NEUROSCIENCE, V34, P433, DOI 10.1016/0306-4522(90)90152-T; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; ESTIVARIZ FE, 1992, J BIOL CHEM, V267, P7456; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOOK VYH, 1990, BIOCHEM BIOPH RES CO, V167, P722, DOI 10.1016/0006-291X(90)92085-E; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; HOOK VYH, 1993, J BIOL CHEM, V268, P20570; HOOK VYH, 1985, P NATL ACAD SCI USA, V82, P4745, DOI 10.1073/pnas.82.14.4745; HOOK VYH, 1992, GROWTH FACTORS PEPTI, P61; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; KIRCHMAIR R, 1992, FEBS LETT, V297, P302, DOI 10.1016/0014-5793(92)80560-4; KRIEGER TJ, 1991, J BIOL CHEM, V266, P8376; KRIEGER TJ, 1992, J NEUROCHEM, V59, P26, DOI 10.1111/j.1471-4159.1992.tb08871.x; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LISTON D, 1984, SCIENCE, V225, P734, DOI 10.1126/science.6547780; LUNDBERG JM, 1979, P NATL ACAD SCI USA, V76, P4079, DOI 10.1073/pnas.76.8.4079; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P2263, DOI 10.1210/endo-129-4-2263; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; POLLARD HB, 1979, J BIOL CHEM, V254, P1170; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; RUFAUT NW, 1993, J BIOL CHEM, V268, P20291; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SEIDAH NG, 1991, ENZYME, V45, P271, DOI 10.1159/000468901; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1991, FEBS LETT, V284, P277, DOI 10.1016/0014-5793(91)80703-6; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; SPRUCE BA, 1988, J BIOL CHEM, V263, P19788; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; TSUJI A, 1994, BIOCHEM BIOPH RES CO, V202, P1452, DOI 10.1006/bbrc.1994.2094; UDENFRIEND S, 1983, ARCH BIOCHEM BIOPHYS, V221, P309, DOI 10.1016/0003-9861(83)90149-2; UNGAR A, 1983, PHYSIOL REV, V63, P787, DOI 10.1152/physrev.1983.63.3.787; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; YI Z, 1993, J BIOL CHEM, V268, P5615; YOSHIKAWA K, 1984, J BIOL CHEM, V259, P4301	60	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8201	8208		10.1074/jbc.270.14.8201	http://dx.doi.org/10.1074/jbc.270.14.8201			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713926	hybrid			2022-12-25	WOS:A1995QR52600065
J	HASEGAWA, H; UEDA, M; WATANABE, M; TERAMOTO, T; MUKAI, M; KITAJIMA, M				HASEGAWA, H; UEDA, M; WATANABE, M; TERAMOTO, T; MUKAI, M; KITAJIMA, M			K-RAS GENE-MUTATIONS IN EARLY COLORECTAL-CANCER ... FLAT ELEVATED VS POLYP-FORMING CANCER	ONCOGENE			English	Article						K-RAS; EARLY COLORECTAL CANCER; FLAT ELEVATED; POLYP-FORMING ADENOMA-CARCINOMA SEQUENCE	POLYMERASE CHAIN-REACTION; CONFORMATION POLYMORPHISM ANALYSIS; CHROMOSOME-5Q21; IDENTIFICATION; CARCINOMAS; COLON; ONCOGENES; ADENOMAS; DNA; FAP	K-ras gene mutations in early colorectal cancer were detected by two-step sensitive polymerase chain reaction (PCR) and enzyme digestion method. Early colorectal cancer was classified into fiat elevated cancer or polyp-forming cancer according to morphology and presence of adenomatous components. A total of 60 paraffin-embedded tissue specimens from patients with early colorectal cancer were analysed. K-ras codon 12 mutations were detected in 23.3% (7/30) of flat elevated cancer and 63.3% (19/30) of polyp-farming cancer. The incidence of K-ras codon 12 mutations in flat elevated cancer was significantly lower than in polyp-forming cancer (P < 0.01). These data suggested that K-ras gene mutations may be correlated with morphology or clinical features in flat elevated cancer, and that flat elevated cancer may originate from a pathway different from adenoma-carcinoma sequence.	KEIO UNIV, SCH MED, DEPT SURG, SHINJUKU KU, TOKYO 160, JAPAN; KEIO UNIV, SCH MED, DEPT PATHOL, SHINJUKU KU, TOKYO 160, JAPAN	Keio University; Keio University								ANDO M, 1991, JPN J CANCER RES, V82, P245, DOI 10.1111/j.1349-7006.1991.tb01836.x; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BURMER GC, 1989, CANCER RES, V49, P2141; CRAWFORD BE, 1983, CANCER, V51, P1760, DOI 10.1002/1097-0142(19830501)51:9<1760::AID-CNCR2820510933>3.0.CO;2-N; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KITAGAWA Y, 1991, CANCER RES, V51, P1504; LEVI S, 1991, CANCER RES, V51, P3497; MIYAKI M, 1990, CANCER RES, V50, P7166; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; SHIMODA T, 1989, CANCER, V64, P1138, DOI 10.1002/1097-0142(19890901)64:5<1138::AID-CNCR2820640529>3.0.CO;2-A; SUGANO K, 1993, LAB INVEST, V68, P361; SUZUKI Y, 1990, ONCOGENE, V5, P1037; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WOLBER RA, 1991, HUM PATHOL, V22, P70, DOI 10.1016/0046-8177(91)90064-V; YAMAGATA S, 1994, JPN J CANCER RES, V85, P147, DOI 10.1111/j.1349-7006.1994.tb02075.x; 1994, GENERAL RULES CLIN P	23	64	66	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1413	1416						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731692				2022-12-25	WOS:A1995QR65100019
J	HORTNAGEL, K; MAUTNER, J; STROBL, LJ; WOLF, DA; CHRISTOPH, B; GELTINGER, C; POLACK, A				HORTNAGEL, K; MAUTNER, J; STROBL, LJ; WOLF, DA; CHRISTOPH, B; GELTINGER, C; POLACK, A			THE ROLE OF IMMUNOGLOBULIN-KAPPA ELEMENTS IN C-MYC ACTIVATION	ONCOGENE			English	Article						BURKITTS LYMPHOMA; C-MYC; IMMUNOGLOBULIN KAPPA GENE REGULATORY ELEMENTS; MATRIX ATTACHMENT REGION; TRANSCRIPT ELONGATION	BURKITTS-LYMPHOMA CELLS; HEAVY-CHAIN GENE; DOWN-REGULATION; PROMOTER SHIFT; 1ST EXON; NUCLEOTIDE-SEQUENCE; CHROMATIN STRUCTURE; LOCATED DOWNSTREAM; STABLE INTEGRATION; INTRONIC MAR	Burkitt's lymphoma cells are characterized by chromosomal translocations involving the proto-oncogene c-myc on chromosome 8 and one of the immunoglobulin gene loci on chromosomes 2, 14 or 22, The translocated c-myc allele is transcriptionally activated, shows a preferential usage of promoter P1 over P2 (promoter shift) and lacks the ability to retain the transcription complex at the P2 promoter. In order to define the elements of the immunoglobulin kappa gene involved in deregulation of c-myc in a t(2;8) translocation, we designed constructs consisting of c-myc and different parts of the immunoglobulin kappa gene locus. Chromatin analysis of these stably transfected constructs revealed DNase I hypersensitive sites within the c-myc 5' region characteristic for an actively transcribed c-myc gene and three sites within the immunoglobulin kappa locus corresponding to the matrix attachment region, the intron and 3' enhancers, respectively. These three regulatory elements were necessary and sufficient for maximal c-myc activation and formation of the promoter shift. Kinetic nuclear run on experiments were performed to study the distribution of transcription complexes on c-myc exon 1 on constructs with and without the immunoglobulin kappa regulatory elements. The absence of a pausing polymerase complex at the c-myc P2 promoter could be demonstrated for constructs consisting of c-myc and the two kappa enhancers. Therefore the two enhancers are sufficient to relief the elongational block at the P2 promoter, however, the matrix attachment region is additionally required for maximal c-myc activation observed in Burkitt's lymphoma cells.	GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT, INST KLIN MOLEK BIOL, D-81377 MUNICH, GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Strobl, Lothar J/M-7357-2014	Strobl, Lothar J/0000-0001-8389-1862; Wolf, Dieter/0000-0002-3761-1070				ALLEN RW, 1987, J BIOL CHEM, V262, P649; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BLASQUEZ VC, 1992, J BIOL CHEM, V267, P23888; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EICK D, 1988, ONCOGENE, V3, P397; EICK D, 1994, ANAL BIOCHEM, V218, P347, DOI 10.1006/abio.1994.1190; FULTON R, 1993, NUCLEIC ACIDS RES, V21, P4941, DOI 10.1093/nar/21.21.4941; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; HORTNAGEL K, 1994, CURR TOP MICROBIOL I, V194, P415; JUDDE JG, 1992, MOL CELL BIOL, V12, P5206, DOI 10.1128/MCB.12.11.5206; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KOHLHUBER F, 1993, ONCOGENE, V8, P1099; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; MAGRATH I, 1990, ADV CANCER RES, V55, P134; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NEUBERGER MS, 1983, EMBO J, V2, P1373, DOI 10.1002/j.1460-2075.1983.tb01594.x; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; POLACK A, 1991, ONCOGENE, V6, P2033; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x; QUEEN C, 1984, MOL CELL BIOL, V4, P1042, DOI 10.1128/MCB.4.6.1042; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RICHMAN A, 1989, MOL CELL BIOL, V9, P4962, DOI 10.1128/MCB.9.11.4962; RICHMAN A, 1989, SCIENCE, V246, P494, DOI 10.1126/science.2683072; Sambrook J, 1989, MOL CLONING LABORATO; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STROBL LJ, 1993, ONCOGENE, V8, P1437; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; STROBL UZ, 1993, EMBO J, V12, P167; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TONEGUZZO F, 1986, MOL CELL BIOL, V6, P703, DOI 10.1128/MCB.6.2.703; WHITEHURST C, 1992, NUCLEIC ACIDS RES, V20, P4929, DOI 10.1093/nar/20.18.4929; XU M, 1989, J BIOL CHEM, V264, P21190; ZAJAC-KAYE M, 1990, J BIOL CHEM, V265, P4547; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZIRBEL RM, 1994, CHROMOSOME RES, V11, P93	62	37	37	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1393	1401						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731690				2022-12-25	WOS:A1995QR65100017
J	KOKEN, MHM; LINARESCRUZ, G; QUIGNON, F; VIRON, A; CHELBIALIX, MK; SOBCZAKTHEPOT, J; JUHLIN, L; DEGOS, L; CALVO, F; DETHE, H				KOKEN, MHM; LINARESCRUZ, G; QUIGNON, F; VIRON, A; CHELBIALIX, MK; SOBCZAKTHEPOT, J; JUHLIN, L; DEGOS, L; CALVO, F; DETHE, H			THE PML GROWTH-SUPPRESSOR HAS AN ALTERED EXPRESSION IN HUMAN ONCOGENESIS	ONCOGENE			English	Article						ANTIONCOGENE; NUCLEAR BODIES; INTERFERON; STROMA; NEOANGIOGENESIS	ACUTE PROMYELOCYTIC LEUKEMIA; PRIMARY BILIARY-CIRRHOSIS; DNA-BINDING PROTEIN; ZINC FINGER; NUCLEAR-BODIES; TRANSCRIPTION FACTOR; TUMOR-CELLS; RAR-ALPHA; GENE; DIFFERENTIATION	Altered sub-nuclear localisation of the nuclear body-associated PML protein in acute promyelocytic leukaemia, has been proposed to contribute to leukaemogenesis. We have recently shown that PML is a primary target gene of interferons. Here, it is shown that PML has growth suppressive properties and displays an altered expression pattern during human oncogenesis. PML is widely expressed in cell-lines and is cell-cycle regulated. Overexpression of the protein induces a sharp reduction in growth rates in vitro and in vivo. In contrast with cell-lines, in normal tissues (including those that rapidly proliferate) only a few cells have detectable PML levels. However, these can be upregulated by soluble factors (e.g. IFN, estrogens.). Human epithelial tumors show a gradual increase of PML levels as the lesion progresses from benign dysplasia to carcinoma. A similar induction is found in the surrounding stroma and vessels, which likely results from paracrine interactions, Strikingly, when malignant cells turn invasive, they loose PML expression, while expression is conserved in the stromal compartment. These observations point to the existence of a consistent deregulation in the expression of the PML growth-suppressor during human oncogenesis.	HOP ST LOUIS, CTR HAYEM, CNRS, UPR 43, F-75475 PARIS 10, FRANCE; HOP ST LOUIS, IGM, PHARMACOL EXPTL LAB, PARIS, FRANCE; INST RECH SCI CANC, CNRS, UPR 272, VILLEJUIF, FRANCE; HOP NECKER ENFANTS MALAD, INSERM, U370, PARIS, FRANCE; UNIV UPPSALA HOSP, DEPT DERMATOL, S-75014 UPPSALA 14, SWEDEN; HOP ST LOUIS, SERV CLIN MALAD SANG, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Uppsala University; Uppsala University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			koken, marcel/J-8154-2012; koken, marcel/N-1349-2019; Quignon, Frédérique/P-4249-2017	koken, marcel/0000-0002-0839-0125; calvo, fabien/0000-0002-0298-7633; Sobczak, Joelle/0000-0001-7180-2789				ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Ashihara T, 1979, Methods Enzymol, V58, P248; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BENCHETRIT E, 1988, J EXP MED, V167, P1560, DOI 10.1084/jem.167.5.1560; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; DANIEL MT, 1993, BLOOD, V82, P1858; de The G., 1960, B ASSOC FR ETUD CANC, V47, P570; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FUSCONI M, 1991, CLIN EXP IMMUNOL, V83, P291; GAKEN J, 1992, BIOTECHNIQUES, V13, P32; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GULDNER HH, 1992, J IMMUNOL, V149, P4067; HUMBERT C, 1992, J CELL SCI, V103, P97; ISOMURA T, 1992, NUCLEIC ACIDS RES, V20, P5305, DOI 10.1093/nar/20.20.5305; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LINARESCRUZ G, 1994, J MICROSC-OXFORD, V173, P27, DOI 10.1111/j.1365-2818.1994.tb03425.x; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MAUL GG, 1994, J GEN VIROL, V75, P1223, DOI 10.1099/0022-1317-75-6-1223; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; PERRY LJ, 1986, J GEN VIROL, V67, P2365, DOI 10.1099/0022-1317-67-11-2365; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; SATO H, 1993, ONCOGENE, V8, P395; STUURMAN N, 1992, J CELL SCI, V101, P773; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; UYEMURA K, 1993, J INVEST DERMATOL, V101, P701, DOI 10.1111/1523-1747.ep12371679; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; VISA N, 1993, EXP CELL RES, V208, P19, DOI 10.1006/excr.1993.1218; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WERNERT N, 1992, AM J PATHOL, V140, P119	46	231	240	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1315	1324						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731682				2022-12-25	WOS:A1995QR65100008
J	ROYERPOKORA, B; ROGERS, M; ZHU, TH; SCHNEIDER, S; LOOS, U; BOLITZ, U				ROYERPOKORA, B; ROGERS, M; ZHU, TH; SCHNEIDER, S; LOOS, U; BOLITZ, U			THE TTG-2/RBTN2 T-CELL ONCOGENE ENCODES 2 ALTERNATIVE TRANSCRIPTS FROM 2 PROMOTERS - THE DISTAL PROMOTER IS REMOVED BY MOST 11P13 TRANSLOCATIONS IN ACUTE T-CELL LEUKEMIAS (T-ALL)	ONCOGENE			English	Article						T-CELL ONCOGENE; ALTERNATIVE TRANSCRIPTS; DISRUPTION BY TRANSLOCATIONS	ACUTE LYMPHOBLASTIC-LEUKEMIA; BREAKPOINT CLUSTER REGION; CHROMOSOMAL TRANSLOCATIONS; T(11-14)(P13-Q11) TRANSLOCATION; TRANSGENIC MICE; GENE; PROTEIN; DOMAIN; MOTIF; LINE	The TTG-2 gene has been identified at the site of chromosomal translocations in acute T-cell leukemia's (T-ALL). These breakpoints map to a region between 2 and 30 kb upstream of TTG-2 in chromosome 11p13. To establish the role of these translocation breakpoints in the deregulation of TTG-2 in T-ALL we have determined the complete structure of this gene. Isolation of new TTG-2 cDNA clones from fetal liver identified an alternative transcript (TTG-2a) containing two new noncoding 5' exons, Analysis of exon/intron boundaries, identified 6 exons spread over 35 kb in 11p13. The gene encodes two alternative transcripts initiating from two promoters. TTG-2a, from promoter 1 (P1) and TTG-2b, from promoter 2 (P2) differ in the length of the 5' untranslated region, but encode the same protein. A high level of TTG-2a was present in fetal liver and spleen, whereas in adult kidney a low level of TTG-2a and a high level of TTG-2b was found. The transcription start site for TTG-2a was identified by RNase protection experiments and it displayed sequence homology to an initiator element (inr). P1 lacks a TATA box, but binding sites for SP1 and GATA-1 are present. This new genomic organisation revealed that all known chromosomal translocations map upstream of P2, removing P1 and putative upstream regulatory sequences leaving P2 intact. These results show that chromosomal translocations disrupt the TTG-2 gene itself, further confirming its role in the development of T-ALL.			ROYERPOKORA, B (corresponding author), UNIV HEIDELBERG, INST HUMAN GENET, NEUENHEIMER FELD 328, D-69120 HEIDELBERG, GERMANY.		Rogers, Michael A./J-9803-2012	Rogers, Michael A./0000-0002-3728-2107				APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEUG H, 1982, J CELL PHYSIOL, P195; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CHAMPAGNE E, 1989, BLOOD, V73, P1672; CHENG JT, 1990, J EXP MED, V171, P489, DOI 10.1084/jem.171.2.489; CLEARY ML, 1992, CANCER SURV, V15, P89; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; FISCH P, 1992, ONCOGENE, V7, P2389; FITZGERALD TJ, 1992, BLOOD, V80, P3189; FORONI L, 1990, GENE CHROMOSOME CANC, V1, P301, DOI 10.1002/gcc.2870010407; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; HARVEY RC, 1989, ONCOGENE, V4, P341; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KURTZBERG J, 1985, J EXP MED, V162, P1561, DOI 10.1084/jem.162.5.1561; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAVID Z, 1980, INT J CANCER, V25, P705, DOI 10.1002/ijc.2910250604; ROYERPOKORA B, 1989, HUM GENET, V82, P264, DOI 10.1007/BF00291167; ROYERPOKORA B, 1992, GENE CHROMOSOME CANC, V5, P132, DOI 10.1002/gcc.2870050207; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SANCHEZGARCIA I, 1991, ONCOGENE, V6, P577; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; YOFFE G, 1989, BLOOD, V74, P374	42	40	40	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1353	1360						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731686				2022-12-25	WOS:A1995QR65100012
J	WOODRUFF, KA; ROSENBLATT, JD; MOORE, TB; MEDZOYAN, RH; PAI, DSM; NOLAND, JL; YAMASHIRO, JM; WADA, RK				WOODRUFF, KA; ROSENBLATT, JD; MOORE, TB; MEDZOYAN, RH; PAI, DSM; NOLAND, JL; YAMASHIRO, JM; WADA, RK			CELL-TYPE-SPECIFIC ACTIVITY OF THE N-MYC PROMOTER IN HUMAN NEUROBLASTOMA-CELLS IS MEDIATED BY A DOWNSTREAM SILENCER	ONCOGENE			English	Article						N-MYC; DOWNSTREAM SILENCER; NEUROBLASTOMA	HUMAN NEURO-BLASTOMA; EMBRYONAL CARCINOMA-CELLS; C-MYC; TRANSCRIPTIONAL REGULATION; DEPENDENT SILENCER; ENHANCER ELEMENT; GENE-EXPRESSION; RETINOIC ACID; AMPLIFICATION; DIFFERENTIATION	The N-myc oncogene is actively transcribed in many neuroblastoma tumors, but is not expressed in mature, normal tissue of any type. Chloramphenicol acetyl transferase (CAT) assays of constructs containing N-myc sequence transfected into N-myc expressing LA-N-5 neuroblastoma cells or non-expressing HeLa carcinoma cells have revealed a 201 base pair (bp) regulatory region mediating the cell type-specific activity of the promoter. While located downstream from 5' mRNA cap sites, the region appears to function by preventing transcriptional initiation. This downstream region is capable of suppressing promoter activity independently of position, and contains an element having 100% homology with the 9 bp consensus sequence of a transcriptional silencer found in the upstream region of the lysozyme gene. DNA gel retardation assays have shown that this sequence is involved in a specific DNA-protein interaction with nuclear extract from HeLa cells that is distinct from that occurring with extract from LA-NB cells. These results suggest that the N-myc promoter's cell type-specific activity is regulated by a downstream silencer, and that differential binding of regulatory protein from that present in non-expressing cells may result in the constitutive N-myc expression seen in neuroblastoma.	UNIV CALIF LOS ANGELES, SCH MED,JONSSON COMPREHENS CANC CTR,DEPT PEDIAT, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, GWYNNE HAZEN CHERRY MEM LABS, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					PHS HHS [P01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKESON R, 1990, MOL CELL BIOL, V10, P2012, DOI 10.1128/MCB.10.5.2012; BABISS LE, 1990, MOL CELL BIOL, V10, P6700, DOI 10.1128/MCB.10.12.6700; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BERNARDS R, 1991, EMBO J, V10, P1119, DOI 10.1002/j.1460-2075.1991.tb08052.x; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CANNIO R, 1991, NUCLEIC ACIDS RES, V19, P2303, DOI 10.1093/nar/19.9.2303; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; COHN SL, 1990, ONCOGENE, V5, P1821; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EICK D, 1987, ONCOGENE, V2, P61; GRADY EF, 1987, CANCER RES, V47, P2931; HARA E, 1993, ONCOGENE, V8, P1023; HEN R, 1983, NUCLEIC ACIDS RES, V11, P8747, DOI 10.1093/nar/11.24.8747; HILLER S, 1991, ONCOGENE, V6, P969; HIYAMA E, 1991, J PEDIATR SURG, V26, P838, DOI 10.1016/0022-3468(91)90151-I; IBSON JM, 1988, ONCOGENE, V2, P399; IMAMURA Y, 1992, BIOCHIM BIOPHYS ACTA, V1132, P177, DOI 10.1016/0167-4781(92)90009-O; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LARSEN PR, 1986, P NATL ACAD SCI USA, V83, P8283, DOI 10.1073/pnas.83.21.8283; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; Locker J, 1990, DNA Seq, V1, P3, DOI 10.3109/10425179009041342; MARZLUFF WF, 1985, TRANSCRIPTION TRANSL, P89; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; NAKABAYASHI H, 1991, MOL CELL BIOL, V11, P5885, DOI 10.1128/MCB.11.12.5885; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OVERDIER DG, 1992, P NATL ACAD SCI USA, V89, P3140, DOI 10.1073/pnas.89.7.3140; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; REYNOLDS CP, 1990, PROG CLIN BIOL RES, V366, P203; ROSEN N, 1986, CANCER RES, V46, P4139; ROUET P, 1992, BIOTECHNIQUES, V13, P700; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SMITH RK, 1992, MOL CELL BIOL, V12, P1578, DOI 10.1128/MCB.12.4.1578; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; TAKEHANA K, 1991, GENE, V103, P219, DOI 10.1016/0378-1119(91)90276-H; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1988, EXP CELL BIOL, V56, P321; TOURMENTE S, 1993, INSECT BIOCHEM MOLEC, V23, P137, DOI 10.1016/0965-1748(93)90092-7; Wada R K, 1988, Prog Clin Biol Res, V271, P57; WADA RK, 1992, ONCOGENE, V7, P711; WADAKIYAMA Y, 1992, J BIOL CHEM, V267, P1152; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	53	17	17	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1335	1341						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731684				2022-12-25	WOS:A1995QR65100010
J	DANSAPETRETSKI, M; RIBEIRO, JMC; ATELLA, GC; MASUDA, H; OLIVEIRA, PL				DANSAPETRETSKI, M; RIBEIRO, JMC; ATELLA, GC; MASUDA, H; OLIVEIRA, PL			ANTIOXIDANT ROLE OF RHODNIUS-PROLIXUS HEME-BINDING PROTEIN - PROTECTION AGAINST HEME-INDUCED LIPID-PEROXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPHORIN; HEMOPEXIN; PHOSPHOLIPIDS	Heme in aqueous solutions actively promotes free radical reactions leading to degradation of biological molecules, The blood-sucking insect Rhodnius prolixus has a heme-binding protein (RHBP) in its hemolymph (Oliveira, P. L., Kawooya, J .K, Ribeiro, J. M. C., Meyer, T., Poorman, R., Alves, E, W., Walker, F., Padovan, G. J., and Masuda, H. (1994) J, Biol, Chem, 270, 10897-10901, Here we show that this protein inhibits heme-dependent peroxidation of both linolenic acid liposomes and lipophorin, the main lipoprotein of insect hemolymph, The oxidized lipophorin is functionally impaired, being defective both in its capacity to be loaded with phospholipids from the fat body as well as in its ability to deliver phospholipids to the growing oocytes, RHBP prevents the heme-induced oxidative damage to lipophorin. It is proposed that in vivo RHBP binds the heme derived from digestion of blood hemoglobin, suppressing the generation of activated oxygen species and protecting the insect against oxidative stress throughout the feeding cycle.	UNIV FED RIO DE JANEIRO,INST CIENCIAS BIOMED,DEPT BIOQUIM MED,BR-21941590 RIO JANEIRO,BRAZIL; UNIV ARIZONA,DEPT ENTOMOL,TUCSON,AZ 85721	Universidade Federal do Rio de Janeiro; University of Arizona			Atella, Georgia/AAK-7897-2020; L. Oliveira, Pedro/A-9438-2010	L. Oliveira, Pedro/0000-0003-0307-354X; Ribeiro, Jose/0000-0002-9107-0818				AFT RL, 1983, J BIOL CHEM, V258, P2069; ATELLA GC, 1992, ARCH INSECT BIOCHEM, V19, P133, DOI 10.1002/arch.940190206; CHINO H, 1969, BIOCHIM BIOPHYS ACTA, V176, P1; CHINO H, 1985, COMPREHENSIVE INSECT, V10, P115; CRICHTON RR, 1987, BIOELECTROCH BIOENER, V18, P105, DOI 10.1016/0302-4598(87)85012-2; de Meis L, 1974, Biochemistry, V13, P2057, DOI 10.1021/bi00707a009; DIHEL P, 1982, CURRENT THEMES TROPI, P49; FRIEND WG, 1965, CAN J ZOOL, V43, P892; Garcia ES, 1975, AN ACAD BRAS CIENC, V47, P539; GONDIM KC, 1989, J INSECT PHYSIOL, V35, P19, DOI 10.1016/0022-1910(89)90032-2; GONDIM KC, 1989, INSECT BIOCHEM, V19, P153, DOI 10.1016/0020-1790(89)90086-3; GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861; GUTTERIDGE JMC, 1983, BIOCHEM BIOPH RES CO, V117, P901, DOI 10.1016/0006-291X(83)91681-9; HALLIWELL B, 1990, ARCH BIOCHEM BIOPHYS, V280, P1, DOI 10.1016/0003-9861(90)90510-6; HALLIWELL B, 1984, METHOD ENZYMOL, V105, P47; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HEINECKE JW, 1987, FREE RADICAL BIO MED, V3, P65, DOI 10.1016/0891-5849(87)90040-2; HRKAL Z, 1971, BIOCHEMISTRY-US, V10, P1746, DOI 10.1021/bi00786a002; Kanost M.R., 1990, Advances in Insect Physiology, V22, P299, DOI 10.1016/S0065-2806(08)60008-9; KATASE H, 1982, BIOCHIM BIOPHYS ACTA, V710, P341; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEDTKE AJ, 1984, BASIC RES CARDIOL, V79, P513, DOI 10.1007/BF01910480; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADDRELL SH, 1969, J EXP BIOL, V51, P71; OHAGAN JE, 1974, EXP PARASITOL, V35, P110, DOI 10.1016/0014-4894(74)90013-7; OLIVEIRA PL, 1994, J BIOL CHEM, V270, P10897; ORJIH AU, 1981, SCIENCE, V214, P667, DOI 10.1126/science.7027441; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; TAKETANI S, 1987, J BIOL CHEM, V262, P4639; TAPPEL AL, 1955, J BIOL CHEM, V217, P721; TIPPING E, 1979, BIOCHEM J, V180, P327, DOI 10.1042/bj1800327; VANDERHORST DJ, 1981, COMP BIOCHEM PHYS B, V70, P387, DOI 10.1016/0305-0491(81)90271-6; VANHEUSDEN MC, 1987, INSECT BIOCHEM, V17, P771, DOI 10.1016/0020-1790(87)90048-5; VINCENT SH, 1988, ARCH BIOCHEM BIOPHYS, V265, P539, DOI 10.1016/0003-9861(88)90159-2; WALKER FA, 1988, J AM CHEM SOC, V110, P6234, DOI 10.1021/ja00226a045; Wigglesworth VB, 1943, PROC R SOC SER B-BIO, V131, P313, DOI 10.1098/rspb.1943.0010	37	75	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10893	10896		10.1074/jbc.270.18.10893	http://dx.doi.org/10.1074/jbc.270.18.10893			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7738029				2022-12-25	WOS:A1995QW60100077
J	DECROUYCHANEL, A; ELYAAGOUBI, A; KOHIYAMA, M; RICHARME, G				DECROUYCHANEL, A; ELYAAGOUBI, A; KOHIYAMA, M; RICHARME, G			REVERSAL BY GROES OF THE GROEL PREFERENCE FROM HYDROPHOBIC AMINO-ACIDS TOWARD HYDROPHILIC AMINO-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PEPTIDE-BINDING; PROTEIN; SURFACE; DNAK; PURIFICATION; SPECIFICITY; CHAPERONES; PATHWAY; CYCLE	The chaperones GroEL/hsp60 are present in all prokaryotes and in mitochondria and chloroplasts of eukaryotic cells. They are involved in protein folding, protein targeting to membranes, protein renaturation, and control of protein protein interactions. They interact with many polypeptides in an ATP dependent manner and possess a peptide-dependent ATPase activity. GroEL/hsp60 cooperates with GroES/hsp10, and the productive folding of proteins by GroEL generally requires GroES, which appears to regulate the binding and release of substrate proteins by GroEL. In a recent study, we have shown that GroEL interacts preferentially with the side chains of hydrophobic amino acids (Ile, Phe, Val, Leu, and Trp) and more weakly with several polar or charged amino acids, including the strongest alpha-helix and beta-sheet formers (Glu, Gin, His, Thr, and Tyr). In this study, we show that GroES reduces the specificity of GroEL for hydrophobic amino acids and increases its specificity for hydrophilic ones. This shift by GroES of the GroEL specificity from hydrophobic amino acids toward hydrophilic ones might be of importance for its function in protein folding.	UNIV PARIS 07,INST JACQUES MONOD,F-75005 PARIS,FRANCE	UDICE-French Research Universities; Universite Paris Cite								BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHOU PY, 1978, ANN REV BIOCH, V44, P251; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FERSHT AR, 1993, FEBS LETT, V325, P5, DOI 10.1016/0014-5793(93)81405-O; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1992, J BIOL CHEM, V266, P13044; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MORIMOTO R I, 1990, P1; PTITSYN OB, 1992, CONFORMATIONS FORCES, P155; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; RICHARME G, 1993, J BIOL CHEM, V268, P24074; RICHARME G, 1994, J BIOL CHEM, V269, P7095; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; VITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665; VITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716; WILLIAMS RW, 1987, BIOCHIM BIOPHYS ACTA, V916, P200, DOI 10.1016/0167-4838(87)90109-9	32	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10571	10575		10.1074/jbc.270.18.10571	http://dx.doi.org/10.1074/jbc.270.18.10571			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737993	hybrid			2022-12-25	WOS:A1995QW60100034
J	ZENG, CB; FROMM, HJ				ZENG, CB; FROMM, HJ			ACTIVE-SITE RESIDUES OF HUMAN BRAIN HEXOKINASE AS STUDIED BY SITE-SPECIFIC MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HEXOSE BINDING-SITE; C-TERMINAL HALVES; YEAST HEXOKINASE; CLONED CDNA; MAMMALIAN HEXOKINASE; ESCHERICHIA-COLI; RAT HEXOKINASE; PURIFICATION; GLUCOSE	The truncated gene of hexokinase, mini hexokinase, starting with methionine 455 and ending at the C terminus was expressed in Escherichia coli. Mini-hexokinase lost its ability to ameliorate inhibition of glucose-6-P-inhibited mini-hexokinase in the presence of phosphate (P-i). We suggest that the P-i site either resides in the N-terminal half of hexokinase I or requires the N-terminal portion of the enzyme. Site-directed mutagenesis was performed to obtain two mutants of mini-hexokinase: C606S and C628S. Both are thought to be associated with the active site of hexokinase I. These mutants exhibited a 3-fold increase in K-m for glucose but no change in either the K-m for ATP or the k(cat). The circular dichroism (CD) spectra showed no differences among the wild-type or mutant enzymes. These results suggest that Cys(606) and Cys(628) are not involved in glucose binding directly. The putative ATP-binding site of full-length human brain hexokinase may involve Arg(539) and Gly(679), and these residues were mutated to Ile. For the mutant R539I, the k(cat) value decreased 114-fold relative to wildtype hexokinase, whereas the K-m values for ATP and glucose changed only slightly. No change was observed in the K-i value for 1,5-anhydroglucitol 6-phosphate. CD spectra showed only a slight change in secondary structure. For the mutant G679I, overexpressed hexokinase is insoluble. We suggest that Arg(539) is important for catalysis because it stablizes the transition state product ADP-hexokinase. Gly(679) is probably important for proper folding of the protein.	IOWA STATE UNIV SCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, AMES, IA 50011 USA	Iowa State University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS010546, R01NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; ANDREONE TL, 1989, J BIOL CHEM, V264, P363; ARORA KK, 1990, J BIOL CHEM, V265, P6481; ARORA KK, 1993, J BIOL CHEM, V268, P18259; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRANE RK, 1954, J BIOL CHEM, V210, P597; DONG Q, 1990, ARCH BIOCHEM BIOPHYS, V276, P77, DOI 10.1016/0003-9861(90)90012-N; EASTERBY JS, 1973, EUR J BIOCHEM, V38, P201, DOI 10.1111/j.1432-1033.1973.tb03051.x; ELLISON WR, 1974, BIOCHEM BIOPH RES CO, V57, P1214, DOI 10.1016/0006-291X(74)90826-2; FERRARI RICHARD A., 1959, ARCH BIOCHEM AND BIOPHYS, V80, P372, DOI 10.1016/0003-9861(59)90264-4; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FROHLICH KU, 1985, GENE, V36, P105, DOI 10.1016/0378-1119(85)90074-5; FROMM HJ, 1962, J BIOL CHEM, V237, P1661; FROMM HJ, 1981, REGULATION CARBOHYDR, P45; GERBER G, 1974, EUR J BIOCHEM, V45, P39, DOI 10.1111/j.1432-1033.1974.tb03527.x; GRIFFIN LD, 1991, GENOMICS, V11, P1014, DOI 10.1016/0888-7543(91)90027-C; HARRISON R, 1985, THESIS YALE U; HOLROYDE MJ, 1976, FEBS LETT, V62, P215, DOI 10.1016/0014-5793(76)80056-7; JARORI GK, 1990, EUR J BIOCHEM, V188, P9, DOI 10.1111/j.1432-1033.1990.tb15364.x; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KOPETZKI E, 1985, GENE, V39, P95, DOI 10.1016/0378-1119(85)90113-1; LAZO PA, 1980, J BIOL CHEM, V255, P7548; LIU F, 1991, BIOCHEM BIOPH RES CO, V177, P305, DOI 10.1016/0006-291X(91)91983-J; LOWRY OH, 1964, J BIOL CHEM, V239, P31; MAGNANI M, 1992, BIOCHEM J, V285, P193, DOI 10.1042/bj2850193; MANNING TA, 1984, BIOCHEM BIOPH RES CO, V118, P90, DOI 10.1016/0006-291X(84)91071-4; MEHTA A, 1988, J BIOL CHEM, V263, P15492; NISHI S, 1988, BIOCHEM BIOPH RES CO, V157, P937, DOI 10.1016/S0006-291X(88)80964-1; PURICH DL, 1971, J BIOL CHEM, V246, P3456; Rapoport S, 1968, Essays Biochem, V4, P69; REDKAR VD, 1975, BIOCHEMISTRY-US, V14, P4704, DOI 10.1021/bi00692a022; REDKAR VD, 1972, J BIOL CHEM, V247, P7576; ROSE IA, 1974, ARCH BIOCHEM BIOPHYS, V164, P729, DOI 10.1016/0003-9861(74)90086-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIRCH DM, 1987, ARCH BIOCHEM BIOPHYS, V257, P1, DOI 10.1016/0003-9861(87)90536-4; SCHIRCH DM, 1987, ARCH BIOCHEM BIOPHYS, V254, P385, DOI 10.1016/0003-9861(87)90116-0; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; SCHWAB DA, 1991, ARCH BIOCHEM BIOPHYS, V285, P365, DOI 10.1016/0003-9861(91)90373-Q; SOLHEIM LP, 1981, ARCH BIOCHEM BIOPHYS, V211, P92, DOI 10.1016/0003-9861(81)90433-1; SOLS A, 1976, REFLECTIONS BIOCH, P199; SUBBARAO B, 1977, ARCH BIOCHEM BIOPHYS, V181, P8, DOI 10.1016/0003-9861(77)90477-5; SUBBARAO B, 1977, ARCH BIOCHEM BIOPHYS, V181, P19, DOI 10.1016/0003-9861(77)90478-7; SWARUP G, 1980, BIOCHEMISTRY-US, V19, P4058, DOI 10.1021/bi00558a024; THELEN AP, 1991, ARCH BIOCHEM BIOPHYS, V286, P645, DOI 10.1016/0003-9861(91)90094-Y; URETA T, 1982, COMP BIOCHEM PHYS B, V71, P549, DOI 10.1016/0305-0491(82)90461-8; URETA T, 1975, ISOZYMES, V3, P575; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7; [No title captured]	51	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1995	270	18					10509	10513		10.1074/jbc.270.18.10509	http://dx.doi.org/10.1074/jbc.270.18.10509			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QW601	7737985				2022-12-25	WOS:A1995QW60100025
J	GLOMB, MA; MONNIER, VM				GLOMB, MA; MONNIER, VM			MECHANISM OF PROTEIN MODIFICATION BY GLYOXAL AND GLYCOLALDEHYDE, REACTIVE INTERMEDIATES OF THE MAILLARD REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGE-DEPENDENT ACCUMULATION; DIABETES-MELLITUS; ALPHA-DICARBONYL; LENS PROTEINS; CROSS-LINKING; AMINO-ACIDS; PRODUCTS; N-EPSILON-(CARBOXYMETHYL)LYSINE; AUTOXIDATION; PENTOSIDINE	The role of glyoxal and glycolaldehyde in protein cross-linking and N-epsilon-(carboxymethyl)lysine (CML) formation during Maillard reaction under physiological conditions was investigated, Incubation of bovine serum albumin with these reagents lead to rapid formation of C-2-imine cross-links and CML. Initial CML formation rate from glyoxal was not dependent on oxidation, suggesting an intramolecular Cannizzaro reaction. CML formation from glucose/lysine or Amadori product of both was strongly dependent on oxidation, Blocking of Amadori product by boric acid totally suppressed CML formation from Amadori product, but only by 37% in the glucose/lysine system. Trapping of glyoxal with aminoguanidine hardly suppressed CML formation from Amadori product, whereas it blocked 50% of CML production in the glucose/lysine system. While these results would support a significant role for glucose autoxidation in CML formation, the addition of lysine to a glucose/aminoguanidine incubation system catalyzed glyoxal triazine formation 7-fold, thereby strongly suggesting that glucose autoxidation is not a factor for glyoxal-mediated CML formation, Based on these results, it can be estimated that approximately 50% of the CML forming in a glucose/lysine system originates from oxidation of Amadori product, and 40-50% originates from a pre-Amadori stage largely independent from glucose autoxidation, This step may be related to the so-called Namiki pathway of the Maillard reaction.			GLOMB, MA (corresponding author), CASE WESTERN RESERVE UNIV,INST PATHOL,2085 ADELBERT RD,CLEVELAND,OH 44106, USA.		Monnier, Vincent M/B-1371-2009		NATIONAL EYE INSTITUTE [R01EY007099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005601] Funding Source: NIH RePORTER; NEI NIH HHS [EY 07099] Funding Source: Medline; NIA NIH HHS [AG 05601] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACHARYA AS, 1983, P NATL ACAD SCI-BIOL, V80, P3590, DOI 10.1073/pnas.80.12.3590; AHMED MU, 1986, J BIOL CHEM, V261, P4889; Baynes JW., 1989, PROG CLIN BIOL RES, V304, P1; BENSON JR, 1975, P NATL ACAD SCI USA, V72, P619, DOI 10.1073/pnas.72.2.619; BOWES JH, 1968, BIOCHIM BIOPHYS ACTA, V168, P341, DOI 10.1016/0005-2795(68)90156-6; BROWNLEE M, 1980, DIABETES, V29, P1044, DOI 10.2337/diabetes.29.12.1044; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; CHO RK, 1986, AGR BIOL CHEM TOKYO, V50, P1373, DOI 10.1080/00021369.1986.10867600; Chuyen N. V., 1973, Agricultural and Biological Chemistry, V37, P2209; DUNN JA, 1989, BIOCHEMISTRY-US, V28, P9464, DOI 10.1021/bi00450a033; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DUNN JA, 1990, BIOCHEMISTRY-US, V29, P10964, DOI 10.1021/bi00501a014; ERIKSON JG, 1952, J AM CHEM SOC, V74, P4706; FU MX, 1992, DIABETES, V41, P42, DOI 10.2337/diab.41.2.S42; GLASS JD, 1978, BIOCHEM BIOPH RES CO, V81, P527, DOI 10.1016/0006-291X(78)91566-8; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; HAYASHI T, 1977, J AGR FOOD CHEM, V25, P1282, DOI 10.1021/jf60214a047; HAYASHI T, 1985, AGR BIOL CHEM TOKYO, V49, P3131, DOI 10.1080/00021369.1985.10867244; HAYASHI T, 1986, AMINO CARBONYL REACT, P29; JOHNSON RN, 1982, CLIN CHIM ACTA, V127, P87; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; MICHEEL F, 1959, CHEM BER-RECL, V92, P2836, DOI 10.1002/cber.19590921127; MIYATA S, 1992, J CLIN INVEST, V89, P1102, DOI 10.1172/JCI115690; MORION MS, 1994, BIOCHIM BIOPHYS ACTA, V1191, P33; NEDVIDEK W, 1992, Z LEBENSM UNTERS FOR, V194, P222, DOI 10.1007/BF01198411; PORTEROOTIN M, IN PRESS BIOCH BIOPH; SCHWARTZ BA, 1977, ARCH BIOCHEM BIOPHYS, V181, P542, DOI 10.1016/0003-9861(77)90261-2; SELL DR, 1991, DIABETES METAB REV, V7, P239, DOI 10.1002/dmr.5610070404; SLIGHT SH, 1992, BIOCHIM BIOPHYS ACTA, V1117, P199, DOI 10.1016/0304-4165(92)90080-E; SMITH PR, 1993, CLIN SCI, V84, P87, DOI 10.1042/cs0840087; VELISEK J, 1989, J FOOD SCI, V54, P1544, DOI 10.1111/j.1365-2621.1989.tb05155.x; VENUTI MC, 1982, SYNTHESIS-STUTTGART, P61; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A	34	500	509	0	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 28	1995	270	17					10017	10026		10.1074/jbc.270.17.10017	http://dx.doi.org/10.1074/jbc.270.17.10017			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QV417	7730303	hybrid			2022-12-25	WOS:A1995QV41700048
J	MARCHESE, P; MURATA, M; MAZZUCATO, M; PRADELLA, P; DEMARCO, L; WARE, J; RUGGERI, ZM				MARCHESE, P; MURATA, M; MAZZUCATO, M; PRADELLA, P; DEMARCO, L; WARE, J; RUGGERI, ZM			IDENTIFICATION OF 3 TYROSINE RESIDUES OF GLYCOPROTEIN IB-ALPHA WITH DISTINCT ROLES IN VON-WILLEBRAND-FACTOR AND ALPHA-THROMBIN BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; AMINO-ACID-SEQUENCE; BERNARD-SOULIER SYNDROME; PLATELET MEMBRANE; PROTEIN; COMPLEX; DOMAIN; SULFATION; SITE; BOTROCETIN	The interaction between von Willebrand factor (vWF) and the platelet membrane glycoprotein (GP) Ib-IX-V complex is essential for platelet adhesion at sites of vascular injury under high shear stress flow conditions. Moreover, GP Ib-IX-V may contribute to the mechanisms of platelet activation through its high affinity binding of alpha-thrombin. There are two distinct but partially overlapping regions of GP Ib alpha thought to be involved in interacting with vWF (residues 251-279) and alpha-thrombin (residues 271-284); they share three tyrosine residues (positions 276, 278, and 279) that have recently been shown to be sulfated (Dong, J., Li, C. Q., and Lopez, J., A. (1994) Biochemistry 33, 13946-13953). To define the functional role of these three residues, we have introduced selected mutations in a soluble recombinant GP Ib(alpha fragment (corresponding to the sequence 1-302 of the mature protein) that binds vWF and alpha-thrombin with the same attributes as intact GP Ib-IX-V complex. Fragments containing a single Tyr --> Phe substitution either at position 276 or 278 or 279 exhibited normal interaction with vWF but markedly reduced or absent binding of a-thrombin. GP Ib alpha fragment with normal sequence but synthesized under sulfate free conditions also failed to bind alpha-thrombin and, in addition, had markedly reduced interaction with vWF. The simultaneous substitution of three neighboring Asp residues with Asn at positions 272, 274, and 277, a multiple mutation that may impair Tyr sulfation, also resulted in loss of binding of both ligands. These results define distinct structural features of GP Ib alpha selectively involved in supporting the interaction with vWF or alpha-thrombin.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, ROON RES CTR ARTERIOSCLEROSIS & THROMBOSIS, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; KEIO UNIV, DEPT INTERNAL MED, TOKYO 160, JAPAN; CTR RIFERIMENTO ONCOL, SERV IMMUNOTRASFUS & ANAL CLIN, I-33081 AVIANO, ITALY	Scripps Research Institute; Scripps Research Institute; Keio University; IRCCS Aviano (CRO)			Mazzucato, Mario/ABF-5472-2020	Mazzucato, Mario/0000-0001-8319-053X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042846, R37HL042846, P01HL048728] Funding Source: NIH RePORTER; NCRR NIH HHS [RR0833] Funding Source: Medline; NHLBI NIH HHS [HL-48728, HL-42846] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEMARCO L, 1990, J CLIN INVEST, V86, P25, DOI 10.1172/JCI114692; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DEMARCO L, 1994, J BIOL CHEM, V269, P6478; DODT J, 1984, FEBS LETT, V165, P180, DOI 10.1016/0014-5793(84)80165-9; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; DU XP, 1987, BLOOD, V69, P1524; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJIMURA Y, 1991, BIOCHEMISTRY-US, V30, P1957, DOI 10.1021/bi00221a032; GIRMA JP, 1990, THROMB HAEMOSTASIS, V64, P326; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HANDA M, 1986, J BIOL CHEM, V261, P2579; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V141, P326, DOI 10.1016/S0006-291X(86)80372-2; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; JAKUBOWSKI JA, 1990, BLOOD, V75, P399; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P542; MURATA M, 1993, J CLIN INVEST, V91, P2133, DOI 10.1172/JCI116438; MURATA M, 1991, J BIOL CHEM, V266, P15474; ROSENQUIST GL, 1993, PROTEIN SCI, V2, P215; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; SUGIMOTO M, 1993, J BIOL CHEM, V268, P12185; SUGIMOTO M, 1991, J BIOL CHEM, V266, P18172; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; VICENTE V, 1988, J BIOL CHEM, V263, P18473; VICENTE V, 1990, J BIOL CHEM, V265, P274; WARE J, 1993, J CLIN INVEST, V92, P1213, DOI 10.1172/JCI116692	37	111	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 21	1995	270	16					9571	9578		10.1074/jbc.270.16.9571	http://dx.doi.org/10.1074/jbc.270.16.9571			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QU089	7721887	hybrid			2022-12-25	WOS:A1995QU08900076
J	TORNALETTI, S; PFEIFER, GP				TORNALETTI, S; PFEIFER, GP			COMPLETE AND TISSUE-INDEPENDENT METHYLATION OF CPG SITES IN THE P53 GENE - IMPLICATIONS FOR MUTATIONS IN HUMAN CANCERS	ONCOGENE			English	Article						METHYLATION; P53; MUTATION	TUMOR SUPPRESSOR GENE; LIGATION-MEDIATED PCR; UV PHOTOPRODUCTS; DNA METHYLATION; SKIN-CANCER; CELLS; MUTAGENESIS; PROTEIN	CpG dinucleotides are the target of about one third of transition mutations found in human genetic diseases and tumors. Methylation at these sites is thought to be the cause of these genetic changes through spontaneous deamination of 5-methylcytosine. In order to define the contribution of 5-methylcytosine to the spectrum of p53 mutations in human cancers, we have determined the complete DNA methylation pattern along exons 5-8 of the human p53 gene by ligation-mediated polymerase chain reaction genomic sequencing. The study was conducted with nine different types of normal human tissue and cell lines, including skin fibroblasts, keratinocytes, lung epithelial cells, mammary epithelial cells and colonic mucosa cells. We found that the p53 sequences along exons 5-8 are completely methylated at every CpG site, including 46 different sites on both DNA strands. This methylation pattern is tissue-independent suggesting that tissue-specific methylation does not contribute to the differential mutation patterns seen in tumors, The occurrence of mutational hotspots at specific CpG sites is not related to selective methylation of only a subset of CpGs but may rather depend on a selection bias for particular amino acid changes. Our results are not inconsistent with theories that mutations in tumors with high CpG mutation rates, like colon cancer, are caused by spontaneous deamination of 5-methylcytosine and mutations in tumors with a lack of CpG involvement reflect superimposed fingerprints from exogenous carcinogens. However, given the lack of tissue specificity of methylation, alternative explanations (eg targeting of methylated CpG sites by tissue-selective carcinogens) should be considered to explain the high percentage of CPG mutations in some tumor types.	BECKMAN RES INST CITY HOPE,DEPT BIOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NIEHS NIH HHS [ES06070] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006070, R37ES006070] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BENTIVEGNA SS, 1994, CANCER RES, V54, P327; BIGGS PJ, 1993, MUTAGENESIS, V4, P275; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DUMAZ N, 1994, MUTAT RES, V307, P375, DOI 10.1016/0027-5107(94)90311-5; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; KETTERLING RP, 1994, AM J HUM GENET, V54, P831; KOCHANEK S, 1991, P NATL ACAD SCI USA, V88, P5759, DOI 10.1073/pnas.88.13.5759; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; Maxam A M, 1980, Methods Enzymol, V65, P499; MAZUR M, 1988, SOMAT CELL MOLEC GEN, V14, P393, DOI 10.1007/BF01534647; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; ORY K, 1994, EMBO J, V15, P3496; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PFEIFER GP, 1993, METHOD ENZYMOL, V225, P567; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RUGGERI B, 1993, P NATL ACAD SCI USA, V88, P10657; SHEN JC, 1994, NUCLEIC ACIDS RES, V22, P972, DOI 10.1093/nar/22.6.972; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; SPRUCK CH, 1993, DNA METHYLATION MOL, P487; TORMANEN VT, 1992, ONCOGENE, V7, P1729; TORNALETTI S, 1993, ONCOGENE, V8, P2051; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Wiebauer K., 1993, DNA METHYLATION MOL, P510; WIEBAUER K, 1989, NATURE, V399, P234; WYSZYNSKI M, 1994, P NATL ACAD SCI USA, V91, P1574, DOI 10.1073/pnas.91.4.1574; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	42	222	231	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1493	1499						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731703				2022-12-25	WOS:A1995QU68100004
J	SIDHAR, SK; LOMAS, DA; CARRELL, RW; FOREMAN, RC				SIDHAR, SK; LOMAS, DA; CARRELL, RW; FOREMAN, RC			MUTATIONS WHICH IMPEDE LOOP SHEET POLYMERIZATION ENHANCE THE SECRETION OF HUMAN ALPHA(1)-ANTITRYPSIN DEFICIENCY VARIANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ALPHA-1-PROTEINASE INHIBITOR; HUMAN ALPHA-1-ANTITRYPSIN; ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; XENOPUS-OOCYTES; LIVER; ACCUMULATION; OVALBUMIN; ACID; PIZ	alpha(1)-Antitrypsin plasma deficiency variants which form hepatic inclusion bodies within the endoplasmic path way include the common Z variant (Glu(342) --> Lys) and the rarer alpha(1)-antitrypsin S-iiyama (Ser(53) --> Phe). It has been proposed that retention of both abnormal proteins is accompanied by a common mechanism of loop-sheet polymerization with the insertion of the reactive center loop of one molecule into a beta-pleated sheet of another. We have compared the biosynthesis, glycosylation, and secretion of normal, Z and S-iiyama variants of alpha(1)-antitrypsin using Xenopus oocytes. S-iiyama and Z alpha(1)-antitrypsin both duplicated the secretory defect seen in hepatocytes that results in decreased plasma alpha(1)-antitrypsin levels. Digestion with endoglycosidase H localized both variants to a pre-Golgi compartment. The mutation Phe(51) --> Leu abolished completely the intracellular blockage of S-iiyama alpha(1)-antitrypsin and reduced significantly the retention of Z alpha(1)-antitrypsin. The secretory properties of M and Z alpha(1)-antitrypsin variants containing amino acid substitutions designed to decrease loop mobility and sheet insertion were investigated. A reduction in intracellular levels of Z alpha(1)-antitrypsin was achieved with the replacement of P-11/12 alanines by valines. Thus a decrease in Z and S-iiyama alpha(1)-antitrypsin retention was observed with mutations which either closed the A sheet or decreased loop mobility at the loop hinge region.	UNIV SOUTHAMPTON,DEPT PHYSIOL & PHARMACOL,SOUTHAMPTON SO16 7PX,HANTS,ENGLAND; UNIV CAMBRIDGE,MRC CTR,DEPT HEMATOL,CAMBRIDGE CB2 2QH,ENGLAND	University of Southampton; MRC Laboratory Molecular Biology; University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BATHURST IC, 1985, FEBS LETT, V183, P304, DOI 10.1016/0014-5793(85)80798-5; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CILIBERTO G, 1985, CELL, V41, P531, DOI 10.1016/S0092-8674(85)80026-X; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; ENGH RA, 1990, PROTEIN ENG, V3, P469, DOI 10.1093/protein/3.6.469; ERIKSSON S, 1975, NEW ENGL J MED, V292, P176, DOI 10.1056/NEJM197501232920403; FOREMAN RC, 1984, FEBS LETT, V168, P84, DOI 10.1016/0014-5793(84)80211-2; FOREMAN RC, 1987, FEBS LETT, V216, P79, DOI 10.1016/0014-5793(87)80760-3; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; JEPPSSON JO, 1976, FEBS LETT, V65, P195, DOI 10.1016/0014-5793(76)80478-4; KWON KS, 1994, J BIOL CHEM, V269, P9627; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LE A, 1990, J BIOL CHEM, V265, P14001; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; PERLMUTTER DH, 1985, P NATL ACAD SCI USA, V82, P6918, DOI 10.1073/pnas.82.20.6918; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1991, EUR J BIOCHEM, V202, P1147, DOI 10.1111/j.1432-1033.1991.tb16483.x; SEYAMA K, 1991, J BIOL CHEM, V266, P12627; SHARP H L, 1971, Hospital Practice, V6, P83; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0	31	57	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 14	1995	270	15					8393	8396		10.1074/jbc.270.15.8393	http://dx.doi.org/10.1074/jbc.270.15.8393			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QT448	7721731	hybrid			2022-12-25	WOS:A1995QT44800006
J	VALERO, E; DEBONIS, S; FILHOL, O; WADE, RH; LANGOWSKI, J; CHAMBAZ, EM; COCHET, C				VALERO, E; DEBONIS, S; FILHOL, O; WADE, RH; LANGOWSKI, J; CHAMBAZ, EM; COCHET, C			QUATERNARY STRUCTURE OF CASEIN KINASE-2 - CHARACTERIZATION OF MULTIPLE OLIGOMERIC STATES AND RELATION WITH ITS CATALYTIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; II ACTIVITY; BINDING-ACTIVITY; PROTEIN-KINASES; BETA-SUBUNIT; PURIFICATION; ENZYME; IDENTIFICATION; ACTIVATION; INHIBITION	The structure-activity relationship of casein kinase 2 (CK2) was examined with regard to its previously reported property to self-aggregate in vitro. Sedimentation velocity and electron microscopy studies showed that the purified kinase exhibited four major, different oligomeric forms in aqueous solution. This self-polymerization was a reproducible and fully reversible process, highly dependent upon the ionic strength of the medium, suggesting that electrostatic interactions are mostly involved. At high salt concentrations (e.g. 0.5 M NaCl), CK2 appears as spherical moieties with a 18.7 +/- 1.6 nm average diameter, roughly corresponding to the alpha(2) beta(2) protomer, as deduced by measurements of the Stokes radius and by light scattering studies. At lower ionic strength (e.g. 0.2 M NaCl), the protomers associate to form ring-like structures with a diameter (averaging 36.6 +/- 2.1 nm) and Stokes radius indicating that they are most likely made of four circularly associated alpha(2) beta(2) protomers. At 0.1 M NaCl, two additional polymeric structures were visualized: thin filaments (16.4 +/- 1.4 nm average), as long as 1 to 5 mu m, and thick and shorter filaments (28.5 +/- 1.6 nm average). Examination of the molecular organization of CK2 under different catalytic conditions revealed that the ring-like structure is the favored conformation adopted by the enzyme in the presence of saturating concentrations of substrates and cofactors. During catalysis, well-known cofactors like MgCl2 or spermine are the main factors governing the stabilization of the active ring-like structure, On the other hand, inhibitory high salt concentrations promote the dissociation of the active ring-like structure into protomers. Such observations suggest a strong correlation between the ring-like conformation of the enzyme and optimal specific activity. Thus, CK2 may be considered as an associating-dissociating enzyme, and this remarkable property supports the hypothesis of a cooperative and allosteric regulation of the kinase in response to appropriate regulatory ligands possibly taking place in intact cells.	CEN GRENOBLE, DEPT BIOL MOLEC & STRUCT, INSERM, U244, CEA, F-38054 GRENOBLE 9, FRANCE; INST BIOL STRUCT, MICROSCOPIE ELECTR STRUCT LAB, F-38027 GRENOBLE, FRANCE; INST MAX VON LAUE PAUL LANGEVIN, EUROPEAN MOLEC BIOL LAB, F-38042 GRENOBLE, FRANCE	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL)			Filhol-Cochet, Odile/I-3962-2016; Langowski, Jörg/A-1843-2011	Langowski, Jörg/0000-0001-8600-0666; Cochet, Claude/0000-0002-1772-4270; Filhol, Odile/0000-0003-1964-7958				ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; CARROLL D, 1989, J BIOL CHEM, V264, P7345; COCHET C, 1981, BIOCHIM BIOPHYS ACTA, V658, P191, DOI 10.1016/0005-2744(81)90289-8; COCHET C, 1983, MOL CELL ENDOCRINOL, V30, P247, DOI 10.1016/0303-7207(83)90062-X; COCHET C, 1983, J BIOL CHEM, V258, P1403; DAHMUS ME, 1981, J BIOL CHEM, V256, P3319; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FEIGE JJ, 1983, BIOCHEMISTRY-US, V22, P1452, DOI 10.1021/bi00275a020; FEIGE JJ, 1980, FEBS LETT, V121, P139, DOI 10.1016/0014-5793(80)81283-X; FEIGE JJ, 1985, RECENT PROGR POLYAMI, V13, P181; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1990, BIOCHEM BIOPH RES CO, V173, P862, DOI 10.1016/S0006-291X(05)80866-6; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; GLOVER CVC, 1986, J BIOL CHEM, V261, P14349; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HATHAWAY GM, 1984, J BIOL CHEM, V259, P7011; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HATHAWAY GM, 1981, J BIOL CHEM, V256, P1442; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; LANGOWSKI J, 1991, N-HOLLAND D, P325; MAMRACK MD, 1989, MOL CELL BIOCHEM, V85, P147, DOI 10.1007/BF00577110; MEGGIO F, 1984, EUR J BIOCHEM, V145, P593, DOI 10.1111/j.1432-1033.1984.tb08598.x; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MEGGIO F, 1986, EUR J BIOCHEM, V159, P31, DOI 10.1111/j.1432-1033.1986.tb09829.x; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; TRAUT TW, 1994, CRIT REV BIOCHEM MOL, V29, P125, DOI 10.3109/10409239409086799; TUAZON PT, 1991, ADV SEC MESS PHOSPH, P124	32	85	86	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 7	1995	270	14					8345	8352		10.1074/jbc.270.14.8345	http://dx.doi.org/10.1074/jbc.270.14.8345			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QR526	7713943	hybrid			2022-12-25	WOS:A1995QR52600082
J	Barnard, D; Diaz, B; Hettich, L; Chuang, E; Zhang, XF; Avruch, J; Marshall, M				Barnard, D; Diaz, B; Hettich, L; Chuang, E; Zhang, XF; Avruch, J; Marshall, M			Identification of the sites of interaction between c-Raf-1 and Ras-GTP	ONCOGENE			English	Article						Oncogenes; RAS; RAF; Protein Interactions	KINASE SIGNALING PATHWAY; HA-RAS; RAF-1; ACTIVATION; BINDING; DOMAIN; ASSOCIATION; INHIBITION; PROTEINS; REGION	Specific sites of protein-protein interaction were identified in the 51-149 region of c-Raf-1 using contact epitope scanning and site-directed mutagenesis. Nineteen overlapping peptides based upon the primary sequence of the Ras binding domain of c-Raf-1 were tested for the ability to competitively inhibit complex formation between Ras-GTP and the c-Raf-1 N-terminus, A peptide containing c-Raf-1 residues 91-105 as well as five overlapping peptides covering a region extending from residues 118 to 143 interfered with Ras association, defining these sites as potential contact surfaces with Ras, Alanine scanning mutagenesis was used as a second probe for sites of Ras interaction with the c-Raf-1 N-terminus, Raf residues 64-67 and 80-103 were demonstrated as important for association with Ras-GTP with residues 66, 67, 84, 87, 89 and 91 identified as the most critical individual points of contact with the Ras protein, Alanine substitution of residues between 118-143 suggested only one potentially weak site of interaction defined by residues 120-125, The combined results of both peptide and mutagenic analyses suggest that the primary site of c-Raf-1 interaction,vith Ras maps to Raf residues 80-103, with secondary interactions occurring with residues 66 and 67 and possibly 120-125, Contact epitope scanning of the Ras effector region found maximum inhibition of Ras/Raf association with a peptide corresponding to Ras amino acids 37-51, A model is proposed for the GTP-dependent association of Ras and Raf.	Indiana Univ, Dept Med, Div Hematol & Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Harvard Univ, Massachusetts Gen Hosp East, Sch Med, Dept Med, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp East, Sch Med, Diabet Unit, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp East, Sch Med, Med Serv, Boston, MA 02129 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital					NIDDK NIH HHS [DK07519] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007519] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1989, CANCER RES, V49, P4682; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MARX J, 1993, SCIENCE, V260, P1588, DOI 10.1126/science.8503004; MELNICK MB, 1993, DEVELOPMENT, V118, P127; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOORE ML, 1992, SYNTHETIC PEPTIDES, P58; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	36	53	55	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1283	1290						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731678				2022-12-25	WOS:A1995QR65100004
J	LORENZO, MJ; ENG, C; MULLIGAN, LM; STONEHOUSE, TJ; HEALEY, CS; PONDER, BAJ; SMITH, DP				LORENZO, MJ; ENG, C; MULLIGAN, LM; STONEHOUSE, TJ; HEALEY, CS; PONDER, BAJ; SMITH, DP			MULTIPLE MESSENGER-RNA ISOFORMS OF THE HUMAN RET PROTOONCOGENE GENERATED BY ALTERNATE SPLICING	ONCOGENE			English	Article						RET; RECEPTOR TYROSINE KINASE; ALTERNATE SPLICING	TYROSINE KINASE; TRANSFORMING GENE; SOLUBLE RECEPTOR; II ONCOGENE; CELL-LINE; PROTOONCOGENE; SEQUENCE; CLONING; RNA; CARCINOMAS	The RET proto-oncogene encodes a receptor tyrosine kinase. We and others have recently shown that distinct germline mutations of the BET proto-oncogene account for the majority of cases of the dominantly inherited multiple endocrine neoplasia (MEN) type 2 syndromes, and can cause a dominantly inherited form of Hirschsprung disease, a disorder of development of the autonomic innervation of the gut. RET is also oncogenically activated in some sporadic thyroid and adrenal tumours. Here we report the characterisation of multiple mRNA isoforms of RET generated by alternate splicing. Two isoforms are predicted to encode membrane-spanning receptors with a truncated extracellular ligand-binding domain. A third isoform is predicted to encode a soluble, secreted form of the receptor, These mRNA isoforms are expressed in both normal and tumour tissues.	UNIV CAMBRIDGE, DEPT PATHOL, CRC, HUMAN CANC GENET RES GRP, CAMBRIDGE CB2 1QP, ENGLAND; HARVARD UNIV, SCH MED,DEPT MED,DANA FARBER CANC INST, DIV MED ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED,DEPT MED,DANA FARBER CANC INST, DIV CANC EPIDEMIOL & CONTROL, BOSTON, MA 02115 USA; QUEENS UNIV, DEPT PATHOL, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT PAEDIAT, KINGSTON, ON K7L 3N6, CANADA	University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Queens University - Canada; Queens University - Canada				Lorenzo, Maria Jesus/0000-0003-4416-0615; Eng, Charis/0000-0002-3693-5145				BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELANEY SJ, 1993, NAT GENET, V4, P426, DOI 10.1038/ng0893-426; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; EISEMANN A, 1991, ONCOGENE, V6, P1195; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENGG C, 1995, IN PRESS GENES CHROM; Favaloro J, 1980, Methods Enzymol, V65, P718; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; KODA T, 1988, Hokkaido Journal of Medical Science, V63, P913; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KUMABE T, 1992, ONCOGENE, V7, P627; KWOK JBJ, 1983, ONCOGENE, V8, P2575; LANZI C, 1992, ONCOGENE, V7, P2189; Leong S, 1981, ADV THYROID NEOPLASI, P95; Maniatis T., 1982, MOL CLONING; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, HUM MOL GENET, V3, P1007, DOI 10.1093/hmg/3.6.1007; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROSS RA, 1983, J NATL CANCER I, V71, P741; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404	42	45	46	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1377	1383						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731689				2022-12-25	WOS:A1995QR65100015
